From: Snapshot-Content-Location: https://kennylist.com/ Subject: Kenny Reference Date: Sun, 8 Jun 2025 17:40:49 -0700 MIME-Version: 1.0 Content-Type: multipart/related; type="text/html"; boundary="----MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq----" ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: text/html Content-ID: Content-Transfer-Encoding: quoted-printable Content-Location: https://kennylist.com/ =20 =20 =20 =20 =20 Kenny Reference
Show temp: Show imgs: Rev:
=20
Data= TemplateImgs<= /tr> <= /tr>
*** Resources: TWDFMR.

= **Admission UCI Workflow
SPPO Hospitalis= t Admission Sheet.xlsx (sharepoint.com)

Transfer Center Notes

Transfer Center: 714-456-2222
- caloptima= : inpatient (no obs)  - "straight medical" also inpatient, even if not= meeting inpatient criteria

H&P Template Simple.docx

MGH Whitebook 2021-2022.pdfh ta= d

NF list

= ED to ortho-trauma-medicine agreement

Review Exam - StatRad Client Portal

- cardiology telemetry: new HF= rEF without other major comorbidities

- HELP orde= r for pharmacy help inpatient





- ROS:  fever, dizzy, CP, SOB, abd p= ain, dysuria, freq, constipation.

- PMH/PSH:

- FamHx:

=
- Living:
- ADL:

- Code:
- dPOA:

- PE: 



<= td class=3D"oa3" width=3D"374" style=3D"width: 187pt;">

=C2=B7 Invasive central venous, PA, ICP= , A line, bladder pressure

=C2=B7 Q1 hr monitoring

=C2=B7 1:1 or 2:1 nursing ratio

<= td class=3D"oa4" width=3D"290" style=3D"width: 145pt;">

=E2=96=AA BiP= AP PRN

=E2=96=AA High flow

=E2=96=AA Matu= re trach, vent

=

=C2=B7 Stable chronic atrial arrhythmia a= dmitted for unrelated reason and hemodynamically stable

=C2=B7 Asymptomatic stable = sinus bradycardia

=C2=B7 Asymptomatic Wenckebach

=C2=B7 Chronic stable heart failure=

=C2=B7=  Chronic = PACs/PVCs

=C2=B7 


 ICU
<= /p>

Stepdown (56,68,44)

Teleme= try (DH78, 66, T5, T3,B3)

Monitoring

=C2=B7 Q2hr monitoring

=C2=B7 Q1hr monitoring not to exceed = 6 hr

=C2=B7&nb= sp;3:1 nursing ratio

=C2=B7 Q4hr vitals

=C2=B7 Q1-2hr monitoring not to exceed 6 hours

=C2=B7 4:1 nursing ratio

MedSurg (T4= )

=C2=B7 5:1 nursing ratio

=C2=B7 Pulse oximetry

=C2=B7 Q1-2hr monitoring not to exceed 6 h= ours

Medications

=C2=B7 Titration of IV vasopressors

=C2=B7 IV anti-arrhythmic meds<= /p>

=C2=B7<= /span> Systemic = thrombolytic rx

=C2=B7&= nbsp;Fluid replacement > 6L/day

=C2=B7 Insulin gtt

=C2=B7 Non-titratable gtts if hemodynamically stable: diltiazem

=C2=B7 No moderate sedat= ion

=

=C2=B7 Non-titratab= le gtts:

amiodarone, lasix, PCAs

=C2=B7 IV Remodulin or CAD (3T)

=C2=B7 IV anti-hypertensive= s

 = IV Haldol

=C2= =B7 Any g= tt for comfort measures

=C2=B7 Heparin

Airway

=E2=96=AA Ventila= tor

=E2=96=AA Fresh trach

=E2=96=AA QHS BiPAP

=E2= =96=AA Continuous BiPAP

=E2=96=AA Mature trach, no vent

=E2=96=AA High flow

Technology

<= span style=3D"font-family: Symbol; font-size: 9pt;">=C2=B7 Ext/transvenous pacemaker=

=C2=B7 M= echanical ventilation

=C2=B7 IABP or VAD

=C2=B7 Balloon tamponade varices

=C2=B7 CRRT

=C2=B7 Long Term mechanical ventilatio= n (mature trach and stable resp status)

=C2=B7 Neuro SDU (DH 56): Clamped ventricu= lostomy

=C2=B7=  New pace= maker/ICD

&nb= sp;

Medical Condition

=C2=B7 Vitals: HR<40 or HR>140

SBP<80 or SBP>= 250

DBP<40 or DBP>130

=C2=B7 Labs: Hb<5, Na<120, Na>160, pH<7.2, K>6 + symptoms/EKG,&= nbsp;Gluc<40 for >2hr,=

2&l= t;50 on >50% FiO2,

pCO2>70 + pH<7.3 + AMS

=C2=B7 Conditions: status epilepticus, septic = shock, re= sp distre= ss, cardiac arrest, unconscious, ruptured viscera, uncontrolled hemorrhage,= unstable cervical fracture, acute stroke, unstable PE, symptomatic arrhyth= mias, ang= inal ches= t pain, severe multiple traumas, multiple unfixed long bone fractures, majo= r burns, inhalation injury

=C2=B7 New onset atrial arrhythmia or unstable chronic atrial arrhythmi= a

 = Specialty surgical care: CT surgery, post kidney transplant, post-op <= /span>trachs

=C2=B7 Insulin&nb= sp;gtt<= span style=3D"font-family: Calibri; font-size: 9pt;"> with stable = ;gluc and Q2hr checks

= =C2=B7 Te= lemetry level of care but beds are full

=C2=B7 Syncope

=C2=B7 Arrhythmias

=C2=B7 New onset Atrial arrhythmia (stable= )

 = AV block (Mobi= tz 2 or 3= rd)

= =C2=B7 Ch= est pain r/o

=C2=B7 Acute CHF exac

=C2=B7 Pre/post-cath

=C2=B7 Stroke

=C2=B7 Major surgery

=C2=B7 Severe K and Mag abnl

=C2=B7 Overdose c/b arrhyth= mias

=C2=B7&nb= sp;Loading of antiarrhythmic meds

=C2=B7 QTc prolongation

=C2=B7 IV nodal blocking agents

 

UCI Telemetry orders:
- Acute resp failure (48 hr)
- Chronic CHF (24 hr)
- Acute PE (48 hr)
- Sepsis (48 hr)
- Cardiology or CT surgery service (ongoing)
Rev= iew at 24 hr:
- Chest pa= in (low risk)
- Drug OD = or toxins with arrhythmias (72 hr)
- Severe electrolyte abnl (48hr)
- Major surgery
- S/p arrhythmia ablation
- S/p AICD firing
- = S/p PM or AICD placement
- IV beta-block or CCB
Review in 48 hours:
- ACS
- 2nd or 3rd degree AV block
- Cardiac contusion
- Chest pain (int-high risk)
- Acute CHF exacerbation (72 hr)
-= Initiation/titration anti-arrhyth= mic meds (72 hr)
- Myoca= rditis/pericarditis
- Ne= w onset or uncontrolled tachyarrhythmia
- Thoracic surgery
- NSVT
- Acut= e stroke (cryptogenic 7 days)
-= Syncope of cardiac origin
- Temp PM or transcutaneous pacing pads
- Use of QT prolonging medications
Not indicated: 
- = Anemia not requiring massive transfusions
- Chronic stable atrial fibrillation
- Chronic PACs/PVCs
- Febrile illness, sepsis without shock
<= div>- GI bleeding not requiring ma= ssive transfusions
- H/o= CHF without current exacerbation
- H/o PM or AICD without malfunction or firing
- Respiratory illness without underlying c= ardiac disease
- Stable = PE without hemodynamic instability
3D""
3D""
- anti-smooth,= anti-dsDNA =3D lupus
- anti-U1-RNP =3D mixed connective tissue (=3D bot= h lupus, autoimmune myositis, and systemic sclerosis)
- anti-centromere = and anti-Scl-70 =3D systemic sclerosis (raynaud); CREST
- antiLa, anti-R= o - sjogren
- antihistone =3D drug induced lupus
- cANCA / antiPR3=3D=   granulomatosis with polyaniitis (wagener)
- pANCA/anti-MPO - eosi= nophilic granulomatosis with polyaniitis
- anti-Jo1 =3D polymyositis
= - antiCCP or RF =3D rheumatoid

At VA: ANA panel reflexes to ANA IFA SCREEN
ANA IFA TITER
ANA IFA PRIMARY PATTERN
ANTI JO-1
ANTI SM
ANTI RNP
ANTI SM/RNP
SS-A
SS-B
SCLERODERMA AB (SCL-70)
RIBOSOMAL P PROTEIN AB
CENTROMERE ANTIBODY
CHROMATIN
ANTI DS-DNA 


-methylene blue also for low BP ICUabdominal pain
- DDx: PUD, Hyplori,&nb= sp; IBS, gastropathy, celiac disease, MSK, mesenteric ischemia, SIBO, dyspe= psia.


GI = cocktail with maalox, viscous lidocaine, donnatol
adequate bowel regimen= , miralax, senna daily to bid
PPI daily
Avoid anticholinergics/ opiat= e medications
zofranachalasia
- barium swallow show bird's beak- need CT chest and abd to rule out cancer first (pseudoachalasia)
#Concern for achalasia= :  CT with clear air fluid level suggestive of advanced disease. Chara= cterized by sensation and regurgitation x 2 years. ROS positive for GERD, w= eight loss, aspiration 

- Barium esophagram t= o assess emptying, diameter, contour, and epiphrenic diverticula that may n= ot be appreciated on endoscopy 
- EGD tomorrow to exclude eo= sinophilic esophagitis or other infiltrative disorders for pseudoachalasia = rule out 

- Will need esophageal manometry fo= r gold standard for diagnosis of achalasia -- instructions and follow up in= structions to follow pending EGD and barium esophagram. Achalasia can be su= bclassified into 3 types based on results with type II being very responsiv= e to therapy, whereas type I may need endoscopic dilation. 
=
- Most patient react well to disruption of the LES for remov= al of esophageal outlet barrier: botulinum toxin injection, pneumatic dilat= ation ,Heller myotomy, POEM, stent placement, esophagectomy

<= /div>
- Nifedipine 10-2 mg sublingual prior to meals, limited by SE of = HA and dizziness as well as a tachyphylaxis effect. 
- Phosp= hodiesterase inhibitors for short term use 

-= Medications can be used as bridge to sphincter disruption 
=


Do interventions give her full= or partial improvement? Duration? 

Eckardt s= core 
0 =3D never
1 =3D occassional
2 = =3D daily
3 =3D with every meal


Dysphagia =E2=80=93 both solids and liquids? Types of foods
Regurgiation =E2=80=93 
Chest pain =E2=80=93  locatio= n, quality? spasm? Occurs with or without meal?
Weight loss =E2= =80=93 <5, 5-10, >10 kg
Total possible score is 12

acidosis3D""ACLS - asystole / cardiac arrest
1) CPR all cases
PEA/asystol= e: epi 1mg q3-5m
pulseless VT/VFib: defib with biphasic 120-200J, then e= pi 1mg q3-5m / amio 300mg 1st dose, 150mg 2nd dose (or lidocaine 1-1.5mg/kg= 1st dose, 0.5-0.75mg/kg 2nd dose)
If Torsade 1-2g MgSO4 over 15 min
= pulse check q2m
HyperK - Ca gluco 2g IV (or CaCl2), BiCarb 1-2amp IV, in= sulin 10u, D50 1-2amp
Naloxone: 2mg IV if pulseless. If puse, 0.2-1mg IV=

- add capnography, peek EtCO2 > 10mg, ideally > 20
- if su= spect PE and pulseless =3D  tPA 50mg IV/IO over 2 minutes, can repeat = 50mg IV/IO in 15m; if pulse, 100mg infusion over 2 hours
(contraindicate= d if prior ICH, ischemic CVA or head trauma within 3 months, known brain ca= ncer, suspected aortic dissection or active bleed)

prognosticate: ET= CO2 < 10mg in intubated after 20 minutes =3D 90% sensitive no ROSC
pr= egnant: left lateral uterine displacement

- TTM if comatose cardiac = arrest followign ROSC (GCS < 8, not following commands, no purposeful mo= vement to stimuli) (contraindicated in major head trauma, major surgery wit= hin 14d (increases risk of infection), active bleeding (causes hypercoag), = sepsis, coma from drug

*** -- if pulseVtach or Vfib, shock first -&n= bsp; giving epi will sustain the arrhythmia more likely.  (2 shocks be= fore epi).



Reversible causes:
- hypovolemia, hemorrhage, = hypoxia, acidosis, hypo/hyperK, hypothermia, thrombosis, ACS, PE, tension p= neumo, tamponade, toxins (drugs)- ABG
- CBC
- CMP
- lactate
- INR/PT/PTTfibrinogen/= D-dimer,
- trop
- EKG
- SpO2 > 92%
- MAP > 65, levophed i= f needed


- CT head if concern for ICHACLS / RRT - Brady (symp= tomatic)  HR <50
- PE: warm/cold, pupils
- review EKG, med ch= anges, labs
- Labs: BMP, Mg, Lactate, Drop
- Hold BB and antiHTN
-= atropine 1mg q3m  x3 max (avoid if 2nd degree type 2, 3rd degree bloc= k and do not do less than 0.5mg as slows HR even more), then  dopamine= 5-20mcg/kg/min or epi 2-10 mcg/min
- if pacing, Versed (midazolam) 0.5-= 2mg, max total 5mg, repeat q2-5m + fentanyl 25-50mcg q5m. (1mg Versed + 25m= cg fent normally by Cardiology)
- DDx:
  - beta blocker, give g= lucagon 5mg IV bolus, repeat x2 (if responding, 5mg/h)
  - Calcium = blocker: glucagon per above (increases cAMP) + calcium gluconate 60mg/kg (m= ax 6g/dose) over 5 minute, repeat in 10m x3 additional, insulin 1u/kg bolus= ; order serial Ca lab and EKG to prevent high Ca
  - opioid: naloxo= ne 0.8mg IV
- cause: meds, SSS, hyperK, ischemia/ACS, vagal, elderly, en= docarditis/lyme/viral carditis, elevated ICP, infiltrative disease, hypothy= roid, nocturnal only (in athletes)<= /tr>ACLS / RRT - Tachy (symptomatic)
- consider: time cour= se, Hx, where the reading was from, baseline, meds and held meds
- manag= ement:
  1) BP stable? if not cardiovert
  2) symptomatic: = fluids, diuretics, electrolyte, antipyretic, rate control
  3) reve= rsible causes: recent meds or not given
  4) bedside echo for R hea= rt, tamponade, IVC size, pneumothorax
  5) Escalate if hypotensive = or need drip
  
- Causes: 
  - cardiac: HF, MI= , tamponade, Afib/aflutter, SVT, VT
  - non-heart: PE/DVT, hemorrha= ge, infection, hypovolemia, electrolykte (K, Mg), drugs/med withdrawal hype= rthyroid, pain/anxiety
- PE: warm/cold, murmur, pulm edema
- review E= KG, labs
- EKG
- if hypotensive shock, AMS, acute HF/pulm edema, ches= t pain: sync cardioversion (100J if narrow reg (if aflutter 50J), 120-200J = if narrow irre (Afib needs 150J), 100J if wide red, DEFIB 120-200J if wide = and irregular)
- narrow regular: vagal -> adenosine -> IV BB or di= lt 0.25 mg/kg) 
- narrow irre: IV BB or dilt
- wide regular: ami= o 150mg IV over 10 min, repeat x1 (1mg/min x6h, 0.5mmgx18h) --> lidocain= e (lido 1mg/kg 1st dose, 2nd 0.5 mg/kg)
- wide irregular Lido + 2g Mg ov= er 15 min 

!!No dilt if HFrEF

- Vagal: tried carotid mas= sage, if doesn't work, head of bed 45, then blow syringe 15 seconds, then f= lat and raise legs 45 for 15s.

SVT: typically caused by AVNRT; = Before taking adenosine, patients should be warned that they may experience= nausea, flushing, chest pain, or a sense of dread. Patients with bronchosp= astic lung disease should not receive adenosine.; AV nodal blockers (=CE=B2-blockers or calcium ch= annel blockers) are used to prevent recurrent AVNRT
- NSVT =3D = <30 seconds- vita= ls, pads,
- CBC, CMP, UA, UDS, TSH, Free T4, lactate, Trop
- EKG, CXR=
Consider: CT PE, DVT U/S, CTA Abd, Eho


acne
- no sca= rring: Tx with tetracycline
- scarring: Tx with oral isotretinoin (need = LFTs first)= ACS (= STEMI, NSTEMI, Unstable angina)
- score: HEART Score for Major C= ardiac Events - MDCalc for risk of major heart event, TIMI Risk Sc= ore for UA/NSTEMI - MDCalc for medical versus intervention (3+ sho= uld do intervention; 0-2 stress test), Pre-test = probability of CAD (CAD consortium) | QxMD for stress test (11-90%= should get stress test)

- STEMI: 0.1mV+ (if lead V2 or V3, 2+mm in = male over 40, or 1.4mm in female) OR new LBBB and biomarkers
- NSTEMI: 0= .5mv+ in 2 leads, elevated trop
- Unstable angina: ECG or Sx (not improv= ed with nitro), negative trop

Location
  - V1-V2 =3D anteros= eptal (prox-mid LAD)
  - V3-V4 =3D anterior (LAD)
  - V5-V6= =3D apical (distal LAD, distal LCx)
  - I, aVL =3D lateral (prox L= Cx)
  - II, III, aVF=3D inferior (RCA, LCx)  !!! if inferior M= I and bradycardic, give atropine first to increase HR.  If you give NS= and HR is slow, will worsen pulmonary edema

- good for immediate ca= th - shock, severe LV dysfunction or signs/symptoms of HF, persistent or re= fractory angina, new MR

- nitroglycin gtt if pain after 3 sublin; no= nitro if sildenafil in past 24 hours   (nitro decrease BP but re= flexes tachy)
- stress test if intermediate risk (
- can start lisino= pril 2.5mg
Heparin 60 U/kg IVB (max 4000 U); 12 U/kg/hr (max 1000 U= /hr initially), to aPTT (goal 50-75); pro: quick reversible by protamineEnoxaparin 1mg/kg SC BID for > 2d until patient stabilized. D/C if Plt = <100,000; pro: less likely HIT, but still can, not for renal issue GFR &= lt;30
- BP goal SBP < 140, keep DBP > 60 !!! no beta bl= ocker if LV failure with pulm edema or 2nd degree or 3rd degree heart block=

If= has chronic LBBB, need Sgarbossa Criteria (concordant depression >= 1mm in V1-V3 / concordant elevant >1mm in any contiguous leads / discord= ant ST elevation >5mm with negative QRS)

=
STEMI
- DAPT with ticagrelor 180 bolus then 90 BID for 12 mo= nths (better than plavix) and aspirin 81 forever

m= yocardial injury =3D trop with no symptoms, EKG, wall motion.
- stress testing: NPO 3 hours before, hold BB and nitrates.&nbs= p; Coronary CTA 99% negative predictive value for low risk patients
- if cardiac cath: hold medications that can harm kidney until after

Wellens' syndrome
- EKG findings only of de= eply inverted or biphasic T waves in V2-3, but no chest pain right now (may= have recent chest pain)
- need early/urgent coronary work up (Treated a= s unstable angina)


If RV infarct (h= ypotension after nitro and JVF with clear ynds, ET elevation on V4R : Tx: i= ncrease preload: Give IV fluids
- If VSD.papillary muscle rupture= after acute MI, need intraaortic balloon pump, sodium nitroprusside, and l= asix (decrease afterload) and emergent


<= div>- if beta bocker, nitrate, and dilt/verapamil still not helping with ch= ronic stable angina, can try adding on ranolazine (Ranexa)


!!! If ACS is stimulant drug induced, then BB can w= orsen coronary vasoconstriction; labetalol is preferred (b blocker with a b= locker)

- EKG, CXR
- admit to telemetry
- CBC, CMP, BNP
- serial= trop
- aspirin load 325mg, followed 81mg QD
- Keep O2 Sat > 92%, = supplemental O2 PRN
- heparin gtt
- *** metop tart 25mg q12h (to keep= HR 50-60) if no HF or severe asthma/COPD
- atorvastatin 40mg
- nitro= 0.4mg SL q5m PRN (max 3 dose within 15 min)
- morphine 2-4mg IV PRN for= severe pain, q15 min
- consider starting lisinopril if BP tolerates
= - TTE for new wall motion abnormality
- consult card
- no NSAID (incr= eases risk of cardiovascular event)


- start beta blocker metopro= lol/carvedilol unless contraindicated: advanced AV block, new HF, severe re= active airway (wheezing heard)acute adrenal crisis
- give fludrocorti= sone (mineralocorticoid) if still wobbly after hydrocortisone givenacute aortic regurg
-= SS: wide pulse pressure
- do not give beta blocker in acute aortic reur= g: will worsen
- Tx: if super low BP, dobutamine, sodium nitroprusside;&= nbsp;
- TX: ARB and nifedipine okay if patient has chronic aortic regurg= and HTN

(Beta blocker OK for Mitral STENOSIS and MVP

Mitral = regurg:
- surgical repair if EF < 60%


acute bleed on antiplt (aspirin, pla= vix, dipyridamole, prasugrel)
- if antiplt used within last 24 hours and= positive CT or surgery planned, or GCS < 14, 0.3mcg/kg desmopressin in = 50mL NS over 20 minutes AND transfuse 1-2 units of apheresis plts (=3D 6-12= packs of platlets)
acute chest syndrome
- most common by fat emboli
- criteria: p= ulmonary infiltrate on XR + increased work of breathing/cough/tachypnea/whe= ezing, 101.4F, hypoxemia, or chest pain
- Tx: ceftriaxone + azithro, IV = fluids, pain control
- common in sickle cell kidsacute encephalopathy, altered mental sta= tus (also see RRT - altered mental status & delirium)
- varicella, H= SV, syphillis, HIV, CMV, west nile, consider LP
- if meningitis, acyclov= ir, ampicillin

- If bacterial meningitis (likely strep pneumo or nei= sseria meningitidis); tx with ceftriaxone + vancomycin (van to cover penici= llin resistant strains of strep pneumo).  If >50 yrs old, add ampic= illin, due to possible listeria meningitis.
-- Recommend meningitic dosing acyclovir 800 q8&nbs= p;
-- consider meningitic dosing ampicillin if clinica= lly concerned for meningitis

- cefepime has better= penetration
- 50+ or immunosuprresed, add ampicillin for listeri= a

- TB meningitis and fungal infection most common= cause of chronic meninigitis

- TB meningitis:
- Sx: CN 6 issues, low CSF glucose
- CT head with contrast= shows basilar meningea= l enhancement
- Tx: RIPE + dexamethasone if suspecting TB = meningitis + (vanc + cefepime)
#rule out meningitis: patient presents with ***headach= e, fever, nuchal rigidity, photophobia, maculopapular rash, cough, pharyngi= tis, n/v, myalgias. Differential includes viral meningitis vs bacterial.&nb= sp;

Viral meningitis most commonly from enteroviru= s (May till November), herpesvirus (HSV2 most commonly but also VZV, CMV, E= BV, HHV6-- year round) mosquito borne viruses (June till October) 

Bacterial meningitis: most common S. Pneumo, then N m= eningitides serogroup B, then strep agalactiae. Consider listeria in older = adults and those with altered cell mediated immunity. Lyme disease unlikely= (patient meets rule of 7s -- headache duration <7 days. <70% CSF mon= onuclear cells, absence of a seventh facial nerve palsy) Less likely ddx in= cludes treponema pallidum (secondary or tertiary syphilis) and leptospiral = meningitis (uveitis, rash, conjunctival suffusion, lymphadenopathy, hepatos= plenomegaly absent) 

Subacute (5+ days) or ch= ronic meningitis (30+ days)most commonly caused by TB and fungi. TB meningi= tis (SIADH, CN VI neuropathy), cryptococcus neoformans (suspect in AIDS, ne= utropenia, organ transplantation, advanced immune suppression), histo (acut= e respiratory symtpoms in setting of recent travel to Ohio, Missouri, India= na, Mississippi), coccidioides (acute or chronic pulmonary infection) =


- Lumbar puncture
- Se= nd for enterovirus PCR 
- HSV2, VZV 
- WNV IgM (PCR for WNV is insensitive) 
-= Gram stain and culture 
- LP x 3 days for gram sta= in and culture for TB -- can also send for AFB smear but this is often inse= nsitive. Would also perform NAAT.
- Urine culture of lepto= spiral meningitis 
- Blood cultures 
- Serum = cryptococcal antigen (positive in greater than 95% of infected patients)&nb= sp;
- Histoplasma urinary antigen assay (se, spe >85% in acute= and disseminated infection but less than 50% in chronic infection.) <= /div>
- Urinary antigen testing and serology for coccidioides immitis.&= nbsp;
- Dexamethasone (10 mg q 6 hours x 4 days) reduces morbi= dity/mortality in adults with pneumococcal meningitis, scheduled to given w= ith 1st dose of antibiotics.   (discontinue if cause is not strep= pneumoniae; most comon bacterial meninigitis; otitis media or sinusitis as= symptom too)



Check reversible encephalopathy labs if not checked recently: Vitamin B1, Folate, B12, MMA, homocysteine, Vitamin D, Vitamin E, zinc, copper, ceruloplasmin, RPR, HIV, HTLV1/2, VLCFA, ESR, CRP, ANA

=


Acute HF heart failure (HFrE= F)
- criteria: EF <=3D40%
- Sx: S3 sound, lung crackle, JVD, BLE e= dema  (Cardiac wheeze can happen vs COPD;  steroids can increase = fluid retention)
- test: BNP
- cause: med compliance, toxin/meds, afi= b, ischemia/infarct, diet, hyperthyroidism, progression cKD, acute AKI, PE = or COPD worse R-side afterload), liver failure, thyroid, infection, sarcoid= , 
- wet and warm =3D diuresis, wet and cold =3D need CCU for inotr= ope and/or vasodilator
- hold ACE/ARB if hypotensive; switch to hydra or= nitrate if renal
- BB reduce 1/2 if moderate HF, d/c if severe HF (new = guidelines: continue if already started unless hypotensive)
- order iron= studies for all patients in acute exacerbation


- entresto also = good for HFpEF (PARAGON-HF trial)
- will need ischemic workup: stress te= st/CTA, angio
- GDMT:
  - carvedilol or metop succ)
  - = ARNI  (if cannot take ARB, consider hydralazine-isosorbide dinitrate -= BiDil); if hx of angioedema, ARNI increases risk, so just do losartan
&= nbsp; - spirinolactone if GFR >30
  - jardiance


ranol= azine for antianginal medical optimization vs. isodirl


ARNI can = drop blood pressure more; if already low BP, do losartan

minoxidil c= an lower diastolic BP

Stage B: structural heart disease, no symptoms= ; stage C: symptoms; stage D =3D refractory HF
NYHA =3D class 1 (no limi= tation), 2 (normal activity), 3 (minimal activity), class IV (rest)

= - avoid CCB, NSAID
- BNP can be falsely low in obese and HFpEF; high in = entresto 

- get BNP and weight on discharge

BNP CAN BE f= alsely elevated in people with entresto


HFpEF
- GDMT: spirino= lactone (no mortality benefit) and jardiance

Indirect bili may be hi= gh in setting of congestive hepatopathy

- CRT if EF still < 35% a= nd LBBB with QRS >150ms after on GDMT

get a lactate for anyone who presents with decompensated HFrEF (usually like 2= 5% and less) WITH hypotension even to only the 90s  - to catch early o= r ovious cardiogenic shock (cold and wet)

- imdur hydralazine for b= lack people with HFrEF for GDMT (will have little urine output)

=

: = BB, spirinolactone if Cr# Acute respiratory distress
# Acute on chronic = 2/2 
Last LVEF: ***  NYHA, ACC/AHA
- CXR
- CBC, CMP. TSH= , BNP, lipid, a1c, urine hCG, iron studies, HIV
- admit to telemetry
= - Lasix 2.5x home dose , net goal 2L
- KCL 20mg PO BID empirically
- = continuous pulse ox, keep O2 > 92%
- duoneb q4h PRN
- strict I/O- fluid restrict 1.5L
- standing weight
- TTE
- GDMT on discharg= e
- BNP and dry weight on discharge
- UDS

#Decompensated = HFrEF
EF ***% on bedside ultrasound. ACC/AHA Stage ***, NYHA Clas= s ***. Most likely etiologies include ***

#Troponi= n elevation: 54 to 71 over 1 hour on admission. Most likely completed infar= ct from several days prior to admission given clinical history. 
=
- Rule out COVID as possible etiology of SOB 
- NPO for= LHC in am 
- Trend troponin with EKG 
- Low = threshold for activating cath lab for LHC, particularly need for LV support= device (onset of chest pain, worsening hemodynamics and respiratory status= , EKG changes) .
- 40 mg IV lasix now 
- ASA 325 m= g, then 81 daily
- High dose statin
- Hold or decrease = beta-blocker given decompensation at this time / Continue beta blocker give= n no signs of decreased perfusion (bisoprolol 10 mg daily, coreg 25 mg BID = (50 mg BID if >85kg), metop succinate 200 mg qdaily) / uptitrate beta bl= ocker over the next weeks for goal HR of 60. 
- Hold p2Y12 f= or concern for possible multivessel and need for urgent bypass if needed
- f/u ECHO
- f/u TSH
- Lipid panel
- = Iron studies -- screen for iron df independent of Hb with repletion with IV= iron if Tsat<20% improves functional status (JACC 2008;14:103)
- HIV 
- SPEP w/ FLC  
- Avoid CCB&nbs= p;
- Salt restriction, fluid restriction 
- Daily = weights
- Strict I/O
- If EF <40% = evaluate for valsartan-sacubitril initiating in outpatient setting once all= owed washout period of 36 hours, and check with Pharm/CM for prior authoriz= ation 
- If EF< 35% add on spironolactone / eplerenone on= ce doses of ACEI and Beta blocker uptitrated to maximal levels, and Cr <= 2.5, K < 5.0
- If EF<35% -- consider ivabradine if HR >= 70/min despite maximally tolerated dose of beta blocker therapy
= - ICD indication -- iCM with EF<35% and 40 days s/p MI and NYHA Class II= /III 
- CRT indication -- LVEF<35%, QRS > 150 ms, LBBB= , and sinus rhythm. .  
- For African American (NYHA II= I/IV) -- add on isosorbide dinitrate hydralazine to other goal-directed med= ical therapy to reduce mortality. 


=

3D"Articleacute pancreatitis
3xULN

BISAP Score for Pancreatitis Mortality

- cause: 1) alcohol, 2) = gallstone, 3) hypertriglyceridemia, vasculitis, cholesterol emboli, hypovoe= lmic shock, idiopathic, tumor, mumps virus, TB, toxo, autoimmune, scorpion = sting, drugs (lasix, thiazide, valproate, estrogen), high calcium
- 20cc= /kg IV bolus in 30 minutes then 3cc/kg/h NS or LR if dehydrated; else 5-10c= c/kg/hr.
- then switch to 1.5cc/kg (water fall trial) - 3cc/kg not bette= r - so 150cc/hr
- get CT with contrast if concern for nec pancreatitis
if triclyeride caused
- need insulin drip if triglyceride > 100= 0 (ICU), then start fenofibrate when <1000  (Dr. Cheng shares can s= tart right away). stop insulin gtt when <500
- D5LR 125cc/hr if gluco= se < 200, D10 if glucose < 140


- if any lesions, CT AP in = 3 months to reassess lesions and resolution of pancreatitis

complica= tions: most common is pancreatic pseudocyst (no matter the size, no drainag= e needed unless infected or symptoms)
- complication to watch out for: p= ancreatic necrosis:fever, leukocytosis. Need CT abd with con imaging and su= rgical eval if positive

- IF young adult with chronic pancreatitis, = do sweat chloride testing to rule out cystic fibrosis
- Chronic pancreat= itis: see calcium on CT pancreas protocol.

autoimmune pancreatitis- sausage shape pancrease with parenchymal swelling or narrowed pancreati= c duct  (can mimic pancreatic cancer)
- Dx: test IgG4 level higher.=
- Tx: responds to steroid


- even if lipase normal, if possib= le panreatitis, contrast enhanced CT or MRI- lipase, lipid
- urine drug screen
- CT abd (= with contrast ideally)
- morphine
- Zofran PRN
- GI ppx: protonix = 40 IV BID
- diet: low residue, low fat, soft diet or clear liquid
#Acute pancreatitis:  Patient with typical epigastric abdominal = pain radiating to the back, elevated lipase of {}, and typical abd CT findi= ngs. Most likely due to {alcoholic pancreatitis due to significant alcohol = history, gallstone pancreatitis}, although cannot exclude {alcoholic, galls= tones}, or elevated triglycerides causing pancreatitis. No signs of cholang= itis currently -- including fever, RUQ pain, jaundice, altered mental statu= s, or shock. ALT>3X ULN best predictor of gallstone pancreatitis with &g= t;95% PPV. 


Classification:&nb= sp;
1. Mild acute pancreat= itis, which is characterized by the absence of organ failure and local or s= ystemic complications

2. Moderately severe acute p= ancreatitis, which is characterized by no organ failure or transient organ = failure (<48 hours) and/or local complications

= 3. Severe acute pancreatitis, which is characterized by persistent organ fa= ilure (>48 hours) that may involve one or multiple organs

=
4. Necrotizing acute pancreatitis-  which is characterized = by inflammation associated with pancreatic parenchymal necrosis and/or peri= pancreatic necrosis.


- Consider: bi= liary stricture, Sjogrens, thyroiditis, IBD, nephritis, consider IGG4 and A= NA E -- defer for now given CT shows no typical findings of autoimmune panc= reatitis (classic appearance of the pancreas on abdominal CT in patients wi= th diffuse pancreatic involvement is sausage-shaped enlargement with homoge= neous attenuation, moderate enhancement, and the peripheral rim of a hypoat= tenuation =E2=80=9Chalo=E2=80=9D. In long-standing autoimmune pancreatitisi= nvolution of the pancreatic tail is almost always evident. Focal pancreatic= involvement is encountered more often in the head of the pancreas and typi= cally appears as a low-attenuation or an isoattenuation mass)
-GI= for EUS vs ERCP
- In patients with unexplained pancreatitis who = are at risk for underlying malignancy (age older than 40) and or worrisome = clinical features including weight loss and new onset of diabetes, CT with = pancreas protocol or magnetic resonance imaging (MRI) with magnetic resonan= ce cholangiopancreatography (MRCP) should be obtained.
-Gemfibroz= il 600 BID if hypertriglyceridemia 
- NPO until patient with= out abdominal pain, then start with low residue, low fat, soft diet, if una= ble to eat in 2 days consider NG or NJ tube placement for enteral feeding
Enteral nutrition is recommended in patients with moderately sev= ere and severe acute pancreatitis who cannot tolerate oral feeding within 3= days. Consult nutrition service
- CBC, BMP, LFTs, albumin= , lipids, lactate.
- Bolus with LR 20 mL/kg of intravenous fluid = given over 30 minutes then LR at rate of 250 cc/hr x 48 hours {unless hyper= calcemic then use NS}
- Pain control with Dilaudid prn
= - Nausea control with Zofran prn
- RUQ US to assess for gallstone= s
- CBC/BMP Q8h to trend HCT and BUN, daily LFTs
- Cont= inuous pulse ox monitoring and supplemental oxygenation as needed
{- No need for abdominal CT at this time as pain is typical and lipase is = elevated 3x normal}
- Fasting lipid panel in AM to assess for hyp= etriglyceridemia {only if other sources not found}
- Strict I's/O= 's, if UOP <100cc/hr, additional fluid boluses as necessary
{-= If uncomplicated gallstone pancreatitis}Cholecystectomy prior to discharge= given gallstone pancreatitis
{- If gallstones complicated by asc= ending cholangitis} ERCP within 24 hours to presentation given findings of = acute cholangitis
{- If uncomplicated gallstone pancreatitis is t= he cause and not improving with worsening LFTs} GI consult for ERCP given g= allstone pancereatitis that is not improving and worsening LFTs
-= Antibiotics of {} given {}  {only if cholangitis, cholecystitis, or o= ther intra-abdominal infections are present} -- CTX + flagyl or zosyn
=
- ESR, CRP 
Afib / aflutter
- causes: recent surgery = stress, infection, MI, thyrtoxicosis, alcohol alcohol, PE, OSA, COPD, pneum= onia, CAD, abnormal heart valve (mitral regurg / rheumatic heart),stimulant= , caffeine, tobacco, electrolytes
- score: CHA= =E2=82=82DS=E2=82=82-VASc Score for Atrial Fibrillation Stroke Risk - MDCal= c (2+ for male, 3+ for female start anticoag, but some say 1+),&nb= sp;HAS-BLED Score for Major Bleeding Risk - MDCalc (3 =3D high= risk for bleed; does not cover for falls)
- paroxysmal: <=3D7 days, = persistent > 7 days, long-standing persistent >12 m, permanent =3D no= intervention

- metop careful in acute HF
  - metop IV 5mg q= 10m PRN (max 3x, onset 5min), followed by PO 25mg q6h after HR <110, upt= itrate q6h by 12.5mg (can start 50mg BID if needed 10mg+), onset 4hr  =  (at the same time  now too)
- dilt IV slightly more effective= rate control, shorter onset, and lower HR, but lower SBP (meta-analysis); = do not give in (systolic) HF
  - dilt IV 0.25mg/kg i.e. 10mg-25mg&n= bsp;q10m PRN (x2, onset 2 min), then infusion 5mg/hr, up titrate 2.5mg q30m= in to max 15mg/hr.
- Add digoxin if dilt or BB doesn't work. no digoxin = if AMI, myocarditis, WPW, low Mg, low K, heart block. 
  - dig= oxin SE: nausea, confusion/hallucination, blurred vision

- if SBP 80= s, then
  a) amio 150mg IV over 10 minute, (repeat x1 ok, gtt 1 hr= )
  b) digoxin 0.5mg IV, follosed by 0.25mg IV q6h x2 (can do dig 1= .5mg total, i.e. 500mcg x3)

- if not stable (cool extre, altered, an= gina, pulm edema), sync cardioversion 150J (Afib needs 150J, Aflutter can w= ork with 50J) and increase if needed. Need anticoag at least 4 weeks after.= If need pressor, phenylephrine
Versed (midazolam) 2mg (+/-fent 50mcg)- warfarin if mitral stenosis, HOCM, or mechanical valve, rheumatic, else= can DOAC (Eliquis is BID)
- BB PO better than CCB at rate control
- goal on metop uptitrate <80 at rest and <100 when walking
Chad= vasc for nonvalvular afib only.  2+ start anticoag (okay to start 1+ i= n men)  vavular =3D mod+ mitral stenosis, mechanical mitral valve: all= need warfarin (doac inferior)

- amio risk of stroke, works only whe= n up to 5g to 10g 

- the only reason no need for DOAC for Afib = is  if it's after CABG; do a Ziopatch and assess


Aflutter:<= br>- atrial rate 250-300 in 2:1 block, ventricular rate of 150

- if = starting amiodarone and on warfarin, decrease warfarin by 25% CYP2C9)
- do not give amio and dig one after another quickly as causes 3rd degree= av block (CYP2C9)
- amiodarone (what it dissolves in to infuse can caus= e hypotension, but amio itself does not cause hypotension)


= Patient should be monitored for amiodarone toxicity including the following: Annual EKG , TFT/LFT  yearly), C= XR/PFT at baseline and then Q1Y , 
, yealy opthal exa= m , dermatological exam PRN


- Apica= l variant of hypertrophic cardiomyopathy -- cannot use CHADSVAsc score (nee= d to anticoagulatn)
# new onset Afib with RVR, likely 2/2 ***
CHADSVASc: ***, HAS-BLED:= ***
- EKG
- CBC, CMP, TSH, Free T4, BNP
- CXR
- TTE
- INR

#New onset atrial fibrillation
CHADSVASC *** likel= y precipitated by surgery, infection, MI, thyrotoxicosis, acute alcohol, PE=  

First diagnosed // paroxysmal (within 7 day= s) // persistent (> 7 days), long-standing persistent (>12 months) //= permanent -- (stop further attempts to restore sinus rhythm) 

- Outpatient study for OSA -- STOP BANG *** 
- EKG 
- Formal ECHO 
- CXR 
- CBC, CMP, TFT, BNP 
- IV metoprolol 5 mg over 2 minutes,= repeat as needed q5 minutes x3
- PO metoprolol -- caution in dec= ompensated HF or severe bronchospasm 
- Consider diltiazem 0= .25 mg/kg bolus over 2 minutes -- usually 10-20 mg 
- PO dil= tiazem -- avoid in heart failure -- contraindicated in LV failure with pulm= onary congestion, LVEF <40%  

Peri-st= able SBP
- Digoxin load 0.5 mg IV followed by 0.25 mg x 2 for loa= ding -- caution in renal impairment or accessory pathways  -- long ter= m digoxin independenetly associated with increased mortality in AF patients= . 
- Amiodarone 300 mg IV over 1 hour followed by gtt -- con= sider risk of pharmacologic cardioversion
- If pressors needed-co= nsider phenylephrine given reflex bradycardia


=
Cardioversion
- > 48 hours 2-5% risk of stroke ->= ; TEE to r/o thrombus or ensure anticoagulation > 3 weeks

=

- Long term anticoagulation -- Apixaban 5 mg BID = (2.5 mg if Cr > 1.5 AND age > 80 or wt < 60 ) 

=
Bridge with heparin or LMWH for CHADS Score >5 


#first diagnosed atrial fibrillation: = CHADSVASC *** likely precipitated by surgery, infection, MI, thyrotoxicosis= , acute alcohol, PE 

First diagnosed // parox= ysmal (within 7 days // persistent afib > 7 days, longstanding persisten= t afib >12 months // permanent -- stop further attempts to restore =

- Outpatient study for OSA -- STOP BANG *** =
- EKG 
- Formal ECHO 
- cxr <= /div>
- cbc, cmp, tftS,bnp 
- IV metoprolol 20.5 - 10 mg= over 2 minutes, repeat as needced q 1-0-15 minutes 
- PO me= toprolol -- caution in decompensated HF or severe bronchospasm 
<= div>- Consider diltiazem 0.25 mg/kg bolus over 2 minutes -- usually 10-25 m= g 
- PO diltiazem -- avoid in heart failure -- contraindicat= ed in LV failure with pulmonary congestion, LVEF <40%  
<= div>
Peri-stable SBP
- Digoxin load 0.5 mg IVfollow= ed by 0.25 mg x 2 for loading -- caution in renal impairment or accessory p= athways  -- long term digoxin independenetly associated with increased= mortality in AF patients. 
- Amiodarone 150 IV over 10 minu= tes followed by gtt -- consider risk of pharmacologic cardioversion
- If pressors needed- consdier phenylephrine given reflex bradycardia&nb= sp;

- Long term anticoagulation -- 5 mg BID (2.5 m= g if Cr > 1.5 AND age > 80 or wt < 60 ) 

=
Bridge with heparin or LMWH for CHADS Score >5 


AKI / CKD
- urine <50cc/hr for 6 hours,= 0.3+ increase in 48 hours, 1.5x Cr in 1 week
- GFR <20, no lovenox- cause: 
- HUS, TTP, DIC concern
- urine eosinophil if concer= ned for AIN 
- cause: kidney perfusion, glomerulonephritis, vasculi= tis, interstitial nephritis, thrombotic microangiopathy 
- CK if rh= abdo
- BUN/Cr > 20 in prerenal
- monitor complications: cephalopat= hy, chest pain, fluid overload, pulmonary edema, HTN, platelet dysfunction<= br>- Stages: 1 =3D 90+
  2 =3D 60+
  3A =3D 45+
&nb= sp; 3B =3D 30+
  4 =3D 15+

ESRD on dialysis with little urin= e - don't have to care about kidney, just do lasix 80 BID
- Obtain = PTH, Vit D level
- Target Phos 3.5 - 5.5 mg/dL, low phos in ESRD = is a poor prognostic marker

ESRD
- = Nephrovite and renal diet please, goal target protein intake of 1.2 g/kg/da= y for dialysis patient 
- avoid PICC lines/limit access, ren= al panel and phos daily, daily weight please every am, Strict I/O, renal do= sing of all medications and antibiotics to current eGFR
-Titrate home meds, avoid hypotension, goal sbp>100, MAP>65

# Medication consideration for ESRD
= - Avoid sucralfate 2/2 aluminum toxicity 
- Baclofen contrai= ndicated
- If MRI indicated, may proceed with MRI scan using grou= p 2 gadolinium agent (note that while currently no reported literature case= s of nephrogenic systemic fibrosis (NSF) from group 2 gadolinium agents, pt= should still be made aware of potential risks of developing NSF)
- Renally dose all medications with pharmacy
- Avoid morphine, n= orco, preferred opioids include hydromorphone


If fluid overload, lasix, then add metolazone 5mg tablet QD
= - diuril first before bumex/lasix to help increase diureses

if unequ= ivocal, then - serum uric acid: if uric acid < 4, then SIADH
bactrim = causes fake AKI (history lab measurement, but now doesn't --- if unsure, ca= n just check cystatin c) and can cause true AKI

To see chronic CKD, = can also test for PTH


starting dialysis - hepb, hep c, quantifer= on- Urine Urea, Na, = Cr
- UA for cast, protein, sediment
- CMP
- urine U/S r/o obstruct= ive
- strict I/O
- d/c nephrotocxic meds (ACEI/ARB, metformin, NSAID)=
- avoid nephrotoxic meds
- monitor complications, K, hypoNa, hyperPh= os, hyperMg



- Nephrovite and renal diet please, goal ta= rget protein intake of 1.2 g/kg/day for dialysis patient or lowering protei= n intake to 0.8 g/kg/day in adults with diabetes or without diabetes  = and GFR <30 ml/min/ 1.73 m2
- avoid PICC lines/limit access, r= enal panel and phos daily, daily weight please every am, Strict I/O, renal = dosing of all medications and antibiotics to current eGFR
 <= /div>
# Anemia
- target hgb 9-11 for ESRD, 10-12 for CKD, tra= nsfuse hgb <7
- Consider ESA if hgb is less than target hemogl= obin and no contraindications such as malignancy, uncontrolled hypertension= , or a history of stroke. No ESA if hgb > 11 g/dL.
- If TSAT &= lt; 30% and and ferritin is =E2=89=A4500 ng/mL, may consider IV iron sucros= e 100 mg administered during consecutive dialysis sessions for a total of 1= 0 
sessions (1g). For CKD patients 200 mg administered on 5 = different occasions within a 14-day period. Avoid IV iron if active infecti= on.
 
# MBD
- Obtain PTH, Vit D level
- Phosphate binders as indicated
- Target Phos 3.5 - 5.5 = mg/dL, low phos in ESRD is a poor prognostic marker.
 
=
# Metabolic acidosis
- Can start NaBicarb tabs for CO2 < = 22 in CKD
- No need for Nabicarb PO in patients with ESRD on HD&n= bsp;
 
# HTN/Volume
-Titrate home meds, = avoid hypotension, goal sbp>100, MAP>65
 
# = Medication consideration for ESRD
- Avoid sucralfate 2/2 aluminum= toxicity 
- Baclofen contraindicated
- If MRI ind= icated, may proceed with MRI scan using group 2 gadolinium agent (note that= while currently no reported literature cases of nephrogenic systemic fibro= sis (NSF) from group 2 gadolinium agents, pt should still be made aware of = potential risks of developing NSF)
- Renally dose all medications= with pharmacy
- Avoid morphine, norco, preferred opioids include= hydromorphone


- Avoid large BP flu= ctuations, goal SBP 120-140, avoiding nephrotoxic medications (eg contrast,=   ACEI/ARBs), renally dosing medications
- Strict I&= Os. Daily weights. Avoid PICC lines. Renally dose meds.



#CKD: GFR of *** (Stage G1>90, G2 60-90, G3A 45-60, G3b 30-45= , G4 15-30, G5 <15) 
Albuminuria stage A1 =3D mild 30 mg/= d; A2 moderate 30- 300 mg/d; A3 severe > 300 mg/d 
UA wit= h positive protein -- check U prot: Cr to quantify because UA just checks a= lbuymin 
Etiology of DM (44%), HTN/ nephrosclerosis (29%), c= ystic kidney disease (20%) 
- If proteinuria -- goal is <= 500-10000 mg / d with RAAS blockade (ACE or ARB)
- BP control: go= al BP 130/80 ,f proteinuria, or SBP <120 if GFR 20-60 by MDRD 
- If proteinuria with ACEI, then non dihydropyridiine CCB; 
- If edema >> loop diuretic 
- CVD risk reductio= n >> aspirin statin exercise smoking cessation 
- Avoi= d nephrotoxins (bactrim, NSAIDS, lithium, acyclovir, contrast) 
<= div>- Renally dose medications 
- Nephrocaps; Na< 2gm/d, = fluid L <2L/day, k phos restriction,protein 0.6-0.8 gm/kg/d only if GFR = < 60 and nephrotic syndrome is not present 
- U alb: Cr a= nd U prote: Cr, PTH, 25 vit D , CBC, FE studies 
- Check ren= al US 
- Urine/microalbumin: Cr ratio (mcg/mg =3D mg albumin= / day assuming 24 hr urine excretion) 
- Nephrology referral= if GFR<30, severe albuminuria, glomerular hematuria, resistant HTN, met= abolic complications (hyperparathyroidism, anemia, acidosis, hyperkalemia, = hyperphosphatemia), unclear etiology of hereditary
- Check ca, PO= 4, 25 OH vita D (not 1,25 as level will fluctuate) 
- Anemia= goal 10-11.5 -- iron repletion for goal transferrin sat >20%, hold if f= erritin >500-800
- Nephrology consult to consider Ea (contrain= dicated in cancer, HTN, HF) 
- Metabolic acidosis: NaHCO3 65= 0-1300 mg BID  For goal bicarb >22 shown to slow progression of CKD=
- Prep for HD access-- avoid BP measurement and venipuncture in = nondominant arm, avoid subclavian / PICC lines 


Pre-Renal

  1. Fluid challenge and = monitoring sCr over 24-48 hours
    • Dx: urine lytes (urine sodium, urine creatinine, urine o= smolality, urine potassium), drawn prior to fluids if possible
    • Tx= : Bolus until intravascular euvolemia. Consider lactated ringer=E2=80=99s, = sodium bicarbonate (150 mEq solution) if acidotic/NAGMA, or normal saline b= olus if hypo-chloremic and hypovolemic
      • Data for fluids subjective, although, consider bo= lus with mIVF if NPO or losing volume vs. boluses, then continue oral intak= e supplementation.
  2. GFR should improve with vo= lume resuscitation
      =
    • By definition, pre-renal volume depletion should improve with fluids.=
  3. Pre-renal vs. hypo-perfusion
    • Cardiorenal: urine sodium may be below= 20, or low, and suggest decreased perfusion, however, does not indicate ne= ed for fluid administration, rather diuresis based on volume status and car= diac function
      • Dx: Volume status questions: BNP, peripheral edema, pulmonary vascular con= gestion, JVD
    • Hypotension: patient may be volume deplete= d and hypotensive, leading to poor renal perfusion, however, if patient is = euvolemic after fluids have been administered, and patient continues to be = hypotensive, go through the algorithm of shock, consider cardiogenic, distr= ibutive, hemorrhagic, continued volume loss, and consider need for vasopres= sor support for adequate MAP for renal perfusion.

Intrinsic

  1. Clinical feature: most common likely cause o= f intrinsic renal injury, in hospitalized patients, is likely acute tubular= necrosis (ATN). Renal recovery will behave with a pattern of rising Cr, de= creasing UOP, until eventually plateauing, followed by possible normal rena= l UOP vs post ATN diuresis. Once Cr is stabilized, UOP stabilized, often pa= tients may return to baseline Cr, slow progression to a new stage of CKD, o= r unclear.
  2. Dx: urine studies as above work up, with urinalysis de= monstrating brown muddy casts.
    • Most common cause of ATN: pigment induced, ethylene glyco= l calcium oxalate, carbon tetrachloride, indinavir, lead, mercury, tenofovi= r, vancomycin, ischemia (early vs late), decreased renal perfusion (hypoten= sion, cardiorenal, cirrhosis, sepsis with vasodilation), DIC.
  3. DDx in this category often quite wider, and involves bucket for a mu= ch larger set of disease, involving, glomerulus, tubules, and interstitial = of the nephron.
      Glomerulonephritis
    • Acute Interstitial Nephritis
    • Dx:= if concerned for alternative diagnosis, consider serologic evaluation for = nephrotic syndrome: ANA, ANCA, MPO, anti DS-DNA, C3, C4, CH50, PLA2-R, HIV,= RPR, hepatitis panel (B,C), evaluation for drugs such as methamphetamine, = consideration for active disseminated infection leading to infectious glome= rulonephritis
  4. Tx:
    • diuretic use (loop diuretics for daily net even or= net negative depending on volume status)
    • potassium binders for w= orsening hyperkalemia
    • acidosis management depending on ventilatio= n dependence or oliguria/anuria
    • fluid management depending on rec= overy phase post ATN diuresis
    • Dialysis as below.
  5. Post-= Renal

    1. Dx: bladder scan, post void residu= al, and renal ultrasound
    2. Tx: Placement of foley or relief of obst= ruction, with rapid improvement in sCr, hyperkalemia, azotemia
      • consider post foley monit= oring for resolution of concomitant hydro-nephrosis, if not resolving, may = require percutaneous interventions with urology or interventional radiology=
        • Percutaneous= nephrostomy tube indications: obstructed kidneys with urosepsis, infection, or renal insuffi= ciency; non-obstructed&= nbsp;including urinary diversion for ureteral injury, fistula, cystitis&nbs= p;OR access= for intervention on tumors or stones


alcohol hepatitis
- alcohol use at least 2 months, = recent jaundice, AST/ALT >2 (AST < 500),  INR >2, Bili > 3=
- score: Maddrey's Discriminant Function for Al= coholic Hepatitis - MDCalc for whether steroid or not

ITP (= immune)

- if plt <30k, give steroid dexamethsaone 40mg x4 days- if critical bleeding (to important anatomical space), platelet transfuse= + IVIG + steroid
- if severe bleeding, then IVIG or steroid

Alcohol withdrawal<= br>- DDx: metabolic, drug overdose, GI bleed, CNS infection, liver failure<= br>- if does not work with benzo, need ICU and benzo drip / phenobarb / pro= pofol    (also seen versed/fent or precedex drip; everything exce= pt precedex drip needs intubation)
- if hx of withdrawal seizure or deli= rium tremens, prophylactic treat chlordiazepoxide 25-100 mg q6h x 24hrs, th= en 25-50 mg q6h x 2days
- CIWA <10 no meds needed; 9+ =3D mild, 16+ = =3D mod, >20 =3D severe
- VA: ativan 2mg PO q4h for CIWA > 10
<= br>- check vitamin K (lost in 7-10 days if pancreatic insufficiency/liver d= isease and ill / pancreatic insufficiency)
- Phosphatidylethanol to= test  if drank last month

- thiamine 100mg IV (better than PO)= , 1mg folate daily, hypoK common.

Wernicke
- Sx: horizontal nysta= gmus, gait ataxia - from thiamine deficiency
- Tx: IV thiamine (500mg IV= q8h), then glucose

- PETH lab if not sure if patient drank

-= naltrexone not in liver disease or hepatitis or having opioids
- acampr= osate not in kidney disease
- else disulfiram =3D but causes vomiting/he= adache/flushing if drinks
!!! give thiamine before glucose

deliri= um tremens =3D hallucination, delirium, agitation fever, palpitations HTN

phenobarb - lasts 4 days (no benzo or porphrea) --  5mg/kg up to 20mg/kg, can redose every 30 minutes  (can double if not= working)

phenobarb - 10mg/kg (max of 900mg divided over 3 hour spli= t)


- if alcohol hepatitis, can do solumedrol 32mg daily (need GI= consult first) - steroid can cause confusion


- withdrawal on di= scharge (4-8): gabapentin taper (benzo sparing)

- gabapentin taper f= or 

- clonidine for HTN in alcohol withdrawal; 

- CIWA
- CBC, CMP, u= rine drug screen, UA with reflex
- IVF
- banana bag(Thiamine, folate,= multivitamin; thiamine first, then glucose)
- hold beta blocker due to = masking symptoms
- K, Mg, Phos, Glu
- fall, aspiration, seizure preca= ution
- NPO until AM to avoid aspiration


MInor withdrawa= l 6 - 48 hours, alcoholic hallucinosis 24 h - 6d, withdrawal seizure 6-48 h= , DTs 48 - 5d 

- CMP, CBC, serum osm if HCO3&= lt;15 or AG 
- CPK 
- Utox 
K,= Mag, Ca, PHos, Vitamin D 

- IV thiamine = ;
-D5NS after thiamine to fix ketoacidosis 
- REpl= ete lytes 
- Folate 1mg daily 
- MVI 

- Use phenobarb if hx of DTs, seizures, BZD resistan= ce, success w/ phenobarb, or prior ICU admissions , current symptoms of DTs= , not responding to BZDS, >30 mg ativan equivalents , leaving AMA
<= div>
- PO ativan > IV ativan >> Valium and librium (= cleared by liver, ong half life, delayed toxicity) 
- CIWA s= cale 
- Consider switching to phenobarb if CIWA consistently= > 16 

-  Gabapentin 100 mg qHS
= alpha-1 antitrypsin
- tests: serum AAT (if <11mmol/L/<57mg/dL= and FEV1 <80%) can provide pooled human AAT augmentation to decrrease e= mphysema progression= ALS 
- vital capcity can assess capacity
(NIF, PFT possible = too)amenorrhea- labs: T4, FSH and prolactinamyloidosis
- Sx: neuropathy, proteinuria, restrictive he= art (low volta ECG), periorbital echymosis (panda eyes)
- CMR (cardiac M= RI) imaging positive supports amyloidosis
- positive technetium pyrophos= phate scan =3D hereditary transthyretin amyloidosis
- abdominal fat pat = aspiration positive =3D AL amyloidosis
- Tx: beta blocker, diuretics if = edemaanal fissur= e 
- Tx: sitz bath, psyllium; lidocaine topical
- if chronic (&g= t;8 weeks)with rectal spasm
- Tx: topical diltiazem/nifedpineanaphylaxis
- does not ne= ed SOB, hypotension qualifies (criteria: skin involvement + hypotension/res= piratory distress)anemia
- causes:
  - MCV < 80: iron deficiency, chronic in= flammation, thalassemia and hemoglobinopathy, copper deficiency (rare), lea= d toxicity zinc toxicity, sideroblastic anemia (lead, alcohol, drugs). = ;
  - MCV 80-100: acute, malignancy, bone marrow invasion or suppre= ssion, or primary disorder, cancer, CKD (low EPO), hemolysis, endocrine iss= ue (hyothyroidism, adrenal insufficiency)
  - MCV >100: alcohol,= folate, vitamin B12, GI resection, vegan, liver disease, antiretroviral- if vita B12 low, need methylmalonic acid and homocysteine lab (if true B= 12 deficiency, both are increased.  In folate deficiency, only increas= ed homocysteine).
- folate >4ng/ml =3D no deficiency. < 2ng/ml =3D= folate deficiency

- acute anemia: can also look at Calcium dropping= to determine dilutional vs 
- iron sat <19% AND MCV low if ferr= itin is high, then mixed picture.  If MCV normal, then only anemia of = chronic disease


for old people, iron deficiency anemia cancer un= less proven otherwise

- B12 deficiency: hypersegmented neutrophil,&n= bsp;
(will get higher LDH, indrect bili and AST =3D ineffective erythrop= oesis)

- zinc blocks copper absoprtion (i.e. good for wilson disease= )


iron deficiency:
- transferrin sat < 20%
  &nbs= p;- ferritin < 30 ug/L
   - ferritin 30-100 need serum tran= sferrin receptor/log ferritin >2
   - ferritin > 100 rul= es out (=3D anemia of chronic disease)


for pregnant patients, us= e sucrose, NOT gluconate
There is a risk = of adverse maternal reactions (eg, anaphylaxis, hypotension, shock) followi= ng use of parenteral iron, which may result in fetal bradycardia, especiall= y during the second and third trimesters. An immediate hypersensitivity rea= ction has been reported in a pregnant patient (Cuciti 2005). Although the r= isk is rare, immediate treatment for anaphylactoid and/or hypersensitivity = reactions should be available (BSH [Pavord 2020]).

- reticulocyte count- peripheral blood smear
- TSH, free T4
- occult blood
- iron stu= dies if increased RDW
- B12, folate if increased RDW
- LDH (high),= haptoglobin (low - binds free Hgb), T bili (for indirect bili) if hemo= lysis
- Hgb electrophoresis if thalassemia/hemoglobinopathy
- abdomin= al U/S if spleen
- ESR, CRP if inflammation
- bone marrow biopsy if p= ancytopenia or abnormal cells peripheral blood

#acute on chroni= c anemia: 
- Ganzoni Equation shows IV iron of ***
- f/u B12, folate, iron panel, ferritin 
- CBC q 4 hours&nb= sp;
- IV pantoprazole 
- Pediatric tubing for all = blood draws 
animal bite
- augmentin most common
- ceftr= iaxone+flagyl (+vanc until MRSA negative)
- Need TDAP if <5 yearsankle
- test: ta= lar tilt test

high ankle sprain
- squeeze the calf =3D pain at hi= gh ankle
- Tx: ice for 20 minutes q2h, elevation, crutches/rest, elastic= wrapping to reduce swelling, and splint wotj ;eg brace to prevent ankle mo= vement, referral to ortho

- achielles rpture
- no plantar flexion= when calf squeezed

anklylosing spondylitis 
- Sx: female < 45 yr old, mor= ning stiffness >30m, improvement with exercise, uveitis,
- Dx = of inflammatory sacroilitis: pelvic MRI for erosions or inflammatory at sac= roiliac joints

RA
- Dx: RF and anti-CCPanovulatory uterine bleeding
- irregul= ar heavy bleeding within 2 years after menopause without nausea or cramping=
- Tx: observation only - normal= anthrax
- Sx: flu-like syndrome then sepsis
- Dx: b= loody pleural effusion on CT/CXR and widening of mediastinumantiphospholipid antibody syndr= ome
- Sx: Angulated retiform purpura (sudden skin necrosis with jagged e= dges), pregnancy loss
- lupus anticoagulant, anticardiolipin Ab, anti be= ta-2 glycoprotein ab, measured 2x 12 weeks apart
- Tx: need warfarinaortic aneurysm (AA= ) (Thoracic or abdominal)
- risk factors: smoking, male, age, HLD, HTN, = obesity
- surgery M >5.5cm or >0.5cm/6months growth; female: >4= .5cm
- statin, BB, aspirin

- surveillenace: thoracic: if 3.5-4.4,= every year, more is 6 months
abdominal: <4cm is every 2 years; > = 4cm is at least every year

thoracic aortic aneurysm
- BP <140/= 90
- Tx: BB, ARB, statin
aortic dissection
- type A =3D surgical emergency, type B= =3D medical manage
- keep SBP < 120, HR < 60; IV labetalol. may n= eed nitroprusside (need betablocker with it else reflex tachy =3D worse) / = cardene drip
- !!! do not use hydralazine - increases shear stress
- = if d-dimer low (<0.5ug/ml), rules out aortic dissection
- Dx: CTA- D-dimer, trop
- CT = (higher sensitivity and specific than U/S)
- IV labetalolaortic disse= ction
BP < 120 with esmolol and labetalolaortic stenosis
- 50% mortality in 3 year= s if angina, 3 years if syncope, 2 years if HF/SOB
- aortic valve area &= lt;1cm and ( if mean AV gradient>40 OR ao peak velocity >4 =3D high f= low)  then classic (classic high flow high gradient) 
- o= nly pseudo severe should not get tavr. (Dobumatine stress increases ef to o= ver 50%)

- Heyde syndrome =3D angiodysplasia causing lower GI bleed<= /td>appetite stimula= nt
- progesterone, dronabinol, mirtazepine (may be preferred), megaceARDS
- Berlin cr= iteria: within 1 week of ARDS insut, bilateral opacities (pulmonary edema),= respiratory failure not due to HF, PaO2/FiO2 <300 when on PEEP 5+
- = mild: PaO2/FiO2 200-300, mod: 100-200, severe: <100
- Tx: 4-6cc/kg IB= W, pleateau (end inspiratory pressure) < 30, even if some acidosis and h= ypercapnia
- steroid NOT indicated in ARDS


O2 =3D FiO2 and PE= EP; pCO2 =3D RR and TV
ARDS: Mild (P:F ratio 200-300) Moderate (P:F ratio 100-200) Severe (= P:F ratio <100) 
 
ACVC 
- = Goal tidal volume of 6 cc/kg predicted body weight 
- Goal r= ate 14-18 
- FIO2 of 100% then reduce to 60% if SpO2 > 88= % 
- PEEP of 10 given bilateral opacification of lungs on Xr= ay 
- Goal SPO2 88-94% (PaO2 of 55-70)
- Pplateau = <30 --if above goal, reduce TV  
- Ppeak < 45&nbs= p;

Pressure controlled 
- PEEP 5-10= depending on degree of hypoxemia 
- FIO2 of 100% then reduc= e to 60% if SpO2 > 88% 
- Driving pressure (or inspirator= y pressure -- Pplateau - PEEP) of <15 cm H2O 
- Rate of 1= 4-18 breaths per minute 
- Inspiratory time to keep I:E rati= o 1:1.5 or higher 
- pH of 7.15 /  7.25 or greater is a= cceptable given high risk of overextension 

C= ompliance =3D Tidal Volume / Pplat-PEEP 

6 P'= s of REfractory Hypoxemia :
Pee: consider diuresis 
PEPP: Optimize PEEP 
Paralysis: early paralysis within 48 = hrs of ARDS onset 
Pulmonary vasodilators -- iNO trial to se= e if inhaled epoprostenol would be beneficial 
Prone
Perfusion (ECMO) -- severe refractory hypoxemia if ventilated <7 days=  




= aspergillus
- 45 degree branchingasthma exacerbation
- levalbuterol (Xopenex) to prev= ent tachy
- can also consider duoneb if severe exacerbation; can stack d= uoneb 3 time/hour if needed.
- can consider prednisone 40mg (methylpred = 32mg IV) daily for 5-7 days (better outcomes)
- IV MgSO4 2g if not re= sponding to intiial therapy

-if to ICU, need methylpred 125mg IB= q6h

outpt
- test: methacholine bronchial challenge - use only if= symptoms asthma but PFT normal (if FEV1 fall by 20%  from baseline, t= hen positive)
FeNO (fractional exhaled nitric oxide) >50 ppb =3D eosi= nophilic airway and will respond to inhaled glucocorticoid; < 25 =3D unl= ikely to be eosinophilic airway and inhaled steroid won't work

DLCO = higher =3D condition that increase capillary blood volume (pulmonary alveol= ar hemorrhage, L to R shunt, asthma)
DLCO low when alveolar units destro= yed
COPD =3D low DLCO. asthma - normal DLCO

asthma - now symbicor= t PRN not albuterol.  And step up symbicort. SMART therapy/


COPD/asthma =3D FEV1/FVC < 0.7
- (>12% in FEV1 or FVC) and 20= 0cc increase in baseline with bronchodilator =3D reversible airway obstruct= ion
both FEV1 and FVC decrease =3D restrictive lung disease
- normal = DLCO or high =3D asthma.  low DLCO =3D COPD


heliox if patie= nt crumbs (helium oxygen)- SpO2 goal >92%
- albuterol neb 2.5mg/3ml q20m x3 dose then q2h= PRN
- avoid beta blocker

#asthma exacerbation: per patient = report has symptoms (cough, wheezing, chest tightness, SOB) that have a diu= rnal variation. 20** FEV1 documented as *** and shows variable expiratory a= irflow limitation (by increase of 12% in FEV1 or 200 mL or diurnal PEF vari= ability >10%). Patient's symptoms are not well controlled -- exhibits da= ytime symptoms >2x weekly and noctural symptoms >2x monthly in the la= st 4 weeks. 
- Chronic cough as primary symptom concerning f= or coexisting GERD or UACS secondary to rhinitis 
- Outpatie= nt eval for OSA as treatment of such improves outcomes 
- We= ight loss recommendation on discharge to improve good response to standard = controller therapies 
- Speech therapy referral given concer= n for vocal cord dysfunction 
- Pulm referral as an outpatie= nt for evaluation of Bronchial thermoplasty (FEV1>60% but severe asthma = that is poorly controlled despite ICS/LABA combo therapy) 
-= Oral glucocorticoids (typically 5 to 7 days of prednisone 40-50 mg)
<= div>- Administration of oxygen onto maintain oxytgen saturation > 93-95%=
- f/u sputum culture, CBC w/ diff, and IGE level -- if eos > = 3% in sputum, elevated eosinophils, elevated IGE refer to allergy/immunolog= y on discharge to discuss whether patient would be a candidate for antinter= leukin therapy (mepolizumab). 
- Add on inhaled ipratropium = bromide w/ SABA q4-6 h standing x 24 hrs
- PCP follow up for Flu = PCV13, PPSV23
- Obtain PEF now for estimation of degree of contro= l (<80% personal best c/w poor control)
o =E2=99=80: 350-550 L/min, =E2=99=82: 450-750 L/min (RT= for baseline and can trend)
- If Impending resp failure d= uonebs, methylpred IV 125 mg, Mag IV 2g over 20 min, transfer to ICU <= /div>
- Consider Heliox for better laminar flow. 
- On d= ischarge would discharge on low dose ICS-LABA such as symbicort for mainten= ance and PRN use given recent changes in mgmt per 2019 GINA Guidelines.&nbs= p;
azithromycin --- can help with inflammation; give also for COPD = patientsback pai= n
- local heat, massage, acupuncture, psinal manipulation
- NSAID if = above doesn't work, then tramadol or duloxeitine as 2nd line
- oxycodone= as 3rd line
- only if >6 weeks no improvement, then imaging  (i= mmediate MRI if risk for spinal infection, cord compression, cauda equina)<= /td>
Differential dia= gnosis includes most likely musculoskeletal pain, muscle spasm/sprain, spin= al stenosis, sciatica. 

Low suspicion for ver= tebral fracture, no point tenderness over the spine, falls, or recent traum= a, normal gait. Doubt spinal epidural abscess or hematoma. Patient has no s= ignificant risk factors for spinal epidural emergency such as fever, IVDU, = HIV, or anticoagulant use. No signs or symptoms concerning for cauda equina= syndrome - neurologically intact without any lower extremity weakness, sad= dle anesthesia, or incontinence. Doubt pyelonephritis or kidney stone, no f= evers, systemic symptoms, hematuria, or dysuria. Doubt AAA, no sig cardiac = risk factors, no pulsatile mass and normal lower extremity pulses.
= bactrim bad for AKI
atorvaquone if prednisone pulseBactrim SE: hyperKBehcet syndrome (oral ulcers, geni= tal ulcers) - a vasculitis issue
- 1st line =3D colchicine
- 2nd line= : apremilast (prevention of oral ulcers in Behet)bicitra more bicarb (30cc =3D 60meq) than= bicarb (24 meq)b= igemy
- start metoprololbilirubinemia very high, concern for cholangiocarcinoma
= - MRCP/MRI Abdomen WO/W contrast 
- Obtain CA 19-9, CEA, and= AFP
- Please send hepatitis serologies (HAV Ab, HBsAg, HBsAb, HB= c Ab Total, HCV Ab, HEV Ab); ANA, Anti-smooth muscle Ab, Anti-mitochondrial= Ab. Iron including ferritin;  Ceruloplasmin
- Start Lasix 4= 0 IV given moderate volume ascites

BiPAP, ACVC, chest PT
KUB NG tube= , OG tube


BIPAP
- increased work of breathing, hypoxemic with= pulmonary edema, and hypercarbic respiratory failure  (or very sedate= d; opioid overdose --- anything to increase minute ventilation)

vent= ilator:   6-8;, 4-6 cc/kg IBW if ards, 8-9 if coming in for CO2 a= nd need to blow off.   but increase rate for CO2 first (more bang= for buck)<= td spellcheck=3D"false" contenteditable=3D"true" class=3D"sorting_1">bloati= ng
- maalox (Mg Al OH)
- Tums (calcium carbonate)
- simethicone (f= orm big bubble and fart/burp)= BPH
- finasteride takes weeks to workbreast cancer prevention if risk is= >3%
- tamoxifen before menopause (increases risk of endometrial canc= er)
- tamoxifen and raloxifene after menopausebromocriptine useful after traumatic brain= injury to help recover, if not sure what to doBudd-chiari
- hepatic vein or IVC thrombo= sis
- Sx: RUQ pain, jandice, rapid ascites,bullous pemphigold
- non muocsa surfaces
pemphigus vulgaris
- involves oral and vaginal mucosa surface
<= br>porphyria cutanea tarda
- dorsum of hand and sun-exposed areas
BUN low - malnu= tritionBurn
- = goal: urine output 31-50cc/hr (titrate fluids to get this) for 24 hours
= - if burn > 25%, vitamin C 66mg/kg/hr x24 hours (no if Cr > 1.5, MI i= n last 6 months, hepatic failure, >8 hrs since burn
(UCI protocol ava= ilable)bypass- micronutritent deficiency - B1, B6, B9, 12, ACDEK iron, zinc, selenium, = copperc auris
= - Tx: micafungin= cabgf
- vein mapping (vascular lab), pft, carotid ultrasoundcalciphylaxis
- happens in= ESRD patients, painful ulcer
- cause: calcification in dermal arteriole= s
- Tx: no definitive treatment, but calcitonin and sodium thiosulfate (= anti-inflammatory)cancer

colon cancer
- programmed death receptor 1 inhibitors (P= D-1 inhibitors) for refractor metastatic colon cancer
- CEA q6m for 2 ye= ars and CT chest/abd/pelvis yearly for 5 years


breast cancer
= - Her2 positive Tx: trastuzumab, need echo q3m
- peau d'orange - need co= re needle biopsy
- inverted nipple + erythematous at some portion of bre= ast =3D inflammatory breast cance r(3% of all breast cancers)

cervic= al cancer
- stage 1/2:: hysterectomy and pelvic node dissection
- sta= ge 3 (extension to pelvic sidewall, lower third of vagina, or pelvic adenop= athy): cisplatin + radiation

neuroendocrine tumor
- if no symptom= s even if metastasis to liver, observe with interval 3m imaging.  If s= ymptoms (face flushing /diarrhea), somatostatin analogue

colon adeno= carcinoma
Tx: fluorouracil and oxaliplatin

non-small cell lung ca= ncer with ALK translocation
- Tx: alectinib
non-small cell lung cance= r with no mutations or programmed death ligand expression, Tx with combo ch= emo (carboplatin and pemetrexed) + pembrolizumab
- if have PD-L1 express= ion, then can just use pembrolizumab


ALL, CLL, AML low Hgb and Plt
CML high WBC. Tx: imatinib
ALL and CLL large spleen, lymph nodes.
APML Tx with retinoic acid. 

High risk AML, need stem cell transplant after chemo;  If = low risk AML, after complete remission, then do "consolidation chemo" - as = some cancer cells still can't be seen.


chronic lymphocytic leu= kemia: high mature lymphocyte (>5) and smudge cells
- test: flow cyto= metry
- Tx: IVIG if low IgG or low IGA and having infections

non-= hogkin lymphoma - large B cell lymphoma 
- stage with LDH (internat= ional prognostic index score)


brain mets with elevated ICP
- = high dose steroid to reduce tumor vasogenic edema

Pdl1 score - wheth= er benefit from immunotherapy

P16+ scc =3D HPV associated
If high= risk - remove, chemo (cisplatin) and radiate

Thyroid cancer: test f= or BRAF gene - =3D papillary carcinoma =3D aggressive form of cancer
in = melanoma, also look for BRAF

cardiogenic shock
- criteria: SBP < 90 for 30m or = pressors needed + cold extremities/oliguria/lactic (hypoperfusion) + hemody= namics (CI < 2.2, PCWP > 15)
- test: EKG, troponin, TTE to exclusi= on tamponade
- cause: MI, ESRD< myocarditis
- goal: CO > 4, CI = > 2.1, mixed venous >65  (dobutamine) initial dose 0.5-1mcg/kg/m= in; or milrinone (also inodilator) 0.125mcg/kg/min

if severe hypoten= sion, use epi, levoped

= cardioversion
- need 3 weeks of anticoag before CV (or TE= E echo) and 4 weeks after 
carpel tunnel
- weakness and numbness 1st 3 fingers, wors= e at night
- Tx: decompression if have muscle weakness/atrophy;  if= no evidence of weakness, then neutral wrist splinting at night and = steroid injection (can aso do short course oral steroid)


lateral= epicondylitis (tennis elbow)
- too much wrist extension
- Sx: pain a= t lateral elbow, radiates down back of hand, worse at night and with activi= ty
- test: pain at elbow with forced extension of wristcauda equina
- bilateral leg w= eakness, saddle anesthesia, bowel/bladder dysfunction
- PE: absense dist= al reflex and leg weakness
- caused: disk herniation, spondylosis, traum= a, infection, cancer (prostate, lumphoma, multiple myeloma)
-  = ;dexamethasone and emergent MRI 
- surgery consultcdiff
- last thing can trial IV= IG if severe  (can be considered to fight infection)
#C. Diff colitis: atypical presen= tation given patient does not endorse watery diarrhea, but definitely +RF g= iven IBD. C. Diff PCR positive on 05/06/20. Non-severe (WBC<15, and Cr &= lt;1.5) Severe (WBC > 15, Cr > 1.5) Fulminant 
- PO va= nc 125 mg q 8 hours (05/07/20 - 5/17/20) 
- Probiotics daily= -- shown to decrease recurrence compared to placebo >50% with no signif= icant adverse effects (Gastro 2017; 152: 1889)
- Isolation precau= tions 

Cdiff: use fidaxomicin in CKD patients = instead of vancomycin or in severe
Fulminant cdiff (systemic toxicity): = po vanc, iv Flagyl and rectal vanc<= /tr>celiac
- anti-ttg IgA and IgGceliac
- Sx: failure to thrive, chroni= c diarrhea, has dermatitis herpetiformis (elbow, knees rash) low fat-solubl= e vitamins, iron deficiency anemia, elevated LFTs
- test: TTG tissue tra= nsglutaminase; (tissue transglutaminase IgA) when patient is eating gluten = (cannot test accurately if not eating gluten)   --- if has IgA de= ficiency, need to test IgG anti-TTG or IgG gliadin..  Also need small = bowel biopsy if test result is positive
- genetic testing: HLA-DQ2 or HL= A-DQ8 can rule out, but cannot confirm
- Dx: any positive celiac disease= pt needs bone mineral density testing



cellulitis / skin infection
- lab= s: trend CRP/ESR
- can use MRSA nares for r/o MRSA 95% specificity (mod = sensitive only)
- scoring: LRINEC Score for Necrot= izing Soft Tissue Infection - MDCalc for nec fasc
- Tx: vanc un= til MRSA nares (nares specific, but not sensitive)
- Tx duration: uncomp= licated 5 days, purulent 10 days

purulent =3D typically MSSA and MRS= A
- Tx: oral Bactrim 2 tabs BID, clindamycin 300mg PO q8h, or doxycyline= 100mg PO BID
  - IV: vanc

nonpurulent =3D staph or strep- tx: cefazolin 1g IV q8h, ampicillin-sulbactam (Unasyn) 3g IV q6h. if pen= icillin allergy, clinda 600mg IV q8h
- tx duration: 5-7 days


= clostridium perfringens nec fasc
- Tx: penicillin + clindamycin

e= mpiric for necrotizing fasciitis =3D vancomycin/dapto/linezolid + zosyn + c= lindamycin, carbapenem, ceftriaxone+metronidazole, or cipro+metronidazolecrepitus =3D clostridium, no crepitus =3D group A strep

(clinda fo= r toxin),  vanc + zosyn kills kidney; better vanc + cefepime+flagyl
IDSA 2014 guidelines to use: mild mod severe

ESR male age/2, fe= male age+10/2 is normal

- 7 to 14 days'

- doxy (<- for MRS= A) + augmentin as unasyn coverage oral

bactrim has poor coverage for= strepchemothera= py desensitizationDay 0 (night prior to desensitization): 
-HOLD PATIENT'S = HOME ACE-INHIBITOR
-Patient is admitted to ICU. Labs are drawn.&n= bsp;
-Dexamethasone 20 mg IV X 1 
-Cetirizine 20 m= g PO x1 
-Montelukast 10 mg PO x1
-Famotidine 40 m= g IV x1 
 
PRE-MEDICATIONS ONE HOUR PRIOR TO = STARTING (ON THE MORNING OF):
-HOLD PATIENT'S HOME ACE-INHIBITOR<= /div>
-Dexamethasone 20 mg IV X 1 
-Zofran 8 mg IV x1&nb= sp;
-Cetirizine 20 mg PO x1 
-Montelukast 10 mg PO= x1
-Famotidine 40 mg IV x1 
 
MEDI= CATIONS 4 HOURS AFTER MORNING PRE-MEDICATIONS: 
-Cetirizine = 20mg PO x1 
-Dexamethasone 20 mg IV x1 
 = ;
P.R.N. medications: 
Cetirizine 20 mg PO q4 hour= s PRN for flushing / itching / rash 
Famotidine 20 IV q8 hou= rs PRN for GI symptoms 
Zofran 8 mg IV q6h PRN for GI sympto= ms
Benadryl 25mg PO q2 hours PRN or flushing / itching
= Albuterol 0.83% nebulized solution inhaled q2 hours PRN shortness of breath= / wheezing. 
EPINEPHRINE (1:1000) (1mg/ml) IM drawn at beds= ide in 1cc syringes x3 with volume of 0.3ml in each with 22 gauge 1" needle= s ready for IM injection as needed for anaphylaxis.
 
<= div>Proceed with DESENSITIZATION after informed consent for desensitization= is signed.


Chest pain
- Causes:  - pericarditis (diffuse upslope ST elevation)
  - NSTEMI, = STEMI, PE (new RBBB, S1Q3T3, RV stain), aortic dissection
  - anxie= ty, GI (e.g. biliary colic)

chest pain cardiac stress test good for = 5 years;  
- look cad CAD consortium score
- inpatient lexi= scan good for 1 year

typical: with stress, nitro, substernal , atypi= cal 2 of 3, non cardia =3D 1 or 2 or these.

now called "cardiac, possibly cardiac, or noncardiac" - nitro doesn't = really tell (helps with HF as well)

-CXR, CT PE, Echo


Differentia= l includes ACS, pneumonia, COVID-19, pneumothorax, pericarditis, musculoske= letal chest pain. Doubt pulmonary embolism, no hypoxia or tachycardia, and = lack of significant VTE risk factors. Doubt aortic dissection.
3D""
3D""
3D""chest tube vs thoracentesis:
- if loculation, then chest = tube as can put in tpA and flush
- chest tube to suction or gravity
-= thoracentesis: upper limit 1.5L can take out  (can cause reexpansion = pulmonary edema if more); versus take out until cough or pain (lung is expa= nding)


chest tube < 200cc/day, (water seal) then can take che= st tube out

if constant bubbles in water sesal when off wall suction= , bronchpulmonary fistula or and air leak in chest tubechickenpox:
- S&S starts on f= ace and trunjk, then goes to extremities. progresses over hours to vasicles= with pusCholedo= chol - >7mm on ultrasound. Add 1 for every 10 years over 60.   = ;Straight to ercp if bili>4 and cbd dilated

Pancreatitis 10cc/kg = bolus and then 1.5cc/kg/hrchorea gravidarum
- rare disease when newly pregnant female sud= dently has random non-repetitive, flowing dance-like movement that cannot b= e supressed.
- test: pregnancy test

vs. huntington is slow progre= ssive condition  (mood and cognition would be first) then chorea
vs wilson disease - involuntary movement with tremors
- test: serum ce= ruloplasmin or 24-hr urine copperchronic hypoxia and air travel safety/high altitude
- o= xygen sat curve steep part if baseline oxygen sat is already low if going t= o high altitudes
- pts with SpO2 > 95% okay
- 92-95% need high alt= itude stimulation testing
- <92% at baseline, need 2L/min supplementa= l oxygen prescribed (no additional testing)cirrhosis
- order factor 8 if not know why thr= ombocytopenia; if increased, due to liver (cytokine causes increase in fact= or 8)
- normal factor 8 
- high factor 8 level also can cause bl= ood clots



acute hepatic encephalopathy
- causes: bleeding= , infection, dehydration, medication non-compliancecirrhosis
- score: prognosis: Child-Pugh Score for Cirrhosis Mortality - MDCalc  ; if alcoho= lic hepatitis; if severe (PT and T Bili has an index score 32+), steroids f= or 28 days; MELD score; MD= F score for steroid
- U/S with and without doppler. Nodular =3D cirrhros= is (also low plt)
https://www.mdcalc.com/calc/3081/nafld-non-alcoholic-f= atty-liver-disease-fibrosis-score
- outpt Fibroscan (ultrasound)
- fu= rosemide, decrease salt <2g, 
- tips if Para every other day
= Terlipressin+ albumin: need liver and renal on board for pulmonary edemaUses carvedilol over propranolol/nafolol as 4x more effective in reducing = varices
Omeprazole is for post banding healing
No octreotide if just = gi bleeding and does not have liver disease

- all patients with cirr= hosis should get EGD to assess if any varices
- only if mod/severe varic= es, start =CE=B2-blocker (propanolol, nadolol, carvedilol)

- check v= itamin K


- furoesmide: 40: spirinolactone: 100  (if need al= bumin to chase with lasix, albumin 25% 25gm BID)


- if hepatorena= l syndrome - trial octreotide and give albumin (if low BP, midrodrine too)<= br>
- if any surgery for cirrhosis patients: post-op risk is using VOCAL= -PENN risk assessment score

- ultrasound every 6 months for surveill= ence on HCC if someone has cirrhosis


!!! if alcoholic hepatitis,=
prednisolone for MAddrey discrimnant score >=3D32, MELD > 20, or = encephalopathy  (If bili does not improve or Lille score does not impr= ove in day 7), stop prednisolone.
- do not use steroid if also have GI B= leed, infection, pancreatitis, or CKD


- hold ACE inhibitors, ARB= < NSAID with patients with ascites
- if variceal bleeding, octreotide= + CTX


hepatorenal syndrome:

-Etiology: due to HC= V
-Diagnosis: based on
-HE: 
-Ascites:&n= bsp;
-EV screen: 
-HCC screen:
-Immuniza= tions: 

-Check Hepatitis C Ab
-Chec= k Hep B serologies (Hep B S Ab, Hep B S Ag, Hep B core Ab)
-Check= HIV
-Check iron studies including ferritin and transferrin
=
-Check ceruloplasmin
-Check ANA, antimitochondrial antibody = (AMA), anti-smooth muscle antibody (SMA), IgG, (Anti-LKM Ab)
-Che= ck alpha-1-antitrypsin
-AFP
-Ultrasound with Doppler
-INR

#Cirrhosis decompensated by (as= cites/ hepatic encephalopathy / jaundice/ variceal hemorrhage) secondary to= ***ALD/NAFLD
- MELD-Na ***, MELD ***, CP***
-HCV genot= ype ***, treatment naive ***. Completed treatment on *** with SVR 24***
-Diagnosis: based on***.  
-Etiology: Likely due= to ***
-Ascites: Current regimen ***. SBP prophylaxis (yes/no)**= *
-HE:  Today, Pt has ***mild asterixis without confusion.&n= bsp; Continue lactulose ***mg and rifaximin ***mg
-EV: EGD (***) = showed with ***bands placed.  Repeat EGD planned for ***. Currently on= Coreg 3.125mg BID. 
-HCC Screen: AFP wnl (***). Last ultras= ound (***)
-Elastography (***) showed *** kPa consistent with sta= ge *** fibrosis.
-Coagulopathy: Plt ***, INR ***
-Immun= izations: HAV immune (***); HBV ***immune, series completed (***), Prevnar = (***), Pneumovax (***), Tdap (***)
-***Pt is not currently a cand= idate for liver transplant due to other comorbid conditions

<= /div>
-

- Volume: 
- Spirono= lactone 100 mg / lasix 40 mg 
- Na restriction <= 2g/d 
- Fluid restriction <1.5 L (given Na <1= 25) 
- Paracentesis in the am 
- Avoid ACE/ARB (causes decreased renal perfusion)
-= Consider midodrine 7.5 mg TIPS for refractory hypotension 
- Given concern for hepatorenal syndrome -- will start albumin and= octreotide and midodrine. 
- Infection 
- Send cultures for SBP evaluation (PMN>250)
- C= eftriaxone 2g q 24 hours x 5 days 
- 25% albumin (1= .5 g/kg on day 1 and 1 g / kg on day 3 given Cr > 1 / BUN> 30/ Tbili = > 4)
- Discontinue beta blockers given increased mo= rtality in those with SBP 
- Prophylaxis indicated = given prior SBP or low total protein in ascitic fluid (<1.5) WITH hypona= tremia, kidney dysfunction, or CTP class B or C 
- Bl= eeding: 
- Outpatient GI referral for EGD to evaluate for = esophageal varices 
- Non selective beta blockers f= or prophylaxis 
= High concern for current bleed -- s= tart PPI, GI referral, octreotide drip 
- Encephalopa= thy 
- Lactulose with titration of 3 BM/day or improvmeent= of metnal status 
- Can add on rifaximin if refrac= tory 
- f/u Zinc -- if deficient, add zinc 220 PO d= aily to help augment urea cycle and reduce ammonia.
- Screening / Surgery 
= - PCP follow up to ensure adequate vaccinations 
- Co= unsel to avoid the use of alcohol, opiates and benzodiazepines (which can p= recipiate hepatic encephalopathy), raw shellfish.
- Recommend out= patient screening of osteoporosis as cholestasis results in decreased absor= ption of vitamin D 
- Protein consumption essential to preve= nt catabolic effects of chronic liver disease -- daily protein intake of 1.= 5 g/kg body weight recommended 
- Avoid NSAIDS 
- MELD > 15, refer to liver transplantation 
- Liver c= linic f/u for HCC screening q 6 months
- RUQUS now and AFP level&= nbsp;


#Cirrhosis probably 2/2 ALD
MDF of 35. MELD of 21. Though patient's MDF>32, prednisolone fo= r ALD would be contraindicated at this time given concern for active infect= ion at this time -- though patient has been placed on a short course of pre= dnisone 40 mg 10/04/20 - 10/9/20. Given patient's Crohn's disease, some con= cern for PSC-- though less likely given normal alk phos and previous MRE sh= owing no PSC. Patient's elevated t bili and d. Bili may also indicate some = concern for cholestatic injury ( R ratio of 0.7)
- F/U on dedicat= ed liver ultrasound to evaluate for e/o portal hypertension and liver lesio= ns
- Chronic liver disease work up: 
Viral hepatit= is work up has been negative (Hep A, HBCAB IGM, Hep C, HBsAg all nonreactiv= e). ANCA negative, ANA negative, C3, WNL, C4 low/normal, RF negative, cerul= oplasmin negative. 
Pending A1AT, but given patient's age an= d history of alcohol use, A1AT deficiency unlikely cause of his cirrhosis.&= nbsp;
- Continue to monitor
- If pt worsens and his lun= g disease is not infectious in origin can consider referral for transplant = evaluation. At this time he is stable and we are not sure etiology of his h= emoptysis, would be premature to refer for transplant evaluation. 
 
# Possible HE - covert
- Continue lactulo= se - titrate to 3-4 large loose BM per day
- If not controlled wo= uld consider adding rifaximin
 
# Possible ascites= and fluid overload
- Diuresis per primary team
- If as= cites on ultrasound please perform dx paracentesis (send fluid for cell cou= nt, diff, gram stain culture, albumin, total protein, AFB, ADA)
-= Low sodium diet <2000 mg per day
- Continue to monitor <= /div>



cocaine
- Sx: HTN, A= MI-like
- Tx: lorazepam
- Tx: Ca channel blocker for chest pain
- = Tx: phentolamine (a1 blocker) for HTN
- do NOT give betablocker, will ca= use unopposed a1 vasoconstriction
- cocaine risks dissection of aorta, w= ill see more platelets, and risk of thrombus
colon cancer screening
- 1-2 sessile s= errated polyp < 10mm without dysplasia =3D 5-10 years
- 3-4 polyp =3D= 3-5 years
- 4+ =3D 3 years  
- <20 <10mm hyperplasti= c polyp also 10 yearscolorectal cancer
- prevention: baby aspirin helps if fam hx. Start = Colo 45/50 to 75 q10y, cologuard q3y, FIT/FOBT q1y. FOBT false positive if = meat eater. If immediate family hx, then start at 40 or 10 years before dia= gnosiscoma physi= cal exam NIHSS (template)
NEUROLOGIC EXAM: 
Mental status: Lethargic/comatos= e/obtunded/stuporous/opens eyes spontaneously to voice. No response to voca= l or painful stimuli.  
Language: Intubated, not follow= ing commands.  
  
CRANIAL NERVES:&= nbsp;
CrN II: PERRL, blinks to threat bilaterally. 
CrN III/IV/VI: Oculocephalic reflex intact bilaterally. Does not track ex= aminer=E2=80=99s face. 
CrN V: Corneal reflex present bilate= rally. Blinks spontaneously.  
CrN VII: Symmetric facia= l grimace to noxious stimuli. No obvious facial asymmetry.  Unable to = assess for facial symmetry due to patient being intubated.  
CrN VIII: Unable to assess.  
CrN IX/X: Gag refle= x present.  
CrN XI: Unable to assess.  
CrN XII: Unable to assess.  
  
Motor: No spontaneous movements. No withdrawal to painful stimuli. Tripl= e flexion reflex present in LE. Decorticate (flexed)/cerebrate (extended) p= osturing in response to noxious stimuli. Unable to assess strength due to m= ental status. Able to lift all 4 extremities antigravity. 
R= eflexes: 2+ triceps, biceps, brachioradialis, patellar, achilles. Toes down= going/mute/upgoing bilaterally. 
Sensory: Unable to assess.&= nbsp;
Fine coordination: Unable to assess. 
Gait: = Unable to assess.
constipation
- activity, psyellium, then add d= ocusate (surfactant), osmotic laxative (MagOH, lactulose, sorbitol, PEG - p= eg is best), then senna (Stimulant laxative).  IF all does ot work, th= en lubiprostone and linaclotideconstrictive pericarditis
- signs: circumferential perica= rdial calcification on XR of heart or >3mm pericardial thickeningcontrast
score: = Mehran Score for Post-PCI Contrast Nephropathy - MDCalc- NS pre and post procedure for 6-12 hours if any AKI or GFR < 30. Not= needed if GFR 45+
- some thought of mucomyst helping prevent contrast i= nduced nephropathy, but research not clear


contrast
- MRI gad= olinium not causes contrast nephropathy; NSF nephrogenic systemic fibrosis = rare but also need creatinine GFR30


COPD exacerbation
- Tests: COVID/flu, BNP= ; + sputum culture if risk factor; ABG if acute hypercapnia suspected (high= HCO3, or severe airflow obstruction FEV1 <50%
- Tx (inpt):
 = - (controversial; some only start if sputum, purulence, or needing O2) cef= triaxone for 5(-7) days; cefepime/zoyn if risk of pseudomonas (prior, sever= e COPD, bronchiectasis, broad antibiotic use in past 3 months, chronic oral= steroid use); alternatively, amoxicillin, TMP-SMX, doxy
  - <= br>  - BIBAP to blow off CO2
  - duoneb iptratropium-albuterol= 0.5-2.5mg q1h for 2-3 dose, then q2-4h PRN
  - prednisone 40mg equ= ivalence for 5 days (up to 14 okay)  (equivalent to methylpred IV 32mg= ); if severe COPD, methylpred 60mgq6h
  - DVT ppx

: ICS= -LABA-LAMA triple therapy (trelegy or breztri contain all 3)
&nbs= p;Or ICS-LABA + LAMA. Ics-laba choices are symbicort, advair, dulera, breo,= wixela, breyna. Lama c= hoices are incruse or spiriva. 



- consider azithromycin ppx to prevent COPD exacerbations (MKSAP)
if on= budesonide, do 1mg BID neb

- duoneb q4h PRN
- prednisone 40mg 5 days
- flu, pneum= onia immunization
- procal if infection suspected
- Bcx
- smoking = cessation

# COPD Excerebration GOLD Grade 1 (FEV > 80%, 50-8= 0, 30-50, <30) Group A / B / C / D COPD: Patient's FEV1/FVC <0.70 in = 20** PFTs. 
- Trigger: ***
- ABG shows: ***
<= div>- Chest X-ray shows: ***
- Respiratory Panel ordered, will tr= eat influenza if detected 
- Sputum culture and gram stain
- Legionella urine 
- *** {Levofloxacin or Moxiflox= acin or Ceftriaxone or Cefotaxime} for hospital exacerbation without concer= n for pseudomonas 
- *** {Cefepime vs Ceftazidime vs Zosyn} = if risk factors for pseudomonas: *** {Previous colonization, FEV <30%, B= ronchiectasis, broad-spectrum antibiotic within 3 months, chronic glucocort= icoid use}   
- Prednisone 40 mg x 5 days 
- NIV if change in mental status, pH < 7.35, or paCO2> 45 
- Fan therapy can help decrease sense of dyspnea (nursing communica= tion placed)
- Duonebs q 4 hours standing, q2hrs pRN 
<= div>- Continue Long Acting Bronchodilators as soon as possible (GOLD 2020)&= nbsp;
- On discharge would initiate LAMA given GOLD C exacerbatio= n history (Spiriva, Incruse ellipta)
- If eosinophilia (>300) = would initiate ICS+ LABA (advair, dulera, symbicort), though caution in arr= hythmia or CHF with LABA use. 
- Would avoid advair if fre= quent admissions for pneumonia. 
- Evaluate for home = O2 if PaO2 < 55% OR SaO2 <88% OR cor pulmonale / HF/ erythrocytosis (= Hct>55%) and PaO2 < 55-60, O2 <89%
- Pulmonary rehabilit= ation referral placed given *** FEV 1 < 50%, on systemic steroids, or re= cently hospitalized

- PCP follow up for flu vaccin= e and pneumococcal vaccination  
- PCP follow up for Lu= ng Ca Screening: Annual low dose CT (55-80 with 30 pack yr hx and active us= e or quit <15 yrs 

- For smoking cessation=
Varenciline is superior to nicotine replacement therapy and bu= proprion (Avoid in kidney disease and neuropsychiatric issues)
=
= Nicotine patches should be given at night to reduce AM cravings = ;
Buproprion is beneficial for concurrent weight gain, b= ut cannot be used in those with seizure disorder. 

COPD
- Sx: symptoms slowly progress, history of smoking, = trigger
- PE: wheezing, tachypnea
- score: mMRC dyspnea scale (SOB sl= ight uphill =3D 1 vs. stop for breathing/after 100 yards/few minutes =3D 2+= or COPD assessment test (CAT)
- Dx criteria:
  - FEV1/FVC <= 0.7 required for Dxthpe
  - GOLD now ABE
    - FEV1 80= %+ =3D1 (mild), 50+ =3D2 (mod), 30+ =3D3 (severe), <30 =3D 4 (very sever= e)
    - mMRC 0-1 or CAT <10 =3D A/E (/old C); mmRC 2+ or C= AT 10+ =3D B/E(/old D). 2 COPD exacebation or 1 leading to hospital =3D E (= old C/D), else A/B
- Risk factors for poor outcome in acute exacerbation= : 65+, HF/ischemic heart disease, severe COPD, 2+ exacerbation, hospitaliza= tion for exacerbation last 3 months, supplemental O2)
- Tx (outpt): GOLD= A =3D albuterol PRN, B =3D LABA+LAMA, E =3D B and add ICS if eosinophil is= 300+  (used to be B =3D LABA/LAMA, C LAMA) + pulmonary rehab
 = ; - ICS don't use if repeated pneumonia, hx of mycobacteria, eos <100, b= ut ok to add if 1+ exacerbation before
  - LABA+LAMA better than LA= BA + ICS (before, if fail would go to LABA+LAMA)
  - Aerobika can h= elp mucus clearance, decrease COPD exacerbation
  - exacerbation ou= tpt: prednisone 40mg 5-14 days
- Rx:
  - tiotropium (Spiriva) = =3D LAMA
  - Wixela =3D fluticasone + salmeterol (LABA)
  -= dry powder only if patient can deep inhale

- measure AAT level in p= atients with COPD


- for severe COPD, can do roflumilast to preve= nt recurrent exacerbations  (cannot use when exacerbation)

- pu= lmonary rehab first.
- chest PT only if sputum
- if refractory SOB, u= se handheld fan (devices that increase airflow), pursed lip breathing (inha= le through nose, exhale mouth)


- lung volume reduction therapy -= upper lobe predominal emphysema, FEV1 and DLCO of 20% or higher and low ex= ercise tolerance.Inhalers: Respiratory = Medication Chart (lung.org)

coronary art= ery disease
- pretest likelihood

Coronary calcium ct has good sen= sitivity. 2 or less rules out.

No lexiscan for reactive lung disease=
#stable angina = pectoris: 2 months of stable reproducible anginal symptoms 
= - Continue aspirin (clopidogrel if intolerant) 
- Continue s= tatin
- Continue ace/arb 
- Continue beta blocker = with titration to 55-60 (B1 selective B blockers such as metoprolol if sign= ificant lung disease) 
- Consider*** CCB or nitrates 
- Consider ranolazine 

#coronary rev= ascularization: 
- NPO for CABG evaluation (diabetes hx, LV = dysfunction, left main, three vessel disease) 

- After revascularization: aspirin forever
DAPT =3D Clopidogrel= + aspirin 
BMS =3D 1 mo DAPT minimum 
DES = =3D 6 months (can continue if high risk for thrombosis -- depressed LV func= tion, saphenous vein graft stenting, diabetes) 
CABG: DAPT 1= 2 months (improve patency of vein grafts) 

coug= h
- DDx: asthma, heart failure, GERD, allergic rhinitis, post-nasal drip= syndrome, upper airway cough syndrome, ACEI, cancer, TB, bronchietasis, IL= D, idiopathic, cystic fibrosis
- acute cough due to bronchitis: reassura= nce (dexomethrophan doesn't really help; should avoid in SSRI pt, can incre= ase it); Acute bronchitis is a self-limited inflammation of the bronch= i due to upper airway infection, typically caused by a viral pathogen; it i= s typically associated with a cough that lasts from 2 to 3 weeks, mild dysp= nea, and sputum production.  No CXR needed; CXR only if  fev= er, tachypnea, tachycardia, rales, or signs of parenchymal consolidation
- unexplained cough: gabapentin can dampen neural sensitization for un= explained chronic cough.

- post infectious cough: normal for 3-8 wee= ks after infection common viral or mycoplasma (atypical)
- dry cough: fl= onase -> spirometry -> exclude eosinophilic bronchitis (with sputum e= osinophil analysis) -> trial GERD PPI
-of productive cough, worse at = night but not allergic: 1st gen antihistamine (benadryl) + decogestant (pse= udoephredrine)<= td spellcheck=3D"false" contenteditable=3D"true">CO= VID
- Sx: fever, chills, cough, SOB, fatigue, muscle ache, headache, los= s taste smell, sore throat, congestion/runny nose, nausea, vomiting, diarrh= ea
- no paxlovid if on statin (can stop statin)
- paxlovid or molnupi= ravir if mild to moderate
 
- classification: mild =3D no SOB, b= ut other symptoms, moderate =3D evidence of lower respiratory disease clini= cally or imaging SpO2 94+%, severe =3D <94% or PaO2/FiO2<300mmHg, RR&= gt;30, or lung infiltrate >50%; critical =3D respiratory failure, shock<= br>
remdesivir:
- mild to moderate with risk to severe (3 day course= if non-COVID diagnosis and incidentally COVID+)
  - onset <=3D7= days and either: >60, HTN, stroke/CAD, DM, BMI 30+, immunocompromised, = GFR<60, cancer, chronic liver or lung disease, sickle cell, CF, dementia= , smoking, TB
  - remdesivir 200mg IVP x1, 100mg IVP day 2 and 3- severe COVID - SpO2 <=3D94%
  - remdesivir 200mg IVP x1, 100m= g IVP day 2-4

Paxlovid
if GFR 60+ =3D nirmatrelvir 300mg (2 tab)= + ritonavir 100mg (1 tab) q12h x5 days
30-60 =3D nirmatrelvir 150 mg +&= nbsp; ritonavir 100mg 

paxlovid interactions meds: ranolaz= ine, amio, dofetilide, flecanide, placix, rivaroxavan, ticagrelor, cabamaze= pine, colchicine, rifampin, st. john's wort, lovastatin, simvastatin, silde= nalfil, midazolam


If hypoxic, add on dexamethasone 6mg daily
= - and daily d-dimer ,CRP, LDH, troponin, ferritin, CBC w/ diff q48 hrs (sev= erity labs)
- decadron 6mg

Tocilizumab:
for patients with high= oxygen needs with COVID
#COVID positive: Typical course for COVID will start with Dyspnea = at 6 days post exposure. COVID Severity Labs: ESR ***, CRP ***, Procalciton= in ***, LDH ***, Prothrombin Time ***, D-Dimer ***, Fibrinogen ***, Ferriti= n ***, Interleukin 6 ***, Troponin I ***.

Risk fac= tors: Age >65, HTN on medication, DM on treatment, COPD on treatment, hi= story of asthma, CAD on treatment, ESRD, obesity BMI >30, absolute lymph= ocytes <0.8, ferritin > 800, D-dimer >1000, CRP > 10,  bil= ateral viral PNA on CXR. Patients with TSH, lipid, A1c, Vit D abnormalities= are at higher risk 

{inpatient admission for= severe dyspnea, oxygen sat of <90% on RA, signs of end organ damage}

#Acute Hypoxic Respiratory Failure
#SIRS P= ositive based on *** {suspected infection + tachycardia, leukocytosis, RR, = + organ damage =3D sepsis, + pressors =3D Septic Shock} 
#CO= VID Infection: Prediction for ICU Admission or Ventilatory Support: ***% (S= ource: http://covidrisk.hs.uci.edu/, modeled from 87 patients)
- = Satting ***% on ***
- Admit to tele 
- Started on = Remdesivir (GFR >30) (**) for 5 days and Dexamethasone 6mg {any oxygen} = (***) for 10 days
- Consider Paxlovid or Xevudy if available vs t= ocilizumab or baricitinib (mortality benefit), will talk to pharmacy <= /div>
- Consider Lasix spot dosing if increasing oxygen requirements wi= th goal of -500ml to -1L
- Symptomatic Control: Benzonatate PRN, = Guanifenesin PRN, Tylenol PRN, Melatonin qHS, inhalers q4hrs, Chest Physiot= herapy QID 
- Empiric antibiotics for pneumonia if suspected= (low threshold)-- azithromycin (x 5 days) plus ceftriaxone (MRSA nares***)= , discontinue ceftriaxone in 48 hours if no evidence of bacterial infection= . 
- Blood cultures, lactate, Sputum gram stain and culture,= Urine legionella, LFTs  
- COVID severity labs q48 hou= rs 
- Contact and droplet precautions; encourage incentive s= pirometry, encourage proning 
- Low threshhold for intubatio= n in setting of rising oxygen requirement 
- Target O2 satur= ation of 92-96%
- DVT prophylaxis and continue unless platelets &= lt; 30 given procoagulable form of DIC despite low platelet count in COVID = patients 

3D""CPK myositis
- statin induced, hypoth= yroidism (delayed deep tendon reflex), or polymyositis/dermatomyositis
<= /td>crazy paving = =3D most likely due to PAP vs pulmonary alveolar proteinosis
NSIP -= Nonspecific interstitial pneumonia (pleura sparing)crohn's: high likely for pyoderma gangre= nosum
infliximab (anti-TNF anti tumor necrosis factor= ) + azathioprine (immunomodulator)
- steroid to treat f= lares (budesonide)

- sulfasalazine only good for colon part (i.e. mo= re in UC)

8 years after crohn or IBD diagnosis, need colonoscopy, th= en every 2 years-Please order iron panel, ferritin, zinc, copper, vitamin a, e, d, vitamin= b12, folate, Mg, Phos, and replete as appropriate 
-Ensure = DVT prophylaxis as IBD patients are at increased risk for venous thromboemb= olism

cryptococcus
- If immunocompromised p= atient has lung cryptococcus infection or disseminated cryptoccus infection= , need LP even if no CNS symptoms.  From lungs, it commonly goes to CN= S.cryptogenic org= anizing pneumonia (BOOP)
- diffuse ILD that does not respond to differen= t antibiotics
- Sx: persistent nonproductive cough and flu-like
- Dx:= high resolution CT, PFT
- assoc with history of dematomyositis/polymyos= itis
- DDx: eosinophilic pneumonia, CAP, hypersensitivy pneumonitis
-= Tx: steroidcryp= togenic pneumonia (COP) - if antibiotics doesn't resolve in a few weeks.CT head protocol- any minor head injury if 65+, coagulopathy, drug or alcohol usedcushing
- S&S: pu= rple striae, diabetes, HTN, round face
- Dx: late-night salivary cortiso= l, serum ACTH, 1mg overnight dexamethasone suppression (should decrease cor= tisol to <3ug/dl - false positive for alcohol use obesity or psych issue= s)
- if morning ACTH high, pituitary MRI, if morning ACTH low or normal,= adrenal CT.= cysti= c fibrosis
- XR: lung has "tram tracks", pairs of parallel linear opacit= ies, hyperinflation of chest, bronchiectasis
- S&S: recurrent lung i= nfections, sinusitis, chronic productive cough, diarrheaDalbavancin


daptomycin: doesn't work for = group b strep, risk of rhabdo, need CPK baseline
delirium:
- DDx: benzo, narcotic, al= cohol, SSRI, anti-Ach, digoxin, muscle relaxant, low oxygen, high PCO2, inf= ection, stool, seizure, head trauma, poor PO intake, metabolic, sleep distu= rbance
   - leading causes of delirium are fluid and electroly= te disturbances, infection (most commonly urinary tract and pneumonia), met= abolic disturbances, sensory/environmental disturbances, and drug toxicity.= The top three classes of drugs most commonly implicated in precipitating d= elirium are opioids, benzodiazepines, and drugs with anticholinergic proper= tie
- normally hyperactive, hypoactive or mixed; agitated or lethargic, = slow, incohrent speech, attention impaired, disorganized thinking, abnormal= sleep cycle (vs. dementia: normal, difficulty finding words, attention not= impaired, disoreitned, normal sleep cycle)
- old people: haldol better = (if IV, need cardiac monitoring), olanzapine okay

To treat delirium<= br>1st line: olanzapine (Zyprexa) - 2.5mg PO daily (max 10mg/day)  &nb= sp;<-- zy
risperidone 0.25mg PO BID (max 1.5mg.day)
Seroquel (quet= iapine) - 25mg PO BID (max 400mg/day)
Abilify 5mg PO (max 15mg/day)
-= !!!seroquel first line if any concern for Parkinson as all others will set= their motor skills back a month even with a dose


Acute psychosi= s:
- olanzapine 2.5mg IM (max 10mg/day)
- haldol IM (not IV, IV gets = torsade) 0.125mg IM q6h

severe agitation
- "B52": benadryl 50mg, = haldol 5mg, ativan 2mg
- first haldol, then add ativan


anxiet= y: atarax hydroxyzine (causes confusion)
- seroquel for agitation
- g= eneralized anxiety=3D CBT first; SSRI. benzo short term while titrating SSR= I okay.


-= meds reviewed
- bowel regimen
- UA with UCx, ABG, urine drug screen<= br>- CT head if no delirium causes found
- Keep LP, EEG in mind
- d/c= antichlorinergics, benzos, zolpidem
- pain management

Delirium
- Maintain day/night orientation with appropriate ambient lighting a= nd re-orient patient frequently as needed
- Provide adequate day = time stimulation such as presence of family, verbal interaction with nurse = or visitors, or TV or music, and at night, minimize stimulation from vitals= , labs, or noise
- Avoid anticholinergic medications such as Bena= dryl and benzodiazepines, which will exacerbate confusion
- Start= scheduled {Risperdal, Haldol, Zyprexa, Zydis, Seroquel} {0.25 , 0.5 , 2.5,= 12.5} mg {PO , SL} q5PM x 3 days
- Start additional PRN {same dr= ug/dose as above} nightly at 21:00 as needed for agitation
- Star= t Trazodone {50, 100} mg nightly PRN insomnia.
- 1:1 sitter or re= mote observation


#Altered ment= al status: Ddx includes metabolic, infectious, drugs vs medications, primar= y CNS, delirium. 

Patient's acute AMS concern= ing for trauma vs vascular vs increased ICP, meds/toxins, metabolic. <= /div>
- EKG to evaluate for arrhythmia 
- UTox for possi= ble substance abuse 
- AM cortisol, TSH 
- Bl= adder scan for urine retention 
- Seizure, stroke, syncope&n= bsp;

- CBC, BMP, LFT, lactate, NH3, B12, TSH, VBG,= UA, CXR, bladder scan 
- ESR, CRP, CK, B12, B12
-= TTP consideration (low platelets, anemia, renal failure, fever, neuro chan= ges) -- LDH, stat smear 
- Elevated T,HR,BP,RR concerning fo= r serotin syndrome >> neuroleptic malignant syndrome 
=
- Consider EEG
- Consider MRI w/ gad for possible = stroke vs malignnancy 
- Consider LP 
- HIV, = RPR, HSV, VZV, 
- Delirium mprecautions 
= dental work Abx (amoxicillin or clindamycin; "clindamycin is anerobe above = diaphragm")
- only if
- prosthetic cardiac valve or repair with prost= hetic material
- Hx of infective endocarditis
- cyanotic congenital h= eart disease
- cardiac transplantdepression
- if dementia/strokem, use citalopram (SS= RI)
- sertraline safe to patients with heart disease
- mirtazapine se= dates and causes weight gain (Good for patients having wt loss and insomnia= )
- can trial weaning antidepressants if in remission after 6 months (do= n't stop abruptly); if recurrence, then take medication for duration of how= long the gap between episodes was 

- do not take tramadol and = SSRI together (serotonin syndrome)<= /tr>dermderm steroid cream
topical steroid SE: atrophy, hypopigmentati= on, atrophy.
each "finger tip unit" =3D 500mg - treats 2% BSA (si= ze of palm =3D 1% body surface area); 
30g tube covers entir= e body once=3D
= dermatology

dermatitis herpetiformis
  - autoimmune bull= ose disease - clustered vesicles/bullae but very itch, so when you see it i= n clinic, they've scratched it and just red scars.  At knees (elbows, = butt, scalp)derm= atology

verruca plana  (flat warts) =3D "flesh-colored, papules= " face and legs of kids/young adults, less keratin than "verruca vulgaris" = (comon wart)
- Tx: topical salicylic acid, cryo, imiquimod

seborr= heic dermatitis (greasy scales)  =3D selenium sulfide

tinea ver= sicolor (disolored dots on skin by malassezia)
- topical ketoconazole, terbinafine, clotrimazole, or selenium sulfide

chronic= spontaneous urticaria
- round plaque suddently, no trigger, goes away i= n 24 hours.
- Tx: claritin
- 50% won't have episodes after 5 years- no skin biopsy unless fever, or if last 24+ hours

lichen planus- polygonal shape at flexing surfaces or white lines in mouth
- Dx: sk= in biopsy
- if positive, test for HepC (associated)

  • increased risk for melanoma: 2 1st degree with hx, 100+ moles, r= ed hair
  • skin: epidermis (keratinocytes in spinosum layer), dermis (fibroblast (makes connective tissue protein for wound healing/scarring), collagen, elast= ic fiber, oil glandss), subcutis/hypodermis (fat)
  • filaggrin =3D protein in epidermis, keeps in water; mustation causes atopic derm= atitis
  • erythema nodosum - inflammation of subcutis
  • sezary syndrome =3D body surface >80%; skin turnover causes metabolic issu= es, renal filtration and cardiac output issues.
  • color, shape, secondary feature, texture, size, palpability  (mention whether well demarcated)

dermatom= yositis
- Sx: rough cracked hands like mechanic hands, gottron papules, = raynauds, arthritis
- Dx: anti-Jo, ck, aldolase. Need Mri of most painfu= l.  Biopsy of skin/muscle possibly, myomaker
- rheum attending says= if confirmed whole body ct w contrast/pet scan (also for polymyositis)
= - steroid and methotrexate; cellcept for skin, azathro is for ski. And musc= le
- associated with ILD , need pft if SOB


CREST
- no skin= rashes
- Dx: anti-centromere

immune-mediated necrotizing myopath= y
- sx: acute muscle weakness and sob
-  statin (would alsobhave= hmgcr ab positive), CK extremely high >10k
- Dx: anti-SRP (signal re= cognition particle)

rapidly progessive necrotizing myositis
- ant= i-HMG-Coa Ab (from statin)diabetes insipidus
- Dx: calcium to rule out high Ca as cause = for polyuria
- Dx: water deprivation.  then desmopressin response t= o see if central vs nephrogenic DI.  IF desmopressin challenge is posi= tive, order MRI.  if negative, order kidney U/Sdiabetes
- type 1 diabetes melli= tus, one or more autoantibodies directed at the following targets are typic= ally present: GAD, tyrosine phosphatases IA-2 and IA-2=CE=B2, islet cells, = insulin, and zinc transporter 8
 - 1st order GAD  (glutamic ac= id decarboxylase) antibody testing is negative, it should be followed by ty= rosine phosphatase IA-2 and/or zinc transporter 8 testing

diabetic n= europathy
- use gabapentin/lyrica, duloxetine to treat; 8% capsaicin pat= ch if feet also.
#diabetes: A1C of *** (date)
Consider metformin on discharg= e given benefits in weight loss, lipid improvement, prediabetic <60 and = obese. Avoid if ongoing diarrhea. Contraindications include severe renal dy= sfunction (eGFR <30 mL/minute/1.73 m2); acute or chronic metabolic acido= sis with or without coma (including diabetic ketoacidosis). Counsel that th= ere is a tachyphylaxis effect and that this will minimize with time and wit= h food. 
- Evaluate for B12 df 
- lactic acid=  

Consider GLP-1 on discharge as it reduces C= KD progression and provides ASCVD benefit and helps with weight loss. Avoid= if medullary thyroid cancer, hx of pancreatitis, or gallbladder / biliary = disease (preferred if A1C >9%)

Consider SGLT2 i= nhibitors on discharge as it decreases heart failure hospitalization, nephr= opathy, and helps with weight loss. Do not initiate in AKI, contraindicated= in those with GFR <40-45, those with history of candida infections, or = fournier's gangrene. Avoid canagliflozin in diabetics with PAD given increa= se in amputations. Avoid dapgliflozin in those with bladder cancer. 

- Diabetic educator 
- Home diabetic= supplies (order placed) 
- Given new onset diabetes and A1C= of <8% will initiate Metformin / >9% (or after 3 mo of metformin) wi= ll initiate dual therapy ( metformin + Insulin/oral)  / if still uncon= trolled=E2=80=A6. Triple therapy (metformin + GLP-1 receptor agonist + insu= lin) / >10% =3D insulin (or glucose of 300 or higher) 
- Consider pramlintide (amylin analogue) as adjunctive therapy= for T1DM 
- Given concern for T1DM: screen with GAD 65, Zin= c, and IA-2 autoantibodies 

diabetes:- ketosis prone diabetes= Dialysis line
- Microbacterial (endocarditis), staph, and= fungal cannot do salvage therapy for tunneleddiarrhea
- labs if fever, IBD, food handle= r/healthcare, >70 yrs, heart disease, >6 stools/day, severe abd pain:= Bcx, Cdiff,PCR testing, HIV if young,  parasite/ova  ; feca= l calprotectin, fecal elastase (pancreas)
- Tx: if fever and doing bad, = can do azithromycin or fluoroquinolone
- STEC/EHEC, don't treat with ant= ibiotics due to shiga-like toxin
- Shigella: can actually treat
- Tx:= can give loperamide and bismuth (loperamide slightly better) if too much&n= bsp; (but don't give loperamide  if fever or blood in stool - can incr= ease chance of toxic megacolon in cdiff)

- azithromycin/cipro for ET= EC diarrhea

- juice (high in fructose) worsens viral gastroenteritis= because GI not absorb fructose =3D causes osmotic diarrhea; instead give e= lectrolyte fluid hydration oral hydration and small amount of glucose (hypo= -osmolar); just eat normal diet - limit sugar and fat

- can calculat= e osmotic gap 290- 2(stoolNa + stoolK)
  - <50 =3D secretory =3D= infection (GI electrolyte transport messed up, lots of Na and K in stool)<= br>  - >125 =3D osmotic (stomach not absorbing stuff)

giardi= asis
- Sx: oily stool, from dirty water
- double nuclei
- Tx: tini= dazole

C diff
- vancomycin 125mg QID PO for 10 days  for sev= ere (alb <3 and (WBC > 15k or abd tender)  ; fidaxomicin if not = responding to vanc
- metronidazole PO 500 TID for mild-mod  - complicated =3D If very severe, vanc 500mg QID + IV flagyl 500 q6h.
=

SIBO - small intestinal bacterial overgrowth. Blo= ating, lots of farting, and chronic watery diarrhea.  Just GI bacteria= overgrowth. Dx with carbohydrate breath test (if hydrogen high, then =3D b= acteria fermenting). Tx: oral antibiotic rifaximin/ciprofloxacin for gram-n= egative GI organisms and diet modification.  Folate will be high and v= itamin B12 will be low.


chronic diarrha:
= - seretory diarrhea =3D large volume watery, also night time, unchanged by = fasting  (290-2NaK) if > 100 =3D osmotic, if < 50 =3D secretory<= br>osmotic: not nocturnal, most likely lactase deficiency.  happens wi= th eating.
- Dx: colonscopy and biopsy for microscopic colitis  (co= mmon in women 45-60, with nocturnal diarrhea; stop NSAID, PPI)
-  h= igh fecal calprotein for IBD, urine stool laxative sreen, low fecal elastas= e level for chronic pancreatitis, fecal fat for steatorrhea (celiac SIBO, s= hort bowel, pancreatic insufficiency), stool gap (stool Na, K)


<= br>microscopic colitis:
- age 45-60 women:
- stop NSAID, SSRI, PPI- Dx: colonoscopy biopsy is normal
Tx with loperamide, bismuth for dia= rrhea. budesonide to help also.
#acute on chronic diarrhea:  <4 weeks in durati= on. Likely infectious though could be early fungal infection as well. Likel= y small bowel etiology given watery, large volume, with cramping / bloating= // large bowel given small volume, painful, fever, and blood, and mucus. E= xposure includes travel, antibiotics, recent hospitalization, food, sick co= ntacts, day care, immunocompromise. Most often viral etiology -- norovirus = (less likely given not wintertime) vs rotavirus vs adenovirus. Could be bac= terial, though often severe, but cannot rule out in setting of immunocompro= mise -- E. Coli, campylobacter, salmonella, shigella, C. Diff. Parastici in= cludes giardia, cryptosporidia, cyclospora, e. Histolytics. In immunocompro= mised will evaluate for CMV, C. Diff, cryptosporidia, isospora, microsporid= ium, MAC, TB, histo, and cryptococcus
- Defer antibiotics given p= atient is not febrile -- if develops sepsis or signs of inflammatory diarrh= ea can consider fluoroquinolone vs azithromycin 
Avoid loper= amide for infectious causes, can use pepto as alternative 
-= Blood cultures 
- Stool culture 
- C. Diff&n= bsp; 
- CMV
- Beta D glucan 
- Biof= ire GI 

If chronic -- work up for secretory, = osmotic, functional, malabsorptive, and inflammatory in etiology. 
- CBC, BMP, ESR, CRP
- TSH, 
- Stool lytes = (Na, K pH)
- Fecal WBC, calprotectin, fecal fat, lactoferrin, FOB= T. 
- 290 - 2 X (Na + K) --
- If >50-- evalua= te for lactose intolerance,  sorbitol, antacids, medication, celiac, S= IBO
- stool pH < 6 consider carbohydrate malabsorpti= on 
- If <50 -- evaluate for secretory etiologi= es: infectious, non-osmotic laxative, microscopic colitis, alcoholism, hype= rthyroidism, bile salt malabsorption, medication
- If feca= l fat positive consider malabsorption such as Celiac or maldigestion (chron= ic pancreatitis, SIBO, cirrhosis) 
- Consider celiac disea= se in setting of weight loss and abdominal pain 
- = IgA, IgA anti ttG, HLADQ2, IgA endomysial   
- I= f inflammatory -- consider IBD, ischemia, infection, radiation, or neoplasm= . 



-------= ---------------------------

Exposures: Food Hx (ra= w, undercooked meat/fish), residence, occupational exposure, travel, pets/a= nmials, hobbies, recent abx
Characteristics: duration (acute <= 3 wks),  frequency, fever, blood, mucus, abdominal pain, bloating/gas/= dyspepsia, relationship to food, weight loss, family w/ similar Sx

Chronic diarrhea (>3 wks): 
-Watery (sec= retory vs osmotic vs functional)
-Fatty (malabsoptive vs maldiges= tive)
-Inflammatory

Osmotic diarrhea imp= roves with fasting, secretory diarrhea does not.

S= tool osmotic gap =3D  290  =E2=80=93 2x(stool Na + stool K). Used= to distinguish secretory vs osmotic.
-Secretory (stool osm gap &= lt;50): infectious, non-osmotic laxative, microscopic 
colit= is, alcoholism, hyperthyroidism, bile salt malabsorption, medication
<= div>-Osmotic (stool osm gap >125): lactose intolerance, sorbitol, antaci= ds, 
medication, celiac, SIBO

DDx: = Infectious, celiac disease, SIBO, food intolerance, microscopic colitis, bi= le salt malabsorption, pancreatic insufficiency, IBD, IBS


#Diarrhea
We discussed at length potential= therapies such as a low FODMAP diet, IBgard, fiber supplements, probiotics= , and prebiotics. In addition, she was advised to try levsin SL PRN for blo= ating and cramping as well as immodium PRN to control diarrhea symptoms. Th= e DDx also includes celiac disease, food intolerance, microscopic colitis, = SIBO, infection (e.g. Cdiff), bile acid diarrhea, and pancreatic insufficie= ncy. Thus, we will have ordered tests accordingly (outlined below). 
 

RECOMMENDATIONS
-TTG IgA= and Total IgA to evaluate for celiac disease
-SIBO Breath test
-Stool studies: Fecal elastase, Fecal calprotectin, Cdiff
-Low FODMAP diet
-Start Fiber supplements (We discussed fiberso= urce, benefiber, metaucil, citrucel, fibercon)
-Trial of Pro-biot= ics
-Trial of Pre-biotic sugars (inulin)
-Loperamide PR= N
-IBgard
-Levsin sublingual 0.125mg q4h PRN for bloati= ng/cramping
-Immodium PRN
-Consider colonoscopy with ra= ndom biopsies for microscopic colitis
-Consider cholestyramine, p= ancreatic enzymes (30K units TID), Abx
-RTC 3 months
<= div>
<= /tr>diltiazem/verapamil =3D do not give in HFrEF pt
diuresis

- add m= etolazone / chlorthiazide to augment diuresis, or if hyperNa
- add aceta= zolamide if metabolic alkalosis
- spirinoactone to normalize Kdiverticulitis
- outpt: = cipro/flagyl or watch if not septic or high risk  (ecoli high resistan= ce to bactrim, so won't do bactrim+flagyl; augmentin)
- inpt: zosyn+flag= yl (zosyn only for pseudomonas), normally ceftriaxone+flagyl
uncomplicated (75%) marked wit= h abdominal pain, fever, leukocytosis, obstipation/diarrhea/ anorexia. = ;

Complicated (25%): with abscess/ stricture / fis= tula 

CT shows sigmoid diverticulosis. <= /div>

Uncomplicated management: - Cipro/flagyl, bactirm/= flagyl, bowel rest, narcotics 
Complicated: antibiotics (IV = GNR + anaerobe coverage) bowel rest, narcot,s surgical evaluation (peritoni= its present, evaluation of potential for abscess drainage or colonic resect= ion) 
- Colonoscopy to exclude IBD / malignnacy for 6-8 week= s following acute episode 
Diving nitrogen in body
- Sx: m= uscle pain, itchy skin, visual issuesm dizzy
- Tx: 100% O2, then hyperba= ricdizziness
-= HINTS exam (if abnormal, urgent brain MRI)
- meclizine if motion sickne= ss of meniere

meniere =3D  increased fluid volume/pressure= in ear fluid 
Sx: triad of 20m-12 hr episodes and room spinning, h= earing loss in affected ear (happens first), tinnitus 
- Tx: thiazide, decrease salt, caffeine, alcohol.

labyrinthitis =3D viral = infection, constant vertigo. (can use prednisone)

BPPV
- Sx: <= 1 minute dizzy when moving head
- dix-hallpike - rotary/horizontal/verti= cal nystagmus; head turned to that side is the affected ear side.  on = repeated testing, can decrease= doxorubicin/cisplatin - increases WBC (okay, assess clinical= ly)
- watch for AKIDRESS (drug reaction eosinophilia systemic symptoms)
- by allopurin= ol or antiseizure meds (phenotoin, carbamazepine)
- Sx: rash eruption on= face/upper trunk and goes full body. face edema; fever, diffuse lymphadeno= pathy, multiple organ issue
drowsy/RASS: 

duputren contracture
- fibrosis of palmar = fascia
- Sx: fingers MCP flex
- cause unknown, but jobs with repetiti= ve motion, vibration, DM, alcohol, smokingDVT/PE
- Sx: RR, tachy, cough
- score: = ;Wells' Criteria for Pulmonary Embolism - MDCalc (not for rule = out when inpatient per a study); if t low risk according to Wells criteria = with a PERC  score (see pic) greater than zero, D-dimer testing should= be performed
- score if confirmed PE: sPESI
- causes: surgery/trauma, imm= ovilization, malignancy, pregnanct, OCP, estrogen, antiphospholipid antibod= y syndrome, HIT, paroxysmal nocturnal hemoglobinuria (if mesenteric thrombu= s), obesity, smoking, nephrotic syndrome, HIV/AIDS, cancer meds, central li= ne
- test: bedside echo for right heart strain (hypokinesis, RV>LV)- Tx: lovenox (faster than heparin to theurapeutic). heparin if severe re= nal insufficiency, high bleed risk, or morbid obese.
- if warfarin, dabi= gatran, then also need lovenox or heparin at the same time for 5 days; for = warfarin until INR is therapeutic for 24 hours
- cancer or pregnancy use= LMWH or heparin (not warfarin), but DOAC better for cancer than LMWH
- = if unstable and low bleed risk, consider thrombolytic
provoked =3D 3 mon= ths; indefinite if cancer if bleed risk is low or unprovoked (can do 6 mont= hs and repeat ultrasound if 1st tiem)
- labs: activated protein C resist= ance, anti-cardiolipin IgA, IgG, IgM, antithrombin III activity, PT/INR, PT= T, factor 8, fibrinogen, homocysteine, lupus anticoagulant refle, protein C= activity, protein S activity, prothrombin gene mutation.
Factor V leide= n is most common hereditary
* protein C, S, and antithrombin III levels = affected by anticoag and clotting, so test 2 weeks after completing anticoa= g (PT, APTT, anticardiolipin assay; confirm with lupus anticoagulant testin= g, ixing study), factor V leiden (protein C resistance assay; confirm with = Factor V study), protein C deficiency (protein C activity), protein S defic= iency (protein S activity), prothombin gene mutation (prothrombin/factor II= analysis), antithrombin II deficiency (antithrombin functional), elevated = factor III activity, hyperhomocysteinemia (homocysteine total level), fibri= nogen

- young person with clot =3D likely factor V leiden =3D protei= n C resistence

- UCI heme-onc: camn get prothrombin gene, factor V l= eiden, beta 2-glycoprotein, cardiolipin Abs first.  Lupus anticoagulan= t to check later as false positive when on antico-ag.


SUPERFICIA= L VT with increased risk of progression
=3D extensive SVT, grater saphen= ous vein involvement, thrombus above knee or close to saphenofemoral juncti= on, recent surgery, active cancer, or history of thrombus
- Tx: 45 days = of anticoag.

PPx:
- lovenox 40 mg daily if BMI < 40, BID BMI i= f > 40
- if CrCl <30, heparin 5000 q8-12h
- if HIT, use fondapa= rinux
- if cancer, only lovenox

3-6 months treatment if : VTE ass= ociated with a major transient risk factor, those with unprovoked distal le= g DVT, and those with unprovoked proximal leg DVT who are at high risk for = bleeding
longer if low risk for bleeding and unprovoked proximal

=
- DDx for elevated d-dimer: MI, stroke, DIC, cancer, lung disease, CHF,= renal, 
D-dimer <500 =3D normal  (sensitive, not specific)= --- unless older than 50 (age x10)

proximal DVT (popliteal, fem, il= iac): DOAC > LMWH
distal PE - serial U/S if high risk of bleed or asy= mptomatic versus anticoag (high risk factor for extension: d-dimer positive= , close to prox veins, >cm)


Chronic thromboembolic pulmonary = hypertension
- if TTE shows RV hypertrophy, elevated mean PA pressure, a= nd enlarged RA, then suspect.  VQ scan actually more sensitive than CT= A PE.  IF abnormal, need right heart cath and pulm angio

warfar= in: can get necrosis if patient has protein C deficiency; if skin necrosis,= stop warfarin, give protein C
- if warfarin INR > 10, then give vita= min K, else can just hold warfarin and monitor
- if INR high and life-th= reatening bleeding, then PCC and vitamin K (4-factor with II, VII, IX, and = X preferred; there is 3-factor - without VII, but not as good)

if pr= egnant, use the YEARS criteria + d-dimer

!!! After 6 months, if stil= l need DVT due to increased risk factors, half the dose (is shone to be bet= ter)
https://www.nejm.org/doi/10.1056/NEJMoa1207541
https://www.nejm.= org/doi/10.1056/NEJMoa1207541

dyspnea/SOB<= br>- DDx: HF, arrhythmia, pneumonia, pneumothorax, PE
- exertional: CXR,= EKG, Echo, spirometry, if all negative, then stress test
- Opioids are = the first-line option for treatment of dyspnea refractory to maximal medica= l management.

1 hour duoneb (6ml)

Fungitell -beta d glucan. D= oes not test for blasto crypto= ear infection otitis media
- effusion + fever/tympanic in= flammation
 by strep pnuemoniae, non-typeable H influenzae, or mora= xolella
- Tx: 1st amoxicillin, 2nd augmentin. if penicillin allergy, cli= nda or azithro

early dumping symdrome:increasing osmotic load to the bowel that ccaus= es dizziness (30 minutes)
late dumping syndrome due to insulin (hypoglyc= emic 1-3 hours)= E= KG arrhy

- QRS > 120
  - RBBB =3D bunny ear (rSR') in V1 = , qRs in V6
  - LBBB =3D large negative QS in V1, tall R bunny in V= 6

- QTc <440 in male, <460 in female  (easy QT if 1/2 of = R-R)
- if BBB, then QTc =3D QT - 0.485xQRS

- hyperCa (less reflex= , decrease GI motility, weakness, urinary incontinence) =3D short QT
- h= ypoCa =3D long QT

- electrical alternans (varying QRS complex) =3D c= ardiac tamponade

- LVH =3D Sokolow-Lyon criteria: S in V1+R in V5 or= V6 =3D 35mm+  or aVL 11mm+; (easier) Cornell criteria: S in in V3 + R= in aVL >28mm in male or > 20 in female
- RVH =3D R>S in V1 OR = R in V1 7+mm and S 7mm+ in V6
- LAE =3D negative P wave in V1
- RAE: = P wave > 2.5mm in II

- AVNRT: has small little r' in V1 or V2 dur= ing tachycardic episode. (Can treat with adenosine 6mg, then 12mg if doesn'= t work)
- AVRT: gets J wave or short PR, then gets a PAC, and starts the= AVRT\

if wide qrs, subtract QRS-120 from Qtc

- olanzapine (i= ncreases QTc the least out of all), Ativan does not.  haldol does not = decrease depression
- depakote?

electrolyte
hypoCa
- Sx: carpopedal spasm, l= aryngospasm, bronchospasm, seizures
- EKG: prolonged QT
- iCa <=3D= 0.8mmol/L or Ca <=3D7.5
- if CKD, treat hypophos and vitamin D. = IV calcium not indicated first
- if digoxin, IV Calcium can cause DDI d= igoxin toxicity

hyperCa =3D short QT

hypoK =3D prolong QT, fl= atten T, large U wave
hyperK, peaked T wave, prolonged flat P, wide QRS = if severe
- K has K citrate at UCI

If high K persistent in hospit= al, can be due to heparin. Switch to lovenoxelevated ICP
- repeat CT head in 6 hoursHOB elevation 30 degrees
- CCP goal 60-70 (MAP - ICP)
- ICP non-TBI= <=3D20, if TBI <=3D22
- Na 140-150

If ICP > goal, 3% NS= drip or bolus and/or mannitol 0.5-1g/kg IV q6h (no mannitol if serum osm &= gt; 320)
pupilometers if GCS <=3D3= elevated LFTs / AST/ ALT transaminitis / ALKP

R ratio


if both mildly elevated, can be NAFLD (pt also with= diabetes obesity, HLD(


Primary biliary cholangitis (Age 40-60 m= ore in women)
S&S: pruritis
If ALKP 1.5x upper limit, positive an= ti mitochondrial, or positive SP100/GP210 (order only if anti mitochondrial= negative), then no liver biopsy needed
- Tx: urseodeoxycholic acid
-= screen for TSH yearly, dexa every 2 years, men need HCC screen

PSC<= br>S&S: pruritis, high Tbili, ALKP
Dx: MRCP string of beads
- Tx:= liver transplant
- screen for HCC (annual MRCP and CA 19-9/AFP) and&nbs= p;colon cancer every year, 



augmentin/antibiotics, anti= seizure meds, can cause acute liver injury; or liver hypoperfusion (due to = acute hypotension in hospital); if hemoylsis in young patient or psychiatri= c disorder, possibly wilson disease (order serum copper and urine copper.&n= bsp; and serum ceruloplasmin)
if AST/ALT 5000
- also possibly HSV
=

Elevated liver chemistries - 

1. Hepatocel= lular injury is defined as disproportionate elevation of AST and ALT levels= as compared with the alkaline phosphatase level.

= 2 . Cholestatic injury is defined as disproportionate elevation in alkaline= phosphatase level as compared with AST and ALT levels.

3 . Mixed pattern of injury is defined as elevation of both alkaline = phosphatase and AST/ALT levels.

4 . Isolated hyper= bilirubinemia is defined as elevation of bilirubin with normal alkaline pho= sphatase and AST/ALT levels.

Severe or massi= ve elevations in liver chemistries could be from: acute viral hepatitis, is= chemic hepatitis/shock liver, septic shock, vascular disorders
in= cluding acute Budd=E2=80=93Chiari syndrome or acute hepatic artery
occlusion, toxin-/medication-induced liver injury, autoimmune
h= epatitis, acute biliary obstruction (choledocholithiasis), diffuse infiltra= tion of the liver
with cancer, liver trauma/surgery, veno-occlusi= ve disease/sinusoidal
obstruction syndrome, HELLP syndrome, and W= ilson=E2=80=99s disease.

Elevated AST and AL= T- Ddx Alcoholic liver disease, Cirrhosis (of any etiology), Ischemic hepat= itis, Congestive hepatopathy, Acute Budd-Chiari syndrome, TPN, NAFLD/Steato= sis/NASH, Chronic viral hepatitis, Acute viral hepatitis, Medications and d= rug-induced liver injury, Prescription medications, Herbal products and sup= plements, Over-the-counter agents, Hemochromatosis, Autoimmune hepatitis, W= ilson=E2=80=99s disease, Alpha-1-antitrypsin deficiency, Celiac disease, Ac= ute bile duct obstruction, Post-liver surgery, Veno-occlusive disease/sinus= oidal obstruction syndrome, Diffuse infiltration of the liver with cancer, = HELLP syndrome, Acute fatty liver of pregnancy, Sepsis. 
Elevated unconjugated bilirubin - Ddx Gilbert=E2=80=99s syndrom= e, Hemolysis (intravascular and extravascular), Ineffective erythropoiesis,= Resorption of large hematomas, Hyperthyroidism, Medications, Post-blood tr= ansfusion. 

Elevated conjugated hyperbilirubi= nemia - Ddx Bile duct obstruction (Choledocholithiasis, Malignant obstructi= on, Bile duct stricture, AIDS cholangiopathy)
Viral hepatitis, To= xic hepatitis, Medications or drug-induced liver injury, Acute alcoholic he= patitis, Ischemic hepatitis, Cirrhosis, PBC, PSC, Infiltrative diseases of = the liver, Metastatic cancer, Lymphoma, Hepatocellular carcinoma, Wilson di= sease
Autoimmune hepatitis, Ischemic hepatitis, Congestive hepato= pathy, Sepsis, TPN, Intrahepatic cholestasis of pregnancy, Benign post-oper= ative jaundice, ICU or multifactorial jaundice.

El= evated alkaline phosphatase- Bile duct obstruction, Bile duct obstruction, = Primary biliary cirrhosis, PSC, Medications and drug-induced liver injury, = Infiltrative diseases of the liver, Metastatic cancer, Lymphoma, Hepatic ab= scess, HCC, Viral hepatitis, Cirrhosis, Alcoholic liver disease, TPN, Acute= alcoholic hepatitis, Sepsis, Congestive heart failure. Extrahepatic causes= include: Bone disease, Hyperthyroidism, Hyerparathyroidism, Pregnancy (thi= rd trimester), Chronic renal failure, Lymphoma, Extra-hepatic malignancy



- check HBsAg, HBcAb, = HBsAb, HCV Ab
- check ANA, ASMA, gamma-globulin quant, AMA, cerul= oplasmin, alpha-1 antitrypsin phenotype
- test tylenol level (nor= mally AST and ALT  1000)
- check iron level, transferrin sat= uration, and serum ferritin
- For massive ALT elevation >1000:= HBsAg, HBcAb IgM and IgG, HBsAb, HAV IgM and IgG, HCV Ab,HSV, EBV, CMV, ce= ruloplasmin, ANA, ASMA, AMA, IgG, serum drug panel including tylenol level,= and urine toxicology panel
- check abdominal ultrasound with dop= pler

Chronic liver
- Autoimmune pan= el: ANA, ASMA, AMA, IgG 
- Viral Hepatitis Panel: Hep A IgM,= Hep A IgG, Hep BsAb, Hep BsAg, Hep BcAb, Hep C Ab (do not use acute hepati= tis panel as this does not include all needed values) 
- Met= abolic panel: Ceruloplasmin, A1AT, iron studies including Ferritin 
- Last ultrasound 
- Last AFP (liver cancer)
- Last fibroscan 

#Hepatocellul= ar injury: R ratio > 5 suggestive of hepatocellular injury. May be relat= ed to pancreatitis but cannot rule out other causes.
- UTOX
=
- Ethanol
- Viral hepatitis panel 
- HIV = ;
- Can consider CMV, EBV, VZV, HSV if transaminitis persists bey= odn treatment of pancreatitis. 
- Less likely could be celia= c disease (anti-TTG, total IGA), hemochromatosis, Wilson's (decreased cerul= opasmin, increased urine copper)

- CMV, EBV, VZV, HSV for other viral c= auses of transaminitis 
- Anti TTG, total IgA for cel= iac's. Consider endomysial given high specificity if this is positive. = ;
- FU iron panel nad ferritin Fe/TIBC:> 45% and ferritin >= 200 should warrant HFE testing (often diagnosed in those 40+, with women m= anifesting symptoms later than males)
- Ceruloplasmin, urine Cu f= or wilson's (hemolytic anemia from sudden release of copper and altered men= tal status supports this) 
- ECHO for evaluation of congesti= ve hepatopathy 
- ANA, ASMA, AMA, LKM1 serologies, SPEP for = AIH evaluation 
- RUQ US for fatty liver 
- U= tox for cocaine, ecstacy, PCP

Ischemia likely give= n recent shock, cardiac arrest, history of Budd Chiari. Can consider rarer = causes such as autoimmune hepatitis, acute Wilson's, HELLP syndrome, alcoho= lic hepatitis, malignant infiltration. 
- LDH -- ALT: LDH ra= tio <1.5 suggestive of ischemia/APAP toxicity over viral hepatitis. = ;
- Continue to monitor bilirubin -- often will see a peak in 1 w= eek later after a 48 hr acute rise in ALT/AST. 
- Acetaminop= hen level 
- Hepatitis panel, total hepatitis B antibody, HS= V, VZV, EBV, CMV to evaluate for acute viral infection 

=
nyha

#cholestatic injury: R ratio <2= with elevated alk phos and bili. Ddx includes bile duct obstruction (malig= nancy, ascneidng cholangitis, PSC, PBC, chronic pancreatitis with stricture= s), cirrhosis, medications. 
- Hepatitis panel
- R= UQUS for obstruciton
- AMA 

<= div>#infiltrative pattern of liver injury: alk phos elevated to ***. Ddx in= cludes sarcoidosis, granulomatous diseases, amyloidosis, malignancy. Alk ph= os is als ofound in bone (bony mets), intesitns (increased in SBO). 
- GGT -- if high concern for liver source -- test fractionated alk= phos (bone gut hepatic)
- Consider SPEP 

Indirect hyperbilirubinemia: consider Gilbert's, hemolysis, resorpti= on of large hematoma. 

if women 20-40, = high likelihood autoimmune hepatitis
- IgG level, positive ANA, a= ntismooth, positive pANCA
- will need liver biopsy to confirm dia= gnosis
- Tx: steroid and azathioprine

endocarditis
Duke criteria: https://www.mdcalc.com/calc= /1731/duke-criteria-infective-endocarditis
- suspect if history of heart= valve, heart transplant, any heart surgeries
- HACEK bacteria: haemophi= lis, aggregati/actinobacillus, cardio, eikenella, kingella
- Sx: osler n= ode =3D painful red-purple papule or pustule located on digit or hands/feet= ; roth spot - hemorrhage in retina eyes, focal neurologic sign (septic embo= li), splinter hemorrhage on nails
- Dx: TTE ,consider TEEEndocarditis
Need surgery if = not responding to tx for 5-7 days with persistent bacteremia , >1cm, and= abscess
enol= ase for brain anoxic injury - high specificity 

anoxic brain in= jury post arrest - studies show MAP > 85 bettereosinophilic esophagitis
- Sx: solid fo= od dysphagia
- biopsy eosinophil count 15+/hpf
- Tx: PPI and swallow = steroidepididymi= tis
- <35 - treat gonorrhea and chlamydia (doxy + CTX)
- >35 wi= th levofloxacin.  If having sex, CTX + oral levo.

prostatitis- levo or bactrim for 2-6 weeks
- if hospitalized, gentamicin + levo o= r CTXESBL
- ca= rbapenem
- if oral for simple UTI, nitrofurantoin (Zosyn IV only for mil= d case) or Bactrim is 1st line; fosfomycin also
- duration 7 daysesophageal dysphag= ia
- cause: mechanical obstruction (solids) or motility (liquid or liqui= d and solid)
- dysphagia includes GERD, esophageal stricture/ring, = CP bar, obstructive mass, LES dysfunction, diverticulum.  If motility = component, it could be secondary to spasm, dysfunctional LES relaxation, ac= halasia. 

= esophagitis
- S&S: odynophagia (painful swallowing= )
- most likely candida, then CMV, and HSV
- can also be pill induced= : NSAID, tetracycline, KCL, iron, alendronatefall on outstretched hand

scaphoid fra= cture
- initial XR can be negative, MRI (better) or split with repeat XR= in 2 weeks
- if not treated, can become non-union and distal radius deg= enerates =3D arthritisfalls
- 1 fall in past year needs Up and Go test. >12 seconds ne= eds referral to PTfast heart rate
esmolol dripfever > 104F
malignant hypertehermia (due to anesthe= sia) =3D masster muscle rigid, high ABG pCO2 - Tx: dantrolene
- neurolep= tic malignant syndrome (haldol, seroquel, withdrawal from levodopa - happen= s in days/weeks - gets altered and very rigid. Tx: dantrolene and bromocrip= tine
serotonin syndrome =3D rigidity, agitatoin, very reflex, myoclonus = - benzo, cyprohepatdineflu
- from MKSAP, still start tamiflu but normally, just 48 hours= onset.foot pain<= br>- morton neuroma =3D pain between third and 4th toe caused by wearing ti= ght shoes. pressing on it will hurt;.  Tx: arch support and wide shoes=
foot

= stress fractures
- point tenderness, relieved with rest
- walking boo= t (no need casting for stress fractures), or splint or hard shoe
- MRI i= f XR doesn't show

plantar fasciitis
- pain first few steps in mor= ning, pain at medial calcaneal tubercle with palpation or passive dosiflexi= on of toesgallsto= ne - need = g= astroparesis
#Ga= stroparesis: Patient's ongoing nausea, vomiting, early satiety, postprandia= l fullness, bloating, and upper abdominal pain concerning for gastroparesis= . Diagnosed officially by delayed gastric emptying in the absence of mechan= ical obstruction. Ddx includes gastritis secondary to H PYlori inefection p= eptic ulcer, and functional dyspepsia. A1C of *** -- sugars >200 have be= en shown to delay gastric emptying. 
- Trial prokinetic agen= ts: metoclopramide, erythromycin (more appropriate for short term use) = ;
- Can consider gastric electrical stimulation in outpatient set= ting 
- Consider domperidone
- Consider centrally = acting antidepressants 
- Mirtazapine 7.5 mg q HS (caution= with concurrent SSRI)
- Second line approaches include ve= nting gastrostomy, feeding jejunostomy


<= div>
Secondary to diabetes. A gastric emptying scan was diagnostic of g= astroparesis in *  Ddx includes rumination syndrome, eating disorders,= cannabinoid induced hyperemesis, cyclic vomiting syndrome, GERD, gastric o= utlet obstruction etc. Prior work up includes EGD done in *. Patient was pr= eviously treated with reglan, zofran, compazine* This patient has had frequ= ent admissions and exacerbations likely triggered by uncontrolled diabetes*= and opioid medications. This patients BMI is currently *. 
=
- Markedly uncontrolled ( > 200 mg / dl) glucose levels m= ay aggravate symptoms of gastroparesis and delay gastric emptying. Optimiza= tion of glycemic control should be a target for therapy; this may improve s= ymptoms and the delayed gastric emptying.
- Medication-induced de= lay in gastric emptying, particularly from narcotics and anticholinergic ag= ents and glucagon like peptide-1 (GLP-1) and amylin analogs should be stopp= ed.
- The first line of management for gastroparesis patients sho= uld include restoration of fluids and electrolytes, nutritional support and= in diabetics, optimization of glycemic control.
- Oral intake is= preferable for nutrition and hydration. Patients should receive counseling= from a dietician regarding consumption of a "gastroparesis diet": frequent= small volume nutrient meals that are low in fat and soluble fiber. If unab= le to tolerate solid food, then use of homogenized or liquid nutrient meals= is recommended.

-Oral intake is the preferable ro= ute for nutrition and hydration. If oral intake is insufficient, then enter= al alimentation by jejunostomy tube feeding should be pursued (after a tria= l
of nasoenteric tube feeding). Indications for enteral nutrition= include unintentional loss of 10 % or more of the usual bodyweight during = a period of 3 =E2=80=93 6 months, and / or repeated hospitalizations for re= fractory symptoms. 
- For enteral alimentation, postpyloric = feeding is preferable to gastric feeding because gastric delivery can be as= sociated with erratic nutritional support.

- Check= EKG to measure QTc
- Metoclopramide is the first line of prokine= tic therapy and should be administered at the lowest effective dose in a li= quid formation to facilitate absorption. The risk of tardive dyskinesia has= been estimated to be < 1% but may be irreversable, there is a black box= warning for this. Patients should be instructed to discontinue therapy if = they develop side effects including involuntary movements. 
= - Reglan 5=E2=80=9310 mg AC BID-TID can start with IV and transition to PO&= nbsp;
- Erythromycin improves gastric emptying and symptoms from = delayed gastric emptying. Administration of intravenous (IV) erythromycin s= hould be considered when IV prokinetic therapy is needed in hospitalized pa= tients. (Erythromycin 250=E2=80=93500 mg ac t.i.d.)
- Schedule an= tiemetics around the clock
- We do not offer gastric electrical s= timulators at UCI, the patient will need to follow up at another center as = an outpatient for this 


= ge= riatrics:
- semitandem, tandem, one leg - risk of falls
- cut off for= proximal; 30-second chair stand
- STEDI toolkit
- BP and weight can = be home RN
- medstopper.com
- donepezil: urinary inconteinence side e= ffect
- SNF should have tapering for psychotroppic meds
- try to tape= r all beers
- cipro for old people can cause confusion if renal
- wha= t is most important to you (function, enjoyingm connecting_; what concerns = you about your health in the future
- POLST only if DNR (assisting livin= g, SNF, board require it)
- ARU: needs 2 skilled needs
- medicare/pri= vate: 100% for 20 days, then 80% for rest 80 days (100 days total) - copay = ~$176/day after (medicaid will take the copay).  (- medicare A: need 3= midnights to qualify for medicare part A; observation time doesn't count);= can go to SNF again 60 days after.
- long term care; custodial care: co= vered by medical only.  (ADLs; normally fecal incontinence)
- SNF p= hysician needs to see only within 72 hours  (only have tramadol PRN in= their emergencyh kit; need 3 days of opioids***); SNF physician only need = to see after once a month
- SNF < beds, 1 RN per day shif (1RN per 40= beds); >99, 1 RN per each shift; mostly LVN, few RNs
- if med is too= expensive; may be denied (as takes from their final pay)
- continue DVT= ppx; No IV pain meds
- psych meds need indication/diagnosis and consent= from family (medicare monitors this to SNF)
- SNF has, dopller U/S, por= table xray, urine, labs. stool (ndont' do misc labs); no CPAP/BIPAP provide= d -- or hospital need to give for discharge
- SNF does not have to have = defibrillator (advocate for lifevest if going to SNF)
- SNF to appointme= nt patient covers by self; exception some HMOs has this benefit
- do not= need a primary care appointment until after SNF discharge (SNF MD should c= are)
- no RT on site
- wound pressure stage3 and 4 cannot go to assis= ted living or board and care
- residential care for the elderly form (AL= F - rent and food; anything else laundry is extra; or board and care - not = more than 6 people; 24 hour living care giviners; but only does things in t= he day shift -- no medical staff)

IADLS: telephone, shopping, cooking, housekeeping= , laundry, medications, finances, driving
bathing, dressing, feeding, toileting,= incontinence, transferring
gi cocktail aloh/mgoh/simheticone with viscous lidoca= ine 15cc (Mylanta/maalox)GIP
- can increase versed to 39gitelman syndrome
- S&S: young adult/teen,= with low BP, low K, high CO3, high Ca
vs. Bartter sydnrome - presents a= s childglycopyrol= late to decrease secretion in comfort care

gonorrhea
- disseminated gonorrhea: - = pustular/vesiculopustular at extremities, painless, tenosynovitis and polya= rthralgia, with fevergood resources:
- b line https://www.grepmed.com/images/11922/l= ung-diagnosis-profiles-ultrasound-abcsgout
- NSAID + choclicine + steroid (20-30mg predn= isone (do weight based too though)) when acute flare
- allopurinol when = not in flare (start colchicine too when on allopurinol; can stop in 3 month= s)
- febuxostat (not in acute too) if cannot take allopurinol (very bad = CKD)
- no colchicine in kidnery failure patients
- colchicine only wo= rks for first 2 days of acute flare
- uric acid goal <6, <5 if top= hi
- 2 episodes in 1 yr needs ppx


No nsaid in ckd, chf
- if cannot do any of the acute tx, then anakinra and/or cosyntropin

gout
- u= ric acid may not show in acute
- uric acid therapy:
- NSAIDs, colchic= ine, prednisone

-  Tx: allopurinol (don't start during acute fl= are)
1) tophi, goal uric acid < 5
2) erosions of bone
3) 2 or m= ore gout flares
4) CKD3 and uric acid > 9grief-depression in pallative
- if <6 = weeks onset, use methylphenidate. benzo for anxietygroup A strep / strep throat
- Sx: ton= silar exudate, anterior neck lymph, fever
- tx duration: 10 days (amoxic= illin or penicillin)


rheumatic fever
- Sx: erythema marginatu= m skin
- 2-4 weeks after

post-strep GN
- tea colored urine (he= maturia)
- low C3 (and C4)
- Tx: supportive care, diuretic, BP medsgynecomastia
-&= nbsp;estradiol, total testosterone, luteinizing hormone, and =CE=B2-human c= horionic gonadotropin level
- Unilateral, nontender, or fixed breas= t masses in a man should prompt an evaluation for breast cancer with a mamm= ogram.hHAP
- Dx criteria: 48 h= ours since admission= Headache
- MRI if first/worst migraine, persistent (>72hrs)
- = risk of overuse NSAID causes
- tx: Naproxen 500 or ibuprofen 600

= - intracranial hypotension =3D S&S: posturalheadache, diplopia, tinnitu= s, photophobia.  CSF opening pressure <60 mmH20  will see some= meningeal enhacement  possibly small cerebellla tonsillar dscent.&nbs= p; Tx:  epidural blood patch


Tension
- preventative: ami= triptyline 

Migraine
- dx criteria: ICHD-3; chronic =3D 15+ = episodes
- tx: NSAID, rizatriptan q1-2h faster onset and fewer si= de effects than sumatriptan (no triptan in CAD, PAD, ischemic stroke). nara= triptan q4h also good - longer acting, slower onset. Triptan can cause ches= t tightness (let patient know). -diptan if CAD/PAD, but causes dizziness. <= br>Preventative (if 4+ episodes): propranolol, metoprolol, topiramate (S= E if long term use: kidney stone, foggy brain), valproate, venlafaxine = but SE. If fail 2 triptan, insurance covers -gepants (CGRP receptor blocker= ) and CGRP Ab Gepants.
- Tx: metoclopramide 10mg IV also good
-&= nbsp; triptans are contraindicated in the setting of brainstem or hemiplegi= c auras.   !!! no triptan if CAD or stroke

Nausea c= aused by migraine - try metoclopramide or prochlorperazine (Compazine)
<= br>"Trial migraine cocktail q6h PRN: 1L fluid bolus, toradol, benadryl and = zofran" 
  • severe migraine:
    1L bolus of IV normal saline solution
  • 10 mg = of IV prochlorperazine
  • 25 mg of IV diphenhydramine
  • 30 mg of I= V ketorolac
  • 10 mg of IV dexamethasone

  • Olanzapine also w= orks for nausea

    he said: 15 toraldol , topamax 25mg, 10mg reglan, 10= mg prolchlorperazine, 2g Mag, 10mg IV dex  (make sure QTC is okay)
    =


    outpatient:
    - quilipta for chronic migraines abortive and pr= eventative (needs prior auth)
    - nurtec for episode migraines (needs prio= r auth)
    - Froba for menstrual-induced migraines (longer active)

    <= br>Chronic migraine =3D 15x/month
    status migrainosus =3D last >72 hou= rs with or without aura

    Cluster headache:
    -  periorbital and= temporal with lacrimation, ptosis, and rhinorrhea. last 15-180 minutes onl= y.
    - Tx: O2; verapamil for prevention
    Differential includes primary headache such as mig= raine vs tension headache. Doubt subarachnoid hemorrhage, headache not maxi= mal at onset, not worst headache of life, and patient has normal neurologic= exam. Doubt meningitis or encephalitis, no infectious symptoms or meningis= mus on exam. Doubt acute angle glaucoma, no vision changes or eye pain. Dou= bt temporal arteritis.

    heartburn / dyspepsia
    - c= ause: idiopathic (75%), cancer, H pylori, NSAID, bisphosphonate
    - Tx: tr= ial famotidine, but if not better, H pylori testing if <60. if >60 yr= s old, EGD


    - test all pts with PUD for H pylori
    H pylori test= can be negative if taking PPI or antibiotics; stop 4 weeks antibiotics and= 2 weeks for PPI for H pylori testing


    KCL can cause non-ulcer dy= spepsia (stomach pain)
    hematoma:
    subdural hematoma - from bridding veins, common in ol= der ageheme issu= es

    G6PD
    - bite cells, confim with G6PD level

    Microangiopat= hic hemolytic anemia
    - helmet cells

    thalassemia
    - target cells= hemophilia C (fa= ctor 11 deficiency) comon in Ashkenazi Jew ---
    - only aPTT is prolonged = (no easy bleeding symptoms, but only post-surgical prolonged bleeding)
    -= Dx: factor levelshemoptysis
    - causes: bronchitis, bronchiectasis, cancer, trauma, infec= tion (pneumonia, abscess, TB), vasculitis (ANCA, anti-GBM), coagulopathy, P= E
    - CXR, CBC, coag, UA, sputum Cx, CTA chest if stablehemoptysis
    - CT with contrast, i= f negative, bronchoscopy
    - cause: infection, bronchitis, malignancy= heparin 
    BM= I > 40 (versus UCI says 70kg) - q8hhepatic adenoma
    - if >5cm or in male, remove as = high risk of transforming to cancer)
    - for women, discontinue oral contr= aceptive and follow up with CT/MRI at 6 monthhepatic encephalopathy
    - lactulose 3-4 BMS= per day
    - rifaximin if still not resolvedhepatitis C
    - need q6m ultrasound to asses= s for HCC (+/- AFP too)
    - hepatitis C: can also get vasculitis - HCV-ass= ociated mixed cryoglobulinemia =3D shows as recurrent purpuric very purple = spotty lesions on foot

    - A= cute HepB, even if ALT/AST very high at 1000-2000s and jaundice, just have = outpatient serial labs - no need to admit.  HepB low risk of liver fai= lure.  If having encephalopathy AND INR 1.5+, then admit to ICU due to= acute liver failiure.
    - HepB with HepC, need antiviral
    - HepB, adult= progressing to chronic HepB is 5%.  Kids 1-5 with acute HepB, 20-50% = become chronic HepB

    - hepatitis B that is infection in reactivatin= o phase, pt who is immunosupressed: treat with entecavir or tenofovoir
    <= br>Hereditary he= mochromatosis
    - OA at early age or at joints that shouldn't be for OA, h= igher AST/ALT, serum ferritin, and transferrin level
    - Dx: test HFE gene= mutationhigh out= put GI fistula:
    - Tx: subQ/IV octreotide histoplasma:
    - disseminated: ampo B&nb= sp; (histo urine antigen very good for disseminated)
    - if local: itracon= azole

    fungal pneumonia chest pain/pleuritic is normally longer than = acute (e.g. 2 months)
    fungal infections get pancytopenia

    HIT
    - change to bivali= rudin or fondaparinuxHIV

    - F/u aspergillus, 1,3 beta D glucan, histoplasma, cryptococcus= , blastomyces, LDH, coccidioides, AFB, blood cultures, sputum culture, NAAT= , C diff, stool culture, stool O+P, PJP, cryptosporidium, isospora, giardia= lambia
    - Ophthalmology exam (for CMV retinitis) 
    = hi= v
    - if patient has cryptococcal (and TB meninigitis), don't start ART ri= ght away , but 2 weeks after antifungal therapy starting;  monitor for= ICP and immune reconstitution inflammatory syndrome
    - to start abacavir= , need HLA-B57:01 testing to be negative to reduce risk of hypersensitivity=

    - crypto meningitis daily LPs
    HLD
    - LDL 190+, high intensity statin; need 50% red= uction, else ezetimibe and then PCSK9 Ab
    - any MI, stroke, PAD, CABG, st= able angina, ACS if <75 yr old =3D high intensity statin, else moderate<= br>- if diabetes and 40-75, mod intensity (consider high intensity if ASCVD= 20%+)
    - ASCVD > 7.5%, mod intensity (CKD, metabolic syndrome, rheum/= inflammatory disease, south asian, LDL 160+, trig 175+)

    - LFt before= starting statin, if symptoms, then measure again (else no need).  If = elevated 3x, hold statin if concerned of cause

    stroke/with CAD or PA= D, LDL goal < 55
    Triglyceride 500+, persistent
    - Tx: fenofibrate
    Eruptive xanthoma =3D on extensor surfaces

    #metabolic syndrome: Patient mets = 3/5 criteria (HTN on medication or >130/85, diabetes on medication or fa= sting glucose> 100, waist circumference >40 for M, >35 for F, HDL = <40 for M <50 for F, TG>150) 
    #Overweight (BMI 25-2= 9.9), Obesity (BMI>30), Severe Obesity (BMI > 40) 
    - f= /u lipid panel 
    - Initiate statin 
    - Can cons= ider Vascepa in outpatient setting for further TG reduction
    - CoQ= Enzyme for reduction in myalgias 
    - Vitamin D level -- "sup= plementation with vitamin D in patients who were vitamin D deficient and al= so had statin-related myositis=E2=80=93myalgia resulted in considerably mor= e patients able to restart statin treatment" (N. Katsiki, V.G. Athyros, A. = Karagiannis & D.P. Mikhailidis (2011) Vitamin D deficiency, statin-rela= ted myopathy and other links with vascular risk, Current Medical Research a= nd Opinion, 27:9, 1691-1692, DOI: 10.1185/03007995.2011.598922 )
    = - Can consider metformin in outpatient setting for weight loss in setting o= f metabolic syndrome \
    - Consider pharmacotherapy if BMI > 30 = or BMI > 27 with 1+ comorbidity -- ask PCP at time of discharge about me= tformin, liraglutide, orlistat, qsymia . 
    Consider bariatric= surgery evaluation if BMI>40 or BMI>35  with comorbidities
    - Recommend weight loss given multiple RF -- can copy and paste the f= ollowing in discharge paperwork: 
    HLH (hemophagocytic lymphohi= siocytosis)
    - mass macrophages and cytotoxic T cells activated
    - Feve= r, low HGb, plt, HGb, ANC, high trig, low fibrinogen, IL2R high, AKI, high = D-dimer

    (need to treat underlying)3D""hos= pice
    - need FAST score of 7 to qualify for hspice care (Http://www.mcisc= reen.com/pdf/fast_overview.pdf)
    = HTN - hypertensive emergency
    - cause of urgency: pain,= anxiety, urinary retention, steroids, other med SE

    HTN emergency- end organ damage: severe headache, seizure, altered, TIA, CVA< papill= edema, pulmonary edema, MI, microangiopathic hemolytic anemia (hemolysis fr= om shearing), AKI, hematuria

    HTN
    - causes: NSAIDs, OTC decogestan= t, med adherence, obesity, snoring, renal disease, primary aldosternoism (l= ow K, high Na; aldo-renin ratio > 30 in AM), renal artery stenosis (50% = rise in Cr after ACEI start; order duplex U/S)
    - Goal for gradual BP red= uction, 20% reduction within the first hour and then goal for 160/100 mmHg-= - for the next 2-6 hours with cautious reduction to normal BP within the ne= xt 24-48 hours.  

    If labetalol doesn't work, can add on ni= troprusside

    2nd causes: renin aldosteron most common (Need to hold a= ce/arb)
    - ER: nifedipine ER faster than amlopidine (takes 5+ days)
    HTN outpt:
    - masked hypertension (i.e. normal in office, high at home)= , antihypertensive medication should be initiated after a 3-month trial of = lifestyle modification if daytime ambulatory or home blood pressure remains= =E2=89=A5130/80
    - 1st line HCTZ/chlorthalidone (UCI start losartan50-HC= TZ 12.5), 2nd amlodipine, 3rd line replace HCTZ with chlorthalidone  (= more hypoK risk), 4th, spirinolactone or bisoprolol

    Aldo renin cut o= ff 30
    Hold spirinolactone- increases renin and retest


    rule ou= t PRESS  (ataxia, headache, HTN)

    Saw at LBM: enalapril after la= betalol (no evidence)
    "Patient's blood pressure is *** and remains elevated on at least 2 o= ffice visits and categorized as normal (<120/80) // elevated (120-129/&l= t;80) // Stage 1 (130-139/80-89) // Stage 2 (>140/90) // Resistant (on 3= or more agents at optimal doses, with one being a diuretic, or controlled = on 4+ meds) 

    - f/u fasting blood glucose, LIP= ID PROFILE (cardiovascular comorbidity)
    - CBC (polycythemia) Seru= m sodium potassium and calcium (Cushing, Conn, hyperparathyroisim) TSH (2/2= cause)
    - Cystatin C/GFR, UA, ECG, ECHO, urinary albumin/Cr = (target organ damage)

    Other secondary causes of H= TN
    - Renal u/s (Renal parenchymal disease / CKD): 
    - Renal duplex or MRA or abdominal CT (renovascular disease)
    - P= lasma aldosterone / renin ratio (primary hyperaldosteronism is >20)
    - Sleep study (OSA)
    - 24H urinary metanephrines (pheochromo= cytoma)
    - Overnight 1mg dexamethasone suppression test (Cushing)<= /div>
    - TSH
    - Ca 
    - ILGF1 (acromegaly)
    - Aldosterone and renin levels (mineralocorticoid excess)
    - Ec= hocardiography (coarctation of aorta)

    Plan: <= /div>
    Hypertension: ASCVD risk ***. Goal of <130/80 (<140/90 if s= econdary stroke prevention) 
    - <10% and less than 140/90 = can be managed with lifestyle changes as if has no significant comorbiditie= s (DM, CKD, HF, PAD, lacunar CVA) 
    - Start thiazide 
    - Start on ace/arb given albuminuria 
    - Start on 2 a= gents given stage 2 BP. 
    - Black: thiazides or CCB 
    - Stable ischemic heart dsiease: beta blocker + ace / arb (+dihydrop= yridine CCB if HTN and angina uncontrolled -- more smooth muscle effect... = NOT diltaiazem or verapamil)
    - HFrEF: loop diuretic + ACEI + beta= blocker (NO CCBs... consider spironolactone if LVEF <35%) 
    - HFpEF: diuretics (+acei or ARB plus beta blocker) 
    - CK= D: if albuminuria present: ACE (thiazides ineffective if GFR <30... use = loop diuretic) 


    "
    #hypertensive urgency: HTN urgency givne BP >180/20 without= evidnece of end organ damage. Hypertensive emergency BP > 180/120 with = evidence of end-organ damage. 
    - Reduce BP to <160/100 ov= er the course of the day 
    - Reduce to normal range (<130/= 90) 
    - Patient able to tolerate PO: Captopril, laneatlol >= ;> hydralazine given more predictability
    - IV: labetalol, hydr= alazine, nitropaste 

    HTN due to pulmonary edem= a: nitroglycerin and nitroprusside (no beta blockers!)hydrocortisone + florinef shows bene= fit over just hydrocoritone q8h 100 mg for stress dosehyperaldosterone
    - S:S resistive= HTN even with 3 drug therapy.
    - Dx: aldo/renin ratio >20 and aldo 15= +ng/dL =3D primary hyperaldo
    - refer to endocrine/nephrology
    - Tx: ep= lerenone (aldosterone receptor blocker) or spirinolactone

    Can try sa= lt load if not conclusivehyperCalcemia
    - Dx: PTH, phosphate (would be low in primary hype= rparathyroid, high in multiple myeloma), Cr, 24-OH vitamin D, TSH, FRee T4 = (hyperthyroid stimulates osteoclast)
    - rule out sarcoidosis; test urine = Calcium ; also rules out familial hypocalciuric hypercalcemia.
    - check f= or MEN1
    - acute Tx (if > 14): normal saline (don't give diuretic unle= ss patient hypervolemic and has HF or kidney failure); if caused by sarcoid= osis or multiple myeloma or B cell lymphoma, add steroid.  Also IV bis= ophosphonate
    - long term Tx: bisphosphante

    #Hypercalcemia
    Ensure corre= ction for albumin -- mild (Ca<12) moderate (12-14), severe (>14). Cli= nical manifestation include MSK -- osteitis fibrosa cystica, bone pain, wea= kness, renal -- polydipsia, polyuria, nephrolithiasis, type 1 RTA, AKI/CKD,= GI-- anorexia, constipation, ileus, pancreatitis -- psychiatric findings i= ncluding fatigue -- depression, anxiety, cognitive dysfunction, coma, stupo= r -- and CV findings such as bradycardia, short qtc, AV block 

    - PTH to determine if this is related to elevated PTH (pr= imary HPTH (adenoma > hyperplasia > carcinoma), FHH (24 hr urine calc= ium/cr ratio <0.01 or UCCR > 0.01), tertiary HPTH, or ectopic PTH. Lo= w PTH etiolgoies include increased PTHRP (ectopic production from malignanc= y), increased calcitriol levels (lymphoma, granulomatous disease), increase= d ergocalciferol (vitamin D toxicity), and other etiologies including multi= ple myeloma, hyperthyroidism, adrenal insufficiency, pheochromocytoma, drug= s (thiazides, lithium) and milk-alkali syndrome 
    - Mild to m= oderate hypercalcemia can be managed outpatient 
    - Severe hy= percalcemia needs treatment.
    - Conservative measures: 
    =
    = - Oral hydration 
    - Oral PO4 repletion to go= al 2.5-3 (IV can precipitate hypocal
    - Volume resuscitatio= n: bolus NS then gtt @ 200-300 cc/hr 
    - Loop diuretics only = if ocncurrent HF or CKD
    - Calcitonin 4-8U/kg SC BID for 48 hours = (lowers Ca by 1-2 ) Beware tachyphylaxis in 48 - 72 hours 
    -= Bisphosphonates to be used in setting of malingnacy, zolendronate preferre= d. Takes 2-4 D. Ensure 25 OH D repletion prior to admin. Avoid if CrCl <= 30 
    - Denosumab can be used in bisphosphonate refractory hy= percalcemia 
    - Glucocorticoids is effective in calcitriol [1= ,25-OH-vit D]-mediated etiologies
    - HD if refractory or life-thre= atening
    - If primary hyperparathyroidism -- surgery is curative.&= nbsp;
    Indicated if (a) symptomatic OR (b) asymptomatic with Ca &g= t; 11.5,osteoporosis/vertebral fracture, CCl < 60, nephrolithiasis, or a= ge < 50. 
    - If poor surgical cand., consider cinacalcet, = bisphos., tamoxifen

    Hyperglycemia/DKA
    - if just = hyperglycemia, then fluids a lot first before starting more insulin that ho= me dose.

    - b-OH > 3.5 or 4 with acidosis

    - DKA: bicarb <= ;=3D15, ABG p H <7=3D7.3, glucose > 250, ketone
    HHS: glucose > = 600, can be normal other labs - Tx: give a LOT of fluids

    causes of D= KA/HHS
    - infection, ischemia, inflammation, intoxication, insulin defici= ency (non compliance, lasix, steroids, etc.)
    #DKA: A1C of *** Na of 141 corrected for gluco= se on admission. K of 3.1. Glu of 378. Home meds: on
    - LR @ 200 c= c/hr 
    - If K<3.3, hold insulin and give 20-40 meq IV K. R= estart insulin drip on recheck. 
    - If K 3.3 - 5.3, add 20 mq= K to IVF 
    - If K >5.3, continue to monitor K q 2 hrs.&nb= sp;
    - BMP q 4 hrs 
    - Mg q 4 hrs 
    - = Phos q 4 hrs, replete Phos only if <1 
    - Beta hydroxybuty= rate q 12 hours 
    - If pH<6.9, give 2 amps of HCO3. <= /div>
    - f/u TSH 
    - Transition ot subq insulin if BG<2= 00 AND pt is able to eat AND two of the following are met: AG <12, HCO3&= gt;15, pH>7.3. 
    - Add D5 to fluid to maintain insulin dri= p if sugars < 200 in order to maintain 2 HOUR OVERLAP with subq insulin = (long acting  (some say 0.1units/kg vs calculate)
    - bolus&nb= sp;
    - D10 if BG < 150 and gap not closed and decrease insulin = to 0.5cc/kg/hr
    - Diabetes educator 
    - NPO for now = until glucose <200 


    hyperkale= mia
    - mild =3D 5-6 (furosemide / kayexalate)
    - moderate =3D 6-7 (glyc= ose+insulin, sodium bicarb, neb albuterol)
    - severe =3D 7 

    -= Kayexalate (polystyrene sulfonate) 15mg PO QD-QID
    - lasix 10mg (low dos= e)
    - Lokelma
    - patiromer
    - if need to continnue ACEI/ARB, then pat= iromer also

    - EKG: wide QRS, peaked T waves
    - Tx: give CaCl if se= e T waves

    - sodium bicarb decreases K and Ca


    hypoK
    - S= x: decreased reflex, arrhythmia, PVCs, can cause torsades; causes kidney to= not respond to ADH =3D peeing a lot and thirsty


    - repeat EKG
    - low potassium die= t
    - EKG= hypernatremia
    - score: Free Water Deficit in Hyper= natremia - MDCalc
    - Causes: water loss (GI loss, central/nephrogenic= diabetes insipidus, osmotic diuresis, DKA, manitol), hypothalamic lesion, = severe exercise/seizure, eating too much salt


    -both hyponatremia= and hypernatremia male: 0.6 x ([Na)-140]/140; female =3D 0.5

    <= td spellcheck=3D"false" contenteditable=3D"true">- serum Osm, urine Na, uri= ne Osm
    - CT head to r/o brain lesion
    - UA with UCx
    - D5W 1.35c/hr = x pt's wt (kg), goal lowe rNa 10mEq/L in 24 hours i.e. 0.4mEq/L/hr (max <= ;0.5mEq/L/hr to prevent cerebral edema)
    - BMP q4h (what for K, Na, hyper= glycemia on D5W)


    #Hypernatremia: Free water deficit: *** --= then calculate rate of free water replacement using http://www.nephromatic= .com/sodium_correction.php     Likely due to impaired access= to free water vs impaired thirst. PO free water 
    - NGT 200-= 400 mL q 6-8 hours 

    Or IV D5W 

    May need DDAVP for DI with enodcrine xx

    - BMP q 4 hours 

    Likely due to free wat= er loss in excess of NaCl loss. Likely due to imapried access to free water= or imapried thirst. 
    Decreased urinary concentrating abilit= y of DI (decreasd ADH) 

    RENAL LOSSES:UOsm <= ; 700 -- post ATN diuresis, osmotic diuresisis, DI, loop diuretic, elderly&= nbsp;

    Extrarenal losses: Uosm > 700 -- GI loss = from NGT, vomiting, diarrhea, hypodipsia 

    = hyper= parathyroidism
    - hyperCa, if T<-2.5 / lumbar and thoracic spine show = fracture, would need parathyroidectomy only if age <50 and symptomatic- regular folllow up with Ca, Cr, and DEXA
    - Tx: cinacalcet (decrease = PTH) + bisphosphonate (block bone breakdown)hypertonic saline - only if someone has bronc= hiectasis; 
    h= ypertrophic cardiomyopathy (HCM)
    - squatting (increase pre and afterload= ) decreases obstruction and decreases murur
    - Tx: metoprolol succ
    - != !! do not give diuretics, vasodilators, or digoxinhypoadrenal
    - -S&S: weight loss, l= ow sugar, hyperpigmentation & hypoNa and hyperK (in primary adrenal), h= yperCa
    - Dx 8 AM cortisol: <3ug/dL confirms diagnosis. >18ug/dL ex= cludes.  if mmorning ACTH high, adrenal CT. if morning ACTH low or mor= mal, pituitary MRI
    - if needed, stim test with ACTH. if  cortisol &= gt;18ug/DL, then negative
    - Tx if acute, don't test - just empirica give= high dose 4mg dexamethasone and IV fluids.  !! dexamethasone does not= interfere with serum cortisol assay interesting!

    - Tx: hydocortison= e 15-25mg/day, increase 2-10x if stress or minor surgery; add fludocortison= e if primary adrenal insufficiency
    - hydrocortisone 100mg followed by 50= mg q6h for major surgery/stress.
     hypocalcemia
    - CaCl 1g =3D 3 g Cagluconate= hypocalcemia
    - c= auses: vitamin D, low Mg, pancreatitis, rhabdo, CKD, tumor lysis
    - Dx: P= TH, mg, phos, ionized Ca, vitamin D, albumin, EKG for prolonged QT
    - low= Mg (diarrhea, alohol, diuretic) will decrease PTH secretion
    - Tx: if iv= er disease, then 24-vitamin D.  If kidney disease, then 1,25 vitamin D= .  Else just D3 is okay.= hypoglycemia
    - if cpeptide high, possibly insulinoma or t= aking ora antidiabetic pills
    - if cpeptide low, possibly insulin injecti= ons

    Insulinoma: 
    - tsh, free t4, am cortisol
    Sulfonyurea = and meglitinide screen and insulin ab (hypoglycemia panel)
    - 72 fast tes= t is - when glucose <60, send c-peptide, pro insulin, insulin level, bet= a oh.   Then until neurological symptoms or glucose <45 and re= send all labs. Then give them d50
    - tx: diazoxide
    - then if ct with c= ontrast imaging negative, do a EUS

    Hypokalemia
    - diuretic use or gitelman syndrom= e =3D high urine Cl
    - laxatives =3D urine K will be low to hold onto K a= s much and get metabolic acidosis (HCO3 in stool);  urine anion gap (U= rine Na + Urine K - Urine Cl) would be negative
    - vomiting =3D urine pH = will be high and low urine Cl (to compensate for body losing H, will excret= e HCO3 in urine)

    gitelman syndrome
    - S&S: young adult/teen, w= ith low BP, low K, high CO3, high Ca
    vs. Bartter sydnrome - presents as = child
    hyponatr= emia
    - Calculate rate: Sodium Correction Rate in= Hyponatremia and Hypernatremia - MDCalc
    - causes: drugs (e.g. bactr= im a lot of times)
    - physiology is ADH appropriately (hypovolemia or hyp= ervolemia with decreased effective arterial volume EAV (CHF,nephrotic syndr= ome, cirrhosis) or inappropriately increased; rare - primary polydipsia /te= a toast/beer/malnutrition (low solute) will decrease ADH =3D restrict fluid= and salt restriction
    - correct for glucose every 100 over 100, add 2.4 = to Na
    - if cirrhotic with ascites and <120, can trial albumin (increa= ses EAV)
    -  Urine Na <20 mEq/L =3D extrarenal loss i.e. kidney a= ble to absorb Na back (if hypovolemic: vomiting, diarrhea, third spacing; i= f hypervolemic: HF, cirrhosis, low alb) ; > 20 =3D  renal issue ((t= hiazide)) diuretics, minerocorticoid deficiency; if hypervolemic: renal fai= lure)
    - if euvoluemic =3D free water restrict and treat underlying
    &n= bsp; - if Urine Osm > 100 mOsm/kg =3D SIADH (inappropriately high), <= 100 (i.e. ADH appropriately low) =3D primary polydipsia/beer poto.  Os= m is surrogate for ADH.
    - if hypervolemic - all fluid restrict + salt re= strict
    - if acute (<48 hours), can correct quickly. If chronic and as= ymptomatic, increase 4-6 in 24 hours to prevent ODS (osmotic demyelination = syndrome)
    - if severe, 3% NS 100cc bolus (careful extravasation risk of = skin necrosis) and then 0.5-2cc/kg/hr until symptoms resolve (need central = line?); can correct 6-8 in 24 hours

    - can consider vasodilator in CH= F (ACEI/ARB)

    SIADH
    - causes: malignancy, lung (pneumonia/asthma/T= B), brain (trauma/stroke), drugs (SSRI, chemo, antipsychotic), post-op / na= usea / pain
    -  = Hypouricemia (uric acid < 4 mg/dL) is frequently observed in patients= with SIADH during the period of hyponatremia

    NS has 154mEq/L Na=
    LR has 130mEq/L Na, 4 K

    - can add urea salt if salt tag 3g TID d= oesn't work due to sodium wasting  (3g TID is 1 L NS without the water= )

    If pseudohyponatremia, measure Na with VBG lytes as uses anode to = calculate


    alcohol, BUN, glucose can increase serum osm that make= s water go into blood stream, and fakely decrease sodium

    - pseudohyp= onatremia  (isotonic 275-295: if high paraprotein ((e.g. multiple myel= oma, high trig) -- because sodium in lab is based on Na over plasma, not Na= over water

    -= PE: JVP, mucous membrane
    - orthostatic
    - serum Osm, urine Na, urine = Osm
    - TSH


    # {Acute if less than 48 hours} {mild 130-134,= moderate 120-129, severe <120} Hyponatremia: Patient's serum sodium ***= on admission. Hyperglycemia {is/is not:9024} present and the corrected ser= um sodium is *** (add 2 meq/L for every 100 mg/dL above normal). Pseudohypo= natremia {is/is not:9024} suspected (patient is not jaundiced, no hx of pla= sma cell dyscrasia, not postoperative after prostate or uterine surgery, ha= s not received mannitol or IVIG) and patient's serum osmolality is {normal/= elevated:21542}  at ***(>280). Patient's GFR is normal at *** (>= 90) and is *** not on a thiazide diuretic. Patient is currently {asymptomat= ic vs symptomatic} with *** {Seizures, Obtundation, Coma, Respiratory Arres= t, Vomiting, Fatigue, Lethargy, Confusion, Forgetfulness, Headache, Dizzine= ss, Gait disturbance, Nausea, Muscle cramps}


    <= /div>
    DIAGNOSTIC
    Presentation is consistent with hypovolemic = hyponatremia: low BP / postural hypotension. And urine sodium *** urine oso= ms *** 
    INTRARENAL LOSSES
    - r/o head injury (Cereb= ral salt wasting)
    - review home meds (diuretic induced)
    - consider AM cortisol and ACTH stimulation test (primary adrenal insuffic= iency if low cortisol and +ACTH stim test)
    EXTRARENAL LOSSES
    - GI loss, third space loss, 
    - UNa of 25-40 -- will a= dmin IVF and recheck 


    Presenta= tion is consistent with euvolemic hyponatremia. 
    Urine osmol= ality of *** (>100) with urine sodium of *** (>40) concerning for SIA= DH, hypothyroidism, or glucocorticoid df.
    - f/u AM cortisol and A= CTH stim test (glucocorticoid df)
    - f/u TSH 
    - if = both negative, consider SIADH. 
    Urine osmolality of *** (<= ;100) concerning for high fluid, low protein diet or self induced water int= oxication -- consider beer potomania, tea and toast diet, endurance event, = ecstacy use, psychosis. 

    Presentation is cons= istent with hypervolemic hyponatremia
    Una *** (<10) and FENA *= ** (<1%) concerning for CHF, cirrhosis, and nephrosis 
    - = f/u BNP
    Una *** (>20) and FENA *** (>1%) concerning for ren= al failure

    TREATMENT: goal is to raise no more tha= n 6-8 meq/L in 24 hour
    - Trend BMP {q4hr}
    - IVF with no= rmal saline 1L over 1 hour and recheck (hyponatremic hypovolemia <130)&n= bsp;
    - 50 mL bolus of 3% saline (pt asymptomatic w/ serum sodium = <130 and acute)
    - 100 mL bolus of 3% saline followed by 100 mL= doses x 2 (symptomatic patients with Na<130 )
    - ID and discon= tinue drugs that could be contributing to hyponatremia 
    - Li= mit further intake of water if with moderate hyponatremia (120-129) and mil= d to moderate symptoms.
    - If severe hyponatremia (<120) initia= te 3% saline at 15-30 mL/hour. Consider desmopressin to prevent overly rapi= d correction in rapidly reversible conditions. 
    - Fluid rest= riction indicated for hyponatremia in edematous states (CHF, cirrhosis) or = SIADH, advanced renal impairment, or primary polydipsia.
    - Can co= nsider loop diuretics (furosemide inhibits NaCL absorption-- causes ADH res= istance-- excretion of more dilute urine), salt tabs (avoid in CHF, cirrhos= is), urea, potassium supplementation, or vasopressin receptor antagonists (= vaptans). 

    hypopituitaism
    - can be tranisen= t or permanent
    - after traumatic brain injury, would recommend cortisol,= free T4.  3-6 months after - IGF1, cortisol, Free T4 and testosterone= and yearly for 3 years.Hypothyroid
    - normal reflex bicep, then slow relaxation
    - take= synthroid early in morning, wait, then eat breakfast (vitamin/mineral affe= ct absorptions, ppi)
    - free t3 fastest to drop, tsh most stable
    - if = severe hypothyroidism, test cortisol in case adrenal insufficiency
    - tsh= > 10, always treat
    - if going to be pregnant, treat
    - subclinical= hypothyroidism: if 5-10, if antiTPO ab positive, consider trea


    = non-thyroidal illness syndrome: when ill - Free T4 low or noaml.  low = TSH when ill, high TSH when recovery phase.  Test 4-8 weeks after agai= n
    Treat subclinical hypothyroidism if TSH > 10, and symptomatic =  
    - synthroid: take on empty stomach 60minutes before breakfast/cof= fee.  (take iron,  PPI, and calcium before/after 4 hours else imp= acts absorption of synthroid)
    - age <60, start at 100ug/d.  >= 60, start at 50 ug/day, increase 25uq q6w until TSH 1.0-2.5; heart disease:= start 12.5-25ug/d


    generic levothyroioxine may not work for ever= yone.  Sometimes need to have brand name Synthroid

    IBD-Ulcerative colitis flare= / Crohn

    Ibd higher risk of skin cancers
    #Acute Ulcerative Colitis Flare - Severe UC= (True-Love Witts, Montreal Criteria) E3S3 based on OSH pathology results.&= nbsp; 
      
    - Please ensure daily DVT ppx = as IBD patients are hypercoagulable given inflammatory state.
    - E= ncourage routine ambulation
    - Dietician consult 
    -= Please consult colorectal surgery for evaluation and education on potentia= l treatment options in the setting of IBD flare 
    - Order MR = enterography
    - Obtain B12, folate, iron panel, ferritin 
    - Vitamin D level 
    - Please order "Prometheus IBD SGI= " as a miscellaneous send out lab to look for genetic markers of Crohn vs U= C 
    -IV steroids (methylprednisolone 40 mg q daily for 5 days=
    - Ensure GI prophylaxis while on steroids 
    - 50k = vitamin D weekly 
    - 1000mg of Calcium daily while on steroid= s 
    -  Please obtain daily CRP and ESR

    -Consider standing tylenol as a base pain medications and dc all op= iates due to increased risk of toxic megacolon, 

    <= div>


    - Please order tap water enema to be= given at 7 am, 8 am, and 1 tap water enema PRN and in comment "to be given= prior to departure to CDDC for procedure"  

    =
    - Please obtain the following labs in preparation for biologic therapy= : TPMT, hepatitis C ab, Hepatitis B Ag, hepatitis B core antibody, Hepatiti= s surface antibody, HIV, VZV (quantitative PCR), fasting lipid panel, quant= iferon (please draw this PRIOR to steroid administration), EKG 
    <= div>
    - If on steroids would place concurrent PPD -- please in= struct nurses to document it's results in MyChart. 

    Please obtain LFTs, daily CRP, ESR, iron studies, vitamin D &nb= sp;

    IV methylprednisolone 40-60 mg daily x 3 days.= If no response after 3 days, will consider inpatient rescue therapy <= /div>

    - Can consider discharge on 8/12 if patient does w= ell on oral steroids with steroid taper starting at 40 mg and dropping by 5= mg every 7 days. For ease of ordering:  
    -Type in "pre= dnisone" to orders. Input 40 mg for 7 days. At the bottom of the box click = "Link Order" 
    -Select "Followed by" "a copy of the new order= " 
    - In the following box, input 35 mg instead of 40 mg.&nbs= p; 
    - Repeat until off.  
    - Tra= nsfer this order to an outpatient order in your discharge medication reconc= iliatoin 

    Abdominal XR given patient's worsen= ing illness  

    - Please discontinue mesal= amine (can sometimes have paradoxical effect in setting of acute colitis)&n= bsp;



    IBS

    = - IBS-D: treat with eluxadoline  (if normal, loperamide, TCA, rifaximi= n)
    - IBS-C: treat with lubiprostone, plecanatide, or linaclotide if FODM= AP, miralax still doesn't work and PEGICH hemorrhage (brain bleed)
    - don't use nitroglyc= erin or nitroprruside to lower BP as increases intracerebral presure
    SAH
    - nimodipine SBP goal 140-180
    - consider TCDs
    - neuro checks<= /td>ICU
    - iNO; ne= ed daily morning carboxyhemoglobin and methemoglobinID infection work up: karius crazy work= upif cannot do P= EG, can do PTEG
    <= /td>Iga nephropathy
    - can get gross blood in urine, in setting of infec= tion or after heavy exertion
    - just monitor, no steroids needed.ild bronchopulm thickenin= g, architectural changesILD interstitial
    - Sx: clubbing, velcro- crackles
    - causes: i= diopathic pulm fibrosis, acute inter, bronchiolitis from smoking, sarcoid, = amyloid, vasculitis, IVD, sclerodemra/poly/dermatomyositis, RA, inhalation,= hypersensitivity pneumonitis, drugs (nitrofurantoin, methotrexate, amio), = radiation
    - Tx: acute prednisone 1mg/kg/d and broad spectrum Abx x7 days= Ileus
    -Conservative management
    -NPO for bowel rest
    -NG tube and rectal tube for decompr= ession
    -Serial KUB
    -Avoid narcotics
    -Increase= movement in bed, up to chair, or ambulate if possible. 
    -Re= plete electrolytes (K>4, Mg>2, Phos>3) at least daily
    -C= onsider Relistor (methylnatrexone)
    -Consider neostigmine if no im= provements with conservative therapy. Contraindications include bradycardia= , allergy, 

    immunizations
    - prevnar: 65+, u= nless medical condition risk for pneumonia (alcoholism, liver/lung/renal di= sease, DM, cancer, HIV, sickle)
    - still need shingrix (Recombinant) if p= reviously had live attenuated shingles (zostavax), 97% versus 50% effective= infection / seps= is
    - score: qSOFA (Quick SOFA) Score for Sepsis - MDCalc (= mortality)
    - classification:
      - sepsis: 2+ SIRS (temp, RR>2= 0, HR > 90, WBC, PCO2<32)
      - severe sepsis: SBP <90, MAP = < 65, Cr > 2, oliguria < 0.5cc/kg/hr, bili > 2, Plt <100k, I= NR>1.5, lactate >2
      - septic shock: persistent hypotension a= fter 30cc/kg, lactate 4+
    - anaerobes: zosyn (pieracillin-tazobactam), au= gmentin (amoxicillin-calvulanate), unasym (Ampcillin-sulbactam), all carbap= enems, clindamycin, flagyl, 2nd gens (cefoxitin, cefotetan),

    - Sx: s= leepy, confused, RR>20, fever/cold, WBC, CRP >2 SD, sugar
    - Tx: va= nc+ceftriaxone+/-azithro, or vanc+zosyn

    - if staph bacteremia, need = echo to r/o infective endocarditis and repeat Bcx until negative, then 14 d= ays Abx from that

    meropenem - for ESBL  (PICC)


    Zosyn= covers for enterococcus, ESBL Ecoli, and pseudomonas; ceftriaxone + flagyl= does not.
    '
    enterococcus - vancomycin also covers.  But if VRE.=   cipro can, but not as good; do augmentin instead (tests for it but n= ot reported, because they want to save cipro for other things); can also do= linezolid
    - if positive, always just get CT with contrast to see source=

    Antibiotics Abx Tx duration / infections
    - abdominal= infection: 7 day  (if = gram negative, study 7 versus 14 day trial 2 bugs, not hemodynamically stab= le, immunocompromised need; may only do for UTIs)
    - C-diff= : 14 days
    - bacteremia: 7 days (even for ESBL); follow IDSA guide= lines
    - augmentin for human/dog/cat bite
    - azithromycin= for pertussis (whooping cough)


    - g= ram positives: after 24 hours, repeat Bcx

    bactrim = - not as good for old people kidney


    - enterobacter cloecae: cefepime is better than zosyn (per UCI pharmacy)
    - enterococcus faec= alis sensitive to ampicillin  (ampicillin + ceftriaxone for enterococc= al endocarditis)  

    - Marik protoc= ol: thiamine, hydrocortisone, vitamin C helps with severe sepsis?

    !!! cefepime does not cover enterococcus; need zosyn (or im= ipenem)

    candida and MRSA need AUTOMATIC consult
    Klebisella consider opthalmitis

    ceftriaxon= e creates biliary sludge

    ceftriaxone - actually ha= s a little anaerobe coverage

    levaquin - 60-70% eco= li coverage only, and poor staph

    cefepime can caus= e confusion and lowers seizure threshold


    for ampC resistance organisms: https://www.idsociety.org/practic= e-guideline/amr-guidance/
    citrobacter, enterobacter, - if suspect= ible to CTX, still don't give -- give cefepime only; ampC resistance
    <= div>3D""

    bactrim - if m= ore than 2 weeks, use CBC (Cr, K, CBC)
    - 30mg/kg unless pulmonary edema in first 3 hours- lactate, repeat in 3 hours
      - if >2, 30mg/kg and reassess, = then 20mg/kg if still >2
    - ABG as needed for acidosis, hypoxemia, hyp= ercap
    - procalcitonin
    - D-dimer
    - Bcx, UTI, CXR, 
    - glucos= e 140-180
    If inflammation, ESR, CRP

    3D"Antibiotics
    3D"Shorter
    insomnia
    - chronic should try doxepin= , not trazodone
    - chronic =3D functional distress, occurs 3+ nights/week= for 3+ months, and no other sleep/medical/mental disorder.  CBT first= , then doxepin (a TCA)
    - Zolpidem: There is potential for prolonged impa= ired driving skills, somnolence, and amnesia with their use, and there are = few data on the long-term safety or efficacy of these agents. Reports of se= rious or fatal injuries associated with complex sleep behaviors prompted th= e FDA to issue a boxed warning for zolpidem.insulin:
    if glargine more than 25 units, give= BID is better for absoprtion as too much in 1 time big liquid 
    - if a1c > 10, inpatient, ensure oral + glargine at 75%  - or stop= oral and continue inpatient basal+bolus
    - add metformin typically to in= crease insulin sensitivityintegrative health
    - lysine - prevent herpes 
    - glutam= ine - bowel
    - curcumin/tumeric - anti-inflammation; tumeric - from = other countries can have lead (check Consumer Labs)

    - LiverTox for d= ietary supplements
    - green tea extract: 100 cases of liver injury (possi= bly due to HLA-B*35:01)
    - natural medicines trc

    - multivitamin, v= itamin C, D, calcium, Mg, CoQ10, fish oil, psyllium
    - vitamin C 200 mg/d= aily for diabetes, smoking, copd to help support immune system
    - vitamin= D3 better; > 100ng./mL is potential vitamin D toxicity

    1-18: 120= 0 IU/day
    vitamin D: pregnancy 2500 IU/day
    high-risk prediabetes: 3500= IU/day
    75+: lower risk of mortality

    Low Mg: poor appetite, muscle= spasm, arrhythmia, fatigue


    Mg: magnesium threonate good penetra= tion to nerves; magnesium citrate: binds to oxalate, good for those with ki= dney stones.  magnesium oxide: most likely to cause diarrhea

    ma= gnesium glycinate -- best ideally


    Mgnesium: for migraine prevent= ion (migraine with aura and premenstraul migraine), preventing T2DM/lowerin= g fasting glucose.  maybe for pain control too.

    If taking PPI, = will get low Mg.

    CoQ: also help with migraine prevention3D""
    3D""
    3D""
    3D""3D""3D""interstitial cystitis (bladder pain syndrome)
    - Sx: bladder pa= in with filling for 6+ weeks, no other causes, better with urinating
    - T= x: behavior, amitrityplineIntubation:
    - induction: ketamine 1.5 mg/kg IBW (onset 60-90s,= duration 10-20m), propofol 2mg/kg IBW (onset 30 seconds, duration 10 min)<= br>- paralytic: rocuronium 1.2mg/kg IV by IBW (onset 60 seconds) preferred = over succinylcholine 1.5mg/kg onset (cannot use in high K)

    - for awa= ke inttubation, use ketamine - amnesia, dissociation, and analgeic, but sti= ll have respiratory drive. Also benefit increases BP and relaxes bronchial = muscle.
    - if intubation fail if > 90% on mask ventilation, try again.= if <90, then cricothyrotomy.


    - LBM: Fentanyl 5mcg/kg also , = versed


    propofol can decrease BP; Versed less.

    Weaning cri= teria
    - HR < 130, RR < 35, BP < 180, SpO2 > 92% on FIO2 <= =3D40% or PO2/FiO2 >=3D170 if ABG, RASS -1, PEEP <=3D8, hemodynamic s= table 

    - RSBI =3D RR/Vt <105 breaths/min/L
    - NIF <=3D = -20 (more negative good) -- negative inspiratory force

    3D""Intubation
    ketamine first, can sti= ll see breathing, then roc
    suc also used for paralytic; etomidate also f= or sedation
    = I= ntubation
    ketamine, precedex, fentanyl/versed
    instead of prop fent as= prop gets them more RASSIT band syndrome
    - pain at lateral knee, distal lateral thigh- test: Noble test: repeat flex and exten of knee with thumb over lateral = femoral condyl (no need imaging)
    - Tx: ice, abstain from activity, massa= ge, slow gradual return to activity= ITP and rheum issues stress dose steroid
    - 1mg/kg pre= dnisone  (~300mg hydrocortisone/day stressful situation)

    <= td spellcheck=3D"false" contenteditable=3D"true">JAK2 myeloproliferative= neoplasms
    - jaundice
    - if painless, CT, concern for cancerjehovah witness increase hgb
    - Increase B12 PO to 2000 mcg/day (10/26-)
    - Increase to folate = 4 mg/day supplementation
    - Complete ferrlecit 250mg IVPB (10/26-)= for 4 days total
    - Initiate Procrit 40,000 units weekly with goa= l of Hgb 12.0 
    - Minimize blood draws and use pediatric tube= when possible

    = joint fluid
    - WBC <200 =3D normal, <2k =3D oste= oarthritis, 2k-20k =3D inflammatory; 10k-50k =3D crystal; <75k =3D gout/= RA; >50k =3D infectious; >100k =3D septic arthritis
    Kidney stone / nephrolithiasis<= br>- 2L+ water
    - limit animal protein as sulfuric acid =3D causes calciu= m release
    Urine more basic so 

    - cystinuria - tiopronin
    <= br>- if prescribe bactrim, drink a lot of water, else will get wheat-lookin= g stones
    #Nephro= lithiasis
    Most likely calcium oxalate. RF include male gender, in= creased age, white race, obesity, diabetes mellitus, the metabolic syndrome= , decreased fluid intake, chronic diarrheal states, and Roux-en-Y gastric b= ypass. Patient fits typical presentation is waxing and waning =E2=80=9Ccoli= cky=E2=80=9D flank pain that radiates to the groin. Ddx includes ureteral p= assage of blood clots which can mimic renal colic pain. 50% of stones >6= mm will pass, stones >10 mm unlikley to pass. 
    - Urinalys= is 
    - Noncontrast helical CT is gold standard 
    - Kidney ultrasound since no radiation exposure. 
    - Vitami= n D level -- excess vitamin D intake can precipitate calcium oxalate stones= . 
    - Counsel on decreased dietary oxalate (avoid nuts, cocoa= , spinach, rhubarb, beets) and low sodium intake (lowers urine calcium)
    - DC orlistat with is associated with hyperoxaluria 
    = - Increase fluids -- normal saline @ 150 mL/hr if tolerated 
    - Decreased sodium intake 
    - Thiazide diuretics
    -= Potassium citrate or bicarbonate 
    - Pain mgmt with opioids = PRN 
    - Allopurinol if concern for elevated uric acid 
    - Tamsulosin 0.4mg PO QD (hold for SBP < 90) (ureteral relaxati= on for spontaneous passage)
    - Urologic intervention required if s= igns of infection, acute kidney injury, intractable nausea or pain, and sto= nes that faill to pass -- urology consult to consider shock wave lithotrips= y vs ureteroscopy with laser ablation vs percutaneous nephrolithotomy. = ;
    - 24 hour urine measurement outpatient if recurrent stone forma= tion 
    - If hypercalciuria present -- consider thiazide use t= o decrease calcium excretion 
    - Potassium citrate to prevent= calcium crystal formation (low urine levels associated with increased ston= e formation) 
    - If elevated urine pH =3D calcium phosphate -= - predisposed if hyperparathyroid, acetazolamide, or topiramate (raises uri= ne pH and decreased citrate excretion) 

    <= td spellcheck=3D"false" contenteditable=3D"true" class=3D"sorting_1">kidney= transplan:
    - if septic, don't hold prednisone or tacrolimus, only hold = myfortic/cellcept  
    - transplant pt: bicarb, mg, and phos wast= ing normal, need replete  (Bicarb > 22)

    myfortic - better th= an cell cept as coated and does not cause diarrhea as muchif on tacrolimus, daily tacrolimus le= vel

    Klebsisella
    - hyperviscous klebsiella likes to cause absc= essesknee
    patellofemoral pain syndrome
    - pain going down the stairs, female, runn= er
    - PE: pain with flexion of knee/squatting (91% sensitive pain with sq= uatting)
    - Tx: cyrotherapy in acute phase; then PT

    pes anserine p= ain syndrome
    - pain at anteromedial knee 6cm below joint line

    pre= patellar bursitis
    - Dx: need to aspirate.  If >50k/uL leukocyste= , septic brusitis= KUb
    - cecum 9
    - colon 6
    - small bowel 3 to confirm SBO
    Long QT syndrome
    - ri= sk of Torsades
    - If congenital Tx: beta blocker. ICD if previous cardiac= arrest


    QTc
    - ciprofloxacin/macrolides (also not if AAA) - al= so causes tendon rupture
    - little: atarax (hydroxyzine), antiemetics
    = - antipsychotics/antidepressants
    - antifungal
    - antiarrhythmics
    = =3D methadone

    - if prolonged QT, stop drugs that cause bradycardia, = K >4, Mg > 2.5  (K>4.5-5 who has torsades)



    vs = brugada syndrome
    - risk of sudden death
    - incomplete RBBB with ST ele= vation in V1 and V2

    low testosterone
    - 2 x 8am total testosterone; 2nd time measur= e free testosterone toolung nodule
    - if > 8mm: repeat CT at 3 months; if high risk (a= ge, smoking), consider biopsy; 6-8mm - CT at 6-2 months

    - 3cm likely= cancer.malnutrit= ion
    #concern for= severe protein malnutrition: Wellcamb classification *** mild (albumin 2.8= -3.4), moderate (2.1-2.7), severe (<2.1). Transferrin mild (150-200), mo= derate (100-149), severe (<100). Total lymphocyte count mild (1200- 2000= ) moderate (800-1199), severe (<800). 
    - Prealbumin =
    - Nutrition consult 
    - Boost daily 

    mania  (psychotic)

    acute mania (high energy, no= need for sleep, grandios)
    - Tx: with antipsychotic first --- risperido= ne have quick onset
    - DO NOT give antidepressants in manic patient,= will worsen mania.<= /td>Mds
    - linalidomide if symptomatic and have del5qtp53 tp53 mutation = =3D poor prognosis
    medication allergy:
    - always order tryptase to any allergy

    = anaphylaxis to
    - penicillin: can still give cefazolin, ceftriaxone, cefp= oroxime, and cefepime without testing (non-cross-reactive cephalosporin). D= o NOT give cephalexin without testing (cross-reactive).  Can give carb= apenems
    - cephalosporin: need testing to give penicillin.  Can give= carbapenem.
    - carbapenem: can give cephalosporin or penicillin without = testing.
    If SJS to one penicillin/cephalosporin/penem, do not give any t= he others.MEN1- SS: hyperparathyroid, pituitary tumor, and pancreatic tumor (e.g. gastri= noma, ulcer disease, insulinoma)MEN1: hyperparathyroidism, pituitary tumor, pancreatic/gast= rin/VIPoma/some abdoinal tumor
    MEN2: hyperparathyroidm, medullary thyroi= d cancer, pheochromocytomameningioma
    - benign tumor outside brain tissue
    - if asymptom= atic, just do serial brain MRI monitor
    - if symptoms, then removemeniscal tear
    - if d= egenerative meniscal tear (in older people), just PT, no need MRI or imagin= g
    - test: McMurray (external reotate tibia) or Thessaly test (stand and = turn body)

    ACL
    - isolated partial ACL tear, non-operative is best= over surgerymeta= bolic alkalosis (pH > 7.45 and HCO3 > 24)
    - test for urine Cl
    &= nbsp; - if <20mEq/L, vomiting/diuretic overuse =3D will respond to NS  - if > 20 mEq/L =3D NS will not work
        - hypovole= mic =3D Bartter/Gitelman syndrome
        - hypervolemic =3D high = mineralocorticoid (primary hyperaldo, cushing, ectopic ACTH production)metabolic alkalosis=
    - DDx: vomiting, loop/thiazide, Cushing, too much NSmetformin:
    - not for GFR < 30&= nbsp; (risk of acidosis)
    - need B12 supplement as decreases absorption&n= bsp; 
    - need annual B12 level testing if on metformin 
    - si= gns of B12 deficiency (loss of vibratory sense in toes, patellar, and achil= les reflex)
    = M= GH
    GRP-UCI IM Residency - MGH Whitebook 2021-202= 2 - Undedited.pdf (sharepoint.com)
    microscopy
    - compare size of lymphocyte nucleus= to RBC to see if RBC is small or large or normal
    - monocyte has vacuole= s
    - hypersegmented neutrophil (more than 5 lobes) =3D megaloblastic anem= ia Ddx: folate or B12 deficiency, drug affecting folate metbolism.3D""
    3D""
    midline
    - smalle= r - for inpatient use (not for drawing blood?)
    - should not do PPN if &g= t;600 or >900 osmol

    PICC
    - longer, for take home

    periph= eral IVs should be changed in 1 weekmorbilliform rash

    # Morbilliform eruption, favor drug > viral= - uncomplicated
    - We favor a morbilliform rash, in the setting of= drug > viral illness. We favor this diagnosis, opposed to a more compli= cated drug rash such as small vessel vasculitis because there is no palpabl= e purpura (I.e. all lesions are flat). There are also no lab abnormalities = (elevated liver enzymes or Cr), lymphadenopathy, or facial swelling to sugg= est DRESS. Additionally, there is no epidermal detachment nor mucosal, geni= tal, or ophthalmologic involvement to suggest SJS/TEN. 
    - Th= ese types of uncomplicated morbilliform eruptions usually occur 5- 14 days = after medication initiation. It is likely that this rash is secondary to a = medication that was given during his recent prior inpatient stay. The most = common causes are: antibiotics, NSAIDs, opioids, and diuretics (such as fur= osemide). 
    - Reviewed chart and previous MAR (from prior adm= ission). During stay, patient was started on NORCO. This is a likely agent = to cause the rash. No NSAIDS or antibiotics were given.  Home furosemi= de was discontinued. Due to the timeline, with NORCO being given on 2/11, t= his is the favored cause; however, unable to definitely say. 
    - Despite this rash occurring 2/2 to a presumed medication, the patient c= an continue his medications if needed. 
    - ~80% of morbillifo= rm drug eruptions resolve within 2 weeks. It is not painful or pruritic so = no further treatment is necessary at this time. 
    MRSA risk fa= ctors
    - MRSA or prior infection, gram+ cocci in clusters, recent IV abx = use in 3 months, flu-like illness, empyema, immunosuppression, ESRD, prison= , IV drug use, men sex with men, recent head injury, chronic hemodialysis, = recent flu

    Tx: vanc, linezolid, daptomycin, tigecycline, ceftaroline=
    oral: bactrim, clindamycin, doxycycline

    clindamycin sensi= tive by eryto resistent then don't use clinda
    - vanc MIC > 2, not goo= d (curbside ID)= my= elodysplastic syndrome (anemia)
    - Tx: supportive care and transfusions/E= PO
    - Tx: if young and symptomatic, stem cell transplantmyoclonus: fast twitching, but no= t suppressible
    tic: childhood onset, fast twitching, but suppressiblenaproxen vs ibuprof= en
    (naproxen least complications with heart)

    meloxicam good for m= enstrual cramps= n= arcolepsy
    - modafinil (also used if hypersomnia or severe cancer-related= fatigue)nausea /= vomiting
    - in advanced cancer, olanzapine can help (also used in refrac= tory depression, but together with another med)
    - UCI palliative Dr. Nis= co seems to like compazine 5mg PO q6h - if works for doamine blocker IV hal= dol (dopamine blocker) 5mg IM
    if QTc allows

    cannabinoid marijuana= vomiting/hyperemesis syndrome
    - Zofran, fosaprepitant.  haldol IM = also works

    vomiting
    - zofran 8mg q8h PO or 4mg IV q8h
    - promet= hazine (Phenergan)
    - prochlorperazine (Compazine)
    - metoclopramide (R= eglan)


    (if caused by opioid, chemo, toxin, or drugs, - target GI= tract or chemoreceptor trigger zone =3D antidopamine good =3D compazine, p= henergan, haldol, metoclopramide, chlorpromazine, olanzapine -- SE: sedatio= n, hypotension, dystonia, pseudoparkinson)

    - can also try Haldol if = really bad

    - if QTC
      - scopalamine patch but useless
    - z= ofran or promethazine x1
    - Tigan trimethobenzamide (200 q8h PRN)
    - Em= end IV (antihistamine for chemo - restricted) or dexamethasone (also che= mo premed) or benadryl



    if due to constipation/gut wall/i= leus =3D D2 receptor (metoclopramide, prochlorperazine, haldol, olanzapine)=
    if gut mucosal injury (infection, inflammation, tumor, chemo, radiation= ) =3D serotonin receptor in gut (zofran)
    if drugs or bacteria, D2 5HT, N= K1 all okay =3D NK1 blocker (aprepitant)
    motion sickness or ear =3D H1 r= eceptor (scopolamine, diphenyhydramine, promethazine)
    anticipatory nause= a =3D benzo and olanzapine
    - if due to ICP =3D steroids help

    Ongoing abdominal p= ain meets Rome IV criteria for cyclic vomiting syndrome -- patient endorses= chronic migraine history, episodic vomiting with period of normalcy in bet= ween episodes. Episodes are often associated with headaches and autonomic s= ymptoms such as diaphoresis. Patient also endorses relief with hot baths. O= ther ddx include malabsorption given atrophic pancreatitis on CTAP and hist= ory of recurrent pancreatitis.  
     
    #Epis= odic nausea and vomiting 
    #Cyclic vomiting syndrome: as this= is a diagnosis of exclusion, will need to rule out other etiologies such a= s gastroparesis and biliary dyskinesia 
    - Gastric emptying s= tudy as an outpatient to rule out gastroparesis
    - Please order CC= K HIDA as an outpatient to rule out biliary dyskinesia
    - Start Co= q 200 mg BID Check levels within 2 weeks outpatient and titrate to goal of = 3-4 (please see follow up instructions) 
    - Please order coq = enzyme level for outpatient follow up in 2 weeks at discharge (goal level i= s 3-4)
    - Start L-carnitine 1g BID, or patient can purchase OTC&nb= sp;
    - Please order carnitine level in 2 weeks at discharge (goal = suggested target blood level is a free carnitine level >40 micromol/L)
    - E-consult to Neurology for optimization of migraine meds (non-or= al triptans bring relief for nausea, characteristic of CVS) 
    - Start nortriptyline 10 mg qHS for MAINTENANCE against CVS. 
    - Please prescribe sumatriptan intranasal dose 20 mg on discharge -- thi= s is to be used for an ABORTIVE when patient feels an episode coming on. Ca= n repeat dose in 2 hours if needed.
    - Ensure adequate volume resu= scitation as one of the triggers for nausea can be dehydration-- 1L NS bolu= s now then maintenance rate with D5 1/2 NS, 60 cc/hr + 1ml/kg/hr for every = kg above 20 kg (ex: 60 kg adult =3D 100 cc/hr ) please adjust based on clin= ical status, cardiac and renal comorbidities, etc. 
    - Measur= e fecal elastase -- start Creon (at least 36k TID) if low 
    -= Continue PPI once daily for reflux symptoms -- please discharge on lansopr= azole 30 mg once daily. 

    - Phenergine supposi= tory 
    - Cyproheptadine 
    - Riboflavin 

    <= tr class=3D"even">neck

    cervical myelopathy =3D by cervical spondylosis<= br>- test: MRI
    - Tx: surgical decompression
    Sx: lower motor weaness i= n arms/hands (less reflex), upper motor symptoms in legs (more muscle tone,= hyperreclex, clonus, babinski)
    Lhermitte sign - electric shock from nec= k to spine with forward flex neck

    vs. cervical radiculopathy=3D spin= al root compression from disc herniation or degenerative spine
    - Sx: con= stant neck pain to arm and paresthesia in dermatome, decreased deep denton = reflex
    - test: positive spurling test (put pressure down on head while n= eck bent to affected side and extended; pain better when lifting arm above = head)
    - Tx: neck exercise + topical and oral NSAID, no MRI needed.
    - = Tx: if motor weakness, then need surgery

    neurogenic thoracic outlet = syndrome
    - compression nerve root brachial plexus
    - thin, young activ= e female with repetitive overhead stress
    - Sx: numb, pain, of 1 arm arm,= neck, shoulder when arm overhead
    - EMG normal
    - Tx: physical therapy= for posture and strentening shoulder girdleneed dialysis
    uremia with BUN > 100 - give= DDAVP to prevent uremic bleeding before quinton as need double dilation&nb= sp;nephrotic syn= drome

    etiology of nephrotic range proteinur= ia most likely 2/2 uncontrolled DM2. NO indications for renal bx or steroid= s for now. At present, recommend to obtain following
    - SPEP w IFE<= /div>
    -UPEP w IFE
    -Serum kappa and lambda free light chains
    -Kappa lambda ratio
    -PLA2= R
    -  ana, anca, complements were = unremarkable
    - anti proteinuric measur= es including losartan 
    = nerves
    common fibular
    - sensation: lateral leg=  
    - dorsiflex  (i.e. if common fibular nerve injury, will get = foot drop)

    tibila nerve
    - sensation: bottom of feet
    - motor: p= lantarflex<= td spellcheck=3D"false" contenteditable=3D"true" class=3D"sorting_1">neurol= eptic malignant syndrome
    - S&S: muscle rigidity, AMS, high temp, tac= hy/HTN/sweating.
    - cause: antipsychotics (haldol), reglan, withdrawal of= carbidopa-levadopa<= /td>neuropenic fever / fever unknown origin
    MASCC risk index
    #SIRS: (2+) Temp > 100.4= or <95 // RR> 20 or PAco2 <32 // HR>90 // WBC > 12k or <= 4k or bandemia >10% 
    #Sepsis: SIRS + microbial source&nb= sp;
    #Severe Sepsis: Sepsis with >1 organ system dysfunction (h= ypotension, AMS, acidosis, oliguria, ARDS) 
    #Septic shock: S= evere sepsis with hypotension unresponsive to fluid resuscitation (30c/kg b= olus) 
    #MODS: >1 organ system requiring interventional ho= meostasis 


    #Febrile neutropeni= a: MASCC Risk Index Score: Most often can be attributed to 60% GPCs, 40% GN= Rs. Given mucositis, high concern for GPC (CoNS) but cannot rule out fungal= infections. Evaluate for catheter associated infection 
    - B= lood cultures x 2 
    - UA / UCx 
    - Sputum Cx
    - Viral panel
    - CMV PCR 
    - Diarrhea: Stool= culture, O+P, C. Diff, CT A/P as neutropenic patients may not have abdomin= al pain 
    - Pulm symptoms: Flu/ RSV PCR, CXR/ CT CHEST, Bronc= h  
    - HA pain / sinus pain: CT face / sinus 
    =
    - Fungal markers: LDH, beta d glucan, galactomannan if high irsk for a= spergillus (SCT, GVHD, neutropenia > 10-14 d) 
    - F/U cocc= i antibody, histo urine antigen and serum antigen, quantiferon with AFB x 3= , crypto antigen
    Fungal culture sputum
    - Cefepime or pi= p/tazo or meropenem for gram negative coverage within 60 minutes of present= ation. 
    - If low risk can use cipro PO + clinda vs clinda (P= CN allergy)
    - Defer Vanc until documentation of a resistant GPC (= https://www.ncbi.nlm.nih.gov/pubmed/15722392) 
    - Fungal conc= ern: Micafungin or amphotericin 

    If resolutio= n of fever and culture negative, continue empiric treatment until ANC > = 500 and narrow to FQ ppx if afebrile x 4-5 days 

    <= div>If resolution of fever and source of infection -- tailor antibiotics an= d treat for recommended course then switch to FQ ppx until ANC > 500&nbs= p;

    If fever continues for >4-7 days consider en= graftment, GVHD, TLS, drug fever, thrombophlebitis, hematoma, hepatosplenic= candidiasis 

    If clinically worsening, broade= n antibiotics +/- fungal cultures if worsening and obtain CT chest +/- bron= ch for fungal infections 

    - Bactrim ppx recom= mended for equivalent of >20 mg prednisone daily for >1 month and all= o/auto SCT. 
    - G-CSF recommended if high risk febrile neutro= penia -- though this shortens duration of F+N it does NOT decrease mortalit= y 

    #Fever of unknown origin: most likely infe= ctions vs cancer vs rheumatologic vs medications. Assessed for dental carie= s/ thrush, sinus tenderness, temporal arteries, thyromegaly, abdominal tend= erness, CV murmur, LN, skin, nails, rectal. If extensive work up is negativ= e, prognosis is good and most cases defervctions, followed by bacterial inf= ections vs GVHD vs viral. Central fever is possible esce. In the setting of= neutropenia there is high concern for fungal infein setting of SAH, intrav= entricular bleed, brain tumors. Drug fever is a diagnosis of exclusion and = can take 2-3 days post cessation to resolve-- often associated with morbili= form rash, LFTs, and eosinophils. Chemo can be associated with drug fever. = VTE can be associated with low grade fever. 
    Dental hx:
    Immunocompromise: 
    Travel:
    Blood product tra= nsfusions: Sick contacts: Sexual history: 
    Illicits:
    Occupation: 
    TB:
    Valve disorders:
    Rec= ent procedure / hospitalization

    - Avoid empiric an= tibiotics (unless immunocompromisd or HDUS)
    - CBC w/ diff 
    - ESR
    - ESR can be falsely elevated in ESRD
    - Make sure to correct for age. Age / 2 for males and Age / 2 + = 10 for females. 
    - CRP
    More acutely rises=
    Falsely low in cirrhosis 
    - Proca= l 
    - HIV, RPR, LDH, TFTs, SPEP/SFL/UFL, ANA, ANCA, RF, CCP, = CRYO, EBV, CK, CMV PCR, ferritin, blood smear, HBV, HCV
    - CT A/P = with contrast, CT Chest with contrast, CT head with contrast
    - UA= / UCX
    - BCx x 3 at different sites 
    - CXR 

    Infectious causes related to lines: lines present *= ** 
    Infectious causes unrelated to lines: 
    - = Abdominal ultrasound to rule out acalculous cholecystitis 
    -= C. Diff in setting of antibiotic use 
    - Evaluate for joint = infection 
    - Meningitis 
    - Skin infections&nb= sp;

    Noninfectious causes 
    - Drug fe= ver 
    - Uric acid for possible gout flare 
    - L= ipase for pancreatitis 
    - D-dimer / wells for DVT / PE =

    neutropenic fever
    - 2 sets bcx
    - treat empir= ically with antibiotics (zosyn), no vanc needed  (add linezolid/daptom= cin for suspected vancomyin resistant enterococci)
    - if still fever in 7= days, add antifungal therapy (amphoB/itraconazole)
    - CT and lab for ang= ioinvasive aspergillusnodules - fungal, norcardia (in immunosuppressed)

    ground glass = - pulmonary edema, atypical pneumonia (mycoplasma, legionella) - anything -= ILD, blood= nsaid=
    - no NSAID in CAD/CHFnutrition deficiency

    Zinc:
    - Sx: alopecia, hypogonad, ras= h around mouth and extremities, slow wound healing, bald, tase change, smal= l testes

    Copper:
    - brittle hair and change in skin color

    B= 3:
    - people who eat corn
    - diarrhea, sun area dermatitis, dement= ia/depressionOHS= obesity
    - decrease oxygen to decrease hgb affinity to oxygen, so it can= carry more CO2 away (haldane effect)
    OHS
    - daytime pCO@ > 45mmold people with hyponatremia - quinine a= lso helps
    running and cramping - can give tonic water (quinine)onchomycosis
    - ple= ase check in to lab after this visit and obtain liver labs before starting = terbinafine
    - if you have right upper abdominal pain, changes in = smell or taste, or skin rash, stop using
    opioid use:
    Adrenal insufficiency
    - cau= ses secondary adrenal insufficiency - gets hyponatremia without hyperkalemi= a (supresses hypothalamic pituitary adrenal axis, but no diret effect on ad= renal cortex
    -  Dx: AM cortisol and ACTHopioid withdrawal
    - COWS (order set)buprenorphine
    S= tarting buprenorphine
    - Give buprenorphine 8mg, 8 hours after las= t dose of opioids or when COWS >8 (plan for induction at 0800)
    - Give a second dose of buprenorphine 4mg, 4 hours after the first dose
    - Give a third dose of buprenorphine 4mg, 4 hours after the second = dose for a total dose of 16mg on day 1
    - Start 16mg once daily th= e following day
    - Pt will benefit from split dosing due to increa= sed analgesic effect compared to once daily dosing, thus recommend continui= ng 8mg bid while inpatient
    - Will continue to work with our subst= ance use navigator Tiffany Hwang (714) 719-2925 to assist with discharge pl= anning
    - Please notify me in advance of planned discharge
    - PLEASE CALL prior to any anticipated procedures where buprenorphine ma= y need to be held or adjusted 
     
     
    =
    If precipitated withdrawal occurs, please provide the following to pat= ient at the discretion of primary team: 
     
    -H= ydroxyzine 50-100mg PO Q6h prn anxiety/restlessness 
    -Trazod= one 50-150mg PO QHS PRN insomnia 
    -Loperamide 2-4mg PO Q4 PR= N diarrhea 
    -Ondansetron 4-8mg PO PRN nausea/vomiting <= /div>
    -Methocarbamol 500-750mg PO Q8h PRN muscle cramping 
    -Acetominophen or nsaids (if safe to do so) for myalgias, HA
    <= br>
    <= tr class=3D"even">opioids
    - don't use morphine in kidney or liver failure- fentanyl safest in kidney or liver failure; start lower patch if liver = failure (fentanyl only to be used in opioid tolerant patients)

    - oxy= codone and hydromorphine decrease dose in liver failure/; oxy variable onse= t in liver failure
    palliative care: avoid codeine and tramadol (Tramadol= has ddi with sertonergic meds)

    - TCA or SNRI (venlafaxine or duloxe= tine) or gabapentin/pregabalin, carbamazepine to neuropathic pain

    - = need stimuylant bowel regimen:  senna, (can also add on osmotic- PEG/l= actulose/sorbitol) , or metylnatrexoneoral contraceptive OCP
    - no combination if uncontro= lled HTN. breast CA, clot, liver disease, or migraine with aura
    - no est= rogen if smoking > 15 cigarettes/day<= /td>Orthostasis
    Abd binder, compression stocking, inc= rease salt intake
    - 1st midodrine if not hfref
    2nd fludrocortisoneosteomyelitis
    - = tests: CRP 8+mg/dL and ESR 60+ favors this dx
    - hold antibiotics until s= ymptoms/septic to increase yield
    - Tx duration: need 6 weeks as takes th= at long for bone remodel

    - now, PO showing non-inferior to IV (Bactr= im okay)
    - if bone hardware, need Rifampin for film. (Start after source= control / hardware cleaned)

    - if can probe to bone, 90% PPV for ost= eo, if cannot probe to bone, only 60% NPV, so still need MRI w con
    - if = cannot MRI, then CT with contrast, if CT cannot due to metal hardware, then= tagged leukocyte scan and/or/or combined with three-phase bone scan.
    #concern for = osteomyelitis: patient with dull pain, local warmth/erythema/ swelling , sy= stemic sxs. RF include ulcer area > 2 (LR 7.2), probe to bone test (LR 6= .4), ESR > 70 (LR 11), abnormal plain xray (LR>2.3), MRI c/w osteo (L= R 3.8). Probe bone is sufficient for dx in patients with DM (83% specificit= y 90% PPV). Thrombocytosis is also shown to be associated with osteomyeliti= s. 


    - MRI 
    - Bl= ood cultures x 2 
    - ESR/CRP
    - CBC -- if leukocytos= is more indicative of acute vs chronic 
    - PPD/IGRA in patien= ts with risk of TB 
    - Brucella serology if at risk 
    - Plain XR first 
    - Would obtain MRI if negative = ;
    - If MRI not possible due to GFR, can get a CT vs radionuclide = bone scan (false positive if soft tissue inflamation) if hardware is limiti= ng factor
    - Bone biopsy is gold standard diagnostic test, but unl= ikely to obtain at UCI 
    - If able to obtain with ortho vs = IR can send for bone culture 
    - Obtain ABI to evaluat= e for possible vascular interventions to optimize blood flow to the limb&nb= sp;

    - ID consult to add rifampin if hardware and s= taph 
    - Home health order in preparation for 4-6 weeks of an= tibiotics
    - Consider PO antibiotics as oral antibiotics are non-i= nferior to IV antibiotics for 6 weeks of osteomyelitis treatment for certai= n patients (OVIVIA trial https://www.nejm.org/doi/full/10.1056/NEJMoa171092= 6) 
    - Surgical consult given failure to respond to medical t= herapies, chronic osteo, pyogenic vertebral osteo, or infected prosthesis.&= nbsp;
    - Surgical consult for hyperbaric O2. 

    <= /div>
    - Empiric treatment is usually vancomycin plus GNR coverage but w= ill delay antibiotics given patient is hemodynamically stable, has no neuro= logic compromise
    - Will opt for vanc + cefazolin -2g IV q8 hours = for MSSA coverage 
    - Opt for vanc + cefepime for 2g q 8 hour= s or pseudomonal coverage

    - Ortho if debridement&n= bsp;
    - Neurosurgery if vertebral osteo with possible CNS extensio= n 
    - IR for abscess drainage 
    - Wound nurse c= onsult 

    osteoporosis
    - any compression frac= ture =3D osteoporosis =3D start bisphosphonate
    - calculate 10 yr fractur= e ris. if hip fracture >=3D3% or all fracture >20%, start bisphosphon= ate
    - T score <=3D-2.5
    - need calcium 1200+mg/day and vitamin D 80= 0+ units/day in diet + supplement
    - if starting bisphosphonate, test vit= amin D and calcium level.

    - no bisphosphonate if GFR < 30
    - pr= olia subQ q6m.  Need BMP and dental clearance

    - denosumab in CK= D4 pts.
    Also can do IV zoledronic acid infusion 1/year
    - CAnnot give = IV biosphosphonate with low Ca  and CKD
    - repeat DEXA in 2 years
    thyroid medications can cause osteoporosis

    - PTH

    outpt
    - annual low d= ose lung CT for 20+ py smoking hx and quit < 15 yrs ago, unti 80 yrs old=
    - HPV/cervical cancer screening discontinue at 65 if 2 negative tests i= n past 10 yrs (most recent must be 5 years), else still test.  HPV tes= ting (+/- cytology) every 5 years.from 25+.PAD (peripheral artery disease)
    - ABI 0.9 or = below =3D bad

    ABI =3D  highest in both leg / highest SBP in both arm; lie flat for 5 minutes first)

    0.8-0.9 - trea= t risk factors

    0.8 or below, = refer to vascular

    - need high statin, aspirin

    - cilostazole (PDE3 inhibitor) for symptom relief. start = only if exercise fails (at least 30 min walk, 3 times week, for 3 months; keep walking increase until = pain longer to come) -- DO NOT give in HF pt


    PAD
    - Sx: exertional pain distal to occlusion
    = - PE: decreased cap refill, decreased hair growth, sensation, get DP and PT= pulses
    - CTA with run off if considering revascularization
    - can add= cilostazol 100mg BID (dilates arteries) as adjunct to increase exercise ca= pacity; do not give in HF

    Acute limb ischemia 6Ps: pain, pale, cold,= no pulse, no light touch
    - emergent vascular consult



    varicose veins

    - Tx: leg elevation, compression = stockings

    -= Tx: sclerotherapy injection if worsening veins after 6 months

    PAD
    - normal resting AB= I is between 1.00 and 1.40
    - ABI of 0.90 or less is diagnostic for PAD- resting ABI greater than 1.40 indicates the presence of noncompressible= , calcified arteries in the lower extremities and is considered uninterpret= able. This is most commonly found in patients with diabetes mellitus and/or= advanced chronic kidney disease
    - In patients with an ABI greater than = 1.40, a toe-brachial index is used for diagnosis. A toe-brachial index less= than 0.70 is diagnostic for PADpad
    2.5 xarelto +aspirinpancreatic insufficiency:
    - test for fecal ela= stase, if low, give creonpao2 65.  If huge changes than spo2, then think about CO and = methemoglobinemia

    - co-oximeter serum test can break down

    - n= on-rebreather: 10L or 15L 2 settings only.parkinson
    - carbadopa levadopa first; if still = not controlled, then add dopamine agonist (pramipexole, ropinirole)PCN infection - need to = be 6 weeks, treat through, then exchange= pericarditis
    - Sx: CP better when leaning forward= and upright; worse when supine
    - PE: friction rub at left sterna= l, best at end expiration leaning forward
    - EKG: diffuse upsloping ST el= evation (PR elevation in aVR)
    - causes: infection, viral, = autoimmune (vasculitis), breast, lung malingnant, drugs (hydral, procainami= de)
    - Tx: NSAID 800mg TID (for 2 weeks) + colchicine 0.6mg BID (for 3 mo= nths).  If doesn't work, after 7 days, prednisone 0.5mg/kg/d (for 2 we= eks)- EKG, bedside e= cho for effusion (drain if > 2cm)
    - cardiac MRI if uncertain (very se= nsitive)pheochromocytoma
    - HTN <20 yrs old
    - look for MEN2, vo= n hippel-linday, and NF1
    - need abdomen CT with con
    - !!! give alpha = blocker before beta blocker
    - use phenoxybenzamine efore surgery.  = use nitroprusside or phentolamine for HTN crisispituitary deficiency
    - ACTH deficiency:= weight loss, vomiting, abd pain
    - TSH deficiency: cold weight gain, con= stipation
    - visual field bitemporal (outside field blocked): mass effect=
    - FSH/LH deficiency: ammenorrhea
    - GH deficiency: loss of muscle mas= s

    posterior pituitary:
    - ADH deficiency: diabetes insipidus- thir= sty, polyuria/nocturia


    Dx: 8 AM ACTH, cotisol, LH/FSH (only if n= o menstrual cycle), 8AM testosterone for male, estradol for female, TSH, Fr= ee T4, IGF-1
    confirmation test: ACTH stim test and dedicated pituitary M= RI
    Tx: need daily cortisol and thyroixine. Possibly estrogen for premeno= pause women and androgen for men if hypogonad. 


    hyperprolac= tin
    - Dx: test prolactin, bHCG.  If negative, test TSH to rule out = hypothyroidism causing hyperprolactin.  Then MRI pituitary

    pitu= itary adenoma:
    - Dx: pituitary MRI, test for hypersecretion (prolactin a= nd IGF-1; FSH, LH, cortisol, TSH, T4, total Testosterone in men)
    - = too much prolactin negative feedback to hypothalamus to decrease GnRH, whic= h decreases FSH/LH


    any incidental pituitary mass
    - test: am c= ortisol, TSH, Free T4, prolactin, and insulin-like growth factor 1, FSH, an= d LH for both sex (if normal periods, no need FSH/LH for female)

    Tx:= for prolactinoma, give cabergoline (dopamine agonist to block prolactin);&= nbsp; if adenoma types that secrete other homones, surgeryPJP ppx
    - bacrim

    Bal if= concern
    Tx if severe iv bactrim + steroids for A-a >=3D35mmhg or pO2= <70
    When immunocompromised and then give Zarxio - immune system back = and fight against pjp - will get symptomsPlavix better (more potent) but do aspirin if any g= i bleedspleural = fluid
    - CSF WBC/RBC <1/100 =3D 100% not meningitis
    - adenosine dea= minase - for TB (but if positive in US may be false)

    - fluid protein= /serum protein >0.5, LDH > 200 or 2/3 ULN, or LDH/serumLDH > 0.6 = =3D exudative
    - if patient diuresing, serum to pleural albumin > 1.2g= /dL =3D transudate

    WBC > 50k /uL or pH < 7.2 =3D complicated p= arapneumonic effusion/empyema
    lymphocytes  >80% =3D TB, lymphoma= , sarcoid, cancer
    - triclyeride > 110 mg/dL =3D surgery trauma to tho= racic duct, lymphoma, or TB

    = Pleural studies
    Lights criteria
    If triglyceride 50-= 110, then need chylomicron. If >110 =3D chylothorax

    If chylothora= x, find cause. If not high output (<1L/day) then high carb, high protein= , low fat diet
    <= br>
    <= tr class=3D"even">pneumonia
    - score: CURB-65 Score for Pneumonia Sev= erity - MDCalc;
    PSI/PORT Score: Pneumonia Severity Index= for CAP (mdcalc.com)

    - test urine legionella.  patient who= exposed to kid attending daycare, think =CE=B2-lactam resistant strep pneu= mo
    - post viral, most common strep, cavity would be staph aureus
    - CA= P:
      - Tx: ceftriaxone (+ azithromycin) <- UCI protocol paper ad= ds azithro
      - if allergic, levofloaxcin (no need azithro then)
    =   - outpt Tx: amoxicillin 1g TID + azithromycin. If 65+, then augmenti= n BID + azithro

    - if severe CAP and history of pseudomonas and penic= illin allergy, then levofloxacin and aztreonam.

      - can do doxy= (also risk of tendon rupture) if azithromycin contraindicated for long QT<= br>
    - HAP (cover pseudomonas and MRSA)
      - Tx: zosyn 4.5g IV q6h= or cefepime 2g q8h, or cipro 400mg IV q8h, or imipenem 500mg q6h IV / mero= 1g IV q8h 

    - VAP (>48 hours after trach; cover S aures, pse= udomonas; cover MRSA if high risk)
        - Zosyn 4.5g IV q6h or = cefepime 2g q8h + vancomycin 15mg/kg q8h 
        - if high r= isk factors (prior IV antibiotics, spetic shock, ARDS, hospitalized 5 or mo= re days before VAP, or dialysis), need 2 antipseudomonas from different cla= sses (cipro + cefepime + vanc)
    - Tx duration: 
      - CAP: 5 d= ays; atypical: 10 days; legionella: 14 days; HAP/VAP: 7-8 days; p= seudomonas/acinobacter: 14 days;  MSSA/MRSA: 14 days


    - labs= : RPP, Procal, AFB sputum smear, Bcxz, sputum panel, fungal culture, CMB, h= isto, PJP, respiratory panel, Beta-D glucan, fungal Ab panel, BAL results, = aspergillus, 
    - even if legionella urine antigen negative, can stil= l be legionella (only tests for L. pneumophila serogroup 1)

    aspirati= on pneumonia:
    - outpt Tx: augmentin BID
    - inpt Tx: Unasyn 3g q6h (bet= ter than cephalosporin due to anaerobic coverage); azithromycin + ceftriaxo= ne; only if empyema or lung abscess, then add on anaerobe


    (start= doxy/azithro + ceftriaxone for all CAP)


    HIV/AIDS
    - legionell= a antigen, histoplasma galactomannan EIA, urine, strepcoccus pneumoniae ant= igen, PJP PCR BAL, respiratory viral panel, cryptococcal antigen and antibo= dy, LDH, coccicdiodes antigen, IgG/IgM, aspergillus galactomannan Ag, = ABG, Beta-d-Glucan (Fungitell)

    Fungitell does not test for blasto c= rypto mucor

    severe pneumonia
    check CRP >2.4 has , start steroi= ds or not- CXR
    - = consider procal
    - consider ABG
    - consider PFTs
    - ceftriaone (and a= zithro)
    - duoneb PRN

    #pneumonia:  {PNEUMONIA DX LIST:13= 0582} Overall assessment of severity:  {SEVERITY:67} Meets diagnostic = criteria given new CXR consolidation AND fever/cough/leukocytosis/purulent = sputum/hypoxemia. Will treat for presumed bacterial pneumonia, but will eva= luate for viral causes as well given lobar consolidation. COVID negative. C= URB65 =3D ***.  Port/PSI score =3D ***
    - Sputum culture and = gram stain 
    - Blood cultures 
    - Procalcitonin=
    - MRSA nares 
    - S. Pneumo urine antigen
    - Legionella urine antigen
    - Given inpatient status will treat w= ith CTX and azithromycin {consider Vancomycin as well} 
    - Gi= ven concern for aspiration pneumonia -- Zosyn vs unasyn (no pseudomonas). C= an consider deescalation of augmentin for outpatient treatment (7 d duratio= n)
    - Flu PCR/ COVID PCR / Adenovirus/ Mycoplasma/ Parainfluenza/D= FA  
    - Lactate 
    - VBG 
    - = if pleural effusion, consider lasix

    Likely HAP giv= en development of symptoms >48 hours after admission. IV antibiotics in = the last 90 days is the most important risk factor. 
    - Vanc = + Cefepime for anti-MRSA and anti-pseudomonal agent 

    POISONING

    Ethylene glycol poisoning  (CMP, lactic, B-OH, = etOH level)
    - Tx: dialysis and fomepizole

    methanol (CMP, lactic, = B-OH, etOH level)
    - Sx: central blurry vision
    Tx: fomepizole

    l= ead poisoning
    - Sx: abdominal pain, anemia, constipation, glove neuropat= hy
    - dotted "stippling" RBCs
    - level <45 =3D mild =3D monitor and = repeat lab in 1 month, >45 =3D moderate =3D oral succimer, >70 =3D se= vere =3D IV EDTA

    cyanide poisoning
    - nitroprusside becomes nitric= oxide and cyanide.  In CKD pt, can build up
    - Sx: confused ,seizur= e, vomiting
    - labs: will have lactic acidosis
    - Tx: 100% O2, IV fluid= s, hydroxcobalamin +/- sodium thiosulfate

    carbon monoxide
    - Sx: h= eadache, confusion, seizure
    - labs: CK will also increase.  get ABG= for carboxyhemoglbin level, EKG, trop
    - Tx: high flow O2, hyperbaric O2=

    iron toxicity
    - Sx: GI bleed, coffee ground emesis
    - Tx: defe= roxamine

    aspirin
    - Sx: tinnitus

    tylenol
    - Sx: nausea/vo= miting, but no kidney issue. AST/ALT in X000s; CMP, lactic, PTT/PT/INR
    -= Tx: n-acetylcysteine

    arsenic poisoning
    - cause: pesticides, well water, pressure-treated wood
    - S&S: garlic breath, vomit, diarrhea= , long QT, skin hypo/hyper-pigmented, glove -neuropathy
    - Tx: dimercaprol

    Beta blocker
    - Sx: hypoglycemia (blocks liver from cr= eating glucose; but in normal use also decreases insulin sensitivity), unco= nscious, AV block, seizures
    - Tx: fluid + atropine.  IV glucagon (m= ore cAMP in cells) if refractory

    Ca channel
    - Sx: same as beta bl= ocker, but non-unconsciousness and hyperglycemic

    antidepressant
    -= Sx: dilated pupil, prolonged QRS, dry mouth, dilated pupils (anti-Ach)
    = - Tx: physostigmine (inhibits AchE)

    benzo
    - Sx: drowsy, slurred s= peech, wobbly gait (breathing and vitals normal)

    organophosphate (AC= hE inhibitor =3D too much Ach)
    - Sx: miosis, diarrhea, drool, muscle wea= k
    Tx: atropine, then pralidoxime

    tylenol
    - Tx: n-acetylcystein= e


    pol= yarteritis nodosa
    - medium-vessel vasculitis: S&S =3D nodular skin l= esions =3D medium vessel vasculitis.
    - S&S: abdominal pain, 1-2 extr= emity MSK/neuro issue. (mononeuritis multiplex)
    - guy will get aneurysms= and stenosis in big arteries, occlusive lesions in small ones.

    vs.&= nbsp;

    small vessel =3D ANCA
    - S&S: airway, kidneys, eyes, ear= s, skin (palpable purpura)polymyalgia rheumatica
    - Sx: 50+ yr old, pain at shoulders
    -= Tx: steroid, which is for pain reliefpopliteal cyst
    - if ruptured, goes to medial ankle= "crescent sign" ecchymosisPortal hypertension
    - without documented varices, don't start = beta blocker (may change in future)
    - if documented, start

    portal= vein thrombosis#portal vein thrombosis: Fever of ***. WBC *** on admission. Leukopenia wi= th absolute lymph of ***.  Unclear etiology for trigger, but acute por= tal vein thrombosis can be due to tumor invasion. Will cover for common eti= ologies of septic PVT -- Bacteroides fragilis or Escherichia coli. 
    #transaminitis: alk phos of ***, ALT ***, AST ***, dbili of *** -- = though R factor of *** consistent with a cholestatic picture, PVT is also c= ommonly found in cirrhosis, will evaluate for possible hepatitis or viral e= tiologies.   
    - AFP 
    - Viral hepatitis&n= bsp;
    - CMV, EBV, HSV, HIV
    - Liver MRI with contrast&nbs= p;
    - Heparin per pharmacy (will need anticoagulation for six mont= hs provided there is no indication for long-term anticoagulation, such as a= permanent thrombotic risk factor that cannot be corrected or a thrombus th= at extends into the mesenteric veins)
    - Utox 
    - Pa= renteral therapy with Ceftriaxone (2g daily) and flagyl (500 mg q8 hours) (= 05/03/20 - 5/17/2020) with deescalation to oral flagyl and a fluoroquinolon= e to complete a total duration of 4-6 weeks (05/03/20- 6/7/20)
    - = Blood cultures 

    post-GI recommendations
    - CLD x 3 days, then F= LD x 4 days, then soft diet x3 weeks (patient
    already received th= ese instructions beforehand)
    - Oral liquid Augmentin x 5 days, if= PCN allergy give cipro/flagyl
    - PO pantoprazole or omeprazole BI= D x4 wks
    - PRN Zofran tablets and limited prescription for liquid= Hycet
    (hydrocodone-APAP)
    POTS
    - orthostatic intoleran= ce with a heart rate increase of 30/min or greater, often with a standing h= eart rate greater than 120/min within 10 minutes of standing or head-up til= t and in the absence of orthostatic hypotension
    - Tx: adequate hydration= , wearing compression garments, instituting a graded exercise program, and = sleeping with the head of the bed raised= PPI
    - aspiration ppx when undergoing anesthesia<= br>- NSAID ulcer
    - critically ill patients
    - upper GI bleed

    PPI prophylaxis
    - patients intubated > 48 hrs
    - plt < 50, INR= > 1.5, or PTT 2x baseline
    - GI bleed or ulcer in past year
    - majo= r trauma with injury severity score 16+
    - burn >=3D35%
    - head inju= ry GCS <=3D10 and inability to follow simple commands
    - spinal cord i= njury
    - partial hepatectomy
    - solid organ transplant periop in ICU- 2 antiplts (placix, aspirin, ticagerlo, cilostazol, dipyridamole
    - 2 = of sepsis, ICU stay > 7 days, occult bleeding more than 6 days, or (high= steroid >250mg hydrocotrisone, 50mg methylpred, 60mg prednisone, 10mg d= examethasone), enteral feeding
    hlh


    pregnant outpt
    - TDAP 27-36 weeks each = pregnancy
    - 24-28 weeks: 2hr glucose challenge

    pregnant:
    - no = atenololpregnant=
    - no ACE/ARB (toxic to baby kidney)
    - no spirinolactone (male baby f= eminize)
    = preop= optimization
    - score: D= ASI calculates METS
    - MELD > 15 no elective surgery
      - correct c= oagulopathy
      - referral for variceal screening
      - diurese= , tap ascites; refractory ascites =3D high risk for HRS
      - optimiz= e nutrition
      - minimize opioids
      - referral for liver tra= nsplant if MELD > 15, child-pugh C
      - no alcohol for 3 months

    - stop ACEI night before surgery to decrease risk of hypotension.=   For HF patients, continue
    - continue beta blocker, clonidine, ca = channel blocker.
    - hold diuretic morning of surgery
    - continue statin=


    - when NPO, decrease lantus by 25%

    if CV risk < 1%, p= roceed to surgeyr
    if CV risk >%, METS

    - screen for OSA with ST= OPBANG.
    - incentive spiroemter

    - stop warfarin 5 days before surg= ery
    - stop DOAC 1-2 days before surgery; stop earlier if GFR < 50
    = - stop heparin 4-6 hours before surgery
    stop lovenox 12 hours before sur= gery
    - restart heparin 1 day after surgery
    - restart warfarin 12-24 h= ours after surgery
    - restart DOAC 1 day after surgery
    - for Afib with= mechcal valve, Afib with CHADSVasc 7+, mod or severe mitral stenosis, rece= nt TIA/CVA, aortic mechanical valve - bridge heparin.
    - plavix 5 days- aspirin normally (5-14 days off)



    preop

    RCRI
    - 1) MI/CAD, CHF ,  DM on insulin , CVA, Cr = > 2.0, high risk


    Pulmonary: 
    age, COPD, smoking, OSA,= albumi, pulm HTN, albumin
    - gastric empty before 
    - BIPAP/CPAP<= br>- incentive spirometer


    if only 1 home med ACEI, continue it, = else hold on day of surgery


    Pre-operative pulmonary ri= sk stratification:
    - ARISCAT score: 50 points, for an operation w= ith a Intrathoracic surgical incision, which lasts 3+ hours. 
    - Perioperative risk category: High.
    - This correlates with a 4= 2.1%  risk of in-hospital post-op pulmonary complications (composite i= ncluding respiratory failure, respiratory infection, pleural effusion, atel= ectasis, pneumothorax, bronchospasm, aspiration pneumonitis)
    - Ne= ither ARISCAT nor AROZULLAH respiratory failure index take OSA, obesity, pr= esence of ILD or heart failure or pulmonary hypertension into consideration= in regard to perioperative pulmonary complication risk stratification.
    The patient does not have a dx of COPD.
     
    A= rozullah Respiratory Failure Index: 35 points (10.1% risk of respiratory fa= ilure during postoperative period of noncardiac surgery
    Gupta Pos= toperative Respiratory Failure Risk: 1.2% risk of mechanical ventilation fo= r >48 hrs after surgery, or unplanned intubation =E2=89=A430 days of sur= gery
    Gupta Postoperative Pneumonia Risk: 1.5% risk of postoperati= ve pneumonia

     In general, to decre= ase the risk for perioperative pulmonary complications, please consider:
    1) Minimizing general anesthesia time
    2) Avoiding general= anesthesia when possible
    3) Peri-operative use of bronchodilator= s
    4) Extubation to non-invasive positive pressure ventilation (Bi= PAP)
    5) Aggressive post-op incentive spirometry
    6) Aggr= essive post-op pulmonary toilet
    7) Early mobilization post-op
    - Pulmonary hygiene, incentive spirometry, PT/OT, OOB as tolerated

    preventative care
    - 50+ =3D shingles and pneumovax
    - 65+ =3D = prevnarPRN pain = meds
    - mild: tylenol 650 q6h or ibuprofen 600 PO q8h 
    - mod: nap= roxen 250 q8h, ketoralac (Toradol) 10mg PO q6h or 15mg IV for 5 days max (m= ax dose 40mg/day), tramadol 50mg PO q4h, tylenol-codeine 300-30 q4h PRN
    =
    antidote: naloxone 0.4mg IM/IV q2-3m PRN

    anxiety:
    - ativan 0= .5 PO q6h PRN for anxiety, or 0.5mg IV q4h 
    - xanax (alprazolam) 0.= 25mg q6h 
    - zolpidem (Ambien) 5mg qhs for insomnia

    diarrhea<= br>- peptobismol, imodium

    vomiting
    - zofran 8mg q8h PO or 4mg IV = q8h
    - promethazine (Phenergan)
    - prochlorperazine (Compazine)
    - me= toclopramide (Reglan)

    (if caused by opioid, chemo, toxin, or drugs, = - target GI tract or chemoreceptor trigger zone =3D antidopamine good =3D c= ompazine, phenergan, haldol, metoclopramide, chlorpromazine, olanzapine -- = SE: sedation, hypotension, dystonia, pseudoparkinson)


    cough
    -= guafenesin 200 q4h
    - tessalon 200mg TID 
    - dextromethorphan-gua= fenesim (mucinex DM) 1-2 tabs 12h (max 4 day)

    itching
    - benadryl = 25mg PO q6h or IV q6h

    HTN
    - hydralazine 10mg q4h
    - labetalol 1= 0-20mg q15m

    Breathing
    - duoneb (albuterol-ipatropium) 3cc q4hProcedures
    - par= acentesis: >8cm away from midline and >5cm above pubic symphysis = ; (4+cm pocket to tap)

    - if air embolism when pulling central line o= ut, lie patient on left side so air bubble stairs on R side of heart. Give = high flow O2 (encourageds bubble absorption)

    - weighted tip-tube: mu= st be post pyloric
    - non-weighted tip tube: can be in stomachprotein gap
    #elevated protein gap / gamma g= ap: >3.5-4 is considered elevated. Low concern given low albumin // elev= ated concern given elevated total protein level. 
    - SPEP, UP= EP
    - immunofixation
    - Serum free light chain
    = - If immunofixation shows elevated Ig levels -- would order immunoglobulin = levels 
    - Consider Heme/Onc consult for additional workup an= d biopsy

    Proteinuria
    >65 and proteinuria >= 3.5g, CT non-con for malignancy before kidney biopsy.  Also test for = antiphosolipiase A1 receptor
    ESRD with cysts, higher risk for RCC; annua= l ultrasound
    myeloma castg nephropathy - start chemo

    ANCA-associa= ted vasculitis typically presents as a rapidly progressive glomerulonephrit= is - erythrocytes and erythrocyte casts on urine microscopy.

    pseudomonas risk factor= s
    - prior pseudomonas, structural lung disease (bronchiectasis, CF), fre= quent COPD with steroid or Abx use, IV Abx in last 3 months, long term care= , AIDS, severely malnourished, recent hospitalization 3 months, chronic hem= odialysis, profound neutropenia

    Tx:
    - zosyn (piperacillin-tazoba= ctam)
    - ceftazidine (3rd gen)
    - cefepime (4th gen)
    - meropenem and= imipenem (NOT ertapenem)
    - aztreonam
    - ciprofloxacin & levofloxa= cin
    - gentamicin (aminoglycoside)

    if need pseudomonas and anarobe= s, then zosyn, aztreonam+flagyl if allergic to zosynpsych hold
    - 5150: <=3D72 hours if= patient unwilling to accept voluntary treatment AND is DTS, DTO (danger to= others), or GD (gravely disabled: cannot care for self)
    - 5585: <=3D= 72 hours for minors same as above
    - 5250: <=3D 14 days for DTS/DTO/G= D
    - 5260: <=3D 14 day extension of 5250 for DTS only
    - 5270: <= =3D 30 day hold for GD only
    - 5300: <=3D180 hold for DTO
    - 5350: 3= 65 day conservatorship for GD
    - 5352: temp conservatorship prior to cour= t ruling

    = ptsd
    - do not prescribe benzo

    OCD
    - CBD + SSRIpulmonary hypertension
    resting= pulmonary aterial pressure > 20mmHg (vs. 25?) and PCWP <15mmHg and P= VR (resistance) < 3
    - group 1 =3D PAH
    group 2-5 =3D left sided hea= rt disease, COPD/ILD/sleep, DVTs

    - Tx for PAH: tadalafil and ambrise= ntan; calcium challne blocker
    - O2 therapy if O2 sat < 90%

    Work up:
    -continue with diureses with at least net goal of -1-2L/d= ay
    -when euvolemic please order repeat TTE with bubble study = ;
    -please order PH work up 
          &= nbsp; -Images:  RUQ US with doppler (check for portal htn)
    &= nbsp;       -labs: hepatitis panel, hiv, tsh/t4, urine drug = screen, ana, 
            dsdna, rnp, rna po= lymerase III antibody, scl-70, anti-centromere 
       = ;     B antibody
            -please or= der V/Q scan and PFTS (with dlco, plethysmography, and post 
            bronchodialator response) for outpatient when = discharged

    pulmonary nodule
    - 6-8 need chest CT in 6-12 months, if s= ame size, then 2 year intervals for 5 years
    - 8mm+: 3-month CTfollow-up,= work-up with combined PET/CT, or tissue sampling PVCs / Vtach (VT)
    - suppression w= ith verapamil or B blocker (does not work if has structural issue)
    - if = non-sustained VT, should have exercise treadmill testing to provoke arrhyth= mia, echo (for any structure heart issues)

    nonsustained VT
    - <= 30 s (Any wide QRS Should be considered VT unless proven)

    - if hemod= ynamic stable, can trial IV procainamide, amiodarone, lidocaine, sotalol fo= r sustained VT
    - if not stable, CV.



    sotalol need 5 doses = monitoring for steady stateradiology

    SBO: dilated small bowel >3cm and little gas= in colon (causes, adhesion, malignancy, hernia, gallstone ileus, IBD) - sm= all bowel has segment lines fully across
    LBO: colon dilated then no gas = after, no air in rectum (causes: tumor volvulus, hernia, diverticulitis) - = large bowel haustra, no line fully across
    localized ileus: 1-2 dilated l= oops (causes: chole, pancreatitis, diverticulitis, appendicitis); can also = see transverse colon being dilated ("sentinel loop" =3D early sign of pancr= eatitis)

    good resource: https://www.radiologymasterclass.co.uk/= raynaud
    - Tx:= nifedipine/amlodipine (dihydropyridine type)reactions

    - vancomycin "red man syndro= me" =3D mast cell activation.
    - Tx: benadryl
    - vancomycin can also ca= use anaphlyaxis =3D epireactive arthritis
    - Reactive arthritis is a rare cause of in= flammatory arthritis that can occur following specific genitourinary and ga= strointestinal infections, including Chlamydia trachomatis and Ureaplasma u= realyticum in the urethra and Campylobacter, Escherichia coli, Salmonella, = Shigella, and Yersinia in the intestine
    - Sx: 2-3 weeks after infectio, = asymmetric and can be 1 or multiple joints.  Can also get  k= eratoderma blennorrhagicum(psoriasiform rash on palms, toes, and soles of t= he feet), conjunctivitis (more common than anterior uveitis) and circinate = balanitis (psoriasiform rash on penis)restless leg syndrome
    - check iron. give iron if f= erritin < 75
    - Tx: pramipexole, ropinirole, gabapentinReversals:
    - warfarin: KCentr= a (PCC) (UCI does FFP + vitamin K)
    - heparin: protamine
    - DOAC: andex= anet alfarhabdo<= br>- CK> 5000, bolus 1L NS, then LR 3cc/kg/hr, urine output goal 200cc/h= r (3cc/kg/hr).  If more, decrease IVF 1cc/kg/hr (min 2cc/kg/hr), if le= ss, if hypovolemic, increase 1cc/kg/hr (max 5cc/kg/hr); if overloaded, diur= ese.
    - CK q8h, if <5000 x2, then can stop treatmentrheumatoid arthritis
    - test: RF,= anti CCP; XR of joint; if destruction of MCP/PIP and lab negative, still a= diagnosis of RA
    - Tx: NSAID for flare, then methotrexate and folate
    = - need hepatitis and TB labs= rheum

    Puffy fingers (sclerodactyly), dysphagia/esopha= geal dysmotility, raynaud=3D sclerodema.  If affect internal organs to= o, then "systemic sclerosis".  Can be CREST (calcinosis fingers, rayna= ud, esophageal, and telangictasia, or diffuse systemic =3D lung, kidney, GI= tract too.
    systemic sclerosis
    - test: anti-Scl-70 (anti-topoisomeras= e), anticentromere

    sclerodema acute renal crisis, then ACEI Captopri= l (because short onset).  If malignant HTN, then give nitroprusside.
    rotem/teg3D""
    3D"Interpreting
    RRT - altered mental status
    - consid= er: baseline, recent intervent, meds
    - Cause: 
      - metaboli= c: hepatic encephalopathy, acidosis, electroytes (Na, Ca, Mg, Phos)
    &nbs= p; - O2: hypoxia, hypercarbia, anemia, decreased cerebral flow (occlusion, = decrease cardiac output from cardiogenic shock), sepsis
      - vascula= r: hemorrhage, stroke, vasculitis
      - endocrine: glucose, thyroid, = cortisol
      - seizure: post-ictal vs status, hydrocephalus
     = - tumor, trauma
      - uremia
      - psychiatric/deliriu
    &nbs= p; - infection/ingestion
      - drugs: intox, withdrawal, pca
    ain m= eds, benzo, antiAch
    - manage:
      1) can protect airway?  -&g= t; intubate
      2) reversible cause: meds, recent procedures (anesthe= sia/pre-medications)
      3) if concern stroke, call code stroke and N= IHSS
      4) escalate if airway, need frequent neurochecks, increasing= nursing needs for patient safety
    #Altered mental status: Ddx includes metabolic, infectiou= s, drugs vs medications, primary CNS, delirium. 

    <= div>Patient's acute AMS concerning for trauma vs vascular vs increased ICP,= meds/toxins, metabolic. 
    - EKG to evaluate for arrhythmia&n= bsp;
    - UTox for possible substance abuse 
    - AM cor= tisol, TSH 
    - Bladder scan for urine retention 
    - Seizure, stroke, syncope 

    - CBC, BMP, LF= T, lactate, NH3, B12, TSH, VBG, UA, CXR, bladder scan 
    - ESR= , CRP, CK, B12, B12
    - TTP consideration (low platelets, anemia, r= enal failure, fever, neuro changes) -- LDH, stat smear 
    - El= evated T,HR,BP,RR concerning for serotin syndrome >> neuroleptic mali= gnant syndrome 

    - Consider EEG
    - Co= nsider MRI w/ gad for possible stroke vs malignnancy 
    - Cons= ider LP 
    - HIV, RPR, HSV, VZV, 
    - Deliriu mpr= ecautions 

    - In setting of immunsuppression, = f/u on 
    - Blood cultures (fungal as well) 
    - Sputum cultures 
    - 1,3 BD glucan 
    - Galactomannan 
    - Histo urine / = serum antigen 
    <= span style=3D"white-space:pre"> - Crypto antigen 
    <= div>
    - Concern for seizure 
    - Continuous EEG
    - Start renal dose Keppra 500 mg BID with additional 500 mg given = back after each HS session and continue indefinitely
    - for recurr= ent electrographic or clinical seizure give weight based Ativan IV (1mg/kg = up to 4 mg per dose, up to 2 doses)
    - consider escalating abx reg= imen to meningitic dosing and adding empiric amp and acyclovir; pt may not = be able to undergo LP given thrombocytopenia
    RRT - hypotension
    -= consider: recent interventions, accurate BP reading?, baseline
    - Assess= : WARM OR COLD (hypoperfusion, lactate would be high too)
    - Cause: =
      - hypovolemic: dehydration, hemorrhage
      - cardiogenic: = HF, tachy, MI, tamponade
      - distributive: sepsis, anaphylaxis, aci= dosis
      - obstructive: PE, pneumothorax, aortic dissection, neuroge= nic
      - other - medications, acidosis, BP monitor, cortisol, hypoth= yroid
    - Manage:
      1) volume status - diurese vs fluid
      = 2) symptomatic - fluid, antibiotics, steroid, pressors
      3) reversi= ble cause: recent meds, fluid shift
      4) beside echo for tamponade,= cardiac function R heart size, IVC, pneumothorax
      5) escalate if:= pressors, lack of response to above

    - if steroid use, possible adre= nal insufficiency
    - labs: morning cortisol, cosyntropin stim test
    - midodrine TID (20 TID max in ICU; outside seems 10 TID); cannot give if = HFrEF- CBC, CMP, Lac= tate, TSH/FreeT4, UA, BCx, Trop
    - CXR, EKGRRT - SOB
    - consider: b= aseline, recent intervention, accurate pulse ox
    - cause: 
     = - pulmonary: pneumonia, pneumothorax, PE, pleural effusion, hemothroax, as= piration, bronchospasm, upper aiway obstruction, TRALI
      - cardiac:= MI/ischemia, CHF/volume, arryth, tamponade, valvuopathy
      - metabo= lic: acidosis, hypoPhos
      - hem: anemia, anaphylaxis
      - ps= ych: anxiety, withdrawal
      - meds: aspirin, carbon monoxide, benzo = intoxication
      - obesity, ascites
    - management: 
      = 1) stablize airway? (bag? intubate?)
      1) elevate head of bed
    &n= bsp; 2) supplemental O2 (NC, non-rebreather, high flow, BIPAP)
      3)= continuous pulse ox
      4) med intervention: duoneb, diuretic, ABx, = steroid, narcan
      5) escalate: unstable airway, impending compromis= e, lack of response to above

    - Narcan 0.4-2mg IV q2m if caused by op= ioid
    - if high suspicion for PE, start empiric AC
    - BIPAP for COPD; C= PAP for CHF if accessory muscle, pH<7.35, breathing fast and still PaCO2= >45
    - epi 1:1000 0.3cc (i.e 0.3mg) IM q5 m PRN, diphenhydramine 25-50= mg IV, neb albuterol, methylpred 1-2mg/kg IV

    NC: every L increases 3= FiO2 (6L NC =3D 40 FiO2)
    simple face mask needs 5-10 L, if <5L, will= rebreath CO2
    Non-rebreather (consider 1st if acute hypoxemic): i= f tachypneic, FiO2 0.6 better due to entrapment of room air, else can give = FiO2 90

    PaO2<60 =3D hypoxemic
    A-a gradient (normal =3D Age/4 += 4). if elevated, bad; A-a gradient > 20 =3D abnormal gas exchange =3D gl= obal hypoventilation
    PAO2 alveolar =3D FiO2in decimal x 713 - PaCO2= /0.8
    PaO2 arterial =3D by blood gas
    - give high PEEP if can't breath<= br>If A-a elevated and  PaO2 corrects with oxygen, then VQ mismatch, e= lse shunt (alveolar collapse or diffuse alvolar disease) or impaired diffus= ion (decrease DLCO).
    If not, then hypovenitlation or decreased FiO2 (hig= h altitude)

    respiratory acidosis (pCO2 high);
    compensation:
    &= nbsp; if acute, HCO3 increase by 1 every pCO2 up by 10
      if chronic= , HCO3 increase by 4
    respiratory alkalosis (pCO2 low)
      if acute= : HCO3 decrease by 2 every pCO2 down by 10
      if chronic: HCO3 decre= ase by 5


    respiratory acidosis
    - expected pH =3D 7.4-(differen= t of pCO2-40 x0.08)-= CBC, CMP, ABG, CXR, EKG
    - continuous pulse ox
    - trop, BNP, lactate,&= nbsp;
    - TTE for RV strain, head CT if suspect stroke, CT PE if PE



    A-a gradient =3D PAO2 - PaO2 =3D (FiO2*(Patm - H2O pressu= re) - (PaCO2/0.8) - PaO2. H2O pressure=3D47
    Normal A-a gradient = =3D (age/4) + 4
    Differential for increased A-a gradient (>10) = includes V/Q mismatch (obstructive lung disease, PE (CTPA negative 5/23), p= ulmonary edema, PNA, ILD (no evidence of this), atelecatsis), shunt (either= anatomical or physiologic related to PNA/ARDS/atelectasis), and diffusion = limitation (fibrosis, edema).

    RTA 1 - cannot excrete= H+, urine pH >6
    type 2 RTA - cannot get back Bicarb =3D urine pH <= ; 5.5
    RTA 4 - high K (aldosterone deficiency or resistance)sacroiliac joint dysfunction<= br>- Sx: FABER test positive (flexion, abduction, external rotation) poster= ior hip pain

    hip osteroarthritis
    =3D old person with posterior hi= p pain, groin pain and FADIR test (flexion, adduction, internal rotation)
    acetabular labrum tear
    - young athlete jumping or sprinting, anter= ior hip pain
    - FADIR test positivesarcoidosis
    - common in african american young adult=
    - non-caseating granuloma biopsy
    - test: CXR bilateral hilar lymphad= enopathy, ACE level very high
    - Sx: large liver, one side face droop, uv= eitis, erythema nodosum, dilated/restrictive cardiomyopathy, 

    -= if sarcoidosis causing arrythymia, immunotherapy actually improves the arr= ythmia (instead of beta blockers)SBO=
    #Small bowel obstruction: likely secondary from adhesions from previou= s abdominal surgeries/hernia/cancer with intussusception / volvulus / forei= gn bodies / stricture. Patient's hypokalemia and hypochloremic metabolic al= kalosis likely form repeated emesis. Ischemia from strangulation likely cau= sing lactate / leukocytosis. Imaging shows air-fluid levels and dilated bow= el proximal to and decompressed bowel distal ot obstruciton. 
    - NPO 
    - Large bore NGT 18 F to continuous low wall suctio= n, goal <200 cc output
    - Surgical onsult to consider surgical = options given strangulation / bowel ischemia if no improvement in 72 hours&= nbsp;
    - Menthol drops for throat pain 1st line 
    - = Lidocaine viscous solution for throat pain 2nd line 
    - Mucos= itis mixture for throat pain 3rd line 

    SBP
    -= If has peritoneal dialysis: need 2 or 3 criteria of >100 pmn, culture f= rom effluent, symptoms (nausea vomiting). Use indwelling antibiotics (vanc,= ceftazadine), and nystarin swish and swallow
    - else pmn> 250

    =
    - Tx: prophylaxis on SBP - daily bactrim or cipro

    #SBP:
    Patient with = PMN of *** on diagnostic paracentesis (9/30). Fluid cultures of abdomen wit= h ***. 
    2014 study in Gastroenterology showed that among pat= ients with SBP, NSBBs reduced transplant-free survival (hazard ratio =3D 1.= 58; 95% confidence interval: 1.098=E2=80=932.274; P =3D .014) and increased= days of nonelective hospitalization (29.6 days/person-year in patients on = NSBBs vs 23.7 days/person-year in those not taking NSBBs). A higher proport= ion of patients on NSBBs had hepatorenal (24% vs 11% in those not taking NS= BBs; P =3D .027) and grade C AKI (20% vs 8% for those not taking NSBBs; P = =3D .021). Despite this though, this patient would likely benefit from nons= elective beta blockers given his high risk of esophageal rebleed. Would rec= ommend low dose beta blockers until esophageal varices have resolved, and o= nce they have, should have his nonselective beta blockers discontinued.&nbs= p;
     
    #Cirrhosis, decompensated with variceal hemor= rhage and ascites.
    MELD-Na score: ***
    MELD score: ***
    ? Etiology: ***
    ?= Ascites - *** seen on Abd US.
    =
    ? Hepatic encephalopathy - ***&= nbsp;
    ? Varices - ***

    Recommendations:
    ? Will need CTX for SBP dosing (2g every 24 hours (10/1 - 10= /6)) with 25% albumin (1.5 g / kg on day 1, 1 g/kg on day 3, max of 100 g)&= nbsp; 
    ? In= itiate propranolol at low dose, 10 mg BID for prophylaxis of esophageal ble= ed. 
    ? Cont= inue octreotide gtt
    <= span style=3D"white-space:pre"> ? <= /span>Continue Protonix IV 40 mg BID
    ? 2 g Na restriction 
    ? Initiate secondary prophylaxis for SBP wi= th PO cipro 500 mg qd or PO Bactrim DS qd 
    ? Would recommend therapeutic paracentesis = to decrease intraabdominal pressure to minimize risk of esophageal bleed.&n= bsp;
    ? CBC q 4h = in pediatric tubing to determine if and when endoscopy is appropriate =
    ? Transfuse goa= l Hgb >7, Platelets > 50k, INR <2.5
    ? Please order iron panel, ferritin, B12, fo= late, vitamin D, vitamin B12
    ? Once hemodynamically stable:
    ? Will benefit from diuretic treatment (likely= 100 mg/day spironolactone and 40 mg/day of furosemide and adjust to mainta= in normokalemia though should be managed through either liver consult or ou= tpatient follow up with liver clinic) with goal weight loss of 0.5 kg / day= to avoid AKI. 
    = ?= Social work for alcohol cessation resources -- will need 6 months s= obriety to be considered for liver transplant. 
    ?= Will need follow up in with Santa A= na clinic to arrange for repeat EGD, after which beta blockers can be disco= ntinued if varices have resolved to prevent complications from SBP and beta= blocker therapy. 

    SBP
    - prevent wi= th cipro or bactrim
    - inpt: cefotaxime/CTX


    - for hepatorenal = syndrome, trial albumin. (Stop diuretics!)

    SBT
    - riskby score <105 (machine sho= ws F/T on top right) means successful likely. Higher doesn't mean will fail= though.
    - need strong cough (trial it)
    - SBT is switch to pressure s= upport
    Racemic epi or solumedrol after extubate to decrease secretions i= f a lot
    - possible get ABG after SBT and concerned won't succeed
    - pl= an for what if happens fail (trach?)


    (pressors decreasing, test = can lift arm/neck, FiO2 <50%, pressure support 5/5, or 8/5, hear cuff le= ak  only if suspecting edema; NIF -20)- A-line, central-line
    - MAP > 65schizopre= nia
    - if males, manifests 15-25s.  If old man, visual hallucination= s/delusions (psychotic) cannot be due to psychiatry. 
    - if female 2= 0-30s or perimenopausal time 
    Charles Bonnet Syndrome =3D cataract = causing visual hallucinations for older people
    - Tx: 2nd gen antipyschot= ic (olanzapine, respiridone, quetiapine, aripiprazole) and refer to psych
    sciatica- Sx: pain, tingling, numbness to leg

    round ligament pain
    - shar= p pain in abdomen, hip, groin, worse with fast movement and change; pain do= es not radiate; negative straight leg

    sacroilitis:
    - Sx: pain wit= h palpation of sacroiliac joint, straight leg negative
    - positive FABER<= br>
    greater trochanteric pain syndrome
    - pain at lateral hip, wose wh= en sleeping on side
    - cause: friction between greater trochanter and IT = band causing trauma to gluteal tendon
    - positive FABER and pain on palpa= tion
    - Tx: PT, NSAID, weight lossscreening
    - colorectal: 45+ until 75 (life expectanc= y is >10 years or if living long time)
    - pap smear: 21-29 pap every 3= , reflex HPV. 30-65 q5 years
    - mammogram: 40  (https://www.mdcalc.c= om/calc/3647/gail-model-breast-cancer-risk. if > 20%, start at 30 years,= then MRI and mammogram due to high risk); initially every year until 50, t= hen every other year (at age 40+, 10% false positive for screening) until 7= 5.
    - lung cancer: 55-80 who quit within 15 years and smoked 20 pack-year=

    serotonin= syndrome
    - Sx: diarrhea, tachy, sweating, hyperreflex, tremor, d= ilated pupils, anxious 
    - Tx: supporticve + benzo.  If doesn't= work, the cyproheptadine- doppler
    - aspirin 81mg (+rivaroxavan 2.5mg BID shown to be better= than aspirin alone) if symptomatic (pain on exertion relieved by rest)
    = - ABI
    - atorvastatin 40mg, smoking cessationsevere AS
    - if hypote= nsive shock requiring pressor, 1st pressor is phenylephrine (increase after= load to push blood back to coronaries)shingles
    -  7 days oral valacyclovir.&nbs= p; Cover it to not spread to others until fully crusted.  IF dissemina= ted (Goes other place than first site, then must have contact and airborne = precautions and admit to hospital for IV valacyclovir).
    - If pain still = from shingles after 4 months, gabapentin.  Before that, NSAIDS
    shocks
    - cardiog= enic - high PCWP
    - hypovolemic - low PCWP
    - obstructive - tamponade, = PE, tension pneumo
    - anaphylatic - high cardiac output and low systemic = resistance
    - septic shock - high cardiact output and low systemic resist= ance3D""3D""shoulder joint

    lab= ral tear
    superior labrum anterior and posterior lesions (SLAP)
    - repe= titive overhead stress / weightlifting or throwing
    - Sx: pain with abduc= tion and external rotation, catching of joint, joint instability, creptius<= br>
    AC joint degeneration =3D poorly localized pain, strength and ROM no= rmal
    - test: pain with adduction of arm across body (Cross-arm) and shou= lder abduction >120degrees

    bicep tendinopathy
    - repetitive lif= ting and carrying
    - Sx: pain at anterior shoulder, radiate to deltoid, w= rose with overhead 
    - test: pain by palpating long head of biceps t= endon, pain with arm at side while flexing elbow and supinate against resis= tance

    rotator cuff tendinopathy
    - Sx: pain worse at night, lying = on affected side, with overhead activity; pain to upper arm near deltoid.- test: pain at 60-120 degrees of passive abduction (=3D positive painful= arc test), empty can test
    - Tx: rest, tylenol, PTshoulder pain
    - rotator cuff tear = =3D pain with weakness
    - tendinitis =3D no weakness
    - impingement syn= drome =3D pain with reaching
    - adhesive capsulitis =3D stiffness =3D no = active/passitve abduction/external rotation
    - MRI ideally for tear, but = U/S cheaper
    - Tx: NSAID and exercise (do NOT sling).  If full tear,= then surgerySick= le cell
    #Sickle = cell disease: 
    Major acute complications include infection, = severe anemia (splenic sequestration, aplastic crisis, or hyperhemolysis), = vasoocclusive phenomena (acute vasoocclusive pain, stroke, acute chest synd= rome, renal infarction, dactylitis, myocardial infarction, pregnancy compli= cations, priapism, VTE). Chronic complications include chronic pain, anemia= , neuro deficits, seizures, pulmonary conditions, renal impairment, osteopo= rosis, cardiomyopathy with diastolic dysfunction, hepatotoxicity due to tra= nsfusions and medications, reduced growth, chronic leg ulcers, proliferativ= e retinopathy. 



    However, patients with chronic hemolysis (such as sickle cell anemia) who = depend on increased erythrocyte production can have significant anemia with= a decreased reticulocyte count.

    - Heme/onc consul= t to discuss allogenic BMT given curative potential. 
    - Disc= uss hydroxyurea given ability to prolong life expectancy (increase fetal he= moglobin levels and generate nitric oxide) -- would be appropriate given **= * frequent pain crises, severe symptomatic anemia, or previous acute chest = syndrome or stroke

    #vaso-occlusive events
    Opiates are the preferred analgesic, with the exception of meperidine, wh= ich can cause seizures. 

    Chronic pain is exac= erbated by emotional stress, anxiety, insomnia, and depression and is perha= ps best treated with a holistic approach emphasizing nonopioid options such= as NSAIDs, relaxation techniques, massage, and biofeedback. 

    - Alternative medicine Integrative health 
    =
    - Two new treatments -- oral L-glutamine (precursor to NAD) = and P-selectin inhibitor (crizanlizumab) 

    #ac= ut chest syndrome: clinical diagnosis based on the constellation of fever (= >38.6 =C2=B0C [101.5 =C2=B0F]), tachypnea, hypoxia, cough, shortness of = breath, and a new pulmonary infiltrate. 
    O2 to treat hypoxia= and the use of empiric antibiotics to treat infection

    =
    pulmonary hypertension is a recognized complication of SCD found in up= to 30% of patients, typically presenting as worsening right heart failure.=

    #stroke: 
    Monthly transfusion begu= n after a stroke can reduce the incidence of subsequent stroke by 50% but c= arries the risk of iron overload necessitating iron chelation. Hydroxyurea = may also help in stroke prevention. 



    Rapid initiation of opioids for vaso-occlusive crisis=
    Use of incentive spirometry in hospitalized patients
    U= se of analgesics and physical therapy for treatment of avascular necrosis
    Use of ACE inhibitors in patients with microalbuminuria
    = Regular ophthalmologic examinations and referral for laser photocoagulation= for retinopathy
    Use of echocardiography to evaluate signs of pul= monary hypertension
    Hydroxyurea for patients with more than 3 vas= o-occlusive crises per year, for those with pain or chronic anemia interfer= ing with daily activities, or those with recurrent acute chest syndrome
    Preoperative transfusion to serum hemoglobin level of 10 g/dL (100 g= /L) for surgeries requiring general anesthesia
    Assess for iron ov= erload and begin oral iron chelation if necessary

    =
    Strong Recommendations from the National Institutes of Healt= h/U.S. Department of Health and Human Services Guidelines for the Managemen= t of Sickle Cell Disease


    . Patients= undergoing surgical procedures requiring general anesthesia should receive= PRBC transfusion for a target hemoglobin level of 10 g/dL (100 g/L) to avo= id surgical complications. 

    Monthly transfusi= ons (hypertransfusion) in patients with an initial stroke can reduce the in= cidence of subsequent stroke and reduce stroke occurrence in patients at ri= sk for stroke based on cranial Doppler arterial velocity. 
    <= br>
    With any transfusion, care should be taken to keep hemoglobin= concentrations less than 10 g/dL (100 g/L) to avoid problems with blood hy= perviscosity.

    sickle cell
    - funtional asplenia f= rom repeat microinfarcts
    - risk of salmonella (encapsulated bacteria).- for any injury that doesn't heal, give ceftriaxone + clindaymcin
    #Sickle cell disea= se: 
    Major acute complications include infection, severe ane= mia (splenic sequestration, aplastic crisis, or hyperhemolysis), vasoocclus= ive phenomena (acute vasoocclusive pain, stroke, acute chest syndrome, rena= l infarction, dactylitis, myocardial infarction, pregnancy complications, p= riapism, VTE). Chronic complications include chronic pain, anemia, neuro de= ficits, seizures, pulmonary conditions, renal impairment, osteoporosis, car= diomyopathy with diastolic dysfunction, hepatotoxicity due to transfusions = and medications, reduced growth, chronic leg ulcers, proliferative retinopa= thy. 



    However, = patients with chronic hemolysis (such as sickle cell anemia) who depend on = increased erythrocyte production can have significant anemia with a decreas= ed reticulocyte count.

    - Heme/onc consult to discu= ss allogenic BMT given curative potential. 
    - Discuss hydrox= yurea given ability to prolong life expectancy (increase fetal hemoglobin l= evels and generate nitric oxide) -- would be appropriate given *** frequent= pain crises, severe symptomatic anemia, or previous acute chest syndrome o= r stroke

    #vaso-occlusive events
    Opiates = are the preferred analgesic, with the exception of meperidine, which can ca= use seizures. 

    Chronic pain is exacerbated by= emotional stress, anxiety, insomnia, and depression and is perhaps best tr= eated with a holistic approach emphasizing nonopioid options such as NSAIDs= , relaxation techniques, massage, and biofeedback. 

    - Alternative medicine Integrative health 
    - D5 1/2NS= @ 120 cc/hr 

    - Two new treatments -- oral L-= glutamine (precursor to NAD) and P-selectin inhibitor (crizanlizumab)
    =
    - Heme/onc consult for oxybryta (voxelotor) -- there is a global thera= peutic's free supply program "GBT source" for uninsured patients for oxbryt= a while case management assisting patient obtain insurance.

    <= /div>
    #acut chest syndrome: clinical diagnosis based on the constellati= on of fever (>38.6 =C2=B0C [101.5 =C2=B0F]), tachypnea, hypoxia, cough, = shortness of breath, and a new pulmonary infiltrate. 
    O2 to = treat hypoxia and the use of empiric antibiotics to treat infection

    pulmonary hypertension is a recognized complication of SC= D found in up to 30% of patients, typically presenting as worsening right h= eart failure.

    #stroke: 
    Monthly tra= nsfusion begun after a stroke can reduce the incidence of subsequent stroke= by 50% but carries the risk of iron overload necessitating iron chelation.= Hydroxyurea may also help in stroke prevention. 

    =


    Rapid initiation of opioids for vaso-occ= lusive crisis
    Use of incentive spirometry in hospitalized patient= s
    Use of analgesics and physical therapy for treatment of avascul= ar necrosis
    Use of ACE inhibitors in patients with microalbuminur= ia
    Regular ophthalmologic examinations and referral for laser pho= tocoagulation for retinopathy
    Use of echocardiography to evaluate= signs of pulmonary hypertension
    Hydroxyurea for patients with mo= re than 3 vaso-occlusive crises per year, for those with pain or chronic an= emia interfering with daily activities, or those with recurrent acute chest= syndrome
    Preoperative transfusion to serum hemoglobin level of 1= 0 g/dL (100 g/L) for surgeries requiring general anesthesia
    Asses= s for iron overload and begin oral iron chelation if necessary

    . Patients undergoing surgical procedures requi= ring general anesthesia should receive PRBC transfusion for a target hemogl= obin level of 10 g/dL (100 g/L) to avoid surgical complications. 

    Monthly transfusions (hypertransfusion) in patients wi= th an initial stroke can reduce the incidence of subsequent stroke and redu= ce stroke occurrence in patients at risk for stroke based on cranial Dopple= r arterial velocity. 

    With any transfusion, c= are should be taken to keep hemoglobin concentrations less than 10 g/dL (10= 0 g/L) to avoid problems with blood hyperviscosity.

    = smoking
    - patch- 1.5x effective (caution in recent MI, arrythmia, or che= st pain but still okay) - -use combination of long atching patch and short = acting gum/spray/lozenges to be more effective
    - bupropion - 2x - avoid = with seizure or eating or history of suicide ideation
    - varnicline (Chan= tix) - 3.5x; use with patch for best effortspep, upep, immunofixation, serum  light ch= ain, immunoglobulin for lymphoma/ waldernstrom/MGUS

    UPEP, SPEP, serum immunofixation, urine immunofixation, copperspinal stenos= is
    - worse with walking and extension; better with sitting and leaning f= orward
    - S&S: romberg test positive (falls with eyes closed) and wid= e gaitspine
    <= br>spinal stenosis
    - Sx: pain better when leaning forward, worse with wa= lking up steps/extending back

    diabetic amyotrophy
    - asympatic wea= kness with atrophy and weight loss; acute, focal onset of pain, then weanes= s of proximal leg.splen vein thrombosis left side - do splenic embolization;  right sid= e can also do to decrease splanchnicsplenic vein thrombosis
    - complication of pancreatit= is

    sinesto cirrhosis- if has SVT, spleen still needs to drain blood,= so goes through short gastric vein  (will have splenic thrombosis)&nb= sp; !!! don't do biopsy of variaceal gastric/varices, else will bleed outSponsyloksing arthr= itis us actually more tendon inflammation not arthritis as symptom (enthesi= tis)
    If xr negative, mri more specificSsti
    Augmentin not as good due to poasible resi= stance. Use cephalosporin. Near 99% coverage
    Also CAP. Unless outpt. If = healthy amoxicillin. With comorbidity, augmentin.  All CAP with azithr= o. 

    Steroid contraindicated in fluSTDs
    syphillis
    - syphillis if caught ea= rly =3D 1 dose penicillin.  If >12 months or unknown when, then onc= e a week for 3 week.  If neurosyphillis, every 4 hours.  After st= arting treatment will feel worse (Jarisch-Herxheimer reaction =3D lysis of = bacteria); no addt treatment neede
    - if titer does not double (1:1 - >= ; 1:4), then treat (no EIA test)


    condylomata lata
    - wart like= ulcer in mouth, anus from secondary syphillis

    condylomata acuminata=
    - genital warts
    #Syphilis
    c/b PCN allergy. Risk factor: MSM, HIV, multipl= e sex partners. 

    Primary syphilis manifests a= s painless genital ulcer. 

    Secondary syphilis= characterized by rash -- often with involvement of palms and soles. Mucosa= l involvement also prominent. Systemic symptoms often present, generalized = lymphadenopathy. Uveitis and neurosyphilis can also occur. 
    =
    Latent infection =3D positive serologic test without clinica= l manifestation 
    Early latent =3D <12 month duration of l= atent infection
    Late latent =3D >12 months(based on past serol= ogy results)
    Syphilis of unknown duration otherwise 

    Tertiary syphilis =3D neurologic disease 
    = - f/u CSF 

    Dx: RPR or VDRL enzyme immunoassay= . 
    If negative RPR or VDRL -- order treponemal antibody test=  

    Primary and secondary and early latent: Ben= zathine penicillin G   IM single dose (PCN allergic =3D Doxy 100 = mg BID or tetracycline 500 mg QID x 14 days) 

    Late latent / syphilis of unknown duration =3D IM benzathine PCN q 1 week = x 3 doses (Doxy 100 mg BID or tetracycline 500 QID x 28 days) 

    Neurosyphilis =3D Aqueous crystalline PCN G 18-24 million= units daily q 4 hours or by continuous infusion x 10-14 days 

    Or 

    Procaine PCN 2.4 millio= n units IM daily plus probenecid 500 mg PO QID x 10-14 days (CTX 2g IM or I= V daily for 10-14 days) 

    steroids (cortisone= 25mg =3D hydrocortisone 20mg (use this for stress dose) =3D prednisone 5mg= =3D prednisolone 5mg =3D methylprednisolone 4mg =3D dexamethasone 0.75mg)<= br>- if concern immune thrombocytopenia, low plt (if seeing a lot of ecchym= osis and pending workup, 1mg/kg PO inpt okay)
    - percarditis
    - polymya= lgia rheumatica
    - thyroiditis

    - if using 7.5+mg/day long term, ge= t vitamin D and calcium levels
    HIGH Dose steroids can cause psych issues, e.g. depression, anxiety, psychosis too.  Also insomnia, restlessness.  Decrease dose.

    Normall= y hydrocortisone 50q6 or 100q8
    For brain cancer, dex10 push then dex4q6h=

    GI UC flare =3D IV solumedrol 40mg daily

    Give pepcid, calciu= m, and vitamin d if on steroidsstrep pyogenes
    - Expert opinion8 and empirical data2= 1,22 suggest that cellulitis is most commonly caused by Streptococcus pyoge= nes. Our findings are provocative, because TMP-SMX has been considered a po= or empirical choice for the treatment of cellulitis. Recent data show that = S. pyogenes strains may be TMP-SMX=E2=80=93susceptible if low-concentration= thymidine agar is used for testing.23 Our results showing that TMP-SMX and= clindamycin have similar efficacy in patients with cellulitis are consiste= nt with these in vitro data.= strep throat
    - amoxicillinstridor =3D whistling when breathing in =3D airw= ay obstruction<= td spellcheck=3D"false" contenteditable=3D"true">st= roke
    - DDx: hemorrhage, seizure, complicated, migraine, syncope, headach= e, MS, labyrinthitis, vertivular neuritis, infection, BPPV, hypotension, hy= poglycemia, hypona, alcohol/drug, DKA/HHS, dementia/delirium, encephalopath= y, encephalitis, nerve root compression, 

    Scoring: ABCD2 ( if &= gt; 5, admit to ICU), high risk of recurrent stroke (>70% cervical carot= id stenosis, or intracranial artery stenosis, or dissection or cardiac valv= e patient), high risk for herniation (large artery occlusion, ICA/MCA, ACA,= large posterior circulation ischemic stroke), post-teneecteplase or post-n= euro interventions

    - ischemic: permissive HTN <220/120 for 24-48 = hours, if no tPa, then BP goal <140/90. If tPA <185/110
    - Tx: per = MKSAP 19: DAPT for 21 days, then aspirin indefinitely (versus MGH: no need = DAPT.  DAPT only for stent/CAD)

    - after stroke, hold eliquis to= prevent conversion to hemorrhagic until MRI. Timing of resuming medication= will be based on imaging above to weigh risk of hemorrhagic transformation= with secondary stroke prevention
    - if cannot do MRI, repeat CT head wit= hout con in 48 hours.

    -if young, then cause congenital heart issue/a= rrythemia, HIT, sickle cell, inherited hypercoag state, syphillis cocaine, = meningitis, endocarditis- CT head
    - MRI brain (no contrast)
    - CTA head/neck with contrast=
    - neuro consult
    - urine drug screen
    - a1c, lipid, TSH
    - TTE fo= r thombus or vegetation with bubble study for ASD/PFO
    - duplex ultrasoun= d of internal carotid artery
    - neuto check q4h
    - accuchek
    - aspiri= n 81
    - atorvastatin 80
    - PT/OT
    - bedside swallow, with formal eval=
    - tele

    hemorrhagic stroke
    - repeat CT head in 6 hours
    - SB= P 110-140
    - swallow eval
    - PT/OT
    - neuro check q2hstroke
    - p= lavix over aspirin if atherosclerosisstroke:
    - DWI - bright 
    - compare with ADC = - black (if not there, shine through/artifact)
    - T2 - also structure
    = - T1 structure
    - DWI Flare - bright (acute won't show bright, vs. subacu= te vs. chronic)





    <= /td>subdural hemorrhage
    - embolization of middle menin= gial artery (not sure why it helps, but it does) - stops it from oozingsubstance abuse
    #Polysubstance abus= e 
    - ETOH level 
    - PO thiamine and folate dai= ly 
    - For alcohol: naltrexone and acamprosate are the most e= ffective medications. 
    = Naltrexone is contraindicated in cu= rrent opioid use. Caution in cirrhosis, hepatiits, or liver failure (50-100= mg dialy). Caution in depressed patients.
    Acamprosate (= 666 TID) -- can be used in alcohol related liver disease. Avoid in severe k= idney impairment
    Disulfiram 250-500 daily can be used if= patient is veyr motivated for abstience. Can cause hepatotoxicity. 
    - For heroin: 
    Consult suboxone clinic NP = for follow up 
    <= span style=3D"white-space:pre"> Initiate at 8 mg suboxone once, foll= owed by 4 mg 4 hours later, then 4 mg another 4 hours later if patient not = lethargic 
    16 total for maintenance 
    2 mg PRN suboxone if needed 
    Cannot give = suboxone if opiates are needed 
    For other withdrawa= l symptoms can schedule: 
    - NSAIDS
    - Atarax 
    - Immodium 
    - = Benadryl 
    - IV ativan PRN 
    = - Melatonin 
    - Robaxin 
    - C= lonidine 0.1 to 0.3
    - For smoking: 
    Varen= ciline is superior to nicotine replacement therapy and buproprion (Avoid in= kidney disease and neuropsychiatric issues)
    Nicotine = patches should be given at night to reduce AM cravings 
    Buproprion is beneficial for concurrent weight gain, but cannot be use= d in those with seizure disorder. 
    - For methamphetam= ine: Likely some element of meth withdrawal given recent use, ongoing psych= omotor agitation, insomnia within this 1st week of abstinence.
    Fl= uoxetine (Prozac) at a dosage of 40 mg per day (reduces short term craving)=  
    Consider benzodiazepines to manage symptoms of irritabilit= y, sleep disturbance, and anxiety, but should not be continued beyond a wee= k. 
    Consider modafinil (200 mg x 10 days) -- some evidence o= f milder withdrawal syndrome and reduced craving 
    Consider d= examphetamine (20mg - 110 mg x 90 days) -- some evidnece of reduction in wi= thdrawal symptoms, and craving. 
    (https://www.turningpoint.o= rg.au/sites/default/files/2019-05/Turning-Point-Methamphetamine-Treatment-G= uidelines.pdf -- page 40) 

    SVC syndrome
    - p= ossible small cell cancer of lung or agressive non-hodgkin lymphoma
    - Tx= : likely responsive to chemotherapy= syncope
    - https://www.mdcalc.com/calc/3951/canad= ian-syncope-risk-score (Vtach and death)

    - DDx: seizure, stroke, sub= clavian steal, PE
    - consider event monitor

    - no prodrome =3D more= likely cardiac (arrhythmia, structural, tamponade, dissection, brady/tachy= , AV block)

    - reflex:
      - vasovagal (has trigger, prodrome o= f warmth / dizziness / nausea) -- midodrine can also reduce vasovagal synco= pe episode by 43% (but first try without)
      - if vasovagal unclear,= tilt table
        - carotid sinus syncope =3D test with sinus ma= ssage
      - situational (sneezing, cough, 

    - orthostatic:=
      - SBP decrease by 20 or DBP drop by 10 within 3 minutes of stan= ding  (within 15 second =3D immediate, classic =3D <3 min, delayed = =3D >3 minute; dilt table only if suspect delayed orthostatic)
     = - check any cardiac meds
      - can be due to autonomic failure from = parkinson, DM, amyloid, lyme, syphillis, B12, opioids
      - Tx: fluid= intake, more salt, midodrine 5-20mg TID if neurogenic orthostatic

    <= br>vasovagal =3D noxious stimuli, fear, stress, heat overexposure, or prolo= nged standing
    situational syncope =3D  cough, micturition, defecati= on, or swallowing
    carotid sinus hypersensitivity =3D head rotation, shav= ing, or use of a tight-fitting neck collar


    - orthostatic vitals
    - EKG
    - TTE<= br>- blood sugar, a1c
    TSH
    - B12
    - urine drug screen 
    - lip= id
    - PT/OT
    - admit to tele

    - consider EEG

    #syncopa= l episode:
    differentials include mechanical, metabolic, reflex sy= ncope (vasovagal, situational, carotid sinus) , orthostatics, cardiogenic, = neurologic. Most likely is { } {has/does not:18049} high risk symptoms incl= uding palpitations, afib, intoxication, bleeding, focal deficits, post-icta= l state, known cardiac arrhythmia, structural cardiopulmonary disease. {Les= s} likely neurologic given normal head CT without evidence of stroke, and l= ack of seizure like symptoms. Rare causes of syncope include: DM (autonomic= dysfunction), amyloid, spinal cord injury, ETOH chronic, meds, syphilis, B= 12 deficiency; extremely rare causes include PD, lewy body, Shy Drager.&nbs= p;
    -EKG shows:
    -Orthostatic vital signs 
    -Echo
    -UDS, CMP, CBC
    -Imaging: {CT head}
    {-S= PEP if c/f amyloid, RPRP, b12} 
    -consider zio patch outpatie= nt  
    {-Can treat with midrodrine 5-20 TID, or fludrocor= tisone 0.1-0.2mg daily. Droxidopa for PD associated orthostatis.}
    {-Concern for Neurologic Seizure, stroke/ TIA, subclavian steal) +Tongue b= iting, urinary fecal incontiennce, stroke TIA.}
    {-EEG for seizure= }
    {-CT MRI/MRA for stroke}
    T1DM
    - measure GAD65 a= b and IA-2 Ab
    - 20% has will get another autoimmune diseasehtacrolimus: increases K = ; (level 5-8 for kidney transplant; 4-5 for heart and liver)
    CKD: bicarb= slows down CKD progression
    if proteinuria and ARB doesn't help, add fin= erenone or spirinolactone

    tacrolimus lab: get 12 hours from night do= se, right before mornign dose= takayasu arteritis
    - stenosis and inflammation of aorta a= nd large vessels (subclavian, common carotid, renal arteries)
    - Sx: bila= teral arm claudication (pain/ache/fatigue of muscle worse with activity, be= tter with rest)= t= amponade / pericardial
    - Beck's triad for tamponade: low BP, JVD, muffle= d heart sounds.  pulse paradoxus (decrease SBP >10 mmHg when inhali= ng; get BP when only exhaling, then decrease until hear all the time)
    - = EKG shows low voltage, only precordial leads may sometimes show electrical = alternans; echo shows diastolic collapse of RV.
    - rate of accumulation m= ore important that size
    - Tx: ensure fluid (250-500cc boluses).  no= beta blocker, avoid positive ventilation.  Remove drain when <50cc= /daytardive dyski= nesia
    - lip and face twitching
    - after long use of antipsychotic/anti= nausea or metoclopramide   (all Dopamine D2 receptor blocker)
    = - Tx: valbenazineTB
    - pleural TB and lymphadenopathy can be TB.TBI (traumatic brain injury) paroxysmal sy= mpathetic hyperactiviy syndrome
    - propranolol 20mg TID, neurostorming (f= ever, tachy)
    - baclofen to help with dystonia due to TBI; bromocriptine = also for dystoniatest tips:
    - if new symptoms for someone with chronic issue, need inves= tigate
    - choose answer that helps actually diagnose (not just helps with= prognosis)<= td spellcheck=3D"false" contenteditable=3D"true" class=3D"sorting_1">thicke= ned gallbladder
    - need MRI/MRCP
    - gallbladder cancer asymptomatic.&nb= sp; Treatment is choleystectomythis is a new clinical pearl MELD Na = (UNOS/OPTN) (mdcalc.com)= thrombocytopenia (low plt)
    - score: 4T for HITT (if hepar= in), DIC criteria
    - labs: HIV, HCV, varicella, CMV, EBV, parvo, tickborn= e, B12, folate,  DIC, TTP, haptoglobin, LDH, DAT, d-dimer, fibr= inogen, 
    - other causes: some bleeding? ITP, HUS, preclampsiia, hyp= erspleen.  If lupus, add anticardiolipin, anti beta2,
    - DDx: <= br>
    pancytopenia
    - labs: HIV, HCV, HBV, CMV, EBV
    - CRP, ESR
    - D= IC screen, EPO level
    - nutrition work up: iron/ferritin, B12, folate, zi= nc, copper
    - autoimmune workup: antiphospholipid (anticardiolipin IgG, I= gA, IgM, beta 2 glycoprotein, IgA, IgG, IgM, anti-lupus anticoagulant, ANA = panel (SSA, SSB, RF, anti CCP, ANCA, ANA, anti-smith, ds-DNA, SCL 70), cryg= lobulinemia
    - hemolysis labs: LDH, reticulo count, peripheral blood smea= r, haptoglobin, UA, direct and indirect coombs
    - U/S abdomen for splenom= egaly


    b12, folate, iron panel, zinc, copper, HIV, EBV, CMV, hepatitis panel, smear= , H pylori 


    -if fibrinogen < 150,and= need any procedure/biopsy, need cryo
    #Thrombocytopenia 
    Question of whether= this is due to decreased production, increased destruction, or sequestrati= on. 

    To evaluate for decreased production: ma= y be due to sepsis, but would also evaluate for the following 
    - HIV, HCV
    - Parvovirus 
    - B12, folate, copper,= ETOH 
    - Possibly due to malignancy: leukemia, MDS, PMF, apl= astic anemia 

    To evaluate for increased destr= uction: 
    - HIV, HCV, H.Pylori, HSV, VZV, CMV, EBV
    = - ITP, SLE, RA, CLL, HIT
    - Drug induced 
    - MAHA --= DIC/ TTP/ HELLP 
    - Shearing / aggregation -- CVVH, CPB, IAB= P, vasculitis, hemangioma (kasabach Merrit) 

    = For sequestration:
    - Evaluate for splenomegaly, massive transfusi= on, hypothermia, gestational 


    =
    - Concern for hemolytic anemia (concurrent Hgb, Platelets) -= - check LDH/haptoglobin/bili/ DAT (AIHA), retic count 
    - Per= ipheral smear -- check schistocytes -- coags, d-dimer, fibrinogen 
    - Consider ANA 
    - IF > 60 yo, splenomegaly, or sys= temic sx, consider BMBx to r/o MDS, AA leukemia, infiltrate 
    - Rule out pseudothrombocytopenia -- platelet clumping due to EDTA, can or= der platelet count citrate 

    If ITP -- severe = bleeding: IVIG, methyl pred 1g/d IV x 3 days >>> amicar 
    1st line: dexamethasone 40 mg x 4 days  
    2nd line= : Rituximab 


    If HIT -- anti-PF= 4 heparin complex Antibodies binding and activating platelets. Presents 5-1= 0 days after exposure, decreased platelets by 50% with the nadri 40-80k, th= rombosis in 30-50%. 
    - 4T score of ***. If >4, dc heparin= and check anti platelet factor 4. Then serotonin release assay 
    =
    - Argatroban in the meantime 

    #Thromboti= c Micrangiopathy 
    Small vessel irregularities causing microt= hrombi. 
    Consider MAHA (decreased hemoglobin, elevated LDH, = decreased haptoglobin, positive eschistocytes, negative DAT) -- TTP, HUS, a= typical HUS, drug-induced (immune mediated -- includes gemcitabine, oxalipl= atin, quetiapine, quinine -- n/v/d, AKI, abd pain, dose dependent-- include= s everolimus, plavix, cocaine -- subacute fatigue, HTN) 
    #DIC (increased PT, D-dimer, decreased fibrinogen) 
    <= div>- DIC Score: ***
    - Treat underlying cause 
    - P= latelet transfusion if < 10 
    - Cryo if fibrinogen < 10= 0 
    - FFP if INR > 2 


    - Soft or puree diet to avoid GI bleeding 
    - Mirala= x senna to avoid GI bleeding 
    - Fall precautions 
    =

    = thryoid nodule:
    - if > 1cm, fine needle biopsy or = if <1cm and risk factors for cancerthyroid nodule
    - thyroid U/S


    Hyperthyroi= dism-
    - S&S: lid lag, tremors
    Methimazole has side effect of a= granulocytosis (patient will sore throat). Low wbc . Check wbc in 2 wee= ks. 

    Subclinical hyperthyroidism: Tx if symptoms or TSH > 0.= 1uU/L

    - if 1st trimester, PTU (SE of liver toxicity)

    Graves -= pretibial myxedema (sugar deposit in lower legs causing swelling), goiter;= if has eye symptoms (don't do radioactive iodine!, worsens eye symptoms)

    thyroid storm: can be normal thyroid level; a clinical diagnosis.= S:S fever, cardiac decomp, delirium/psychosis after surgery, infection.&nb= sp; Preferred treatment is PTU, steroid, betablocker

    patients with g= races can have isolated R heart failure.= thyroidtoxicosis
    - esmolol drip, methimazole 20 = q6h, solucortev IV 
    tinea pedis: topical terbinafine or miconazole cream BID 4-6 we= eks
    tinea corporis: terbi= nafine 1st line, miconazole 2nd line.  BID for 4-6 weeks
    <= /td>

    Tokyo Guidelines for acute cholangitis

    Tokyo guidelines for acute cholecystitis

     

    toxic shock / SJS / TENS

    Toxic shock (sta= ph aureus exotoxin! + skin scuffing from tampon + nasal packing + surgical = wound)
    - Sx: palm and sole rash
    - Tx: clindamycin (theoretically prev= ents toxin being made) and vanc/oxacillin/nafacillin to kill the bacteria. = Need LOTS of fluid replacement.
    = TPN
    - no TPN prior to 7 days of acute illness

    = Transaminitis:R Fact= or for Liver Injury (mdcalc.com) for cause
    AST/ALT >2:1 alco= hol and rhabdo

    #Hepatocellular injury
    R Factor > 5 suggestive of hepat= ocellular injury. NALFD fibrosis score for steatosis ***. 
    <= br>
    Ischemia less likely given AST/ALT elevation is not in the th= ousnads. ETOH likely given 2:1 ratio of AST:ALT. Viral infection is possibl= e. Other differnetials include autoimmune hepatiits, celiac disease, hemoch= romatoiss, A1AT ( can occur without significant lung involvement) Wilson's,= and congestive hepatopathy given RHF. Medications known ot cause hepatocel= lular injury include Tyleonol, augmentin, amiodraone, allopurinol, cabramaz= epine, fluoxetine, heparin, INH, labetalol, lisinopril, losartan, nitrofura= ntoin, NSAIDS, phenytoin, ketoconazole, protease inhibitors, staitns, sulfa= drugs, trazodone, VPA. 

    - CMP daily 
    - Viral hepatitis panel + total Hep B antibody 
    - CM= V, EBV, VZV, HSV for other viral causes of transaminitis 
    - = Anti TTG, total IgA for celiac's. Consider endomysial given high specificit= y if this is positive. 
    - f/u iron panel nad ferritin Fe/TIB= C:> 45% and ferritin > 200 should warrant HFE testing (often diagnose= d in those 40+, with women manifesting symptoms later than males)
    - Ceruloplasmin, urine Cu for Wilson's (hemolytic anemia from sudden relea= se of copper and altered mental status supports this) 
    - ECH= O for evaluation of congestive hepatopathy 
    - ANA, ASMA, AMA= , LKM1 serologies, SPEP for AIH evaluation 
    - RUQ US for fat= ty liver 
    - UTox for cocaine, ecstacy, PCP


    Ischemia likely given recent shock, cardiac arrest, = history of Budd Chiari. Can consider rarer causes such as autoimmune hepati= tis, acute Wilson's, HELLP syndrome, alcoholic hepatitis, malignant infiltr= ation. 
    - LDH -- ALT:LDH ratio <1.5 suggestive of ischemi= a/APAP toxicity over viral hepatitis. 
    - Continue to monitor= bilirubin -- often will see a peak in 1 week later after a 48 hr acute ris= e in ALT/AST. 
    - Acetaminophen level 
    - Hepat= itis panel, total hepatitis B antibody, HSV, VZV, EBV, CMV to evaluate for = acute viral infection 


    #Choles= tatic injury
    R Factor < 2 with elevated alk phos and bili. Ddx= includes bile duct obstruction (malignancy, ascneidng cholangitis, PSC, PB= C, chronic pancreatitis with strictures), cirrhosis, medications. 
    - Hepatitis panel
    - RUQ U/S for obstruction
    - An= ti-Mitochondrial antibodies 

    #Infiltrative pa= ttern of liver injury
    Alk phos elevated to ***. Ddx includes sarc= oidosis, granulomatous diseases, amyloidosis, malignancy. Alk phos is als o= found in bone (bony mets), intesitns (increased in SBO). 
    - = GGT -- if high concern for liver source -- test fractionated alk phos (bone= gut hepatic)
    - Consider SPEP 

    Indi= rect hyperbilirubinemia: consider Gilbert's, hemolysis, resorption of large= hematoma. 

    transfusion criteria

    HGb:- >Hgb 9 in critically ill
    - >8 with preexisting CAD, ACS
    - a= ny time >1.5L blood loss

    leukoreduced (decrease WBC) - all at UCI= is leukoreduced: if had febrile non-hemolytic reaction before
    irradiati= on (inactive lymphocytes): if had stem cell transplant, on immunosupressive= s, cancers, or immunodeficient
    washing (remove plasmta protein, electrol= ytes, Ab): severe allergice reactions, IgA or haptoglobin deficient, pt at = risk of hyper K
    volume-reduced (remove plasma): thalassemia major, sickl= e cell, CHF


    Plt:
    - >100k if neuro or eye surgery
    - >= 50k for surgery or active bleeding
    - >20k if 100.4F and invasive proc= edure
    - >10k normal
    - hold anticoags, antiplatelet if Plt <50k<= br>
    order ionized calcium if lots of transfusion; Serum Ca can be n= ormal.  Muscle spasm =3D hypoCa.  Citrate binds ionized calcium (= active calcium).



    TRALI
    - HLA or neutrophil-specific = antibodies in multiparous donors that bind to and activate recipient leukoc= ytes in the pulmonary vasculature

    TACO 
    - respiratory d= istress within 6 hours of transfusion, positive fluid balance, elevated cen= tral venous pressure, and radiographic findings of pulmonary edema

    a= cute hemolytic transfusion reaction
    - fever, dyspnea, hypotension, flan= k pain, and pink-colored urine appearing during or shortly after a transfus= ion.
    - Tx: immediate discontinuation of the transfusion, volume exp= ansion, and supportive care.= trauma
    Differential includes concussion, pneumothorax, pulmonary contusion, = rib fracture, extremity sprain. Low suspicion for intracranial hemorrhage, = SDH, tSAH, or skull fracture. Patient is neurologically intact in setting o= f low speed traumatic mechanism, no vomiting or difficulty ambulating. Doub= t spinal fracture or c-spine injury, given no spinal point tenderness and f= ull ROM of neck. Doubt hollow organ injury, acute traumatic abdomen, or sig= nificant internal hemorrhage, given reassuring abdominal exam, no ecchymosi= s/abrasions, vomiting, or bloody stools. Doubt significant thoracic or aort= ic injury, no chest wall tenderness, hypoxia. Low suspicion for extremity f= racture.

    High risk populations: age >55, antico= agulation, pregnancy > 20 weeks.

    NEXUS chest cr= iteria all absent - normal CXR, no distracting injury, no chest wall, stern= al or scapular tenderness, no significant mechanism (fall > 20 feet, MVC= > 40 mph).
    NEXUS c-spine criteria all absent - no focal neuro= deficit, no midline tenderness, no ALOC, no intoxication, no distracting i= njury.
    Canadian head trauma criteria all absent - no blood thinne= rs, no seizure, GCS > 15, no signs of basilar skull fx, no vomiting, age= < 65, no retrograde amnesia, not dangerous mechanism ( fall > 3 feet= , MVC ejection, ped vs auto).
    traveler's diarrhea prophylaxis:
    = - rifaximin recommended for patients with immune compromise, IBD, CKD
    - azithromycin if fever >101F after obtaining culturestricyclic antidepressants, TCA e.= g. nortriptyline
    - careful with people with heart disease as associated = with arrythmia, heart block, sudden deathTTP more neuro status affected, less kidney
    HUS= nore renal, less neuro status
    DIC - cancer or infectiontube feeding
    - tuve feed <4= 8 hours reduces mortality
    - no early feeding if in shock
    erythromycin= (prokinetic - better than metoclopramide)
    - residual (content in stomac= h when feeding stopped) <500 okay; if more, ensure head of bed > 30, = erythomycin or metoclopramid, advance to post-pyloric or into jejunum (if v= omiting)
    - gastric okay for intermittent or continuous feed (no changes = in outcome)
    - post-pyloric only for continuous feed3D""tumor lysis TL= S
    - give lots of IV hydration (and lasix to enhance urine flow)
    - ura= te, K, phos really high
    - IV rasburicase for all high risk (bulky diseas= e, high leukocytosis count, high urate or LDH, very bad CKD), or if rapid d= ecreasing urate level is neededUGI GI Bleed
    Glasgow-Blatchford Bleeding Score (GB= S) (mdcalc.com) - whether to discharge or admit
    - DDx: esophage= al varice, mallory-weiss tear, peptic ulcer, esophagitis, neoplasm
    - nee= d endoscopy
    - test for H pylori
    LGI Bleed
    - RBC nuclear scan if pa= tient unstable.  Need colonoscopy
    - famotidine useless for UGI blee= d (only do PPI)
    - if unstable for colo right away, CTA 

    GI B= leed:
    - PPI BID
    - retic count, iron panel/ferritin
    - 2 large bore = IV


    - admi= t to telemetry
    - no anticoag, antiplatelet, NSAID
    - CBC, CMP, PT/INR,= albumin, BUN, Cr
    - CBC q6h
    - type and screen if hemodynamic stable, = severe bleed, or high risk
    - orthostatic vital sign (moderate blood loss= )
    - 2 large IV bloores (16 gauge or larger)
    - IVF bolus and maintenan= ce fluid
    - NPO
    - SpO2 goal  92%
    - consulted GI
    - protonix = 40mg IV BID
    - transfuse if Hgb < 9 in elderly, CAD, <8 in CVD and = signifant UGI bleed




    - recommend intravenous fluid r= esuscitation with the goal of normalization
    of blood pressure and= heart rate prior to endoscopic evaluation/intervention
    - discuss= with the patients cardiologist regarding safety of holding ASA, plavix, NO= AC*
    - trend H/H serially and transfuse as needed
    - bloo= d transfusions should target hemoglobin =E2=89=A5 7 g / dl, with higher hem= oglobins targeted in patients with clinical evidence of intravascular volum= e depletion
    or comorbidities, such as coronary artery disease
    - check iron studies, B12, folate
    - check PT/INR if not al= ready obtained
    - please acheive goal INR in acute GI bleeding pat= ients of 2.5 or below
    - transfuse platelets if <50 
    =

    - Plan for diagnostic colonoscopy and possible EGD tomo= rrow (this is an add-on case and therefore there is no scheduled time) = ;
    - Clear liquid diet today
    - 4L of Golytely bowel prep= starting tonight. After finishing this, give additional bowel prep until B= M are clear
    - Make NPO at midnight except bowel prep and essentia= l medications
    <= /td>Ultrasound 
    Nerve like a flag (hypoechoic)Tendo more lines in between - fibrils (tendons are anisotrophic . If you = tilt then becomes darker)
    15+ mhz for nerve
    Cartilage anachoic
    If = dopplwr flow in synovial fluid, likely respond better to steroids or ra med= s (inflammation)
    Cellulitis lights up on the surface. Edema does not on = doppler due to vasodilation there
    Ra synovial is normally 1 cell thick.&= nbsp; Ra had more.Ultrasound
    - compare liver echo to kidney for cirrhosis
    - 20 hounsfi= eld unit spleen to liver difference on ct also
    - portal vein flow toward= s transducer 10 - 20 is normal
    - >125 cm/s ICA is moderate stenosisultrasound
    - EP= SS: anterior mitral valve to IV septum: if <8,mm, no systolic dystunctio= n (EF not <55%)
    - a wave not present in Afib

    ultrasound
    - Kidney: mid axilla= ry, T4-6. L kidney even more posterior and towards head (cephalad)
    = - Cardiac: EPSS (e-point septal separation, i.e. mitral valve to septum) &g= t;7mm =3D EF < 50% (87% sen; 75% spec)
    - Gallbladder: thicknes= s >3mm vs >4mm =3D nonspec gallbladder disease
    =E2=80=82=E2= =80=82=E2=80=82=E2=80=82=E2=80=82=E2=80=82- pericholecystic fluid + wall th= ickness + distention (>10cmx4cm) =3D 100% acute chole
    =E2=80= =82=E2=80=82=E2=80=82=E2=80=82=E2=80=82=E2=80=82- gallstones + suspect acut= e chole =3D dx acute chole
    =E2=80=82=E2=80=82=E2=80=82=E2=80=82= =E2=80=82=E2=80=82- X-7 =3D 7cm right of subxiphoid, lying left side, hold = breath
    - CBD > 6mm =3D choledochol
    - AAA >3cm =3D= mild (5cm =3D 20% of lifetime rupture; any baseline size, but >0.5cm in= crease in 6 months =3D high risk of rupture)
    - IVC: eval 2-3cm from RA
    = ultrasound:
    - lu= ng use linear and then use abd probe  (anterior, lateral, and posterio= r)
    - a lines normal 
    - pneumothorax: no lung sliding; M mode sho= ws barcode sign instead of sea shore sign
    - b lines: edema / blood / col= lagen /transudative/exudative: more than 3 IS pathology.
    - posterior vie= w better for edema for HF3D""<= br>3D""
    =3D""
    3D""
    =
    ultrasound
    E is diastolic filing A is late di= astolic atrial kick
    A > E: early diastolic dysfunction
    E > a = =3D normal, pseudonomal.  If E/a > 3:1 then restrictive diastolic r= elaxation
    E/e' <8 normal; > 15 is elevated

    RV function =3D = do TAPSE:
    4 view chamber, normal TAPSE > 16mm


    RV free wall= thickness < 5mm; > 10mm is pathologic

    gallbladder: <=3D 3m= m thick normal, can be thicker after eating3D""= ultra= sound
    renal
    - don't order renal u/s for pyelo (clinical diagnosis; on= ly for complicated pyelo with abscess/stone) or infarct
    - inptiatnet ren= al: just for hydro; then if imaging, CT for further (cancer, stricture, obs= truction -- do not rely on ultrasound for cause rule out)
    - mass should = be CT, not ultrasound
    - ultrasound good for known stone; gold standard i= s non-contrast CT (uric acid stone still show on CT)
    spleen: <12
    -= ultrasound only for size splenomegaly
    - or for lymphoma
    liver:< 1= 6
    - only if history of cancer/liver metastasis (but CT much better)
    -= outpatient: screening for steatosis (how bright the liver is - bright is b= ad; normally sould just be very slightly brighter than kidney/shouldn't be = able to tell); cannot rule out cirhossis - looking for border nodularity, t= hen parenchema for echotexture like porcelain (portal hypertension)
    - ou= tpatient: appropriate: screening for HCC q6months (then confirm with MRI)- simple cyst growing is benign.
    - abd limited: without kidney
    panc= reas: nothing (limited sensitivity for anything)
    - don't get CT imaging = for acute pancreatitis; should be 1 week-10 days after initial symptoms if = not improved)
    gallbladder
    - acute chole and CT now complimentary (if = ultrasound positive, straight to HIDA (most specific and sensitivity), not = CT); but ultrasound better for seeing stones(as some don't show on CT)
    -= gallbladder wall sensitive but not specific (pancreatitis, ascites can cau= se it; wall takes in water quickly);
    - gallbladder distension sensitive= (if flattened, not likely), but not specific
    biliary tree:
    - can see= CBD, but not know where it's due to (i.e. should be for screening) ; CBD n= ormal 0.6-0.8;  if after chole, than 1.0
    - if CT done already, go t= o MR (should not go back to ultrasound)

    https://www.raducation.xyz/<= br>
    uremia
    = - echinocytes (spicules on blood smear; vs. acanthocytes projections are la= rger)3D""= urina= ry incontinence
    - stress =3D decreased urethral sphincter tone and ureth= ral hypermobility: leak with cough, sneeze
      - Tx: exercise and pes= sary  (if menopause, can also try estrogen cream; NOT oral)
    - urge = =3D detrusor overactivity: sudden urge to pee
      - Tx: train to hold= , oxybutynin (Ach blocker - relaxes bladder), mirabegron (beta agonist)
    = - overflow =3D impaired detrusor contractility or bladder outlet obstructio= n: incomplete emptying, dribbling
      - Tx: timed urination; bethanec= hol (Ach agonist) if underactivity<= /tr>UTI

    Complicated: outside of bladder. 

    <= br>- Tx duation: uncomplicated 5 days, complicated 7 days, CAUTI: 7 days, p= yelo: 14 days
    - Tx:
      - 1st: bactrim BID x3 day (do not use if = used  previously), Macrobid (nitrofurantoin) 100mg BID 5 days (do= es not work for pyelo)
      - 2nd: ciprofloxacin 250mg BID x3 days, Au= gmentin 500-125 BID 7 days

    2nd most common in young female: Sta= phylococcus saprophyticus (gram positive in clusters)
    most common: ecoli=

    asynmptomatic - pregnant; 

    pyelonephritis
    - most com= mon Ecoli.  If pregnant, must admit; else mild-moderate can be outpati= ent
    - Tx (outpt): cipro 500mg BID for 7 days, levofloxacin 750mg QD for = 5 days, Bactrim DS BID for 14 days
    - Tx (inpt): ceftriaxone 1g daily, le= vo 750mg IV daily, ciprofloxacin 400mg BID, cefepime 1g TID.  IF enter= ococcus, ampicillin 2g TID+gentamicin 1mg/kg TID, zosyn 4.5 TID, ampicillin= -sulbactam Unasyn 3g QIDpsuew


    pyridium (phenazopyridine) relieve= s symptoms from UTI 

    - enterobactter, staph saprophyticus, stre= p agalactiae; if struvite cyrstal (coffin-lid), then likely proteus; (also = can be klebisella, or pseudomonas as these secreate urease that create stru= vite stones)
    - UTIs occurring in hospitals and long-term care facil= ities frequently involve a more varied group of organisms (such as Enteroba= cter, Providencia, Morganella, Citrobacter, Serratia, and Pseudomonas<= td spellcheck=3D"false" contenteditable=3D"true">
    #Uncomplicated UTI: P= atient endorses frequency, urgency, dysuria, malaise, incontinence, nocturi= a, suprapubic tenderness, fever, chills/ rigors, pelvic / perineal pain. +N= itrites are positive with enterobacteria. Differential includes vaginitis, = urethritis, structural abonrmality, PID, nephrolithiasis. 
    -= NFT 100 BID x 5 days (avoid if CRCL<40)
    OR
    - Bactri= m DS BID x 3 days for females x 7 days for males (Hooton 2019) (empiric if = resistance is >20% E coli to nitrofurantoin)
    OR 
    - Fosfomycin 3g x 1 day 
    Alternatives is augmenetin x 7 da= ys 


    #Complicated UTI: UTI and = systemic symptoms -Fever 99.9F, Chills, Flank Pain, CVA tenderness, Pelvic = Pain in Men, special populations: Pregnant woman, Renal Transplant. 
    - Outpatient-- ciprofloxacin 500 mg BID x 5-7 days OR levofloxacin= 750 mg x 5-7 days OR bactrim DS BID x 7-10 days {susceptibilities recommen= ded}. 
    - Inpatient: CTX or cefepime 
    - Add va= nc if concern for GPC infection on uringe gram stain 
    - Add = Meropenum if concern for ESBL coverage (marino trial) 
    - Ren= al ultrasound 
    - f/u urine cultures. bcx

    #Catheter associated UTI: Signs of UTI with no other identified sourc= e of infection AND urine culture with one uropathogenic species > 10^3 C= FU/ml from single catheterized urine specimen ( catheter in place > 2 d)= _ OR midstream voided specimen from patient whose catheter was removed in p= revious 48 hours. 
    - CTX or FQ AND VANC for 7 days 
    - Remove cather ASAP 
    - Repeat UA/UCx

    <= /div>
    Fungal -- common colonizers, only treat if symptoms or neutropeni= c or before uro procedure 
    If resistant C glabarata or kruse= i use conventional amphotericin 

    #Asymptomati= c bacteriuria (or bacteriuria without symptoms) should NOT be treated in th= e absence of symptoms except in pregnant women, those with renal transplant= in first 3-6 months, and prophylaxis for invasive urologic procedures).&nb= sp;
    - ESR, CRP 
    VA workflow
    Admissions: June VA Ward Team= s Board 23.xlsx (sharepoint.com)
    ED Board: Emergency Department Integration Softw= are (va.gov)v= ancomycin

    if MRSA, vancomycin MIC >2, needs daptomycin or linezol= idVascular insuf= ficiency
    - if very bad PAD, can be false normal (if neuropathy, diabetic= s)vasculitis
    -= Sx: hemopytsis, kidney pain, scleritis, SOB, fatigue, 
    - labs: ANC= A, complements<= td spellcheck=3D"false" contenteditable=3D"true">va= sotec over metoprolol if okay (enalaprilat)Vbg to abg co2 decrease by 6.
    Ph increase by 0= .05

    Nonanion gap metabolic acidosis.  Calc winters formula. Ord= er urine cl, k, na. Urine osm gap

    Rta 1 cannot make h+ to urine so c= annot bind with nh3 to make nh4+. So anion gap is high. Ph >5.5
    Rta 4= cannot make nh3, so also anion gap high. And ph<5.5 (still H+ in urine)=

    Both above, urine osm gap would also be negative or <100
    Then= look at serum K for type 1 vs type 4(high)

    Rta 2 anion gap negative= as just cannot absorb bicarb

    Ua protein is albumin. Urine spot prot= ein is everything


    Rta1 cannot get rid of h+, so all acidic goes = to bone (good buffer in body for acid) and thus bone calcium and phosphate = gets released -  causes calcium phosphate stones.
    Ph increase to 6.= 5 with potassium citrate then stop. Else more alkaline gets likely stones.<= /td>venous stasis- Sx:  edema, varicosities, eczematous changes, brown pigmentat= ion from hemosiderin deposition, lipodermatosclerosis (fibrosis of subcutan= eous tissue), atrophie blanche (pale plaques of scar tissue)
    - compressi= on therapy (but if ABI 0.5 or less, contraindicated)
    - venous stasis ulc= er =3D irregularly shaped and shallow, weep serous fluid. , and evidence of= healed ulcers. 70% of all leg ulcersvolume overload 
    - IV diuretics for all cases- strict I/O

    If inadequate response to diuretics, add vasodilator = if SBP > 100
    vasodilator nitroglycerin 0.4mg tab x3 q5min, and nitro = gtt 20mcg/min
    - labs q15m, then q30 mi, then q4

    if also low cardi= ac output (low CI) =3D i.e. narrow pulse pressure, AMS, prerenal azotemia, = cool extremities, decreased urine, poor response to IV diuretics
    - admit= to ICU/CCU
    - if on betablocker, then milrinone 0.125mcg/kg/min and titr= ate), if no beta blocker, dobutamine 2.5mcg/kg/min or milrinone.

    VRE (vancomycin= -resistent enterococci)
    - Tx: linezolid, daptomycin, tigecycline

    =

    warfarin = bridge before surgery
    - if clot within 3 months or CHADSVASc 7+, else ho= ld 2 days prior
    <= /td>warm hemolytic anemia
    - postiive DAT
    if Hgb < 7, blood transf= usion likely won't match, but still transfuse
    "Therefore, if crossmatch-= compatible units cannot be identified, type-specific blood should be slowly= transfused and the patient closely monitored. Although the autoantibody wi= ll shorten the survival of the transfused cells, the hemoglobin level will = often remain improved for several days, providing significant clinical bene= fit."
    - prednisone and rituximab to get rid of the antibodiesweight loss:

    - C= achexia due to cancer (likely because of TNF=CE=B1 and other cytokine produ= ct) cannot be significantly reversed by more aggressive or invasive methods= of nutritional support, including enteral (or parenteral) nutrition, and t= hese interventions do not improve morbidity or mortality.
    - Meges= trol may enhance appetite and promote some weight increase but is associate= d with adverse effects (such as risk for thrombotic events); for those who = do gain weight, neither mortality nor quality of life is improved.
    1. Focus on portio= n control. Only a quarter of the plate should be carbs. The other quarter s= hould be protein. The other half should be vegetables with some fruit on th= e side. You can have one serving of dairy on the side. Refer to ChooseMyPla= te.gov. Other options include meal replacements such as Jenny Craig, Weight= Watchers, SmartOne, or Lean Cuisine. Your daily calorie goal should be to = reduce to 1200-1300 calories a day

    2. Try intermit= tent fasting 
    The 16/8 method: Also called the Leangains pro= tocol, it involves skipping breakfast and restricting your daily eating per= iod to 8 hours, such as 11 am - 7 pm. Then you fast for 16 hours in between= .

    3. Try meal replacements. You can try to drink a= protein shake such as a Premier Shake or SlimFast for lunch after your int= ermittent fasting ends. 

    4. The largest sourc= e of excess calories is from liquid calories. Examples are soda, alcohol, j= uice, milk. Try and reduce and eventually eliminate these. Instead try to d= rink at least 2-2.5 liters or 67-84oz of water a day.

    <= div>5. Try to limit carbohydrate intake. Examples are white rice, potatoes,= pasta, bread, french fries, chips. These have a high glycemic index which = means they will make your blood sugar high quickly and also plummet quickly= . This drop will make you hungry again more quickly. 

    6. Decrease desserts. Try snacking on vegetables like microwaved f= rozen peas before your meals to limit your hunger and as a source of fiber = to trap cholesterol, or as a snack if you are craving desserts. 
    =

    7. Increase servings of vegetables and fruits. Goal is = 6-7 servings a day

    8. Besides diet modifications, = try to exercise 30 minutes daily at least 5 times a week. You can try walki= ng, swimming, or even biking. Your step goal should be around 8000 a day.

    9. Please call weight management at UCI for a free = class (949-824-8770) 

    10. Try downloading Noo= m -- an app that helps with counseling to reduce appetite. 
    =
    11. Alli (orlistat) is an over the counter medication you ca= n purchase. You can take 2 pills (120 mg) with your main meals to prevent f= at absorption. It can cause diarrhea with fatty meals. If you take this, ma= ke sure you take a multivitamin at night to make sure you are getting enoug= h vitamins. 

    12. If you are diabetic or predi= abetic, consider starting metformin, liraglutide (Victoza), semaglutide (GL= P1) for added weight loss. 

    13. Talk to your = doctor to see if you qualify for Qsymia or Phentermine

    =
    14. If your BMI >40 or if you have comorbidities like OSA and HTN a= nd you have a BMI >35, ask your doctor about bariatric surgery.

    Sleeve gastrectomy is accomplished by excising the part of= the stomach along the greater curvature, creating an approximately 85% red= uction in size; similar to gastric bypass, it results in restriction of cal= orie intake via a smaller stomach and hormonal (GLP-1 and related hormones)= appetite suppression. The smaller gastric surface area also results in les= s production of ghrelin, an appetite stimulant.
    wound
    - avoid d= ry gauze as when pulled off, will also remove good granulation tissue
    WPW
    - do not= use calcium channel, b blocker or digoxin if also Afib; use procainam= ide if pt has Afib and WPW 
    - Afib with WPW is risk factor for Vfib=


    - if AVNRT - use Ca channel blocker and B blocker to prevent re= current AVNRT
    AVNRT =3D p wave buried in QRS or right after;  AVRT = =3D sees an RP interval
    ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: image/webp Content-Transfer-Encoding: base64 Content-Location: https://rk.md/wp-content/uploads/2014/03/thromboelastogram-diagram-rk.webp UklGRhomAQBXRUJQVlA4IA4mAQBQogSdASo4BDgEPpFCnEqlo6whpTIrWYASCWdu/BCPPN6Z3aLs ROr9vTl9+eHD/0P9w/bXxoY58jfjP7R/hv9N/f/3A+aSvf2T+t/4T/Gf379rvvr/g9p3W3/P+4D4 lPK/2P/ef5D8h/mv/pP/B/i/cV/Fv8d/4Pz/+gL+G/zP/S/0v/Qfsd9FP/D6mP7L/6/UF/Tf7p/8 f9b74H/H/YD3df4/1AP7P/jP///3vfx9Sb0Bv3W9Xj/q/tx/5PlJ/qn/B/cH/jfI1/Sf8r///3Z+ AD/+eoB/8utH6pf2T+x/4//Gf3b5I/If1T+0/3H/Af5b++/sr7m/jHzn9k/vf+M/yX9t/9X+w+5f 7W/m/8X+7HqW6k/3n+g/0Xsb/Hvsr98/un+O/2397/dj70/wP+N/xn7a/3j9wvaH87/fv9H/nf3X /wnyC/j38r/u/99/x/+5/uv73+7H/M/mj/fPIH2f/Yf6H/V/ud+//0C+w3z7/Qf3v/Hf9//F/vV9 A/vP+R/wn7b/3r///KX6l/bP9P/ev81/1/9D///wA/lX9F/0H95/y//i/xP///5v3d/ov9h/mf8d /+fSS+7/6b/b/438o/sC/ln9e/5X+E/0P7afTD/Kf9X/Lf6X9oP/////jF+d/4z/uf5j/Wftj/// //+hP80/rv/H/wn+j/+/+i/////+8L/+/7P4Aft3/+P9D8JP7K//3/Qf70wX0Cg8NfRfMvQKDw19 F8y9AoPDX0XzL0Cg8NfRfMvQKDw19F8y9AmRQ/ZclmIUMhDJ7msx5uYOTRPFEo/++ODxWfj9g1mI KVGASVJgFDCiUgIs50hZocF8L9zhqpC/usuiMKkUFYFA6QTrgjnpQbxchXw56FUAjdgsaY6ZNIpN O17pLvNOQMavI/+kI7lg16ubmDk0UgAI9f1avImw95Eqdm1+cRBI3TLySe9BrH4yV27bffvo5YEp yVxB6x5uQ9W8RKkLq7e21WBBrIa+nokXsfr+8UcWatU3FFVZRiVNp3KHKMJfRq2EzaNHZAcvvjbr og1nFEvZXOJoy0jLi3Odk4mz4AT9kGNInF7gZr8217ozF0DSEFcqf3wAeCFh6h5eDjOucom02GfD 5etcje+UWXUpGqd+nYzJFN0WZmr0H4B50S1gw2nxozzY69qwc0lmaem8Cfg5FpDwUVhdIi1GwoBZ BAVj3cN96u2TkDUI1J7srt4Zl9ALP8jNTUgyhjZtpHT7BJAbylaf3Vh/7yyxjfwRzYpHIrqIeCb5 K8hq0XlGLLXURAw1u0RuSK773u6r+U0rTmuDxXfOG8vlocUQALwf1eGCC3HcSRhVxlF/5fPjDI+j n1CmlNRYJFjAI5TtKoJ4sPTYrObyT6vxDgcq7jnA7yB5QhNerYUgCck0EDeBrBdGBSbad9qmpK80 ICsiUCg9z8vDVjDMkHpjNWdn2RghNLjdm3s+wP+rMnMspAsTe9py8kxPqvPCsvZ7WpVyTrqzT9FF 5qZIiuywShMMBjAXduIpVnuI8wRBAWxwwpIpycXGEHt9AACk9OvQpSGIq1kdniL2HImi2OJzTEBR Ap7GiEIcLpS1VdAhkBaj8YaxLupaESAnGCUCOMKlKUvTlOoskddPrXMnUmIJYfNOagHPb/C1aYt8 nLWBZtN8kR0vwIlZVYSMWnN3rC+WsqdusQ9KY4qHhsSqchxUha9qZbR3VdxroO5U75Fj4mAvjHL0 CgimjZQdKu9tcGgtCyb1kmFVBHiNrnVMIglDJqnfOfjklDCXBeTqXhs/y5mR2XdMqFvCRQWSkKmB hbCJS3LYq7xCZm2sWlTR5AjW1Ic/Ziy0CI8YULeDGc3pkAy5BNsHxDsem9rJrBmBJJrAQ6KRMV+G Vzi1yCls40EdSRt94pER7/7oFB49x26kC1Ak47dSBWd108LkvJMUKNfRf2KBagJ1PC8z2CVcvC8z uKFGvovmXoFB4a+i+ZegUHhr6L5l6BQeGvovmXoFB4a+i+ZegUHhr6L5l6BQeGvovmXoFB4a+i+Y oBVvUmyidguylCIG5NqmpuuC3w5MUDrU7rwm/OEg0IVl/lPoA+pUA0Ihx+ITvihRr6L5l6BQeGvo vmXoFB4a+i+ZegUHhr6LghROV8Cpno0BZ40GFpUGie64LfMuJMmAcxDxFeqQ080jNoO2AmS0ExB9 TqxOVBpTfwnCYX/3QKDw19F8y9AoPDX0XzL0Cg8NfRfMvQKDw19F8y9AowA8Jhf/dAoPDX0XzL0C g8Ne3f0wBpZ9GommOKWwx4oUa+i+YjRSz/77wRtjJwfX/S4B6uHE1FwZzoPK/cvTfbLGe5n7O9L3 IIfrGK6AXbHdiic7AcOIMVYu/6iWKWxXoPniqYRdxIsOAjEM2OKFGvovmXoFB4a+g8fD+P8Fo3sp chuk5H/xNT6VKoVKlSBqG1pesNGcYVGQo4W1GoA51gjaHIe9WWUqzf3JmyiBIdp4+r0uNXZP8XIZ KddwLyDSvhLDi3GUo70bkZQYRA/gP/uTz+x4d+0reOMilDN/3SEXiB4a9gC82kif8OB/3hOkWNX0 zUXIHKKK4n58At5eq44//skAA2wntVvjYbhievNHBIgacL88tnJlS4VGY9iiJ0TYJBuOYTquiLEI TPYThML/7oFB4a+g1bqpifqy8Yi9MeWyRG0eGJf6v6o0LpILWJWlH8iGYy5y9SgYlHDezIqBNHkw 0wr3Kt29R56M+14UO3/hAHSIN3zrj56Vk7fECFSpXmDmelIhqlnrLzm12lRpFiqGNH/otGa3ptXC +2UmNkEPoPb/4STRWgLjkZAUlQwoglEpKzL6o2ShX33sc2qAjLxaxulo6fhhV2OEfc4m9QRKK1RX IgoPDX0XzL0CicPwfaoPql9eNGKSc8UQN1YF/0la0Kd7G7Y4OyNyCpfQJarzD7V/X8csPFRsvJMT tCwGriFomIngpYv2essAXD2AmTBrC6GeXWcfKnnCYX/3QKDw19F8zZvihRr6L5hStaFOtZEERdfW 3TfQKDuHhqmF/90CgdvpQQ2lBSg0FiGJT8/+ogD76gVnEzfxf3kQcT2FdPfRD+1qSCVSwHFgUHhr 6L5l6BQeGvovmXoFB1rTO47EHm8nDWNcFvmXm3uIHhr6L5iYD5MpBZcbtBa+49peGPiHzcHN8HWi gkixZD+k3eC6+PVlkubDJwv/ugUHhr6L5l6BQeGvottCnywMtcWhGveiRl/90CbzwecJhf/czz6D k8OYED7EMXx+CtF7vf3UL6xaQk40s2vWUryNX0l5AXQ87Vyk64LfMvQKDw19F8y9AoOubxbi4H4t aBU4as6BQeGsxqpX0Cg7IHhbMFGF+q72Svmk3Mhr4nnvYeOIEuHOz0usbEExeUAvamrr+zHFgX/3 QKDw19F8y9AoOtaLe0MpNBWvEHI8NfRfMub3soPDXt/Co6yC9IIv60Aw6xPhqMwBDIjURA6vY0U6 0f37CNj5YT8/CWaFi0fS6ENB8zXn/b3f/dAoPDX0XzL0Cg8Ju0wpoj0iejtcFvmXoE3ng84TCx9j iGn2CXxPGwI9eN1OE6hBJofXZOuUbKOAtAtcoeUB47MvfI8w7oF54cShdVhNLwZgWOgUHhr6L4f7 S9K1yj8uXWS1gUHhNTwNGw/hKa1Uk8UONMGypUvLkGX/3QKDuHhqmF/9jHvn4SukaaCT11hpsUFk pT/s1HJ7pna6RQeGvphgt8y9AoPDVw0Zj+pQngtaXdcFttUqtxHfDXp6JJ2MPxGt7yti0BlFTdcF vmOivXihRq7GjYvzDTkvtsvh35kp09ihv6AgyEwAp909quTPdVAlWuC3zL0Cg8Ne1Da83LYxBKeE VYu4ewYkmXO1uD1C5yoQZwVWjU/+RQwvpjalTO1Uo3gUHhr6Ln8SK7TKHQ7PkmqWrqJIbfF+tNrV 75J6kFILvpkoYlSfQEHkpA7Qc06BQeGvovmXoFA8lMwoMlMTFOpNOTjWYu5IwNWsiedC8k1UVX/1 Nd/HzYxD0QL7XYyOTcNKMcNfRfMub3smiP9tVir/J0eXkKpiP/NnG8eX0sCOsgZboY8h7+v29IRE BhDNk/TpasbGCjQkuuT5d9Ndw/NW5E4PC8sejsJNtrb9IFTlAKQlc5mUkrPU9WTrNqWMV4v/ugTI cHrRue5wmF/1IHWyx6tsPmRrhJOpDMGg7Ca7JaNoXs1yNacvlKSwU7Qe5T4xAv/ugUFo5a1UbpEG XzZJw5vKfT+m4hdV6QV+5bnsXNkxWpPACrYVoWIRQ7GhvLJ3qkKfrUffaWZcyCJ8ZBXdeDrcKNk5 hMBHmih6/+w+32Xx+E8tQV+SmCvUG843QJlISUUcvchnqfK9c99pHtuUVL6BQO8rdeJh1xrMXckY GNbmiDZqYPQoIiS2oVz41wfA+uAKI7Dn5AkA09zvx/tZqKa2wnXTio+2vRJFM5huNVelyDvY8vUB ivO2ujQ/HMM/qs49R+Rm34nfdiiKAFOnddWtSvOvzbhuuiE7NaaXbfwrulUYivVdZc1qDdGS+f/x wFkbIfzQzrQMO4U8dPtOfTTt+7jnOAPSNXEaERy42qKNCWUmXRYy5TGOtV53L1HgqkGhqt1X6oSy M3GX2739EL/hOEt43w9ctml/kLVmLuSL+/C2ZxvQo5YPSjSmMsVZx83Cq2VzdRyuOk0ajQdp8Y80 bzMp5V/0ehV035hmZPlo1KvyavZcQVNI0A8eR5AeQHJlyYgEag7stPtj/7ymWEBjSB3aMkIOPF7G xX3RMR7Cw/l3Kz9LgdoyZyUH2hJVzqGm/8EvbpCE23Zi3L0s3l/6o+xXNks2Mv7qt63Kt+PL4Gbz TUuBiV12bhp94uiDcNfRfMvQKDw2Dsv+nKDRSWsJm/Md7t0DBcwED4ZQzD778x8v/Lojdvdv9jwC ptI24+8lOrMwHYin2TjeXywnoA7pm65YJprkGJZXTHWLwCkFQhR5/bPmF/90Cg8NfRfMvQKB2rUs fOX/4oc00gbL7TmN+CDGuoTHFBpy8kxQkeRw2lmfwvgG4WCROVG00tF3K78mPhzl8e9G37dIHtA1 84ny7C5FC+qwjwpWLbfCxwMxJihRr6L5l6BQeGvX/8PEY17SnLadiIR1v2GJRXD2RjpuuC3zGCMC aFSEdFyTDKKeeoNqNwTO1eL76Kzvbf3MDG1FZgBBxBdC6fp0OTpsaeskF1vl6tue2zL5JqgLtvdk 9/TrziTM99Sut2ian5Gc2CxIsa9GwdNgYKyXqkWq9/lCUzviW8BpfPmeXCkIbSXZYbVWrz/3QKDw 19F8y8/vs5L0pDbshZLT1TGB/CbAyAYMch+ZfQKDxPHErnQUjMtbe0V49vIa96Wi9pnQOy6gvJjv 30PkSos8kwMCzEf61kf7aUneRIs53jYQ18DQ1G8G81NS66JwCVib+Q4wodoWH1S8BIfNsGtXnwS4 6NOUnHUp/w44mCn7+0I8NfRfMvQKDw19FrswvHMiZyhxIESDDOvICEmKFGvmXPIlDR+ubiKzehiR RdcdZq4zuzzlvnSJXiEqt/MqzUs5mjvFCjX0XzL0Cg8NfCcACFFDU1MBpyt4FB3V7FkUWefuhjkk VNk5N5/wFJid7hUSJcERoeID5LgKXGqfGkMy+gUHhQzDu/waUEqLjdcFvmXoFB4a+i+ZeWhZkPad jPtt0I52HzLzPpxZBHSnofq79EfSbapB1ytXvY4AiJHbkYi2Fv7syYOJ3Vovgo/7JihRr6CNSNEW b3sT7H3wh05t3QKDw19F8y9AoPDX0YmHVSFvcB+HhF+IYfReKTG24tMUoLaCl2rsxwmQi5EQJVcw 1UqY1HoUa9nnfzL6BQdaz/RoaAHioStC3YHlpfQKDw19F8y9AoPDX0Wr4LKgwerc+FACB0tjKqe1 nLC36rkAp177UpVEKj2V8mEcomz6GXLq6XoxvrQLfMtyP+yYoUUmihD/5o7lv/dmQnHkxQo19F8y 9AoPDX0XzLz/KvGomoixgC+6fSMGOU/EYauOsYIc2qOKUoC3VyHJu1fEjm3PFCjX0XzDm6IKDuoo f/yuCxOiyRxxevWaGhdegt8y9AoPDX0XzL0Cg8NfSkOMd4KNXxAW4LiW4aAlfxuGz+Rh5UfgH5mH 5Fd0oAApBS/awjxaxp+0FvmXoEtPnZ2ziCBisxkF4a9gC8yAbru4kPbttnShNQGeZegUHhr6L5l6 BQeGvovmXnRTEhH4b1bmH64awTlEhwcTjP8infW3R6Y1F8kV5bXX/xo/BeyO8iebgTM/mujEJfkx Qo18/3460sjOwJBnYT12iO+U6F9sbQIz/5fdmv1h8kxQo19F8y9AoPDX0XzL0Cg8NXvYEa5j0gEy pk79jZvQYyIXx/O5XcTU+x7/ZnWtMAyTD0ueZ4Q5Vi3yHSyk4GZmUipb5l6BQemWUQ9OKkOh37// q0mv+WLfraVT/68WYFB4a+i+ZegUHhr6L5l6BQd39bKkpgmxvbbQQtLf53Sr6Tza6Ex8yTrG/1Jv Azt1XvzGpwyVTx8q0lJdIUvM7sD9BHjIz8nG9uG3zLzjmt0OEdW6pX9mLKfO2n81LZq//JzPdonh l6oVBySjMvoFB4a+i+ZegUHhr6Lvl9hRqXu+fG0J1F++6z+GdXVQLqr2uuPE/Lja+FowYHhplUPy bz/rUzl12MffaM4m9ySjxtLCVBeEudZcdOy1d9Sm20fA4JZ+AFPMOsSoBTrTaOj9B29ExEHBT0J2 95VqZQWCsvT2lZ+eeRoeSswbzXL5dGdwo19F8y9AoPDXuLX44udCPNJ8+ABBHxSBABCPHeMMVMmO c9spM3P2zCGX8U78hr9+7cNw5Dz+cHp6M2oz2vf0/bdlCKjv2/0Y9SnorZQ1E+lV8VhgT08m2fzk Ip+LxqnWJKYtdEuWBdAgAj0+4y10S5YFs8tHxMk5Ui229FPC0+c1NcojqA7cnzU/cL19q3QTQCM8 ASPqXCKx7H9ekCxSGdMnscvLz1HwEmlZ5vp0DJDDdvRf7mQtFp0o5J41aktxhsrhdxWDqTBXQq3Q Uvt9JlUoJqHlypGpKvOo9MpvBJsEp5+NoZNMP13nGN8K0RZ3fP2qOoybUg139KKKz0hrN4H4fBD3 UK8VgdQNmJmG0OfzwzqevqjXu50pBpBpLNg/vwyFjdSfRi6iQgFQAnsaDAJSlKlwN+vSu/xk8eLa I54c80yHjB2DgjvaScp4Zn/UNf2auXJZFP4/ezVdA3Fb9xU5PrZl5QmaeQ8v5v1Zk50CWqaUzs/K JsiBiTsJUezXqlai+2E0STEWpCUkPX/J/3Bsf1WeJlcAvgayJinbvjRS8UooTvbvLKmTCk6glBhd eongYQvN1+ojJb0v3Vh1dcTjZsdDxGZ+ZHEiIYEfGnpnz+cqVe2H8kVz3V6/gPN1nbA9+nM3Srvq pY0/wwLCbLxKrD9phYlJIuXVFv6I5J+PTrIkA9Dq3ZLEIsJjfR19L/ZRm0PV6LsCH76pbYu1Mtsq XgJwmW+i+qqoQtl+g+605pnVBsZ8fLihhxXfjtO2tzHoBA0iK6rcsx1tgW40/lpp6qC+J7MaMw96 ZGyIVOs+uUdGnDw1zaQ0iDHO+yWtywNArsl+uRVdGdxYnOWFQ4IpAjTDWjOV0oMeSyjJe8PgNk+P hcCMcrASybMcwmWpuw+uWAFJ7D3biLM7cPhMGVeC/iVy3U7fv9nxwCri7OnCVydNP5r35n+b60gQ zNMN20AQqBj8ieJygNpjsPEIUMgOaDEl8vwOLS4thzhp6O9G7L+pSqtfMwwAMCxmY6hCH1IaDplf m/GQS1D8WdnZCuRMecPbKXmyjw5g9vFwZ9E8CWXqvcVpWzsswJmyMqZR6BiMyRpzUCMjv8xKKU7A mBf6Ni6cX43Wnd6AbSJFDX/8pNV/vX5HGgF7Ns41g8NmcLXbgneDQQ2jLa/vXcOWV8vMmJVpp+vE DybveHPnjzuk1B24apRQVij/IdQrmSORcB42b5r2l/SNvjsgpqmpfQ9aqoOqYF/Xs5Pue09vou4d 7tHqenhXIL3lEXU9m4k/Jz+NZQC8ppt/5L+p2M5yaS3A2Scvs50WY8/udSx6lUZsgOa9kRQWpFT5 wSY5YS37AKqUPULoAsZUaEjqdzDZAd56okHceJTHuYyrZotG/1my4mkJ1+g70TYJIDEUeOoWMk+Y AzJVWfRIqOAsr1jhFlykcEh3DIa+Aan9CKWNWTUha4ie72g6qVm9hV32CiDLKbwFEd78g9u4BVwI vJ+p2wxZRgNMbwh0mMBHt7EEgs+eKFGykCZOo91gty0dedi6Mw7DkRhpMWJFfRFRAKCKkBWXH3tf dnAj9NeomWyAf7PNI5YIZkcNDy+qt9kSJ/lKRL7vPgv5ELMiWII+IBamWudR1awNqHoRBIiPxL1M ugKG2WsWKOI5fEi7zfJzm4GoAhGGeuIsjFUaUO/VpkdWtdGAweV5sGi+Ze8ATL+H2lhXp7bHXBWR MqGzvIfXFjPZ9sBybHtCKTJUmpLQD2bTzxv8PL9W66YvNSnoXaINIjDLRUKKOGlQu5X9zGdMs/r4 PwKK7HrMUM+gxlyyJyLrC0WwRUfzNEM8Y19A5+R9B4a+i+Y5mDOmz7qEV5sFtzKvaEngqi17QQ+9 zGjEVkMA02CCEKNv3jqg05ZAQHmYrvBqMI9Qdb2ps+4wHOTu3Xch5STz09OaMdQlWmWYCqk2YmXK IEZyCDqh6+ybUHZqiaQcxYlFPvJmBkK4JqIWQzaTlwja3V2JUh5G6fJOWnYs+x9pxdLv/XaXlhtQ DCDQIAB+q1ArXi6cTo8Fr9DMaZkKh8wHFPW9iMY7Saf0SUknAQ5APt6Qzp9qf4+1zHZ/NDboOnKJ gDPVbmKZAyoCIE1HPbPQSzMs44NuNGNViFIDP70w7WOgPVdRpjFSheKlou2pKIqfhUZkHwL337sF BHHGTey1YcDCwMsPKzi1n3DuN1x233HQMKX5AKqBZdPqoYeJT94AehRKjQleON7n7EusSZ5LIhVu hdVLmJPXkWneacfDF4tKIJfbqwMfUf7kPq17pSygbc4bSOepAiAg6h0nvISujJnlbPy+O6FmNP1t ad+FZRqMGSgye8vDTS1iukH+3pvu1bDHLhaFXby5frd63gzVUPYkJDUizfcS2FJykwZNa4TR1zRL TjSxkMsHbpX4Q7mmSRHFhV/giywgMZeIe8SJQpTV7diu+gA6y/YlNzZoVRsGYqgNAlfWXV5sGi+Z ebZ3Vttu8R6SCQOEi3p9tyxhkxE2m2JGN7UYpBwuo2pWsMxJuzWiLRytFFDfATFiEq9Fifdx8dJy MSShf1Wz1DdRfQpOpRRCqQZ2w+IIoBiBaeYRfs1nati43kHIOq+Kf2T9IQ5Zg0Xxia+32NwLz7ak atBrv7CFGSS2COH5uQ3oGFmzu+9qWevXm/wLbcpArlwLCwtI4Ew980w7V0uPCo3msn/FtfNAAYro lywLnyAo0TIeHhjGpxsg5n/VQvdg22V2FpuPn599l/A1oCQ6H9cEviO0HrwcETxv7nZ/dIY/r/x5 YA/SHCsvvVnumcu5FJBukr0nCtUr9JseqO/7dMf4mdGsO6n9f5+piicLFvhI1EuWANzMuDxy2sqG TDuZHWC2T1qM7+5kdWrzUeHHZ3CY+qbrfCrLrJLedcuQ5wDQtuPQmyG1brh5HptFpE042kcjC3By bM/ERoK6QVidbz+gqEUfEpYEDDKNX8mnhPqw0kmzEtYh7NBexwNWXfxd/QhNruK2oR9YA8bjt0wJ pgu3btAgd0Q8LL8u8YvGBCMUmKTv884HNnvjAsIMmwoS/rX20IReg/Z08PVee9uLoUhMOed7gpuV Zb2CWVPsw/GV/rZrQg/J8vsKtzEzFDHT0igLnWsTotGdT3FIxoTQFzmCGwl8qRcwfHbQMMZZ4J4s LJDv9i4qEH30q1bVm5scNs69rfliYdHCnWkahwfPa2wBOmtDaIYL40lFAUlyb9gwmU9B04j/q8rn u+5itt/OcrVSFuKkvuSf/2Wt00bB/xBK48Aa76CzBCb/n2m7RqehbVhN/INd4rymSe7Fq/EEvoWW xWQVGgeiqvIif5HU9KX9vUIeAOoLluCFIBYwldXhNkDwbw7BRyUBrogusPzoPZfTVW71jBA+7G3A Z7kpKuGfiZBQCvLVPdCFhxDMKUzAmObNV6U/7PmWGdXYG5gGm6OO3EHX6JaWAvOjR/4fMATr3C7e 5oVD0EhztjWT8j6Cg7sICC/QbnrGxm958NBDaE01IUox8f7nO9o7yss8CoUH3NP/bl92uaMJPrn4 mOzmMl7zlfgPGf2WomBNnzNfGFvy8gwSjINdVxjpcjN98BNTw4t+njFae0hm0dCt63gBvqiBsyw/ LC3doS67AaRaI8Zwb1Jl9yGmvTxWi9Gj/q4HPZgLrQT4+xS/A9D1zyC72klL4ngrUfqhHDlD6PTn D2fYFzpeTO61nSEOygO8qGGOqxqNUmi9kzJIOg+IzMFGILmzKLGvnfcQ0wpgijX2k9csBCwQ/FbQ Ifz04AZ2hXRV5KTWJ7xwSgFGOLN3DHdAaUazT+XDuZdpn+tXQhTDW9YvUDqIRoCbNhaLBtlreauq rtB7I+3c+TgLoBVx5Osd71ELIFbwVx4tLbwQzxNxqFk1m5s/DOYuJAfsCtuM9n/ZoKcNFuEf+awn 5P++NWh1YyCoCL9quynmxBcah0/D91Y9nmKxlxZeI6AXsxUyzW3mYHO3eBIx2OfZgbEIJCIkaZM1 pUfW6ezirf2PC3XvGc5z++T86IV4axB3QwOu2YwTFirNDgjZtvz7xOXZnrPxV9RX0UGW29pM7jIw 7CBWcDUo6oU714WHdwKaZDm4NVtPFEXp12/eZUinnCcqrKhQsYA8evw4FsnzLtqRfjkEBtNQUPrU XwuTaJjs1fTUcItXHKIMLTbLaDeMuC/sVXLi8vQ9PaUR2D3HbeBRNMH/eMTysZ1mRunhtsHRwirP AduR+bmrJdnGl7Y/1J3DZT/qYooTVWJ0D6q0gnTZqhnjN4v2kslrP1sVtr1QOODuf3VkucOvl3YU 75Jcdq45euAlx/IOvJSu+KlsIsO832QomaqoiSd8U0LMfjDBpGjXDLLFQntC8xtPtFlkWQbTSsSk FyroKfal4oE8a1PGVVpXQiyFUjzQEXh4GTNJUfXkNNiVPtdjqEPp85Qs5al7fg2yo23Az/EYsDww ZwJzY+N4EKvczNWBx3PaJ1CgZOBF7ZMcHg4cS9XeTJXeMLWpUM05Js5j3Tvu3hsBeJyKuPDLrFI/ ho5A6Fb7EuMXZsWcutTdviAjWWX8lrnSy9/nbsbORQFZFq2Ax9528wJatln0rCZY3iewdv4tv5Zc LnpVSl5Np3c+1zD2M+B4q5XSQa2rPk/f68hU9CRd2j+uMKEDatzOYLh9IczmgnddPC2/HMd/odwQ ymKq1Hi22T1/Dgh+WZw9D3V4gWX4QJ66plp9l0snh6DRJvzTd31c0oMqKVvIJ1+qXqJrGwBZgfc4 raYOJbZhELwGR9E0NfRfMvQyd08Ne3fkdheCmfRVa/kIe/gnHV8rSSz28E4LOG+7sn73WSZucOg3 KUClPg/rAGXD5idi6HBYZPkCcR+nvJaFYrhxE6Ps68xMe2K+LjDpgoUKAQR5pQ+uV1tAgDTgM5Eg WpofXLAugQ/oR5pPqe7sudCPNEREegRqRYTlq530qzr1QJj+5oUUvgcLr9OHxTVhpXQVZPe1e3i5 0I80ofWlyuptMf9c2w5sZhsjvuQZZvDKswFABiKl+0pquM5Qd/CY7AjNg1ENl+woOjOXooKvHJvu 5annfAkJF5GAj0+IDs+5IfDDpHEVpuCqEVpMA1PIDaBxq+1TLu/0I7tl67jUwtN5JoBFmriRuGhc IiDAAEiSzA4wKCgVFlv/HbQxmA2zSJB2x7W8CH6NwPk8zBA96Ijptb2jQXMTrVGIIrR+q34P0cLM iQuuV/uHEgj5iGGw65rjOfh92xRGdfEExupBgo0BQaan256b1W+RLxmXCWfI/nQYU5HFq8Q96D3N ElhfMBJ/eX0y4KWNL1URKsHTnlj9pd8N1J2VJzkzluIEokBm8ERnpODDxN4aNkN8WlCojJhHnYrF BftwtHJ62Oa0OwLbNoOnuL2W9/5EhrOQUzH7bt4FV/kt3/9RxBHmVBKYVyWckoHxkG3QULPfAbHJ mwlqtITvr7/9F1mvIsvb5VJOq7ufsn8DcXsdDxZBLHmHgEZOCACgPke0tMn//I6WHItZvrBVX80Q Nn8yVcs1IWNW21bTUpX9GFx4yBSb/G3YtoptnvR9yiZEDjuAP3eurpf70CiaFvnnPVBV8JXc+Nvn 3W30UOGDSjxelIlEU7R3lUDTwknqnbzVON4QEJlzyAXMJ29947PQDpd71kfagRI1HSbHEMX7Zkps 0Pjb7Eyg/idE5qOdB6haS34jIz/4kI6NyHmYzcuKAZAPO1IBTTHJwJq2j4RtxvJwY0k6siwMVG+W hD8G9YGngSKyuNu3FGjVRsKoAQ2dfYE0EGH0j3GvOKrmO/KgiudXSLxywUpNuD65YFz6D1L7XOl5 RofWXRHLigqtdYG1AEIscjmXEpiiyeulluiXK/0XWVMuo0mTDuZHVrA2kL+qDbpHMjrBbGF8NWAA AP7/MKAAAAm1ZsJ3+x5KOqVQJQmYEvApssLZ43OsWunrc0MQf19me2jvzPuExtcW3lu/NggcW6V+ 0NiAv6YY8bswNGgT3t/15C6jGPHs+d3S5D+Nr7U9dhzeGZHwx6sVAN8MomAP+m+kxIPKhT6QB1aP RdtnnVi/Hv+nIiWGLhM8zvFpGAIYLyABuc8TeB4ddZJw8UOqjYJjusS6jb0RMP8NkboukU5dz8V4 OLlKo/THhCqP4WH8M2kng2x9YjjX2kjRxOL4BHrrG8itMeTqB+0VFTB/X2Z7Z0bSMGi913qyt6FW 5RSkYpWirI5ceq0o9TOn4h/8vnhxqBS8jiQf/Ny+eckPu0OXWsCb1HX9bBNkidbLu6QydX3aKfdX CUkEpA3/MnwfF4cKSuCHbGgUw4BgRCmtfW2MlxiG3hmDFGK730kKN4vCXZXlNNG3Yd+AkYKGU0/H IE+dj8fDt2gtaSx1WfoQIk0bavEj4GDC2rfqFmmLK7UQvwvOkS3ZMd6FBQEAzH8Lde5NupiLXx9w wdP0FGmarRHpzLWRBmjuSmqq4mQ8Guuw3PekHTK0Q2zZk3D24RTFHI6h2RU+n3QYAr1Dele7VSFf akhG8rR7MhpBTYw6iP9pUVu/2m1UnISiLHXttuB3umXNYcG2LwBmlfz9xXx4vYsWNaL3Q8qEj80z NwjLdpRVjjwq7wrpEJuJhcFLxR2Eo8Psxeu2z72Uli0BmVTSKEdccX2AF5aecnUs8jj0ucrGN0b5 Qwy4fTl2oC2vJWOabn+wAKu/bczyQZrXO5O8Wm2U77K9mxd3y9s2BYi39XSnbTBbUVdVveQOkF/X Th5fHjcY17olqTN0kQDp1FbTDgkaQkcw5rUx7UqJFzQ0Aja7FQVMdhoWNGH9slp5646bqpsE6ZNm khYiU9F80sC69xcVodazZ3RN/SKx5Y2+HiStSNRdtgoAoBRUhMrHiykDO8KyIVPb8vB4iY5lOlCZ TeM4IIBaSy4CDRlJJYGV98GFKrsi4PXG5raF6SI7ZNnMuYfSSjm5jK14GmQTzfgvYeEoOR4/z+O5 szLGMOsv94oCstpsRFjr223A/t/zPZoJjmU6UJlN4zwxP3OzCN7lYfU/NNLbiFK5VcPKlHlV621l zKM3m5DVilX5c6Q8ZsfCMKa7T6jjch6nT6W9K9u5PJSGIUxl1sYlyrvVpVR3pIQTPbnj68AonjwO YVnbA1MbOcs+LN+9eEa9UlQXjtghLhFn4AZ4Sp4uCVwvOkcGPqAZJN+VFZmAW2wtt1m5HSHi0LJR IVII6pVQF6kcZ/L5KCFNkyByGUwUfy9M461Qg+L8TUKe9qw4fTijITRQfZBRgPmgzRJ20LYmaeyZ 7PgXlcZTPrJlsFQnI+cvhb2WmnZkgsmbUL5zom1oOn4IwHIUlg6WmTx2izy4NpNADYx0JripHqC8 vxAdr7aKLngVGb/sJ1IlVq1QOPhTvHhMT+yoh/0AsotV4IWd0POmxeEC73bvi0FW3d9gTEydT0eY 5zCr7ANSjAI/PwxNqEm+MRAYHFU07Ltdh1CJT1PxrRmX6DTgRRkKCn1aiuHVok9WJZfxYE6sPiPW OCMzxCTdEpNm22TJVBXGCg+1bPgofJMqxjCEvj8xH9J4FXPkOYRFQDwQlwiz8AM8JVCR3ncSvEHJ ulmi4DoqC+M7KL0o7XSHMuxa00pRDFuOIUE3eLv2KIa+J8owHg0x1rtZmwYtnf7Uj4/ucKxMnkgC j2RONnexWFWl93+9xUM6pL2UIK5pl8KSjb8OQRUg7s26a4A+99D9Y+RU8pNSMCE9+lLquyZxr0KC FTDbcTCzirqgCbodcfw5HNiWfxw+drXl8IHjqwH45dcDWJIYJ4q0vWK/j2/UScMF5Dbx0LevRXCd oviy2t//Z5yOyGZQy8XRfQj5wbE8lf8HTBxPLWrg2nP1kpWvKiH+4nugJUl/au5tIpFgCmO2Kv+C wl2/3vRrGv/EZ0LNCqrpQAZdxumCV9FTmC4chNiEgLVJD8qvbPmFhxDQ9LIz5R8Ut1CYibppYj9A Fhwm9r5rkvCIBcJvmZ3gBF7Dio0f+WrSYQK27vBdGjiherCUPt+3BorXd5HSrPnwSe9/BQSS7+h9 BJwkK1Zz9jOxZFGXIC5wWFjb+o4uxB/AgxQKy7eTSI0WZ1Ocya6OkCE9z9gib2AxR7bBXqbbnUaS iyFzVtgIaAYTrYD0ZFr0QbnqN6zluEhCd52QtcL7l4p6+dqwkamZwtg6vyk9oZ8hQ2zqXv8Xw0/2 eXFlnD7MUmHLaSt+2S0NXY+qrYLspjI2nosh97CaYZhN42qUn+nj0Dl1lF2mMTffMiVgs3z9gd2r /H5wmwdwTVsI5zkUa0ETvr3do/Cjn/ckNzBj9ZntKXJZ/F1rI4PyzjQ63Bw6bPUu5SAlsq9ynTka gp/cW+U631PbSrWgO6BobP28i1sKBDlMgNqemCqaKlBrq0yo/QUdUp5olMxMoEwYj6/Pvrys2St2 Jm2m67pkTvdvh7pmjb8vengNkAw8F/vkPgflwtkTAG9n0Jga3ARtZKmSP7TJ55y0hrYA4IWiXYV6 uxXNehQQqYbbK/5OM74g59aTHKMmWBBCIIZKyZTLYXmf8vkdD36nvLhphwx5MkhJu6csTR79YRCd Y139RL0WwL/5+gjdr7eivPukXPChRK6XDc2xIIoX4Xo7VHx68s8BTIOvVzSKCouxVUmcbHBPoFLE U7w4a9tGioID+Q0cOaIwaA7XTpUHRxQL2flh2WFuJrn+ymqHkrpXEzl0ZdL88SOVYVyJBgS9upCx iv74/w2nJ+2AKNILl2NgpJFDfs/4xXg5f8Ys9YIYQWAaYcGOEzCB39fcVg6elCk7p/y1aTCBW3dz lwAPwp0ZjclTtwaK13eR0qz58EnvfwUEku/ofQScJCpyv87+CJxzXrpXMN0r3k0m7/0XAOBsF5Xx uUkUWXucj9NPLzMrUC7qOIm2qchtVcg7bLzOkrYLG6svbJenhY21la8nEpNm5Ry+CETKNUbj7ttX rn+b6TpZzHBB0ZuQrklRP0NvzgBT4VOvH5yRc52Noe8iO+BEI39FG8uODtleIf3hdlbFAbvkpuHB lv4HoXqfGt8GYja+HRGv9y2G0JWRtw7U3iP1KunOkTXf1juwlTXErwhJkITSUxlPSTc8z5Hdy/Cg 7+zzOIFNp9au7da1rOw8MB7mgDKMcRADxurE2+Fm0KteS/0drzK7byP9nHyo14xOy3o00IDBfmqu bHBKA0HW9uRI9DXKLKaFFljgtA3t+b9+H3fAmWd/hpxRQCaGZ8WltChfxCayQQGjKGNBnQo4Ibf5 zyVLLHe/IfWFLD7OL/Gxq/pgF0it98nYi3tzFa3qbcpvXVaCd7uS+Dmsm//I34bou1neJU3JOOM3 JTeOg4nK4xwKAnS0d8gVM9fSjIdha+j2HDgg1uM2cW2u3yn0vZywacZwYc3deMW7J2pZOEkxtVk2 uGB8E31PS41tJmxikch77ofzr13zrxT71mbpK00Q3poLPzshRwNutXX2xiOUjw4DtfYb5kqF0j6E 9vIjAY7IhNB02IANAZT3CrmXbfBgkAURmOIZEm0TGua5PJkxLqoy3WkInx2liBFDtOAYCE1yVQkU yY0Md7UtwjuSB6Gg+2l7rt6rSyRU1fiWIRRmJIh7tpXH+QSfMhOv/Wxm1o4apjlD2vJ5aaihbMp3 0YYDU4pH/KPdybOuTmoxGYlFDE1lMlQZG1jJkcmHmeuNYLbsr+I87pyCUNccculMSaWtyhZ0Sr5i XcOILc6ieiKkxjec8P0BRexyEWmcKbvVC6hIbpxiKYluuERlLV3MLZS+kdZoSe+lPPwO97F+1uK3 IK7vyHMBeUob3KR/MrMy/RReSke1ow2/u6pJjzcLluVuZALUtMM3XReNun9lrds7PHwcz/qk8mp0 pBaW71l2iYwauCQS60b70vLoVsHJyIiLmtX590GNkcfgehnKEiWQbUYNcPB/KjH7yH8TmMrBdwoB mzh3HEv2K2VOQoJoTXFeX/wRmRaCJAI0loqqiJdtgw23tlLDeUtY9uLz7WDH9NzaVJsF/3LX3cIe OM/yOl2y2AyS8rBXwHf+X9BCAiIooQ4rA75AH4vj1PeVErVHjPxbLIW5yp+wXuu8fHBetZKkR5Eb 5Ws/7riYLM3qaGwlWhaZ7VfqQmVZzW8R8gTn23mj0UfojlgbBUX0P4l+qgp9WU3l2uyQ1kqaxFwA /OrmhXlQcfmEOddf1BGiVbQe1M76UHFqxPRW8G4pogKxlh8ODbaCmiSYiD5hvW7J8b9CbQUUR0Oh y6MZbZQ0oceFKuBMQ/3XULFojFW/liTlOAGt9dQ74U2s9ZV0hjGx55tlh7eoHT3p73eSUTPUMdUW uYwNGY/yqDH1Yo+McQzbLGiqqyUPldfIzo4bUvK0Rfum5Kz1rH5om0orpTzIwEhQbnN7a4ybZhKQ OvE4tsxP4KWdpBNI0TDaRDfT7x2t815QSj4OUlGcD65dwgAXVP2OMQXafjioi3JJi9cFsgorB6Pn 8g75UjNQ5NZiCAq0pf/MG+EO6dA2j4n/oR0RMMinYVbxCV+IvOhP8ngzj8w2UhK12i3u+dfj62Ap f3hj5pP7Qoufy8+65PZE1NGe9HdactMsmNCstcroret9rvg4NE/KmdsBllpeypKYVLCZfuFMFAhn JzAfjgPGMddjq5h8BIqXBxN9lO2hMmKKFTgLqcXcgxZLS2LQmdsAL8etGiUdoQUQbvdLeb4bcy0d h6LJJFGLqzME9HlaoQXfXOdvKngLHuYDT1RHB8E0hs2KihnyVLGz4DjjCMsrguD7uuIxXDl66PqE 0BL2o9xq+X6uRRSKe2UyBQfVb+/1NVleVZYBBD/Uzc31PK2lkY0DqWmQxcHhnkBscwssr0RWzNpS z07NOEyDRscLht71oeObAKlgVgxuTCxPahzLBpLljoenJZNEGUJNv0qHh50iBs+jZVP2XyqjnoWP ULPuNtWEZyfWzj3kSAd6vMzkMoNz/CWS+mMUkG69co8IY3eCslF96/7iaJ6lAA9ocF1z618Pv/0E Zm1F+NbrsLAoygiRjvNPXShiezE4NKOTHQWatqolNqnjfHdZSFLEtuYw/Kx8eOnKBTyYmZwKyeX5 8EdiiAGkipu1d6Y6HADCWrwKxAlb1tCQHjiy14KasANeVXTPCm6ztkuQUc+Zvsxd0CiS/YwCqxMF IZZ5tSyxHNHSdcNtzRcLN3UHRBX2ILpzVHib3sCq75mg3OUB3KOLjoOJet26hkXBLDqM+qZAT7CL lzIRKBHFVGPmHBm1c//OUNz7C6N+CKDBWAVG6jDKqRUKd+083iaxSaOrjsEVX6ZMtPB+o0KWtn2w 3xLDQuArd8CGq7cxWHe1R5MbiO22BNhWuYg7OSm1DvQTIk2GQIipjKp1Xtsz8+i8XBpccaKwuKcs OGc1CzQ3yaptUlPIaJSQKUHnz3ra/4dkm9Vl0k5DrERownQmvLoQGK25iQUuqHeZ2jPYt1rbUyfb TK5zfN9YNbitzPjJy3rgjjnQdY7IpMIq7wv+FW4qz5hx/WTIKdwQCD55WGxK/ZayPIv8JupXqdB5 Sqz+N0MC0BUm+GXj9bUi5bGTiav4QHqJu/7WtZ4xR+MgQKlGWkAuMUE4gWdOqE6qOs1FG2KKfOBl FqHJgKNR9jBjU/8UJaHUr+Tikac1kLW5y3L0cH+vONC8Ho8AttJAjenKE+EIak2Qi/bWGQu8ZTwh dH2oKQPVMk5oihkq8HlRMaYPx4xHXVooL48eeE9NEQeoGH9iXkHc/DTBFG1Fh6FaqI8vTtZ3FyjX AGSY03LweEpwxrPzRvVxN3v90ssnaVdVEFcF6EZdjvcqdOudgHXT0uC6LR7qKDBhD3B1+24gDOq0 urYQBIKl3X6C8U0LujMxmu83chFhCgdlAGO+CY0KYzG3WK8QYJO/qA/n/JDWF0T7+1imuh3bMaJM zW58/NI6XsZGo9AjAxppDWnwRczm+1e64HLW6ecH/Eg+r/YRjkaopjWQkBx60ZLd7agdJl3MaXGX DxDa3udcL8OO4qWvv/uLsFugjFrOsEU9l81CBK4Rj1w5JGpEWwL//PJvvDDMcZrMhK45UoaQ2HCe +gJR7ZYRRMXS/1h4AssJAQj0JLFLeeYBBb+E3mf2XruG1PZzhmW6Pt6oYgfyCThIVoETAMKC/nR2 8FMFYI3L9b7KMD8zfuXfxsaBQoXS6732NJWS5S+coVPbSDCMMBQ6EcwKLLncIS+8ZAmDijpC/RBQ zmulS4E4nS+pjSDwyynR9d/QN4xV9KOuly85eJ0FnXNmtiDM7oMKEMrgh41nQN2w9nGB/ugsHgDD +59JUZaQoIVtLqGzDoGxOh8yER9kSXu2yCU8a6FYk9uJrKUrfn5S3GIPKqNfv9BMYApTvQHFi7eK PNuK1lNhLbjhBwjltyojvmup+cQCoWE7JsN+S4E7boyuAhjjLkpXp5ilCP/BpF+psJFjSSQtLSj1 laN+KrrmWLRAF2xXFDrTi5qa7RHBS8r6Cay6Dj+ndtcStYxY868XtCGX31yQUCHmtoa2/Hh/7J5e ChVe5sQNsefupSSlloEIAt8OBy7cfQKXOUpQWogkl336ztK8SSlWNFn3D+xgAlSPni32etYMHtbB KbsEtFPE3guxOYZSlDxNjDS+PRhsgFKVeNoodasZP8WPn43t8EgxyqnZqfvFXpGBThxuwBQxgzZW WUHkz/cDFPpfzHQKOfRNA+RULaKU0U4JrrWv1D4IGUiSN9+gI7kS3e+cGTFrCj0fflduS9SBUYfH Ajc70vRHofEMDZk2ATm6SESgmTHHAjCdl12HCfF2IMTkRdrV170RuAAdk6Z43lFUpr+wJc6WXs2B 1uWC+Dm+imsNzSKQUAgL9FTGEOECIvFL4G2ILniIhZEF7RA69sGs4JSARZY6wJiuvwG2PY9ifqwA auYUMSLdfoRLvxSoJbFLOnKiAQ9fsv4h7OdwfL9g86vJUq8bRQxnbD6SsqqrBnKGHTkYE88OeUU5 Z7amDJfsmQKLLGu7kf4zqp5tLypMgTlg2AFhjdg/IMbVIxaAyF5UZ8AAAAAAAAAABbDcBLxi9AEa yz6sXj1Ck6ZPLoN40KcLq6ohDVH77TDzyebe3cnMHvVA2E75ujOhe4OSQvDOO2SGiIwnFPcY2XYl qOk8LgyQtXXmilwK9x79mOAr0QxTylFj4MBCaH0gsH3gkY91b9EMV7fNygw605oZikTwfhWe8cIg /UN40/PtMwPuy3RIc4UyHjVNxcOkF2YUtIx3RKZmB+N9IKBjLWB1YLjZtKuiXtE4NF4u1VFIG7Ft U+xiymNOg63j1YkLocfZXW+zbCY0Hruhzr+j+7FKCiH8huKtoEwuNFMBBybWH8LcW3cI8bX/dL3D QTrFCxQrp3NRwdLWgMQd3bU1rR7W8l3cSKvJeFyzdpLJWUznT8Ie7tw5peZDha26QHy6iSevtUW2 uSq8b42upYSJwHFzTC7Xh/Yb369Lbb1yS3TWiG6Y9S7lpmmmqKzasEZHDUVE9iANV9jGUpx1P/od hoH6ArIMJBnlBFDrQzvHJBdv1IjmfGUxSayOBUghrIpM8SemJLKZbPv0B65Ct9ZtiypZN9R/pPaE nh5NX/iLadxEZIAAPDpfBUECYOgy0QMPGIwnuJrzlvivsF+jfnV8Jzzwqqu02VZS10dLv9yWJEQK ZpmA+fK7mpdg6F5ajowe2Avro2K2V9ZN7KO9hf0N6Tj39h/prLau1A8dVSF+mK/JxGgblW4khmVk FO7B+w0BUo/aY/CzVkLa71Lz+sj51nptUUmF61zCj5MRz1cODAqwQBNcIORcv8BKwkzu1U+IcqLP LX0J4vNDReMHBwzj0hPJafoOZQUWBs1GJQLSSCRJOHih1Uira54BM+rOgU6b3LmyVKhGjHAGqqKT 1M5APGJjMHB2KbJu9Op3SbufahhxMyJVrTIN2oaxeOOYn5kjm8ktZhGhzY5MALglgfZoTHP+l71/ dn9ue0Twa9d9PkliHcu+GTWk06zM2zCE0U5iThFe53szbBRWVIocmEZXvlJ6QC3co/Daft59LHDW DI9c8fR6uqL5z7RrMkuthY6EXsXyn+2W/HZJhW0AgA0RzI8iN03enrcQYOmb/7usGLhVOspcUFlu HCq+w/mQkyuL/39Au5EUSYEK5Sg5g0SaFyH5NQfEd0A17VeQ308W/B7BNh5YE3CNwAAAAAC3y/i2 yUypOcKipxupEPZpZ9JfNOY+CCyjfzqS9jx0PZS4+/4HDj6Tuq4/vINy4N+01FPJIqyWSy0GEkpE 81PFxJ4vNDkMHWqk0QTayd8E4CZGWwDhPVb5xxQ6H2NnCYIXeKPDTqtOgPI8hcvkX39RrU8S1LeO YVDanrFv8J+cdbzNLQYfkwyKpTMgombeT6ZgCO9snnmXMp5lgl4x3sXInD1bTBQrN3NSY9FSflqG o+1g+wG3lZ1jJCNaF25Kynn/ekhKZafA1Df+o68K3hO3ei3adeoEYRdsPip0GMxCcNNb85T/nQFo /HMTe+ZkzhpLBp5sGrcmbBm/e8pDxs7okCGPlQBveOS7FNt+w3a+hQUjy1O/SnrPoZSfqdREusv3 uax6+MmD9YQ/Q/HxZGxRADFS4p/8dmh0eMOcCDPiU3uApMrqObcNixc7X4qIfknsZICiGZnootJ3 X7+V9IpIGrSrhvMdev0gyFtpe9QRs6GVlO8BAOkEkQ6COrpe8v+Ek4D4dbodAygA+kxdAcjAOnC9 Ti7WLex4cwvaJdDajgmS9FbW5rFNDsqREUFTiBtoOJBkObcE/dU9iZd9Y1Z80FF0AixlSQ54U4F1 +uWOEd75XW9yU+xXAz2xCqHMPCuFvs8OxKiXZvXYk3rhJHz+0s/4dcE3lM2OA2+9LOfd8eMjAdDu fLhu7u9Qvl/BokYRSCftkFw9UfsGmWrPlArbF4SUcZLOcF1rIkYcB7kCFc6Xi6eihPI/s7nZBb+p ybOyN7Y41s6IpL/RbFPVQXDv0I+IO14olSg/pH19PHCQeOSuBfo1cYATH/qF1yF7x4ZUUEVSd9R2 nmg6cPxfqWK1c9sBO8OjoQF2kf+uu9C02TBvDgi4kGBFAFU/n9GCxdsJ57TTBEMdYlq5IQjUl9hi mE8Cet+sG5Al5/l4rGuTvUYt6CDd9IjhSZk78if9sWPNYeJJxQNJDan7oXCciixwvJ6yqDvGQXFg LALPxr+lCOIh56rDXWSabHHlkTEyKuHJqDxqwGHhzWFoLNCQW+m7LTnA7DAGoW5BB9sp97Nr2uc6 VY9lnTyy1nsZ3lHgOIJkBHBV4iegcVP8ShZFJYCcQn6YzeaL+oc4Jf62qwz1BwzlXVdE3Tt6b0tk VPNgTLLv2sn6E6a1bPHaIl1/jkwqWqxbRryrEYSIJXh8DFHbzcMCwy3ED0SeyXYoEn0aUng/C4sr M+azRcMHHARuUHocglWBE02DZNhPAGOJSdRpeACokTRzk4prT+uA6byqIJqVt73nJCXQ36Mb+J2O EbPy+13UKZdHO1Ijg5v1sWVV8om+wMYT36krkC02FOcv8j606/AKry7PzslpwM1wL2Hwj/wsalxR +rmzryPC32MU4lhGWnpJ2ck0QggYF17eLtK+heMgmYwPSl9Ke971YQocbl22EixEDpEMatxQ19Bh mUYVsJbFEDiX0r48L/bYRS2EH1lPAWLj0Fd8OZiLYbaHdUBWa/gawvPVGx3TKBPxO54u2kctHfLK z8NiMbwJ5bq6v+DbsBfZb3C1CJLUvH6CEbxqgXi1jnZppJJIXLHhIeLx+UjqhVOkv8id5Mchz+C1 QDezMGssJ4S0bHiEe7MOcM/HxuntkqF9qpc5k3wnaN2joJucrraBBaDMYmMfJWGEYMps8Q5BND4R h9FcY8E+qVjVQmLA64aXJUKc7ukL0r8Zlmw0dttbd9XHVEGj9AXKpp50kcxRyTM40O8dse56yhT8 K1/bHl3wMJI/lTg7XM11bJ95IRMbP3UuK5YOJO/PYg/UTbjW7EdXQR/Z5lVpDwhAs3y87MmUJNWL eSx2y/fCfwxoYmU292MHskSFlwcX2r48plLGezf+zKF3+PuC6tzLRMkW4yq9BN1aphqwVAsUdUbx H0CAtBuf/zJMUbBJJq8HIIdN3WNxAHjgbxYKnet4sJWXftZP0J01q2eO0RLsEJaBtIXM3IaMd7Mq 9bXj4GKO3m4YFhluIHok9kuxQJPo0pPB+FxZWZ81mi4YOOAjcoPQ5BKsCJpsGybCeXI03AM8I2ZL B4m97PyQ9heaYpMMQPwt5pN1gjFr3kwFpl7zER9b/xLU8S+lgcgCWnIJfX8bNl/rK7hduszYLi1Q jNRREpW1NZ3Wty574oaY4OWY7k84GmNcz/HmbkTAmAhzrs9qKZBIE2nNvfH72RP+tfM0/8DAjmum JgpzP/8xFJMow/PLlkcRbvCbKBS+jHGhLCMsLi7RpY/qQziLYQTkKymY6k/PhcTihluTpN0lUTRR iguLEErv+mi2TD9e74BrORi4EwjMAiR8fti9eG0RrA+O1pUjexFFDVP95gKjXgJr8yw2nXCGoHIN K/U9eGQIlgJfxUsygapdv+gtEcNpHaxCocesqSyBPHVN0ssbBL/BZK/lkgNe92US24dZHRfdSM3N Ih2Ewc7K5MYSgaVdk+S6xMg+TFkZLw0DOMjVhyagR5foCpvZOua/8M8dPminxjZi6t24rOdpm1I/ AzhEqYg4zzsFGoX7EDtJMHIGAW5abXP/XExYXlchM3gasz3VwfB/9EdepR4NldpsPF6u3jXG9aED MpgYfLAycMbdjmMUl2bofBlqVQeQ9EQIaNUSs/rkEyklISGWA6bPpwUwuC46msRE1+qwE6S5BNKC t4QaZz/nDBipAWa/CbtDTdJxMuTljdTzi3sHCXarYXG6Qw20fDfsxdOySX9v3irLoBob6h1w4xL6 rAMTa+OGTPNTSaj+PRexEdGvxJci4RsnStp+SuJMxOGTvrIjOsn56wmkNjlxZ9sDBNfLPcdvz/dB QmQ1yatiDikMOQ+duKJ7KRmvvG+z5WGa88X7BCMyBtfa+EFMj+YI+XWOXBEbvx3vFY0sItI/R167 ah7c5/BLdQni8j5T4LxFpVDs91SkDDW8H4EzQX67Qj3um0ep+Bg0cwBmgc0kZ4MmA8DlJpeE3rY9 YYUnEsFJQ+NL4FDTEmZJlCZQQ+kUjmcGubvTkt2G1Px0+zSxYKez8PCrMwDARBFRd2PCoE3Gqk4v 7TygFr4rCIur5If6VtSMQM32UaQ3xteeVJoWCko7PcsSSqW5NkNUF6jkTw/D6v9X/J4S0bGMKQys tWnpmwzI5CVn73lMOJdtuNX+QR+ilWsPY5CZHNxAMNB/Dj9hcSZ+SArEa28oXZ2WoglHlxT4GZsV Uc1ta0I/gJSYFROZTaEMxgKTC92aHReWPjV0OnK0bQom1E1YoCcPUgCHIZcZ5MJYBG4ka+KkAlji IlISKMvpmSxtBO6hdSumZpljOXESksF2xYrQLnZ++Kw1tBi75WIZvaNMNf3Al58cVTOzwPL/gtoh oR78C1CcJFk2pA03BHsSiH68Zqih06ea4bvN3vq8K7v4sSNn117p0cW34MCLuMYuXWhEc9dad/BU c1baQU4MLPYdHiO/LqVNi9/MABqFNdTkRDjb5hsVHtEoyJ0axl5f0vI+WzcvLKbWhwX0Wc1BfiZ0 HDguT9Oe2UcWFYovMT8CdkZotwMjTTDa5/DRpj94lRa0bkx0Lt8UTTnw3rV4ma3RFgOdeIxZq5As JepkF4JQqQRbKKDOgKgVpQ/tzcLEyC3+fhIxa/XT2YnpNi3d7x+adcYINATbhxpPiUEzEdGf866e D4T71md9n4eledm6zFgsvQjuYpsffApWTp2lV7vF6I075Hh3fERV/QFTk9y+kVB6QA6YlWrBtksP z+pFwnanMCSenhiA2zCz1TSpthoKVZ4Om8Z9OTnA/Rv7bpLgLPgmzEJ52B9E4VQk+k7mcrajwAv0 eXKBOAjU9XH65ZM0DpgUEZLnpDz+wWQnKnwZ5voVoXbBvKnOOvw8uETX+kxZ5KZp7gW2g72F/1SQ amGYH2ACML33JKEy0+fq0+a5qim77geQpfmo3kVHOmRKCDYF97ts8xJdcMWfb7iUGD6DyILb7ybG NSCfVkb3H6SXSvr4yP4HEVELIRJ+NsU8cuLDf82MxeElC4yMfjFNQtsUhoiz8rS+v1CEM4AbgA76 0tJV2FAEgF/BMBnmQsVzQnCRZNoCA+cpNEilHW8CLWejzfHDrUH8L+wixgl7jfiSFzgjUoVOkH0B 9HeZFmX1AceVyiAQooFqx0L/y3uWqIse1rWH++d/5ZKr5Qm5/1aH9x3i2kLHI4RQMmiYe9MhQ7H0 sCN5laBKe2/JNEqh38OfrD2degF8E6NqI7IAN6KWUtXnbr2g6zTdVgCxWVUIvNOoBbexTdrBUzOS p3T3pEjhx7c9VlfaAWcxx/KZSy+xlnaNoVMeRUN/6hEHm6TwapYB5El9Op9658smQqc/wOff5kc6 GAf0FDSZ7NQ3ISgojyzLmoYVgi1iVMRLxRxPp711Q5G8UvJIci94uW1TyRDV31tA8AC9679byJqE DbhAq9GGSEYvxrY93mzkJfpvLgkQp4IG6V8UG+NlgtJ6DFM78VafN5Q2wyEBtRNjuLAHKvYnldC3 F9KVwQABI9EfgoP7ex9COB47Ij5mNTVsngVCkjpm99pGzthngEpeHmMVw4Bnjodh61bJdSMs96FA uF8r+2mtFh5Jktke7omMGrgcbtQhMTK4LOY6dnTZcMITAPLoOuZCYj74p76+pr8aLg+3+hjMnKXP lHtfgckGKarJVg041Sa85Q6V3Hrqn74C7elmocL5WURpYbZ3tqbInRjXjD/2l6DrKv/W38E0mBQR F2eYmoIFLnSFvV29MwF5UYzU31xD6i06a7ku4EqHdjVy6X7J80j0hlg/M14nQLZmxlXGjLMa9Pwu Ny6AnHoyLqiiL/5XXxVrU3tbKBa2zi8IvPI023rfzlPaimkidakO3Sn88+T0wg1NL3QmCmow54vH zMWEDC4xklwKAxvFabKai1NQoGEt5o9FDlas8Ewka9ETocA4YMrPX9wW3jJSkNmQRdA4Osp6tfj8 nxNcAofWzOLoTG7AsLugdhaK9bSTyaXJaJLShlnjMVWg6QitoPJTGpGjsNwKOVzjMOgIkX2DoGQ2 ld649dj+7/D8rFQC+Dp1jZM2xdxWLO8QjhshtdGOOeEZ/X07kkyx8X6UfhRHLEF3K7FuIuW8NMZU GTQCq4vywWNkJzs3v02rDbvrMLvfVJcLcd9AITV5OKWeqcGV0/n0JvBek9FtJ+caTDcZSLozKdBK CSAPUc48xCbBI1vcUA5lhy3YTQvfpJPXqdqG79YkBJN/aAGy1GLmdtoLTfeDe4hoQPaPZinMIDMs f+DXkpkg5UpxiBA3UkIzX+xNDRhfg/A/LbupUQ1vIIGwnMc7lWDjqAAQDL0OhL7FFnAfahjt3u61 9llT/aTvWxFQxnM2osAWW+LVdPLhEZmjOxYABUNxxxa+s1GIA7FFPnll7ENCea+CEGUhIVygZ91F ylPSEuSG2Zu76vEuLHWQMBfRGyJaSQZPlAALB3RqSYPJ+wK3NnvbVN97nhFPiEtTHlTK21YI5/z8 sYcY+lgxtG/ANDNN2+pUc1s4vutet/waczy06aONmAarRRyZnETZRVJUILFHyOjn//Pu0HHEXma2 bSepQ9vjCoXBfkUzGydyW4QbOXV7ZtNSmLY3uH5LNIq8Ln1dDb33YoZQi17HlN+7p6WxZJs+TTcy WgNI+zjv9p0GCYFXn9dxlcRl3EEADVkGerUTXUQeiinZ+P2bIw777bdhinhGf9oNS97QHKSfmX9e XliZ5RkbchKCoWELCrxA15oz59XoLzfhKr/RubDXv+QkDWxHna3jrZfY/r1MgboXMvYzoBHrMwB/ vq1gSQeYqGHd+1eCo+ButzWMwtzs2Dz0whlPKJFn4oTwJ3auzzndB9qjFB6LLFHLL7W9AdDAoPTu HRDAsOt0+aMVJBL+tRYrxH+Aktrs/Hh2ofA//3xisqcYhPKYxZpJh7eXYPSB7P7sIdvXxpyEKtBa z5JXXwe1di29af++IZuiHQVIaBrGCW2E6klhdDuX4HBsQYjfnZSQsjCL1klGZuviNpaBKdLLr0Kq AtJm+a/LY4u9lQhHKuAFEwiGvqVHpmYu1z2z/DheqqEXyQawIrhAvClUF7PBpSngHfGK2G2yPS1j KswLLfOMRSEOSbRBR9wmSnAJNXSVNacYjMPh8AIx+zAhP7/UDzDhk1uLW9eVrIujsae6EsUnF8F/ 3Fi1+03eQYFENq8q9AQDtULYS3f8eFJ/RcXQV5Dibli8T/BvxPwwJ3mR+twdbasoUezrw3QBVuwk PLjzIs90sygpqruZy3MVb1E67TxKDfb6vQp7iHA4nd69J6QNywPI47ibW+jkUMpstZSYCMHwukdC 4oP2/pPVcRb0EP+YJHnfVRIeFhi4tgy0fH5sNaWWN6tSsh39WkJ1jLIMJxrvmQ4NFRfpFYEDk2rT pEa9pDJqBtS85inxO5JHrHQ1OIBGlo+O1hUuGpQSArCCx62NSWmhuEa5JyzDSIABfyAyUOUO2kMo WLhygzJZiR2xi86H/h+eWc/BAQ0WHvefOKxbGkm0XFwPppE699qcWkRnKZpH+Rae5WG0sJDSBWAJ 0veHad6XpD0ZtReeH6A6atDuQealFZvj9kKijvy0AyUgDYwPfS5Lz+u4WzAiXwJ2ZafUXrG1x3Zc nuv9iHEuZ6IbdPKP681tE7l7+0iy9AFTIclRvwtcR1vyeAX07elFuRHsOgG+oDP8D1lQiYYEFOvN DG2h4PUfu1ZxdULyvtX3J56RrYbofYdeBmzyLbrOHc4wEuJiNmu3JqEMuYkhOiMw0czPO4fxsbN1 Q54eeTsRIeDXYntf80NPUiqUwz8QLgvW9U+SE0D14gQu2D+upfRKCGq9aLTMvpgChMEct9RsfxDn n4IALkxCMDTuVGF8UEWTabWYmFnhCdx+YWwCFCBpNgABjh7G8Uyz4NDgc5YYDOQuThD6/04ElZme uaUNlqhl4yvlBArhpG0SUG8KhvbMcOGXMQBoMqRuCczwvtc+X7lIBKWp3LJVeN0U1KyThiP8ZgY3 AU5q8G7/Gflndi5/JoIplXGUN33T26wIS1Yux28j7joikpdicUWTImZqaLs+eMdnlaxXfCWPFgni fir7aqyOzeb4xZz4dBMbXcakCBdIYQW0ben038875C8IJdw5HToeRc8BCpCKGjgLx+WB9EvbnUw0 8s+D1WPXF9Wsc16z+Ss9QVrFM0cNJwsIxVQdMaSdG/pZYDyIvZfAfkFOcdyUVeR8i8cs/YUPDn3y PfUHExv7de3wHQKANuiQJEtSngFWRvspt0m4ZMeEeP+/XHrFAgEFu4jpNRJ1CR4bIK9h6LM/ZrVw nQzeTfoh1aGXkHWjXrifRw07bSslhhZRPX1nMGVr0HoP3VVTwm+RyZhwGzJx0F1lJvCbrG5gO77w sDMRcSlpwPyC5MpWK4ZY0mJgwaLGcLIKBEOX54Px3tzMa5tkiXcqcvZjzT3hBIR2wzdyKzFawkFK Q3TpOmcZWAauUHZ++w+MoeE4zZ76xz1Ouf1ljhaxy1ZlBD8MYeSfkPR4lykovIix0R2p81BemPlp 55huv+BnAOZ/ssTW3krJIgpsJi/0gwNAg4vprvdiF+9rEKurHHwEMdThbl46nPdsN8OLZ7ciyevs PTgeg6XWnvVurlhC6JdSI2yNqK8h9XSUW6BWJ/2v+WZ+3eVh+m0eaBBVed0GhBI0xrRGIF2MLnh+ /dujYt4o4JQeK5ONXgOP9yino4ARzntjT5IgEbCVBO8xzUdnIUWu49nRBCdVGOuP4HlQxcd+0DCd jxig+jiZ9QGNnBbiZXISmCyy9FJCpsHtGZHA1VsKUFeynO+VamnblRiZsXFjAhH+EqqBURvnWtmx VyXW7spWapFvFHrhk3YHpqvtqroy479rG9vyetKPuJgnWvCNDeV/VsUFUvrGzn9BV3iI9wO0Z40h 1Mkr/j63xE0BbKAAClnG29AwHfQArHEadkzY3qb6AJ8VhM3h0nO+I9NAPzEzThJLNmZeb5HqXiSN TX+Nbvezj7/123y4sAtP4N5sybOQ54G2aybGYxrkLnNvf/fvUZbTRmf/j+h4QU2jWhLpQQPV3VZS EXpbhHrx/haMDgLliDRYwAly1SGQWLi9EGmLCe6MWI8BfFRvtxNkE3fAwt/b7A5OSnt0mBoOlL6A XpmIahCAAwYCFT+IDF3Kfal5077whpMv+EY7ZRIfMAh8bbWgKP4Hjdmp/kNpnBgwNOABgRgnqLsf Wo0kpkrlavk4cuqaImJprRVnKIFVqH0SzyXctY41782JoubuIbk+/qCHMSSrUgR9soxoePn+SPd4 EKZs9NiOkZpojWkCWJmSx0jSMMowmeB2q+fru5lL1LQNhKV+YwqdPO94ZjxkLAX8AWNE08Yn/kcv 8BE4A8KP/Bz9LqLu55k4zGTn0nlcoFd2Ra8TfE5WyA4z/9G/pDglfEBz3vfORoB0BEi+YPO1P+jC 7zDXwHRXtNYWFQKa0xzA/o3Pj3wp1InE9/bd58QfAVe58UP/8gQ38dC0m5qJxALgME9+n3dMWKKS 3+hjvM9XQsdnV8fvB4clP+KbSnCJtWVYItQiADXPe8cp6du+PBTLmICJ3KzfVla7KMuu7oI2Rmi3 CJJW8bxhkt9HXXfaetEcwUi07a3HuH5QTKlqkMmjhS1Vt6HJiGLAAR1IgBuYBcbyw42FkD/5KohD y/HZtWretjkglTAajv9tagVkJPjznXa0sVuBmXVHmXHpsAp63a34DWFBc6YaJ2pClqTry2Dh653E A3+BnqXeD0QoPMp+p/wdId47XpvvTNJTaJLgRU+IB8ddX5kzHRcEs4v8i2nNhShM8w2saKk37GUy 3r5o/fNvlUY7BmOmv6VDLUimbxqYC6iNlOX4a2Ei82qTivU3ZP1do7O9doSr7HTuRV1c+l4TWQpq wGWWBTJMUJ8GXu9faVAB6fTKHFYyORWAlEAGcGvjOeAKcxuSE4nwHbgpkrJQgd9FyGnoiv4R61Dz AUFJcMuw1Gvj1VuH3DBhE0s43z1pS9c4aJJDL2Lh8kbQ2a5Y3tI4C9Nk/WNNAgquIflmu/EVuvxC 8yJV4E4iyhUnOUPanVCsIzUlL0EeeK9P3LnkSOTACC/xUUxYBQ1RjWyZygdKNYk+rSCMFTGaZFgH BYyzRxKNde5+phSd7mE2W5M8E46zGiEBV0VhSbcs+BxssVXoeoAu7jOOqAOCsWP4ZULhZonenb+N +8/uoIuzD0M2c1MfBvW3G6B+8HY1t7RyVLLqt7XAbT2b2VqtYypPPGjOQy4pc1U7aEJigZYY2XEm TXSHadp2nadp2oLVB9VeP44NnzVZebKAXykJ4PZYzxvkg2pfMwkjQhowCbuS15O/t/EnlgR1vuPj xHEM9N4D/H3Fg3mKXIJ+q+LmszEDQwiJMLSJjOZLjWC2151HeWyPjPHWcLIubmVdHkgTwv/ob/WR BVj1ym4M88gIL8OVEBZ7omS9IywMkeY23GnuavDraShwTnEQbl2q7YnDnA1d6dE/d0s874gRgQcJ g3ElcoYqKJw4oe0K1QAcXYs0NRCdMKGXxmoN+9j2NneSEvQ/Sb54EWDDI6SUWyOr9IBsET1r8bzr wHd3b071SL+AH4tUhk1JkaKJfvUZLo4v6Mj0ronAaX52c9sbIi5/7WfdVF9enTotDkvnuwQK9vrl a/d6t/txwBNNQkooJVSzEzJzHry1cn9G78HcwPVDiXNmflKfZigQX44+Es5GRPogMSmCymfkP2ge TKGzxo/zqgAlLvm/oFsgvBSgJyFEzobPmYCD0c7Yd7hQVjJMq8aEXeeBxNB6Vt9YsbE7lbZhif4N kW3UA7EHTC0AlRmetfuYrdgkmJQX+k/dGCR1ZUYX1SEMX+k/26x+YM8JopJtqpjHSkUw4ca91zQ8 k8uLD0G5+bhDv9Vq+umE8Sq5ix/sMoBH8oh48D3Lk4FHZyYNN/uB6P3UKwkuqD7UAfnLutTK763H ehUkueUmMxsKbPSBii+1HySwXLVV/4LPLWbX1Y4CWU1W+Vd8BK8WaRdco4HQ6vLgJ5NravgyOw42 ey260uTLDPptbMFKlTTU/vNcmSDhCXPSBcT2sD1FYyRlpoZcS+7dwfLj6HNDja4SZmwXeD1En5H/ Xsjslqq7G66xAS2XkN05uOG5He2SL2flgntjzj3aEEh1uKCZ3makOp7ZGMAhJEzGsog6IycVdg3n Zpv/Q49G0OoxfYnGRlYgLBJd/h9ZZSb5P29W+vtQFyxtbZryoB/p4QufwmqqhhUosII23HQ72Y8o 9USEQ2z6h69VTA+5CSKiqs51Vl/oPCIKveRQ+JPtcaEgXCQwh9V49ygQVXGNK/90XBe/KaYfVaVk 0UFkg4OGB0z8bKlltpFMyOKmI4U9Unc1slePMw+qmLbSwwdTL+3+uL9LdT9yrOAuzDPOO2Xvhd0s /edm3A3FJoRe6cxAWcGUugGR6L56S4bpOUz439l8KLLk669h+IhUfLGDZvQhJRL4uEWMCYpYgyAe hVDv9/LnrMFcdawxIt5Blda4st0DZhbJ+sQo7NEneKJUadnXirYWpmERlVW7MgVTJ5Kh+XSxDlxf k2Lb0sciq2zeNQjgiXirl1fEUT6r4hGCGvN2CeoDZUEsRw1PoqGKcVNx1VUPUhqS8MVVz2vxf6ft ZZQ/Od3x9KmcAHZBTHK6I31iEnZU+mKD4Sfp6XKXDjSgX5vyQQWlmgARS3UhweEgKDcy4S7Jl8nP 2FIRanUyT1qq8ooVk0tIo3vlk6OK1S7grJT4v3AdAEj4lJSzXez6r63CjpxL95IORrYeXVAyicMN eU8XKQnqRuPj++NQTdZlfxxITi6m+UponLRgT5mrCh5nESf1u1xNIVk8xkFActTPbxBmiN4GjDWN OzBdylvoliKKQTNskxzO/8SKVUhsTFN01Js76GGwtVIuvDdp16BcK0FDMhQG7Wf1AiuzT3RC5CoA PXYQHc+q3GWiXeZZPcRWA3ksBXbTyfsZoJ/6VToWLyEcrCH7S7zo4RQzJvkcwN6KvPIK3qiJP4++ 8xqLbPlxOHoLLwnCXoQlX3lYRXPT6nCawsyUlqABbqsKeEy7BYvrFwL51p1uF7fiP76pXxKlKAuW KB42yziRfO6M/EZtcczNWm7HH4izptX8Z/x4FWCpEkBF39A64x5axU+wF2UWWZhrjA4RfS0Y04GF qrV5l7Q2MY7N22+JYye/5ai09H8wsqG/maYqWz/E0VfqrG1fX5HdPjC6lJjerEkiSb/Wrhc0tbwf xfTBYikbptbkTu11i2NLdjLF2FrME6Bp0qWdfrcQTvL4uBMO6mbgISNHO8fWBbGQlY2IqQHb+BIR G71NSAEDETYl4wjOkxQ+PVkQ/87GPf23NaU8fbdhuccJTVQBbfz/EXJfgw5TrZaYfSzRA4Eyr2QS kdlyGeX05b/momps1VueabfCmZ7+5eXew8NA/V6aR8TiJ+XdNlWCNpGel5+6IxEVBfctXWdDd44w xlYgCWVhnj5V5yu4oQ/Qr31zb5zWE5rZEkqmTjn2RdPe4lJyv6oaWfZjk9pZLy+fEHkl/Kq7Tb0t ghUI0OZN8W8ZdAN84eOJEeJC30eJX5QuifOhfVit43gtAUWakt8+WSB4mao4rX3zrGFtZ6UmeNHH EPS2ELQMfjrwpWkBnvJJxIL0fWhpYDJpEg+NVM1DcaENa5fjm3ESJRT6gWmvSvTM/9AiMBgmGHHd s6z7l3BlmIFH0BNRZe3ro1mw0L+tGu7MHh5y45Q/zMfC967uGSZGVvHL9BY9sxE8tCXUQK82UaUl WEmbDN+pGbGHBrDFKSr/vZJvPuXBSowrIofKDxcxw1dmnkIq9yI7rXbFVBDk6jR0Dqc2pVahdhFy +OZuI4hrONYFfqGVGGD5qLj2BN3xMTqwHM35vBXdowHR5suPC9nsp+6PKwF8+p3eiyhzouNOGcvf LVxgWsTP256zARsamJ2Wl1CkHzNpavg4uyFSZWeEeR1vAjaol+YCjRyOns4UkrwTTxdLCBcOogRp Tu7WNQ0o+UFXbxxo2ZVQaCBmXaPwBNvfRhQ7R8EHLSWqgFYy6lgQymnmjAWqMfgsHFwNH1RBEUoV OuqPJ1mEk+ch2H+M33TxaBKni1DCfJQ67sSswuRma0+QefiuIVX2K/XRtnzYmhOu5MAIOUwqJagb LiD2ec3p8Jm4dug5xtDnHdKjOxq+scI1j4K8ZpA8Yb8fnlry8yJhxVAFSkY55og4jwAQGrBvv8py +CAAY5ILJhq0/niyDws3zHBSRWhk63EXFAl7AJ3u8nN1bd0YTXuNDLDArNrH1yusxhii6liF+K68 yP1TDz2ij050FfolTmIIgyhhAzHarpEjMZ3CYYECapuOXLOxff4Y5gLeJQaC/GlWiGdwIro2tbir kmNhWKkQwAIKnU7KwewAMOIYU83MOOMQ7nDAGcF6eEbBOnZ/OBBzSyURL8jmA6uuHe03atRBopGf kEKkCR0QIw1u4DmjWercAQ5MwmlF2d95emefStLjYAJ7gr1R8v6XsAhHSeQiCChiIY1/IDapXGsW znzUC0v8oGuZWEZW9AE6QbA1GTqGKpXxOIFl/MAOJbwrC4puoRnjzrMNzzZiUNapem85ZeGdfGsA 1wqQVg/hDkbN3LDZcEyXujpHSn9qud4W7V/w7srb078NE2iV044qAp4XeUuvXKOmbmFBpj3gawcC 8VlsLp6wiWxvDbj+b+fjg0+0wZ81dWW2HxSHh6ihV1L1Ae5GzuutlK8MB81JsEH5juJ0Ktgst5et vexUHOcI08tzHEsrQnLBxPvwAaoNeMma7PIeb2KFHxnW0LeYOApTSGYrA5hYutSIEeNHsI+sVXhX 7dbw79CodR0BqTf8stCcBtQo3zQ0MBQ6By2232mjuCn5GOFiJNaL7GKPc4h9Vs11WQA1EJ/9YS7/ t8o775Afv/2rwdkgJHMGtec04/GX7wD6GxoNam6DZudHXGsH+0l8CgPoS8cnoTROf/e+IsDlW1AD dkeFYwNq3jIFQreawAA4AEoWbRTkzbWkYW03/+Dv2OGXisLgbshmFcoUJJDu7HCfr5IbtA0iFxWa 7yTXbSoETVtkcV5wTOYcazKatyL2PZJ8z1J6RIOxshmqVBqinAKys5xVUbxbnUireTu4KY6u63uI di8QBCqEQQA+Nn90PyJnhtFDE4eHlF9rV9eV6BoLCu/yA4unlaaaHhwjkcfkJzvboAb0HJ94A8fA 6dyYxSp6LJPv4zM27cMhKcS6XIDoHLqWYHoGs1n/ffOMg6Eyg+6piA5ory/uJpn72u2YGFOcRlxM 4pJwSmbgEtE3o157mOhJzCgcD8Tuo4DDrasf7vk6p74nq89xwqwdPLJ2hisPTX5emd4WkBdN2ivF nMfWbt66hYo1JUn4qo9QbVedHyKfAyV2PbuVxPd6cx32UcjaGCuJO5yI7feECkgsuLFo5tgi/6+k ps++IF2S+bIlibhooUsX2q+agbjCFJfDmayIbsWqa00FOZIqFvGO9Dq7zAN2NlgJooSXTbN6zium ieHGS7U5Jrx9s+86YPZkiEFqToQGD4C6HGtU/GjXyPQhTiQsjaQVKA4/7GNy2MqfMHSU3inKJb2j DnIqZpBCUUTONc+0k8M8Xp/WI4g+4v3yOJdICb/PZY6HkrLWQ/S57TIWhsT5Vzqmtd2u7YnRYt0h wcqhl5s2TC+Ps1P5obgsiZaQMDq03uDbtATg9ism21/rQzT/Fc4s4vDDIlKHQMrZ/+fZ5pXVby3F c97awANBKAdThnohLe7wAD4P81Pt6qBi4FXCnppOrbya9oOOBd/Pz7G7fVYG88duB2/jFVop2WMw O55sl9GsMt3NrAMNo+MarpMKe/RTSOzVWBsKVFskx21E577O3mk4zq9kiJ5OWTxzdrMwah1g6w8C Rj3qqod7XUONCZ89TT+NOR+og/3Coz7ii7FEGZKIqVDplDaHjSErEuCr0G++WH4HhiT90tkBu3hx zd1E9NBVm7JnO80zAN5zAl/nUq0T4TVGpK7VldGh+hKdyDVaCh3bhCUQwyqth1+EhvgsmuX6yXSt Y+iCaLq46jyHPxRylxyQ5M3C9ZUcpntF4YwKORvRFLFgNAnjuR8w6ynpVqAjwbIWunxWG9+nYdo2 6weHjBnG+ZfWcfkzqfWUUVtHi5l8T99SaAd8BE2tKj3kgLjofW+sAgARXl7k04gyBF+opO/IQ3/5 w9EpBOCdV4o5iWs/Yyk8UxK/KqTsR8yEBIEK5O1ohJqNkHK4Zi+GpVSffYz4H8HnNbDQl4hF1lNS N7M7qd42xx9bJq9fpexpbeZVziU2+1M6MLhJ5i1tARmqTIrC2CEWZNJuxxSmwrKfh24wET6D8bNw dBaX3A/XEXXbCkiNvPRgC/57GnKFK1BVpgNQYGMAlqhu4NsPP0tMCVnjTTErGedsefJvXeygAgTn 3G/mu1t0XgNSIA1u5rsVJyX5axVzCiyNg9nsbtIXsUWhqVVupBXVREyx5Gc0gIRORcbkfFbUuNla fFirQ+0VsZD4U0dKYutZG3vqUUpMqHOc2sEMoQ30IH26Si/hnbQbLod7lv2RbxGDLyLwjmpNM/Pf JV7ORGl30s8u/xTwif1K1GIhz2jrdbnzGOpnbimbB7CCVa5fg187mf6mxEAmkqceqVHhLS6RmXnN aZMpncRO2HyojFVABAnPi5EVaDYIaWiOHP50gFhpab9RvnGhOT6DmpcrtuWMhNIDZacV+dKIUaHp kGczSW3u/LeE/BCQMWeaSOJs4jOeQCB3K+5q+AVNkHNz8GFr+jiCopx/wIXGTB7umZUPZVc2Ujyy t4aChf7Vrcwv0JJLWNnWzL7+PeXdUv6JV3Yq/U560IeRDnv1yTO/s5InQCNBcVRU2L0yIMgcahqG RTMspASnyb13tOLNrHDjewvrbsm8MKk53VlSyLURTfjDQRvWGPr7W5Y/TE11IQviI2EeYHRnxI9r Zgf378mJTXZG+X58SUiKPxLZs7jrSapj9dDZvfUA8GvU91mCjAng6gcOyevCETyoDMWtoCAkFQ3l JJVosK+Xw5yKmixfsxx5MPprQ/u30HKttWxtyWC0yIZzaw0aRYCoxxDxoe5dgyaIHhw9SvAiYsmv ZuPT5OKCSqZWbwJz63td68gYL18nYNJhI+W34wO1+TTu2O3aM8Xo7jqrebL65a7a9s46ktk4x+Te J0LagVv4mj8QcWMbwpAe6lKr8m5PYzYmavjWef4zeQJPsJ1xpIegZmS9BjfexEr2qYHpHHeLJlwO NluaCedOLe7AXAVWhf6/oYBzvYyQG9ue5D1p18wQDvQH16iJ+l6oia7kiQoXVQaWp1pBgikRt5u1 9vOljQUI80Jdw0qhgDfoc4sIUrSGX7r+jO6quJsQTm78T4o+bqPpBhCou/wD2lErZBoLm0cL6gTA llQgluzEKNlhNxRIvZEdfN22DTOfI7gnVfIJ/eBB9C/c5sCngG4UNDvCFSE0Wze7biryMYo+i6dG dEJGb925MfzZO0zEiYL0H9cyY9DFNpr/22oFbF44TyjMZJE+MWcCnp3RhQ0WpYkrVeZ25gPOP9uA pfdrmFe8hk0N9kd14t8PN/832LmTnuzfizNqMBbN27cPyVzv84vHACkOVgXkvR5YfKkUf80vdC5T k/MG1mkOQmoeQQ/u/kLBMnxe0P4nW8PNUy/58Dx1uMAVqdPjvrSfR6dVruUTsXGCOtluEESabiCp yQbJYQZoA+zQ/uwFq6aalO4R7bp5dnVNnmi/Ywg3cfEZzzwo3F9gqFXMBfgTM3hk+htKMux7LShK 7KkU3ZKobahWrsTXm0pE3+3l/c9Qc7SBajGGnNbXBRXV8/uqjIPeqAFIwnP14KyHeqnsCuRBQts+ n5Iu4D58T7sE9fgAiX4HO2heMoPmklB1P/3Zcx7VhR+ZLzkGXacjMTRhP0rP3Y9e2FKACGzCCvuw pv64xIuAmEoani/CutiD3/BzzZrzLc0Riaud7lLNrLIx4WPO+AHKiu5iCoaN0kq+My2TEeczP6Jd N4OwwBKfRHRwm7wTvt/pCvgooBVmaTdvFzp263FB4aALEi42MrUU8mPsSklSqoliaOrH9x3hYtT9 v1wIYAlg8Ct0/QCxiaPC7WZM4h9qaKLOXrCwXnvPwBcJnSz7ofadsMyJA1J5Lc30Y1mUQsLY5FUo h9XlVPpSta0ZWG6in/+WuPtvZ1nyXRJ0UmjAVqdvfD2gnxWjzGIrnDH4spLcmL0ISR7xZ0+fl29i qjLvGqeQQ/IdEcRdyvll1eO3yqKySwuUcgEpgFvuL3nIBcimGN8XHWk2wJlNpPVE9OPsvJpgrOSh fk/Rbt/hCSUgy1FFFEWhZKO/UJ/+pzmRAe7E6KhedQepxE2TM92cwkIt/UjzjvjZFzIWW8cv/Vp+ pkkBurYRltxilB3muiVsxEQJ76iJupKkdBeRJqsbHJUHpWzLMOIyF0RIwrVtL7ToY4pqhNxIXESA fPNcjkW+6SqJesVCsKwXTvUzUdFkxpvHwE6Ch0pzCPdV+g0Uw8j47wKfg4Ekvsh7/7Qeug60PKiE UdIBSjZDk3v7UNf4xstXCjihBClwPzDtk/J8NpXRymGL3Z7+9yUT3lIxRJuxjqP7OMeFi7vNwW0y ifhzi5d3kzSZ+GrkxoJnAv5v70HG4+nvqLxZQ38YnYQdbb4DMvCUurblfXKxkbe2njZLsVqSIDOE 2UKrA6wdN+l0BWhW6tOg0zEwJsXnZvYB5BsbnARbSovvBsA45uQWtBw4PFVHKkh6YqWYrEyb3CNb c91WGlp/Ls2X4mNFS/7hBYiLy7wfGS2Lc+0an1lBCONPpgaGGTmPHW/hYMjMF3TmaN0hz8rEBVEI 3psV+XZDC2iF6gZoBMwO6/8hWAc/q5G1WVbm5KorvpUb3Id1kjexnea5Yq1hAjepUtAG9dyJpfA6 dVCam36+BB/ZBQuI0KCzS36F+Ijuq3Bk0vSTO+CHJm+mH9k4rHcAE6lBszTO76YSJKNJSSPN6WaQ kjspj5fqMC25FeqE736I1uAUoreAe78xZ/BuRXQSWlfIZIhyuRhzTzj0JzTZ/shgiPNpSlwNCdvZ GK8mFLN+PB8dNTeWOMnUe8b0jAoEMxi6nVHeJ2lL/bN+SrIxTDxOMXywx2aAQ1nm9akbK3fjDX7r EznT57Ji4HHKi655OsYaUnKNz3fZ5dYcB0erBGeE2QF4UKedUtj9GabpL/ogESknOypTDT3UYRld f9mhNIMqVYIuVCJVHU8/rypCpBxaNNep1uTP3a+mP4BfjVgkThY9cTjp+U5TlVn6IbTosYNilE7x aRAufWxJHpC7b+Xr3Ao2oSijW1rk0F+7/XfkjI3vlbvYIUvQ2dvIJfPAeOVq5zyPD0g8sA2A802O y6UYOyLGIuZHOSQ6YV+z3oZ4k8ljIfaByKoohoN1L9EVmogPhOhHJ6QXqO3Qw57ezULdfx40zkv5 2UCNjNbb3zUAiVGbqPnE2jxZlRkyQlwlevqZzhiKEgRmDAzttiTJzw/Q5xTYgAef+qn9sVwb73IT daavHhjc2USfDzCCmA3fga13viAfcgo3Dy7I9p63x1BLsKEEThgKnXkCnWLAJkqpXb5C2ENkcFRr myKBJLvCCr6KynF+D2xmUapKmqQOJZEtJmZ28J438FOYHUB9GdrSHcpH/zIBcz40VRqo0b/ghSMY xMo8vt9Lk9MVh7Wtup8j5soAkCwlWk2jY4w492UxcS5euedyRQNE7RcyOMuEwTZ0m/ROEu0DWn3m 5e0Sq/0kZEBDCJSbPqtWtMjh6o+LRvpJDnGBaSeuDz3K/Bt3TEQUifbwtnKwHzyMa063+FU23VX7 S4ej3U7m+R/DyW0kK61DjH0RPqBl3KmvYlqS0mg9EMv9dYtXG5TPVR8dSPK0n/3QBvMPwRUm+A19 yQNAvn4SNcnLqcx2X97zB7J8adv4I+PiU0t9rKOYjhzd5+apythRwz/oqDJ+QwzhN66H/ZgMyyqy N9aKBrK7z/e69RHAACFCW7nPinzbF/70ACSZktT8MDitxizdv7PhRVrKr9TBaAAMd7g2o75VvY2f n4mi1ASde1kSisQOzZceFeJ6BoZqLICpNlxYx483dVgQp2qK36mqepg/BGQXamjwT1ya8yqF9Dtm 3iyUoXfs4EY4v1bnbbveeW1eCmGaYWBxUPDz8Agq4MD7jdFVuXnuOpa71xLRCVdZKTQHN9HZjT9C TIqoGNmAYkQA0LrzLQhU8qEeFdqDQAqnMG8QsUodxj9nrUFUIvEfZNCWDcnrfbhEmBhxW2Bosqom 98/OiFcTtNy0M8ZQnwIkAT3u6vUUUl9qNb+AejI1hiDIn1yDn0pldtaanVdr3yC4Mti2OtPJlRRf 64Cg2OD6WMN5aodec4sorl2RirnJbko/yv312tUpKTQSpAFFJ5TuR1VY5Kt2qMTig8Ct8iw/GdJ5 14Mqdqda9ODWe72xQriM9g0P7tCamnbyIdsxoi/17F6QNq/aVFfzOBkBK1o/VdnxClalwpUUkQcT +uPWvuypoxV6cIfY77JdwA37vTkbVab1bQe4ap0/0jSWWwy3L7nlUM+IWhf8R1erSn8fOL6UYLUw 5bzUoSD+E/qnqvQqTfYPBn5Ip3lSY/vastF3/znTIVpbxfAyQin5jJf3m5d6QqKe3zU17THBKzAA tkJjMjUhrljCIfLowZf5DFFU6igfu3n3Jrb70jyrZBW+8nE2DtoBNZibwALo8CRGXsFGNi6gzw1s A0yD/ottzAyRJr1SBDBxwjFyTHnU6fz/H5oibyS9PEcAiLJyceMZqWRemP2vGnEbC4juwFTNAz/O chvSit3GnsBZ0Png3dy3s4mKPxNmtYfurPh7lXi1QXJz1X94jTJBICUXIDKHpemGRDG2D21Z47qp gvK/H3XzZ/xswyIiYgD+7Bef/tFzQ4jQwDmRYNzLPwtbzr13omWYivNkOOM1vbwGqN04L3IPFc9S 1EfZSaTn+Sa0FZRdZXpEFld7holxBZcGlu3r2mZIJTSt8G/Hwn1EYe6UnH3VyLq1PgwezkVF/xbE hx5TCB0Wxao+3HSrAknPmpdhZql0robEb4pX2f4zFUUwxsoAieWXAZLlQV9XcIIzjjDfx410z8PJ UjKpQYNnA4edFrlPcteUkQeHXMeG0iLZAEWfMOyfgOHIy2PoMk8mr4b+pP7cJqm47eCyt7aFbssH Znfz3gb4wr7n1/KJNUjdYSndlSKocfAmqs0l6x+4c5sLjp21J4cCeaKXxyWm/Cc52t7MU8NhL3XX gYHNRf3LtLSh9sae35+kD9j4ymr5tPLcByZLuWx/dAjv9DBkyCGhKe/TnOi6m9yHLb9IJsQWNq+Q /cKC2OUsgOkxw+JawkjkMGFVexIn/u6LgG8C6TwIF/yJi3cxsEjCwDnm6tUrR+qGSemBzY6BAvAJ 4v8E1lYZFcTYcmVPOKOCcLJ0bdEh8DAZAyT+NmDoqI19pGLP9FfeXWIQ3oD8NxlJvX9CLi6CU8xN rZo6kj0N+KyZ9i7rbiKRSYfLNCtU03V2JJu63vcajl+jz4k5TeuwnvBI3cfxxmw8s+eL75DN09Xv lhoJzsZWev6OjJinsBAsFTaTEnZQmdNvHxDwdp/g7t+E4swWkEkMlPfXLxi0Obhw69Mme+bQmnMe 7WVbY/l50cUQptoadRga/lbVb/q10kwKvCVOFONCXaOsxogBndRRoXOOHauzmMmBvAIbyn/8aiLz PM1vpfBDi03bWodFEXUOurrL36lAiNLPd8cFRREW4ho6lrooLGDRn9Z7UeXBYohAwla55Rfg+vDY c1ojX7jVa9e4USbdIJxvvkxNRxHRyg6B9xbAA1PoECVDFp/LcIAy0UHlK+qVh1Y3px8a7btOIzgs 3emofSIMy4c+Et8zSI6ZBb7F6ZQ5r9jm+5/sWbdtE8wyAXBpWBV7LugJ0YTE3yWnU1SK/wNJfpeM B4BrtWz47Op/WS0edHRKfqTDGD2TYHHkBHeWr++XwjsvBcPAO09UihCmPvG09KL9nPgE0K11PGhM 3nKaoL80LNC9vHVxCVM0LV3ZZLnp79cWACT5UTS51/nMlx731J8MwW+uRBzsJSuTBEGlvifIrzFc CjrnhmFrZzmWaGU87bSVkIppTL9Vsn+6+U9yOHXLfblCPYlvsqzCkPBWH3c5ZfHwtH+om3n8sTKC P+fTyvmgXGjkUatnlv001rsF1t/u/oQTlERDexvBWM59pRzvr/3tSI9U3oJVTMU/k3aBt47L8WvG 0NzijXbWUyjEJRmKN0ZGym8dTjg5mIbtdI4QQMUHg61U84fnlhMhctiF/WMtiioum7SnE7UOcMZS 2v8RESuOlN71rNNpoy0E0uCpz/EyMa6eCKP65YKUbUooCMbXzpJvGeDj1HiaYBXsFDSu5cbjZrbx y8u/MeNF4th/252YzNwGh3515uq+aYlUauVp4SrfeoPVRE6YIL1S95bgWI7KR1Q+eQ+40dnzEj+z 2eP+P6/20XUKYGkKBnFmQ4CfugOnpX1+fSfN9iESp4bo+p7mugH9bz0AHoUBGDrHJeYYsNTQao71 oxjqQbODMFF/Ry1Lx0PEahyRF/rZEisEY08FKRQ/MqdvS0lCWwUbjGuxy7xT3lbkv1jIoird3ODi bdWtLfmnr2zXN30CJgAINIxK3QcwE/gSoJOsu83fydR/TyM1u4k7B1pFWta4UdIZlpJCgAHS177E dWWnJ8IvVo2cWIu9vAhAAm90qG+1DzzEO7Bv+GKaQP4CUUyt5FkdFXR1MtIhX9DWY8sTCJCnlNaS VrwOHWX51zgi/Q7qRRee0yIvjb5ca0MkRcyoMX68BdZ+aYN5Q5I/pwPbOE3Yt9kWPLFqvwy9k/xs AhqWitubpmtp1Fy2B69hNTv1d9moQDPf7XssHtit9+ZntshlUZETxbGGu1HSUTOcwjhOaZ+oYaJX vSUBEML+WNEjjMibASuB5aYdBCeXKdZ+z6/uvg2APV7lQyO5OFkur3kIhR6i1AIBOEIzTtFhW7/6 ZupWHFKRylZ/g60AAOlYZ6DWsO94a23LX5RW+ri/kOaz8+kG+/lRYZF6Qbgz4BVN5EkGHNjB8ahk Eomu9ot6eAr1eUvTzaSCupgiIVWtBtmKgPuHQSmrstxkbNyPW4tm406VBGnSARymP0g2+cpZ5LBF ILZ0LOx3TC8cY1Efnpfftb/NkpRhvREXGd4KI/ArPwMI53IMDsmqNmInQ4u+YkhRA6CADGzAuoel RQVcCwYgmr4PpJuAn6QQ0pv88s4NvyH9H9G+P0O8crO4nrfPMjGfuRrrGnCtidiUNQNDIAAfK8id GzCqNAwt8MTfBji4tMdp8BTApBQv4gNw2iHutDOBg/meA/W55M4bMOTfuYVXfuOgHfi1XxKh67XR s5iilzWH22XMiHsT3t33qA/wPcRlrVr763LiZSL6IT59nALrKsi3zsB/Qj8snEkB3TJ5SFfi7cnV gKRElDK+Siz25+Z2kkYG3e+zmrihypLwYwdG4P7Q1y4QAF3QSROl48dkOHQESLQ7MuR2jvJb0ahQ lfrp2zzwl7sxpnvNo/pgpL8Vapk9GTPTM3HF+nKFd5SbszK6za9Dg8HtklXjRjvpTauR6eVhD1NS W/SGOgNuwue1TKOcCwPvIyDHJaZv/M8Mgy4JQnDKqxxg0tfjVpBkWHAU+lGKpRYTC6e80wk4JKnv I1qVMnl5vauc3++2YEZhNXKWiKVJ0heSubRub30f9K1U5qO+76F7dt+yenA5wKNE0I5Hgahv+Ypq jOloZQSaWTNhbpzJYUZq79rmSQ8k0KSs99hDyGIew3RcDdx8aA7ZghFhd8vjTdXug0dUx/6w65pn pjMC8ATGL2VwrfXf/IDGKbu+Ywo6BZ6DPeOljL4P5/SA0k6qo2QrXVnDypnZRdoLLK8QbilVimBK YPwnc8P4fN+JaEipZQueqEGIXYqMYG14ABilhbRvMrnfK0Zbse5X1iiWg133DmBoADmDqhzRMlsh XgDsnlAIYk1YO+gd76q2AOBGLtuz5ZOECmLDDFWCNjBNjErt4o2ve9YSbKhrJeKXr4ermJSu0SVQ 4+nF3PBQAMJvwfrKF9l/AC5yc13UsFAyFxDDjfbOi2bruf7jvN8mObSNfkCU09qYi3GB+NurbhRB kmuoAS+LeDZDRGQRM5DjjeAnY6SZ3uyRW/a8WR2QR05gy14s4ftNfgLA3gb7iGlFNT2TuAy8AAeR 8aGqi0VEYD1LHGTCEgtt+8Hn9Vf9cZ7zbjGfdOIEhiQgD845ptmroJfq8qTxtP2q6Nl1gB92ux1G xNT8oZunjABy4A7PRPCRufHDoCSJQ+RclDn3bZmldWGVVES8GJjSBI7BWVr7mVfdXqMxl4XQu6p9 86a2Lxx1PC2LeZTGA2hj9Fjc2UsWuJ6xpb8SkLmNE/TIXyMJRT4Rw31anWj7L3WGsQugDrelex2W cEpVgjF1yzL3T7SpXBqH2xEWvROMthJTspBBEvdtabSCSczdIAAAwddCpp8yB0GA+8jEOIDiC0aO 79po///O5plyx6iPTHn0xaw3HMBKL91xtELmzq+/dcUDkrkAsJvZLCU8/UfQHg/BrZoO02sVGpvG VodD/B9SFvBL+ium4q/kn0SyqgX95/pBXNnvdgl22GJ1PIEiWUaM3SvF7tE1Q1kK9JVMZs9ZmIEG SzQkOydM9ThX2+htvXZrTJxdls1ONioZGrm0htX7c2dM8eQBgJoyA9In7c4OlRyatF9uKETeg7P4 v9xeKOlkbSJ67Xmm9SvjMBdaeB8ck+9YzM6sHHON5EjShXNO0SU7rWqLsX77eBpZoixjXockLCc6 tJfK3YRRlyeqzKBbJNXTe8+M8WR7DMXx9QR+xM9jncMpGX6wBI1Hk9hL8KrblLkjpBtD126UbQDw FkDmivoCPqDW1xGENJSnzLO0grRXEHOOmV3t2y0jthrN3ChwwTkNjDYkGYrAZ9GLr3EF2DNeJk7j VEAAEaexQT1Rd/1FhVUHF7qRDdkJ4thQJR3CXc2mcK5746+pDgp4naAtZfH32EYH7W0XAtXlojMo 8FbqGnBHqLkAT4htd5WDg9Fs/v3fbBLnQlaoQXN49fbYXxzVzEFkPoS3+Oz2luQysOsYOUjvHwKO 3O7A6tcdxRo5tUlAyANTx4AAS25Mpa+K3SOaEsu1wAAGk4sRap5T6K0o9NFoA9rBFFzHd+9fhDnq QKhgEeAkifdvy3ytirvgQj9xP/yetIAeGeXg3gIkLwVVcUHvDh6o95iWe4kOThVkGNzuavjfsNci b05tyCJB1iAgeTqOz+J9wQB03haXC2dLYbZQc44vCKK0jiCIJle6zZf5rag/zc2Yimm9FkYlaZTQ g9M0xh/nUD8P5Gnc6vZUWo1oqg999lcxG7hlDjAmC5QupX6gCyr7ma05qS9hDshJ8UdM0rCtLINa IdN4z8oz94Gacm9cwT0cABg5odZJIFpMRrly+PUOEJOjcRHYV0ftzMZ3EBe5QDyz+AQR8gW445Uy O/wkuo4RpAqvWfa5IEsR6zm6qJWVs0sUZzdRVRyon5W5kvLSBfqKvQWaLEy0D82xGHWrvWGHZUHH bROKS1x8e/a1IPIB6A4GaKoVyF9HNRUwhnDZgAuogAKafeIqusjps4wYORiDMPop0Vz8QytqvWCq XoLrnkMv04pA6LPss58oz/afwYcAItoMYuu3GfIlpI2NCehEK0uaF1oAj5sNnSi3Q8rJ0V3ZF4M0 fZp/fUOhxnnHum6iN7c/zC6emPuLYTTR4u+kqHPUYqs6NvjDw31DOXFmdWJLFvUEjiR1pD5TTx9u 6SbboRNujkMFJFIilJ1r8gOsBnta26fSs9iZnzsSQRGrgVaJ4KSENSDcZVWn91sNaqSklmwLZOHb wBNx9dHC9aQTupl1swG5mk7CnvDjvP6eAnDNljfRdnm6VtbDMNILejEnvnnOoqOAHUAd9OMdTgfc bMLZmeAB+CkxKbbld+I15CDpf6np445iURP7TeSX9hoPxp7jpQkQjWTr0AO+8kjdqX3rYZQY5uiw aTPOAACHd5bKd1SoggMLpw5u7oIYr8To7gBKELSHs6CuaWwJnLVu1dcwlJL4V9jXUpEQ2mkZChF2 0zVnQ6viHxOS6+bSVv3f6YWL/FuasL0Xh9PMEnXLC4+w/EOYuLvxQCwNDeG7OzIAz2aOaZ33mn2w riYL99eaQS4u3d2oNLhs4o+kHTyh3tg7yyL5v//0SN9KpZ96OP5lAASpqV4hzunqpKlIabSVuZaU 5ozROx/4gtKKB+g4UYx27ki1Ncf6oH3JRaj2vUW4NePys4kPu2u3M8OlEsteSOoMfJEF2ftCxA5o XXmduAACyIXqG5FtCL3s2eYP/stHq2gyqscVI21C37Kf9vEUw0z+RXtNAj4mwDPQasmylQoVrsQ3 h17l7W09njwC+TQ8GmS3Lar0a5a6uo+k3Gw4vk+i9lHrpC2XtU7o+vkzZxy41zjy7lN7eAhc00OK gHJETQ4G5Tvu0XjjQKhXVUr2GTq9ZyD102NhdnDKPsfwYsjkeMcGyf4hiLKWOPOf7MeRJJkZ0/DS JX3Q+yQ3hdFjur137jEL8+xVEu5/KKMSMshz4OaQNFssOAbtkEt/IkRi/z6Rp4sTIuX7cFLX091z 7iUrwpGVd40coytdYXQYxN9UkgCnV4xdApHncedlbG63cZADXCZlzYMXX9KVJIR9z92xrDbHk8Yv DVxSbtSpCFKKUA6Xac2huY2JzTN3J7dCnnf0NF6ks8AUY5TRaF1jHACJm4EATrq0DePq/1AVzirO PB82mFUqP4MobRNHvFK1Y9r5JjUSI6UQJ6DKzfyX2c062LbgQXmhrnUxZVtgnKMjghrK17db85dP f7cYS+/R3q5xf4YtrinAwie/Q2PqRJBAbyK43S7u0TnOcT1BAc589GhvP2L9f8ls2NQsMVM82/gT 2nQFj9IfnDvVbNN7Ghv8rtfaJQNiaKofwoxllMjO+6m5hfo90oa5hVuFGJSw7QxikotWkLPAPToB wKegG0AUI/+n1/fL4S+3vj28TOQG5ctMplZ95rJVqzFs0PHEONCs3G791uCjh6s0X2qfRCD8SdTf sbg2mxQzBJYSt1AaDmC88uLAPfsughViybDpN/ZYil6oAAxNrBOC8R0ZYAhdhKMTib079sp6RVHa oUieDZOurNDV2zbZlqRydS5CFDLQlTZUDY8asrLoiPmzCu1ZlGJVlWYAm+auPqvqUTKrieiDBDUZ QIYh2f56ku7LA6rHP4uOYaMp00elFkSY2ikmVfA0wsLoewDgr+xPWpiSf/Wy1bM6rWkTJfhIZwxO W+AKtI5F8DtembO4dBB4bJWJBi9ty/26XfYw6gbpIShifkyoivlPAg7pE9yYtOjWOeFj2C2zmpSz DIf2gpommwTeEbSiesDnN5wW72XhJlXmzDkMIc533UDcuIRIZGXNinWGm8ULi48S4WcIDtafOS5c y0NTP+Rnq2YMNBjevl4mLcXMKzCcAAS7KvKvn0W7j70fFjrJrtNxpsEINuozLUcOF9aAAC5GTESi Z5rw8OGhG3nS9Um0GEAC/RLuVZjpS/NzfhWRi/0VVLAiHELenWiSzQXV4+2Y1Pqh537fJt5jGJvX zfg+OsLrgmqNOtiIgpFPIwIUzgQibnp9BjnhE07YyNzfKWM7ZMKvth2Qwgb6nVTKMIYvbIPixeTc AYDpQt+hWESyARh4YRMp98R6Nhrm+N5BgHt/nAkbcPWjOXykPnQpfce8PHOQnD+p0HF9c5CmcoLJ sdu66thxndc908ZBp9Kl70lVXHSLSfdZjfGdvgB/AXU34QJK5IXfBwZtQ93R1ifnIzZr620PofYU NvaTLyAiwT0LcTCyo+Yta3PdMRAQi4wSDubklT7tLtjjBJe9naiA7bzARr+mK6plcBLyRXBHGfND JENKxcuKKrZtYWCiTy8GK+n42Tc0q0AEzueUHMOEPgP7NfS/nEZmnNM/fSXq27DepjzdQ939tSca l1BhauOu0/Ypdd+tIGmenuxiRqJd94nrKZ/cB4r7CrNi2J32BnchG9uT7DmF7HQDso3IwBEqi+Hc ABjwLRwyxfOVrUVzWt9oY3PJlQP3oo0e0WpgWEcBE49/AmNpsDRtDYlSZ5Gh0MOFwVpSPa7CpQ4b tu3cNAovP/IO6DdZxTduwVaxNsLoA97D2XClrHq9Eh3kQoMF9gN+WocJ/37a3mdFTanPkqPaqNLz EH5ttbADS0Nqvm6o92lyfyR0nlyfKtJOGvzwn4+IPiUn5LxjxJ5RTSnOzOjUyG6eROdWsJBU/vcr VLhg0g08H+fITjr5fWS2kCnGgF2dGVPt74BhUT2d8+arj4pB9Ai0LcrrGpFAvkpkyHRNkg0WBlvA ycF6Vc5cPgFC77ITAcAI9GeqAoCX8hJ+lqgBnAEB4cbM5oceoucGimLnKFc31OBwEG6H+u0Kry/x ZAMKSx4ooDFQ/xxODUMhwSPLryIxROZTQAAPSjCU9qUpQNMgbbDZM0FnAB2SibWuPQVDKkZexyyM y9WRFdxwyH2QGXKOkF/75HqEibkAbyI68x6Uz7wb6nXkxUQrJ45aXOVHVooa+5Nip3HRbsFwN9kI EQndc1QQNVt6rez+BxQQq7qpulOEe08sMhNuipGxnr5xCmFjiAJEzDVmsndzPIMkJAUptJEvQQfN r30cT8BVc1zeU1oB5zNvXnZTOU0JSOgYL/QBTuWi1pjYm7ez42yDHX9aaf4zi0tDcRSeeB5m6dqA IPNfpaztaCFYGHZIQPQrzibYoD2dpTWFMT9qsrayHhcwqIo9Jf/4NCkUNmJn1pWdwINX454V1qJR VGGn4gL36kg/BtOdyo3ItJhTdi/tsoQDklVrEX2CaXW3yEOtwoAiFatL05xjak3xkFIZaQGrIyep vJIrpWz1U/QjvUBozjal8MZI/FJa3LS5se31rvWjlbMTiDnpvfmToLt+++xLwCHPzrJyxwkzOxC1 lucxNFolVhS0rLwZuqeedm5C2XbJvQkqYlDrv+LELJbZmZIuwZfrcAPAzsxh+39wyZ1PQUttRCeW IcAHdeIlr3djgEZHRXzBuEt01L1TokMccNRVa88m9EyCLy+epCTxAIGwJB8mTmSOJqPhiZIkS4Oj V0Mwj7Urjxevpw0s+SL+J5OHojBMV12ako8J5flu4Z+3HL7oIcQjixvqtCLm7Z0JeSOKM0qXWsW1 f2Jv1cf6LbNljZXlviLHNCCLSI1viKGKxEOxgaetOE2KaucqTrp3ONiDYbe2jvV1x87GMthUr8nA fTrRKGCpkyrfjsGWVjnG5yFMoAov35PNZptNsMg8yarQVvdi9HOe+ScyhUAq1J3hp2ZJpITBeN5o t/lmAu2ZH3QrA5cpERb8wEvZRE5poB8gVHB4EhbpIQmI4AAMDlmQYAZpiZm3ibDzpVhzWlsk1sFw rGADw072NHaQqBL2ii7vPjka08PYP8UPsD0OOiAukt6ROD5y5N67awIeXZl3U2UKsjgJYiQeikiU np3jm2hPP3/qN+dwQczdKy/S2LlQYDegpiIiKJ/nInwTu9U0wzUJTWswdVemzkJAHd4l+sNPm201 iyBSSnYdwjLDt0KLeSozjbelI1CwFVJHDJlyGT6xtHo/KFw43qZyV4qm4Kcj2l4w/PTTTqjALR7e iYElMCYdAvYT3CCtgWQ6uxg04OxNZUFLLbGGbb7k526IS2TfeoHsSecdzYjPOqKnFoTGDCCB31If m0753J0fQ8d4GogMyQNRAaiAypIeaeVcvd/IAy5EC8p0iMbhocdQXahR5N8zwcuLdaIyIlshVnZM 7X5Xt1//60v/dqlTXq9YvVG/jsX/o+f1xmpoy/bbj9HMQ1+GHdXjnTW5EEfdYQZhtVOSboZcsmyS qu/7KjzfeUPP7k+xE0HOvEKFdhMI0htq2otTFUaLUXp8c/SkRSk6+Ie6dUNZLaGCV1b9S/OG3KYI AtLsS9vl2vTf3G1BMyGkX1wGawitvSaOq9RPSoXZa5dh7ACPG4HRzYCNfImrMmARm4+z2EBw/aBs SH0ErJ0Vl9NzhY4ThnF3zAORUQwEoCQlzN653pV1cMReiP6wVM2LKJyneT4w/5R2TqxDaFnfX7PF FK0skI/bCahsXlkUHeReNlqHxeR5hBRlK1O8b5oJDVBRDrgqJf9HqodVY2AhFnMScHrBqbkTW7YS uFfZ/piMnXd55XP41G6pC0WSUsOhq9uZMgU9ejialUBE7WhoIsJG59cPipSyDaiCLEuRpd8XQhur Zv9nlBXhxsl4qQ6Cn8fQw9O0AtbdE6WnwnE++Jzpp4tjLXqREHPBZVtgi5LdbAKryCWaoGTwjNBG GizK0QohL8GJTSOfZErKJdp/5v7X9r1RVT4toq+h4kgBgieTiCGL0thKBiq0hmagzaDShklrHw76 I/A04CaMDfSaOfd+J5zMNhq21A6mU3i0ImZGvDVgIuO55esdyU6F5CnflL1m2pTwTzpBWJU+n1LG oqGwWY0STvOKaDru0p21saLEC8I4+uzTdTnfMmnI9tdRGE+YdBxmYHuZXWOE2qlvGSC+3jy0QGTx BEAOljew/GvgitJjC+4Qj+yAoK0x4nCfm3IQOsZfpIwEqvIB59XUqpf4JfQxYOZOsJ9pi1qDfS75 ztFOBFDfJZYKFfMSjOrCwvgsMC3emC+V52uOmnPM2gj3FDBmCORf6VITOSeTv0F7iR6fnjOvtjcS VCKhCF2zftzbLoKDF49OzhqTIuzJBituvB3fGV1mikv6/1rPzt1FVizjJAZ0pHwq4gkcf7Ql9qbO 7rnNOPED+tYB/0jW1YrIKZz98cKYYOEnmYuJ5K0TTrF4Tn6E71PiGrbCKdo+2PvWKgcSnb3Cw4yV F0y89qxb1vZdPlMWbLNGvcf/aTzGhFWkx+01ToAsZcBwmzRnhAVE477sqmlrjAo6fUD+3n8XV+zQ MAFIsUhBtBrqtYgLdfRDh4rQR1wYRVzE3sTeMwW9xoi9hkunNNQU+NhXgWt1crv5pqG8n3fpGV0X MFEsjEtsoxfx98OIA8P/98vsGSFpIJwjWm8Zkn0Qk0NixpcYuT4uUblmc+JN3fdkJHiRQyGTZ0/m /Fsxj+eX4+bOheYlFXexj7yTF7m2fLss1Z9bIH+/IDZc2e2t8E+hwGZnXOegfi6m9hEoyrVHeG/P QRAemUpajSUkwxSbr5YnpQlPke4GkcF9kaXUh/AR+DP3JpbB5lqdE8Zez/8jnLEcfD8ixOQUdC4I 7QMPWJZjZbFOI2O80iblGhgAMqlGCxAsBUDJMl1Ln9VBWWwCO7X1d0eokH3mmFP0xm1uAb03yJzx fZXZTJpLB1WVrVsJR/Bplmo2Ckv8SJJ6pAt4g+llgyiL8hr41u9Q2rXEUCRw+XzdXGtiOQ4gfBtj NzBvvtL4bujJcgMAMaUie23BESeRPjsfglLvl9V6vCuNFDzxhquMD80Su4nXsZlAu9s+4A3zt8Ml wVSH57fBslAjegt5UUsar/w4WMMMAIucTRJN4HrSwOfVV+sX9b0+ntVgcKy9uDeJH2FLXVwKdGbY NtdeNM2zCipQ6baJ7T7pthnSnMUS5zJqwRsTl4cHDlwBis/nXez875vI7YtVXCrj70Okv+ZrYB5U X+ZoyO7WDDmPrp/A9rPtuDJP9MjD6nPzlLwUNsLxDmt9WSS+VCmeUO/s3//RO0bbqhIUazxazrO/ U267/VJLDXhZ3MNeXFReyUpHGnoQWhqUQpGtiI0efvMOPwrOBzVwhqblNa3iA4kMEqIT8EPXfG0F 3WKKU0vGCYzaf0Vi0IN2d1VfgxvqL4gvmwZlMnItaxsLiJiq3m9+kOy26MxxbbSG/vBdOrP0H8ns lE/1BUrqXTd5zG+NEOFYz/wjx9430amEoeoHg9SKTrJQCjsflPMrwS22a/ipeVwugyqNnkwpKZZ/ ja7wT5UbXsRej0MEXEYCpCuHe3G84yRaNv2MbtW3IawOjkOAVWSiXfoytaX8sGaxaDsuDLvvwV8q WC2leetJemTOZzuaGuJdAoU4mokhcx26ZkiUO+gaKQ8idtQPoDzL0B+sYim6MKkfzN0v5GCx+iFl dQ4xJVt5wQqy1MZsyFZpZbi1lqy29RXOm9iPWIFo5y04Gij7MK6lhVK2m2IymVuJZ4k4S96sFn+O PyvNIgqTr28zp7de/g79JVzfUOegpHCs2La6cqe9z4WSf5WzeBqxc+W3C7sZrTpd491/f+PvleZv jL1G3C8EfxQ0YMfZNGPlgefnWBdfJ+W152qi6jIOocI0ZSNdrCVdz6WKVFON8xoftQZd8HXdrHlT F7H+pAx5MJvQHRWp4dbWK7xfLQICzTBK3w0pC5JbgJjf1bqbsRNYteqyQ3+m9/u2zITru0uhtjLF FE2dDKoYD9zzVwqXAJWsx9JHxb+fbHUqO8lK87ZkYcm8rMd5vFgU5mCxSfi8KIfpIvzXMWkNH+5E pW5HnmL+Xo5S5d9AUcD6XwRKLl2WcFIyQCHzLSQHYDK43E2BGmM4428AiYouYkeFM5xhK72o2rbS V3mV4JSABHWlx0XbCWHvcPJrZqVHYk/t2KAK0y+0Vwhh/vv8Dm+zPfmAQ86cYDMP2LqMSa7YjQ4M /Y56QoAC6fefcidtUOKxOuiH7C1pQVXcNIJxiKRQ6mCqbxwB9zMOrvBCscN1onN8ELOOUHB59M0/ JAlrbZzU2EQ36zRJ1PibOQ1q2OrmOhY2FxDpZeu3OoKMIhcuTFX3Mmp6blV06wDFg2InovFnHO+K F61ga4/3RX6dUHHWbzJpWWiDzgdckT4rQQHDEoxdyFKvvxePDdDCLLR9vUQbRtV6cgJZmQUn35co uUEZA5t/1+rWulbceMc3cXz98SvEIgBmX3hwFaINs1ZdBHCQd9+rl6lKA8TZbeBlnO1Mi7WicBnu HqvcWTFfwMWwzRCoBsQyPjBudIniMbDLSr5C8FvJNGUV09WUTAdwmuXXcpUG+yrz8AD2RllZIIwJ 0ZA+KuLxS8qwtsjyYlOx+yNh8W8JoLe55Dmp9ksDxpEUI42OouH4+l68t5lYtP4khKt6HDC48boU tMvO/BoU0a0QcFeGvcoO5/dnFk3XAd7CRrf6jQ9x/qczSC6Y4h/NqNH5k20fx3cOoRrVx/3fkNhM wcCiwWPdk5ByEWvM1aMmXp4oX7OgkolKcQmE2BF3uOGRt1HddkS4YuxMjyhoKjQquwYZXmeI/2ty 0EMCaUHRNz5ZI+HlzQUtBFPbOEchSGutMMpqKes7a45fr6TvQXxcbhw9kRintR026uIXEnbplNZd yTVlQoKhVtjyvKcadKgjJRaWwp+Eto160a7qSHvpTnwYQP1OSJ+SoPX1HonI77b3WxEunmUlAQ1a GWMaYHLwFJnXs7KJ1aV6DV3VuvVn9Qj13v+qhZlaezyeDr8a6nf8BNo2e/BkuqDZihvZDuCei/zE 7tzL31Xg7vzcmcceWp4KM0HMW4mCNik2rti5odpumyJCbdy4kgdoRoZzrBWUCm+EfrQEemU/kAJf v847SP4aCTqAlRUXmXjxqTJPlqll5sG3MiZQxcHnNg/Vao0k3VaD2CoHz2Ys2+mBJIqD002xglSr CuvWGm4LAAnUkN8i+riHwvA0Lr4cr3ViKNuyo53iUeD61pR5B5dv9Dh93j4y10rbZVWOtGv7YpFY IxY0iabH5wgjb8c9pDjA08qlv6vFwL4unBdNMeCKFJyWdDvtvd/t5vcAPkJhLFYe8RTapBLn6fIg 8ODW9bT1iOSU1J//v+od4i3TP3nKILoQkfe9LAabPyFguWqe898tLLaJ2/XheQfSsha8pbLOFjLE XamYvNwsTP/KcFxNqEkHX16pYMN0aPULRkn7iRuhDAOQuHXqJMCtLa80rR3Q1XUz4Y7iKF+cQrcO VxqIInOdYf5+CNS+Ml8T2N29IAW8bCCLGcwRpcrJ/QhnxfgYMJGp427Qfm8h1V0/sqmeFRw3ZxSU xznLtLZ9xm6TVVz5Y/Hf/WU3713elAa7eWgnNpCo5Gq1F8eGmP0aYqESCudCMGfgMV1veeHLX3WL kNkIuhXa5zoCDBXRUFv6HBnt2PzLogju6mmr8uPoZhHq/7NE0bplrm9l+9PArwW2TmegVyDfzc1Q E/bgGM9tJr0lQoGuWbAS4wB2fH1I2uPmsmzPP51PvP5vH70pEdImZ5rvlN28dZuoUKOxsPhhShWj yNaVcd9dRo/4spykwNvktKnUFdbRl63/ISR3dJxBKUo8V+ucjI0tbg+5ZAvWHAVZPYL4M48r2FDL kg04SgEq9w1NLkIPwbX7iq7N9Lu/dHLAbF8PcvXf+m9SB7jN7hz7nK5CYlXWMPXlgNX+lxrys5Qq KhHpNDL48w1uENW04YBTavsTqSCuYaAe9f5WtoPbaMKUQlf0Z/l7WshM3sTYXA++XSbSi/DtoV5p mMsUcLKVft3v68fvOFYOi4oixHC0XGqaafdpYqFXkIh/KOL5mPeNiCZaXd97aiGu8JDl+r4DDf3S OUvT4UHnxwurBmPtpbMzl4e+pWbTKODftLwJEkAbdj9bqIcgEdFKyRVQ3z+nUrWPwR/2DdcDqCWa 0UCoi/Zqixjm6tQa5Vqrvpy7rWYUpnohne+UZYPtFYy2C6BNcBaUjbV+pxM9KJ1m0NrTZ7GolfVm DRvg71AG4j/fvkkrL/+eNbJP9J8zd9R/32Iq/iQZXttRCy0wS65Nr9wfLL/uhS0ijqDkgmLpgWUw tZWV/kDkuecU13Xya2DwgAwMRmHFSOiSOKuUGlmgtbQ6aER/AdJrp9AWSpJJAnhnjAYdvDcpIC0v pE0wfRroJrpfqv1H7Za+8ujbxA7GFoT9n8SgrxVd9Wtp7F7W8ktZw+WGSnNoAsyZPSUowTamdFf8 rjare6xsZpSJiXT5Oz/3kOVfZhlEwQh73NTgbW7KI/bz1jDFcQ/nKagzymKjgw7CxYIKrwlg1oT9 FXp6hHHcS/1iynHpOpS+WjXRo5bMS+L3aQh3G3SYf7kwYqOeXXzTyDVmhKdvPCLV5naPJBJz17i8 siyPSqsqrCG6TlXJ1AXUlrl/l8Pa/mhLzbnr8u4OISRij6/LTmNczHoBnNJZOkWlHTQMoOuzyOJ+ ng4Z+foPUHOKhheYzaHUeXUmhfyy6nN0rGMkMbrBnoz87Nap2jbKYLgPKucxHdCURvewggVYVnxM eozN0cGRwPWDmkbzVPc+u0JuJgxLJ3QK8X4Etfb5NDnDwhUTb90VI0JB5LTs3uR4tq9djqyPGPdH c0wPHdryZo0iFpSuXjx9fz/tXO/3TTnKaOf648IsYmDkYEtUaIko0mTJZ0v7XZO66iW7Atxa7Mgk GllwR0dBNQqRLMnEmnhuNRL5pO3ks0pf6fK7pSCSlJJ/H2PX/NXnuiOwxltcJevpOVqH/n76BT/6 1AHHLrkxmIuMTenHdixqi1FM1UU1hU/d3tXMwf8s00A2Ld4TkpP7UQTQ2dIKkH7uo8O+8ALDpjKa ZDyvBEWtsfsRwEohfib/cepg3aLkGZkBYqgaefFuXUcdTZE/Ih/W4tlMR6+SiyG1td+U4Zlb337d ioCCG3+oOIKxO1GTDvr9nQAgO8I7zTEWyTU04WhN+tRBWhuFZ/iwH9oSZDhZ8Is2yG+ZBLt+EuaW Yo+stlJ+/AESUCQI+DGBRrWMVuc2xLkMudLgf/8F5UnNDfpx7/NE23a7JIMZwf43g6/MTM0OnUi9 SibA4p+WYd2hrdmFnLlExehtbXvmVNPeTUO9pGYQ02ue8+UclNO9fBWdbuHvRaEpqnf1v/zq8mHB uJGri/Iot3hBna+vphJJY1P1EwLIE3joJQDNchq6Vh8Lnk/GCrVAco9RHR//32xgkTb2hnr5TnJo 0eHeQgD6fI3YTGTy7sans9AQrLNhVDjmVXaGy14hltmQtZiZmU4iXXMHaq5ZM8VrIiYYq8wmuaQ2 PVo7ndgKNbZLczBahnD4T8jskNg4kX1TVEsT0dK4OgUD10Q6mpNUQFMwm2jyzdDC3fFcdlG3Mi7E clT21hQywDYPb27WPx01nu8jkjE+lweFDQSYfQEMAHkAfQOfZw3JZ7J4X0cc2XfmzPfCqYv2L9ak s3gc0mdvJCXjvtBoI3aPYIDCRmANTQoE38Z4IJjo894Bn8a+GI1QYxEs9yoAFIRTvi1PArsrqPzC ERhJF/I6iU7GvqxxVcwrX6+1BuRRbM9zRkyMGwzcuvzJzqMYqLdFiUEOVbfmgic9XoUzFW535g23 x0ro1I83Ah5VWX+Hktr0L8eZdrcV4OItOJIZ32iKQmcaEsa4IuiggDHbJsQmP8w42l1SHs2zkZbM C/NgoPdiASPxlUy/70PoXIicWyObO1+W7zaHQNJ7O3ohAllWWY8Wv3IfK7SzERsosLSAnAHf+WBF bcFKbLIbkOAwJ2RPGkcqfx7kU7kcVnTXNaIn5g7OjEZdshOSWcHE3j+OkMuQbkT0g/DoyEISxjLq 58xDlFVeCtRihCOQx/il+tK4gIMPBkPbLGHqgJbtSfCWIz/aFqIetH5U/7gTg4Uiq5oPOi14+skr LA+U3cCwZZHAsjLIYu0gegpiwp22DZi+0rbp01QxKSAip+gm/sONGZEuP9OrK5sMrpymqu/ZvUCV cuSmP8HE06/lU+xIAIuxNxpo0nWUo9Sj4MoPSpJSqcY/HiXi3BQxdngE+Ik5IEiOGzkuhwk3vsoc KJFuTAcZlJTYqjG8tnJ3FNwXkBLw1M9Iu6AZ+RxNFkhcnGJovkEmVdJj5ME+1cvyNGZpNHiHQUSw XjnMmVoHh2x5XUM2gBaTnAnf1QFFytOvwmzEE9wxu+YeEwkBOkbwJl0cnMm4W0hPi09ZoVlmWruS xn3thrP+gSJQsaJdhGGYy6zVU5K3LBU7anpDOX5YzdIRfQrgcrW6zahdOwSHYEM+IN8OgujmLzgN v9zZUTP/3isRSUm9grF7lue03KJRsipcjKiRjnkda9LEeqCHLjL5P6V2LwaXlk3+382xbds1PtWd XMIdosw/y6ENuO99IeZpx+71CxQwEEcYPfez93P2pULBqNoTKM0YLOUl+K8oYLZBINhWjUvDwj8g nw6KZaKG7KSZykMrHUZGA5adZ9a0fiO5IditF6pFePPLk0CpOb0dG5XRy5KX3z+Bz6Le4NxEnpwi jRjY3F+Ncgug+Np+Bpm7Sui/s+zqB/q3EJ/QKqXh30N9B07mpZe4oYTyV91Qf7oLCsVLLAv2+mfu K3Qwl5cc/aQG1lx/ng/nyod0JY7uiky+2MXeVN5PHbsqMobp9IRoqD+6DiWNrmHSSeIB4UNYD41j PY385/6tavwORarz0DM6a84njj/wiBsXiGYGhKTccHW5NRqgLz3kwux/mOtM91bIOBdOW4VlL7Th w54ZlQGQvs/lCvdemsJELroQn20cW4HNEJNp7XMeCPu77BbkZLc0tm5ENGvjwKUg3LDOVtjdRiYq y/8TQSuaf4X+Xl6P4Qqz26KvPKtggRPDAoWRl3CKEO2rjej0hnB94wX9AX/aLc+oAvY1K5Y4pO81 u8W9tjByG6o5TAuqPsbM5cHC6vMc1fs+/tMRHw21buh4WbrvRsFVTvWZDhFjf9D4zlaAj/FSL/BM 8c4w+wVF8YuVQHU2pbB9RPIKa17kGCNWl2QT7XmwHBIiQ8MZPS+VySlvXkUxp3eRsii1pgzRg597 kV0/6YUe8NlGKWT1H9+qXL+yudXjS2cIxtff9nbBxJ9HH4DqgM6ZA/QzB2ZQTdPB+R1MqwBGELz7 ZDuxvB95J3iNYxhBNihqiUK2haxr29yD/oKY3zw3zlSt2vm6oFtaox2coDkRWeWjnBd6Nr3u2Kls 8nrcjjWeYN/WUviK1BQSp7FV0ntYC4ZucyhV8U+B6llAmwRjoxwI5fQZy/sbVE2+hhssqvM8mqJ9 QTkkv7iNk2uhwxAjIVSjtPRNZxveQJ0kN6dAlxYiBJNpPTo76tDEsVjw8T/sMx1q+vz1NBtD8c0X cc0nTLM0KhIqRgEI7b9L4UqKOAb/6ViKmqfhC9RI7OMahR4NfTLXmUCPNWp+kLcqg4TN0hy5cEKM DfEgLYJU5bBzQp8l0CtKqT62ZJg9JtQtREKdA10tV/ppc4oQ+aVVsGuXeyG1wjEBJuTqN4jYn9X8 +GipaCGBWXDuouzaGDWXPlEPsjZbuWcKl9OiqgdnZFUdOr2x1DtnJjQlH/jCC71iEUy/xyc4OyUx xUgi8yspQ/fgRMP81P6N+ppHKy9GJHbN8J5yCzEtZWMJAasWmJC81yDKzxqfL2Pp4scrEXekAEEh ZYiMNeozkomn6FXD5PtRF7QomtktFxYnIfBZgSrJMBn2P+Iul2xlEjuGuSYN0cQjMMwd7QBCuIMt SmFfUpJs6jUTu7tsyezvmrGCLOSbHjVkpOeZ66bPBMGAP4A9BKF9CcQHP/9HxgPhU48qZlqhOGDm GB/57Mp0rodlUz5MaWci4/l+z8A+p45l0amaNzT6lOGeNAjfNF13JJUQBGlcO2L79mCYcWmEi1th OaQF9LwtYiAmgyCVTwaGK2n531f9ftfIYrNTe1tk8Ip1tQPd0CsLD7OvHuA0aDChs7XRfQj8h8MC xv5IOI3xHh4usb9I08i2+jQdzTRpL67Jpwwd8z2XWULEmYqaSKKDVfyRFBM63kx2YBtvngs/LQ+e rp9x3KZHYVNIP6e1J524BwFW1QAqcZ1KSn3OGSlTLaKYsKeJMSfdL23MuaR6T6VNAyy19lOEz2TU 83Zuz/YcECWPthS9m9CAHGht73TunpYjTwhNjTF8voJIATObdNMg2B7IQRyRYYkFfBJUKkp3uYY4 Qc4l/WegmrN2WqPhXSfXdxCV0S7eqfwsfzIpEWZcD1eWWVPdK34c4C5D4XeLlcLkjsPYrbO6o87c qGlhrcD0lZUro+6W28VK9YR0k+Ad6OEBWI0PJSz0hp3GidUfn2kTvMfmhSbfVOTFwQRdgW59LL04 bs04MBPsBXWIh9RnrOnM4uG2zQXEOA6ht9za15orJhAvh5aKnQt+m9jhxTTTvDoMX3giO1hFKPYl Ei5beYl+4iM+GmxZq3VgPolzYxfHeq+l+jV2sLN6BHsi6faaeDb24U79XBbC1oYfD+2PVoqC5zNz rzwNW/XpzkPYzuwwpkwBZ8uJtSFNDV0ZzUGTpD1OwVMj7WdEXoO/+bKEfiFlCnhAdIoxwU9MasrB yxFbAqZg4uWa8+HQkMtSlSre6rBjhJLUsBzc6+ZeI2tciEWN5jWJyhpjb7OpqKTsefNvsAiK/7ts XnK5gKvR1RHZiLjcK7Zxa0V2FSXAb4Ko5hEgkcsIkW+KootvkHzEz4246s9W/swFi9q7qWqBfBvN Ubh3G77KArvZlb4d3+OwQgdQkWca9f0uYUhHgVs4AT09/fPuajUOg6Xb0odh8VnL5kRAv+yalbe7 I144bKsRfMgn5FCgYOxQm27sFWXhZntMlpHIOAkloNoVSuw7K5XqL/uB3DvYuiMNsHOZx0ABurn7 EuUWs3SlHhJ/zMg2uP68e/GG25pVJ4OfmRB69IwEt31RbBQRjFTQfzK88YdzbhAPi5uqRkMou9qM v/4xQNkF3Ct+ejzLZJX8blgzieLgWnEqTBLr5Rb3Zfb2XyHGKPlUr/ksys2a56JLjctlxaWexwvC 3QU9t4mdE7oX4GNa5diwbkEXftr2Y/sJSXKadJimk6bieZAJyyfoPHhMDv+UWVdQoelW2/iYEeJC fd7RYTxE9j1kJ1ouUaquYNXK6Ar2qSTA1ieT5GoZk6LPgR6FQiww3Ljn49zqL8/piM/pzLLCikCo 1qkB+fXAwQkZSNghNbNLHY0xzwCtBarG6XlqUX03Pmhu4ofZIGRYWzETwcoQATThjy/7MD0fmE4g vDFNHn5sMAtbN8fNd/DNXSkQ7BSi3hYXOXXmmo1Fov8ZM1V9SyWFd8OFqDR3GmoDcr9oFB0BiKaE 0KPTJBJ18qWIhkRHaO/L+GpAe+vqxQWqYXuzpjPPDAAPcTIkI+2kOu3taUn+JeysIZZAz4cwTZph ua3IIn7UiV/sm0zW0qMzwypqkVXmRKUWGXZHfhm7XS+sG2/xCXLCQrGdrMjWVaxJXXhjxDMc73nW XbSmaYO/TWGgfYs1DuXqJkHDMYGoeYkYF3PZIFPXZfFAi2WWE6R/Hxuv6BCGv2MBdio4PPU1K0yW qNy/I4MmeyCCrJbzC37itCHaOUjVeMG3FY7McOp40R5GrHy7zgHhpPewaWTkFJOFWp9l7bouwhKG uqjVjVaDaKilcDwVM1aoejt+ThoivespsNI8gAmYXaCl9pk14zZpIv2Eoduh2pK/FfV/EhpooZ58 qQ2R1mmoUE13RX46G8ekF/F4fSOLVEmYHfxt15yUm/6lLDPP/5mtp3123WcMdvtowWeQ3Id0hEK5 o6Y5Y/V4S1/I4+r8FvN6FfMcApi1uw5swiZqOYEp1Ko4cxyhg7G8djOtxCzLVlJk7LU2tQwo4jQJ 5mILnBnP6oLxYLkn3ChIwBc2K2H8C7ftWnuH9WzdBkaedhL0gatj/yZxQdvN8lQkUuNCSBt0G+ZA JG2RnJahREa6mh/HQ3i5L998vsunnb+HchzrzzbxZEuCfzjhmcnAjwyEdlXQtH4YdmClQXC/4uUW db3Lje86NfOxSOVdtne0K7wQ9BCsYGS9O1K6rRMtTG23Xtm+/ujTBQRZ2cmfKd/YT+cW+Y0QSVQr Vo1h4RaJwep5JGqRK6BYGiVpVjbNeSw/Lq045cJ3yokOnwOpU8ZlpOxhYSTetKM6P/MjAJlUzfOy 0dzeCwFjvcE70NDvLVzqDx/gmya2spOF/1hoxuYRl9aiwJKExVPiIU3AXpwfnCXbKiY0Et9capGy 5qS3AU8TxxaA4TJsIYNwHuDNATWUOuetVTtjQQq2Xt9WNgF7FJHvxVf3efa7I5sosNC3W09q1obA MBp0DbedpYEsbJNyAluauPNfr7gzptIRnAlZ/JDLYWzpXMR2M53CF17JIYmzupW8WyXfNr0g1hZT HQ9Kj2UFqwnWzgfrsoMfoGnRPtc6qfFNxWi5US6/o5E6Fjj8X0naZipgjuT7Qf7HAitq7bUsu6GE KdJTNd+eji07pbC2VNu6DGjOP+ri2RwzGL1sNxlKEOrYtcUpHXivmgKtAjcZJe6acxGSk2WHNLX6 hG8XUIQXIyGf0Ik7mSbTTHxQ8NP10oH4Zz+XwuRIxxySwWZuacQFPXmtX/mZ2cEq2c7U99FHu4/B tvs07Hs41+FRFPkZMZvqVbg+jWu2ZVastHGITfc1aW4/goNiWZudxo2SQf+xv33WsRx+JKlUoUKN lPtU6DEsJ906lRVchGFyyoN3f7Xz7ccQWYSehRw5tAmHKFwfgEN5ZF775IO1HR+EMaFyFXqerWzg YDpBceR1w35fHikXzdJAWk3pQvXDyRMlOhV7iI6kd+5h++E78kLu9PRu/Z7VXNn5rkUON2eP6l7E iW1rH+CmYzXWn0/XlC5frLcXBE2ZFBtOdsM1Aouq9dx+A3psDinjcnGe6u9GdfHbIpl1pc6SMirP 46Jt98P/qSAy0OYPTX9I4rr5nu3WCNQsQfg5xP+QG8AXbY1obsYGobYqmkIaNKneozWXlTAKQPeA vSm8oWNnB012eml3iHueeXRQc993LYNONSt6ETA2RMhNBYgdhGvQ+3xVp2d0ZmLoA/gK0OJbmiw7 fBthwQzZr50SvhGZt+iqSELg6sxQ12hKqj8/FoFb9sd8oTZM/N7AoaUCNtuqaXm4GL+atUzminO4 uNDnagRUKOMKOYEBPGphmR2MHKxluNu+LpfGtQZ+oicBRpOj62yNyfGV9QGdlSxfQcNi1xIIBsnR RuPjGaedfXucTCodGmvfyC3SgCVRiC/T26IA9Xvl6FA8cyLgyzeo8+j61tapf2IUIVkG4qv2G2ru 8fdn28b5Y+ogpGAaFvullcY57S9S7jVN791Fj/1xxWhNyZbD4ik6bwhG1psURJl4kF3JWM4ylLBH Ue0he20Tu92xPYlEMj6qWr5mSl0lMLr5oiPLmVnFyeF94ikgaehDNbRJsXbuYww2dS2BdC87eMnx EXgo4PR1fQ1D/zkF/CTmlplU64Wl2x1p6Pmid+vkhNGW0W4HzWLwmjRW3K7WFqZ0mu+m0GyrdwOG 2pVYuw0IB9U3n770aqiaYNpKUUFWDpyvYmSVsgWJXmseLu4b9q/qfyAmMW6wQ6zhBjOixQMofddi e8EScvYTRm73yZW82t4GJJ8ezIM8p+LbnzIF1+/X19aPnDKtegbBlHAKHi/Qj05YtDbiW6QBDh0K jgSQr4DGeMMocFGuUEKTAVWFFJ4cMyvZpC+DA3R8d2uEKUF3qRQIwEvCPs3w1Np8l1I42Mc7xjko df5uXKnkvULcDQHSoCMCMuzQBjfADfS4eGFJUSPaWRKFXmCA+nphHer2UwWz3/aOgJKdOw7XKx8e h4fBOh6rKTWnyQUOvQ0zpu3V0DKSnQwHEuc47DVXt1Vnk46wzAvjyewT+PYgqvcOvg5GazfELyPX 6pmE5cJu7kceAzi6OpW5M1bwuIB1x2iBHBj0Sj8/L3V6xrOslO8LLBPkp+0uv73YTVcmZU0jHR+3 wa/qcH4n8hD6meVZ2NEFVu9EzMUlj4MeZiQoVChhUqEWCgeSDstdipRPPaBhqkKHyImOMvIx2JZB AnVkhf+oc5U7OaNRv3shnQxTRISN4OwKyYwjXwKvZEBcdAXAykoHkRt5DfS262mwvD2dW9tZ0thg GZtVLEJ9/ZlsvCJMvMfuzkqAdvi4trgTdYyr5jfVWabgN8lcuj6E+sJfqGx2/w8MT7Ux/RMgtfZa UGuzuDvqslsN3BUJAvSlRM4M7ywwZgywGBaXpS16BZOxNXl66h2uzqSkzFhWEBDJPTJzAOAG6vj2 BrSNd7jzrVatNPNdtILHErAwX3lwWM2MhB5aLNMLhgsane06MYeHOmTdfFCoRGVq0ZaxIAC8ThSx tj4RtvpwtgT/mcKQuom1PRC5ydr+AL3+LM2yTiGzu+KNBvNSNhM3OGzC9IfULVe+GjvaDOzqyv9k lcP9AEQe5whDnbmqxZJAwjDwYdsTTgaEfShmANKHFrvEuGsYtKmW+rXlk3ipPrw5nTcH4qAgmId8 tDVhIGwjP4UBodvTe0i7Xqfb6l4HodwL8QwTgRrRyTe9wHlCUIbFpgfmQDvsGN+rnp0oDYAxoZZA /qsMz2OysU2S/0H/HiJlDtIb6jFAk4We8Bkot7iWOcJgIWs9c/qu2f0q652+aZYllmiiaabfCcfh 6WpePBd5lKGT/1LB2jquKu3pBLMyabcHTz1+YLM3DaCiLA5+hdf7uCQhfTfT+lqUYPyoyd0LLl00 EcpuzMQrP9QJ3fcoNhTy8aIcqP///afHg91lRHWlilPZ/IDI9414QPvCVBdLJJI/nIBjQz/pcDFq gzMNjQgmll/tvmkXRaDI29rcAFWmlnyka7j+hV5ysB0pUcs2RDIasVBG/4hUbbLGNirfcXWTxot+ yy11ebDE06OI73BlW7Ztut5t74pTdI8LZHF9OSq2QqHzvl/bRc7Nrij317ksly6+oiDjFNJ9BBEi /hsjUfW4S9xyCn2qCjcdi1enkN50UgF4hzgbDZps2vzMUzoVhC4hNbLIW0Y/3PyhkWuFRMmwLXzx rphmTbm5nEqIhxHwL5NUkTLbiJjMCuWKtmgMLDWoTbdqZwUptopVcCt8p5vBQge7N5ft1o6NyLYw m9+nYDZM81OiPhi4VPybL6eKaeqrSYNQTqlczqEkt7lRhmYraNGZucP/9urOQxrQlwkiEsQKAGTR tBCgk+EzB1gacfozcWi8f//2f8Lwp+O2LYFRQuEGMhL2Zj1svvEAwLtwazgV8B2QUJbFcekKbv1A EOJInvlcUTMWhzx8lLoGJyQjOo5Isg/KKn83S0CEHJ/jiLp/hABMbfcAVXQmGdNiCdy7HiajpDNm H9NCsmKyq6UFq/0lwxRo2joVxNhEt1Ct+4TRoXlbNKtn7WbYbwTwDGnYXiyS1/0jWye9Jv9WpiLj WDSBO+198RB2eb0Ivpr34dpXKcgHEjsc8SFUd73jTKgOVdR85c/f1XlzV37RjCKNj9DgOPV2Tp7R VaE9lYO68CT4uHendDCU7olNJzYOtf5S4dxDF48MlGB3fzs4yU39tYr1MO0j4G9ZDi3HcCWjEdNb mkgloPa3LCkdWb/82sZeylTph8FrPBmB6MFAw0Ig8/XXCWfS79Q3JgilpOO/+HzJKN/v8M5D9JDk 97aeW4a8YqmTIJdaiBUm+UGn7z/il9FlXBPqrPLSf0kGoAX3uoey0cN29etpbDPxwo8QUmEalZbr lqSFpLm4jq4InxsVTPYsKQXBX9C9MRC5V2ckdwrvHfX1/aIEbjBL/q+WZF/KHRpL2D2gVrqL41Dv 3gMdvm/V52AN6CRFUn4o0ZrH6DCfXvDUmaMMmFDHJjVg9HHHEv1Sj4YGm9KkiUTa0VGp6QnLPgEm luEBXsxJJH1A4czOU6KHY/xGH4tXKOPFCkKOxH61k/6XceIAsQ5kVK92FxAbyLiiiOXIj/448DTe iziQN8He2Hj3QpwuzaUXl1mYALKyMz1fdXBDhlm97NlO7pr+XgH2mqt39Eyfgk7JzsYbZsmqZraK /Qi92KpJfHAD//qpQ6sDnDJR9wo2vZQShqCp4XQAO3URpqOk6as8puFLmCK6wcLzr0v7WXgvqmjJ X0FPq/NCAnq/msosAi8IAMbN44I7xc22HipsKrJYv+qcFAc6lBzL5XizQMsbr1qtg4e0kQN4M0Gw n4fgSU2eMA3Jzv0ZQGNSb+djST042dJtDPYqw+vtfDGekO1OkXLQcDf/nCkyXmpH7N7K+mkJ8MJV YqpUWykk1DHIKtnGf9OyHEe7d4O7S8bP91oPqwOFpqrZSrUjddUmhSALPWmjm9L6xVHY7sDbuGM4 z/5LTeTVnUaMiYla//9q+jxYP6vU+HcWRDm3bf6wUeJRJkRyKxcZwkJ9Z5rVEY5C8Om3LehBhDMU gOiRTbTEyE6Yh35TT9H8i1B3QZZy4Q1et2uZwhlAPORI+SHVv9WHYl9lhC9YmdfuPyI55i3OsKuE g3OdishekE3mdup/vjGMaweum5Wq/0WXFj6PrpRvCcRfrUnWIhtpk05KUCbUm+ctCEi4guudKEIY 2StO5xRGFHdB/b5Rw1ij+0qFckQmMBvIggRLyBVggLRPG0Cf8NkW81xC9WpwVqVo7GV2g+ueQbjw 3KQ+35M4ECaknUTvBMwkn4EDrPInbm3eR8S8au3CXRahkHLDVj/9UpnaGwLkN3cwAGyx6il2isEj 7SIrfzckJ0drXRSR/I+v+sdi1IuvGfWzd2hCFtsmPuXKHWaaf6xsnDTahQ91ONGVbrv+5f6G9+fV k848Nq8HahxFZztjRXXrdJb+NSCJzDV2h3bPzCDpdyEU7KtNPznJUkPv8CRA206gJhzshuVe6vQI nB/kUPycBy1BBFvH5uL4DvSFUE0E20eFSdQw5lS6iNiZoWfCr3ZRT2h3DngJbJRyeZP/NXpIpU03 xLaeHnigFmKwnVpaarPhRsJgcXkyuy5dnKJY6r8Zzfz93ymBtVR4B8kv7TWgFV8WR0NDlmLbjil1 B7yXSAJq7G5tS3U2G8mEMPfqx94dNZNuFPXMg0d9wbgVVIpEAp7A37O0r84b1YVGZUzroO0mDQ54 Y2U+tUCyxZY9zAdl5vY67fMEGTtlKoGCkBWkOapZOsPv6JSomEdDsUq1wi0qSF2FZhoC6d1d0DjS +B0uS0Yr7gg2Bmy/WhPCLAXb2xZBo5K5lvRx6iUTxrphUSxkOI3ktlww/E3xnDF2CQdU2SRkmJ92 yk9TjfDcplYAsw8c3fYHjTrl1mfo8cycUHq/PaIbUUWbenfabD36PdG9hEao3gVmXSqroMvQU9A+ FitqNfhd64thZPrBfTb1w5muZaHDb3mp5S+5r9NyYv6TT1nWanVTv1Xpt/dCiyNzQNBDKoSh3Whp UDpFF6CbfsjiRCtIVTVqtvKY49QwaIc4S0N2EpfPQ7CYL6ePfPUM7GXzhzzN3vBIdA6cXe+Yw1It u+yeV2KPr0l4fHHyNo52f8l6R4zTQ8xqO1dP+oYoG8tDVQ5/OWgVkqbib7eHlSB/ERaewZu1PCRm RtIO3SZltOrbubRocbTic7r0mClycxVBAhj4UO7TdcVj1u9yXaq4hHZwQRqte/15pBXZZDlXIJR6 xfxCux+E/taYNxMhfv+eXnQlbQBHuC9qPjH3FCzp2w0Ovu+GVgpggovMJXxgWVlPbgPiVQ+jq4ch Zk/q6nShm4vT/RZws4NlfS1OwRkKoIpk2g8oSYwcZySY4aPhyOEUnCcDaIJpCxnao4dgC7dQStQ+ IYMYWKdH3KAz2B9+LJt4a72jbBDkuLw8ulfcynBFJYyDIw7nMqkkoBwEPhuhC5iNeYqHiyY1I+M7 MScwBhmTn3f3rkRVHFk7PNTckNIrbOBjypY9zhdH6U7avzGgP7rcstUrvR15mZXOBMR+WZkrpKUK /IFMy+Jhtq5U7M35oJJlOyPnputOV3E93EEtCgjw8h+3DxMKzudKD7U/+Ps2QCbJXwSNJJbPQB/1 533sRcxQZxKg8AhfSeXzG7+2AaPoFV7rsFzn+tE1kjBIsL9EQIWDQ8MaFpD5QWfNIDqXo4QYBHiW 9g7pBB8ymDC6RMb4G/nJxEsLlZORdOhi6kJQElLg8/75VPbhVIR3ju+ougluGdVCFkcmz15J0JC9 YiIZhsALzHYrY6zzWwsp/EL/j/b1oZhFe3RQa8LzVBStWmdcnC9bB+A7zw352vpV+/+Xo312Ub0r UsEgNn36bxsMCdeJWwMThskW4pMyHKcgOyiDlXXXQWsgjPDwAiIDN+t6wHHPNsfYwBpek/rK97gB 7qQolMjcYAzO/X30Ys5wjLxp4WsxgH/yv4kF4I3ZSP3jIVr7l6xio73Peg5c1vUBur9J6PGxojXR 6GFPmFPFMl6uc0c7K8dSs/CQw+yk/JSv9jpNGQb+S8/cfpSwWIN0ov9bkfSVDPxl4RGTTeD1fOQI L+O95Fo20tjz6dkp7gYvC5+eGOZ0sUfPEFlDd/+9Oz4+K4Lf5qV+9Xk6mT3TFEogtjsdcxR1hEp3 UYtYRPfMjfaP5taLyXPkWc0FxQ16m6fYX1dmQH3RSNAzzkp3TEomRLDkyTSt60ZUalPIox/sar0g Bshgt21pR/OZ8B0XeE8YbXcUUP5RdRl5NN6W8sbAA9mA9Y9F4qjfIUJJ0UMiS/2w3kp4Z4U8oE54 DsHcRBhXJkvMacwLjGX2QXjSQJmgIlgxjehzl5eJFfmLJlbrdS457XDwc/e9K8gv/A6nSyOFNz84 GfE34t/jxMAo5Ke2R3ToxHSlpqA6Vz3utuS5KG0+xy2YRrhDPLiKBFEmN2BtTbdH+qyPneKldVMN 5OxkorEeJE7Vjp+McZbGY3sGIb865VOOUS1FhujwFcvLxS2lBxwHjUC7LkTITAWTiSw2z1CAKnCt vizLXbnYr1L0/1/EJvCws15etUlKHOkOAj9rq2+63FnuxOKNF0oV36m27yWccT8sicJRa3SVcwV6 fot+5RBzjGT0gGBYmiyhcQoarGKbGndD/K+/lvgpKpNAcaR6Nl0bv3xiSdjLm/AamsqI/n04OCh8 E+lip1EXxaPdt0bvGZ32hqCHHRXanMqvNtn3hnjheiyIZZ07yutG3u59KpsaE4BcNxOYCz7v9+tk JH48y1CHFHCoZroUdHib1noUlT+tmMYsZ6r/yt89UAKPUhVTzZ6/ZikPrzIpRIZNZC7db/3PZHbY PWjXtQ6pKZIuaOtBOD/Re0+hy0/+00DVd1o44Rwgr/SClnJYLlyXEWzvRT39K3Do6NywprRA6fUn wIyBFQyUkRT/ISqycbf4JQYNQpVdpmt2LteaYj0zJ1zkhQStJq7FZUoZkSVbFFuVDGd7WLH/58pj G/XGwsfsSDbxccKOL2XwaGCNbo0z8MvmM+y/f688DRglFlIifzjnqjqOqxw02QtkHT3pgP6G94Q4 8Dbnu2zTqHYqVEKWqxoWPB7yliqrfcyoxwfS70P1OITecqk6AIQ/4x7zBhJjNulBrRQaIIvIFA0t eR8QoAjqOPaVtS+MvPqtG9VqpzqC1TBHezHuSR65NYbhkKftxMVKDptshT0CQFBIN93qdDyrhxrC r9zyEecnGkHhogqeD/aYR6fd1VmncGry5Kr+DGecPiQVDSIUFxs/5yOpIcNQH68ENLj/iS8c25J/ TwFfdmFYfNhpdObaEg1FnbzJoFv7y1cdo+8rclNN41xSCMxuOTK+irxPw09yCvb4VlxFTjqUdeCH opiUNQiMb/o6Lm83urdWvZt+KZYlXPM7nMWuhpvaz9Z9Kolo7NL+tjiq1pkrJiXVMTjvm0pcnMT3 /gog5FUmRzheeI4BkvSGCr6sOofBlA+Us+Po7kxf8yxUKYVPFQewdzeY2jCdligSqIc5AyDM73Fj rLj9QfGfEwvaz1GJC+XINHR9cglbuloahhGjHtB1yN9BXzZKAByzSaIa7ZEOWF6uL8XbAxY4kg9a qEgJrRQjJUree1tM8jOtkLQFxpAAlhUUC0RanAC37xxbgp3J0Ee7UqfLg+wfeOSo7Ler4lkib+o0 GROzVAB+RTB9Gblt4Bvvi3bHBwMJSBVuPx+9LravlznHU2dwaOAj02+rMU/mlL+3wgjtkiF/HGcM LrmIS6dshLFf0F35mBt2wirE8FlSUNgxBg3YlB2B2ZizyVuyL1uYT220WlX/fz0v+1UE3lngPPUa Kyta9wEG134R9c6X7G+VdKz8xyw2jijb46/9cBh546Z4q19HrzP7D0MCQ2qswMZ3k06LKHm+dPhE uifnwEME0Vzt25dc1gs3nFob1NwnMThCJO6xjqNhwSHw6wljYJiQmAoj3bBW9yT+Z3Jr3AVJFaEi 1OtF7lV+OEqxtK053GsgUryQ2ESrR0K7hXDTQGYHgGDAcAqInVMMxxhAbKAbVb1Q2TBMDTJDu2r6 1gQw+sKxJwzfiD6iy1TMS36htYv6sEO5s0aTwfxyabmdjXP2UTdk9CQjcVk+vgvBIfRtTGvhOxQS LHVGesHT0TdpJ/1Xnm33U/rfyjAYRrBYq+JAsvzZ02PDUucMgieMmxYdbZNzoZQfxQbbjwb05JN+ RFt5smMLo10u57JwPUJnUdyLsTadWZFldf85qQUyY2swBk5u51i1KcuZdzK2GO5duxU45Du3Nsuf 5JwXVg99zLasVhx16adik7VoQj23j+LM32xQMvzOyOihDiRvpgV+207uGezGFoarjAP2+6HHvdOf vpsPqvmxjkmWnjOzWkEnknRlRG9KIxorWgFPX8G5tXZhZhutVNJAqjrYnx0Akfv+EtT13nxDExSp CJkSUzLUSRUUPNhghVZEbP4g7eCelWD58K5gAeoSAf5lnK1wKA51V7WbzcS3gR5GeO5Vsotl+sD2 ewP4mLaSzIwMp55awh3QVDR4/ay38QKCBC+o/UROHY5V1uUqNH001F9n1TvkyfDTaG/4Nja0u/tC juLaw7Yj1baPXG8nmG2EcH6OcEu0+t7lUYfJrgwlfK4Jsj1KdeTtCK0K7Z1wxwBTVQLYEbkIScSf jR7+qjFAmItAOZyAOTv2TNmo32yf8Dz5N9xowj05Q/OzrsJbBurySrOPH7NWd9uK4MLQmbX0NUTR 84yEyeYmqggfAqk++DVrxi2CUyxVlwFQKH/7LHoE3ndtjMNx9A5jmG3BFuFLcakUrr5GBGLqRXnf BTy25zqbTgVDCabnjMAoATxv58iIC2jF7VzfRY5gkL4z2jRbiWdLUN5cGNSNzXDLAjmmXzIRYvTx ZM18gqXnHLQHRXafD1fpVttD84rvaK96AKdcOmTuSF2Qt5287HLqUc5FwUTR4SiDCzGQsIsH22nh MTTMRKd2kfvxH2eQrprGt+Ey7QO165zyo3BHXU/WyjQQemacc5FAFwOg4/651qucv4CjpD+3CdBs sDIy02AhRKAa0dp61L6GQ4N87qqAqkIlWnGUgEju9xWxZNLRWoACnePHQTYysb+X4g8hgHq5wku8 jSAYeexYRmOrjfq7dd3nPBvdQJKZcBTJBk97i9AYIeNO+A+ezxumoEZWE9792GhNkJvBDfYlNiYj ch+haCe8YroLcT/6+G6vJHmfLYNP20OTH2YEFsfD6B1gjp/dwWkKc/TZo4tCoHGbkyQGHtPkJb2t sx164TAN50WtoIEVQlTEnKaAEnkXUhQw1bCAgZX/YqZdXHaefpq66dg7n7N+bhW5sMuPh0h/51Sc qfuW3+QpfSMnbKsOuxa89WxNPxVmexypnDi8iGahbJtdfTmDl3ikODJmj9FNvZ3vYvqAg+DyqIEq XZhm3/v/Eexp5G76iXjU1tsRaDB4NJdLoCAZnHDrC2+u9z9qfhsaQ6pFcuUezmBqjtfoc8RY/4In l3UGfu2jH+Lbf4IEoVqcWkgpYcRbH+5BDfV4KPlbMIkRXnvug7Ugey2u+CZZKR5RStYYyY0nPqsQ 5e4Ht7r6ZqTUikdUmGlT0wreN/HHUgNG+L0WfmjZNpv72CbFbK94Uc0NcagQC78aFRBEV5t26yHe y7dw0tlmSuESh///AOpHKcCAQewqS0tYv6Xx+hj0ef+B/2jHqvzBu1b+tj/0O/QFlJmxh7lZOlM1 pRFsMDirVOVJEMoZZ9y1e7v93VxEUT1nkZ/b/oTa1o1i+rDttBFGjfZfXXbtDurP97xIfk5Lv9VK DIUQjDe/px+QgLiK0J/FjJJQgt0OTyovcJZKH4/1W8US8/OSqYnpTkNej2ciLyFZSr5xskfj3GWB L9GFRNL9xo6gtiEzdYbuChaj7dUsDbnDyKRJVWqwVh0kihE90/5Og9076W1/pgKZpnU84eNCLJWu yplOjAjcgyxjjYXVpcQRYiPZwITjyqMkYiWTLsWhBkfvttsStA5tk774mwKRdPzIeNVkZhVJmDGz 6pRTlKZuI3i/DGRPmbdwiX/Rs9DeDH79tsmheVJJMauh+UQOPHfHFU0KplatjUcUKbwnLUor9IJh okRc+GPLU/B9U6hp9eLzB9v0KCV0KrfZ9sq2aO6yeESSJLU6l8gVozJhvfXSjWgD/G37NKRuACaa V1OGuZWtizj1db/H4a5w5vO4AsYxY2NINZXKxun+JmL04cE6IVEFmQjGQL5bRG8hRz85WRsruVq3 EDyufKA3Y+CpqmhzvdxXvuNBCM67nnDN8IGK762CsLr6Zf+y67nu+CMVIfSBxPSmtbK7SoLkAhNs PtB/xXA4BSXt9tnGpl656fGrZkjY33jVwXali2EQ0v284XUKCwtx8Y+IAwEZDQ2FQPcOnQ0HJtTi uL6SCg6MpVsixEYnfOUiGhmtTrBlGhGxRf9ERkHz7D0I6F1TjtXKbfocYEMYAcww21RhbZerX+jb LuSOY1naWpcszZ1vvnmff16H43tCbo9lzPzqRS1tO8rn0GiMclrv28CdXjtraOJaB5QViPl5PAcm j7ZeBSaBDgasviq4tUgNDQsks/r28pb6MYGvvxii7KBP4DAnFzsk366QP5o43on+QaiEmbdl0XNL VVS7KO7caElhn3GXwAZ9L/ZCqUkNSf1p0c8wMNCqm9xwzcinpsXyHb+HL+5R+EtIZBkykZJhbe0Z c0yeMleMslF3vwdLN0udjaFh363d3TuLDR0OYobUUFP1RyCcLCAt0eSUBakiRbDcC9gcTQrtTicr pz1slyvK0bqagyeYHrNUhbBFWL8w3QEeg9HazcBL6yfvi/UN89EHQA+k9pZghrXkO9u/S8GPQQLd BRXVAh2Rcp1iYa4jRRCjzwZ4Jv4bSU5K+Klatg3gvXz7ERKmYsX3+uaek/Y8jtQxmPmIkC5BCPvN 7PyxJ3ttWzWmwkPyPXIgMhjcO37ErTLKcGKR5Vm/hgyt4zmY9z+rYyhY+L0TxTcUx1lhpKr80HRK U9vt77f8LV9BNy+QUsBqBvWd+RVmsvM1J36FNzmNtzm1lag0UYySfXKKinDIY91Na1VtntbDafXj aBa8sCz4L/GuNhxx2nBA9MUsaj7SAjLdBNhLwRWeervF3yZKzMP4EIvBvoRKnrZcoX/qO2QUrGb+ 0BnfH/XaFKJsnsJHOayXzcPywSDFQQtW0L1EWL3K8wXsNFPrXA+MFc4tSi2G2HN/fd8i5xfEahjf mo0NvL6R+0qt/VF1paYMgXhvhPHQGuItV/x1cY0dO4CbCBM+A0QjLVHnpe6MuRYl9gL1N6p8h9s3 75kJziaK+KSQF9J41ozTN79VwxJZBOJX3XJ6XNdR5yq2nwG4oE1JvhmPjr0HwchNUxitc9Ve1O2f TN6tm+DPqVgFgfpppJ3C+9W4I4bUX9gBsO7drxruuj+97WrNEehMIG4mwZZfXghFIKqpzPKXHzQn hvkcKBcexWutiKGKHkFCcZpfglMioG4Wix+9Tt2QJ2upw5N6CpD4j3IAsP9lXuBVeSZ9ntdcyHqz jS+cRzTYHmzokrv6qWV08nZ/pbaSiyYciggMXhPtbfIJxkep0KpFI0Etp3gyrdtc7L90nZ3UBh8A OT4RWJN2Ps+zlxyk2bmkLR/+57IEJ56euIETAZoySwaHXsKNGsTGEo83py3f7ti9O25WNderDhnY JvqDUZyGgLWUvXpPLGB5mVjssE2vntsvRnWkWDrrGgwuW+dkOtd5wSkRZ02ZSlYGVsy2zbqiw02A QFH0E72DZ2l5vJ8AnNJ8FwOu5/QEzl3DuL57PjNy6gEgNYP7cDj2SaLmOE/ZlfwW9OBv4aWQATjg 6r35jI5GJeu7F+BFtVi7ZagGsjeil9iO0pcEqnn5uRTA4BvXS6Zv4RRguj9arYJc1lfedgZNftt9 uB45lxf/8/MMg7Fum7BrQdWMXeuFnMdiugryOvWkBpAmEfHLGC0OrqWO/OHoKSm0R+FyjTvIW4fo IxW3ZF0BK0HpoAwyQHXKDd5nvUkIqVQ/3H52dwBB2Ly4QkNyMYaxgcIL7ywLq4RvNd0C9eKLBeRD 2p8P5oTgEnUlZ7qqfe70ztElPuGRv2HHtEfbJyl3hSL70UGD9UFtI2WaQwl2i9Vtf4ErVA+cCCtz Cm3jGqk7QTNaCZrQS/lJG0/zjEF4dzgMYHSFnVG4DxEOpK2F9JRjxkLxKM3pMO26lekZBlwrXR7l 5XREdwZLdXE/Wwk0BBejqpD2Ba32sYDyK+W/9IuZqlkQYALRHP1u9YhW+g5QIG/FC6+fIUxzbzWJ uu65dd5ib7wl8EI7H/zjG5gFMyFFNURD/uNJa8/HbPiCmny71Zsym6TyPFcUWaBdeA/NHeOpQF+F sGd0HaeY2MVQk7su8Fioa1SAkZXl3zn/U8rhwEyVXf5RU40E6VfR5xNB3bLOLyRdKPd4W3DrWo8Y FCv9bFg6x2nnjhuoV7mOGbhyA7j+aAxpnNlLu5/nHtX0KGY3iNigZ5M/nTeqJkG+UTfUAFGySFNv tbMTVCAwSJ/tf8EXU71dO0tkOn6HkPitja9Eq7dsOIZB7dx7Gp9tUHNPhYSvhCWd3ZFsn96OfU8X vvwJwC+rjA68mPbjpY+fhaVfpsmbBiSE9gvuFIQvW5XwFprgkN2rrf4bjRYfy1828JPeP2amgka/ BSQrsSQiH/Puop68+i4SiQGro1r0Eh+bXHNKyX20dS6LVq07meLDatGP5dJTS6DT7vWQ2gn9D5es 6QzOl2kDlZ3pX2jWccbQ3X1wiNPDnSVGQJAFZGBODdaZhWIwUR9K2wJ3zu6EBEkh7/JUEOvxdrER cAVepmj38pRrlcntIuz6bfGm8SooyeWDGmc8DmkIVW/7zMdxItDWxRN4lcqQmv8yyHPp9Y+seWnR FElimG27pW9yQng8o+yLmbF0xHsNdJkUCmUUS6c6Mg4H0Ie7FzuuXD0DGm8kM78WeiMiqhIPnMfD Cvx4VWUyEeG48ySiZG2PxtZN3UxWLQgycMLj7ziXya5IhKkEi5/6Qe3Dh1YUjvxPYCOt1uq0qtx1 9bxb8eDCgB0P++wRRS770KTXCw40GnKTUZiWnokAX24QzWjLtZiy2YczEJVaabulJaDF4Y+6F1Hc qG3ydKBElaaAg1WTVVTfbm09VF6ZJWqRzFmC8y6a13OssyVDf/emTnm1xooJZW4/cMxuDhc8YbRq 6awQF6KkVpJYkcwCmA1wjc7BgtXfbnis72KMz7AMGskXTTG4TCX6OEEsPqJgE0X+F7XeluYQ9OgW xB36AqE/+G0gEDbs3/7PH7avEEnUwfGWODGJXs8PUtrfdJMGozTOw2L/vSzOk+7dD6G5jADyd1+j MRcxsI7o4NtoN5ADCCw+cHQAJn+WKDA40PJRfLyLQM7bpjo37jzmbovkbXL7nDbe3HkDCj3J9+FU hmTQ7flybMAon5mZjElO/mk/ODquu2oD5JaDd4jZILzG8+y11G0URSGvotmLzTplvWexoXI/Q/tg rJPjpVzZF4k5XjzOATt5NerGsalxCvtTBq8CPZ0TOPz+VhOKrJOwwXN7e6+YHpGcWjLutF8osUoM akI3zMOvmg+it0eOGIcTppFJYHF02QclUE+RS6E+UhgyDPP70E1a5eqv10uufN19d+jQLUPU7X70 yoO+Nao2sPga6gLcftuUikfD+DzNtSVDzf891YD0M3KgrjhEOIB+/0U4ZFXociCJLL7u8nh2Xhmm tZcPq79o2QGAJebrtT4ZeF3WDxxfb30pGIMUp7HTgbOG9ECDBl3XESZPE6B2GmKtGfBTACDbT8ph PuifxK5gLjxBR9HhKJso/21oxIrYUnTrZq0P3qLQLotlgBj2kieqQ1qE46k+BwZOihseTpn6jjOb onkr7c+au91BWoDPPrUfjOSWF9EI8RF75XcS4wBvr7nlecR3GM9tQHRtkOSS286XIfr7R7yCjsNh d971cFD/zDMHLCHhI1raqkm2iIqXOT+maDTCikH3GpfhJ64gXRTTdxNO/jpzFPp1huYnKLRrjGHk XG8IxcP8rHEe9XmYpGwIihZNZRYzsjYnFmGK2DDwU1XEsTaN0T+jQi1yTHg1uulYsd0NvaAmn3pV 8INPWi7ERp3wXbPJ5V6O2h/o2AqmFwb+lreaXw2B88i2xO4qbT3ExIFNGyyGUDz7tOqBF4WwGyt6 ywmwNMlgsurwhMjM96EqvqmJSPTF+ebKUpWgZFICa61CrmUFdgbE3uJ9R7TSCqpP+tfYjvBO4HC4 +kE7wJVsSkHSgDcmve42G0qyKa9mfVKH4La9GDujcmWMiEM0HebwRKEtkVWK9yLvRo8w8AtHZN4E GRZkHAh7nr507S0RNNvbyceYcRxo93WiguE55VzY2TUOOqUBZly19M1+Ddz0lMl8+pCXc9Ejqsvg IAZysvAy0qYlKW/R/FtQKo0UgGtPlLuyArLc4MLYwopd340sNMZarhEtAU7NnVn2qvW9hLxqzdku hFylYITAiH3B0aL9Hu9Icq7G2ykdSum/AhlZAiMEDnrlerENb5aO//HqZ2KzvbzUs0bFCGF4bMcS ftiCH5ONnyX6fKctwbfSBZIicpWeuiI0NkculqiOfBaUJn+LzSD9xaZsth90nKoxy52bzm45A8+L wCeyK8RzEmzilLDJDrWttWDvw+Y8H0dNb33FCqZu6AH5IKdtvze0TPyPDN2KXSWH4aTNteLIQHh6 i/KscD7T9m8RKvyRpDYXhfNdw7omaNvHItqxW3DevPlfjYHP4J1bbOJ1jcvix7W2U6WKwIdpgTuj B6ItzGkpzErotxOHOO7atqDqHiB5CdWJ3X/dkNQMKjFnjrgnuqCjw5jzLufo7NbAOYh1XrrPoPt0 vUlvrDhXQxLa6hx2dCvJ3/wE3SUmaNFnnx8if9RmE+Ueo1jdpIHYreDcyMby3vdkNfveCsXNLy8v ADwVG7nWHa3jLS5Re7TSRg4giHohr8/BY7hdosrg0Aa01fMybwuofwlKtpZ83UB1WUFE2LYIz/W+ MfprHaXdz/rPbAcukJh3dbBJQNRxefIRzHuqJTXKWecwmLnUcwEUvmPQY5OIJ5XeHcJWrhcMEsm0 VLIlMpHVqhR8MvKPb/uWd1/3wkKtkw/c7pRH99LeuXbr47vlQSpDgFHcUiI8sgRtcgBJIhzqcynB I9QMMRq1jNHybXToIMYtDoX/cLzSzSpDyRC4LrQEMTP6u2KvPjvOXMTLcw6fuJ8zoZyZEZefTM9w 7O0ASLh/l5BuNImygL31Dy7dfSWzlWrBhYPi6s39uRQeb7eA/qEMzXl3KMTQuoyGgtz9MO/UZC6t w+cro+PlXgKpDFNcihIvaUJ6VP1rk+/Zmw5kNLh5OEthX3YXqH3Mq+Vhb/DMKcMuzvBZW0MbWhIa XYzD7lbhPqnke2NgxP+PENtY4BwkRBfIOUeCrraTFCl3VHyeGtTaux7ILFLpxlz0IQfpW4akOb/K 911eu+xC1OhLyFV8V5yEygpSQoid1tvRla9i0S86ku3D9/DYymIzL9AVOjnvZ/Szo9mPg0ie2x1W WPF4JmtZTq7CUYtVexaGsFFNhKWYcwpuGioTGdSaTpeZawYjnj8DA6MiRUKwjXx/2YJ/dz9/+DU8 TJHLMtyol2xzAYTnQc/e9SG0vfvJuN3u/yD+fGdmP8D20XzapPEdrQlZzuPbC2A0HDo2m9vm+lSY 6DXhrH/mQ1YQFMTENKBu64JE2AgAB6WouCGyX5HJQhlfGUBAWp9NvJEPlyn8N7I0z3mdaCFyEVaS V6DKyqrtw6e1FqdQRGnzvkE1aeW4dHz9Xxkvgm3RfQZEHfr3Wuoriu5GJ2LHEVZDoqWcufDxPDwt IMBzXPArAvE0Syq12qh5XHy8hb73bkD4tL/6ahy2qqw7sczMvxy9keXtDrwSrhlROCzLSVYKXnCQ 8YSEreXggB2XWwTIn/8BZ/Sr4TFCK3MTdg0Nkv1T8dPrD92gyPhevGINzPdz/xA0WUf3GbDiQpgx VdnIxMstmeQGb2WNjmZuJBc5n8cBZ/etMyAJUkuten/UCOpmLVdat2SuutaetxvlnnsRmPlIKwAR bXSVwKK7t1KR0knBat51DndigEj922NoqFZabpZHlL44tiNNmT8r/EQCJzk4q0fUSfr8rtPI4BbG qESWzIwB3CePxOCMK3eOL21pn8KXJtXIxG6uznRegBE2DqjM9u3kUVf8GjlcWPO5oKk+ZuRC89Oj BH/k3Y6Li7YFzyt9I7285hI3vCnrraVsWvUZszv0U15r+C9S7KEKGtvyaaAT3n/aP3hOvUP4LJ2o 3f5IEHqRvdgcCLzXSgrtvnnPrcN76lGkXp10hVwZo7HxOuN4wF5BhZCG5lJej8y5KnkFrmbVlvwz /xFPLhNvJJcbPLk9srxXv1Qj4c8AO2U1SxmyZeCmmSmD28VaQODnKtIGBZKXp2NiSa9YkjJiL71A OconG1fWgRdTCSiSl0D7eMkMGdZI+Bn9hYf9haKsNasB8xKIQk//7dAvaqZ3+Gl9L8ua4USu03ZE C9LDY3O+o2vPVTHUXxntFIGEtPaQ2UR+zZmW33FczrURPVKf9i9x2RuNWcNezpNjSM0cN0zBK7Er zEJOCmXghuBpcsa8xfDipckRw6DBaJFcrAaWd21VTYfGAtbxsC/HfWe8OlqQuTyCxEBXNJEga1g4 PFkSc0uyvOdAH+94LxoX/uXQLJKRT3n3lXoqcOVk5GjSIdxKZ+ROOq4ymbv8uUVztFdKmt1unoJI DQmM3VhcgkOIqQg17sA5QCCoWLUlaB6jJjofzGHwnUtRtplQtMXn4YE3yn7ZjsR79dPeqOTB4QM4 8IaU49MDeDOB5GWYX2NAz99lSD8s4u0M3g5cm8vPPUfgCZ6bbVuTwF0NN+hmY3r2s8TMW7Q9NCln PSiPhnef525FpR+pZU5VCfKI7mr/+rwBpmrdxSIJyzPcf1SJKWVHzzearj04Hz8Aippj1yD0H+DV xuS9DDTvUga0EbFsaaV/V8kHRgfCyckxnyG/lQHuvqGueTEVd5JI6d3r5eo0XqYrfJoa5O/zY9yu 9HbU53yITrNfQS3wkcGX8geRK/aN6/w/zqu7PUSgs3HcwU7jR6BfOzOwO1g2JW2TCLmzFXzOIdJ+ DC6irWEr0yMi+G5a2qvXi0QTihW54n+W95gspTcUfXjW2DrrjCzlfpupnDkfAgeU/GvrjWbvhArE MJkhpUWikGpmv13Vshu0v1G1l7+67QvyYJU0Y1gWTRT0olAFJ6nT2RIBabl3gPBfS11cNOtHRskD r8DbUvnVOLWe5iqjuIwwpdkc9RJj5NtXGR533D0gGCzyQFlAkIGRoQFxzbVNDZ1sPUQ1/Jq5PwvS 5It9ro1aW31NJx0uKxWrm/ACz5yWXlhZk60QoyudwDjtRjQUieUxWMs2xCiehOMnwGj0bla/Jci2 ekkc3pLa2lf0Qsd+8oVJuqP+fnkmzVA65NBGl9/cnSnRmig2FFodZZfBqgc+WO0GfZw7nPU3IJ71 xUvdN/PiMnwyqzchT8fHI4KarmMlhZCfBKTMultbRHIB9cvxR4YkcGH/+7yoZcUfy/BhDdJWLMEX 8DqyqArVvgueS61Wq/27D6Em4ENBLNojAXvG6SVX672K/ZYuturQmLfCwuhFVDT4ZfYsrXco2EyR Iq99Z5XUU733BBKVAEHSo6Lm4tc/wvOunzM8VaEHUnkGYadKJ3ZOROefPNkwgYsakRduvwj+ZaZf SUagGsRAgSOBMKX6Q6cx9yHr204eAAQdzzL9xrTNNYQtHG4YAcKtYJtl2HDITvMs0m7ANynPnMzG AQ9/AlUiHeest8MNfnTNsRfFIZaPs3zhDEShnjcc//Gx1zv+KW5jRkIObTbV9AUQKcg9bfY3LWjS KdO99BPceJjuvbh459u60y+XkiZqn9g56WxGzhYa5whZyGOLJ0/siUYv0+M6TGJFeKCCDPrj9HR9 BRJPDwGGz4mQ2w6U2dLulmuQ3mtmKuGPu61nLHKRRNWYkaDArbAqsPq3i8+nblEX3+79KJonSjd9 DqizzJmwO95kzz0irD2cE94ZmGsFMqCSmtQSCS3urR9kY2o5b0Ie0ipR3lf2LST8TeqlTMEQIhSi cd0YLkW3sni0+FtDSYm2PAQktsZp77k4PvtRbm9vK7gTVkbZzk8dtyhJ5epYoxqOW3NeFfkZ2mla h7Kk3X5o5jwMAyA7WPTHMrkT7RoYPZpcg12krv4nBxxov1I57DF3w16pXn8o8zs4otJsrUenT/xy j5Ig0FY2UFhSmRXys7Mfc5re76eapQDhXx6VUNjU4VxHu6jrIEwtWzH1J+HpqemCtnRgrh1wMmsl EQ8ln6BuFjyZEIw1BVJe9wEZ+psFudn/UjEMjRR0GmPpWeX6h/hcaJN5i8Fe90WGiUnYDS7q2/i+ 1tzMqnxCqwETdDAgzg6wWfz+sbKN3mKbx96YY/ZXf7Oq5MS8thP5PL1UpKIxi3XSwJwi2iyBpFFZ nkGrXPuYjFjHi9wQlu0AZY5NPVEzDVuCP1KQ67GU5NGHFliUim+ndjFJrM1znXjgwVs07BjtvIO/ GwtNGctbXb6KXfZsiV/AypJI/q/Nv5FoQl1MgY5KtjzP8IPXAN2CGyNmpP4f4teI6ug+3qmbC+Em uCNhf1bEkFqxpBhYIvjxZzHw7GOETIQktke8OgEiPvHoJZSTQ+X6IIRkL13Iq0W2Uf1s4OLS2ttw /2UaQ8iLM2J/AfwcEFyhZeiOPa29SHjF/R7NwsxLbsAxUBctEPFx9BmrKzvzSKAFr7TAry1bFXSN G7VQG989iOgRPJKYhFLx9z4UmR4G/ZtAW4ayPWRu786Zjv6/a2jYDN0ls4jPlH5vwm8K0QUPNTe+ ywE7OJ5DCxuSAcOMzej4l86gggGcareqkmkf/Vnl31bUC1pqwj/cXVwI02FBl2cShXF3onaiIUp4 xVZbv4Jc+3flwpOepy3uxdpWQNEC2y24ryZLFN1cn8KWRLZdNv5Ph6GTWII+NSWHgitdWMhacbwi vXTwc+alsq/ciX9tb+NlL5ybl1+au5wEvVJk2kVUPoXJaDN1SbIhTTuUUniHWt8G+Axeh5cb/swT +mC5vnbCRkrh0NhoNF/1pRJDOFwm+OtspFUNHC26ICa0JTHWY3DJ8nidy7URsi+48DgApr2XS/Q5 q1LpIdGFoF/TZqJWYvFGNIN2+v1Ex4Xsrw8P4lSTP2cGlwnTASqw4MWiScDRtrpQg20HXV9jAa7E kvUoQ0JiZrIPvbkA2vFJnE4Hg7bO21hXAai5dfdiWr8Vka4zllcgR8Tr/DVa6xtVE1Ns0a/AJTTd WkrLs02orLPx+gOZPWeSCdC02MMOB1l3eRWM0h5Tr1EwfTKFcfXPJQ5LUjv+TP57OlPTNi4scjyu NiAls1Of9rWGdq1M0TU+0bbClFMsW31MJ4U/8mwDeo/6aLyEhhvJpQ7poOnhEygNNFEPN+VAsr/p NCmjb9p2hoBmqQCLpfF/ANTjnSuNI0iDv6gvpv1QgrqVN8GgZfdShzkPonDPM1zhD1h0UZ+yYhyo b8EUQd7FvoQkx+Ao3m/vUqwuyw1no1AEmKma5PrUnYEofzx0i5XjH25LCeH8H1ZjkHAWfGqa/sv7 P2Zdfb1/Ln2IIV21uXus7W1OROUC7bT0e/SBbwqznKRiuRcmCQWM7JAId1cr2ActVWZK7WWwQ8xL BChoAI0musEP0bp5NoM8m9JWVi4pidMsKQhsVWATKVZqgGMeEi1708AnPk7+vuox/dQ415bnRUY5 kF6+Jja8QrHlxXxqPzpugVT/aIIOHgUWxsGcVq4QmKMK0dGrjczLPNMwE4rKkYlthUY23V4HgWVA +hRoNwBP1xOlxyhy4kceFSclI+TaflabUEnaNT6rjRrDv0S0C1VAEkvJgLfNumU5pJUDkicmTAUh c9HZMZX9J2aIfAFeQQNIBE0weBsqVoTCg7JWmeCVCtcb/zVdwOfN7EJeqF35IJu+wWUlAvv3Ls8p ehxkagijf9FPZMYZ1iNCYa5BBCoeyE9IDYTuZW9h9RqlXmTs5huoWvJhWkKWffNo7l9A5/DIqbJn 2KvqMecw1N6kEXE0jsRPMujH0IyZY240hH5cjb9pw2XX3x+Gr2Z+RQSsawPR2m0F/Ilq+XXtZ9nG R1gkv1fqBs6Hsz4PkLyLOPU4ixWp/koIdXd7LonD4IhAxoE2TII/WnpRVQK3515jc5hEFNoTzBkL C4qv3NKkTTpmAsENV6v3XYDMq6al9I7lW2zHvDC0nmh2/vR5ltD+tI8eZy0H+iJ3jAWtPbCUIfd4 OP32TxfOXQpGkMaOcZf5AXI0KT21UaV68+8pCAu7lMkYTBOfjr0MFWKI0VSc+TuUqzXyPpg6RmoS JpCiqg3gaZ7ymUr+6l8w1hgIoc2RuZ66mguwaJTcndMDJ7eqV9IIusiwzDZX6UjPWBxOG74j1hYk NX6wrWo8p1vu55f35S7r3LhOET2k7/eqdmCl5oGLXiE7CmvkC2hQOYB7hzl34miA2SvIoTduI4eZ 5HKq7FB6nXSz+CriqfnEfVz+/1sOeJuLe1HVA/gxFCnHuOdh2OB4kYwpxhW+1X0EI3YtAdaJmJ2R cL7c4c6+PTqQL2COBv9K67z/WBYPxosvl825AJmB5gD0cggcrIFgTGSaHCBBe5Uit6Rgh7qobpG2 LYwpgndHwGJPiQ/kIFz4lTnfOKfCQ1Q+xl+jxnS1XuHl8laJWKgfal+rQT6CrcKf0YdKdDu0LOIu ZuthNluxZuyTgrkdsHkyZhPCvgzLs0dQcAJZRzmlhDX6I2ymLGUYgPFELeH7UY6zNZp78eU/I4L4 BUpICX24gTe4gyDWSmDIO/NBCnxHCQE1Ixc+lBFI1zEX125EbJNsQrWOi2eQIYCxfW59VyX909FP z4nej6KSrcf7LurPoKZBI1IVIdaFm8xOijak6XVzgTKIWchkOwT1noWRE+DvwkHa7RyqJ43sP7yK x26zIgMKzZBSvqzen5bl/h6gIN5D2qzMyo0d23d5lrO1v0Tj2CuBOzZBQ6hxInN51btjqggQUueP PB98I3sUZzk1T+ZQQsjvdllQs8uNDqps+ElkQHFSnnrIpXv0EufOS1HubSg03hylyUdFGx3RnjgA S7QahU4AQemxXa4jHKbDPOvjktWKijkDVy/QhVgN7iiPr+Jtc7OSMpEh5/n8SYx+LghVC2Q6rHcN GmPSWd9XJonbpni9SBZecECwVrvZ/2vHOTg+Hss457f5FHr4PPTaWnKb28GKQ7sj1/iqQYT01bo2 u3NgjMM8dMMfwq+G+9tQ/OMKV37Z8HZSAD8Bhhi2d96HKCyfGofocadjgacDVgTXMVFUH1Mv5bXW KUubpsYqyH/eAw22abT79EjXvkrIcO4FMqbzJNK8kvr8j9BBIXacbgqj8Zd5KVuTF/gTraMu3Jfq FXO8HfHwOCJgvcexdazSRsCXMQbTpT5kvyqAw/kY6JeMLb0de0rzvteeJkqE0CRqZxdHnTTdXino R4bg11HIkDG8YsP5AwDpYCHijh17xaJl7z2XKOibDB3pgmNhEUvde3JXgU0yPCY6tLYIau5yjNa8 jwpGr6iKn+jtD4fmf1BNVGU6Pygg9mAwi/lkfEzwP6/zR6CFE+LwWF8Igyqhp301oNVGIaLJ9PkS qtCZVoHL1xR9ilJRlE+4iG2NrDaT8tzLkvAddZBTfkFg5Y9Q2Bkmo6afYjaHvMlQeOjmisai0POR nEqGCv4gLjaaOQ4EKROmudZZiLIWs/rg4L45hcmXlIlI769O0Bz+rhwKupvejRRG/+HkcaZSoV47 1taMkM8p/2mLM1x4tENviNs9pYWKyoBZsimXKzH1biBBRAhs8vxwSHgjf0zrU8llZYQZsw0KIkw0 3Zi6Enb7X4WvyXix+Xrb+krX1ab6LrPKPvMq6EY2tq4P7/qeypNF1AJzV8tHXtON/n3zoGdZGV0h eAtwj2zspTB1VD0WI61aPUtYlxxCKDh7UNrVjHNVS2zoV+0Wd8nGCE6bc/QXyFrt5kgW/1BCfRAN 5o8swBoq6Ovi8ZQ9ngvWXOVSmeNQJpdcQGT68FfvC+nQO4p2hPfeyxZ71h7EcfnW7HfHLCfKW8zA dk1p7hzeI/kaL6zZdprgbfDNmbMKOdwU2+2gaGVzYu+BRdFJmCcAFoKw0L6twvu5abHjGJv1G8VR PYzOJSe629Wpinovmr/ovOB3amjYC85iBiYe/Bp3Jwxdc2fm2NQvU95b9MfTfKI6T9GkbscBaxWt LEITmf4+XIld1F0nG7BYl5jRUDvwMmvkSLff0mlo5/b6UBwywR61mnKGEb1KPeHw8HAVwEH0F3UI cHKmNai1dVSpGNmMiTZqscus1FcGFzy5dufeR1gMoIIro9PBdDXV+lTCA554D3yJhAsACntwDozs GMKu1SQwdGRRz5sLRPcr9sOYaD/VZN66BrvwGcbqbt0Ig1zmPvG9LqfCpZGypGCoY+qDGnm2Yn5g D9U6oFiFZOLH6igNSh/bJWBovF1Gy+C9SZbI32t71ud1fUc51np/XRU65pjPNHLp6XdYs9ZAWwz+ wct5i25FOixMU9j4PsBRG7afjwsgREXT1CGtk9QsIwXa4f9T9ULqPkU5eevEi/+WiAF4xxOmBGs8 8a0+Rj+q6ErLiGbn6VEhigNF8NU0awfnrdve2N8lAm4bTaZyT309gbils17bPr5oCRN+dL1d0XBQ vY7UzXvbhRRrhe03m0QG7xRFNDEU1Vhp79gKoRMeW0vqRcZ5BWXUa6W37p+45PnEDvkOXeDTat86 DqQPkejf5+12HKJT4wnFEHhz9qO2JcGo/I2k4jAG8peCNz42WoegVcCxObNzPDPO/Bc+8e+tZ1BA qZiSTHcNxt12DDwVs6ueHeu3dZvjs9naWdMo1b+hsGEpWnAbRsHjyAwv8x/wxMVu+PyOO/AnPhWe g1nunDrfdLNpLcBzcwSovDtDtkf9Wrm51WdQRKns6kGencdYLGSZCP2LWfnZWg5VLlmL7AFGunp8 1YEhFS+JdajQz1bBmhM1VZb5DcGtp+gzJdf1YVyZxQcRDO2l1+5ELc+f4kVlrvXgy9cQiENThu9w s9X3qcJYQeNlYkNOWnsDbEBA+xIn3lfnexwoK5vFo6ffnzV8k/OAsuk4Cf0v9uOcmsrWRF4JB2O+ 7FTQcf+tPUFooSI+EJTXhUKwoJ+8jiFRyeDKbwjFNgwogTnYNacleG1bxIhKTXxF4KNTSH2gjvrU VByE3MEnDdhCwkaTBv1KK4dW4IPxuo1OySg4O0y96P8RGMqfopX29IjFCaEVpY9IyuVFNpqB5a/T Dqv5X+JKPjPXSIkrVj+AMlsyQ9lV9SrvbGWIk9GB6p8+I1RM3HVD2D0yoqeB6aeQxhViehN2nS/P WyGyswJoGaINqpQp3ejX39Xpv9p1cGD9FHJ1vbcnPXLFRjBqBVytsTGHgiUN2tQgS70UWIVrmIow uuZie0ZXztLH7/FZWECmwB2cT8CcpSKEfM6tTE7gPc64BnwHGePHYp5vwXsO/nA38YkmNHSTxm26 yQdW5mLolqsHssh7BfnQeU7Izg5JAr6jEbS9kONrd0lUUTGuY6Ere+s5xJmg/jFo3f1md6WgI33v aXK5pdHjLXlzRItaQgwQ3bI9nhm+u3On//Zu2gf1JRUmKJT0QOkKpKjS8xNpnKOa659lR7Dam4J7 e2KO8/XCbUsM1h7v+XYZoa5HPW+rIVJGg9+nZRMV8wvWP5ArwDWDgSZCRn6Oa5lIwBA1O03OsTfb D72hi8hVa4IvlhvXHIPtHAjIcHNOCqjh7A+e1SYhmhlWACyrUfhnI+wZp27zMAlc+DuUjVMpO6+P vl3IB46Qib9dMKwjt14E3XWgcqrP73Z5YB5Zstz5yGAGs0I/9me9vsLatk9wyLJbKOpcWi2O/CZs j/H9kNLzpyzei6juohzYVOt1f7OH/5o9LWxGNAxHLwhUZaCrnbYbwnYQOPAB5aX06J2S8dtcN0cg OMnFo7/p0a7hZYRX56JrVPj/xb5ZBMqIHvyL+BiRfEgxAP1r5R+AAlFjwt8x8hKudUZ0IOnwsYhH KiIr367ZpUIJpytruHmS+OvRv+qV126SeJ34kFaFxig5Z1moXNPK4x+ts3knSJkTDf5HsynnDffv VzA+fQRe90T8U3i027Eb7hjNRZblKzQMUn9CnBJpUWomUjrsnT1KJVsTX0f8IHhq5J0llgkJ7+ML zPrRjBiZDjEoDRBXG9NrsHx8l4gKrBmDshoHDOVI1yP7oDPMObR+O5agbrm7Zpd88Ukdu7EqpGiB XyNfcvREPzdh2RixljhygS03wB3gyzNAFBqugu1u0NU6prJPGH9eTxlhUbIijMLJOiC0PjHx7YoV RbxjtdxyGv9O8WNmBh1aFEaTX/OQza0tD11ydnfqbNedlLNXuWfau3JEhHz7anblh6+Ea5+p7O/T L/PauEQYxmgSFmbNYRMqKtgYmQo3PV5GI/7pMu43SN1UsuUJnUxixOdW2Uo3Y0mcqUPf/hUaW8We LgZlCy8Yz9RV5m2NGnyqxuUcglVu5T7683EWJOqXqQAk71w/44/6HZTSQRVlPGa8sS7P6Rlz3uO+ Ktk7/Axl0cfYHcMyt5m/2l9CuMhE/2n5jFGICzKOBSLbfj2u0JmZ87hzYnvn005JLmkuZWBO8DIg DLwTEJNJps+RR18r9pXEHLodrV3yyMdnVYdA2X16Gu8wnadUKWMw6Y3wQUX5oBq0ITL2aCbo8Xjl /cE/R5g1mbO0VYD7z8LN8x8ZDV2yPRaMe+1Aovpzm7Dx5cmNuP8wvLyiiQDd+2gnvOE+sJwAxW2I 6kuMTzy1JCOmsFE78TlR6rFQlrr3NS92O7T+t2EFhL5JpkJDZBka0tXT0SG+Sm6Qq+5PD0+Cblx1 oA6NDRFNjN1+eADtJswFC2JN66/hSshOyoELUYpw5JHpLyLqcW3mCHdf+3Wj4rbRX840za+cAg4q pCxvrHsxpILdGmccDEccJXrOYmG3ufZU84CbM0IroL9FXP8WPdwgH3Qs7zIlQ3YdnCq7+hBKZd2K GSRA1rhpVaTeOeNGHo5CYnRKLp+0Sr6GZaZEbDDrbtU5QjCCV1NDW8CMgwXYSPslECHOg/BUEXBr qPYsMqhWU1sQOO6upKoohLnbysvxfzuM/dFW8rgQ4HOpByMprftDcp9PcwJPJ9X7ZSSUatnczbNl 3mYDbWoWfB8GLF1aayuz1aMXHxuoysPGVe1Kcxuv3rCDZJo1uKipSfS6M/kyhOoPhe3PSeu00WvH eHRrC+Ud1g59c52hwU/EJL1FvffAGubif9ekVO1tcc63wPpCD4D9KasAY2+dLTS1r2SUzrW1Uf6N KSWuevfXwx0PTE9mdZsknm1oO9Q5Vk77Pinjj/F4ZtLluOWucrM+XQBgr1Vg+MBzyZy3PQTD9CHQ f4jd6s+6TB3S6rb/bFDhv28JVyzAYZ66IJ4l+jqqhOsNVszVjUn2wxojTWBq6ZHWJo5X+HlV7EgR GKJsCnwlekZPSHLtnuw1iw6ylMSxs3663u5F83FrJqUtnA6WF4WP8EdbY6z3+ItBKzpDuGoM3G2M i5zR65aA7oTudDNoWgn70Hz0wliARbVdxh5qIv8Xy/PM7BP5G8k7KgXXuIiFUM+tWcf8G1v2u8SC inpNOj098H9mvN/76hTHHNmIGKcKxbZp5RP5j5KMjom2jMDqBFWraDXIDknF8iSnhZ22N3kAklBG y/8TXKTS5qCXVj1Md3Cf5x0SoCjtECwxIwcczcsy9gOVfByABeun8hG0l0AdYRRXpxG27E6V2pro A7p/v+lRl6VGrdiOjRmiFHYfyL1qRSwZvObSRZX60whsZ58uoSrBMwA54e8ETJQddyLifYnXHJ52 FOJoovSlzhN/kkNo+CcK14LcpU9x06QPTEVn4avPOoTAPpsXHSKDrqX5VkLTGqE/NgpfPU1aeoMy PDz1tXr5oHMqgH23uZYh9SDwaZhSJWKdy9JvCcCE0ynEX+NiOEHgoNEe4YFhDXafQPpj6a37whFv CsowvnQnn0RcDKlwjL3WHYCR79YHwv1v72lxa1wDOynoF2QZgoKOxuh64ODnyfW8pkyhx/y0vVk4 3eOwquYRB1iFs+33dfYcwsLL4P/V17MWWcZWjHyaDL2TjYFKp9rl4ZSbiBd6FhSD907I8Www8/aT Ozq0n5V3ymE44tvJbaYtM3hOj49uIzF/Pwxe4UlJUoglLAD0eiiHpuO54md+pfCKmD/C4Ohig1Ko nSIg67gJpV2yU3BJi1CX/hKpa0LhMUg+72zHOYRVHUYuHP3f4xhptapSJtsJheF+NLYfdwPG2fUX fx46TgiZ9NugGMN8Va4w9fIpb33Xo1wTQjj1dabG5d0Ji3oNUeb20l3tPLurN9bQ2x8+44lEoWkg Atv/7mYLlHGaOUSiD0f+XLvGh6bYA+sMHmfqbkELulsZJTkf0V2+V4sXKU6QVRClLJFq2SJDRKTt AaR7XmE+Q/GUo3e2jX0DpYN9LxGMat6oPsuXLirHV+wAA+nWTic0OK1pzTi3kU014j6RQ11kNE6n wXNS1X7Rkt6ErvxH2TRmGIZebbr0IuOvATn0HUXLfRmv3+/D76wAtWzD95AdyaUt69nbeypIJZ65 wVBeSijB5R5z3wcmb3w6tf2fv22Xo20Cmo6UUn96dDwBz8JGFc/v3Eq7uXA5SXI0VYgOXQWHH9WG h4oCLByPNnhKqsky4ijDeMj3MaeOkE2J4GGVEw+3Av2/I4M2eiWMXnOoLkHnEOP2xbypb+YcligF ymanl03Vie4meg6UfzArYQum/B7ooGrQCe8vhBfakIjNR3zOrLjlBiQLg2e68u4v1BG7ZAtAgmMg ZdImOQyRjLnr29ouz1aZTFyDwXlf+ztEYkDP7+EIv/djmfm50Z43E8NP2XHAD9UoV9y41ysmhvAw jTxMsqaQIVQl/b/RZLVd/RwxAQpDJJ4plQmS+49KwmPbB/YrEtbElk1CYlnIu2I/oTBZGElMDOn1 9wiI3amx1/W5OVTygBwtgwskFydbq1dM/XQLbkBjZHvms1v0qJ6/utAfIUVgZACVzSpNG/3p8txF mqeF5KDiYnoYQO1rgt3HkGAkwKzVa0lS301QoRpoUKIfUFKiaLZ+X2UdAcvnQr7PGaKk0wSdSSRa daBfEsBKNAOA6lW1n+4ljSY6KZNFk2NPwpCdoJt9pCBRWotARJ10CuYDoIcf1ZNvPPM+E2KlIVI/ fg2aPm0FRWwRM1rbfEbGj5MLBYcE51ax+fyQS3+kBnShlJTTdlz326rRo2kWwCxPbe4fZnJjNTYG tPe+3g/JkyKzIxLyjxMlipGz7H/2ev+Ow5Ctvu49RxsF7P92derBNYq26FB3PLNovApuf76SZI3w U9WtPzJUR+EgEVwUj5Redf4mkpVgM+uxzyLVWzBaJJ0da0Kp81GrdcbffaqVwZnj8ohMLgEufGQn 1NrW+2VfnYFbqEqhC5301vC3Hz/HqPbP1gc8nKIBDvsW3F7J1wQ1XYke/YkgVpNOTXPlJpzVccnu 1lz0osZxOw1UToEYpHaEz5sMnzs/4ge3Exyh06wPgoQQRfZaQeFTjSM3zBlppLbLMMSUIsfAheB5 YBSE1U33+2JI/cEq2xzjAKYXpqPjmM13E0RCQ48gxVYNGE6/TJaE23QM5OK6iQCLQUkaAQPc5L86 V1L2ZO3x+Wah8yvJ793ju88iGQ9jlBdr+wXZ/i4F4a0FWlX+5r6cLfNhO9vPJ6BJPdOETIM/vtPA HhNVcV4Nu4rf4xkRpIJKpBln6GOwVPk5PLYHANzJYavuZxnqQprnbgGk3/KkEY0yT2zJX+k6G6Es hmkScq0TunpQQtjXLsiZhrsYN777+cakma5xdlo1iVD7Lmbx2WL9XCZvF+8aDGXJRNVCVWR8czo7 es61SsLYOE1M5V3F4XV+zpjWhLpUAixHAnSSal/aRijy2h1SKBxDH0W+Cr+S8v22sDNOq+9VnMDO NmCk8uWgq0g6W8cpjY79qjyjM9YhE/uJw3tUjqJVVcVMb292/LJ/9RqfeBZ3KZU5SdqAahOJIqin DuJn5e3BtPXf7wsoWwQAYJa+s7w/rDD30QwElYPTi6D/0VKLXzNVQrrBcjIk1FmKQPsdnDNTYMpx TH2HMgA2smhsUdpHh8kD9IN+snTFCH0Duf5Tesc6xSG3QDAJz/Qva99fO3LolvlwAKfln0x/kOMP vTJiSRTcNqonCceYDF2y0QZgE+ofmVIjpwmpRDUtr6JzKWXfB4p52U7DELvQO/6ViiSpTpDANmhH SisaaWHzkC4J7cpoviQngNLGvsSaIuQCSkoszqhU/xiEm9Q0439J4NZyvBtLWpf7BYpy3J99tNLL Amqr0dwCyVNXIhO9g3ivbAiBGZJJWNRYZUv4RC1LJa+E4pCp3tHt1xCVtWFqlARGN5LkOazWt6Hd NcaHiAOUkcLQPxKZN+5BXqLngQ0a8sZqmyfUjK8RoKV+tOp8CiTC0pbDVtEvX1pYg31/yZga2KVL SVNBfzFG74PyWezAvN8nUt0s5ZRURCNGK6h6nGZP/aquCVjetCz7J/QICFRKOhJx4HuGAutIrFaz jv8qGY/uzuApbyWLDuYjFs4VIkG9Y+ZdsnXi+dT0++pNaSkWIMkLHBIT7t1fsPkS0QX9zT5IkStF VxRF4/BIzkBwOfI3beY5dyfdck81TMcnRKSvgttJNJq10Ep0Bycz1eFTPdOBOmxWeQkuGlQhh1eu 2cGvmTTrnmAWKnzkqt0RgJt1zYH/OhiaeY32H37LYEREejqwXeeWc9+NTa5zCqoaSZIRDiDhRtKp ueAUc3ylpRnlp2uWQIbe1mWmQmrtfmNSEb4HTiOnzIeJ/ElC19c+MPNVS5eCIzaiOEjLlqtEIU3G 7ALzd4TzATpmHy90/6KSsKZO3989LjjmyAxcTd0lQJ2jaMmNK4ReHTKePa69g8+DWL4dPjPx1FGG RoFm1bUf2nUQaVv3kFBvsJQRtJGzzclAtLEha4y6th5qN/vFz4dvttudbFpVsWaVXFosi6IEP6Ya n1WmXa5y4aZXXEEqjfBwx+AiuiDPXyqRCWh1Cc/iPxvF5EDuJ3r3jIOhY8IIR7uKFBmlxGqMnQVQ f1/aqyUmwZT4eMCVZe94LN5TfAeS07/nfC7tAPGWNr0jAzUc4HBtkeDVTjoCtVrmBasVQ1xlWJEp /MC8gxXv+XdX/Oi+lYLDTI3ce5+4H78+GzEziiw7Le/pJwtdDkfilGT7JpKCgiRssBHSt34EvZNp N9u5iwlhBaWWUJuLhRD6YaDx9V54jHgOFBhL39aYSDCaNOau//b5C7hkP75OMujJu6xfL7eo4Yik BO8NdQkeWZxd1GHAuNVjQbAXUhvPKSU71YgPgVes4T/bMhR846MGr6L297Dnrqd7CD3n3CRZaE2n WXPiyEFBc5kz6hnPX1aQ4q3+dXAb0FANBgM7wNqfQ7IYhh1qSdpl9d6mcJv/cU5Vmsp31X/072jm ycHPpkOYDkBsGoQxyxXC424BxsQRcgMMtdd9TaBwXlf+ukB7q4tkcX+LDLgRISotl561tjgsVSr/ EzOxrGIt8lEARMnMKx/cRP8wYF3YICpdnsLfabEqKUg7jJH2olcQ9K/bMafs95Pgy2DqDhFsSMV2 i1H4poETXoGhC3WGcLuw4Zyqq16TnrWYoWYj00GznGqMwbzQBM23M2au9ILuEQUIjcnvwAImwjvv xr2mE703VTyvd3NdIeRk5D5Rex/p7RRfkQaZ4TQdQkHdWlUuQ8sOCUKQZ9/pPLDt3sjl4gqmYE39 Gs1AF43hje4QI1mwzSGFpD1JLw125erAFRoPYQv2YtagmJp3n3dAtDW99ioNSykWJJd/NHioiwpn tWfIokBy1FtwauQ7El8nWqMmDYPmfyjP4kQRybzHgwf9c4tZ+Vg6XeLFSCs2AUj7YZRRetnfbbU7 TN1X2IeBc4ZD8J2x0ZFmOSXhUr+tCtIas6v4BmgWiiuTmVs4wUpvv2QGo/jahEzmgufqOoPLHmmR 3b+w8FNo4izup2+UHcEUNIDMvNruIL7RVclu1L1+cSMn1Oql1Fc0obLUu8uxuGQSuw0ifGiglxXD oWyMaW6B7lZnOjpMaSJq0ypZPYg7P56q5n0LN/7l6VepxMyCi9pjBmj92gZe1Pk/OXzAO+ch9o+Y Kln67OiDUrKe09N96E8fYJsFuWLtYjFozGqGsykfyoEV63QpwKAZIFL6Dlz3rt1p3QMp7mkJHmXi oNJoKfEmEC2H3HUS7eiSqlmpH/DnjAkZec8QjsxnSviaLLxCCDDtmwApqMtD2tcoUvgjxEl/OD1o yoxvvhLxQsYpjQKLjSW5RbCGDlWMmZhMqwG+I0545w7NJV3Zywp2bCJK3ZNWh32jFxCuycWxP6+0 L5e9lk6Oknj1YtJdmGIfCqEvhGyiSCaQgY4tGDLFISXhOxvewfBrJ44arsNVSolNtZD59CTOBE7C BKI9BL7tYr+qnZUpEv626lD8KiN65r4QRs90mtWPrlRa/D2ryMk64Ca3KRmwsgWvQ66XHlxzBAcN l8PPs6jVN1KDJ/EuawJ7jtS/x2TtwhFdxIap1YTY/qKIerfxMo4HWROua5mwb6wDWhNd+dp55Acm DZkSaH93sn9SZF4roo990csjshhFGuBfu7JzlhjrWxuNDstd5A7VefbwA3AHX0NMNka3Y2tkVIyZ z2PDxTrSbB+JHgYANG3OTDWCFES5Lwuajxtb2PdexB4iTen6OsK+rnZq6xv2c6gI+Mtt+tc9YD2C BmL1cuV/TxnT6ebWavFDQ2OVgF1tq8FjuKgYkaKXig9Qhm9CO5khE5ZoxbuNPni2sK3sIYQtmOR/ 6WKeHsnZzxqr9b4gRE9X7X0IreGapyPtcCdhCjdYEbWzRvC7lWAlY7UeybXhxbjTwEuGaEOxbxmc SVef5jR0HdirX5u+Pb2jRl/nZS2GRcG6TrzQlUmC3Z672X4HqdQsgN0ppbNjLFbW2qFTzhIrpFV5 v/5CM/4hB8/ued/Psv3X23ilThOTT5Fhjt7ULG3ccJfrMpDRzsxuj13OOsQrRjwrhCm2EZDVeQKS YZRsP03FY0J3WXJohA2Lf5qC2KMC+1Z9JHiAi9frG4vM9pt2Ks9gYqfHgU1xSx2bFau7zsvgW82B HopPNF2ZioNMFVr4DBnssBT1tpudMLldJCnV3aBqACpXzqWQH0HkCm6UXy+WIfyqmp3D9nb/wJBX bGJ5rviGAGOKOevsDfq+83VSsDiCJIHxzPP91seOciaJ/RlB3T+10EcECxKIv0D9MLVed15sSGVu dRp06tDU2dnNzeVmViS5QFCy4O5pzli8/vRqoB3WuccNF1OdGX38TuBYOw/AyYeDcvJPCfkdLzx+ D/TJaDktFdkvMrO4aBJBznHbiD63oBAs25DniWIfDADto0CpK0Iuka6KfjUuGvApljXPAv3pLU43 eP3r7QjKG4DKHbZaEAVMeAaAETiJoKlaZONlhEPiHp+MTJbCmlFF0blTCtlfnCa6PcipcdNoceDI EqIt8tJ/p6SoYL5jtELlZU+Cx1VIUqMk2CpUcS36+qXtPOkN4TFrHh/Lt+h7zFZmKqWmcmlJzG4Y AUzKsi9Y6+qRPYXV+qaI2jzc6n8cz7JKKjI8D2iOyQB0QijH7/eKfMrCSKp6OmMobaYuyIGBHpsz TME/lhe/WXDUbnpnAQjONogoyu3tAQglh0MYpwHjWmdr9kbCGkzSIria/FqMdZAgwu+hi8Yoyu8+ LVGBzqmsNT5LliLfCLlehzrCs3ys6PJCjyK6pzJo7cCipkfa7biRq2GsakMPD1WeLSq5xQAZJaAs tcry1hKS+8M7Z4oEpdKwXBAEoBQqrq1+Z7i4hfz5t1O0F1tjz651l6dA7inaE+BJ89ZNSr9YU8Xv UWBuZCfyEukAH2+N581cHvZw8Q+8Nf4KzVx07VEsy5Z87iCyan4n69czmW7O8+lhy+BtC7IcBs3N WAQtQD2Tc2GjMyflaHtv/L7pQbitp7+mpoFXbzQtUq1x03cdz4QSs/z6UCBBVSwea/VIpzT6musq o/X0wefcOSMAcq5NPJKTOpa0rPq25iGD+1+H1gWAf33PVAAo0nXnHgNuV0e5SM9RBDprhgHKtCnq WMuSVMocIgaoZh4tZLaJb8ccj9K0GTH5yU5tkoaM1+eVehGc6QMU/YvhYVvIm7c4ppns1/FXRpgy KzdZQjJiNqJkvqSjtQstEO5bMI5DtDrg02WS1sqtUX9an8EvtpsO2+e5A3gWh9RwotWrkfpVYQlI 2zThLtLHNgU9EYNsNyFd3eWOb2KDM9w1WdXPuWwzDQYv2iIwZPcyQojMAzvaEqZgquuk5zfzYfan CKlilh0RI9LmqllkG4hXwN+WagHTsBPdX0yEn9OV27i/CY5MAUmYHyn7Vsue1jDmfC7aBsQ+ZGhi 0IMNSYddrBw9w+Vfg3fjyiNpdYIQuVzXsKRRZXeu8xMJF9qHyMfuVu4ZAemZBIFCQWsJa62vzGBk cNcUDbKLD7CH3/yshU8mhPxgThRQGDx2pUcBelB2JgVcp1+SnMCuT82yijsSkps+VdwdtcZrDxhH dcxd7vd92f/UkgWHHN48RHQIw4NDZx3iB7DOjZW1S0JVHvor3CM56/z6TE9hQjbpl/5OQfBSY6NG 11nhw8V8jc2SF7jnt1X7km1klyeoUKRjKEdrLNEU3gZHFdjEN0fNQY4tQmusP9MLQJQ9Q4EnyKda s3NQr6725aBJ4i++MP0P6yuC4ejtb2sPuhr7tHr5NNgcdJfFshQ/gIzmCp4qkncOib4VXI1Qh7nx /uK6geLv1UIkIFWw6wGAK4GG7XXTkzBjV9xbk5S6CV92Mblq7/Z4ARJrtAJFqDm/8OwOq75am+vn SFf+C5Hqw8iJbmDdwXBMX61E7JXTs+0LLPv2IGhcu138wDjTeutXXjQUwivwOOtddW07h1SL0aXU oFi0w+TC3ADN7bLtTvC0ge57ys1leIWhiVN4Q2e8T6GAIcm+ulUyeK+jX3vo7c00F3j7MYSfU6S5 Ltq5w7TBJY6o7vGYLe29DJ2u6M7cg9aGyyisF/CmiZIaep+6UjXHIcow/4DP/dvlKBNrgW4ybShq qcGT8gYnRfatAsJQgR2aFsDGpW0vJqlecwHBZv7qQCaozlsZn96cKwwWU/wVeUgoo293QDnQZbC/ 1zKbKNw0UYGJT5dxaqq6eiqCRmmchx93sr/sbij+YUphK+WNhD6oI8mbrqDrX+IV9jpQKjfnsz4m 0pHIz9xaNFgq+bZZ8kyS2anJs5dz4yBh1vIvPStzQH/SmisX/ychEc1TekTcBjabjcgV7aH/baS4 Tg4J09qOc4zOgPDxBVXLXtyrvTFHG3UcbWkB66tex7vFUfq4yrm2I4TImLYNSvxV4Kd7Y6Ltdkhr JU1iP8KVqBPRkSj2Bdy8QqcEU+z4TZ9aG/Udy/3Gjcfeari4aLaKUH8NpZT4tCe/DXbTDh9/tUJU fhz6u2DR3G4+PuGmHML7sIu6WAiIoOJ5FNKOzKtSGDE6vG0LtmG0wPPDmxknvj2tsTD74pl6IruS bUkwYetKcBKxLz4c9OVvD8nOkTg9vGYd/82jFzcc0FOmnYzEAzy/N2uRecHRhSm2YJ5RTR4ZQnAX jqO5nPJaAC3T2tgJWU9s8L4ApIUfT923yWzxZsvBumT1/rAzApZqOt9/8EfvUPo9ZD5RO3WC7tes JP5TKsAZts2TnsW+cM8h5HgirFWwl/QkWa5VMU2EUbPG0edz3J7yAIqRO3ZMCo0FcSzFYkWzu2Zr 8k13lxhRG0ifia9lzlkOuaNDnsD2YGT2nbV44/n9uLJJ7KToOx61VOQvrwGBuwENV1Hr1WlRusLE +3rruKsL1EKTSmiyPZolvS2z6ONA1XHKIThCqaxSS/V9weQTbDDmWFlsdbAccPPAQps0duzbXhP7 sbVJiuUaOS8t6xpLKkDFN32KV5G2y88kGtsqvchfAGBV4SpVFiWqOKP2meBHfe5LVoNvsTN1Xdnm 3DS29SibFC8fkHWVVmmA7B3J6RU6XkhL4FYaRb8snkkYTf9Vp0PGZ98HiN9SghqHi8GKnt/W9mzj TO1Vp7thPhM9tPFbxTTM52lv3aZlTRHAhzg7qIoGdHR1Xc9wdD3ava+YmjLaJT69+5NtBn/FjPmL s4xLarVNU6oRMWpfBXAO9ByUoRzGAGy6zyAxery65/It3aOE4e0OUrf/yGmey6q43DgZ0AV5CAIq Cwj8KWUMr/ok45s47XjA/9nNqjgjbbuwi40eiQpAju13PBLA/vzyzIvX1I7PKNC2d/QHFs03pzaY C4/Sm3IBTomAVa6IL7Ecbj2Aw1zDCAsWNWCLxc/y3S7zOxjZZU2wA8PoiHZuR9/MLUUG+aufKb1S e6sPhWwrf1bL/mBn630Wx8vIzvNvESVeuIbTuUONsdEWx9/B99JOYoDPTIcle33wbm8RTMUVVfxE 9/Kh/+xBO7QUk0QrphLFLCRoNHOkIxH+eMK905jM8nedmV+4PF5Scd4KGGO5AISFjilgkvMY2Gwm BNeinYGAEKzxFkrpTRMUtq+XFGDOXW1VTMNq8MoKxS9XO7MedzGgqT8v5PN8yS3SfFbRucWjyOCW viGvozkdXAMi7A5JUn3A9HwBpc+xggOC9wdEJlL6aGh8QfRaIQuWhNpVj0X+3gI+WZKTJfCTie3P vPC9HogfNrh19ntTZ/su0qlCYjObRTkIOCf64UmS90RqFEMsj7kU5U+kmuIv5kNBNSvH3rGqVDY8 8vTtM1rsOUZuVEJOLqWEIYhFjfO3Ou0p2+OvEJuXcu+Vzi3LSAaQH9FT1CbI8e7Ws8E4xm9YBN3s oZJ/3GEa64r8MXCvCtShqstBX4bK7eA19H3C1kKXjFvRigYdMCXgxJrH+Dp419GEaVf5mgXGHgFW zGsOjlMYLRPAhLXUeRGW+XwdIuFZ0aYRerwTEz+AZuF25zj2AEIFldclKlhKcL9dw8aTLS3uPfRp jeQqCcAjNxuRyxpr+s+g+VJoNnAdhK53TLwNi0QqbRr5idNaJJy1UzOPhSwRkIy7WwcJkcRRzxE6 J/3wjkuy6REWnWH22kv+lia+o2h7drhQpVE0GvWW5+DgXBVvl/4UyNpr0/wlf92EHuXvqL5Op6yt ANuNmh8diA6tMw+Wga+yQU29JnAeNUVZ2HkhtlS1bLqGEQFA2Y6z1NfUOPb0CHh5Fj1C8Utu9CbT 6kklhHO/2B7fvdCaEl4XrvrBRecM+NFn15GiNFYvePuq0UAwlCNUP7b9+ICoNUMHyySjDxu4EvFt fRWIHS1vjEZg0zBUv6rwKbGUBJnSzQTUQBsQ5LXDeJ787g1Qrk7hgYol1Jdnr+DoY1fCgP4pTAsx u/8ztAXW9XKyJvHsLVm4vqNN2GJI7kPpGl1flTqqtLbNJYgu3ZdPaDJIxWAxVhGptOUUz0mUhoSS pYz7QlSe+2+QLvQoOXjrXNwxQJ9YsvPzn/aRskLU5kpwDY36L2Kw03QCpeCASpnpXnv/7kbt3WmN +bPWcbpw93QfAtEmK7mE+UNbRgfaLi9pJX5TTpcPP+EV5tppec5n6U/qKJq4ZCR48/icx5cIUFh8 9df1V4Zaupnjb/Z2NVyma9Z2q1Dxu8UiP0p5RScDJDTyC/5Yl8lHrEDna6xO4TiZVcvokMyJqd10 2dnJfrekk5JIwfj6ravQWygGXKcgc5KWdajA5UVruqOP30yRnHNl/Y2s9/H2qel301lw5HjlaBJv Aaq/StmT0oOcr35bkC2W1ygL4IpzhFuRKJWZdC/B8XgyozswxsW+ycydLPAd3FOYjt34SW78QswC GJwH0fYjsQoTxnK5djzuR+LkAcrHQN6Mv3TrFFbrGOuVw9mpJMvYWjLytPX740Jf2Pg4LktnHg6k p3jSkl2txIBpqAuevdUY+BY75WX7HotRaZ46Y5v/A5eXOJa2wC/howF7KjC7Uarzp9ldopj3BFwE clCuIYCCoqZwgdhtBXaxfcdTsuXZylJ86CDq5ki4WTqB6Cb4BGeeDztoK/mOLTI8N14+C6EjTx5Y BhdNE6i0nrhejFWfbnHph4PyfAXEMh3IcNYVVEmRGimFTURJak2OqfOoTaS3mLHH6C7N0xkPm1d7 gB1bmh7FRnSHeVDDAtGu3V11TgRuayDTG0f7FBDqt8glExD2bzfdPHb8sfyayrW42vCK0uNlDaXh 5iMJn5Bf8sTbKRPo4yD6WuGbS6CrlNo5NyyXhjzHaNhIYDj+qXk5NwjenO8RF335davDagxcmz6N aH8weGu2vOooyEs2jvjQgAvR8YOV5lx+J76PuxZi0lmmXY8ajvpAIqm7DaHXzm3Hoo6EtGRHqgQ6 MQRFIo5ePixUXeu6LswzhKdFgvMa63kBdiHNBvVccRiTe3miNhIVmV7h6VfBAdfo7W3DGteY1R5Z LCK+2RuTOtZ8/htFNGYrW9/skA0AH/9ODcMEqiGLWvMIDO6+YU+PrtlYR9Shd3RZzSCWCCedu1p5 ZFFofFTmhQJfuGtxWEahC6FP8RKPOXr8PGCEvCmgTLulv61aiOiFOUq0eF9mRdKtFvHU/KKg2y4t MckPGlezd2bUb9Nog1seIyaIhgmOUGDJIVbVJ2F87Wh7f9NbxQG9M1OO3/wYuXj1qMjKrH8TbCJA Vf5XtmLxzFHW96QgjugPAtE3n66dQRgua7L6UBW4rn9QdFEqyboq36JZ/XP0ILN4M89Ki/5qiinm knbg9yRvWepjt5agHgG2VnQPfIQcCFwfDP6Dujj+mW24G59DquM02SgolaMrhbJIFxlSNOfoRFyL hlnMIfpMZfU+2SxHL/e7iQz3bNaG8OBlcw+zPmBhMS+lqZvZbdP+HUHPCkcr8KuPsByjiZXESPBh kCTSl+L2JYfKc+G5PBvSzpXeDiC5Qa0NxCZBGgZjBjD9kpP8TAE80S1MipMiC1rVVdtv7q8yzWyD /w8/ujc4M+TSmtX64yf70Srdy5VCWjnRUBMz/ogbxLICF0wvKuFbpu/on3hk+MXgCSnB/hUCR+iW T1HDR4uACLnIe98+3b1esBGNRl7Oap7WPl8LKV6hZd9LAyUlHJRsHEKQ0SQtI1Ydh7V9Q1YNa/rh 9XGPikqBNHNj/Uue6GDwDiCEV37/xRQF/WcrrdfFMhIJeaM4HiAouQujVjNyX15MbyRKGHR1NY/M 2fNZ3y6uZHtrEjthN98G5MYE/OvjK9aJuOyood6rVEAQ4UrzB3/bTqqXe8p/AYWNW0wlwAK30obi uoJKUSsiD4yeJrDZZMllqTR5VMzkGuyWm8rAzSlD9xPwX0M3LPzYGO/D50LUKHxPQbbCrPMHsYJu SVKrCKWudhZ4tCAwsbyIteEGY4McEjCQgsXUgrD1cHOYEv1Jf1iPvLR6aHskzyYRUVD4cAprCeNk t3Ai82QIWwewy2lac6Rd8HYKYSN1Sicvx+R2DAvqUgHIvH2uOlX42OsxVwxBSJuzcnm+JwEkA0gj 8HYxLsqcVcksW/9XdZYm+Az7gb+36pN2/u4AD/y8XKAyjN8PFyl4DPAIl5iiENsfvj+PJu8qFpis wbA4fl/UQl4XRh081JQr+4i2dlZjvl0CA0VU1HWxyEE81w4YUZ3TdQWLB/Z4nKcbxy4u0J09U64+ DI9pgZ4DCGt29S5mHSiOERLPtst0Fjiz4aw4N9ObJOUHESMbaU8Azq1DwF0w/MS1jSnJvMsiRA8y M/RCrYIS4rV3627NsA2DwcwLKZKX9qmL3s/ep+oyKmVhIS54ERdk9Sv5hbPO2XdZlatViqrzkJxK c17at0vXDoPbeeds84kWMH6xMLWpcClGWJbtU25sFJMh/BgcZEl0gb1oGsTSr7I/MHAvsXp25m/J OTBBqKqs2Lu/mt4uWLJ2R+ezaz6QJdLSkBoK2OisG9lS14rVOs+2zN0Nv4QqR+hiaHPGCQqryF2z sff+uoOpkyuWE+VLgddSQy2a0wYtbFbEWGezp8pglQcgQ3DxNjeV78MAog/Exbbbj9ZUrnG4HaAm J01VScCdyr8Tc6nHk8X0xsiUnzdv5RFd20XxR5hGvZ46LKE+D3JNmxyqa48vahOttU/3BblMO6QT A3xE4XD07+XtAs4/L071XVqZ1JiG9Xiz1TWkWMgGnEZE5iK33JZLSFCGyK/1HuBhcFb7RwTA4W/8 +lWcLQvMzAuF2B5YtWQq85AKFuI/3PzNKxQxrk2TiDGcDTLwN6hAznWqbG54mH6uKTCvUWdkji5e ZX9qwHnM9tSdFMmYKV3KMMAFK4rafsqCvC50KtHNqocAWYelFOc42tlXbL3vCLnV7ja4h6aNVOyz 4CqzoUekQxvsHnls5la2rm9rNll0kWnYvE8Ctqvt8yUSJ9gWaZvRTWFQ/HSn1X0n5UAkCIcM2tji SpApnJpS3Ux5s+ksIiIkZMOhqzVhZ1bMTKZlYMxNYUdJAfS5ASO8ZJLZBxnoYfzX8Z1S3mVTPVbm 5flbBH4mPq4ZrAo104LNty6q376rAwHFYEHA5WqBZBvRamON2qe9P9mr00rG8bXbcD3SG3T+dmE8 cbd7nFdPEPqVK8tiRurSBCIzj9LBWST1RUj2aIfNelaL/G6SKWYdfowzfUJYnNy2S18LHZkqKsjF z3EOOqEAyXV2ZoX7xVXl+ZoJMTRZzktHXHKP97XB12TeVh5RP4b/CmtgXgsOVWXilevEySU1mnhK KHnhs6N6sJEN/ySylPstzXz0Q6MFty3bYlrWsPBxc5FY0yLavPAe1Snw4kpI+pVbiJq5Rr82tcUa eE4JHopPNF5OmavWrahPJ3FBSU3YzfEIZ6uIDPNGbXv8osQjlJMgmFEB9Pc+1SQYwNU0dqAFnRxB O7HEKiK/q5qtCwGO6TAq6n2EWWmsBuW/iV0TwhGjfZqkWBBIjBdjj01neFx8yJKteS9wAxSfO/nq v92nZ8NhbhmVwk2Ytzo0nQLXwjfwfkjyjJS0n+2YF8gvY5VsdQ2j2Xe9EzghpNrUGLZsaTQd8nf4 Akimae78kDD7eeBaMjRHAoW4P/ptn1XhQUmlRo7IMifDHI5YH+BKPfYJ0yB5O7dmMoTv9vV2a9PD 1ILmRK43ZsWMGaCm1KyHLGEMCNDF3SfqDwX0llNeYGJiiZA/U/TT1UHLdYlTy/Or7lSjpaJeDz3Q 7cX9FaADISzWkk7/5+fAo8VH+wWx1xi0KvJ4c4ZmiZ2RJCVuUnjYVpbRnwR6lFhwyjzGKMErDObr gvQHbE0u0CHFvu23DpL72x1Yu2Rq8/M7E4Br2M78WLV4/pkhWJrkyi8FvXNygi/fIjkjJvKW6hWH oXVVp8x/10R+RmjluzCu7E20usbMaEB15JD+uCYx6I6eBXgDeRJRJseHOZbz++cno+BOQnpomDhS JgZSQU+4Xszm2tcmFMnRMWTqDrERsdFQkCvsftsolWFiIH4kHQlLB4lFT72TvDp3jDIi9PuLrBrX ZOOc3j9TxwsR8CoUpQJadO5DlHmGHprNcmTYeLFHAUYPS+0+hhB+Y7KCGmCX58oSJ6g0QXjTs/f9 JYF6hnLazLm8vo88zmS/KdAsx+jw38uPoKI5E9Bq/UnKhEXha1TQCvzowual8yD+rEiGZuiD0+cj fyajjBlM2pysE8Q8caqsguzoTGJVe2pwwiblQ0tyomG46RqTPH7x+McEBoWWR267SghF06bkBP7r C2149l/Oij+lBk7XwO4yL6+3t0N/ymqO5Ej8+5tGi0Hqipluqw5VA8dkJR9iPEOFraj+F+8YXBH4 aY6c5111HG/qkO72rAieVv+Y9gQzkALJ0OETsGBjKhFtmGOK8B4psHhlYj8KU8sbC6N4f/tEEha+ AmZH6OFpMQFFs7RSEbbQEo2NbARcYM6Q34b529QjC85yytbACS9p9vMYGXqLY1wlXioq9Yga+1EM iE25aZZoQxgBfAooMMA+AhsTHFlgOZD7Qy8FkWc3gjAajdAjhIdXuVbOtmpgR+sa0qxn7jn7rmn1 LYljp8FavK74M9or3ohz8V6fFAcjCEoJ5/vuh5yrJR5vquJQArNX14SDwATLOLZuwFgm9HeAnyAA AA== ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: image/avif Content-Transfer-Encoding: base64 Content-Location: https://static.wixstatic.com/media/8e982b_67f39fe7f6d54b309cf98e35b904e6ac~mv2.jpg/v1/fill/w_560,h_560,al_c,q_80,usm_0.66_1.00_0.01,enc_auto/Shorter%20Is%20Better%20Master%20Table%203-24_Page_1.jpg AAAAIGZ0eXBhdmlmAAAAAGF2aWZtaWYxbWlhZk1BMUIAAAGNbWV0YQAAAAAAAAAoaGRscgAAAAAA AAAAcGljdAAAAAAAAAAAAAAAAGxpYmF2aWYAAAAADnBpdG0AAAAAAAEAAAAsaWxvYwAAAABEAAAC AAEAAAABAAACDwABPaUAAgAAAAEAAAG1AAAAWgAAAEJpaW5mAAAAAAACAAAAGmluZmUCAAAAAAEA AGF2MDFDb2xvcgAAAAAaaW5mZQIAAAAAAgAAYXYwMUFscGhhAAAAABppcmVmAAAAAAAAAA5hdXhs AAIAAQABAAAAw2lwcnAAAACdaXBjbwAAABRpc3BlAAAAAAAAAjAAAAIwAAAAEHBpeGkAAAAAAwgI CAAAAAxhdjFDgQQMAAAAABNjb2xybmNseAACAAIAAoAAAAAOcGl4aQAAAAABCAAAAAxhdjFDgQQc AAAAADhhdXhDAAAAAHVybjptcGVnOm1wZWdCOmNpY3A6c3lzdGVtczphdXhpbGlhcnk6YWxwaGEA AAAAHmlwbWEAAAAAAAAAAgABBAECgwQAAgQBBYYHAAE+B21kYXQSAAoLAAAAJMxfF5tfJUAySRAA jYA44lEAALvJ5SU/dhUj5Z33aySNpMfcUpS/2jf+OvKUDghjNPQItODX0JTzS2YP12RLl9kyULWE CaojzIbj6iYUgg/LZw4SAAoLAAAAJMxfF5tfIQgykvsEEACJAAgggglEEAAAuwVfraEhUqgLOePv /+xVCV5o0szrFlZrMiNAbSAkzbo6yCLVEZsNKVZTb31MwREWU/5GC4vEL+RpymTGit+BY3+ooPpJ 1+8CjtzrQQ5Iedc0KTbrHLuKaNrIsOyBotaeDYMd9lzkfJZrABjizkmdz8+FzXlj9M1cQ/zNFQU/ yIZzSOVgIrR/gUeNKK8g8gr0y3ioxhHDzWG8iK6FSKuvW0q6UlbaDU78I8aK+dxBaLv5If41XR5I cyrvoquiOgiyvGwSD5IXkQ6lVrVa2OzeVIQuQ1lOJ2RZJpBVwFpyskVMEZTrU9mATZonMnbfc7Q5 Vpih6nbSUSjFFhSRmQraDVpyLnuuZCo/SlxiXBL3AzrqnvbygapPFRGjVFLMTy+/Yu8McysbLK3J dBgsL8AYUAxEfsF/Y1N4YRdx3JYYiIwjwU+wq/B48Lzv3k6Nuy9nUaP2o9CTB2zbLsVr2+U8Akt2 rQElmGprti2V+BynlFZaLjAr8LcYQahaySIEbBm6vAKy9urZH72HoT/ExoGfjIiIrVmr5DFw3rWd pOgI868J4sdYTe+Ev3xAlbYAMlhhKIW0O0QNY6aG9RrBn31D+gvaB/SYBxci/Co8giYmyd7Yf0K3 ZsiYj2Hffl27R4kEWElCGv9cGyHqzqwGQ9lrDXe/OWoBvmjCtaoZnxdbwF+Puis4q1SHAMGjr5gb zSWjHmtLtMbgwgRaHTypGtrc6ZXSlScAybZqgNO6M0V/4dSOQXGfSEoXm+BCr49TLHkK7/PzonAx CBSgb0L4RC0fjGTdt+/W+Az/oRjmfzMlscWGjay17Rx2rmdlUB1kr8AnKPoEGF22ZfnX+0VTfTo6 7HNWRyscikwmArllbxE5RfOiS7Q+VI0Rd6CX32brDFWoxdx5lvzxYX3zK2YpMUYtCjx/ibtRmchA M80vHJUpjTjxCa4cZ8sMfve41x7llaoNAkTx2qPl+0du93qzEj2l+R7iLj2cpTBr9AJCapXaZLkv nsetBQ3uCg629oBLARrxO9h6+URWzPbHMfzh2sH9jOpRnWbaW0gmRcp9wvYQ1ziRwwuACmO7/J5w nQT+Z2aymS3ZGfN5lQgJDd+ARlGQyoCS1pr9tUS1yd/04Y0ndWON6/yCA6fyMQBVSsqRbEI1wp3n yDqP5eOsN7N86lGpWFr9bUGkRDZfsv8ugxTrJjHhQaHUXUTJjKYrQp/YDB+LjKN3GAIOPQ0r+d+P pWhTgLIROAzFFVwZSO/h9C22ZkVbwf33ZiF9Oi6gY1zvkotpXvupeN+BHYkeHYVahz9eXropD5g/ Al8v+KHO6g76NaecAUUKAgQVmRbE5m9OqWbIS0aUiNORAp7sKtUiRQoC9LWUgh+DmjpZrIhD8Nyh ckTeNkw3PJ3i2incREbkB2nGNK0w1hMlUnFiubXf5rrjt1LAuuNGc71VdBjAK5Uos9x2HVs7Ej81 qwrSJ1QEY4OeCm1NwCvjUv/ZtN1cTPGcji9Z7xGnrL34MprRVJ6ZEnyYwsbrBVa5bNHSzB3eefjc KHgYHuvjii3aAA23SqWMOZWN1tS4iulAU+M8KcLvy0IMaEkMDBsB97n+ZCnFkGAzduQaprg79Tk2 XbaB1kbrSnIFmFhA3Rlka4O0rOiLM9BzQxsctW4el4TJ/xY8eJMw2X+AS5I/V9zwPxFGVhHPh7wo 5yy2MUoS7ncgZ7q32TCAgbZI6fh+vVzS14pKnx5OnMl25Fw5ZOqwl5uXB5OOQQsBYqG74l+AOZO0 dZ9QFjXu8QjVhnNZMoNTp+euOyIM6q0HedMRVTDEPztQGfshCs8OR8ClS8WHtB9uVENuvaKBRq51 C2Ed+CXdo2h4xRQnMOJc4GkumrMYtYldQIQsuS86C/J6Blv9/IKEIJ7pA+aWZ3pqU27mtWKTQ1Yi 4DNP/fZMX/aQrSuRXO90Brcwq4BwXM1+JyR+bJanf/O1KZQZRgERL8u84tIl7TihdgVFcnFshwfv EQ11uIqww1FFjJoUSiHy/TcVawC3dbtImPjmnkoPxCb3kCVitX4pWDA5VsTB4s8fFcfRnUvbuyMZ c3xwxdOxYQE/BVhDWl+Q/73TxtbKBND4gXjS0iZPje6cpDXpjDxZBMdx9TI7OMfbZ8BSPdl8Y/Er acEZFNZFH4GG733tBwvYFtO+Krdz6L3aisqypQZKoM93vJKAtw3uIStcAtn/sRJg12VscgGPOCxS uFgs3DmAjULrjBNKfwKSXARkGrDtAD9R8Fw8nNFjXuxdEhWvXFQK6i94jetvpDEGTOzPVQkeGFY8 mShBdkQEMv6z0aNQkktOb/ZlN+68gRmxSzzNtQxxbTfNyzzBaaLaN39hEoX9cBCqPzXMRJRaY1rM DueR8nCBw8eiIDoqK67zFwzi+bJaKGX8ClccnpmdL2SyOppmmFgW701FsltAYhC3rL7Zh1EwyHlb oS/5u+gW3P/vIrFkoXUAGWC7EgXVMpvbluOLsDjasYVaYRtD4UZTbkzROmKaWP8B46divOrvhEme 30fmnxvjCgl1azJiZLk+DjKfKuSPWZVXzgoBGtJIYUVaxlPEfqGU1A1IuDsEEiC6nYj8gBjsklf/ y7OmWb/eX13umdQj5+QWMg60fjGaer5VPBUZwf4HZh7XdkustbkB+c4F7OWlP5Nz8czp+sO5keMO HT8xMvKDcVkaXM3nQnpp1xMW4fGAv8DPyiATm1rS7Q1/s+u1wvG/IX/HgCUOnZdo2c5IUnexWJrH Ynelt9Sd0eoT0vczMc6zFqVORpc9kUkMv9BS73y0Tng9tbZWkYsXhudVUTlvwtgpnEEHsZS2ozd1 58JMrdlaEjUw4zNask5+0DVQ9Up0DSnkMioulJonr3uptQASybBOHIN1Ln1xSABLlQYbtQhMtg6G GfW3FDBfhKy057lSWkS/4GYuOMXPgW5bbVJxi9f+PSFHzqXbpzG5kXtq+ixpWm0aeijn8ikjfb5N nvJd7PezbYVstWGGadHlDybmLwoSGwiZgsSmrT+uyMjARD4UDP0aI8PZIVFGtqojTMy/B+jTMLRS T6K5xuB4Psym9I/vPouWr10epX9rE23GIssZD/qQX4xU9JJMGa9aWkvlBeps5PrAxCsUNmhHbhBy Wv7rGuh8mpSUWANE1fZCz/2lZGZUJA4zSuMP6m7b25ETV1ALQmsPtBkulh4efIXa0ohyMdjYxn5x xU0GaG9ZPjyEJdvYpLaPxuU9G4bFp3/J7LKoVtT5H1GAXy7I+7FqCrENLhqgFy5CeKO9PHuUYK2g zN5EgPoUJZ3bWx3J1oz+WOyw7YQq/jyH+KW2evaHgWwm2PVoiZyDM8xsI2o1qBFbKjlpznpxVx+y QvQRyw68QqDK4SNogmwcyIphyLa13/41jwusRU11GLxiefmxYtPuST9SQllEv9gRPMxeHaNQPiWc bQ0hUkGf7HTeTgPlZxEJBHedZsPcFfeQ6wInr++Z49zp+uNLfXDbyw3zefEZ1QkeJWGQdDK83C21 zBgQ+6yfS0F8XbHcQrV3OO2BZ842i9J7j1PH8S94pKEZdAyAlzvJaMkr39H61/8XS+N9F0HkD3T5 1Gs7nDJ/A6QtsxONP9RqG8aZQbhWEJuAKjfH1gwc1/NnKM2oJv7LCfXbeHIUTBuQ/RTZp33+z/Ti PXZpilcaLKLw365Smk1Nj87jhATqI0xSsJHwTvKB220ArPgJx07nmv8c/JX8fMU0os357+zDhHNh DjeLGsILKYL4Rzg+pG/eA40O41QlmZ0XHl/Cff9Tj3rFe2hxwL7y2Jm19NfvStLDYMMGqBrSXhJy NbPxmGXEtfoDzNUZL0EZe0zEazqfoPqjhVtOepZ/sM9xVJPfEk86p0C3LjCF/+rQjR5eSjIQzo6+ x4nvtTF3C/3xrRd/+LDdDluUX7llDeVNGAaVTQuzshYlSOLfcd/gljDE1pauDtD5rBo0dKpnoMrr 0WQqabH79y4SZdVXNSLAXjQfHH9ZqkJ3ItrAk45AYc9Qwh3S8nRECofr0JfnCtfRaDUwIlHVnfOH JWV0LrA/1X5VNFzGb3qsWfzEeYJPHc59U8T3M23fN6qDa48noD5O8wPNFfzSg09imcnosIaW6ksX u8q13ySpQBd68tO5T6G331+uI5RXlILn+ttb5TPgjW7pZwlzXi/IygmSPLNgNNujamVvNZ77/W92 mMNM+tCJbufCcxfnXZPZ4iZeGF7r9bxVz0GYEn+7jO2QuutLWOr1PNm5FDRONBFr0MP/MJxbreVV SvpM2mi+0WQt0OSTJxoE//eesxrpDUbJ0KRIPg5qtaEJSIEPypp/2RqfWIEV9mUx8ExRAdUsjY87 66/BV4WxYrk9fC1ic2////oZOpFRZceeeeeeedPwxUpOx5UwUHQdvlz4V6wLjDh5wiTHECrYepll 2sC/5ypUpCjkH9w7skdZEzoF0VL619SA/li/xT/aNV9U050z6GnPT1otptqIRHr51jwxVSc1sxif du3veB6CkeOfOkDkcbIGJpxtxmIymY52wrAMbDnjb6clsPO9rYZr2gbvKHWIHEnTCHcJadX5+llS aTOQ4+SOGLQ0eO3/Bn7QlDs562pELUcdPn8sWNWEdMkkAth0iYyhUBSAHXUzx42rsmgus3Y5oulO +95qeTrCu5v3sFhb7HLDHaFDsTtqbijJ3KCAxlN4VQKoMOkmyjf3nzw7uQdryFwyGPmuoNBZkNGv +mW4YLHMuFQxqvsUiT3JQceLSbfrshmv+NJF8VIPjz+35VN82gDEvYoMk8dILT6X3iCS7/lw5cZd 6HsJkyMGF5DUWCmYMuhklsj0VkSo6xR6FELInXnhyx6cAVBWW5N4Fush2cleCMWsMi3Va9ZS97+z 2VOV8KaoEXaxx/Vp4W0UxDe6931zpYJa93jN7hSkrOFoWMUNbL6XbOAZiA8BRR+ygs50HaT5gtIU MqTq88QjB++6thNMwscBVhWDd9VcVQOD3ZitRZyzhwvLmop0H/AnynwgsIcgbEbTmgWQhyI3EH3e BkmoRQKQ149uWznxOxM0Ty2KA15z7xH4j2J+muYsbh14vuOpaZXWwlflf/XyKpScFbXFjF7Xn37H /KC9aUHmrbCswo+IqskhfcOGaMcQpVzioaJvi9QA/DkJLh7Z+bD3iIXofxsOj0gmD9G8V8bdWHtf 9EDdKExMbFAKNzdnf6gO4HkmEkU4LfAPwxh6X6ptq95+6pOMkHGwJEDNI2t1mOVfFC1ArpikFu2C hSq1T6KxWkpXH2v4uQ3LT8mIpk+hutWdj44cO7Jdwakr/j4IBkLllKTpETlMf7xQn4/C0t6AiCY6 jwiqODA1DSFpbgiQuzY4Uzi1XEWBSXSd42Aj3choIj0A9DeFRf/5h+T1tVVkXozQj7281MFzwuaa RH7fjiVdKgwWq49GQHuXkNZHd3JbIR4kork/agpXy1uF2b6/rX9JCUPXNTqBlEXpPQ+7/JnWPHsD uIj178O96iy3SmZek9EHYXJ7QAL6JW1/R0MypKPhhQRxK+vlJh20vsr6DR23c0K76Wa0M3BVrXlX 7s6VNrBml70ucdmEVm4WL3BP4v5+HCSajiBmXNnDHpWjA9iryN/i6O3jWB+3yMrU+VqQX8vAslUN awWeqv3Hj7eSv61t2ZWWYycH0CfOnpPJ5hXdTIZEcskKD5gE+GmLKfpldJSr9gJ7NtMCyRZ8RtCM RbjSBoSd0DsjTFufMHg4m4K279A8M7o2HuwX40K+oDFG11nYMH/nuASjMtt7hHQ4gMi2tLOUJ1nt UP1uP8FNJWVKiXyAhRXi38rnkg5B7MZMpEhYCNiE87gXQS4qny6o1HqbYo7nTd5oUC4BrXHaZ8je 3E/hY5TvLUtyF7TKOEN/3oi7tc/5XUdwxHb3c5fQkWUHt33MqpFaQ47jTm5u1yZlMavCYZyHo8fW e3AylXpgaYO862K5WRX9IMEt8HYRiuvy2oOyvbDFdEMeMaGofbkMPsUXvSzZoyxW7SmG35NYBwwh dxXABdeG0uw30EQHXJ8fdJaawq4xtFS1wW0QkUNo+NgWSATkfaDJHstSKzSxzfmUIx2aW+hOTMSt 5eGVnyAoWNrpfx8/t/JM0ED/MpF2/WPy5+9CXMYbxm+pTsuOSNcjK7aO/mWN/R/OzP8P8D1MzJ5K ltmFOR+GmO7MGQe0vr4+Id31WQYlWRa/YuBrt8oEabf8bMiJuVtcuZzXtkzbd+AAbAYV96annoWX //wB9lZVhq6ZqKbN5IC4AlsR4tcO6GDRcSze6LHL6dr6+Hl70gUWpoWRQ9KLIEy6n72kcU98QSui ynwfA6Za9fZ98XvBQSoJUtP998+VcgRgU3zu7+eVh8XiUgannn84Lq3jLxWJNJ9lkrtmHCwH4Of4 p25sc83eks3uSkO2xPuS1xl+ikdiKt6EtP5DN5U+ZYcckaZ6W3xVgIOz2M9riuQSTmf6JSGrmbqn m8Iy4Png2uXsllrTRyTMkXG5JW8z34hu9fBd8YZBB2Rm3qtMZ0hiWqsVbwR0D+WWJj67bzNH0Cym Z2iYg3Q5yBmDdwob9TUMRnF48kpV9lL4Mr7hKKqzKib7lMfAM6terTVGuvQGjkQSw/33MlEy1DRz 0ZF0VWCIca9qUgFG+mgeb+cd/RhPLvVnr5e9jcdX2sMx8oK9+qbaeK0Cgpa8HdyhNXaXma8BkyWQ sxnpBxESOe97jWnkYlDhhg0kRft8STX31OrOpWhOFBC4qmZEqlA4SdCGobBYTI6/7PhW9v96bPP5 OeKCHC4y2AbtMfCNP7OetfOuImQnbyneLXeBvBsCbXn1Nf+CfipGipswP6170t4LPxIA38W6I/yp mwwIaCdIofZfRc9VJ2d7kf0aheIIwNldhFYzVv7tDL5ZYOJRgS8Yp3I+pN6qTd46gy2h29tZaACG M+xorWrhovG8Nl+fzaXUqWhts3xU98wwIbL9JwNexyrs931CwuIG0M0xgyrM2kuj0Zo90db0F9A1 ApvBSeg7VhvL6P31VX2+f2xGA29sIYA9fpZsWdABs3CGC/4Ccu72hOkO0l0oL3tz9/04/JM7lipe bU/1xcNmc5fe+fpFXAebeaCEkz2d6+RdxJQLJacdnNxSBFIicSz3elLlRqIYzfzXitrNNW0Gdves f4B1ueXWVvW34NLwetwKSJebukLG5cfiqsfZAjRTl+5RRoLNtKgLwe0CncHloGzOzq8FCSijc5ZX 6GR/ZKqYVbkrEs0VE9qy6gaP4JdUEN7E4bZpn8UJsG1kFEqHWZyXeGmGcChhsorw656YgFKp4/Fp on/fAEWqawELFiz8lDus/U8/2kTO8Le4+GtdFWW7voI+A1R3+GQHnzbGRTnKT+HtNrB9bPUrBAm2 Vq3+AouKXdKf03broDyfeIeGPPlo19Sz5LqM//0yjg/+fXQdWuYFRLCwG+NvQ/YgLTpOulSgiCle K6vYX2utMo6F6XHc+WLHgV1unRQAy6EU/e+SelVj14x2lTIfhjfJFa2zYnyOvSWQZIp8c58nIETQ z47AG5NInXqcTbkGoFEIj4AKQar1aTd1FicmHoybamdM+NWlfpePj7byGPf9wbKeyeWOIYXtma9H wwTpdnXS+xWuWrM+oApH8bk7EyVEiJlQy0p+4fmVrs03UX+e43xb+EEZ/HcHnjbVJo8PfEGRQXA0 OzYnFu40hemUWpdEzDET8745vefPw3vOZaaZk9lOXloJgWWWLtyJt578n9Rx/+lSioZ3S69LTwhR UeLlSN6GxYQf7DL9+20tf08UrPlj+vganxz4i/GwpeY/F7tfKimGM78SUy+B0jWBpmTgHvwKfkcS 26hIv0IW40EilXy8AwBzRLJn4+A3EKU+4lsZwJ76a6/UPKYWjNq9X9ebC8oRE0fg63AXfeJiftEg PztRl7VoZyzo96AxuCA8Go6kHsz7q8PFGIgMYKKgtkos2B5a56lLypHepSe6bH2nzCWJTt20kkGk +9Wt78WOlyV6dI9ZG4CYHija8cT/yxCw3H9zQfEejLdmtBDjun/bLR7e4K6od1dY3RuCJknBDEKh bIQA5C8UCeFWSwCFd8b/jr2SzreRc2cGXjsssiEVW0Ac9rhTwXG4XlxQv931/EITYN4GCveCIAln //MyfAngKXNmzIc0LK6PVNne+95ONGKzTaIzE+iUFWyrxg7B57WLENBBFGKLElBGGKrLYoBuaDQa mRoGdWBMpGkZ1f+UUDHMJ3kQ7kmlcIzep9T/QQpJakV9sJpiwZc5TY2MBa8/IVgXl2KBCXHBVf++ Y/26PJ0umBJB63bDglJxGIRKTHYnyElnAGrTzluKZBWim/bqgdAvOFu2xLNii48v0CrI2lUWcHoo knxxGG+w8YsDgi6HE0z87lh9wHDWMihcJTmsWTZEJtPsLbPkixjYjzSU5neNM+jutoHU9pc1yL8n 9MnKLfNFhz+YJO+IVSHrYmebTMqUIKiBacz8Lod7PnMRozzyNqmjKIiENSMYcGAVVbT8nJCU+Hez Y7VlGZDpc0OR2ADXRTTiKD9+XHWN8d0coLtm4KbY2TlTxy3EovqTObBTe4qDc/8A1GrdCg/M/Ljs KUPJ6JVGB9seow1cwSzqgOnaRHqZ9rCKVo9GuBhKdnB6afnOFn7vbLnovgIL5EOlkip0fa1trW6/ UgWE9cxtQFm6ErW4nH7sK6iTPZdXWdJKu8w6ZwyfrYlzn+AWyFCzaDu/Q/kadtofJKxPvsCwg2OD 6FiIrfDfjh0suKUovO7ldrBHYwHeiVaH1W6s/4yJSvZHpenTXMWuUGID8Rt4tOHq1ANufoqszmLh 8YMsVAfQGoRZIeH8jsBYOg/6xU5QRLL9diP4nDrZSIfJ0E8Ko94057unVg7hHKsmzRWLGa8MqEuW DwFrDDddMV8l6uNjtIu9ii3URjuLdphvVt2a9iKlnr8DrmiIeYLYHFzGv4Z2IkC+2LA0gxDE1OKk INT9MfW3e+ltryXWRJwbKNxWxCkuiL8KN5yotLWNo8QR/p7lPvAgWB9ogFlY3/h57ALGuPVX2T2o ATMr4Vwf6a8PlqQFroEPhICu+9K8hyfFPGchmWJmkvJOmIZvx/25DBH1xXzUodWBA+YxaAFaPpy2 zuFM9shpbHo2Lk9w8jwRlEZioVKiTuqkvxi+zZvVzKqYFe0v9lhfInjPlQ+67ZgCHvyCawsVHNIb gjNLnwOaQq/kbkoa4WyvWnjrWVhAFCLch/h8/Iv8gO4oEq0dxWzeN5Ouj/eyngtP7Bcy0CC40jrb tqzg7pmwyvIpDlfmDUPUl2rB7IhUBoUfHZuOLp0q8gcJL37pBj4qS6ir1OcyAHD5m9wKwVnsFUyX s5A5vl6h/pq3O8gCOz2dMN1gmr9gJjrDAn0AYI976ZXL4yC15rhTt+jm1Ysb3fA9vAXg6MSwzBig WS9Bdv4eHfs0fRTGTU3vHKueyjVMpwZoe2euqmu95sLqzYlK68nakhymrLvX6mJbxfUeOaQoDD82 lrFuMppNABReifW+4qFNBnxPqnYJXLDcFfR8WIUmNymMk4L/gWKijv2lnbggP7714eHEibVv3PAb FWs1p937TlygBBLfXOCP/gCCc8WwE/tym+Rl2hXfiNLYpDGW+FFLMRHoxaGNKqZlas42CifUbkUd Mrtqo9cMMKZVSHZTIuBxAf0wuFeaNy7WA/aBW7yR14cndG725V50uaIgHfQiIz9oaFuIGMI7yXUh eCErh/Jfr52L5AoxEywvP8PTmI6uVC2M4r8MalpaWcfzT40VoHQ8JOkpeQeGw6hcavfEe94bcfn7 u+ndx3Wo7Lke/GnT7kr35aEPvQjNuSu0c5pxnm9VerWC2/pXU/qdcTuHCF70QEOO5YWaXWzQjxqR fauOs5glimQR8K5KI58pTW7JcENVFtbPhH2lWkYlEb5EotBqygp8ms8G1oCDYcHvJfVZ6aIsZmTa x6dxslAsJfOWBkhw3m0RtTvzNNDnaWoX2xZd42GmF+8fS6g8PtlOip7iY3NlakkEO+LCyqLPJML0 W2/0xqdyX+0PbMpUYVw1NWs/skAdE/ZK9RN9lEmPJ5S0tPr5J0Mq8hj3CuDNaeW5t3TLtr5oLHM8 8yYy1OS/FS8kZXoUse5ceIWpuXdYIMJ2HTU9LRvpuB4AZq90ZoZqPwuRvUjp+zxTGMOqSPUHnnGn WQeDps+OgSY/5GynoY1338fvQQrhv32XBTlimkPMvAKahzMpPW1qUO56g3WEMfa13ob4K9cFqeQa m0kQlFvrl5NCoFPA6g3KbujTqhDblYalkM7FbISmyGDl+uQHzBlTuOay5/SZvvNY7g+SDk4nx1b+ 1waGwOVFey1bfPr2FBHI9/3R7aOIc5rAMhxeGXH4D+Ly32lKCZoufOcJWUnqTsyLSDqQMEsPnIVl Nmfu2+/F/gA7IAjLzSWRHDpPtAr9Wo0vpizAX+HIS03XTT2eUrEuZlElteOeAIeH//IeQbneSlfL +0K9wHUDk3zcIcfcIEbqIUNblmIOnqTDy88V9P3fZwuAj5AbPZRSbB5KER9qEc1GcN6gE0s2VQwc 7IRlZnvnVELzuA6IC/jMiwSTIA4+Ipy2tMDDObbm+E0CvpmwXLQzl7SifY5V6coPn/RgTyvqVPg4 BoZZBFavK31f25wL/PkEP/WgDywsodDdGnfJH0ofofDBcdpqL47AurEhzUzpH9enwHFw/tV1IDOR zaqbaaXt31VSssv4xQHp3639YaCjty08qRHmGp4T8u6uCgqoWKin61OYIx2XeAH/hN0JWH2wETnm pAV56bBGarvyjxNut7Ay+biVe75nubGRV7tvMsxIHfShxA9cma5OqmHfUS8cg2H3+46UCcEZpfdK GW960/BdxKXApiNPyx7ZY+DBTljX39QbmoTX6GjcKkos2rVXX9aLF1rRZ9e02j2yzr7p63nOPFUl FSzmCjbZzZpUAveKXKRA97aXGswXfrQYc5ii+9JBLg4WqeVi/KxQjj5KCukv66QXbWRrwpN2Vk0z RB/zZ61p5tN1ydvBYVpLqdivLJrnk4RuH68o54cD+TVbi7k/x9/v7d5kd+m9RIDGCJKHkBu8r1e8 g3d0lmU1liBBS4B2ySf+EAhHyWelFQLWqQBoVr9LdLDZVnDR0xkKLpYpvaBofJJ3jbixd3P6HOyP sbcr8AYF0yHW1cHZwmFHsj9VjJJOPm6PuGRQu0wvG10mldBA4zBRVUu21h4U+L/JnKHNSZvbm3qn RdaObgqmnk8DhkkHbKxQrzVu4AMVE861GUTHscvEPvtagrmQmb78f/Khyr9BW2p7V4Ir3e3gQMBC xvbGh0lyZNZApZiSeuDp2ZiuwsyWEB/FfxP3HWR7j/csYXMuxiKk4wM00IyGXql5RvyE/q4Hzz5A 4GERRsi30ZsM1TckmAirQx7CIsqUyNutQeLMKBwNPdk29FeGgnJGYhP/Iv7wgnlAV/8IoncSM1UZ 2C3h1zXMfKNBxzz8a4CkjRe+HEJZ8fUhTyWmSCDb4bj7dZ06wnFPRbr+1/zklYFM3PHPdHgpfgoj jOcwdCMKJS1MsJUUFet2pcIPPHNcfjh2Xbat+x/Y/eqkj7Fe2x5btCi+lviaCHxPLnurfkorqOyy TwYa6rcECklNq9dC7CjvC6SOirkoxDWOJywpvgqvF2XxrrA0S+dZ6IHFwZJrlaXdSQHVwk5Q5Ija X1cldyWa6JKxhrOo8OXCjHmZpfExu3AG+WycIUfEkep9YsLHr7hS5sDKytzHGFxDQmrHhszoVTjn 9hgNGPzMDQx91TK9EoRClX9cPDnBJHlxkqn2cZLMSxC1dw2RbSkLG36tRp29FFZG4yl1dR1CA9ug X32C+Rl47f6XPfyA2il4RAOvfdWFgqTU7DgAuaO5qOoElddrXdiQF2UcZjpXqhXeVe2ZsCAEKpFX /981Sf8wFWVK0w1nVX586xV0BCMzpMH6hYPOmU62UctYxUFg8uqMvzGP1ABUBiqZ1Tf7+00z+eMu xAGqKC/VPrqPZfF/d1Z2sedFeZ8qGNre0iWkTZlf1kKrkeZvwxpLzh46hBIO+H3MA5x3MHSjk7V+ SBNS9Uwqqwxcj95Dh9MfnZwXT8RQ9GqZXNpJ7NaCBSLpYtBKjJ93yHZhqF3bBxwEQt12jB2R6FLu sK7/iwFkPfT3GhwBYGvDfSSZE12T/pGHm1qeaAwTD3PBHxRaQ8ZZNIkqyHyYrX7tNdszywDZllhe yU2QtuTdLhJ1ABJZMt/kuEh5iLwnoF3ZaQC10dRz94iSoAkAR1Xzg48wDEcqAbQceAGmJbYZfovO WQrOtH7iI2zlQ9qAYgZXK8Z/dP8cgtBGXVCOHB9lIeLrjBBDtefpDwaK+DJaHADeITmzYdlAV4Py Xjk0EHcZTxB/GD8Leu6Q3CvZH8/b0YwRwOWI1mV3pshp6DwEUbHpWl5Ymq/TOVNwSHlZghpWFOsm 73aMA1gVP/+M0Agh++Dbx5tjYA+7p95LfGqLBICYgExR6Jtk6/oKPMZcpz4E2F7gxJsEt3iYPOIG TcXcgPSXbrjOu0pT+QqQtUdas1wEiJtXoT/oc8jBB6mTpry/9pDmV/5JhOmwZg/V/FACJhpFS/lm e4UBxpS0W1N5GG7hTl1mZwlp2G/dDSBab4Os64rRqQWo+gv6NDBn4VlK/0xXQ1P2knVm6J0qqK+J 8lWYkRvED3+5gnX/OZhP5d8BZL0ZSxZyWD8g/DRMfhVRqodXNPXClcjhXEbv9/xPnHo2nlyCrmTW D37CcU8dMdJ9Q4N11b6mgO4QL00k9Oy0Hms9w1PU8mLy9nmiXSHokUdmMbqljTKFHTU7JsiI/Hmd GKFI7DelcF+szdmFIUQsUGvk/z5Akca6ZmFAhieQ3N12lrKJPWKaIuL+J22iOsIbS6B28HAXju9L rBuPYt7hV6p9KovLGXeb408z3iMHJazFML5JWDER/VezJldrd4WpnTLH4caGg41Axkb/JSGcyawx CDmuSbvjzRGi6+oBfy3ZidwhRabQYfwthSF3+IEBVQktYJND0QLaZxNiJtE07vrWiJofDo/SLCe4 zaZDts8z5EH2ZmxGZsoHe+NjdF5AxetD0J6nM6JexVwcMRUFHNy6C+goPW3KYdPt6TN1ufBM56hr hVJlu+v5Il8/8VtEwsyA2lXqbKeH0doUllIUQXLuhpOQ9EIR4GOkXwSKTUU/JgEVShMSm7Wqqqqq qt2gk2UvsKeKeHCz+4OfIKwKSHCGbxxKJfb/YSjqInGheQzo3Av114RApXszPIuKqdX2qYnss+Bx TH+OxTylgOrrivfRnE+1jY2UfQox7tT7kSRkuvJXG+4znQBG7P+OC9803ltftrDdbFaugt4EoHC7 KNXeJIft6El3bqXSb7WyUtY73yFIAT9XOioa/7mQhjkb5S5AtFatcpgFY3wSsClcuMYJJxjzYfO2 /OcHyLAF5byUaTPRoiQbnm7OzYxlw5bAGAyzINYg05nZYHsOzRvfa+Z5uyr5ljEHkKdUJlthMkS+ 4m5vYFWTEKTB8jZ6UCUKHOA+xBWqFxe+mv4K7Iu8ysCHE9/rXyBrGMaKZyCxz0zUmQeocw/ud5PL cOLHGd0qI4h9wYaIxQPWgwIJ75MfkaZ50IQnXtB6mPKb2H44Y9JE0lx8VviqXHW46g1rYSiwEOUZ zjVxC4VzCiQRkvIo5EsyEMEVoSiPdplx6rb03SXqU4M/BrZivhoFPaO+DBg4u1zJDGXdEUSFhg1h X5yi72JWwmYnf/SjnWnorc8+N5ObFEdqAh0CWs2ZKqzdkyBTbG1YYRnVWb6O2/LKQ2RhSeqfO92R s0o3nkEAxWJQSJopJIGysRYWLb74YurUvEARapv4g71Xev8jPtrODz27UkM+w02AMaXJ9tshvFWM kzpRojNIAfZCT4f5bEq2oUOCdxw6QlLCggKQJp1OdpLitTDCtmOy9H3/eq4IBQJyytsAEsb0ocFt XjBxC25AhGKiyEl0FD9xdecw/p5MgPPAu5OQAl6p3dDRyvd+q2Qo8QQ+63X8rSDoW06QBRskoP6Q D7rAxspQZZaGqBqVW5GQdRUfOmRtMM7Lj5Q8cWspg4dBUJfm22UgHA2PajohDzcL9H8T0QalTTF9 ftY/MgXvHj4TGc6VjqRCIDlgJNZEfd6U9YEykbVjzqy3/qfkReGAS1Vq55W1M0lICzi+8OEarECV /gEATof5BL7b2/j6XF6bwMjl3zVrUEW1q8AIODBXXdhj1Fc65sxzVC6GhwN7QbvSFst6KCif+jXA Zaymm2swgNQ48cuob3L9rU+7wtITgndua3FDVc0GnZLjDId2HKv+AIw3nJz4rhdU9gbXMpB7r9g+ XSypVuovbS+YU8pD6uDqQnciF9HPRXe8K56vXqGdw4URZ253VMNFQo3j8jx6bGkj4bgDis+kAV6n mxmGNvoub/vEb4h0ozJWhN/vbaxYHvKb0GKuikxUKX9J7MbSV56Y1+ahayl4r1IO73xl/jlmD9iV sycRPos9H5WUVg5oHOORCf7wKw7Yj5xjQtE4WMmkwDT7+/QpKMwh/NWmqNsz3h1kpg4/NjDdQp9Z oYdXBbOew4yZyUiWQgjkEQ7+SYUYvsW+dv3ZTs8P2oZrAGAQEpOK0eWNZjIFNYhwUIfFYE1XsyEf KtHpjx8UJ5J7egW7C7LihHQHmdYxiauhtIO6xvI8emj+Spnscno1xFcsDtohQ/rG4gisG65qfc4I 7CTBTj9bcah1pUtTecF6rVuhtyPRTEwY2XlYaWGowZ6OjtzYxxBXz6zAEHO9iLnliod97Gq4TEWD 0HZ8RjzbdIX6MvS5ZCMPCK3ZJIda/5fKcWH8/9FwfcdU/pKe9xCE1NB04iheENr9xZJqmoz9tk17 QWiZzeYr93AQgocDDg7sIF5FOWmUzLqymzd7raA23ms705Ew3UyPxuolTFQ1OXqmwKEvaNLhl1Qc P9PCk2pp0j7zayjDpD9tRuWJED39GOvAzRPtiX33b+VQbJiBB6Bwp15/HLMrxXVJ2pkGEsZMZfTi NQ7LX2eb5Nl6PTn/1BiM54Ir4x8qImRQrhWI2DqinxpPL/Y4hxyxh9lxaJUTxV/LcZO81SM7XsqF 8rbaFTpvT8a9k67CNsZ1+KGHhSiVngN2ohjn+WMa8FAT4uzPivC1s2G+jCZlJb2FggcjXCDtDUzZ P3R343cy4cMWDEEbU7IQuAla6qa4kkMk49djZQ2rM/kpVfE/bfEBNyitkScAagLdX+R9uZb2Scpr wtZYv7iyJ0jnnmsFUpVt8kCa7xHFH/4YpeZ/RT6iJFJ6UNvVNq5AUQftvn65ah4exLauZAmnY03z O1nc/NF0J0x9/rGoh7v8XJmIQqSzTJFL6nEnMcJ9tXMxAHBDSXgAWhTE3DFw17OmW6efn8A/+P1n ueU3TJPUWszFdp5t3nBHPStt0jwp8IYUVkjz0IIYKo+Jn3h5csDpcGP5eXqwwWMufw+CoZRvIHp/ w6NDFixY+yeWXG9x+XoXe3CC9aWLPGmQtMDnNrPKSS9AAQQ6aiWzbaxahAazDv5mHaHRF5znN27j x9Fj5mTM8HKy/q4fI6F5CEFXgqRJe8Qj4Q9sR9wyOP6lqCi7nW9Pq4GxW8eta+9IJ34Cdtl/h1aq 5CNguURsgvzg9c46UE8d0k3Kvi1rS2wZaqTtvuW7p2TL1DvvwsDVXq5rzGqKfDYYZIYlE5cQxa2h lew40CThpJjyUvKj2bfejo9C4+HA6YZlmhHjjVJDNELTZb2kqhT6g9/sBO8j7Slkni2U5BLwyDPI 104tS8gTJuIVnirr4XssmBTNC/EovbXXEUITmzZVy9IIaCif5MynznWnsxKDMyr4pjVDbLlGaeco R4XDAhruuHYgaKvcbUBrXLzTPiZqrKhmArjylqJRtHhV+QifXDFbuwISXQu2QUzbkBuvJ+jAo3D3 tLArx6fblcvEa8/EBLV6eNjD4jN2wgdg/d7zRN1ECjIm+GG94e4FwDC3Bo3FgiFdkWHnW5UR1OEF I2WF1goWwFyUK8ZGO6ajIDGF7Z+YRpR82eKyXSI21kOB7qbkvEJcJfjPkVG5gtTEU7C1yfvAjVSz a899omyb8vSIfcVGGnZP+hTobXf5ZwbCjQgo4w5FHCwwgI+I5nJ0yUa7U13TxoRxGu1uurF3aGIk 1d+vQzahr6bSaNnnX6AizZRAep3jZr4Ftrg0G1hStPsPvOZJeyLOAehBFS5MZ4DxjXYCyMkAUYXn GhxziO9jy92+p0y+QAYr5EdiY8JHTUrvGq64frz8AaL0hQd68NsTbohHrNfW7vJBgzRErYO/MjnO fQXYNdnL3S/EA05CC4k2iy5KW03y583W5r40GbTQZAT8pcDvLbXqL+YIieAh23K1PvUEzo/Q0Bc6 7Jnhyl5iBwiZJ0S+ge4TBv+H98jafnHN2yZnUWsaywDIqeHg8aKPfvW0W1uIqjkW5i2BNRYmm4DE JBoS7Goh1gawAteiOkK8Sjcf2B7Z3XpMBgu8OKM+yKug99QLZnzXBWgLmolb4RG9PQPTDOIvfoQT HwznxzBqwoSu82EMBgi+HiViDHPs1k48S78kDjC8taPRXzpLe7E/SZHKCOWX+JdfDe058v72uaJy jdt07UwAwlO1BmU1XuLZ7WJUt/9qAX6mTI3vdF2b9UVrzRC/E7ANntmSSyvTZsrkkpm/tD/9UEA2 7qW7DXFZH1/y5J6esuWQJIcCWKQ7H+oG7BM8IJPaq61fenOgRG/Wlt1vEgHv6Pe8UaAt2OMA3qHW +Ag1TGBldrRgN6tWhswEIi1xt133ALRJ/58bw6fZrFsftOiUpIsbpItddD8tw1vYYNGHgUjMKAIW wmMBfXKH0mafp2xc/2I95JuBn2gfdehGOIvUor9RSrKGcCbHexdDyWUbPvarJ3hD81gq+i1E5Ww1 Cg4vKqmQldWB1FDYFnsxyzeMEF9Mh5wYNVtJ/aLBr77fPankX0vKfGuh1sofMNtC8xyHwoMDF85+ nGdioBPGkQ5hJ9mtR1OKcM5sC+gRhhs+yOYNpQ57YHw4o3GVBhC6QYPH57vrHwTez9ZexslDQxRx 3xoF4vDh6aaUDlYF88yrndwgJbScgKPnWZ6XGfSagbqvGtw/e6OUWzPkawomt4ZZGf7PNrSZz7AC botzWD97CNSH7fUV/2tmkZMgzRiXYmzTz8oIcZY8HeF/RnKXkAEkPSy8LeWW7H1zvpsjhCZZgfmU mLeoG58zJhWgE0dhMuQ03TJyU9ZYNqq5Pz0W7aNEYU+CpUTWrXw4P79ljc1FMH57mXHn8hpN3Bul ludQrSeYUTp+osVwVTYPujngHT/XA40K5GZucsRIjc28H4zcF0cG650s3mUFZxdill4qDkZlR4CH DcXUrSLI2z7qei06omw+KV/ECfvnMVp8hV6R6z9zUnvN6APxp025Mn7ddd9EbjdKSTHZSOlSGgAF waSSXrBMASLAHXvj////9fEBumZICALZZb+yRLiJf1BjqEPFyRg2w0yrxJ65wQxcdRkMSddM08yT xNnQ8aZ4Uz38m3PJX8sGAxT0UyGkP1w+GMrPWrGSHzn9OlP+pot9jd3Qea0k3lX3QPXkUbNuMOoV KiGgKFW0aq+FzmpLaY/XKEiWyML0tsfn/XSfz/k54HTjV1yfpK1bDM4lGIUR7KOfzv8VKtqpvetK lzWdjAM91kbVasyNWEQV9sYDnYKBzyuY4Le8+YSd3LLlVGjndvdzmSBT2kBBspYuna7RH5WOab/e RS+ZcmfHmBbqP9MhJB+r69UBdulNIfjH/A6E20ZJoNZgn05D/Z3kv390r7AfYeS4YnrtV55CfcN/ dpct+YGrQbzXOKQgNJpLqFwEzlV/gl7D3Zy2rsRjaexUWvFjI4N8fv05soDqGpgeEA0WaB44idoM MpV1HYnps0gPiDLZk5b7m0vQXKW/++le5s/DAtZKy20I1dZR/vg9uP3/UKl6YLT8VW00J8cjNPw0 revJKnNPgCh9wJnshIIp1DXP9Rw08js0DknGElApvWynJUhFXQOifD9Ig95qDzDFXrT9Tuxsad5N zS6dnkBEHEf/f7uPo/vYd8JdJb/iPINYo9nMp0ApAJZvKrHV7VCbHHx0fCbeaVeocQ92yVU3pSY0 CvQSq4N5UWBnKSjiqgJqc6kZEDUzXNokUjv97W7xlUVIlIct2mPq/S8vaOodrXhZmIJYKyoc+CpY 1A78uv4OyNUoubjNBNNtKX/8RKEnwrpGgxoaH94dbYp6XIDN/hB00Af4Ejl9YvGRRxHjSQh5WCa9 rzyAqYhIqnkrGZFSaU8ZGPKxv8cbngkuOuutMd34Iim9t/tDOg2gQOgLUuCp3+PqYrQ+c1Z+UtWI Vx0YOEv3f88UfYkLMVK6mTk3qjee7QM6tnOi1rF/JadrFmJuQh4Zw44fo6nTuhL8m2lPej9xW9uD nvXs5egVTbP4Cgf59ApT8bgxsOgyDQRMMaAAF2+SpPcwDP033vg+vS4TyJ+t+7TNYpHVThFLAOzs XiXQ8IC0SG2KOh1BSLpq1DzegMzcGKbIazfAkYlVw3IqPLq2ldI0wk8axEpktQG+9HarTjKMFbEd LWB6U5TdiTyd5xQ1sae+wybSckkfLA1tHU2QDhxVPg4hU8aBXZAfB6w8yydQfnJiZvJim26FKa+A ODztEdSCxKQ3qrgR/FGKNUwLC1xQfqpfOs+eUEzEwdZ6VoMmMQBQykTJ5NUePYgpJF7MjBUQl1Oo ueHaoKoG4Yk0mhLVFjwI+92eeyDJLx3qtgRLDiD7cF2nIDVkvBUfTPprIjUu9SdEPk/w51UN2nFT tt2cuM7FM0llgxRC51LsSnt7GcmUGShs/1KMYHzvEhsnQr5cdfT8B3Q6dLkwMxAZJlrTsATWRSkP PYMPBiRXAyaEJPXw6XaS1/5jkmTczGU2iOkuzGIGcFfd93E0+mAvbHX+3MdAQ8yOMBv9sUJGReSf 0PJqdtixGuOy7sUA3MiLajtWYz05eSJEQxdp22rX0fRJgmVNgRIHwpCIosOsbgW+584aPQpX+F+y 2Kcrt/ef//5peCOK4riuK4uDk1FZ6WX3hHnvYftEpMlbHR9iSKvcUtB+oqzR2Ta8k9OiQ7Kei/5e aAOktooW2ZoDcgVj2gA+n3p6vE5TUg7giICqauX5NakrqVBF7qew25biXqKeCd6EC/sg05ivXI0u dOiMYPwEhs0Cwq6tDY4hoZqvYIL/BhC71H+MNcyxRi74OmWP5ljriK7GRPxDCmf66UHQtsWwBgaj gTFoBEmnPT7QKPkBBUg7uXMMKbeKOLqUTIoWndPto92ocqBh0q7IOVujYsH3Ebw4j8fFdHzZvW6G 1+VFdufG72bY3gDi5a4wbvInibP9rCO5fq37i3MsBUCg9ujwXy2R4hgkBWYodUjYdkg8m4TT33ns NZOoXHptk7h1c8plk8Bk4TD9JodaRhwbe8u0EQeJTBmQz9hExoWmfmvsksK7NwF6H8cUUQkZuZf5 G0k3c/jN7CRisN5JAuU7DUHcpc4/0HENRUsoW/mpN6ovxEZ2lLjj/7HhF25eNgliq8GTIKfLwWKV dBRcORCLyh1eyTVWitVcT052PBDSUeD59jTR+LO+NB1rcmQHe8oq8NpxaVEV0SwSsa0ockKW9Cpa ZgxWUQ0blCDpQvBUxP1CVo/+o47koPUpD2RCoDwEljk7qAJkWYD3GL7oTXDjc47bSp+aOyfyjjt2 FIE3OWSe3n5L5k18NiIA//055mE6usn+i29mF1m5kKMxO0bj4A1w2UWVcAROolnB/FkhqHFN84Th bkx0iFsQTL8GqaRCsVuDQZf/JBCFyO4oOZbea12fspwGYfU5t8EjN5cMz1OGqvq162cuwo9T7aVb JrD3K1rWOHy9s9WnTZIhYsapK+mFt9IVgPHUxIZSYa5KYXk7fVysE94DWUpd8B9ZS5rOQkoaEuh4 uuaJoJMQ+2X9khiW1MQleIWeT3Rri59vfsREgejI+8bk1xWOf5RhT/Svmmt321QAtMDnj+vD87Ta EIUa8aHi/QpdODH0ysOqY+w6knmYkGJ0pwNAFIOsS9k8pW5CTwfQuZxEWrmKatsNx4rn6hoVsEGz WLqPV1TMS+rK7iwEZBZZmSxzl6EEId8zaLf6OivQImjQv5GQeM4le2Y2XbLqK44cRFWfwZ7WdRR5 aVR7dbHKfFtT6AQfeC7q98LGmh98txKtTNU/5NjuDclt76CYCq9NGVkrMZfqHJod0RMEgXh8axv8 zkXcmJCJfF+6wr5m4+BAWpXjyVvNKJ8fxH3dIpxzJckisodhBBql+mcJg4Ork2VDsRdgo64AAKSr hDRtJfF7k/S9mgafk6yty8ibdvCwJZ0npYJV0psLK0q82NvEeEo/EtV5ucxO8BlA/Opxb5dFE+h7 po9kVNSqFudu5lVIKFQqMAt2HwX/dsEcmfI1R6o805bQcxUI+1VPhxvoVpKCi5iszGTU47qOgbbY 7pb4/ebx3XRM0fVQ9YSHoJL+gDSsInq5xogiqIEHzVXv802Au9h8u4+hsK4Gx/+1IEuxCK6qRy2K ACtRfE80wf8avn6On2LMmrni/GqY4x/B5Vu3/eXB9QE0d6a4/enTsFiPj0U687zhUqyXRvw/QtUb JoJz1bFYZSxUS+OSJG38obo5p1jSgzXUvsZFBVGjTKgh/8qCx8AsQ/o8ldAac9cL2V2VEZ7Kt84l ixTniinabtJucvc9Hc7nIqIGxzbjvVV4vEvqeXUUbuMBR/1n0l55aSEzP9sGa/v98Mi7InRRwrlJ buGuIbSm9xo/Pbi8yVB/pr+JvcFsff1lZ8aQGTxlOGhGr9349tPf2LYiVg8AFxz5y5+nUimcJVkv 1yCQjiIa4VhdaudyjCE5hwDGHQlzT7KtsoW8956MhZqZZqqEBG/aVB3wNOBPCwdORldj8mlfLPvn FJZWXgB9EbPqZkf1X5H/7CD6d0hIy3Ui5nafPyFshGcUMJS/yGi01GAKP5xqIpJz7acgfqQ9Al00 7S6e2d8ZsyMt5ilkHRaJODQnyAAOi6Pl5KGgT7EDuQtdgIdejgFt2X2m2Vt0jO92FYyVQpjrwIHZ Vkvx7m1RbI6BSHQDnga0qE2q5gpuiSMpd7cecqO8qZbuU8dO6J9gsqaNGRQ3geQw1mBu7Cdv934q QW/ua4CP5VPAcJeph1pLgP1VtmsNLU9vXF4ojJtU2f8Fa1j81SJllneLb+DizmqcT3KEwsggyFEn mNAsaBVLKDxtraaeoZ0ipW45Q9K0oChHk5h5AubnEMm23JNvaWi54ceVyqUT0p4dlkAbgG34y6M1 eBlNOVhHW83MDR6PuLM0L07FOx9pQ5Yk+0zpWom5Tj7wfC/FpwX1HAcn0iJ2AeBRgsQlqmIUYXPj febn7eGHKI6ArB+9KxMcWhH1OrcbR4H/NaFbVNbeMXXf+FnyVnIuzpMsAOzlQoP+5NRz8YiiL8Wx tkz71Xi1hYpOIaxSIeaDVVk3Ht1VHdH0rpOdAhLDNgvye1239o+bvivLKAZjQyXgjbCEUIplDdqW 4HdIqCV4ZRm/bd3lUPPRZ8+3OtLyOnI1BNzdjLOiBKe2KBxFI5kWmw3m7D1b4vzRCWodR2BsJorT h35iHvl+Z/nckCgkXVyjndeFyLdIaueRyIM3qt3nNp+S7D14dsRwu3UuRlOWhKkLh8L1SIuP0u/G Yl+Y74GiGO+Sj4WUJDplIvuyMxZHLz6HD61WRjYeL/lxV4rEzFMjwFTP8lM6KdhPewcnkGJ92vyG 8jdkq9Kv2tkabtD5SreQL5J4DHgyiqdBYef4YYbN095ViNNf3yKEMFvEqsVCyJGDr2oxOYXGxS56 g6N2PTJYZITl453fv5zQscizjlTwF15mnPibxDTQfwyitiDh7cjRG5WKuh5RpQqrj+WfHKLzO2Wy wds4gkW2yqof9E9NNkKec1XHt8mHJp/y+9SeTtvfU9VMdtQLptBo7qYxv7wy6AgcX+yOiS9UhFT8 W7YAmFRnO9MWtFq4qKoP7lZR2uFl0JPg6eEJa1hA+qPm0+eeOJssKq57ZO/0MwL963epFCbJzVVc r+00/cTgiN59SAk9rOKlujyxHEl7uHfvFIN9vYBVdxdJG1COEha44U8Cgyvapi5f0YkW3d+yYAOI 0ZEWawiPy1B4Hividdcm2dne+oAwaXrUJJaIq82KcZwPeY9WGZP698wMvXpOuvIt2t4j7MxvPdG0 2vk8G4ayQt/oTCr+cYprEIwSGoMVhNfDS0be1NJYZNbDNGbDPnGqIoUacXXRf5eJY7omr4/2tW1v O3N9Vdd8kpazb1ZZh93/OHVXuvS0Monke0RL4VTY1T/bAWmxZ5HJbVRX/yPQCImUBxrLDojDuSoi jFkeBnAyaPAHoMBgeGCf+FYZPPqI1ukxPRs+SNsXkW3OWAf1Db3r3vlWAagqFDyiebHR4DL5YnGB 3G5C7kXNMaXywqCN8JtYa5QwXxIN8gOsWomIaMxO0xcABa1zCEUE0p4SD56e8b8IFo+gIfWHQm0n 8bmhjMP7+zweFL2IhsRzhuDHU8b3ifuq5vAYiHbJHlFsZoDaH5QnhF3FJtSE9V3nEO026OqpDOkI 9enUA7OE7drNGWXp8SWpokPXRQCFKadC79mohDrru73paQVnbG5j77d+m79U3fqqbv1VU3fqqqm7 9VVVZECqqqsiBVVVVVVVTd+rIgWRAm79VZD197jtGGzRCGF8LY9oP/sKoXZclv4o6ch7ycTSLWhs TExliPaQtYNI+0qV9PnFl6c+S4guA7l9VS60rA1HNJBaZGxs9NXJQpVteubvjPJ4AEZYb69mTug6 dgKk7wSjsc1q9oODexa1hLa5G5h6ihKYxKFZsyFhjgfBZBqlNpjybIlaq/UM1YeWlJnjUUDO3//G JvKAAXkSsN+WpZp+NcQw8wnwOvtEXlGYFPEAbecShODba0qMym0yCAoeNSRjv26iV4qmhHcM2CGY Ojo64XCJTL10VDYWLDzK5Oi2fqusj0SAOFae7uZP7thVAxVLvNIq3zRTTbaD2E3bgZET2P8mp0kf Q9ulzAFXTQKlzylKx+pmTdnitZp87sM78b11K8yPuONKBdXVcFuz+CG2v3DhZltY87gPAvKWkhZa kaR3mKWpEdzkO5PlZAHRScTFqlpeB033u3DOgsjbB95OpgBXL/Eo1yrKjux/Qe2ojHplN2xRJjnP wScGOvTGwIE2CvHOD3mAhgj6wDqzVbXKOnqqNR6huhQ5nUmHwAY40HBGDj4XeA1QLRbaTkMrb2AW 1hC8xHMzvRVG/snalnsd0fC/xCF4WcEog/fSJaSWZIeu43hgkoegx2kdNrTFpYIOCL8CUB3wPuEq byvoS066UZ5FJmR2Bf3+Dq6ZKQYEd3SENIBawg0dokWk+QwB7M+0PqUc9UTmIPDvTDA+dsclMqO9 9LOUWEpAC/nALRUOLzuY0CCqEtXIlDzxW6UeCVRuLPgk/x5ILJaLfPip0B4AvP7LjQWqhn8o8pr8 /ZjZL44eJ4SlO3BIZluIWzkU3vb5dfVEG8riVHNnM58GoTe7s/AXocPN2Pyrx+qXmWgR5zq9cBwB InpguuFVZG5+CS3QZ79uwKQo0dK3cxn8FQsGlJ6Knb+5GgFBdY1vLSlici4ZHkkHwijCRfhD1fNa M1IBxL6dK6YMWnGutErz9D4eK87+YWXjPUpuXZsPNNbRPFg2F1aF0NL35oFxq5n/ygT3sycOswIG 8+z6QbsP5JqF+i+qcpxCopQkYlUHSqt2MXtsQICBRQpaoGRNHvCbBYw5llTJA0UKXJbw2brTe8jP gwh1ibGRdQYk8V6Ua5S5eD3tkrkB7nLasFCIiXCAFOePmZYshLJA9yO3o3SbjoUMLot6f+DtOvq7 rSbknaFIwCj+wXpyUIEjmBTnWhs8FGJKUXZZ++/+XL21fDckA9zPpeZCQfH+c5bSwP3kwO3p+SJ7 VQ+EXWG6D/qC6/XkVgB9y+eXaGc1XqWECs4205oQgk1VtKVAwTva/ojrZ7dQsDDviCOJI91I1Jdm JG22iBh2DjMo7v3Yw5TxYabuSXHneuE47IqY7PPTEx/zvOLEcu4opklX8QcgxuzG6CA8wSgKnM4f uNxhVJqRrrafPvdIf9WP7ONExKm59A6TGgvQO4qyFpiWvRjTDv14Rlfc/g4viuChOVNHsf2TqNV3 cnNLjAtyUxPDUT2gTteRvQi+KdkFnkiOYDVi0OObEXbkhbbW08TJdvuZSeTk3E+gN+sVGu1/64dQ awB2MfR7izM0t2luAnfDMJRb/L//ugvV1dXV1dA0q9kY6qZ2Pim27CemzJkz7huHOaViZ0+Knrkt GApFeiR+Odm7XpM9C4gGBnzRqg2U2WXx4S3vQOEyTSL5bEAoOek3A8bLr8metpGkH7lN8XL/+51p OK6vqtZJd6z/0ZUhcK4FIsaWj2J8SXeHvOgpVhY+9ElWxYyVm42pdteUmda+b5wDirIIVgaBe7jl wPy39ktruE0nwp+OJWLOIPOhmI5Y5ZJyHxI6YpznCbCil1AvdQh0gjM/aRkW1eHzCllakqSJxMRx wFyxxbyokGpkoFMBjYUsNrwapzwqGGyl4hWq8V+EoWi4ju3yLzpQMXUQkOg5fAo/VQ8IqHxzQpd7 mq4bGnWhuCi2uuqvdhTEhz5hg5X/rojrL1EEExmuxj1nj+rW6DRURed+pCxtkcsLW3An5zqvtnc7 u6b0307J6wsARjdbFX1V59S28F10RRA9Zoz7d3jYlMwnO3ltumcIY1hfLVZQlfuEuR7j78SQuAH4 WrP+3jU8FNPalsCx5kB0M+AJ0v5gOqGvGIS26rI28jtLDL1fOdbA5hbD9J5BkzpvLsQ5fi+0ZUD3 0T9YdIUSY/c2nD/dF3Uz5i8R0iMDyyqNDWd8b4v7+3DkWZoP3RUjJ4urYQ5Y8KavzNYEccHuEf/X A2yho6keDH8NyaERmpClcK38ROZ4qJ15bzMoShZ9lIhAOBnEc0OT1C6mwHgJhAu8l15HJQZaYNRn 5ltTVK9pUYgWuNJnz8W1EXSI2hvLZK0YlLc40zsLxIU61yNEhKbGeLMeYqKQ7/l8KinQnMBuY15g 4dwI27kPe/2SnQYBIMxfDjsVP8cS8C58++RI3WJ69V5eNnFqp045+1yiy6FFNXs3wVAJrzuwXBI9 ZKfTBLxef/cKcqoFV7XlrniAkMDK7bezYJD/M2V+iqx5yLzqRqLe8OGJ5c9Y2a0yRxxZCu7H0FEs g4bMNUYGyZFmiTBvP4J5zwt88mAC9GFxLL9n1SC3ywLaQBR+UTb3ZJs+dygVFU25u4vA3hVNtwh7 C88wTFj3rNtMjqx1OE5FS/1Uz1HrVXSDtOPKG9/L0gdr1xasHVx1XpG4oG4cp/9QzrxW/1L9Mb81 zwUOqCLL3sDit5d5up2HakVCVQ8Nnc6zKTJMam5CS1YEsVt4LDURlGfkOEfn/39CSuztBWLcsAl+ WRqe2dvIAPOgzGa9X5lZbKo45sIq7DfgdhNLxVy2Vhsf7o6yGFHET4IlP2nUABisdE++VHgjyyrb Ka6RgnJr2WEtjPMNNpE6kn7s+/xiBDsTUbMNHgt2gf8aMjBTyx793V0B2j+y6fh7WzoymeCTiptA 7t1GLQnEWPt20/Tw76XTAR2KKE3g9PsPgY4j31qdZlwlu7U6tYlNrIt7+/AjKSvIBf62nBbHG8ti aSqBF8ATOaI3bJ1IAwgS2uqnDnwvYgFUCERH09Qqbs8V2R6Y247WEO4aPOPtel7p9kOfsL8j330w 3Tl+ZoOGc6ko1hlE1dQuH3E4Z4QlnCxnMHPlbc3PR1F41mF/kMebH+C4T2DHH7Hg2FNySUaeISM/ 4Qlgg2nj0o/oVrjcthkUQOaduxMZH0J0PGx9deASpSMxfasJbmLKHadwCnpn3nOg1VsnpCTagfvi hWuQ47riWLW0c3UCgpFe8TXQAwcPxQnwWbSc11/P3Sk79YJLh50HQbvdvEX3R47RX96s/R2GKTBE JdytOsIXerucD1r/5KXhPvKBBWhLDrqxJ5rkdGRt+c64NoDDgcZldUmOF0VtDITP0U0FFmY6GDnV oyxjyPLur1z3idb/2a6cFlTqjDmqiF8OP+Og08Ljp3wVqg0AtjR6m4Bf/B6zVLXj1FBd3kAjUY7l ICDPSFE1bKkncdySuc5WnF/6MYHS5LU+k0aQR1+HuafaV34qKzS2JeD4lvSTvx1agvoEMlSXrlhB dXwU0B5kAEQjXkI8A0rs393p5xItN10Hv3FPAGw1WFDNATnRQZmL+slws4NhGHNpiiFchGmEobQa kKlTDGM73xAW8X+pfxSrEy7nBrvd1w/vUQUs8tGUXCPC5V/fs4BPSRFOWE1aGrwHTXi+yUd+nIqk Ycyu/fEp63KtInkE09RkBUiSXged9a+Y5zr2dOeoJTf9FRyYYLRX5wfKT1XuUMn5TrAJ80RgL2UC lgiaZIKzZW/Z+ovrfYQ8v6JbMideqhtgL6vy4T67LXUFRqbzMHMDyAnAgkgNgcCd53VNN0GJ3Jap l8mJNDmN1mQrfDNDOM4FVpYx5ZNKt/d+SzBljrygdXLmPpRbBoEV6RLPTcOke5zbKi3Hk3Bhz5Gl a1s7vSUBBe41+gysA88+1GxdEtD0GkbCzJDS9CZYb+vu2D5pogsUSypq0458Z/R9IejGsMvU2U0x 6qod1dG5nGZMipZKQgvcZqqZz6LXxXxU3SYXcUAJuVU3DTwkzOYMyMlR1T5ZdexQCT7B7fSGt3TZ f4vKmEl3QNv+ZbZu1mgm02DrSjftthIqOPTtWCJ+Zw5pCUStUDRjH0DiErJ3qWZ9jS2W8wAofC/I A9PEuxbTRio6XU+tm5yJhfhB1ntuKx07fKs+gSWoThMJ12DIVjSdc57zj+/hLzvYnO4QGSv8Me5R 2uuV278iXCNrUzuyieXqjMGy1RW3XOZjsI80bylVezmJEq4yecKxlXuYGYItcACxYD/ROai4UuWb eGHrIvDSYW/eEKP1r1ns8vOORjoxJDqowN/0866tWXFZuaEMVjanHCX1ry6QMD7cnrWtl9qFwDn2 HTvpNQPsexwXw3goP/ZJkFJssTaPO7xCqbUnZrMYA97TkrDbwepimYiMtCHwgVgdjAJQ63qVsjyb b4oC0KHzm+UjURsT2L5d1V5euIV3mXbNINurkU/2QW9i29Bk1ihtHb7RQS0VDaVDmsrZNdUIh02x 6/1cxLIpimBj2j8Ov1zld8kKdlKL4fmSMfINociwoMnw6ofRewRiuzFQ62WObpC5xVTTzZIfO2VQ fzaSluJD2UxX7nNMg1E9FxKfFQ68sw3VV0zcxprShzBagVw6lxcJQ/3p8loJZXn+eMpjODTUWUwD peQZaV31jHLlvyv3LfT3Hj7EqmnThXG5FuRH94LIFoeCXDZ/fuR9KMVYILaV9ZhKiuCDnHvjtKwJ e8rSoSMUchKDcs1cHMAZigPLeliD9X7JKWh/FW91ue3/FSM12TAJ0OUGd3aEEGbqGdvUu9fvje3E GNP1vGcTjA1/Eey6nfHPt5kNMwB1EkTVjiaeqKthDB4hnX/+6aPqq8naldxEYXIvN1q7CAJfBEvr oSS6u4SPkPhh6tnyCKgQD3HjrANaFfR4IOXYA75eExCd1voYIn2+BqTOcOreLeiusZODYexXWLFd PJCgitPeQ6WWrDpaaekZDgMimlWwtD0Flq9QMSmSNapgRyDXWyZAIKDQEBlNNAktX4L3yl+rx0Ww dak1omouAbFHkBM6DloFOZ1tXg6fj3CDkeAZT8cMuMpfBMLcLGGHfUgI8cvsQO7E754ZQikxmYQp yjkIbIjc9g/qFTF0/s+E6yj5LiIDYLG/s9IQdtQujYtTqE8pEGWwMivGQv1MbwrMv4nsCc5DkcSA tDOpQRlRSvqIJbMjx9SG3sWvDp4o41UzM8XygS5GPeQ1PajwpfwLQB2lfWfrCAq3sIDeiak82DjR 31Y4SDx8kYH09PXk3RlH0EwwNMeDDiXeGs6phsoolxw0Gljg66oWCErZzbNNPIBWPcuAI0tTa4pK ahj/5fNf3pTpxSaic6uaUKpKUbk2iFOnEuARgkEaqDDWkj5tRVSB8zFaMq3HHYTBaJxT9fIgavMd rQeovtzV/jeMW2qDDA0CcW5aqLDBYYSDimtqsRPtKAPGaj5b6Xg3+mIePZozvf1W7vyJMyErUyH5 o0NTMmDLd8bQ2ICtp/jjauixJjca6SBuMVvLoYdzcj/PxdudidkN1/Glq876mnLtJOX7j9VbHHsh 5BwSgqTKuHe//XKfhLkx5qO1GlgHvbPcvai57OQg6orjP98XIKymS3zbZTOjUxbsZkbuBEQiq2MN SzFwT0KIN15HWpcb3qxkqzku+XjJSHjdK7Gh7/1+mYPKEJvnUMJrZ7VqFqlOIjWTBWNCSw+AKYLt iHq52vzwI0SpxlmLX6CEE2kVIqkabN0LIsv0vERbe/5lqsaAGP/JsdmupnaOw1AhP9endGA5PGxa 1yNNNTSLMyoax6jNWabhTAfFv/nWoh8nTNEQkAr1Q9hdf+l6QvVaQMj26DZCm0IfFQSBGW8dJraR 2SQ3g/O1CqM14lHqbZ+FgG+psUgVV1UnDH/+9NA0P01Tw+3kGpG+xJgFQfvNzX5iaaFVn6YKjVNl +ML+2lwAO0OjC5jryvIwMVjnhkwfk0Un39Q+ZKKWR6RP6QYVXG3ee3Jm4ZxEu0vKrm9tCFGIIdmd CHBh+BE/A4Hzbc4vEOa4ZfYWERx8ZpxESAqPAHxivMaYPZrEpf5AZre14LFffcX2NVvdcq6RMqBA c4ZzaZr2hTexq0tljCdEJpnSIuGL89vjL6fcQM8KJHt8D5Idie9wMaNx3hDfGu1a5zzhfiE+ybqw ARJdSClQXyPQM7kYF2w89ykEcoth0dgQ9ai+zjUQVi1qap7M+ngupdIeFOv5SIDeWG+Uw9dA9tWy q1xZqZKASBz3Gm5Wygo2Z6rWGsHYRKAtB6GWC+reIygtDuPZ7h4+rg3gfdmOVrTdtEYNPEe4uzmy uRQe9IiWnayU4B5TqHhwNyOaBAVEh36FmA/yoLOfAirYVGkAVuG1sxBtnohZ1JrjJMAyzMEA65i8 /Gb1c+SJtosG/rdH0MlNTTBOwDHoRsmBBZ0UoXqcVDdJrr9h+yreRg7B1WLSh9Hf/hn8QAvZytup rSnahI1b8XzrqIlxo1bd3mb1lDuwcZgZfYaipIXn16a58jGcU/iP7DiuwVw0UYxKcMConQDgRqlx DoIp+E8lPveGe1yLOT1i0eOsJfcplvsCNu0cAspAoGK9l84o8wv+4HZC/VpfjCX5gjYB8FTaXctg +GbT1iVsO2wGIa95/IZGtUWRTYSqm1zj80ejiEMN3yNPh0oyGYqsC9hsgoCGSSdWqJ6Vx25puEIR 3l0zlhXu8fWXtfHMEdFMlcEhVyiIJPGtg79clPQTAd01iPe50wfXhOoS4EkrzIb85Z42fNe0dVN/ f9XwoYkq8LaiP0urR8CsHUd5jcxMWxsTrY6WPaI/S6xDGXM1nLtFNmLdnUlMa7+uWHAXNIpt4fzs 4Zl4oM4ahrr/7KoL8y5DrFixEZPAmixwFlFI4yIHzn51PCuIwM2+T963RbzkcsB6Nvx3iLqT/7Vy mhJWY97REkgNE1ajbrVrGuA/FXn0Gm+Itwgy0zA29XSRIrZJXfPA63LFDr3RxJJE14AAd5UTMTYa TwylhRRz0SqDjRK/4bWXxBr00zOi9XsOYSH9ZrhmtdJevcLmvIEWDZ2XSKKSVQnInkdr4Mw7KuGu 51/dXFp52pN1/ysP6IcnRVJT5kirPmMIr1eHk0RhNjLz03uGEfgA/4xWLdCJxlgFxZB93UX557wk HnYtv2BMYJfWb8r23N+bFQf0ssDtbigW5rLSfl9Ka7V6W2gPb240nYecoszpeG7CtvY5IJzIoz9e s7HBVOWgG9k2dLOKkcPxpnIF88/LrmgXgbeKNOpYbSf/ukraHFE5v+CLbxKEcHO5cK4mDsNWSmVo rO1XtvdZmEJAE9wiJjQgkmuDaDFKvjF/vCv6MZygr0gPRITLcPovoJo+aiZqddg/+yqsfnzZVGFZ elPooCWd+iX8YkqUDFePFLGE1IxQW95jbpITNm7npHAATj9VeFqHePIDLJ/8yzHyk6/jgff/7ZHj h4CIheFboIK45kWlYM4RZ1y2ECxUSDhYLf0QhaxM1nN2RAJOEhkJMUrR+vrDudhbH81ac1IyZJVx Zv15p7ggWMIZsXF+xnNXZGYcEX3sv9XcwRZfakLqOd2zQT2IOGWRNIFCOfZpA4GramSrGl8U89Fi FofcWo+nQ++vT1fUPRyFobxGkMxCZmmkYu9G/W7FbQr2yHwRn7yX/K/wM6n918Q9An8Q0wIvSdHm ILOgz1ekelzSCNoRrEEftzcFst4aw2C93JggfHC1DNWsBP/FAeDJT5zR7DvT1sagbOAvwAODGDAY H1hHBBhwv/MkqtkDTleKIK21YmkATOP03lxEERKPnimdijmsoYVQO2uUaleNAZEpZanzzOJlTSRh XV67hmzrMjUuLMMGbqGz+/GC1dRAlV4Vq2qd477ghEVqN9k1eoDTEvOssFBjPesQf3HkrqiqgRiO eIDh9wsFW+GN/BMvA4WNC7+7denfMK6YiOitONMb6R3MFSP3pN50OCIyKKL/rsMuiOYId3IoGWJO 3KpLOIHM3QNmtfdjZhSnGhj7noRd60E7hLbRx/ju+lkCy3MlY+TYkcWa6tG+l3EHl6uqU0FcQNNi lYQRuM8FeYRhNyyo8iXzVApvFfjNvF+ih7AD9t6ecdstTOKCv9Jl8Q957cmgaK3NOL5AlEpFkGVG krqjKzPebbXcGCe6TERtOhgEA7R9ca/WSQG8ayiEdTwQGjBL7akB8zSe0+KxFP7jXtwC4r20VZut bo3F+UUUFON0y5NrScA+0i6tnZxfkWDHT+ecA28fu0o2r7EiKt+kHMGKnzSIg4cWu2DDne7XikmA oaLH28ffl28DnoMXBUXqezNWs3JMQCwA8+MLYzQLRAGT4uPy79LTCE/l/uMHv8zJZqZWh+UYZiqT AxfVaAdozQYCDB8xu/bpc3elHl7jVy3CEQXXToAd7oWU0mfIxANvnM3Y7Sm1pXMIUAofkmP8+XBX oUeP/tUyYUEyUvCF7vcWNY14FdKW4UE9IhZ/PHJo9/GAo5lG71wWUVzxHz4szbq3Ho7o+OrS8419 tRP/vzmV3KWwt2tgqddPaS4b8+c3aCmR34GXUc8Pvq9tNHwrDF/M8IUzExZSgIUqgFcmpSFpHYJI 3a3BTDCTAJxtZZwyk+LZzu7ICf4eShlj+ju7/DWAJQhc04y5rRd54sQtRYQQbPQQFQdM9au8ggdU v8b62/CpK3yvCtkmZesPg8eE6V4wG9vUvwYYv3DEykb6T5FiqsXU+xM+47XBaXDDdp7NZ//cnTzu Ppv7v+397BtqnC1NUCCFUeeDxXM0EJf99Fx8/tK6kerGTLigtjL45q3xAYtQZL7QKPIYelUmhdls U2PQZr0ilecrHdkKer5H0pWvGhOMGNR1ZFKxtBYuEwfXqBkQ9ilf4TfSVBJsjrlr10CGAu8m1MGS b8gnOnN2OuTw6ZP2U3XH4F4oD2xi1xaQPFjz8l7PMHJqhuBLa40DYY+gJ1nCtPUx04UWvTJ+9Fga rsf+HsaoOWRRCEsMr8W4HXL/9EZot8Kb/b6KkTWiTYpViDFA0O2tJ4WPHxplMoBHUKkHSCiEy8QK +SaillXaC1UptqM2mqSiEsbbL2pWLC/sXYSZTckRhz5qT6iOGvTLcktjI3GxlAxE6eSNgk0nvi2w roa0I/34xv/BJiE3lEWIfxSjfg5d3V8utdLB4L8PFNfGhFZmuoJ/SPdHIATpfbKJ0J53lTOt5TVw 8He6f/87QSuCVLkka8of0tH8nYK55eYFyR0BkXCc1AACCvQC2y+VLyDP8Lv4kogo8nhqlXxCG9su 6mw3tx24XEfi4sReX3oSEc+5ZDO8w0Sr1TvVGmmzUzS1VTZbVm0XRllAxjxPragEF0u4ydNGiaHG EU/8eiWefRSOI+d4yhulgfOoIxdxoIUSEC7ErMlFobdHqtEcKbv6skgNn4Wx5JLqGpF7sd6c+tsB YjrgdGnD0/rMPKNmXFUvJIZStDD1/XdcPcxBYosH3y8xzGuR74Sqj7p+9+yW6+4BL5v1Zgltp5+a K/yEl6H2/xtPPxfzS8Wv5mtEVSM2iFVxAqQKg+9qUqGO3kzrYZIGWnPuz220gAg/lj4aPSXqvG9K dc9pCyfU/i+Vvo+zH14TbUmyWmL8xt5MUl08Enal16UsJ7wd7E52ZRhwfd1HDiwocIy66clDZfB+ H8DZU5ZQ28n4KSN/F5kd17rcRXigFiYcLn5s15ZvTJKUhaeD7mreADHiiEvWfcSwbKmBwHDKNqDE ui3uJiObgROjvf8t4aSiSqb/t0ABq5EdT7BnvIjYt/fr3e0oQqf1X7GHVX++kTGmBIwkpAAcoE2m 1no7WB0k/+Sl+GXGV2swue/377TVJFmqpKZokknFvOYMFbgFnmwJy+phjFgKlSWMAqV0f/kSwaWt 31FXgKNE0o5DmI51P7DFltws4Fh+ioIDhFJD/PpHVhPeAJRaZmgRTIx4u8eupE5owOICsggEMvJx JVluEC8YaJ5f0HylBixtb8lpUm+7NUPl5jxqA8WqhV2G25vW8nzeFTFy2y9SPFIJyRUyvhV3wPKC UiNK6cxXpMf0y2pMdlD4ci+j5kCIUBzY7a5RSFPRd61oGfXQ8CRk6HKf8SDZAZbhTwSkOtiIJQRY RMLGziDrBUPitMW3cteJ3xD3ORGdf4ZXrxfaMFk1CyuT04Rb7BTohJIvTsbHPbl4+noH15BxShkX CazsZb/y999Y+WoYpYuTtibkKshGg2nuuHLeAwVZuiTjMbw+JcZKts7tr1BQLv1A20VdILXuVIwV wrn7/aofqk6Cb9POQ2WI+rervoqL9Vrx7OntKdwGI0aINggIzn+hePjcNC3isLJqZG/V9+JD8SHD sHhdcenIoeTCcuxH+cOeldM56boupEvfbKZGqAjr8j1CYzrVkE5Bl714Fu60Bh/mpTrIidEiaf5o RGoS1wdt+un7Me8hzJCUltP0yi7N1wTS0GKcGGImVn1kRybL8MDvh/mf9N9tfe55gyhlFFIYIsPX AV2Bf/vf50LGULF3/3rkJpQVywTzdnkgNas2Mo+YLJK2u5lwwhTvbEwyVDl0xgYQwNBXGnIQJQ2I eXp89oZq/qHRNhDq7ffRrVGkzVY3uJAz2w0DT6x95XfouYlb/mqPVBa+eZg3aBrSwxNhYgw+D2Th MWziGyGXp7NMr8MY22Ohw6P9k0sA9TcI/o+gRkgs9topNYgNj1Jb/PKdnBOdURMwT7K8QzVneyCX RnQrrfVy0gGNUrSrGHngtWKLMxrNUJ4J8ad0KUSMN1UoO4/6WcwiFXTnyAiDfbDgoMQNJ2W0eIqB PKJsCp/XAYVeAvwOSTwhYZVYRPPA4qoOr0vQlHYbP4D7rgC8kIf2rEJznHoWK6h0QPiu993W2mlu ODs77X/FjpHYTUrP8JDaz0PApLJebkAxfTCQlekWBePPO74bHZXwH9TJN/nLpucV2zU/o97OK401 z0jwceOXxxwsyY6f3TQPYLeV6RxdgZCimdT1ODluBxM8YPd50M9RUTgI0tS219bXi/KISMM6NksB eVMeLh8Y0uhWAtPctuKZS0smYrxslx+o0jHg9rwSHFsojRsNL18c0D5NJXp+2u5fgD0Qfv3hip/5 uXLBvoiu9ODHbT2PUrwyG4gM70WIjTshLkHRBw15D1D5lAqRdyKEn9A6yelw9C1hiwsXU0Zk68XK PXNOjJN3zupsuQwAcfN8amaDy8VE/u++LKcUABU4cEBHNqx5PEr668uChlZ3ZpRx7G60zaq7jb6a XTK6mcOTRKEnEd6/mBLfLS3+0amcJlmnhaERhnBdFbHmsrWhvUcmUNjpYdy8vb5dufcRHa0ZSTXr rB73MzfIjyM/eeycmuJsv5xNhU8QrOdplpWJz0/N2wM1hQmzVOJbx17I+XuSMUHXdgwkH4rkxDJf Cqd8u0vyZTXpeZvaavRK+JD0+nCLSGzHb2p3Wz6S0u3ZVLN9W+cjjPFrcQe7gkTuc4Rw+HkOuEi8 K83DyjjV7NGEXnDoxhZpjHy9VF0CMI0Xxw9reI3ZDx9w23gDS4B3uf0K7lS9aiu77sGt3oSov3vb C67dFOJfMoJgdXBEwdcAfy1nScJu4zFaW4GhJvJ6cEcKLrBkVcMPnc6aCQu6a+UsH0eIWpzSyM/F 8VV1zqbFi+gxlRF8lsjKLPl2Hh8iXBXXQPAyCh1ovFaiVwoKQ5L05UYaIemnryXwtty+sicJ1KGR F2IOu8swZHC3dxjydNRidNKRdpbJlUtE5ZWmRb0cHw5/7mgfRGKq2fec2wRSNYtKUR0mPHWI901S H/34b8qBVxTh7hDVteuQ9i//lHhZGYG6hsq0oxMEF6qFe6PPkIOnUIeO08HHIAwPk5xQVaKn6EJy MiHURIBdGkWILr+7cbLAHJE0tOGQLsiOyPYQK9rKdzjvpCsaQ10L55EBqHZzCAA9T6yDrWXVgwz/ nc1WQl0y6oJmc2VErvmNoWtEvCeFCyp/eFqeGAc7VI7zHX+eLrh9Xso2W7dX6twfySwsHOOcd/2y 7FNTQ43584CIKQ5LukWQbd57nDDTPL/LeJNahYsegUU+/iMU9E3XtyFwJTigRMit7dH32hUcSp+K /Ie5ZgvEfuZMjrIS4vkjrOKEEU4srQ06fS3Yac0rLPiNb26gagXWLwj+vktIK8vGKSIU3fMl9MCQ +wI1OXQdF1ziXLS7XSp2AFQXcXJNC5iqZRWKFprVe+8tm3cxHpvcaSiBA+V2b3JVNWUMyPxiT/Dv GcRUFQ14vRHiLcF450bWzgVG9EZZ9zXfYMZvS6i6pFgU81kUA+V4seQXiVqJ8Ljoe5QJUs6q1PHO kXZu7pWk+eKsogP7EUDZsgnpRus7kAxq3ZOVMKf2N5tg9+smTq7/ldrYIwUQwK4Afd264m2MMbfk 61mPwRRZpt3+RysneRkHbnQgoS8sZHjpVTuI0/cV/K0SFytDbINeAB3qysrvIhcEhro/J3nMgej2 0KV/rJj7JZTnZHhpjRtT6y5EzX1PaZNOJxMMHfBF09OmNVk86xepubtry5r7PPN0EzIQ8WntykDO mlNnx4WrvlrzqFFzJZ4oeMvsv1etrMWcaVXNg3QXqjhj9+NjCKB4qnqhxgGJToFVVW/ImbNmX4X/ 5NZe8d3kiHYUGCDasffaLbPr5c+560hNqgqcEABJX68WlYelAGxYPD8Nv2xYrsO/JG+Kuh6hEm+I OKe8FkEzMLw4E0KD6BMyUeGnwGcM2HuOBhgHid4VKJPoee0WI1IHhIqYOPXZeg1tq/Rsl4Q9Cu9K INHchuMKpZjG38JbsrKIy0PmU2DlVToF3rTtslAnP6ScTu1mf7C+PkuCxfzJjfulnoqzk6uuLsN+ 0XGQSL+bN68f7iQCtK6lwdHiFDFDdmUI6WMLXhDRBPrG1g4LGurh/8NNfnoW3Y5XlcjQxKT07Kig jroP8dLgJ7A0tdkq4TE+hcPc/x0tWJrlSz9iMBzATUUVYxmGPlbvHCre9/ACoUQ3o/bUymNWdbQ9 rehNYsBN2rhoRvgK7/+V8eEZSWjFsqTmgiUpHFF1I0Ttf/uinYIj2kOQzgYqkcRnIk1Pgh26N8jp kY1ka0AAAAAAeiVV0vjit/DgGbvLMq//W5HQqG/pTahBG7Ld+XZyTvWTjhsKFHL5FaqpVQAAAAFa y44nsJqRWwCs94/v5QgsLDvR7lKD9OQo/N7vUR2F8zEoXET3f1kZ9vApIgZfx/Ku9Pn6ERKr6R0I o927sQZOLg7QzzHkmAIRkaf8OAdSmhxALy8Vjb8X0nz3mrVIMbI2n98Be/nOPdnvm0A55k5LHlaI iI6YT+o+IYbVjET9Owcx442TcZqzad9zNBuu4HtV6n6rgw59n/i/5A0S2cQXgQuxZgInnzuDu6B8 kVWa6kufizzHrbYiEknnaB7Mf1UbmuOYDyTfBzauWf/nGBjCVxyTKDth+fhZrn7ld2lBBnoCUDzK G+ARYZAr8o2QmdxQoXuz2VBRpEOlw7hQn21mBZQ38q7N2ddnqK4tCxiIdQGe9GXW/dFRBbwmON3B 9K/kFELNla8iq5g4W19oyn2RndFYfc58xEEkRbDoApfIfinLsUojUK1eBRK4zvtye1BGqBe1SIAY /bWhmuxzz7UvwirYltb4ZTPMS1jpnaxQLjtXWZI06tYcamNyBZKmCYT3lJnrMcVLHEubPf2GsraV NxLrb7o8YVeq9wX6wzyzgZnfExVefRrjh1/WryCPA9uLbanVg/WUnH+5Z9lKkD4ClwhJmuA+sDNK JvyKdqBLcBcByKajCYpZ+wa6kmzBTTre7VUlR1GS4lkQPs2/i5eve7YUry6sbUoCwMtHLC/ZpFGo C6lZ6SM7Yc2BA4OVZM1fYWeNi9dxGQAYzu7/b1DQ7McW9le09h+3AKgidOmDgiEZJ1zpLqV3eO7r V1a7OxXKaWLsF+oRrNDEH6huLmdUzyYwc0tw8JMZawmewoM2chMI9L7/IuBrtAdfx0ghoJ5xp5dj AamsOrfjHR0O766Sa/BaQokU4136+h3g387eQlllWIxeslVIvWdy50Pb//8ya2tntn76n/d85aBl +0giBH55tgykVUxSjFWyYQ9W7FEPuw9WIhvHZnD1SVQDtU+CJepFhf/0GCBJnLto9/FNrO4aGRS5 qCUWGw9Iw9bNo/1HBHcz3IoMjZREKGxKQWyXiDtnj8jURWGOMAbqKxe/7xedXtS3fCftqtjmJf6N MDtSNQ/iBdcQrKcZstJ/h8Qr+KlYLTovf1iAHCFEeeZPfu5bl+lhl5Jfon5MtJ6e2d/KBLXUbFVk wUI18PEqh2MWPhwFCQEPj6pKL1+0nyOzT/mlzOIIjCXKrrmKcqRNwK/h4JeBXPnUvJUSjQ6s+FlU fxx5llt22l2aF6QwK2+JferviCynzfCbOuVc+1baJ97JnBpemkl3vqWGCfZOZyYiXEbgdx7dNrLs 7KT2+ipTJ7aMylCxCb4FQEWVjpgayyD+/d8+Mn9n6IXiW9QFY7yUcI9bTKLuJH/KiwQSu1RXPy6X VbejMy6S5SB4FX/gU2qnn565XdkTYdEM5Jq89wrPCKNF9ZV9bfDd4FPS9ny1mPCtvq/bMdcBUOre 9NQ7wuLGiU/7f7g+Gaxz+Fu/aTKQlCozg+SZLwuvQbPM80/2v0brA0bLaIqvl70J89je1qhdw96f XsKqpBNxsB3qIaNbGP4qckgIMpqnRCRQQUZVH0ZFPGuJ7bdIicMQaNkI9uFfg5rO4JrTuh2sGhTG M5VF8UI3XBaRJOt4I3v0HhnKz69PzR2ZUD2D15NBn7SJQMq0k2XxAthxWlo8LB6cGqJsSFKiF229 3Jqn2bO2wstomD/eIAk3P55EjEOvaN/o4eyPSGbYpMedhQT2esNVG3Kum135sXY3WHSlIRrdpCXq 57YgYmt3nrtND4C4Qlr/mOnW0R4qpNjm1ObeO4KlrewNxinGIbvDaXSUJ/GxA9uTt2AluGW8ZfQg MekqDKq4D8pP6tPJKmHM3/VZmmDBWkaLu3y6BkqbJsrz/ZCwSIvPSsd31SmRfJAqE/4FiL7CP7ET RUrZFFA8xAtnCofKY9oZV1XpNZBpSzwvLJ69EOuiIKmb6D/va06f+zZkKwgVdgy63bvgXLrxjLHK pb9H0I7suQDKn8R7Px6ctGQ1D542SXAwl9641wYdUDK3UYjXR4fqpXzm6Lmi57kokCDXZXCkrxkm a+5LmqmjV78kT4OVQN9OgAPd7QCYKzLpnLSxcMcsOxXGOHbTi538UTjaZv3m4B9Fs4EUi2txbj5y RwotHBnibPA0X/GXkxmcJfS45KslI7w4n13aXsjD50NvYkIxsshMYQIaDA8LdF91p9FwL9RzTXOn AypLmc3mbKa5E8aFNypVvUhBbPyDDX1oQUtdnhftZ3IvKKa4u/rTL+/6OvufWgcJ7ZZufTbCkWG9 hLbF2s26IR0nUbrBop4BQM+QFUsTAEVDyDhW9WIFi4CCTbYFj5j1737bwqFgHzOF+mzZKw/kktvg khRtP6YSegVxpGBqN/FRpXfy3nwSlYpAVjG7mIYCpgif0nV81LgLc3PmmC0RNbmshFezGOWeyj7x TggNjubnhinIdtKYgDZuJLak7KJ8kUzes1XtdgldC7faj1Kv7YqFmdsq7Fj/dFTZA3olOAbdjGDm KbP/f42EwleWLAuk4uN2OWlk6PMjTQsea8ghuzOPyESypGpR6In20yzbjhuFyPVf6aykmB/uq16e cD6R1VTSjbNekYfOKD0FMLv5ZYF++HKv3TXbY8/o0PlsWIsbkGMlMvoEGvaKg8py+SwEEgkPDeHB R5BSvtESmxIeBW9zdyig/lw+o7BKMq7mwOwcz34WiByN5jTFWXP6Fc4P/JMHcCGBQY5avR6yhNMI bNsxqXdvQJi+MaoQuthOkEYmaEXDljNxm5fxHh98TJUEq0tPY0JEzI0nesJ0n9ErXLmupLJcPn/y szY6nkpPFCCy8q1aHyxFT8wqcIQM88G1dy+t3yuBhNgtdesWWH6l7M6BhixkTmpk5fOKzmPTXBrk 1SLwhMGPoHbXdXWDj/F3ZmEIh+X+I6EemjnZcAA4xY7ZPw+zaE+xCfRUI73xhyIjx8lV8b8NBkMC jWhbH2wbUaGkFgSr6SVUrhFC2E99K1PXDZK/1I9uPnNw996vG0LTSQ1hWh+jCR5eRU77FBOwbtar UtXDpxDTAuvRPHsnh/1rOx6jEMZgCn8kwXLa1/iKV8H6by/W5GM1wHzMDkR8Q/j3KYc5ybEcx4OM vIBUOHrL2ZX3b7LyGjWb+ZKGG9r4LJG8caAfDi3Q0RV2wNmY4BpD5NNogr5BKAunbZRFikLPSzmV C2VKRrsvNiRsLtAafqPIlkII/tE1kuPjOdL8wTMkB476wf7ZaoUqke39cAb8E61Kb1zi2/zeJMX4 E4qqttOd6ScYrTB353rkqQnXrkG2n8SK3QXwLC+11YnMZHJslnQWzsDjRkpLgcrBIW6FTZHIympf PVlrQT9EGCaF006wbJY0tkvvjS0AEkPgCmP3aqEU9Bw6hk4HAddiwoiI647TGgN0Fd/V6fgAwPlV Ege6pxGDey83IIFU0F++3YzOlRIEjrojLONuvolEeKRbd5lhW78g3nnL2942r+mVWaICKNxu+5c0 D4CJhuI2wZBiseudjFzvFzVT7MFWnW3HfErQ5E8xK7pDJCvGvNCiieFiRHaiBpBluYRUMZKsrzpa wcJW1ZVIBrBCNlva/J3NuzLilF1KRbqjjMnZ5OmCN87OjVqtcPwztY0tISs9P0M8A7Zk3uDi9hA0 1GuqCmuAAIQZHG4gtJKtsoilU3BSZwQS5sjiiCDy/8iGqjA8dmRyuXwmt8BcA5YCHayDSVvK+lvo i7nGfCknHGWg96xiSFcSmPaZP5zjF3gCuwLPiGD4BA5+jaeaDqRJxNMbvbBRGkjXJdTwRVPR5LXF np+6rUiu6b/KlRUXlUpearGvXFlo904MRihQZuVcbY0doOBBjhKBPQ8e7TCgeUe8T+TVeGwjv40P MhA2TKKu2+8jMiiRRlHLyIfJbjU1Mu29h2qSdebGbYmFPkC1g8cdl2S7qHC99SnMNA8Lxz5HCzHv kJXub0by6v246l/goXSUBMu+Cq0TsPgYzEAhqmI3Z4jpe2ceiN6MZfyNueH5GRw6YwIqtejjKzhM 8FXO7N6PRGFzTxVad9J372iket6XuUZ1xtCrywg7oVcW6fks2ubtrLKuS7daP/IbvlDQV/xfS1ar 769s/mvWAQDgx82SxFwg/M9IduPU9irdUMnne5R0AkC32aFhpVX8BzNe8eBCYWpBE7cho/drbnP8 GrzHUBH+Go5UMGnvb6HXrD4bE46B3ATA66AhOtxVworRdyC9kuQzuehZyXWkuoO0ZGFpQMDAqg4p Q4dKOgDYaptMlpP6A/GiZC7fsbNrf2AQ/J0X7xEIT1VC1zjSez1w6J7NE45t1C+tuCnyGIY5D4Zq RKhy9u6VDoO/euqwfpnKY/okZTyNDxRZf5nb23QdYlRqjNvJPiSqihPg8nLQKvpBB0KEjS6O2hfU s2cGyiqG8tRttVaEUyA/Y1MU7uKCNuPWV/PbMj7kizaRu7w4fBG1c+QGrIOCGGMWSc7/gqmKtZHu 9qjkutooDVoVlBfyLLOK1AxshKR9/B3NL33IHUL+HYLCYd/3nxHIOBLsKoehplQANIul3qY8lyQK 6ugYpmb58POYwwnMQdYg2jcKfNV0UxbU4xtZuVXa/28TE+v+ALkl6Ha/RmeEmUGcH3VLO0ECLSpO zpr/6BgIEXfyDK/LMsuSLfg6+7aubEnemsD86PAwucuSCviAFJi9pe7so9MfFQUSiEscuy1GN8il ACqNrhvwZ8n2x66Y+1awlA+8fvvzFsqD3w05A35TYBSXaEoEDDzNKhu53nrz8xh8+4dB+d86nYSr aOcY1r5NIT4AC41goKLpOGxv2bQI4PvTMe8w9QMsQm1ih8vb/d/O0VtbrPARSORODs2Q9ouc/TGu VX3z2BYaexqsjQoAOnlJL5DySx6QJM9ClgOqcaBsqSR6Oe8NNP4Zr8p4K5Oo5Qo9YvIKOJefWzVR YCVxdbrrcoouAy79AKd+fcjAAntKkkv/nPa1wKqhhUxtBcF/y+1DF8yOT6FXDwLLlQZhd9RGe9yn F/YDQR0TI/5ziNu9EhibmTK6bq/56eYCVUTVVszRFnQCHtmpuDFd+JHJzcWvAtN8p7JO87u+7P6F xWLpEg8aMlck9wMZFJ9mdKkkd65DFjqRpNFGkRrTi5PMxRskywHds3C8wzIOMmT2nNSTuHdJqLxJ l7aEKHhwaPjI2pMGCqpGZw2Suq170EbNxDbND9RN6XV++qd4mj1qV006hWVcJeiKnT1WD/y1z9JD z5FxhmBt41RtSRO6dHquZ4Z76NTp/uIx5pW5TFXnsPDfhWUV5S0TpiTOfKeadeNtmoW9YZ5WW049 HQn7rMw3tMDC8DaGJI61Be0kzjnktQQE56SgRyRIgj5g9pEx0hf4kQYPPSak72XGTlg5BLp4TqGk nusuF163lFPQabPZ2/8cNApIGYaEfBXyOke2ULqAjaYrox3efzC3fafJ7GRCjfwhaB1ER50cS979 Aogu81luts73MZqzPf2buzS/LwCBgN39YMKkXFs3ttx8hThBGSX25EOjx6vvdH5yiTYtt+//8tIF l/AWaLhZ2ADthA3ZL3ubCH4sQLr9CUw/A1BG5Y8DIxSF6zeszfIXt1pbfrkXDrcmyu53KfF7OKpJ jxaZUn5TbQrQ9g1y6fT8j8L6r31z2xDTjOmg9zxIbtZZSr2lUQVf8uhCd8ou1tzwfiCWP418ZhLe Y75Luy3PXo7xP6VFHyoncgoo8Nb2Xa0q5k6bzw8jBuFAYz8FhkXMIHl04Mwdy2AzcpKq0DE1sCIw zz7PXVCVeYZ1wP5B0P09CmD6LZ5yPGn1GjtXbhMzOHYKaBB3w1hc/E3TQi0HEdFJep78/CuTDUPc q9RxGx7SLER+4dbs/4j2KcXpdZlTT8ASgU6+qL24Sox75ysMbMc72zZXJVzTeIpq1L09rpjuhBbu +MYFJgAk+hgSVVjP6L2G0dFXjh2Ki+YpmewgTOZ0iC5hzj/evw0xBa7x63955LXFjTj7aQNXqLic 5++S+LlqXohRoavl+0Xzbnx0wHOgh18HadUAek/ikg57Ert4t0mEvLjb0VVZjE0LiGwRWor+BvIY HbKX0ygfZdjNrPxchttUQdVQkWCaU5aToyEbgHVveU7QlDiPuvqt7aduTlApsPpSdm/XXitR93OA 1FdxOG9LYm0KAljSfKTOIl29XuVOY1xy9mc/TKYqCmiY1Fu32Pxro5p7PApX6clhTK8841pjrG5o e3F6+caUQyss9fvB11uHn+5K4vCJT/TGEUpxWPjOUfGHLVKUs6ebrlpFY0MPjc5kd6bo6p9Oifyw cEaInf1I/DRpq0yIHPLQQ6Nuhd/NEvQsI0KwncSR6y6aswRkAZ+LXYxC0xav+BhwOZLrUe46I2xs oO3UWYoyJVL+2CA8tgRSqFcHSFb7xNCorgQ7magHoeZ/u4E+i/Wm34mnERQh5v8WgMrwRJjYejjo Ma7ldDU+wThuztql/kIBcBK+Esqjd4CtWmxl2F8RhDFDpWXRwXUafQOzu+TtpgKbNLQPn3Es02gE LAJRiTuZqskQBHD9mTr3qmW1d9SANHu7ItaFtZX5KMd8hS6OeXCuOxt5Pt0/Jj6OUQfk9gdasqjR mPsVU8L4ECDL9ABpKD0FVVjf/vQ3KA8okJf305/9WYUfONveLGjRKsMjQlpUGV/wPiSgo9jk1IeP WlpXNxdbjsfhFx5L3vhAh7SWxnSGNlCmqPUR0MMakwtmnhrDkkdFuidcR5mj7Y4aPkkCQCTKNV8O a5mIFcJW3QxK8GSsin2GZlU4V7B3EObSEgTY+jKMkuxOCYDIs4SJD2wK3mTh8XCAFgYuJKrJX/Pd MfB4YONL+5FoT5Z9QJlZlvXXxXr/zYyzF+Vlz2y4p5ckUKz49kSjDT5s9Yf2F5XZ1rITTUjMWV+D EYDnWZxll59cPN3iPoUaJ6yo2Wbcyn7Bb7kLhKPhmGElf0xWRsCEM2mNObwHgaSt729GHGXuXxLC J9g/6QGCnEXWb9LgqzIjHfCx3uvZd/bg9zBA9n+C8KFbUDEoIw8HjpOK7LxryD4sghgiLYDYKfdG 8DuZedO0seUEN0TOjsJfs8PXjDe0GotyvuSRtjeV98qolajbFOc+sHuBLXldtex4iz55Z8fn50iP 4MCIog4iHr+DL2+vIC/VUHiQlxSiJdwsBvbt0zisGR+lG5RRRwTuO+ZTGkZvgeegT2L3QgUGhDlt 8YkuOhQXV8HnNk8uN6s+ChMtbo88lCdCRQvyO6KCvuZBBIdENQ0sYk2mQfitz5H5atcx0VnTwZXu Y6ng892VpwvkljO4nax1UsHhCsi17WpS0noTNC+Ex9+mtOuWJbzlHaTmnT5+dyp25Ve1TfyiVSW5 VmIbxsyGruAfSCjIXbLJ2G9oTHma4eXUQQe8SQ/RZSES2U742OaMog1AFHb3e2WkFdXsmEYW5X8t gaeVa3Dxz5Ri1I1ZcEFLnHbtS9GYVoK6Z92pwjQJxws6rvbRtM0fcVh12KSuSegUB39Di9BxUsfz Rn9ZRcTbkqehc3TvFcMSwXp6BQepjHwYXfZVVcBMLh5j/CwFV0/HSY7RAyzYDF1rD0vDbr7vtz2d e9/Ss4/bxikrLdaUtY8L+lu2tzwNUkFAvZCo+T5Be53JBwLWtxt8oQ3uJ5P8AFnhXPYEL0H+0Olo fY3yf2zdMO4dwoW/jGXASPnyNScm7umXQceM453hLP2PKSpr39uwdbNb22l0TRYW1bonYll9qrEs BxOnxzb5vnTEmXhvVjASPlWmvijIya+Fhda1z2kTcYE3iSeqMiysIjD+BphTq884roaX4hzbxkIy qqdb78UbFTbqg4LvPEsmT5Xjd7OKYBQHk/ZI/XVkvJQI0wvXg/gHPt788qKFzM8jm2iNOwEoS9T9 NGAO/blSWiQfPoE9JT1ldcArEktiVRTQO5nVG1/TakXco7ZAe8aDKPUJr3ietjk1qtSCFgc64t0w EbDwFk3Am2rO8IT8tQZEiW3hUgLRkWs0Z9Cqf0q3/+kNVYVvm3Wz5QKvmCQqx15dtpi+AZ7Z+a71 EgtTmJoNKt8tLCapYEQtWZxm3FoS6du0c7k+QayzCu25ImL67Dl0B7B70L9gFXBe3o9EWqivjN8S DjBXHI1C2g0Qjrr4RPIvYSxcmv7qMjnmMG9ip58kdArxQ515FMs8yveGSy57Xg21q1kepTpxYBPS zd/RWYviqj41/wmtMwCJ1oHoD/7MpL5u2+4O5/ScuPbr12e9FCnpsuEnAw+gIM6dE/MYboe9Hn3r gCv+HWP9QcmedtbmRu+D0UxIWiYdP+v8ZmxOEx2JNusuJxRs5t5JFr/VtJV+RC/is9sizkWUU5X1 kDC4RcLwgaIIdJFwExpEe0frDu70IcojdGazf/u0cZcnPVsep0OFgxAgKveler7lNqPbjLI2BiBq KVfD4Dmyu4cA0I2bBHSYVVuLApu/TIGF407A5vkOcJ6/Oq5w6xnXEuXIT4rScJ1lnMGLIIwks/VG AnDtXMkyeVIIf0uQAOwWdsD1sC96L1uwa+1y1vRlUflWaIUOS9dP0zcG/fUMKYLTg08Y+uWyIjvW dfL2hNrJBEyi2ngCOw6IH5sTAvO+n9ZxoIovw1gMcqKtWp/74lqJ1NS78LUfajy9Sg+AmrkdKnbL 5M0p7SY/b5UFFrXBpEXSBfT8qtqj6SEUJfz35qeHhDhDJNRyu72FbV1MUQPQ5Vb+UaykZt6MUOJi 56zqlnG4nLskg5brKCnf6pkQSrXnOfoAROUSSeMBwvIMYqGtYcuJoUjjcqJtHKFYDTUlbSGiCyTI Bnw8urpaHAh/9blfxo7g3HbbZY13TKjTbXxJnr8aWaNPx1WqNdhH93kd8dQSFmNfEOL8FaN0iZTi Tcx5xQbJnWhHL5pwAJxlVcv8ajQG+VQmoB912IYtrY0wOK8FNXi7SZIhLIzFe1MVfvOxiEtWDteu hetmzIXJnKsm71Dlo0b9SWePR1MMwTLCacg2mp6roW+pJDz99g7E18qnKX5+OQkYgiNVOFGIj35u RjgF1s28KgKa28Duh60cGeApVcVL+X1PGDjhConhSc1SU6KT2B/i25zQoRbptY+t7cTozsA9h+Pu tImC8S2MAi3FGabjecAQA8UFpxUol0z3bd92Suf3pbnhmIDgyzJ8yiCMJzb+WqvEi1AASsiAIWQB m6ua6BevSy/4Y0WO3wVbZaq/ZSF4h5AJNYkLHWVMguXCek3sbyC2RABFdQuFExlqoMC5Ou5i8swm maJ8rsiJdgHcGkedxmqAuMn906jUFhaTa0yGk9Zc4/p6/z/POmwNCVgEMAOtHTtd2CLS4amdXmPP uS+p//FGSuI60IcmlE9jlNrlnrQkDDmRbU11AuXCktwSBycs87dI2YrBMYDb5w0XCu5LAKns+qyA uJzvLxSctflmf4r6DFI8IgvJvdUeZ6NksyVxHKjd/TSx8eThQCK/zPiUxmqjYZDXXoFChpwiFWew YO41z5N/Es1iSPN7/Pfc675NyBi8xol5JctQieIwtzu347zY82spYV0HGbR9Q2zBtNKRzfOu7E29 QZH+fuCeo3aiTv3dlp3DNcl3eQ6JhWg+fnSDPCbYzQW+nszDaMY8TB0RxEB32KWN0KJcktoYwtH5 zHpqg144ZZY4iXL93i3p3Z63xTLVmeI1SYOm3li75FAoOS8YY74UE2Ra9Cd6K4C8xZXaL2FoHKuG DnA380pqGW9ITO6iK7qLdMIb5M3VDknj+PB0B1pBGCrM0dcip5m2sAMogyEC0dPavW7VbZG99oli I1xhw+uoDmYOpjdYCs2TBeAqiI0ZL3zts+A2DITNv5Ao7nRYLzEDU2mmIpsGTHlyecAx2drhQvY0 ZgzJnIip0b8dwRc3XUdemLtazmGr1SHALAM20UVGQ6PiwNpUuoWQAEk1T93gkIgrfwlqL7X/I/0t UprYh1wRtbgY16BFX+n5WBQY2SD65Ddr+zeZBsmEgkmOxGEq27a5135h6vgbOVZHuxjYG2dnhvSw ZBZqr9TFILxgowcw5v/flBofrAc3RIgD1Nupb3XdAIFQfV5TQrMlLKV9uZtNAFVOda4cMnOtYmoO LIj5bhv88L9VHhkazlpifR+JWxnYP15iG7+eP9/b30DKgypwpYiXp8BCc2FPaU19pqUVsPoSMYgm lbDhBpCDHzhm0PRpOzjo64/HwPbqNtj69IJCRXmhSh6jFbKCOiqc/OlmH5u0RGqDqqYpJPFTse1Z ihSADgna/D3q9ECEzlZW+F7qafv3p5TUe+9ou/HoGTFxCf0+YH8QegD7VjVCQl1Df4+eCH/GOgiM OM9+k/b1SOyJO2Ek683n/ufFA86cIB5IRcaH0e3YrlX+mUUbCPFrAskSA8OJOTlcMO5lZFMg7cQ2 Ey5tjS5wkBHPeEaXdEdR/b61vN518eo96bFwu/l97HOurjVIqcnaGrNOIIQFWvgWNjQQsvOrFqry KNeaXFoS5Zi+ABrLC75Ox0px4quctE3G4C57iJYrUi/uqfUEvjvdoFT+elWpGtWxsNOXe4jqbiLq z09iM5aLAJn/IEmI7B/QRp/Bf8EAixy38jeQhMEPTdrm8zcv1otX7BuakwWh8NGIXqxGNyJ/pyNf tWwWK8ojhh1oayeEqOoBu0V8C8V1uHKPdbNzH1Z4c4fBBWBMb0fkFf0gNaCRD8tcndYPuwOqQQ7Z 4LIXUksiFoQXmlGr07methBkAI5Ygj1y5HJhbwCX6GWHGeCstnxbfbqH3OIfICZ9cRsLY7KlAISs AjIAMnKtESIf+sYIM3rYWcOrFJ2HwyTG6ugR1rp3cPhF/zU0vpGmK3o4uMdEo8n/OBJmXkEjvIFc Im9+zPT5UWkN0DbXBcfTIsjdzEYo6pM5Yv+YpxlUFneVOl/NfVf1nbbVilRq2WG2CnM9pcuN5/gQ q70SEabLWwgEQQyDNUP1P+PgrkrVtwllpffR8ORdIuZqyTNatnwB2gd0qF+YmVR30dKXktDFT+47 Fl055WnfSYEvi5xWGTsFVkWRPprCRiTa8NT1aV1g6izrYssIe6mBh5ZSGKPzlUfjdnpKL5iZ6x8f JJ24W2Lj7Xea/N1jBlv+41evE/UrvaNFF7fEAuXFl94NWCQ4Mv14ofH6TXnnczff2dw66+93w3NH +J7qGE2/3s7FS6yRYCdKBnMbT9S8T5jRf5/sCa2VpSYRUFBKigD13hzTIEno4m64E75RpNiJfhrl BlFKmKW4zZuXScP12REBiChAfF6/dMJLPmM5d95HcLlNU2IQTWMWhsa+dO56nJDJc1EnQHwWC7AA IzVbE5pPjvhTBkMiuIfzmxh9RERtf2NzE9gCmviHffqsVVmpazFsqjF2+xdGMzlvb1pVcOA681Zi zAKWxBKjtDonolYB1x4a6NqfLiNipzMTMe0AK0i8eWRoXY6eEWC8H7fyPWRurcKB5XDl8cQXiv3W WiD/+owQ4/IFX4KarSLuLO4TmG4c94Jd4DUKMYGEDT8S5CFJ4hnGlG9bHAHLPITF7WYgZey4DeUV jUbP6nCsrfEjIGrJo3I8cVgx0qhPqwYRpCUPQfxI3Fv1Y0WZOLQBQP+ClD2woHHquSSMK1K9b9Dy nEpN84GrNv5VZrbro3UsIq9chAXRM0ETh7In2KAOlBEH9Amb9Wr0R1u1KOweig0Zv7hYZXjQ6yWX kxAxXDBJUGlFboaDSpLSws7fYm3sQUpfj1CfNjWYaa1X0HPXSaPMqkc8HLOoUHTz6JYYk+qqhGc+ S6ticylxmFk4VzYGtqXr0GTG0YEy7yUAza676cXaaPHff/Ix6iSdOuGMn63dxYZe/Ky0GZdFgIvH 1Iag2VBlzJoQUROzFr8yK/uIM0b6uuHD/ZaHA2hlnO0FU23b9QEoToHluFF70/w0D8yDqX2MKn13 +bXzd6INHOBR/rLSBHhtpnkS2uO5d7qQXIiyHaC2HeejTNEUHHnb+rG+KZvcgspPiM6NCluLaJ/b Hpd3/LO0XYKUAL5UUJQ5V0tdb76qYbcoTrgiTgOqGbHWYBrWCYGrFFV6hXH/AdZ92KbnTqan4H/0 uyFzVbn6oH17+08AK0kcFTlb+qThQQDmKgNXnxKgc3t4PyUiaarKinhcq1VUXpYAsjaX7ynhETwq +cJnMdSXlJDcacVvTas+yRg/zdVUdovxxjdzNXoZYQ2Fcg/2LAF64xw4K4yNGiBPgeWuG6lZMNOc MY6BjAVvf6VoAAyU6gFnm36AZcJhhIEzrtwy/ScX8HtO3olxikmJcrxslyFu9vkAsdpur2T/ScKR qnezL39VZ2YPmdz+8y3qc19m39FGXAQT0J5fX6UMa7lspLXykcWQLS+bMh1DR7xVt/+4xsiDqv0y IfLmAC77fp4WC41OwLyIaVlpDkc+yBH1UoGXMHArQAY0MumSlUFx1AXIDQ4JFIYhIAO8HMl3zomF RqhB23Z/nXyeTITtbwhCdjJwF9AbztUO/lnOWakabQk4Tr05UoLOtUlaKIJLeeSGJ1rOZr6mLBZf o1C2maN8burKIe3fV7rbBI2fw1VOQRDua1r9h7PopbgWgDrCSxNP2hbi6DY3Bgja7NTVBWBht4aO by+eir906RHRMdt9v+hIBBuNaigGO7lJEwN47hCjTjnw5Sgv2Ghc+Hz0GqpYAk4XSXfHKXWCpXGd t4G1/TknjA7UxJjoDQU79hZ03vKsXBztFzfwIpXe8gEFMOAD/RmVLFZWqN0OWpZvctx8gCpgn1G+ qZU19anHgWzERbEES2Wh4Z41YjS21MLIM40lGRREvaXLcw68U365Xwwj0SUhXrg+sKIniFsr50oA FpQz7RIssnfjoDs4DX11LZmpXUv0NHauqKk0WVGpcm/dejkmUgIdYokKwzHUU3CEp+IGCRQM8K+T WFWhNlTNQf6afO7+B4/1f1icaksS1j6EH4z3h/8ihCZ+DFAyR87/X8LbMy3bP/0y0rfED7cBKBwz 02jZ4rA/6ETghYzRlK4onmsu0Q8IXRmUKJbnCSDGRHOD/kbUBJ0qFRKlL2RlN0weH8BlObPnKhbm XNdKAvpKe4D2Bj+ZL1FCaKcmhf+1uAw0/i2IuqJVb9y02F9SVrSBmIRH0AtxH1+BGMPkYshqSzjX F/RxtYLq0qaSX5Kb/95Xi0wnCqts71O5u8koKEiQ9bXu8CT2gV4ESbwlcXsDNZ3Nb9kDy0uY+7X7 yOTwmxy5BuF+0EWZUcaNKd71B+eTJ/uhQT0MWfS4Ga7JmJP7674NFVfymSI72XiQWT9nb97WjnfJ ezsuylLa4GjHePlWfux1qif5rmkmhl++qTd+SJtdLfyrHI3Djsp+PhQ6se4C2dwrobJwXGq97b5C K8EGngpFNG/Z1sbF1743LB+r5EyLInZiCLqzUtSR6bN7wFDfdr9JcBxZvPArlbU3/6RnHSRMbXen jvP123lP4me3wQGDGc610m3Voptm5f8znTOKzZkacgagHI9YpjZuw6VleaFUQ3l5Tguhs4mRERz8 N9zkQC7RbD7H4I9hJD5dhgKni0DFEVMnHf+knaPQy8GVaufoEPhqcQRVD589mGqmLI6GrbkVSf0i byd4UhVPXSkQW1QUBWru051tIsuE1f0zsKRlhthH7jTfYdTupvl+pCvL/8QdoB67jM8vKcAmegQ8 lvYglsnQs/hAsJO2e+QNa+teUOP02CrMknksT2vCG2/QtRtyxcZoO34dbPjLIds8P/REsj4gFsoy tu/GmwiQJgR1hJVfxh9xPUJE9WK2peaLjxH6FCMrd0hu1qS5wV7Zev+0Kh3vFUhozFemNVsKTZab RBmwta2cUU8lIXbDpqzY74lkmqWu+PEywyhLTdQWuisYaD2OUk1EYQS+eBNhBdYKC+aKeCivdIfy s1tU/ycNJp5WIvKEDpWxNUAsjT5pR4GKXtTNTg/G+BmfpAsjZVuyJbRbIJSfrbUlO1mRWUXAPaG8 Qnafc3rq8ElyfsvC4YsmYmdsPU5B7Te8gK+nNGFpOC6iUlf6LNngdeCIxFtmAkJO7uxjQ9tdz/PN JyeBVH6fYBHLZLKxM01qymJU4TbKZIRl75yPujgNG5ijBsl8Qxmt2gWgXAUn//3T/779SVxyEWxZ N4rWMQbQj436XZf+ctXLUtkZIXAbxgcK3kxdtbziTWpZW+CKcfSR1nllgLde9LLY7Zcb64j5nSY4 wyvxKLXgXV/ocU/UXHFV/VvhBkPCv5f7VV5k5IAYcEoOO7pgY92g1jH5RbCHU7gsuPcjm7Z1rq1b RG1yuAsTu/7qeGkhEz+2M/wBohwMKVViSa2HZEoO4R3BW8uSDU7ZarEACkdytzKmQDjOKClR9VCx sAK8LQooSH6FSkbBR8BVL6Gw1uM9Q0ICSWlQMXscFJllZB6JBoo0ptt6jykyD8B4pFBns1YedBSk UrsdsyTGbkOhqh10yGf/MTdoN4i3GAK8+rvXnbnQ0y1czTpwNN2UOYFr1SB/NbR0lRzOr+CkNycf +IXOm944YjTb5c9RqdcRwfNH1jYTQQzo072d0mZ7ckiW2uc/3VfGPp+zFPCaqJ9kaRIHs2GK+GkU RP8ufu05EWVWzjWiBWJUux/TR5M2mqLCkhpsWiiOvWNNEKk9nkYJmw3+ebFSMGE+zqyTsMsbPBlQ C/bQKlyeIaIiinUZSfpbignBwjXUQxOyr6f7r+dSqVeCnopB1jni1o/pYZdoTvW58EVySZaTp4iD 2AtjRV4eGbbUzRfm3oS/ARri0KdGx9/n4NN0XAF4FpEl7K/cpZPjq94W52N6mSh9oSGNqDDNyGhd fvJsw29p4JXh/oBFikUxtfimC2pH4kcLLbA2VyBEz8vMz3VuDFuYyTSn2RSHGCkG1YiD95Wr2T9t 9LPwH3FnxmIFHvliMI5B5eje0lxsIcvbBsMBbeATRN6+CMvCQVRcfX4Inae4Xw9VQkt4PUh636sC E+5OCLVDCsxzblbM8arZSGUami+1G+BvICQ4QCLDSTIu8JFLotX7y9v0VBmHwxHDWXC3FOBrhBRR vz9/VMNJquNY1iQqHn0zgdJ6aWx9pDdtq6rCZe3i+5YMr5Wr0kG5gYuazFkEb6cRD5PPviUrrASz RsYZZ5sf784rxxD0yFB4GxTLJMPhc9YOqOplTvC6LbKb1ue6wKfzzC1tKli11SjTxSNGve82dLT8 LrgqDpdpa+7+7xLL0PR/+JwMmGEoZby+ODsnmfV8UKxsVRYsY6DK6gohI8qsB28eoPzCnYWRQuyn TKri+c4HThWe4dKe2wwK4ZWWpzQBDXHnel3K2kiTDgF7RZ1Xe2DyQqdICRASSj/mAcsTTfcfr6Ak 9zfhS9f3uv3mn18OWK3QO1kr/oskpiQxPrAapDShDabJ3dAHFGcuhhGS1qcAAAAAAAAXDcxUGgmG jWwkQDH/MpzhNo7MfO83lT7e581nB4ZNHafYYe01Gak5Gedh6doaxOqN8JIEluFP4yulzzUY1ba1 LfWWwll2XBIszv/HpFIbiv5LunvRprWAV6VTnoJ6NSPJ768HTVBREvQ3ngc2bcqJ9inAaK3euCdZ 6swjenNl4G6fVqcDubJ5ox9njFl4LMgMu2uMg962yBBvKqgjRtCasucOsZn4bzHeUo5USNL0REQj ei6kO9BPF7knqq5/kkrzTRQbAIxfKp4icTHRxDrU4+UM+u4JXVrVyJxr9lpY5lUH14RkuuZTi8EB HpQlR/YFxQFkb+WWwai8SfiZvra/HlC9Vp4EnQzXKJkdmQW0qKCi22GtpT7SyNNSh91gCDQvKbVH 5gf9/1QQTGvouwk6tRzTtPKg+GjCPPttaJPIyfTfLdShU8T/MvImL0vv2ru3LBJqNvnZJwn6waxr CQi5v9sjdYSYecPeVsSF2f/YVrAKcidrt01WatEbu289S+7t3vwKxEafBy0alqs7IutlfhipSfL/ dkAAwH/zNpplVdrF/vLDgWP6KA61hbGqBaS9C6LKpS0VhCI5GwIU1XDBwqAGsCR1D+9b4gVUJcX7 vHb+r8anmNlGvVKC9+of/zTA31HWQMdT2qQKs3wvFjGeEjqlOGjxxwxcPGc+xysLufxTpf2/7FPs EInSuN6L8f7Xa9HppbQtry+JqL07SvD1vLS99QJ1D69V0c8ekUupsT2pRePitaw6CvS2LiRImILz ncZVlfq07nD75522KdRRbJYdfTFnwtsEZRqvkqjqHsc32pHkKoOZP4oXpj8J+z4ySMhJPHGeTLzb E57bTBAqYqxOYGTheXd4efPZ4vDK26qKW3buS3X3PkSaHb9hq7Nh4AxQm/+TU9ZP/1Y2OFIYYnUy sN1FHEQrR1qwQ7W2omTVR5+fCHHDDMQ/v/W9Yygd+7mFIJcDtigQlJ7KUGqz8CwHORjFvrqYKhgR VccD4IOZBOcq4z441vyPjJ/FSfKLeRHmEhnPUIrTuRew8pA0xhJiwvTWNbrWFvCgMnhllWX3CiBE rdZP42krog/CUVHOHQR1VRurIO5+OGEm2v+cMcUVU2w8JgZhSylt2dOBDix4xfshxE2QoApyiCIP zz0V5PMjLESsMcvMVJ9JZrTUykoJdQYTG8qc7MZluLTFZ863PjBY/0OYPwlxIniADfdl1Oo0ZYzr +r5AiAwdWlA+FqljdPydffYiJEEKTVZ9cH47huHECu9ElztTmQFLCZyD68SwnIsbaajX1pohwzI/ 165514jhvBI+LWCstWJ+/uvhyOrqF5G/dZdIziBLcl/wG3oB6ifwpKyLgkoNGs2gbSQJFoWfRRC/ ATODvZc2M3hgb2LGG/l+kDdlv10Nk7XK1SjTtKZg1OqbiDp/AJNCAAjC7DQMYgCaCiEkR8AzykqD M6QSFF8f7h8Hps5Yp/ITbTnKbtJZpZwK3OwPvSxp92XNu4et607K2mZxCnBswxIM/YtfS9iuvVEt dApMRWfkdF165bmiGckBHXQpJle83/y1wjIBwQCKSIltIuhp83Bps1Yt65wBjHqqDux1/HpPa4mQ 9OlyYUI8UN3muiXIxSBE4LJTVmOoRbPLJ1npltHx4rXXQf/9J+av7UznoQAl3LzL5IdpzWXyC+F4 3pVj5xAaGAtz865wLZx2az9MVf8Ly0jiU5hzL8K5Q4VP8MxGCYfFq6Oi4AcQJ1/hSP2KSl2hLPuw L+wt+a0NBIfhkM6/bPau3lIPK9fRO8awvKUU5q9DQUCGf9Jng90YSsAP5USIK5FYC7Tox/IVCLIZ QBZZd/R2A1Z8TU8VeEYWjgOt0gC6qou5MdxHb5R/bdYZdUmL8Psc/3aPXe7ICrCMCK2np895DodQ Sdh8FDGtHpjp1LW/7SQSJ+Ogx8R8vUKaz2ooOupwQ+KmeA5JzL7styq8F215Cve0LpVn9rTgm5Ae lXiE82IzyUA1imIoWRk1z7LVEG7fzToodTerHsO0jRowliRQxRsnJ7U+SpU9D+wfrmrBzzoBG/u4 MWqDpAFBYZBsU7HmMIEL6JherkxSiJcrywzzP+y2qInr2GQYrKf01SExb9vyhZK9GB9NxYLEqEaU QiUGqo1ayzp8d6OPLT4cuMtsOCJ6Q2fPDC1EIR0r168QB6zEQtVHm5y/gVgE906PJaWVyJotwXqV vzaA5wdRPZuGA+SggC0ibVF7rx/q1GGWE6Hvqelw5Oy4hicEt2X0Bo6WkwOyYQhURr7PbLzH/xqk E57bCUlOTm2apUYz/vSLaORlAnpLpmaAp/nFPAWubinZ0e3ldvzHaH4zstGSqD8tkz7Zn6Ib2ZuJ p/+g9teL3sioxwUFjZ0QZru2AJGz8pMj7SEbEwWFIRHP/mnhVk/kOCg3muIsaSXmuQZlGE2N5jwj Ezh7Pg2dET1B2DN85lTgn1czlHcmxphYPyjOwEC4aeszvZBB/oAwWuEksNzZT4WC+RnuxTMtjSo6 G2b6h3W5l9ZsA0L4kCZd0m6N/dGVKM6qpDQdsNZ3BfZv2QDOOyi/tBdSV5Q7otL8BbxjfXToNvwu 9FgdJNS0hfEVpT7Z5T5ebEs5RWZfAWXi/No3AISjCcTgZ1XXPZwOSHyiXLkm34p9SAyMu0tTHiGd jyG3PJbh8KDs+N+cOk8jkbL4z2Z6Ys/rJyQHRxTYD1kueMENingz0kQ2OASeZqyhntqW/hlFXggT UTUDyDsA92R4S+Uk7HYEDbvxcFvKYley2xlckWWAGxDykzuTrakURLFg5XGgZnZjaB2Et+uyP085 6wEU8opb1d7Di+0s+dOCZa/QtGbY3Yc0edwbFJFw680jBO037x6L9ACb1dMRxRk9+o4NaHak2RkW JLqg+ZEo1onSV9GoSmKY78hySH7a2xiOdyRXeHHsA6nt3sCVbSXE2XdiEeV6FtGmKUV8HX4h2bgx fy6R+jKl3tGUFx0jX2+9RXlO6cAM80hbI6MGS2xdVTPLpX8t1Vq+mpiSCl9IaWCjSSn18JVqO1kL OK+MWnQFjES//oJQ3wU9ApMK9q9mQIGDOTNMsAnSoN61oHCBQfa5ikn5l8Ah+1nBIppSM8clwrca Jq4vpnkkKsI1f8RcHG9iM0gWPmB0YfTGTzJU3OzX5QJmtkqSfj1mmFr0xOT8C5loREyZ5DMrJAZs SpnPZtWXhUOpu23RFaDMhLR3nQFoUqTshNWyfCjog+68xBJFWh4b7m26WvA/i0Tr5DbuZoADGL+K gDnJvIluxgfUjVy31jEcq8OwsQ39qWkJ7h2Wh9lwpOvMNlMEumyQANq2pK1QJvWRPvI6AABY+WZN iDXNVoamX2piaCnL3cDBS9Gc5PoxxQrdYot+wHi1iEQ/gk/dImnloKaAlsA6xjkkxyW50N3J6kZ7 worhXJMERAwoikipXwEzP1wW5jmT7pSzo1QjF7HgP+1S8QSdzGAquA67PcHv4ogtKT0D+ge1baoP ew7DUeYiTwmq3bxUzQjNu8mHn0FxDI4JWpyr2N1yTKoXqfp+8DpHIy9oTOa7wXtxStA77dIiY9OZ ZKa5nOHgZerYOVePIlBGTDYpgVPq3DHcPvBzm3Hu6NxdSKWmTAZMB14OwmnUYcvzr2NC27fD77I3 v/hlPWBgE9eBX0p1MsmC1rT5DLUxnFkhE0RiDZVyfH0ymvvfdLHBHmvlITh+uuoCxLLzXhKqKXLH Hb1V+rvo5cav14Sj1QR4ykKQfeUIbXQCRRr3toxjFYM23J0Fwdm7ZrmKcFbfvBBnv+BKCT0IlfH9 erjHpXPCXWfy02NgyJTg2rSZqth4GEZpVEGOtVAB07KkGKtZrgQfaElSqqF6MFWEGiu7qME9V0ju mrm0DYLdTQuI+2J+JQ0FF71fVQp8/Pu4/C5UkMMfxUIeaIYRgDjXxPyNFB8Jlr5gz7TYXmrj1kn4 jMZujuGH1Y/L8AXz6iJ43HXp0UBn+Wor6XiArrEA+DpX/Q5Pdzg3cPpzOHjn+TW0gaQSp4ukaCMf jLGcRW3S0Y9JmZOPe0C2J5vFzK+Kor2ir5GVyBCiOagtfi8FND9JMkOcQtwigODLCtkXvosjh/Sl sBaG7VkQtPvRfbhH6OmVEyl3RGCbhEZsNK6PWBYcr+2ThdYujZQZ92ygkNvNVJ5ARR3asJ853ElB kNjJ4FvwhLGBRr/VPBIBp5BfQp5S23Pynwu4tQJZQ4LMl27lu5mFxpugjCbGcgUanGCnA9Vl2Hau JAdpf+T8TRxk4ZvNyYEkg+dqRRCnVXtpB1OcMXcrAPvmyvLqrdDa0BsbgnUoEBh1395IVydtoPUm CMry8GVI0SIk5/p9TxI9ngaEGvH5Vu03cqmgEZFExFKiQpZW3wWHnFFWTIMjENNhIn34yf3oQ9ga mOA0TgKN4/p0nHpub3QtXCC72PgZgYvAR+3GOhgoMeeVQPyF3DbfqgcCClTwpNEKQWb/g7yYh8lj qbdABKZD9HaPRrMPVdNYl5UAvvsrZxNSzEI9E770tEn5Qaff9HTTI/aaUU5h1qC4C5Ta5l0fiWjn Ru6ZMTXzoKxBu9sNOY7OQ9s+VVmzErE7nfsQE/XOoN16xkg6VaKpJA0dHkBx5dKH5vJAs2CVWGtX x65qrd1UzTP3iLAk6gmwpQU/3c0rQpo6FeeBfm8Pe/sqtrmXBNoMpgCwD9uAwoECpk53UObwSMaY Az7+SAfIv3BV+ONufhiy+XM3/WyyXoT0kzt2s0zDD0XKumxuk9984L6a08wszwlR2O3/DF+5Wj3S 6/a2ZfRrJRancquHpWwWAGKJ54vNYfUCMyjf/IrB58lN5p62Q1LubUSb3yXmk86IZZwHq73pDvuq YM8nUlWRUqw/bSbEI+aKQO8vG5qdacBjM8Oywju7M6dncuqlVlOG7MSiEOqotPi8L89KUhq1WKhE wUdlvpm8wnBrq4KqGo2oTcTb9TfB/VyGtJRP/+uWfdUfmo5Ss8fHMeeuDkWVA3BICS6VdfctUeKH PIDLGXKAlVGgyPgoT3IM7geCP09Xe6oJW8BnxSeMdK2MFSt3QdAKmKGjiGNgi7FjtsIlFFw/gGZF zEyZIdRuKzEm2TId2jRG8Kn5DA1RpStQqIRElPbhW00l6redxUoVqPWaoJd717Ymsj/I9K+GPW+L nQdZEU1jBt6LdQ3z0+QeAd9PnXd7fQKgbAYfOjBwdyd5HEIWIFHia709uwYG4IWdWjpZUopTvNcd gKPVDmwXqWl58lz/10pD5e8WeEX4kgJRYOPM8DY7eWVpTaool9cKb5uOxSU0GD+Bke++B4akUiRl ql6sCYx1zikfc3Ii9gwCHVAx9rSYgKxZ5IKKByNR1wfFJg5WizC4QXJMDMunvBdtfYPHc30I0i2K 89yBVLRQjpYjcJrwcZgpo0IzU7+SAIjdnoBTy1aOigLpvFTp/iB4RPAHICJjQ5MSYB9lsRh4g9Kl eraY7TdzNrWOBTcsr8rPZZGxy8ZRh82tUBEn2X5xG6wR322U/cyscVY4qBhObxMvegQzQRgqeWWV ufrar6CfMYMqDq81EWkABm/K2bxfJiYc6zTqjNOOaHscySx9sGuixE5qlDbmj0fLAWqdDymhu4wK 2i2MAIyVgV77e117B423+kHrU9YxI3tc65wIYf+FZ4sknQoHE/cz3GNvSQv1bStE4grzAmwQVpVC loW3XCsJNXuMns2QAZLdlIGnV+pokwgwTl2Srq5LScf4Uk5jtVh0NNOAEnnOnCd+1gI+Est9lYc9 7oj9EW1B+jx48j4wD7g/A2lVkzK0AsjsQBZ1RAs2L01eFgMO7eqbmN0jKgC/IweoyejDR3CnvGLP uQAKzt1f236h8TQBf5MT9TIKXou1tWJuy5ISWsCq/JYng6YBTsSM5XQ2HhAUOZEshaDw79P3fKW+ xVpTVgMcynEDc2Xe+E2nzmzftQ0vgYbX5Kx4MG5y5f6fziEwQV5U4NqQY1NJU1Cun+/rA9OeKSPQ Dwl/WH3hhu09GrjgaHCVY58BylN+liv9GKdZEc/vcg/q7td8ZcV5yYA4jMGIvKzucBu9UgSXDxIJ +3j+rj0vQ5AXu5t/e3tMVbBQEMyhf8EstLuquT0AbkAaz/WU7VCFjVm1EhqXRFwwzdZMdiy3EoTy +CIhd/rVaCMXu2HKCRL/2+l6QzuD+00ZJcJMYXDJzravf/nPQWRCZgc1cHcp+AVBB7t/JF4OJFxm 4Gk2pKK3rccA0xT8l6ukOhmYBrXN01XfkjZ9RM7Ei+flogP8E6o/T/x8LJ4p3enoUGK9Z0PW6XL6 JyfiSMS8h70PgcRGEsv6y1cT74b/BQr+OntUmNKtoelIYMwmtSAgrNAxhPuiFMBuD5kuCzjElfB+ bXMyHq/nfeZ8J2mF+GMM47YVbmJcKcL+JMfktOMnaAV/BaPIIVZlUQHZr0JY1QoYCsme1noHroJI jPFtN5uZ7/K2ypCMmNsR0yU9Vx57ykEyr8f9p7yQyZJRas5DJ0VhbxNcM+0Gzr68GM0u3sgztgld oTbr8k3GY6niTdv+oa9ROD2dPqnOplRVnjZDakbxkRfHVXrAEjdYaGncUPsN3OdPTTgRCUabMDNy J20nUSxuunUf4dxSEUHRH4M8HpxK6SpM7kE2hLZRjvbYqNKPHVk3rBSCOyszqd4xQlwBkhhxv3Wx SdHOExexLl0f6fXJVErQmbrGZWrsiYka7sfTjfkMuoODAoWHq3sQTyPLRHCyEa7QZzR3YXoiV3tz 93i4XWC9wfRQJQjI4cGzveri9a0jd/2QOa2TodoAv7wKLRegK5o/j3HmTTdSyQDnNS6Dwc/Fxl8a Y5sXzLSs523PLRrZJtSc/VWdxyLWNzJKIPWQBx4pq8GToD04YzaPTsKsMSZg/5eocO2BJH9MO2AX 4iE8K2rrzkNiI4Vznnsg6HIgVNOSFLbl6KH8jcX6FI0IG1kuJ0Qu2hWgBZO7RZy4OfigDKid5fOC waojn2azEhxVmweuq77HO+MrN+6IEn12CF16cJ6/xj4mFU63e9zOx/ghlFlTeI2BtFRQ0QF//0CF JLl04b/zg3ykrfvG58S5X2YUb2Yj/V903QYTT/B8k6Jx1oc12NeAzvKV7pqiIrWMHrRSiJaX1p2L 6OrY0we1eHilvJjdI84pVJrj5uRu60kX8B1NwVWVAX3hRb0Pmjnb9bBGA6stf73cWThKbh2xW+Tc JhtWQryXFJdZrJyac++/aatCZBGqP0hGCISdqUf2IqHUF4lwzecY8jH6Wtl+CsBx1vuktqlrkWvZ g+uFiIgjNyHFqx7Drem7+9RemVUhL/n3FGm+Tu1ZMPwIoWJ/uJeeshiIkFkCDWaw+xTy5rF+45kp u1AoQ/+L5gXyQ0qAWSZq/SW/SgqSBbAD7EtR7WljiCPFxxsKuMz+4K6XKq4avx0WEUhjM5RErAtG W5H0jvkWg1t4h/5bgIPsqXyOUs0FUKV4kewYvrF5rdirzt+HRX1e9vdZNoM/36Iel1c6YTmYAYLl 336IXRNhCfFOAfprv6yH4qO+K3lomNwuoiSOV1fz9N6LoINZE9oaoiM8BbJnYG+HGByUNrTvrWG+ 6PV0FXkfa+oNJAHgHTzwQAlAGZfg6fcrBeJb921QSmZ6o24xRZ1y3naa1gZgAj6Xr2IN9IAyAnSU fhrR4vx/w9H+UrOoHucpMnY//p38xFzJFo/46tVCLxn+YRTwcefkeBsPi6b35NunWJTAWt8kuaX0 Y3BKyKAv3sPxyBvwu04faTnPYc45wVzF8s5NE0iXVkhjZhtim8+lOHHfLMEoa91tJj5REAcqnAaS 2QXPkivezCOguasPbwjeUNZ1RQrGrxfVqOuoIsY0T2bkTR5ndoMGxNXl/RnxBKnGzmzkYbrI2N1r IU8F0WEER46Ar1hISiSV6P3+qxDrzU9WlPOktaFRfp9hpg8ffyV73m+e0IbVajPU2aRvpqqLNz5L L9CjfPjgGqPTwjsouAahDM0tQpspD3oJVJMkiuftcWNMGky4lVFjElfSIpPq7VrOwNHD7j62jhN1 Hkfz1f4QRT36u++BQP+dhfMSBFzNZQhDlvvr19TKqH03367mffrePI6dx7U/oSfEf1HqYQyCikTN KMw7cpaIZePeLhLl/849AESYDwPjjOnG7Vx+ThRBX2mmx1GTNrPO2DYPy1iGm6HiPuWuNgCTko0c DKPVkKyW5ZLWiju0SXjRM7JCN5GHmI/RWEGsEszLM/AzK42KJyYQKaO13nXUnPk4RSZ5J4d8xjTX dVaoaTs2u6FM7/JHK94+az+Ux3DyMSk+0aq6kncWRX7NM10kIBzhkNlpCEmn1oIgsh7dUnRMjhAi WzNghsLefsdBscTrcMyvUWG99+CqmW1njnJNRBLh7Tcp4e1EPiFWZkEcH7QgjBmInmi4rkSDmVDI 2oxB5iFPs0sIhE1wPLAv3zYQGbZOdAILjNli7kTLypKR+IIt8El/h0Cn2S6Rs4abfPVHORraMdkz lAR3fJNXBB8Ruch1Oxb4VaHrp+eYga906QWktC3mHXxJtmEjm/0+WEHSSWqTBWo4AJ5vcVoc8vgX n+YwntvOkz5Tc6llsQgHjeT9v+6TFoyso7wMJQ0Ct/Sk/7b1kkTjSnRggMVnJlN0af9PA8YBCJm4 xWxOSE58B71tB3DJzkVOeBzt1Pd6zLw4bn+1neIxb8f8pvvVke5g0zfwEjSbsVsGBui4sgkaq0h/ mAiUWDFyxK9Dbyh4PkgukNJbP3eP3dCSm3/hoDk/a7f5DAtFGlps/9+iXaJdol2iXULwkW9PHvXL GW+dWl1jfjmP/areBXrX3gJ1XvR4/oowXTWYpA7csAbxygDImCqEfo8mmuct+/AAm7+eQPuc4d/9 /Q3naAxJrxV+PKNVm1VRM9Dco9JrvtHYnHi/pNZ1wzjm5oQ0PDshxnKgJVWWyRV82ocUTvvhtxJe duJAHtB/AMcZSHLefGKLopLJ1lGkG1mN3DusTmtKt0u7C4OloiXVotzmEl7t9s1O3wKjjRg3wDnQ qNXEceguWJNcCc9COmVlKBeFOC9W/k99dRgS0YVokeSto2zPq44kCXpNTITDceQug/b5jvg+HEAD OK/hJZ09S2pO2YV0kPLHrXlaQeNTwbZIp6rvGbzkWlkXDqX+NWgkn5kvpp2Fu3NGC2ZrLqOecJFZ uGfsJiqmU+bsLizJu36VuAr89akmt6fn0giax3WPfZ0a34nFwoJ2gWtt1sKxA1AO63puZzFtJXu1 axASBpcZzm3OD/AtgBEp10Yk+iEOaVe2kpCZDeqOqj2uy5AkqFNsXsa4udREPGDOfH392PbtgEwF PgKzSbDOEd9OQre6DScn+oUujrup/bBKWbdXkj/SnezLh0Tbw0Dqh4BXkgjbQ5SQc35cA7xRZmny JaX7sfNZ4n2xvUItq6fHCq688058pgVugU+wW3jOvbdzfIKhPGvkWl3wmj5b8cdn0Ju3Rm2yXNou 1X9WtU4fZEcysaD71VT796CtsXqaskCzyxn0WHb4+ytqfscR4h09ajyl4UQQFGaIinX6emQUOf9Q gqMgAOhIK4nZPQUcOjuxydg3lpHthLRi57zO028tr9qCBxN/6eoVQo+Iscc+qqbrtujNlxXsH7j+ nH9U5AHAVU4/qpx/VVVYPeakD7OlFM4moQBYvLnEcZd11MkEwuno/O7ACEYA7JKaBGpd8cx5NncD BNGrjedkc1uieZP2Ss5nFU8udsHdV9MYvaU5vG7WLtjp6nQX078pg1xeJCRwJV9Q5tFhEJHEhvpw j6dnA6yeK/6wcE/BsiZR0tprcgUDvVmBeCKBk6BpC7FRM4MXMV9bAKhmFXSPrcC6BorLlTZNdY1s J2mSxaOXmT8AR4a4tAiTLvWf3mr54VCbMOhvDHJTFO5fatCW9MZpAxxEHedhRyH/Lg3K1yzM0yXg 7u7NMT28nUHUudWTyi4EmGeOhYrKqlqSyvnsD9RnWTqeSg0y/vJNR8hAHhoDUn0thnWQo9LHxQoM cpTw4SQX9wbmvJllQtj75/wqOYRhgRGfEj7EnPbrmCumCndv/O7iZBmtQHc2MU6DF8V7YyfGmfMi vAmwC2dIOVEisa4kZLD1UK4mRzUdaZGyCNJYT8ytIlTDd+sZXabO67aKP7LCKVmQlOyix542y+X3 PtMKcymaPnK2mq2+7LrHMe6XuO77qroMAPqtrbc/7HJnfrK1kUW15yR/sD79s0JMAdrGtWIHpxC6 n6trX8rY59/UN3b5AD4RBKYKXKMcl8S91IGNzwFMxRVKChrBZ41qSsw5EVRKKAT7kyuObsod7/J3 q9YrJ1Cg0r69x3F4nLcSCBzfWKTdZK8K/YI/z30P9UPk5MZ5s84n0NR7aWUVqLYG4eqTDcxNX9b1 DVCSVWD9M09d1n29q5Z3LfP7l9sYyW6BMrfwcLQoKe33TKHzy0lGHu0v24H/KFGVJ8njZ4eMlfxX Z0YIeo65xvTMEKWhTtU0cVVmDwd1W+CoYKX04AlCeObgeCMiitJB2W2r8EMuD4j33MqrOpgY9Yb8 jZEwo0ThkTaxAmk2RNz7s+6qx3Z8i1UIvoZTbgXN7LrnFuzAduMbPYgcnVeA0ZYG+lpCCo42j3tl crfbTSkLKnDry9RY0q4hi0rDaPMR9EuFVnn1PhYlV06xURiaOfmqg7765u6mcpQKUIize+kGHNqA HX2HXtHaoEl50U3lW7JrYLI44lb/o21WtXhCPQSFoLszNsLHJyq5Dyb3jOto1LFe9G5Gxmya6Oou 6dv/rjp6TQoD0c6B5F2WbtdL+RalwL1Uj/wG1MpXjR2UJR6c0KxQxqe+MVX19+uUsq1SnjS3xGHi VqNF+fNEEx3O5fJyLtQd08gxDFrp1t4LSfIxFahB07s5Gs/svtCNCM2EGAngQhmbooK9Dl8eUI83 tN8f5DuFLLLdL9g4HZ/BRC8X0RQgrzku+ApsfzdBHjE8rZiV/W0pF01O7dP+fcN3OrYEDmwoAKqL wXNRK970xW/qK3q3T3xlbsvjDbuC75O+NOe9ZxGZGgrq+UvCDTQVpQVm66v65dP+miDwE103U/6t h4P9BgJAoZ22X2I0syZi0uaRaucmk837tNMckhaXKpFSmfzIS29pyEkE3MwhrgHALRRqSMj+h0BZ P63Y8y9WOyOcCSeytnGAHZ2a1NE9TVX53qW8mNuVaYl/5BhFeaj+AP1RlJiY6uuYpmtvrSGbzhUL FXSfBhEUq94WlZDA3Lm3GLKb2CRpEnIwSx2ogAMD0pgx5gKv9ZyLSKEURPQawElvi9Eof0btqopU 73S0uSK0btMOUFxN1Jwrv/mvkZZk+dPXN0lW1GJV0gDVYmE4a/kxE12aigM7ud59m3t6MxnJvLG0 SE5BOM9VYa0PURwmkHAklxZV1fBPeGzrqOha9lSmII5l5bq7LvyTjprnTMdJSKx8ZQ7WWX0Mi/vA CXsZonLcqQ35t+oBQjFsZZ29yZyQzUm0m6nO98MFHu++1NUffy8OsDBRbPzF9RzLT9+tLN2Wu/lQ jwrDs+tO5GCTHSKChQREn1JRiUSZ1VgoA4Wrgfxws/XCxhNpSxGxXeQViwnSjrr+umo2G22UiZh9 9OoRXfqBCq3kFpHCcT3iIUwIoANrp8Gl1ljr01vAuTB5nbBZu7E2SG885zXJr7pCaexQSFm8UjND m+XRQuSSEK+9zORatiQSterroOaeFxHBj4MQFk4RIs5ouhPzB1mV+8zhFx1lgkGH+Au+i1ktcK0+ 7I9kXkERzGTzCTA2AbVqX5LC8LKigImRi4060SffPpTTmH19EWxBw0vEJqrxpAfSpFk9e3lbT4OV sy9NIJ5jBDc3VscjohomLoHtbUSv6+Q3YJGXiuNX1I4grwXQlgGqoPz9LYkUqkk2EVTyzlxJSDUR /VpRFCwlLfiw3o+ICpX/SBjqC/vJ0WePBB91MMSv2ayxyTExv69I2kbo5skFGqcslBk+T/3r5o4F IWJt3KnTRlmX5VPq3fxI3VNY0pRYT7igM+Ufoow08JsjQxionjzL/k7QQvvN2bw+yWVT9i9UYTf3 4TWzeDTI+1aQ1EuGvhJtv6LAcD+8uAPisyO16DTpls1HtoSHKWXf9aivJvv4pkL4Sex/F7+cCsvB G32g27RPyaeQEbgdbPcHhyE00z65B7IMw7y1aLkanNJEhYzzGS/C9dtqFPE+jPvX+avU4h4wp4/b cs6zsk2rbuvwFDNBsmMlmYNpX08vYxC75ImvYqJn1zCK1+HLhZlD11qkjzTDrVmQaMcV1R2x+Zbl JzWYfpXX2pyVr9/DCzuko9WALKWqd5p9l9myhGfx7LoG4zMoQUUSYPLZwjuEYDddtnxCmj7pz3Wc MQK6mEi9PhF9oBAzFq8nIS1MV+DpboaMnYeO8D3w5nCxXuvPUWgLVo/dfs6JNW+rTozVkg3LqWvK Zy1idJ7TYtzjCD6/pdz5OVtEU9Ex4ctReJaYAe/NjxTuU+vHUsdjFaf5otiiVMQbVRTOee0IyU7w dInzRAJdgTHJENVH8qdPpx2FuzNcuQdpBo63URmMe0epMNmGo3Igz98DHszoFtrQtaY/9ZfkKACO 7CEOQt1KVMxgZ/pYXSrrTHh7rAYtcndCFKHCt2P2x+qXp6CUB24Whs7ecXQE1EUIDJjrtY9Omgpu PkpYNg29+e5DJfhykeL1oyvfg7+W69R2KXdhT+64M0ciRouN81D0EvBxXKc5HvyatCmozq7kmmAJ fSrguG37+rT/qZpWvNIGSpo6MVJJ3HGzjc9TqalEnqR7gY8s0mdJiwKTXHNqgMbRZu1sT/4nNwzS 526IxeI8M6g1Kvr88s1+rx1OeHNCMg9rRLK3r0JALgWR7xf3REj7yh7x7Ld1xoM74ehaRhoesr5U f5Cb3dhedF+0q7txHJK5i8hxmY9iJr+8LR8F+LQwez7qE9wSSyauVVpuwQA7/bFC4C564pFbPPPf 04MtfVX6/eFHlbjlTQ55ztJccjgchnxqQTzLN1lhwIoghADQr+Da75EhnqvvR9ZkGgDfmvnonVpr MbzsuHWawmlthkygQToj29jlbtdgB0Q1jASLqka6E06UnTQzJaRRVpMN/uQewBu13cC/uz46tn2T UQVM/qNFQPvMplJ6AWlS9VHo9hSdEKhZnL3VtpaBlp7/dEZWlKJyese68BrHt17jKA8FxCnCS1j9 91dGolp9pafTxdqdRdBJaTF9cMvvcJE3eYG9y7vo8LW6P57CvUwYC7GCKL/sYeYosW9RG28297eQ S8q//Ji4APbybwc57N80OQ/iZWwjci0reCtECesFggCEIc7S2VqGlroz3I2spAB2AhGPYhED0P38 8w9GVM2xxFlUhEPjtatHhHjlJSwSfJzEirqFqOhTlXd4l6zpuEp04HkEUsJlms7smuLt8/v8Wb8m hH0aWWawhUMx+3QECsjX6LiO3hhg0rOPFdTcUwsUvxM6cJZdl/g7uuqbMssW3kKbISR04pntt7+c fmnbiqHnzIOZuXKD14LjS17yhDGR7uems+UuUKX1mOOJDpi26lCPwJXM88UNCucPmlNCjl7IEmQV Q93fXpGmcJIo5kHESytW6nUrzm+fHNd9g+wzDzGfPyjDCgaMhwwH/k677xxvJFUeRXsbf0ucx+cw 7x+bVTEmjea4gCfP0XXzGGX1z1wUnC9W5oQKLQKloYlW5TJRL+zzldg4zMXgGd8qqcckOHYW5pIm Ol5QSBS/2V3Y8xUMnZ6jhOFggi/3GKFtnEBKFOqGPv0kbBGo2hMvjdswhHG5wsRmEul49Rfresqa cBcEP/SfK61VuqHbspEfRxFXGS5yP2h+xiyDs2kzSofyIVSY2rdptTTRppfpUJfhMwhbgcANgqp7 Qopx2lyZDysJQUEe3y6fY3WxAzfi62TgCtjRAgXqucA7EZ6bbBaEEbhVVrr9oc8wApT2wxvqMZfV Cr1z9t5YDZTpUzpv9nu7t7AdeUoHZ1rMmpZng7sKofc3zQchhGQoYU/a97zBIo9Y9ASSQziy0G1i Dcby1ALp1zVRdTypn32wJmvEtNONC+WCPv/GpCzo5aYqJhL9DT5XC9Ldgp2kIx7ZPYyS72Q0YDwu YxjU+jhPIRBfZUgq02iZSxk9l/gdwB0gKjCfWzak5W2BPDjSWDbsXWHto6fbLfVbtTvu246aFypj 1y4/h52512SfFWG1rWe2BeRxXy0AyUbMgHUdw6+xZN/vqe7rIsiE2KCTMB4c2aH33/i95uTVeMW+ omrzC0x5qDbMwOopCK55YGmROybvhMTik2wh/UGlv7VU36dCbd5lgoL6ffH7mwe3JOAPAYTjFvT3 eGLIYS/kjwn1fQL/mWkgdAiVk0U2XiUS+gOuDtqY8kvUYmPpzxS9uk0gScpkFmcsaqhnv9YLgXlJ vuqZIuKGBxL+FmdlS4o86rleAhVAgd1S2IcoJO342XVFY0nDFEgsfmceQmhNUwwAjwzsasmWh8t+ kWaZuZTe5UPo3bxT3y+xeAxRzaJkM4ImL0H0l5sRsYbL6hGhgkqF9u3BACYqNgXjHVg/i7n83yiw dUBYh5V60oN+/LIZLzNUBgT/eLxAzznJMEA9YnSr6AVgfHJH3wvJFlXXasWcn1zvNiCqfRxyLtwt D6diBo9KknFOJ+TwlP8njHJ/i3HL3wNBbbEeOcuFqHG8xCeDSEJTdPUChez3nZPa7msOFM04yEyc b0peQNRioHBsgNWlxsozQoKWvZCFFTfMAAM5Uie1dBvHvgWzMCdYnWJY+fRxw98x9xSlCh+HYsli S1R1ljq/l+FKAIxZkhKTNJn4jRJDEwFkSsyf04s3ra5gJ3N0qTBudrCtkZsHvyBuGgUudT4qXmGe gIQIRiIN8WdPp8DuvFcEGqBiRR3hZfe48RPR1RgZa+HvRg8/LunVxfssm8n4trf7uvePx8NQ3Jvb kz8KC3pAvp/La6q/ydZhEnSx01alfDBWuZLL/WUaUQhQNBYoIILts97yOFSltcSutt/rtWcU4L9R tLUW7tw8BS7xgNCciyb8FKMWs6TBCQV6mGAYT42jln5aJ26m+DCIgdhbPfTOw2FywspFqWI/Dexp qbXE5LOn+vSJVucwL2ddRhM75vMQq0gZ/KOloxHWX2aHFS2tSXjXY9sxl6MM02WSgHtQeo8nQyhU eQNNUn877wO73LjUe2//QZs0iDopL2auposa15QhFqPg69Ipy5Q59oUN6oY0QvsxAYRBLaRHHgt9 LjhejcTDPORqq0q9eKLI3H1GEvMcQWtkOkkCG4DuwBy3V1HMxO1WgQzKbURVQ928z7XIaKP/80b4 k+zlSbDA+UtyXcSL599slrZRrqVv1E6WZWBeA2mwZP7l+k7NxvqPiG9wFaoqpEEoLr8uG/Y/4uoa 5zixxOemDRNaCFzaJvvjYN/xCUEJ1BClKUpSAvh+YEseCftXgIg9yhh5ANY+P+8AMUr5rIj4xPoy Geh88feHOjjRugXIJgyxvDDlzTn6SAgfero18KUBIug4g5qsN7VTjySe7P1qd97C6iCDBurdiA3B lXLjEeBizdy+UrPDt1jE/zfGWwjlJkf0NzSnzDXcrurr+LkyCNQII/tUSC6Xk+S5plk7D4Q/M/jy sVVHdwn3jkB6rfuJfE6zy34pqH0nizSLCD46VFUPBIWguUxTgEc1aWyvMkNIN2QKiSsZfOQ/msKV cN8YAtQW5AcvPS43bUOVlfTi0ouQHmfxGdJlqyQlPQn3pZT5uEhyi8noVxvLzsfTkZEqM7PD9/Xi fFWSPvyhq/A/j7nmFYBTHd1uMfQ/5ucw7zCk3k+lq+bmfxdxqocScqa7pPU913wGR3fdueToR2xp jPyoWin+aParUHXfsX076iyJXfsYzQeX1tuSeFryOTzs/rnPxnSAQ08aNqNkh+1BR1T83k4CYb1L YTF9IA4QanDXANVmxg2i48Y+HwIQQyGUIkJ3HrlQ+OKCJ0J8ZUwy7Tn+1G4rSFyTxjzULNR1iS57 UTGpLskRKQBso4aSFiLCfMIeq09V1tmsPPDnWz3guTfs/ujzXCGXet4hN/UCJjpfK69OoYpmP3Fb BY6nhnaH+3SvYnQbIWpwwVRBrOpheDivcoFlLNFbZGVjXpDNSDtF3eXlh/lVThJLuPBzUdTfUnZR usV/fN9w1PPVcy2QXb/jj3ig0f+/asfU+8qctg6OzIwcmpSLdxBvq2FjJXcCaw5kjt/hmwEuOP3I 8lliXHB2g7GsraJDrzvLyE4tTywm5YhYk6jjE88rYdjLxep/NoIUA2NQPJ441wYNZkoVTgge3DhF s74gQxH8Taq/u/ufps5mg2UpqoE9jFkAprgHvkKqu+W6vfe+hCFpSgVhI6EQ4nCaFmZKCDpOCWQi Jg/ooJ56/RGQUExy4DAXFgeKgmp+xL27HZbJVLrSJHe5rVjmKihZw2f4u3nzTABR8u6zL8s1d13B JQkCeKqldBwQca3QeQVDT2SuGnGPA5YOf/wt6hxWbluvdZcHUlbGQ8OoNk3FOaFa/HjS+zlWcvsN 3vNkfCgSY9LIt1a4EgrxGszWX6QdDFTcJp5oTHixElVAWDoO1mezCnfDsmqZV/23vQ3b+FcxuC4J CUs1qma8diIgE71HpSni1Whbj38RC6lomxDGzeVGb+e6B+AJDSN80CSPdJw+ssL8DZZ8wezcPOUV 3rtwFsmBkAWzuOZEW7w25OTi5+J45W4RHMrP+SvkB6tt6jvn9ye9HeuiaLtfNjg9fW62+tJhxTTg QRRp2MPnINJXtwuK0jvVUHyYvutoJ6NtmWjSBUT/36jTmSpIQSzfafcnIL0McvvJaKWXpqmnxvCa 1ONF7TtwZeQIuc0kOavk8nT9YmYARYBO4HVYihK16xDQtjnf6l3fkxOsuT1FBGAxEyjAPCc3H8Bd 4EvrKuyj46pXo0OfX4EEj124s+TkeaKR9jWplo0Tkuse+VDV3UKbKZm+7DIjuuiXqvH7g9nbjHr0 uddKSPUg1MF1wuAB5xFDtNvvvALYyG7hwLjVmn6DLYCb7LkG4Pu2i3Zn+93L/0Y4XHDzbTD7lYb1 kiB14N7Gx9TNbI1DaEitaG+CrMMaqxiv7lwuwWtNJQjwBhafXEHYUDLzZBuZPY9DVdlNRPh1EV+8 wPKvHjHrRyAJ4Yr3iSzNxp/o/Pc6NbWkTLpP1RnWstXwQiLvMAS3rLOTZJmVTFjtd6hY7QJWVAqw PL4K1UMiFBKupvwSZORbTdhqbAMUtlwS+5vy6SqGFdj0YPtX7uNL0VO9EaW8nf/YuaUWRlAoUUGL gyHvQ0BFjEDM9o2ynxli/4X9GL9PS/iVLlJ9AWeRLzcD8nqbv0X+tWdTk42CCM1FqogLDtAfbRB7 IeI2wY1smdWbo+Z6dGvAGt6qSdeDjEtUFl9Dk09z25rcUegSUeDSAOngdSdTquPe9Xm5eankSNCV 0MsWCZOCM1C7XT/GyAweMPTpY8E7H6VM+Cmlhc12+vD5xE2HW1wEGTNYBMR7wyXCgsTYA8OQ8gfc 7BsCvq0i9hdzbgQ679dXH1WJWgUnPjtCeI6/OXW8o81xLHDNb7sifbp0djpP0+0c5uLUDTxvovrf vVn5yiqh65Gega73FxDapklvbPrOGNLJ5JOUdCM8txb/xYYFlkx+Z47EolM4jprJ8q2yCv5i04EU HX0qN7xrv79kHt6AEQ6PdiLYlKeB6KdcOLmN6xqX0dFYVaJyguB1jHYrUHOLt/BQ2BOTInOACXtL GfgKM1rE7TzQ+Osf2l+Pu84krRjICA5ZMVYDCueCXfIwS0nNW2nIXBivmzyjxZxLCKtPh36yDnH3 /6bLa7lg/07wY5PpxRJ3HJAV7DBhcau4EivjSfDG9nLnKbSgnRkzJU//az5zszozPcDwRkrRWelz zWnkC9jUthpjGW0iOvoi9AmwlynFZeAuqhuInl75ymlnB0p18RZrMymxHt7IX4tCSucLt2pEIfvC KvCgMn3BRWLkobG9i+Gwrr/xAkD9rbAW378Uellrc3n9+V3+QdKYMzPy7QaBm8A52gWBZlFJUzNk w6JIG5EX83D2jk1dRNVyCuMwmg69fbNJJI3iGEWdBsaEaGUYqSZrvHc8rAI3HptkbEb1lXnvgLex b3dexpSFI2t+ZLBj104BL79GqtR6ZUk+ZLKqsxKkYMyfnzGvxEG+7wSzVAQmwrhE8qcwrCDuBYhd EZbmQbLHB2QoXcg92evEnPIE9sQvEQfeDBK8bGAs0wsoVgmmamYvDlb0v0ClKnOt5COpjj5rslMw XVcc7zKKujg97M6RactcUSMEm1w8BuuS+lHY62OzPRHxGVqXqnGtcXaXfXYwPgIv/eBiQM9/Qp95 dnHdCKXOestKuGDXUMWIJ/nPNILJbQTatlpY9pWiBZRCEaei1Otv62P2vZzawsHGM6kabw3OqdXz D6VDEpp4YABNjJHJqvD+XEdkcHCoC6M0AULTwaEI7WIqD4UyrmXvVJl7LIlIovd1DPy3zjA19z88 oroItH6y8c86NgMn+/qncSipbnTW0CXJimw4VXgUoMoKAn8Y2fwncvAWVSsMorOqE3PZKglkVpoQ HNxjj3Tgw8142R+9Ls07B9/nENlF4iYK5P5+gsHOGjj+uDRIqrm8UIS6RZMg6qoEl65FcCSuWoGs 4TH6c19I1Mk5fCQ/X8AnmMlcNrGrlOJ4hktT0mCdEWnScF5dysiie2YSvjpajG3runR/4qujqsC7 P8L60qWU5fHfE7jABOcFna9/SSfHMy2U44HJZcAAro/J4nh5s1osYbiq1wI7x7ja7mMHHHqHc95g bNOvR59f3gYCrZdQ8eJiHr9pgMDiDekzDDCw+BFYsf2F60n+v+v3Fwm4si48AWXtzCBNtT46XMcS 9Bxz26Sbm688bJ9IF0PsZHZSUD0EKIc7BsWE8hfoMNkX2DPlVpK8oREFpGRkPtjEEglrWRdbh0b3 8q1YKRpWKgYIX6ZxtSXSh9DRsBHNBnnAKUQBsCSibXKXh1MygimLKzcHjAcdgI35aQH/cQKcK1rU qwreTeKOyA3cQ9bPBHFF8716Kn8WZ94E4txB65pdLH0F7x2OmswG3nvEj5syF2Ewi8HumE8UIoTw EC5zZvAMl5FZkGcT5uFCeKwSc9L6iw2BUn6EBNtq3wymjqWiRhHSbHeZg3nqs7uZr1GuFjN6nGKU kWF1/njL1mvVuckx9fHgLsZjkw6XMjJnbxk7JoPZQ4xdH0946X2WaAESd4T5d1hif3aosSXHj/6h APwmNcgNmK32r3nNIaR27SzAY9HwVOlMDqrmA/jTuP0yMNDdwqpKUOSeKsBvrJzsPLjvI9kBgko1 Gnr5Fx/nRZs1q7XZBTYerougXf5N9KW5SSG6pEgY4/bVrX2qmixuT1khr8BDmyfptMuNQcoXtUgW ZVbyMVVILdG228Z+MRfGzC6qXXYfMZCqkr7nG3V/cOreviCO+deG3PWeLi23TZ1tF/89f4u8kYuM SplSxWhvcipaBrBBhKLS2FUJZCeRqeMMUkJeviofI/O4uIUlHecj2zyu9gZHjbboaR5sCFAE/IYK njZX4x6KO1FxSzoXm7Lik4gf/1oN/dbtwm5riiKXfZn3gLXvWvpFmkXfZD6N0wr4pZ1iBq33cwO6 kTTelBYSMPYfu8kVbuMCk2KPpxBCskgs26bin4iFHFtI7I3bkH211gZnXiMn3/m91e+m0scXawRw gOBQ4mCOhkAOAwkXJlobsOG2uV0eR8TcgFjSixhGsLTsrVzeUj5eYC5CSQ1hfpL1Pg1PgFoV7jaA kMEVSNvjLld/C4vca8AUKxNQrpEa4b/uhTkm9uqqx37toolf9qGtQpMIys9mNBDPGudoHZ0Q0IIc rWO6V/Yz/pCfnNOxz/EJIMtPLqSVXI3fQEb3255tqouDaeLfhmka0Hz+hUXh1s/0MjWCoBdmk0pp DVxcJcJ3ZzFXAw3xC2YTys4xj0jAkhB6JIYdTwhLgHAltofGNSExCnMGPOM46T91Ub+fpKNkmcHe cat2T+tt9cv19lelOehRpC96dNm5Q8Wy32X0cW+XiEj4pnctv2EvWSW2faKpwawYYLAvjI1h85EP beCfkLA8LdO8snckJBqbz/WoKSaUZrkgQu5Kg1epp38nmkNX1KTEbcjG7QDlgKTlsr7htsQ8LEHM 8wYF3YT+ux2KUCe4OVLvAjCQwOhXgfEbJtFHcTBcIBb4b6y2t8ToiINvkxLqQKGbXYoVT79oF7sa vgCYZASAPfXbhLCdDnX7vUWKldofPA/A2WE3y9ucqAUkgw/mDg5hIF161hmGP1RgmuVJo4TI2Sgu HWAR1G+BjgsWfTWgKmKkxuiL9XX7MzHMaIDhjfQ2chgKxQaxXuH9vF7+SQYsCcIHVq4zygiK7ThH IW2ZnG/EgcnpY9bct5Z8nJ4BxgR7/NmRKdZmy3GhFjKdE19GRnQ9aTIc2LPsdOMF+JIpZ0HJNO5f BImRdIMDjXI+HDnYSpGf/6hU6uZX3/A79rH24qYAXl1kQDyzSYEFzEkBb2yh/pnoteKmBSucqY+y 31Jl6O367+VLHIcUYTBtqfsgjEE9RLf9es7BUPLPcUN9+Fyb+sVLHg1xCEORZzVkKN2mAcD9X/RO oaKGSDjecOsHylxrvoUID1AyvyPc0u+fNawRmUQG++B1QaJkyMbfgw2jNq59NH1iO4Wv0wpIH+ss 48NXjQa5Ulh1TVGdvDxZw6JcTyjqMZ2iOZD5nLhxeWJ/1fB1vh/Zbz7CirhrHQAk+X0xs5MrRiVH CEE96J7tzKWLjljV2r8fxqpUHMC1kYNLbuHScKugM+rKih+mle34B2hij3pj20dJ6V2EZQwUIkl+ WBY/AyD4bdFdswINjdlWiwMnPmxv8F6Hzs9V2F/Suf+d7SZLifXXehcIJUxWdMnTyrvKDqMH14bX d7cXIlvAb+UNDJ7BHfhmWNig/qIneUMW+YJgTEgNZK8cm0Ls+6/5j0DU5ofQJbHsEDA8aYVJ5BhF UnfRTSkfxUwwxWovN3h078TxCaz96185PnGBqC+RzhCEUlzGQrG7aqe+SsLqdTVdlnW6Q7lQpd0n 6lyllEyg9GBaGUXwRJxZCVaLSe6nUxUaoX3v24Duj1Jx5fxRn4IMZTt4bH919ytf4/ZWEWy2FFLt 8HZE12zC4vo2gbxLPF+/YKL2ZGskXuBM3XiUaF3M9z8M6ETT3A3RnUNhztIa9bYlr62bpNiJsDDT jhu+8yAvL8hoNviCYlxtynZnqV9GUK2J+nDqKucH3Rte2RyXL/zdIR9iaUkqDgKrY5/Av+hEs50S 0RgWZiEQcTVeD07YMeu5H99yt5GNoga9spZsaWczq/b7cY15DuC9DdwoBixmDooIcRxnMll44qkc e8onNyk4fycE2xlxGbKAlWK8QIhxMKF++CVXP95X+uo0vRSCJle5/G4GeyfYHiRSD670+iUUuxtd LM+MPbYZz3UMtSJFocAPsjYDyWEvlQ5A66m12gtC6ZGSQi1j85VeYXSt1Cspx6PP0sYzStaRyVZ2 eWj4okbvAM9nyg9x4p8gBqdkdiqX8Fy2j4C6nlpV+lbr4ehrRocwvElmynm1Ln0G4hixCwMsSotA +9rBohCB/edpEw2pR/ZJf9gXRDjvnQRNwuLeZGtjVkbV2t+bGge7pZQOuLN5+6w7jLbOZkzKKPaY tinzbs9dmstgn2Pt5iEesue7DwIoUQip41Jc7JuMa7vRRpIV71s/wMZbGVNOWBL4JSZlWnDupRd3 7Lw94YKR7j/uEbdrTawbY2BZ8lI0HV9JvNzkRRFSzoj4wwaRbkpT22lYXg1OCnwcVxZbZACATZEU nkROtWnyJ7beGAOCKI+pnW1avlBubtXR2guXN1DyFZ78OGY3S45GsZYCjSpXHNFTjMeLXtNw/vC+ TUC+q1zX8yfzWPfWxTRAaO3rmZr3nDrQv1eFMKSZ6FGJUY0geADRtQecuwyCZqMEkcU0yZ/Eb3Eu RdUPfhUl63hrCSy+6A2NDTN6JAJEVV+ifDlApz+Fji3vMPze+Yq+XSwNb5ZNtnf7g1u4dMg7Gev/ tsKhAYktTF5IKOt9eG3qdxYqxP5YYHKtm3ffoC79sXtoyVpYaAiifYdVz/uQUQpDtD1cItdC8eOz +BaVyKm22o9TX3C4YMvOV4cIeHhpovg/AfAfg+mOP/kxpRMw1Qo4mkJ7Qy2WZCOZVCWrdI9IIjtG AOOz28G599KHq7I9AZFjrz28r93CKNaZqP0buZ9PtGsHHT1WdLQvsJ6w99Xo7R3nTDO77YJt7Y0Z C1M3z6RIjB14AqbohgCJnxjJUvwFoGAk4+UKMQmTDE5UgMRln3uzjrsy4SwSAc5xeo2HztFJK1yV 7G8Lr4V2YM+oSpefDASLtI98uR9of/EUGtl8dHdLSUAHLfHZzu+fbyN0wX9FCZNkYi9hZm0E0Gtj ZG85MQWw7gxy+lkjdGj3EbJMRZ51kdisKEs+SOgw5o+40EWtgT10rsieqs9Va/VZEBZXkEWyvX4H 7qniwT+YffRVRWYtPLw8Gw4aicKdIGH7uLPhAVEBdYWP0eGDlYTU0dtaL9xHnrKfxE45XKOWCMuO ffVkAGqJVgCGjLg9hPJQClRdoaAWYOFg5CcuutAwyW7PqxImKbbjVhoPzcGha7dGNGh94dUvL9n5 0mawt1iUps+CWUmxTREg8yOw5tfXMYgbaKTtT8w3y7A5iV3CGuy071lBsgPzeO1Wjhw2YoteF7E+ Amp2HLfIomBErrz6LQsQbkIvZtcm0wnPjDOPxGpZiqf295ku1XJLkzQymVR8FcuBzF2IeOA2Mk4t DFqVmC45ZkEou6C9IA1bOSBTa7y802HeKgiWP9UPb/RSqaVjJuMVRbuTDc/9ldiVqSACYah1E78B YbGuAa6hJqqih4V8PCmSql9LMHuMeBfIoYJSHi7IfoPcZ2IUE+C5qFWJ/UnbP21Fo7Mvt6X9bbHf tJlKMpef+8sRkPkkeUtoGGTIbvB94mAdlbztvbIzR+CLHve+8lab+K2KQdjZiICp5cbQ1p6r/VKv 6Vf1qe1/VVWqqPhIXOG+mNfQddZG9GZQ4IAAD5mskCVYEvjHBUxM/Dh3YOlt0MbWQD0oRq+d6FRm VKTzWpoyH6RMfwl7l+tB8MSCIfVkruEmgEfHxvX43b9vh5tMmR6GBwD8PqN6oHkKzS6m9513omm9 HVSQOTcX+K8H/hlPibYKdkKI1rKlNOHawQRZGkI+tHKjM8jnAyp/AmB7Ji9gj0HeaKuN6cVZFuzY xZ3lQRBA2kZa3u2cipthWy37GiKtmdyme7U3I4R6sERMOryHzuFcLS62rnOuoCfDzelqD8KPj20Q FyFlwcoE7r5Ch6ohKOY8fGbEpSh3gDJl+ar0R+fps/XYSddUX3JcOySJl3yAMa6oor5H8gagsJCw PyKSRreqUn2hkvB4Wl94OYIDdFOlr6MQUFf5rhyMFPkjo+HDI7205JcmJ7yXIcPnR06sj0yz7R2o fjzMTGoHazsmuu3Cgj0sjsbZeawrQrM2J5hIrXJS1Wk91DP15Id/9Dsc26eSHk/r+TDHfr9Gmb3d A0FkwhM01RT+Dh2HXaEXC0HmCNhoL8UsOamG/U2q8OSHAj0MJlfLHwawI9uhbsSWY/dVVq6ydd7W hRwGPXPkkgU9Rjt25NJtCGajFsmusYxQReuX3NhmLG3tH6gOmBgGMxc2gS4jx/jcI3WaL9UbBUCq AklzAJYyTbzEFMPilNoQGR86Wo8iSB9MRyFHy+kiuGg4nU9+w8gQwZPPLccac4wDtXdDyCwAwVF4 WmB5VE31ZnupJT5GsirO0neyuyfUlPhCUpU+rptLKyh740fGdnhQFKKQyJQnGmagriGCijZcGHMT kxsee/ZDxFMo1Egc/rSsT1AespKmYI7TkrutJlyk171wOipha842cizcMirFQU28G30nwVsABgeU 2qs9IcyAT07DHdghczYKDM84bsjGnCpxVCK+G0GB3Ay0gaBhCNnDlV1nfRDJtSJBrvJyXGqmKLCD uapkTFBwTRlC8H6uRkCabwm+NsoxhvyE6J6Qemen+l/CITEprLAARFbbNiNOuYP3VKzY0eSgkUed WpD/VyE79uCthX59Z50fPVSGabD2H8MQgS4N5zBJEdjzYs/rOqOWZPP/R4ntNCUF7weXmuuH1o06 7LQSQRB2pI2hNqQMFcoPJGEXoF6rRQlT3FN91Oy6UwMApBR+NWmm2khvaMmaMPUDu+8EE9mJVs2X 54YQ/CqbAUN94ZsjWinTVpwhJ3VFR+qS+mVjPj0LcYMmdGB8h6wFY90E5yEDBuO4GBH6lIK6W265 2U20hqvz5E9gUqUzq/eOdWzKqH5l+NCj4NEYq6rk/KPg7eV4fFxyyaOvst73Eatsucm6c4qJB1tR rzIErT1mG6G8PZ+BIqUK0J9Nmt2j3a5fUnqeW/1z5kWufIyRdHHcut7h8RWKm9L7UOmb+GnUC7jQ B3Z2ihmQ+E5RtD1ydMOQDUX7pGrHUePD/nvkxiag40JtysbAelPNj0OMF5qTa3pj3+ob2vL/6Ckt +Rr4YP9+CjNGaHF8yAcJoXgkMKKggf3lAq7EErOf3SiwYBraytR5m0iNil6b2O5QhfKDl3Ybd0Vw BrCrWJ1Xtb8xjF5MYe29vAI/u2PI9au9FFAkbnhTo4JDrkhc3XPV1KhTbgM+YMUdRWhyPZtCfXMA pj0R21oYkwKlxRlYa6GP6VlRDW8ZW/dOOn+3JTpslmLsWCzslZpc0b0eRFBt2m73E6IVtIkKw3q0 +m7Akq+2hcPSQNYsYEKt3uTZiACbOR2+YHtlG2JsnVMJq8hr+sKq4qEbo2AZvLnW/jhyZrR1m97R Jt5SQco3P/b2u3nfMdWF8xkGk8SUoVSBmUYifX1dJ2v4PhX9Hi8EZXMrFlguhtd1Jmf9tTp3UhjL 7wX9zNZVKyh7d/DGmdzuluwWhI2ykaf3tMzoY6+Tw0QGnMyjTki6VEvlWvjH5cpOBAXK413JAPYT A2gkBiYLvAJqDLku2pLdP9PvuRFFtPt3yNSNh5oE0sLbcgZ1lrpw6dFy2yungPPW8CvTcoqDEyLG T+WVkQOtBM4cFKri4v4dxkyjlaQgO2ZRpJ1EUQRAjbvmKL74yDNpIDAH+IjRWrWuqJDFAiINRwyx /VIwDYN86vz6+wi6mg1QxZuJDtNyfgBmuK34eBb6JXnJtxPLBIZDNqMuuGwHjNxTmxyHP0n01Um5 JmqL32VwKWH6DCVTj8FpsnkaSSN1T2MV7ExJSOKU9JQbcZHgoWS9lstQHw2xdV/xCFConc370J06 V1WLV+jmETRYb6tJAW5KJGXFCAsDKLhA/OMqoHPQhcKWkxLsCOhAfMvxUqXd2NZzwr9JY7OZMCHq /EcBiXk2vrVP6dxu+njzSm5XDcNUZZxLD6C4b2RJxvz3hcWIb176DBIrHHBMjaH+PkW7F8hmE0Fi r/8f/xkC8VwUYapd3IQuhjvCOktHU7kIsW/+MHrMXJaBRH0AP9A3VT9YJw/7kDrhoRafVwm0QXFE BTxTwrvygAAAABQQxI05zxKDsTM31oAMRIah3vm4FvJHT/BnZoSyN4wAH4u5vHGqAmvQR3cwMAhb iZzThIeTKe/dXsM6IuVNZNcnbb5cErGEoRUO6g2CpCANcDjdlHtaeSjL2RWFNVGTIKsgL7mqiDhN nqrXzZKLDuM3mTq2O+ezKTGXHzuehkTr3d8/d5d6bzAL6DBxYnxJ3bVn5dr+c7ZmAqsZVnlrvesF x7QRvrhmllih+IA42j4UmJ0Wor+mlstRHVe+oAFnk9o0UDyR28xnB+Ck5mt3uWP9Krh9iSoO4SZG YXsOCRMIR3W7QkaCpBB9Ba/T/ACc7ZtTzCSiWaUv1mDgnGRKnAPXmveh3VWmMBYswu947rEoyK6l 59wqL2oi5n6dYVRn/qDAld0jWOOW4c5BTzux/zPqwm350e6WVyNAFfTERgBfqSrygsTBFt96/oDz bu5pEndr/eU0XkuA8J2UwPnkGSaaedXjD3vFNlxZj2ZXSqK/6u+0/5azeTW2Msg1/4uiOWYfGJpJ ClNWyFmNONaR7uzz2/vd8TfwjBmOuzYLOg3XihnQzSPGIZKG1/XfYRMy6GSAxuLDeSBcwmeJLRQI afZtuCTG8qycC2n3KU3R+ajSxHhZlFg08d2m6e0t8OmAo62jWy0P5M/brHE6leBOhk7vr9qti97g up5e4Uod31NJJvBsEwlwiqZPeTbXiUjVAjeMchq3yxQJ4W5CxuV54Ud2cjpOUw0/i7X5x8+SrFsI o7vKPfj8dsM8q6ZFm2DjvR4ZZ4KUw8GrKu0xzVdVfuHmzdfxpdLon3TNGleRuBHY5wbOB4YFCeVJ 6XYsEbqlTi0oVIYfETrqXw9Dsu8pcvoYl3gTlzaXyakWIp1pAVh5ZxeQn981JMLkxZr3CZHeBHGM emeyn2hP0GpUB7ZHFoMqgFUtBAR78PZ/yQyBhl/yhvCUqz3mRTnMq5/uZSeh4wyu7yCi3mrS8eZH mCKjJfeiLtNWYCmLR0UHzPcUbp3PQWZOzbuSVzl3wET070c7dsw1VUdnMF9TjWw311T9uxLvgmiB VIM6cai3ndfak3TCIohdt4G6bLwRiKR7DJilYEtYHMkq2ggAgsTfm0g2PnjGIB++9s5cIugX8Hbp Ugg7ioXBv1NHSacacVDcFgiEbMoi7JQ9ZYw/vZsix71kIFUh+0JjpKKTw2R66AGJbfCEUCA8d+Za iMw2K5YYxb0sbWxrT4ON5o8FPQNYu8VUF80Jv8Vrfx6K1+mNm/e2JesU8ws2d3d25+1fgNnF9Nnu X30oMFplYUA/ZuEmmW3OMIB2tTf0ylThgcFtukLxbV+DyYTvs42CWQU9q3N+BcanZzdHKudI6a9H 7tN1m0LgAnDyaTEUMz8TR7M0dJYfMDESLu3AFCMBTPwIFSyqv3TBAe1vHThzKnud48+bjoNEv2w9 tk1kJwtOy6TTSwa/wcTep/1vt73X0brLydpbDayF7qjQZzciUnr1pmoyCjkRNgkcM2LFpqLvVxpH maG9i1FZvg+aY+E3+PLmFt+RwGL6+N6Qo4En+aXniO2xsN0sNAJ6QjXlM07j4hLOpaVvEoU8t7+K ZSYRi7oGv6H1X5jPJgTlVmtmpCtMAN2GJXb9p1B/NRT5r6c3Sy6G9IO/QskEemnQwcTRKP+Rrt3l olKKwI1gKW8GF4IfwHtKorQTdIlaTeTRw+WcCsip5J+Z1c54QOiQWo1vtD74u29bSS8uQJ7eHxfN ZtZ0v25FQtOGuq2z/K5uMGs1mQE3BA3Qa4Pz6ejZdfwcWBzDaQYGkZ62DAyvbJCE/lhC4Eep5S8S 7IB8LaCLqu/JjqCJS1t6huew/MW+rCyO7igyn+IosdA4lrbfTga4KYOfdc4nEV3nPVl13LcRdGi5 4relW7id+fQ4C56i0BHu38UJYqKkxdTa6u//4Sh23TxdbDAH3QQcPdOuXI4yrHJYJohsyL6MtC3i fLbQEF7w5YbUErJ4pc2Llzeq+oZNatLrk5LGczZPUibs8Hh+7svelsBHnSWAZPNBXZ06SDApReI1 R8hglpRQqj0vTDnbFUPadZWfRfowhewdGMG6qj0pNvEMjy1Yesp605+HwYE1TJHkYdHR0EZAfL4d 3449+or+iPKmQwJnfxIvsE9SILoM8wNsK5lfw+XcK5tDGB03S/PGurUQcleo4YDo2oex7VeLiKyl r6FUFw2CDf13fNjMYCjJtZmrDir7jq4EN65zaslauGobGxlfVKtX5IqMWPY0K5hClDjH+Sjlr5fc zL7fNfr1jow7xx5H0g6N4Jwxtk1cxqJHAe2JxMfsyhof4tErys5HSFV0y4vav5GqAKtHwMT+OCl6 ubmY4mEOfynLXDECUdIY2yPiCTnWvBjMwRZ92yDJLUCeROy9gcMKMVnyIkXeTcxLABMLINOVxROi K5YF7XgJP7HK+y2Fl1lX8cx4dfFqPtSYqjCrShp6j1R2keiXRBoM57nm6jvV4fUw8bsu0hRPm8rO qAiYHzk0Piy6dOyfIm+H99pWUZsLOu3STUmFHTZTDIwnvktecNjcrTt3ZiH0xiA/rX8Y5BKrWX4w GGAf+Ne9ski395ueWI+zttmShtqgmraVXEEPzqJG4it5ufryXGSTnjLY2P4XWkJAps6M2zXQoZCh RbSxC13jlD8+EspfW7e5W17uehWnlt9+tjSu8GWBsHLh99SMzDNa3fZeK//ZYpvYrjy/Mya4qhce t4mQZR8Ee2OoSZqUmFMKmgZqfkPtMnq/Aq19yu7tt3sIqvwoeu/0PEOUggDcFAbjkMNxn+COB7b2 8jY+Q90zVicRb0nof/wZzrE3bZfymhmrGfYvnoNwHBDXAttUY5jyTJb8yU6+hN5QCHD/wMmJWz7U +huPA0elXNEG8/tkeMP9Wc5xGzCQBSpYQOOtE14Kpb+qdzE5gOI653GvnpeMNwr1/PUyjSshZEO0 HVg73LD9yRVqzU+jY1zf8/ZDvlcN09Z8wp03NK2gZjqxGEUG2OqkjAqxexZdUFwXMr7fugZGelqX Yjd2swASTeNrrRMpWgSMo1sxHeT2CEITboGO4mKYdu3mezgSIiZRm9eseKFCHix3Q4+o9xbEgIpZ dW/PriXqYd+ptLqsR7pExCqwohr0EWG/t5qba6KRuFOmvKNkhajrem9eQJRoJZ5eRO3LS1iSBbNF B6C9fH7Q+jplnjphGXayqmGet42rKMg60kwGQoF2MZX1Ev8wGPkxug0/sqHiE3s4Q2LmA0CMZaeV YtA9N6hPM7j71/dpIQSkELwQboGmdBgqOJ6w6IEp0j0Nkit61lsVWJU8cJ8gbOYbvazWC3QNPlhr 7RrpxEl1dg1DAA7wwF7qrWyW7IDnjF/7MwzrQXZVRlS2OEbLZTHh4n8DvG2Dy/0A8uA0lI7ay8rK W2+TOk5cZySyb65a1KdoQDVkXID8A3hwfyLvIam1B/6IuDMJSyVZrCBwVixVMx4ATDLtrfrza/f5 NxYjaydVVttvxI4lhxLfLwogl58E8wrAXpYi8f64Qmcp8+kxpcbJ0fIxNv8qGg1Oi56Rf+WnPzH4 2hl5deZqr9BUT61zslVqt7gE6lBaXBGPgI/bnWO1uMTysbUiVop48QoQFwNJZVLmtjU8AnbU8DmB PVyH3YJ1rGTUDw6PuHO/4yKUrxvnaCBszIo8QzNEmhU6P+6Tx0oeWBsvaCF/k3x0LIx0JDV6WZ42 cIXBtFQJEg4lG5GrIa4N9xpaTG6D47EnUDe1NK/fyxWJB9kOKNIryZtabAoLu8iXDYPT+d7PIoVv s/6TryvrpbLrP6iU9nvJuolyCnqHGgy5Zz0/RzD7RKznlm47j7FIjm+hb+clvlhK2fZk4DHxCw8b 6HM44OvCDwNVkzg4LjdcidmuoskLcx53lNj8gJXMTRpfU7PUiZE2F3dwtpcQME05gIw3hY41nw6i BJpKJW4fTWTKvDG4fbSu7MiyU9/QCjYpKTRJt/fqp9o+twHbtm84XuZehZy1xPqjgQNCwmJscaps /NUnpb7yPLKpC6NWj4NhE7GuUI27PXrD3qVRAP/6pEmJ8Kzu9vac7pJIGVo1+5kvrhM//LDH/JRV FBRlsLCVD1EkQnd85gSd758wZp9pVt+JiulbpFwFLDV7ANwZWxntmE3ilvW4emRHW6znki8/Hj28 jlvk5ewTVgYd+ygmiRMSloW3t7lajbVfPJJ4w2r0apGVjfcVchIK/0IAqwSMIGiUQEkELyG0nmwA E4ZsF6MKJb8uKFNkLgqy4cOPm0vrXdVDvRW08p16VyoWSTcxcVXWtdfdelMOcyI0pX5ZLEUsswqv nZ5s0e4t1Oo6kfMAlrMrmTRrc9iBIgO2tdfWk+BhWv6MCSwZvp9advDpd2dptIZZcUNJe4vgO6It Lgcf94MBDxyeLbUPVM/O0/03npFueiimhXV7AoWBm4rteq03/oR1F2RTA5/7xTrtxhDwbbRbDjo+ 9n6OoF1m/V27OPDmNYLEp+5PSeV+NnPQnMA6fFiszmJZS6e+K3SP9D6MUSUq5njTXcIyvJijiZpz HVwUkOOEMG6qGOP+uPWvvRL19TANHuXF5I78G4ey1Uqo4wl8oN2FIniU/ErXOhhYO+LT4htjoY8c 4jJmGrNBnXzYB9k3t6nreSlh0hv2IjyFwbEFXF7ypkTOr3TE2tMh9tZoGYyht6ota28UDwe8oKBk Di8ZDPAIN3R/37lOFOGjyx3fCRfkPSs3+dS3HyJ+pq2xNXD5zeJCdLJIp92KaIpisQ+QibxbZqs+ 6R0vl5QVS1qpEHFIfE2rF8uBRECFLiDb2Bh9rzm0P46x4kX2390gJj0cdvHIGP0S6HzUGsL+Ri7P 3drgl9+cxXrvInj13VOTzhOSmfLOqsCdNTBNvXKl/suK+WJcE4rFbMgpQvsANaVkiR1wQHNLwys1 R/3J8JMpl7R0Bk+cqOCeP1srEP+NXT6o8FnH82cp5vH3n3xMZpGs8pSGAvmTrHyyoGnsgAo6w9wM 8SzEsKcJD4PrfgZDeBeO9KwFUGyJSRRnh30+GIF/+47tbNfkmfOYONCEZUzaYaMJQlf8rX6wHUc1 Zp6d+IqAgk7RNcGajIPXfSTNVUHUnNqy1U9qvtaMhJTc/7WJge7+aWi/nhLQXAEReT/T9aMVssZW axJE8dsc/liY01ZN5PsB5x8MdmnUZ+qke4tZunYzOrFJrA2QA6gxCd0FHArOe9HvSWW5zVnHqnjF iShJBccn7cV6bSUZKHOpTD9wmM1cKjDRcvRmPK87TIn3Nvi7lKEML84oWewVGXQV/TIfTzxFC46L SxSBdlcpqOPr5mUztY/br/x7mhjJFaRLrBCai9l8wJXJdmk1b43Dezxw4gF82ul3HYb9n7fSDBlX OybAAPuZjVk/qGuo9yO4fSqbPhonuBi5rl45DTwE8YlEmvQ7rddPH1ANsXqkT9cBS7ag4y009v3x 92x3aOOw6lMVbIRbP/dcnyAcWnL/wKtzIuMv/NqThUzIyGBRTZv6b6v1Q7IbORZvmPNoRebh0gyY AcqN5xfNYko1FVgy2k2aDQdqG6vCYnWrvYVwlfWYLJ1mm/FMiTr0wm3rTpZe4ZaqmiT7+hcvw7zj 74VVvBAn+mSxdiJLTDilrTXvJpPDn0geUSX/tNmNfqEvel3Ki+72DGI+xlY3zJaLxJp7OQfVj9+7 weANSeIlDrzSzfZD0okXE1293HKx2klyL39uxb0LxHEqyCEYgOD6H7VhDe+igpZGp4gYvPlAS25H 2WqTWpNMmeQgOxOo+FiO9zMiyjMSu6Cebf01ng7hYyBLaa2Gpw2nPyH2JssJKWsS1Bzat5sCO/XH f51WwXIUcLvJfya7FAb1aIHpnCxPBfQpkHdNGdI+EWK7lal5doj04ufOef1Cu7ctZW33lsQkUIYL Ts0/jlqwJf6QcU2edsL7T1BCXQe3MEbWaHSEzp/hEnUGL8h1WvMy8BueokNit46tgrDFoUgC9ybH ABDIGb6PjBJL54QkBrqUOF8SMsKvnu3W7+OaZJkxb7dniygiQvkKjhWrB58nOdKnCPfBPyBgyhxM MxMyBz5NTZSRWlbvqfMsbGBiCNbDp5eWi5LCvcLvaK7QhMAseTNWhlPBbVMdDW58F04fPldRz5w2 4butieT3haTFSHMM9ZX7/KIMhmDaUdZCqr56gjwu8MQUGvqwEYRUYr8Y9YR39cYoJmSLZHL+W813 yZoedvIuq2ovvZuCRrE6Hkfr6bjIoTuwT40wHbpPFbpxWxhGfGd3nWu5qXAi2+lefOmIjB9368df ADH3bYadstg1/S20ZPjkoaIucdlJrlL4WIRmVsfr7HNkMEuu5HDcU4d+F63jbGy5o7LHVDr2+1ZB 2Ff0mh+/hHav6cREe9/FzVLc8ZXpfzagEjQw6DTHCiVi/xhY2l4SvVnNvKhPuAChLTma0g7EA9Ih XD0NozbDehKrGF4NqFFTWzFSmaIB+fBe3hBCHBr6YGUWlmgxICT/rCBljonwa5Jj1FzpJ5dT5uOE P6ce8cbTSFR8yMlgKKBdU2GdXupEHR8yMh7C0VT6Cavo6/+ZJ4JSd0vQYMSx2jcMkYvjFigL/XBm rMvBSk4K+GY5k6gTT7+vy0p9sVZnKEFweS2tZDFrlIys/znCrvuee/3bEfprmN2aBYGPyfdu6G9j SAmBYsMxFqOE3ghbDOEb1mJ6u4kXhr/NBDJhWwdP5Mz2RIkJaYeU9UL22Mvp3dXI8vgT/qv7hY0x Q46owB5S8OtyctyF4Rs0IhotqmAoqRWlUIj2HF2C1fystnyGtcbGsue9OcZ4BeH4YxByiGut411K MmK/+YW9alR93L1g3QCu5K9EXc06gy1N6GnQU7wu+ppjzDAqG6CLgKhQeNSXtrLE0vR8a1aeK/1K DkoSInvXKqTmOcPNWkB8oeOKOc96pGfow5ZtW3hrDTotKCA0+GhcPmjayajLAqSQVmE91QxBigrb Ru889z2UD2oj5cPvTLRfUMH5rGhBLiDDww7f0ookKNakC/eJ5dethGtUIJbE10sfbv1q4cjGrjaM uGhMuZDnVYKYlXCGY+6Uqle0+OCjHwUGNn+iGu2wSMWVXhYGVChmR3ipjzO4QlQ/8Q625/wE0CQ5 fSYh0LrMNo8jOQ8P72PjojJbiE+MtB90gE3ftj03v2rx/q3z2hAriNNJpZz8iAnDu+y7nY/lx4Kv EvkwIzpNbNHbhWzxTvbfzMl9hEY+w/LIDxQnbDYsL6zHsmyQWS+yldYMlmSuFRnjj+cN8uPmqb9+ zLODawYZqptAzwucVcLxM2W2bn8+Wzp+12RIkNZHfSbKm9hZhSlSjb7+HRalW7qDn6bpQAMUkypL c0/MwygLNuTba0/zs8lFcQmUEfHlDNvWo+TUZE6LQWJjJqaGajs3HTUbTK4HnjnzaCcREhwBr7u7 zfkA//MMsKDpdl7Ub4G1gaR0oD8jX47kcQez1d7O7K+Vvb+BM3QYnOW6ahjVwjjRFmacL6AulYDL AK3L1r7RECfdRvlAwpxg83ZPfsMQD0L+7Fs+78N1LrPHhBXa9BRK0+xL0MjgeIYSD9KEVp9+yLvq 41GxqrDObMHG/G8zRK4BIuKDdAD3ni7s2D5QuikV7SUWzkKot26zrY4Cy+6/xjrUoL6r+2kzLdxh rFcTtp5x3CeM5sZHM1NKUiRX+YUC/zTMV+Ormy+m6Hyp4Bhm33vKdFeRKKBHLd/SfF+kilr0uGhW ZJUsDu+NpxRK/zzyPKO/08JuBK9S3zfOjytYOaxalsQnbETvf2jOjGTBmJdcMjuxjItOPGCWqCx/ LmEzPFGH25ORqsFg9sQW2fol7Bmlx0LQJpCeXOkEgHOKkDmt4+ZZsGJLmLk1dKwIvHKOcJwrXU2T hdgs4UTI69yhWj4MH6FbfmL8uEF+3Yic/UYiOehcseF9yQudZmmMYsRnca0YpW6cv0XTCCyRrZvX uEd1Ptxkam5qfGdf0/ftTZdhOGqKnMFV3igdZotP74Dbmj+Ba/U/H+8W2VLmBZ0RlNcHWve/RZ32 ACoTzytBXAi5wJSxngCXZ142LGlBs/76V49TKhk8AHpAbApRJzmIZ+bZDw3MugjMXFW3gIZwB5be PLNoIPVX4T8EBXABHEZkJTyHaUpKbqV0FPDRBgY4J7I3mD0+qo7uw5xPxpWuQfxivDwqsi7F4nvQ 0pxeC67vJHG6nCNhl+81zlNztjVoVCuvTtyT3UgABXeTf/gFsdkrGHfD+FoXyizPFPT3pF5EKo0Z /NtChrshc3rGBJskHgvfGS5U2nxI7+iblQcZGipGbyAMutt0q7kk43f756E0uFGU5EcSgny1cI5G LC4pjEKlembeGtXl1rbfsmdzb5eO87l7khoYw9/jIiMOqaFoNszURW+7VAsLEkZoyMdLhlUuERIc GmTZ3N9s6rtGK5vkBXzNFP6aCwpJmf5DRKNr2X+SVPzgeUVQU2CRUTOxDJ5meBSVk1pCJvaGXccZ lLUSHe8nnOOg3jkIQCDpDs8QPL68Dgri/hWzIrMVuozYrjcvx520y2JQofJkDx01ggf3wMUtWBFf hXoe9emw29l3TbngvLZ1wZl9NWcVYyW/qgLA9sgk/gvDi5idm5X8L5h0S8BpzjBHU3j8xQAUj1N5 d5CUcu+FPsvE80nK2mGGEfKEEzzkKGK16b9225YaDv7n+8vuuKQH/on2dGZT9ZOR0ME/prHuG8EA SGE206feaiiaqeMvMleBhL+C9URyaflZVQE2bfab107Q+9gb9DQJ24s3PI8Fsie6jC6c4C2tvqwI mBJ5ZGwWSPXKUIiUYNU1OlxWPc7CiU/RF6VQonXt4DLGImQBcf3bx/zugs+M6xESoJnUv46LBCvp MNExDNT856lpF2++hWtTr+wsq0B0Y/1VCJqvM9mPbiWh5rJQR9EAgZ7LudfaIXgEoSZ+TY5mdsb0 Ds/TONB4Q1PdFJSnidBrSeMQxKM/gu8zoQXlFNLX4km7anBW4Sr/6Mfkf4RUpNLZAUeGX93y35Lz ZVFA0IAfrpcXsyL9FeQ+DqpQXO1egjsBaRODgN1fgRWLbtbo6/woOSc6+3GIeU64mejtjt4ETNjs aL4SJLaQxx+HSlhqez08FKVV/EpAZFIcEPcprYzH9/9m/Xu/q05XSpUnkOcj6lcRhFiD6eMbEmgr rxQK3TMXqQ+gSBM+8I4c7R67I95wmrlaQ/nLWXOeLLyUBUrXyz+9meSwjbazo7b2su5Vx/yW+yjt 7qeFLetSjaaT6h4dncvcPUrr0a55JZZownJ9eFcqrpfF6WDZBuvhvxNnsnxXb9uK1bqbs2HKHlx0 /hPZjuKIqyGo8rtNaOlEyL8fMrjEyBMKCvnVsVlSWE8sWOoKqzvj6ckE3iXwyQMl+AdpCF5+xFL3 kzP8GQShixL+PAi2ObX0lGdTJ56VnrtbBZDkO6JC8llwcgJ3YcDE0nSNp4lp0rKF6dekE5jBHDgo 0r0cjzBBQvxD116erpRlgZvInn2phuWXUQ6ago7QwpxCfRtMHVZtb/+uCkiIu1WqJ7tpbtvsit5U C+xHvS902Vw0/0O31bd5MeFqHZd/xoUvLlRS9rM+a2k11U0DziSUeOXNPwqpqclFoLl0LbmDu2jg j0c0FwBXzY2REDtn18gnbNdIRoDA6ehUgMUuhvh5IxMk9imTBGdBIUHIpPvRFZYbGYnRqaLfxSXe pg4mOho0m7RnjWi+rzdXoppjNqYjpOGpTuM+6vrXdLYTY1vEK6BBJtx9UVrYRl7inJoiYGJKw3Qm JjX/UErarcZTStay18TUA7DlFcYNkP2r7mmRYYCQyCEF9PfL1Sn53IKGZEJYhNHz3FTndkaOQtQq bV+Ke61HHJkdC1Zxvvil7BVxWtFYLRMOpeslwyBGzS4V1g9b/UXFOr5kQhOLiKNPP05t+D/vQuJG 53EMPHnjWe8jSTnweQQMJUP239ZZj/xZ15d1h3ywwrsEruslohSWdwLN8GopVlNBY6QKVZOBPpoc gFylBN/uiqSICJDzY6AN+apBQcuTFfrB5XG63dmazUdAqS17TOBXRA9gAeFRKlhI//ytCP6Itb1M 0wpNztaozwMrqIH18NMROeP39DWl/LdfDZ5GCVel+1mYulChoEvMlpRooYySyU66naCfJ9d6ceZS cxiMe3n4qiz2hcZNjPD8loiFt4peKEEDUtzHv9IShTmBh/bDTdQnQFagIc7tFuG5vT466cECRNoT YOD5rw6AqO39b4OU4qjB3JZAEpLvWpOThLSRizsGEHBFuYnrbwzbOV1dl7zTWFdF1d8D39i6aXyL /niIJYi3USH5kP5U54nCbmBr97JNwH1WHdTul1D722xk95CleDa/RdWVZcUJmRwIWkuaMwl40Jh8 MIHDZowVZRD8tQ9u/1hqBe556BscCB8xeS98x4MaH6tnFaPP6C08Q6FEmU/rPeUG+HSvcZHCyaOe evUHCut2Uewq11KE0O6Rm+pzSoWQ39hmEn68uVFT9NTVIIlnkzxm3H9oLtXBRDH73kIfgIxqKxb6 4k90S8mmjZo4owleJJB2gthIiz/LAecXW+aESwjXczU5cfp4J/rUf3fmU3xKIrpuKLQu3gLbrZwR iOFNjJaVNewbWrkdF3U/swup/uiDBuIFvDM1j/sLt/2ArFidwKfg7a3TvcNoWuVQuPIsGEyd+lT/ kjVd6RrdgBPE4ATnOBIxmMVvy+TttIUtGnbFbkHUizx3+mOGsyV1CgNnmi6u8zTId6odkXCEipJY 6GlqWHBdDR+3P+EX2VoyxLANEosbtfOerxJjxvcu3eECSTqCgTI2GMo8CdthMEXaKzZ6p4XXY2xp N24cSkR35uS4asYQhD/rZFUYh7RosvMltmyQNHHN7j0rJBbt6lBehfy0CjiM9FWsIkEbXpXt8Wwh Gyf8smTJXOYJT0FA+Xar2z3UCrPs79m8Yplr2VIkv7yaagg/Z6Jm84UvxJDxShR/TgfElV1b6hBo 7sAOxemC5c3d2tlzhXrUK7cie393kSjLGf3CDJXdmiGJqSEgz1k5H2fveE32HXd2MSF9MfGX4im/ BlamJe8XDqwwSmms2Mx8Mp8xSCMuZSdkv5LVGwG5+Lq5nAqZynZEujWbS/Z9CcumneHmf+hwwEu+ PiW9jJcLNgBn/sEY5O6VoD23vyZ81cM2O4rx7D+P2QRNYI2zXItbhMZoe6Oa/4rBPx8z5TqP/mP2 T5uRmxJHyC4hHQnpETfOy9OrcyXt0ltE0M8fQQQDvjglGMnwiV7QAwV8Gp9xVykOd9wvphfIrRbi CoawzM4bwzmHU0Ra8GMT7iPjPHToZjaC8zZiLDQmKLndD1Msu5mELrbBctZf74nP6RshcZD8Key2 QJ8yzrYpb1175bRjAF8jpL9VzImNKG7+7m7JQ9Qy1h8riy6PvIlF/rTqYhr8rkgZZrbqzWeaCNwY F+gd8gd43Hwj1QT8GsGLaM/5+ryOPbE6Z86nPRit7MGk6gYKPglmpK6+e1ADOdJQSD1AlEKE4S4x 29St7JVH6w9Rz0c9r5YuKSh00rHdeqBfaDlVwKzukMlUeEWZhTP7PZfNrUAG9BXkNt0Kx757bf2a 5Es5yUJ3/zng8fEHa+W8EgWaRItOgu4tPP5o48lMc3nhtJoyh2rGeCoL2fMoDL4O79MS3nfqBFW2 eWjSlR6MwjYnT9sAOOnQ6g/dMUG8450KWXb8MX+xr4Q5hQqO5mTEKHEG9m8KvdLXG0B0Mz623yIm Pw4Q16YNGHwrNk52Hv7Vi7WSF3REhxbw94lh2AbCGNOWrP27vMtXMHGBm/MEO9x9nZt8uLLZxPfO 3nk+3HMH84zLXAYJMr7Uh4GiVgXWn9HSa7yxw6ZF+MTJ+V4jDF4mwuDBqKWtZZQBGyyd6BPSEAkq XBXERlPiuTnCo/FUW+cwyRbIDoxmMIDI2pm0Hanfg6G0wd14AB4azHKA2oqUB+P5gHTU+7zERrcj o+M8TnE3tMfZyDCK6Yt79fD1cgtTzEgwK4nXKnPax/YnjhtNRcUS867nunoC6fjNhiHhGDdlNp5+ AnZqnIId2y4/yR0TBeiC7CmmlDFOar8Cu22n2D1fDJ1AYBOVhZtf+SOO8Bk0D/FlMQ6QQHoqgGzW c41agoX7TDPZX5A9amjqXGmLoOdDpkMG02l7aOo8NZ9BzhqczzXS2XGHa6AL0WMs+nyHLayMyiwy yIlg+myMry80+aOryH4zT8FuMGjXPPgvlQIqverQkktQny1boR8nTLPVcMJDc2uvNzsHoEWUYLoL pVAzLfnTRU8NyQcYEH/YIwwXnJRp82kWZ/FFiJW8hYz+VtsQou5FwHr7YVj19UuRgDViZXj72wk4 FJo2GaJ8Dvx3wsQFqOS6/a/osYjKKEYa2/hmZUX5DXlw945bHJWDNs9MZrhZ3Nd7KAXomkbIXPWL brloQF+ON8P7Vm9tYnXSfOhZQ7kFJa/PSwc97Vxcq3OeORsRJBgYFdrcAp//j013eDxvLbdSfgTF GjKxaEJ9jPGknL/5tVa8Po1Xeur4PtHFWl3RHCWGOiz3geP0u4Etmb3oWnzAuWYvv6/uFlEGwK8p 8zp3Ub5Rz5Qdt9MfnEzUiebdYy23SiDZN2Nqe9DyTLZsGWVfzg/3E0W17Y7bUTFeSgmT8tQOVUWz Tlx7q5s9tZe2D3hRt9rIvhGKyYQgFUFq7svygg5IqhPhWc0N9R0LxSt5vtXorw28VoleBHYtPrww 5QM1WX7Po9DGd1dLl8i0v3uYZQoN2iPd+URPc+n/w+paJsL/K6oEL4FdynpJiC6vCqbypgK2CD0w 6xl3UQcWZlHerPq2mqZKPgI/96XAEXrpCAV1ceNXq37TSckyGLwPp0aiQHH3GsLwLA5cMUZoglHP 7KjxdrAH7hzasgB5PcsMwBeaTIHi1nlZQywJs3WBKNrwYp1ygrZRPg5lzDuW4ZH+GXl1O8ZHPAwf DQg1GGwbo20t09SGipNGW+uDApGgxhtfbuO20/zJD3VtdEja4m3cnFODW2H8I6RQq2c6up+nAmrq YmeeRQl6yVX3EUkvD38YJO1m2zZ9xmqPs5DVbtGYCyITYSWymA/efCjM3/YrQIWreroNS1Kx/A+6 VjFvabB+2fLfxmHf2lrUyeFS+b2Fxi+SmM8gLrBAQTF1aSpUSjkcBKAa68pakEGBs7Y+Cx1jy1gs CDWe3bOcpXukVAjxzF12iLGpR2uHvSyckCXcGNkXW/QePTiB6IJipPHyQuwLnPlwF3sb9I6DuAQ8 RjbaFWlpE/dObug7iIt92K3FfB6J7813QRhJOJSKLV/zCeH0LRunMUBvDY0fmmFAIDhRlp4IAo7K 6XK8LhX8tyQRxrmuXZPyiSyQSKPfZhTDn8wrQDN9p++2bponE32+hTLqoZVAcKNAaQCGnXveIEhC SXx5/CRk4mgdZxo0/fjwXHvZyYMTf96qli9dvo9oxIt/dLY7l2udaM0CgfIKcWpN4QQLBTrFqOht MGeTTPBLl8TrtWTC/b+JtYiHX4ViWlkllyNEwHkVuanr9Ma8L8BOqUEKDYa8+8/yHGtF4L3LUiz3 b2MOlEVBCRIVfmnJeAeF7wR5cQEYocljnB0m+6tN37K07kOLt7+stslVJzMFxxXDz+Y2VN0fjbeR gkeaSk6utkyMVix2VwY7HM1CwWjhoHtSGy0auMh8YBiGhOv7bR724o2o2wn+ricgNdUMTVG7lJgd vc82NRXVKDesBc78nZJzvQJJbbo32cvTYeMyZs8m1IhrF9/kP7L1txJXZzXDFNtoYCiI8cFs47JT mXU1WLoIdw9Enb9cWCEh3wxnFH5HQUNk21ifHisfhb0S82MnZP5/V86yvPapmId1qFbCrok8NV3V 1ZcqK5CLVvQRRRQbse6ujz5eRMh2OWR25hcl2UWygBPWqEjVztviS9AEQol9MNfD0exoY17R2azX 0BZ5wmPmSjujGwS4u6lTU+RVija5+/9LI2JZ4w7SW6sqb5DKqit3ZNKJBGWUfPvu2tIQSvm8YkZY DPcpfxPYtal/kRI8m1Tef+BsqmuYLf1uYgDzb5RGKNbZYNsGw2Uew2h3TblYYgaCnpNi/pAJDgja sIAI7hlTUKUCeu26WwWXpnm1XnGs7HKcb9FJ63i8NlXwAFow3DNkzLQBMN6gOvtLb5RaqlMQOKyt 3szkNWfNVz/FIjh73WzN+G4nlFiLdVMub9IvKOUDb+D7X2J7guGk+8i8IMM/1d+P1VdgDpI8gMMQ bLopzhb6lxLxGXfHqOLw0m4jxMEO3FKL4NEtWIPgfnZMUkrvd2hwS8N2GHhBRIy2aoiL8yZBemc3 Y6U0HuDcdM5iqTI4EFIjUupaC3ydHjtSpc70cLAORREl3T9J8AYlaYGkyEEOOELXSx9x/D7UM1xa vTjVh74o5WrJTs0nVQobkkQGV6rwoqxAFuSj0SGAtF8IvyYC3SVbtyN0z0kM4bTLZYj9vRxmgFyN Yn7ApEyqHcMqcQPboNhUBWeXR2e+B145TgyO0wpvIMhEnfNbP5M1WFI6OsJLSdf1tJp6sFGBZJKX OH9TcLPkFRhJR8gdyi03nBjiLbpd2B3aN9kzCAx04LQI+dxXA8dzp9brT2XJVjyUlquxe3iudWbc ibhxoJMFVYXIRwJxKALulYUFCwog+TL7cUqrCDxw0YWzr/+/0I6pSsc/pPOmsWU7v+xGae6uZhLF FZZj3Ab97n3OjPv5J5Qoq3oC5AhqKF2WDVMDNilAuynOfPLo2RGuaePEf7UYBdpa42EpH9TDAI0E xJSzAqXYy6rI15Sv3P4Ju6eifMp0OnVDkRbspLiSS/+Mw2jqBNEj4ybDzie5WlQBxuEIP+lPC/ev dbbceR4ZQDVddma4CDbf7eq6TaPzsaqxM6Z9wzDptdyp/C+BTdeybQwxz+QEqlV1eQqvFQ4N+PzJ IEzAFFcGmNExs86dCfh4bySkMhoTz7iT8LbMY4yP04QL2L96tZZfymOuHiMm59UI0lY1ScOCeRFj 9Y4G1kCJsyNLs8qSapY4V3bNizS96L7dadhjXCZH5txCpf0OIquV7P7Mt5KlguvkhiUdZZERsezV /ZRH1vP+BG1krs2hNUtebJL4/A1CjKFGFWCqBNFYP1r6/MRk+Cxaaj7MkU89Lkas5Kmtq+YLWYO3 PYtHj7Na9nhPkes6T3DgNlD7+NqQ0TsG9ef+1T8a2fiQIIWmaggwPYfvMguVDwMw6wVYzaspEIuW ZJIPJTYjk5+uY4QJaT1DTY0XSzbsltJPH44f0MaIgyyMkIIVUg3VWM2MQtkw9TeP+BdJaAtjGAEs nH4sAoKZPJ7apTmELhc7ywsCYk5Ja2xLwrE3jyFNBlq8PRDLTTE0FHjdOtLm1OP4UdXuqUcfOGMQ dVloVs0VTHWwt2v7MpMwpaGPWtQV5ju/veYlcLUUhYzgiyHK7Zz+i17M8JepxCEtTrF7zQWiK54r AIxoo/eLnQ1FimHZUpjmhvc/TQdUv7Rztpl6eMGrav+o6aZSLL9aQeQZBw3RjnxjKKxkfS41KgXK NFno/faFcQakNka7RTgc08QQGjstQJqyFMb3BPNx4hrtuGJLN4FAbcZGzyjniNzfgph/MUAKLFuK Cu/THVLm8sqg4FIIbILQL/1QrybZZiQa/MmE+fmpAd6L+Alu03NDDv1dn/CEKuh5xcrNKvp94+ZE xAfTp/bx+dWbXTFsG9/61pIGMJ78RMYQiE7cDzpRXhkTOkmJn4xUTv5Ow3DQ5GH6OUZfOY4SuUg4 L5blCSs/a/JMfGn2cikQXD1o1pqx30omjICls70sMjy/oahJWMn1O4TCMIdJarfRrpheggueBeng Zw0UOU9Vhqong/4y8CpTCH2HkNKgzVjgkuspepPCdPFuCnJshfAKHsGhj4qANLTeabwoI6WjPvpW XdRcsDmyUPUAmLb8Xv5Z2z6Q8k9ZW8NQ83M0XdGTqaXKFvr43/MsY65BlEwUReszJ4SL36orHveX 2RItNc6xQCsTay+UplgXZrZ2svOmPPsZ3qKeDDxXrssTixgqyIWjutU/j7Poxaox+TJ1r1XKfHMp YWfnJMw3RjtIMpB3hUW2teJKAfdm6RflmUCW8FEOeWynQDZXzOxEm1sl+Y3Z9XPblrnrYdmDE06k +E17Gjae9ofC0xlyA9MSSPF2khb4RJ++cCRPVgMwoB/g8v31jKI/A3/qEs1+nvQ1coFm+iaxB9UK KmncpGiTfpxxC2/0gSMHbKTsq4nhNqHfOLEhs+OXDZ3Hn+Sc1AFvDi9yk2E9g4zQsVE+ulwSb2Gs d0/d1dLOMfd241IVQM8MGhLA1V4pStyLm2QJxLuUmo06sSQWPGUpnTGF13c1sZHclIeNN87YO6e8 un3GiVeEBo/uOHxc9lDSmUv7+uY86+0H3NNdS9ngkAkSjHj/FUbVJ3H9xRlKHrw3Wm3wBuO0cZj6 mgU0l47MKcC2awt65xCNQ312QUiMnYrH6ScjwYDXgmjY1ggGOMGUrZJN+PaPYKkSbc1XjPeQ7OXa 8mw+5l4nqJQZnQstmO/KsNQwHVrnJNbuBc8+ZC/IRJqYcELDC/JTGcYVm3bAsnuVr1o5FqfnraWb oDo7daut6d1yu9Uo013kjmEtb9C8qzIbfE3vE/vdDed2h64b/+o/j6YskGZak7iWkFMqbuuju63U dxnq4coNCxYNauLvVzeFrm15Yod7JO7iVa4Hf40MTNIbH+18Xix8tHLwjQcPmRV5rT7w+UxAO7aB e6ilzaY95RFfBjFzSPgVU+hr7hjf0G8hk80S/tQnEFN0tkGiRvOzqUzo8T/TuYjEcwoW4/HMacF/ eFtA73c3DzOlTvqkWYScXkZDNYW98IL+2pdfkQFCdeW2QEJEN/v5RO0sIA1nfIvRtK7rP1at3BAE vXgKAWx2xg6GIamMaGei/foxYHSpnUzAHevIp3PpPEpRX+loBKODiH+ykEeKmqjBrHdoVFB31UyM eHOmH1We+7KIfS/WNH6NAgoSrPTIskAfWSwVLlgTMx3mU4HTgtvjWdr1PlAdViPCanW1X4YuL7YZ fa6PK8KeKvZvgwndrCVP1j1AWJOkS293fcOPcRZR5CDkbLe/6iOfiSXVmYlaW8teZF3R9amyZfmR XDdtL8HbyPOYnqJG37b3h6kFeZ3CEzv8xMPBsV1DkU4dY/FpokFXQsRRzWu47VHnDoAegodlKmWc FBpnXrwLcI0Rcb86Og4JrjREfid4/N7kP5U/Wwvk7gk3Ulxa+h/w9v97XQ5nKlUJbwBR6AaVa4u3 R8I+i8I899JMFlP6iFKrKbLAB7PyOtc86DnsWVmFbHq2KLu08yc4r8UpX517sOjvvoy8sI36k8Zr 5pr+A2n3qANITidfyZORctGhEHECMOoH/3dKzq/cp29dutXFAEsS0fLSm38oey5w89nOw60jDrVz IWlWDv6EalHBmh2XP/J7qYW2ZAoUDn4atQZWt2ClZ+AeDn+it0r0nT6EG+UO6tP7hrkl8OGF4Is2 8Fq8CT4eQJaJnTXxw3yS4wEZIpuGKw4pF/GOJxph8ywAXAlWx0/11gtAUDK/35+vx6N4TQSgvF9B BFMvpCe7Dz+xQnP9rBqz71cKnYUTCybbAxM2Y/xcvH0O9SVCvqU+fEmfsUM8xSD3g3Sr66KYwyNh OaCv3XupdYSNgvae7TkbAP5Xb2ID4AyUbNaGKDi89BjTCft5yyFX0i0v5TDB0EovJ/6Be/Z7MMXx Sr3fxgVsabfViTDRINd+bdmb21TGEBxBEeVfNLApd36v/ueNC6qgp8zx1JdTWt3RO4LfqY8ungHM Ev4H5VNtBQX4747x8vdG+oMf72TOeRZhXngVC9oCvOL6ci+c819t293qJUe2s2o6x+/lOlgCcmY2 xicRRnQNFuPdShkFE6rOt3H6gyVIMTLemUWCZyt6jYEJImbUd6jZYyhH45titaulREHNkMQ2OPUJ i4JRIuRFrR2tujFuOR7YEn7bO1Xi6/qYIdaEItsbKH4/lP922xdiBzUTKyP9P0Als8cJWNO/yy/x YkheCk9hzQ3tAdfzH1xwhCaBmTXsV9rIa84QUSUh8BUfjrnLAQQQTcqRvFf+zRABDgEAdKsE4RX8 ujN82WxC1FSYwdWAVjqrtQunxMwVjKBqmfFjoeT1tc91X41BCsTSmWK8gAqOFlpOovslbVKRNetf LAlwH6H40GDEUIPtkaonL/m8UkSyyV+9MC73M/Pt+apkVTWqeaOPYrPlAxm3uXuellVCcsz4f7nT sPpCRlHc+aTb3O8bD9ZgUiUk6RiAo9kwgggjUDacy1NonVAbK/ZRN764itWKJ4+L0A5rPMUS+E5O Gx1BBvcPcOmL4WZcrupxOPy24UOpZVcHuDGg41s77CUOaCFFnEv4/HQhNSNmDxivNLo8z5P6LeQF JWhzZ4qvEYUi29rPVEC9FfVIxcgRo/ViprYkmkC+6MurtoMy3rcK1o4uSGP+3CtGCyaUTIbQirUK Rxa59sM1ZNzk2atAhHQAE3CWIQ2cxbTBza6m7V/motzn39E0/bhhLfM+1POEnUuFUAp6PtDWGAAL bSCGtj/C47J6ZWLTX4hJDtTwAKGJBEYCJcePgkPjgBRGAeUk/DQSWD0Ym0Mscrt0PF9h3YhEgEYU Zo/Wf5Imt8agYmsrxizcs7bbtqdOQGSvD4pnxU4LIHw0oyQmTrYWzqDKtGfFTo973x2MuxKSGDi4 sO5G7ffJtAIotsluW2eiCeS3DWyJfICLBlVq6Fa25NjprgY7bGRNDlmTVKG0W+5g1Ve+Oxj5TPlQ z9Ven4HKjikBMTCACQhH4bnUv3bx0yqVp/7//QQd+fullLjhP5mA+UsyihC2qVsicbLE3qznUmnx aoDkJ94wXn1CDjlWu1UpSLMuGM9Kfx1rOjLFOxAfI6JM0NJOypKZ96iflHNsyXkS0nBnL6e74k38 L8R/11xhkodJ2+OW2KkOLbwbq2CBx+in5e+UBqBQWwt0nfy0/QDmWsTSj3yOREu1LL+WAZRfzeqe pjOa7M2eg9EcCAZiaQKmAOEmT3b6Q7VnGEAiZwGk4C4qvBu3vwsO+R34J/h9LRUA19EtiFZYvge1 T+iFVQMmkIrks/C7QJqedwBEOEmQL3U83Su3y//JTXHRh11NdkawMD/iFcrUp9va8k4qD9iCDSku GwyPRJX6KwqpPRMM4mxcg7U/rw8qWe/u3PNKaieV9kOXjLkiInaSdGd/VEpXi9kOT6jKvOOqN3xt DJzuJzx41l31eXZUUiOAmzyZD72sB5xyAys+8D+c6Ey18TFyzL721jo6Q9+2Hukmiaow43pWvvX4 bpl+IL5j52pKWRNwzG7MDdKjku9Idwuw/s0R6lTE1Tt1W3a6uQw1vTTeBF3zHoNt9U9suGMhMmQI V1qoWB5da1Z7nCQ/IhMv/0V7gdiCWBv6UhAl4HxetOrZSYpSYCYVvP9ECZLue1lpn7+3Dp1XmOw4 P+HS5VjV3hCc/g4HcLuoeIWiMvqIwjecoo2aKb5QXg3fzrHxY5sW/f05XdkyFUj3WPz5aIeNyb8C EFBwDtreJwj0UyheNTXlEkJaEoP/4pWaY/qV/OK8zXOLbtPHOFD3jQSYFuer77wkbzQXRI9ELCPz 3zWlqDYA9EMClPmz5sBsh6q+FWbJpTSvVo4JXrIQp/e0DUOyTpQNoo22FYhRyXv1ZiEUFKIbeSjE /CO2yMfk5/6a5vUpudEzU08uhMc2mgDkfJgB9pvkSmwSr+X/GvQUz5kDUQbbA2j5Rx5sF5W1QbyK tTjc6w+DNy4TzIXawx9+5QX8jQE7GJHo5PJF1kF2uzWEcLIDyxEX4ifQzNDg+ceVNmMY+d/z75gr CXMu0L5pl3wHKQ28djz4GRn1b+UTPdvEWYLvO+1iaeiXrD5cReY1jP+vG/2H6TEljic7Jk02eeLu jksQNLZkV8RQfCK9RUITW32l/IRncUXsW8XyJvxIa2Rb9QIID+ACGBxwoSUMi4YRvv6nBxRHnLLR x9N9a2nTJOLc5Pud2KGCPvlcvLTxlpVWv6b++7fLpJKfDuqc5PYwg/jfdBU7JYQnV+290OV/vjy/ GSjo0WubDxi4OqJUwjAJ6IxentSk3MoxbV5G2r6vUvr35PTsxwyT6BatQQkh2Q5+MpON1FUC0iMm iqHvQnYf3tmYXTzEkO5yb8zOqDyoSSgi0VzcayKU+rAEcGnED/NzwTGeGUYeYyFbuXYPvLKsYBmu rXaIfG0x7UMdLATISlXe7FbMdfmUGClg/VfXb1qi76OJLkTbRJVyDNnV/pGosnHwIN9PAWjfUE5m /B/bGHLo9dg1Cg8EQp6n2EGo/5WzI4p4dS+noQrfCpqyxGBwNYk7pDGREh5v6QYPifCU19L1RUf5 bF0c6weieZhkKdkj3idv3GDA6FzqyqTVAVvkQSHWZiXsLR757G/PIwhXl4a9WlqAAGFU2TDZRdHJ +yDxfZSVjX479zFpHSYmgJKbRHYZcxhGLclDj41tVrgHBrfxNNPnFDOo4BzyEhB21D8Q2tCVA6fg sba3pGU64DD++wk/FvM7UIz+3T1/tU043er+xNSyX5K/IBo8TdL4n7Irf3+R36hYu4S2e+EwzF6z IJs8Z5Ms5r+F3KHXzJrdjKaHwgI2aqWe6QpoaphkOICB2uzeTDX0+vthRc7ZcJ49tDELcvQT/QJy 1b1YpwDUfmv6+VE5hf1kWTknk0BnnIcBjCW+I94u5b+J+k/iHo/MPs5lU4Vm5dyIFWcl97sW4SQZ RSxWYBdvgx7cSCMXKUVGSW9c9bKK/ozdel3RNY+TWeHiCzr5GHOa65NBcoO8flRKMOneSdNdu3kE rB5K4/oqMAWQnRCZv1sodc/VkPkoAGbMFYQGKFtvp3Gvhy7+Cy9ypxqG+mZCSmQk1e3WUleB8rr3 eLHFTsILN24ddQX2ejVDKyNndUMN03gjkIk0Tamd5MSKCJKIgyDA5gGomAzsmahs5Xme8xIllHwI pjGIuULM9uWBJ4bj4cBWU5xskX7RYBvrRqe91zRentkhvo9Cr9pv/+tgieRdhwH/65kjsUmUW4vH PP4l1l4X5oiUDdsO1plc+nRqa9FEZCETi5b3uFTjDWDk78IA/Pjw1MfYsPW+lLkfRzdYiz/ijjxj /aPfY+8ppMbemW6CRGK4982199s1ZKGyFM3auHUzs56SIVHmvvg+ygGHPaI4oXke9//7dA/j4fF+ mXlzuAdNTUvwUN6ARZOn7ZcxHM/ooBz5GBltCKdYEIDlZQ2TOkQLRH3UVFhZZnlavqVHrMTknbrj BwVbVmM09oyDE/NP450IoJmycYCaS5291/8b1sygeKwkzxd1vWwAT6IzwImszdKxkcmzRmDTqo9o Z3L7rBRuOnPt7stpwoUBthwqz4ejmzbdm2Q59x7iZbCiqqTfnV7DBflXLAlyIIUAb3bD9AgIAeH9 DDfYxA70hNjDJsOGHZC68FHLSy0KxRKH+3HEBGsih2EGktvEv6NVOy+LJLoO9aO/UyiPMOvNaviW 5ZSgal8Mc2oqep86gUZu4nOl3WWh6jrA61vz6aK65OO5n+CwMCahuVitskDKt1i0MXrYLR+RjbWv 3wpzTZAuDzjlaUce7Q1RUPyMCbg28b4U3jMHQEcJ6uFaiTqYnVMUg6VIQRIGW8oCKtMKtwy2S6WE KbLIzY5h52j3b1N6fpH/LTQ65D0P0dTx2bXX7nvpEeBbxWvSHOP2v534oC4/SB1v8Ege8q/23sUE 78Lk1LHVHzpP80+ywati3yIImcUsuV/rOh0xQW+hhUFWikDBTEjkZgv9P7B2FwuCoC/y70tD2tPF SgHE6gbMi0huK/2jY3NX/1yAAlZzz/QDCrn3aS5+acj9m2hO8XL4fLuffXLoYTe2f2nGC8DrxlkC OVlTlYfPyxffbcEQb+XHcBiybVYzTHisjAHNpF0+fr6rSsjsvlXMdYoGvJ1zd34H8JLYiWZ9/Crw ZV6jOVU7tV8WzmCcHA9KPai/XqXyhkIF/ukHXgJ5bPr17SvQwb7O6LOwg3WBH9+RH724XAYobE5G muI2WNO8a9DOLGE1FmfyOwGDWBveZx/x41BkqwAfth04sRBZSY0nT/cPneA+acIVcSdwmek6bHr2 AmQuuSwnZ18zGLjgU0YCITKcjZcrZt0bAfw7fQHTKg0YEwnAja+UCP8ibRzrO31I28lXD8EMyIyr LiMYbQKUvfPjvCFu8nCjytD4fu51f2ZWNFUBXun0Wwbr6ARwu/CO/YI1PiyZU8cNKydGhvTmoDVK XRYj0V/QULJigTgelei4KQywwC8l6Ke4EhQX6+r9XWgKxa+6OP+Cbqp2paagmEluhJN12FfrUyj8 /ENmHYj2gUqolq1LsGnvkLJ2NQqlxYdx3P5hsjmzkLj82FKEABcmXgFHjCb3UMrbEN6I8lPESp0T ZM5Dqc6Uo+u78aSndnPDb3OhSZ+WmoN8PEl1DSqPCIgA3yslecieKGgKEk72Y2/98uy12lYvenkM iZd6g/81jboS4Io5AgCejsNnrhyus/yoZUQBciXsO8LwbfDew95NqC9jcmag0jpNsW3bSTvlq19b KwxMELrlcunbfulJWOL/vCXHzo5Utq8A3luShTZRKAR6+PPruMd31gg/AShyYzXMK1bCSPKCf50J k60eys/N3r3ZcuxKqKh/6SynIkzgfkM9bhXMKI87TCGSOXZ2ZP9DdtJBjLlkuDkFmLmWEcas7L96 Mhw70sxgIQC32H7SYuETxKL9xAnC5oqCmBvoIegMjYetqEC3lOR3g1/8G7slkqF36BwH/kA5DgWs LfqfhV74aND52vF21cYRysF+cpKBPe9gNTnbSWLHJa4O4d3yep+D35VReCaIXc3UgKwxm6Mc9bil XswTf5XejBlY6deJ+pLe4WCGkoGMwuSAMqyM/aQZE8Lo64oo7MAmBCsfCixkasXBr6tlr9FYdyKO q7V+Nl5IRUXIBgVvsdy9yXNAaDlHBUHFNv9AtZ6+3B+LAU8Dni6WZ9EHqJ1WWJs8HwJ7AUUjpgow Y3l3YHdO23lo+zVjcvg0u/ehoiWQKmCBh+mKCMCRuJfc8BILPXMYUECqJhNY8L7WsimwWkwwNk5l bnwcqehZixZNwT0QV639Unx0tKvOEVy4r+oj439JyECI/3Zm+v22RYRVVolmXhGg2Tqu/9K7UlTI ARG4DGxFzT9ZQjmnahrcS99ALJIQl+fUm6L7UCRFexOGkT6TJZ7a/DQQur6ynvpdXV5TPZEOIq0s dMdMXHhauoalBopKQIwhZkAxIYUd9HatAjjs4JpsjVfnskEeQUiGftWYFAnniKZYdQP/jfZA6GnV RDsuTHBuuKS72bDVkQLJh1bLQpfZLJGybKBr4fIsEgg5gCS5dQuWIOi8/pCc5syFtS0RMuLLid5i gY7u2adDdsizETd7fl4B5rlE3g/OKrGYbhn4mT3IO6uNIJfMwnjbbNZGqrHgCRAuwtOklWNkuWBN H7EWYM7zMYbR/tJq8dGq5TgvsCuCPDMTZI95oDlMakcV/py6XRfmaU57ONB1JZWz90wF+v5AtoGC XwO2aw/SBKUc8vueri3N2d3gq/sTmEpVtitseZxkJlsfGUH2+AziQFA/dolLVYdhVGZlincPE4ke jCTyVIxJ5P2UoY8a+l1b/BYR32Iq56aJAxUfPrMQ5/ZLEtwHk6Y3/vejaQIhb3NrRGdb8sHt8hYV OW+wQVCeR5/cjpDU4bKckst4MD50u2GbWkvIRAqhM1vEQZUTXBp8CCCzh5Hin3UipZu+Mmh9xKpM 4PPlqBuqR2rsk44Wu+ZwWyRD4E3TkA0slTWWRN9ZbB/zx3y3nLJIY3KRBORY6aum7NteREY+Tna5 eZ7LySzmWsjl0yrOpk3t35GMi6uptKbpL21AZZqNXh5OPdRCri5VzGNx586kSvSDkbF6tQDAr9Qe hpyl6bBsio4TWWYQ+GHXHnxLGzZlE8+NFlaLMwFQgvu2FpyFTzyu0HcLMaaR/QGZ3tMHLAjv3KY+ jcOGRRVCG210aVEjfhWHHPqD3N+K6J4JNzz11pdWTLqxwBMepTZrKoIYIAqHD42WZ2RSxGuCuk9P tJeWPvZgPBLoAbGHgC6MyNKWKkB59sK5w0e9kocXyr9+3s/Tv4DnoiZYfyaoPormv0Vngptdp6KF l86Ip/tvWbc9oR3F5dwZp+GIMjb6KIkFD5NEul1Ng8Sq23tPgUM6ZI4uhArhhT0bOD6HCDJzWa07 77aA87Dhr8OQ+qVyXzHxB8BiAXvFCiq6kQaZlI9GthlGvwpALdnKYr9dP11nQkgDz11OKgl9gCiJ lOK4Q5hWBjVfrUKAGCJ2cQnAl2THcLOy/0L26FsI8IDulPgrd++q5HTaPkx9beMQvEzMHI8B/imW mN6TPLcyIN4BPw76qbHGPGuj+pbd9Z7UXsA/u6T+5//x1+BBL6weFdwjFMPSqH8DAhcCCM47EuIC FTnqotmoqGomhQ6/Dk61+xXjK+CRdvuGOvVzDJnDe+7CypebXKFoKsCTSTin+WHbrEGWvnCdpJOy jkQy/V+bskoq9inDBiW49SCacff9vsYqcLyvn0LsrGsOmujxTiz1xq7xyJu4735vSCGfQckIH3eP ESWixCHQC+otFw+i00HG5sLOle62gtSkP0grYqB3cLtxypRxggTp4/fAUzbHnO4IFaIygFm4lGkI 0mjcscNkb9mByiyT7VxE/ivFHQmtdPjtVp0nUJG44ENRDl9OjzH+QqauBO8Tu32svtSPUey3qjzd Fed1ChTVq+4qiGe5tuczhZbzeB9q8e1bjLUO2UzORRrXjeRPnJsb+4Oy5mdm33K0BBHXH+3Cb66y Mzeq4/oSuxRNGylzeqJCpZrnum0JTc780Dmfbb16id2GBCIZb13LWnahFEWSr2BOci5FyEu2N3iD wZ0UyOi+DJZu9KVD29jQKcYWn3KIuNgqnfmw4Iqe6gsOy6G+8YofVm+j1clHv6EGbCzEx4qJPlN3 jzC8YhpBpQ5wfpSK3msEtuKEVVjdekmedIqquh8Xspr17FuE9I0rCsapXVjHTdcQ4iefZZ/EGQ+e 6+dt0zYycboT7SWn2QaOM6aPyrOyBRp1SpiPPU+eKZckrZTnClVuIS2Wmrh3IXOVJ1U9ZzBCnnZH +aFllY8nFYdLkLaqY1VLaa3e8ZIsMNsQRk8OaQyYeobxAOT/3BWdNXfd9CuYNRdPuw8gXOBoja0Z wR4wK++e0Uu5WHs3crAcW5/Z/5ZVCNw08Un/1h/xfn3R1i+FxwXrcHGmeKKWbW1a56pbC7HNoGhz 7TxQYkknAOjlF4gWsAZoaY9lL7q0VNVMwOSQuzrw3cY2k2Z2sUD+G9hgn1XtM3frIwjwVSYnu1lY 1IgExbi74+0jKhEWOUY5tbtWfBubqsqaBSUK992MrYlBAdEOVNGgbdVkHOUlkWEAjwxeWjXLSnHe 2CO9zApqKmofGj4PhEG7aFiWC8fpA+cF04JreslVfapzW2rdpZlBHSIp0yuo/EJKYFHXxESNeq6F PIpLZ/Xi5Qj+bVAOw/XVK8JpViDHSkv0gJcJP4IpHNEOFVvPKsNM3eWjXm2xkzAWTFO9E4fDMQ/0 7WzcZ//xAISAsU1dTR/LLqv5+BMOF7RYt8NS/u+yr0j/2XefxT3TLTVD5hzTJUdxD1ZN8igisGE8 cQGTisZpsBNlfagap0tJTWoEl5YXyeoRbPySRkPd0BOFLfjiiR1ArSIAKU14Pdtj7EwvDHdEiAND EZ2uuYdW0uZ23x73ny0MVSTljAf0DhfRAtFJ2mB4IYLLtWS0i8PlXC3YlSp5Z+kaDGpUJ1Ze0e19 rJHTmNOjqPuwNdB4mYoGSAZQZUS91zEGrR+R9tSpnj4q/LTHQphFe9JBNRPl/NTEMBuXAeP9/UrF XC3zwNEQe9xmm9Z1aKja6PaMSQdui9r6gSPUVr5PczukEXOA8bWrjLr00UKVyoDzA/vYpD8XRKsO 5bwCO9Agif6LXPq/HzKuX2SrGbJnuUD3wPy0vBEhjxO3A+mjU8R+SprTIwdJ2Tmp5+O197xNeNdT Ia0Sss+8su+4oQNr4D00yXWi14DJmlKXk+FEOdj6jFSYv75WQWkAOTgR0wYg1eBlIMt9AFU4T3ZY Obz7BKFzsexxL/6ein0KAO3bU+xv8okOog0OpJG1b7sFtA9gYiJV9ew9K+6dah8UjInWXIiXIF+G BpvEBHzuHKN/17Bbw0J47uw1UYmhDSLn5eB/9nHARRU3OKqnRurTZUWgvOk0ImvfcUw9TsIlgGHB swEjMH6qhrI2POWseHgq3QNBtfHiyS2t9BABpZpzeLUWRL5RsD/7heDP+3Yq+35F3SV9gRKXc328 DP2SCpWs21b2+IbvMn9rXVkeVt8+3SCuVERgo0eoVzMhvoEqVVtopJn6++Q3kRvHFNW0sF99dpZc moG2MyUyT62ql3xDujWaKJ42Ztj4MV+oq3EFExLm4dqx6TUCn9mdX2omZYLBzrl105pTY5bBXcO2 S8OAMEvwcGJkRGOM95136cyRsFZBoLyeLNVLixBQphS6z0lzJTzCW831jaDecG0UToMIlURfk122 ay5aWGNw6686IC31d7XPUz95CYdMAhGgm+Q5X32Qk1KtNsBAWK90xAkSplJ5sTtJJ2742ucwwpSN fGBuv7lSTCI7JIkY24Ow0PeVFGdMtUyZeTugThBWzhCpNYPBWOfDPbGLVil5d3aC1i2dVCjNbaHD DBc97rOTFrEP71it9hU+VgZdzEO1zyNl8kTfPtnAV76EBA0jp/cqJkNe7gWmcj6SornzgQ2Or/k0 CTLX0UgYASN1ywnV7CYQnu3aU7YfR/zEKV/9d/+XDPxX9IjJYFHfogJpxlY7YxOGOgKRmxxkm2X1 XZS3T0C/wHUmGEHqvS1Lkvr8BIbPj7rLajoePQ66ZfKvL43jSkypFtB1j1tVTmu6HFalpppX9kgu 6TbSAKd75UpL6Cweoprb+T+a+PFPVyotzcu/hrXB8gy1DRJUKaPW/kevgMC1cY9nKAZpIb9I4iLo NGrretKUOTf1rTyqpQ/Mihmr+VkGHNL9rJd+5E2X+5NQt6l3SCS+PEL8kjFguMSY7FGsRct3UWe6 4ELDzxtiruEK7dMcTuUyCUlCF6UKHDwCo9nW4CLksyLg6liF4Y4gKauPptmh5HQ8aH1mgMaa6z5o OU/UfYiFf6vPlex82WxTPrL0SdzJLp4yNY1IvBjTuK7CGqNjJ0IFvvDu26IpeJbboLH13NvL8+yf 4nIDkogFBVY89igJz41yVFWoiqItGWhMrB+/67CkfpyH6dxJ7pJc8E0epQAzPDsn2a/jMjsglBna Ys21kv5sPmndjYSmEOmO1O81omHyZrQkoM56O3AjQnxXQlfWiu4yoes3vcZm6vyFmWBwA2s+2xtm DTCZF86pqZb8lj+bphB+X58cX6KpSnw6hpUruA3T8Vhdy+sWy00FXjaa5wSY/OGItac4Jnrb2oNk yQFYv9AuyAVfVLUWgOWRw3q9IpMTik42tlLIUnw4+RvnEkWxzAMgoQ4dMBvtQRRQpnkk6fkXFdgM 039M/XM0VthimDOXBlvhj6R4BPE+Yq3G2WSkBgEq6uN2eqcKur5NmdnZloptgMw5mRHat+vK9/WN QegqbAVskKsozBdNqRXC0Rnb9fPTVG3wOaU3WceVZv6KH9zokOAaLg0ZyuL4/xpla2a7YUWWEaCg 7WaKrCiG8JI3yeK1tv6MpWgAmvYrVD9Y2PAZGqntaUs47Zkb0chS5Zi+VFyPGI1uUgKOh3r99W9f 1nTV/OlQldd74NKhNJsx68cp1aq96oXpHGKgJ/hj5Z12eZFO2QmbhnUzO3p7JJq9eyJCTYlpDpyh xqyW0rwv4g8vl4xsCkpyTYLB43KKwcLT7kwLxcpJX4pF3D/MXex6HpvSA7IApvnwad6+sHJmRMdq pqZOR7L3N4AoeVVIgF0/cyZsTfAVHKDiFH+f4I3861xA5WAO95m7/AXQF3CqrwWz1i5cJU/VK7ds dpx2K3Zp4Lj4oblQL8yikppZCXSwPzKmW6LKWHLcWB2cevAaLFpfGpv/ymcxl2FxOLC4EBJzZ3Dg 4+vow8mg4OiGaiLvtmju6L52UFoE9iR/QQqB1U7gHLi6dZ5ydvU/1H84Omp8jRedo9hyy2dJeZ78 C6B6WVjxQgkbulWqHznhC3o9q7yfIjXJbNFprbeoUqiDi+NuIOMqcuG3u8i6uTEfJuOcW53nmtjB pzTdKVpL+4cbyZdWmxDf0AgVtDd568OZ54wbT7gQztDRrN4wXXCt9pGpgVoqTFsdDJNlLpt5rEQe N7nzY7UaMKJ4ebzJBo15JDMGTpG1L7cpUlSWEl5athUBWgLjD2MlNOvw+P6FHAJ+Mk+e5Zr7ZtaR LKoxUdXHFCkIznucgecrDwQbnSC3lwD2xFRzR5TGE0VjU19QUGbwBhADs1hRH35ryYMzsPmChQs2 Z3ZKn3EDEe9gmQj8BpCJtdCCdIyxJg+bYzhJyQe269DwkzJll5ZfnF0IVTKmnT1qhlhmqSzmdxMD vxqhFphSu4SyL/e6yWuCMFyNZSOCLSERNKr5U9GlkrtN0Z6BOMAzCopfTuQcdV5RYOhdvzU3b/rp 9ofIzpmLjgPm2JFi9efaoEnz1ZlrOZ3daPEDKMw34h3FVbdSAtQsfFHbzXinEdBos/Knaf9oFrKT HU8wnAQowgtrweXhFxW/wZyYt0jzg16R+0YWJp0FT+pZbcWRMv76l30wHNU/YYD1EaJMfKu2eHdG xRfoW1q3GOqzilPupz5HuCHGIXRnD1BiORiYEkPtkVTxBIswlzWji5r4aOSDI1//72LCskHmiZMT cIxZxcAmIdNrA4Q/F2ezomE9nDgLGfYtMQzHyOBpBSWg59Br1nxEChs0W4RZOPdJ9lnVT3SaBNJI TOxui7okqDReOLftXUv7PPbsLe7GAkrjxWP1yQRF1IYa79h876D8XZtm90AXm5wh1PuttwUS2KXg c6jXs8OzJ7N5nE57/Aw4705ZJwEYPhdmY4u7CK5v/JhhkI7o7RF774y16g1/lSinMyHa1DTzBbzR 393qBxI9i2mjKfZRx+76aZ0wuuz7iFekMRFWHTiLFrMVFXyAtxaM5PjZCk9tWznkIqKZlMv645FG +css54gu18vGq9P3cr5ST/VTqlzNboHCoW0QFK06hko/hBucP+jVH1RavGOMybgHq4Th4/7oQp4a IvPKbRdrLaiEQbwaVEtJIeu1eZbE9Zg8x1RxO+Tw6zGMIrHWS44jwAPmdHxY3cDIp22RUR+3ivt6 kpnCeogcTMWup0bLbOZ7LkT7qAz6/Piq0V4W3XGuuFaeJrIsoG4H9uXP3dtauB3K87320eZD00fi fumkovOGIb3+h/86FRlrR4zWHwiQFYikA8xkpShsUVaxdYsqbnVPBSPyCV5/Hp1axj9FLCd4EF6q Lh1CgxpbLRI3LJ1RBJB/YSGPp54Ulpdzh0smt9vlXKUUQQFqdKI8xHzpY34U70Znk8BtcCutUA3E 1I1o8Ci6JJjsb4Ntux2kfNuTOd/4Ev0Oe+uZyNFlXqkmC90v6+8edcondYkyHU6vsOda8+HT8vIV PBSsVLNcwoFb1toyAob2YBxhw+rmo6QLLKJ6W8iUybOlsAI2aoVrrCt3kmbpJC/heOKb6KvDeCJZ Chborz+ZTul0Axdfe2arux5TKqxzB1VGLwyiR7KqVZ8FCeGYq3LsfcXyRtvPqGg7WBEeUFqgXPyG kODICHW21avZ2UGzLDsdfog1jDoBam1jsG9etc1ggLp4+40UU7I2s0MduIBgEpujel2pXL3oR+H1 oVkFYxClfEa6Em8gCvoJOtW7VPRqtkjoVSZMJG4cgA9db9CIspHosHfYYlwEm3IPlu2VHOFcufwc nvnrqWVUCjkoH9tjRe6pGuTxHMRTUs6J1lHyUT4HESjJ6WxnBhtF169RvxV3EaQDd4PvG/AIhhGA Lc7UxYRsVRXKKDziPqacBGle0XF/3UBAIMHJycl3IC4XAe8a1eySKbYGGs0xSgddg5qQDbksdMRJ hpbFROhtuz0FB1nOHKfA/mEB/VdivPtMtORbpOTx//JPhzgtwxpE617JMfCXXQhp40vIWmqnOu9T vKEDLQ7SW60wPF17c8kkGjmyrwghIB1lMsoasPECf3pw2QiBxPjC7bPTP3BZq8Wbns1PE3QazVpO C7LZohjFsrbUSmCScPR5ynNgFhTCiu9kSSwZhD3vgNBXiNS6MmzrEak9wfqreAnCzQ7XTPaptXuP yxgZMDDzJk7O7V+t5fg3lDKfEZxKlDbi0x3c5s8KUD2kMCC/TKRtKbrD+9kpgdE9+9WorvyA+I8B P16LhfU0kN/KVgs/MZnLA9JyLut26id+ot2SSN8dzFPRcOdL9g/+cJZLul6W0b4ndeFVZXey7b/q 6um6co0WFzGzRkDO2wrLTuPHrKRZuY9SepD3CsZatyZu7hEyGLKJywpXWgoXh3SdLWu3mfs8pXgy lBHdUkWk/r3/5JccLNwyrK1ckJyAGJHA0qnR2faldhY5oJ4bG4xJYfLLy1Vmu0K9fn8Q6tNnJEsZ HgpQPhdghDM9U51W16twAfeSNeCG0ZO2s+6eggiJpTkSFb9jLi5fOD3b6IvudRc+wudnG+24qQU0 TwkDtppUghZ1Fdh66fR0o4F6n13NibOrFwHK113AxhAWbS448UKO4H8PS7TRlx//tiwJIiIiIiFn SSOR9ZgBIa5mGglrUt1tPD4J7eG2h4t5aJ90Xxqi3HMX0tXIWA9sPDv7RIMIJ4q58gvCWP38E5D9 kdlcyZTB5fGDjF1Y/BlIIdUMzNiUxZwQbFsGG6LoBw//oNRY7j0xs5MnU+DPeQa7V6w1E2Z4ImxE WtDSBQRr8nG8BdY/j4samBVFLcbDjT3FMGHw2XiWzXnDbCsczSm8RLhtZi7lPhn+Y/OtJM13Jlc/ fy0twAzjTasxEY/NabKPoZ+/5GxdPEXVvdbPFvy5beywN0zJ0XCwZyayIFVOrqiNM0VzQepAvO4d i3JkeLg7CeBVcG2oX3Ol3NgM4qC9P1CkPTT6NDVEM/JO01guW67EswerJYNPtFvTfG9NkBNzJeuO U3AFN58ERrMq9b9JpwHruDFoLH62jTY7cS2XbVZFLoT1MN9sK1m8jHSC/+JLI3YTjBUEzraFI+wf DNapmES2xYXMSKe5skUU4Zv0AMYB4jxpjFMuKc5cUiR0Yo4jD9xpR3+b6vMpU881KA== ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: image/jpeg Content-Transfer-Encoding: base64 Content-Location: https://upload.wikimedia.org/wikipedia/commons/thumb/1/10/Antibiotics_coverage_diagram.jpg/1000px-Antibiotics_coverage_diagram.jpg /9j/4gIoSUNDX1BST0ZJTEUAAQEAAAIYYXBwbAIQAABtbnRyUkdCIFhZWiAH5wAIABQADwAPACRh Y3NwQVBQTAAAAABBUFBMAAAAAAAAAAAAAAAAAAAAAAAA9tYAAQAAAADTLWFwcGwAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAApkZXNjAAAA/AAAAGRjcHJ0AAAB YAAAACN3dHB0AAABhAAAABRia3B0AAABmAAAABRyWFlaAAABrAAAABRnWFlaAAABwAAAABRiWFla AAAB1AAAABRyVFJDAAAB6AAAAA5iVFJDAAAB+AAAAA5nVFJDAAACCAAAAA5kZXNjAAAAAAAAAApB cHBsZSBSR0IAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAdGV4dAAAAABDb3B5cmlnaHQgQXBwbGUgSW5j LiwgMjAyMwAAWFlaIAAAAAAAAPNRAAEAAAABFsxYWVogAAAAAAAAAAAAAAAAAAAAAFhZWiAAAAAA AAB5vQAAQVIAAAS5WFlaIAAAAAAAAFb4AACsLwAAHQNYWVogAAAAAAAAJiIAABJ/AACxcGN1cnYA AAAAAAAAAQHNAABjdXJ2AAAAAAAAAAEBzQAAY3VydgAAAAAAAAABAc0AAP/bAEMABAMDBAMDBAQD BAUEBAUGCgcGBgYGDQkKCAoPDRAQDw0PDhETGBQREhcSDg8VHBUXGRkbGxsQFB0fHRofGBobGv/b AEMBBAUFBgUGDAcHDBoRDxEaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoaGhoa GhoaGhoaGhoaGv/AABEIAaYD6AMBIgACEQEDEQH/xAAdAAEAAgMBAQEBAAAAAAAAAAAABgcEBQgD AQIJ/8QAbBAAAQMDAwECBwsIBgUFCgcRAgEDBAAFBgcREhMXIRQiMVZXltQIFRZBUVNVktHS0xgj MlJUk5SVJGFicZHVMzRCdrQlJjY3gSc1Q0RydHWksrNFRkdzgoOEoaWxxGNlZoa18GSFosLDxeH/ xAAcAQEAAwEBAQEBAAAAAAAAAAAAAQIDBAUGBwj/xABEEQACAQIDBAgDBQUHAwUBAAAAAQIDEQQS URMUITEFFUFSYZGh0SJxgQZCU5LwMjNUsdIWI0PB4eLxJGJyNGOCg6PC/9oADAMBAAIRAxEAPwDv 6lKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKU pQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlA KUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApS lAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUA pSlAKUpQClKUArlX3X+RX2037AYdhyG9WJiVFuzshLVcDiq8TZREDmo+VE6h7Iv6y11VXIvuzf8A pXpx/wCYXr/24Nen0XCFTG04zV03yZzYqTjRk07Moj4V5f5/5v6xv/bT4V5f5/5v6xv/AG1rK/PU Dkoch5Im6pv3olfpPV+D/Bj+Vex8zvFbvvzZtfhXl/n/AJv6xv8A20+FeX+f+b+sb/21pSmxR25S WB38m7opv/8Adr9HJYbIQcebAy/REjRFX+5Knq7B/gx/KvYbzW7782TTEHcyy29FBXU3M7XDjQ35 9wnO36S6MWKyKK45wFdzXvREFPKq1vUxvPbyduPBdQ9RLvHm2524EN3ukizux2WzAVcJXS6Ztqjo GhgS92/d3d8IxjJ5GJ3tJ8BuJMI4z0WVClopNSozo8XGjFFReK93f8Sonl70WUXDVeZMxo8bh2G3 2+yjaZlpjM+HSpRsR5BMkX5x0lUlFWU4p3IiLttsnfwVuj4KotnRhb/xjbt58L6cnb/PohiHleab v83/AMH4j2XVaXbIdxi5fmD8aY9EabRvM1JwPCnelHNwELcAcPuEl8v9Wy1l3DEdYLVb5c+blmW+ DRI0iU8rOci8fTYPhIUQA1IlaLZD2/RVUTyrtXpE1ru0LG7TYo9ltoRrd72KJDKfQTKDJF9skZ36 bZGQ7OEKbnvuq+KKJry1VuhQXYfvbbhacgX6DuJObiF1kjIeJP6wIEQflRV376y3GTl/6ena/dXK 3z1L7eNv3kr21fMY9Z9VcrtiXHHsvzKZFKQ7Fb3zFWnHnm2+oTbbZEhGXDckRE8gl8lZEbF9YJjU EoWS5tKdmLHRIzOXkciMj4qbJSGkLkwJCKqinttsu+y91eWMaiwcMxG0tR7TCuOQ22+y7hEkTuqI QupHFoHRUVQXF/SRQLu8i9yoi16t61XGK65LWz2b36neAle7ich9HLoMMdmFIUJEYIV2JTbVPGFF 227qmWCblLJh4W7LxWvz5W9eFrcVCrKyzVJX+bM+wYhqLebpNtsrUrLIchpu3usPsZakqK61KlLH Q+qjqeRRLYURSJU47JuirjZFj2odhsnvm1qFm1xFg7l4Z0clLiLcSWMZXGdnCJxFIxUk2RQVdl3r Hma4zpd2k3pi32lnqM2phFcmOyF/oEvwlsnHiXk6ZFsJEWy8UTbv3Vf3D1tuMC6WS5Wy2WqPEtjl 2UYnhDjrMoLg+j7rbhF5UR0RIdvjFO6qro+ebNsIW0yx7vK/jL35Ft4hZraSv83r7H4fxzVqOFyJ zLsvVbcb4Otjmm7jqsAJP9EOW73TQkQ+O+xbj3kipWHjkHVDLYD07HMvzWZFbdJgSLLiaJ90WldJ tkTJFcNG0U1QfiSsu26xZFAxqXZnkGW489OeamJPkxyaOYZG+ptNGLb/AI5kQdT9BSXbdO6tHZcs atWN+8VwxqyZFGYlOzLedzEz8DedZRky6aLwdHim6CSdxd+/cm2ywMcsr0Kd78PhXLXmvDtXbz4X z2/Ff3krfNm7j47q7LgQZsLJ83lhN8EUGGMvI5DQyl2jm81y5MgfxEeyJsu+2y19SwarLcfAUzPK l/oSTvC/hyngfQV3pIXhHPhuricOP6W/xbd9fu3a13XHelcLba7NCvpNQI9zvLhuE5cWImyNNmBL wb5ImxEHeX9WybaiBnNsijOhW/CsfbxW4wGYkqyMyX0B/pPq+28clF6hmjir3r3cdh+LeqrA874e Fuz4Y/Xt8te3KS667KkvN/r5+lz3v6Z3jVrtUi657n0edMm3GHIiOZA5swcRwAXiYmvPfn5dkT5F VO+tD8K8v8/839Y3/tr3veTPX222yA7b7fbo9umT5TIQG1abHwtwTJsW/IIBwRB2+Ly9/l0u6J5V rrpdH4bJ/eUYX4/dWrt2aWMZYirf4Zu3zZs/hXl/n/m/rG/9tPhXl/n/AJv6xv8A21rKVr1fgvwY /lXsU3it335s2fwry/z/AM39Y3/tqO5HqNnVquEJqHqBmfTeiuuGh398vGFwERUXf5CWs+oXmhCt 2tyISKqQX90RfJ+dbr577RYXD4foqtUpU1GStZpJNfEu1H1X2T/6rpzD0a/xRbd0+KfwvmmbDta1 B8/8v/nr/wB6na1qD5/5f/PX/vVD6+KqJ5VRP+2vxPea/ffmz+l+o+iv4aH5Y+xMe1rUHz/y/wDn r/3qdrWoPn/l/wDPX/vVD6U3mv335sdR9Ffw0PyR9iYdrWoPn/l/89f+9Tta1B8/8v8A56/96of/ ANqUpvNfvvzY6j6K/hofkj7Ew7WtQfP/AC/+ev8A3qdrWoPn/l/89f8AvVD6IqL5FRf7lpvNfvvz Y6j6K/hoflj7Ew7WtQfP/L/56/8Aep2tag+f+X/z1/71Q+lN5r99+bHUfRX8ND8kfYmHa1qD5/5f /PX/AL1TLBMhzrKYuQXa96pZjZcdx6GMm4TG7nIkuKRmjbLLbSGO5ma7IqkgpsqqqJVO1LsFzxzD PfaLJtkO+2S9RhjXK2zCMW3wE0MCQgJCExJNxJPJuv8AUtaU8VVzfFN2+bOPGdB4DYPYYaGbh92P K/G11a9r2vwvzLTvdo1bYmXMsa1BzO4Wu2W9ifOfut2esz0MXVcTg8zIcTxkJo08RTFfF2Xv2TGZ x7X2S7a2YuT5RJdub5xmRZy9D4SBYKQrLqo7s050RU+Jqi7bfHWhy7Xy75fYr1Z5Npt8aLc7bAtq kLz7zjTMSS4+147pkREqucSIlXfii91SOZ7qq+SXbWQY5aGGrdKWU0wL0gmhNYLsQgACNUaa4O8k bDZEVPj5Ktde8Qb/AHkvN6+x4HVGIjTSWDpN8ecY6K17WXGV+SXBfUwchga54xYJF9u2X5J71sNR n3H42YDJ2ZkKosvbNukqtmSKIn5FVF2VdlrytkfXK8YsGSWvK8rl2x2K9MaRvKlV91ll3pumLHU6 ioB7IqoP+0nypWju+tt0u+HSsafttvbjSLBabIrwKfURqA8brZpuW3IlNULu27k22+P5i+tl3xK3 2+NaoMFHoFgnWZiS5yUxGTIV9Xdt9uQF3Iioqbb7otZ7ws37yVra9t/Y6V0PPYXeEo583cVstvR3 4fLsJJLtuuUK7wrW/mWQrIlLKHm3mYuNMFFFCki86Lqi0raKikhqnl2Tda942P69y5ZRI+WZE5JV ht9lsM0bNZIuNm4CM7PKjqk22Zogb+KO/wAm/wCk90G5luXwJGWglps7kWfGuQIcy5tP+GNoDqdI 5Ik013IogyQqHfty8ib2V7qRjFLs0xp5YoUi2QWLewxJe8IiE6kZgmVFQF0jJjYlUG3TPiS815Ev dqq0ebqyt8zin0dWSUI4Gk52v+wrXvre3Ls59vgYJWLVNbdbnouqGTzpV0sMG6w2WMgLihyZgRhZ cInkUO9wfH4qiryH/YJa0jcHXJTbGTl+SwRLw1TdmZejDbIxHxYfNwycRAEXSQN1/SX9HeopN1am TcUasZWuE04FhZshTG3HEcJhmWMlouPLihCQqm6J38t/iRKky+6Rvr+byMll2mACSrSlskRID78D cOv4QbgPMmLgOE8pkpIvehki7+WqbzFv95Jcu1nSuhakIv8A6WlLi/uR5dlrW5+OnjwzMXY1XvWW 5Ni171Dy/H73YrVLmmxJvjnE3GREkbVwnRABJCReqpKKDsXei719ZsevL8iTHYyzJHH2hQ2QHMhV Zgqyj6LHTq/n06S89w37kVPKipUOgawT4ua5Hk9wtsK6OX+3v26ZElyJBNrHdEQIefU6q+ICCiqe /f8A3bTaz+6lu1lXjBxiztxmEZjw2gkSQRqG3H6AxnFFxFkCIqRCrvLiZmSeVNkcRFr4qkuer5EV uiKkJN0sHSfwrhljwl2+Nvn5n5sNo1turNgny8wzCJZ7tJgh1xyRTfaYlvoyy+sdXUNAMt0BS4oS j5UTvrMyKFqFYMSuV+HVLOJQwoMKUTa3BwEBZEyTG4OL11VFTwbfcUNFUtu5E5LD42tjjMbGnHMT sL98sXvc03d3AcV848JwTZbROXFtV4oJmKbkPctY981qud8xa7WB+129iPc4sSO442rnIEjzJEoV Hcl71KSQrvv3Im3fTeUk/jly1fMdS1J1E3haaWZXtCH7N+OvZ8vkaLta1B8/8v8A56/96na1qD5/ 5f8Az1/71Q+lcW9V++/Nn0/UfRX8ND8kfYmHa1qD5/5f/PX/AL1O1rUHz/y/+ev/AHqh9Nqb1X77 82Oo+iv4aH5I+xMO1rUHz/y/+ev/AHqdrWoPn/l/89f+9UPoqonlVE/7abzX7782Oo+iv4aH5Y+x MO1rUHz/AMv/AJ6/96na1qD5/wCX/wA9f+9UO3T5U/xr7um+26b/AN9N5r99+bHUnRP8ND8sfYmH a1qD5/5f/PX/AL1O1rUHz/y/+ev/AHqh9fN0XyKn+NN5r99+bHUfRP8ADQ/LH2Jj2tag+f8Al/8A PX/vV6RNVNQJNxtsc9QcxFt+a205xvr+6iqEqpvv3eRKhe6L5FT/ABrItn/fqy/+kmv/AGTrswNe tPFU4yk2nJdvieX0r0P0ZSwFadPDwTUXZqKv/IthMvzHb/rAzf1jfr78L8x9IGb+sb9adHW0Qt3A 8T9Lxk8X+/5K/dfpexpd1eSPynYUu6vJEgtN7zq+3i22m25/mizblLaiR+pkj6AhuEgopKm6oKb7 rsi9yLUzudjyo928M1a1FyCWF6SzKMqRLgx5L/JQUo8lSJshE0UVQlRe7f4x5Vpb58q03GFcbY74 POgyW5MZ3ihcHAJCFVRe5U3TvT403SrEZ1rmQuoNpxa0W1qRdo94lNtT5Zg7Lbf6ykAGSgyJlvuI D5V33VdqynRV/hivJGM6CuskF5Iw37Fq1GZuzj2ZZVvakeWS0GcibpKy0LryNgh7uK2JjzQfIvi9 6ptWdHwnWaUjSs5hkqo6TQihZ82JIToIbIqKuboTiL4o7br8iJ31qcZ1Qm4vik3HodnhOMS3JxOP DMkR1IZYqjiG22qA6o7pwJxFUUTZERV3rxHU6a3dGpx2u3dZLpabkgq6acnIEfotj5N9iHvVfKnx b1XYvj8EfIjY8/gj5GNYJOpGTTHolnzPOFfYjPSnfCsnditg0yqI6SuuKgeKqpv393evxLW9TFdY yelsjlOYm5HLg2I5nv4YXQSRtF8b8+vRVD2D4t/jRUqPRM+v0aFdoEiY9Pt1wtU+2NwpMgyZhBKT YjZH4iFN0Hfu2VUqVRteMhi2krc3b4vRajtNw1auMuMjJBGCOpGLRijwqLaFwPuEu9FXuqZUe7CP kJUePwwj5GE1jur79oj3RjK8xcjSAhGAJmiI+KTHBbjKbSmhN9QjTblsiJvvtxVE9Vx3U5qFf5M7 UjIYgWqxleGTHNeu1ObRxW1FtwXETuUSRS70QuAr+mK1vQ1ZsVqxTrW+IzeMvmNWRuYUq0uMIfve 6Jor7ium25ug7CrQiu/jEnciDFsk1Zk5Esv31skJYsixSrIYP3WU+fReeF5DV9wlNTAwTbddlTu2 REREpGk39xeRWNJyf7teRs8sxfU7Gb3OhsZ3m8yBHjzJYzHMpVtUYiA2Uk3QFwkbUVdFERV3JFFU 8vdpchjao4pbG7jkWYZrCjE4DLqfC03HIrptdUG32xJSZNW1QkEk8ip5FXavfItX7zk1rzW1vxLd EayySEiSTCl1YydNht0GiXv4upGb5b936Xd5NvzqBqvedSbKltv0ZtnqOg9MeanyTF8wbVsVBgzV phNl5KgD3l37p372hR5ZoLx4ImFF8M0I+PBHs7YdXmWraa5Rmzh3KRHjMMNZfzfbcfBTZF5pD5M8 hRS3PZERF5bV7BjOrzsoGmcyyl2ObHWC4BnCLBJOt0eKSeXDqdXYOH6XL4vjrDf1UnOX62ZJGx+x xcsiyo0iXeuLjj05WGVYEFEl2ZAm1VDRvbl3L3bV7hqyMawpi44fYwwIGkT4PHLkK11UkpI6yyFX qKvURPFXxePi+SmyfcXkv18vWw2L7kfJfr5etjwlWjV6JYrtd3smzhqNaxmk+DuXKLyjEPhJMG+f Jxts9hIx3TdU233SvHOJGZ4XmF3x49Rs9kFbjaFXHr842Zc2G3e8RMhT/SbdxL5P+ysS45uF4xh2 zXLE8ZfdBuexbZgxiFLYzMdVx1thjfgiiS/mzXvBETbfv3wc0yuRmmWXTI7ozHhy7mbRGyySqAq2 yDSIKl3r4raL/wBq1eNFZvigrcexfQvGhFy+KCtx7F4W/wAzy+F+Y+kDN/WN+vnwvzHb/rAzf1jf rUoYly4kK8fLsvkr4LgOIvTMT28vFd602FLuryRrsKXdXkhH1AzlyRdAPULNVGPcHWG/+cD3cAiC onl7/wBJe+vf4d5v6Qs19YHvtqMxP9bvn/pd/wD9husqvyHpLGYinjasITaSk7K/iYxo0rfsryN5 8O839IWa+sD320+Heb+kLNfWB77a0dfhwiBsibBXT22ABTdTLyIKf1quyf8AbXnrHYtuyqS82W2F LuryN/8ADvN/SDm3rA99tPh3m/pCzX1ge+2rpzzQeJZrTgsWHActk1u92+xX+4NPC/4WssGk8LQe S8EB9TaQSEd9/jTZa0zGiGPvLGuAZLe1x0HbhEnSXocOKbcmLMaieK466jQgZuqooW5qgbIm67J6 kqfScf8AEdvmznTwzX7K8ir/AId5v6Qs19YHvtp8O839IWa+sD321Y8/QqFaLBfpNzysW7pHcvCW lriwDb4W9VQ+qBOdVSPb/wAEhI2neXlRF1tw04xWz++8i4X7I5MPHrJDut6ahWxhZH9L6XQajoRb FtzMnCJNhRARN1UlTNLpJ/4j/MWth3yivIhXw7zf0g5t6wPfbT4d5v6Qs19YHvtq4ZWhFnjyIGJS rnMayR++XKHCukW382JCDCalspLUl3ZQQJR2FFXkpL3IirWJcvc+2u13WzWmVmnGf75MwL5wjtPi x1IZyeq0LZK4AIgIO74j3Krq7Anfdw6SXHaP8xVPDP7q8iqfh3m/pCzX1ge+2nw7zf0hZr6wPfbW dqHiLOF5AxCgPy5UGZbmLhFelIwSm07y2UXGDJt0fF7jHZF3Xu7t1itcFTF42lNwlUldeLNo0qMl dRXkbz4d5v6Qs19YHvtr9tZ1mxOCi6g5qqKqf/GB77a0FejH+mD/AMpKyePxdv3kvNl1QpX/AGV5 E1x3KMsuWOWabMz3NykyoLLzqjkkgUUyFFXZN+5N/irY+/mTefmc+s0j7ajmH/8AQ7HP/Rcb/wB2 lbmv0k+aJZg0HI8yv62+VqhmVkgsRTlTJ7+SvqDAIQgPcRiiqRmAp3/L8lZ1vw7UG4w7kUfULKUu EC/+8RQXcxcZN15ELchIjTyqicR2VSRVJO5K02N5tdsQt13j44seJMuisI5PNgH3G22lJUbEHBIN lUlVVVP/AMCKmfP1Hdv02c/cGoFqcuN4t10ducfqOFBlxkBvwkWkVEcVQHvbVUTvXZd++gMe22XU S7NNOxMxzBsHIJXBVk5ocfpxhdVonT5knAeaL5fKiKqb1tJGFakRmWAezDPI1xR6aM5qZlZsMRGo /S/Oq+rmyiSPAqLsn6Sbb+Ws2/6iWbIsmz643O0jcrPd7Qza7Za5KONtuMtvCaiZNqhNbqrjiKnk UvjVO/Huer1xvwzI2R2O03S1zkkNy4KuOsg4050OAIQLuHBIzaISb79+6Iq7oBrFxjU9AuqFlGat v2w3mno7uaEDxm02jriNBz3c2AhLce7Yk238lZ0nDdQlbWTZ86zSfbvBIrwyH8uOKrrrsZJBMtCZ /nCEF37tt07/AJUr5Z9V5dhg3KNEsFnjMTZUh8giPPQmWwea6ZNq02qA4giicVNF4ruqIirunrZN XbjZIzjTFktr6lDYioRyX0AxbjDHTrNIvTfHiO6CSJsqr3r8QEIC/ZK4AmOeZyokiKi/CaR5F/7a ++/mTefmc+s0j7awmW0ZaBtFVUAUHdfj2r90B0H7k293qfkmfQb1kF7vkaNCtL0cbrcXJask4UxD 4Ka+KhdMN0T9VK6hrlL3In/TPUb/ANG2T/259dW0ApSlAKUpQClV5iWuGE5tcbXAsNymeEXiO5Jt SzrPMgt3BptBU1juPtAL3FCQlQFVeO67bIqpPUmR1j+EI+0rG2/U5px2/v8AJQHtSta1fYTki5sE TrC21wG5DkiObLW5gJpwcNEBxNjTdQVURfFXZUVKj2Q6rYpikqVFyG4PQHozEyQaOQX1QmosduQ+ YKgKhiLbwLuKruu4puQkiATOla+DeotwGWTXhDIxZZRDWTFcj8nEVE8TqCPMVVURDHcS+JVrYUAp SlAKUpQClKUApSlAKUpQClKUArkX3Zv/AEr04/8AML1/7cGuuqqvWDQ6Dq7MsMuZfLlZJFmblNtF CaYcRwX1aU0JHmzTuVgdlTbyrXbga8cLiYVZ8k+zmYV6bq0nBc2cHp3rV1WjFLVc9PcPgXOO247b pUG9XBpDQXJyXNyWEaGip3opk1EFf1QIiXbarA/I2t3n5kP8DbvZ6819xdaVXdc4v6r8vvfbvZ6+ tr9PYSsklnVnfkvl3tG/59h5NPAVYN3s/q/Ywol7hu6g2W0RJ9xt8m/Xu5XJ5iHbojkObDbfNlgH nHPHBtWLeS/mxVVR1V8qpUOxErvFwiLJt9nk2Zqfb5V7ceiwo86xXUZCuE1Bk8+LouiqhGBkCJUL ivHvWp+nuL7UgqKZxf0FfKngFu9nr8fkWWhS3XN78q78v+99u8vy/wCr+X+uuNdKYGKslLs+7Hsv /wB+jsr3tb5W6N2rvTzfsVbebHabZpTdbDaZkGfd8XnW2TenG2HUe8MccejSB6pIgONApstCje/e 0RF3lVW11QnuMbWnHbOcg8X9H+gW7u/9Xr9fkbW7z8yH+Bt3s9d1H7QYOkpXU3d35R8P+7Xj6HNP o+tK1rL6v2OVaV1V+RtbvPzIf4G3ez0/I2t3n5kP8DbvZ63/ALSYLuz8o/1GfVlbVevsUtos5Bt+ cJe72wkm3WeMJGBAhArsmSzEb5IvdsiSDL/6FTO047GxLHrXYbZaVye62y+zpl0GKjZyZJxowtEM VHAIXSjHNY2bJFQjjvFt8s0L3GVsP9POsgLbybwLd7PX4/IstGyf89793eT/AJPt3d/d/R64KvTW Dqzcnns+yy7L2++tW/8AhM6IYKtCNuHm/bwREHRvTGRvTjYyLJblHsceOsuBbonwltByXHHAJ9le bJmLbKNqfiEAPInikqlWXYbXabfqa5KzO8WW43DI5w2eAbdtPaXHRtGJMpG2uQNPuP8AFnmSoCq3 IIdxJNpH+RXZ0RETNr8iJv5Lfbk8vl/8X+Ov0PuL7SAqI5xfxFU2VEt9uRNv4esn0rg2mviV1bhG K/8A64cexcLcOfE03Wt2pc7837HKcRt1mM01JRUfaFG3EX9YfFX/AO6i17V1SnuNbcibJneQon/m Nu9nr7+RtbvPzIf4G3ez16j+0uDf3ZeUf6jj6srar19ik9LmZ0d293S2Wi8XR1tluED+PtMyLnbT dVTSSyy8KgoqjatkaqKjy8VUVVVJll1rtUKxXq85XbIeTJFkXCe/drapwSuL0bwOEywatqotqbr7 xOoHcpsqYpsSVorvodYbHJzx/J84yCNbMYvEW3Nux7HDlOuDIiwzFFAGeRETsvgiCPk4/wBa1lY7 oRiWRpcVtGf5KzItLrbFwizsch29+GZghNo40+yBChiqKK7bF5EVVRUrin01g51dp8a+SV7aXz38 uHg3xOiGDrRhk+F/V+xuJWkWOR7varUES5yTOavF+OchDurLcJ2RI6SGqArfJGQacaRf00QzIlrC xvArPcVkQrjjztluFyt9oizoazzfds70h6S6SCbm/B9xiKwiI5txckAG2xEK762+5mYtj0uNb87v 8V65xHba+C2i2IbjDnFXG0RW90TxRVVTvRPkRVrTWv3NNivNuhzYmaZKLE1txxhuRj8Fh40BV57M uNI5unFV24796L8ab5LpmjZpzn2cbLmnflnt9PW10W3KfZGPm/6f16msj4FAmx2J8fC5yX9uJGOX hSXV/kx4TKcBl+Q+So60IsNc3B8VBVxsi4CqpX6b02sUmLHaKJMtdsujNvehZO/cus2kqZLAAgsg io0+jTKucz7y5NES8RVN8NvRvBZCONhqDlBvNk2Jx1xaL1ubtvO4CHT6HJTWM2Rcdt904KnLuqSt e5ds7zbToZtkCI+z1QA7PbgNQIUJVVtW+SdxDyRU3TdN6067w/ZKfl6fvOP1v43siu4z7sfP/b+v A0jGDQ5COyG9Ors3cILrLPwffvriHJjvSHACbKXdHIqADB8u9G1VwC8UE8am9bWI9tvWHWy2uOrE axkposuvA8TBS5SyEbVwURDVGjZRS8i+VNt6tTJdIcExWa/Cu+e5W47DjDMuSwsSjzQt0Y0JRelG zHJGhJAJU5Luojy222WthH9y5Ysh1Ks1hczO9y4UvGZdzZlsxYIboMqMI8VFpRICF3lv8fiqi7bo vl9LdIUcdgqlCm5Xla11w5rtzyevZfja9kj3OgZLovpOji6y+GDd8vPk1wVorTt9TlGunNL4l2xf SK0XK1w8qVLrMn3J2Zj1lizEFprgwAPuPivFBJp4kRPiNV2X4rL/ACDcY888l/cwvwK+fkF4uvlz LJP3ML8CvgKOAr0m3deb9j9Y6Q+13ReOpxp5aiSd38MHfg+H7z6/Q5bw/EJeVahHEyyJLlTHYMi8 uwWCRuTcF8FKU201xEtie3DbYVVEJVRN0RKtNnTHFmoTN0yHDZNrgSUlt391i9m+xjRRo4kqCQ8l 8IdNwFFl8iVF/N7KSqoWj+QZjG23wyyXb/5mF+BT8gzF/PLJP3EL8CrwwNSC4qL+v+058T9q8FXm nGVSKslZRS15Wqpadj5W5XTojVKC1jun9rtyIMSWhW22nGaQFRSjwBlyicJE7z8IunHuXu4Ki792 1IV3OnuDcYTyZnkv7mF+BT8g3GPPPJf3ML8CsqnR9epK90vq/Y7cF9sei8JSyONSTfFvLHj/APoc taIxoJaj2243yO5JtNjZk3iYDYCZKEVg3kRBJURdzAE2VURd62mo2Sln+OwJFqZu18bx3mt1v9xg RojirJMRaZVthVRGxVslHkZkpOHtxRESukfyDcY888l/cwvwKfkG4x555L+5hfgVZYCuqeS64+L9 jKp9reip4pYlxqXVklljZc7/AOJ2p/Lk2nYp3HdPcOC22yFOs3vvfCCwCZu3J6OD865mbgR1EP0W hjeMRJsXIE27lXf1nYXjca2CjUdy72tptEskCVcRjocu5XGQEQ3HRRFEPA4bbhIpd+6fobqtW5+Q ZjHnlkv7mF+BT8gzF/PLJP3ML8CtVg6qVrR837HA/tLgnJy2lXnf9mP1t/ecL8eVrX5kQiaQQsTv Vtm2jEpUqfbYd9JyEjj5uXEGIjLIKgvAKk6T8pSE22wTgKKIEqIq6KBjVnwu5PTYcPpeCykuMmzj IR9hiVbLQUp9gnVUiVBlyo7Wylvuhiu+yVZn5BeL+eWSfuYX4FPyDMX88sk/cQvwKtulRclFfV/0 mEftDgndVKlV3Vn8K1bXOq+Xn4lX3bTeyhY8okXOFJuz2OslahnyHnI8RvwKCAvA26yhI3I8LUuA SQ4OgoiC8i5JTukVkDIdTsUgym2XYa3Jl+YL6ogLGaXqvct/i6bZ/wD4K6y/IMxjzyyT9zC/Ar7+ QbjHnnkv7mF+BWUsBVlJP4eHi/Y9Ch9q8BRo1KbdVuSsnljw4W5bT68LFYypMBbbMybGRbbxC4We 53cnpcWOkt68m4sJAk8N0AWTntutgKA2gEhIilyJZDB0px/DMuhDZsYul0u9iK6vNxnEcE7vGjQl HqqDor45SnGukTIKCiSonMm1VZZ+QZjHnnkv7mF+BT8gzF/PLJP3ML8CtVhavao+b/pPPl0/0fZx jOqk7p/DHinyvaqrtcePb2WsiqmNJseQrzOLGXTaiWxpZkYrhISHbpbUNXpsdZQIZMvjzY4eEITf PrNLyJPFz4uluPOrLcyxJt4YsSNWib0gcFu2Mxre09Le6rWwo713nEaR5eC9Mx8dVREsb8gzF/PL JP3ML8Cn5BmL+eWS/uYX4FQsHUX3Y+b/AKTR/aXCP/Fq8rfsx8P/AHeHz5vtK5h4bFuVmx/GDgNk rrduakMNooyH2olvduc4RIG3HEcV25MAgAKkXTRO7Zdqi1mxm14rlUGDZLe/a+pZoMqZHNHUbCQ6 1zNGkdUnEDZRTYiJUJDTfu2TqP8AIMxjzyyX9zC/Ar6nuDMYTuTM8lT/AOphfgVSpgas45bR837H ThPtT0fhq20bqtW4rLHi9f3mn/PYUDpddYmE6dXi/wA+7zbK7d73Ht8aRbbZGmyuEdk3XxRHyFAA lfj7ki77iKbKm9TObgVh1GtsfITsTeNyMpubCBMdM2m2QfmNR2liq1vGec6aOm8w503OamY8QHZb L/INxjzzyX9zC/Ar5+QZi/nlkn7mF+BUxwdZRyvK1837Gdb7S9GzrOvTdWM273yx5di4VFoud+XJ XZUd+0pxx1ybGsGMX338j43NnNWdpH0fNVmMxobzjTqdUTRHHXHR2EFRsSEREu/eWLTPHMOvbl6b xqXk0KwT5qz5qTTRi3naojbjiGKDspvykPYXF49NRQU71IbA/ILxfzyyT9zC/Ap+QZi/nlkn7iF+ BVlg6id8sfP/AGmUvtJg5QyOrVad/urt/wDt8vJ3RV7mjVgSfarVebY/CIrrBEb4dw2S9x+gcm5S Gg34JGbbFOmbabpyBCVSJUH7Z9LcMytu3xUsZY47c7ZbJqyAvRSDYclz1bYjAJ7CrjsUTNVPdOaj sIIioVn/AJBmLp/8csk/cwvwKfkGYv55ZJ+4hfgU3Ofdj5/7R/aXC2/e1b/+K/lteT08uHApa8YT itutMu+3HDZlpn2+yk/Kxty6vIrMh6e2xBR0jTqo4bSvOG2m24tiSdND2SQ3DRDH4zWfTYdkfK1w kvTkJ5yVIc8FGEyYoAGCC2hLKA02dIzJoUXpj3uLZH5BmMeeWS/uYX4FPyC8X88sk/cQvwKjcqnb GP6/+JZ/abCJfDVq/lXLhw/e9mvHg7O5z3q9p9bcGxqxi1ZJFquhyDjvOTZDrcpwm2g63NgkVo2+ qSq2/HPpqK8VQiTlU60etdzselVvudqtmVOyLzeJjxy8atUacfg7DbTYA8ryKgJ1CeUUTy7Eq77J tZae4MxhPJmeS/uYX4FfF9wXi6+XMskX/wCphfgVEcFVjUc1bzf9JpV+0/R9bCRw83Ubvdtxi78+ FnU7OGvIre3vXtnTOfMuDcu1pIs8y7z7mcGLJsl9KShuCLx7NmMtDcBkWxVzgbaKgCnNV8cjsefR Zd+xfF7Tb2sBcFq02KHObZVi7q/wbYlRnEROvKVP6SryLs2iFyUURAWzvyDMX88sk/cwvwKfkGYv 55ZJ+5hfgVfdK1rcPN/0mEftD0ZGbklLi72dONuzj+958+PZfhYg0GwYPdImChjdyttzs2GZKXh8 oILjRSo4wfDH3H0cTZxTcgyeKIqijagO9aqzal2jIPCbxPm3e4Hi1tnXFy+SbFDblNvyunDYZajg fTVts31e2M+8h7uKJ32d+QZjHnlkv7mF+BX38g3GPPPJf3ML8Cm61+zKvq/p2dhC6d6Jd1N1ZaXj C/FvNxz/AHrvReDsQbHXLbqhbL2UOOsqXebauMQbpdhjxn5MlmLLnuSXW2kUG0EgitIqKSoGyqSr 3JWesMq02+TpVZ8ajCxaLfCCW24Qj1pPWefVJDn+0iuttNPICr4iOoKIm1dCfkGYx555L+5hfgV+ 2vcIY0w+y+3meSo6w6jra9CCuxpvsu3Q2Xyr3LW9ChVp1YTlbg03Z8bJ30/zOev030bKE403Us07 JxjZOzjdvaPs0WtlxsRW1t2i3R7Y3MiRI110usI3iZ1tlW4JJtxvOCqbKhE1MOPsirsiOL8flrPE sLf+EE2y5Lbpz0+zWd+cdlac6Uu4PNNAQRgVN1RTRxDJR3JAEtk38nQv5Fdn2RPhvf8AZF3T+gW7 u/8AV62Fr9yLEsyShgZxdyblNIy+1Ks1pktOAhiaIrbkUhXYhFUXbdFSvpljKcU7X4/rX5nzCxlO Kdr8f1r8yr+zGzRb4IScZlux25cWFfmffl0Y2Oh4C3LlynJCFuvFHuDaGvBVYLfkRIlaS34Jj8+3 NWkmpMG7C1jYSLy9McQhlXJ9FJpIy/m9hjKRL8aGKfFvvcdy9xxAvFyl3G657kUudMeJ+Q87Ctyk 4aruqr/R/l8ieRO7bbasdfcVWck2LN7+qL8SwLd7PULFwtxb/X1IWMhbi3+vqVDcMasFrs8m+XvD rnZ3bdbJb7mPPXZ5H31WZHjwHHiLx2SdU5O4jsJI1yFERU3lUDHMXtV0uONR8b98o9xym1Yo8+d3 eQ3XGh8Kmvht4zYNrxFBEk5KiclVPFqZj7iqzhvxze/oqruq+AW7dV/h6+/kV2jbb4b3/bbb/ULd 5P4ejxVNq15fr6h4um1a8v19Sp4GnNmmWaEjseZAgXWLbX4OWSZaoBypssBbhtsbo26jbBGri7c0 JolXiO2+xummdk9/IbNos1zAIsCfOl295J/hEiMDwMRHDY4rIQydIuaNo2CgKkJAPjLYv5FFl3X/ AJ637v3Rf6Bbvj8v/i/x0/Imsuyoua35UXy/0C3d/dt3/wBH+Tuqd7hfm/L/AFJ3yF+cvL/UhpaT 4nbL9knvrFuTtph3N6K50jlI3bWGIDL7zvWRdkMnXvzSSCUSAUREMiqstLJ42O53DKbhCauHwbsM m4jFeDduRJLhHaaJPkUn1/u2/qq/09xNZE22zW/Jttt/QLd8Xk/8X+KvRfcX2olRVznIVVPJ/Qbd 3f8Aq9SsXTytSu7/AC9wsZTytSbd/Be5TWo2Jxses9lg4qBT7IyEm/Ozm0VRbi3CSjdvEyLZd0aY 47frKv8AfXrbMRssfGYzk7HCvN5Wz2yeRe/z0VHJVxnqzDi9ME2Eeiim4qLyXZNuHetW8PuK7OK7 jm9/Rd990gW7y/w9PyLLR575B/AW72em+U8tuP6+pO+U8qXH9fUrm8aYY1EsuQu2xq4THHXLk3a5 qG/0oz4zihwo4O/6F0icFFcFxScUXEUURBUl8n7HjVruEq6Yta50F3HL1fek975lIKaxbYSKjqo4 ighLMcZEUFNlElRUXuWrJ/InsvLl8Nb9v/5hbvk2/Z/kr9L7iuzr5c3v/wDAW72eqrF0+1y/X1K7 3T7XL9fUrJ7TnG1el22FAmOSLLenbaRR7k6Um+OxbY5IkstNkii2pPi0AKKKuxl8eyJs7BhVqZyS BCSySLY7clx+Hc7U5NOQ02+8T1wlsKTiKZIkeIzsCLvyPiqkirvZFr9yHDsrshy35xeN5EYorwSL PapDbjREJKBNuRVFU3AV70+KvxdvcfQ77cpVxu+f5FLmyiQnnTg27ddkQURE8H2REERRETZERERE RESq73F8Lu368Su9xfBt2/XiV/a8JgZRcMfffxyXcmykQo9wtrc0osbHwkNLc5T7hCiFwFJItNg4 qiqtGO6qoinjasVhZrNSXeoEmaC2+LM4uOux4MKRPcfuEgHzjorzAjHdZQHTEmRJCQt+5KnK+4ms i7b5rflRP/4C3ez0X3FFmXffNr/39y/0C3d/9/8AR6neqer8v9RvVPV+X+pxhbjR1+9GCEIldnyF CXckRRb2RV2Tddtu/ZN6za6/D3ENjbN8wzfI0KQ8Tzq+CwF5GqIir/q/d+incndX6/Ims3nxkf8A CW/2evgcd0TiMTiqlaDjaTbV278X8jVY6kux+nucfV6R5D0SQzIiOuR5DDgusutlxJsxVCEhX4lR URUX5Urr38iazefGR/wlv9np+RNZvPjI/wCEt/s9ca6Cxa4qUfN/0k79S0fp7nJsW/XeBKuEqDd7 hFlXKS1KnvNSSE5T7bnUbdcVP0zE/GEl70XvSsyDmuUWxd7Zk97hLu+W7FwcDveNDeXuXymaIRL5 VLv8tdTfkTWbz4yP+Et/s9PyJrN58ZH/AAlv9nrXqjHr76837Eb5R7r8l7nK65hkpRLrDLJLysS7 kR3Fnw9zhLIhQSVxN/GUhRBL9ZERF3r8wsryC23crxbr9dIl2JgY5TWpZC6TIoKC2pb94ogDsK7o nFPkrqr8iazefGR/wlv9np+RNZvPjI/4S3+z06nx/D41w8X7DfKPdfkvc5XazHJmIk6Gzk17biXA 3TmsjcXECSTv+kJxN/GUvjVe9a/SZplAs2tkcovgtWlUW3AlxdRIioCgit9/dsBEKf2SUfIqpXU3 5E1m8+Mj/hLf7PT8iazefGR/wlv9nouiMeuVReb9hvlDuvyXucl3e83PIJ7lwyC5TLtPcFAKRLeV w1FN9h3XyIm67Ind3r8tYVdg/kTWbz4yP+Et/s9PyJrN58ZH/CW/2es30HjJO7lHzf8ASSsdSXY/ T3OPq9GP9MH/AJSV17+RNZvPjI/4S3+z19H3FFmFUVM5yPdPJ/RLf7PVX0Di7ftR83/SSsfS0fp7 lL6GYpGybEor0th64OW+zW0Y1uZB8lkOvrw5n0PziNAg7koqiIpCpEgou++Yw9l685Q9ZLROyO3w m3HrDbBl9Jy6D4Wkbl1A3JWWi5KZDsqogryRFVatCL7jO2w4MWFGzq/pFisiwyB2+3GogKbInJY6 qvcnx+X463Nn9y85YVcW16gXcOo8y8SPWK0PojjKkrZihxV4kKkqoSbKm9fbniFB51i3vflE+243 DkM21+edstjjrqu9V9vpsvIhr3rxfNU3VE+KrZuzdktGRSMwiRmHAteP3SJa4mwkiO205bLko0VO Kp4sYBRd91k7/wCxW0P3Ikd11117UHIXXXjI3XDt9tIjJVVVIlWPuqqqqqqvxrX5b9yDDadBwc6v REBCSI5abWYqqLuiKKxlQk/qXdF8i0BXr+CWGI9LZssCbkcw7Yze7Xa401wnDiE0w2DLiiiEqm88 66RCvIWmBRNue9fm+4Xa4dsuD8bHZcWPLtEmVGuS3opLMG5I6rDFuaIE6cgieBUJC3LZxO9OCqtm XT3J43qfInXbUPIJcuQSE44dttm6qgoKIn9G7kQUQURO5ERETurzg+5HYtk6JOgZ9fWJUN9uRHcG 12z824BIQkieDbboop/hQEOk4xacNv0y4fB+VbCxmdPkxRnTTdK7Q4sBwlkK0fiiCSljoCjshdTb v2VU8i0iiWm12Ji62m7PymbmzDuJwFfJ+UIQnJEkm0d4g4PIBQFZDdUQ0FXCSpkfuQIjjrrrme34 3XjJxwltltVSJVVVVf6N8qqv/bXmnuOoCLumdX1F7u9LZbN+7yf+LfFQEOawnGY15jsXq1qLcyWT BhGusoAiMMW1ZUmSguIjolycZFGHd1At0UlTurIxDTe0ZLKssw7E6zDuMK1C/CC4Sn0hyHwN95TI EQx/o6s8TcMG+oaigmuwpKx9x7CFNhzu+on/AKMtns1fC9x3BP8ASzq+r3799stns1Aaj3IZCWaa kK0Lgt+AWbgLv6aD1bhxQv7W22/9e9dXVVukWicTSadfpse+3G+SLw1EZcKYxHaRsI6vKCCjLYJ3 q+W6qir3JVpUApSlAKUpQHMdu9y2+Oho2F65SFzwcZctUaVPu0idDgm4HF4Y4HuLAuAnSU2w5C2S om6boWsw73N091/HiyvGLH7yM3q53KVaJzkR8Wkdt7MVn81Gisx91cZU1EQ2TcT3I99pva/dKW9M g1CbyGIMWw47DeuFrkRjR5+dFivnFmGoISoPCQ3sO6pyBwV28q1+cv8AdJJZ4QpbsYukCV1LtGmO XhpGxtb8S2LPBXm2yJXBcaVs0ECRePLyEnFQINC0Cy60Y9ayumPY9mq2+fa5Uqx3CaKM3Ho4+3bi 5G4yYorb6E4PJFQh3XuJBSvs33OmXlbZ0SGxY4oOWO6QG2I854mmjfx+3QGgbV1CNW0eiOpua8uC Aq7qqol15XrZjGJQ2+Ukb/dFmhbzttqfYKQEkmXHUaMXXQFolBlxRAyEiVOIoRKiLG7n7o6BY1yd +6Ypki26zTWmG5LMUR6rZW5uaZuI8Tfg5ADiIrTioZKQCIkakAgQvJfc53TJ2cuC826xXJZsfLnL R4UqPeDy57kMobycw/NmKMO7kPeG6bKu9dKWtp9i2xGpx9SSDAC8XJS5GgohLuvevfv31WUb3Q2K z7/Httuh32ZBdft0dy8tW0vAmHZ7QOQxcJVQ06nVbHdAVAJwUNQ5Iq6HTj3S9tyqw4+7kljvFku9 0h2x9BchoDL6S5AxUeZ3cUlZGQQAqkiFs42aIokhUBe1KpwPdBWk7veBYiSJ1uYCFHtTcUBKVc5r 0+4xCbaRTQFHe3qYkpCnDkZKgpumbG1/sNwdtjFosWUXSVJBTuEaHaVdds4pLKIXhQIW6Kj7bo8W +oqoy4aIoCpUBa1Kp8fdIYr4LMlO2zI243gqy7O571k4l+a8JCKKwuCkpqTzzAih9NVR9s0TgXNN gGt8E7lAtnwRzL3ydFHLjFGz8ztLRSVjg7I4mqEBmLiirKu8gbNxPEFSQC0KVR9190ha1k3S1Wa1 3GLfYE23gMe7RugkiK/dW4Dj4oJKYbEaqgui2aooEgKK71KM51qsmAX521Xe2XyUMOAxcrnOhQet Gt0R142RefPkioiE2aqgoRcRIuKiBqIFkUqpZPui8Oh3K/Q5fhzIWiNc5AyCBrhO97/9cBgep1FJ td08cAQ+JKCmIqSY56/WpXor0xiVjUSJcpMW9R71CIZLLbdrcuAuCLREgorQIex+NshCooabIBcV Koq/e6BksWq6zYGOXWxyoOL3e9N2/I7W7HdkrFZjOtEBgRN9NUkKhjy5iWwqgEipQvdDN2dJs7KY gs2yHMvsVWYEd2TKfWHdYkBggFF23JZSch71VSFR2RFSgL1pVNPe6VxhhqIy5Z8iG+v3KbbTsSw2 xmtOxQBx7xVcQHdm3WTEWTcNxHR6YmvJEuNs0dATFCRCRFTkKiv/AGoven91AfqlKUApSlAKUpQC lKUBjSLjDiHwlSmGT234uOiK7f3KtePv3bfpCJ+/D7a55m4fjeR6u6pyMkxuxXx9iXaG2nLlao8s mxKDuqCrgEqIqinkrO7MMC8wMM9WYP4VAXx79236Qifvw+2nv3bfpCJ+/D7aoyLpZgL0htssAw3Y l79sZg/hVUmn92wrMbXhx3XSXCrRd7pJMLvDDGYrysxitsidGkxgFsjcB5tjZEVFXkLobchoDs73 7tv0hE/fh9tPfu2/SET9+H21xbLyfTe4R4DOF6UY0/eH8gtlrlxLrh8DlEYlsuPo+oMKvJeky5s3 zEgJFRwRVOJZ/vtpkWMP3FjTHH5b0bH27jKucfAo52mNKctyzm2HD49bZW+JLxFUFHAEjEiSgOw/ fu2/SET9+H209+7b9IRP4gPtria837DrZJuzKaYactswQu5jKdxdkh4Q4FvktmrYt8vHKcSEm6Ki CPxoqrMWX9Gnctk2J/T2zQmI0+4wTusnCoAQVfggrslpHUFS5C0JmiqCCSCSIu6KlAbLNrUGYlrH ZbbdIkaRMzCyug4t0CIYgzFtLzhA5vuJILR8ST/aRPjSoxqZpHb5TNsl4hLj3wo92enXaLd8ghy5 F2JYysRzN+cEhpegikggbaoIumobH3rpLKSZPiV1yax6Q6SRodhYVydbbhYB8KlujGbmOssuA2gM qDDwChOCaE6hdwjW/tN90Yv8G4TLNprAkpboC3CdFDAoZvxmVFomOQoGyq+L4E0oqokKGSqAgSoB h2HRpLXeYVynS8XlXS3TsP8ABbkt2adfbj29psJqAaoKohcSRERE6gonJO5ETXYhpNcLAWNsXmBg +QPhDtjSXOXfgFzHyhzJDzng6iiOOK6jokPEgFT3F3kCbLIIt10hnwWn7VpdBu0lZM+PIt9vwe2y ZMVISgkl0+Cq0TYq60iE045zVwUBCXdE09wuWHRLycGJpfp5Oa5vCDvwYYZXcMhYtfBRJvfdG3lN V7k5p3Jx3SgPzD0mvDGIzLWV1x3wl+DEZBUvTWyG3iUi1Fuu/cnhLo96b+JuXxbVv4+mLUfJ7LkQ OYwF6hZTZpb1wG5MeELbI9nbiSGBc33VFeEl6fchIu6/FtqFyjSC325uReNObDKUI7s2dKtOCRDi woiXF+ELzvURDFENnxkFDL9IkFRRdrUe0rwRh5xpzAMMQ2zUC/5tQfKi7L/4KgIPmVlygLrlzWIT bS/Fy84kpq4R8wSzyLTLYhpF/PK3yJ+OqADiCCou6EBJsu9TTTZJLOquBRLrOjXG7Q9NZEe4vx5I PCckJMAXC5CvkIxJUXZN6+9mOBeYGG+rMH8KmCYzYsb16sw4zYrRYxk4XcifG225mIjqpPhoikjY jvsnk38m6/LQHQ1KUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAU pSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlK AUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAV5SWifjutA85HJwFFHW9uQKqbck3RU3Typui p/UteteciQzEjuvynQYYaBTcccJBEBRN1JVXuRERN96Ap6R7mHAzxy2WS2R5VkbhWiRZ35VtVqO/ cIzzCNOpKJG9nlJRB3kqb9QEL5UXa5loRjubFdjuc67RjulwfmvlGebRUV61pbHWxQmyTgTCIvfu SH3oSJ4tc8xdYc0xIsvziexcoULN8bm3vG1vTzT0PqxFJyI1HbZdXpdS3m2bguoBk4waopd6JvM4 1C1AslnzaNfMitV+tkF+9487HGzHCcfULA7cwkdVuRyAhJEY2HbcPG3E+9AL6zDSGy5bb0ijJlWQ nHkdmuwGYxe+KdIm+Etp9lxmQOxck6gEokIqKoqVDJvuVMRlI03HvGQQYrMduMzHaejGDQDBagmo K4wZCZsR2RVxFQx4btkHI+UVvGr2eWe85DcLS9b7narZfLvYIdhG2GTr5xbM5PZd66Oc1NXGekoo KoQud2xIi1o5uvV+gNxYUTUnGLvZpV7tcF3MhtKNxYvhUac48xsjqtK42saOSKS+IkgUcRdlVQLA xH3NzdhyqdKnZFdnsbZesjlvtbc0eEsrbEZaZdmJ0kJXBdaE/wA0YgfBvmK8dq9cn9zpbxwl22Ye Zybuzh/wTt7l2mcWWY6uCYyS6bSqr7ZALgqKIikCJ4m/JKyl+6GzsXsbCHPsr5OMtrD5x2ogZKRX WTEE20deV0QOPHadFI7bxIUkFXxOKFtsu1Ny0bXmaXqfAuFmudhzbwGC1EOKURbTKVhpVfBzm4rg EvJUUNth47KiqQFrPaAY14Bbo8CddrZItUG0RLbMivNdaGtuKQTLwc2yEjJJbwOcxITElTim67+U f3P9mgSYMq05LldrlgijdH4VyFk7yizSmL4Soh3Krzr68mekXF9wN+CoKVRmWsF0dmZHDm5NaH5b F78GTEve58JEGPHvEVhqU4+04Jojrbgu+OoiaPAgISCaFp7VkVxbzeQ29cZ05gbiw0LL815W9izt 5hD2Q0TkLaCKfFsKCqKHi0Bc0f3N2NsxHIjl7yWRGjxli2MHLgH/ACC14W3KBIio2i+I6xHUVeV1 UFhsN+CKK7JvRCK3c41zTM8098lQQuckbsIndWwlFJbae4tojYAbjgikdGdm3Db/AEV2qj42u2oY 4c1fpmRY20V/x+XOiDLtyxWba6xdYsNNnlcVFVxuUve6iNg4AERI3z26A0UzY8/0+hXh+W7PeSTK inJciNsdVWXza5J0XXWT7gT8404TZLuo8f0RAh1l9ytiNjlg9Eu1/JpllmOxGV2MDbbTU9mc2niM CpkjzCbuGpOEJkhGS8VHaZrokWf5/dbpe79dIOM3CxW+2S7ZbZYtJcUYlyXnGpKK0pdIkdbFFbcA lEnhXuLvt6lAVK97nnG33sk3uV4ahX2BdIRwmijttRkuBqclwFFlDM+SkodYnBDmSCiIu1bG+6G4 tkt5utyvXh8lLtMOXNi+E8GnVO2HbSDxUQhFWHC/RJC5bKiondVk0oCovye7VKizm8gyzL8ikTLL Pspyrncm3TCLKZYZNAFGkbEkSMBISDuRkZOdRV3T3unufMXu7bjcmXdhByXOlkjcgE/OS7jGuDmy 8N0RHobaCnxCRou6qhJa1KAqLK/c74/lcHIoT96v0GLkU+TOuTLDsdxt0n2WGiHpvMuAnFIzagaJ 1G1U+BihKlWrBhM22FGhxBIY8ZoWmkJwjVBFERNyJVVV2Tyqqqvx1kUoBSlKAUpSgFKUoBSlKAoa 6WvJ7DqRnc9jCb7frbfH7c/ElWyRb0HZmKrRiQvyWiReS/IqbfHXp745L6MMz/f2f2+r1pQFGs3b JmXBMdMMz3Ffn7P7fVfHpRFeYxRuRpTqCbuMWWTZIkkbjZW334T8ZyOTbxjMRS4i84QKPHiRKqdy qi9Z0oDkOw6Pjj8xqXH0+1PlOtSoEoEdnY822Jw2X2GNm2ZDYinTkGJIiJyVBJfG5KXuOlj7Vles kbB9Wotlk2xuBLt7F6sjbMpW7f4AMhxElcup0OO6ISNETYETaqNda0oDkq6aUjdwuAStNtSk8Obn NuqFzsiKgyosWM7tvLXyBCZUd99iU1XdFRE97xpot7jTY8rTXUltqZdrrdXejc7Kiq7cWDYkgirM XZtW3DQU8qb+Va6uptQHId7jt5Tfc0jtYjqxbmJ0liJlVktU2ztwZTvgzRcSQpJk2rkZxkHCYMOY bIS8kVawZuA2ieN8Q9NtUGff1CS5o3Js6tyRF1pyMBNHJJtAjdBsGQQeIt8wJDQy3tOAiLneqm6f /GaL/wDsa31uNk+RKApeBhw2tqT72YprJBmSZM55+dGmWNl8wmCykllOLqADZlHaNEARJsk/NkKd 1ZLmKwXJxzF041PR0nXXU/pVpVEVy6t3RU75Sr/p2hHdd14boqqS86t/ZPkSmyfIlAUo5gdrcst3 tK6can+C3W0lapC+E2jmjJT3pyqK+Fdx9WQabqipx2TbfdVsiTml5ekOuu6ZZ0BumpqnC2J5V3/b ay8tyiPg2KXvJpbYPBaIZyG2S3/Pv9wsM93f47xNh/8ASqi8XyLPcHC26eXp5+15TccitSjNvyxb m+kWew8Es2wZcIFEJ0V1QQlVRF0UJO+gLk+GF29Gmc/Vtftta+35HkMDUm2ZUmmOaHboePzLU4H/ ACb1FeelMPCqJ4ZtxQWS37991TuXypT1o11zB6141Ivl8x23tZIxCkFcHbKDTVqaO4OwnSVFPie6 Ni6qmuwluibB5No7qlehlwJg3WxK+9Zjglkiw1GIEf4SDCS6rHV7oo30vzuy926ovLp+LQHR6ay3 Uk3HSbP1T5UC2bf8bQtZbqG3PSfPx38nILYn/wCO1z6mUSLtl2KkF/h3xPhDjTC3e0tPQ2bi34be mlVWuXTUVRgeStorZkm6KQ8NtZpzleRSY+PWSxXGHBm3ccTgO3OZEKe4IvWSVIcPg45wU+bIoioi J+sh0B0qOs10PfhpPn5bbIuwWxfL5P8Ax2vi60XMVVC0oz5FTyoo2tNv/Xa5iLUjI8/xq1yYXUK+ SLOFjZj2cSZJ+53GU8Dzo7mLbZtW+3uOjzJBbKSi7olbUc/y2yYoljt01u1XzDrPkL10avlvZnSp LdtGM9CAyBxQRXY0ppDdBSRVE1Fd+9AOh+2m5einPfq2v22vqa0XMlRB0oz5VXyIg2v22qFn6l5H aby7jeTZbj+OgzOd62XSbG2McEW2xZjMTwcjVtCIpDqIpFzMGFQVU13rU37WPIX4Nyh3SPBhQ5mF Fc3zW1vtjHuR2d18rL1RXuM0RJImpi6Le7W/JRWgOkE1nuilxTSjPlLfbbhbN/8ADw2v12x3dV2T STUFV/8Am7Z7bXOeU6j3A7LmUR/IrBFCFZZEKNipwXCmTGQsYy0njIbcV8BIyVEUuLaCCopdRUVd flF+lwSzR1ZTslti95QAMyJDyt7JdrG2A+IYkiALp8UEkRN1+JVRQOme2m5einPf8LX7bTtpuXoq z3/C1+21WOPZfkU/PIDF5uFum2a/vZO3FisWsI7kFbXORlsleElV1XAVeW6Iid2yboqrY2yfIlAZ HbTcvRVnv+Fr9tp203L0VZ7/AIWv22sfZPkSmyfIlAZIaz3NwxANKc8UiJBTutad6/8A22plgWaQ dQ8Tt+R2iPMhxJvUQWJrYg82QOE2YmgkSboQEncqp/XUPtaJ75we5P8AWW//AG0ry9zP/wBS9h/8 5uP/AB8igLZpSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUA qs79rKFqyq749acMynJZVoGOs1+2Nw0ZbV4FMB3ekNkq8RVV2RUTu76syqDYTfVnVb/5+yf8G9QE l7abl6Ks9/wtfttfV1nuY/paUZ8Pdv3jbE//AB2tFk+TwsIxm85NdRA4lmhOTCbJUTrGKfm2k/rN xQBP6zqhMZyXUDBOlg2Rm5a8pvF/sz7Mm+HGuTqNT+TE8mgZMm+m3MZImxVUVBdFCRN1oDpftpuX opz36tr9tr6ms9zLfjpRny7Juuw2zuT+NrmO262ZkkCxvXq+49HavrYKs92xtsNWsG7yNtdeJFc4 mhASvKhqiAQ7CqDvtt5eqF8nWi3SoE2PdLrYVuz8SXbY4ixfJayitVmcQEPggOvOPuqCEoqsZSTx dqA6FLWe6AqoelGfCqeVFG2Iv/G187abl6Kc9+ra/baoHDLrlVkbgaZBdJdhv0W/OsNzMihR7pMS 1PW+TNZdJQeJl0+tGkN7iaoKcUVO7avkHVHKvArGmRZHj9pj5HBsNzcvxWRtqPYWZzM4zaIScIHP HhtNi673ITy7p+ilAX/203L0U579W1+207arin/yVZ79W1+21Q1r1ivk654LEekW/wAAvygN2ujd kdFq3Ak2QzFf7/EAbiDQi2jhbNKvNPFIavFwUTmijxXv7vk/qoCZ6f59G1At1ylRbXc7M/bLi7bZ kO5A0LzT7aCpJ+acMFTYx2VCXepZVT6Gf6XU3/fq4f8Au2atigFKUoBSlKAUpSgFKUoBSlKAUpSg FKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKA09gyuyZUlyXG7pFuoWyYUKWcVxHAakCAGTakncpIL g77KuyrsveiomY3dIb10k2tuQ2VwjMNSXmEXxgadJwWzVPkJWXET/wAhaovL9HH5OLZ/aIGOA/ab vl8G7x7dapUaKRx2o0FDIW3myjOF1o7iqy+PTc7+RCqoVa/THR/LbNeYky6sRMRnPYzBivXWwNwz caJiZLJYZA+26go4w/F5q14gnFQQVAFtKA6QrTXfFLRfXbQ7dIiPFaLgtxhcTIEbkK262pqgqiFu LziKhbovLdU3riHF8Cl5o9kWL4QzCjZWOH3m33/JWDfF+5TXbpHLjNR1oTjuvCzJ2FxSNBM1QVbB tTsS1+5xm3mVZVyHEYDePMS73KCzXJ+IXgivwoseP+YiNBGFVcZdcVG0JBU0PkrirsB1gTQGQEYC RNruCqm6iuypunydyqn/AG1+tq57yrTHKJunmk8e62SHnbuLQGwvuNzpTfSuUlYCsI6rrqKBK26q luSLuhESbkIosIXRLJMcyGVe71bUcat0NyW3cYElh8I8ULKsT3uFXmlnPbOoqoKmjZiqOLs7uKgd R3/JbRiowZF9kjDS4zo9tjn0iNXJDx8Gm/FRVTci23XuTfdVStxXHOn2id5v+B2EUwuz2CxS2sPW XbHTaVLgMN0n5s11pAVFJ0HRb4mqmfTXntsO/wCNRfc+5vcrcxa8bx+2+B24LydiOJJjsOW91y8O yWB5OiXQbWN0RbWMIuIaKBmAIioB1pY8htWVRZj1mkJMYizZNvkKrRCgvsOE06GxIm+xiSbp3Ltu iqnfWzabBlsGmRFtsBQREU2QUTyIifElcrZtohlNyhS2vgzasnGaWUMRGJMhoRtcm43BZEa58jTf cG9hLp7uhxThvyLaJ6s6VZTYl1Kv62U5LNxskxq5XZ19qW5clKPFaYSP0xCS0puNKrkd3qMNIm7J Iq9wHbG+3lrDuV0j2llp2Z1uDshqOPRjuPLzcNADdAFVEeRJuS7CKd5KiIq1y1M0Yv3Ucub2mVou mLldp0iLp8Nyjx48UnIUWMzLXYUY5c48klFOSgkxXB3cRRXPsegGUQbitzvke13K/MuYa0N3WUrr 7jVvNgp6oZihChE0q7dyubCpd6IiAdRUrnPQPQq56U3zGpXvdAtbCYWsC/eCSVJZl08KBwXXE/8A CKgK6iOL3ohcU8XZE6MoBSlKAUpSgFKUoBSlKAUpSgFKUoCk5twznKdRc2tdgzJrGrZYHYLDDAWN qWTiuxkdIyMzRd9y2RERERE+Pfuy/gvqV6VV9VYv4lfcS2HVfVtSIB/p9q/SNB/+Dx+Vf/376n/N v55n98H20BX/AMF9SvSqvqrF/Ep8F9SvSqvqrF/EqwObfzzP74Ptpzb+eZ/fB9tAV/8ABfUr0qr6 qxfxKfBfUr0qr6qxfxKsDm388z++D7ac2/nmf3wfbQFf/BfUr0qr6qxfxKfBfUr0qr6qxfxKsDm3 88z++D7ac2/nmf3wfbQFSR9Kcxi3C8T2NTDSTeJYTJpHisJxCdFhphFRCJeKdNhtNvlRV+Nayuzr OvScnqfA+2rR5t/PM/vg+2nNv55n98H20BV3Z1nXpOT1PgfbRNOc6VURNTkVV8n/ADPgfbVo82/n mf3wfbX1t1sHAJXWdhJF/wBMHxL/AH0Bz0N1k/CQbD209Oadz96W3zwFgIZ3BEUvBBmKHg6v+Kqd NHOXJOKJy7qkeTY7leF2KXfMn1b97bVDQVefXC4bnFSMQEUAEIiIjIUQURVVVTZKw9O8dzfCIVl0 8ZtVkcx20XlyWWSy7i1JCVC8LOSIhF8VwJaqaCpluAKKmJEuyVVePe51ydLXdLffokV51xqCzdH5 d3iOsX2QF4ZkuSuAMo45+YB785KJXUWQbaIoqpKBcl10XzDIQtyXTUZyQECazcIqJikNvpyG0LgS oip5OZeKXy+StmumuoQjwXU4kTp9Pb4IQO8NtuPl702+L5KpWw6UZvY7vld2fwzFrvJulouUV+2y 5kP3snzjubb7D5Ag9V1kWuRIsgydUhIPzKKhL4ydDLuGPxoNpwS2GR2OXabcMy9xAWyXJ6Srh3nd pOCKaK0uzI9RvwYGwRALdALSstryTIpr0GxavOTpER2VGcQMGjIDTkR0WXm1cUUBCAzFEHluqbqO 4oqpuz04z9lUE9T1FU22/wCaED4u5PjqrM20OyfIYOSxIzdrNm5P3tRAroII63LvkCWPJU7xUmI7 yrt5F2HfvSrNwCzzNOMlueP2zG4w4recinz4bsCW2Ea1RRiReA9LbYUdfF5EAVHiqquyoqqgHumm 2oKom2pxL8aImHwPj7t9t6+9mmoKov8A3TS222/6IQNtv8e+qtybRzI7uGcsQrDZ49+lv3F34Uhf +D98hSJzL4wCHbxU8Hb8HUXwNsOA8NxM9otP0lls+81hnYKxkgXCFlUm3Wa5XeEI2UHytzTTqKyA R2VQubitsb8Oq4YERjtQF2RcLzG8P3eBE1V8LdtUxuNcGvgXC2af6LT4CvJNiVG3mi3HdE5bboqK ied/x3LcbbhOZFq94EFyuTEGMp4dDPrS3z4Nh4qLsRF3brsifGqVFImiF6t2T2vJDdtN0y2Hk1ne kZE7MQJMqDHsrcWRuXeXE30cUm/KaFuu+w7RnANFMls625tyxW6zMjcMXlyR8OggKOW+U8coxSOK KaEjyK2TpOPGIfnXOSoKAXJ2bahclLtOPkrfT3+CEDfhvvx8vk379qxxwXOnbm/bh1QeWY1HbkuC uExEBG3CMRXqKnBSVWi3FCUk2RVREVFWl8T0CyyDa73CntLGusu3MwH7ql/joEq4pcBeC8j0Abec OOgk8JPmrym4TW3BVNZFG0OvUyDYLbfrfZ5kOLKsDd5GVdBkhcvA590emSj5bqav+FNPK2fxumC7 8VVQLLPTnPhJRc1PVF790XEIHx/9tfjs6zr0nJ6nwPtqQ6W44eHYPFskpIcVYtwuRMMMyQJtqM5O fcjgPf3CLJtog/7O23xVMObfzzP74PtoCruzrOvScnqfA+2nZ1nXpOT1PgfbVo82/nmf3wfbTm38 8z++D7aArBvTzO23AMdT0QgJCTbEICd6Lv5UWsbFtMM3w2wxbJj+qDjMCMTpAjmLxSJVcdNwlVUN E/SNfIiVbHNv55n98H205t/PM/vg+2gK/wDgvqV6VV9VYv4lPgvqV6VV9VYv4lWBzb+eZ/fB9tOb fzzP74PtoCv/AIL6lelVfVWL+JT4L6lelVfVWL+JVgc2/nmf3wfbTm388z++D7aAr/4L6lelVfVW L+JWizZnU3EMIyfI2dTAmuWS0S7iMdzGIwC6rLJOICkhqqIvHbdPlq3ebfzzP74PtqE6zuB2L6k/ nWlVcTuqIguiq/6q58SLQFr0p8tKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUo BVT5BpFe5mY3zIcWzZywe/QxfC4p2WNNHmw2TYkJOJum4l5Pl/vq2KUBTiaT54nk1RFP/wBUoH2V +k0qz5PJqntt3/8AROB9lXDSgKMvGhmW39mEzd9TCfbhT49wjiOMw2+Ehk+bR+LtvsXfsvcu61sU 0qz5BAU1T2QEERT4JwO5B7kRO74vi+SripQFPJpVnybbap7beT/mnA+z+ta/J6T54404y5qkJNOB wMFxKAqEPyKm3en9VXHSgKfLSzPyQ0LVVSQ0RC3xOB37eTfu/qr8LpNna776oj3/AP6JQPsq46UB CtM8BewC23dmfenb/Pu12fukqW5Fbj7uOICKIgHciIgJ/X5amtfgnWwXYjEV+RSSvnhDXzgfWSgP SlefhDXzgfWSnhDXzgfWSgPSlefhDXzgfWSnhDXzgfWSgPSlefhDXzgfWSnhDXzgfWSgPSlefhDX zgfWSnhDXzgfWSgPSlefhDXzgfWSnhDXzgfWSgPSlefhDXzgfWSnhDXzgfWSgPSlEXdN070pQClK UApSlAKUpQClKUApSlAKUpQCvhLxFV2Vdk8iV9r8OgrjRgDhNEQqiGG24rt5U3RU3/vRaAoyze6I kxbrerfqBjPvVJgQbZMVmzyzub0dyc8jLECS30wVuWpKJI2PNFFVXfZEUsvLvdJWKyYK7e7Pbbtc Ludruc5u1LANHovgRG08ssR3VlsZAo0R96b7qm4iRJn477n+14/Y4dkXJsguNqhXOHdGGJLcAF8K jyAfR03GYoG6Zk2iGThERIqrvy8ZPLIPc7WW9tzAi5DkFmW4x7vDuJwiiqUuJcZRyXmC6rBogi44 fAhRDETJOS770BJsi1ax/GY0UJTrl1vMiWEIbRZg8OlrIVtXTDph3pwbAzVS4+KPyqKLqI/ugMPm SrC3BK5So13jwZCzGoBqzCCaatwvCF8ravGKiPcu3cpcRVFXF1J0ukPraL1pjbLbAyqFdFlvTm32 rfIeQozjBkTqxZAOEqGKKjjReLuqKJCK1HsS9zBbLU3hlwvF2khfbLbLPGnpBZjKzKet5c2iRxxh XwTkqiXTNvqAgoSeXcCe4jrFYMzyZ+w2uPdmJANynGH5dvNliX4NISPJRlxe41bdIBJO79JNt+/b UOe6GxJv35Pwe+OQ4DisRJrVpdcYur4yRikzEcHdHTSQYtbLx3VeSKoIRpvMW0ns+JTbLLt0u4vO 2gLsDHXcAkNLjLCU/wA9gTfZxsUDbbYVVF5L31GH/c52ORaZVmcyDIFsfhBybda1OKUW3OlMGZyb bVhUd2dDZEf6qCBGCIgkSKBkzPdEYnDtMOckW9yzdSesuJFtxPv27wFxtuZ4SIqvT6Sujv3ryRU4 cuQ8vmOa5wrnmt0xu5W2Y0KXU4dquUNg5MOYCW9qcCdUUVOqbJuGgIi+K35dyFF0Uv3OrqpY7TaM ru1pskaz3qFcJkNIrU2SU+RFcJsR8GVltriy4idIWyDi1x8i1LR0Oxtth2PGkXSLGK6HcW248pGu iRWpbWjbZiKGADHXcVQuaGiLy2TagI5J90Xb5b0CJYLRPbuS5DarbcIV3YOG7HizkMm5SJsSLuDZ qgKoknFUNAXbfPh+6Qw+daZM9pi8tKngZ2+NIt6sPXRiW90Y0iOJkiE04fchGocd0U0FCHfW4v7l vFcYNDbut5mEku2SUFwIbLf9B6yMt9NmOAqJC+Ynum5b77ou6r6x/c2WlmzyID2U5DNNLVEs8B+U EJzwOBHIiGMjfg/TebPkiOI8LimgBuu4otAbt3XnGo9ztkCZBv8ADcmNwTkHJs7rI27wt02Y6SuS IrSm6Ctpui9+yr4vjVjPe6MwuKV9OWVzjwbTHlSQnnbzWPPaivCzKKMab9VGnCES8m+/IeQ+NUcs fubxtmQvslfZjOHsRLK2xBZJgjnnClyJW0rkx4gI66HAGCbHgihxEUFE2cn3NNgnQbjbZ2QZA9aX 4s+JAh84wja2ZkluQ+LBoxzXcmhEVcI1ENxTy70B+nvdEWm1uzWrrab29NOS4MG1QrQ+5OFpqDDl PI+2SIgOCktF2QlRR4oiqe41bFkvMHI7LbrzZZCS7bcorUuI+gqKOMuChgWyoipuKouyoi99QiVo vYpeYS8ncm3QbhKcmmYC8CNIsqJEiubJw37ghNKO6rsSmq7oqIkuxLG4uG4rY8ctjjzsGzW+PAjm +SE4TbLYtipqiIikqCm+yIm/xJQG4pSlAKUpQClKUApSlAKUpQClKUBQMLB8Vy7V7VN7LsXsWQvR pdrbYcudsZlE2CwBVRFXBVUTfv2SpR2MaZ+jbCvVyJ+HUSaymbjermqIQMQyXJ0fl2sycs7UUhaV IIpxLrPtLv8AH3IqIip399b/ALT7z6KNQv4a2+20BndjGmfo2wr1cifh07GNM/RthXq5E/DrB7T7 z6KNQv4a2+207T7z6KNQv4a2+20BndjGmfo2wr1cifh07GNM/RthXq5E/DrB7T7z6KNQv4a2+207 T7z6KNQv4a2+20BndjGmfo2wr1cifh07GNM/RthXq5E/DrB7T7z6KNQv4a2+207T7z6KNQv4a2+2 0BndjGmfo2wr1cifh07GNM/RthXq5E/DrB7T7z6KNQv4a2+207T7z6KNQv4a2+20BndjGmfo2wr1 cifh19DRbTMzEezbCvGVE/6ORPjX/wCbrA7T7z6KNQv4a2+20HVC8iSKmlGoW6Kip/Rbb7bQFa4R jVoz523ZLj2immUzAbnPdixwC1sBc2owSDZ8Oc6jQtKO7amrI7mgkmxEXi16Rr/7n6VGmyWdN7Gb LTLUiEoYMwa3RhyWMMXYgiCk6PXcANthJeYqgqhIq/mHZlhXGEjOAavDjMC8+/kPGhCzhAZm9QnU JFGQjyti8fVFlXFBDRF22RESKlpw5Z7HLgYRp9qjbnXJVtGIbjFlaW3xGLjGlOI2YO8nXUFjxDf6 q7iAquykqgb255Do1bJUJ49HbI7akgXR27IGGxjmWp+E7FR0ZDKDsDYtSeoR8lRU4ceXJEWSTw0P gZRKsAaYY/OfYMowyo2HxSiPT/B1kjAB5RRFkE0iEg7bbkg8uS8a0rGOsjbrxHm6davXCZe7beIN 0nvpaOtKW5Kx13lQZCAJiMVkGxEUARBE4r5aymLW5GyqPeS0+1Zet4XQL37zGzZVjHcRipGSSRJI 6u/FOfDmg9Tx9vioDGxS+6GZGONNzNK8ctMm9x4KErmLRCix50uN4QzB8IUBQ3TbVCHYdlQgRVEj Qa88VvujF+tWFTbzo1aMeXKvBW2Sfw+M5GZkSScGO0r/AE059RWlUSAFREIVPhySsLF8Gh4te7Dc oenGq8j3mSOQNPw7FykOR44R2CceF4XthaaaRWwMQImxJRUlJS1Ns0qhWy5WOY1hGsr6WV63vRW5 DFhcVPAnOUZvqK71BbFE2VsCFCXcy3NVJQLCwZjRDUK6FAsGmNibU4bs2HJm4SxHYmstPIw+rLig qErbhAJIuy+OKpui714ZjhGPnl7WG6Z6SaZu3Zu1DeLhOvtkZCI0ybpssMgDLauG44bbiqS7CAhv 4ykg1p2LNcLFYYMHBML1Zx65Wy1TbZbri5HtMkmG5UxqU4ZAspEMkJlAHyJxJd+/YkkGUXC5X7Im MjtGBas4rf2oZW85tqjWVSfiE71OiYPyHQXiXJRJEQhUy79lVFAxVb0gtUu02zMtIcbx+9PMxCvL AY5Bmx7G5KdVmOEmS2nBEddFRAkRe7YjQEWo5Zch0jL31PK9HbBbmol0mA45Gwpl1u225qUcRuTN c4cQU3mJHcHLijZ7psBFRcCtLN5sdwtuluqUALWxb2XGAiWRxZaQ3SdaI3nHyeAiIlRxWjDqCuy1 k3XFWLm5PAdPtYYUG8uve/0ON70AF2YcnSJvQdLwjmAI5LeDdsgNWzUFJfKgG7lM6NO3KRZrPpvi Hv3BuUSHc2JuIMiEFHrkzDEXSBtUFx1HSNhN1QxHmqoG61oLRfdIpg3CVeNHcatTLMpq3xrcOJsP z3Zbk+fEbFRRpA2PwHbZC3A+YkuyCRZsfH2I97n3pNO9Y3LpdZ0addXnXrYaTno05uZGUwKUoijK tIyCAg7Mkod6oJJ+IuNxo14cuXZxq86a3uPeGmiSzoDJszJksWh4yEJW1duEhV5KpbcE5Jt3gWBi WAaS5pjkK+2jTLFmYspXQVmbiceM+w604TTrTjZN7iYONmCp3949yqnfW67GNM/RthXq5E/DqNYz ls3E7MlqtmlepTsdJkyZykMWwj5yZLkhxN0mImyG6SJ3eRE3VV712/afefRRqF/DW322gM7sY0z9 G2FerkT8OnYxpn6NsK9XIn4dYPafefRRqF/DW322nafefRRqF/DW322gM7sY0z9G2FerkT8OnYxp n6NsK9XIn4dYPafefRRqF/DW322nafefRRqF/DW322gM7sY0z9G2FerkT8OnYxpn6NsK9XIn4dYP afefRRqF/DW322nafefRRqF/DW322gM7sY0z9G2FerkT8OnYxpn6NsK9XIn4dYPafefRRqF/DW32 2nafefRRqF/DW322gM7sY0z9G2FerkT8Oofq5pFp3A0j1BmW/T/EYUyLjFyfjyI9hjNuMuDGcUTA kBFEkVEVFTvRUqRdp959FGoX8NbfbaiGrGo91maTZ/Fe0zzm3tyMZuTRSpbEAWWEKM4imajLIuKe VdhVdkXZFXuoDpP5aU+WlAKUpQClKUApSlAKVqcpyKJiOMXrIbqjpQLPAfnSUaFCNWmmyMuKKqbr sK7JulQPtiu3ok1C8n7PbvbKAtKlVZ2xXb0Sahfw9u9sp2xXb0Sahfw9u9soC06VVnbFdvRJqF/D 272ynbFdvRJqF/D272ygLTpVWdsV29EmoX8PbvbKdsV29EmoX8PbvbKAtOlVZ2xXb0Sahfw9u9sp 2xXb0Sahfw9u9soC06VVw6wXct9tJNQe5N+9m3J/+GZX57Yrt6JNQv4e3e2UBadKq3tiu6f/ACSa hfuLd7ZXztiu3ok1C/cW72ygLTpVWdsV29EmoX8PbvbKdsV29EmoX8PbvbKAtOlVZ2xXb0Sahfw9 u9sp2xXb0Sahfw9u9soC06VVnbFdvRJqF/D272ynbFdvRJqF/D272ygLTpVWdsV29EmoX8PbvbKd sV29EmoX8PbvbKAtOlVZ2xXb0Sahfw9u9sp2xXb0Sahfw9u9soC06+L5Fqre2K7eiTUL+Ht3tlO2 K7bf9UmoX8PbvbKAh2E6d4dlmSakzspxDHb9P+GUlgZNytLEpxASNF4hzMVVBRSXu8netR+x4Vbc qui3jF9FdL52EDd3bYjblsYauTzbMsoz8wN2uiggQGaMkvIhBfGQlQVz9Os8usOdnrsbTjNpvhGX SniRhq37sH0IyK2XKYnenHfcd0VFTv8AKiYCWeUN4J4cH1gTHTvaX8sb61oWB4f1Ee5oqyusjXXT r9FHen1FVeO3i0B4N5F7nt2PPkhpzYiisMhIhvN4Ow4NzYKYEPqReIKrqJIcbDbYSXmJIiiqKuvu +R6O22fZ22dGLRKZfau6XWKGFR1n25+EMYyA2ePHj05PNS5Kipw4qqkiLo5GlLtrsM224Np9qdbD ekQhhqYWNpbfEbuUaW6jboPdR10Uj7Nk+ripsIqqIpKsth4wDD70ybp9q7c7pLauoT50l2zq5LOe 2w06ZIMlAFQbisg2ICIig94kvfQGw8I0GO+NW2HprYJ7DyMgzcWMLjpDelPR0kswxeMBRX3GSAhH bbdwBUkJUGtVit+0MyNvFxlaU49bpd7YtyyRTFIj7FukzQ5xo7zyAmxOoiKC8dlQ21LhzFF+2bFP eW52Z1rANWpFotcuJcRtDyWPoPz40NuI1JcIZCOqSA02aihoCuCh8firV4/prBxy8WS5RNOtVnnL WEFCR5iwEUooSCMUjdR5HA4NttNkLRNi4jQqaKqmpgbTE7to7kdiw+5XLRa02QslVkNnMRiuMwnH pRxo4uPcB36rgLx4CSoKoRoKKirvsNhaJ51e37VZNL7C24MeRIjSJmFx2I8wI76MSOi4oKhK06QC Sdy+Oipum9QOLpXHgSrQ/AwjV9o7SzEZik4xjr5gMSYUqMguOOEYIJlsSAo9RBHnyXdVkzdqudns jMTCsI1SsN0hQLrDt9xcas8hY/h8xuW64oeFpyUTaERTdPFVUXdfGQDKzLC8ZLMo2F6a6T6Zu3sb T78T5t8sTQRWI5PKy00AstKZuOGDm67oICG/jKqJX4dTSCxvWqBnWkONY5enWIzl5ZTHIMuLZFkP Kwx4RKBOCC66KoCpuqJsRoCVssok3O/5HFyW0YBqli2RR4hwPfC1s2MjeiE4jisOC/IdAhQkUhXi iipKqLsqosQc07tg3CxSYWl+qERu1sQmHm0ZsbpzRivG8BOPOSCdAzN0+oTRtqYkor3bbAedoyHS UTvy5Zo5j8Fm3Xaa2RwsLakjAtjEgoyS5ho3sKE8zI/QQuKNH3KjZFUgui6Lt3CfZ7TpxiCX223d i3XGPPw9poYiHNjRxNzi2q7PDJE2CRFFzvXdBA1HW3TDguJ3JGcB1ft0W9nJG/Roj1nALrHemPy1 juqslSEUclPChNqB9NwgUl3RU9puKtzr/cb6en+sLdyutwam3MhlWkm5isSmZMVs2ylKKAwscW2+ KCSAbiKSqalQHhZ7npJO+EEq66QYxbIlpMI6QgxNmTOdeO6ybe2ogLSCSGbApwFVIT5iu6IhFYmE YFpFnNnj3W16Z4oy0ch6K/Gl4tEZfjPsuE2604HBeJiYqi96p8aKqVCIePDEu12uK6d6svncbnFu HScWy8GCYurtzFsOMhFUFkvu78lIuJIKEmyLUvxPIpuHtTmbZpZqO63Ou826u+EDaiVHZTxPOCO0 xNgQiVETZV28qqvfQE30I/6j9Nf91LX/AMI3VgVDdIrNOx3SjBrPeo6xLlbset8SWwRIqtvNxwEx VUVUXYkVO5dqmVAKUpQClKUApSlAKUpQClKUApSlAK+ESAKkSoIom6qq+SvteMptx6K82wTYOm2Q gTrfUBFVO5SHdOSb+VN03+VKAi2H6n4vnjsprGLi5JOPHalEj0J+L1I7imjb7SugKOtErZ7OByBe K7LW0nZdZ7dfLNZZcxBuV5J4YLQNmaOK031T3IUUQ2DvTkqb/FvXPrGiuZZTMusrM7TYIEecWPRL haQuTtwhzAgXFJDzrIPB/R45NE4ARe8V5ry4qm5+2P6FZFF1Lh3Q7ZZbG1b5d/VzJrdKFblOYnq4 sXZtWOCFHEgBBc5iPTHhuO40B0p1QR1GuY9RRUkHdN1RO7fb5O9K+A824TgtmJE2XE0QkVRXZF2X 5F2VF/7Urj3LMOdHWe12goI5fkbeYWS6Bf7lFdC5sW5lhpHRAgitxyYEmTIiB1B5vKKh1dlL1xP3 LuRRIkyBkUeDLbc97o9ycfnMuNXsWrrFlvPuttxWzJVaZeRFkG65yeIOXHcyA6+ZebkNA6wYutGn ITAkVCT5UVK8hnxTaYdCSyTUhURk0cRUcVU3Tiu/fuiKvdVEsaJXuJpLneGW5LXDZuWSyLhaIDUh xuJ73FLbf8CPgKK026AONmIIoijpbISbotb5n7mnKsiSNNtFgsFljyYk2JGx6FNZCNZHX3AJJguP RXkRxUBOaxgZISbDpqvIzQDrK+5FbcbtF0ut5lDHhWqE5OmEiKZNsNiREfAdyVEQC8iKq7bJ317R r1Al20bizLa8CJsXOqZcEEVRFTly24rsqdy7L31yLbtFshyxzO3LPi1msEqTfsu2v775tS7kEkJk ZiOYdPl0eo827y5KOzIEKKRLtvLj7m+8WkH2MZsONnZzWxEVtaVgUV2NGmNSHhGRGdZ6im+wqmbZ kTYHts4gLQHSwZLazvNztHhQjOtcNibMAxURaYeV1GzU1TiqKsd3yL3ce/bdN9gstgTYAnm0N/fo ippu5sm68U+Pu7+6uWoegeYsYrYI15hWa9+8lssMOZZHbgZxryFuduaE0ZkCIgKkuM82LgqPNpAJ EROVflrQLKI9/wAGuMfHceiP2+Ur6uNy2pEe1MleHZ3gosOxt+LTLiNtORiYLmOxoraDxA6nSUwv W2eb/M/6Xx08Tu37/k7u/v8Airyk3ONGtxzyMnYwM9ZFYBXiMdt04CCKpqvdsgoqqqoibqtcX6Z6 F5HctNbBJtuF2GxixZo6SoUmSrTmSqlyiS1bmirC8PzMZ1vx0PxpJDsjaLvMo/ubLrcI/hFxs+Pw 2ljZG/a7J1Scj2KRObhhGbZXio+Ksd5wyAREDeLgK9yqB09BuTFwjRH2VNtJbCPtNvtky7wVEXxm zRDFU5Duioioq7KiLWXXNuO+58ulnvGMXzwSxtX+2ZHbZMi4tL/SFtrNhagvRxe6fNRV8DJG1VBV F3XZV2rpJPJQClKUApSlAKUpQClKUApSlAKUpQFPYlt2sat8tv8AX7T5f/R41P8AxP7NRq76RlNy i83+x5tlWMSLyrBTWLYcNWXDab6YEiPxnCFeKIi7EiLsi7V49k179Leff42v2GgJX4n9mnif2ain ZNe/S3n3+Nr9hp2TXv0t59/ja/YaAlfif2aeJ/ZqKdk179Leff42v2GnZNe/S3n3+Nr9hoCV+J/Z p4n9mop2TXv0t59/ja/Yadk179Leff42v2GgJX4n9mnif2aqfHsVyW63vNYMzVXNxZsF7at8VWkt YkbZW+JJVTVYS7lzkGm6beKgptuiqu+7Or16V8++tavYaAnXif2aeJ/ZqC9nV69K+ffWtXsNOzq9 elfPvrWr2GgJ14n9mnif2agvZ1evSvn31rV7DTs6vXpXz761q9hoDeZw1dnsGylvEFNMjOzTBtKs mIGktWDRniRKiIvPjsq92+1UDYLth1us02X7n/E7kmaWTD5xzhZtrjPSkg2HBi5CQp4RLV0TUA8d xVA1/RLdbi7Or16V8++tavYadnV69K+ffWtfsNAc4Zq/lepeDOSDyOVk0O33ue9YpdtZZkOOuBj0 x4fziQWBI25AIAG22JATxDv1WwMJ1Ycgv8pbDe1u93y6w23IWGbXGeskd1xxlvGHJKyG9mG3SeN8 1bReQ968O7ktWr2dXr0r599a1ew07Or16V8++ta/YaA57xTWrUy6Y3O95LoWT5GS2KRYITtuZfS6 HICR4ZEccCPHBptpG+ZkJKjJt9NXiVVCpdZ9TckeyewQUzSddJz0yxMwLSWLtsjfbe+20U+4O7Nq TRNkcpFQDAWFiCBiSnuVrdnN69K+ffWtfsNOzq9elfPvrWv2GgKHg6mar27B4d3nXmfdZV1xl25v rJx5ppLSYXeNHM2xajqSIER51xeoDuys9Tio7hV16IZDfsmw6ZMyy4xL2oXiWzbbnHBdpsIVHpuK fRYB1UJXAR1toQNAFU3XdVzezq9elfPvrWv2GnZ1evSvn31rV7DQE68T+zTxP7NQXs6vXpXz761q 9hqtMquWU2rI7rZ8PyPVXM1x9hl/IHID1laKKjoK4DLDbkNCkyOknU6YbdxAnLkSDQHQvif2aeJ/ Zql35toiXdy0Tdds3i3RmAs96G61AF9ppGVfUSBbduLqNIrisr+c4opcdu+oXiOqdgyS0S5lw1lz +yvw2IL0hh1La8u0tgpDQt9O3qThC0JE4gjsHEt1UR5UB054n9mnif2aom5X+ywJZ29nXfLpVzKB 4bEji/axCU2scnwUHygdLYmx5cueyCu67VgS8ut0a44xaGNZM3uF+vr9ubW3QpVneOIMwOYOOEkL hsgpy2RVIg2JEUVRVA6F8T+zTxP7Nc/N5hj8aBZnMi16yuy3C5W2PO8BdlWp0musx1gb5twCAiId 0DZfzipsHJe6trHuthlycejxfdA5U+7kTQO2tAftio+JkoBuXgGwKRiTYoaipGJAiKSKiAXZ4n9m nif2agq6dXtFVF1Wz5FT+1avYadnV69K+ffWtXsNATrxP7NPE/s1Bezq9elfPvrWr2GnZ1evSvn3 1rV7DQE68T+zUK1l49jGpW22/wAE7r/wjleXZ1evSvn31rV7DWFedI5uQ2a42e86n55LttyiuxJb BHa0RxlwFAx3SCipuJKm6Ki9/dQF0b+Wvu6fLVUfAK++lbOvqWj2CnwBvvpWzr6tp9goC190+Wm6 fLVUfAG++lbOvq2n2CnwBvvpWzr6tp9goC190+Wm6fLVUfAG++lbOvq2n2CnwBvvpWzr6tp9goC1 90+Wm6fLVUfAG++lbOvq2n2CnwBvvpWzr6tp9goDb67f9R+pX+6l0/4R2pE/w6q78f0R/wDZSqV1 cwa8x9ItQZD+peZz2mMZuLpxZIWvpPikZxVbPhCEuJeReJCuyrsqL31O10nvaqq9reep/d71+w0B K/E/s08T+zUU7Jr36W8+/wAbX7DTsmvfpbz7/G1+w0BK/E/s08T+zUU7Jr36W8+/xtfsNOya9+lv Pv8AG1+w0BK/E/s08T+zUU7Jr36W8+/xtfsNOya9+lvPv8bX7DQEr8T+zTxP7NRTsmvfpbz7/G1+ w07Jr36W8+/xtfsNAVlqa1gjGp06Trtb2rjjsjG40TG1lwX5cZt8npCzm2gBCEZZ7RVEhRHFERQF 7lSo9E1Gzy26m4xjrLsyz2tEx6NAsd2jk/NnxHWBKZIfVIzhuOs/nBN1H2QaJhFcFefj3b2TXv0t 59/ja/Yq+9k179Leff42v2GgOVNMwzKw3zH7RYcsyO0P5PcY5TzdtEZ41ZW43tZL3FyPxFxVZi/n T3VPCB3QhRoRyD1YzXD8MxoLE6tieYjSbidsGytR2JgJepAOgjKRzceUWBU3BbWPwEkdVwlNETqL smvfpcz7/G1+xU7Jb36XM+/xtfsVAUtcdUs9hXbMAfurwYzDkCtku7GPCTsi3Lc22rhNXYHBMoLa q2HiijgF1yBxE3TxezbUS641dpNhy26FEttmym6Wi7MWiErt8aiHF8BJ0SjkGxE9ID82LfVFoTRE 5b1d/ZNe/S3n3+Nr9ip2TXv0t59/ja/YqArBnUPNJ2t7NjbmR4ltK7tD7xutJ+etJW8XCmiKRFcT 8+RbOrJEBIekocu9b6Thsm/Heop2TXv0t59/ja/Yq+9k179Leff42v2GgJX4n9mnif2ainZNe/S3 n3+Nr9hp2TXv0t59/ja/YaAlfif2aeJ/ZqKdk179Leff42v2GnZNe/S3n3+Nr9hoCV+J/Zp4n9mo p2TXv0t59/ja/Yadk179Leff42v2GgJX4n9mvhcOJfo+Sor2TXv0t59/ja/Yadk179Leff42v2Gg PHRbbwzU7/feb/7iPVp7J8lRTAsEj4FBubDF1ud7kXS4u3GZMuRtK6484Iivc022AjsAoiIKIlSu gGyfJTZPkpSgGyfJTZPkpSgGyfJTZPkpSgGyfJTZPkpSgGyfJTZPkpSgGyfJTZPkpSgFKUoBSlKA UpSgFKUoBSlKAUpSgFKUoBSleMqUzCivSZRo2ww2Tjhqn6Ioiqq/4ItAe1K5Ox33SOR5jdsll4tL x6ZbiuWL+9VuWYiuxYM6asd3rGAEqyC3ZUw70YR5E5EYqJSbSDXu9S7BaB1NtrrqzLNKuke628Tn SJbTM5uMquQo8dCbJVfaJEb6icd1JRUVoDoulUNcPdHybbKl3SRiB/AaNcrtbVunvkiTSdt8KRJe XwJW04oRRH2x5OiXi8iQUVEXXRfdKZHKYt8VNOHGL/cbvbbfGjyri/Eik3MZkOI713ogGqt+CuIY i0Sd4qBGq7UB0VSqeb1umTtP8XvlqxkXcgyS+nYYtreuQtsNS2nZAPE5JQFXpCMR80IW1IthRARS 7tHA90dcpeYN469gz7LsN+2w72bc12UkOVMfVpBbcZjmwYAnTcI3HWV4mqIPMSCgL9pXLWV+6My+ Zp2/drFj0SxzZzL0yyusXYZjjwRLtEhvtOi5HFtlXUkoglu5xQlVeJIiVvcm90tdsas15ck4bCev djmXCPcILN6eeAkiR48gjZNuIThCQSQ3Nxpptte5wx3DkB0RSqEh6yZJIza6WPHrWzf5lzuyJaId wmjbmoMFqzwJT5OPA06Rkr00BQUE13cVeSAFYd191A/bGLbdHsMfi43cccavES4TZxMpKdchvSRi sqLJsq4nSEFE3W3F58gbcFEUgOh6VRcTXbJXVt9omYJFjZdd/ew7bBDIRciK1MZlvc3pPRRQVsLf K5CDbm6iCApc90jWV+6Ov52i8t27F3rStptCy7vPYvLCvwpI3ORb1YYbcjuA+iuxHFRwkFOC7qgl xFQOmaVUOL6z3G9Z9Fx67Y1Ht1tukm+xrVOZuqyHXitctI7iusqyCNIe5KOxmqcdlTvRat6gFKUo BSlKAUpSgFKUoBSlKAUpSgIDkmteD4nfJVkvd6Ju6RBbKSwxBkSVZRwVIOatNkgqQoqoirvt31qv yjNOfpqZ/JJ34NYmIOmOq+rSCZiiT7VsiEqf/B4/Yn+FWD1XfnXPrrQEJ/KM05+mpn8knfg0/KM0 5+mpn8knfg1Nuq78659dadV351z660BCfyjNOfpqZ/JJ34NPyjNOfpqZ/JJ34NTbqu/OufXWnVd+ dc+utAQn8ozTn6amfySd+DT8ozTn6amfySd+DU26rvzrn11p1XfnXPrrQFH4zrVhVvyLUOTNuU1m PdciYlwjWyzlR5kbXCZUk2ZXb84y4Pf+qv8AVvI+37T76al/yO4fgVZvVd+dc+utOq78659daArL t+0++mpf8juH4FO37T76al/yO4fgVZvVd+dc+utOq78659daArLt+0++mpf8juH4FO37T76al/yO 4fgVZvVd+dc+utOq78659daArLt+0++mpf8AI7h+BTt+0++mpf8AI7h+BVm9V351z6606rvzrn11 oCsu37T76al/yO4fgU7ftPvpqX/I7h+BVm9V351z6606rvzrn11oCsu37T76al/yO4fgU7ftPvpq X/I7h+BVm9V351z6606rvzrn11oCsu37T76al/yO4fgU7ftPvpqX/I7h+BVm9V351z6606rvzrn1 1oCsu37T76al/wAjuH4FVvfc4x34Q5NdMG1Gex1MrYYbuyP4hc5brLrTCsDJiOCjaNO9Ppp4wmO7 Ylt5UXpXqu/OufXWnVd+dc+utAcpRJWBQNQkvsXO5rlkS6reUhSscvD8jw3wBIiErir0l70R3qdH q77hz4rUeG34zb4cKHYtWJkeG1FtjEmO7iF2EJJRrd4ASkrJtnwUPziN8uPJVQ+abcezuq78659d adV351z660Bx5DHGQbhxrpqYxdIMDEkxa3g/gN152+OsboOvR1R3gLzviqZkBLxFARUHffZxbhiU W6WMA1GIrDAvFrvcmOWEXBZD8uHBZh8Re/RbaMWAPbgpIu6clFVSusOq78659dadV351z660ByJZ omntoG2imoU5xIbuKmW2ITx6g2YNuP6HkdXv+Ph/arVQrDgkG7C8Oo0mTbpsxiVd2H8Tu3J/o3OR NAQQSRrvSR01V1t3iodQOJF3dodV351z6606rvzrn11oCtC1/wBPyMi9+ZSclVf+8dw+P/6ivz2/ affTUv8Akdw/Aqzeq78659dadV351z660BWXb9p99NS/5HcPwKdv2n301L/kdw/ArL1IyK/tXzBc Vxu4y7IeU3SQxKvDDISHIrEeK5JJtoXUJtHXenxQiEkFENUFV22iV31fvWnTkfGCl9qeQv3a4sx3 2G3Yxx4kdhl8mpiQ2Ht5IeEtNorbIgQkJHwVCRQJF2/affTUv+R3D8Cnb9p99NS/5HcPwKrxj3RO Rjm8tti1P3KDeQtoY/Z3SebdigdsSdJckeDRX3lc/ONNoIoaIq+QURSWXW7X24XC4Mkxiqs2VpnH HZ78q9GEthbu4LbQDGRhUNWyNEPk4G6b8d17qA2vb9p99NS/5HcPwKdv2n301L/kdw/AqIY7rvk7 2OWRyNYW7887CtBy5Vzv6Q3lfuNwkQ2AQI8NW1ETYRTJEHYF3QSJF3+3j3TNwtG4Dg1xuUm3tPPX xq3zJMlI4NXKTBVI5BGVHSUobzidZY4qKCnLkq8QJd2/affTUv8Akdw/Ap2/affTUv8Akdw/Aqz3 DdbcMeq4vFVT9Nftr89V351z660BWXb9p99NS/5HcPwKdv2n301L/kdw/Aqzeq78659dadV351z6 60BWXb9p99NS/wCR3D8Cnb9p99NS/wCR3D8CrN6rvzrn11p1XfnXPrrQFE6n60YXftLs6tFnuU2X cbljs+JEYCyT0Vx5xgxAUVWERN1VE71+OrBX3RenKKqLepm//oSd+DU16rvzrn11p1XfnXPrrQEJ /KM05+mpn8knfg0/KM05+mpn8knfg1Nuq78659dadV351z660BCfyjNOfpqZ/JJ34NPyjNOfpqZ/ JJ34NTbqu/OufXWnVd+dc+utAQn8ozTn6amfySd+DT8ozTn6amfySd+DU26rvzrn11p1XfnXPrrQ EJ/KM05+mpn8knfg0/KM05+mpn8knfg1Nuq78659dadV351z660BCfyjNOfpqZ/JJ34NPyjNOfpq Z/JJ34NTbqu/OufXWnVd+dc+utAQn8ozTn6amfySd+DT8ozTn6amfySd+DU26rvzrn11p1XfnXPr rQEJ/KM05+mpn8knfg0/KM05+mpn8knfg1Nuq78659dadV351z660BCfyjNOfpqZ/JJ34NPyjNOf pqZ/JJ34NTbqu/OufXWnVd+dc+utAQn8ozTn6amfySd+DT8ozTn6amfySd+DU26rvzrn11p1XfnX PrrQEJ/KM05+mpn8knfg0/KM05+mpn8knfg1Nuq78659dadV351z660BCfyjNOfpqZ/JJ34NPyjN OfpqZ/JJ34NTbqu/OufXWnVd+dc+utAQn8ozTn6amfySd+DT8ozTn6al/wAknfg1Nuq78659da+E 87xX8655P11oD5iGbWLPLY7csUnjcIjMg4rpdI2ibeDbkBAaIQkm6dyonlSt/VW6LkpTNTlJVJfh vMTvXfu6EerSoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgI7 dsDx29uXNy52ph926JESY5uQG74M4rkdVIVRUVs1UhVFTZa+2TBMbxt2A7YbNDtx2+G7CiKw3w6L DrguuNiieQSMBJf60qFWzXzHZOQZ3Au4PWa3Ym2r/vlJRenOYbM2ZLjQ8eSozIaNo9kVN+KovjIl fiZ7ovBlt92Ky3VJV0hW+bKbhzI0mCjhxmjdNknHWkRs+Ac+Kop9P84gqPeoGKHufoD+qp5reJ8W 4RxkSpTEFbNHacI5EVIzjbz4p+eZRtT2FQQ1Uh6jjiACJKMf0YwPFwZGyY1CYJiczOacPm64D7LZ NMkhmqls22RAA78QFVQURK+JrNhIZFIx6Zfo8O7RUfSSLzbrbDZstI88CyCFGuQNr1CHlugbltsi rWri+6K01m2f30jZKhsLMjwxZ8AkpJN6Q0rscRjK31i6oCpNqgKjiIvFSoCTTdNcUuGL/BmTZIq2 RJBSgjBybRp8nSeV0CFUID6hESEKoqKq7Kla9nRnBI86xTI+MwGXbC203bhbEhaaRpSJpVbReBkB GZARoRARkQqiqqrijrtp64zYn2MmjSGL4y2/EdYZddAGzeRgDfIRVIyK8vSRXuH5wSD9ISRPC565 Yq1GyxuxTguN3xyBcJb8V5t6K0awl4vgkgm1BeBqIlx5KPMVVNlTcDX4T7nLCMSsTsCfbGMhmSRU Zc+e3yceHwtZQjx3UQRHVElQERCIBUkVUTaS3nSHCb/Idfu+PRJDr0p2W+u5Aj7jrbbbqOIKojgG LLSEBbgXTBVRVFFTTXzXnDbdcrlZ7deIUy9W6W3FfZeccjsI512GnQSSoK0bjXhLam2KkQqSCSDv umpg6/sT74dqCxOsOA+LROyJggCb307SqdwqvPk2riDtsu6ByRfGoCT3LRPA7tYRsk/HY7luE2jQ BddA924wxR/OCSH/AKABaXv8YE2LdFXfX5VoFg+Rx55RrLFs1yfta29iVCBWwjoMdyOw70BVGjNl t0hbIhVQFeIqid1ekH3QOnNxbuLkPJAcCBG8JcXwOQPVb63Q3Y3D+kfnlRrZrmvUIQ25EiLvo2pe LybdZZ43UWo17uRWqD4Qw6yZzR6iFHIDFCbcRWHBUTQVQh4r37IoEftXuf8AT21Yy9YW8binHkHG dkP8nBfN2OCAy4LyF1G1bRNg4EnBFVB23XfbM6P4KxZzs7OLWsLWdvZtxxkYTgUZp0nQbVPjRHHD Pde9SJVVVWtYet2LTGLC/jlyiXVm7nDIFVxxovB5KSembYq2quOKUN4UZREPcF327t9BhnumMSyy 9RrbKbm2JbgzbHLY5OjuIkgpzCutNkQioNEqiQChl+cUfEUkVNwLJj4Tj8S4QZ8e0xgmwHZrsR7j uTJy3OpJUVXydQ15FW/qtS1rsMLUq6YPfBftkyMcBuJKNozZlOShPgCmIqLS8g4D1CHmS7DuvdXh lfug8IxOy5Lcn5kyf8HmidksRYLvN4QkJHcVgjQW30beJAcICIWyXY1FaAtGlRG0an4rfsnkY3ar or13Y6yK2sV4GzJlQR4G3iBG3DbVwBcACIm1XYkFUVKl1AKUpQClKUApSlAKUpQClKUBzv75ZXA1 d1RTD7bjk9gpdqWQd3ukmIQH4CmyCjMd1CTZN91VNl37l7lrd/CPU/6AwD1juPsNfmyxnn9VdWui y45/T7R+gCr5IHf5P70/xSpZ73TP2SR+5L7K6oUoSV2zGU5J8CK/CPU/6AwD1juPsNPhHqf9AYB6 x3H2GpV73TP2SR+5L7Ke90z9kkfuS+yr7CnqV2ktCK/CPU/6AwD1juPsNPhHqf8AQGAesdx9hqVe 90z9kkfuS+ynvdM/ZJH7kvspsKeo2ktCK/CPU/6AwD1juPsNYF6z7Pcctp3G/wBu04tsAHWmSkSM ouAAhuEgAO6wfjVf/wAK+RFqc+90z9kkfuS+yqu1c0qyLVeZZ8bAQtOMsQp0ubOm2pJ7bkx5sojL Yso62aG009IfFz9ET6flVNqpKlCKunctGcm+JLkuurKqSDi+DFxJRVRv9zVN0XZU3SBX59+dVtjX 4M4Ls3+mvwgufi/3/wBA7qpHsf1Fy66W+7Z1Y7qU/wALxmNNVbxsixWwdYu5ojTqDwdBAIh23IXN kTdF28o2kepDUG2R3rHfSyCI1Hi4ndUuwGxjaN3WSbxvIT/JxCiLG28R1TAUaXZUVKzyRWpe7Lnu WX6k2dtly6WLAYgPS2YbauZDck5PvGgNh/qHlIiRE/vr7cMt1KtRQBuVhwGKtwkpFidTIbkiPOqB uIIr4B+o2a/JsNVrZNOdQI+TnN94L5AtTt8t0izMOXdtxLTa27x1pUVwBc2U3A2f7ursCIxy8RBL zwfTPO7VfcRflYnerdcIN3acy68nk3WavbnSmob4x0Jebe7jK8j4EnUFvpqgKQskbkZnYm9t1WzC 8PRGbVF02mOzHGGmAZya4kpm9FWW0myQe5SYFXE38qJUgcvmqjKoj2N4G0q96IeQ3Id/8YNUxZdI tSLRh82HDs0yJcHYMJsUamtgpE1h78FRUhPu4zVaBO/y7GnipyqwtLdNr7hM3JmPe+dCt0+12ZyO r8hyYK3IY74zXVFTVeXPoc18VHOKbKvetI003xDk0SNcg1RHblj2Apum6b5Hcu9P4GvC4ZdqTaTt w3Ox6fwyuUsIcJHsjuQdd8hIhbDeD3koga/9i1h6YYlqFZL5l72cXNifCmXt963i3ZjbUkJmMgSA XwhzpsooOJ4Oo77oRKXjIlVxjGleY29zEDjYHdYl3tF1hTL9PuWSC+1d7g3EuAOyhHm4QiTjrO7y 7Hs6go3s0qpLhHgQpMt4rzqs2m7mM4KCbb7lkFzTu+X/AFCvo3fVcjAExjBeZ/oouQXJN/8A1GqI wrTfVKxWq6XKBitztt7guWW8Wu3lMaajTJ0dXmbgyS+FPknWZe/0pqiuKAmvFUFK3tp0u1Fw6+wb LEtd2v1seueKTHr0N2TpNDCPlcTcbed6vJxxSJAASQhPy+JxWMkbdpN2WTY811Eya0MXfHrPp7c7 W+hq1KjZJcXGy4mQF4yQdu4gJF/rRa2BXnVcUFTxjBRQl2He/wBzTkv9X9A76oW06VakWJMF54dc HXrAESQ29DkMmbKjen35bfI5bYNqUcwTYGnFdQkEjFBUUk0TSfOMfst2uFisE2Rk12sOSRrg29en WwkuncWytwqQu+IoxleUFbUNt+BECluhQiMzLNkZNqZDkxo0yx6expMsjGMy9k1xA3iEFMkAVgop KgopLtvsiKq91e63rVUXQaPGsEBw1RBEshuQqu/cnlg1REDRvUA4UNy2YxPs863XW8u2Jx2Q1G97 Wp1mRpk22wkvI0IzG+RDzIgU0JN1Uqm2mmnGaWbCM/t8aBc8fK5wyYx+JLUB8GkpBcaN9EB+R0+o 8rZEROrzIFc4jv3lCIzMkUbVLMZkexSI0bTNxi/yHI1pNMpuG01wOSELS+A+N+gXencvdsq7pvvf f3VPbf4N4Htsi7/CG5eRfIv+o+SqPk6aZtqbi+O3nF2W7GxiOG2uPi0eXbwluvXRnpSXlAuqHgjg vQ2IhE4JdyO9yIu65WQYtqhEcvbyWu72GCzOyi/+/rt4DpQ2ptrdSK0gNuE7yaeLiXEFFtW0IVJF 3SFFdtybsur321Z5cfgtg/Lbfj7/AFz32/u8Ar4t31XEhEsXwZCL9FFv9zRV/u/oHfXP+BYeOol/ ucPFbDdo+nUfJ7KkqD8IPDGUjja5iyUR9l9wXBV19hTAHDUuSKaJyUU/MDRrVO0YixGjWu6OLNs9 mdyeI9PSWdyfYnvrKZ8d8eRLGVjxUcbE2w6aGnkooxF2dBJeNV15bYxgy8P0v+X7n4v9/wDQO6tb HznUGZcwtkK1adS5xBINGWMmuLi/mHAbeReMFdiA3AEhXvRSTdKpuboln0/Hnhcs988MtmJyExwD vCtnEuSXV96KiIL5IBtxia4qThiCL0+Zcaz7ro9nSSMwiWSwXSDGul8ukt16JdEYCa3IvdskNuDx dQgJIbMgVXYVTgQ96knKckRdlsyMw1IiXWJapdk0/j3GYw8/GjuZHchN1trh1VFFg9/HqAqp5di3 8nfWR8I9T/oDAPWO4+w1X1mwu84vkeL46FvlxGY2pVzutkZ3OQjGPjbTB3YvGVtsnZAggEqeM6Kb d6VdSW6YiJvEkb7fMl9lXhThK92UlOS5EW+Eep/0BgHrHcfYafCPU/6AwD1juPsNSr3umfskj9yX 2U97pn7JI/cl9labCnqV2ktCu8qiZpm9nK05Vh2nNzgq6LwA5kVyQmnR34uNmkFCbNN12MFQk3Xv 760E3T+7z8Xg41I0901S0QTcOO23kt0acEnBUXVV0YSOF1BIkc3Jeoiqh8kWrj97pn7JI/cl9lPe 6Z+ySP3JfZTYU9RtJaFRXXB71eIUiHK0+0zZjyDYMxh5Fc4iorLCx2kFWoQqCCwqtbCqIoKoqiou 1Ry84jesPul91JumFYFcQsVtjTYluYv04G4DVujOcUYb8CFsiRO8OSIgEibKi+MnQHvdM/ZJH7kv sqH6tw5LWkOopOxngFMVum5E2qJ/qjv9VQ6NNJu5KqS0MGBp5nNqjMxbZp5plGjR/AkabbyKeKAk R8342yeB/wCw64Zp/WS771g3XSTLb3LhS7pptpjIfhvPOtquSXFEcV2SskxdFIezoK+qu8HEIUPx kRFro/5aVxm5UilrGSqq4zp8qqu6/wDOaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0 +9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3S gKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NP vWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWP zY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sV W3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j8 2NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FTfWPzY0+9Zp/sVW3SgKk31j82NPvWaf7FX zfWLZf8Amxp96zT/AGKrcovkWgOaNOsg1Etc3PwgWPC3DPLpZSutkE0EF5WIyqI7Qi5IiEPjLx3V V8Xu3Wb/AAz1R838D9ZZ/wDl9arAor7911IVlh1xEzaYviApf+KQ/k/uWpl73TP2SR+5L7K6oUoS im2YynJOyNF8M9UfN/A/WWf/AJfT4Z6o+b+B+ss//L63vvdM/ZJH7kvsp73zP2SR+5L7KvsKepXa S0IrK1M1BhXa12mZbdO2LndQfOBFPKZwuSUZFCdUB97914iu6/1b/ItbT4Tat7cvgthXHbff3/uO 238uqrM30zz69ZxMzqzQWElY1c7amP2xyGgyp8SLucjpzOtxjjIWXKEgMFUkaa5cdkWopcdAMok2 u6yBsl4K9u2e+yGXUvbwEV1G58rSfivoCEEYjUF/RHkqF391YZF4miky/EyrVghEhxjCFE+4VTIb jsX93/J/f5K/C5fqoPHljuCpy7x3yO4Jv/d/yf31T0/TTL0ya+ylwu93SU85fnL7O9/RabyGLIUx tsRhCdJWVb5MLyUW0YSOSjyU9i3GO6a6tw8KvEB/InLflxldfDJ5xkmDfJT0fjElNyVVDhC3+bbQ BbTirSrt37qUI+IzMn8vULUmBdbbap1lwGNc7mLxQYruS3AXJCMihOqArb914iQqu3y1mnlWrDe/ UxnCA2235ZDcU8vk/wDg+qNXSzL2QYmYNpvcscbh2u9MMQbjkiPOOS3rcw0jiEDiqzzdFxEIHOTh B1CVrki15W3S7UqLi8ocSsl1x66R7vIC2MvSW4rIWy425uO+YstyX0AmJLQyUbI1LcV2VSMtihEZ mXmWY6pgSiePYIJIuyouSXBFT/7318+GeqPm/gfrLP8A8vrbQcdKzW+HbLZEmLBt8ZqJGV0TM1ba BAFSJU3UlQUVVXvVVWvf3umfskj9yX2VsqNO3Mz2ktDRfDPVHzfwP1ln/wCX1+2sv1TecFtvHsDI yXYU+Es/vX+X1uve6Z+ySP3JfZWTboMoJ0cjiviKOCqqrRIid/8AdR0aduY2ktDc4DkxZrguM5Kc ZIRXu0xLgsdHOaNK80LnDlsnLbltvsm+3kqQ1X+hH/Ufpr/upa/+EbqwK4zoFKUoBSlKAUpSgFKU oBSlKAUpSgFeUkHTjujFcFl8gVG3DDmglt3Ko7puiLsu26b/AC160oDnd/3JdnaxyJbrFf5tvuLt gm2S9T3hOZ75tyg5OuKDri9EvCUSR+bVE5KYruhKqSTMtBPhfEySO5kTkb37vE25KSw+p0fCLGdq Rv8ATTfgh9VF7t9uGyfpVCsY90bd2I+mUG429i/FeoVhj3ee0byOtTJ8cD5nwY8Gb2UkLpE6JkJo oiiceXrK11zW727D7narXj1otuRXa0SIqFd/CZR2uTIRohdZRv8ANOKiiqmikAbkPLmKcgJjevc/ Q7/GvMO432V4FeMguN3ki1HATEJdqet5MgSqqIoi8riGol3pso9+6RXJ9FtQpN4xq/DmUe+ZW3kN sckXL3kajxYcCHDnCm8XrcnVcdmO9RRdRfz6cEbRtK8rH7pe/XW1vuriluWdJk2MLWKT5jDDrd0k PMNETj0QCIQVjkrjYG24heIvd3/YHujsnO2OSbni1iZdlRpa20Y95lPo49FujFtdQxGIrmxuyEJo WwcM0HhxQiSgMqX7ltJvgKzcoauLkhsByFyfZW31nr74vT3SZBDFtjm5KkDsYPIIkGycg5FIL9oA F7tkmGuQEwT0DKofNISEie/UnrqW3Pv6P6O26c/LuPkrQF7ou9rjtlugYtGYA5Vyj3eTMemNRYqw 5SR+8hik4wLnjudSQDYN9MgMkXvTc4Frtcsx1GdsD2LuR7FJdubNvubXhK7FBkKySuq4wDSo5sRD 0XHVBUQTRFXuA9rlohergxeLMmcutYlMu7l3j21LQ0rzMhy4NTjQ5HLdwEdB7giCCij6oROcBr8N e57bavTtz+EThG5Makq2sIePiZAd4235b7qp9Hf5E57f7NRqdrxkVkteQv2eys347ZJyqdIW63dI /Sh2mW02TbPRiryUhe2AT7x28Zw/j/MjWLLbbdcwbdZj3HHXrxMg2yakwY82CaWAbk22LXg5tkA9 NxOoZEvJxNxUQ2IDdt+5vBnFrLY0yCPPbtVnmW1EudlalsSPCJ8aYpOMESCo/wBFRtURULYuQmBC hVs5mhcq6aMy8BuGYTynuy/DIt6bA1cgODKR9kWEcdNwQb4iAoTpEgovj+TaHYbrblQzVk3qFGuO KzbzY7U1IcuTaXCK9PtkAxRGRYAHgR6QpmW4rs4aiCC3xrDxLW3O7lcrLa7bCtd2fv8AYsedtCXO abPSdkW+bLkOynWo+xGSQyFBAURfFVEFFNBAmNn9zXabDOakWq6nGCPl7N/jNBFRBYitMug3bgTl sLIHIfMVFE2Vxe7yqvjiXuc3MbswQZOUrMdGRjjhON27ogTdnNpWw4q4S7uCyCEvJUQtyRNvFrBi e6IvuQ4+d3xXD4j7bVht9xeaeurhu9eXLfio20DTBdYAKK6fIFU3R4I2CkaIlq6Z5i7nWHQ7vNZi Rpyuvx5ceK46YtPMvG2QqjzTToFuG6g42JCq8VTu3UCJX/ReZes7ul8byNqNZbxMs8u5W1bZzecO 3O9VlG5HVRAEjQOaK2Sqg7Co7qtRNj3LLceyZJZY2SNx4Fwtlyt9ucbte8iMMyUMklecJ0ke4k2I oICyhDvz5FsQ9D0oCkGPc+OSc0eveS3+Le7dK99mZsJ+2uq7Kiz+KnHN8pBcQaVttGkABQQEh2Ui U6uCyWWBjlng2iyRghW2BHCPFYb34ttgnERTfv2RESs+lAKUpQClKUApSlAKUpQClKUBzRcNPsUz PV/VGTl+O2+9vxpVpZZOWBKoAsHkqJsSfHuv/bWb2G6ZeYVi/dO/fr8PXu5WrV3VFq14ld8lB2Va TN23y4LIsqkHZBLwh9tVVU7/ABUVP60ra/C7IfRdlX82s3tld1JRy8Tmne5rew3TLzCsX7p379Ow 3TLzCsX7p379bL4XZD6Lsq/m1m9sp8Lsh9F2Vfzaze2VpaGhS8jW9humXmFYv3Tv36dhumXmFYv3 Tv362XwuyH0XZV/NrN7ZT4XZD6Lsq/m1m9spaGgvI1vYbpl5hWL9079+nYbpl5hWL9079+tl8Lsh 9F2Vfzaze2U+F2Q+i7Kv5tZvbKWhoLs1ErRvSa1wpdwu+EWGNboMdyVLeVp382y2Cm4X6fxCKrVL 4Jc9Kb3ikebfdLrLPyGTf4lpYteOokki8NjeEw1UnJAAP5tDBwlNEE2j7kRF2unKJVzzDHbjYL1p dmfvbcmxalDGvtoYNxtDE1DmMzdBLjxJE8oqSfHWsnWcJ+VQMkLR/K4k+E/FkA3DvNmjsG7GJ4mT NoJaISj4S6O696iWy+SspLj8JpF8OJArPcdDr3b2ZUPSOaLktuI7bojtvaB6cEiYsIenvL4ioyE4 EjhB3KhjyFd69Mhm6EYtaY9xvembUVtZE2NNaNuOBwHojwsvNnyloLriEYkIMK4RAvJE27qybppp JCz2WDiGnGa2V62lBjJJPIbU44MJm5eHGja+Gdzyub8TVO7uTyJ3+9x0uiXKILDum2ozTjtul2+5 SWcoswvXRuTI8JdWQfhPjEr/AI6qHDf9AkIPEqlpaE3jqYWYW7Sey2vLnrVpaix7A5JiLfysbkm2 +GR+CvMqIyQc8XkoIZ9MCcEhElVEQsWRjuDN5NFta6eYo0xJlT44OJBfcJFZyZi0tbp4QKd7TykS 79x+MiKidNZPdsGavj95W56Z6huQ7v13JEBvKLQ1FSS+go/KFsJSIjriD3qu4opGoiKkq1t3bN1r ozcT0nzTwpmQ7IbVL/Z9hNy6t3Qu7wvyeEtAv/k7j/XUZZMm6RpcKxzR3PJ7cW1aVe9oyocmbb37 jFAW5rMeSMZ5W+nJMkUXDDuMRUkXkndWXbMV0GvOWT8Wtdgw+VeYbTThMtSwPrEavcmm0F9SJxvo ErgcdwQhVfL3bTGoD2IlaCselOZtFaYEu3xVdv8AaHNmZMkJDvLeX3l1AHZfiTurMgq9bcjn5BB0 cyBm6zmGGXXhnWJNkaV1UINpW4kvXPkSLuXci+StYrhxKXK8uZ6F2m45VCkaZtuLjDnRmusx2yQn Eksx1FGvCuqCKb4qBOAAuCBqCrtsuBnlu04srmTMYxpxjpv47b7+UtbjFd4nLgNwHA4cH91aIZyo u+xKoptx23KUZJise7SLxc8t0+z1+JKZktshMyuzCzbCkONuOFHNZSG2quMgQiRkAKi8BFFVK84e JW6RbZbR6dZvd1vzF0WRLeyyyvOzUljGblOISS9l/wBVY/RRBBd9kTdETPjyLKxhXyNotjsO5PXr Sb3sm225BBmW2Z4Iy7H6kZZLbhvFNSOgE2ioP5zkpooIO6V5yIWkMm3SZeK6OysijNW1mWU6NbFG Kw6/BWZHZeIn+QcmlbU3EFW21dBCJOXdsncE66xpb+AalO3pqe/McvRZVZvDn+tGSKbRu+E7cOgI tiooJgibiYkqkvvbMLC1PQuhprqGUGNEjx3beWU2hI0pWI3gzLzrYyk3cFji3uiihIAKSEQotLS0 F1qaDGWtGbxNw+03LS6HbrvkVviPin5omgeeheFIIh4Sj5NqKEKPI3wQthJUJCQfayx9HrytuMdF 58CHOatcgZsqJGRpmPcXujDeNAmkaC45uOwiRCgqRIibb7K1YGtpl2t+FgGpX/J7sN9htcnsqiUi PHSKDpf0jciWOKMqm/HjvxESVSXbwILLMBiFB0zywmG4lkgNoOSWQlULXJI4g7+F95dVCEv1lFU7 lRaJNcxw7CJ6lYlhWLS7+1YtN8SfCxQLQ9OOU0+RFIuNzGO0AiLidwsg+ZLuqqRtfEJIW3ynE9MM Izm6WmTplb7iy37zR7WzbI6rLemTnpraCpOyG20BPBB8ZVHjuqqqp5Nle49xy+83ebP0zyC449k9 hZt90ijd7Pu65HfJ2JJZdCb3EHVeRV+JRaVP0V38bdiz0V6PLuunmo2QXZq7QrqtyumUWh2Q47ER xI7ZcZQh0g6ri8EFN1NVVVXvpZ3dgmrcSM5FP0KxrHbNeb1piES3Tkl7gUZlhYSxpKx3wISlCjri Oov5tjqEoopbbbb+05NC7fdsmgStNWkbxt9WblLCO2bbW0lqOZk2krrNtoTyGhm2KG2DhByQe/Nv emMW9tOKemGocEHoM23SyiZNZ2/Co8mYcwmzVZKqiC+4Rpx47p4p8x8WvXKMbvlzDIrhb9PMwud6 uNtnwYDOQZJanYMNJqCMpR6cnrcTRFLp8iEV3QEbQlVJtLQcNTT3hzRGyTrrGe0lkzGbQEt+fLiw G1ZZixphRHZHjSkIg6wGiIIqaoBFx2SphjmkuntwuGW2u8ae4y3ccdvhwHFjtvcHWHGW5EZzZT3E lZeESTdfHAlTZFRE1TeDwImOFapWlmYeCjijeMypKX6zR+pEFxXSdJPDOIum6RGRfGpqlSjHrplV qmZPcbtpvksm5ZBenLhIJq5WcAbbFsGI7KbzN14MMtoSr5TI1Tu2SpinfiiG1bgzLTQ/TNEVEwKx Ii+X8059+vnYbpl5hWL9079+tkmXZCRII6XZUqr5E99rN3/+uUXLshElEtLsqQk8qLdrN7ZW1oaG d5Gt7DdMvMKxfunfv07DdMvMKxfunfv1sfhhf18ml+U/zaze2V4TM9utta6ty05yGE1spc5F8sjS bIoiq7lNTu3MU/vJPlSnwE/EYvYbpl5hWL9079+nYbpl5hWL9079+sqHn10uLKvW7TrIZjKLxU49 8sjgovybjNWvf4X5An/yX5T/ADaze2U+Bj4jXdhumXmFYv3Tv36jGpmjGndu0wzubbcKs0OZExu4 vx32m3ObbgRnCEk3NU3RURanC5hf08ul+Up//NrN7ZWhzW75PlWB5ZZLTppkSSrraJ9sZccvFnVt t5xk2tjUZiqnEi8ZETdO/uqslC3BBNnS/wAtKrJdV7yirtpdl/8AHWb2+naxefRdl/8AHWb2+uHJ LQ6c0dSzaVWXaxefRdl/8dZvb6drF59F2X/x1m9vpkloM0dSzaVWXaxefRdl/wDHWb2+naxefRdl /wDHWb2+mSWgzR1LNpVZdrF59F2X/wAdZvb6drF59F2X/wAdZvb6ZJaDNHUs2lVl2sXn0XZf/HWb 2+naxefRdl/8dZvb6ZJaDNHUs2lVl2sXn0XZf/HWb2+naxefRdl/8dZvb6ZJaDNHUs2lVl2sXn0X Zf8Ax1m9vp2sXn0XZf8Ax1m9vpkloM0dSzaVWXaxefRdl/8AHWb2+vy1rI6zdrLBv2C5NYmrvcAt 8eXKftrrQvmJkKEjEtw0RUbLvQVTuplkuwlNPtLPpTy0qpIpSlAKUpQClKUApSq3u+rZQspvGP2b DciyKRZ0j+GPwnYDTQE8CmAosiS0RLxRd9h2T5alK/IFkUqsu1i8+i7L/wCOs3t9YsnWqXCkMx52 nuRxZD+3Raeu1jbNzddk4itwRV3Xu7qnLJdhGZPtLXpVXjq7dTVxA0yys1acVtxBuFlXgabKortP 7iTdN0Xv70r9drN5327Lsu3/APPrN7fTLJ9gzLUs6lVj2s3j0X5d/HWb2+vyert1aRFd0yyttFMQ RTuFlFFIiQRHvn+VSVERPjVUSmWWhGZaloUXyLVWrrDcU2/7m+Td5CKf8qWPvIiUBRP+UPKpCQon xqip5UWvTtYvK77aXZcv/wBus3t9FGT7CbrUqu06a4dl+T6j3HK8Ztt6nJmMplH5QGpIAxIfEU2J O7xlrcdhumXmFYv3Tv36xMbueU2edlr8rTLJHAvGRSLnHRu62fcWnGI7aIe8zuLdkl2TdNlTvX4t 8eWZE2qIeluVCq96b3WzJ/8AjldtNRyq6OeTd3Y1nYbpl5hWL9079+nYbpl5hWL9079+tj8ML/6L 8p7v/wA7Wb2yvi5lfkMQXTHJ0M0IhFbxZdyQdt1RPDO9E3Tf5N0q9oaFLyMENDdLUXlIwbH2GART dcIHEEARNyJVU/IiIq/9lUpp/M0ryWw3y5XfS6yypDF4t7Nug2VBfdciXJUSALinJRsZHJDB0SMe Koi7InlunILpdslsF1sdz0wzAYV0iORJPQvVmbNWjTiaIXha7biqov8AUq/LWom2MLjfYN6Z0cym BIgDFEWrdd7LGYIY8tuUwjjQSuJcHW+5fLsRJv31lJcfhLxfDiQ0GtGvButI0anxzdM2obBQo5uT nm57MB1prjMVOTcmQ2C81FFTchUkTv3Nvx7QyXbZUmfhllstwiPz4r9lnBtcevDTk+00y28SPlx4 kPSIkJDDvTfZPLKMTuF3stuhWTTrM7W/Cnq83JS/2hHG2nrsxcZXAhl7o4px06Zf7K7b93fUnsIT LDj8uzRtLszkhOOU9Pmv32z+GSn5CbPPk+EsSBwk2RCDjx4jx22SoSdybqxBsdDQ7JW7YcPTNhn3 zG4HHUmmXwIYcZqQ6vUYlOAu4vCKIi7oYmBoKj37TTvCNMM/XIJcTTuxMWqM5aztqOR3AeVmXbGJ n51EdIeaK8qeKuyIm3f5V1c7GbWxuF6xbPBvz0p1x+6v5nYWJ8hCjBFcYMhlCiirQAJLwQ+SISlz 8apziQv4bDfZxrSrLm40tuEi8r9Z3UUI0RuKyor4Z800G6/GvfUR4tXJfBGd2G6ZeYVi/dO/fp2G 6ZeYVi/dO/frYpl+QL5NL8p/m1m9sr8O5re2GnHX9M8mZabFSNxy82UREU+NVWZsiVvaGhleRg9h umXmFYv3Tv36yIGhWmLk2OC4HYh5OIm6NObp3/8Al1lllmRASiWluViSLsqLdbN3f+uV7QcwyIJj BDpblaqhoqIl1sy79/8A55UNQsTeRMdCP+o/TX/dS1/8I3VgVX+hH/Ufpr/upa/+EbqwK846xSlK AUpSgFKUoBSlKAUpSgFKUoBSlKAg/Y1gCXWDdUw+yjcYDcVuJIGGCEwkbbwdQXbuJtBERJO9BTjv t3VkMaUYPGG6CxidmbG6ympc4UhBs+6251AIk27+J7mieTkRL5SVVmFKAhVo0ewGwuC5ZsPscJwX m3kNqA2K823EcaLfbytkiKH6iIiDsndWTO0ww25W47dNxi0uwiZfZ6XggIgg8+L7iDsni7vADu6b LzFCTZURallKAr97Q3Td6NHjHhNi8FjySlNsjBAW0cJAQ1UUTZULpNqQqiiSgKqiqm9bmzac4nj2 SXPI7Fjtst99uiksycxGEHXVIkI1UkTuUiRCLbbkqIpbqiLUnpQEeLBMZMJYFYLaoTG5jckfBQ2e CWQlKQ+7xkdIAU9/0lFN/JX6PB8acbcaOw21WnJBSTDwQOJOlGWMRqm2yqrCq0q/qLx8lb+lARGH pZhVuyGJkEDFbNFvURkWWJrMIAdbAWkaBEJE/wBlsUAfjEdxTZFVFxrzo7gWQQWYV5xK0S4zEWPE YA4o/mWWOXRAFTvBA5mg8dtkMk8irU3pQEYm6c4jcLVMtUvGrS5bZkOPBfjJDAWyjx1VWG9kTuFp SVQRNuC947LW1sGP2vFrRGtOOwWLbboyKjTDAcRTclIl/rIiVSIl3UlVVVVVVWtlSgFKUoBSlKAU pSgFKUoBSlKAUpSgFKUoCi7UqJqrq1vt/r9n/wCAWpPuPypVfu4eOTawaovlkOT2VWJVqa4Wa7lD A94KLyJEFdy+Lf5ET5O/cdlYefWovrU59ytFjIUllaJ3WdT4kSjcflSm4/KlRfsrDz61F9anPuU7 Kw8+tRfWpz7lT1hT0G41SUbj8qU3H5UqL9lYefWovrU59ynZWHn1qL61Ofcp1hT0G41SUbj8qU3H 5UqL9lYefWovrU59ynZWHn1qL61Ofcp1hT0G41SUbj8qU3H5UqL9lYefWovrU59ynZWHn1qL61Of cp1hT0G41SUbj8qU3H5UqL9lYefWovrU59ynZWHn1qL61Ofcp1hT0G41SUbj8qU3H5UqL9lYefWo vrU59ynZWHn1qL61Ofcp1hT0G41SUbj8qU3H5UqMDpUBKifDvUXvXb/pS59yqksNzW+ZjcLJ8Nrv EZgXifb3mnNVyW6dKI64BvpASKpLuLRGgct9u/fbvW0cdCXJFZYScebJ7rVYpWTYrY7bbYbU91zL 7KTgPwVmsNtJIXqOPsoo82RFdzTkKcVXch33qC5VjFx0hs19u2MyITL5WHJLu5NtNhat0S3y+lbG mAZBFc6KELJLtz3dJCUt9k2yrdlGE3S5OMQs+1geg+9cS4R5oyLlxl+EPmy22y2sbqOEShuKiKoS cuKr0z4+l2naWXCA1BvWqWfXO3Xe2HMcZcuU6Qz4F1ijm5JRIyoy2Lok2fV48STYtqzeIg5XsyVQ la10abIr5nsZl+PY7lmcnBfhE4wN8mxJsW8CHveJIJKEQ5CMJNUhQkYVFIekqoHl9JF81KjWe/Xb IHs2ceZh47D8Fhs+BNMrIjR3LjLUWmHHEIDAwNWQM21ccQURV3GXTHMHg3O6W6bqzqExJtjcxySR X6YjK+CBzlA090Om840O6m22RGOxd3irtjW2fgl4tzk616p6nygB+OwkZu43FZbhvsq8z04vg3Wc E2hJwSEFFQAi32FaqsRHRk7B6oi8DIs9lW/G2Mhnah21qNHuIR5Nks7pT5d0buO0VqUj7SITawya IeugA5u4pkhAu2NExvIZGS2mTNx+aBN5BZjUm7WrTYNtZVdXCPYRQURGTacIv1TE1VeW6y5664Cw 3BdTVXU6UzOhxZsd2HcLlKbJqSRAxuTcYkEnDAwFstjUxUePLuqWWPB7ZktpYutj1C1IkwXycADP I32TQ23CbcAm3GhMCEwIVEkRUVFqrxMFzuWWHm+CsVhhbeoDNhsMhx/JrQljg4ojVnjwkjRJJSZb jdxF2OjSISAzspInHp9xLt5atTPZ2cQslxZnA7fZplpeuhhNOXcZDSmKRJS8X0bjuI2xyFpUcQlV XEAVFELdMvsrDz71G9anPuU7Kw8+tRfWpz7lSsbTWpLwdV6FbazLfrLnMHIMeayUgdxFy2m/Z+qT UYiukYnlU247xNbMK6amLZGqAKgiEO6acshyibj+KwrvdtTLJPC83KPOututdwJGba3JQ2iebWKT r77jHBtojBNkMjc7x4rcPZWHn3qN61Ofcr52VB596jetTn3Kh4uk23xJWEqpFIZmud5HaM0tT4ZV drhcLdfkv1mftzx2+EAPolqGAvSETMxRtURsjVxFcI+9E2z8kyTMo9muUTHZmoN1sUm+PN2W9OxZ caeopbxJW3uERZBB4Yao0nTACVtwDNAEUW4OysPPvUb1qc+5TsqDz71G9anPuVXe6fiN0qlNOz8+ y63pByR/UGHdbnjlvbt0Wy2wGIkvq28kuJzCMUbacST1BLfg6CdJWRXl3+WGZFmdsyDC4KDmbVri RLVbZEaTCmmykYrRsTpNpERof6Yoh1TeJ1CBU4gA1dXZWHn3qN61Ofcp2VB596jetTn3KlYumnfi N0q+BV2ORdRI7FluVwyXOpchqPic6RCmcTYefnPq3dGXG+ihK20yIr090VpVU1VFWt1qBcYluzLU N+7Yszm78fFbM1YbMVvW4pIaclyleI2EEl6SSW2SdJBVURpvbxuFTjsrDz61G9anPuV4npBDclNS 3Myz85bLZtNSFyY+oDZqKmCF090ElbBVTyKoD8iU3ula3EbpVvcpILUuDY8zEwSVnFshnBuVwnXC yYnKgSLtkyq2sZk4yxk4ROJOI20KA13cTJVRd9+9K1SvWZ3ixtTcgt1/lWl3peCdSPbbdJGADja7 HHOObCymyFHm3xdLrGBgojulp9lQefeo3rU59yse4aNW+7wJdvu+X5/cLfMZJiTGkZOZtvNkmxAQ qHeiouyp/XUb1SWpO61WVcd9z7PsVk5Va7rlePsXXH7/AJHZ7fbEQRaJkowWyISoBclcEHnlbFUV zqqneiKizvTp+Y7nOpavMFGiuu2OVIb6CNAF0dt28xET4iUUiKafKqb9+9bxnSWPGZbZi5rqDHYa BAbaZyYgABRNkERRtERETuRE8lRnNtOBwzT3Nb5jWZZzDuEC0XC6tr8ICUHJIMG4huCgJzVSFN91 7/JVo4ulmvxKvC1FF8i0dx+VKbj8qVjroZHVVX4e6hp/dk71OwuP5/aietD32V27ytDk2XiZG4/K lNx+VKx+wuP5/aietD32U7C4/n9qJ60PfZTeVoNl4mRuPypTcflSsfsLj+f2onrQ99lOwuP5/aie tD32U3laDZeJkbj8qU3H5UrH7C4/n9qJ60PfZTsLj+f2onrQ99lN5Wg2XiZG4/KlNx+VKhupulzu H6a5lkNoz7P/AHwtFimzovVyR0wR1pgzDkKpsqbim6VmOaVAJqnw71F8iL/0pc+NN/1KpPGwhzRp DDSqfskm3H5UpuPypUX7Kw8+tRfWpz7lOysPPrUX1qc+5WfWFPQ03GqSjcflSm4/KlRfsrDz61F9 anPuU7Kw8+tRfWpz7lOsKeg3GqSjcflSojnSp74aebKn/Te3/wDDy69uysPPrUX1qc+5WNK0bgTz iHOzDP5JwpIyoyu5OZdJ4UJENPE8uxEnyKirvVJ46nKLVi0cHVi7l+p5K+1R3Zkvn5qF6yL+FTsy Xz81C9ZF/Crm29PU13aroXjSqO7Ml8/NQvWRfwqdmS+fmoXrIv4VNvT1G7VdC8aVR3Zkvn5qF6yL +FTsyXz81C9ZF/Cpt6eo3aroXjSqO7Ml8/NQvWRfwqdmS+fmoXrIv4VNvT1G7VdC8aou3Kiatarb qn+nsv8AwbtfvsyXz81C9ZF/CqrdRbTC05ye2hFyy+x52SxH5Mq4XzUhbKyXgistA2jixzQzVJG6 CiJ3ASrvtWlPEQUuBSeHmo8S9tx+VKpzUfTB7UfUC+sONWONb38JhwkuN1xhLoTTpSpyF4K6rraN PAJga/peUFVO5K106+Y1ao0dmbnmplxvv/Jay4dhv066R2BnOgLBpLbjI0YkJoQd6E5txFFJURdj Nu2n1uau707VrUiMxaQVyS47dZ4ibaSRiq4wvg/9IBHzFtSa5oiknxKi10yxUJcHFmCw8lxTRD75 dMgxi53iyDc82tLCTMgdtCWG2k7KujkWPamoLjqtsqTwEZOorpbIZqgmfHuqQRbvqiup9qYvLtzj OEULwuBHjPnbvA0toHMJEBhGOfhZOojpPq4BtgAtkKpvmS105Yit5FK1K1GJ2IM6IriTp7k6EDKt HMB1lIyvRwDaOTimIiiK0qr3jvswawxzKwxhvVXUVy7m+zHDhfZixiddj+EtNpK6HQ5GyimKc/GR F27+6sliIrsZfYSfaivb9fdRMdseGPBcs+uF2csFru01TYkPicp6SBTmiYYiEJIywBirT7gIAmii BmSlUsjv5NLvsgblJzCfdfhVGO5WyRaOpZoMZrIIyRTjG40KIvgaK4hNK5uPUccUCBFrNakYQ9a5 Nyb1Q1Q8DjhDNVW4XFDdblOK1GdZbWNzfbdNFEHGxIVX46zMZhYrmFwcgY9qTqg9MBp51W5N0nw+ QsuC28gk9HASJszADEVVQItiRF3qN4glxTJVCT5WIBg+O5BaBtqjYJzJe/FjEketamgMJlN2ddLY wXjxZcacU02URMC3RFRVmGjz2btXizhm9xyS5w7thca53A7w14sS6eFI2bLfiCjS9JV3a8qoKEu6 7qs47Kw8+tRvWpz7lOysPPvUb1qc+5ULF0k0+Jd4Sq9DTYRddQH9Q8rYzC22qPjkc4KwyanvuA3v GVSSNyjAjyEeyu8iTpluicqpPJrtnOGxL7b8IHP0uES/XicwvgspyPJeK7KaKDYRSGQKxERwuo4L K9ciHke6D0L2Vh59ai+tTn3K+dlQefeo3rU59yjxlN6kLB1EVbLvmTzMj1EkWK5al2+3Nymo0KDK t8hw0iLOaWdcIanHVoeMcjCO0hG5xAnNuSiKaS6yMgkzLFdrjM1LCxQiyOPYbtAtTzl1ejENvWGk hEaVwRcfbeRtXRAjEG+fiqSrdvZWHn3qN61Ofcp2VB596jetTn3KrvVLxLbrV8CqAyvU6LnloC4R b8N0BuDFnQCjSHLWbrtoUlNQZjeDA0VxIAV1XyMVEk2bAVrCtjuQSoWGXuVN1Vvku2XNiXOjz7Ur Ks3Ry0zhdZjiTSHwWQjDKoaKw31dkNRcLjcnZWHn3qN61Ofcp2Vh596jetTn3Kne6fiRulQo/Crx qTklwYs8q6Zzb7PPvlmR2cTUnrtRnIU1J3GU/GaIQ8IaY5bAINkSI2qIqLU60DnZ69erUmokvILg xc8WiXGWt5j8AjXJJxsqyHiCjf5gQUm/Kvca96qqzbsrDz71G9anPuV97Kw8+tRvWpz7lFi6S1Dw lXRFBwo1pybANPLBk+J3CZ74wpU7K8oLFH7pKbdKa/4XBYcaYcNuS7I6vMlUEaAdx3Ih2k1uvGXs TpTeNOZtFfbi3xZFsTHv+TrVbWo7yWdYEdxtsFeXjF4NCXM1V0XOO3dZ8bR2DCR5IOYZ9ER50nnU ZyUgRxwl3I1RG+8lXvVfjWvbsrDz71G9anPuVG9UlqTutUpJnM9RrZiEB+2y75NfnXd/FYb10ed4 SJc2G34LOZWVHZfQWJTbiELgHxRw0EzEfFk1saydclVc8vGSzsOl3vJbNeo90FFgjY2IjysSD/No g8lBFR/dOXJU3VFRKncjRK0zLhAuM7Kc5lXG29VYEp7IyN2Krg8HFbJW9xUh8VVTv23T41r2maPQ 7jDkQ7lmWoEyHJbJp9h/JjNt1sk2ISFQ2UVRVRUXuVFpvdPxI3Spoj10ukTZOluCP3txxy5O45bz lG8Sk4RqwGxGq96ko8VXfv3Vd6mlsUffCN3p/pR//DUNXSwFVVXOtRe/5MpNP/7K9YmlIHJaFc61 E7zRO/KHFT/DhWyx9O1rGbwVTmTDQj/qP01/3Utf/CN1YFV/oR/1H6a/7qWv/hG6sCqEClKUApSl AKUpQClKUApSlAKUpQCvw850mjcQCc4iq8QTci2TyJ/XX7pQFC4LkuUJiuF6hZXqDElW/Ibe7Pn2 SREiRIraORHJYMw3dhMTZFpRJX3TEgB0l4Kibaeze6kut5iIwxgzY3x662iDFYcurzMV0bgDpNu9 d2KJqIdE+Sg0YEmytke9WjA0N08t15nXWNilvWVNbfadB0SdYEHx4vo2waq011EVUPgI80VeW+60 sWh2A44bR2vHWEeadhvC8++7Ic6kTn4Mam4ZEpNo6Yiqrug7D+iIogFV4R7oPI4GAhc9QrVbpL7l ju91gTwuwNDM8ClAyrbyKyARuSvsoKoTm6eVEPxVz7Z7ozJb9dbfYMf0+Zk5G/MuUaRHl3l+3ssp EjRJHJFkRAeXmk1oEEmQ2LdV8Tx6nzGgWm8di9sN4nAJi9xChzG3FNweipq4QNoRKjKK4vUXp8dz QTXxhFU0V49zHgd4uNrcct5t2yL4e5LhJJfVZsiU0w0b7j/U6imrbHE15L1EMufJVVVA09n900uQ ZHYI1mwu7ybBc3rZGkXAW3zciOzobcptSEGSY6YDIYEyJ8CTkSoBCKKWvs3uoLpLsbNwveCDbnrn Z7fdbMzHvBTUkNy5wQ2wd6cfm2SE60ezYPKokqIimnBbWDR7B2ckg5DHxuDGuUEGRj9ASaZBWW1a ZPoCqNKbbaqAGoqQD4oqiIiV8f0dwaRb2oDuNwljM2kbOyiIQk1DFwXQbA0XkPFwAMSRUISFCRUV EWgKxuHulLzBsaXBcEFp+Hbbxc7pGm3N+GTce3yGWTJhHIiG71EfEwQxZ8iiuypWZkOv+RY3DuXh 2DRim2e4SId0cbvDxwGCbjxZDf8ASxiKgdQJY7E+LLQq05zcHZFKxG9IsLbtS2xbCw7EW3ybcaPO OOm5HkOC6+JmRKRq44KGRkqkpJuq7718yHSDDMpkPSL3ZRefkSXJD7jUl5gnycZaZcBxWzHm2bbD Im0W4GjY8hXagJq24DzYuNEhgaIQkK7oqL5F3r9V8ABbAQbFBEU2RETZESvtAKUpQClKUApSlAKU pQClKUApSlAKUpQClKUBzwOXWzGdXdUmbqzenTkS7U4C26wTbiKIkFE2Io7RoK/1EqL8fkre9qeO /smX+o949mr7jpkOq+rXAiT+n2nyLt/8HpU06znzh/WWvNrWzs9SgpZOBCu1PHf2TL/Ue8ezU7U8 d/ZMv9R7x7NU16znzh/WWnWc+cP6y1jwN7S1IV2p47+yZf6j3j2ananjv7Jl/qPePZqmvWc+cP6y 06znzh/WWnAWlqQrtTx39ky/1HvHs1O1PHf2TL/Ue8ezVNes584f1lp1nPnD+stOAtLUhXanjv7J l/qPePZqdqeO/smX+o949mqa9Zz5w/rLTrOfOH9ZacBaWpCu1PHf2TL/AFHvHs1O1PHf2TL/AFHv Hs1TXrOfOH9ZadZz5w/rLTgLS1IV2p47+yZf6j3j2ananjv7Jl/qPePZqmvWc+cP6y06znzh/WWn AWlqQpNVMdRUXwTL+5fMe8ezVV0FuLbr5dHomVZe3YblcrjOetq6SzVdTwwnTdAZXg3V7idXYvLs iJ5O6uhus584f1lp1XPnD+stWjNR5FJU3Lmzmq9Y1jlwh49Ftt9zeHHs9itFodiSNN7pJjXEbe4Z MrJb6AqbZdZ3kzyQSLpqq+JsUYh4TEts07BaL7mluxF/FXbJPlt6dXBZMtl+5SZDscWvBeDJI0+o I6IqOxlsCKibdedV35w/rLTqu/OH9Za02zM9gjmSVg+Cyrxksnr5Y3Cu7d4WOAaXzvC4z1yaNt5S l+C83Gw6rqthsCpzVCM0RETYZHYcRvlwk3Nubl63AnLY7HC46aXKdFE4cV+Ns4wUceqLjck1VOQq JIKivdsvRfVd+cP6y06rvzh/WWq7Vk7GxQNntmFWSLHjQ382BphLB4oaeXJoSW1zHZSLwCKIj1XH i3RERB+LepnjWa4zjVqdgMhmUoXLlPnq45gt3FeUqU7IIe6N5BV1RRfj23qy+q784f1lp1XfnD+s tVc8ysy0abi7ohXanjv7Jl/qPePZqdqeO/smX+o949mqa9V35w/rLTqu/OH9Zar8JpaWpCu1PHf2 TL/Ue8ezU7U8d/ZMv9R7x7NU16rvzh/WWnVd+cP6y0+EWlqQrtTx39ky/wBR7x7NTtTx39ky/wBR 7x7NU16rvzh/WWnVd+cP6y0+EWlqQrtTx39ky/1HvHs1O1PHf2TL/Ue8ezVNeq784f1lp1XfnD+s tPhFpakK7U8d/ZMv9R7x7NTtTx39ky/1HvHs1TXqu/OH9ZadV35w/rLT4RaWpCu1PHf2TL/Ue8ez U7U8d/ZMv9R7x7NU16rvzh/WWnVd+cP6y0+EWlqQrtTx39ky/wBR7x7NUZ1Hz213/TbNbPZbZl8u 53LH7hDhsJhV2DqvORzAB5FHRE3IkTdVRE+NUq2+q784f1lqvNc7lOgaW3d63XKZbJCzbU0kmNIJ lxsTucUD2MVRU3EiRflRVTyLVoWckZzzZHdky7cMV7/6Ll3qRefZaLrfiqLssXLkX+vB7z7LXNX5 Ruogp78PTcUW3BZUyE4bdseQyYS7LBSMjqvqick/OK6oqokiCgqO61m3PXPIsWK8RLfeMcitWaPP uEe23JJEiZe3EvtxiJFYcJ9SFVCO3txQ1EyFERA8VO7PPQ4MkDojtxxX9ly71IvPstO3HFf2XLvU i8+y1Qd290Ll8DJs3jRoloODZ2chCNFddY6zBW5l42XzQZSyHEdJoeQmw0KC6Cga9yn+8r1wzbEp dzx643GxOXSJkUaC5e2YDbDDUd61lNEejKmtNIfNFbEnH05CJLsp7IrPU0QyU7c2Xz244r+y5d6k Xn2Wnbjiv7Ll3qRefZapVvV3P71Gs0i2TMcspv2/FXJcd21uThOReJLkciBwZQ7NtoAuiPjKW6Cp bbqtraY5bJyCEzGv91t8vI4c2fHltRE6CutRrjIhhJ8HUzJsXFj/ACqPLkiL3bJV1ZpXsWVODdrm 17bcX3VPA8v3Typ8B7z7LXztxxX9ly71IvPstckYhnedv4VpxidxyC6FNiXSy5DPu5Snldm2iZKh tssG6pePvInSG1RV/Rg7KmypvI4vumc6uMG9zG4ligzDZB+HBmo0RWwlu8WEjT4MyyfNOEk1JXWm CRxtUFFTuS+efYUUIdpcmrGqlkyfSzN7JY7dl0u6XTH58OGwmF3cOo85HcAB5FGQU3IkTdVRE371 rOc1Vx0i38Ey9O4U/wCg94+Tb9mqto+s+VRcil2+53vG35cS6XKyHYkgmzOXwK3vyPfRd3+QtOuM CqNoJAjbzaIal3rHR90flaY7Hei3LHMil3KPYXjn2uM20zYjnjLJ2O+L0sWzcDwUEDquM+M8nP8A 2RLKcZVOa5G1OUad7PmXT2p47+yZf6j3j2ananjv7Jl/qPePZqpyZ7oPOhxp/IWHcZYh2awxrrcG SYV/3wU7tKgqjbzcg22gJuOLm4q7sRbIRD31mXX3QeXwMkzePEi2d6BZ4+RIxHceYR6KVtB1WXjE ZRPuI6TY8xNlkUF0FA1TZTy2LNduWv2p47+yZf6j3j2ananjv7Jl/qPePZqi9rzbPbfqCxZcmvOP XS2BlQ44+MKyuw3XFetK3AHxNZLiDwXZpA4ryFFVV5Km1uo86qb9Q/rLWUoqPM1hKU+RCu1PHf2T L/Ue8ezU7U8d/ZMv9R7x7NU16rvzh/WWnVd+cP6y1X4TS0tSFdqeO/smX+o949mp2p47+yZf6j3j 2apr1XfnD+stOq784f1lp8ItLUhXanjv7Jl/qPePZqdqeO/smX+o949mqa9V35w/rLTqu/OH9Zaf CLS1IV2p47+yZf6j3j2ananjv7Jl/qPePZqmvVd+cP6y06rvzh/WWnwi0tSFdqeO/smX+o949mp2 p47+yZf6j3j2apr1XfnD+stOq784f1lp8ItLUhXanjv7Jl/qPePZqg2eXe3ZVd7JdrBecux2fa4k uHyPTC43AHmpBsmSKD0bYVRWA2VO/bdPjXe7uq784f1lp1XfnD+stTGSi7orKEpKzZQLbNiSJe3H r3m7t6u7likuTU02uTbbcm1k2TbgsDHQeJq0PIN0RPiqvLxp9bYEK4y8avmaTb7IVmOEuRpxcRkm 378RpyyZEgo6rIkNoyfeewmiCIgC7qXYPVd+cP6y06rvzh/WWtFWaM9gcx33D8YyDqz7pd8qnZHN kz3LnOm6Uz5Md4JTbDRC1GOPsyTYRGEbNSNUVDU0PkqVJpMTB5BttiWcMwW8ghXkYoYHdRHjHtoQ Ej90ZNhJsEVSFEVF8iJtV7dV35w/rLTqu/OH9ZajasbE5uw/GMNxSEEZJGUvLHk2dYzsbS64xHFj W6SMhpt4gjqrzhkIobqqiLxRUBF33mFivGLWK6224A7m0g4A3wRA8DuyIfvnOCWaqvg/dwIEFPlR d128lXD1XfnD+stOq784f1lqHUuSqViFdqeO/smX+o949mp2p47+yZf6j3j2apr1XfnD+stOq784 f1lqnwmtpakK7U8d/ZMv9R7x7NTtTx39ky/1HvHs1TXrOfOH9ZadZz5w/rLTgLS1IV2p47+yZf6j 3j2ananjv7Jl/qPePZqmvWc+cP6y06znzh/WWnAWlqQrtTx39ky/1HvHs1O1PHf2TL/Ue8ezVNes 584f1lp1nPnD+stOAtLUhXanjv7Jl/qPePZqdqeO/smX+o949mqa9Zz5w/rLTrOfOH9ZacBaWpCu 1PHf2TL/AFHvHs1O1PHf2TL/AFHvHs1TXrOfOH9ZadZz5w/rLTgLS1IV2p47+yZf6j3j2ananjv7 Jl/qPePZqmvWc+cP6y06znzh/WWnAWlqQrtTx39ky/1HvHs1e0TVXHQlMl4Jl67Gi7Jg949mqX9Z z5w/rLXvBdcWYwiuGqc0/wBpaLKVkpWfE1uhH/Ufpr/upa/+EbqwKr/Qj/qP01/3Utf/AAjdWBXs HjClKUApSlAKUpQClKUApSlAKUpQClKUBBIGs+D3PFcbyeFfm3LHk1ybtdokrGeFZUs3SaFpAUEN FU2zTckREQVVVRO+p3vvv/VXImK+5pymxx8PgvJDKzWE7DeW4fhCqrN4SRAS4GK8uKiLMKQYrsnI 5zu2/wAWOz7njJrnZ3bLPxO3W9EiRYeQzyvKurlr6XeJJdmuoic+5liUXJ1UcQpZNinEUJQOw611 sv1vvEu7RbbI6z9omJCnD0yHpPKy28g7qiIX5t5stx3Txtt90VE5WyD3P+RMxbxbYeGWXIMeelZD GstpKY2DFqScsU404BMURpGyafRRaXmHU3bReRIm9TRXKWtTGrmFqgyLpHvEG5hnDsgBkvNR7SzF ciG2n5xBfdA+SIpBwdMv0hDkB06q7Iqr3IlYDF6t8q7TbVHmMu3GC0y9Kjie5sg6po2RJ8SF0z2/ 8la49xf3PuW2qzIxNw2MdpRbDJuOOpLhNM3UoXhSSGSRkREhVx9h5vwgnSdSMKPOIq8R3E3QTII6 OFAwWztQJ8OzDOt0aYzMNlth6cpx2ymbtvEAvQu98SaQGVRseTTKIB1zSuR7J7mi6z8YtUbOcftV yutqtmPWmM5JlDJVuPEvMl2WjbioiiDkM2kREQVUSVvZNlSl80DyWNcsdLHMVtxnartOdtTqzWPA bewd8cltI5GUBcYRI5CoOQ3Ec5CLTgqAoqAdcUolKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUo CqL1pTkR5jkGQYjm42IL6sY5UR+xsTURxlrpIQmRIqIoom6Lv3+TyrXl2b6jek+H6oRvv1blKq4x fYWUpLkyo+zfUb0nw/VCN9+nZvqN6T4fqhG+/VuUqMkdCc8tSo+zfUb0nw/VCN9+nZvqN6T4fqhG +/VuUpkjoM8tSo+zfUb0nw/VCN9+nZvqN6T4fqhG+/VuUpkjoM8tSo+zfUb0nw/VCN9+nZvqN6T4 fqhG+/VuUpkjoM8tSo+zfUb0nw/VCN9+nZvqN6T4fqhG+/VuUpkjoM8tSo+zfUb0nw/VCN9+nZvq N6T4fqhG+/VuUpkjoM8tSo+zfUb0nw/VCN9+ojeIGolpzi2Yx2hQXfDbNMuRSFxKPuCsPxmkBE6i IqF4Sq/1cE8u/d0VVQ5girrnjfk/6HXbyrt/47ba4cfLY4SpUhwaRrRblUim+00Xwd1E9JUP1Njf jU+DuonpKh+psb8ap3wX5R+un204L8o/XT7a/Pet8Z3/AEXse5u9Ignwd1E9JUP1NjfjU+DuonpK h+psb8ap3wX5R+un204L8o/XT7adb4zv+i9hu9Ignwd1E9JUP1NjfjU+DuonpKh+psb8ap3wX5R+ un204L8o/XT7adb4zv8AovYbvSIJ8HdRPSVD9TY341Pg7qJ6SofqbG/Gqd8F+Ufrp9tOC/KP10+2 nW+M7/ovYbvSIJ8HdRPSVD9TY341Pg7qJ6SofqbG/Gqd8F+Ufrp9tOC/KP10+2nW+M7/AKL2G70i CfB3UT0lQ/U2N+NT4O6iekqH6mxvxqnfBflH66fbTgvyj9dPtp1vjO/6L2G70iCfB3UT0lQ/U2N+ NT4O6iekqH6mxvxqnfBflH66fbTgvyj9dPtp1vjO/wCi9hu9Ignwd1E9JUP1NjfjU+DuonpKh+ps b8ap3wX5R+un204L8o/XT7adb4zv+i9hu9Ignwd1E9JUP1NjfjU+DuonpKh+psb8ap3wX5R+un20 4L8o/XT7adb4zv8AovYbvSIJ8HdRPSVD9TY341fCxvUIxUT1IhEKqiqi4bGVO5d0/wDDfKiLU84L 8o/XT7acF+Ufrp9tOt8Z3/Rew3ekV/8ABXPlHiuosDjw4bfAuL+jy5bf6Xyb9+3y99a1NNctTInM hXPYJXc47MbrHh0YkAGnHnAUBV3xC5SXVUk2VeSb+SrS4L8o/XT7acF+Ufrp9tT1xjfxPRew3akV 4uH52smTKXUK3LJlNIzId+BMXm62nkAi6u5CnyL3UmYdnVyjyI0/UG2y2JKj1mnsJimLnH9Hkiuq i7bJtv5NqsPgvyj9dPtrFublwiWufJskZibdGYzrkKO6+LYPPoCq2BFv4oqaCir8Sb1K6Xxrdtp/ Iq8PSSbK3sa5Vl0u9N2DVi23SVZ7j73XNAwtjkxKa8bplycTdRVe4k3RFRURd0Xb2j4llzWUy0ja iWocmS3tLIQcNjeEJDJ50m9/z3cCu9Ze7ykiqvxVXjeiWY4Jjs6HYBseoLt6x0IVxi3qPFZYG4My OszJLkKpIRDkSy/OIpKot8iXypgW33PHQWywYOA2q22UmrOzPSfdI0t/hEuzz8rqkI7OLIZcbJUH YU6aN7IggietvlR3axHDs4R+rfJ69n1OLI+TiXGOHaiC2IDqDCQEEAEUwqLsgiu4Jt1fIi7qnyL3 pXm3hGfg5Mdaz63i5MMXZRjhMTd4h/RI16vjKm3cq77VU0jQfLJd1zFWDCFcJcK8x27wM2I2xdGJ TwGxGIG2kkIKNB0l6pqLPFOlyHuSS2LR47xdrc/kOGWKzYm5lbl1LFnCivsQY42koqLwbRWiJyRx cUB3RNhJfGUqzeNrqN94Xkv1+uJbKu4S24aeZ1dEn+H57DNyfCODJdHDIwPHHJFQm+ojvLbv8m+y LXla9Ls0s2PBYLdm8ELOLAMLGPC4riOiICCdTd3xyUQHdS3VdqquFoznMa/4BJmWm3vHjcPGGxnR 50TqAzDcXwxkjdFXeS7rwFgmmzBV6hESIBaOL7li+WzG2BtlnsLOQR8WjMtzAuPFxLwF18IKQjm2 6H0O5Hf0kRemmw91bRxNW3HFLyXuRlXZAvtcVz5W+muosBQ6Qs8fgXF26Y/ojt1f0U+JPIlfksQz spUqUWoVuWTLaRqQ6uFRebwJ5BMuruSJ8i7pVjPDyfdIVHiRkqeOnk3/AL68+C/KP10+2vG64xv4 novY7Vh6ViBLjOoKnzXUeCp9TqcvgZG358ePLfreXj3b/J3V+vg7qJ6SYfqbG/Gqd8F+Ufrp9tOC /KP10+2nW+N7/ovYnd6RBPg7qJ6SofqbG/Gp8HdRPSVD9TY341Tvgvyj9dPtpwX5R+un21HW+M7/ AKL2G70iCfB3UT0lQ/U2N+NT4O6iekqH6mxvxqnfBflH66fbTgvyj9dPtp1vjO/6L2G70iCfB3UT 0lQ/U2N+NT4O6iekqH6mxvxqnfBflH66fbTgvyj9dPtp1vjO/wCi9hu9Ignwd1E9JUP1NjfjU+Du onpKh+psb8ap3wX5R+un204L8o/XT7adb4zv+i9hu9Ignwd1E9JUP1NjfjU+DuonpKh+psb8ap3w X5R+un204L8o/XT7adb4zv8AovYbvSIJ8HdRPSVD9TY341Pg7qJ6SofqbG/Gqd8F+Ufrp9tOC/KP 10+2nW+M7/ovYbvSIJ8HdRPSVD9TY341Pg7qJ6SofqbG/Gqd8F+Ufrp9tOC/KP10+2nW+M7/AKL2 G70iCfB3UT0lQ/U2N+NT4O6iekqH6mxvxqnfBflH66fbTgvyj9dPtp1vjO/6L2G70iCfB3UT0lQ/ U2N+NT4O6iekqH6mxvxqnfBflH66fbTgvyj9dPtp1vjO/wCi9hu9Ignwd1E9JUP1NjfjV8XHtRER V7SofqbG/GqecF+Ufrp9tfFbXivePk/XT7adb4zv+i9hu9IrjBrZqNma5KK6hwIi2S+yLUijiUde qjYNkhru4uy/nP8A7nkSpZ2b6jek+H6oRvv166Gps5qT/vtO/wDdMVa9fpOGSnQhKXNpP0PAlOSk 1cqPs31G9J8P1Qjffp2b6jek+H6oRvv1blK3yR0K55alR9m+o3pPh+qEb79OzfUb0nw/VCN9+rcp TJHQZ5alR9m+o3pPh+qEb79OzfUb0nw/VCN9+rcpTJHQZ5alR9m+o3pPh+qEb79OzfUb0nw/VCN9 +rcpTJHQZ5alR9m+o3pPh+qEb79OzfUb0nw/VCN9+rcpTJHQZ5alR9m+o3pPh+qEb79fW9OdR2zE k1Ph7iu6f80Yyf8A+SrbpTJHQZ5amiwjGQwvC8dxpmQUtuy2uNbwfIOKuoy0LaGqJ5FXjvt/XW9p SrlBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUrRws0xu5X+Xj9uyC0y79DFSlW1mc0clgU23U2kLmK eMPlT/aT5a2cy5Q7csdLhLjxFkvCwx1nRDqulvxAd17yXZdkTvXZaAyaUrwWdGSYMJZDKTDaV0WF cTqK2ioimg+XiikiKvk3VPloD3pSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQHH+ pkK0ydUczYk41jF4v1+yewY/bbjf7U3PbtqPQCcNxGz2U9haPi2hChGQ7926L+ZGG4tp+7Hh5vi+ nWSixNkGTtvxOEzMeiDapcxG5TG3CM5yjLwcBSRwR7xDvWpFkkeddNS9VrU1g3wwtz82zPOODfmr acZ9uIJNqBqqOCYqIkhgSL39y9y76+Tid8OwzbfC0qlhcJPhL3vpNztmdIWU9Cch9d03SUneLLpC gkqiieRErGXHgUZpwu2nax4TbvuerM1eLq9bfemAsC1r4UxPaknHeJzjs1ssN4XAIdx8VUUkWtPl eR4AGD5BecU0RxZhH7HLueKXKdard0bizHfaZfeJrihtcEfB0ALfqB8Yr4tSzFsIuWLwLI0Okcmf NtDkB9iZJz5t0kdiMuNMqKOGXBsUfeUWk8ROovd5NjeBuNxrxDHRWR733SO/FOEuoLfg8dh94Xn2 47XPiwLjoCZI2g7qieRO6qWiRwNI3LwW0267++Gi2MZLJsB3abenYNjt8VYVqi3CTFB1RMeLrypE dJWxId0bLZU3FF30s9Kod3ym1vaLY6MjGI7824OOWm3NMJEQBKK+LxijapI5KgipIrfTd57cU5et 5w+VfnxeuGizvNXJRSOjnzTKS25MgpLzD6ASdVknzJzpHuKKS7IiKqL+LvhDl9k3KXdtEFkzLmck 50gs8ZRyQr6tESGSF3iJMME2PkaVoFbQdqWTI4Gost004yaMkfFdBsbvt/bmz478GFEtps9KGEc3 X2pSgguiSTI4gnAVIjVF4onJcaTcdPLTBvMhNFLBkCwJV8kyACxWyCUG3251gXlJC5dUhR9ETbYj VFRUHy1tH9OXJVukQpejlykJKkOyJMhzUvlJfJ5oGZCG/wBTqKDzbYC4HLiSAPd4qbbkMfnMx7nH j6JAxHucS4w5LTWbRhBWJytrJAURdgQui3tx24oOw7JvSyJ4Fl6J2i0WK4alwcXt8K1WgMoZcjRY UYY7ICdntprxbFEQd1JVXu8qrVr1z5iN+z/FJ2UvhpmLrN6ujU1loMphbsAEGLFQCVV71/oqlv8A ISfGlSftOz/0Vl61QftraLSViyasW5Sqj7Ts/wDRWXrVB+2nadn/AKKy9aoP21OZE3RblKqPtOz/ ANFZetUH7adp2f8AorL1qg/bTMhdFuVSWo+NWTKtasYhZXZbZf4TOJXZ9uPcobclsHPDbcPNBNFR C2Ik38uyr8tbHtOz/wBFZetUH7aid0vGoFyzy2ZP2bIAQrJNthR1yqEhGr8iK6hIveiIKRlRfl5p 3d261k04tIhtWZIOx/Tb0b4X6vRfuU7H9NvRvhfq9F+5WF8L899Fx+t8H7tPhfnvouP1vg/drjyT 1MMrM3sf029G+F+r0X7lOx/Tb0b4X6vRfuVhfC/PfRcfrfB+7T4X576Lj9b4P3aZJ6jKzN7H9NvR vhfq9F+5Tsf029G+F+r0X7lYXwvz30XH63wfu0+F+e+i4/W+D92mSeoyszex/Tb0b4X6vRfuU7H9 NvRvhfq9F+5WF8L899Fx+t8H7tPhfnvouP1vg/dpknqMrM3sf029G+F+r0X7lOx/Tb0b4X6vRfuV hfC/PfRcfrfB+7T4X576Lj9b4P3aZJ6jKzN7H9NvRvhfq9F+5Tsf029G+F+r0X7lYXwvz30XH63w fu0+F+e+i4/W+D92mSeoyszex/Tb0b4X6vRfuU7H9NvRvhfq9F+5WF8L899Fx+t8H7tPhfnvouP1 vg/dpknqMrM3sf029G+F+r0X7lOx/Tb0b4X6vRfuVhfC/PfRcfrfB+7XjKznNYTCvzdNBjsoYArj uYwAHkZIApuqbbqRIKJ8aqiJ3rTJPUZWbPsf029G+F+r0X7lOx/Tb0b4X6vRfuVhrl2eiqoWlpoq dyouXQe7/wDpr58L899Fx+t8H7tMk9RlZm9j+m3o3wv1ei/cp2P6bejfC/V6L9ytLdNR8sscduRe tPWLaw46jLbkrNbc0JOKiqgIpIiKSoJLt5dkX5KzBzHOzESDS8iEkQhVMvgKioqboqeL8nfTJPUZ WZ3Y/pt6N8L9Xov3Kdj+m3o3wv1ei/crC+F+e+i4/W+D92vw9mucx2XXn9Muky0BOOOHmEBBAURV UlVR2RERFVV+RKZJ6jKzYdj+m3o3wr1ei/cqnWsGtWRzsoySxY1pPYsdxnI5Nm96bvi8UGJLUZwG n3pE5EUmHCIjJtBBRFEbQkLkqpaMfNs3lx2pEXTJH47zYuNON5hAITAk3EkVB2VFRUVFTyotRS5Y 9dLtfXrvP0elOOyZLUyZFHUBoIcyS2oK28/FEkZdMemHeQLvxTffZK1gnG92XircyNXCbp3YPfds tFsfyf3rW83Ke/FsNthpEtkK5PxTVBPfquALKqibiriCq+KvdWZKl6du5Tc8ZxnQGwXy8MXKRboA pAtkduc5GbF2SaEQL0wBt1jZS/SN4RTbYiT8XfT29X3Kju9y0ulFbXLfKiO2xnOWmEeOTOOZJJxx sxVxtwzXdkkUPkRNkrcXTGLjdFedPR2TDnOXh+8pOg6gNRZTct5tGnjB5skMBNsUAgRUBURO7dEV LWRNkQlLhglyzzHJdv00wm3aeTrXBuDzsvGYTjxR34NzlOOFwFSbMPe5W+A8k8Rxd15BW2DItKoN venZVoXY7CwzFg3Z3lZ7fJJuzSzNsJ5A2HLxDBEdYRFMUJFFTRFqWs2m5x5VukM6JtitujxYsVtc 0jE2DMdiSw03wVeJCjU2QKoSLyRzxt1RFTU2zCJNrhNwh0amTYTbsQgYn6iBLbRuKprFj8XTJFYa V0yFldw5KiqiqiKiyFkYku4aW2vIMVtF50VxS3yL85b2nGHIlrKXDOa4TbHKMg8yFFQeoXioHNEH qKi1+IrOC3hMOmDolYcfsmS3qC1a57+PW2UNwhvi8qchTisc1FsT2/OKgkPlXkiekbTg4UiA9C0a nxlgLDJgG9SEQFOISLFcMeps4TSIgAp8uIII+RE2zbVhLllujNyt+iCtyostiVDU88ZcGH0SdJtp gSJRaZEn3S6Qogbl5PFHaUkgkkfdOGtMdQJoRH9Fcbx52VYo1/t3hVot8jwqC8atoa9MNmy5J+gq qqiqKuy7ili9j+m3o3wv1ei/cqIWKHfMalwZVk0cWLIg2RmxR3PhrFNQgtOdQGti3Rdi7+S7kvxr Ui+F+e+i4/W+D92spRbfBlGtDN7H9NvRvhfq9F+5Tsf029G+F+r0X7lYXwvz30XH63wfu0+F+e+i 4/W+D92qZJ6kZWZvY/pt6N8L9Xov3Kdj+m3o3wv1ei/crC+F+e+i4/W+D92nwvz30XH63wfu0yT1 GVmb2P6bejfC/V6L9ynY/pt6N8L9Xov3KwvhfnvouP1vg/dp8L899Fx+t8H7tMk9RlZm9j+m3o3w v1ei/cp2P6bejfC/V6L9ysL4X576Lj9b4P3afC/PfRcfrfB+7TJPUZWZvY/pt6N8L9Xov3Kdj+m3 o3wv1ei/crC+F+e+i4/W+D92nwvz30XH63wfu0yT1GVmb2P6bejfC/V6L9ynY/pt6N8L9Xov3Kwv hfnvouP1vg/dp8L899Fx+t8H7tMk9RlZm9j+m3o3wv1ei/cp2P6bejfC/V6L9ysL4X576Lj9b4P3 afC/PfRcfrfB+7TJPUZWZvY/pt6N8L9Xov3Kdj+m3o3wv1ei/crC+F+e+i4/W+D92nwvz30XH63w fu0yT1GVmb2P6bejfC/V6L9ynY/pt6N8L9Xov3KwvhfnvouP1vg/dp8L899Fx+t8H7tMk9RlZm9j +m3o3wv1ei/cp2P6bejfC/V6L9ysL4X576Lj9b4P3afC/PfRcfrfB+7TJPUZWZvY/pt6N8L9Xov3 K+Fo/ptxX/ub4X5PN6L9ysP4X576Lj9b4P3a+Ll+ebL/ANy4/J53wfu0yT1GVm30AtkGys6iW6zQ o1tt8XNZzceLFZFppoUaY8UQFEQU/qRKt+qe9z5JmTIuoci629bVNdzScT0RZISOkXSY7uYeKvds vd5N9vKlXDXeuR0oUpSpApSlAKUpQClKUApSlAKUpQClUpYtaMyyWxWy92XS9522XSI3MhuO5LCb I2XB5ASiq7iqiqLt8Xk8qVky9Wc3gRzkTtMgjRwUUJ13LYACikSCKKqlsm5EiJ8qqifHVcyIui4q VUZam6gCqoWlRIqLsqLlMHu/+7TtOz/0Vl61QftpmQui3KVSt21ny6wxEl33TuNbIqui0j0vMbcy CuFvxDkRInJdl2TyrstZqan5+qIqaWKqKiKi/CqD3oqbp8fyUzIXRbtKqPtOz/0Vl61Qftrzf1Vz qMw6/J0vRlhkCcdcPLIAiACiqpKqrsiIiKqqvkRKZkLouClU+xqrnclhp+NpejzLoC424GVwCExJ EUSRUXZUVFRUX40WvTtOz/0Vl61QftpmQui3KVAsC1BueU3292TI8Ydxm42uJDmcCuDMwXmZBSAB UJruRUKM5ui/1LU9qy4kilKUArzfBxxhwGHEZdIFQHFHlxXbuXb49l+KvSlAcVT7fcfgBpthuMYF k2N6iWWQ14VkCWRxlmHObbIJBrMAVbeSWSEKHyJsusJOqCpUkx296hZXkOOSStWYsWuNMxZuUl3t JM+OMacs9xAdHdERwmBNxERVIU4qoqJL1jSgOR7ZB1EsmOWlu5yM8mW652bF52Su9SW/PYccdkpc G4yD+cbNP6KjjbSIYtoRInNd1x5VnzoxtN2SLmXMLDPgncBjmtzC0HkENQBV49TwxbcDhIm3W3RV /wBIi12BSgOSZ9s1CvGOXT3tl53Gt9vtOUzcbRXZjE18mjiJbW5XLZ0zU1lK22745toHNC8ZFkU6 TqI7q9LeaLImW1ml4I1FhyTirbPerkifnCCCLqy1LZXFV5HUAV/MqtdKUoCiPcyO5T7136PlqZTI jtHEWLPyHwho5LisJ1uEeUHXZVFEVMUcdZ5mXRJBRRS96UoBSlKAUpSgFKUoBSlKAUpSgFKUoBSl KAUpSgFKUoClscFV1X1b4oq/0+0eRP8A83pU16Z/qF9Vaq0MSt+SavapPXGXfopx5VqbBLXkM22i qLBRdyGO4CEv9ZIq+REWt/2X2T6Vzj17u349cFW2Y552uTPpn+oX1Vp0z/UL6q1DOy+yfSucevd2 /Hp2X2T6Vzj17u349ZcNSvAmfTP9QvqrTpn+oX1VqGdl9k+lc49e7t+PTsvsn0rnHr3dvx6cNRwJ n0z/AFC+qtOmf6hfVWoZ2X2T6Vzj17u349Oy+yfSucevd2/Hpw1HAmfTP9QvqrTpn+oX1VqGdl9k +lc49e7t+PTsvsn0rnHr3dvx6cNRwJn0z/UL6q06Z/qF9VahnZfZPpXOPXu7fj07L7J9K5x693b8 enDUcCZ9M/1C+qtOmf6hfVWoZ2X2T6Vzj17u349Oy+yfSucevd2/Hpw1HAmfTP8AUL6q06Z/qF9V apTVqPj+lGFO5M+Wd3gGpsaMUZvP7uJqLpqhEOzy7qIoqoPx7eVK1VwyHBrdqJfcYdm5+/bLPaIs 07rFza9yDkSZDrAMxGWG3VV0iGXHVFFd93RRURPGq6ptq6LKNzoDpn+oX1Vp0z/UL6q1RS5JpK2x CckZdqCw7NJ1qPDcyi/JKcktSAjuw0Y6vNZQuOtorG3LiaGm4eNWgm5RZY2T49Y4cTNLgl0kk1Km tag35GI4+/Q2seBqqIRoZKZoXAU2QRIuYEpU2xkOlOmf6hfVWnTP9QvqrVHx71pZKYuMpjKNRit8 Fk5KzlyW/pHkRgeBl2Sw71eLzLbjgobgboKLy/R8av1Ou+l0CFHnuZRqG/a3zNEuMXKL6/EBsX1j 9c3geURZJ1OIubqhfpJuPjVGRkZS7umf6hfVWnTP9QvqrVHXOfgMSfLtkK958dyjzm4YFOyzIY0O Sfh7MJ8WZKGQuk06+IkgoqclRFVBQiHbWWLp/kWRSbDZ79qOU9lJagUnJr9GYk+CvdGSjLxuoDqt OKKEgKu3L49l2ZLDKW30z/UL6q06Z/qF9VahnZfZPpXOPXu7fj07L7J9K5x693b8eq8NSOBM+mf6 hfVWnTP9QvqrUM7L7J9K5x693b8enZfZPpXOPXu7fj04ajgTPpn+oX1Vp0z/AFC+qtQzsvsn0rnH r3dvx6dl9k+lc49e7t+PThqOBM+mf6hfVWnTP9QvqrUM7L7J9K5x693b8enZfZPpXOPXu7fj04aj gTPpn+oX1VqCa0Q5knTO5jAts+6PNXK0SViwYhyX3G2blGdc4NCm5qgARbJ8lZHZfZPpXOPXu7fj 187L7J9K5x693b8epVk7hWTK61dybLsqiQ7hgcLN7NaAjXVCBmyXKJNO6ILSxFVloRcJribih1FS ORiSOqmybY+QRdaYs3I4NocvDqwbXIv8OY2aEMiVIissJb203VF6L3vg+DPI0RUipvttvZvZfY/p XOPXu7fj07L7H9K5x693b8etdpFKxpmRR2cYhlGTWG5t2iJm14sUSVeW8eC8BOKYrTuNyQcV4H0R 1RKYQttK4m+7jgJ4piiye3hmETLAbltZuwka4SWZsZhmb72Djg238z4OgJw8M6iNcemvX63URU4I lWX2X2P6Vzj17u349RnUjBIFh01zW72e+ZvGuVsx+fMiPLnF1PpvNRzMC4q/suxCi7Lui/HVlUTd iVNMquc9qwuNNQrzF1EW6vOqSyojktAaYG3L4C2QxRQyfJ0zV9UcbbF9vd4lbVoV3MSXqFd22Xcq j6l/CGRYLctratsHpW01K1O+G+HNGKM81lo6hi4KPf6v0E2Va6F7Fsc7/wDlLM/Xq8+1U7Fsc+ks z9erz7VW+Rl7FI4vadQYlyxO6yXMtQ28gstsm254nAhNWwrCyspxYyIjfdLUkJzZUAw2HivJFv0W 3Nk3At//ACVrA7Fsc+ksz9erz7VTsWxz6SzP16vPtVZzpOZWUMxn9M/1C+qtOmf6hfVWsDsWxz6S zP16vPtVOxbHPpLM/Xq8+1VTd3qV2fiZ/TP9QvqrTpn+oX1VrA7Fsc+ksz9erz7VTsWxz6SzP16v PtVN3eo2fiZ/TP8AUL6q06Z/qF9VagOrGmdrxjSvOL3ZLzmca52zH58yG98N7ufTebjmYFxKSors QouyoqL8aVmuaW2MC2S7Zwviiv8A07u3xoi/P1nOnk5sq45ebJj0z/UL6q06Z/qF9VahnZfZPpXO PXu7fj07L7J9K5x693b8es+GpXgTPpn+oX1Vp0z/AFC+qtQzsvsn0rnHr3dvx6dl9k+lc49e7t+P ThqOBM+mf6hfVWnTP9QvqrUM7L7J9K5x693b8enZfZPpXOPXu7fj04ajgTPpn+oX1Vp0z/UL6q1D Oy+yfSucevd2/Hp2X2T6Vzj17u349OGo4Ez6Z/qF9VadM/1C+qtQzsvsn0rnHr3dvx6dl9k+lc49 e7t+PThqOBM+mf6hfVWnTP8AUL6q1DOy+yfSucevd2/Hp2X2T6Vzj17u349OGo4Ez6Z/qF9VadM/ 1C+qtQzsvsn0rnHr3dvx6dl9k+lc49e7t+PThqOBM+mf6hfVWnTP9QvqrUM7L7J9K5x693b8enZf ZPpXOPXu7fj04ajgTPpn+oX1Vp0z/UL6q1DOy+yfSucevd2/Hp2X2T6Vzj17u349OGo4Ez6Z/qF9 VadM/wBQvqrUM7L7J9K5x693b8evi6YWNEVffXOO5PPu7fj0stRwJp0z/UL6q06Z/qF9Va5uueYY namdWfCRz1ZeASGmI7AagXgluyul0muP57cVV9UbLZC48kXvVdq3dpvWndwctcWXd9SItxnRo5KD eU356KMx2GMtIISuojbkhWiQhbRdy7kTxl41psmWyF7dM/1C+qtfCbPiXiF5P1Vrna4ZppsVmO74 lkOZ5JAZYkuuuN5vfmkMmra7PRhk+agT3TaRHAIh6XNELx/EX7Ysow9+yuTMwLUWzT25CNLBt2W5 DPc6SQYct6QTfMXG220mgJKQ92wqm6kiVGzYyF06JoqStTd02/58Tv8A3TFWpXMESNpJAuj9utmU 5YxPm7XE2omY3jlLacirI8OTi9+dZVpvveTdOQoC+MqCvkF205dhSX2bxqu5LjzGoS2ob5kK3A3n GTfbQYvV5qhMtm6i9yIIlvsqbV1qp4M1zeB1JSuUxyDThGzkLkeoE6LJkgzaBtWVZDMkzUWAxNJV ZQkUCFp9CVO9EFO9RJFFJ3bMDxm9WuBdLRf84l264RWpcR8c6vAo6y4CGBohPIqbiSLsqIvy0dZL mmM6ReNKpjswsv0vnPr5dvx6dmFl+l859fLt+PVdvEjaIuelUx2YWX6Xzn18u349OzCy/S+c+vl2 /Hpt4jaIuelUx2YWX6Xzn18u349OzCy/S+c+vl2/Hpt4jaIuelUx2YWX6Xzn18u349OzCy/S+c+v l2/Hpt4jaIuelUx2YWX6Xzn18u349OzCy/S+c+vl2/Hpt4jaI89FgJdFtN9hJf8Amtbvi/8AyA1r 9fLTcLtpFf4tptk66ykkW15IkKMT7zoNXCM45wbTvJUACXZPkWsyDpDjNrhRoNrl5jBgxWhZjxo+ b3VttlsU2EAFH9hFERERE7kSsjsvsn0rnHr3dvx65U0pXMk0ncrnVnJ8vypqNPwSFmtms7cS6IKN WO5xJjl1TpLFUmWxEya4G4oK7tHIxJHVTZNsbJ4es0WflEOyvXx5u3QZF8hSWXBVJL0phhlYLXlQ vBz98nm2eRcS8ETdURN7P7L7H9K5x693b8evnZfY/pXN/Xu7fj1ptIovmRSOfYZkuXYdeI1ui5pd 7FFut1THG7qE5Z5MHjcsSV4H0R1QWaqNtK6nL86QJ4poiyWP8MGMvkDPbz1lWLlcG7gxFZle9g46 NvXwbwTinBZfNGOHSXr9bqoScUSrK7L7H9K5x693b8enZfY/pXOPXu7fj1O1iM6KSckaoDisSHkk PUB28SJ4JKkxHJiNsRktxLETaIiOE4Tir1lAwFJIfnS6StoXvFl6gXe3q7k8fU5ckfx6ClrYhQVb tp72hxJnhjRijXUWYjyGLidZf6N0UUVXe5uy+x/Sucevd2/Hr52X2P6Vzj17u349NrEZ0QDG7Tnk a9YvdpL2WJxyG12yZbnSdGE3a1sDRSHFjoiNoiTFJFc22ExUR4rui3kLbnFNwLfb9VahnZfZPpXO PXu7fj197L7J9K5x693b8es5SUismmbnEkVNZcx3RU/5q4/5f/ObrVnVTmmWPRMb1azaLb5F1ktO Y3YXlK53aRcXEJZF0TZHHzMkHuTxUXZFVV23VauOu2n+wjaPIUpStCwpSvhEgCpEqCKJuqqvkoD7 SuOrT7oXJrRMzvKJYzZFqvtgm37E4t4iuQ4wjBcUQbj81QnevEJiSfFU2VDVE8qpIcz1iz2z2bMo 1+94HosA7vZDfs/hUOT4U1ZHbm3IaMnC6aIAo0o/pIadQT28WgOpKVzje9fclxi45HPegWa4YvZL tdbOkUDdCcbsK0OXAXFeUiDYkZNtR4bpyEt170r8ta25qxdGMRlzNP5mST51mZjXmFJfW3MBOiy5 CgbKkpm6iQTRpEdDrJJjl+b3UVA6QpXJ+M+6Fv8AIM8xvTlpKyMQ7S3eWYstxyGxGO73aC9PjFt4 ybsxXFUk2VpC+NErZWv3ReXPRHrveYmK2qLaI8J+6WSVIeZuExZkV2WyzDUl8Z8WkZbRsm/zzoSB Qm0BFUDp6lc19umbR7TJjEGJXS/SYtiuFvdgOF0ejcCe5MA04+KypABHcMAB1tXxJFERVOJa3Dtc ciye4q3YZFjK7Xy6Wm2JJlSpbkCM6sGU/IJuKaNuAqrDNsW1UVVwvGVePjAdTUrkrT/XTNI+NYq0 TLeRo3Dtsm7y3A6pzFuFzkRgBmQTzYNI2jK8FIXOqvFvxF8ZbT051TvuT6i3qwX1q1s2/hOftBRG nSV5mNMSOrgSRNxh9FQ2+Y7susmvAmi7zQC4qUpQClKUApSlAKUpQClKUApSlAKUpQClKUBz/NvU nC9U9Q3rnjGWT4l4ftr8KTarG7OacFuJ0zTkHkVCRUVF2XyeXes7tVi+Z2ofqfJq8qVk6UZO7KuC fMo3tVi+Z2ofqfJp2qxfM7UP1Pk1eVKjYwIyRKN7VYvmdqH6nyadqsXzO1D9T5NXlSmxgMkSje1W L5nah+p8mnarF8ztQ/U+TV5UpsYDJEo3tVi+Z2ofqfJp2qxfM7UP1Pk1eVKbGAyRKN7VYvmdqH6n yadqsXzO1D9T5NXlSmxgMkSje1WL5nah+p8mnarF8ztQ/U+TV5UpsYDJE5vyvKbTl8a1R7liepTb VuvMK6ijWHv/AJw4znNGy3RfELfZfj2qromLYZj8K0WaAxqxBvEG3uOWx9zEjekq4zPjyQlqJNKj nSJuMyoqnHpqI7Juip3DVK6hoi61Y3v5oXb/AI221hiZbtQlUj2G9CkqlSNPVlKFZbE8EWQ/2yDe Y0129BPYxF9tSvTjwGU8mumrZqjbYxxaIVbFpTFE3JSrZx2MUjXG3TW7HqmhQXidBv4Gv8CUr23d u/xN/wDSto33L+gq/H31buyfIlNk+RK+X68q9xep7/UsO+ylItusjNtctEhvVyTZGLY7ZbTELCnE KBbH3WjkxxdRvmauAwDKOEvIG99vGXlWnybCsWyJi2w0iarsW61Qjg21h7BjmFBYF9XowsOPtGba t7o2pIvJxptsCXxeVdB7J8iU2T5Ep17V7i9SepYd9+RUqyLa5MmhITV87Ed0S6QbOOGutx4kgrk3 cHSXi0hO7vNKgdRV6YOGibqu6bizX/HbLcrHPYx7U1x2zrfFaQ8Nk7Oe+cpJDvLYf9kh2Hbbu8u9 WFsnyJTZPkSo68qv7i9SOpYd9+RrO2G2eauoXqZM+ynbDbPNXUL1MmfZWz2T5EpsnyJVOuZ9xepH UdPvs1nbDbPNXUL1MmfZTthtnmrqF6mTPsrZ7J8iU2T5Ep1zPuL1HUdPvs1nbDbPNXUL1MmfZTth tnmrqF6mTPsrZ7J8iVENVb7PxjTu+3WySQgTWEjgkwmOskRt2S007I4eRem24Z9/cijuu6ItXh0t UqSUVBceHaZz6GpU4uTm+HyN52w2zzU1C9TJf2U7YbZ5q6hepkz7Kpudm8jTXKr/AI3aJGQ398oc M7YF8vDV5acV2axEGZzB3rtiXhCL0C4CapuJBvWTL1eyxLbMciWqxR5lns17utyGa08nXC3SgZUW gbeJWTcQ9lFwjVsxJF3RO/seMr8MsFZ+L0ucSwNC15Sfp8i2+2G2eauoXqZL+ynbDbPNXUL1Ml/Z VYWy737N85uOFS79KiMJmc9xyRZ3vA5EWzxYsYgj9RFUk5yJsYVVNlXi742yoiRfTjK8ii4NicqD kjFwvWS2y8XKZPzW8PyIjLVtecBG2AFR4maOApmhbCDRmomqbVO+Vct8sb8Ne27/AMmU3Kjmtd2+ he/bDbPNXUL1MmfZTthtnmrqF6mTPsqncY1Wv1yyeRckcsaY7crti0b3mlzHSuEZLpboxf0dUVA4 g44TnFQXqIL67hw79XdtfcqseFWjIZlvxiTIk2IMilQYrEtelDdkNsstk6bgg0RL1fzm7i8+IC0q IprO84nNlVOPZ2vtV/12Flg8K1fO/JF7dsNs81dQvUyZ9lRzUPUljI9OsysloxHPnbhdbDPhRQcx CW2JOuxzAEUlTZE5EnfVb6i5Xlk52/wMDmX9LhdL1MZtAWyGso48K0s9Nx0QDvFJFyIWiMtxUEVO 9E78/ttvmRzoMjDYeOBapy480KTRfecF+7dUNuTTgjsw62qEO25IJDuK99FisRZSUI+b4fp8PoFg 8Mm7yfDwRfq6+2cVVPgpn6/3YdO/Dp2/WfzT1A9Tp34dcwTNYMgeGHd2Yk2TOjXa1MSrRZJDjgXE gdvTDrLDR7qAulCA1TvLig78lBN5K1rRc/hHikBkscvcCfJsUO5yLcxJEUfuIkaK268YoHEFbIG+ DpmnJT6PcKbPpDFr7i9S6w1C7vN+SL57frP5p5/6nTvw6dv1n809QPU6d+HVC2/VG9XWJgtzuj+N DHyKdEnRoVnub4yIsdxmeXRlIqqj4/0cEJU6aK4Jjx8RFqV6ZZre8pUGsoj2hp2XjdqyGItsB4Eb ZmdZOi51DLkYq0i8h2Txttu7dcp9K4mnFycFw8X8jWngaNSSipvjy4ItDt+s/mnqB6nTvw6dv1n8 09QPU6d+HWDsnyJTZPkSuTr+r3F6nb1NDvvyM7t+s/mnqB6nTvw6dv1n809QPU6d+HWDsnyJTZPk SnX9XuL1HU0O+/I0OqOrsTLNMs0sFnxHPDuN2sM6FFFzEZoCTrrBgCKShsiciTvWs5zWO2Ee/wAF NQk7hT/oZLXyJt8lbDZPkSmyfIlZy6cqT5wXqVfQtN85vyNZ2w2zzV1C9TJn2U7YbZ5q6hepkz7K 2eyfIlNk+RKp1zPuL1I6jp99ms7YbZ5q6hepkz7KdsNs81dQvUyZ9lbPZPkSmyfIlOuZ9xeo6jp9 9ms7YbZ5q6hepkz7K8ntbLHGOMErHc8jnKeGPHF3D5Yq66qKqAO6d67CS/3ItbjZPkSoxlqJ786d 93/x1g/8PKrpw3Skq9eFNwXFpdpz4joinQpSqKTdjddqsXzO1D9T5NO1WL5nah+p8mryTyUr6rYw PCyRKN7VYvmdqH6nyadqsXzO1D9T5NXlSmxgMkSje1WL5nah+p8mnarF8ztQ/U+TV5UpsYDJEo3t Vi+Z2ofqfJp2qxfM7UP1Pk1eVKbGAyRKN7VYvmdqH6nyadqsXzO1D9T5NXlSmxgMkSje1WL5nah+ p8mnarF8ztQ/U+TV5UpsYDJEo3tVi+Z2ofqfJouqkVUVPgdqH3//AKHyavKlNjAZInHM/G8XuOSP 3x+wasJJdud1uBNDiTnTU5rDTfFRUPGRk2Qdb38h7qu9Y8HHLbbJMFuDF1bGzwXI9xYtx4VyBLux DGK1OU+mhFsjYO9FV4K4KF5PFrs6lXyItY4rbwnGmbS7aBtusj9tMZbiNy8YekODJl256FLfR0g5 7u9ZXiFVUUdRVFEQlGtpMhRGpD07GI+rdgukhXWn5bOFK6pxXokKO61sba8VVLcwYmmyiXLyou1d gUpkQscfnYsaCd4bbbHrBa5TVmHHYrsTHZIFGswxVYSIG6Km6GqSEdJFNHRFU8VOK6LHsNg4pGce xtjU+0XtJkafGmwtN2GWo8luM/FMhjiz0+LjEhUIVTfmKGhbqqV27SmRCxybbGbLbL9bbv7z6vzp UGQ7I6k3GHnnJDjlrYt5E64o7kShHFzdNvHJe7bZKluMZzb8Xxew2CJiWo70ezW2Nb2XHMPkczBl sWxItu7dUHddq6FpVXTi+ZGVMo3tVi+Z2ofqfJp2qxfM7UP1Pk1eVKjYwIyRKN7VYvmdqH6nyadq sXzO1D9T5NXlSmxgMkSje1WL5nah+p8mnarF8ztQ/U+TV5UpsYDJEo3tVi+Z2ofqfJp2qxfM7UP1 Pk1eVKbGAyRKN7VYvmdqH6nyadqsXzO1D9T5NXlSmxgMkSje1WL5nah+p8mnarF8ztQ/U+TV5Ups YDJEo3tVi+Z2ofqfJp2qxfM7UP1Pk1eVKbGAyRKN7VYvmdqH6nyadqsXzO1D9T5NXlSmxgMkSje1 WL5nah+p8mnarF8ztQ/U+TV5UpsYDJEo3tVi+Z2ofqfJp2qxfM7UP1Pk1eVKbGAyRKh0wuMjItRs vvg2O/We3uWKzQmSvFrcgk6609cDcQBPvJEF9vdU/Wq3qUrVJRVkWStwFKUqSRXm+w1KYcYktA8y 6Kg424KEJiqbKiovcqKnxV6UoCFPSMCuuJ4/LfYsk7GpHg8azqUUHY/59Og0DQ8VQUIXOmiIiJsS ovdvW9mYnYLgMgZ9jtkoZDxvvo9CbNHXDZVgzLdPGImVVpVXvUFUV7u6qIxKzZ+1pXp5hpYbfsfu OOyrCs+Yd0geDvMx5bPhIirMkjIVaQy4kCckFU712RYZatD88t2NW1HbZeHJ9xsKtZYw3kxI7cXA u8R1I/U66ChlCSa0JoooguKBGKKlAdYhYbSEgJAWyEMgJZTBdSMCEMgm1aJ5F23Q1bIgUvKoqqb7 LtUOvmjGKXLEjxixQWcRtRzRmuM2SDFZaedRNvzrBsmy8iog7o42SbgC9ygKpRN50xy+cwCWTA75 aS8C8Fw8TysCTFpPh0gilvoLuyCTJRjRttJHEWlY3RC2X5e8B1BS86inacOuEuJeHXxfelXTi7LZ K5MmCNqxcGkkh4Mr6i24EY229o/VMSJCAutrQnFounsfCIJT4Vp8HbiT32HACVcoyOG44w+9w5dN 03XVNG+G3VNA4ISpUouMDEyzWyy7pbrU5lyxn/euW7DApYMhsjqNuqPIRTr7KiKm/UX5VrmsdJM6 vmEuW+fYLvbZdnt2UnYmUu7UboznZUZ60q30JJCPAeogoRqLatqm+3BS3N80kzyxTMst+mg3S3WU oV8GxqN8Vem7Ig2tWuKuPKYqUhq4cSX/AEZmTnchIqgXPa8R04kxcixK0Y7jBw2pLRXu0M2xjpK8 Qg62TzKDxIlHgSKSKvcK/FW4k6f4lNtLlpmYvY5FqcbYaOG5bWSZIGU2ZFW1HiqAiIgptsKJ3bVy 5P0jyluJLDHMEutvxCXlDcmRjsuXGlSX4Y2gGGiPaeCEASgUkBZCKiqB7Lw2Tp3Ta33i06e4vByx +RJvsa1Rm7g5JkI+6r6NihobqdzhIW6Kf+1tv8dAey6f4ksi0yFxexrIsybWt1bazyhd+/5leO7f f3+Lt31kWrDsdsN0uN1sdhtVsudzNTnzIkFtl6USkpKrpiKEa7qq7kq96qtbqlAKUpQClKUApSlA KUpQCq4z3JMpjZnjmO4bNstt98LXcp8mRc7Y9O/1Z2G2IALchnbfwolVVVf0U7qseqxysSLWfDUE VJfgvfu5E3/8atVXgk5JM5sTOUKMpQ5o8OWqXnZhfqhL/wAxpy1S87ML9UJf+Y1LOi582f1Vp0XP mz+qtdOSB8vv+N19F7ET5apedmF+qEv/ADGnLVLzswv1Ql/5jUs6LnzZ/VWnRc+bP6q0yQG/43X0 XsRPlql52YX6oS/8xpy1S87ML9UJf+Y1LOi582f1Vp0XPmz+qtMkBv8AjdfRexAb/kOe4tZpl5yX PMCtVqhAhyJUnFJYNtoqoibqtx8qqqIiJ3qqoiIqqiVpbPqhkd+tDN2tGpmn8mC9IejCfwQnCSPN Mm840TZXBDAxabM1EkReKb/Gm+61XxS8X+BjM2wW9bpKxzJYV6K3Kogs1trqCTYEaiCOJ1UcBSVE 5Nj3p5UhmTYzmeYySvUHDPg5IKdJcY5OMNXJ0feKbGbflOtOkKl15DbbaCSkApuSoi+LRxinyPRo 4mvOmnKfH5Lh6E/gzNTLlBjToGX4W/Dksg8y8OHTOJgQoQkn/KPkVFRa8BvOohXs7ImbYMt3CIM0 ofwRmdVI5GoC5x98f0VISTf5UWqzx/SjM4N3xzIH4c9vI495t7MiW7c1fRq2JYG2H921dUCTw5FU kROZqKF3oglURtOlWb2yxXNyJgV0WbKsNlgXoLpdm5Tl0ltzjeuMhpBloTgmhcumbrIuoSoqJ+iU WWhptK/H+907Fr8jolB1VXfbKcOVU8v/ADOmd3/3xr4qaqIuy5VhqL8i4dM/zGucJ2jGpNzxUmFs 95j3C02CYzYwW9gwTE334J6MQK0+QiQQzQRXkqCgqG6oib7G+YBk2MXoMWx9120xMqyG5Y/b4KTy ddYx59uLIemsipko9EmZYpyTcSlonduCLFo90Z8Q+CqryRf22qmyKuVYaiL5F+B0zv8A/vjWGd11 HbvDNoczLChub8ZyU3GXDpvMmQIAM/8Avj5EJwE/+klUlccD1ScyHOJdixu5WmdeIl8ijOjzWhB7 nIZOEiPOS3HFVY7LrQH0mRYJ4RQBRCJMi+aWZk7YLlD08xW/YnaJECY3CtT2SobrBuT7W4ips6Qx 1JtmYSABmI+N4wq7wqbR0IVTEdtX0WheK9qYrsWV4YK/IuHzE/8A9jXzlql52YX6oS/8xrB0zwuV hXwvtjcKRDsZZE7IsbByjkCEQ40dS4ciIgFX0kFwXbZSJUREVN510XPmj+qtXUINcjz6uNxcJtRl dfJexE+WqXnZhfqhL/zGnLVLzswv1Ql/5jUs6LnzR/VWnRc+aP6q1OSGhn1hjdfRexE+WqXnZhfq hL/zGnLVLzswv1Ql/wCY1LOi580f1Vp0XPmj+qtMkNB1hjdfRexE+WqXnZhfqhL/AMxqA3Sz6gX3 WWwxJeU4qM/4K3M2n28Vk9MWvDIKGJNrPVVJSQFQkJEREJOK7oqXV0XPmj+qtQtlpwPdAY6RgYiu GXZEVRVEVfDoFYVqNOdNxkrpnf0fjcVPExUnw49i0+R5dmmofnrifqdI/wAxp2aah+euJ+p0j/Ma uKleT1bg/wANH12+4jvsp3s01D89cT9TpH+Y07NNQ/PXE/U6R/mNXFSnVuD/AA0N9xHfZTvZpqH5 64n6nSP8xp2aah+euJ+p0j/MauKlOrcH+GhvuI77Kd7NNQ/PXE/U6R/mNOzTUPz1xP1Okf5jVxUp 1bg/w0N9xHfZTvZpqH564n6nSP8AMadmmofnrifqdI/zGripTq3B/hob7iO+ynezTUPz1xP1Okf5 jXwtMtQTAwczPEXGzFQMDwx8hIVTZUVFuGyoqLsqL5auOlOrcH+GhvmIf32UDC9z/e7bCkwrbN00 hwpQG3Ijsab9Nt4D48hMUnIhIvAN0XdF4D8iVks6I5RHhDCj3vT9mEMRyEMdvT8xaSM4XI2UBJ+3 TIu8g24qveqKtXrSrvAYZ84fzMlXqLk/5FJR9H8zh3OXc4eS4NGucxAGVMZwR0H30BEQENxJ6EaC iIibqu2ybVhztCcjudrYtV0uunc61R3OqxCk6eE6w0fjbkLZTlEV8Yu9E/2l+VavmlQsBhVxyE7z Vta5RpaK5Wd8bvx33ADvrabBcy0/NZQJw4dz3h/NPE8XuXyd3krGmaCX+4swWbjcdOJrMBkmITcj TpXRjNKmyttoU5UAVTuUR2Sr7pUrAYZfc/mN4q6/yKRhaO5lbTZO25Jg0I2WPB2ij4I60rbXPn0x UZ6bBz8bindy79t++vNjRXLIvdFv2Asfnm3/AM1gLgfnWzIwc7p/6QmZkJeVCIlRUVVWrypUdX4X uE7zV1KPZ0Zy6M6LsbIMDZdB0HhNvAnBJHBJwhNFSfvyQnnVRfKiuGqd5Lvgr7n+9q8w+U3TRX44 oDLq6b+O0KOdVEEvDtxRHFU028hLv5e+r+pUrAYZfc/mRvFV9pRUfRDJ4j8l+JedPY78qV4ZIca0 9ICekbGnWNUnbk5s44nJd18cu/xl3yo2kWbQiEoWU4TFII7cUVZwd5tRYb36bSKlwTYB5FxHyJuu yJvV10qH0fhXzgSsTWjykU72aah+euJ+p0j/ADGnZpqH564n6nSP8xq4qVXq3B/hovvuI77Kd7NN Q/PXE/U6R/mNOzTUPz1xP1Okf5jVxUp1bg/w0N9xHfZTvZpqH564n6nSP8xp2aah+euJ+p0j/Mau KlOrcH+GhvuI77Kd7NNQ/PXE/U6R/mNOzTUPz1xP1Okf5jVxUp1bg/w0N9xHfZTvZpqH564n6nSP 8xp2aah+euJ+p0j/ADGripTq3B/hob7iO+ynezTUPz1xP1Okf5jXm3pDlk+9Y7LyTL7HKg2a7NXP oQMZdiuPG224Aj1DmOII/nVVfEVe5KualXhgMLTkpxgk0Vliq84uMpXTCdyUpSu45RSlKAUpSgFK UoBSlKAUpSgFKUoBSlKAU+KlF8i0BTEDLdQcovuXBYrvitot1lvjtrYal4/JmPGgMsnzJwZjQ7qr q9yB3bJ3rWy5apedmF+qEv8AzGtdpqw6N11K3acTfNJRJ4q96LFi7LU96LnzZ/VWumEIuKufMYrG YqnXlGD4J6L2Iny1S87ML9UJf+Y1Ess1TyDBbhDt+X6n6eWibLBHGmXsSmqSNKXHqnxuC9Nvkip1 D4juipv3LVs9Fz5s/qrVP3WyZXiWb6g3e0YfKziHmNuhNxWm347TcZ6PHcZWNJR90f6OfJD5Ahfp uIoqqpvMoRXJDDYzE1JNTl6L2N63lWcvXdLSzn2Bu3JXTZSOGIzCJTBlt4h7rjtujTzR+XyGlblA 1VUkFMpw3kvkT4HTP8xql79pbqK29fQsVtSI3Jt12aBuzy0hxCfPHrdEjdJlTRRBJMd4W+fe2gov cioq+ly0mv8AZr9Lgw8Zvt505DII81bLBvSI/KRbYoK71HZAHsExEM0JxFIlFzxuK1W0dDr2lZ2t V9F7FrWe76i5Baol1sea4PcLbLaR2PJYxCYQOAvkJF98fJWdx1V23+FOHbfL8Dpn+Y1QUbTXUS1F pk18EZjx4zaMfHwmHJZI2XGZXK4MqRS2wbVWvF/NtO9dNkU0ROKYcnQbN3LbPljaLmV/KyXaQy6N /MVW8jdFO2Odz6ChBFI+BbcUQlE137qWjoRtMQ/8X0R0Rtqoq7JlWG7/ACfA6Z/mNfUHVVVVEynD d08qfA6Z3f8A3xqiJ2P5Tk8jU214407kVkxia5arUEWSaeF+HzmJlwaVRkMqZxGk8HRvrNoSKbaq m5DXlC00zV+3WuLkmEZDc7bbXrylrtka9x7csGU7Maegy+o1JLpNgwptDwV0mVA0QDQkVVo6DPiu 2r6IvC13TUi9RCl2nMsKlxhfeYJxvDpuyONOE04P/fHyiYEK/wBaVlctUvOzC/VCX/mNUTlejmoF 8HKZbkG6SLlGtU1zGjG9q307it9mvsOCiOCiGkVxhUIkREFeC7bKKdSONGrhqLZ7KS7eKtWjGL5o 5q+JxVJJxne/giI8tUvOzC/VCX/mNfQ7UjJB+FmFpuu3/RCX/mNSvoufNn9Va/bLLnVD82flT/ZW rZIHLHH41tcfRex+dNMklZlpziOR3NtlmbebJCnyAYFRbFx5gHCQUVVVBRSXZFVV2+NalFV/oP8A 9R+mv+6tr/4VurArjPsBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKA54x33V1vv+C4DfxsCtXXK8mYsL 1pGdzO3dR0R8IM+mnMEbdjuJsKIvhDSbpy3qwu3TBEdurTt3fYO2N9VxHbXKb67fXSOhR+TaeEor xC2is89yIUTfkO8WtHuaLDZ5NqkxbtcFet1ussMEVU6ZlAkRHSfVvfijjw2+G2aptsLA+X4tHavc otWlydIj5pcPfF5ngzcfe6MUonm7gzOjSZDpCSyXgdZ2Mj8UxXZBbVFVQJmfuktNGFIZV/fjONQJ NwkNv2iY2UViO64y6ryK1uySOtE2gHxIjUBFFUwQsDI/dEWe1uM+9Fvels+914lTTuDci2nBcgRW pHSeYcYV4eYPgu6AqoKoSCe6JXrO0EC+x7seT5XdrndLpa4sN6agNtKD8ec7NZfbBEVBQHXUQW13 FAbFF5bkq66Z7nL38Yub+U5fOuV6u7N2C4S2oLMdoymwmISKDSIqgLTMZtBRSJVXkpEu+yAby8+6 BxG1ZlbsabmBIeOdMiXSYQPNxLekaC7KfJZKt9Bwm+mAGCOIQdTckTiqVnR9eMGlQnJLFxuBvNy2 oawPeOck4nXWiea4w1Z65CbbZmJoCiqNmqL4pbR28e55bv02bFueWXNcSfl3Wa1ZWo7Iqy/cY8lm SXXUVJU3mPmCbeKrhIvNOKDrYfuZo8XGLjbzutkk3CdLiPPG7h8BIL7ccDAG3oginNV6pmpo4JIa ooKApwUC7bJeIWRWa33ezuq/b7hGbkxnFbJtTbMUIVUSRCFdlTuJEVPIqItZ9aTDscTEMVs9hGfN uiW2I3G8LnOq489xTbmZfGq//wDK3dAKUpQClKUApSlAKUpQClKUAqK5lptiuoKwlzKyRbuUFHEj E8hIrSHx5oioqLsvAd0/sp8lSqlAVZ+Tfpb5mwPrufep+Tfpb5mwPrufeq06VNyMq0Ks/Jv0t8zY H13PvU/Jv0t8zYH13PvVadKXGVaFWfk36W+ZsD67n3qfk36W+ZsD67n3qtOlLjKtDmPHNFsBmai6 kWyVjER6FbJduCG0Tr3FkThCZIKc9k3JVVdvKq7rvUx/J+0z8z4H7x779YB5F8CNVNRXrzYMqkR7 tItr8KRbMbl3Bl0Aho2ezjIEiKhCqKi7L5PLvW37YbR5uZ96i3P8GvBxKxLqvInY7KapZeNjH/J+ 0z8z4H7x78Svn5PumfmdA/ePffrJ7YbR5uZ96i3P8GnbDaPNzPvUW5/g1zWxmjNP7nwK31DxXSTT u84xbpuARJyXiSiTHwmuNhbYnWZjrKc5H3j15TAbd3cRlv4iov5yyy6JYq5d4C4lHbvlviuyCYuc G6wI5stvNtuGktWjFW0IwTkCGhKoInlRa880tWA6iXXJbhmmM6gXV+7Wlq1QicwCfvamQF1VJheh 3mrrquqR794gnkFK0dzs4X9vKGclvmp91byWK3HmuuaYSRfRG1BWRbcRjYGwUCJG0HipOuEu5Eq1 3QhUcVmzX+pg8t+w8mrtoS1lM603vAzssGIzLMrg/FuDgose4OQ3CMQBUbaRQAleIkEVc4FsQrUr esnufmZlwgt2DwybAupWh2PCs9zkuHNADccZaFsVV4gACM+nyQBUVJU5DvoZtgx24LnIyu08o+UQ psEGh0+nD4E1KmuzHOK9Dc16r7myl/sqifFuuZKi2iPJK7YsWpVoyVrILneYVwd08nyQYSeiC+wr KsiJhsIqKqvJCEV3VN0W7g2/vepCsl2GRLje5zhvxWStLcg5bEJ9hYdnusoTGWKlFTk2JJzdRF4A q8iVFRE3TatpbMV0AvEZZFutVvdZQoA7rHnAqlMkHGjiiFsqkrzbjZCne2TZofHitRCzWzT61vtR bQ9qMQ2Wdj5ORfgXOM2XLYCuNtuqkdFQnkeRw99l2MVFERaxLVBx226g4hKGz547j2OxblJlyXsS uPO6ypUp91hk2BZ7kjeFSXBdXbxnE49/Lauym1wcr/rwLJeBJW7doJLkwm7Zj0J1t40N1yXHuMRP BFiS5AymOYKkhshgu8SFUBUFVQt+InvsLwPQ7UFqQ5iWOsS0jsx5BjIhz4ZKy+JEy6Iv8FJs0AlE xRRXiuy1DIUayBj0GxXe9aoXS3WlpYloaPAZrYxIiW+XCAOIx0Q3UCYqk6qeN0m04oiLvM8Qy/F8 QmvSo8TUGYTtjtVn2ewe49wQUeQT7mU8Y+uqqnkTbuqlSFVReTNcmMePFEp/J90z8z4H7178Sn5P umfmfA/evfiV+01sx5fJZ84X/wDUi5/g197a8f8AobOPUi5/g1x5cZozbLT0PP8AJ90z8z4H7178 StfieCY3g2vtlaxGzx7SMvDbmT/RI16nGdBQd+RL5ORf4/3bbTtrx/6Gzj1Iuf4NRftQtfa7ZchS xZt72RcYuEF11cLuabPuy4jgDx6Kqu4tOLvtsm3l3VErrwixO2W0Tt4mdSMcvwridH0qru3vG/of NvUm6/gU7e8b+h829Sbr+BXuWOXLLQtGlVd29439D5t6k3X8Cnb3jf0Pm3qTdfwKWGWWhaNKq7t7 xv6Hzb1Juv4FO3vG/ofNvUm6/gUsMstC0aVGMLz6z57HuDth8PbO3SUiy2J9ufgvMuK2DqITTwCS bg4BIu2yoSVJ6gqKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUA pSlAKUpQClKUApSlAK57dwHHM81h1JLMLWF3KCtpai9d95EZAopEoigmiIikqquyd6r37923Qlc9 Lm9uxDWHU0LnCv8ALKSVpMFtVhl3ARRIhJ4xMASCvd5C2X5N+/blxOfZPJzNaVs3Ejt3xbSi0apW PBXMEjurcmR69zS4OC1DkOg+cWOQK5upOjEkKnem3EE2Xmm2PItmiK3Bq327FkWeFwhRZka5wrvb XGgkq4jZALjSq6ZdI+AJsh8V8ZNq194t+n96uF8vk+3Z2eXXC+x7xDvq6fzVkW8o5M+DMtIsfirY AwgeMiqSGe67lXhaW7ZHksOX+96jXsWcjjZEpuabS2X35jThkquuixuQqBC2goiIANgIIiJtXFGn Oyvm9TWz0MfArrodmt0C3y8JKwOyktaQVlBcDB450cXWgccQUbZVTUmw5H+d4cg3RUrcsn7nKVbG LnDtqyYDwSnheZtN2NEYjkIvyC2HcWAI0FXl2b5ISctxLbVYtacTx20x4D8rUm4JHu1kntmeAzm9 gtYthHaVBY70UGgQi8qqm/d5KwjxvFo2N22zWK4alW1Bx93GrtJXT+c8c+1uOm4TaITHFpxFccQX ERdkNdxVdlS+zbf3haS7CUXVn3O9mu821TrU4s6FJfivhHs93kD1mW0ceATbFRMgbVHCQVXiHjL3 d9bRca0AGE5NOHbBhhJdjK8XhqAptwfDiIV38ZvwXZ1HE3BRUdiVVRFjqRcNC7eHtJqS3xul2uDb I4NPQA8OhpFVtP6P+i2Ioor5VXy71GLXjuJu3q+RLzZs/YxgcLi4rCVvFbib0x3oA0/cumjCiw6j TEZlN03JG13RR23psp24OX6+hPxaEwlsaCQCkvzrCzAt1viS37oc+NdIsqGrJQ0QViGHNUJJ7Jct 0XYh4oaKSjL8Z0v0fzGDLl4/jTTzcSUcOS3JZnRHmHxESVtxl4hMC4mC7KiboSLUBvSWrLbcYZpf dTrxdHY8iO5MHT+awIC5IgPILTKMKLYp73BunepE64W6dyJYFg1GxnH5uUSmbdnr53+8FdHUcwi5 fmiWOyxwHZnvREjou69/etZ1KdVR+DNcmKd+KNdpXodp5fZOoKXPFIL6QswmR2ORu+KCMx12/S+V Vqwfyb9LfM2B9dz71YegFxZu7Goc+K3LZZk5nNMAmRHIzwp0WE8ZpxEMF7vISIvk7qt+vZhdQV9E cckrsqz8m/S3zNgfXc+9T8m7S3zNgfWc+9Vp0q9yMq0Ks/Ju0t8zYH1nPvU/Jv0t8zYH13PvVadK i5GVaFWfk3aW+Ztv+s596n5N+lvmbA+u596rTpQnKtCrl9zjpcooPwNt6Cm+yITiJ3ruq7cvjXvX 5a/P5N2lvmbA+s596rTpU3GVaFWfk3aW+ZsD6zn3qfk36W+ZsD67n3qtOlLjKtCrPyb9LfM2B9dz 71ftv3OWl7TgmGHQEIV3ReTnl+tVoUpcZVocy6RaJYBd9JMBuFyxmLImS8ct7z7pPPIpmTAqRLsa J3rutbLNdJ9NMNxO63v4Dx7k9FaEYsJqTIE5kpw0bjxxVCLYnHTbBF2Xblvt3VrdINXrHbdI8BhP 2nMXHYuOQGTOPh9xfaIhYFFUHAaUTHdO4hVUVO9FrKzfMMNz+PaYOR2bOpFohXEJ8mD8Cbojc1Qb NG23dmk3AXDFzj3oqtjv3V88o4nacU7HoWWXguJoGrZonCwey5RlmHSbEzcG0GU0Fuuk4YMsXeg7 GdcZFUExkcmk5IKmSdyd9aC/ztHccnPQpunRvORyInpEZ2a7HBoL2lrPYkHmTgqquK2ILuo8BIuQ kuPNsONsTreeH3DUKw2q03l+82q0HpzOmxIMt0BFTBtxrbxS6ht7/wCjJ41HZdlrcSGMSdvMO5NF qK0TMl+Q8HwCuC9VTvYXYERej4nF0VBfLyEvIipXWoSXH4jLLI3Y2b3P5MwXVtbTYTfDlHqwbk2s dIZoEtZCFssZGlVOSvcNt0XyKleLdu9z+7EJ9uyPE6k9u3+ApaLss7ruMG+0ngnHrcTabMxPhxVB LZd0VEwSZwaR8Im5zGpD0W/MX9iQA4TPAmxur7DrvAvB1721jog7ovl70XbavfHLtaIGRwsnyuZq DkmTMT2ZLsxdPZ8UHWmYUuK00jQNKIbeHPOESfpGS9wjsKZ7Odn+1+voT8WhmY/aPc+5M7AatNtY 53F+MxBWVDuUQZJSAfNlW1d4oQGkSRxNPFVW1HfdURdY+XueVjIdtt0GU89CWTGV1q5Mx1Im3XGW 3X+KiyTosmQCScjDYgEkIOUdy5i1lgbVhxKHqC/c/efH7DFmniNwirbkt0l11u4oXR5KYdUl6bfj Fsgp5VId7KTGmXbnAxmZqVYcUukNpiZZo+BzjEyahJCaUXSY5I30m2eTa78laHvFFJCsqU+fxfr6 C0tDcWSwaGXi6Wuze8Mdu8T0jtoAR7kcRJDsMZYsDMIRaI1ZXmKKokqf7KL4tTpNAdNl/wDinD/f v/iVXVuk4fbxs4izqI5715DCvgKWDXBFccj2pu3o2X5jbYgbQ1VO/ddk7qsdNasfRET3nzj1Iuf4 Nc1WFdW2akXgl95HvpjilnwvVPNLVi0JLbbjx2xyljg6ZB1jfuYkaIRLsqi2CL/5KVcNU3pjlUPL tWs2m22LdYjTWN2FlQudrfgOqSSLou6NvCJKOxJ4yJtuipv3LVyV7OHzKlHPzOSX7TFKUrcoK8Zk fwuI+wjzsdXWyDqslxMN0VOQr37KnlRflr2pQHLB3O8aWS8ruA5XluVyrflULFbPEusvwqKKzIkF xH5DbTaOOKByXFRB2IthBNlXlXpedes9hBjt0iwLPwfi3GFJt7/UZakzWbzBtwv81QnWQRZXLpkn IN3QNCIRJLTm5zpBerlkuJ3O74jNlmbj98t0gmDR82G06hPCXiuG0DA8t9yBGk324ptIoOCYJcrT YDt2M45KtdvDr2VWrawbMYXFFznH2HYEJUA9w23VEX4koClL37pW9YnkkuNcoNmv1sgsXSPKK2JJ Z4zbfbllvILzo9MtzbdaVoEJW/FUnCXcKy77r/kuAQupmLGH3x4mpDIJjl1cdXw84SSoEY2iRTHr o282Jd6uKrRII8uNXSmnuIJkRZGmLWNMgM+oVz97GfClPiocurx578VUd9/Iu3krSv6NYoiWOLZ7 ezj1mtN2G8LabRFZhxZk0OPSdeQAQlVsgEkQSFFUR5ckFEoCls31ozN/EshkMXbF7CLEx+1xxh3B VugzIUtlqS4DTiKJtESueLshA0bRqq89hyrvrtlWPhe4+OwbbcUssbIr9OK8TXVcdiQrzIjlHaUB 8VVbDZtSRUDYRXdO+r7f0/xKVdrhd5WL2R+63JoWZ0xy2tE9JbFQUQcNR5GKK22qIqqniD+qm2Ld rXg1tNxm82/H47tyaOI40/GZQpLcqSKONkKpuYOyHx5Iu6E46m+6l3gU8XujMgHKr82zjlvfsMOX fLfFR+YUE/CLay4fNyU6ng/TdJl0dk72k4maqiqg2DovqLcs8tl1YykIUTIrTIaZnwWYsmI9FJxk HUB1l9FUVTkSIYG424goYl38UkL2KYSOWvypFjsPwovUF4X3zhNeFTIodNt1CLjyMERxkSRVVNlB F+KtljOI4/hcByBh9jttgguvE+ce3QwjNk4qIimogiIq7CKb/IKJ5ESgN1SlKAUpSgFKUoBSlKAU pSgFKVU2rOc5Zj+TY1Y8HesUQ7lb7jNkv3eC/KREjnFAQAWnW1RV8JVVVVX9FKtCLnJRjzIbUVdl s0rnX4e6tfTuAerk/wBsp8PdWvp3APVyf7ZXVuVfu+qMdvT1OiqVzr8PdWvp3APVyf7ZT4e6tfTu Aerk/wBspuVfu+qG3p6nRVK51+HurX07gHq5P9sp8PdWvp3APVyf7ZTcq/d9UNvT1OiqVzsGdauO GIBfMBIiVERPg5P71X/7ZWtDV3UNyDb54ZlpkUK5SxhQX0sc7hJkEZALIL4Z4xqTZjxTv3EvkWoe ErLmvVe5O2p6nTdK56+GesPJA998F5qm6D8GbhuqfLt4XXxM11gXnteMEXp/p/8ANq4eL/f/AEvu qdzr931XuRt6ep0NSueVzTWBFFFvGCIppuP/ADZuHjJ8qf0vvr6WZ6xB+nd8FHv278ZuCf8A43Tc q/d9UNvT1OhaVz03mesLyp0rvgh+TvTGrgvlXb9rrFtmo2ql5t7Nxs+RafT4DwqbcmPjlwNsxQlF VQkl+RFRU/7KbnX5ZfVE7enqbGL/ANYGqf8AvJF//Y9vrb7r8tVpHZ1Aj3W/3P3/AMLdk3yc3NlI ePzuIOBGZjogbS02HgwC9+68lLv22RMvwrUP6awb1fuHtlVeAxD7PVH0eG6ZwlGjGEm7rwLA3X5a 9oiIcloS70Uk3qufCtQ/prBvV+4e2V9GZqIBIQ3rBkVPJ/zfuHtlFgMRp6o6H07g2ub8iv7DmNzw zDcBy655bfMqdv1imXC72S4z2ZHIGLa/LJ6PsCGwguNA2u/IdnURe9N13GQaz3jBLRd5uXw8ZuLt mS1SpDdluLv9Kjz23+m0x1N95DZMoaou4mxycRA22rOseM37GHXncZiaVWR19vpPOQMLkxycb8qg ShKRVHuTxV7u6v3ZsfyPHW2G8ea0vtIMSDlMjExCW0jbxArZODxlpsSgqhunfxVR8ndV9yr93+R5 UelKUFaM2vozHuWs0+wLMgXK2Wy53iFAS+Oe9ch04kqzpbDlHKYdXlunhDaxxNfFXkJbd+1fb7qx fcHY45hExi5Pmw+y0ePz3nhW4nDGTBim2W5h1tnQEl3U+IEKChbV42rEsus+Ryr3Du+D9Ry0tWeL D+DMoIsCEBk4rDLYSU2EzLkXNS32RE2FNq8bLgWR3nOsZxC1S8Dx+2wAeywIlqxSQzFkTI7zTDav NpKEiUFeQxUTTvAUJCRERM54WpTi5SXD6F49KqXBTd/keWY6j5U3jl7kNy8csgt3N21RfBLgfvkE mHPjMSTRtzcTbPk54qIhNtm2RKvLu/N41dyGyMXlLJb7bcWrLAu19mld5z5PORmL3KieDtE2iIi8 G04ESKg7IKoqd9W25obkr1xnXJ+Rpo7cbgAtzZZ4NIJ6SIkJCjhrP3JEJtsu9fKAr/spt6uaLZY6 Elt2fpyYSmHI8gSwmSqOsuOk642SeH+MJOGRkK9ykSkveqrXNY033jfO/wBfUgNj1Rul21IdsTll ZZsL11u1riykR4Xhcg77uGZbNOI4oGnTbTk34ikq7rtZ26/LWA1oxlrF8lX6PcNOWb7MDpybk3hU kZLw93cTqT+Sp3Jv39+yb+RK2HZxqN504Z6rTf8AMahxudtDpSnCLVRtv5Hzdflpuvy197ONRvOn DPVab/mNOzjUbzpwz1Wm/wCY1XIdHW2H0fkZOi//AEm1S/3gh/8A7HgVbtQLTPBLphx5LLyG6wbr cL7cW5jiwLe5EZaQIrMcREDedJfFYRVVS8pL3JU9q58vUkpzlJdrYpSlDMUpSgFKUoBSlKAUpSgF KUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBXPY/9cGqX/zlm/4RyuhK qG+6VZQebZFkGK5FYojN8SIr0a52N+UTZMNK2nE25bSbKhKuyj/20OvCVo0KynLkVfkgzL5qzbce dy694rZQxORdXnbXcW4n54J7TXUcJwSEhRsy3RU27v76iGN60ZQ/iVtvNztUCYxabZaZF/VxHGpt x8OlOMMuQ2h2bFVAAdVCTYic4Cg7b1cF70LyTJnGHMmf0zvjkcVFk7jgr8lWxVd1QVcnrsir37JX rM0Vyu5Xa33a4ztOJl1tvFIE1/CZJvRUFdxRs1n7jsvem36K96bLU24HbLGxzynGTV2Vo1q/c251 7C4QbE3bsTu0WBkktuc4X5l2acc5kYU3/MtCgKfP/bR0N06e6/nHtUcsytxhbVacXtgg1bnJDF5u T0dx33yV0oIskm48kaFlTFUXmZGAKKjvU4u/ud8nuthfs0W+YLY4r0EraR2vC3mXPATc6jsQS8OX g04W/JB2XclJFQvGrcSNGctl3iFeJM/Thy729tGoM48IkE/FBN+Itms9VFE3XZEXZN1+Vd4SRO/v vsqe06z3nMfeyLiFqtMSZczZhDJu7j6Ros9u3nNuDLqAqGvSTpNCncvMnFXdA2rAf1ZucG5Xe4uO BNZYjXm4R4ke69aEgxrJa5QtCYinWbVyQ4omijtzUu/farRhe55yhjGveC73vBMkhHNeuEgrvhb7 5SpbrhOOSDFJyB1FI17xFERPFRETurZvaK5XI6vXnabudVtxtzlhEheQONA0Yr/T+9CbabBU8ii2 Ar3CiJKSIeOzLjN3+XzKxn6p5VbrlIxd+zWl7LUvLcEHYLM2XCForck7dWwXrmaCvT7uKLsp7Igq K2LiOQLleIWO/LFWAV0gNSlj9ZHUaUh7xQ07iHfyF8aKi93kr2u2h+TX5qU1fZWm10alutPyQl4R IdR5xsODZlynruQgqiKr3oKqidy7VsmdMdQY0dqPFyPB48dlsWmmmsSlgDYCmwiIpcEQURERERO5 ESquNzpo9JQhL422jM0D/wBHqP8A77z/AP3bFW7UG0uwWfgtuvgXq6RLrPvN5fuj7kOCcRoCcEBU BA3XS2Tp77qS+X+qpzUngzalOTXa2KUpQoKUpQClKUApSlAKUpQClKUBzNpAv/ciwD/dyD/7kaz9 Q7jLs+nWZ3K2SHIs6DYJ8mM+2uxNOgwZAaf1oqItbHGtG8+xXG7PYbfl2JPxLTCahMOP4tLVw22x QRUlG4InJUTv2RE/qrPk6X5/NivxZ2Q4NKiyGiafYexKYbbrZIqEBCtw2IVRVRUXuVFquXjc+m6z obLJxvbQp+85NcdMLsUGFk03Mm5thameD5Dcm3lt8t2dEiMOuSWwEgjmsoyIFRV/Mkoqm67fjI9Z rxh8YgvULGZcyLkUvGphxrm4yysoYzT7EoUc3UY4dRRkoRKTXcqEvkqz7foTkNot0622hzTC3264 DwmxI2BvNNSh2VNnQGciGmyr3Fv5Vr9RdDsmgwGbfBk6axoLMZ+I1HbweQjYMP7ddtB8P24ubJzT /b28ber2RwrHKPCEmloVlkGtF0x+ffbQ/aLYV3x6TIauiuynGY7bRvRGbc/yXfi28U4DLkW6Aw9x 70SsstUb7bcj+Cl2iY3Pv8yW3b7S9Zprz8aTKCaDMxt0V3Ng2WHm3iaVVVEQtyVF7pxbdBcyt0vI n3cnw25pfwYjymJmIyCYCIy2rbUMGhnIHRATPuJFJea8lXZNvKN7nzLoF8x+52zI8Lt0fHY8pq1W uHh77EOM5I2R2QIhOQldIdw3UuOxEvHkqlUWQ6wl32V7C1JyC/P6dyjl2G2wcmvltlRotsuBOTEt z3hQqxKbPffdWw5OAgijgkG2471jYhqxkMtnHG/ArfMtDK4vBuUmZMecuL53WO2SOCopwUmzPdeQ +Om+3FatqFoZkttlPyrdI0zhyn5YTXnmMFfbNyQPLi8pJP3U06jmxeVOZfrLv6x9GMtiNi3EuGnL DYHGMRbwmSKIUdESOSIk/wArSCiAv+xsnHapsiFjbO+d3K80q1Vu2fXAGrvZGLZEuFlS9W9xnrCo NK/0kZcV3brEokBdVpEDfkG26brae6/LWuteiuV2OTPlWOfpza5Vxc6k16HhMlk5Bbqu5kM9FLvV V7/jVV8qrWy7ONRvOnDPVab/AJjVHG53UOlKUIWm238j9aY/9bWbf7t2H/iLpVyVXOnen97xjI7/ AH3Kbza7pLukGDCbbttrdhNtNxjkmiqjj7ykRLKX40REFO7vqxqseFiKkatWU48mKUpQ5xXwkVRV EJRVU8qfFX2lAcgDheo4YXh+DWjC7nbxxuEVsugIloO0yhWHKZOdFeNUlI+8ToqqogcUdcQ0VVLl 9h27Ppt6u+A45cXWp9mw+PfXFjTkQrdenLQtvj2w1E1ABUg8MT4uSIW2y8luS26/4+9f89hXxh6y WvFGikBc30IguDDThsSnG20HlszIaNotuW68VT9JErDyP3RWJY/HbetEaZMlzjuIl17e/ABmRDge FkkpXWkNpCZRrYlAl4khIiiKqgFN5DgeWvA8mPYHqFDxcYk9uw2pMvBJcS8mEfoT3F8KXptIQv8A FVdeQS5udMep42/gWnO7tqjN96ivEnJLPf4ke4ZEtz4WdqKNkhlJjeBq73q5IcQ0EWE8YwPn+aVE t276/wCBWC5zbXd7rKbuEA3WpLUezzZIo602LrzYG2youEDZi4QiqqIbmSIKKqbFNYcJS5swYl0K ZImgDrLkK3yJDL5FG8IBsX221bJ4o4o4LXLqECiqCqKm4HJkCx57iOM2xjOouWMFdsix63yoI3cm HbpKRJaz+m4s97mro9NCPkwDqCKIAKm6T6HphmkbIcBvcCx36O+yj0N1x+985EG2/CSLLYjySWQX NBt4vASIrir3AvLYdrgx3XzBskDFgOZIgTsgiw5MWPKt76Cy5JAyYacf4Ky26aAfASNFNNlDkhCp YOD+6UwXMcSZvTs87ZLG1xLhLt7kOSroI+50RFjdoVlJ10VnkyJop7D5SRFApcdM9VHo9wfhW2/w c3bsdwhXe/yL228xc5D1xgOr4A34QKsocVh8R2GNx/NgpgoIQ+N1wDUdvC7SMOy5VOeauU9+2W7w pYzURDZjeDgYDc+qx+dB9W3vCHeghOITWzgiF63zXiywgtr9lGPMhTY0twpE99y3pHejz4UM2HQN pXGz5zfIQoqE2gqnjch/cb3Q+D7SRu8ubaHY9ynQXBk219RAYslI7kkzAFFqPzIU6xqIIqkKqhAa IBabKuK0CviIOqKcxAlJEXbvRFVE3Tf49k/ur90pQClKUApSlAKUpQClKUAqkdXGXH9U8JFhs3S+ Dt9XYBUl/wBYtnxJV3VQutuK2fLtTMHhZJCWdFax++vA2kl5jY0ftiIvJowJe4i7t9u/ydyVaNZY d7VrkZ1FeDMT3um/scn9yX2U97pv7HJ/cl9laDsUwHzdX+c3H2inYpgPm6v85uPtFbf2gpdxnnZI 6m/97pv7HJ/cl9lPe6b+xyf3JfZWg7FMB83V/nNx9op2KYD5ur/Obj7RT+0FLuMZI6m/97pv7HJ/ cl9lPe6b+xyf3JfZWg7FMB83V/nNx9op2KYD5ur/ADm4+0U/tBS7jGSOpv0t81F3SJKRU8i9Eu7/ AO5VbtYBlkPO7m9Ctch3GoB3PI7ICvq31rxNjC14PuoqrQtueFOCadwrIFfiqU9imA+bq/zm4+0U 7FMA83F/nNx9orKp05RqWvBlopR7fQqHDdNc9kyIcDJLBktvx6ZfbLJuDXXeij0AjTG5+/8AS3nN jcOOp+Miu7IfAe6tva8EzhmHjjV8x3KLpNhwlj2h5i8LHG0yhuckkfkmpryHwNYqISg8pACt8UUt 0sbsTwBPJji/zi4+0U7E8A83F/nFx9ornj0rRXY/Q0c0+30/1Kvt+nudOWaXFYseV2hx62W1i+lJ uhk5c7qlyjnJmRjF0lAPBgkIpire4uCKDuNfbrpbfrHHvL0Z6849bNslErlMvT3RhxWXmnrKqq44 vBtCbVE2TfYzQv0tls/sTwDzcX+cXH2ivhaI6fGJA7jIugSbEB3a4EJJ/WiyNlp1tR0foRmWvoV3 aMTzC73G1ZNfcdye5uZCjd4hsQLwURrH5j0wnFRxSVFEBhJGBPzbieI4PBCNVrCe011Ak4i1JkQM iLKLXYYCWva4uDxnpeJJvEoo5wMvBDDvPknBeKLv3VahaLYEZKR46REq7qq3m47/APEV+exPAPNx f5zcfaKnrajo/QZlr6Eml2+SUuQrEOR0ldJQ2YLbjuu3xfJXj73Tf2OT+5L7K0HYpgPm4v8AObj7 RUPl6fWZnPIOMQtKocxme0/Kizy1AnM8ozLjIOOEz4yiSK+CoHJd9l7+6u2PT1N8FB+hmqafJln+ 9039jk/uS+ynvdN/Y5P7kvsqiLJc9Jr5hmF5BHwmQ3JyjI2bD72Fklw6kIzcRCeM+r4wC24w53Cm /XBN035Vk40Om95vtsh3fB4dnttzlXKOxLHPJcmSz4F11ccfh9QDbbUIzi80IkHcEX9JFrXrpcf7 t8PkW2PiXd73Tf2OT+5L7Ke9039jk/uS+yqRxFjA8wvlrtsHTcWXJL0NqXEcziUlzjjJYbeSSEBX UJ2OAPtczQ0X9NUFUBVXCYvOkzmnUPL3cIktuSMkGwLbfhHcFMHFLkrvU6uyh0FR39HbxkHf/ap1 0l/hv0Gxt2l9+9039jk/uS+yvuCxX2NebQr7DrSfAu4pubaj/wCPxflqrbXieC3PLnMUTTucze7d KlBfkLILh0LZGb/0Enqq6PWSTya6QCKL3ubqiNqq67MYWn2EXaU3BwjqvRZ9usjtxkZjPtTLb8xp yUrZyFdLi0200yZL3opOgiJuO9c9bpaNeLpKDu/lqXpwyTudzb/3/wCFN/7/APCuI7FM0vuWPpdb 3bbtZdpE1pUj5He7rGNqKTYuy25Md1RKKiutp1yQBQlIV7xWtjljWk+GrfGbmN2fuNnjvuvRI96v ZdRxplHjYB7r9JXUbITUOe4ivIkREVU8x4pJ2ys6totDsvf+/wDwpv8A3/4VxYUjSI56sRDnORop Thuj799v8dYRRYxPuggG5+ecEQXmArybTZVReSIuVb4uld/lLbMWS53K+OgYwoL93yCEj8joG80y TzriA2TgApBy7yDckRU8re491jaLQ7J3/v8A8Kb/AN/+FcpY1g+B5ZjVnyCz2+5rAu0JqWwh5LdO QIY7qBbS1TkJchXZfKK1s+yfEPo64+st19qqjx1NOzTK7aKOmt/7/wDCm/8Af/hXMvZPiH0dcfWW 6+1U7J8Q+jrj6y3X2qo3+noxt4nTW/8Af/hTf+//AArmXsnxD6OuPrLdfaqdk+IfR1x9Zbr7VTf6 ejG3idNb/wB/+FN/7/8ACuZeyfEPo64+st19qp2T4h9HXH1luvtVN/p6MbeJ01v/AH/4U3/v/wAK 5l7J8Q+jrj6y3X2qnZPiH0dcfWW6+1U3+noxt4nTW/8Af/hTf+//AArmXsnxD6OuPrLdfaqdk+If R1x9Zbr7VTf6ejG3idNb/wB/+FN/7/8ACuZeyfEPo64+st19qp2T4h9HXH1luvtVN/p6MbeJ01v/ AH/4U3/v/wAK5l7J8Q+jrj6y3X2qo9qBpvjdn08zG52mNc4dwt9hnS4j4ZHcyVp5tgzA0QpKoqoQ ouyoqd3elSsdTbtZhVos68pT5aV6BuKUpQClKUApSlAK+b/3/wCFQbWyU/B0Z1ElQX3Y0ljGLk4y 80agbZjFcUSEk70VFRFRU8lc46nYzj+neLy8hgYbMyGBbo6v3ASzy6QTZD82gqCK651FVTXu8Xbb 496wqVlTaTXMpKSi0jsff+//AApv/f8A4VxLBbwyNl2T4xnGKzsauWO2Er5JJnOLrPacYBOToifV b8YQJsttu/mvcm26xccrxJyww7wzgrjbBY6N9mMz9UJ8J1oFkyWFZZEz/PuIsQl/2O8xFURVTfNY i/KL9PcjPfsP6Bb/AN/+FN/7/wDCuFL/AHXBLXfodpt2LzFGXGYfG437PblZYbTjkZJKxnHDePi+ jbsbYNu9XV70QFVdtBTT0swbx3IsdvWNOLiqZG69Ny25F0BE3OqwSDJ2UhbaN0TQlQwFV2Gm8q18 r9PcZ/A7V3/v/wAKb/3/AOFcG23IMFexOw5JecGya3QMgiShtQMZReJjki6MyXGRtiiDqcHnUBDb Iu5fHHbdtVWxhxGDiN906uNshzbLd5GTQYs1kcinzmwRyNIJ1jd15QcFCBB5cU3477d9FiYuSi01 fgM6vY6tpRPJSus0FKUoBSlKAUpSgFfN/wD99q+1zNkeM23L9XdQ0yMZ8wLctpbiAF4mxgaFyK4R ogsvAneQ7+TyqtZ1KipRzMrKSirs6Y3/AL/8Kb/3/wCFczDpNiCqm9uuO3+8t19qqnbxcoNgj5q9 dtKpSJh7cErgkfVG5vE4csRVgWkTblvzFF8m2/dyrmhi4z/ZT9PcpGqpcjvvf+//AApv/f8A4Vw7 klx03stxSLa7Ddr2BYXIy4Xgy66sj0BbVxplfz5eM4Ikqr/spsvEt+78xnsQVvJWJ+Hyzu1mjwXm Y1l1CuN2ZmHLf8HYYR8HgRp5XVROBCviqhJulWWJTV8r9PcbRaHcm/8Af/hTf+//AArgyDe8NuGJ 3zJouFyZNugWly5tBC1InyngVDQQizGwd3iPmhISD+cTdCHfdFrbPuYLLveG2XE8Xu1/uWWY9Ivc Jr4ZXOMjXGObrLBkUhRQnSZeb33TgoKqoqb7N5S4ZX6e5OfwO3d/7/8ACm/9/wDhXHGF2fBs9fmH YsbvzFtgx2gmSZuR3dhxm4l3uQFaWR3myKp1DQtkIhHZd96lhaT4ggr/AMnXHyect19qrOWNhF2a ZV1orgzpxO+lU/7nplINrzi2sOSThW3L50WIEiW7IVpoQZVAQ3SItt1Vdt/Kq1cFdsWpJNdpquKu KUpViRSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBXlJB1yM8EV1GHyAkbc IOaAW3cSjum+y9+26b160oDnyR7k3Hmsch2+w3aTargdimWW83DpJIO7NSW0Vw3EcJVE/CBF9FFU 2LknkJa32f6BN5w5ejG/nAK7XOVMdTwNHUBuRZEtRtonNPGQUR1D+JdxUVTvqmLDrjmluwXB4OZ3 eTKv8+2yb41PjtNR0u9uKyTpKCh8CEHo8htts/E8nQNULmqVLbFrxlsa+Iw7EiXaxzJUMGClSCGV Djt2SNcZhL02kGQZC4fBE47uF3oIeQCwHNBmDyQr0mQTBMr7c7x0kYBEQ5kBIahv8gInNF8qquy1 qcW9zVCxnILBP99IVwiWpYL5pJsjRy3JUWAEMCCSpL0mlFptxW0BSQxVUcQSUajsXXbJrq3jreQ2 mPanLvJxu6wjst16g+AXKarAsSCcZVFMeO5cEFHBUuBBwVV1dn91Nls6PbLjPxKxxrXJtduvj3Su 7rjzcKVN8DRsRVoRJ7miubqqCgpwXdV5IBvbf7lmXDm4pJkZqM5McOzHFWRZkcNv3vRGxaZInlRh l1pN3BBOROr1OfH81WdB9zVObtVsjXXN3blLxqBDhYpIW0ttJbwjSmpAE8AntIVSjRwLvb3BvbuM iNYZk2s+apg+QsYsrUZbKalNu864i5MRXr9MhNAwCMC0ewwz7i2XYwBORIpLPrdrjdrplOT2piLZ I0GLAvMi23GU5MYitrbn2mHCkSHGRbNsid5ETCmjXAhVTVd6A+T/AHNbF1tpN3DI3vfSW7Nk3KYx CQEkSZM+BLIwbIyRsBS3NtCG5eKW6kpIqlq797lRm+Xy5XB3I4xt3F6a06EuwsyjZhSZpTSaZIyU QeF16UiPEBjweRCbJWxJfJ7XjO27NFkpi+PtyVtVzyRxZVxkxm3bPDJoBIebKKDz/V5ih9zQcFNO RKKauV7oPJrTNv7dntT2QnIucmfBZlRZCnFt7Vttb/gyhGZcITJy4IPUc2BtVJSJdkFQOo6VSdi1 wud31GtNmnWSPZbBdWYwRXZbjxPnIeg+F9NXG2zjg6PeCxjcFxURHRUhIUK7KAUpSgFKUoBSlKAU pSgFUvq2+5a9RMPuj9tvUy3hY7zFcetlmlXHpOuPW8mxMY7ZqPJGnFRVREXgtXRSqTgqkXF9pWUc ysznf4aW/wCicz9Rrv7NT4aW/wCicz9Rrv7NXRFK4dwp6v09jDd46nO/w0t/0TmfqNd/ZqfDS3/R OZ+o139mroilNwp6v09hu8dTnf4aW/6JzP1Gu/s1Phpb/onM/Ua7+zV0RSm4U9X6ew3eOpzv8NLf 9E5n6jXf2anw0t/0TmfqNd/Zq6IpTcKer9PYbvHU53+Glv8AonM/Ua7+zU+Glv8AonM/Ua7+zV0R Sm4U9X6ew3eOpzv8NLf9E5n6jXf2anw0t/0TmfqNd/Zq6IpTcKer9PYbvHU53+Glv+icz9Rrv7NT 4aW/6JzP1Gu/s1dEUpuFPV+nsN3jqc7/AA0t/wBE5n6jXf2asEcgtqZjZsk8AzVHLXbpkEY/wDu6 i4kh1g1NS8H3RR6CJtsu/Lypt39LUpuFNdr9PYnYR1OJLRp7jNpetjwJnrrsC32mMAlp9dun1oci I4chA6KoJvNwIrRbeRG99y8ibdjG8Zi4NeMah27L4sq8NTGJ17a01uIzXWJMs3nW1PwbdUUHCa7y VETYtt0RK7EpWm6rvP09i2y8Wce3q2RL5lEafOk5o/ZI96j3hiBJ0xuciXDcacFxGIk4mecdhSbH xBBVQVIRVEJaioaT4wkNuOcjUIuNpagEqaeXRBJ0JgPrK4dDZHFZbGN3f+DTyr5K7spVt2S+8/T2 LZPE5DtFutdnyRvJmTz53IZcuW9f5bmAXchvDLyJxYIFZXpAz02ejxJeCASbL1CrT5NbDyO+3joj l1qiOX615PbpZab3OaIzWIhQ3o7rBsihAog24JbptyVO5RTftSlQsLFPNmd/p7EKmk73OD7xpba7 1b5rEy6Zs49dUmnc+elNxSMsh8WRSRGig0Dcd0QYEOa9QlQzXdDXkkomWcJjOVW8bxn0Sw5MM+RP t0fTW6JznzIqMOvK6TSl0kLd0WE22JURXFFESuyKVO7J/efp7E7PxOKrhh1ru1oWJcpueOSjeyGQ 9IDTe6ALjt2YNp1Ub6K8RBXFIU5Lv5FVPLUkukuEl5lZHGgZ1Pms5CzkjEBcFuraPvsWsoQR+orG wofikrip4vk22766xpUbqr3zP09iNnxvc5S07lQMHwHGscct2YvvWu3g0+4OD3hRN4lJx1R3ip4v UcPbuTu2qS/DS3/ROZ+o139mroilZvA027tv09ijoRbvc53+Glv+icz9Rrv7NT4aW/6JzP1Gu/s1 dEUqNwp6v09iN3jqc7/DS3/ROZ+o139mp8NLf9E5n6jXf2auiKU3Cnq/T2G7x1Od/hpb/onM/Ua7 +zU+Glv+icz9Rrv7NXRFKbhT1fp7Dd46nO/w0t/0TmfqNd/ZqfDS3/ROZ+o139mroilNwp6v09hu 8dTnf4aW/wCicz9Rrv7NT4aW/wCicz9Rrv7NXRFKbhT1fp7Dd46nO/w0t/0TmfqNd/ZqfDS3/ROZ +o139mroilNwp6v09hu8dTnf4aW/6JzP1Gu/s1R7UDImrzp7mNrtVizOTcLhYZ0SKz8CbsHUecjm ADyKOiJuSom6qiJv311TSpWBpp3u/T2JVCK7R8tKUr0DoFKUoBSlKAUpSgIPrRAlXTR3UGDbIz02 bKxq4sx47DauOPOFGcQQAU3UiVVRERO9VWqSzyZac7w2+Y1Jh5xAZu8IYxyG8CuzhNbEBboKx0Re 8NvKnlrqWlc9WhGq027WM5QUmnocc5ZjOOZhmUzI7i1nzay7rbZr0RvAbrwNmMybTsQi8HRSafEh 57+Tpj3LXzE8VxXG5MeTcrTlWSvRrcMJk7jplcTJsknSpaugpRi4kqy+OyInc2i7qvcnY9Kz3VZc uZ2+nsRs+FrnIFyhi+Ety1T80jybhdZ8+6M3HTC53KBcBkqCC27ENoUVWQYZBtxDRUQSRUVDVKjq aY4otpt9tdXURxiG3b2VP4BXYDdaYOd4Q0qiwnFp9u4vtcB2RsEFE5Im1dw0osKkrZn6ew2fDmcZ y8SsF2YWHfT1Cl26MM961x4+BXWL733CXNeklcAMWFUn2+oAN77CCAS7buFtLFuEzIrpp1Cbg5Td LnCySBKuM+Vh0+2MmjcaQLsglcaFttCMxXihdylsncldQUpHCxjJSu+Hy9gqaTTuE8lKUrsNRSlK AUpSgFKUoBXOd7mOY5qxqC/dLPkhxrmtqchyIGNzp7TqNxnAPY2GjFFQiRFRVRe+ujKVlUpqrHKy soqSsznf4aW/6JzP1Gu/s1Qi8Wiz3d3OHVTPI7mWP2V9zjp/dS8EK3E2ocd4/j81aTffbbfu3rr+ lcscFCPJv09jJUVHkzh8tN8abavLcE8/jBcW70w2Jae3VxI0ecw0w1HDdlF6ccGtgTdN+Zfo1O5h YrIds4Qcayi0W23Xcbq5Dt2nVzijJeBlxtpSVuMOygbiOoWyrybDybb11LSrPCRfOT9PYl0r9rOH JuAxLyEz4RXjOLhLWzP2eLcW9LLkxNNlwg2OY+jSrMcEWxRFJA8ZSPbktbGPh9otN5l3rG5WfWu6 rdbncID5ac3R9IKSozzTTAArKIrbByX3QTuRVcVFT417SpVt2Xefp7FsniclYhAx/A50osYiZ8za psNkJlvfwi8Oo/ObRB8PU1jpxecbTi7sOzioJr3pUsXM7eoqnvRmfk8xrv7NXRNfF8i1m8FCTu2/ T2KOhF82c16SavYxjbmfNXZvJGXJWXzZIAmJXQ1ECbZVEJBjrwLbZeJbEiKiqnem9jflA4T8uTep l39mqsbM4Y5LqPsZJ/zzl+Ql/ZIdbrrOfOH9Za+YxXT1XCV5UIwTUXbt7D36HR8KlKMnJ8SaflA4 T8uTepl39mr5+UFhHy5N6mXf2aoWrzuy/nD8n6y1Rt61Uyi3XrVCxxphOzpNwcg4aSr/AKu6z0hl p3J5GmpDchN9+4S/rpQ6exWIbUKceHi9UvTm/BMtUwNKna8mdTflBYT8uTepl39mp+UDhPy5N6mX f2aubsW1fv8Ac5OOQAs5T2JbFttztzdGVuc9+1tylkGYtpHFtDcFCbQ1dVCUxHZERcTHdY8sl2y0 RpFqtM24yY9ghDMdnOsi/cLmwDrRuAA7A0IdQj496nwAE790363x3H+6j2dvY+0x3bD9sn5HTn5Q OE/Lk3qZd/ZqflBYR8uTepl39mrm+56yZHDj3MI1gtJzrBbblOvIvXOQLRJAm+DPDFJAUi59xApp 4q8hLfbv+33UbJAt+aQMWAHbhbfhVNKbc7gQ+CxIDqMgjHBririG4hCB+KKB4xFy3SF0xjna9OPH hzDw2HX3n5HR/wCUFhPy5N6mXf2avv5QOE/Lk3qZd/ZqoC06oXSZlNpx+MxFnsPgFvcuLhSw4Txt aTDJ51G/B0TkiibQErgJuS7fo152bUfM743Y4saxWGPccjemHZJUm4SmoUuHEaE3ZOyp1kE1cFGv FRVFDcVOKDyp11jVzpR5X59nH/JN/JFt1w/efkdBflBYT8uTepl39mr7+UDhPy5N6mXf2auZIusN 9mXB1+0wnZSX2Pj5Wu3vjJkhb1kQJcmSSjGaJ57uYTZBFN+4vFFFqzcOyh7LsSst+chyLS5cY3Vc hvO8yZNDICHknlTcVVF7l2VN0Rd0Stbp3GUFedJW4duqv+v+L2p4KjUdlJlnflA4T8uTepl39mon ugMKJUQfhOqr5ETDLv7NUL6znzh/WWsiA854bH/OH/pE/wBpflrkf2nrpfu16m/VkO8y67DfIGTW O2XuyP8AhVsucRqZEe4EHUZcBDAuJIhJuJIuyoipv3pWwqv9CP8AqP01/wB1LX/wjdWBX6AeAKUp QClKUApSlAKUpQClKUApSlAKUpQEedwPFn4ltiP45Z3YtrjuRoDRwGiCKy42rTjbaKOwCTaqBCmy KPcu6V+IOnuJWy9t3u3YxZYl4aZBhuczbmgfBsG+mII4g8kRG/EREXuHu8ndUkpQEOsmk2CY2DwW DDcftoPS2ZpjHtjTaK+ySky53D3ECqqgqfoqq7bbrWWGnWINxwjhitjFgIrUMW0trPFI7bvVbaRO O3AXPHQfIheMnf31JqUBD5+lGC3WXClXPDsfmSIRuHGcetjJq0RuE6ajuPcquGRr/aJS8q715uaP 6fu3G43F7CMbcn3InTmyDtLBOSFcTZzmSjuSF3qSL3Kqqq7qu9TSlAQF3Q/TV63MW53AsYKBHlFL ajraGemDxIAmaDx23JGwQvlQBRd9kraX3THC8nbcDI8Tsd1ByZ4c4ku3NOocjiIK6u4ruSg2Aqq+ URRF3RNqlVKAjLenWJNZYOWNY1aAyUW0bG5jCbSQgoHTT85tvv0/E38vHxfJ3VJqUoBSlKAUpSgF KUoBSlKAUpSgFKUoBSlKAUrX3K/WqzvRGbvc4UB6Y504oSZANE+fd4oISpyXvTuT5UrYUApSvGRL jxEbWW+0wjrgtNq4aDyMl2EU38qqvkT46A9qV4tymHnnGWnm3HWxEjATRSES34qqfEi7Lt8uy19f ksxW+pKebYb5CHJwkFOREgim6/GqqiJ8qqiUB60pSgFKV5eEs+ELH6rfhCB1OlyTlx325beXbfu3 oD1pSvJuUw68bLbzZvNgJm2JopCJb8VVPKiLxXZfj2X5KA9aUryZlMSDfCO826cdzpvCBoStnxQu JbeReJCuy/EqL8dAetK8nJTDJNi8822rp9NtCNE5Hsq8U+VdkVdv6lr1oBSsWXc4MD/X5keLuhkn WdEN0EeRL3r5EFN1+RO+vV6UxHNht95to3z6bImaIrh8VLiKL5V4iS7J8QqvxUB60pSgFKV8VURF VV2RPLQH2leEKbGuURmXbpDMuI+CG08y4hg4K+RRJO5U/rSvegFK8mJDMptXIzrbzaEQcmyQk5CS iSbp8aKioqfEqKleiKi77Ki7UB9pWKzc4UiQUePMjuyBUxJoHRIkUOPJFRF37uYb/JyHfypWVQCl alrKbE/c/etm9W1y5cyb8EGW2r3IUVSHhvy3TZd027tlrbUApSvLwlnwjwbrN+EKHU6XNOfDfblt 5dt+7egPWlK+KqCiqqoiJ5VWgPtK8Y8piWBHEebfAHDbImzQkQxJRIV2+NFRUVPiVFSvagFK8npL MdW0kPNtK6aNt8zQeZrvsKb+Ve5e7+qvWgFKUoBSlKAUpSgFK8kkMrIKOjrayBBHCa5JyQVVUQtv Lsqoqb/1LXrQCla2FkNouVwl2+3XWDLnwl2lRmZIG6wu+3jgi7j3/KiVsqAUpXm8+1HBDkOA0CmI IRkgopESCKd/xqqoiJ8aqiUB6Ur4iovkXevtAKUrzKQyD7bButi+4JGDakiEQjshKieVUTkO6/Fu ny0B6UpX4debjtOOvuC002KkZmSIIineqqq+RKA/dK/LbgOgJtEJgSIokK7oqL5FRa/VAKVi++cJ ZKRfDI/hKkIo11R57qJEicd991ECJP6hVfiWvUZTByXIwPNlJbAXDaQ0UxAlJBJU8qIqiSIvx8V+ RaA9aUpQClKx5k6LbmOvcJLMRlTBvqPOIA8iJBEd17t1JURE+NVRKAyKUpQClYsW5wpritw5keQa Ni4otOiSoBKQoWyL5FUCRF+UV+Ra9PDI/hfgnXa8K6fV6PNOfDfblx8u2/dv8tAe1KV5MSGZTfUi utvN8iHk2SEnIVUSTdPjRUVF+RUWgPWnxUpQFDXDSHOYmR5NMxe74stuvN2cuYhcrfKN5sjaabUd 23xFUTopt3fHXn2Zao/SmB/yuf7TV+0rzanReCqzc5002+fP3OiOJrQWWMuBQXZjqj9KYH/K5/tN a9dE86KSUkh0zKSTz76ulYJimrr7SNPHy8I35G2iAS/7QoiL5K6NpVF0TgFypLzfuS8TWfORzVF0 EzCDeYd5hxNLWLtCjBFizG8dli6y0AI2ACXhHcggiAnxoPiou3dXk17nzK2LRNs7MDStu1TxAZcM cdmI08gKqhyHwjZeKqqivlFfJtXTVKv1Zg/w/V9nLt7Cu3q945qj6C5jEhJCixdLmIaQDt3Rbx6Y IeCmauGzskjvAjVTVPjJVVd17687r7n3K742Dd6t+lVxAJb00RkY5LcRH3VRXXO+R+kaoil+sqJv vsldM0oujMGnfZ8fm/cbera2Y5hme5zyS4T3p9wtOk0ua82Lbj72NSzMgEOCDusjycPFX5U2Rd0S vBfcz3z3tetqWTSRLe8+EhyOmNTEAnQRUE9vCe5UQiTdPiJU8i11LSrLo7CLgoesvcjb1e8c0XLQ HLrzFkxbrD0smR5QsC827jsxUJGBIWU/1ju6YkQjttxQlRO5VStrG0p1KhRmIsGbp7Eix2xaZYYs 85ttoBTZBERkogoifEldBUqj6KwLVnT9X7lliay4qRQXZlqj9KYH/K5/tNftnTbVJl0HBumB7iqK n/Jc/wBpq+qVTqfo/wDCXr7lt7r99kc0+xlzC8CxbG35Ay3bLaIlvN8BURdJlkW1JEXyIvHfb+up HSlescopSlAKUpQClKUApSlAKUpQClKUApSlAKUqo7nqrktoPLSk4xaHmcZbDrqxfHSOQ862psMN isZE6hKTKLuqInVTZV2oC3KVUF+11bs8a0PRrIU1JGNSMhuW0tAGCy3GV1tvko7GTheInk2RFJfK iL62vWV+U/eIr9utE6TCYieDOWW9+HMPS5DpNNxDcVoOm5yEVXuJEAua7IibibFtUqlGNd5cqFer lCs1qnw4ESU4sSPfB98I77aqLLEmMTaE0TxpwTbkoqqboqLum+a1YeuF5wqz2izDInZFaSuUpXJa i3bxWOrjQkSAvNTNOPcibIJFt5EUQWbSoFp9qLJ1AAJUWynb7axEQbg9IeVFYuKFxehgnFOp0VEx N3dB5bIPJefDe2TPMVyWYsPHMlst4lo2rqsQri0+aAioilxAlXZFVO/+tKAkFKqxzVK7Wu7ZCGS2 qzW6yY4TC3O4NXSRIIReRSAW2RiopubK0qhv/wCFHZVrNkaz47bTnHd3X48dknOmLcCW4+gMsNOy Dea6KK0jaPhuqqqd6IqoW4oBY1Kg7erWNPRHHo53J50ZiwxiBaZKyXHOiL/iM8OZD0jE+SJtsSd+ 67VpZmuFr9848ay2+bdokhy2oxMYjukEgZTLz+7QiBE4oMMoaoif+ETdU4kqAWlSoO1q5ishy0jG lynwujUR1pxu3vkDIyj4R+sSBs0rh+KiHsu/l2TvrzDWXDiZnSCuElqJDhyJhSXbbJBt1lh1Gnia JQ/O8DIBVA3VeY7boqUBPKVXcnWPH7a5MK6uPx2GyUGWggSzlbhGCQ8rrHRQmkBt1st1VU2JEXYv FqQ4vnVlzBJa2R98lim2BjIiOxiXqNo4BCjgipCQLuip/X8lASOlQ2z6pY5fDhpAfmqE95lqA65b nwbmI62442bRqHEwUGXC5IuyIO67Io7x29a0MNOdPFrct5R9qEkRxSdbRx6VLdjtooo2RI2iR33F PbvEE2ReSUBalKhI6r4z0Zrrz89gYhQ0UXLXJE3UlPKzHJoOHJxDcEhRRRfJv5NlXxhaxYnNF0vC p8YW2XHd5Nqks81bfGO40HJtOo6Lxg2rY7lyMRRFVdqAnlKqzI9dLPaLYsq2QZ1xdGHc5DrRx3I6 xShNiptvIQ8m1I3GQTxV36gqm6Km+6PVrHWopm4tyWY3JcinAbtMopSG22Dpr0On1OCNuNnz48dn ATfkSIoE5pUNZ1VxSTMahxrmr0h5pt9oAjuqrkc2FfGQPi97PBF3c/RQk4KvNUFfwOqmPFbblPL3 0bZtjgBNBy0SQdjiTfUFw21DkIcPGUlRETyLsvdQFbZ7ZJd/ze8ts2W4SpM/wSzyLfcrMsy2XK3b oZOjKEU8F49Z7knUVeTSKjZKo8sWLc9RnIWQ3eMN5auw299uQw7AfVpl92U2jasMuLxcWMwLqp0B JHu5SIyVEq0ourGMTZVtjx5MxffDoCDhW2QDbLj4obLTxECIy4YqKoB8S8YN0TmHLAx7WOyXaFZn LiL0GRdegQA2y7IaYGSapER14Q4Nk6KgqCSou5inxiqiTQ2+blFi0zy65Qnbg5MekElgZuQuK+0h A20OySi6hkTvMwbd4qqmgIiIopUPGbkUpjInsTcyq+QLdMnLGC4cnHDWLayFBFSFDBxyZJFRHuJF jqiIKJxS2dYcliYrp9dLhcLFHyhvdpobTIUUCWROCnFeQkncm594r+gtRjIdW7bgVym49jdhiJbb Tamn1eSQMGIzJfksNMRv0FQEVJIuGfkAVTuVVXaARWwYnfMMkQ5+MRcifbjTUhx4pqTYP26FZzbb 6wF8bskU4qfenMduOy7/AIfk5FebZZmL5HzB2wMrYYs2V72PJKN6MD0t+WjCD1U5PBEZIkHkioSi nchVMR1rNm05JPlQLRLj2c4LQzrZeSlQCckuq2ouyOinR6KcHHV4nwbcEu9V41mjqlc2cKl3grLb 7xcXZRRbCzZbwEqNej6XURWn+KK2g8XkPmPi9A1Tkm28g0y3HKoGn8C2ymskaknNbdnyxjHKmxrU /Lf4NiQISuSAZBptzhyMEPn4yohVpyayt+dFt0A84iOc4Ttj8MVSFllyQTkk5r4qrbittoraMukp 8BDbk4amlvBnNhZxi1ZFeLrBs9subDLrD06UDIErrfMRQjVEVdt128vctajM9ToFh07uOXYv4Llr bGwRWYM0FCU6riN9MXR5Juir39y7bLQFV3a2ZzcIV0ntS8zjSJdru81plp4gRp9yWg25hGxTxVaa RTMU718hKQ+LX5zs8wUrvNtttyKNdrrbylRnoTT6k2gmrUVheiPcbIdSQbbhoCnJNEB3ZEGyJ2sV tiZg3ZgjG9bW7V4dMuIqRdN0zYBiM20IkTrrnhALxTZUQg2RVLZMPJ9dLPZbSzMtcGdczfi3B0W1 jus9F2KYtE08igpASvuNt/oqu5IqIqKm4EUu07OpN/yWY01fUetyXU24UaPIbZeiNxnG4rLRKqMu OuuK0+jjfJwV5AvBE41h49iF/wATdhTMXZyB8o8xqBFYdI2W34EK0GLfWA/idlJsin3jzDjx2Xez n9W8eAQeCV0IzD0wbh4bGkR3Y7cZvk4SNq3uq8jYRELjujqcVVdhXAu+scKPFMrNBfkzhaeT3vnM vwZKvi5Gaab4G13IZzGE5KqdxoooexIgEGsEbObtalZW45Oyt3k2uLKmHGeiuMOAZvTZABITkyJN iLOwgjaKQ8N13Wgjlbt0sbAjlMZX7i4840DDzO7J3BW2nTlCJgRsRGAU2ZKKjguJsSltxn8bV23o 9OO6tJChwpL8dzpi/JfJUuHgMdRabaXfqvA8iCi8k4jshIqqMihZ5YpuLzMkSU5HtUIJRSikx3GX GfBiIX0JskQ0UFAkVNvi7t90oCjrba70zbmrgVoyCMD1+kqvUZlK/FflPOuSJHARN3piwLURtxpB X8+8SEKL1U9o8LUG8YmSuv5Tb5sW1p4E2DjjTnhkq4uoHVUtycSKy2zuhESEDiqSnvyq2Y+rGNSJ UGOL09s5jrTSK7a5DSMuOkosg8pAnRJxduInxVUIF22Md/BnVmx3KPHdszxG1IkRhZfmxpEZh9hx HHFeadVtRcFGmHzRUXj4iciESQlAqS9WG9y2st52/I0iXW5zAum0M33CbeuTEQXI4qKqqN2+I4ac EVFF4U2LuGtrLLNWIxybYGSFbUO4TYCyIyypkNk3IscC4uDzJ1G3J8htotzQeAEi7KFWEusFmeCy OWyFdpbN2uIRGnStr7Io2UdyQkhFME5NdNtV5Dv8aeUSRPYNX8XJtVJ25NveFtQwinaJSSHHXWid aQWunzVCbAi327kFeW2y0BVV4yC5Y/AuZz5mXM4q0M+5xG+u4l0UGWGAZB0j3eZaceSW4KuIneIC SiKo0u0kR83tkNx29yskmvxxtlhQoaudPbwYHZdxIGWyNxTccNnkA7io7j09lMZrbMlxPULLrWEe wN3dyPZmrzEu8q2p/RRceUW2xJweTbikyZce5U6a/GndHImvTsiPebqNnhSbPaos2RLjRbsh3SCj HPikmEQITauKHFERS4Kqb7puQgRlmLqHecYbAXcotsmLFeGKiOONuLIlXU22FcU+RODFYaE1Q1JC BzclNF3qWS7Dfp+nObWaQt8dS7Xw7dA8IfJySzDcdZjG7z/S6W/WfT5Gy2TuREqWO6sY7BJwL0c6 1GzBemPrJt74tgLLSOvCjnDiRACoqoO/xom6oqJgXDWO0NJBS1w7jNffuzVvejHbpLMhtDjuSEcR lW+oaK20SpsO3l3VOJbAV2Q5kEe5DjbWVQbgxGuUE2XGjGJGQnUj29uOBpwc6Y8Hlfb38UD6i7mI pM83bueMx8ctbD2XXSyNMTX5sq2o5JnypIIJMMG4Cbtiak6vLxQ3abBVECUVlMXU/F5seO/HuJEE mPbpDKLFdQnG5xkEZUHjuqkTZoqbbjxVS2RFrVY9rBZrtGsvvgD0KZdBYJAZZdksx1keNGbdfEOD bjgKBIBKipzHf9IVICt8XtWa224YzYHku8BYDdpJDYYf6DyrxfuT77oqjBk6avNKDi8hXYwDcuVa y0tZTFjWKJbIWYWx1+fFuEkjalKguTLkrkvn3cFRlpVAkdIkVFUxb2XqFcjGsGLSmnDivz3lXorE ALXIU54uoatnGHhu+Ko04vIN0QR5qqAqEv7XVzFFbtzrU6Q81Obad5twHySM246rQHI2D8wiuCQf nOOyge/cBqIFXPx8n/pd2mxb5bpTsdEiyI9rckORwm3J6Q8y4DOzvdHjQo5G0im3zEvKO6Whp1c5 wYmyxe7de48+LFSU83OI5J7OE4Ysi8QirpAKCOypzRFBDVT5KvtaNU8avU5iFBkTOtKdabidW3Pt jKFxt5wHGiIEQ21GO8vNF47BvvsQqqNqpjU2RbmLe/MmlPFkwKPbn3BbbedNllxxUD82BuNGgkWy LxVd9kVaAqq0YbkWK4Vj1ynOzevdHWnbyFvsQFcLakkjekkBNirxHzPoqQopCJkaJuO6SjBbTlFz u9r9/wCTkVutFrYkTY7MmSqHKSRMd8GZkHupGTMdkOQKu6ddENSVN1nl3zqz2O9RLTcTlhIkuMtC 4EJ02QN4lBoSdQVAVIhVERV+TfZFRV1r+reIxrW1c37oQQnbedxBzwR4lKOLoNc0FBUl5G4CCO25 b+Ki0BW9xuGoTuQ5JPtzd1S42wro7EhpEfSI7GbYMIjI8lRh03DVt/kHJxF3AlAe6sa3s3Sz5K3k EMM2n2grlDgOvzYDrs2RHahyXzJG1bRxtp2S8wBIoiKE2SbAHHa0x1Wxnw5uI7JmMGYkiuPW58G2 3BYWQTJmobC6jIkatqqEiCu6IvdX6lao41FBneVIdkSGIr0eM1DdN57wkXTaAG0HdTUY7pKPlEQV SRE76ArW0Fl0uVYmcp+G7csrbBnsN21BbAZbrzr8oJDpfmuLYi2wjLi/oqvBCIkUNCjWT5XbL43e 42Wt2q7NWdZcRxiXyFHrkSywDkAkPSjijZI0AiomhbEicq6IZv0F+wDfBdNu2lE8L6jzJskLXHlu QGiEConlEkRU8ioi1Wdt1uen47gkwsccZvOU3PwN22rK38AaF8mnnjc4d/Himw7IpKSJ8SqgEWit ZrIG0QXkyi33d2JbpUJGGVCK1IffJ6c5KcFOmXSH830XV3JB3FCNzkns69mtsZcvYjlkh652y4vP RSUjSCsmewMQQaFs9jjME6aoIEaoCoqHuKJvbLrjIvDF1ucayw51ot8CXMkRoF1F26QuiiqDUmEQ CQOOcSRBFS4kmy7ovKtnYNWX51nu92nRLLPt0cWBgysfvg3FuVKdNQGF3gBA9zVpN1HivWFdx2JE AjuFW3IrtkFkbvkW6Fa7df7ncmDuLb69FtqMEZgEN9VcVHFkuvDyVVTYk8XhxTVLkOU3q53u9Ysu S3CVEuF4NuOIkFuWHHjPR2GWVXZt5xyS204nFVNF57qI9x25jWdw7ngcHKcjKLjrJsos4ZMwelEe Q1bNtXi4oqI4iihd2/d3d9fhjM8WiYjd7piM603O2WSO6661apLRtgogrnD82qoJL5dv7W/x0BW7 R5PfJURk7jk9rxsHoMKTPfYOE8caLCffflF1BQ2us84yySqiF+aLbbblWhx685lPxxq/Wd3L3TlW bndDkxjPouSpjBAsJg02dKNFWSqEAkh/mkLqF4ozYtaYky2YY1dLK0DmRxHH74xJlJ0bRGBh431e JR2PYmXG0FUHlwNd04qlbqVq7j1tgRvAYlwJRubdsdhrbnYzsRFYJ/qG0YoQtiwBOb7bbCqeVFRA K3va5aFrKNZlzQ7dLuEt+1R3UlDKeYFhhoG3JaITsUifV55vwgVbUVRHOKJwTPemZyd/vk5ZOQx3 retz5BGtTzrfgoiTMQWmnFGO+4q9OVu3uS8TbLiioFTWwaw27ILXZyaZWFeJqwOvBmtSGUbSQyTx KBk1+cEW2ZCoWyCqsruQp31+y1nx19hl+3uudEyFxTnRZEQXYqx33+uypN7OCrcV1UXdBXj3km48 gI9YpGX2zSzJ5cNu9O3jwhUgHJ6sl4mkBoDksR5Io8K/6VwY7vLcxVB3AhStdDhZJKdJiO7mYYt4 ZLuDRPvOhNfjsQ22uipHs831pDpuAC8S/MqqcRVBSS2/WRvibmRwGbE3DYF64o7IcdNgQtwzJKiI NLyRrrRw3Xjy5kqd6IJTPG80tOVeHJajkg5BkDHfamQ3YjgmTYuD4joiWygYknd8fyotAUi07meL s2q/XJmZKyPwmx2Mozrggd3425zkpFt3gMqc44ap+ikZwv8AZqx58fImNKMktFilXS5ZXAtz8Vq4 SW1juzJisc+swq7IiKTmwKi8RIeO+w16tajYXd1j3wI78t+MgDa5S2Z4nZISRJR8DJW93RMWSVem q+KHIth2KvZNYsRMoAszZb6TW4zgE1bJJC0Mh8o7SukgbNKrwEGxqiooruibKqAQWYEcbI3I02wS 5WQLDbhjQ7mVrOPMii+80MgI8VwUN8gZQ3VIkUScBtBR1VLj4DDyeS1MbinmYY20tzucMDkPNzpD TUWO0zGIz/PArr5yXgElQ0QB34p4iWG9qnZ325KWUjkuNzGobL8iNIZiSHTljFUW5CNkJqLqqKoO +ypuuw+NWHj2sFqvs1tp1py3MvSfBWEkNPC844ciQ0wSD0+KNuDEcJCUt0XYVRF2VQK4mOahRJUs W3Mkut1tVhcFFFl2Oyshu2qnJNkWPMR2QYkmyg8BoifoCSLtJJ5DepjTx2/IbnYYd0hixHmRDYdk NQYLspJKgaIQk7MJhvckRVJpO5NqsKNq3ikyVAZizn3gnPAw1ICE8rCOOEosiTvHgKubbhuqckIC TuMFLV6g6pP4nf49itcS0u3F6F4YyN4u3va3NJTUBjRjUCFx5VHvRVTihNqu6F3ARJQvmB6daTwc WOa7ennAiHDlqaK+8/CfIjkAfj8GnlF008oiBJt3IleAnmlvuRpCTLbndrG5MEgkiQw5MFmG6LGx dzT78h5WXNx8cCIxXgAcVmC6nY0E+8XW92KbDnWBxyCUxLUcl0GkYZfkKhtgSi0Cmgku/FSBNlLc d5EmpeOFkCWRJcjwtZCRVcWC+kcX1jJJFpX1DpoSskhonL+ryqiKBWkL4ZZGES3xpOTwba+tmtR3 J9g4khRYZekzJfFwUIFdXpR1IhReSd3xKuwzyLd4+XMvxGL8FpgW+FbXLjAjuSZIR5Dzhy1b4oTh kvgkMCMUUxR5TTvHdJDh+s1iyWzWyVNGVap01q3GUV2G+iCs3kkfiZNihgRAYoaJx3Fe/vTf1a1f sr1ynNsC/Jt7Ix24kiNHdecnSnCk8mWWhDc0EI3U5puKgSlvxTkoEDZbymSzarXfVzmFBkNSXbad uXnLE3ZpowkqQqqIKxG6Z8Xl4nzNC6pgiLqJ7uZ5a7fo/vZkbEW/WiVBfiy2pHSYOTNYjimxiLaK wwTp8mh2IVJebvFSq3R1cxV0rakeZKfCe2w6jjdufII4POE00r68PzHJwCD85xVFEt9kFVT8sav4 pIiypDcuYgMjHNoSt0gSlg+atsnHFQ3eEzRUFQ337l8ioqgRDWWZkiP+9WIxL5FSPaxchyLa3I6Z SHHkbRfzI8d2ABXFB0+BI4iI24qeLhXRnNm50q9x/hHIdcfv76W9t4hZGIw0bERgG0TuN00afAv0 +89l27knsfVzGJMiGw07cOq+QA6hWqSPgZG6TQDJ3D8wquNkKc9vJv5O+sg9UsYCAxN8OdJqRBhT WRGI6puNzHFbjIg8d+bhooiH6Xcu6IiLQFIsY5cbTEsUJ+FmT9rt8eZ70rAjvNyleaiRocds3ePJ lHFKa6KucRFCTkQj4qyB9cshTFbzD4TTIfIIsuVYYZo9NONBYUAAmkFxtp2S9MLqeKPJoBUgEi5W 78NbYuOx72jVx8GkOdFtj3sfSSrvNQ4Kxw6iKhCqLuiIiJuq7d9a1jVbFZFtduDU91YzUFicarDe QhaeeNlvxeO/InGjFA/S3Fe6gKqC55Y5Pxy0X66XoMgZnWW2CsB4VivKDISbi4+4Hik4QtyG1AkR RQWzARQ1OtfkT2eNYq2LYZed8udpdvCm0sghjTHzXpxBBkUQPBhXfg4SCfduLyp4tnJmun8TILnc 4Fu6+QNyXID8qHYHjlSXW9xdbAxb5PI2jSIaipCOwIq7qKVv4epeMXBpt2BcvCWXX4Uds247iibk sBcYQV49/IHANV/2UXctqArK+2/MZ12uFzccyoYhvXl9YUGUTCLFitCxHjtoKeKb7oo+Bp4ypy2V BVUrMzyyZQ9juGp0rhdb5j9mk3N2QyPNHLk1GbZbUg7hcc5vuOiC9xKySfHVlYpnFozQHnLAUt1g GmX23noTrLchl1CVt1ozFBcAkEtlFV+LfbdN4fk+rq2nNJuM208WakxGIy73zI/e43n31Pi002jL insghuvd3uIiJQEdtVoyO83WLboVxzOFi0m6dfwqa641KOOzEUXORuCjrIvSHG1FtUFfzLhAgiQ7 bHNbhkPwvu6jHy1Rt0dl+xM2VraM/wAWzdeN818RxSMUYVktyRFEmx3JTTLb1ifey6baWoNoGNbZ hxriy/exYuDDIBycmpFME5Rx+IkLcg8dE/2a3eM5jlV/fs9wexRmJjV4QjZeW47zIrStkbTr7Cgg ihoIoogZkCmKLv4yiBXdmxbJLU7BsRje4lotLbTLz1sHwfwqLDtjadIXBRDVXZcx1UVF3VWC4qne q+TJZixAsruUM5P0AiWq3Xd23RicmvK3BdkPEBtD1BR2S6yybgqmysqm4bqaSxdcGyx/K7w3aBbY tTkNbWUmcjQXGPKIW48kjUV6LZuc/KiqgChL5dkwS12fBXGfAcdNffZm2tXFvI97aRFGekObyVYR UNsWdlBBXvdb8bvVEA1AzMsjZbZGUZzZI1ofZjyFlCT5SIzcF14jcJoUjOE47wZVd3CQhRdwVdl3 kVq8YLhGmERIF5MY7ou34LXGJ9w3FhvuEBgKKuxyiHcl2RF25KiLvXvjWuIXq92S3TbZFix57Nxc kXFm5I9FaGO4QtONuKA9Rt4WpBoaoOyMl+kmxVIMN1Qh5Dic/J8haZxWzs3J+LHeuEsW0cZB3pg6 akgo2plv4iqqp3Juq0BWkaRnxy8WbkNZNLuYQIsmREMXYjISTU5DyrKDkw4CbjGJh5BURBFbVCJC qQ6WXDJWHnLlkp5DMYmtQorrMm2yA/p5qZPPi26qEy0KEIrxFGkRE4qSoqrNb3qZYIGDZBldkuVu v8OzxnXD8DnNmBOiHJGlcFSQFVVFO/yckXatFZtXo7oK/eZOOSozskIMVMYur17dclqBudIm244q P5tsi3+RFVdk76As+lV0Os+PuzoLcVufJgzLQ1c2pbcN0kLrO9NhhG0HmrxqDq8Nt0RolVE2VUyV 1lw4RYJy4yARyI7LPlb5CdBttw2j6vifmy6rZNoBbERpxRFXuoQTylV1N1itDPvX4FDuclyTdXbd KirbZAy4xBEOSq+D9NTJVFGdu5E2eQt/iXat6oY289ZQjyZTzN6bjOQpQW99WCSQKkwiucOIqaIq oirundvtum4EwpVdnrJYZCwwske53VyZOhRo/TtzzYOtSXCFJIOECCbKC26fMVVFQN07iFVyQ1hx I4cyX4ZMRmMkQh/5MkqcgJTitRzYBAUnhcMSEVBC3238ioqgTulRifn1mttzt1skLNK4zm2XUjMw HnnGW3XEbBx4QFVaFTXjuWyIqEq7IJKmoHWfDljzJJ3CU3DixXpXhB2ySLbzTTyMuEyqt/nuLhAO wct+YbboSLQE+pWmxzKLflDM1y1rJEoMpYspmVFcjOtOoInxIHBQk3BwCRdtlE0VPLUc1I1GHBnb PFT3sjvXQnkCbeZ6wYLPTQVUTe4F+cLknANk5IJrv4uygTylQO36p25EtUTJI71ovUtIzcuK0hTW YT75cWWnJLSK0imW3DdUVUIFVE5IiouseJTpIsQpU+QRJIMTC0S1Am2C4POIfT49MS8XnvxVe4VV e6gJ5Sq9uOsVjgQWZQRrm6q3YLZJZOA8y7FJY6ySccbMUJAGOiur3eTu8u6Jn23Ui2PyLLAuSPR7 lcgZBOlEkHFSQbHXRkXybEVXghEm6CuyJugqqIoEzpUTuOpOPWu7TrbMkyUct4Gs59uE84xFUWFk KDroioAXRTmiEqboo/GQouvb1ixRxjqeEXBtwpEdhqM5aJQPvE+BGyoNK3zITFtxULbZOBbqnFdg J5StZj2QQMps8a62Z03Ycjkgq40TRiQkoGJASIQkJCQqKoioqKlRm85je38hnWLBLNDu0q1x23ri /PnlEZbNxFVtgFFtxScIU5LuiIAkC7ry2oCc0qsrhrFGsixjv1sfhNKbLM8BU3XLY6sJyY+L6iCt 7NtC2u4GfLmvciJuu2j6tYzJlw4wO3ADlOtMqTtqktiw48XFkHlIE6JOLxURPiqoYLsnMdwJvSq6 xrWSxX2E69Ibmw3RCVIabSBIdSRGalKwjjKo3+eVd2lUW+Sp1RTv3RVyZOsGLxLc3NfeuGxFJRxg LXIceZGMaBINxsQUhBtSFCJU28ZNlXdNwJ5Sq5LWjH4rV1eu7NygMW+bLY5+AOuqbEVRF+WqAKqL AmRApr3bgv8AdUqtGXWu/Xe7Wy1HIfftLvQmOeCOgyDuyKraOkKAZIhIqoKrtv37UBvKUpQClKUA pSlAKhrmnUV0LkjlxnKtyyGNfZBeJurkcmFbaTxe5tEitJ+tsi9/fUypQFVxNCLNEgRoXvrdX2mu aOK8bZK+BS4z6gfid48IbEdETbZodk7++ple8OiX2XDekSJUZuGzJFlqK70eDzwdNX0IdiRwQJ0R JF7uqS967KkipQFbM6SFJkwpmS5Nc75OgJHaiyHmI7Riy1KYkqBqAIpq4cVnmq/EK8UDkSr4QtEo FshJHtt/vcV3oy2ClA8CP9OQ8yRoJ8fEUWY7ccCHZQbTxdi2KrQpQEVxrAbbiR3xqxOPQ7XdSbcG 3s8WmYhiyLREzxRCDkIAqpuvjIpJspFvl2HEYuPPuPRZ95lkbaNqM+7SJYoiLvuguGSIv9ad9b+l AQ13TqI/75q7cJhLcshi3yQvid7kfodNpPF/0aeCtf2u5e/vrVTdHLbPZuzT10uKJc2LhHdIemii 3NlI++iLw+MRbaTffYGx+Pvqx6UBV+SaJW7JLk/cJF1kjKkTJL7pOxIslEF5qO2ogLrRIJCMRrge yqnjb8kLatpE0tgwL87dIVwlxwR4n4kRsG0aiuLCZhiQJx3Xi2yvFFXZFcP4lREnlKAqpnR9cfg9 OwXabMixGokiPaJStgzJmw47bUYnHRDqIG8dg1FF25hv5FISWHRZuJZrTEyG/wBxu79tiwIscjRo AZZjvMvm2iCCIXVcjto4RIpEICibKiqtq0oCuZ+j1uuDd6R26XADu8W6RX3B6fJAnOtk7tuPlEGW mx332EPjXvrau6a2WVJvEye0MufPn+Hx5j0dk3rc94M1HE4xEC9MhFkVRe9d91XfyVMaUBVVt0TC 0sMHbsknQLk3c/fEpMOFFZbJ1YzkciSOjasiZC6REaDuRbb7iiCmVE0VtUGJCjxrvd2yhNx2Y74u gjrbbNvdhtohce5R67jyL5eou/k7qsulAVbjGh9rxy4R5y3F+S42/DkG0ESPHbccjtSADdGwRV3K R1FUlUuYIu+26V8k6GWp+yMW5blMcKNBixmXJDTL482ZKySdNsg4mrrnHmKpsqCm3FURatOlCSsW tErW2Fpb98pfRggqONBHjtA+SzWJZKog2KChFHAFEdkUERPKKLXtcdIxlS3pdvyS7WuVLcuCTHmE aU3WZZtEbYkQL01EWGgA070Qe/ddlSyKUIKtkaH283bjIhXy72+TNtjtq5MOAIswtwVhhseOwgzw VB27y6rqmpKe6YxaExhtr0GHkEuHGkXT3zkR2bdCGO86jDTTYkyjPBWwVpDEVT9PZSUlRFq26UJK 5c0o6t0mSiyS5pGkSluKRRbZQQnrHRlJHLhyLjsjggviiaIvkEUHGt2iVns+SM3mE71hjJHcZiPx I6/nWIwR2vz/AE1dEEFpsuIr3GnLyeLVn0oQRJ/C3b3aMYj5Xc3bjNtCo7KeBptsZryxHY5kQIOw ivWI0QUTYkH4k2XQ2nRa1WkbUA3S6SggjB6vhDgOFLcjOPvI46SjupG8+Lh7bJuy2iIiJstl0oCD TtOSKTcpthyC42O4TLy3dkdji0oIQwwiqybajxcaUA5cS70NUJFRRTbAteiuOx5fhV+BMjNeu6YX CKwTZSnzRX5PAQQUcIQbbTu8UA2TvM1KyKUBEIGnsOFiVgxxbneFj2SM1GZfYuDkR10QDgPUVlQ5 dyJ3eTfvrJlYRClxLDEflTn41nneGCMmQUgpBdN0EF03OREKK7yTv33Afi7qk1KAqMdALQ3ZIlvC 7T5LsRiKDcie0zL5uNOOmbrgGCi4rnURCRU2RGmuHFQRa2jejduZdsSt3ScMe0oP5gGY7YPGkxuZ yVAbFA3dZDkjaCioIpt3JVkUoCtp+jcCajhjd7hHldaXIZfAWVVt9+4MzeaooKhIJxmAQS3RQDZd 1XesodLWX5TMu8Xy6XWWDkRxx19W9zJiWcpEREDYQVwm04jtsLDaJ/tKs/pQFcWrRy12x62O++M+ QUFYKlz6aeELF8IIFc2FN1J6U48S/r7bbIm1e0jR3H5lgct0wOvOdWSJ3c2GVm9ORJJ99oXeHiga uGKom3cXy99ajXS5FGtlmY5SDiNSH7rcIzTSGkmLCjOyFbLuXcSeCOKp8aEqVGoma5tFzCDi10vU R68xZlvbfZFhpvw8HUB2W4jPEnEYbaUxbcFURHALqEX6KCSbydHrbJzWdkxTngelveFKHgkY3G5C RxYEwfNsnEEUADEN9kMUXyeLWFaNE41qbJxq/TmbgT7spJMOLGiiEk4rkZJAsg30kdQXnCUuPjEq ckUREUh0bV/IL/amExudFduL8VxHy8E5hBkzLo3GgNuD3eOy2r6uN7ov5tFLZF7/AEumpd7sbcqP espbt0BuZeXI91etrayJAQeiCRG2u4DcJ039uKczbY2FN1UxAkrOg8GPajhxL5Mt5urMNxYEWPGb A5EcGFJloQ4sqItovibKpG4qqvNa2uNaP2/GpoTI9wfJxu4OXIG2okeOyEg4YxNxbbbFEEQE1FO9 d3C3Ut6rrErk9ZJ9rj5WMdhuxNq/dbg+LmyMwbc24+4rimqbpMubnxeRs079t0sHVK4zrusfCcei zZcm6sk9djhyBjuRrcm4lxdJUQXHDVGx/wBrj1SHZQ3oDY4vplExiLLix7pcZEeRY4NnTmYg403G bcBDBwBEkIuqpL39xbqO261p3tHHLiwXwgyy63ea1b/e6JLfjRkNuOrzLriHs3s6rixm0NT3RUQt kHkqrX+LamZNPbwqywJjMOcFssorFe4k7cDPZJpmBCritNgDgobe2zgmpkqIiVkzdS8hGKzKuOUF ZIt6j3G52lRtDZOm029whw2APfrPuA4BmK+MuwiCDuRoBvr5oSTgXWTa7zJfuV1SRCeeeajtmMSZ MYckGriNKbjgNNmDaEqjx2DiibrUshaYCxclu02/XKddyKS6cogaD886y2wBiIhsPSbBRAU7t3HC LkpKtQE81zSZeGEmX1qyxjnvRZLUW1C8DDMa3I5MeEz3VSGX+bBV3FE8qOV5WbU/Ipz9mCffY0W8 RltYTrMkIOUlg4bUmbNd3Xm02IuOICjsKOM8FUyNAECR27SFwr4RvPv2u2WbHWrBZDYlIbxKDTja TTTggi4APuACeNt1HVVPGRE2waOwBnOj77XD3hN0JCWgUbFpHwiBFAlNB5qIg2BCO+yGiF8QokCY 1Kyyz2dydkl7aQ5lgtctepbW2m7fLnSHAbHkpCKCAASGTpbIoCW3jdNcJ7VrISstqBnIm/C5M24N sozFZcnyRCb4PGUGTEGpIooOK6DStucSaUeO6qoFjM6TTI0O0Ixmd598rQSDClmxGJGWEZVnpoz0 +nuoryU9uXJE7+PiV+m9G4MZSjQL5d4loftrFvmwm3G95YNC4IkT3DqIpdUiPiSci718poWvzzOb nb9Q7LYLRd2YbZJFN6IyyDkt1XZHFTVp3j1YyNg5zJg+bWymSKI7LA42sF/l2Rm6w8utbjVyiRik OHBBY9kflT2Qjtku4qRhGcfJ0TLdOgJr0xJNwLN7KJixLSh5pfFn2x9Tjy0ZjJ02/Bij8Aa6XTFe JqXLjvyVf9nYE8oWitvhXjG5Y3aa7Fx2PFZt7Jsso810WumgpJEEdRs0RCNvlxIt/iUhX7heokdu 2Tncrv7EiKc59bPPeZFgpsEXGWkeVA8VU673TA0REcFWyRF5brgalW+blufWGxW+BDujFutcq4y4 9wkvR46m4bbLCqTYlyJESRsKpt5V7l2WgNvL0kiTc5DKpN1kuyGbk3PYZcjMOdNRjqyrSOECuI1s vNAEh2NSLv3rDsOisWzxIkeXkF0uaQ2rTHYV9uOPTYtz6vMtpwbT9I+KmXlLgPeiJtUKj3nJMEgn a3cmYhWS0zYtgdnyo6m1Hfda8Jekk66REjQC63HZEiVBNBRwj70rX3HUXIo4265+/wC51IUCU414 a0MRmVFkXRuJFnvjxROIMIbpKnEU5NkvBDVEAsJzQmzPTMjednPoF5C4IihDii8wcxDR40f6XUNU 6h8EIlQUJUVCRB4rhoqF0t85i45DKnP3KUD085dthvtugEcWQaFomuICCh1AUe8TIlVSRVSoZI1g vePW3wm63eLLZctd5l2kyYE3bmbTjDcQEVsRAyUzeXdoeJB0z8iqVSXF83u9z1QWwuX5u5RogutP tQ4rRCPRabbcWSK8XozpSFMgLx2nGuPFN/HoCXLg0mbhl/xW7XiSduuEcoEQwVDfjQ1jgzxV00VX HF4mame68nVTdURK1xaO2srpOnpdLs27LuT05elIRtWecZ5hGmiREUAFZDzw7eMjjiluvciV7etW 74zdctO33+CMeIrsSLxii7Gt5lKYiNnKReD7LwuOOHwJCbdbAlBU47r8k6o3JqQUV3OWY1occuUm BeEtrLj9wjstRQbbYb24OEsp98QURVXQY2FC350BP00plyFWXdMyvMq+MQxhwLo21HYejNo8y8u/ BvZ1TOO1zQ9xIUIUEUIt/sfRu1ybwl3y2WeTTXHUflDLiMCw+6AK2wRNiCIvSE3eKKq97pEqqohx 3WK5mxOhWe33+ZDYyt2OLc6EyX6EwGGnZDY969wdUfjXZCTv3qrbtic/ULKc1uYrFi26LcmYEe7P S5LcqA1GabJ44zYbDy6pvbHyROSbkhonFQLTtGntusuKLjcGTPjW4Zj8lnwWSUU2RckG8jQG1xVA FT4on6qIi719m4DCm4xKx87hdSiSpDbzzkiccp0hFwDJvm6pKgEgcVT5CLbZV3qnJupeXhZWilZA zbr1crE3fbPBG2CTk2RII0j21oCRVNG+II8SePu8JcmhRa3mU5nlL1xzLHopNm1b5YMI+cFSAkms MNQ43lTl+fkOmZiu4gyKLt1EVAJDM0Ls81i6tSLpc3ffF64PmritGjZyTQhQRUFTg0nMQbVFFUdc 5IXNa/EnQy3S7ANrO7SoyOSJL8pyHDixxdV+KcUhQAaQQ2bcJBVPGTdd1Ldari66gXJ2Z4Za7mzK +DY3eeOPhEIW4CRFWFGGS4K80Vev1nEJduIqQoiAhFJbPmuUXbwCFFyVlyFNuzxBeAiNSC972IfO QQkAoyv9IJsANENERSReSiu4E4vmklpyGdc5FxmTkC4Oum400QAgIcBYSCK8d0QWzeIe/wDSdJe9 NkTEm6QjerY5EyTJbtdTchyoiuEDDSNg+yDK9NsAQAVGxNE2TyvOL+qgwS06r3mRCt8q/ZI1aptu tEKdItg2hXHboKw/CpLxj5WmuO7QmKoIOgSEpchbr5jWcXmBlmKYpHuMaI7HlR7bdbf0GwBXfAXJ Mlziqk6iKeyNluA7oqIjieNQFgXHR22XR+4PSrncepcPDBkqKtoptyZEdxwF8XydOIyynyAi/H31 tnNNrNKkXaVcWxnT51xK4x5j7DRvW9/wdpgTjEQL0yEGQ2LvXfvXeoFmOqVwsef3CNHurBW2zxje ft0ZkHHlRqI7IdWSBoLoNkPSRt9lSBDXgSKq7JoYeqF6ZahNTs7tbsKbItsaRfigttxY0noSX5zT ZLsOyAyyKKal0zf2JVXxEAlaaAW9bajTl2I5vvj4eTvvXE8HJzoEyRLE6fQ5kJqRGg8lNEXfinCp DE0ltkJlGWJ03pJItbiDs0niQCE2m9kBE4q6JOFsiKpGW2yd1e+muVSL1jsZu/SikXkWDlkhxFYe dhHIeCK+bSJ4hONtISiiJsXJOI+RKmturmS5G7LPGb1GdbuUWEUJHorLngZy7ijDS9JtVJFaZRwn WzcIkJB36e/GgLDx/RaBZrmNymXaXcZqzmJb5rHYjpLNkXumbwtAIm6pPqZO7IRK235ERUXyiaG2 xjFHbE9e7u4ZrAEbgBNtSG24iCgABCCIPJEc5Fty3eNUVFVNoLkOqWR2O3XJmXkwQlj+/T9umPWs CkXE4r/g7UQATxCXqI4pcUQlDpKm25FWy1IYfxbGcCs6ypYt4rFC/wA95g3DN5q3dADAuPefNX+X Ff0uC+WgJtE0ds0LNiyNkxRtHwktwvAY3FtwI4MAgu9PqI2INgotoSIhJvvtsKe+T6ZHlEq8NTMj ug4/fAALnZ1Bl1pwUBAIWyMCJlDFE5cO/fxhUCVSqqQyi5WnMshu+Q39zFgvUxiG/KltKQ2xliJ4 UEVgDQm0fMZbaLuhciB9BQlQNtqGfZucCPMuc4LM2wzabZcFetaCEWdJbR1+S9yXcBBp5lEDfijp IhEo7pQEiyHQOBkgTmZ9+nrFmFcCNo4sV3prKeV0lDm2SCY7qCHspcNh3TZFr9Q9IZl2iXVcqvs1 kp8y5ymokQmuER2SjzAOi500MyCO4iIJKooSquy7Bxr69az3yDhzr8bJUdmmF2nW+T73ssHKjR3i YjDsaKJqRApmLYclFUXdlNt5XctQcot16fuoyjnWlm6T4zNnj21EWSxDtrhvGjnjHyKY1xBU7uJI mxKqKgcTfZlphIunhUXHnXoo3qVbRlTRlIydqiwjEwSMiAqqaqhom6pxVxS32Tiua9pHGjyBk4ze ZlgkszvCYyx2GDbjt+BtROiDZgooKNsiortuhb+UVUVrqHnF5yC1Njeb1FuVqkXW1KU6CQuNNOsI 7OnNtuMigkx0YoCKKpnuZCRKqolY+L59eoFzxHH2LqrE4pcBi8QpaNKpyJTBzZRryVXVHZxAbJOm KGij+c8iAWTF0agwkfhwr5eGLHKhhHl28HG08IUY6sIZvcOou4ryJOWymiEvlJC/AaROoMWY9lVz dyCEcfwS5LGjJ0mmW3mxa6KN9NRUZLqku26kSKiogAI6nMssyo8zkW/GLn73RI9wtVrabK2i+j8l 9TekkZKqLwCKokiCqeOneu26LF29TcnlRo0OLkTYXjoA/Z47tub69+V6fIaZQw7kFsWGW1dJpBUe oriqAiiEBY7WlCMyJaDlV/KDOZFJzJOtdSU+kbwbrG9w5ruCCXBFQeYoqIibiuuTRUVtMiI/kk2a /JCEw8syBEejuRozZg3GKOrXBWt3Dc28qOKhIqInGoldNS7/AAIcm63bJm7RZZoXi4QpKWkS4Rob 3CPHb5L+cdeAuqu/jKDaoAovJxPRdTsiYyqwWa4XiNFuMR+3wb5FJhkGydKGUqU7x3J3googtmig KH4v53yUBPLjpLCmY3i9hZu1wCDYFRBGQjctJQo2Tf50HRICVOXIfF2AkTYdkRK10DRKLb/edlnI bqkC3RLRHOKjcdEk+9zquMKZdPkiKZciEFFFXvTbckWFw8py27xrZAyKazc/f+DY35ME7b0hjrMm GTjQKK8vFiMP8lJVVCACTZC41ZOkt+j3vGxfUmG7lOUru/GbFUJpmW647H5oqrsStIO/9aKuyb7U BqrxodbLvBs8dy6S+tb0nCch+LGkk94Y8jz58XWyEHeoKKJinduqbLv3ZrmkUcr49OjX25wYSzPD o9vjNxwbjyPAPAhMSVtS8RtBIBVdkNEVUVEREsalCCu8M0zk4RNbO1XhPBpMg5N2aCEyw3KNGkbb QGWxRtpVXdwzFEIyREXcdkHOj4HcIGTXO723LLlFj3O4tzpcHwWKbbii0010+ZNqaCoMincW6bqq LU2pQFbBpC1LcjM5NkV1yG1wFleARZvSU2euy6yfJ9B6rmzT7gDuXkVFLkSISfhNIXJds8Av2XX2 7NNw/e+Op9BpW4pEHVFemCIbjjbfTV1fGESLp8FIlWzKUBXq6N44zeCm2hlLPFcdtrrtvgMNMx3C hOPONKooPxk6O+3xMtom2y7yOfiMG43+zXaQpf8AJLEppiKgj0lJ7popqm36SCBCm23c4e+9b+lA QHItJ7bk96O5XK4XFOcuG8UdswFsmY7bwJGVOKqrJpJe5j/tIapuiKqVtYWCxYuMtWM7jdCBJLsp yUzMOK+6648brhKbPHuU3CXZNkqU0oCH3fT5i5Yo5YGLtdY4FMYmDKekrNeE2nweEd5HNFHk2KKK ptsqp8dfmNg0spltm3zJrjeJlsdkOxHHWI7SATrKNIqi22iLxTqKiqn/AIQt902RJlSgKmmaDW2R Ct8Zu7yyG2w7dFiDKiRpTaJEakMoRgbaofMJTiqi9yGiEm3ei7RdH7c1a5UOBc5sRxxi2Nx322mE VgoL5SGT4I2gEpPGRmijsvJURBTyWLSgK0d0jc67E6Flt6hXgvC/Dp7YME5KWT0EMtibUWyAIzQN qCJwEU35d++O3oXZ2r/GuLU+UEWE6Kw4fRZXoMpCKJ0BeUFdRpAJSEUNNjVSXkq1adKArNnR4DtF stt2ya8XFi3lwa5oy0iMJCfiI2ItgKCvCQRKaeMpIPfxRBT94xo3bcdK3urMJ96HNalfmYEaG270 mHmmwIGWxRURXyc3Xv5omyoKIKWTSgK7zXTmRfb0GQxJyyJ1taF62wX2mgEJLe5AgyUDrNNuEgI6 IkqEI7bbKSFGuxW6RbJj8BrIpU6VB97oaS3kaDwCHFMH16IC3xM3Ho7CEpou4iPk4rvdNKAgkXBb tZohpYsnmJcJktJNzlSWGTWU4TzKuObcPFVGGVYbEdhESTfkQoVZmTYXPvd0WbbMoudlB+H4HLit NMyGHW0IiQkbeAhFzxyTlsqKiohIXEdpfSgKwtOhtismRx7pbXSbjRRYWPFchx3FbNmMEdrZ8m1d 4CDTZIHL9MeW+yqNe66OQG7A7aoV4ucVSsMCytyAIOYtRTM+S+LsSuqezqL3EKbd261ZFKAqQ9A7 YVmlWoL1PjxpU+VMdGNGisj/AEiF4IYCANIIojalxJE5JyVFVa2sTSKJGztrLHLtLkymLg/Nabdj sEqI6wbPSV7h1emCGvAUJEFO5ULy1Y1KAqHNtGX8glXq4xLu65OujZQRI2WWTYiSCFuQCvA3zeEG ldJpt3kKGo777Co+83Sy9O5Dbp8bJ5SSkkSLhMupssE910Y8GjMg0rfBGhaekl8vNd+/mtWvSgIb ZMLnYwlng2G+SUssNxFkx5INOG8KNOoW58OSm484LxmpeVvYURCKsO9aYe+l4vMqHkl3tEC/i2l4 hRFaFJCg2jXIHVBXGVJsRAlAkXYUUVAvGqfUoCtbvo1Au8qY85d7iy3PfknLaAWeLjbzLDCtpuC8 URmMDaKnjcSNFVeVZzumLb2SS7md7uCwJNxC6lbOLSteGgyDQOKSjzIR6YGIKuyGKL5EQUnlKAqV rQxobFGtsrKLtPWDGiQYLklmOQtw2CEugbaAguI4oB1FVPH6YeRB2XMs2jLGPuQVs+SXaGDPWCUj LcdpZLTkxyV0/EbRGkQ3TFVaQNwXbuVBIbOpQFTvaDWmTcmJcu4vS05vLJGTBivK8BzH5SCJG0qt +NIcAiDYjHbdeSISWDjdgZxu3Ow47zshHZsqYbjvHkpvvm8SdyImyK4qJ/UiVt6UApSlAKUpQClK UApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQClKUApSlAKUpQC lKUApSlAKUpQHhMhR7hGONOZbkx3NubbgoQlsu+yovl8le9KUApSlAKUpQClKUBjXG3x7tb5cCe3 1Yktk2Hw5KPICFRJN0VFTdFXvRd6xXcetrw2gHIoqFndR6AKEqIyaNG0ioiL37A4abLv5d/KiLWz pQHjJiMTGxbltA8AuA4gmO6IYEhCW3yoSIqfIqIte1KUApSlAKUpQGBc7LBvKwlubCSPApQS46KS ogPBvxLuXv23XuXdN+/4kr6FnhN3l68AwiXF6M3Fce5LurQEZCO2+ybE4a7om679/kTbOpQHiURg 5TUo2QKS0BNtuqPjCJKKkiL8SKoDv8vFPkr2pSgFKUoBSlKAUpSgMC9WWDkNskWy8seFQZCIjrSm QoaIqLsqiqLtuif3+SkizQZd1g3SQwjk+A263GdUl/Ni7x592+y78B71TdNu7yrvn0oBSlKAUpSg Fam/43b8lYjM3VJSJFf67DkWa9Fcbc4EG6ONEJJ4pkipvsqEu9balAYlrtkOy26LbrVHCLCitC0w yCbIAImyJWXSlAKUpQClKUBHb5g1jyS4NTrzFdkPNto0oJLebaebQ+aA60JIDo8u/iYknevxKu8i pSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlK AUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBS lKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUo BSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFK UoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgFKUoBSlKAUpSgP/9k= ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: image/png Content-Transfer-Encoding: base64 Content-Location: https://assets.radcliffecardiology.com/s3fs-public/article/2021-04/table1-optimizing-guideline-directed.png iVBORw0KGgoAAAANSUhEUgAAA7gAAASmCAIAAACLIJBpAAAAAXNSR0IArs4c6QAAAARnQU1BAACx jwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAP+lSURBVHhe7P2NVxRHvv+B//6TPWd3fzm55+T7 SzbEkz0mOtFV0blKZBYQJPIgCCZZ8OGKyVU0C2YjGAWvQTfBrExixiSDZogJJpLoBJ0YJGCCCgro iKCgg6IwIiMzNL+qfu7pomdAUNT369Q5MP1QXQ+fqnp39aer/z/DAAAAAAAAAB0QygAAAAAAADCA UAYAAAAAAIABhDIAAAAAAAAMIJQBAAAAAABgAKEMAAAAAAAAAwhlAAAAAAAAGEAoAwAAAAAAwABC GQAAAAAAAAYQygAAAAAAADCAUAYAAAAAAIABhDIAAAAAAAAMIJQBAAAAAABgAKEMAAAAAAAAAwjl cYK7c+vyzYD4Y1QEfFev3PFz4i8D7nTdvHFP/H9yMnEpfIh5H3vNPmFMfvt8wKBAHhZoswCA8SM8 oXyt8mDEK9YRwt4Pfh8Sj9Pj7z34v9YI88GDV8QNwVw5+6bZGvG/Z6/5xQ2jgwt0VB6aMXMUMfg9 Vw9+eChmvpT+OfvS3687dskXhlIdmb6rHy63Rvz9u++vjDIabvD0nvIpMz/LOdxrfObdhhOLIq0z 8s51DYpbxh3Oe+NYefWalL1iyczcG7PedfCMNxwRTwiZQv/vLtMrVtO/O8KpKMHk3qzsJf8/gLxr uNPxwWvWiNdcv925j5p9QAz99m9SX6w2KDQ9Uo9/++KD33QF19vxQSq/16BthkJdoeNTRwbdhdBR CJapCzQNIbuaB8vEGa333On8TNpIpyx1naLt474QGhqrVQqmJbbBB41svfoQsqvXtll1TwIAAKMn PKF8q8aVtfrgm3x47e+0tzK95hB+vrnmuwMXHppQ7qt3kdEorN6Tx9tYl2Xhj5+59+9vHHxzxX7z HP5npL2gujdMRUjwnm0o+bfrwFmf+PvRF8r+ztaCpXxRvGI1px18c5Xj78K9xJzPcw50ecOYnYFQ HjW3rx742FXyzVXvyA0oFGEI5VesM4vcfdr9fb8cnUluL8neR0Uo33B/sE7sgt5I2zeFpHz+l+mr xC1vVXgCT4hQFgwy8st1exo+q3B3j6nbVPPQhLKx8UvWS/siYaCRQtZu9y3j7ghCGQAwnoza9WKU vedECmV/29kcXrXTEEYMXFdz7iIikT978z8X2rzixuF73tMVP8YQtT3vwJ7GcMe0x6zz5W62FaXR YowpaDjtkUahgO+S05URPW4yccxC+UGjFsoTyn0+TqGEJZQjXj30fZe4meL3fv/PT8Rd4ySUx4fw xK5w3eBym2RCeYIInDsZ/Tfr1IILQXc+Y+ahCWVj4xet1/BxZXhAKAMA7o9HVihztzpKMq0Rf/s8 d1Ply/pRUw93r/YDG0l51M7LfUETElzAfeDrF1+xTlnb0BGeT+Fj1flyg799+AXJzsx/neuUpshl bp278Jssne8PCOVgHoRQ/sT8d2r2mRU98r0O19aQSa67YJ+Z3B9CKD9SjHuZQygDAIAh4yKUfb21 9qPpsfwEFelzUw59dEJyY5BGr70/NX/41uf0gekrVnP2Ucc5ySdY113euXRhT57dxD8XnhLreM9+ +ZpOvRH8no6yt7/I+rLrVr1q1Lx748D6zyIs3x64qNN2Ny/k/Z2k5OsDbazJ0duXtxFtNKd8byvd K/Stb9jcR/4jeTMv2J9/8Br1QBBUFJ8RPvBduXaQ1p9ueqO6ujMgOxeq/RlU/bhYtkFBLGp1QUmX O/Dr5c/edwjeI1MSDpXV35Hz5u90qwvcfrxpa+II4k/K+55zIQSxfsjRDNtBVckFrtXWrksV8rsv fetvtd9Va8b4gK/t+EnxAD6Rn/2qeL9orjXKvHPeG9WfHhYrjvdBr+0yypq/q61MMrngsmLV7JsH Omo/O/Tfc6TkGWaEwPV6vi+VDGnm3pi82tquwaC6loslhP2TtmYTs0b2bv7q8nfbSDwGQnnv9s/r UuZZI14/ea6f384Fzn1aTk5P+fjUdlLvKmUZotyMK1TXkL2t50rWixmJmG9fZ2sTM0Li+bXuvWze fYLflWN1dwm7tKU9EsZCWWMY8d98KPdFxhlUTm/bs/7zKUIawuzZcsVsmjJ/HGPPxgW6TvySI70e QC5Ucuhqd9BNu1ihSpDNr/UHl+bcHzxC30JgW6wK4YCwhLKxnYdRVlLZOt58U4xEPFh/dTGzIwvl sK1oxJ5EQHtXPLYGDgB4rLl/oSzMR5JRJ7/6g3+7drzPC4LI8g8beDcGVeduzvph267jm9/mhwrL N1808wdoe66B5lPUhzjakb/n1MFvTn2Yt58cHLOD7Yrn9969E9COmj3uzQnUuWLzLwPiQRJDrXXx ZOx8s65VLTtkhgaqCz6NeOXTvOP0RKG7JIGMZ//8PylTr1iTPusa8N2qtrk2r95Hc7T66Acf1lRf 4ZhdMwlktNj8QfW6DFpiLy76Mno+LaUdBQdJFxzxty/3nKNjgKof564cryFlKIQd/3LQlxQj7R/U 8ynWi0VVqb63mtfECUdP9NBjRSeToDInB7CEMuc+lRxpjcg8ee6uuGUkNEMOj4FQvnWymjq0CIZR clR+R1A8mBtsPfANyeCMN3/8T/mZg+Un1pNSirQX/uwVBiDNtUaT9+E7ni/+9zNiA+mbT37xzZkv dh9+bYF1ylLnz9fZI5vsdsIuK1bNTjfvnTJn32srvvmgpj9kRrjers/e/oycRY2hxLUtn2q4KStq f/i+5oPCg+a/WSMWHdy80/Xx8VvEGkLYf6C/dpedZDbILI2F8ge/9hxc/0nE37748Ayvnu5c/ZDk d8G3B8+1U4kgq9JQ5RaiQrW1L74MQO4K3j66Y1f1P7OooEn+3DPIDd/9zRX1N6G0XXI8i/ZcvUuu oy3tkTASynySNFUZpmEIp8/ca5pnnfL3/W+sc53wjKlnkz24RtOziQ7NWUc/rTh7sOLXbf9rN83R vYI55Dvzjev//rn/RdKZpB3+P+EdCcn8iFJc8/7xD7bTTJE8Zh3wDPDZYlisFuGA0ELZ2M7DGQWU sj22t5xh/BrE4h1RKIdvRSP2JAIsoTyqBg4AeNwZjxll7ua1s9eUmafe4z++/Ip17sdX6Sahz/rb 5/lHpVtwLtBZdXjmTOuL/zznIb2Vuufy3fhiFek6D3/fIcUW8J22Hpgy07bt1xFdIoJGzTtt7iO/ 3iACOgj24KqgyZfQXf73+83iFAU5vePceiI9JV9PTedLYHXN8unc9eb1ZIycX1F2lp9tkqb01NdS lyfF763e+jnZnmS9Kk4O6cWiulQHb1MxNHPfh2eHSPxn/kNdKZRz6duHtRlk6GIJZV3JDLVWfKd9 gUYcX/VJHVEo91/b8zoVDR81SBNsAV+TrYKM8cLBQxdPpczTOHtwt69+9CZJYXXtbfpTc63w8z7M XSr/asrMz9ZX3ZanfLwNvyTNs87+4HK/tEVBqosRy4pVszPeqj0luaOEygifHjKE7+6QHX68rReO C6usBA3boex/8NzJRURkv/nLab6ICESFl636JIRQ/j3Q4zw89RWxBPp/rZ490zr1X809vbxEELMW qtxCVSijIUeWl9QLao0efL7mwiXhxQD/nfMtyoQcd+NCfqw1IvXEGWJi2tIeCSOhrDYM0RVbKJxQ GRROJxLzsw55KvdB9WxC57N3W52UHy5wve2mbJBqNC1OMr8pma5Tt/jf5FTBJ23eV19cpMnSW2wQ wgEGQWiDIRts6LLSlm2w8QchnKJLDAli3sO2ohF7EgGWUB5NAwcAPPaMh1AOfspv/WG60p1p+iwR YU7r7z9U39T0XMLU5os5J12/dfz2uxjqvz0a9Tfr9B2XpfE5mFAKWGQMM8rqPErqc4QDDLpmgs7n VX0A81rCmncz1jdckmd51V08o1TFsZZqAp9nL+nHg97f0qVBRng9KGLlqTZxDBOrWB1GSupIQlms SkExSKgO5trKv4p45ZM3P7koV/Rvv7cf3EpKWJQLmmuFn/d7N75YaY1YcHBPtRxtx2+/nt2cbI1I qK7tpk8D5Dl7+sb9AH+8QVkZ12zIjAjpCYpfRjtsh7J/8Vo5VeqpLFXegxBSLuwSnrRYDh/pvHPk X58SyUIfuQjZFLJmXG69ISs0dO0r+Hp/3vMNfagieI98dvKf5BaUVdojwW7y92MYpD5Zl35gPZu4 CMl8+5r/+/Xg8cutI68BrClzyfy0JjHsqTpEbmCSy2+QjYzuRYtwAJ3o1dwb0yAscMSfG7rBjrqs tMYfjHAKiUq36gVd4YQcELYVjdiTCLCE8igaOADg8ef+hfJdz94VVrpc0WfNtb93nPj+5Doy9hh3 keqNqp5LHP+YYaT+lETGHDX1jN5HOWh0UW8MPsCgayaMUigPnK+jM5rq+SeCuotnlKpKEzA1MXOj gFHJaKpbn9SRpJJ2OBdRbRSjZQbGtUabd12cNJBTzmv3kghvhyor45oNmRGDYidoh+1Q9q/KpgJz I4+QcmGX+L7mJ29uP/7mAmtEqus3kgMhbULWjMvtSsgKDV37Ilyg9XM6xf73vF+P/Npx6pdze/K+ pOqKVdojIRaUVG4i92MY5BT96Q+yZwv4Lv10QvYzjpi597XC0+eUdqagLVt27auP0bfZIIQDWJUl 2jZ/rvg/M9ADxlBWWuMPRjiFadiE0VjRiD2JgLaFjrqBAwAef+5bKOuXK/LVVd/PvMtoVz5ij5p6 RrPqBWN0eVAzyuKT00h70Umtp4C6i2eUqmrIHOWM8vDQwIki6kT73/+nX6BUU936YtEM26oUCvP3 oWaUxcJkorlW+HkXJg4F0wqHkGVlXLMhMzL6GeWR7Z9r3Vc+xhllyW2DJJ6ERZ9eGyRRCNkUshaq 3EJVKKMhs2eU717bQ8xbfaHey9sS2KU9Euwmf5+GoTv9ofRs3J1bv1U37FhLp2Zf/c/Ve7pbV02Z j9+MshShGnXbD2HnYykrrfEHI5zCNGzCaKxoxJ5EIIRQDt1TAQAedx6MUP7bFwXHpQ+8hfTkU/tB ksO9N8+2j+R2QQkaNUfyUSaEv46y0F3ep4+ysjd8oax3TZZRFxRj4FFpglH6KBO4axc2kRTO3Ju0 7bSyjjIX6D7TkM9/v21NFS0vIanK+G3gpSoohlA+ymp3W8Kdjs62PvF/TbGEn3fJJ1hTgAHf5ZYb TI/P0GVlXLOhMzJ6H+WR7f/emROv/m0MPsr8rns9B9byQll+dKAWyiHLLVSFMhoy00f5YQnlkBnU nR5ezzYaH+WRa5bzdDhVn8Dk2hsyiFFtPNctJ1VCK5TD9VFWW2wQwgFyhCo0Xb2xnT9iQjntxBmp GwzqGEffwAEAjz0PxvWCn8caxbvhcz5/c/uvB74980XZ0TfjpSfFI6AZNUde9UIgzC/zCd0lCYxV L/hj+o7/MJXsXXLo/YLvSk4OGHXNhHCFMtd1+Dv6Anvkl2u2Ka604ivh6oJiDDxqTcBa9WLeXtPf NGkIwnuuYT1fcfQs9Zf5XrHG/F+rcMMgjBnhrXvAeY5S0RBy1Ysp8Qe3ftZw8JtT/9lKFwOJ+rCD vrceVIajybu4uAG5z1lTTdcQKD+5efXnU5ifceYJsUKIcc0SQmVETo921Yu61ruS0wup7veP5nxM P54Xwv793iObaVSjW/VC2iVMNCoTvRqhHLLcQlUosyEzVr14SK4XBOMM6k9/YD2btJD5f68+StdV +OYUnVEe4WudQUJZNr+IBfvXbXd98H8/0AXadKteaCxWi3CAEqGCtqs3tvMxuF7ojF+DWLwswyaM 2fVCuGMZqbGPrYEDAB5zxv1lvpXVjs8Yr3GMah3lvdIyqHRUfu+Xw63KNIwezahpsI6yhN9z9eCH ssLgL/F+3TFhhk9C6C7pQsi7xfdFlHWUBe54DvyTz86cz9d+3zNk0DUTwhXKYtkGBbEkRyUWyTXd qgJfWf1tfesObRr0cN4bxz5XVkKlKud/q7/4WTU9H/CdO/gjXX+K7J1vzyk9d+6n48qwHVSVdGnY E1lEDZCDSSEz11H+WVkJlYi/vLJzrVKZacpwlHkPyggZFD/6UVlZVo/RmtPGNStgmBECax1lPjVk DK6gy7WS7f+9qUlw+wlh/0HvMIWxjrJSLHT1lU/XOyWXniChHLLcjCtU15BHXEdZk4WKbV/++iBe 5uMxyiDr0qPt2UKuozxSzQYlbEr8Nx+o1kJWEyyUCeGsoxxksSqEAzQRiui6ekM7D6esNNXKMn4F 4RSmYQuEbUVBJaAsZk9a4nrX96c0HePYGjgA4LFm1EL5iSDk6DLZ4QI3PXfkCXKC/+KpDPMoPj0I ADCCKf4AAAA8bkAos3jUhTL9fsG8va9trN5Tfubgtw17d/GfIVD7jAIA7gcIZQAAeCKAUGbxyM8o a5/GCg8ZD6reFgIA3BcQygAA8EQAoQwAAAAAAAADCGUAAAAAAAAYQCgDAAAAAADAAEIZAAAAAAAA BhDKAAAAAAAAMJgAoXyn6+YNLNY73kxUqQZ8V69oVlx+PODu3Lp8k/XBhknMo5jm8Bm33E2MxT7e hQ8AAGCsjLdQpiv4Rlpn5J3rYn4weFRrKgkHCwucyWHm3tcKT58b87ptuo/kPTgMLs3MqRD4L3uF KNUxww2e3lM+0sdy7xfhy2RB2eHDhK+713f1w+XWiL9/9/2V8c+WsHSgJvBfWfv2Plffm/g0h/X1 tQnifnKn7jQmyGInsvABAAA8ykywUPaebSj5t+vAWeHbtWMUyua0g2+u5sOK/cIHYF9cXdcyNqU7 uYWyklMpZO123wqMn1Ae8p35xvXBxw1nbvM/H4BQnrPvtRVBmfrmg5p+8Zjx4vbVAx+7Sr656hW+ dzvxonPK3/e/IWRnlePvwrep53yec6DL4EPZIXiihHJQfRkzEUL5ARoMAACAR5kJ9lEO/nLHWISy 5nP/3O2rH71JNn6ad3xA3DQqJrVQ1uR0QhhV+d8nglB+MEUtXIuffZ9oGKIz4Gs7fuJNizVi5me5 R72TUGo9fKEcxKjqayKM9gEaDAAAgEeZR00oE6ncVv4ViXPux1fHMnkHoQyhfH+MJDpvnXD+999I fqtrhdn6yQSEcjAQygAAAMIiHKFMBqp11og55XtbxckyrutczqvWiLQTZyQN1Hf8h6mvWCM/7Lgn j0C3eV2ouHLyKlAa8w78evmz9x2CH8WU+G8+PNHL8O9ky8dgoXzn0oU9eXbTTD6qWMd79svXJEcP gr+rrUzaa84+aj/etDVRUW/BOp4c/7vLpJYU2m9Bm1IPl9UqSb2fS2tg51SFblw3vjTX6/m+9FCM 4BIwc29MXm1tV0DIGt0iBD4lwSUQlN+UQyU/eGR3AvHgAx219qPpsXwkcz5fY+u4wVQbQppHEsqK JbTtWf/5FEEGcYFrv9a9l71vipDC+fYcq7tLlS9v67mS9WKuyd51trZrPlHqyYHWnRS5LK2CC2S9 6/tWn1iNTJtMOFRWf4c5Nzyi6LzXc2AtOVd81hHCtITCebvht59Prknga9anSXPoouYCXSdOZMUL u/alb/2t9rtqjemqGDHNeqFsaADDvt6frZpiFL+LLpXh3p+aP8wVK8iU+aPjXHAhH7zCqi8+ZiWn /HU/kvsEbW2qCjY4KiGIeRnRlh60wQAAAHiUCWtGmeuo+JqMN5kVPcJI4Kk69CIZP/72xYdn+CGU u1f7gS1ipm3br/cUSdd/q9rm2rx6HxlFzKuPfvBhTfUVThxj+PHJnPXDtl3HN7/ND6sJR0/08FGr EQ/WyEf/NXdRBtkoypGB5lNZFmtEtCN/z6mD35z6MG8/iS1mh7ubVwTczbaiNN21yNXDFMoB37kv v5lBTplvX/P+8Q/+7wc6kM/7am8zzfV9XloDK6catEI5xKV7uz57+zNyLaI2Npe4tuXTsXzKirrz LRc+3nX0zUWk4va9Wej6wHbhyj1tCXCDrQdU+d1++LUF1J0g64BngK944WASiDT/5/+5dhQc/G+i EmZ+tvkXlhtMOEJ55l7TPN7fd53rxI3hu7+5ov4mlJjrg5Kja3i5tmjP1bv81b2NdTTXRLW8fXTH rup/ZlENlPz5Nffxmg8KD5r/Zo1YdHDzTtfHx28NSVJG1D13PF/8r6pANtLiirB880Uz7/Gts8n3 Vn9O1RXTJo1EJ9e6r5zsit/nIbUYwrSEwoncayL5TeM90e9p0hyqqDnP0cMzSS6IRM6vlsuKBFbC DNKsFcrGBiD5B6dv/fXAt2cPfFZNL5rq+o2cqitD0eDnHdjTqCpkmjvuir6+uMHfPvxCzMu/XTve 5xVqZPmHDUHn0l+qguWj+rdLCDv+5aApj7R/UE/l8Mi2xErARBoMAACAR5nwXC+4toZMs3XKurNd ZKT1e7//5ycRC/aZI62v/ufqPTKC3rn6IRGFwkNnraQLlgvCGPO3z/OPytNFfGxMjSgNSPqX+Wb8 76lWIr98N75YRUa7w993SFNeAd9p64EpgmTnAuc+pcIlyXpVnhLznq3NIGNweEJ56OKpFCLjMl2n bol7ud5rx2pv3CGx3felNaiG3qCg0VVCqRpfepi7VP4VGbYX7e7oky/deuH4JX4+LEgQaEuAkd9b HSWZ9N7gi4v0bOHg/36/WZrl5TorvyW3TGw3GCHNuhyJdS2khIiwzzq65WXv/HfOtygT9tyNC/nk ziT1xJl+KdeR5SX1gminuT5fc+GSl/9fa3XabDIKpK/etSjSOmXVqUskI8LBapscvH1w/ScRM/d9 eJZx3yIUQkg9amxaYoIt35TVS2tlaKsmRFELLW7egY8apGnOgK/JVkEOMEiYQQjLAATfoYTqWjlP vr4LV1R2pS5DLtBZRaX8i/885yEJ0uYuuL7I4Tevnb2mGFHv8R9fljPLKhl1wVL83uqtn5PtSosz sCXCAzQYAAAAjzJh+ij7PHvftEZEHz7iGR72NK+Ltr764fmKjZ8I3heBcyej/2adWnChjwwT2hEo eFQLGi8pwpyWkVBWhyl/P7Bu97lWPj7OfSo50vpizknXbx2//S6G+m+PRv3NOn3HZR+RViutEa8e +r6Lj01A6yhsqGYEH49PcqoYr2fd/6U1SDnVr3rxVoWHDtaqUh3LpWV05a8qAXZ+hacHyeU3yEbD 4tIhpFm/6sWa7w5cUJxwVJZAzKz35z3f0KlTfiZ182cn/7lILDEx14Lq0mOge+6xCkS4PYv86gu3 9JQjTJuUCoGV5dHPKKuUYlAyjE8faq2LnxNcGgZ1IcSmrNShCq/9nZZ2WAYwNHCiSJxn3WY7W33K oyzszaxNQc3//Yfqm7oDdNn3d7o/fIuflyWtIPuo3frDdDkvoUqGiPKOykMzZlpnrG+4dFfcZmBL lAdoMAAAAB5lwhTKogigDg/UHZk6XfjpCEodl4fkXfRA7QgUPKqNaowRDpZ29f1aTbRgRPyP1USs 8wjKgMTPCCQBgpN0kDAdhVA2Gvzu/9IatDlloCrVsVxaRlf+qhJg51ctvwyLS4eQ5rBTQuRO6+d0 Ju/veb8e+bXj1C/n9uR9SZUTH4PRhQgGuodd7KrM6lNiWPVCITBSMgYfZTnBBG0yjE9nloZBEY2Y ZjGn4RoA571x5D+S5y4JC/bnH7xGZ3AZZajdGHRAUPbvevausEZEfrnus+ba3ztOfH9yXTKNX0xw qJIZOF9Hn9Won7EY2hLlARoMAACAR5lwhbI4ifXy+43fbv40Itn1m1d8pS9+z7l9K6V5I4J2BAoe 1UY1xggHy7sC/dXv0wmtqA87BKdVYZZRnMnWI8yCT+SM8v1cWkNQTvWoSjXEpZnzYTK68leVwMTM KDPzS9Bbwt1rezJVhkTovbwtQYxh8s8oi6teSI6qIcoqKMEEbTKMTx/bjDJrl5DTcA1A5s6VjmrH 8ax4q/iiAqMMyUHhzihrHknx+Oqqw5xRFp1DIu1FJ/uVFBraEuUBGgwAAIBHmbCFsjjs8a8fzf7g Mh2UhCk0fosyZmtHoODxflRjjHCwahd35VzO35XX6US/VbWnJjnGe/NsO/+TC5z5zxfk6iF9lEVP a4LW0TO0j/J9XFqDLqfBqEvV+NIT76M8knoLRkjzOAnlCfdRDlv3CIWgyXLAd8npyoimLtfrq24L fqvGphWcYII2GSGKekw+yqxdaqEc0gC47jMtv/GuQAJXKirIuWuqvGLix+qjPHahrHdNFrgfoTze BgMAAOBRJnyhLIk/cXULfpOwGoZmFko7AgnLxk1Zcuj9gu9KTg6MbowRDlbv4gLuA18TNfDi/za0 8y85ies/zPn8ze2/Hvj2zBdlR9+Mt4pv4pPDu5pzF5EYtG/iq57ACspgxKUDghYBYK56MdZLaxBz OuKX+YJK1fjSwe/sS6tetN4lGR6oLviU7Pr7//703ibXiR6t7JDzu2D/uu0uMb+6VS8mSiiHelwu 5jp41QvPIEnbzQt55A4q8ss17x/N+djdp11BQimQjMPbdokFEryIQdi6RygExpf5SEF9qXyZL4Rp BQk1gjYZoYqaserFdPNeUiDMuhBiY+3SCOUQBtDb8UEqb3VbT37xzdmDX/IzysLX7CQDJiHUqhf0 V3B93Rmb6wXXdfg7fqWLL9dsE9e+IIFfRiOU68UDNBgAAACPMuEL5eHhe7+7IsmwpPqkgrAaRsT8 b5QxI0gB3PEc+Cf/js6cz9d+3xO8DBNlNEKZcKdrTxYdvOVPoN25dGGvtJop1Q3v/XJYXvGUxBH0 klDQYsYB37mDP9I1sMgB8+05pefO/XRco/xCraM89kurEXPKCkJJ6nSV8aWZ6ygLuwZaGnIS6PYp Cd99184FC7Jw1lGeIKFM0LyAVbHty181L2DRqXH9Osr8DqLwKg4JJ/73pqaO/uDIw1kWN0zdIxSC JvDl/62worCMsWndr1Cm8V/6SVlHOWPH2WDTVSHExtqlFcoEQwPQWB0p6rVSMUqJp+soSzY/wjrK /M+g+rqnbSwrqx2fhfMyn5j4oCCeZWxLD9BgAAAAPMqMRiiDhwXX3pAxzzpl47luSbKAJ517d67R Zw0SXODSgQoiNOXFzh8oDO0IAAAAPAZAKE9ybl898PHxvDfpg+CU8huYsAIU4dsfC/av28F7QVTU ffBP+lEMtXvxAwVCGQAAwOMJhPLkRljtIWLm3qTt5y4J30oAIMg3gIT59pwPz55WvWn3QIFQBgAA 8HgCoQwAAAAAAAADCGUAAAAAAAAYQCgDAAAAAADAAEIZAAAAAAAABhDKAAAAAAAAMIBQBgAAAAAA gAGEMgAAAAAAAAwglAEAAAAAAGAAoQwAAAAAAAADCGUAAAAAAAAYQCgDAAAAAADAAEIZAAAAAAAA BhDKAAAAAAAAMIBQBgAAAAAAgAGEMgAAAAAAAAwglAEAAAAAAGAAoQwAAAAAAACDsIRy07ff/LLz AwQEBAQEBAQEBITHIBBxK8pcQ8ISyiS6g0uTEBAQEBAQEBAQEB6DQMStKHMNgVBGQEBAQEBAQEB4 sgKEMgICAgICAgICAgIjQCgjICAgICAgICAgMAKEMgICAgICAgICAgIjQCgjICAgICAgICAgMAKE MgICAgICAgICAgIjjK9Q3nOqsV/8IeK7e/Hk2f/LCboqwuMWXv/0WkCscokB7+kD1W8kqw5bXXe6 j9/V12ldrdouhORD1t8H6V5u8HTZIfWutLU1VWe9viH+3OHhezdv1Dp+zklTDhDDat78AneObpG2 pHz/5bnA8PWL217nf450CeFENUN+z+9nCt6ke8Ws+XqPFlfKp4gbu1o3L2NdF2FcQlrVv3/w9Pj4 GiE1cK3zq81KFchh85E7ZG/3keqg7SQY7AodtrR2kzoWqjhoF8IjF+Q2fvfGgVzV9twzF+/y2/uv fUY6JcOuQAwj91QIj2tYu6u58bqfNwhqErcutn+9/XCafMAbTqvzuqdfGqKI7Dnx+2bBZnSjg9Ap MeAtkA52Z3r7pUv5rl+r2lXFX+ibgqpePzfUWVWdnnb4X/88XHDkTqDx1Mr11f98Q4wZYcLChAjl of5bd7q773Tf8N3jLcd/7fLHbwVdGOGxCqJw9N+7ReqdhFv36M+he6c/+V4+ZvVn1wY4ag9kgGn8 TNkuhrWnGr38XqKxz55anSJtz6yuaufNyOe70X3nltAZcf4LB35U+ikh6AXr27839w/frD6eLvwc 6RLi6CjZbfddoZ+683sdOUa+B/B3tG77h3gKhPLEB35gIIU8cOfiuWvNV3y0wG93WnV33RDKCKGD ooC5jm+PyF3Hpu97hT5JK5TZXYEY1UjdCMJjGtK3NHfyt+v3+hSTGO7vPvAOf8DqmuMdwibebCTZ 09/cSO+vdKPDhv3XPPwoeaOPP0seNC9d3JVfd/o23SZsFA8YuHXovW/UQnnZv8513L1367afu3P3 9oDv1Me4W5voMBFCWWUTaTknjlyile2/2LghXb4qwuMWNMKRbEmu/PfJAbJhqPXM/wgDiTC5Oxxo d98aHB4ePPe7uF0K//OFh27vvNF+l/Qxni/fFrdn7Gr3kn7n1pXdK/ktyZX5e9sunVM0qxJ0XRKN 099/rJj0MtJP1iX0J775YXsvSezAjQPrFaFMctN15LgwRw6hPOEhu/YUGTP83qPv89WXWX20kyO3 WKdKv9UcBqGMEE4QFTCF62jeJNSpYFQCaqE8QlcgbBmxG0F4PMM3u05SmXynvvZN4QHpG87PXDcv VPFjQcr31t/vkb3+61e/fE983vXGew2NNzlfZ4ftn98YjA7BgyYJyZXbjvR6GhrE2ei0qi+b6LOL 3p9/Fud6pMM2fXX9DpXjQ13HaxgPVxHGOUywUCYhLa+xjUgmMuCRjcLYc/PaL2e9vsE7R4urj3ap jl+m+fnG5jOnr4k3ar0t7U032daGMBmCvs0Hb9nY2EZ6GzKuFNNZ3mFfz9cbxSNpWPrD124yYgWa 7Ud5Pc21Vfwg7MosvXKX7OnvOVKietTFDEFdUpDfxciXYPRlqi1iRu7doxMJkgMGhPKEh/eau0iB y/aT/N2X54cMhPKt8+3Nt/iZnCF/l6t2LT94aIRycmXBgatd9K6LHtR/9ariyBG0q6ODjnlqoZxW ZT1Fb/yEWaI33vu99hI/w00sQnYIEbuvu021nZ6BsapzhAkKQiPlAvfuccMB8eY5vfjizcAwd89P to0klIO3GHQjCI9n+HZ3PVWrvkutO3SPs9I2N3eRnX7vse1SZ8KHN3J+XCPo15FHB4ZQ1gWhBws0 nnpd1ZsRTXWh49qvrb6hzs5ad2/th5pLI0xAmHihLPUsfIcijD0E393LjRetG0cWytknTlwnZw37 um80NXqu9PJjGMvaECZDCG7zuhnljd9SFUMnktOEqWXNA9C0Tec6yG05Pz0jTNgMtZ3bKDyCyJGe RpH69/ZeOHXx64+Oalyf5RDUJfEu0bLfhdEldH0ZY0b5mvvLauoJIDhgQChPeFDr1OTK/E8vd/mG uettH2QHHymMH6Q++654Gs/d6ObtjnryaYXyBvt16rZDep5myZGj7/qX/N2auMvvu9Jyrcl9xzfE P2p/X0pABp3mkat+6f/UniI37X5f26mLzl+uEU08fLvLtl7qvujF/bfarx/bUyWnEOHhB6mR/t5A O6LbP5/IEGcKuY6GKzdIRYc3o2zUjSA8pmH1J5389C1t2/3Xun/7qXH3O6I2/Z/9N+ieztaCDM0p Shh5dAgtlMUnHuLNmOa2n3fhuFpdk6k+HmGiwgMQyknfftZIbYlWsDD49XZ9to7fpZ1CVv8U5hG5 roviE/bsmlrMKE/iILZ5yd1KdK4KDJz6z3f0gGXOqg5+GuYL6posDDDKA1DJU1D0x+Adi4cHe6s2 i3tVzxZERPcv6epi0HZJ/yjrHFD5XRhdQjhRdkyUnMx662pXyj7KpDvLEW7eqAPGyr0QyhMcZKFc LN1d3+n+Wnq4qQ7C+NF7ska4fXpj+0UPMZbbV3Znq4aWN0+c6Cb22X9iJx9DcuUHrn5Sl1Qw6Xb9 a/vPdEJaTMCFjx28jO65auUfsvOGxHl+cgmX4z3vOc+R6nSh+xq612gTXr5BmExBbqSf8o+2bl3Z nc+/W3z3xoFP+Ipm+ihruwISj3FPhfB4BvrEiT4mUhi6d+EgfVVd6GGEGV8idXZV36ZmIwZv4/4f DUaHEEKZd8Ogw570YkaQUEZ4gOGhzCjLljGyUBZsoqf6uDjkBB2JMMmC2OZVBG731H4hrnqR/n4r 1S6yP58wwAS5n0oyWvJm5sWHFD8Jb7xT+/WR9uYu/jVBXuIsf6fu8I+tR4/QcHjP0XR1lyS8mS77 XRhfQhwdVfh9bb+Iry2ru7M3d7bdJBnx9R772SNvhFCekCD3FRvrjjWIc8D8DdI3eXvOC5V+9Mfz 1ne+CR4/Mo8fuy5Wh7JLcOS4fnFrphh/2raLPSTGK835W4J3iUFIgOByE+g/UcLLaKE3G7rX/MNv n316igZHe9e94SF349uvo4+axEFupO/zbZ8bbDnbPcDxkld4dKARyipUXUGYPRXC4xmSK/M+Onu0 1iP6aAXunvjgmw3f3iYGIT04FecEZWjPM/LoYCSUiTQ/2E3vz+95a/8j3nhDKD+88AB8lIVnVWof ZQjlxy6o2vw3mypvEWmhPA1I+mZbNT/4yK/3Si8OC34RgqegMosjL20hydw1b/2g9rUQvDiIxCnY p6hzek+v7pK0fhchLqE6Mf29cx0D1FxlnzNNdybNRAYC/OnCxpG7QoSxh6C+Irlydz3pR4hG+UE1 Gg01fvrt2IRy+o426s8VUihL9J6qo9PMQkekh6TzH+ijJnFQNdLg5XeEita5Xui7gpA9FcLjGdIO r88RbYCG9COH2qgBdX3vFE1i4ObXearj1U/RRx4dRhTKaVUf/+KlI6RKJZMAofzwwgQL5bS3amuv UYsRV71gCuWhgRM7+JlFlX8FXC8eraBp86J/+VBHpZPq1H/U1PbwBqKnp33XP8R3ihkM+Wp3fZP2 zpkLt/obvz0hvtubXLntJy+N3d349lJNGtRdktbvIsQlNH2ZJIX9l85t4t3OgrszyXueImwcuStE GHsQ+oqb7bsEp2RRKNPBSXPYRLte9N88VFpPnZKH7jXbf0wTnlRwg81f6PwrcDM/mYO6kQYt6D6C UNZ1BaG6kaArIjwuYcMBcld07dAO6W3yf7iOdRG74B+Spx/5+iJVOPeuXNotrYGblnPiZ341lbEI 5TerDzbTji5IJZMAofzwwkQIZZ2DV6CnS3hpJlgoi4+uhv09PcFv7OFlvkcqBLV58e0H7/Uv1x98 c/cV+r/sdyEEwfti6N6pL+pP3aJVKz7NFIJkGHfqawsc/BMoAr+Osuj9rF2hWQxKl6T1u1hZa3yJ N/9H25cJrw9KYkjfnYkOGPJGCOWJCEJfQcq193Zzo/iO3bCvt2pLsCIRxg9iE6qX+bib1a4M7dAy 9pf5ZJeb/ptfv/uNuKiq39dxus159OKvzb13bqhe5oMZTM6gVcDCTZf3ZA0xkhGFMtml7gpCdiOq p14Ij09YdvQrQbkS7UrXUb7TJ9wuSa7D8mzg8JC/74Yie4b7ug8WVIoWpXoKQYLwEh5DKL9x/OhV 4eThQP/doOMhlB9emBChrCLoy3xBQjnp4BsFjfKiTp6zbeo14LA83CMUgtu8dJ/dW3fqy9OD5J/g lflTvv/sLN0euOenJ3qvfbZWtVf+Oklfp/V/KvPLWhs7Rddkgtr7WRPkQe4jjd8FnV0mURlcYpN2 dCTK6WteCd+88vH/sLozaapJ3AihPBFB6Ct6b5x2DwhVH7h9s7pUN48rjR99lzovyMvDnfwtn/9a lWZo0byRM8rl4eTJRX7hi5wd505flQzS72tznaKXg1CezEHbSOnq7H7qY0p3GQhlVVew90CoboSc rtqO8PiEN5zWH7uk/oEw1HfpsrxqMg1vVn954sYt+XkDuYv+vfnfgp2IQlmD8PIfY2RhHUwIWh5O PBjhwYXxFcofBMV+X2Hlv37+l7yygfAxpLueL7WdFAICwuMZdDfVCAgICAgIDzxMWqHMu174um/8 9vOFo8faW6jXofY7oggICI9xgFBGQEBAQHj4YdIKZc3DUP75prxGDwICwmMfIJQREBAQEB5+mLRC GQEBAQEBAQEBAeFhBghlBAQEBAQEBAQEBEaAUEZAQEBAQEBAQEBghPEUyld+/038njACAgICAgIC AgLCIx6IuBVlriFhCWUAAAAAAACeNCCUAQAAAAAAYAChDAAAAAAAAAMIZQAAAAAAABhAKAMAAAAA AMAAQhkAAAAAAAAGEMoAAAAAAAAwgFAGAAAAAACAQZhCuaMizVJc7xV/aeG8nW3dPvGHSMB7pb3b z4m/RoLzXmm74Rd/jCPhXV3DGE55guDctvg/zMx39Yi/qT381WRJWZaWtmTurLjCo5206MjGl+PL mgbFY7z1RZZljg6m8bBsRoJhFQ/XnMBDpcux7I8p1uZ+8ae/vvi5rIquUPVMznquqH6irOFx7i6M 2ubjAdfb8nVhsmmWJXrWjKTCr5t7x68ijQbKicHIFB9gVfq7HFkRE9fgJg2c9/zXBakzTFEW05zk goMt3oC44/6Z2C6LhdGI+SC7uAffakbN/Qtln9uWPjXveB8p2oYS0z8qPWTbUKttUVS+66ZwhJb+ 0yWJ2ZWd5L8hty3hr++6+oaEHeOGfPVAw85paw55wjBlowQDf6djVeTcOTOK6qROV2UP3M2ThfEp djdHN/7lTy/kOXuEAjcQyorN6JGtIjxzUqxuoswJPFzI+PGHP72Ye7RH6LQng1B++N2F0ouOD0pX adQ2HwsCPa6CqIy9jVTiBLyNezMXFLjELmt0KB2Uwv0O+aw4DTEyxQdZlU+GUOY8rvzETOtpL+mL uNuN1uyo/GNivzQ6WO33frusUfcJRiPmA+3i7rfVPADGYUZZxl9fFJHm6BJ/jYSsnyaeMMdUEILr VWvSS499lTO3tEkcUNT2wPlqCqesqeqhG00Wi3lOUd1dut1oRjkcwjOncA8Djypk/Pgvc0xUfHF9 L/05KWaUHzrj3Ys+OV3l0HlrVFJpk/SAYri/qTQlwdY6httrVs9zv0P+I9ubPRFCeailbOGC3U2D kjQePFsalWlzj2HOntV+77fLeoDKapy531bzABitUCb/RL6ZtzEzMSlm2szl9tZBqYX4WuyrLNOf em7eklX2loB0vP96fdnq+ebF6ZY583O+ahm422J/O2baMxFzE1eToxTLIHf2+1aYo5YsjTXHbXV2 Esuj0T77xjv/ykhOs5hezLS7Zevk4byN5TnRMyyJMXOTtziv+PmEZW8rWPZ89M6Gc/TqtXXlK2NN f4wwJ64vbxmg93+2NXxKFsQrrgLaU2gGfZ46K58SywzzekfLpK68B0SvM/f5TS7vxfLkdCspSYps DwQqlCPoLAjdWPS9Y8PUlRWdg4ZCWe5VaRVozUnsL2qbwjEnLqC2uiujNaebrrzIFx/nybNJjO+G 50yT54ZgToZQeyj8virv5UxHJ6k0RdLpa1kFOeuZjPx331iSajG9sKLc3dvpWDmvtFG40Qs0lc7L ILGpzM9kXmE7QyeKdNFyPUc3zM7nn5P0t5RlJlDnohENko8+CG6g5au1loVL0hbPN6+xNXYzUtIp p5ZcdMu3R6xrk5KWzJ2XaWsa0JjurFlZ+xq9dzS9KLMclOzrI+T8nlprVvT8xOQYU/RaR/NAoEXV VXqltqnvYycxozKn2fINP4VUQSTVpsYjTvC4oOl5lNiUvo7znrEJhSyXHsNavC2O3Bjz4mWJUfOz 9p2u28eKU50wMng5juxdn5yUYDZl25rJhaQrBhv8XXY3SxLz7Xef5aQmJ5pnZOzj06CkmW9r5ATj K6rgrtdsT5sxNyE5KadgnUUyG13Gtdmkc/mcfjh+WAz5b1y6eubSHV/IeyVSLCsipZbLc7epNJmO cYzCV2GsgsSD5MIn/+lbtK7NkqMGmh058fMTU5eYo1fYTtZ/yYrTuOoZ1S1bvt6u2F2TUOkqKzI2 NgXO8/P2pEhzYlJyTv766IX8uayuTJNN2kWzDGzCGYNQNiXvbqDJddviaY+jFJbqblg6nrt+qvo8 /5ziWlVOdK6zW3PfI1uG95fCWSvKL5PaD/TVbI1MsbcP0WifTtrDN6oLtrjE0ia18fXWFyVm2i/S MvJfb23r5Z/7T52f/6OkgPmrK2PqUJ/rvci1hz20ptSjne6UYb+nvuYc/1TuZtW6iPVOfhbrSYbr d22aQsthoKUsNd52gTd2ubjIfrXrBdnY3W7Pfpk+KA9TKAeZk2IV4ZmT6rBRm1PA295wqq2PzxF4 gNw6WR0TaY14xWrK/uW3W+LGkRCqdeBieUb0Bud1Tm7UjFoWz6CQs/6ctvvsbW7Yd8mWToY3f7s9 5dWyFnoMseR0yWJF8xseOF0al0k9oRnRDnZWrk8oOdXf+e2qRf9uuKvqLlgGqeN61Zq4whrakXDe 9tZrPk6fEiW1Pa68OTNyD5NOibaIl0pO8x2saLrD3sbSdL7vUvWizHIwipAMUQ3VTWQXabtVa5/b 6OwdUnWVctvU97GTldGYE2PKVuw3jEccxrjAmv2V+zpyE574VhW9sxsebLIu4k1Lby09VTnPF570 kU0Bb5v7mp9Ytz5OVcL6XfnPzNtQ1eGnVp02vaQhIF9RZ/ABRjdLO/NnTXlVRILQPMbtbOjX9M/6 omBcUUY1qvo7qnLn8dfqOVmQIJgN1/fLltlZ5Zd9umwGWMPxQyHQX7vLPuUVa8TMvcllHX2qzDHQ T9lKJcwofBXGKkhGLPzh4b7j+bM3VHloEQ42WxMWWVsGOV2bHeypentKQQ3VklxvW+t10iEy4jSu eiPL19sVu2viK124kGBFxsYmIzcQzt95eINpAT2X0ZUFdNlktayJZwxCmdGohMJiKBvSMNzVtpId pfuPVGyO5mtRVZ1iDLIU46GPxjJs7n5WHUiQ1vs8378rqI+R/ld6/27n+gRhrCJwHfbkONslOp+k O4Xs9V78ybZre6mjxrFJ12c9gfTVF8VnOtqJQfvqi6fTeTiykRSX8jJfTK5DMzNxt654Vpq1+bpU 0epyFpBtRrVL7iakf8IzJ9VhYzYn8EAJ9B/Z9AmRNXz4ZJ0zRD8nVevd+u1z4qwtxLpoox5k1TI/ AyEgm5NsbJy7PPl1egzptRdll7ff01oCGeEy422tXma0pEdOSMp+PYkqdbrDyCB1ECmQEZVrb/BI ydOnREmtvntUj0b8/STtu+TDmNbuM4yQnNR36afPdxbv3l/jKBB6SL1QZvSxk5PRmRNDiTLKmdFF 6McFlqiVTux15r4gSEPCYIc9i59i0FkLHenjN9h/80hTqqw4VQlj3M9IV1RqXN6lO0YTv7xRlVl9 UTCuKEOUU4L0hre0V2M20txKcDaZw7Hw6wHjaV4XLViONSL68BFj53C9EpVyzSh8NYYqSEaMZKjX ufFFQRoSuLbypOV8XxHcZqmGXrCxvIFoRwFWnMZVb2T5QceQXfqexPBE5hVliJ28sMnVL9S6sLeP 2ZUFZ5PdsiaciRXKXOe3Kxds/Np9y+uuzDdPDTYRRnEThHNvsepAQqk8GfUx0v9KIydbpsesKSgu KhLDv50dQ6xTuI5D2Ym5X7d4va2H8qKfCu6znjzu/b5zVrLocUGM+7k1h+idrlhcXKdj+VT57T25 PAc7K9+alf2ZY6tQ0epyFpBrXLVLrlPpn/DMSXXYmM0JPFC4e7Uf2MTBaaZt269EsRohGwZtm5aV Dvs22qgHWLWsqlOli5DtQZy+DbTbU1Ps5M5Pe5ZwWE0HO1p/pyP7qanF9WIHLW5nGiQDrrelcseK BQsziw7xr8nrUqKkNlT3KG6UD2Nau/HwRprn21HrD7q9t9yVm+b/ke8h9XpIiWGSM3pzGtn1QipJ nTmxxgVVByWjKv8/W3K2SsNNUfGHzvYAy1o47/lDxSuizK8XV9JJR1acqoRNLqGsOlHeqzEb5RRt NsmJ+uFYOOUBc/vyttckofxade1tcTMbkp2RXS+CC1+B1UuoWqWMqvCftqzZJhdO0R5nh5fRZon+ bj60PcsyP6P4EF25hRWncdXrq1tvFUrW9D2J4YnMK8oo0RKEveoxWt5ITtFmk5yoa1kPwHYmVCjf 9lSuniLmXC5lfXE/gBnlvvqixJyq6/xeGdYpnsrs58WrsvqsJw76+sJz85akpS+jISVm2iz+yZFc dOoHZ6ryHGyyxplM04ROQV3OArLNqHbJLUf6JzxzUh02ZnMCDxh/p/ujXLtpgT3H6u5STQMzkQ2D fxAZ/9J0059Jox79jDJvzJYsx5lv37KUnef7DrUlGM4o3z21M2FN0Xuvr6rs4JWykUGOCHe7cXdG JP+qa3BKlNQaj0bjMqPceegfcWKu5R5Sr4cemRnlUZoTLaKgl/mSFtJaUJezrotgjQusAUI60VdX PG1dlWYxjYCBtXDeht1Ji4vre1lxqhI2uYRy2DPK/A+ClM0O1nD8UOACXSd+yUnZa0o59NGJ3lCu 0oyX+Rak0FkkRuHLMOs92AAoYiT0ya2JvhyvhtVmRQLes3uSZ2+vv0tEji5O46rXV7feKpSs6XsS wxOZV5QJe0ZZ+KVk89avupb1IJhQodzXX7PFlF1Jn1ZyHmeuOdhE5DoYwalUVwcyTB9l+Rjpf8Wk uLsNu6JT9l2kJh7wNh7c67rGPqW/pnDa2kN0mj/Q63zn2eA+60mDelzNKfldmqTxeyrXROS5+lVF R191Et/eU5dnoMeZ9+If/sJXtHq7gFy5ql2yMUj/hGdOqsNGbU6cv9vd+ngvGfsYIFcrgbvuzJ31 pz/wjZrpmyujnKWqetL5RkfFvKp+J1Xto8y7QzCiJXeDbyy3XxzsObYpahP//MTAIIlRtV+h08Yy d9tO/sa/CEG7FHEkCEqJklr2aKT2UV5Ml2hQHcYsB6MIb50sSFhZeYWmute54Rm+MBl66NHxUR4d Iy0Px+wiJFjjgqqDkpFP7G0oSU21tdAZBHKDtN/+s2eQYS2Dl0/WXqVXpFtic53drDhVCZsQoXy9 ao2F17u+zqq8GZLJjXxFGdLJ54floxycTQ9rOH4UGGl5OEbhy3AhVJCMHAm5LX81y3aRushz3rMH Pj3h4RhtdrCtvpZ/3Y1uoTcnpMHq4jSuevGK6jTLxwcdQ3bpexLqQMzrAZWfsfEVZWhPvjgMH2VO l81bupalKuwJYzyF8rC3tnjBHIvlrf3tF8TD/FechRlL1mzalJv7P4tn8qU85K3bEWWKisk+0N4p 14H+bUdm5SlIb2QnLzEnbjoqrHohHyP/31NflDAjOn7lfjdHX7zNi5sbm740Pi5z13F6CeYpvk7n tuTENQX5G/+5Ov7/BfdZTxhce0VGbGGN8n4MfQ/ppeJ6X7uq6IiMSOOXhNNW02CLLdnE17h2O0Wu XNUuuUHK/4RlTqrDfvl8lOaEVS8eBZSemsANXtyXQmeUyW99LatQzlJXvfd0ieVPUcKLdARiCSFX vRjwX96/fNHHjdQL3++p2hhd+Euf/HoDwyA9zvUzn1ZPCNHPW7wbT3sedTq1KVFSyxbK2lUviKpT 9aIcqxyMIiQj09EtSSk5mzdteGdV4n8JhSl3lS2dUnHp+tjHBfYHR4xHHNa4oHRQsruH6sSB5orc xWZLSnps/PKSY/ROSWct9OsV+Un0GHnxB0acqoRNiFD2e44Xzn9+3pKk1LWb11okkxv5iipojhJN oVa9YGSTMRw/GrA/OMIofBXGKog3PooSCTfQ4tgQuyBmaUpcbPbO46QM9W3W520+uCmOHiOVMytO 46oXr6hOs3x80DFkl74nIcr/p3fNL2tXrjC8ogKfo9hZoVa9COiyyWpZE0+YQhkAAB516KdzokW/ C4K++75/An01RYnKQ5iRCEqJAayhFwAAwIMCQhkA8GTAXT2UlaZa9msChDLXffLzb/hJX0OCU2IA hDIAADxMIJQBAE8Anh/yY6PiNv3Er94qMBEzymHASIkBEMoAAPAwgVAGAAAAAACAAYQyAAAAAAAA DCCUAQAAAAAAYAChDAAAAAAAAAMIZQAAAAAAABhAKINxhPN3HtuZMW+GJTHGNC/zgx/c3gBdnPyP 02OW8l/AVj7r0FGR9leTJWVZWtqSubPixFXojfG22LKmiIufS19DiI6aYV5X3nRbPJm73WRfN5+u Bh+91t7IX2g8UBZd51EW4TeGG3R/tdIclZi6+5Qv/KTwK7HHLYhZbDbFGnxH44lhsmWZ815puzG5 aoCZpIdQbmMz+AeL0h0tNk9LFD9hwEM/D/6HmdI3mSW4C7a4Z56lnx8TfzO6OIVxWqKEUXfyBxoS 5pvX2BqlHk+Eed1RLeqCxVVCQovoqWmW9LT0ZYlBnbPvki31T8/I32QW0VmUr/P4rsyZs2JSLTNm vl5SdUE7Qo3LIjzMevR1OrfGTTMvSYyaL36xSA3ruqPrPR7S8kEPEAhlMH7Q1WEtG5z0a51Us37n ujTIaZrcwG87zYv55WNVTYu7ebJw8XLHZcOh1dd5tCDeHDldjKq3oSRtOf1QKkc/nPbqroa75Gz+ Q+WZ+9vpR7Aulmem7WwQvxt/vwT1GuEK5btNpYnxtguG+dIx2GRdlLar4RY3HOirK3v/h07N6aPr vx4LxjXLgYYS0z8qPeKvsTDktiX89V1XXxifCnlQsJP0EExlTAb/gFEVC/3G8qw3ysVv4NFPwETO nTOjqE59b8p1OjJnzzObiusF6c/s4hQmTCjTT/4m8tflBpt2RylflxSAUH4AqIuIfmN5TrJd/AYe /YSt2Tw3rrhe/ZnXYIviPJUrpubx38An97ZN3//kpt9hVpgoocz1HN0wO5+/bn9TadLC4O8cQSiH BkIZjB9MBalpcvJnMNVNi/PVFE5RffU30Lw3PbOoouG6EtFg6/539zY07xej8tUVm95x9grtvdu5 Ppnvofrqi5Jznd38xqFe5ztBY97YCeo1whXKqm9+hgt3r2FnZIZDq45VjK7/eiwY1yyrvqr6uPMQ TGUMBv/A0RRL78mCuJyq6/z/16vWpJce+ypnbmmTMuMW6Klaby6t+o7sEr4OE6LtT5hQ7nXmPi9N WDLSAKH8ANAWERm0nn+7ile9wz1VOXN3HfuOmEqjarY22KJCdT4TJJTJULhxivRIhJUGCOXQQCiD kAz5b1y6eubSHV/IWbSbrryomMKfutR+FJom1+PKi+O1rJFQJlv8nt8rirLig+SyFBXXYU+Os10S L+K7ZFuebG/juLbypOU2t6iN6WOvJHuHkhDagzz7xjv/ykhOsyyIL3Qc2bs+OSnBbMq2NZNkkPRE vpm3MTMxiX5T/tvvPstJTU40z8jY1zKgnRQnKAMV84P1AoEeV3HctGci5iautrcEuNuNtjXzzYvT 6aUFPxM+Pf8o3J42fXpJg9S9ko0rdXf8KkhKnsnIf/eNJakW0wsryt3hfNrtESc4y72djpXzpAEp 0FQ6j9xXdCrHzJi5WnowHfA27lthjlqyNNYcR5+TBlrsqyzTn3pu3pJVpEqGOe8ZW1b0/MRkWuPC I3hG8XIDLV+ttSxckrZYfOStGENw/FobM72YaXdrphtVMOyBWmD2toJlz0fvbJCe8xOCjxwk2Y8U P5Et3VaR7ItJ8ntqSpJN5iVJqWs3r7UIG0e4lmjt02Yut7fyM1sBb5N9rXlOTKqUHcaJKoL3ag1e PGjyoWnLRChbsis7+X95Jeq9WJ6cbm0Z4PcSyE14XL7rWrs9S/reOKuLU9DLFLLten3Zar6g5szP +Yr2J+zyZ9WdjDrZ/a78F4Ke8qsNb9Ys8fG60scyTD24uu8oKfe7K7LTNh294h/BchhW+kSgrVwy aD23+pCHlLOoRL3t9pRXVTP9eovqO57/14Qtx6+qK1aFUl8SZBystQoVZ4pe62imsTD6KHLg9Zrt aTPmJiQn5RSss2gtUJ1srt+16UXFj0hAZY2yb6Rsb8xOQHRxtPAjKdnYLqWc87c7VsYVkN5jhN71 9aLtmVNeKjk9eTsINhDKwJhAf+0u+5RXrBEz9yaXdfSFMHDOe74id+HTc9eW/XRRdMBSunhf99kv 1i4qqqF34apOgbpexKfY3eqOn0eWy9sPu+/QDVJU2ttiqSMImmhRritAD3s6aQ8dQshI88y8DVUd fiqy03idStJjSt7d4OVoV/KsKa+KCoULtrg4Oh4ERaVciIyaiW9VdXJUMR/eYFqg7ebkCbYhb837 czJ4nxCa2YRUu3uIT89T5s0qRzcCOSU6cdtHW5LilgS7wfGQlPw5bfdZIgRJytMjNRMYjym6LPuV AWmgpSydWo5yDDfQ+HH8ImsLUajeXwpnrSi/TAYX+pw0MsXeTgpdsRy57gR3l0xrM1/RwcV7vWpN XGEN9eHhvO2t13yKMTDiV9kYNZ7EET5SzbQHYoFT5+f/qNWjQ32u9yLXHua/4dffUpaZUNZ0j5l9 IUlkJJ69ocpD/vN1VuXNoBsZMQwq1s7fT87mZ7zu1hXPFrLD+a+527yDrBNlmFl4xGaUVa4XtNVP We/spUWaqniPkI7i+Y3O3qGhlrKF0p05o4tTUIsSCe76qerz9EjuWlVOtDRNoCt/Rt2JEVDkZBPZ vXtFQskprWGpDG/Y21iavtjWyluU0Mf2nCxIyKSOanyWZ2eVX/bpqtsnppy71bDzjeXW015uJMvR W+kTgrpy1a4X0uzP0HlrVIY0U8O0qIC32bHBPMW8Zs9P7j5dCcr1pcB5Gqr5N3C4m1Vrn6OmyOqj VDXl76jKnae1QDnZVHbvzszUeSQq1jg8cLo07nWaBdHemM2cu1u/PVLYOOy71tru5cSUc95Tu5JX fULnKUboXf8YTW/AhMs+UkAoA2M8zeuirRFEKJMQffhIOO6dPk+DY0vSvLgtx2jTpc1DeHsmbcnc 6TFbXN209ZCmJbzMl86er6KMv1AWexDlSHmj0kmpIpc2Klngw1KL6Y/86ZqpHSUGCVk3yPPoFGnQ VXe7MuSUeU8t2FFPb0h8Vx1rpucdV3u9qTLFPP1xRJ9lzl2ezPfmRIwuyqZCR13XVKFm2twD0kDF I41hSuX2OnNfKDwpvnM22GHPooMZo3iJRMiIyrU3eKQ7FvEYeSDkEePvV1WK3h5kmPbAPL7buT5B kOkE8UHKEMk+P0dFLvpqlir72ukicSMrBvW1mNmhME8UfhGYWXhEhLLyMl/8BmGWjnptxWc6iOzh fPXF00XfJ9X/vrril1ZUdMqtTdvFKTBbZcDrrraV7Cjdf6RiczRfPuzy19Wd8INH2OJrKV+VaJ65 +vPmXs1ltdcNtihJ7vM7Bd3W6g2ubiEGV3vVpvjcw3xvHMpynjhoESkv81nyKlr4clBsQ7YiAtOi ePzXie0kmxK3uK5pK5FVtlzfpZ8+31m8e3+No0AYsxTbkCudNMYE6ZVBvQWKW3wt9tWJ5llZXzQb vcwnyXrxKsxmrtnIw8dQ01SVm85PP4XsXR89IJSBMbcvb3tNEsqvVdfeFjeHhNybxi7e2cCrTLl5 0FdSkvJdNw1lBGGiXC/EHmQMQlndwuXTNdv1OZJ1g3aXeJa+RyOQPiWb5kX4RY4MekqlXJF5+uMI I8viTGqg3Z6awk/qMCrilrZ8xCpQKpec8mdLztai4iIhFH/obB9iFi/X21K5Y8WChZlFh1rIGCMe E1T++ovq7UGGaQ/M48nG6TFrCqREFhX/29kxdK/dvjKVkX1tkpRo9TGorsXODoF5orhvhCw8QjPK 1IPl5dyjPUJLu/f7zlnJ4vNxIiufW3OIzux6T5fES35QRBxEr6i8qnQnBLGL626x5/K30Bmr7Y1X gotxmOv8duWCjV+7b3ndlfnmqSMIZWbdCT94VFvou1lRW0/ePle+KoO/bm55i3eEquevoolNuFBN R3A66fb/tzgt9fmXV1Ze4bPJNABtvT9ZSHXEXa7IjBZf6OTdn+aI71bSu52IrEp678S2KBn64Ctu 9s7Td5tVldiiK9vBzsq3o9YfdHtvuSs3zRdmZ5TalG1GXSlaQ6KotwR6nJsWFvxym4hmetH0ZdQJ jXV6kAkJMDdSyJaZiWkJU/4r55AwXJMjjXrXRw8IZWAMF+g68UtOyl5TyqGPTvSO4ombNGpqmgez bQfDeJlPQI5qLC/zqfqL8RLK4z+jrJlYovcDwmNZGSUlzNMfR1hZJmVoyXKc+fYti6Bj1BUU5owy MaFp68R3cWQMipe73bg7I7Ko7q54jHYKdqJmlIlJJ0pvmylwRCJnflnnyCFymRqfKkm6WUlmDKpr MbNDYV9agpmFR0goq54IC+l/bt4SQTqkpcRMm0WzRut0qjkxjd+Ynm6Z/qymfAj6/OpbZcBTuXqK uEU+nl3+oWeUxS16U9Fcl84RqC0q7Bnlp8yFx5p/3BS1kfcACWU5TxxyIXODzdYEwb+LlmdSxNzF gpHQh43PSL46eotSo4xBMvqy7Tz0jzhxC2N2Rk4PaYyhZ5TFLXrT0lzXd8mWOaYZ5anzN/3YfKxg oeABEqJ3ffSAUAbjBtdXu2ujuEwjdVfSeDsJR9xw5cfxEzNj6nCVqMawPJyqvxgvoUwnyBffj4+y tkfjuVtX/GruIeqaPNBuX0GVmbiDR0nJCKc/fjCzTERMdFTMq9JbMuQYtY9ygo2UbygfZWJCqam2 Fup3S0TwfvvPRBwwrnW37eRv/JPoALn1otpCPmYEH2WpUmSL4vzd7Vc0jztH8lHWtwjepFP2XaRD csDbeHCv8LhWyH70SnFpMylJ/DpQQX6uzBhU15KzE+y06mdfWuQx8FEO9DjzXs50dHLU13OO+H4k we+pXBOR5/ISuTlr5+l7Yqbp2l7PbTredZLRxSnoWyXXX7PFlF1Jpx85jzPXPIJQZtYdH4EAOezP yz/hPS7okVNztDOU9LpqH2XJn1i4ymh8lGmx5PMOr6Es54lDVbm054+mS5rS2/IE+uBUgK4eGJ3v 6mJZ1E9ddf9559PTvF97wNvwodhNKejL9hapOGGCn+t1bnhmJKEsVxnZxvZRfjptL+9xwdu8MOet QK6r9lGW/InpVUbno6waEI1710cPCGUwfnC9LV8XJk+bak5MME9bvOlr/hUW0jwUH+VZMbkO6b3v 0Xe4qpamfHBEWeWAtknpgyPyl01kVN3ceAllqo9HWvWCoNINjHeHVenRQMYkupZCIn1H3t6kEVjq Ehjp9McOdpa9p0ssf5JXkyXHhLHqBd3mrS1eMMdieWs/kZgDzRW5i82WlPTY+OUlx2il6K9FTfrd +Lmx6XIkyjH6+NUplC3K41w/82nNoi5MexipRXhbHHlxNAHxcZm7josvdw60lCVqsi8mSfqygGbl BH0MqmupsyMsg7B08fxY+t76CJeWYGTh0RLK/KRyXHxx3emKjNjCmlv8JgrXbk95qcCxL/vlghpx ipdAPePjius6GF2cAqtV+q84CzOWrNm0KTf3fxbPHEkoj1B3EuQwwcKXBn8nhYded4yrXojVrVr1 guusWpuwtvKy39hynjjUlUsnleNnba+/8FXm1C0nlRVI7rXbX5++7cvPGRZVXH/j3NcFqabn5/Ev ar/7dbCjub5s+fElKSVn86YN76xK/K+RhLJgY4mmkVe9EGwjnfmCOL3uGFe9SE9cGEff7JRXvSA3 g4ffmr2eTvQY9a6PHhDKAIwLpLtJePKWTHpY0MX8pRW7tOpn0hHoqylKVKaXABg9j7LIAA8V1s0b GCUQygCMmYH2H74/RVeo4PxXv17x0uT6YNvjDH3EmaYsvjaZZQTXffLzb4SH9QCMEQhlMEYglMcB CGUAxoz0tDRtsdmUtv34I7lC5KOH54f82Ki4TT8pnnaQEeDxBhYOxgiE8jgAoQwAAAAAAAADCGUA AAAAAAAYQCgDAAAAAADAAEIZAAAAAAAABhDKAAAAAAAAMIBQBgA8Qoz5kwd4+xsAAMCogVAGADxC QCgDAAB4cEAoAwAeISCUAQDgCeFe59HNyRkb8rPWWxt7xW0PHAhlMI4QEfNyfFnToPjTW19kWebo EH89aLhB91crzVGJqbtP+aRPU4jr9rdXZETlu3rEjeRQ4Vv84mH+Tkf2X/JcyteoOXd5clxx/dmK tL+aLCnL0habpy1csZP/fv1Y4bydbd1B39x/iAS8V9q77yM7E8hAsyMnfn5i6hJz9ArbGS9HbCzy zbyNmYlJMdNmLre38sYW8DbuW2GOWrI01hy31dnJFyx3u8m+br7JkmZZEF94tNOvEsp+d0V22qaj +EDME4iv8/iuzJmzYlItM2a+XlJ1wSs1+prSFbNM0YlzZ8XlH2wZ1ZcU/VeOl7w+4/l5iZYFcbn7 m4LO9dcXPxdhTkxblpZOQmaRqt8ZK1yn4/XsSuWDOwSxZ2PcDU6yrubxg/N3HtuZMW+GJc48LX7D /kbeokg3JQwWtNKXZexw9fhI1Tw1zZJOfiaaTbFSN2WEr6vm42xiq4vNJss7+5tuCxXOeRvLc6Jn REfNMK8rlzaGh3qWgQxzb6+svGp0Oue90nbDoJOU7JAbaN6X+bxZmb8ItJSvyhDzvtRi+uPCnQ03 mXkJA85/+/YdcnSXI/vhTXNAKINxhLTDv/zphTxnjzBUPFyhfLepNDHedkHTIMXhxHfJlj6n5Pd7 4la/p3JNhEoZc25b/Kydp++Jp3KeyhXPbXL1X1Z6Ge52o3VlfOHPPWE3dy0+ty19at7xPvHnw2ao 1baI3DncFH9OIgI9VW9PKaihQwrX29Z63U9tzJS8u4GMRrSaZpc2EVvz/lI4a0X55QFyfF/N1sgU e/sQd7d+e2TG/naq/n3XWtu9nKQhuFsNO99Ybj0tKiTwJEHb8lSxg+K8Td//5OZvtLyNpenxO09R k6Dmkbqw5JT0efSQ+D1VeSnKucnzShs1SpkK5ayKrnEc4od6ne+m290a+x1RKE+yruaxg+ur3f7q 8t1neeXnv3woZ/EG53VOI0kF1FVDu6k5yfZ2wy6Iu1n11qubeT3NH7/I5h4im3sbStKW2y/6iYK8 vH/5q7sa7hrGokGdqm5n7lvl7dIYyGLIbUv467uuPnpVFqIdDnb+uClugfmlBdr8ihAxnTl1S03H YVZewoeM0e+8VXVd/PXAgVAG4wgVMRaLeU5RHT/MPFyhzLq69CXYoZayhVFlLWJb7Xaut+Q6u4Uf lKHz1qgUawsRXvRHr3NjxHpnb1DfN3i2NCrLuKMB9w032GxNWLCxvIFIZAFVLYi1yfW7Nk2hFcRD 6y7D5u5y5cVp6lQcqFztVZvicw/fz9MA8Ojiry+KSHN0ib9EqHqevb1eFhwDl+trL4e6jwp43T9Z 17+e7/SIG3gY8Y+/UO5x5a2QeieJkWeUwURyr93+hjTeqTEWyuT+pabw+berxBklwkCLddXyoq8b POpp5nu3b/WLZihbka+u2PSOs1cYusjIlVxcH/5NkCpV/a78WHkEHBuCHfa492//T0ODIzi/AkTg 5kwvqOln5iVshjoPv7N2/6WH12lDKIOQDPlvXLp65tIdX8hWRdth0feODVNXVnQOaqQqd7vRtma+ eXG6+BxcbfHqHkRqycEP3I1jGOa8Z2xZ0fMTk2PmJm9xXvEPB3pcxXHTnomYm7ja3qJM8EhCefje 7ztnpdvcfK9Euozn1hzyqNut93RJgjQbTbqD6BX0EVVQ39d/uiQxu7JT/CXASCQ5KzJ7W8Gy56N3 Nshz1nKW6V6GI0GTfa15Tkyq4Ehwhxz87D8Kt6dNn17SEGBcgvN7aq1C9k3Rax3NdAjVFaCuiNRI WSPl80xG/rtvLEm1mF5YUe4Oe1ptAgl4mw9tz7LMzyg+1NyrqQW2OBAOaNJWFoEe9v8Wp6U+//LK yisa6wGPOr4bnjNNnhta7cik73j+XxO2HL+qsn/VUwsNzJZLECRy6pL1ZT+5+7SGRGWBqahOE5Wx LFBaHGnsW749Yl2blLRk7rxMWxPNjP+KszDRNDchOSmnYJ1FNHLSdyX+m3/e5ffUlCSbzEuSUtdu XmthC2XjrkZGtZf0D99+91lOanKieUbGvpYBciG9axON9tk33vlXRnKaxfRipt09+Ig2qfBHN2b3 fr1qTVxhjd53VtVNiWirhgjl51Yf8qifPfg8DV8XZybq5DIPGaRe2OTq57gOe3Kc7ZJY2L5LtuXJ 9jZV0RvXo5wq7l7Dv5fQZ6qGx8vDJXNcUOxQuG5Qfnm4q4ey4gtrbok/BaS8iD8phsnwXyh/fWPF VV2ZPEAglIExgf7aXfYpr1gjZu5NLuvo0zxU1CG0lu52e/bLuUd7OFkoD3lr3p8jPAfnbp4sTEi1 qx+8qHsQIYZe3QP3oT7Xe5FrD/Nuef0tZZkJiic0oedkQUImfRo1zPX9smV2VvllcqrRjDIZMOuL 4jMd7SRB9xp2RmY4OtXNdpjz1RdPFzaS7mA20f3knKC+QD8mMbNJzpo6P//HEe4NyF6dI8HduuLZ giMB57/mbvPyzm1m4bkVuxw4T0M17/XF3axa+9xGZ++grgBvuvIS36ricznYZF2UaW1Wj/1S1kj5 /DmNf4xIvVMigx4iP0wC3rN7kum0n8oBRqzNUcwoP2UuPNb846aojVWa+yLwKHPrZHVMpDXiFasp +5fftEMyA3Lf5dhgnmJes0eSueSON4H14IvRcrnuuk/ZEpln4HRpXFDLInZHhPLLltjYuKWLzaa0 7TXXNScqLY7ckM+ZwT/roF3BSyWnA6rG7u+oyp0n9DZDLWVxgp8YEf2zN/CW7OusypsRWijruhoF eS9tTc+a8qpIb8NdsMXF0ZsE5UL8E55F1pZBGu3TSXsavQH+sMTSpslwUz1aRjW6sfreQGPp7BWs uyCpR1VQV42B64Uslw+7qbTl8V+v370ypfQ0GRK0jyz01W1Yj0qqBlrKVvBv6RgeLw+XrHFBsUPx ukH5pdBnNS9tOanWxKq8qDBIxo2m0rinLWu2FRV9UOV+WOMRhDIwxtO8LpoOQjREHz6iec6oQ2ot ROrNSrM2X5ekKhkDFNVC3R6Ue2KCurWLMegeuHc71yfIN+7au2r+DvV5og4F7U26gFR+MthYKMvq Sj5eixSnKrVBfYG+k2Jmk9mDyOeq9jJlH0V9oRHKgeu79NPnO4t3769xFPDTV8EF2OvMfaHwpPi2 4mCHPUubZSkZSvnoc/dQ4Abb6mvpHQIR/M4NtEbadCVG7olG46M8HOhx5ksDHnjUCfQf2fSJ2EG9 8sk6p1aljoD/eoNjS7IpcYvrGrujoDBarqFQ9jaXvR5dXBu8g7t+8tMvXNSGqVNpZpBuUFqcKhni RtKfJEjvHMvWS5TKKr6ToR3Fi7JSEU/RN1t5i76r4feLKHtVUkzY2Nvr3PiiPOPOtZUnLbe5+1UX YhTUI8KoRjdW3zsoPS5QXl/L4J9hkjIxfJnPklfRwiyxIKEc6HHtyExbbJ65+nP6PC0coTxSPZKN 0j9Egy7exI+YhsfLdqIYjN4OBZR4VMh+FwLBeVFhmIxJAIQyMOb25W2vSV3Ja9W1t8XNbGTLHuys fGtW9meOrULXr7X44G5a3drlI/UP3KfHrCkoLioSw7+dHfKktCZCOTZjocxrx+c3ubwttrjUYIc/ CukW4/JdXZdsGQvLzvOXCmq3d5tKk7XxM7MZdJaAweil7/uCykdfDqS0345af9DtveWu3DT/j8Jz Xm0Bksj/bMnZKp1VVPyhs101qS8lQykffTIeCiQXBzfFLYhZmiJ5jOhLjD9s5FUv0hMXxtF5QVWO uM6qtQlrKy8/7NyB+4e7V/uBTeygZtq2/Rr2SwPcQOPHcbN3nr5H7htfZz08YbZcAtP1ItBXt2Nh 1I5641lJqjLjNY4cig3rhbI6AZL1clcPZb/NP+DStlDxFH2zlbcwG46MslenVG6RGIQpPan32OPs eDyE8mhHN13fGyAVmqYaPlilLSLX4OWKzGj+hb8gjFwvuJ6jG2a/5+obCsP1YqR6JBvFfzhP5crl wkNUw+NlO1EMRs6FbIcCSjwKTL8LVV7E3xTDZEwCIJSBMVyg68QvOSl7TSmHPjrRq/Ef0KOy7MEm a5zJNG0q3/WPekaZ306QH7j31hcl5oz00utYZpQJ16vWJBY59mRGBj2FFAj0VK0zbfvyi4wU6ami Nm30Zb5M0ctZ5AHMKPexyqHz0D/ixEiCHSKlArz1a/G0dap3R4KQkqHvEIX9AExa/J3uj3LtpgX2 HKu7K1hhGCE1FtpUF+xukr1s/X2375CWwmy5MuqX+Th/Z+XaqRnW5pEOlqBCOUnjpaC0uPBmlMnt /WKh83xgM8peX32xaU2VdlU79YWMC2oyM6rRjdn39jeVpibbWqSyZJW2iLxLdl9RX475Mp8aKcIQ L/MZ1aP0T2+vc1Oi+ETR8HjZThSDkXKh2KGAEo8Mw+9CRH+wYTImARDKYBxRW3agx5n34h/+wnf9 xj7K9GUafnU2Mt4c3mCiq8zoHrgH7jbsik7Zd5F2LgFv48G99JmpzBh8lAn+TsfK6dNeDn75RoKu a/PSdNM0eX1lVe445vJwI/ko61u74ejF8lGWxiSOVQ63SPaFF9RocT3Du14EF+CthpLUVFsLdewm id9v/1njpCslQ98hCvsBeBwI9NX9551PhZUBA96GD+MT+GWqOI8rPzFTXDHQ11m5PpK+YsFsuSwG mmwZ0Sscbk1j8Xe3tnaTLVzP0Y0J245TAcRf8dXdjdK6kxSlxemFsspHSPRRruut2RonTX7zM3Oj 8lHWdTUKyl6GUrl7auerWbaLVN9z3rMHPj3hURyZVIeR/qq7/cqolqB+lGD2vcR2Dr81K+uTRn55 OK6nvjiOvnKtLm0RVYlx15250csdl1V2wIDrcb67ci/1AhfuxMRZWOPl4QzrUfyn42TBCv3sz2iE ssYOeeR4fN2tbn5Jfrro6l+kGZ8R8iJjmIxJAIQyGEe0lj3YYks2iV0/431hBc7z07vml82JSck5 +eujF5JbXt0Dd4K3xZEXNzc2fWl8XOau48LjdQnWkg4hhTL/UssfZqq/PKKBvkzwzLOa9xWkD448 PyezhPXBEUY2ma3dePSSVr1Yunh+bIGw6oVq8NOXA+l6jm5JSsnZvGnDO6sS/4sIZR+jAAeaK3IX my0p6bHxy4MTLyUjuEOULwrA4wDnPf91Qarp+XlL6Ecf3v1a8pUUts/gPzgSI340hNly9QQ8lauf +uP0mKW8N6r4SZGhPte7L74grEHLfzbCNNW82GKO1X1qQWlxeqFMWmHQqhfHTpeuUs0g+jqdW+Om hb/qhb6rkVH2spQKN9Di2BBL+5O42Oydx0l/or6QfJjHuX7m08Fzz48TzDGIuocVJs3hPziycEXx If5rNXrjUZcYnVSOn6VakZAJ1+eu+kD+OA5f7Pxm+YMjM1fbBIGuYFyP/D+1v5TG7dDP/oxGKAfZ IUE6pe94/guRdEl+6ncRpTgxj5AXCcNkTAIglAEAAIDJDBEo2dNLXK2uk5fkxRAmHYG+mqJE5UNO YFIy4P7Z5da/lDMa7lya1HY4/kAoAwAAAJMNzt9efbCed+/yt1VkxU3Kb2eq4LpPfv4N/3gdgMcK CGUAAABgssG7VMXOMiemLpkbmVxczfD1AgBMPBDKAAAAAAAAMIBQBgAAAAAAgAGEMgAAAAAAAAwg lAEAAAAAAGAAoQwAAAAAAAADCGUwQUz0auHcoPurleaoxNTdp8S10+V10dsrMqLUnxHh2u0pL8kf 2AtCSifnvdJ2Q7sK+pgYQzyjPmUSrcQOwCMO5+88tjNjzpS5cTFzF2/Y38h/n08Fd7vJvm6+Kcpi il5r1+0dE1yn4/XsSvrJPRH5axTqz1KIcN7Otm7N95UAAA8SCGUwQUy0mLvbVJoYL36wXkIUyr5L tvQ5yrr39Fua/CeymYjpHHLbEv4qfElrDPSfLknMruwk/40hnjBPCTSUmP5R6aH/QigDME5wnVVr s3c13CI9Cec9tSs2Sfq6rwD/4eJM/rv0/ovlmWk7G4SP8t4PQ73Od9PtblXfZSCUfW5b+tS84+rP oAEAHiQQymCCmGgxZ/SF6qGWsoVRZS2i8ux2rrco39IMZlzSyUrMeDM5v+0JwCMJ13fpp7LcpAJn j/oDGfqG3FdflCz1HkTgvjOjqO6+Z3d7XHkrrC3qj6MZzSgDAB4uEMpgPOE8P29PijQnJiXn5K+P XiiIOc57xpYVPT8xOWZu8hYn/5H3gWZHTvz8xNQl5ugVtjP0aSZ3u9G2Zr55cbplQXzh0eCl9YP3 BnpcxXHTnomYm7ja3qIMdPIn6e/9vnNWus3Nj2j9rvzn1hzyaIYeRjrlc+V/lEGLCNPI7G0Fy56P 3tnQr8vOQIv97Rg5MfLp4hNbS5qYZm+LIzfGvHhZYtT8rH2a71epL/1MRv67byxJtZheWFHuVma2 Ai32VZbpTz03b8kqcg2anjfzNmYmJsVMm7nc3jpIjjAuQACAgCCRE1Nzy366FPQZOe7qoazFxfWq 2VuurTxpudiTkF9uW3ySvUNpW7SLePaNd/6Vkcw3c8eRveuTkxLMpmxbM38f67/iLEw0zU1ITsop WGcRFTDpnRL/ffoeN8xdr9meNkOzVy+UNb1QcKsX4NorMjIE5U3nCP5ro7N3SJD1poKa/uGAt3Hf CnPUkqWx5ritzk4+L0pXQzZu+faIdW1S0pK58zJtTTQWRmcy8tWfFGhFPBVnbRkUq181c/H4EIaf z6SbpnkAvkkQymAcuenKS3yrqpOMAP7OwxtMC/jm1HOyICHTfpFKx75ftszOKr98t6fq7SkFNdS0 ud621uv+4aE+13uRaw/zTnv9LWWZCWVNqo54yFvz/pwM/uknd/NkYUKq3T1kOKPMzwPFZzrayQn3 GnZGZjhImlSw0qlWqwyhPHV+/o/8gCGfOzw82GRdlGlt7tdMRImnc3frt0cKaR72XWtt996synm+ 8CT1kw5429zX1EJWfek/p+0+e5sbpt4jkaWN6mFcO6NsSt7dQG4w6Mg9u7QpYFyAAACCv7v+M7ZE pnADjR/HL1KUEMVfX/xcVkUX7Q4oSucgQLuIp5P20PteckP+zLwNVR1+2njTppc0BNTdmr+jKnee oICJlo2jnmDMvcZCOajVi0cMk3v1sgy+u/N3OlbPmJbAa31pLtz7S+GsFeWXiQAO9NVsjUyxtxMV rXQ1Pa68OTNyD5POjUb7UslpdmdicPUnBFoRf/rDrA3O64J9PDyhrHj6jQ+Bhp3T1hzykBoNx89n fIXy/eflQfgmQSiD8YMMFS9scvUL3YjUnMjG54UZDgLp0FPjba33mq0JCzaWNxCJLNDtXJ9QWCM6 /3Ed9uQ42yUhGgrpyuNk3wk6ZUL3Ggtlrt+1acp6Z694Ra0rMzOdarUqRqIeoqSuodeZ+4KgdwmD HfYsPnK9UNakmUJVdfwG+28etUQWMLq0Atv1QjzFuAABAARDoTzQaE1O2V7Xo2k3YQhlsZ0qR8ob SSeQIL1VLG8kMnoV3zMw9+obvrxF3+r5/RQ6HWCm3d31qpy3v3C8n1x2fmjovDX6rUOeQakn5CEb ozLoBLkSg77vYnYmBld/QqAV8f+iLQtnba+/S23k4Qll1th3PwQZeQhUljAOjHdeJgYIZTB+aDpQ qTlpNsqdfsDbfGh7lmV+RvGh5l6OHjw9Zk1BcVGRGP7t7FDebdO2TDFCY6HMK9rnN7m8Lba4VK07 YKh0KntHGKL+bMnZKqWzqPhDZ7tmels8XZtmHs57/lDxiijz68WV5zXvzhtdWsFQKJMtBgUIAJBg ul5wPfXFiQuLa/uCbi/DcL0Q2ylDKKs7AWkjd/VQ9tsVneQw1l5Gw2fFpnQUEuTmf2Zxfc/x/Niy llvO3MU291VH5iIicIMilCJRYmD2XfrOxPDqjzBD/huXrp65dMcXsrvkS3Lbwarc6OWOy8QElA7Z yO2NG2j5aq1l4ZK0xfPNa2xnGxwZKdLbonebSlPocwBSniO6wdCLSr49s2ZRn707Gk8/hl+N+hS9 OxDn99RaBddBU/RaR/NAoKV8ZazpjxHmxPXlLV7ZWjhvY3lO9AxLouIwKUIsQeuEQz1/gjLl7gxO Nm1oIbwWQ+TF9GKm3T3I6fw2FQtnOHnqU0s3jhoIZTB+hDujLM/vBrxn9yTPJjfovfVFiTlV18XN wYxhRplwvWpNYpFjT2ak7inh/cwo++qKp62r0rwARNAPNroZZQnO27A7aXFxverdeaNLKxgK5T7D AgQAaNG8zOfrrFz3ctKnzQNqiSNg/DKfqp2GOaNMbuAXC097xnFGmdDtXJ/1H/v2lNLGANHiK9/5 4ssNMWXnh5RnazxhzSgzOxPjqz+iBPprd9mnvGKNmLk3uayjL6hXD0KoiLqBy/szp+YRs5E6ZKZn oAwZhuKE6XnO2956ra/dnhVN64Wvi1ezytvv0fIc0Q2GXlT07Rn2Npam824wqipj+NWoTiEjXbA7 0DDnaahuItciia1a+xw/NDNMl47IgsPksP96a1uvqmEQSwhywrmny1Q/K9l6J0zSklR56TueP3tD FX2biBtstiZQJyhVXrgLtrjE0iavzm9TTjMzfn1q6aVGC4QyGD+462QQCMNH2TfYVl/Lv1PC9To3 UBkdoGswpey7SL0DyW3lwb2ua6qWOQYfZYK/07Fy+rSXTfq31JnplM/tqcp5jpfRiuOgapAY7m0o SU21tdAbU+524377z7Rh6wcbnY/y4OWTtVdp0jiPMzdWo6HlSyvplxu/gqFQ5hexGrEAAQAjwQ00 78ucmVPRrn7uxPm73a30DSHj5eFU7ZShNgI9znytF3Jdb83WOPHdA/1ecoq+4ctbjKUq7e6mPDeP V970DYeI58jBvN/mSD7KYgysvovRmRhf/RHF07wu2hpBhDIJ0YeP8GtvjohcEURExseXNd0VO2Tm PI7wi9DfUpYRlWtv8IijEF3Un870U92WkGxvJ0ca1YXGHqjU00wSMe+CqEgVT2HYJDmJ3CJ+vrN4 9/4aR4GwV3+YZnorCIYl6DLFSraXOWUm54XchW58UVDABPFJjiov0nWphtb4bTLTLMc/PnYLoQzG EaI7j26JnRVq1YuAt/ngprgFMUtTVI9IvC2OvLi5selL4+Mydx0XXs2WIZI0+NmWqk+R0bYE2j7/ MFOas1HDSqd8Lnft+CbLFM2r6KrGRhhorshdbLakpMfGLy85xidmyFu3I8oUFZN9oL1Tjkdc9SI9 cWFc/o+dPee+zk+iZ+kfz8mXVtKv6WhEvLXFC+ZYLG/tb7/AavyGBQgAYNN56B9TnppmSU9LX0ZD drGLCKabrrzIF4U3hJQPjpjFJXoUVO2UKUqCV704drp0lbKqBmNNDH3Dl7eEGPJpdyeud8HLtWfk h2b6J9qafkMnzuhGXWcyPoJjknH78rbXJKH8WnXtbXEzG6VquM5vV858q8LxHi+UtaODvnC43pbK HSsWLMwsOtTiDUhzrt52+8pUYS1to7rQ2oO4UT4syFqElNxSNjJscrCz8u2o9Qfd3lvuyk3z/ziC UDaqYpYlBGeKlewOdZzyAZq8PG1Zs012+Cna4+xgCGVqzxq/TWaa5fjHx24hlAEAAIAJhYzc2dNL XK2uk5cYDh7gocAFuk78kpOy15Ry6KMTverJCway9iL0t5SlTZ829enQM8oS3O3G3RmRRXV36WTn 8hXf1nybtVx8eUYRcCGE8njMKJPbwjhROMp79YeNckaZn8FVZ4qV7BAzypyvvti0pko7raWOR3Vd iuy3OchKM2aUAQAAgMkO52+vPljPL6Phb6vIist33RR2gEcQrfjrObrhhT/9KbSP8t22k7/xzw8D vc53BFFLxLTlVUt0tPRJrFBCWe3su9jWqnE7HMFHWUwnQyjfOlmQsLLyCkkQ9Xt8ZgShHMJHmSE9 tZliJjuUj/LdUztfzbJdpC8Fct6zBz494dG4cIjX1flt3pOOGclHGUIZAAAAmIzILl6pS+ZGJhdX axyuwCOGWrQR7l60ZfIzyqSeR171gutt+frdeOrEovJ7od/Denah8PYbIZRQ1i0fofL049grRYjp ZChg3iaTUnI2b9rwzqrE/xL29tQXJcyIjl+5v6VTOlda9SJ5iTlx01HBPVJgBOmpyRQz2XonTII6 L9xAi2NDLPXJjIvN3nmcHKAuc+G6vTq/TeWYEVa9gFAGAAAAAHhUUH1JMRRqpTi50WTq0Ul2eEAo AwAAAAA8CDhP5Yq5Ya5T9sgoTm2mIJQBAAAAAMDoCHiq3oszJ757PMzlOx8JxanPFIQyAAAAAAAA TwAQygAAAAAAADCAUAaPHPJjnYD3Snv3GF8k51/+jVsQs9hsipVeRpa5j9djAQAAAPDYAKEMHjkk oTzUalsUNcalSQebrIvSdjXc4oYDfXVl7//QqZHbEMoAAAAAgFAGjyD3/6IAd69hZ2SGQ6uOVUAo AwAAAABCGYwrHRVpkW/mbcxMTIoxmVfYznipEqUbs7cVLHs+emdDP2tJ8IC3yb7WPCcmVV4yXb+I OhG312u2p82Ym5CclFOwzsILZXktcdV1p81cbm8dJMf7rzgLE02a42WI1F6prPeuhwjlZzLy331j SarF9MKKcjf9VhAA4JFHdQ/M9dVuj0rlHysZ4a8vinhu3pK09GU0ZBe7POIOEbH7skTPmZ9jb+I/ rBAuJDF/nB6zVIg5PbPIpf1+rwau0/F6dsXvj9diAgA8EkAog3GECFZT8u4Gqo8HTpfGZVqb+/mN U+fn/8h/r+imKy/xrSp+Jpc6P/AH3K0rni18hJPzX3O3kZGm73j+7A1VHjIccIPN1oRF1pbBQJ/r vci1hz3kTH9HVe48nVAWr0s/Kz+7tCkwxDpexltfFJ247aMtSXFLEkfwUf5z2u6zt7lh3yVbemRp 42hGPwDAZEUWylxPfXFSfOnpkF99oEJZ+AAbE/rd3VV89zXQbl8VXXJqFHfVKtUeiqFe57vpduXD aQCABwaEMhhHZOVKIBIzM952gVNv7HXmvlB40kd1MlHKHfaseFur17VJ+AK+BBkSNr5YUCNKV66t PGm5zd3lykvIFydcZNcLtVCWLiGOPT2s42WIUJ731IId9X1EAPuuOtZMzzveJ+7iUQaw+3fzAABM GsSmHeip2bYwZd/FQaEv0hPwun+yrn893+kxFMqcr754htx9kf7NVFwv9m9hMAqhTDq0FdYWL7oj AB48EMpgHFELZb2c5QeGP1tythYVFwmh+EOn+2pw109PfNqyZpt4DAl7nB2thjHrhTIzJTJEo2cn 29vEAY2c8lLJafWksTKAQSgDMOnx3fCcafLcCOObwELT9hzbNOt120Xm5K8gkVOXrC/7yd1Hn0gZ CWXhbv+C2JNwF2xxWeUd1PNLhFxOdOKKNcdt+faIdW1S0pK58zJtTTStSj8jw6/GEzvLnJiUnJO/ Pnqh2Ind+31n4r9P30N3BMBDAEIZjCNqecqaUfbVFU9bV9Wj1qRcf/CMMp2kMa2p0rrrMWeIDYSy 8YwyveiLea5+4UeHPZl6a/A/BCCUAXhUuHWyOibSGvGK1ZT9y2+3xI0jQZr2/++N/NzYZFuLvlFz 3XWfqiSyABXKL0XFxcanJ5pnJJXUUJcwGW99kWWZo0P8pekAecjlRCcu0iPNmZF7uNPPUfcw4c5c L5S5687cxbxzGlHMhzeYFgixDbWUxdH+Ct0RAA8BCGUwjpBxQu2j/LrN7dMOHr0NJampthY65cLd btxv/5mMOnofZer2lyXM93Deswc+PeHhAj3OfEMf5SChzDxeBbnoq7mHqGvyQLt9RWRRnWZyCUIZ gEeDQP+RTZ8QlcyHT9Y5hbvfESFN+w//X5Mlen6Wo123BDtTKHOemr2fuvhXLEhfkT29oEZ1iTCE stiTqI6UN5J/gl7m63flv7DJ1S9cXI7Nd8m2KtfZje4IgIcChDIYR0jPzlz1QjV4DDRX5C42W1LS Y+OXlxzjhx9p1Yuli+fHFvDv1XEDLY4NsQtilqbExWbvPM4vjsFYxUKOWXUJeRAyWvWCIC6skWhh vauuDG8YmQCYzHD3aj+wiUJ5pm3br/fE7SNAmvZ/rau62eXKT1rhcLPadbDrhRr69EnjphWG64Wx UBb3Smi2SN0ad/VQ9tsVnWQruiMAHgIQymAc0WriyQIZXbKnlzRotTAA4LHA3+n+KNduWmDPsbq7 tMvX6JGUKNdj4KZMUF7mEzfw6Ny0Qr3MN1qhzJxRJtEutl2i2yCUAXgIQCiDcWTyCGXO3159sL6H H1zaKrLixvgBPwDA44SiTQM9rs1zkg0WvhAI9DjfXVxY7fFzw9ythp2p0aVn7pHupdvd2s2LcuPl 4UYrlJUFNGUf5b7+mq1x4gqVEMoAPAQglME4MpmEsvjyeOqSuZHJxdW8jwcA4MlGrU05jys/Tnyn wgB/Z03pihnPz0u0LIjL3c+7aRE5G/miuKak/MGRWbOy9jWO6MQVno+y0nHJq154mkpXEblMT4RQ BuBhAKEMAAAATDaEeYdrl1wnLw3gPh+AhwaEMgAAADDZmJyvfADwxAGhDAAAAEw2IJQBmBRAKAMA AAAAAMAAQhkAAAAAAAAGEMoAAAAAAAAwgFAGAAAAAACAAYQyAAAAAAAADCCUwTjSUZH2cnxZ06D4 U7XG/kOAG3R/tdIclZi6+5T8UVnOe6XtxqRdrp/zdrYJn/sKE8aXvQAAAAAwbkAog3GECOW//OmF PGeP8HmqhyuU7zaVJsbbLqhX6h9y2xL++q6rb0j8HZJAw85paw55tF/bmih8blv6VPFzXwb0ny5J zK7spP9CKAMAAAATCYQyGEeIUDZZLOY5RXV36c+HK5TH4+r++uLnsiq6JpUUZX0LFwAAAAATAIQy CMmQ/8alq2cu3fGFnIilK+QXfe/YMHVlReegRtJxtxtta+abF6dbFsQXHu30q+d5/V2OrAhR70lr 7A80O3Li5yemLjFHr7Cd8ZLDjWIY5rxnbFnR8xOTY+Ymb3Fe8Q8HelzFcdOeiZibuNreokwIi8qS XvHZN975V0ZymsX0YqbdPUhjC44k0FK+Mtb0xwhz4vryFi895R+F29OmTy9pCDASo45z1qysfY1e elldwoYZWRORy4GdPJ6BFvvbMXK+SHaeych/940lqRbTCyvK3fT2hHFFAIAAaTJ/TLE294s/J+Od 8H0T2sFM3eVODia3Uxx4woFQBsYE+mt32ae8Yo2YuTe5rKPP2AlBkLnd7fbsl3OP9nCyUB7y1rw/ J2N/OxGU3M2ThQmpdrdKdKt7bSGG3p6qt6cU1FB3Xa63rfW6f3ioz/Ve5NrDHqoY+1vKMhMUT2hC z8mChEz7RRID1/fLltlZ5ZfJqawZZZVQfjppD9Wy3AVbXGJpE5GYrEiUcZSe8pR5s7OTxMzMjirO YW9jaTqfwpuuvMS3qjppqgebrIsyrc19uqzJyOXATJ6Mdkb5z2m7z97mhn2XbOmRpY0BxhUlTQAA IE3mD396kfZO/M+HJ5QDDSWmf1R6xF/3j+KRFYaDmdzVjA/3n5dRO8UB8ACBUAbGeJrXRVsjiFAm IfrwEePOUJoPvltXPCvN2nxdknQ9rry4XGe3cNBQS9nCONsleZJU02uLMQw2WxMWbCxvkHVkt3N9 QmFNr/CD67Anq2Pod+U/v9HZK3SyAy1lqbxrcgihHHRFdiRaoSydwsyOZuzh3LZ4svG2M/eFwpPi q4SDHfaseFvrveCsycgxsJKnoBXKouuFdEqv/ooaL20AnmhIk/kvc0xUPLkbpz8fnlD21xdFpDm6 xF/3D6u7GxFNZ3X/jHdeAJhcQCgDY25f3vaaJJRfq669LW5mI6u6wc7Kt2Zlf+bYKvTdWrWnyDsB pi4MeJsPbc+yzM8oPtTcy9Ht02PWFBQXFYnh384OefZBE6Ec2yiFMjMStlBmZkd9gLSxw7Hsz5ac rVKai4o/dLYPBWdNRo5h5GtRDIUy2cK4IgCPNb4bnjNNnhsD4k8DaJMp/L4q7+VMB33sojTwgLdx 3wpz1JKlsea4rfyDIxUad6lTzY6V8+jTG0qgqXReBomKtNPIN/M2ZiYmUZenb7/7LCc1OdE8I2Nf ywBHLyq5SM2YudrWeDvQYl9lmf7Uc/OWrKKeYSx3KcMI/dfry1bzrl9z5ud81TJwN9gjS+gWuNtN 9nXzTZa0YHc12l1onbsGO/WZ6gxONj1f53UWOi+q7EseYt4WR26MefGyxKj5gpeaKs2GXm1BrmgA PAgglIExXKDrxC85KXtNKYc+OtGrdLVMVKpusMkaZzJNm8pLulHPKPPbCQHv2T3Js7fX3+2tL0rM qboubg5i0s4oD9QVT1tXJa4BEoScNbkg5BgMCoRgKJR9BlcE4HHk1snqmEh6J2/K/uW3W+LGkRCa zMDF8ozoDc7rSgP3/lI4a0X5ZSK1A301WyNT7Kr7y0CQu9Rguz3l1bIWegDpKNJT7G7+Tt6UvLvB y3H9rk3PmvKqiNSmflNxOxv66UVFFyluoPHj+EXWlkFyZXkWluk5Zhghd/1U9Xn+zY1rVTnRfF+k 7xa4u/XbIwUPsWHftdb2oNchgpy7OH2mGMkOMJ3oVHlhuX4p8UgeYj1VOc8LD74C3jb3NRKbmOZQ Xm0MVzQAJhwIZTCOqFVdoMeZ9+If/sL33cY+ynQcishzke7f33l4g2kBiWGwrb6Wn9Thep0bqH4N 3G3YFZ2y7yKdSwh4Gw/udV1Tuv0x+SjrlGhoH2XplLB8lBfbWoeGextKUlNtLdSdmrvduN/+s2dQ lzW5JORLMJMnYyiUGVfkowHg8STQf2TTJ+Ijr1c+WecM4ZIvNhkqIufEWVvu1vENfJCI0SnrnaJr 19B5a1SGzU0bKQ8X7AnGucuTX6cHEN22KLu8/Z66napUo7RRaafkXCL1Msm5ymHs+3zDCEkf6K62 lewo3X+kYnM03xvouwXN/bwWVg+jzxQj2V3MKQ8lhUzXL303RTV0/Ab7bx7ShQqw0syag1CKBYAH BoQyGEe0vdhgiy3ZJPbdjAdqCpznp3fNL5sTk5Jz8tdHLyyu7/U2H9wUtyBmaYrqWaS3xZEXNzc2 fWl8XOau49pno6xnl6MVysxIeuqLEmZEx6/c39KpnMLMDo1Tv+rF8EBzRe5isyUlPTZ+ecmxTn+A lTUBOVXGA8OQt25HlCkqJvtAe6duBCL/Bl9RU9QAPF5w92o/sIlCeaZt269EtBohizau41C2ZaXD vo0K5QFViyPoG12Qu5Q45xpot6em2NtpC1NOCSGUpY3KYZq9ckM2ipDr/Hblgo1fu2953ZX5ZuGp nV4oKzHoYPYwukwxkt2kiVM6QJMXveuXEo9yXc57/lDxiijz68WV/NQ4M83iRuP+EIAJB0IZgHFB 3ZsDAB4U/k73R7l20wJ7jtXdpbl/ZqCINjpPHP/SdNOfQ84oyyjuUkMtZZYsx5lv37KUneenghUB F0Ioj8OM8m1P5eopYnyyPr7vGWV+BleTKUayQ80oM12/lHiCO0nO27A7aTF9sZKVZswog0kChDIA 4wKEMgCTHo34u+7MnfWnP4T0UeYY7lJETEdHxbyabm0R3iA00LW8UFY7+ybYqKuWcthIPsojRdjX X7PFlF15nSMneJy55hGEcggfZYb0DMoUI9lsJzpVClmuX0qZS9cdvHyy9irdQNMfS5WxeMyIXm0Q yuAhAqEMwLgAoQzApEcRbQRu8OK+FDqjTH4brHrBdJfyni6x/ClKePuNYKBreaGsXz7CW1u8YI7F 8tb+9nsjrHoxcoT+K87CjCVrNm3Kzf2fxTN5fczyyJJWvUhPXBiX/6PKC2sk6anNFDPZTCc6VV4Y rl96oew9/3V+Ej1GjkQ+ZgSvNghl8BCBUAYAAABGhb/TsSpa9LsIhUadT2a0mXpkkg3AxAKhDAAA AIwG7uqhrLRw1yl7VBRnUKYglAHggVAGAAAAwsbzQ35sVNymn/gv6ofBI6E49ZmCUAaAB0IZAAAA AAAABhDKAAAAAAAAMIBQBo8c8kvQAe+V9m7lVe7R4L9yvOT1Gc/PS7QsiMvd3yR8HESAu1yROeVP 4mvmMnjbGgAAAHjigFAGjxySUB5qtS2KynfdFDePAr+nKi9l5ym6sCh3q2Fn8rzSRkkpB3pchZZp U5+GUAYAAACeeCCUwSOHelnNcUC1TOnw8MDp0uTcCsd7yhYRCGUAAADgiQNCGYwjRE1Gvpm3MTMx KcZkXmE7w38Lim7M3law7PnonQ39rKX1A94m+1rznJhUeal/1uL/3PWa7Wkz5iYkJ+UUrLPwQlkW r6rrTpu53N5KvwtF1+RPNGmOZ+L3VOaYiur4awy021cvLmu6q5bOIqxLAAAAAOCxBkIZjCNETZqS dzdQfTxwujQu09rcz2+cOl/8LtRNV17iW1WdVD8PNlkX8QfcrSueLXw8lvNfc7d5A8N9x/Nnb6jy EGXLDTZbExZZWwYDfa73ItcepksX+TuqcufphLJ4Xc5ti59d2hQYYh3PQknnMNdzdMOr2072BTRz zCL6S4g7AAAAAPC4AqEMxhFZuRJ8l2yZ8bYLnHpjrzP3hcKTPqqTiVLusGfF21q9rk1T1jt7+U08 Q73OjS8W1IjfkOXaypOW29xdrryEfFcPv0l2vVALZekS4tqfPazj9Xiby16PLq7toynqrS9KF0T8 CEI56BL8ZgAAAAA8vkAog3FELZT1cpaXmH+25GwtKi4SQvGHTvfVYBVLT3zasmabeAwJe5wdrYYx 61UsMyVBBPrqdiyM2lHfx08Oeyqz/xhhTkxblpaebpn+1HPzkotEoc2jvwS/GQAAAACPLxDKYBxR y1PWjLKvrnjauqoetdcC1x88o8z56otNa6pUIpXAnCGWY9ar2JAzypy/s3Lt1Axrs5BaDZhRBgAA AAABQhmMI0RNqn2UX7e5fVr13NtQkppqa6FvwnG3G/fbf/b4GT7Kd0/tfDXLdvEuPcp79sCnJzxc oMeZb+ijHKRimcerGGiyZUSvcLiZchdCGQAAAAAECGUwjhA1yVz1QhbKRKE2V+QuNltS0mPjl5cc 49/wk1a9WLp4fmwBv8YFN9Di2BC7IGZpSlxs9s7j/OIYjFUsDIQy83iZgKdy9VN/nB6zNH1ZGg2Z Gi8LCGUAAAAAUCCUwTii1cSTBX+XI3t6SQOWqQAAAADAqIBQBuPI5BHKnL+9+mB9D53R9rdVZMWN 6QN+AAAAAHiigVAG48hkEsqdR7fEzjInpi6ZG5lcXM37eAAAAAAAjAIIZQAAAAAAABhAKAMAAAAA AMAAQhkAAAAAAAAGEMoAAAAAAAAwgFAGAAAAAACAAYQyAAAAAAAADCCUAQAAAAAAYAChDMCjzVDn j+8kvZ6ftzqn7PRk+ygiAAAA8EgDoQweAJy/89jOjHkzLHHmafEb9jd66dc/OirS/mqypCxLS6ch Y4erx9flyHpqmiWd/Ew0m2K3Ojt9wvkh4Tody//8l2WODvK/v74o4rl5S4Ro07KLXR7hmDDwkwRE FNX7+R8kztezKz1GHyoJeK+0dxt8yoRrr1iee8jjHx5osmW8LMc8PDzQYs8VM56WEjPtmeklvw90 nSj9h1lbROHh77t9J0DL8x8l8gUAAAAAcP9AKIMJh+ur3f7q8t1nb1Pt5798KGfxBud1jvEZP7VO DfTVbJ2TbG8PRy9yHld+vGnaVEUopzm6hF2jQ52AoV7nu+l2t9H1h1pti6KMPo7d69yw1N4+eMWZ nzR/7lSVUFZBxHRGbGHNuaq1qZuOXiEHcH2/bJmVYXOHe5MgwHkqV62t6hF/AQAAAGAcgFAGE829 dvsbc4rq7oo/ZYyF8vCwr6bw+beregLCLzoLa121vOjrBk+QguQGGv+TsvIzx1bLuArlHlfeCmvL AL99bHD9rs1xZed9bse/Pq5tUWdNBRG4K17acrJ/yH/79h1RlXvri8S8hMvQlaqN+eXu+0ktAAAA AIKBUAYhGfLfuHT1zKU7viFxw8hw3jO2rOj5ickxc5O3OOn86PDw9ao1cYU1vfx+NWEI5edWH/LI Qpng8zR8XZyZqJHL/ovlmW9Ym6/L4tJQKNNLPPvGO//KSE6zLIgvdBzZuz45KcFsyrY1k5SoEnDv 952J/z59z/h4OQvkn8g38zZmJibFTJu53N46SK/lPV2yZmeDkEFt1hT8nsqc6QU1/eJPAaLRE/Jd 6tlh42QMXLKvW+to06twAAAAANwPEMrAmEB/7S77lFesETP3Jpd19Kllq56brrzEt6o66cToYJN1 Uaa1uX840Fg6e0VFl17Fjdn1QpbLh90D/h7npujCX/o4ZRaWCuWXouJi49MTzTOSSmo86kvTSzyd tKfRGxjud+U/M29DVYd/2HfJlja9pCGgSsBQS1lcnqs/xPFqoWxK3t3g5YY5ty1+dmkTKaeh89bY za5+IQPqrKngrh7Kii+suSX+pPg8df9ZnvyfxgF1zo2Sca+pNPLPlpytRcU7qi4Z1w8AAAAARgOE MjDG07wu2hpBhDIJ0YePGL4Y1+vMfaHwpE9QeIMd9qx42wXOX1/8XBYVyoGW8lUZ/OtrGavtLbzK NHyZz5JX0aKW0TIqoXyztvjVjVVUCitCmfPU7P3U1UnfsRtot2dr52tVglVOmLJR/odo0FW5zu5Q x6uFsiT6uxzLnqP7iGJOXO+UJtJV8aiQ/C4kTdzjKs5IWzJ3wYp9QS/zGScDAAAAABMChDIw5vbl ba9JQvm16trb4mYmRCMKU5tFQij+0Nk+xLWVJ6WpnH31KlNG2sVdrsiM5l/4CyLI9SLgqVz9lLjA BV07ImJuetAaF1yHPfmlktPKPKux4pQTcPVQ9tsVnVoxOjqh7PdU5r7ukCfEVfEoMP0uSKKvO3OT tO8IGicDAAAAABMChDIwhgt0nfglJ2WvKeXQRyd6DZZCI/jqiqetU71+J9DfVJqabGuR9JxeZcrI u7jBZmvCImvLoPpyI73MJ8B+AY4KZcERQsRYcUr/9DpzF9su0YsbH28glLud61epVq5QxSPD8LsQ 0B9snAwAAAAATAgQymAc6W0oSU21tdBX2bjbjfvtP/P+wZzn8Fuzsj5p5JeH43rqi+O0Dr4yKuVH Z1WjlzsuGwpzNbJQDvQ4311cWO0hmp671bAzNbr0zD3xGIKx4hT+qeut2RpX2sira+PjRxbKvTWF sbtZAp3zd7tbu6mApn4X/7+Nzl7+FUmS300bxCKiK+glYkYZAAAAeOhAKINxZaC5Inex2ZKSHhu/ vOQY7yhMCHibDxYmzeG/prFwRfGhFi+RkIZCmZ9Ujp+1vf5umFJZNaPs76wpXTHj+XmJlgVxufub 6LVkjBWn8M+x06Wriuv7wjh+RKFc27A7vqhONfUtn3LTlRf5Yt7xPup3seYvihNzwOv+oYR+kyUx xjQvUyk6AeNkAAAAAGBCgFAGIIg7l1wnL2kWnRgt3ID75M/uO+IvAAAAADyaQCgDAAAAAADAAEIZ AAAAAAAABhDKAAAAAAAAMIBQBgAAAAAAgAGEMgAAAAAAAAwglAEAAAAAAGAAoQwAAAAAAAADCGUA AAAAAAAYQCgDAAAAAADAAEIZAAAAAAAABhDKYBzpqEizFNd76b9cT31xUvzOU17jT0H764ufizAn pi1LSychs8jVI+6Q4G432dfNN0VZTNFr7Y0hYtNAEvNXkyVFiHlZxg5XT0Dco4drr1iee8jjVtIP AAAAgCceCGUwjshCOdBXt2Nh3MeNA6GELRXKWRVdfvFnMNzdhl3Rmfvb/dyw/2J5ZtrOhl5xT2hU qj0kvc4NS+3t3GhOAQAAAMDjDoQyGEdEocn1/LwlKst28a64WQfnvfhT2YbkPGdPCKHcV1+UnOvs 5v8f6nW+M6Oozsf/CIPwVS/X79ocV3Z+aFTaGgAAAACPOxDKICRD/huXrp65dMc3JG4YEV5o1rld +XEptpZBcaMGQSIvSdxg/eki9aMwFspcW3nScptb1Mac2xafZO9QJqn9XY6sZ994518ZyWmWBfGF jiN71ycnJZhN2bZmInaZqtfX6dwaN828JCl17ea1lueK6umVvadL1uxsGOkUAAAAADyhQCgDYwL9 tbvsU16xRszcm1zW0Teymy+FCE3z/+StnpW0z+3XOV1wnvpPVRJZgArlly2xsXFLF5tNadtrrmtO C5LRXY5lorQVoEL56aQ9jd7AcL8r/5l5G6o6/MO+S7a06SUNAZbq5XqObpi9ocpDovB1VuXNEGIb Om+N3ezqJ1eGUAYAAACAAoQyMMbTvC7aGkGEMgnRh494xM1siND8y5+mLYwxr61oHxC3yTCFMnf9 5KdfuDp95D//5f2ZL205SQWrRBhCOULYoBwpbySJCXqZz9/v2vRinqtfOFuKjXPbEtc7ed9nCGUA AAAAKEAoA2NuX972miSUX6uuvS1uZkOEZuTaqis9roKoLAd9A09HsOuFGupoEb+zQdSxlDBcLwyF cpDqVR1PEIWy31OZ+7qjnY8VQhkAAAAAChDKwBgu0HXil5yUvaaUQx+d6GVpXxWS0OQ8Bm7KBOVl PnEDD5XFSaVN6lcAjV/mG61Q5lgzyt3O9askLQ6hDAAAAAAFCGUwjihCk+s5tmnW6wYLXwhwPUc3 Jmw77iE6NeBt+DD+1d2N94gW93W3urupKDdeHm60QpkI7+P5QT7KvTWFsbubRNdrCGUAAAAAKEAo g3FELTQDPa7Nc4Q37YzwddV8nG2aal5sMce+s7/pNp2yJnL2hch81026X/ngiHmF7YzWWyOkUNZ/ cCR41Yvaht3xyiw1hDIAAAAAFCCUwZMKdb3Yerzl5M/uO+IWAAAAAAAVEMrgSSV4DQ0AAAAAAA0Q yuBJBUIZAAAAAIZAKAMAAAAAAMAAQhkAAAAAAAAGEMoAAAAAAAAwgFAGAAAAAACAAYQyAAAAAAAA DCCUAQAAAAAAYAChDAAAAAAAAAMIZQAAAAAAABhAKAMAAAAAAMAAQhkAAAAAAAAGEMoAAAAAAAAw gFAGAAAAAACAAYQyAAAAAAAADCCUAQAAAAAAYAChDAAAAAAAAAMIZQAAAAAAABhAKAMAAAAAAMAA QhkAAAAAAAAGEMoAAAAAAAAwgFAGAAAAAACAAYQyAAAAAAAADCCUAQAAAAAAYAChDAAAAAAAAAMI ZQAAAAAAABhAKAMAAAAAAMAAQhkAAAAAAAAGEMrAkC7Hsj9Oj1mavixtsXla4hbnFb+4Y5hz2+L/ MDPf1SP+FuAu2OKeeTbP1S/99nce25kxb4YlMcY0L/ODH9zegLhHgMT/XFG9HCkAAAAAwKQBQhkY ohKyXN8vW2a9Ud5+j9/h73Ssipw7Z0ZRnY//LcB1OjJnzzObiut9HP/76qEsywbndfqDu930nevS IL9dBkIZAAAAAJMVCGVgiEbI9p4siMupus7/f71qTXrpsa9y5pY2KXPEgZ6q9ebSqu/Irqa7dIO/ vvi5rIqukYUwhDIAAAAAJisQysCQYKFsya7s5P915j6/yeW9WJ6cbm0Z4PcSup3r4/Jd19rtWdFl 54folpuuvKiYwp+6/NqJZBk5/r7j+S9E5rtuitsBAAAAAB42EMrAEJVQVrlecP2uTVPWO3uHB1rK UuNtF0QV3O/Kf36js3doqKVsYZztkuB84T1fkbvw6blry3666NWrZTl+ztte39AW5MEMAAAAAPDw gFAGhhAhq7zMF7/B0czPHvfVF8VnOtq5Yc5XXzw9w9FJFbDqf19d8UsrKjpljwqfp8GxJWle3JZj niCtrJmxBgAAAACYREAoA0NEITvY6Vj5cu7RHkHm3vt956xk0eOi35X/3JpDHiJ1vadL4heKHhc9 rrzoFZVXNap44HRp7OKdDd0t9txlaUR5Z6y2twQglAEAAAAwWYFQBobIQnawyboo09pMl32jnhXP zVtCxS4JKTHTZuU6u4eHzlujppoT0/iN6emW6c9S3ww13voiyzJHh/hLAEIZAAAAAJMVCGVgiCJk Az3OvJczHZ2c75ItfU7J78IqccPDfk/lmog8l9dti5+18/Q9cRKZ81SueG7T8a6Tuzbua+Q9jznv qV1xr9vc6tXk1PH7ulvd3SO98wcAAAAA8MCBUAaGqGd8B5uscfHFdacrMmILa27xmyhcuz3lpQLH vuyXC2qk74yQre7y5Ljiuo6WrwuTp001JyaYpy3e9PX54Pf55Pix6gUAAAAAJhkQygAAAAAAADCA UAYAAAAAAIABhDIAAAAAAAAMIJQBAAAAAABgAKEMAAAAAAAAAwhlAAAAAAAAGEAoAwAAAAAAwABC GQAAAAAAAAYQysAYX+fxXZkzZ8WkWmbMfL2k6kLwF0PCoqMizVJc7xV/GYAvWgMAAABg0gChDIyg X6KemufsEb5B3fT9T+5BYcfogFAGAAAAwKMHhDIwwl9fFJHm6BJ/jRkIZQAAAAA8ekAoA0P6juf/ NWHL8asa7crdbrStmW9enG5ZEF94tNNPvTE47xlbVvT8xOSYuclbnFe0WpcI5cg38zZmJibFmMwr bGd4/42At3HfCnPUkqWx5ritzk4fPVAWysGXGOx0rIouOz9Ejhk6b42alevspsf3OnOnbTnZPxZ3 EAAAAAAAYyCUgTEBb7Njg3mKec2en9x9vCAd6nO9F7n2sIf+6G8py0woaxocvunKS3yrqpNuG2yy Lsq0NvfTY0WIUDYl726g+njgdGnc6za3j0rw2RuqPFQUDzZbExZZWwY5SSgPeWven5Oxv51IcO7m ycKEVLvb31IWneEgF+A6Ha+bTFFFdb5hzldfPGO9s1e8CgAAAADAeAKhDMLAf73BsSXZlLjFdY0b 7nauTyisEdUp12FPjrNduu3MfaHwpE+Y2R3ssGfF2y4IP3jUrhcDLWWp8baW286NLxbU8NPIJJa2 8qTlVD2LQrnHlRcnzhkTYd5StpBcwvf7zrl5zl5/T1Xe659/WZRkbRkiUS1fUXlVdSEAAAAAgHED QhmECTfQ+HHc7J2n77VXpE2PWVNQXFQkhn87O644lv3ZkrNV2lJU/KGznbpJiKiFsr/LkRVRVNPh yHrasmabHEnRHmeHLJS1Ps2Kek4trm9z5a2wtnQ416+yuVsrMt6g8hoAAAAAYAKAUAZh468vfi6r oqunvigxp+q6uFHAV1c8bV0VvzgGC7Xw9V2yZcbbWgfqi01rqnr4TQoGM8rcUK8zP+bjfR8mf9wU 8Hsq33nri09zLWUtKj0OAAAAADCOQCgDAwJ9df9559PT4rt3DR/GJ9jcQ9zdhl3RKfsuDpKtAW/j wb3UH6O3oSQ11dZCF4/jbjfut/9MnY9lgnyUeQ/mu6d2vpplu3iX7Oa8Zw98eoI6PY/so0z0MNfp WP78X6bmufrJ/25bwnMRc6inMgAAAADAhAChDIzgvOe/Lkg1PT9vSaLZFPvu1829vEOwt8WRFzc3 Nn1pfFzmruPCghUDzRW5i82WlPTY+OUlx4SlMCSIUNavesENtDg2xC6IWZoSF5u98zi/UIYolMlO xsIaw9wFW9wccaaZrn0Rme8KnpIGAAAAABgvIJQBAAAAAABgAKEMAAAAAAAAAwhlAAAAAAAAGEAo AwAAAAAAwABCGQAAAAAAAAYQygAAAAAAADCAUAYAAAAAAIBBWEL54NIkBAQEBAQEBAQEhMcmiDLX EMwoAwAAAAAAwABCGQAAAAAAAAYQygAAAAAAADCAUAYAAAAAAIABhDIAAAAAAAAMIJQBAAAAAABg AKEMAAAAAAAAAwhlAAAAAAAAGIQplDsq0izF9V7x17C3vsiyzNEh/goPztvZ1u0Tf4wWznul7YZf /AEmLcRO/mqypCxLW2yetnDFzmOdfo7fHvBeae8W/x8HjGyJYSphXn18E8kNur9aaY5KTN19yqeJ k3Pb4v8wM9/VI/7uciz74/SYpel8oSVucV7hE09K8uX4sqZB/hBViwtqiWPmrtvx1nxzfFrpqbG2 SRYkL88V1Y9vQ1Xi1KeZ83ce25kxb4YlMcY0L/ODH9zegKo8U2JM5hW2M15a/LJlpi2ZOyuu8Khk mQJCPAvnL7aYF7z9eeNtcR93u8m+br4pymKKXmtv5OPRMtBky3g5Qkid/8rxktdnPD8v0bIgLnd/ E0kJJeBtsq81z7FEz5mfY5c23j/+LkeWeF0ef31RRJqjS/w1Qfg6j+/KnDkrZrHZZHlnfxNfSv76 4ucizIlpy9JIgadnFslmzTMR9nCfGCWJ1QM8KkPPKNIZbDzjx4id3mOBYbmxyv++NI9I2B3+4AVH dvT8xdml9X3ilofAfRoAyexfnspwdCqn3jpZMO9PQoNVOnb1QMnDXbDFPfNsnqtf/D3+TLBQDjTs nLbmkIcMDz63LX1q3vG+4f7TJYnZlZ3iAUYoRw65bQl/fdfVNyTsuC+UJIUi/COBiMpOuNuN1pXx hT/3EKMfarUtisp33eSPGSWMWpBtiYFsKoGGEtM/Kj10k9HVwzxs9NxtKk2Mt13Q9Rb+TseqyLlz ZhTViT2oauTm+n7ZMuuN8vZ7QpfxpxfynD1CxsdbKAcaS2en29zjKZIpEyGM5Dj1aeauHsqybHBe p4VMRO13rkuDnCYNA7/tNC8ubbqrtcybJwsXL3dcVqqG6ziUnbTJ5eGoYq5c++qO+rtkJ3e3YVd0 5v52opz8F8sz03Y29IrHC/ivOPOT5s+dyo+dfk9VXsrOU1RMc7cadibPK22kNXf31M5XV5VfHiBJ abevii45RZIyHjwEocx5KldMFQwy4G34MG72ztP3SMkQoZxV0TVClU+EPdwnBklSeoDwhp77GSDG e3AZzRA5eqEcbmpH6vQeD4zKTSl/payMxill3AlBuB1+oKk0Ms526SEXvcoAxmLh/Kj3Z3KWVMa+ uuKpf1KEstRyVQMl/7PTkTl7ntlUXD9ht2cTLJQZ3Wj4s9HhHzkajHt2NeEfCUS0djJ4tjQqS7bm MTLWWghTOkyYwhjJeq9XrUkvPfZVztzSJqEP0YzcvScL4nKqrvMlabJYzHOK6nhpNd5CeYJseyKE kRynPs3MXGjSwCw3zldTOGVNlTL32VOV83zhSbGT7XHlJfDz/X31Rcm5zm5+41Cv8x3l3obCDbod //q4toU1dkpGxfnqi2esd4r6uteZO25d+YMTypz34k9lG5LznB71JeSSNzakibCH+ySsJIU39NxP I7qfc++X0QvlcFM7MUP2ZCG8cguvrMJusOF2+BPXA4wGlQGMxcJJZqeapkWuqLzK95LcvYad86ZN f1losJqWKw+UhEBP1XpzadV3ZGClcyITwn0KZbI98s28jZmJSaqnnBKBlvKVsaY/RpgT15e3eHkj O95kfztm2jMRcxNX21sCJOfPvF60PXPKSyWnB67Xl62eb16cbpkzP+erloG7LUFHimUU8DbuW2GO WrI01hy31dlJRi5qvs++8c6/MpLTLKYXM+3uQXUivC2O3Bjz4mWJUfOz9jXebgpK0rP/KNyeNn16 ye8DnlprVvT8xOQYU/RaR/OAJvEDdH7UtoZP3oJ48bkt5+88uiV2ljkxKTknf330wuK6xoqMFKmq yK1VSqajfVxGxYfNkP/GpatnLt3xhZyuCLITeWJG3k4NJntbwbLno3c29HPeMzahzOcmS09SxEfV Mal8/XY0aGpBRO6wVOY3beZyeyt1VOBNpbbJvsoy/ann5i1ZRaxHvrrPU2fljccyw7ze0eINtDAP G62NEVsIMo9Aj6s4TrZe8SAeopae3+TyXixPTrcKOQpu/xa5xIq+d2yYurKik2SLKfgE1GmbNYsY OX2+T0tm5HL2uLYlGdq2+vRzoarM76kpSTaZlySlrt281hJahfD4bnjONHluyHU6MmL5aNMsctOV FxVT+FOX+nG5pjyJ6o3jxa663HRC2VOZ/bx8iu+SbXmyvY3j2sqTlssT2NRhJsneEdyemWOn31OZ Y6KqerDDnqVMsNHng1nlHZI3DYEk9ZmM/HffWEKtfcu3R6xrk5KWzJ2XaWsa0FQrqRfHkb3rk5MS zKZsWzPJRfB1lWHSf8VZmGiam5CclFOwzhKcthB1rXl0KUjkJYkbrD9dpB2795fCqNxDtDkEvPU7 FmbyT0iNh0OlLgbaHW/H5//Y6R/odG6NmzZKawnJqM1JXfgW0wsryt3yY4du1tDD+Uc9QMiEOleG GQmjQlXGrM4O+afdkSnM9BPu/b5zNuk97gR1ehrjGcEeNJ1quKkdudOb1IQ/usnlpm6b0nAglL9P r3nI8cbjDmlo+k5VRlUdisTSjVA9rqJYwwiptUtaK6Af4NSw9mpO548i+IM0m18xgH1ffR6idTC7 HbIx+l8lm+ZlVXpoNr2nS1JWlLyfrrZwsXTkgZLQ7Vwfl++61m7Pii47Px5eBwzuXyibknc30Mob OF0al2lt1nqJKN2obGSqew6S8z9GbzrKVyR3/VT1ef7B5bWqnGh+bNMeKZQR6axnreAfZQb6arZG ptjbh2jMTyftofqADkWJmrsKZa4o4G1zXyM1pE3SU+bNgilwnoZq3uuOu1m19rmNzt4h1ZFDfa73 Itce5iuvv6UsM4E6j5JBOvGtKjJYEMV8eINpQXH9TaWqhs5bX73vydRJQaC/dpd9yivWiJl7k8s6 +ow7wCA7kStd3k7+mTqfjpekKOUCHB4ebLIu4o3nbl3xbKF+Of81dxupU8ZIrI5WND+qY2bzc7SS qajusOWr+z31NeeojgzcrFoXwU/1MQ4brY0ND3lr3p+TwT+jp4/1E1Lt7iG19Spw/a5NU+h1B1rK UkUJpWr/WtcLkpjudnv2y7lHe7gQQllM27C3sTSdN05ymGE5h7Bt9emhouo7nj97QxV9WObrrMqb ofRlI3PrZHVMpDXiFasp+5ffbokbR0IuH4YlkCHhfEXuwqfnri0TxBxBKU9f99kv1i4qqqHeAqpy o3UUn2J3C4dT6DP3uC01N/m2/OMm8zPUuoIup6omFbIpqlB6wiAb0NUdifPPabvPkm6HCPo5M3IP k0KmlkxHI1W19rvyn5m3oaqDjLiXbGnTSxpIqwi6rmTGqtr0d1TlztOmjWmo6vqV4Dz1n6okskjA 2+zYELv4f9alR2V8WNPFj6C0lF62xMbGLV1sNqVtr+HdYGTEQgt4Gz5KydxL8zIGawnJ2MxJKXxS qumR1FVGriDG0DP6AULB8FwZZiSBHme+rkJVhqTODvln0C3fgQ+1lEUn29uJSg/u9GTjGant6zpV VmrD7vQmM6Ma3eRyU7VNeTiQK0IpK+V4w3GH1akqKNXBdyyv01t3pRFxg83WhEXWlkFOFWHPyYKE TPtFupsMKLOzyi/7aPJkrcU6nZ4nwBj+eOuST5cx1mwhWger2xEMu/pw4Us51PuC3OlFrj30u11j 4XwKNK4XpHt8nrYpYvALJ8z55P6FsryddDeZwf5JDKNh9EE8Aa+72layo3T/kYrN0fwB+iNlncFD xGhUhs3dL8VMCEqnYHnxG+y/eeT6YCSJh+u79NPnO4t3769xFAgHKEeSW5aEwhrxslyHPZnUh9eV /8ImV78QrXhdrt2esohWFeliEmgnxe98tPE0r4umgxAN0YePGHtVBZW/XMLydtUBvc7cF+Tn3cLc W6tXXb8CSi3I6KNV2ZL0D0so85Nktl3bSx01jk3CXt1hfaO2MWXakiI1V+aY0VdfFM8/Z6AP5acL by2QBCvvKMRvcDTTUU6+CrlzmJVmbb7OanECGjOmYxu9uuowRjlfIN2qkW2rT1dfcYQqe1F+i0LT okci0H9k0yeiRb3yyTqn9t5ahxwnwxIEfJ4Gx5akeXFbjtG+WCnPtCVzp8dscXXT9JJcCC/zpTPn /Aaav1wxc1bM0sSYpM3WbUm0PIMux86atg+heJvLXo8uru2j0QfZgK7ulDj1fZ0qZiUl8kb6z1PT LOn8K3R8pqY/Rc1Y9huhp+nSxjRUXaoITKHM0bcO4tb85/DR/VuSU+QJjpOffuGicw2c//L+zJe2 nBS7RB6al2017Yc3xG2q4o8hjWuU1hKSsZqTcnW5oOSiYA1Sox0gNPZlcK4MMxJmhaqqLDg796TJ GnIrni7cDeo6PTmeUG1fjpyR2vA7vcnMqEY3udzULUsqLkZZKYcZjTvM/pn/waNunsL0Sstt58YX C2r4+1QStfjgS4lQEo78bmlGRk4e9SJjnC78Ir9Zwx+vs8XT1RhqthCtQ50vGWFjBxH6OVXX7jXs jCQiqlO6NEkDY6BUjaS+uuKXVlR0BqdyXBhHoSyYxfEmey7fd2fQ5y8Mo2H1QSS7nd+uXLDxa/ct r7sy3zw1uNDFI9UGShCufothtSo47/lDxSuizK8XV/J3Pyw7JgbaWfl21PqDbu8td+Wm+X/kD1CO JNFOj1lTUFxUJIZ/OzuuqE1Huq44kextt68kd9gqc390uX1522tSV/Jade1tcTOboPK/21SarLUT 1QGkTv9sydkqFWlR8YdO91VN/fIotSAjV5w2Nrk58f8whDJ9Zysx9+sWr7f1UF40Lyz0h6nNiblR dVER7RYxASrrlSG3yLOSRY8L0p09x7+1IB4/2OlYyU8e80cqcRLLfGtW9meOrfoWJ6BtFGJsqsPI luBybh8ytu0h9VWMo9JWmXh14cdIcPdqP7CJFjXTtu3XEI9d5DgZlqBi4HRp7OKdDaoRi8Bdd+Ym 8a9n6cttJKjCoEXNdL0ItJSvyuD7t1z+MXRQjxToq9uxMGpHvTg1FYbrhZhUw76O0WUFXVc2Y3U2 g48JLgTxQiOWTJDrxZDbtliafOJ6jm6Y/V7wq2O0xOI1/hvkEv8Vuyzl5f+XXclPNWuTpK6psTNW c1KuLqdKLgp9dYx+gFDKxvhcGWYk6trRp5ORHa7dnppibw+4y1NW0ik3RqenjsfwinLk7NSqzEY8 ktXpTWpGNbrJ5aY2Y6kcGGUlHWY87pAT9f0zjVlAXc5ChDUdjqynLWu2ybVWtMfZoRLKckqUU+rJ H2kj3aI/XThaOV78qcudCs5Ys4VoHVr7ERE29vXXbDGt/+ZEaTK905MvLf4TNFB6T5fELxQ9LsjN W7Tk3zzOhCmUyT1BnLKglXI3qc7t/cwoBzyVq6eIFSEfoD9y9DPKEpy3YXfS4uL6XlaSCJ2H/hEn nigfoBzZV1+UKHmOSxCho5tR5kfZ5Su+rfk2a7mohx55uEDXiV9yUvaaUg59dKJXMw+nR1v+9GW+ TF5qyNtVB5D7v2nrqsRVHQS09Sug1IKMXHGq2IKbEzlPJ5RVrqjyXt1hEzijTHc9N2+JOAuYEjNt Fj1LTrnmuZvqKmR7nMk0TeiJ9FfXdG2MGWVGOatLlWXbmqsYRzWmOUJ/p/ujXLtpgT3H6hae4Bsg x8mwBDVSgWvSwDIVYzh3eXIy71pj/DKfgLrw+RUzpmZYqQ+xQKiX+ZSk6vs6VcxKxuWNmkonSGbM nICUYRpqiJIR5HJyXlWjJjbWWVQoJ2m8kkhe/hj97rGGY/kpgpfaWKwlJGMzJ+XqckHJmdJXx+gH CAXjc2WYkTArVFX4+uwQA07JcdR9uZzIZWJrjE5PjidU25fjZKQ23E5vcjOq0U0uN3XLkoqLUVbS YcbjDrN/VlA3NEFitQ7UF5vUr1jwKBGGmFGmnZL+dInwZ5RDabYQrUOdLxlpI83CLPNs3nlVvrT8 j3qgpCmcKi9PmW6Z/myQfhgnwhTKfk9V7pycSv55JT8ezMrlfVxIxnQONGr0RsPog8h/HL2HEGYd OI8z1xxc6PKRI/iPBlutzODlk7VX+SuQaGNpw2YkiXDrZEHCysor9Pq9zg3P8AcoR/ILRaXsu0hn UwLexoN7Xdc4Olm1WOj9JR9lel3SZVhetURHl7VoZ1ueDFTlzz+oFZeHU7arK6i3oSQ11dZCZ9jI wfvtPxOLGrWPshSbrjkpHYd8WH9N4bS1h66TgwJE9zwb1GHJh43WxsJ116OukHNKfpdmvEj/uSaC iAalFQR6nHkvC+9Iaa5Ct7/4h7/wsemvTtOm9lFebGvlHU/lw1jlbGzbmtNDRMVPLo6316kauXx0 lsD11e7aKLy8SPTcqV1C/6OUJ9l6w5Ufx88x6MtNzZ1G6wdft9Ma9zZ8GC/Om4ZaHo6iMgy6pnL0 Codbk3vj5eGUpOr7OlXMjC5LbZAUyYyZLq0yI/koG5SMDHevcXd03IcNtLQ5/9WvV0xdTyqd1P7G hG3HPaTb54vu1d2NwptkAlIGZSOZcGsJiVzmSuHLhSkXhb46Rj9A0JMFjM+VYUbCdDq/XrXGwqtn VRkq2aGPRKItljThkSaj05PzG6rty3EyUvt4+CiPCmbrk4qLUVbSYSHGHVb/rEDi170GRnuVLNtF 2pdw3rMHPj1BzEMV4Qg+yqJ5CJ1S8OkKI/koy6eLhNJsIVoHs9uRN3Y7109/SnBelS+tpEEZKOnE 0Czp7VWakMoVz21y9Q/5u9uv8OPCeBGmUCbZ7qwpXTHj+Xn0zc2ZK0prBE8QkrGRV72g9NQXJcyI jl+5v6VTtK0hb92OKFNUTPYBxfuEQN/tzViyZtOm3Nz/WTyTL2vmkaSgGSsSBFutBOc9/3V+ktmS onJM1CeJHkiXsEhKydm8acM7qxL/S6hg+UjS43hbHHlxc2PTl8bHZe46LvjkBa16IVyXPl5/VnoW 8KRByl/64MjzczJL5A+OyPWiraCB5orcxbR2YuOXiwdLq14sXTw/toCvX3UtCMg1ropN35y8tcUL 5lgsb+1vvyAd5ut0bktOXFOQv/Gfq+P/n9CtMA4bnY1RSAcX/Favbszg2isyYgtrlJeNqEf7S8X1 bapWQCeP4+lzj6CrDLbYkk18bPqr07SxVr1QHaYvZ83Ip7dt9emhoqKlOgHrGMjIFaofrbnelq8L k6dNNScmmKct3vQ171tFjld8lGfF5DpaBshWfbmpITX+xdoFZvopjVjVa+DKB0eYnRtBNgw6v/KU eF0apE9vyB8ckatGhdL1j5dQJv+NYdULg5JRQUpj/zsxz5tiFs+bYnp953HhzR5fV83H2aap5sUW c6z0FRIZJYN+T9WGSDrVMjGrXoSPnCRV2qTClItCP/SMYYCQCXmuDCsSRoX6PccL55OxWF2GSnb4 +d0/JEqPNPWdntp4DNu+EicrteF0eo8VzNYnFRejrGSBYTzu3GN1qjIkfr3E4gZaHBtiF8QsTYmL zRZaokooE9nDWvVCMg/m6Sr0w1/Q6RIMzaY2AOPWwex2lAbY68yPEUSUfGl1GsSB8kanY8XLBTWK sxd9HhhXXN/qXD/z6RFnzcdC2EKZDTO3TyCkHBJE5zyqhzIeF78LMPkJ1kwA8BDDyOaXyJiskJFP vdoUCAFaOgDhEOirKUpUHt6OAxDKY2ag/YfvT9G3dvgHkS+JX0Wik//ytyQAmHAwfAIZzt9efbCe d3fyt1VkxY3flybHCX/bj1//zi8J4rvqWDN9hO+WARZo6QCEAdd98vNvgh/f3R8QymNGeuKcxi8g Sp9fBDxV78WZE989rnZQA2BCwfAJZGR/sNQlcyOTi6u1j3EnAaIjweJlieYZSTu0LgrAGLR0AB4O 9ymUAQAAAAAAeDyBUAYAAAAAAIABhDIAAAAAAAAMIJQBAAAAAABgAKEMAAAAAAAAAwhlAAAIh4D3 Snt3uOtITNyKQHfdjrfmm+PTSk89wDUjpOxw3ittN/RfPNHyqK+GNKqKDoeHWyDcQPO+zOfNfAI4 f+exnRlzpsyNi5m7eMP+Ru1ndLz1ReaIuYuFj+Ysy9jhGvHTyveDQWnIJf8omtC4m80ISJ/e4Lyd bd3h9AFYL+V+gVAGE0mgYee0NYc8YfS24R8Jnmj6T5ckZld2ir+MCP/I8BhqtS2KCntl4tGO9GGn NtBYOjudfqz7gSJmZ8htS/jru66+e4+zUB5dRYfDqApkfO2WKOMfN8UtML+0gCaA66xam72r4RZR c/Sr77FJpU3qr6o/mE/rjVwaSsk/giY0FrMZU12LQtnntqVPDWslcgjl+wVCGUwk+s8Oj0T4R4In mvDH8of7Qd3RjvRhp/bhtJSg7DzeM8rjzqgKZHzt9q57//b/NDQ4GAnQX+jBNJlwSuMJMaExFbj6 Y85hAaF8v0Aog3HE2+LIjTEvXpYYNT9rX+PtpvKVsaY/RpgT15e3eElbffYfhdvTpk8v+X3AU2sV PkZvil7raB4ItKiOHBjmbjfa1sw3L063LIgvPMp/NEH+kkJSck7++uiFxfW3Oh0r55U2ClPQgabS eRmOzol/6gUeNAPNjpz4+YmpS8zRK2wn6798O2baMxFzE1fbWwL+6/Vlq3k7mTM/56uWAeGJbWT2 toJlz0+NSUtXjhTjonDeMzbB9uYmb3Fe4QcP6eNBSalrN6+10EFIPbTIYzb/T11jRUbSzgZhCPee LknKdFweDLJnzVkBb+O+FeaoJUtjzXFbnfQTGzTyZ994518ZyWkW04uZdvfg3Ra7Kl981Dz6cz2u bUlKS5HgvI3lOdEzLIlSpnyeOit/omWGeb2jhSSDvyjfAF9+442U2TtP3+Nby73fd85eWUHaGKNY hjnPz9uTIlWNzisN0qryYbTWSaxyNOZ0xstRg3kzb2NmYlKMycxvIQdJ6SeZfeb1ou2ZU+intvV1 wUuWZzLy331jSarF9MKKcjednWWVpBQhw2KD6q61UWMJ4RiPEAmj+lSwaoS7eihrcXG9ekbSWLep L03q2nFk7/rkpASzKdvWTGLWd9GayzFsid1+hXTy/9C2liLNed9tKk3JdLTT3D4c1NmfNYsMcPTb bySdQocTvbPhnFzIjOrQ2BIf3/CAttWzDEzB76kpSTYx+yjtsEtTFfA22dea58SkClHdYdmMURdB P30vfhsoITkpp2CdZeTG/kQAoQzGj56qnOcLT/pI4wl429zXSCtSZr9oI3zKvFlo/5ynobrpNjmO u1m19rmNzt4h1ZFDfa73Itce9tA22N9SlplQ1jQ4fNOVl/hWFVHCpDs+vMFEHyNy7faUV8ta6IfD B1rK0lPs7iel1T5BBHqq3p5SUMMbTW9b63UyKihjOXf9VPV5qmy4a1U50bnObn7cmjo//0e+B2eO +rIhDQ8PNlkXZVqb+7meoxtmb6jyENvzdVblzTAWyvU32+1Z0WXnqd0Nnbe+mlXefo9hz/JZfcfz xci5wWZrwiJryyCN/OmkPXRI4y7Y4hJ5KcBKrfeXwlkryi8TQRzoq9kamWJvJxEzZpR764sSM+0X 6Sb/9da2XtLwPPU15/gh82bVuoj1zl51A+Tc5cnpVl5nD7WURSfb2zlGsajKSml0OqE85K15f07G /nZS4NzNk4UJqXb3kFJikw29OZGkmpJ3N1ArGjhdGidkXEo/yewfozcd5YUOsy7IAX9O232WVL3v ki09kt6395wsSBDqguv7ZcvsrPLL5GpShAyL1dedyhIYF2UaD7P61OhrhBto/DieWiM9SYJcesH0 6Ni42GT6ZcftP/OdsIzq0v2u/GfmbajqILdkl2xpVFcxrUWBtZfdfoV0Cv8w2poQ3cNAlf1hb2Np Oj8wkXTKHY6ceJYNqG1Jwbiu+UMElG5E10fph927dcWzhag4/zV3m9fHshnDLkI9Cvs7qnLnCY39 /8/e/381deX93/ifMvdy+nF13su529G62mWLuXSpYBagyYII5IKAIKBXAXUAXQI6gFOBqxKWF9gZ nKsw7RVnJtAGexeuMTM1WtIWfRunsYWRqBGDRokVDWeASMLhs/f5fnJ2QtCgoK/Hyg/JyT7762vv /Tx777M3qWt+JQChDMQP3EZn1Jj/4cOtBoNcKPPKA7cft87/qc14qnvA0sA6EF0+sFVlNg74OYej ZoPOdIuy171Vb59kveXbI9zf78aLNVHl31H6QttQYJFgxGXK4S4n0jQsUkEZotwXTK0n2ru/6jmm YS4KfRWCJD39tuq32E4FMTNqLskwXafs9W/X2jllES4EEYKf3BfhCY1XmSR75hz7/bbDb7PKDEGP dOUUm9yTJM+VsaUn7fVrcQfGgIRCaiG2dqVQRqplNavORWjq5nnTyZZ2y4Clfk2+5Z6sAj7h9Qf/ hEnIlhsoeEKlC8+fcXutjpE4GJQh21FtxcO0bKKWGkpzkkYVab4inPDwxKK/IpSF6IDPEFlZoOzN k3motFhC2QmWQAyUZDzE4mN+8ChKZHqw05Dbcnlc7izoG/jLJ3ZGzAVvdhXqGgcesX8wSExI2bAT rUWA/G+U+st9wXVtB7Io1NibMtm69sKQ1iAcn4xwU+e/E21ANBUp0cuaazbYfyO2UeHdrtwrjDTm YoSjNhGoXmfW2cfxV/E6qWt+kSXy/AChDMQTmrrWZyxLVe829jJDBWShPOPtPZha9YWbeuTurU9e wTgQXaKavD6tvMHY3Mx9PrKN3pG2MkJV57r5kMech56/X40a++oRoob7Wkq0yYXGvmHZeBvt/XJv yuEz7keUu7dOvU7e0SKU0pMdAtRWfMibVrPxdzb3XdEyYxLK+Aktd2+Xh/KY9+bheQySPXOOHyF/ XteWHxeMuflj22iMQlkaBwTvUimUlX0wPdpXqq8+46Ko6321mpXhveAc0h+4yoTYhDwhZYtnVuYt H3p4/gjxZ+D+lV9cWoSZkzSqikSJORChLJQOZJkW7iHBYmXuWQRLIAaKLYq/KImGsviYe3h4lyz0 uMOo3268NBGtzUSCu5gZKhaQxEfZsMsSIg8OQfo3av3lv3ADyUJde4HIi4NLkTSl/HdZYon5IxC9 rIUMJAYtXpR3u2FeIaRXeJ/naSKkERCuo4uKrlluZy8rIJSB+ENTzlM5WUaHP4JQ9va9r+MqoeBA dDnhaNZXWMfwvwIRhitmXR3aEssPXx7QstNzwEtLiPrxY8PmFscUMg+2awn5evev5SxK6G+k7btw UULgsjHhkFW26VXU0Rp8SfBT+PLEY95XbPnaUrSPmccg2TPvOOAwqsqt7MgMD9FzZWwjDDKJQfAo RyV9vaWruQCCjmbFcBHyG0nkCsvlvxSzT5iEbIlQ6cLzZ3mNKAsI5nRbEtXFHlF+TLBYZdmJlkAM lPSURSw+GdISCXh7D72X88kws0I6Mkgo72YWkwhITEjZsEdoojkI/5JyQ7xR+ILysLjsy4EvS4rZ xUIvDlkNWkIjyuxF5Ijrdh/JvMJIXfKRnKeJII4ok7rmVwMQykD8mLl98dJdXM1on606HXefyvYU u3t0sSFzb+8d1GrSflvNKsaB6JKecp7U5J6+iRfPhajBLz6136fpMVt1FmEBHGpQNKlp27gFl8BL Bz0z4rjErmtHpoK7H7/YtQw0qUp7x7AZIXtTyztahFJ6IvzO1rw8kwsvraMfD3abv/Gh9l+5/g8v Zl2DeyapvYme4ye0bVptHjuPQbJnwfHUlbZtJaab7GteP372ybc+2ZCP4Ccptk+9RnlyoDGhsg+v Lwj5bUfeUAplZjZGo9Xmc6N0pGwhVrrwTnp5rVFWmtOIfI0ys5RLiL9U3ERao8w5EDIkyhrlCZLF Ps0aZYXxkIpPhuCS2VN5Y0WPR9pg0sEH7usPArjEa3Y39Xtx5KkrJ3V57YP/4pxgJEErG/ZITTQL 4V9ibgjxFL5wdU2jYV9HeYHglErXKGeZrstNXfgeYY2yYEsi0cuaccIQ7T0KZbdLWqMcbjPzNBGh cVudYo0yqWvGjl9+QCgDcYOmrp2py1FrcyWvxI47mjM3aDL2dru8YiVEbeW5ppzcimP1NUf26X/B NriCS9RzUy5LrS4pvWBnhq7oZD/u2JhbCK9UU1dbtT9PfeFtKLBIhKjhL+p1KWk7c/n3x2epyydS ValppZ95Zu7YGguzy+vrq6t/nbVR3tEiJC6lzfn0cE91FrbS9Izi1q8ZK1XueoE6nfNH1e/J7U3i OR7y+dV2bh6DaM+CY3raZalJx0nQpZe29aMkSDskwRkxtqQX4QlCGVU9ducEQ7Zaz7wwhFJ03KAv b6g7/Jv9Gb8kCGVm9PdnevEJk5AtpEqnHM0ivAgvLYUlhdKcUFSj7nohihtSWRCEMiqLKLteKC1W WXZSS1AGSjQeYvFJEVx6+95fuzJBW8AeKZJfarT7mDftEt/GO/KiZ7hv299PjHAciSRopVCO2ESz kP4l5IYQT0nSnnzftukNvq69QHBKSbte8PGUfCfveiHakkD0spYSeWceQrfL73qxMys5vYHd9UJh M/M1EcRdLwhd8ysBCGVg2YGqemabk52GCnot+7jXogHg2SH3Z8DLilToAPFC2kQ/M7Snp7BwCcwZ ynXkKwRKeKl8tforBwhlYFkw7fnbX69MoKpKB++eKXv3qH2CHcu721eSLz9cCgCeARDKrxYglONF hCb6maF9vWVJ7UMvXqa9UkKZDnoufOFgNkUJjvSU6OJ6UOXyA4QysCzgJ57ys9Sq/BY8fz035/tb XXqqrv68fLNPAHgGQCi/WoBQjhekJvpZCfmsH+jU+qP9S2Et7CsmlLmlMnl4R23jBcVinlcLEMoA AAAAAAAAQACEMgAAAAAAAAAQAKEMAAAAAAAAAARAKAMAAAAAAAAAARDKAAAAAAAAAEAAhDIAAEuY oHegvWyTSqNP2pRW3T2EN/kXoFymkrXcJhUBb//JItU6dZZWnX6ke+gxjW51NK95c2u27GyF5whN 3Rn56dnekY/6oj3n/yu7vWu8oGfcn+9Vp+rzTl0JPNur/QveMiVE3fE8iLCfAE15Rx6EHegQzb1I HAxPypTbciBZnZHffkUSG36PC31qMnf0hhTiXiIL2mAErBpYQoBQBgBgyRJ6aD2sqfs73pwIn5Cs y8THxrIEvOcaMtSJ6xlpQvvOHjD83ok77BDl/J0uEW+8ioUyPnEq/oScrar3e6Pr7lm3KfOdZ9xN Nppc4P1/ApLi2ZgaatdnmG4g+RlLsSqYvNqqL+314q8LFcqz1007UiPsUBtwmwrW4dPyJLGK5l6M RjwMT0JosH1zAXOytwhzonKdbRxVt8mh9hzFsXkglIGXChDKAAAsYYITj//FjVfJhO/M9e6jnzqH uwnShD9fd/GE8uL5LCcWuQCS4hmhHM1a9jTppypW8fZF2oQ7tlhJohFfCEemz/pth9fW2rnDUQnR A6EMvFSAUAbiiNAUEmczmcnxjZvS8rQbNu5utd6gaNwarkzQFuQX7NqJLu43DeIZc9zfrFiftrNg V36WOkHPnZUvQk8Pny5arebaXPrxkPlQsipVq9JUmgcpLjTusHutZktyhVk+X69geshU+B7XKAfv 9Lfu3rB6q16bohMn+hfi2wII6zli7epIc7I8hFnX2KZrlwH0pL3+bb575iBJE3yUV4LREaDnURjo 3lWFdUf3ZOelq3VNX37VWZmTk520tcg0hE/LDd6xNepVSZmGnIqGQ1ppnx1ymfdp1698c2v2vv85 182foD57rTN1U7XtAXbht1UnNF288TkfN85+0nBAH9q8AWS0g6byZHVWgTYlo/Fc+Gb+9NhAS/4G WdAB3+XOMnVqNqom6iqLi7EZLu2spBjwWPZubR/k7HWofWuhxfsSlHncCY45OvYzOY/q8ueu6eC4 3ahLWLUmSV/y6/3/wRWr2RVCNekHU4kmWW9ISzJwTRA2mN3NLUVr3229yrUB0y7zwTTm9v3oJtGi tKq3yrrczImh0cpaaAHQl8T/qD1cpM9JS9hYbL4+wyvFgGhsKADefXgqpsKjwRoeIWjs7Rt7jvy2 0JCvVb1dZHbPyKxEkWqf/XiOasUatb6qSzxEWqpiSbVSmhyVusz0A9MsC4kNUYOnGWPmqwMmrI78 Swwi6O4pza8/dydISA4OqPR4w67VmjbnmMtSnabO2kVeDfLsML2VrtPF59jCH6uk+fa8iPM6nKVC tE4wIoIFLhgQykAcEQxRnM0UwPJlXS0zW4esfOiv591CZ8A2uNPOk8mbmaNKhYYeXZ34rmnzvh7v DP6BoYPev9frUtTvpjAB0VPOk5qibg9qNIM3u4ry25x+7GrqStu2fV23Ucs+7THv07ReiXjINdJD dTnJSeuYaAR91trctiu4WacfOdsMnPKI3beFEVZvYxTK4pysEmHWNbbp2qeba34h0EHfpVNFJe2D 8mZOYio81GB7QWbHELIY3JO9m6pLzyjQqzfktA745P0Fuve1/FM/omezcXvtlg3VZ1HXS7tNGVgG zU7YP0isPIsPfQyOWqu3hnVvQh856+rQMJKU9lp2q1SpzZeRCg44jBuqbH4hblOXjZvLGPuhg/fd I9SM6PncpKujiI0tDzHooM8x8E9mYclD66E1yHPkkPOfq0QzHnPutg4X1uzTro6CXLNbWvsADnrs yoVrTAW/b63QMA82xBHlh/Za/QEr86wxM9S5o6hzeBJn+AoNVmzYgYB8RJmzqMAtU0Eibj0kpUko a6EFQF9UhlNOFDFsgbgZFNtGSax491FTwRvGLDXwn1sKmbYRL1vKzDO7Z5km9/Wcj7GOpG+YdPr2 IWljNn6xIbPIfBMFyjS8JV23Ayh4xYiyEDe2VhZxra6ImJy56avtut3Myg0+8tR3jZvY6hCaGPgw MdfsQUYbXkcCXBC4Hd5T3HmVook5ifxcl8wuzRq3VqxuvIjHZULUiPs+ltHxBaf65z/bVGMbY71e FkI5zutwlgrROsHI8Ba4cEAoA3FEMESC5iM1K/KGQ2iRBYWB8V9s0FVYx9gfqEF1d7f8t9Np4QKa cDQbuGE8PCF4ZINUqTBX8fCeCo8vsr/k0DNuy2//cMlFar/4CMfu20IJq7cxCuWYiLERX3hb/0Lw 2ZtLd+nVm0r+PBw2UCQzFQQ9PfxJ7rYTjgnmecw38OkndmbkCT3hlK5vGIgwGq0UGUg6Z9bZx/EV Uvcm5tuT79uSam3+4Li1dvef/tKc0+maRTq1uKz3Ls15hYfc1gr2g3lgq8psHOAu0KNmg850SzQo ctA0dfO86WRLu2XAUs8FzfnPu6HdXQZGkSABtKO0y/OE8QEII0S5L5haT7R3f9VzTMMUulj6YrGi av4Wq7oQM6PmEvzYH25sLErjQd+Egote1kILIGkKwopVGivRWbRUSGxYx7eN+IluOw5aasxh7Q/S n/a61YdtflZUITPOw6mOLJQDLvN+Yq2U+cz7w12ckFUHPA9TaHJPK+oIG4TdY63PYJ5gI9QaSUD4 eSajxvwPX/wlMguO0i812u2bWhxTOIiFN57SzAeePwqDjxkQysC8zAZ/unX3h1v/Csz7VMoaol+Y zcTzgNxfSNP2172T2dR/V9JMyBsOoZmWdUhhQpmFt3h6pCunWHjRBA/G5JhHab5j467eMOlKukYl 4zjhENuvoK+3QoVl93y+odhGnMHHPvMTnSkZjZavPq0y5GSqVaWmYVRdw+qtpKuLPO8viS26PWy6 lusjLw3FMl1LS5YQ4HIizDUvLULjtrrEsFEEmanM0ROXWlL1LZfHlV0l7lnFGXMG8V6lyJAWDcE8 JH0kkiN5RseIvbas0zVqq9pncl/vKdyDbZLzSnk78nx9WnmDsbmZ+3xkGxXrFiloerSvVF99xkVR 1/tqNSuJQpkfSA55zHm5Zs8iqYVlDu39cm/K4TPuR5S7t069LkxiisWK8vY1bcWHfAE1G39n88yK BiNFaTzom7SSxlLWkkJXmI1SKEdPBe+D1JAI3sotjUGWQN5ltBFlBKqV9dsbvqNCrq59hcz2MtVd LpfEZ2lWoIuPJPciiBcR+K5fZuXnrX5vb+8dxpaRS2VOypJAU9f6jGWp6t3GXma4PSZi792YhBz/ wlqtKbbcRt6L5RJtdQ36V7mSitjYUmFLR4K+S52sG5Wm0jI8zfgV9J5rSt+k1ucYKuqqNNuZtBOX svBIyl255IamBrsqNBu0ei4ayLG4uEjpLZ5AUEQpPNpRc4OJxvuNLfnr17c6QwSXxARKSjncjOf1 cI72fdOSkyj3cMGAUAaiE5q8dNK89t8612z81NAxygzURUYwaEmrLRKihi016rXq8o/PuyeY2iOY O/rqGzx9KLPxG6xxJO01ngHctEcxPMYHFNaIczeGhS5rTElIoiGAZwyZ+dbwtCh8Q4FGnMHHPnMT negxYNXWGutoEE/L5uNaHe6VEFD0eX8htuj2sOlaMeuUnStpulbqjDTXvNSQGAaH9Erwdl9FqqFj kGm+w8FCmc0iAfFepciIeUQZz2PUpf3h9O8MfxhCXVvvkQN//qRayyyB4LxSjihPOJr1imc/AVLQ vt7S1VwMxKA5/8Xozbo6tCWWH748oA3fhQBgCfl696/lMlIodLH0xbwNXDYmHLIy68REpMYmojQe 9E0olOhlLbQAkqZAUayKuvw4eip4HxZ9RJm7RMgWqc+ouSt6uhHllerGr4f/Xp962IoXTRFzUpEE VNMp56mcLKND4llEFtS7sam+PH27u4hZQ8iXC3GJiwCxMSctcVEsHaF9zgvMNpf0Q2vlm2y5CK00 EpRna1TM+sOJ/rrNNUwW0TPDnZk7xFXUGIk5KZbc+FGWstGYC45dH/HjORNhcRHJW0KUwqMdirrW iC3WY4zsJq2locds1VnhCZSWcnjtmM9DYo4tHBDKQHR8w4c0nWtQU4I+mrNfRV/OKhi0pNUOIzjm tDQZVPom+32atXL2Zb78LPXqzKYBZvkXrq7sy3y5EUY3+YAWSyhTwx27NcZLjJyfzzcuUPRN2VdJ fBajKlxEXr2j0uYywzBMYhPeYW6PrtKkt4c1H+IXReeKnCmnayXOiHPNzI8XSmjc9uE+vEIRfQ94 e6uYEWU6+MB9nX2TQ5L5LlPpphIL7q440L1Hsxov4KlYvNIxT9P+g+x5K1rBMaPXEZ9VpNmLVycX r/7VOuZ9JvTEkvnmmi14IkLif/j6yyBeWJ97+ibuz0LU4Bef4rogQAp6cqAxobJvDPkV8tuOvMEG zfkvsRAkOzSpadsKOsX3rgAp9ORAk6q0F7cytM9WrWYKXSx9SbH6na15eSYX7uPpx4Pd5m+QYhAN RorSeNA3oVCYlygilrVQN5V1WSxWRV2eiJ4K3oeIa5R5Y5YEyrGANcqv53/KrLhA5lr7Xkkvo04E kM/SNcrsUzcf3ILWKIvVgZiTkiTM3L54iZmuxHmSLjwhRGVBvZuQdUhfZmR0DE1x5UJ8IGF/IUiN OfGBRLl0hJ64df5PbcZT3QOWBrYI0I1v1dsnWQds2v1+2+G3GwaY1hDdIptixShbCSHTZNFgEA0Y b2xC8FYZpfBoR19rJI0GySWlTGD02vF0Hi4YEMpAdB7fPv7vfFPy7xcuPeYukxEMUdJqE6CnB/+g 29x29YnUytm9OT/Arx2I1TUSfECxL734/pyxkNWjkg+z5EBeexGhicsntqdy61zDVSNx6QUXW2Vf JfGZLJSl9Va4XXo9LG4I0u1CHPgvSqFME6ZrJc7Qjcq5Znz7C4amblj/a/cmlTZfu2lT4cl+PHLw 0F6b+Da7BkNIuK+3dMX/EZ86Ck/Yx0PsYSWKPUx4hHuJWifa6hd0xyVjyhat9kC35wljElu4nhKP kCVy/aLoP/9G/86s5PQGZvCDcllqdUnpBTszdEVsoiQQgg54bccN+vKGusO/2Z/xS6HIsP9SC6Gu tmp/nsq+0geQwHlbmF1eX19d/eusjUyhS0pfWqzTwz3VWWptbkF6RnHr13gaVyxQKbPU5ROpqtS0 0s88XsGBrFAil7VQhZV1WeKDGKsbnDNCKkjRIMxESyMmbWc4CEsCIghldh6/QK9WpSum+7HPT7vr BVdHJLte0F5rZWZl7+0gISfFJNDUtTN1Obi8iOsfyCyodxOzDrelGw/0WD5gGk95NoYbifRf3geZ G4m3sqUjM97eg6lVX7ipR+7e+uQVTBHIbmR9xqtWXteWHxdWpDR/bBuVFIfSnIQohUdVGnnsXuEt RYhSeLSR51HWGoVFQ+HyjjKBKOuEL8rkPJ2HCwaEMhAdOnTv2+8qcj9V5fb9/lv/PK2PYIiSvocI 1/hOS6wcwd+urMDhCAE948t8LNLKRge9vZXrCjvxGmKW+XwTY6vUWxKfFyCUF2NEmThdK3FGnGsG MCjDS5mlMkufoNfCb1cHAIuFslFapiyod5OmetLVkb8+Yd3ruPGM04gy8wPBLx0Z6ntfxzXvQt9B GFGmUPekKreyARBQ9kRCxxFtRBn3egpvvYQo8fDRHo261kgaDdJaGlICJV+UyXk6DxcMCGUgjgiG qBTKoYnL/33kE3YOHZ+dlpFpcs9KrXyO9vfXv1vRF3GKU4oQ0DNvD4eRRAPvqawps7hlgUf3TYxt vIRy9Hl/0u1CHPgvsU3XSp2R5ppfXeig58IXDualwOBIT4ku0v56Swv6bl9JvnzDLwCIO7J2+5VB lmo8//nWz3+OG8/oa5SJjTlpiUv40pHryA37IiPtt9WsYvoO4hJe3D2VmG7iWk9TP372ybeyZTDK nkjsOEhrlLm+jO31wrx9RIhSeLR9UdcaSaNBXEtDXFI8Zi3XMg8bAa+1doMsOfN5SF70vGBAKANx RKiBSqGMJ2jONOSpVm/NxrN1R88M+8PXKCdk1LAv0kqrKxmJRhQPHBHm+BDCESGbNs2/+bxQ2fC7 Piu55dH4U9TMDgVE9U2MbbyEMnIS464X/O1CHIQvMU3XSp2R5ppfXVCryr58nZedlGgwXlgGueH7 W116qq7+vHy1KADEHUmz9goRluqpm6YiZkQZ90HRdr0gNebKJS7KpSO4CcrJrThWX3Nkn/4XbN8h tEvSPRzoaZelJj0lbWeuLr20rV/+So+yJ5J0HPyuF4ZstR6/wyf2ZfhPhbeEKJFWvERZaxSWh0qX xAQGff2NyUg55ORVHqvUypLzdB4uGBDKALCUQQ3Bcpn3BwAAAJ4PSO9mtjmX3t5EcSNsIOlFAkIZ AJYay3PeHwAAAFhEpj1/++sV/JY5Hbx7puzdl+/IPSkglAEAiIgwW7R85v0BAACAxSXgtX2oS1Bn 52epVfktYassXjZAKAMAAAAAAADA0gaEMgAAAAAAAAAQAKEMAAAAAAAAAARAKAMAAABABGR7ZjHQ 1J2Rn16q5aHKNCqvAMCrCghlAAAAAIiAQjLOuk2Z77xcGw6AUAaAyIBQBpYgYbuIc9CUd+SBdPdy Odwwj/xe2tNTXI1P+5uXF9IxBO/0t+7esHqrXpuiq+4ekhxlQnstxa/9SnJoS9BrObi3986M9+u2 wi1rk3RpSVk13YP8ASv4beiMJK0+aZNOueP9skYslym35UCyOiO//QpvBHQQ58bWDVp9mmpr0X/9 zY0yELnnjozJTRPPoBntyX9Hpc3dlZ+fHWsWUS5TyVou6IC3/2SRap06S6tOP9I99Ji5WTiGZkty hVlads9GuPFLTk9cPISc1OFzf1i7wkfkrFHr8+WH7wgsoXfSF5dXQTIq0/gqpBoAYgOEMrAEIQrl gNtUsK62f2Ju8mqrvrTXy13m4Yd5nsju9dtqdpo9sejGp+0YQs5W1fu9Pu7Xggj6rLW5bVewKKEf OdsMW9sHObVF++x1GaqEdRKh/MBWfaDr9oi1svSk8xG+g7pyMj2HOa+YnhnuzNT9zom0Gj3uOHny by/T6dNCuYQG2zcXmNySJyV8YrO2xoaP5cYHNP6v/dYMLSvH6X+0qbOYLJKoOnzMbFax5XZUowh4 zzVkqBPXM17RvrMHDL/H2YvEsfN3usT2IfR1Ycekx86LEMqSnGTsKqvNSUnOkiSyPIVycMzRsZ85 RA093nzumkYpRglJ/I/aw0X6nLSEjcXm6/gUd1Q3B1oNKrXkMDDmdhbOxnBJvbHnyG8LDfla1dtF Zjc+OxdlIHvamZ47dA05XrW7uaVo7butV0MhavB0mTo1e2e6WvehjT05zHepkz2kTaWpZI8mxQeM Vaeps3bpU5PZo0Ajn/2GnqiLtnW48Oj2tKtD/8sqG3OI/wNblb5x4BHxRuWxcJJaM+2xHMyo+7vX w17x9BTm8oeiTw215xZZYmpNAeBlAoQysAQhCmUBwvnYEqT30pP2Y7qOazFNkUoF1kKIl46R+ENP D/537t7/sXwoSeakvS6d7Q4FhHygrrbmvLQdmFAuSt1GVHKychSySKrq6MBA49pyqzA+Ghr+tKCo ucc5Jno0c7376KfO4W6CSfCBBhzGDZwowc9j1SqjIxCXElhsoTzt6txX3HzG6ZM8cshyks+0l1Io 02NXLlxjHk3vWys01bYHTEJUhlNOdJF2mzI2M09BE/11m2us+IEz4LXWbggzA87GcEm9nvMxI2Rv mHR6RlD6Hc36IvNN7Dw4dn3ETyPHKzT4fGB0RfSWebjd0emaoWmf8wIzR0E/tFa+edjmn50bt1as bryIzSlEjbjvB0MT9g8SK88yh5NPujqKMjuGGDXPMHutc9u+Hi96nvP0FCeqUk5gOwxcNqqO2PxB 0o0P7bX6A1YvvjYz1LmjqHN4kk8Reg78fW7RpzhF3JUnHnOJhm1CcUAlXZ4nOFAAeJUAoQzEEcVA CGH8RjHiIu1xJT0QP1SzaRPrFScg+ofMB9MSVq1J0u83u0LIvTBaMyrey+sMpCDL25yDPYU5eISM u4I05e0Z5SgOFzQSEsOWioxkfV62WsNM3Ad8lzuZQSDtBnWVxYX8YaL3fmNL/vq12vw92vUr39ya vQ/FJoJLxZgTiaCvt0LVfBmLl+DNrqI9ncNjkucB+onzo+zW72V9FB4FzDI6JpievqDTxQxFEUD/ 8gNmKMO//N//qcgz6NUbCk8zxcHvYE8cOVs8Aj/5fhjy/RQpzhK4cvHZj+eoVqxR66u6xJSiLj81 rfH8Pek6CqEcMeP2Wh0vhiIKZXQl6Pu+p7kkI0wuy7zioH29ZQlIE8+MmksyTDe4gLFOKukaFdXL PNmO7baw7uie7Lx0ta7py686K3NyspO2FpmGpqMJ5eiFpRytFA1Vfgp6wOc8YyzSS+Ty+MWGvMre 28g/mrrUkrq/xzsTs1Cmgx7LXl2Dzet/Mba0MEKU+4Kp9UR791c9xzThD1FciaMH7Pq3a+3c6cBK M+CuSEuK9wQ90K5mxK6AePus33b47YYB7gGFHunKKcYzJPTErfN/ajOe6h6wNLAZjvVrRo35Hz7O sB/YqjIbB7iHMnrUbNCZbokmj9q0Amzk49bK4o8txytRUzDr6tCW9Ppo0o2PbdVvsSocwZsxjuTx Ac/ZGl29FVuOGG3aY87dgYNDTxGZhthm5wDg5QKEMhA/wgdCUOOqHL9RjLgQOircA3FDNXPUYHtB lun6rCggJCPKyL0wWiO5l+u9Zq91ph+zTwaUgyKEURzu9tC49eBatjOj/SPXkWwK+hwD/8QxCT20 HlqDBxFxECvVxxgtItUxZJeKMScS01fbdczQzlxo3FavafxugpYOnE+7OsrqZGtE6enBP2QwI1KM oMlp7jhm0GaRFuCi7GUHzHD3/4aqFneEODK6NufkPCNni8SjixfSEjvX/FunqvS7fzziLkaC77CJ uo2mrvVUb389qbLj/E1sZgjB/VzgwY9/rtzRPDCOSkRiY3jpRUau2S3NIwZBLrecdf8LXxC9EsDW yAzLSUsHIfGfI2q2I59fyz/1I7JAJOW3bKg+i4oMD2fi2XmJATOIBha9sKjvGjeVMUtBQhMDHybm mj2zMkNVIMjls+5pmslJvW5/xa6UPScHvNhjnOHvadPTdTuZY8AGmCUuIlyS8VINw74/Dj6mX4gt LRDa++XelMNn3I8od2+dml3aJCk7rsTlRaA0A4Iz3pOIjtE3pjXQlh9vbjZyn49to5S392Bq1Rdu 6pG7tz55BWfhqDj6jGWp6t3GXtR+Is/Xp5U38Hc1Gz+yjYpSHBnY0U3Nl8bx7NnQY1u93jR017I/ Ez/FkW68g2xPW/Ehf6XZ+DubZxZF8hfpu3Lf+2VpL1fMQrS5NpPymPfmEWoNALz8gFAG4kf4QAhC MX6jHHGZr6OadXVsxyMowkW5UBa6JcW9SHnomclxPCjCLONDXmnYQRHlKA53OzMlmnK4SzKySFM3 z5tOtrRbBiz1jGSRRU86Mx7VpSSZ4VDDHbs1xksTKGJTl43bDjNqQ5JMJLCy6mWZNj3YachtuTyO MxoLmlWp7O3BkZ4SXZ39IeuKQQxXElX24sQ8I2eLQmjyq/o/IpXMfP54yMaFHgkhVhEHOJHgszTl bNU1fY2nmJF77mW+/Oyk9WlN9gc4j1B62Zf5CpSrPHnmFcr09PAnudtOOCbw81sMQjlStkvllNKY sc2sTNAWMK/QMRFevxLfHn2YE/+7VlgKgsRNaqHJPSk1VAVSoRykBj8tTj/QcfZvlsZCvESVecq9 +Mmf7Vhk08Hb3UXvNl2clGYak5aBIWt1QY11NDhP9JYIIV/v/rVcvIScl5QdF+350iIpqfDaHW1E mQ44jCrZVAbC2/e+jgtdYeE05TyVk2V0jDqa9RXWMe6qEr+tWnui66OD6Dmc9vXuq+z4S1UJM8U0 QbgxcNmYcMiKnx4loEiu0Bz92vl1XS63KkOMNnpKLy77cuDLkuLI01YA8DIDQhmIJ/KBENL4jbLX IXRUMiWquKjUFkRnQV9v9W525S7t7srd2yUOiswQRnFEr0LUcF9LiTa50Ng37Kfp0b5SffUZF0Vd 76vVMJJFFj1RBs3jUpJMGaGJyye2p7LyC3fkeCEHVki5zAqTAqPdhzq/vcUWpvtioMcdRv12Vhnj nyNdOaX8vD8KsVQ+zy6Gq1Bsj0j5zP5YPOgnl/7LxAnljabj/3eeNY9CrCIKZYbpq+3sK2jSVNBj tuoc5rEhUuazxLT0gp641JKq5x5OhDlr5q8ISy8iZfv8QlksFPF2+XV53Jhyl95FKl8RxdKL2eum THZCQ5ppErCNZeCxcBEUxEZ9fubaX1T04TyLHr0lAj050KRiB01pn61aHUEooxp2ria2Ncp8kgVP SGuUhdvxC6Alppt4Wommfvzsk2999KOLDZl7e+/gGPltNasYC5+5ffHSXXwHjmR6tc035TypyT19 Ey/cClGDX3xqv88ZHgvt6Slav+ado3b0JINMccc7aza1MCvmadKNfmdrXp7JhY2VfjzYbf4GJVOZ cEm08UKObVqNJuwdCQB4VQChDMQffiDkIWH8ZuEjynhK+mlGlB/YqvbxmyQ88Zj3FVu+thTtY15G IY3iSL3ChKgfPzZsbnGMfFm6mrtOlCyiDPL1RnUpSaYIHfT2Vq4r7BwOu44Qkjnrx9OpvCZDPXfv ofdyPhlmFnwzjNtrM/mFGUjA7U4Uds/AiOEqFNsLGVFG8fC6f19tVqWYKzrd94irAiQIsYoulIXs kqVCyH9i5nMQXuZjkXoVvN1XkWroGOSH1PDoYNSX+aJk+9MJ5XiNKJNe5iNnmgQslNktVgRQWtYl 1/99+OuG7fh1sWUxoowSd8fWWJhdXl9fXf3rrI1MzktsQ4x21OXghJISPeHfwTBkq/V4VZgsK+hp l6UmPSVtZ64uvbSt/w6SpkHvuaac3Ipj9TVH9ul/gS2cpq6dqctRa3Mlsx+Uy1KrS0ov2JmhKzrZ H76WJnDLlMfvd4H3vnhDKAjijdPDPdVZ2P/0jOLWr7H/YiSDPmtNYkUvv+sFdj735Pu2TW9sj/Gt aAB46QChDMQPxUAIafxGuUZ5zFquZXSeMHiDeyDpGmVmVajQLcUmlCcHGtNP4RfYGdhBEW0e+zIK aRSHu52eGXFcYroT/BfS9Pe+aUyoZMbMQn7bkTfC5a9EBqEQo7mU9McC00OmQk2Zxc16JUdIJopt Ga9R6Onh00UbK3o80jlQespxQoP6NtThBW92FeqNDk4vMYjhKhXbPCNnSwGhiJUT0xOXTh5mX/RE 6uTKSd1u/FwkNQn6J3udrqz3rmwdfOyIXlEuU+mmEotHumBjnu3homW71OeYhfJ8w5wR1ihLvYrI kx/at+Wx2w4yq3c0lVYvCu5w5vF+rKfxpngZ204NPpEkX0gLHoHOOmD1zi59WwKeDtrTU1gI6y6A VxYQykDcIAyEEMZvFCMuc0Fff2Py6q2SwRvcwUfY9QJ1vrPU5ROpqtS00s88XokqkuuMwNCpDHYT CRY8xvYrflCEMIrD3x6ihr+o1+EhH35TjoDXdtygL2+oO/yb/Rm/DJe/SKBcMqZs0WoPdHsmorpU ajVmoQW3oBZ/5Gc68BIqNNiuY7Z8wnj73l8rWcBaarQzOzhzu6Xq8CYeZuEUEpaoig2nbmnvVCBo SuWIMu13nWk0JKxT6zPVCVn1Z5jXRpF7cY3yprRqC79Xbljmx4AQtK+3dMX/YZc440/hCTte4ikc OCKYqJSo2S74vBChPF9hkXe9kHoVGZSW7hrteyqtTr16SxE7yjgXuDfwh9LwY1YExATifaY3V/Ut j10vgAWDd3pJYnbNA4BXEhDKwEsJPe2++A37StZyZ9r9jd39PAZzkFDDuy5wv4AlzRIvLLCll4SQ z/qBTq0/2i9fFQ0ArxIglAHgFSY48vcz3zMvBQbuWsrX44MPgaXKEi8ssCUAAF5GQCgDwCsMXhuj VyVl7dKrN+ScULwkBCwllnhhgS0BAPAyAkIZAAAAAAAAAAiAUAYAAAAAAAAAAiCUAQAAAAAAAIAA CGUAAAAAAAAAIABCGQAAAAAAAAAIgFAGnjs0dWfkp2c7iyDaSQo05R15sKDTFgAgFkLUHc8D6eF8 0XiqI05iYsptOZCszshvv/Ic95Xgk8NV3uiVa/HSDgAA8LwBoQzEkcmrrfrSXi/3KwKzblPmO0ft E8wZeU9JlH464DYVrMN7uIJQfimJycYYYncZG7PXTTtS6+wPuZ/zsFCxGHNsQ4PtmwvwYd3PFS45 fOV9AkIZAIBXBBDKQByRnMe7uMQigkEov5TEbmPPzRqJLFQsxhxb5VHez4Ow5MCIMgAArwoglIF4 Me0yH0xLWLUmSb//L3/tLizsdOFzl2ddHdt/cdjmn0Vf/bYjqoaByXuWXW+yfWyIGjJXqrek5aWr dR/avIE5+vGgqTxZnVWgTcloPOcNm+amxwZa8jckZRpyKhoOaZl+OuC73FmmTs3eqd2grrK4UN8s dOHslwGPZe/W9kH2MN3QUPvWQos3xslzYCkwPWypyEjW52WrNWWmi46/8DZmdoWCY46O/Yy1bEmu +Nw1jcoVSbTE0uMNu1avS8svEF1yfmFo6gdTiSZZb0hLMjTZ7jBSL+C1fahLUGfn5FUeq9Ri45QK QUH2MV8uD/YU5rQ5WRVIXW3NKbLcnvFd6mT9VGkqLcPMeePCXSFq8DRjoryRM5b5xp4jvy005GtV bxeZ3TNTYt2RxVZ5r89+PEe1Yo1aX9XF1C8WmhrsqtBs0Or5RJHrxRvvN7bkr39vz57czW1XnzDV 4Mn3bZv39qCaRsiWOdr3TUtOolqfY6ioq9Jsx8nhKq8kfwh1FoQyAAAvDyCUgTgijIpNuzoKiywe ei7otezfkJBpdEzMzU04mg3Vtgd8Xzs3N3XZuLms6zbq7+ngffcINTNh/yCx8qwP9+CTro6izI6h GdZjzKz4b3DUWr2VVcM+x8A/KSQtQg+th9ZU2fzhQtkx4zHnbutw4YUeKFYFuWY3IxCAZUFo3Hpw bcMAXmdA+0eujwWlI6/02JUL1yhUnPR9a4UGmxaWaOuS6/7OyDXiGO1De63+gJV5VpoZ6txR1Dk8 SY+fq9lcY/Uhiwx4rbUbogtlx0OPuUTTcQ0b1Oy1zm0lXZ4ntM95YegxjshDa+Wb7GMhf9dEfx3n OT0z3Jm5o9M1gz1/PefjQWS39A2TTt8+NEWOLfVd4ya2goQmBj5MzDV7kMeEEWW/o1lfZL6JLwXH ro/4Ub0j1ouV6mPM46i7y1AgPMdqDGYPTcgWSV7RQe/ZGlUKSSjPUgP/uaWw24MynH54sTEzz+ye BaEMAMBLBAhlII4InT39xNmmxt3zmLXi4J8t/2lAwgKpCs2BPqQYuL6WnrTXr8VuBB7YqjIbB7gL 9KjZoDPdwl03y7i9NrPOPs58F3UMTd08bzrZ0m4ZsNSvybfcUwjlIJYFu/GaTiRKdpQiWcP4ACwL GHGZcrjLiSQyi1RQhij3BVPrifbur3qOaZiLUolGkp5+W/VbjRcDrFXNjJpLMkzXKXv927V2JAwx yhHTcKFM0fyjF68yUTQnbp3/U5vxVPeApYFTsaxjv992+G1W6CPoka6cYpN7kuS5MrbyCoKqT2oh NmOlUJ60161m1blI5HqBeMJrff7RkZAtN1DwdW/V2yfZi3w8w/MH1Uod84iCwdNHuM4KiQIAAFj2 gFAG4oiks0e97EajY7y/Lr3D9chWnWVy37UU7WCEL0GLsKD+dX1aeYOxuZn7fGQbFXt/ae8riODR vlJ99RkXRV3vq9WsJAplXg2EPOa8XEbWAMuJEDXc11KiTS409g37aYmN0d4v96YcPuN+RLl769Tr YhLKyPZe01Z8yBtYs/F3NmSYEjuMQSjjEdncvV0eymPem4cnKGa8vQdTq75wU4/cvfXJK6RC+RHy 53Vt+XHBpJs/to3GKJTDKgjvUimUuThzvzDR6gXzP1sXQmxCnpCyxTMr85YPPTx/hPgzcP/KLwIA ACxnQCgDcUTa2T+wVZX8t7klt30wRN/t23vkz3+pSWMnrLneVDmiPOFo1ldYx7hf4ZBGlH29patx d40vOZrJI8rMQJe2xPLDlwe0bASA5UeI+vFjw+YWxxQyEtbGQr7e/Wu5whcMTyrRSEI5cNmYcMg6 Llu0jOxwQSPKzIjsvmLL15aifcwEhbfvfR0XqKhiOccBh1FVbmWtlofouTK2zzCiHK1eMGCtX2G5 /Jdi9tGRkC2MtzCiDADAKw8IZSCOSDv7oNeyd+2bWxlpG7hlKljzJuo7J/A/XF+rXKMcnHKe1OSe vjmD+uYQNfjFp/b7kvHf0LitLnyN8uRAY0JlH56WD/ltR96IIJSxyNCkpm3j1mUCywd6ZsRxCb/E Nkf7bTVYDvp5G6MnB5pUpb1jyB5on61aHZNQnvM7W/PyTC689p1+PNht/sYXlCwjFtYo47XRa7B6 lizPlXiOH722abV57ATFo4sNmXt77+CIoEiukgnluakrbdtKTDencIDUj5998q2PjlEoo2tPu0Y5 Wr1gwdMsGq02n1uyT8oWesxWnQVrlAEAeMUBoQzEkVnq8olUVWpa6WdIQNBuUwa33wUz1LSKH50S hDJSw+yuFzuzktMbmJf6KZelVpeUXrAzQ1d0sp9RSCLBO7ZGvUq+64XXdtygL2+oO/yb/Rm/jCSU 8e4E2p+nsq/0AcuIEDX8Rb0uJW1nLr8bg8TGZpA9FGaX19dXV/86a6NCKMusUWR6uKc6S63NLUjP KG79mnntT7nrBdLe54+q35Nt+CD1HI/v/mo7N0GBdOS5ppzcimP1NUf26X8hF8pz9LTLUpOOk6BL L23rR0kgCmVibJW7XhCFsrDrhSFbra8/h3e9iFwvOHCV/JlefHQkZAuTrvRNsOsFAACvMiCUgVeB oNeyj9upAACiID7FAQAAAAAIZeBVgL7bV5LPbMIFAFEBoQwAAABIAKEMvOz4/laXnqqrP89szwwA UQGhDAAAAEgAoQwAAAAAAAAABEAoAwAAAAAAAAABEMoAAAAAAAAAQACEMgAAAAAAAAAQAKEMAAAA AAAAAARAKAMAsLTBB80Y1FqdOkHPnDkiJeDtP1mkWqfO0qrTj3QPPcZbm+AjOdao9fm78gvQp6iZ O/f8eRGi7nge4HM3nprww0Fk0NSdkZ/kp5YAAAAAiwUIZQAAljKTro6ijLYrFD1HT1w62fR36TZ/ tO/sAcPvnVQIy1Pn73SJ7UPoK+nsurgQcraq3u/1cb8iMHvdtCO1zv6Q+/k0RBPBs25T5jtH7RNP QCgDAAA8B0AoAwCwhHnyfdvmvT3eGAShoI8XTSgHHc1r8HHQi00so8UwogwAAPA8AKEMxJHRnnyt 0UHNzdEz7s/3qlP1eaeuBIQBQGaWfOOmtDztho27W603KBp39isTtAX5Bbt2oov7TYPM1Pk9y64V 69N2FuzKzyLNtpOYHjIVvsfphuCd/tbdG1Zv1WtTdNXdQ3i4EcXo8ZD5ULIqVavSVJoHqWeZGJch JJmFcjRrd1lGuV+RoSnvyIMA9yMMbm5dyrPP5i9bkDGkdrhiOHyc9vWWJRgdyN6iC2Xk4arCuqN7 svPS1bqmL7/qrMzJyU7aWmQamkb/4mUeelVSpiGnouGQVqpEQy7zPu36lW9uzd73P+e6+RPRZ691 pm6qtj3ALvy26oSmi5O3eZMIUUPmSvWWNBzQhzYvKu4QNXi6TJ2avVO4IoEeG2jJ3yALmg76LnWW aJL1hjRkt5ZhHEPuSBReKHstRew4OiI02J4Y20MFAAAAEBsglIE4IqjGqaF2fYbphlTZYR2zrtY2 jrt0mhr663n3jGxUjJ52nkzezHT5ktPR6Invmjbv6/HO4B+RQOKmLic5aR3jVdBnrc1lZurn6EfO NsPW9sHQHD3lPKkp6vYgrRm82VWU3+b0c/c+K08nlANuU8G62v4J7qcMfm59VpzojzabP3m1VV/a 6+V+vXTgQdysxs7GgjR9ZtSnJmqwvSCzYwgbChbK72nT03U7s9Sq/JaBMdkTBrKu1/JP/Ygeycbt tVs2VJ/1Bmnabcp4t/VqaHbC/kFi5Vm8uiM4aq3eKhXKCGFEedbVoSm0eOk52mvZrVKlNl8OzNEB h3FDlc0vmMTUZePmsq7bSNzSwfvuEfTANtFft7nG6kNe0jPDnZk7Ol0zQtTIQdM+5wVm4TX90Fr5 5mGbfzZcKNPuLkNBpwtLaBwrg9kjSy0AAADwTIBQBuKIoBoJepE0bS2fPhYGAiVCeW7Of7FBV2Ed Y3/MzU27OvcVN59x+oTROHrGbfntHy65SDPRfKATjmYDN+w3N+u3HdmAlU1ceMoR5ViIbaI/niEu QXAmrNC1XB5HojR490zZu/gRgvtPhJ4e/iR32wnHBDt7MHbxkz/b8XgtHbzdXfRu08VJiXgUrUuS ddxFJJ0z67h3/+TGySCWyJPv25Jqbf7guLV295/+0pzT6ZqddnUUl/XepTmTmJi016/FulkAGd7h txsGOMOjR7pyik1uwQwjBE1P3Dr/pzbjqe4BS4OsdghunnjMpZn4oTRwy7Q71+wGnQwAABBHQCgD 8zIb/OnW3R9u/Ssw7/w3KxH843ajLmHVmiT9frOLnRPGTPTXvZPZ1H9XojzkWmTSXrdaOmbGXg0T yoiAz3nGWKSXy2WCrEEXfb0VKqSJ5aIEDx/mmEelggKFGHE6Hvv8xp4jvy005GtTMhotX31aZcjJ VKtKTcNIH0cWypEn8SWxRbcn/kft4SJ9TlrCxmLzdTwgyiT/0pAw0Y8ykQ8lOObo2J+szirQbkmu +Nw1PeUyH0wTszrqzP7yhB41G8TCQvmQ2eacZH8I0BOXWlL1jJhWgIs+Q3aLaF1KoSwtTYJFSR5d kK7NMzpG7LVlna5RW9U+k/t6T+EexsZYTx4pbscevq4tP97cbOQ+H9tGhTIiBj3j7T2YWvWFm3rk 7q1PXkEUyvxAcsjdlbu3y/OE8QEAAACIDyCUgeiEJi+dNK/9t841Gz81dIyyI3YRETp74jBniBq2 1KjXqss/Pu+eYDSNRIsEfYOnD2U2foPFjihlmKUXm/aQun9BLp91T6N7CLJmbvpqu66oc3gSCRzZ olWJ/xzoSsTpeEbf5Hw8SIWwlF+1tcY6GsSjd/nrW50hmb5BCAmPPokvxBbdrjKccuItHVBw8pUn ElnGh0KPXblwjVlVct9aoWHGyCVZHW1mf9mC8vytejs7JIxVb0770BTzB0/wdl9FqqFjEC8+UKK8 RSx9pVCOeUQZDw/Xpf3h9O8MfxgKoeexIwf+/Em1ll1LzRaWckQZr81QlVsj7FVHDNrb976Os67w +RZJ9GavdWoOfPmDpUwT02JuAAAAIHZAKAPR8Q0f0nSuQUIZfTRnv4q+NVZ0ocwQHHNamgwqfZP9 Ps0IAu5lvvws9erMJnY5KZIC3Mt8uWlJhgjLUucVytRwx26N8RKW5LEI5YjiSeKz6I9wESX5HZU2 l92yF0c44R3m9uiSS3o7r7OFOPBfCEIZPWy4L5haT7R3f9VzTMMEJErzqDP7yxe/o7mgsvc2frPt dnfR5hbHFDKcB9evP2Dyk3KZSjeVWPDqcx56/NzhzOP9eLYB7xmXse3U4BPx36hlHRq31cWyRhlB ey3Fq3+1rtY+ib67TZlvrtnCrefhC0u5RnnqStu2EtNNrNpp6sfPPvlWstUdMehHFxsy9/beQddo v61mVQShPDft6ijQaFO17PuFAAAAQPwAoQxE5/Ht4//OC+V/v3DpMXeZTAxCGUNPD/5Bt7nt6hOZ gkT6pmbzB3gFqihliMSy9CI0cfnE9lRh0WoMSy8iiieJz2ShzCtdjHC79HpY3BCk24U48F+UQpn2 frk35fAZ9yPK3VunXscEJISI/Yw8s7+MoakfTCWa5CzNBvWhLvxm2+yE/ejbbzGLlX29pSv+j/ig UnjCjt8WDdwb+ENp2CkkAtHKGuVilAUz6I5LxpQtWu2Bbs+TOfqGSbeFW/iO975I5J+LhDLld73Y mZWc3sCshKGnXZaa9JS0nbm69NK2fvkTICFoOug915STW3GsvubIPv0vIgll+omzbcvP9OwrfQAA AEAcAaEMRIcO3fv2u4rcT1W5fb//1j/PDmWCRJBIECKc4pyWK0j+dlHKKFG+zMci0w1Bb2/lusJO vIaYZb6X+aKJJ4nPCxDKizGi/NjXu38t548QkPAl+sw+sFBQGZUyq2uWAbTXUrQN1l0AAADEHxDK QByJIpRDE5f/+8gnV5kNjJkJ8UyTe1amIGl/f/27FX0+YcyMuRorEq/wnsqaMotb4sF828PFXyhH n8Qn3T6/UJ6YHGhSlfbi5Sm0z1atlgvluagz+0As0EHPhS8czEuBwZGeEt2zHbD33Aj6eivVeBtE AAAAIM6AUAbiSBShjKTbtTMNearVW7P1alX60TPD/vA1ygkZNbIjFdj7YkSQniFf7/6V3BJn/Clq ZsZ1xQNH1GWmH8IPHIm/UEZOYtz1IqJQlkz03+CcYT8Ls8vr66urf521kQlolrp8IlWVmlb6mYeO OrMPzA+z1CF9k1qfl52UaDBe8C6DQ1681lp9cnpTP36JEwAAAIgzIJQBYLFBsnjZTOIDAAAAACAA QhkAFoNlOokPAAAAAIAICGUAWAyW4yQ+AAAAAAAyQCgDAAAAAAAAAAEQygAAAAAAAABAAIQyAAAA AAAAABAAoQwAAAAAAAAABEAoAwAAAAAAAAABEMrAEkRyxocEmvKOPAg7uVoCTd0Z+SkYdi/t6Smu xqf9zcvTnHISJ+jbPUVrf84dwhfw9p8sUqfqterUij8PUsLmy0Gv5eDe3muOZvWapCz2LJVdhSfs 44wDfBjhe8ocexl4geXyYqCnh08XrVZLTrFRELzT37p7w+qtem2Krrp7SDSSMMj1CAAAAIgdEMrA EoTYwQfcpoJ1tf0Tc5NXW/WlvV7uMs+s25T5zlH7xBPZvX5bzU6zJ5ad2Z5WkIWcrar3e33cr6cg NG5v1Case50RyrT3y70pDYz8DXh7qzXNl/GB1JgHtuoDXZ6HyiMP8XF9dTnJSetAKC9/6KD37/W6 FPW7KZGFctBnrc1tu4JPl6QfOdsMWyMeXg1CGQAA4FkBoQwsQaJ38ITzsSVI76Un7cd0HddmmT/m 4WkFWdDRvIYbDH4qpq+2G6p7LB8wnoTGrQfXNgxww+aT9rq36u2TjMxH39M7XLPKtNMzbstv/3DJ 9bJKoldLKE+5u1v+2+m0yM5Fj0ZU8wOhDAAA8KyAUAbiCOWyVKeps3bpU5NLTuNlA8ExR8f+ZHVW gXZLcsXnrmms+WhqsKtCs0GrT0syNNnuBOdGewRZwKki3MG/sefIbwsN+dpNm1ivuF6/f8h8MC1h 1Zok/X6zK4Tcr9rd3FK09t3Wq6Pivbw4oK62lrc5B3sKc9qcrOxAV3KKLLdnfJc6SzTJekOaSlNp GZ5G/wiCbHrYUpGRrM/LVmvKTD9QdMB3ubNMnZq9U7tBXWVxIX+Y6L3f2JK/fq02f492/co3t2bv Q7GJ4JJLiOrtIrN7Jmxwe9pj3p/VMTTFyZ2Qr3f/WkHZ0DdMupKu0Rn07Ynzo+zW759EfEiQpppF GnRKRqPlq0+rDDmZalWpaRhFTDgPJcdQUVel2R6jLIsbgZ98Pwz5fsIZPw9CueCyLqw7uic7T6t6 q6zLjYfaSbaUWHq8YddqTZtzkqZ+MLGlzP2LckVpkAqjnQtRg6eZckxX6z60eeWrfejHg6ZyxgeU q+e8wRmvZW8iLhr83xNnW2KhxUujiCmCFmx1XX6JIbd9iJ0qmBpqzy2yhM15SGrEPAR9vRWq5suy KNJjAy35G5IyDTkVDYe0jFXQwTCDpz09hWFxuD3l+rxSuz07PytZXW4afCyJktKw6emIjgEAAF4q QCgD8WPcWrG68WIAdZohasR9P4j0wtiVC9eYOeL71gpNte3B3Jzf0awvMt9kVcv1ET8dQSi/nvMx o1qowfaCLNP1WVELSsQicr9CU3+OFyJhQnn2Wmf6MftkwGMu0bDjyujKtpIuzxPa57wwhHt3+qG1 8s3DNv8sf7tkTJf2j1wfCyIt4hj4J6OfHloPramy+ZmYrFQfYyWUZEiP7JJLCFa9el6acNDj52q2 Hb84ERI8wQtINn2IruClF+eOJa/YyuTMtKujrM4+jnLD0ZyyXpOuSzfgA/9avvFxCkWSag5J0JP2 ulVba6yjwbnALVP++lZnaO6hvVZ/wIoVXdB7tkYVZaJ/EXh08UJaYueaf+tUlX73j0fcxUhw5cJ8 eS3/1I+o1FAqChLxegOiLa1Lrvs7cw6ikMa5uZmhzh1FncOTBINUGu1Ef93mGite107PDHdm7uh0 iY83sxP2DxIrzzLZPunqKMrsGHriMedu63Bh80LFVJBrdtPEoEVbRXeEGyT6KiFmoTx9tV3HeC4i iWFw1Fq9lbUKhcGjJ7SwOHis5brGAT+6QFOe6/el2ltp2GORHQMAALxUgFAG4gfWBBk15n/4xOOa Q5T7gqn1RHv3Vz3HNFjdItG2mhGmImShLMi+WVfHdp3pFi1clAtlVkWJ38V7abdJjzv1OZqXMsgr jYFZskxP3Dr/pzbjqe4BS8ObJT33gvztjDZKOdzlRBKZg6ZunjedbGm3DFjqGTkri5507juqS6X6 QTqvgJVTEk8o11/KN6m0BXqdofH3zVkafAsS2Vn1TKYFfQN/+cTODo7e7CpEYoUVmrIoMUiuBB1G No3CRemijthlWXwITX5V/0ekkpnPHw/ZpCqPgFDEYllLUhHFlvy26rdYBYyYGTWXZJhu0EqDDDfa Wb/t8NvC6hd6pCun2OQWhOADW1UmKxAR9KjZgCxz1t1lKOh0TYuqlxi0xFaxQe5AJo1NNJM1SBkx lgg13LFbY7w0Ibt93F6byTxTISQ2oDB4RRyQ7i9MrTY7fQTVqzDsaI4BAABeJkAoA/GEpq71GctS 1buNvXjcjsavph0+435EuXvr1OuwLpHIBZ55hLLiYoxCOejrrd7NTmrT7q7cvV0eymPem4cH/Ga8 vQdTq75wU4/cvfXJK6RCGbkOUcN9LSXa5EJj37Cfpkf7SvXVZ1wUdb2vVrMyilCex6VC/fh6S1es Uevzd+UXFDDrNwzNnMDhQMIrdS/WNL7evcV4Ql8OUmDFzPAwQp5jGMkVpVCW5lussixe0E8u/ZeJ E8obTcf/b9hoajhCVMU4E1PBIrel17QVHzYbm9mP8Xc2T0hpkOFGiz1/XVt+nLsLfT62jQpyEPm/ Pq28gf+r2fiRbXT2CWtXIY85L5dRvaSgZ6Wx5SS1YJBhsKlw25tLue1NxE91F1LkmNDE5RPbU084 8OSDFGlp8hlFNHhlHGi/q/dEWcr2ouY+Fx4/5iEYdmTHAAAALxcglIH4Q1POUzlZRsdDyYpbXt0u fESZdpsynmZE+YGtah8/FoikzL5iy9eWon3MNLe3730dF6IgIqVeYULUjx8bNrc4Rr4sXc1d5zWx LHqiUEbCN5pLqYIJRzKiLILH/BLbh0Kzflu9Ho+GhoGE8m5mBQJCFiUGyZWlNaKMYuF1/77arEox V3S67803JCmUi1hAklREsaXAZWPCISu7fR6HdAm4xIoYeKN9HHAYVeVW2ROLyISjWV9hHeN+8aCS yiv6y2VLBac4CUHLbRUv0igu+3Lgy5JiPBQdzrwlQge9vZXrCjvxcvMwiCPKJIOPFAf68eCpwkRx uxWiYfMoHQMAALxcgFAG4sfM7YuX7uL+lPbZqtOrbb7JgSZVae8Y0g74iprRJcp1pWPWci3TtQe8 1toNvNiVrlHO7BiaEXv92ITy5EBj+qkhXqvMujq027TaPHaa+9HFhsy9vXdwvPy2mlVSoUzPjDgu MYuP8V9Ih937pjGhsg8vxAj5bUfeiCKUUYjRXMYmlJ/8+McP/j8PXt79yNmWzyQcxbaMW9xMj9lq djf1e5GHNHXlpC6vffBf+Lo8SgySK0qhjPypznpha5QXhFDEYlkLSYu63n3O72zNyzO5ZtBXpOe6 zd/4ZggGGW60D+amrrRtKzHdxBlOUz9+9sm3/EJwBD3lPKnJPX0Tr1oOUYNffGq/j/+cvdapSU3T 7OVXGyuDDn8SYw1So2EXN4cxn1DG22Zryixu3jMpoXFbnWKNMsngw+MwNXLxH8zabmy9a5k1SxwE w47sGAAA4OUChDIQN2jq2pm6HLU2l98QgMZb/DYWZpfX11dX/zprI6tu+Z0KDNlqPfNuU9DX35i8 emt2Tl7lsUotL3Yj7HqBev1Z6vKJVFVqWulnHq9EfMiFcmDoVIZ0NwC8jOFX27mt4pg9H3JyK47V 1xzZp/+FVCiHqOEv6nUpaTtz+f0KAl7bcYO+vKHu8G/2Z/xSIZTnqEvGlC1a7YFuz0RUl7EJZaSr Th9MTdLqkzbp2DwMDbbrTji4Ba908N637e8nrk3SpSVl1XQP4vfSMPIoYSRXlEKZzYEXuOtF7EQT ykpbkmfy9HBPdRY2yPSM4taviQZJMFq8pYOlJh3bgC69tK2fWREuQrkstbqk9IKdGbqik/3cnhjT rg79z1MlqlcZtFwozz35vm3TG7xBhhFdKONx8ZUr1qft5NZjFIWt2MFp1KvCdr1QGjxCGgfa7zpz NAOnS7nXh6IKRHMMAADwUgFCGXgpoafdF79xs6Oty5xp9zd2dwz7qD01SM2q40UAAP/0SURBVJZl tjnneacOiDN4g7ZC0rqL58hSiAMAAMDSBoQyALyCTHv+9tcr+D0wOnj3TNm7R+0TpJFNYNGgfb1l Se3C0qAXwlKIAwAAwBIHhDIAvIIEvLYPdQnq7PwstSq/JXx1AbCohHzWD3Rq/dF+Zn3zi2EpxAEA AGAZAEIZAAAAAAAAAAiAUAYAAAAAAAAAAiCUAQAAAAAAAIAACGUAAAAAAAAAIABCGQAAAAAAAAAI gFAGnjs0dWfkp2fbZkF5voYITXlHHgSiuwFeFuY7xC4+xMWWQtQdzwPlySMvhueTbwAAAMseEMpA HJm82qov7fVyvyIw6zZlvvOMG/dGES4Bt6lgXW3/BAjll4OQsy2hvM8XabPfZxF8MZkrw9PbUsjZ qnq/14e+zV437Uitsz8kCOV50vg0iOGSAaEMAAAQEyCUgThCOZq17DnVi0wswgWE8kuBeP42kWcR fLGb69Pbkng4uYBSKM+TxqeBEK4MEMoAAAAxAUIZiBfTLvPBtIRVa5L0+//y127+aNxZV8f2Xxy2 +WfRV7/tiKphYFIUCiFqyFyp3pKWl67WfWjzBubox4Om8mR1VoE2JaPxnDcoPwyBHhtoyd+QlGnI qWg4pGWES8B3ubNMnZq9U7tBXWVxoY5f0DTslwGPZe/W9kF2sC401L610OKFIxaWCyFX19501Yo1 an1Vl2uapn4wlWiS9Ya0JEOTjT0kRRB8IWrwNGMJvC0xBvDG+40t+evXtzpDwTFHx37GtLYkV3zu mp4SzdXsChFuJ9qbgFQ683FAhr2qsO7onuw8reqtsi73VMhl3qddv/LNrdn7UBgSZ1KhLEvjVNB3 qZNNo0pTaRnGVQh7u7u5pWjtu61XQ/xJMTl5lccqtUI9kkdeHi4TCgPt+6YlJ1GtzzFU1FVptrNC mZCr08OWioxkfV62WlNm+oFC9SV6xQQAAHh5AaEMxBFhiG7a1VFYZPHQc0GvZf+GhEyjY2JubsLR bKi2PRCFwtRl4+ayrttIDNDB++4RambC/kFi5Vkf7oUnXR1FmR1DM6zHmFnx3+CotXorq4Z9joF/ UkgLhB5aD62psvnDhbJjxmPO3dbhwgs9UKwKcs1u6OSXE+Jo6/jFhswi8030jZ74rmlzSddtJGd5 9TnRX7e5xurDf84Md2bu6HTNYANYqT4mqN4rF64xmu++tUKD7VA6oky4PUSyN4EIQvm1/FM/Pqbn ArdMBYnM45lkZDeCUEZIRpRpn/PCEPJhjn5orXyTecJE7ldo6s8xElaMZ8Brrd3A+kOIPE0aUX5o r9UfsKLnRDroPVujSmGEsjJXp8atB9c2DOBco/0j18eC0qpHqJgAAAAvMyCUgTgiKA/6ibNNjWXr mLXi4J8t/2nouDY7e61Tc6APdeecUKAn7fVrsRuBB7aqzMYB7gI9ajboTLdEVTtur82ss48z30WZ QlM3z5tOtrRbBiz1jDIIF8pB2t1l2G1yB+boG6YdpV2eJ4wPwDJBEJGT9rrV7NQEAj3z5GWYbtCc +vT7bYffZrUdgh7pyik2uSclWhYRotwXTK0n2ru/6jmmYaxUMNdZ0u33iPbGE0EocwpY/HehQhnJ 1Vvn/9RmPNU9YGlgL4rucZV5u9Y+id0JSziIkQ8QhDLKwLfq7ZNsjeIjQ8jV60+Q2k453OVEEpkl esUEAAB4mQGhDMQRyRAd6oA3Gh3j/XXpHa5Htuosk/uupWgH079yHbxSfKDOe31aeYOxuZn7fGQb FV/547t2jCCCR/tK9dVnXBR1va9Ws5IolPmB5JDHnJdr9kAHv7wQRKRMXwqFy1rFI/TzdW35ccFy mj+2jcqEMu39cm/K4TPuR5S7t069Ti6UsW+K268T7I35wSC9olTA4r8LFMoz3t6DqVVfuKlH7t76 5BVhCZdHQ1KPFJEnCWVZuMTICP6HqOG+lhJtcqGxb9jPPI1EqZgAAAAvMyCUgTgiEcp4FKrkv80t ue2DIfpu394jf/5LTVrHNdy9cn2zckR5wtGsr7COcb/CIY0o+3pLV3PdPK8MhM5eVBWzrg5tieWH Lw9o2QgAy4iYRpSpgMOoKreyxsEjGsDcXMjXu38t912wUuELTbqdPIPBI70SR6Hs7Xtfh91IL4ru iSPKxMhLw+WJdUQZ5SpLiPrxY8PmFseUP2rFBAAAeJkBoQzEEalQDnote9e+uZWRGnjJ5po3Ucc8 gf8ROv7wNcrBKedJTe7pmzOopw5Rg198ar8vGf8NjdvqwteMTg40JlT24SnikN925I0IQnkOr/pI TdtWwL5fCCwnRBEZdY3y1JW2bSWmm1PoDpr68bNPvvXRUi1LTw40qUp7x5Dx0D5btVoulJEpKm8n 2Rt2yhIatx5cgzWrZL1vHITyI5TGvb13cDT9tppVYUJ5jh4/V6Nco0yIPEko02O26qwY1igHZkYc l5iF3TgOWEaHolZMAACAlxkQykAcmaUun0hVpaaVfuZBvbHblMHtd8HsfbGKH80SO35+14udWcnp DcxLV5TLUqtLSi/YmaErOtnPvoYlELxja9Sr5LteeG3HDfryhrrDv9mf8ctIQnmOutqq/Xkq+0of sLwYdzRnbtBk7O12z0bb9YKedllq0lPSdubq0kvb+tG/UgNgjacwu7y+vrr611kbGX0sNVfl7UR7 E6F954+q35PtIEESynPUJWPKFq32QLfnRkShLEnjjPdcU05uxbH6miP79L8IF8pYHxN2vSBFXgxX WJSP9PG5pvRN8+16EaKGv6jXYd8k+Ry1YgIAALy8gFAGXgWCXss+Day7AF4mkIDGG8ZxvwAAAIDF AIQy8ApA3+0ryW8fwnPTALCMCY78/cz3E3hiJnDXUr4en0AJAAAALCIglIGXHd/f6tJTdfXnmV1g AWA5w60GydqlV2/IOQFLIAAAABYbEMoAAAAAAAAAQACEMgAAAAAAAAAQAKEMAAAAAAAAAARAKAMA AAAAAAAAARDKAAAAAAAAAEAAhDIAAAAAAAAAEAChDADAyw7hMLz5eIpbAAAAgJcOEMoAALzsgFAG AAAAngoQykAcGe3Jf0elzd2Vn6VO2F7W9rU3uKBDPoL3LCVrwsUJ8WJ0UDS0RgfF/VriTA+ZCt+L mkA66P26rXDL2iRdWlJWTfcgFTFTl1XCnycglAEAAICnAoQyEEckQo1+PNi5N6Pxm/EFSOVXTygH 79jqcpKT1kVLIO21VpaedD5CGUlTV06m50Q+i/tlFMpIsK7a3dxStPbd1quhEDV4ukydmr0zXa37 0IbPpaODvkudJZpkvSFNpam0DE/je0LUkLlSvSUtj3eGPSmsO7onO0+requsy40zkKZ+MLE3Jhma bHeY/A/6BloNKnV2Tl7lsUotCGUAAIBXHhDKQByRC7WZH9tTS7o8T7if8/OqCWV6xm357R8uuRaQ QMrRrN1lGeV+hfOSCuUVmvpzjJCd6K/bXGP1oa/0zHBn5o5O1wxN+5wXhh7jp4iH1so3D9v8s3NT l42by7puI81MB++7R6gQ9uS1/FM/ImeBW6aCxPbB0NxDe63+gNWLn+Nmhjp3FHUOT0r8D3ittRtA KAMAALzygFAG5mU2+NOtuz/c+ldglrsQkTChNnm1VV/a60XfSKN3EsfcNDfWxG/sOfLbQkO+dtOm ktODSOJIhDLJExHa901LTqJan2OoqKvSbGd8Vg5Azs1ND1sqMpL1edlqTZnpB4qez9uwf2lPT2FO m5NNI3W1NafI4qHpx4Om8mR1VoE2JaPxHLPghEnL+40t+evf27MnN7F9CCUFERpsT9zb45UGspAn AfpuX0mW0THB/WQgJTzgu9zJJFy7QV1lcVG011IUHodHLkt1mjprlz41mctqnuCYo2M/k5wtyRWf u6ZRcqiIjhcbzjbQt1m/7fDbDQNMKaJkj3TlFJvcgTl64tb5P7UZT3UPWBreLOm5NzNpr19bZfOz zlhET/jc9tuq32q8GMA6GSnlUXNJhuk6Za9/u9Y+yVyS3AIAAAC8uoBQBqITmrx00rz23zrXbPzU 0DE6EV0hhQllQQKOX2zILDLfRKqDnviuaXNJ122kdshC+fWcjxkdRg22F2SZrs+KnpCGAEWEf+mg 92yNKgX7TH3XuIkdWQxNDHyYmGv2zIbGrQfXsmKL9o9cH4vZW+HfRx5ziabjGn5omL3Wua2kyzM9 Yf8gsfKsDzuadHUUZXYMzTDRXqk+htU57e4yFHS68KKAWVeHxmD2sPKMQ0jgvNDTg3/IYIZRuQsY UsLngj7HwD9xNoYeWg+tQapRGYeH1orVrFIMUSPu+9LV5PTYlQvX8Epo+r61QlNtezA3HtnxYiPX uK9ry483Nxu5z8e2UcrbezC16gs39cjdW5+8AgnlaUJ+KoUyuvKatuJDwSvj72zuu9IbQSgDAAAA IJSB+fANH9J0rkFCGX00Z7/ycZfJRBDKk/a61cycOGba1ZGXYbpBRxDKglJBem67znSL5i8ShgCR JzwoiLfq7ZPsBdbnCdnIIhK1qYUmdwBP2acc7nIiicwQ3VvSv7Mec+62DtesoHof2KoyGwe4cOhR s0EabXzticdcmom9Ddwy7c41u0X/MbJUR2N6sNOQ23JZvuqbkHCcpTR187zpZEu7ZcBSvybfck8Z B6z7M2rM//ARVG+Icl8wtZ5o7/6q55gGr/SI5niREQUrHXAYVeXWcfY6h7fvfR1nRUGHMfYR5cBl Y8Ih67j0wY9GN8KIMgAAACAFhDIQnce3j/87L5T//cKlx9xlMmFCeWqo3YBllkxzCLpwHqEcfhH9 DB8C9IhrQWRBsD4/kgtQIbgQNdzXUqJNLjT2Dfvpeb1V/ku7u3L3dnkoj3lvHla9yOf1aeUNvJtm 40e20VlZWjhJHWJvDFu0zbsctxsLC3blyz/7zC5Wy9HjDqN+u/HSRJhSJSScQmq9r1RffcZFUdf7 ajUrsVAmxIGmrvUZy1LVu429zPgxD+39cm/K4TPuR5S7t069jl0SHcnxoiNN4NSVtm0lppvsq3g/ fvbJtz760cWGzL29d1CMaL+tZhUSykHyGmXOE6Fc/M7WvDyTawb79Xiw2/wNeggYP1cDa5QBAAAA CSCUgejQoXvffleR+6kqt+/33/rnGVCUaF8EfpmvCK8ifaoRZdptypAOzRKGACXEPKLM/sJy+ceP DZtbHI/+bzRvyYE+8Zj3FVu+thTtYxTnhKNZX2Ed4/7kkKUFh6458OUPljINHoqWI3dJJuDtPfRe zifDeLmwHOKIsq+3dDXnY9DRzIwoR4wDTTlP5WQZHcIIbMjXu38td3f4u4MKx4uP7EmAnnZZatJT 0nbm6tJL2/rvBPGCk3NNObkVx+prjuzT/4IRyqhw2V0vdmYlpzdwu16EC2W8Wr2nOkutzS1Izyhu ZbcyDHhtH+oSYNcLAAAAgAOEMhBHJNpXtj0ccY3ymLVcW2cfl4zeYREjXaMsLPZllA1hCBAHxEKP 2aqzYlijTM+MOC4xb/XhAUgs3x9F8zZCoLOuDu02rTaPXW1MTzlPanJP38RLh0PU4Bef2u/T4fIX PR4UaLSpWnZxs4x5hTI9PXy6aGNFjwevMA6HmPDJgcaEyj68uiTktx15gxXKYXGYuX3x0l0cKO2z Vafjhcgc9ORAk6q0dwylBv+lZpZeRHIMAAAAAC8zIJSBOIKEMn/gyOotRdwoHYa8Z21/Y/LqrZLR OywZo+x6QRoCFGBGFtM3zbfrRYga/qJeh4ckxZhE8zbCv3h8+lfbRdVLuSy1uqT0gp0ZuqKT/Tig MPlLP3G2bfmZnn2dTs68Qtnb9/7alQnaAm49RqnRLl0pTkx4wGs7btCXN9Qd/s3+jF9yQlkWB5q6 dqYuB6dL3KmDJ3jH1liYXV5fX13966yNSChHcwwAAAAALy8glAHgeYA3aGNeAXyBLIU4AAAAAMAy AoQyADwHgr7eSjU+5+IFshTiAAAAAADLCRDKALDYeK21+uT0pn7Z6ufnzFKIAwAAAAAsM0AoAwAA AAAAAAABEMoAAAAAAAAAQACEMgAAAAAAAAAQAKEMAAAAAAAAAARAKAMAAAAAAAAAARDKwHNEdhzx 4iE5IPCpoak7Iz8F5z8N5LnwnPINAAAAAAAZIJSBODJ5tVVf2uvlfil5FsEXcrYllPf5YtkF+KmF shj/Wbcp852j9oknSqEccraq3u+VHo73zCxmvgEAAAAA8LSAUAbiCOVo1u6yjHK/lDyL4As6jG+W 9NyL5eanFsrK+BNGlIOO5jXcodDxYjHzDQAAAACApwWEMhAvpl3mg2kJq9Yk6febXaG5EDV4ukyd mr0zXa370OYNYCeC4KMfD5rKk9VZBdqUjMZz3iDNqNvE0uMNu1Zr2pzjvsudzL3aDeoqi4uaC7m6 9qarVqxR66u6XNOk2+do3zctOYlqfY6hoq5Ks10ulCXSmYsDVsBv7Dny20JDvlb1dpHZPTMli7/E mVQoh1zmfdr1K9/cmr0POQqEx5MR1m+839iSv359qzMUvGNr1KuSMg05FQ2HtJw/4ZGXh8sGgwn6 BloNKnV2Tl7lsUotJ5SVuUpPuz6v1G7Pzs9KVpebBh+jvKCpH0wlmmS9IS3J0GS7AwIbAAAAAJ4O EMpAHJGMjFLfNW4q67o9jbTdxMCHiblmz6wgUmcn7B8kVp71YX076eooyuwYmsFadl1y3d8Z1Rv0 OQb+SSHRGHpoPbSmyuZHDsURZeLtD+21+gNWLz1HB71na1QpsQjl13M+HkSh0DdMOn370JQs/hGE MkIyoqyMJ3a/Un2MkbCSeAZHrdVbGX+IkSeNKE/0122useKD9AJea+0GVigTcnXMWq5rHMA5RFOe 6/dRuEJWzM3NDHXuKOocnmR8BAAAAABgYYBQBuKIIPjoSXv9WlbgImavdaYWmtwBXn0+sFVlstoO QY+aDTrTLVq2XoKmbp43nWxptwxY6jlVKgpl0u2Uve6tevskFoekpRdkocwrYOHfhQplZTyl7sft tZl19nHGoXCdmHalUMYZ+HatnVO4XGSIuTru6ihMrTY7fcyYPcJvq36r8WKAzYqZUXNJhukG+wMA AAAAgAUBQhmII4LgC9OXvBLlBB/6uT6tvMHY3Mx9PrKNzkq0LD3aV6qvPuOiqOt9tZqV4UKZdPsd 1md89/MTyoR4Er1FCNdJkZ9VCmV5uOTI8P7TflfvibKU7UXNfS4qhB2/pq34kPe/2fg7Gx7NBwAA AABgoYBQBuKIIPiijyhPOJr1FdYx9k8eiaz09Zau5vSgqEpFoUy6ffJFjCgT4il1TxxRJqZdKZRj H1HmB5Lpx4OnChObL08FLhsTDlnHY9keBAAAAACAaIBQBuKIRPBFW6NMTzlPanJP35xBujZEDX7x qf0+LdWykwONCZV9Y0hthvy2I2+EC2XS7fSYrTor8hrlMWu5ltGswnrfeAhlQjyl7kPjtjrFGmVi 2pVCeY4eP1cT0xrlqZGL/2AWduM4MDLa72zNyzO5ZrAvjwe7zd9gTwAAAAAAWDAglIE4MktdPpGq Sk0r/cxDR931Yo5yWWp1SekFOzN0RSf78b/SYeCA13bcoC9vqDv8m/0Zv2RV6dy4ozlzgyZjb7cb KUvF7Ugfn2tK3xRh14ugr78xefVWyQ4SRKEsib83olCeoy4ZU7ZotQe6PROKeMrdE3e9IERemm/M jRiUCR/qEubb9YL2u84czcC+SfJ5erinOkutzS1Izyhu/ZrdFQQAAAAAgIUCQhkAngNIQJfiDeO4 nwAAAAAALANAKAPAIkEHPRe+cIzj4dzgSE+Jrs7+kP0DAAAAAIBlAQhlAFgkhNUgedlJiQbjBVgC AQAAAADLCxDKAAAAAAAAAEAAhDIAAAAAAAAAEAChDAAAAAAAAAAEQCgDAAAAAAAAAAEQygAAAAAA AABAAIQysNSQnjwSI6RjQWKGprwjD5hzOpTQ1J2Rn8K8jeZeJETd8TyI2zYX9Iz7873qVH3eqSuB 57Z1hpAEvkTE82IAAAAA4JUAhDKw1HjOQjngNhWsq+2f4H7KmHWbMt85ap+YnQs52xLK+3yh6O5D zlbV+70+9G32umlHavw2Tp4aatdnmG7ERSOLkYyOmAQQygAAAMArCghlYKnxvEeUYyLoML5Z0nNv nhCCjuY13IHb8YVyNGt3WUa5X8/GwiMJQhkAAAB4RQGhDMQRpKgSS4837FqtaXNOztGPB03lyeqs Am1KRuM55riNgO9yZ5k6NXundoO6yuJi1DD9eMh8KFmlzeeceZAn/1F7uEifk5awsdh8fQY7ClGD p5kb09W6D21eZuUDPTbQkr8hKdOQU9FwSBsulAmhYz39xvuNLfnrJadJCyKb+XfPkd8WGvK1qreL zO4ZmpOGAVfX3nTVijVqfVWXi+Ldh6cl5DLv065f+ebW7H1mV0iQ+6SYI29XFdYd3ZOdp1W9Vdbl nmJiwhMe89C43ahLWLUmSb8fecw5iuBJ+L3BcVtdYvU5fDzgzFDnjqI/WP4giSTjD0aa9k2bSk4P Uug/IQlhQpkO+i51lmiS9YY0labSMjyNfZAXPQAAAAC8FIBQBuIIUkvrkuv+zqjS2Qn7B4mVZ314 ucCkq6Mos2NoZi7ocwz8E4uw0EProTVVNv8cPeVoSSzs9jAy+v51D0UjT1SGU06KnqPdpozN7UPI +UR/3eYaqw8pYXpmuDNzR6drJiT6Hxy1Vm+VC+VZauA/t7De0g8vNmbmmd2zjBxcqT7GqVUOmVB+ PedjrBHpGyadvn1oShxDFUeURfeKtEgHa3lxSX3XuKms6zYSk6GJgQ8Tc82eWUbjvpZ/6sfH9Fzg lqkgsX1QlKzkmJNGlAmekPKcHu3bW9zm/MnbW5XZegWpadKIsiTtc9RgewFTWHwSwoXyHO1zXhhC 4aIIWivfPGzzoyRJix4AAAAAXhJAKANxRJBWiAe2qszGAaQeMfSo2aAz3ULaj7p53nSypd0yYKln 5Nq4vVZXbXvAOmOQeMIps1m/7fDbDQOcvKVHunKKTe579trMOvs4c0kQrwIyb2ddHdtx6EpnCFH4 Sv4Nl4YkoaxMi1IoT0za69cyGhoze60ztdDkDojexhrzCEI53BNinuNHiyz97j2p9bZxLMgjCWUh Gvj5BN8oFIQiN+iJW+f/1GY81T1gaeCyRVJqAAAAAPCyAEIZiCNStYS+r08rbzA2N3Ofj2yjodG+ Un31GRdFXe+r1azEck0psCRXOGWGZdzr2vLjglfNH9tGr0tuVMpNubcSf+TOEMJF6b/87YI0VApl WpkWpVB+JA9R4W2sMY9RKKN7FXk+i3Stp6dw7XvNl9knjXmFMu+zEJOwaM94ew+mVn3hph65e+uT V4BQBgAAAF5aQCgDcUSqliYczfoK6xjzncfXW7qak2O8XItlRJkOOIyqcis7esyDbnyhI8qEtCiF 8nMeUSbl+Rw95fwoq7zhmKG6z4vXe88rlOcbUfb2va/jCkjMFkmpAQAAAMDLAghlII5I1RLSZyc1 uadvztDMC21ffGq/T08ONCZU9o0hXRXy2468geUacY0y74mgBaeutG0rMd3E76vR1I+fffKtjw7h 19QWvkZZ7gwhXJT+GyYNpYqQd0ZIi1IoR16jHFEoL2SNcrgnpDyfGerM3N91+1/j9obtzFt9kYSy dI1ylun6rFiaYbnx6GJD5t7eOygM2m+rWQVCGQAAAHhpAaEMxJEwtUS5LLW6pPSCnRm6opP9+BW6 gNd23KAvb6g7/Jv9Gb9k5Rq/60WBfrsOvw3mET0RtSA97bLUpKek7czVpZe29d9h9OEdW6NetcBd L8KdiRel/4ZJQ3Rl3NGcuUGTsbfb5eWckdJCXTKmbNFqD3R7bvCpiLDrRUShTIx5jEIZEZbnjz3m /ZntV/HGFLTXWpnfNPCQFiP5BN+BwT4sYNcL77mmnNyKY/U1R/bpfwFCGQAAAHhpAaEMAABJrwMA AADAKw8IZQAAQCgDAAAAAAEQygAAgFAGAAAAAAIglAEAAAAAAACAAAhlAAAAAAAAACAAQhkAAAAA AAAACIBQBgAAAAAAAAACIJQBAAAAAAAAgAAIZQAAAAAAAAAgAEIZWGzoGffne9Wp+rxTVwI0dw0T 8PafLNq4KS1LrdIe6R56jP+7Z9m1Yn3azoJderVKvfckewIfe/1na4osHvH+yYHGd36OdzQbtxsL C3blZ6nfXKXS5u7KL9xvdoU4RwAAAAAAAE8PCGVgsZkaatdnmG5INfLcXGji8gmN4WPmqGQ66O2t 3FxnGw9JjmWeo6mrfyzKbxp4wAnon/0/r5f0+jhf6IDD+N7P/h/J1r9whDIAAAAAAHEGhDKw2FCO Zu0uyyj3i4V2dxkyjQ4/91NAIpTxUPTQqe0GMx5GRtdfW6dKqOzzsf9RV1szVQlrQSgDAAAAALB4 gFAG4glN/WAq0STrDWlJhibbneBcaNxu1CWsWpOkl62IGLdWrG68KFuJwSATynNzIWdbQnmfjx1p rmprzi3rvYvvefJ9W2JZ24kCEMoAAAAAACweIJSBODJ+sSGzyHwTiVd64rumzSVdtwPEEeXQUHti vuUe90tCmFAW5C++/uEFe9N6vPqCfuJs21pi+V526jIIZQAAAAAA4gwIZSB+TNrrVh+2+WeZH9Ou jjxmaTJBKAcdzWsYoRxymffnF+zCn+ou13RUodzs8A80vnvIOu6/2qrPNbu8IJQBAAAAAFhMQCgD 8UMmc4P3OCFLEMr0qNmQ2uFiFTVGLogFoRwabN9c1nMvyF9/dLFBX/23r9oT93R5Jnn/WUAoAwAA AAAQZ0AoA/Ej5hHluZkf21N3m9zT3E+yUGZe5tthciP/uOv0pL1+bdLWRPyGnyDEWUAoAwAAAAAQ Z0AoA3Ek1jXKc3NBn7VmS+GnzPZwczR1qUWd3uaclArl8O3h2Ot+W/UvfpVrdtPiiDULCGUAAAAA AOIMCGUgnih2vUAQhTJy6nedaTSomANH1GUtvdcodhs47sCRrWtVu9ukB45wAvqBraqk0zUtWdrB AkIZAAAAAIA4A0IZAAAAAAAAAAiAUAYAAAAAAAAAAiCUAQAAAAAAAIAACGUAAAAAAAAAIABCGQAA AAAAAAAIgFAGAAAAAAAAAAIxCeUvdubABz7wgQ984AMf+MAHPi/Nh5O5UYERZQAAAAAAAAAgAEIZ AAAAAAAAAAiAUAYAAAAAAAAAAiCUAQAAAAAAAIAACGUAAAAAAAAAIABCGQAAAAAAAAAIgFAGAAAA AAAAAAIglAEAAAAAAIBlxBPvuWOGwpq6kqrOQT93bXEAoQwAAAAAAAAsI+jg48f/oufm7llKmx1B 7uKiEKNQHu3Jf0elzd2Vn5+dtEnXeM4bRLGLOyHqjucB2WcUAa3RQXG/nhc05R15EOB+ROGeZdeb uKBidR9OlIS/aPikIeiJSy2peSedj6JHNOhoXvPm1uz8gl34U2q0+7g/GKL/G5XgPUvJygRtQUz3 Br2Wg3t7v7W8CLMBohJWlylHs3aXZVRWvnq1Kv1Dm3feqoTuVa9JymLsoWBX4Qn7eAhdpanBrgrN Bk3qBvWhrqHHcnOVhLJTu2HjftMgckAMGl/8+YrSHq/QAtOTA03rfrYVLGopITEnetxhzMlou0LN 10IZ31yj1uezZlPUbB/n/mAhG1VMoNZyxfq0nWwDpfRZBu217C7t+d5SsmaR+3ggAj57cykjadZw dX+f2YWKenrIVPgeUyhCs4DcbEwu+V3//C1SGHTQ+3Vb4dYNWp06IaOme5CxTEFNCQYWWHjTF7g3 8IfSjZvSstQq7ZFuvpWL2vRFR9oss73n3ai3zydaaE9PcXWfb2Z6+HTRarXYZoZcXfsKubTv1KpW bG9zPiSmJWaCvt4jB6xj3K/FIXahLDRGDy82ZhVbbhMTE3K2qt7vjV37IMRbZq+bdqTW2R+y1+WE da7PRMyRDLhNBetq+ye4n5Hh1GTM7hliS/iLRhDKbCfUfnWa+yMiWArnW+5xv8KJ/m9UcLMVc6fy wFZ9oMtzI45mA8SJsLosE8p8+YYmBj7cYjB75mkyhXul+J2t+cXmm+i5NXi7u3jbSeeU1BdpKPS0 82Ty5vahUHjQiUUWL40v/vxn75SJHcaEoznl5yCUlxaCOYUmLp/YrvvD4PR8/SwWyiU99yI1JESj ig3JsMJ8zPptRwvMLi8I5ReMvFsJ3rHV5SQnrWOuyJoFavDTYl3zQOxPTah9mbjUsq341I+M8gve 7qvIqrGN0QQxE97+zNv00Q+tB7YdY/Q0436HyT2LLkdv+qIjjRXbez5hvkdgXtHit9Xs/MvNu3+v 16Wo300htpnoWbFoXdPA6FlSWmJl1nv2SGX3rUUeZ1y4UJ6jAwONa8utxGflp5BBsd2itK2n5xm0 WgQW0D6KxD8aiwGXtND4wPHtuadvzsjMMTT8aUFRc49zTJr06Ol6hlTLW7ToTNrr0jtcs/E0GyBO hBUKUSijp9SBxtUHraRuiaZunu+oMdTaxomaJnDZqDpi87Nt7QNblcHokD66hvWLrGaaJgWNh3le T1ivKun1sVb/5Pu2xPWqdeRGH3hBcOZEj3/TlFpiujnFXWYJXfvjzlKj5XuftB9dEkJ53F5b1umi FtCmAYuCtEGgZ9yW3/7hkou7EtbjTA615+Wa3TErsice854tzZflFolQ9kqxNn1Iet8631Gd02Ab n3r8aJKLiWDP8zR90ZHEius9mctPCT1pP6bruHKju+W/nc4I87pBX2/F+oaBybknhLTESPBG1+7D PXcXOtK/YJ5FKKNnrNNl6tTsnelqHZ4sCLnM+7TrV765NZuZwqCpH0wlmmS9IS3J0GS7g5OO2pFV hXVH92TnaVVvlXW5p+S38KEExxwd+5PVWQXaLckVn7vwCIHStvhZBq2e9z88PthR9BDvoH93N7cU rX239Woo4Lvcydyu3aCusrhQWIL5otAT/6P2cJE+Jy1hY7H5+gz2OugbaDWo1Nk5eZXHKrW4fZSY O/14yHwoWaXN16Zk4JUq4Z6TEx5bEpDv067PK7Xbs/OzktXlzNzxosE2/b6v6zftDu+EMHTQ931P c0mGRC4/k1AWE4tyoOnLrzorc3Kyk7YWmYamw5stloDX9qEuQVoK6CL9xPlRduv3T0hmA7xowgol slB+c3+fT9ZbsBI5W1/Tef4mM4lJ0DT0qNmgM93iqkTglqnYYB6RVBB5KKhLWH3Y5n8SHjQvlNcc PWFMrOzzoX+QUbVtLWn+r51gUUsKxpwuu+11ulyTi2mZ5QTHnJbmYl2JKJefSShL+gLU73z5v/9T kWfQqzcUnsb9FNtahnkcvGNr1KuSMg05FQ2HtJyZoYcu/UdXnxDbNOB5oiwC4Ur4X9HmounHg6Zy RrSwPT6ytDFrua5xQPmSmbJXkgdEavo4iazPq+44f4uS/4Uasbfq7ZN0LE3fG3uO/LbQwMgSy1ef VhlyMtWqUtMwiowQK2nvGdnUBfcEfYKgrraWtznZNCrTy0Df7SvJaBx4xP1k4dPC/cREiQZ6dNG9 ri0/3tz8X1Y36cEibjzd0osM/FxFfde4qazr9jQ7YJ6Ya/bMSmXQQ3ut/oDVi1M8M9S5o6hzeBLn 6Wv5zEwEKsWCxPZBlDbJLXwo9NiVC9dwR0jft1Zoqm0PSHntdzTri/AsA/Ji7PqInxifeUJE/67Q 1J9jRDwSvo6Bf2ITDD20HlpTZfOL5otCVxlOOVGUaLcpA8/Vzs1N9NdtrrHiHjTgtdZukAllesrR kljY7cG1JXD/uodCejLcc1LCY02CWANpynP9/mI+TqHQ/989ddXpBpNLaC8UCHK55az7Xzhd76bq 0jMKkDXntA7gLBKJ/q8kseP22i0bqs+iFgfnOX6SCW+2EPT4uZrwUkCXp10dZXV4faDSbIAXTlih EIUyMwcnnX+kfY5PpBKZBd2bsl6Trks3ZCclGlq+8dHSaoVQ2ozkStA3ePpQZuM348wqC0XQ7EWr vSGDWX2Bmv7cMlj1vuRA5qT+de3+TTmn3VGmXwW5fPbmNBbK72nT03U7s9Sq/JaBMfltBKOSIPQF 9KS9/g1VrdUbmKNvmHS6NifTwYUL5dC4rS6x8iz2JDhqrd7Kmtmsq0NXa58k2CfwnInSRCj+IpQv y+yE/QOulOcmXR1FmR1DM6HB9s1lpOcxZa8kDUjR9M0FHzj+hyyREcExx6m9ucySyFiavtdzPh5E niA9umprjXU0iEVF/vpWZ0iMlbT3jGzqgnuCPkH5ca0z/Rivd5XpxdC+3rJ3my5KNbEkLRKiR+M5 sdCX+Qr4B6ZZFOm1jODDoHxJLTS5A2JR+W3VbzVeDLC5MDNqLskw3aBFOxNLUVK6QoaGKPcFU+uJ 9u6veo5pmE5UkdfcUJAwPYAzURkfiWWTQpTbPR6vMp1sabcMWOoZB8ItktC5W3Bwb+OWjoG7KLhH Ik/H6HsRhefKhE/EnARUFQtTq81O36LPOODQf/b/U2k1ySUWRvcTkQll2jfw6Sd25pF62mMuZeZW RKL/K0msZFxHkr3cGw/4U2q0j5FKAYVxw5RVz9iGwmyAFw8qFMm7LPm5aQnvCEJZfKNFW9uDZ3V4 yEI56Bv4yyd25kE3eLOrED09Poqlt+CtKEu9OrMJ6yTJRXEyh733sn+gaX25dfzJ922b93R5boJF LTGQOf3q5wnb09SVPR55DytFKpTpsYuf/NmOixgv5SwK661JRsX+wSA2KYSeCzVB4S/zob4gk5Ed +A7eGpGk2Md0EEr7BJ4zyiIQrij+ErunMB7YqjKFwWNuZHeGn7gQX18r3I/n2uUNoPJlvrCmL6JQ Do3bTxShRmzj/j8N+5EFx9L0cVfESRXhIm/DpN6TYOpSmw/XJ3g8US8oGYk/EoR1FyzhaZEQPRrP iadYesESVgycAzElKPte01Z82GxsZj/G39k8s6Q8VSae9n65N+XwGfcjyt1bp15HFsrhJkuOD7EU ZZEUPKFH+0r11WdcFHW9r1azEjsQbpGEzt0iDy78oiK2BM+VCX8UexLmaL+r90RZyvai5j6X8ikz jqDQf3HI+vCevS6nzOLm4yZAWHohBTcZeDCY+xkG4V8xsWShLMkfBLEU8KPq3mILM5ehKAjgxRNW KEJB86VJ3+4p0jBvvYSjWHohBT2NF69vdQYXsvSCmZH4wD4hX3rBwbucHGhMOPL3bz/aiod5wKKW GqhEEiutd8btDanEh3nl0gsp9EhXTkbkoSnOqCRNlGgAhG5bbL4EpAYjWPjdvtKDzG4q8hYMeAEo i0C4Ev5XaKg9kSvxMFApr08rb+DVTrPxI9toCJlWfqdLeHgTfJOaBAv/V+SmL8rSC74Rm13AqrPI QpnYexJMXfgi2rzgFRLB1bstwpi4Mr0o0qR1F5K0cL8x0aPxnHhqoUwewRVTErhsTDgUviCdkKfK xD/29e5fy7oSO1FFBOI+ouzrLV3NfecdhNsQ/o+7ZYEjygTPlQmPfUSZh348eKowkfC6QPzgQ6fH CcuUiS/zScFVl12pQoLwr5jYWIQysRRm/bZ6vekGU0uVdgu8cMIKRSGU5+iZ4c7MHZ0u+ZujAqxc Zl7mk4I0zW488begl/m4yIQ9o7JIq3OKOmkr8x4PWNRSgy8R2kdYpkx8mU8KFso57UORWlDeqLif CNEAFA04USiTRpT9tuosVtAo2zTgOaMsAuFK2F+TQ+25mabrUhHHM+Fo1leE71CGX/6TLFkUfFO2 IcJf8zR9kpf5pL0m72HsTV9Eoewn9p4EUxe+iDYveIWC3oelC4fojwBh3QWH0nH0aDwnnlooow4u +hplv7M1L49ttpCe6zZ/4wuS8lSZ+InJgSZVaS9+qqJ9tmo1WSjHvkY5SojSdg2PG1X2YckX8tuO vIEdhNkQEzp/C2l1rOBesUaZ4Dmp1GNNwtTIxX8wqxewb6K2XgzE0EPj9mNbDOEbXygIjduOZjVe wD0T/cjZlqdp/wFvMxN8cP36g2CkfwXE4GIRysSV4o8uNpTxPR/JboEXTFihKIUyqvhjtmpNpD0o RZCzmt1N/XhojqaunNTltQ/+i2l5Ytwebo7299e/W9Hnk+96wSG4RI9eh3+5opjZLwksaqkhlgjx YV4JaroPZx7vx+vWQpTzdxnbTg0+wQ31g+tuvC8s2agExOAIDbjYfAlIVq9ya5Qv+wc+1HHiW2KN wZ9G7iimSYBFR9mtCFekf0m3h6ODDzx3ZMO69JTzpIbbFQq5/OJT+330jfadPbCp5I/s2/b0uMOo k68GFpAEFFvTR6N+dO+neLUxioy3t5IbhY256YsolEeJvSfB1Ak2z3uF1E76Kcn4l3ALX8XwkHP5 r3jdEiEtAtGj8Zx4BqFM3KKBumRM2aLVHuhGncr0cE91llqbW5CeUdz6NRZ2yjyV3cLveotfEy7M Lq+vr67+ddbGCEIZtWLsrheGbLWeeSEvwpYRUUL87k+Sdi3gtR036Msb6g7/Zn/GL3F5hNkQE7ro oXK/BUkQ/K4XBfrturq/e4PTCs9JCY8xCbTfdeZoRlJ6gdTZIiGGjhKFx2zYlxqjEfQOtJdtWL1V r03RVXcP4QqAeoujb791FFcAwr8SxODIQlm+RtlHKIXAYLvuhINbHP+8qxMQA2GFQhLKzMhKxqYW xzz7gNLBe9+2v5+4NkmXlpTF7+fPtwyaVP48ESlSK8rCpwBYhiNsqCK56LdVa9n9ksCilhrSEmEe 5tnXlaLBHNagWqfO0qrT+QMO0CP3W4nMvrBko+IRgyMLZeWBI+G7Xnx9tX0fP9Qn2Fho3HZk7WsR NgUDFhFl3Reu4C9MW5GfnbRuQ+FJ/sARn61q4+vhO+RSLkutDnfKGboiwWWIGv6iMWcLc+DI9jIj u05S2YZI4xBb00dPuK3/VbRxU1qedsPG3W397IYE8zd9XCiRhPKl74i954KEcmDoVEbzZYko4V0K VQyvu0gVp9wjpIUnejSeEzEKZQBY8rA1lnJ/Y3dHfqkHAADghcAqifMu+8VbilNR6InvmrI+uorH toElTmhioFmPN1B76Zh+9t6TnnZf/MYtnYR5GQChDLwsiI+2AAAASw3pwGEYofGLn3+2qDviA/GC fnDxT//ffLMWwEsFCGXgZQGEMgAAS5coQhkAgKULCGUAAAAAAAAAIABCGQAAAAAAAAAIgFAGAAAA AAAAAAIglAEAAAAAAACAAAhlAAAAAAAAACAAQhkAAABYptBB79dthVs3aPVpqq1F//U3N7dvF3Oq yMZNaVlqVfrRM8P+hey8xvq5JcKZI5SjWb0mKYs9VWRX4Ql7HE4JCXotB/f23pWEozjZQSRE3fEw J5y9EALe/pPC8RCt1htc5jAnSW1SafRJm3R1XzAnawDASwIIZQAAAGB5gk/50tbYxrBaox8P/a/9 Fj5GmJ4e/EOG7ndOLNeYc6pTw47zjQrttVaWnnQ+wh5RV06m5/CH+rJIDg2NGw9s1QeYM9IFIgvl 2eumHanMIYIvANrXW7au1sY8G9DU0F/Pu2fwZWqwvSCj7QoWzfQjZ1ve9tYr85wkDgDLBxDKAAAA wPJEPIxXAlbPOUaHn/s5968Rxz885DHOaVfnvuLmM06f5MxdGUpZvAhCedJel86ekS4QZUT5RSI5 RlgEq+fNklOXp287Lt2WD8MDwDIGhDIAAACwTHlor01Nazx/T7oUYdxasbrxYiBMqeHzPt54v7El f/36VqdENQd8zjPGIj1ZLmPNnWV0THA/MdGFMtK1if9Re7hIn5OWZGj68n//pyLPoFdvKDztwsdW 00Hvuab0TWp9jqGirkqznVHA9BPnR9nMkci075uWnET5v0qhzF+5Z9m1qrDu6J7sPK3qrbIut3QM l0nsniO/LTTka1MyGi1ffVplyMlUq0pNw9grmvrBVKJJ1htwJG13mOcMScwTNhabrzNDxQom+uve yWzqvyt5NAmNWw+ubRhQ5B32sPR4w67VmjbnJHcNAJYhIJQBAACA5QpNXeup3v56UmXH+ZvsKGbI 2bpeMerJaseV6mM2L3HwWJDLZ91Y0bIwSzh2dLrwcg4BJJRT1mvSdemG7KREQ8s3PpkgR+pQZTjl pGh60l7/hqrWioKjb5h0OkYsIlmvP2D10lgxn61RpTAKeNrVUVZnH4/wb1Sh/Fr+qR8f03OBW6aC xPZBifrHiX0952N80vKkvW7V1hrraBA7y2ceEoSA5uZmhjp3FHUOo7gJMZ+j3aaMze1DxCH4uRA1 bKlRr1WXf3zePcEkffJqaybpyQF5uC657u/eF7acGgDiAwhlAAAAYFmDZK6lKWerrulrJFuJywNY 7Rj5BGmSUJ4e7DTktlwelwu9oG/gL5/YmVHY4M2uQl3jwCP2DwZR10qiwV9EmvWtevsk6x9/Ecno rHqbf5b8r8RDHv6KeGi/MmmSK+LqFP6i31b9ljDiPjNqLskw3aClAYk+RyA4hvLboNI32e/TEYfY lTEHgGUJCGUAAABg+TN9tT09q81J0aNmA2FANJJQjrD0gh53GPXbjZfYUdMIIJVZLF/IIapDglCW CVDuIu3r3VtswaO7pH9JclPp2wKFMrrxNW3Fh83GZvZj/J3NMysNaF6hjMHD7brNbVefoEzYLR/P ZlHGHACWJSCUAQAAgJcAfmhz9lpnak77kLAu9snjR5M0WShHepkv4O099F7OJ8PiMgwiSo0oqsPY RpT9flu9Hg/oMq/0PZ8R5cBlY8Iha/iudpKAYhLKos+zro7tKaeGhAUqwYnH/0KeK2MOAMsSEMoA AADAsoSeuHTy8Gm8EhcvVr5yUrfb5EaSNzRub0gt/JS5Tge9vZWb62zjAZJQJkJPD58u2ljR45nm LmDo4AP39QeBOXrMVrO7qd+L/GFCzGsf/BfnBCOqQ4JQRvdWZ8lXIY9ebCjjtp8j/Ls4QnnO72zN yzO58Ot69OPBbvM3PvSvJCDB5+BPI3ek21eEJi7/95FPrjKXmH33Mk3uWeSJz16nL+pkr6NnjKrE 6nPjtDLmALAsAaEMAAAALE9ov+tMoyFhnVqfqU7Iqj9zjZN17HUVc+CI9kj30OMII8pEvH3vr12Z oC1gjxTJLzXafcybdolv1/ZPIBV779v29xMjHEciqkOCUMYKWL7rxaXv2nUnHNxyYcW/+Bal3OSv PL1QnpubHu6pzlJrcwvSM4pbv2bet5MExPkcGrcdWfvaQenYM01dO9OQp1q9NVsvO8mFvb6BOXAk rbp7CD+iKGMOAMsSEMoAAAAA8JxBOjKzbeCHb+xu6cD1koKe+K4p66OrT2SPAgDwqgFCGQAAAACe A9Oev/31ygSzIOTumbJ3j9onZKeMLDFC4xc//2zwMchk4BUHhDIAAAAAPAcCXtuHugR1dn6WWpXf 0s+e9AEAwJIGhDIAAAAAAAAAEAChDAAAAAAAAAAEQCgDAAAAAAAAAAEQygAAAAAAAABAAIQyAAAA AAAAABAAoQwAAAC8RATv9Lfu3rB6q16bouMOv5BBU4NdFZoNmtQN6kNd+CySZyfotRzc23tX4pXy WBAemroz8hPsdwEAywUQygAAAMBLQ9Bnrc1tu4IPzKMfOdsMW9sH5UrZ72zNLzbfDM7RwdvdxdtO OqeeXSo/sFUf6PI84X5hIgrlWbcp850lvoMyAAAiIJQBAACAZUlo+NOCouYe51ikAVrJOdI8gctG 1RGbn9WpD2xVBqNjgvn+DEza69I7XDLpG3lEGQCAZQUIZQAAAGCZQgd93/c0l2SQ5XLQ11uhar4c 4H5i6FGzQWe6xQ0iB26Zig3mEfmSicT/qD1cpM9JSzI0ffm//1ORZ9CrNxSedk0jV/yJITl5lccq tZwCpp84P8pu/f4J+ub7piUnUa3PMVTUVWm2k4WycAV9WVVYd3RPdp5W9VZZl3uKc4D88VqKtrHK e9rVof9llc2PLyNZr28ceDRHPx40lSerswq0KRmN57xBFLHo0Q5Rg6fL1KnZO9PVug9tXiY/IocO AIAUEMoAAADAskaQyy1n3f/iriGmr7brijqHJ7mfDPIx5uA9S8kamY5FilNlOOWkaHrSXv+GqtaK ZCV9w6TTtTkn5yb66zbXWH3IecBrrd3AKWCkZcvq7ONzcw/ttfoDVi+N4uM9W6NKmV8ov5Z/6sfH NNbrBYnSJSKz1zq37evxBudoT09xoirlhCOAXLFj4UFq4D+3FHZ7kD6mH15szMwzu2djjTY9M9yZ uaPTNUNHCx0AAAkglAEAAIBlDVEoU8MduzXGSxOS4WJEDEKZWTIhc8lenEAa9O1aO6e7Bb2L9GhW PV7LMWmve6vePsmGx/sTXShzfymjQV1tLai2PZgbt1YWf2w5Xtnpmp51dWhLen30uL1Wh/9iQBe3 4wHyKNH2+22H324Y4IbV6ZGunGKTOxA1dAAAREAoAwAAAMuUSEsvQhOXT2xPPeGYUGx5Mf/Si0iK 85FMUPJCk/b17i22eJEXMk38jEKZnrQf3dR8adx+TNcx9NhWrzcN3bXszzTdoCUxxHCezBPt17Xl x5ubjdznY9soCGUAiBUQygAAAMCyJMLLfHTQ21u5rrBzmFeTUuZ5mS+K4iSOKM/6sYpF+pV5pS9u I8pzc35btfZE10cH24emkBbfV9nxl6qSTtf03NxCR5SpgMOoKreO4ysSQCgDQGyAUAYAAABeIqaH TIWaMotbpvyCD65ff8Bcib49XDTFSY+fqwlfo/zoYkMZ0rLYFT1mq85a2BrlKFKV9vQUrV/zzlGs vOkbph3vrNnUglcqz81GWKMcMdpzU1fatpWYbuJI0tSPn33yrU82/g1CGQCiAUIZAAAAeGkI+Xr3 r1yxPm1nwa58/Clqto/PzU7Yj779Frd7sXjgyMb9psGwA0eiKk7lrheBwXYd86YdBunjc03pmxaw 60U0qRq4Zcrj97vAe1+8IQxmk3e9iBJtetplqUlPSduZq0svbeu/gwMCoQwAsQFCGQAAAAAWCBKa 77Zepdzf2N3T3CUAAF5CQCgDAAAAQAwER/5+5ntmG43AXUv5+tr+Zz6qBACApQ4IZQAAAACIgeAd W6NelZS1S6/ekHOinz25AwCAlxoQygAAAAAAAABAAIQyAAAAAAAAABAAoQwAAAAAAAAABEAoAwAA AAAAAACBmITyFztz4AMf+MAHPvCBD3zgA5+X5sPJ3KjAiDIAAAAAAAAAEAChDAAAAAAAAAAEQCgD AAAAAAAAAAEQygAAAAAAAABAAIQyAAAAAAAAABAAoQwAAAAAAAAABEAoAwAAAAAAAAABEMoAAAAA AAAAQCB2oUwH733b/r56g1anTsiqP3ONoufm7ll2vdnsCM7RlHfkQYBzGAZN3Rn5Kcj9mA/ew8WA FMnRnnyt0UFxv56aBaXxZUbIT3rG/fledao+79SVADIUloC3/2TRxk1pedoNG3e3Wm9QyKYsJSsT tAX5Bbt2oov7TYOPsWtkBivWp+0s2JWfpU7QN9nuyPL2KXObcplK1vLWRVODXRWaDZrUDepDXUNM oPjq4yHzoWRVqlalqTQPYguPD2FmRjmatbsso9yvWFjEeoGLYM1i1bl4IKZ9ym05kKzOyG+/EqGt eYaMWsyW57mw5MtxiRC9bYnGU3cWC72R2Hi+fISoO54HweWWwKB3oL1sk0qjT9qkq/vCRYW4608B oSN7PrU4llCilQ5BSsXYKT9XpRQndccQs1Cevtquyz/pfIRyjqaunNQZ2px+vncJuE0F62r7Jzin Mmbdpsx3jtonZrnf0VnE7ooYyWfJysmrrfrSXi/6trA0vswI+Tk11K7PMN2Q1jPa11u2rtY2jlsW mhr663n3jKzG0tPOk8mb24fQ/xIzoCe+a9q8r8c7g38wPFVuB7znGjLUies5b/3O1vxi8030iBe8 3V287aRzCtv1lPOkpqjbg1qH4M2uonxs4fEhzMxiFMqigS1mvXimpjnkbFW93+vjfi0OQtpDg+2b C0zuiCIZ89QZtYg5/HwAoRwbYW3Lpj1dnifMH/Py1J3FQm8kNJ5LEkkD9RTMXjftSK2zP+R+Lg+o wfaCjLYreAyFfuRsy9veemWK+2vBkDqyJSOUo5WOKKWE9j9qp/yilNKzqLtwYhTKQV9vZWLzZd4m 6OmRf1zyUHTce5fn3V09S1YufFzw5UfIT0LmBB3Na/It97hfLPIaG3QY3yzpuReUm4H/YoOuwjrG /lggIcp9vrNqd93Zr7uPfuoc7ua8DVw2qo7Y/Gx1fWCrMhgdqNZPOJoN1bYHzMVZv+3IhubLUUVZ 7ISZWYyWI3G2iPXimZpmUpnGGyHtgnlE4akz6nm3PHEHhHJsPH3b8tSdxUJvXC49yyvXA+Kxns0t DjyqwjB923HpdvwmHhFLRijHRmzt/4uyk2dRd+HEKJTHrOW6xgHFABvX6Aj5jmKW+B+1h4v0OWkJ G4vN1/EwoNAwcfPa2nxtSkbjOW+QDvoudZZokvWGNJWm0jI8LXUsEqKGzJXqLWl56WrdhzZvAPkz aCpPVmcV8P6wBf/GniO/LTTka1VvF5ndM/Tc9LClIiNZn5et1pSZfmBn+VnjoH3ftOQkqvU5hoq6 Ks12Nitp6gcTG5kkAzcfhyKzandzS9Had1uvTo85OvYzgW5JrvjcNT3lMh9MS1i1Jkm/3+wKidEO UYOny9Sp2Tv52BLjNke5LNVp6qxd+tTkktODzzJ98zyYDf506+4Pt/4VmPdBkDVN/7jdqBMyh/sL CdH+uncym/rvSopXXmMn7XWrD2P9KjMDRWfG/UtPuz6v1G7Pzs9KVpdzazZEWImcl13Vcd49wf3F e0uPmg060y3uauCWqdhgHqHpka6cYmHAknabMnLMo6Kn0nJEhmf56tMqQ06mWlVqGkb2I7F8ZD9f /u//VOQZ9OoNhadd08iLsBorNBx00HuuKX1TmCkyTIcb2KrCuqN7svO0qrfKutzoiRWHWHq8Yddq TZtzklQpJIGK+Rnw2j7UJaizc/Iqj1Vq8UWifUaoDpwnXKkFXOZ92vUr39yavU9azLER+Mn3w5Dv J1zp54EL12c/nqNasUatr+pyCXcp6hEho1BilJmDEsisvdHquQSKqZv2WA5m1P2ddSZHaXKK+k57 egpz2pxsOVJXW3OKLB6aXDpi8RFyW0RiWio105QRyiIofpG4J5iisoFifAvPtIDvcifjTLtBXWVx 8VbEtofr8ksMue1D7LDJ1FB7Lk4j8+OFsWBzYn+gtkWLx7pisRBpxgq9G+lGdFHe03n4mkgHPZa9 ugYu21nCfQiRG8/w7owYtNSo/kmo/mJBo9Jv+vKrzsqcnOykrUWmIVnGSexBXA4XHpy8BwyG9Y84 fuGVJTwJKLZsDIUvQlSljRIKLqyxjS+x926hcevBtQ0DytGTCOIhrE4pMkQoF3psoCV/Q1KmIaei 4ZCW6xDnKd9JJmQGgktl/WWy9P3Glvz161svj7JthddSlMhM4SJCg+2Je3u8XMWQFAoOVG72XFMj a//v8GkJt4QISokQZ2mhiz0RT4QUKdwT1d2zE5tQDjnb3i0ljOVIzJpvo1WGU05UjbHOkE2j01OO lsRCZl57LnD/uge78TkvMMtD6YfWyjeVColh6rJxc1nXbVSR6eB99wg1Qw385xbWH/rhxcbMPLN7 lsmy13M+xj0lfcOk07cPUaJN0/6R62OSjuShvVZ/wOpF9we9Z2tUKUxWChfn5maGOncUdQ5P4sis 0NSfY+yeHrtygVmWTd+3VmiYcUfSgB/1XeMmNrahiYEPE3PNnlll3Kbmxq0Vqxsv4vVnIWrEfR/n yZIlNHnppHntv3Wu2fipoWN0IrogEmoX8SEyRA1batRr1eUf8+JVKBT01Td4+lBm4zfj6A+JGRCm R7l/xYc3mvJcvy82X/SDy5+ESWQW3lv5czAfh7ABS0kcGCTliAT9qq011tEgFtn561udIdHy6Ul7 /RuqWivWTKi4dUyLJmQLi5A5RFMUkBvYa/mnfkSVBYVYkNg+yIS4LpnTc7OkSiEJVEgLelbZXGP1 oW8Br7V2A75Iss+58YsNmUV4aQq79KWk63ZAkiFiqT3liPKjixfSEjvX/FunqvS7fzziLkZCCFc5 oqysR4SMImaO39GsZxOIWvbrI36+0wpRzt/nFn2Kc4OAwuTE/KRnhjszd3S6ZgIec4mm4xrudWev dW4r6fJMT9g/SKw868O2OOnqKMrsGJqRFR+p8RERTItd/8Y3TeFlIXwR3JNMkdBAEa0r6HMM/BNn Quih9dCaKhtOM3LGtYdPFGmMcfXC4vB05sTaNm5biAWksBBJQfC92yzpRmVPx9VEvGTRsO+Pskd6 onEqG0+JROO6M2LQUqPiAsV3C0kWC3rcXrtlQ/VZ5BKn5d3Wq1J7F53R04N/yMBWHZonnoT+Mayy TCqSIMRQGdXojW0cWVDvNnm1NVPRqSEitJbhdUrRenCJlRRlcNRavZWpxfOWrwDRpbL+4ixdqT4m DN7hUGh3l6Ggkxl3mHV1aAxmyfOutHTCzF5oaiTtP5cWlLZYlBLR7CWFLvZEAuQUKdxH71KfntiE cqRJT4lZ8200qXLiL6hm6vh5bR564tb5P7UZT3UPWBoIc+4I3NavZZtpDpk/qHS346FBseSEAsb9 VsrhLieqkCy8G1Tx3qq3T7IWwUfYb6t+i+1xETOj5hK8REwWmRDlvmBqPdHe/VXPMQ1T6sril8cW dSGphSb3pDJuTHeYUWP+h09m8UsT3/AhDe6E8Edz9qvo61EFA1C29TzBMaelyaDSN9nv02ztZV/m y89Sr85sGhjDOYLyk3vhJpcwxsblNmoUClOrzU6fKJFZFk8oc+UouhQuipYv8Vy4iL68o9Lm7sLJ ZBKV8A7OHKIpiigNDH0jhBihUkgccLdj+3y71s6pMO6iJF2Cn8LQPmba1ZEnrw7iLU8llEOTX9X/ kbOof/vjIZtUFRIQwlW2Qsp6RIgkKXMoaQIZ8I3HBzxna3T1WFmSCTO5Wb/t8NvCCBM/I0F7zLnb OlyzQt/zwFaVKUzH8bMZktIhNj7MDwZpQaNOtyhCWRAMQ2GKE6QGivwIRFM3z5tOtrRbBiz14X0h +helcQeek0F9Z6asf33+LNycxJf5MmrwTCapgJQWIi0ILiuIJavs6ZgbB4as1QWM4JNCrLnKxpN5 DJN1Z/MZFSG20hIkti080itYghSZ3Pfmi6eyfwyrLMokCDFURlW0Q1JjG0cW1LtF6NRibS0VHRbn BtlAZp19nLkkOJ63fAWILpX1V5p7wnf0xFuaiVsb1LDszjW7Sc1OtNIhCOWYlBLR7KUxJKQ0aop4 9/N0qU9PbEIZ9wE5coHPEJ5xyjwVvigjPePtPZha9YWbeuTurU9eQRTK0rxgkfsTHgGE4CBEDfe1 lGiTC419w35Wk2E3siB4x+jia9qKD5uNzezH+DubZ1bikvZ+uTfl8Bn3I8rdW6deF6H4w2LLev6I FDdU6tf6jGWp6t3GXubxa+ny+Pbxf+ebkn+/cOkxd5mMkMAIbQoHHqjQbW67+kSWY/T4uZrNH+CV /rIyUiD8S/tdvSfKUrYXNfcp3j5elKUXXFSfRihz/zLwmSNLZpgbhNLA0DdCiOH3co4lF7krcvsk XORvkUWMd0CIgzSxsUM/ufRfJs6iNpqO/995RiOFcJVCGfkVVo8IkSRlzqg0gQzo+i/Sd+W+98vS XuZZLQIykwugIF7Xlh/nGg30+dg2GkCm05W7t8tDecx783DfgyKwPq28gXfTbPzINjorLx1l48OE xiCNf5SyIKRXYYrStki4KC1u3hN6tK9UX33GRVHX+2o1K8P7QkZk44FkIY0vkKczpxmvZe971efw /BXOB0UBCVPJIpKC4Dwh3SgtWQ50ZaM+P3PtLyr6BJXIIXfMeUtsPMO6s3mDlnwXCk4sQWLbwiO7 wvozFD2eNKF/DKsseCxQkQTWT2VUBWPGRryYQnlBvRt6iN3NjA3LkWUXH0nxoiTaYRnCuZGWmuAY XYzFtBAklyFl/ZXmnvide5gPsU2WtOoIYUkCVZSOUiiTLEFpbPKEKLyVBcpCaJFI7vloMCg8eQZi XKOMnpNyU9t/5LceoIOPH/9L7JaEGCvzVPiifM729r2v4xwLlUGWTsTTjygz/yNC1I8fG/AC/BnO DfGZI3DZmHDIymzIICJGJuTr3b+W818odWXxxzyizENTzlM5WUaHJH1LDjp079vvKnI/VeX2/f5b /zxD4EICJZlDhCvxaUnmIPjbw81ATti/9OPBU4WSN02lsHJ5d52NGSoQbnyal/kkNhYvofyKjiij 27zu31ebVSnmik73PUkeExHCJQllFrEeESJJyhziiPIKzdGvnV/X5XKrIKLAmdz/feQwqsqt7FiQ hCce875iy9eWon1M34PsSq94Y0xSOsTGR0Ra0M9rRNnXW7qavSLxRHSGQFZRXPblwJclxezU7Yvk 6cxJXOVCKiBZFWCRFATnCbFklT0dunFdcv3fh79u2M5NkQsQa26UxlPozvDKkGhGRYittASJbQuP 9EpMI8rE/pEnvH0WknCbj6EyqmILI6n1kotxY0G9G5PwlFNDwtrZ4MTjfzGLQ2JrLTmEDOHcIBtQ jijP12iIkFwS6q80GpLvqBHQHPjyB0uZBk+CSRDCilY6isYhRqVENHtpDBUpnSdFvPt5utSnJ0ah PEePf12fUsqtrwre7qvIqrGN8dYgxFiZp8IX5cqtRxcbMvf23kG/ab+tZhVRKC9gjXJYls2MOC4x U6jYc2zHTzg39JitOkuxisXvbM3LM7m49zO6zd/4pJGhJweaVOxQE+2zVasjFD+6Rl6jHF6cM7cv XmLeacO+pctb1WWNYACK5hJlyOX/PvLJVWb4PEQ5f5eRaXLLMgeVVH/9uxV9spwnwf07NXLxH8xq rRAStfKnqQiI3j7F9nCSqMZLKJNNUYBkYKQQUVNDqhRj1nIt0/4Ky5HZMXvCGuVw+ySuuhu3VrzJ tEHiQjppYhcNIe1KoaysR4SMWtAaZWkW0cEHnjuymQqFyU1dadtWYrqJNQBN/fjZJ9+yMgg1/dpt Wm0euyaBsavc0zdx/xqiBr/4FC86khYfqfERQS6la5R3Y2lLKIvYTDHSGuWwTJscaEyoZIY/cUrf kPWF2DsEm0ZNeP+65BFTERq31b5XZPHSxAIirlHmi4zzhHhjxDXKkvouEOMaZVrRnYXmMypC9Zek ndi28KAr0jXKuKGOHk9i/xhWWc79FJ6EET62yqhKGqXFFcoLhPbZ6/RFnWwvFvD2ViXiSYkY3+hQ tB6cG2SHdYo1yvM2GgIkl4T6K8096Xek7As02lQt+8qBiBCW0uzF2xVCOUalFHGNMh8rRUrnSRHv fp4u9emJVSjjMhj+ojFnC3PgSEZNN3McQ3jGKfNU8oV/F7hAv13HLEjHr/zn5FYcq685sk//iwhC GYXL7nqxMys5nXlfGPUlpPcl5VnmR7Gt16Wk7RQWuQpumHCVWw1MD/dUZ6m1uQXpGcWtX2NvpZEJ 3rE1FmaX19dXV/86ayNT6rPU5ROpqtS00s88XsElslTCrhdhxUlT187U5eCwxCS8HAgGoGzr8Sz5 mYY81eqt2Xq1Kv3oGTz7hjNHXKPMLRmU2AwR7l+/68zRjKT0Aun7+9GReCseOCK81o2vCgeO8NsL iEjKMV5COZIpchANjBAihlQpfP2NySi3xQ0ukDvyrhdh9on9U77HTd/vr9euDXs1m7pkTNmi1R7o XrzXuYRSUwhlQj0Si1iSLkLm8AagNWSr9fgFNcmNPmtNYkWvNzhmq9r4unTAmFaaHD3tstSk43ZG l17a1s8vpseDtb/aLvY9lMtSq8M3ZuiKTvbjG+XFp2x8RJBLxa4XhLKI0RSVDZS0XgieIDs5btCX N9Qd/s3+jF/K+kJ8B+bJ922b3pCkcZkgTcXMUKcug5nQUxaQwkKkRSZ6QrhR0dMJu14g8XD2wOaq PtYZC8E4lY0n7nzl3RkiulGRqr8k2grtgr9yoCvz73qBrkkaqBlF/xheWSYVSRBiq4yqpPIuKaGM rQL3YhuYA0fSqruHmAfpWPYICipbD8ENVhd6VVjTOm+jIaJ0qay/0tyTfqefONu2/EyvmBcSwlKa veR2of3/7k+StMSglGJScdKURk+R4D56l/r0xC6UAQBYPFBVz5Rt+rPYoFYv7G13QEZoYqBZ3/r9 oj0BxIiyz1ga4I3wCl/8ugsg7ogiD3j5ob2WIublYyAKIJQB4EUx7fnbX6/gPYno4N0zZe8u/pFF wZG/n/meebcxcNdSvj7CaZoAhn5w8U//X4R94p4nS1Qo48MXkvhNWIGXCRDKrxD4LDm18g1FQA4I ZQB4UfALIfKz1Kr8FmHifvHg5viydunVG3JOcDPFwJJmCQrlkM/6gU6tP9p/Hz9zAS8ZIJRfFbzW Wn1yelO/7KUIgAAIZQAAAAAAAAAgAEIZAAAAAAAAAAiAUAYAAAAAAAAAAiCUAQAAAAAAAIAACGUA AAAAAAAAIABCGYgjcX1Dn6bujPw0/+u4/DvaNOUdebDwbRxiDOWZCFF3PA9kp0gsDgvOCume7cuU F54EOuj9uq1w6watPk21tei//uamQrggVqxP21mwKz9XPCUE1453VNrcXfn52UmbdPzRJ9EI3ulv 3ZOs1qUlpVeeFk7A4c5g0mq2JFeY2SMP4kF4Ti742MVYd0sgtRJLYacFQlNAimoMLUbIZd6PD1HC nwLt+pURNyx/cVuaLCjDY8uZWJud6SFT4XtR62zA23+ySLVOnaVVpx/pHuIPhFqOPL1hL7TXeHG2 tFAWnCfPqwONDAhlII7Es67Ouk2Z7zBbC4ecbQnlfb4IgoCrdQG3qWBdrBsDT15t1Zf2etE3MZTF Y/a6aUdqnf0h9zMmxBgugAVnBQjlZ4a+21eixef54++Ph/7XfmtGfqjn9D/a1FntQ1Oy2oEPbs0q ttyO2vbPeHsPptZ9PY4cBW/3VRQwZ8jNzeFzs/cxx1BPe8z7NK1X8AnaceBVF8pCUxBytqre7/Xh a4SoLrDFCHotZe81DEQ4SejFiZuFZHhsORNbsxO8Y6vLSU5aF6XO4vMLDb934ifAEOX8nS5xOW/X /dSGveBe48XZ0kLh80RiTgTEf5+mA40zIJSBOLI4dVVxdrGMp2mJCCdsLzGeKoYLzgoQys8M0Thl BSEUpbR20IGBxrXS87FFQpT7fGfV7jqb01quaxxgxPEcPWmvf7vWPoludBg3VNnYq3N+W7XK6AjE ZazlVRfKAqSjv58W/ByV0TjwiPsZzosTN0+V4c+cM/SM2/LbP1xyxV5nozf+S5/nZ9gvzpYWCp8n 0VuYBbc/iwkIZSCOoLqa+B+1h4v0OWkJG4vN12fwxRA1eLpMnZotnHGPmB62VGQk6/Oy1RpmYlpy ozBVzVangKtrb7pqxRq1vqrLNRX0XepkT9VXaSotw/j8XK7WCd28z95cykx6ZqnffEPTcS0UHHN0 7GeOld+SXPG5a3rKZT6YlrBqTZJ+v9kVEhsyZTyxn2/sOfLbQkO+VvV2kdk9Q1QkUmebNpWcZo5z wykqPd6wa7WmzflPoQmjqR9MbPyTDE025oQRFIFVu5tbitaK87PTshgSM1Ak6BtoNajU2Tl5lccq tbKsoFyW6jR11i59ajIXK27WPi2P9epfpAQGfJc7meC0G9RVFheKNpPA9xtb8tevb3WGuFNLMg05 FQ2HtFyHRzi7P16Qkk+PDbTkb5DHIULeFtYd3ZON09v05VedlTk52Ulbi0xD2HLCDUMWZ4JvsjIV hggf2mtT0xrP35MmWTQqxLi9VldteyDvyYhCmZXIedlVHefdE/Sct+99ndDz0W5TRo55lJ4ZNZdk mG5wgdE3TLqSrlGmnrFET3K0fwWz4RA7KmKJKxE916reKuty45HuCNnI5oPSdPHfi4jk2O1ZV8f2 Xxy2+WfRV7/tiKphYJIptUtD5n3a9Svf3Jq9D9U9SbskNGhc4cbUOODzC99tujgpNy3fNy05iWp9 jqGirkqzncmK8EqHDxYWRlJDg+2Je3u8jxTVmYdgyaSYR8nwOOSMYD/z5ky4pUUBZ2BCvB4FnxlC KxdzPpNaSJoa7KrQ4FVbXO3AvoX3GqRqFSEmkXsZ4XArMUqoxHOZmS7E1FB7bpHFI+Yy/XjIfChZ pc0X/I8x7YSenW/0uIrDfZGbU7j9h1xhxhY5acT8iTcglIE4ggxaZTjlRDIX9+ubmYae+q5xUxkz UxyaGPgwMdfsmQ2NWw+ubRjAkof2j1wfYxoI7sa56avtuqLO4UmxXkkGFWif8wKzZI1+aK18k2nN OWfhjS89fq5mc51tPIRE1ZUL17DP9H1rhYaRLJLxWiEUQjyxn6/nfIz7JKxI9HyzEobE2Rw12F6Q 2TE0g1O0Lrnu7/ImbPxiQ2aR+SYKjZ74rmlzSdftAI7ACk39ObY5E5DEkBAxxgnLRH/d5horPlop 4LXWbpBmxbi1YnXjRdzHhKgR930Uk6nLxs2sV3TwvnuECpASGPQ5Bv7JqOqH1kNr8OAl9nCl+hgj Umcn7B8kVp71IV+Do9bqrUyeSy7OTbo6ipgciBNiAumZ4c7MHZ2umRApDkiw6g9YvTgKM0OdO3gT ei3/1I/IYJBa3bKh+iwqDmyZ7DMJwTAESCUlK1MRmrrWU7399aTKjvM3sW8IwajmAg9+/HPljuYB ZIeiGaB7Hl5szMg1uwWP6AeXPxElMkvAbSrc0vgd/o0nrDUrsZ9hUw0SP1miJznav+E1iBfKxBIn IXoeuGUqSMTn4kbKRibOBNPlfFo0pl0dhYwgCHot+zckZBodE8jCHM0GXPp8qcnHTRUNGucslsYh 6OutWB++7kIwVDroPVujSmGKT1HpaHeXoUBQrhqD2fNQUZ0FCJZMinm0DH/2nBHsZ96cCbe0yAjN 6VKA2MrFmM+z1MB/bins9qBSw3U/M8/snp3zO5r1bO1AjzrXR/w09k3RaxCqFdE33j2x0hGi9MRj LtF0XMOdyey1zm0lXZ4nOJUYesrRksj6Pxe4f91D0ZFCDEs7sWfnGyjeikjmpOx0wowtctII+RN/ QCgDcURZK/CU8VphphhVyNRCkzuAFU/K4S4nqkgskhuxuRfhMTOhXkln3+iJW+f/1GY81T1gaWAv cs7CGl9JG4QH6i6YWk+0d3/Vc0zDiAylUCbGc1LipzSGYciCxk2GznRL+iQt3Dtpr1vNDtUgUM+U J0umDCGG5Axkf7H/MjPyDGFZgfViRo35Hz7c3iHkXmGkMRcjTFM3z5tOtrRbBiz1TFMldYYEVmad nR0JFa4/sFVl8osE5uhRswHnAPvrGZn12w6/zba8CHqkK6fY5L5HiIPfVv0WKyMQ/LCrmLekRyOC YfAQSyqaDQR8TktTzlZd09e4H0VBcC/z5WcnrU9rsj/A8UK3sy/zFSjH3UlCGYV8zVyi3qA1ZGsL mjoa9TjaMQjlKEmO9i/OyZUJ2gLpW2i49IklTkL0nHcWLRsnSKbL/lg86CfONjWuAmPWioN/tvyn AQkFVKc0B/qQhuDjQOqhlXkozYoIhkFcd4Hy5K16OzfGLN6oqHRIx5Rm4uxC7eFu/EwVXp2lKC1Z GXNiW8H+QDx7zggZMm/ORLUiEXp6+JPcbSccE4uhfJ4CYisXYz6jSsROK2HwmD26l5LWDhZpdvHf xZIS8o3kmxATQqW7TpGKnvaYc3fghhr1WZnoSUw0K5n/DFFDRPBpj9azCwnhv0jMSWn/JGObpwON 0a6eBhDKQBxR1oow2xUchKjhvpYSbXKhsW+YfZLmbxTMXagAolBmXm+q+sJNPXL31ieviCSU6Zmb p/O2nXRO4apPe7/cm3L4jPsR5e6tU69jehGySlDE85HkojSGYcjv5TyUuue/CynCKJIpQ4ghMWJC NIhBixdp6lqfsSxVvdvYe42iw7xCSK/wPtOjfaX66jMuirreV6thpBLJGUa4ji6uTytvMDY3c5+P bKPS9v/pwUG8ri0/Lvjc/LFt9DohDijtr2krPhScGX9n88yKeUtQjSTD4JEVijSZ0sxXMH21PT2r zSkvaHrMVp3DvIky3+1Y7kiXXsjAnRMuixiWXkROctR/hWRy8B0VscRJiJ5LCoW7IrnIeSitXNJ7 FxnU1240Osb769I7XI9s1Vkm911LESMXhDjESygT113IU8rfSKh0/EByyN2Vu5cd7ZNXZ9YHDMmS lTGXl50sGgzPmjOC//PmDOvgks9+ooh/KuM/hcxiMww9caklVd9yGb/LujRAaVG2cjHmszwf2Iuj XK5KkDrjv/OZr6hBct+EIET3CPaWgVFClJCFsQPJlMe8N08yu0UqtaghilfQt8g9u+CG/yKaE8n+ CcYmhoLgc0O8KM/5uAJCGYgjyloRfUA0RP34sWFzi2PqtqQeRhlRlqzaFC5yziSVBEsTPbcRwVzI 17t/LVd5BHGgVAnEeC7zEWX2InJEOU/lZCFpIvMKI3XJR9LXW7qau8Q3VVJnxPHFCUezvsI6xlyM L/jdNVX4Wl5SHAKXjQmHrHiFgwQxb5UlTjQMHmJJRbMBFt4fWZkKuTTv7SysXN5dZ5O+Dv7EY96z Fc8qzvcyX7QkR/9XWsoYvvSJJU5C9Jx3Fi0bX8iIMuKBrarkv80tuSgz6bt9e4/8+S81aewENB+H qHKQmF3EkiWuu4gwokyodExl1xz48gdLmabDJXns5KuzUI+JlqyMObGtYH+wPGPOCBkyf85EsyIW vM1LqqFjEC89WSoQW7kY85k0IvuiR5SZf4vLvhz4sqSYXeTDI/OfIWqICNFPFlLPLrjhv4jmRLJ/ grHN04HGYFdPCwhlII6Qag5hiS09M+K4xLyVRfttNdj0R4TVTswa5d1YCwo+iEL50cWGzL29d5Ar fOMqolCWrq/CIUwONKlKe7Fqpn22ajXTi5A0RIQ1yooWnw4+8NzBq6kEsDPpGuUs03XJijGE8D3C EiuunkuRxDDqGmVmKXbY4jM+2jO3L166iz3GCU/HzRxpjXJ4AicHGhMq+/DUWchvO/IGbqqk+RAa t9UpVqzSU86TmtzTN/FbOyFq8ItP7fdpQkY9FXg3tBLTTbzMkaZ+/OyTb300MQ5+Z2tensmFB1fp x4Pd5m8kU8akEicahkDUxbUS6IlLJw9zb1bR1JWTYaaLr/5kr9OV9d6NQWeHQT8ZPH3sjBvHAfvM rLpGRN8eLlqSo/8rLWUM31ERcxt9/2nkjnRYU+q54FW0bCSZLuvRohL0WvaufXMrI/3xosY1b6LI MHua8fGPKgeJ2UUqWbzuIlWuNhjwY3xW+BplQqVDIClQoNGmalm1qqzOHERLJsR8vgx/xpwRMmS+ nJlf0FAuU+mmEgvfhi8RiK1cjPkc+xplIbv477y3knxb8BrlSEWPJK92m1YjfxLDKY11jXJY2pU9 u9darmUtSgxXaU4k+ycZW/QOdF67enpAKANxRFlz0DflrgUhaviLel1K2s5c6du+3PuzYbteYB/G Hc2ZGzQZe7vdM95zTTm5Fcfqa47s0/+CKJTHrOXvrUnKEify8Dv7hdnl9fXV1b/O2sj0IrPU5ROp qtS00s883ijxJLb4PlvVxtdlY5zYGWnXCz4rJN/JL+1yEZAiiSFN2vZBRPk6Mx9t6tqZuhy1Nley Ipbf9WJnVnJ6A7vrhSKByMPjBn15Q93h3+zP+CVuquQNEHkPBMplqdUlpRfszNAVnezHkVRm1NNB T7ssNenYWnTppW39TKYR4zA93FOdhdObnlHc+jVOr5i3JNVIMAyRqNs1SKD9rjONhoR1an2mOiGr /gwzJ46CENcob0qrtvAbEShujwqKw58q0tVanTpBz8cBIRw4IhibhOhJjvavvJRR9ggdFSG3kXo+ sva1g7IhfNFz0auo2ag0Xfz3YoPnfLhdHZixsVX8+K4Qf+qSMWWLVnug23NDLLLwPJRmF6Fk8bqL /1cY/ZKC9PG5pvRNYbteKCoddvnE2bblZ3p2tI8mVGcegiVLoiSWyzwZ/mw5I2TIPDkjNQ8yvt7S Ff+HXc2PP4Un7GEzRS8MZSsXcz5H2/XCkK3WM+9zS7OL/y56K8m3OOx6ga/OPfm+bdMb29knMSn8 rhcF+u069uXCqCHykVT27EFff2Py6q2ycAnmNEGwf5KxRe1A57OrZwCEMrAUkDYQS5zQxECzvvV7 4Q3hRa2fSxuU8P8/e+//1dSV7///KbNWp6ur81mdTx2tq122mIsLBbMQTRZEIG8ICBLtlC96Af1o wAs4FRwlLAtOL/YWpp0408A06rsw08zUtCWdopfYYgsjsUYMNkqsaDjliyRsPnuf78nZCQFREV+P lR+Sk3P2t7P3az/Pa++zdwlZMI7/GYGyoICnHemOE49O9h8uPyD9PfCIIIvEbY3w9gHAw4GVpbgU qWxZQCAGIJSB5cDTI5TRnQt//r/hbrxnSiijoPeLcy72DZvg8JliXdQNkygFBTyNUO94aOzCx38d uA8y+VES9HdVqh/NclfAs0Vw+J9nv2VfEJ7+0Va+XthAkYx7pLBL2gExAaEMLAeeIo+ykmdMKPMD x/k5KckG8xdhQ8DACgTu+BPBZ6/Rp2Yc7SHzSgHg4eBnT2Xv1KsTc0+wk0ZCfvvbOrX+cM9taM/z AkIZAAAAAAAAACiAUAYAAAAAAAAACiCUAQAAAAAAAIACCGUAAAAAAAAAoABCGQAAAAAeDWi0p7bQ WFNdWv7hADM20P5m4rO4lCQAPMWAUAYePYi5OfxTlL7hSa93ESttETy61S3QjOfjMnWaPv/UJfl2 xPPzVK8WEifiqgtZqepyS+SSZNSbsqBiecyLliwiuhBz03snyloTiPEN3wnfg2YBVfqhkVb7fzaJ 426iwPDV0eDczIi1qtH2yV/aGgqf5QJ7qpn5wVaiSc0uaeU2LHxEPM72S1Calxi1OjTmPGEsKNyp 37yG31PJ1OGemgve7Gnenbh6s167RWfqHCSrgpJAXkjQFpJNlzakFr/LLrXxtAJCGVhCJi4360u6 fPwvgVmPJeu1w85x6rr5T1jqxUxbBAuXOKH+loTybv+8y1RODrbqybb1/M/4WWzpxZuwZQDZ8ldf 5RhF+HFi8FRaWsT+C9SbsrKE8uxVy/a0KOtVT3sshevIqqhS04tZpektND5o1z5KoRzqb1a91eXn fy0npOYT990M3rRXv93tJzuJljy+ygYsJaHB1mSd5frCzXQcxNl+aTykMRfNy4JqdVjDD/rtNXkt l8impOhef4thM1n8Wx5IiBn4cJeusXe57LC4YEAoA0uIbF/ceHmKfKILlzhBl3kVu8/2PCyi3DgW W3rxJmwZEHCYVgtb6VKSTb0pK0sox0WcVWjRNQ1Du/ZRCmVpD+3lhlQP47ubIY/9xKHdpnM/Bsm2 6iCUn1IeZYV8iIa5VMZ8QbU6esMXSikikInB1vw8q+eRPGU8ekAoA0vFlNu6Pz3hpTUp+r1Wdwg3 pJd2NzYZ177efHlEaFTBUVfbXna/+E2pFR+7p3CroWga+n7uLxXVHn4zJ1+reqW0wzPJnclD20Zf WGI9y5BbUX9Ay7ZYWVxiO+e+eG3GjS38frwPvm3ZWHbG97O/r71UnZazQ5uoPmhz46tkLZ++8X3y b2uqjfrc9IQNu6xXZ0LujrIM1XNr1PqDZHBKJPLa0JjTrBPLjT/He6Yot6WfKxbmcnOu0eZFMUpv ashWkZmqz89Ra0ot3zEIBf0X27kyVGkqbUMkevGOrNbs3C0mbDLKmdFL+zEj3inMhLP2FUE085Cb 8vKbh35XZCjQJiUVn2b3AhRvdIgZOM3exAy17piDH/sLMYPWSvWm9Hzu4M/SbQ16zpQU1J2/GYxy f0uO1+9crWnpn2DDwUQrZ0XpodHepoLEsNoowmbhrYamgvVkd2h61Gx2KCFzdbJnMKLp0ZvbZFgL pRcOhzJf4a2bP012dxTJlm2/POVu0//6oCNALrjjOKhv6L1Ha0GM22ZKV2fv1KelFp++3Hd6j3b9 C6s25+yRx/fQSGWIc330k8/aK3Nzc1I2Gy2D5N5Fue/R2zUjq36qV41Wz0xkRgbGx+/ff8DeqVru JoJQfioZczZmiBWS1nZI1RK6PLHGytps4oa9/Myx2A0zepuarzZOTrk/rtRuyynIDp+lFvTZ9mja rpC2OHulPS3J5LhDDgccpoSjFyZuEPNysW++Wh2OmMhIgv6uClVj37S8u2ShDBBRMii351GifhKA UAaWENljMW5Iz2mI5uC+8y1/9NIXV9gBmtv2Cg3bXEVNIzJ2oT7LaL1GTh//+ujG4o4b0ySE5wtO fY9b/vR1S2Fy2Laus+POt5MrP/WTBjXhbjNmtQ3OzIXGHLX8weCI3bR5HqE84+kwFHJb3s+62zQG K5alflfvv4nqCt21H1hDunmx5VNjxIGrDKf6ce6Qx5K5kd0XlPKsP8v0/n5TUacXGwV090JDVr7V M0txJzzwWosl07a1uMP7IHrpBcbs+9fW9xJrzU+InEP+/i8GiaFEd+2Vq6odgdmwOyJLGP3MqKX9 2BHvFO5dTpVmNV8Kl+3kpryY+z6rj5mB1sJsy9VZ8UYzXzcklXbcwLc1NN57LDnP6sUFOtln3sgd RMHbnmFmmr+tZNDwzV3tlxkU7f6uS639J2vNJeIrPVmAUm0UIVl4QX2E7W6jRS0I5ciQxToZ3vSi NjfZaeM9tRur7GTjNzQz1J61vd0t65Mo+aI6vfi4aLWa1Ns9Z3xB8tS3K1m15YRrGie8z6w65AgE Kdkcs1esbrhA5uiHmGHP7SB6JA48qQzHnDWbEk2f4htKGiwRN9S2Gbtdy6of+sGi07cOTs5FZOR+ f7uxoOJYDfsyH6keIJSfUqQKSTUsuGqJBlZEqm9oauC9TK6VxW6YQptaeC8zai/XNfSSB1LEeK/e lh59SadWZPPhq3y23SpVGhGyaNplTiT9mmBeYtfqCPhE8r8kpi636oztQxNcIGGGLvISanOLI+on AQhlYAmh9dZh30OM5wtL84nWzs/OHNGwZwqtVGTCWbua65gxU+62fDJ5VwpB0fyIjyqLsw4YNGI1 kGlkuBfMqnWOscfES2RxiQHyX0RhimMs5EaIEHPtc8vJplZbr60ufCyJGiMtcIpQxgnT8Q/0rP3a Rq6lSBDkteaxDjlBuONjUUuPCJ0t1R39RCLzoPHrn/+5xXyqs9dWz6VBKsPwhMU6U1najx0uMdPu jj169Ya9fx4KkJKQCEuhUJ5csYxPOOvW8o5M/N+V9rQii2cq7CCBC8HptddlsrIpSo1SVFSOuEqP WhtF5EdiRk0JWfxCbXrKCiOeNhtwVL/KPVxh0HBH7i6LR+pZKfmKJZTptfpycyE5OGav3PW+7Xgl fhDFf2mLu/yIls0Hg+3bM6us3/iFR5FHJZT5wlGWGDUXsdu1/N4JZ85EZgRYGQgVEtEMC+vN4auW DPlBovyMbCuL0TDFSxbRy2A9XZRmsvb7ZQ2Z48G3LSk1+AF1zF6z+88fNea2u2dxT7ertOtHFEUo R9bqCKiZnWOG2nZrzBfHScWXB8ISeQm1ucUR9ZMAhDKwhFB7a+k78n1StqX6rOce4+mqVa9jz1Q0 hrDmJDQb6aCi+ZEQ1qeX15sbG/nPHxwjs/JgxUtkB8UAxbR5rfl5Vm/I05FXxrpvR7pL9Kazboa5 2l2jeSFMKM8Xoxg4RSjLEyaeSZMgiEsJ47WW4UdtbHlill6IGepuKtamFpm7iZSc8XXtTzt4zsPc 83TVpT7HpkEqQ3nCYp+pLO3HjizZaOx8VdqxC/f/3bGnaGcB98I1GSWUUsifzBXLvfDEUw9iSB5/ nV2Qv/qNsq6brLTBZ8auUSJxlp78WmWRyo/EjJoSsviF0vRoFUY8jVz4orb8uBhR4/uOEbF/peVL HoVIWIFH1GqsJw4nNV4ccx7RtQ3ed9TpLYM/2vZmkZdWqdnEj6ZXus2laerd5i7ib3vsQpmaC9lB 8dr5JEVERoCVgVAh5TcdI9x3qWrJCDvInxmzYcor3sJ7GRRwd50o3bLN2NjtJoNsIliV5ptdw86a 0nb3iOPgHovn6pmiN1nVLoT5sEI5NN53YlvaCdc4F29EKbGvQoY15/CQ+QDjiPpJAEIZWEKUrZ09 zH8P+bv2ruWPiWcqGsOCPcrjrkZ9hX2U/8VD9eHJ4hIDFL8QYVph6/toF5bLuG/zd5Ws5qNR2Edq jLTAKUKZ7nujSBAy+2LPLtuXNuMeItzn4im9EPP9+4aNTa7Jm91v6fjjYhqkMpQnzBfzTGVpP3bk yaaYzrAUkuFIye+yAI/yC+qGL4f+WZdWzU5FmO/+SsRZetTaKCI/EjNqSsjiF2XTo1YY8QsZeFWV 27k0KaDlSx6FCB8XtVazkyC1Jzr+sL91cBL5u/ZUtn10sJid4ETNJg9i+k/lZptdgafVoywgZoT/ DTzlLJFHeSJmwxQveYheBt0fOFWU3Ngnm7UwG3DUpr93+l3De4OhoL/r0L6/fGDScq8QCGHGV6t5 IjOLgr6uynVF7UPimfJAMBODrXlZZF6cCLW5xRH1kwCEMrCEKFs7e5j/jiZ6j6pKukaJd9TvMKnZ M5WNIcocZT60iOaHQZP9JzV5p6+RGZYhZuDch87biD4rdNRermX1yrTPXpPIBSiFTCZdaLTaAu7N 3InehoTKbjKXIRRwHHo5TChTY4zPhMU7R5mAbYd2q1abz827iFV6M8Oui+wLJSjgqCKPGXdxGXL+ UXLkJTYN8jsiJexezDOVpf3YwYl5ftcf2RkXxKO8roKssSVBUiifoyzM5GPvxYLmKEvz2ue7vxJx lh51xryIvJBjRk0JWfyibHrUCiM7bfJSy9ZiyzXSmSLm+79+8C92NiQHLV/UWsrHRa3V+GLvGeP6 Na8dJu9fYpWw/bU1SU1kpjI1mzM3Llz8kWSOpDYD96CPXShHm6Mco13L751wpiIj5E/g6UeqkNHm KPNVSwY+KJ+jnGXxzM7XMPlwFtHLTA5f+IadPEb6rHB3AJmdvGv1b9bVOCfwd48la9WaTWSmMkYI M3atjiAis1ODliJNqc0jHggPBKdfuTxc1DnK80T9JAChDCwhs0zfiTRVWnrJX70+WUOSmvRNR0NR Tnldncn0n9kbWLtAaQz0VS/40OQNSYRx22p0KRmFOzJ1xpP8wuaUVS+C/p6G1NWbc3LzK49UarkA ZQ2ePNT+Qs+90kfEtOO4QV9eX1v9X3szfx0mlDHKGGkmbG7M1ZiVqMks65Qti0N51ZcmQTDEV/Gb bdwrfZiopRdghs7V6bak78gTSozdpCM3r+JIXdWhPfpfRQg4jJSwmVhnUkv78YITw702viNbnaDn 64MESeEiV73YkZ2aUR+26gXy2SuzKrtuYN0Z6/5KxC5nWelRaqNIRCFHj5oSsviF1vQoFUZ2GkJT bltVBqk2uoySlh55wdLyFXYtf56UJEqtxkxft+QL613gB1H9y2w/zRKZTcRcOVubq9bmSSEwF81b Nmm1+zrJiMoSIZWhUppQcxG7Xbt90r3jz6RkBFgRyJ7caIZFqh4y8EHKqhcxG6bUdS6wl+m4dOXs 4UxyvnIdG1y3f7DoNvGPbaRnSRbGuMQwY9Vq9kwZYZklg1cv8PuPkI+xEQdNTJOw4ci6xCIu/eFQ mpvcGEaJ+kkAQhlY8UQIEeCpgtr9AAAALH/AfK0IQCgDKx4Qyk8z0NMAAPCUAuZrRQBCGVjxgFB+ moGeBgCApxQwXysCEMoAAAAAAAAAQAGEMgAAAAAAAABQAKEMAAAAAAAAABRAKAMAAAAAAAAABRDK AAAAAAAAAEABhDIAAAAAAAAAUAChDCwhKOj7sqVo09oUXXpKdlXnAMNtSoXuD1oPpKrStCpNpVU4 +PgIMTe9dx5qf6yYC8wh5ubwT7I90pYEcVOiaIl/+ExFIAa4jPZDiuSpWGsJFoQCgJUIYnzDdxTb y8WPYBkeNpzFIFr1SY9tX6o6s6D10mJT8KiXWw2NOU8YCwp36jev4Xf7M3W4mSe7xisIZWDpIDsA l5zsv4fVFmIunczIbR2cxF/JnvVGdkv34LUOY0FLv3wL+oci1N+seqvLz/+KwuxVy/a0Wudd/udi iGUaZj2WrNcOO8cfPBKhHC3xS5CpcKQAQSg/HCCUAWAFMu2xFK6r6Rnnfy4c3jI8dDiLQbDqoYHW jYUWz8PI9Me1L0GYIX1ckUYBhDLwiGBcjVp2F/txV6OB32J+bjbgOJTY2LdUT9OyzfcfKfG00qVt yU9QrYJQfjhAKC93pm/1vleyISk9W63KOHx2KPAQ4zLUgZ0lb0G0AMVqxo9oyVnq4aaZH2wlmtTs klbX41V3D+/EXVY8ScsgVKGgy7yq+Myth0kECGUAWCrQj93F2WZsWNFwR+4u8REWeSyZudYRuQ3H 7eGlotrDb+bkZ6h1Rz/5rL0yNzcnZbPRMjiF/w3edDToVSlZhtyK+gNaeVMJua17tOtfWLU5Z8+f znfu0bRdmcVHZ6+0pyXxujzgMCUcvTBxQ+hmQsygtVK9KZ1EdMzhm55D9wcs5anq7ELtlsyG876I rgWN9jYVJIZFPe3vay9Vp+Xs0CaqD9rcbNfFt2euJfd6bWWbWwdCbAChwdbNRTafLFTEfGcp1qTq DekphqOOm2xesAlLLjlev3O1pqV/gj0LI3aNwpepIVtFZqo+P0etKbV8xyD5Ccm/rak26nPTEzbs sl6dwVdT8kWS9/Kbh35XZCjQJiUVnx5gcBrlUf87MsblQtDf22xQqXNy8yuPVGp5caDMIOO2mdLV 2Tv1aal87kLMwGn2Zgm3m4pU/bSJG/ZaBu6T2xWtAN9qaCpYv765n7u/+Lyg/2I7d0NVmkrbEKmx 1AAViUE+m3Fjy+UH7J8Pvm3ZWHYGR0OpHsDSgqYG3svUvdvP1ZD+dzPTTvZPsndhEdAHdpa8BdEC FGSEMKI1Kw2vLfVwE7ZjyTrL9UUVUlyDflF5Is7XaIhajWZyo9pn6U6F9xT4gNwmq141Wj0zYUVM sQbEtuxubDKufb35smCDFKZvWggfIyaD++JxHs9VPbdGrT/Y4Z6iWTlF1pD3TFEeOzKMmRxszTPa PD6pHGh5lFKotMA0gxkNMUwCvawoRRR5I/BJMXv5+AChDDwK2N5oe7sb1+aIR9iw2s+CjzxfcOp7 rCfGnDWbEk2f4qpM9DRpabPjzreTKz/147odHLGbNgvtn0f0KM+62zSsJMX6Y7dKlUac1mjaZU48 6AiI7Xmyz7yxtOMGbpsoeNszzMxIgc9NuNuMWW2DxOTxUKMO+l29/2a72Lv2A2tI4GKOePM347Xm bW1zE80+5W4rzLN6ZO1y7EJ9ltF6DWcBjX99dGNxxw1sO3Dy1qXW/jO8AYs2iPsSGLPvX1vfS7Qe CgxfHZUZKfxFZTjVjy0CKbSNrYOhWab395uK2Lku6O6Fhqx8q2eWNTQv5r7PKkhmoLWQzaw86ogY WfO3HBjvqd1YZffjMpv22WsSSVHTMjhmr1jdcGEaZyTEDHtu47+kC9HMUHsWVxuVSNVPrLQhWsUg BfiC+kiE4Eb+/i8GiRRGd+2Vq6odgdnIALMsuPTnmK8bkri6FxrvPZacZ/WGPB2GwnbcXXG112D1 orvOGv0+O/tgNTPYvt3YPiQ+OAFLBHmAz8UNiv859/Ow6xsvaRRLyJK3IFqACkP66IbXHibkxzXo 9xjgLTxreyNMbii6fZbdqfCeghPKvE1GP1h0ekGPctA6CxzCc5q68+GP0JGmTwwfIyZD+CJ1x9Ru Qpm1B15rseSE2lrc4Z2QlQMtj2IKaRaYYjCjIYZJoJaV0mCOK26ErB+n9PLxAkIZeARMDbQb8pr6 xkjljEco80fE2RriQSyds2qdY+SIZKckJCv84NuWlBpHIDhmr9n9548ac9vds1in7irt+hHx7Xl8 wlm3lpO2PHccB7MaevkDaMRqCPOa0KNGzLXPLSebWm29tjo+aj6pwjkIC6DdxIOO2/P2kg7vAzYE lgln7WrRNODk5WdafhCSF9Gtigf5L8TQbKnu6Mctn34COSYVmk6Y60JE2DaSr7DSI0aQHJRHTQvw yYPwXXu1xskLxhgZfIANZWaV9Rs/Ef3kcMBR/SpnMTHhwxphSNUPn4ZNsNHiuUmrGJTqR0Dj1z// c4v5VGevrZ6r5/IAyfhGkcUzFVb3+IPjQg8kPFAFHKZXuA4PMzNiLWarBxAH0z/5vxv0/xTLP8Uj qYpw4vGu4dOiOw6R/6um3GS1PtdQUXtQs409qPSokVqkGJfAh0ddbXvZ2DelVnzsniLJowVIG11h 69vFQXF4zeoOyVJF90ryIx6qV0o7PHJxRiuHMWdjhhgyf1ZY4ajUvOtOkV/ZoB++Vjkch6bcH1dq t+UUZKeqy9mxl2jOUXnrE3InZQRHpxiKXHrENEjFKzR2VgjS7bPMwvBfxHBomRKhdhZiUHKIRpSb PmqwwhepO6Z2E5RkI681bzvpGXGvkUWe52OUg+xLNAusNJjRCMssLVMUg3n1QeSNiN3LxwsIZWCp QWMus36b+eI4Vx3jmXrBtwelUJY1xbCmwiNzV+Bmn292DTtrStvdI46Deyyeq2eK3mTj5QK5p7gc H1+fXl5vbmzkP39wjEjPt7So0Uh3id501s0wV7trNC9QhbKge0Jea34eNitsABz0li+PSEQ8KH4J MUPdTcXa1CJzN5lVqTyBWmjK5MkPys+kBfjkmTfZUqki5kq3uTRNvdvcdYVhrfmL2vLj4s1tfN8x Mp9Q5vM+SKsY4SnhmfF17U87eM7D3PN01aU+pxDKfIARdY9PP+6BSA0JeTryysgDFb7weW3FMTHB 5ncd3uj+FkDg3oUv0pPb1/xHu6rk62/u8QejEOpvXk9xcMbpXYvhOBSdWyjo+7RKtYUcpHjUSC1S jkvModFLX+BKi7/ctldoWPkSO0BxdEWqwDJjKKYqileSH/GYvm4pTBbmibFQy0EesohUOHNTl1t1 7OiHcthkVn6tcjhu1F6u40QMYrxXb09Hd47KW5+QOykj2PhHDEWS85YaMQ1i8cqtRzT7LDuH/xIz UyJSyBjhzLCDEkrTpwhW+CIJ5fAY+ZBpyeYdyYzXWobrA4pdDlIKyWkKC8xQDGY0wjJLyxQ+gWIw lTciRi8fLyCUgaVl2td14I3cD4ZYpwjLfC/zSe3hITzKJOTa9PdOv2t4bzAU9Hcd2veXD0xabgoE 166UHmWcMH2FfZT/FQktan9XyWo+BVLUfFKl5OGnc22x7btP9mm5ESuRh/Ao84exFfj+fcPGJtek OPFadoJUaM+eR1mobojpP5WbbXbdn3aZVeV27v7FQqp++GLOo3yHVjEo1W9uztf9lo4vK7EHogRI 9ShP49vQkVdh6/toF/dANd1nTjhgH3sknfzKJTTxWd0fsUpmP3884Ig9W4Wm+TDUGqVsWdEdh7hp v1LnnOBqIXcwQPOoicPWEYQYzxeW5hOtnZ+dOaIhNpASILFgirYgfZFlTZaqWF5JZZWmtyxaockK hwhuY6blKkOr5PJrFcNxE+62ojSTtd8vdAhRnaPypApRSxlRdhzk61IjpkGW98jolPZZeadiZkok fo+ygGD67tKCFb4s3KPMxr6r9JPeT4p3sVPFYpaDdBWZ+qiwwDSDGY2wzNLKKpbBFG9EIGYvHy8g lIElBE0NnTZuqDjjlY99zbc8nNQelPYuNOaojWeOMgb5bLtW/2Yd25GQQaJVazbxilxoV5FzlIMk YXmnr5GpqyFm4NyHztuceWahRT3R25BQ2U16yRBW/C9zUfNJlbVk3Elo0tK38jNQZUSboyyYGwnx IP9lZth1kfVCoYCjihjQ4YgTyEV8SuKao5xtucr6zMSoI2NkDz550Nj5qnjmKM/cuHDxR1L4yO8w ZZAOYPJSy9ZiyzUysoyY7//6wb/YW/nT8E12lFgEF1rklGK2xkZWDLmlFrmHb2hZ1018HrkvLwlC OXLSM6I629geqFCj1RbwE9kD/c35+RY3/zpmp/UrkmsgNujBxXcsvFDeYDn+v7KpThTI2CvxDfM/ BcLrPN+OlC0Lf4viOJROwHAHyTCCwqNGF8rI90nZluqznnuMp6tWvY7YwCgBSteKJwhfKEI5LBCh AksHlVValmUMJWQR+ZlcOL0jYaHxJ0jXUofjUMDddaJ0yzZjY7ebnSkexTkqT6oyd8qOY8ptNe0s KNxZULRXPmHkoRDTIMs7Hx1S2GefvVzL+lmUvv+YmZKIMhrAZ1lGpOkbHbPvX0P6QdlYhBi+JE+j jaJEZI18xTJau1Wr0XCOJzHZo9HzSK6iWWCawZybvnPVQ1mkJSyz1LJSGswZxY0Ixezl4wWEMrCE 4OfFtS8kaAuJhcKfErOTfd1Z2nBEnM0mQ2oPNMdA9FUvCMxF85ZNWu2+Tu8D1nu3iX9EJv6MZMEf LLYrYdWLHdmpGfXs6CfjttXoUjIKd2TqjCd7IsZDKVFP+xzHDfry+trq/9qb+etoQnmOudys/WUa Z1bCiLLqRYSJxIgHuS8BZuhcnW5L+o484cKIE9jLxUKjTLgkyaOteiFGTQtwWYDL/JguYZ5VL3D/ erY2V63Nk2UZTbltVRmk0HQZJS09uNDww8+htc/vD3NC4EKjLFKhrBjy+yuCu6LzR3PzKo7UVR3a o/+VIJTjWPWCvZx15PxCLz1QTQ2dMWWTXGRk7mr+ks0FMB9Bn+e/TVbVFmtFu+dWeBNWQixDbuug 6Hd+cP/eBDt2H6d3jUPhOKQ4gBmaR41ai0L+rr1r+YOCDVx5HmXqcBwHbs6nipIb+8Tp0grnqDyp QtRSRmgdx9IjpkGWdz46/PgUYZ+D/p6G1NWblbPJ4xbKtM6Cljul6UP+zw+r3wif3S6EL/fjUroJ ZdbIV/IKUNLL2/gBUin90fPIXkWxwDSDOd5T+wrurBWLtIQFFaWsIg2m8kZgYvby8QFCGXhawE2l JOwNmOVL0GcTlqtbLsgNzbML8c1k/4FflI2D1vcAK5fQmLM+rehD9kERd9tdlRtrHWMz8XnXlI5D YWAHjTpM2ZFTiikeNWozRBO9R1UlXaO4VhKnoJpoPlqAtNEVqQJThPI8XkllYhY9R5l9fTn2HGXK cNzk8IVvWH1GjhCRHekcvSWkkMwOj/SSShl5PEL5GYYsElekGCB9hgChDCxnUND7xTkXt3rG8Jli 3VLuRffoIEtQFYSv9fPEAaGMCY1d+PivvItXAHrWZw0UcJ9tMKjYDUe0hzrZxari864p/VXiOayr LCMp3I2n9KhFaYZk8Koop7yuzmT6z+wNrOajBkgbXRErsDS89oOY8pheSVpiKOUQTSjPv+oFOVFK 1XjkcBy5EYcziauPP1/hHJVSSPGSShkBofxoQf6u0hTlhKVnCBDKwHJG7C3yc1KSDeYvOMO9rPH/ ozYjTVf3Obtw4/IBhHIUoGcFgAUje4oAVjIhv/1tnVp/uGcxU3tXDCCUAQAAAACIHxDKwDMECGUA AAAAAOIHhDLwDAFCGQAAAAAAAAAogFAGAAAAAAAAAAoglAEAAAAAAACAAghlYAlhXI3qNSnZ7G4j hTuLTjgfyX68sabHIcY3fGf6YafQIebm8E/hCyHEDJBy/tNAXMmGyYgAAACLIMTc9FL2nFt5PNoe cGn7oMWEBkIZWEJk61k+QmJU9GmPpXBdTc/4wzWtWY8l67XDzvHZUH+z6q0udnfBWAGK5/O/w5i4 3Kwv6fLxv+KCdkmovyWhvNu/lA8eUrJjBb60RgoAAGAlI/Uas1ct29MWsvb/IjqLZUHMHvDhWdo+ aDGhgVAGlpAnLpRFlqZp0Ta7WiiLKBPaJfKtR5ecWIEvrZFaJMhjyfzFBmFPclj8WEIYQnkYnhm/ F4ZWc+Itw0XUOtHTNvODrUSTml3S6hrn/glrWWjMZc7NbLkUub1/BKSdrlHrC7ghO2Oj2B54EDPQ UaFJ1KQlqg90cBupxAtOzGsqbV5cg4HIe2aXqfsbK7RBKrT9WeLk8XSgTx1L2wctJjQQysASErud kz0vXn7z0O+KDAVk4yXbZx8eNORmqVUlliFca6k7UUkg/1dNuclh/wZHXW172U2kNqVWfOyewv2C uK0G2xj6Bs4U5Qk75E0OtuYZbV6+85DtyTnrbtv2q2pHAD8NzwYch1T1vRNsj3hx0LpHu/6FVZtz 9ljdIRygsBNVwoZd1qszXDgcYg+Kv7xUVHv4zZx8reqV0g7PXbd1f3rCS2tS9HtxGJSdq+RlonrV aPXMTIZfwhJyd5RlqJ7DfeTBDpxm2u5ZAmjK/XGldltOQXaqutzyfb9tvmy6piMDH7QeSFVp2XuE A/fGyvhjgmwJnpyyKbGxj5czi5AsKwlpBEAcQokX2SCJwIL9Xk8zlJoTdxkuvNZJY1ODrck6y/Uw 6Sp22KHxvhPbdO8NEAsWk3melgP9zQW7yIbVKHijc9fWk/2T8wUosRD1EHBU7bB6fc9aG5Tb6qSk 4tPsLujT/r521qRrE9UHbW4m5I7oNfhSpW+RGKOzmBqyVWSm6vNz1Bph40OO2N1oZHrYni5KJ8gF 9VZDU8H69c39IWq3QvaM1KtSsgy5FfUHtFLfylUVsUXwX+IIkGf+Myk9PjXqyA4LUftHWmgLAIQy sIRgobxlvSZDl2EgG+k1fRW+Ox1pGy/mvk/sy4Sz9qXNVfaR4Nz0dUsBaSpzd501+n12H67m0m7+ ErR/0eilL64QC4Ju2ys0JscdLgpZY77rtRZr2q6QAaHZK+1bizu8D7jg5uam3G1FrMnAImxvYkKW mXh6xl2NBhKO0AjDPcoqw6l+HB3xbm4M389Tbi+eLzj1/X1E8lWY3DoQkj88jPfUbqyy+0njnhlq z9re7p6RlQn6waLTsxYttkd5lun9/aaiTi+xCHcvNGTlWz2yEa9Re7muoTeAvyHGe/X2/XiyKQsc TbqakrnA56ZvX/UyKGbGHxM4U4WtX35cIW6jKqb82WQewRSLh3B3rQgepuY8xLVRdoEmvT4a++po WrHlWviO96Erf9xRYrZ962e7eZ7Y9326z6w6xD4JY+44DhrYxh4nMgkyD2jCeUSHjeoz1wZltnqO GWgtzGobnJkL+l29/yZHQnftB9YcdGDLSxuHFPuvubmZwfbtxvahiZidRWjMvn9tfS/xC6DA8NVR WTHH7kaV6XkQvRMkQb2gPsK6bGbHnW8nV37KdtkT7jYjm7vQmKOWPxgcsZs2xyOUYwYoMu+ZVD2g jFrZYcUf2gIAoQwsIUF/70cfONnH5eC1jiKs2O5xf7CQtsHvoixZfOEgbvOv1DknSO2mWG36vyHG 84Wl+URr52dnjmhY+yJGwZ+DvNa87cSRg0VelsEqPkpj8/Ogv0VN7MiovWL/X2y/N2BTgu2IZl83 FrJC+6eZPFp/GWkv8CExJaLtmw04ql/lbB8GDXfk7rJ4JqQykaKILZTHnDU69qmAQPzEYZ4qbBqK 0kzWfj8XT1zZjBY4S8yML5rpn/zfDfp/Iq7u+Qk4TKvrnMy1DkMh5x3nU+K1Gbe2uUkPgB979L9m eylWIuhxxQv6L7ZzLhyVptI2NEX1rER12+CSU7olcFFEONfD/fcDuM9TFhepCZLvhDKqIMKe+WaE ywpFZiRseIER608cLqvJcHcXFylGqnhumyldnb1Tn5bKx77ikJVJ4oa97C0Tm6q8/LnhHXzTsU1r NqjUObn5lUcqtXz9jzI0JN1lAa4O+J2NGVGKvc/jrNXlWdyUgZrgaL+tcZeuWJLLMYUyGrEaJFOA ldMug3VYVqNltRfXkE/+9qeKfINenVh0mh2Lk9VbEYo3EcNcbi5v6WeE6s2e+Uwg1hMC8RqwpY2Y a59bTja12nptdVxnQek1sAV7peHCNHc3ZkasxZmWH5BUgGLIouVnPSlbqjv65RKZQ5YMZTdK7EBk eqJ3gvIcYbOZxXlYMEJdwt1BljDhTTxZVlXELPBf5g2Q+4WZ70yG2uMro1Z2WPGHtgBAKAOPCGwO doX1GbFbeJjZVVRl2r/I90nZluqznnuMp6tWvY4qlIVnaMZrLcu3eqR2isHie4PZNdZTm9Hmvucw ZVs8P9qMrEERo1tSoUyOvKgtP97YaOY/7ztGFiGUwwtHmRgUcHedKN2yzdjY7ea8DvNlM2rghJgZ Xxz3LnyRnty+5j/aVSVffyN/lKKCJpx1a4kIxmo4n3Qw+BiXkgf45u454wuykyaTVVtOuHBXJPjV kL//C3aaJrprr1xV7QhMKTwrk9HdNlS3BC6KCOd6hP8eh6QsLnLfBd8JdVSBxMHC1pBIl9WcIiOz tA4yTpeVvEqLCGkes1es5rrzEDPsuS33Za4YpDJBUwPvZWZZPLNiGcrKXxzeke7XtM9ek8jV/yhD Q9JdFhGaTJRiV/9nzd6k3NOeGEUtyuVPr02R+/6GNiNDtyNbrSpo6h2VXxYehZgpEbH2kgb1sqrG jpNKsqlr6Z8Iq7c8VG8i23YyjhDNIWTtmSG8SLnsz4x0l+hNZ90Mc7W7RvMCW/6UXoPUOm3FMdHy m991eGUueTFkueUPMUPdTcXa1CJz91BAdqNlyVDaAURJT/ROUJ4jnNT16eX1QgobzX9wjMzKa4V4 suygmAX+y7wBkj9Y5jvzprx2iTEqo5Yd4Yk/tAUAQhl4RGChvJvrmwVkbUPZwhfsUb7v79q7lq/8 YWI0vDFjdbWr9JPeT4p38c5ICfzoWfw/1qY8nEj0Y3fZob98VJXOCSmh/S+pUEbTLrOq3B7+/k2E veCiiC2UY3uUBdD9gVNFyY19k3FkM1rgLDEzvhhCE5/V/RGrZPbzxwMO3EvHZNzVmMnOHiEFuL7I RsQgnxLmcnMhSe2YvXLX+7bjlfgW4wLRFneR3h2NX//8zy3mU529tno2dwrPSgy3DdUdoiyKCP89 RnmO/BZTRxXEa+VnSi4rZUYozSdel5W8SosIaSYKO7PK+k3YcP8KQ16HsYBIK5KN6igb4zjWlK/W OPkqyl8779CQDCG6KMX+m18mbEtXV57xRh9akQtlNHrhg784iRYns5CNrx+9wJtEQhxCma+ZNLOG v0S8zHeH5k0k1VLPDd3IS/KZIKxI+eY52lWymj8kliqlePHTe8IBe8T7kZTmqbT8Ieb79w0bm1zS dHNZMpR2wE9JT/ROUJ4jbGb1FfZR9rjIw3iUqQGKzHcmXQ8oo1Z2WPGHtgBAKANLBxp1VO0+2uPD tR8xl07q8lsHfub/IsjahrKF42tN2VFnEVH+HZ/oPaoq6SJOFeR3mNRRhDKRktqtWo2GG6OXE/TZ ytau2swaAuJyW7MKX8LO6hPaP61HkRs4gUh7gQ+JKZHZvslLLVv5yYiI+f6vH/zLj+T2QowitlCO PUd5cvjCN+w8gVDAcYh1xM6fTVng1DnK0TO+GNCDi+9YeKG8wXL8f8UZc3QefNuSZODtO7Z3q8pl k0bQhPNwUuPFMTJpcvC+o05vGfzRtjeLeJ1nfF370w6e8zD3PF11qc+xuaN4VqK5bXCuY/pXxKKI 8N9T6on8FpPvilEFulAWLqdlRNl88MlxuazkVVpESjNirnSbS9PUu81d7Oz/lYdUJhgu4/eEwpGX f8RfLLIbGnNoSIYQXZRiT6603xxz1qcV29gWF45y6oUcItAzWWcwT/joNnXqBX+XaWZN+ldAfkQs GazETLu5t8HCSvJZgL3vsgGfbMvV2YnehoTKbvKgTezty2yp0oo30N+cn89NsEH3BzqtX8lnvknF K3lVZoZdF9nRCRRwVK3mXsLmkNVSpR2gpQcTpROUBYUtf/9JTd7pa2SAK8QMnPvQeRvJB9akUYVR e7mW602kMRZZ04gZoMh8Z9L1gDJqZYcVf2gLAIQysIRg3fev1reS16bo0lOyqzoHwvvamC2c1OAY q17Q/iVT6IpyyuvqTKb/zN4QTSizSuvlbZwPNRziFeAXgmBdsy8JD52iCWMumrds0mr3dXp/kAJU 9hDiEYrtm2X6TqSp0tJL/upFaMptq8rYkr4jT5dR0tJzk9Y34yjkl5A/WMZcjVmJmsyyTg+iTJ8V wLrt7OHMlIxC2RTY+bMZHjj3EnGhfpuu9p/sqhfRM744gj7Pf5usqi3WinbPLVEm0iEJXrU5h3N0 FeSlJyQR/4GYkoDDpD3R8Yf9rYOTyN+1p7Lto4PFrKr2db+l45MtVbZonhWl24bqDpFVqoiikPz3 ynPkt5g6qiAiP1P0KNMyomw+8bqs8KWxhDIHYvpP5WabXbxDfUUhv3Fk4oFx4R7leYeGZAjRxSp2 5KdMU6a+zCeHCOVcYc49yzwv80l3OT6hTPUm4mD38GMg8pJ8JiCFoFz1wuc4btCX19dW/9fezF9z pUrtNaaGzpiy1dq8wozMXc1fEqNNaZ6i5f9o4Mq5Oh3pKaRXDnhkNY3SjdLSg6F3grKgCIzbVqMj fUemzniyh5tERJmnHvT3NKSu3hw2a5/PSxwB8sx7JlUP0KKO7LBwe4kztAUAQhlYhmCrnSV3ljwU spXggKcN4gLf1Pyt4HUO+rvK12DhIvYx+OYa16957TCR/lj3bH9tTVITmak8d+9CfVZZ1038jbhk XuK6kwjPSgy3DdUdIhMTfAKU/nulzyO8S6CMKnB/YMiZkS4rakYoHWScLquYim3mxoWLP5LTyRBN RviA5koBl4l8jrIwvZgtHPmd4ssEjZ2vUs5RnmdoSIZwC2I/n6CxL+uSdkcufKEAJ6Y663gPmecT Yvrfzdx6auABrhfTd6562GWwYy8PJ0UXn1CmeRMnehsyTj2rK89EucVPBUvQCT7N2X9oQCgDy4Qp 7z/+fmkc22AU/PFs6etLts0P8neVisuKAU8XxL5nyNdOIfOMXze7hsVOGivpfGG9C7L2xcu8/491 IeTmVRypqzq0R/8rXiiHe1ZCzFA0tw1G6ZaQiQleJSj990qfR0QHoxxVECFnUla9oGREHAFw+8TA 43JZ4WyJ7i5xzgufL8RcOVubS0JQjlSsGHCZxFz1QrhT4r2e9jmO6RIiVr2IPTQkIz6hjKvimPPI Jv4ZKQbTt3rfK1GtU2dr1RmHOrktRcZ7al9J5pbBljYc4bMmR4ouilBWbDii8CZOD57KfHbXMo9y i58GlqITfIqz//CAUAaWCUKHVMC+0B0mIBZNyG9/W6fWH+6Rz44CnmGW9fDCM90VAcsYrmb2MZ4L X3nkr508UzylzXOpOkEQygAAAM8Ay3t4AYQysDyBmgk804BQBgDgWWD5Dy+AHAGWJ1AzgWcaEMoA AAAAAAAAQAGEMgAAAAAAAABQAKEMAAAAAAAAABRAKANPDLKlwi82CGvaY8QligpyUpJ0/AJV+OAb mW2Dwmr84t5F0mpHcfBY5tg9pvWSFpRxAAAAYAlAjG/4Dr843mIQOoiFh7OsbH48nelK66RAKANL yMTlZn1Jl4//NQ9Bn21PcsqmRHFhTnnrIpszZ+aRfYbxwd/88pUaB7/r2JMUyqH+ZtVbXX7+l4KH Ecqh/paE8m5/PMsxrDQbBAAAsOyZ9lgK19X0yHc7XBh8B7GIcJaVzQehDAAPhahi42HUXl7Y+uXH FdJyXfLWhaZ7G9aSfWLxQZVWq95E9gfGPEmhTNs1QMbDCGVpr7V5WWk2CAAAYOWz+A5iWdl8EMoA sHim3Nb96QkvrUnR77W6Q2Tj39Ol6rQcadOycAIO0+o6J3Otw1AobAAhb11EKK8h7ltysPHvtqp1 ZWd8MzGEMvLZjFu5rYnJDm3Cbm13HAf1Db13cNsW9jxTvWq0evitiRUpxLZM2LhL9Upph0faVDbk tu7Rrn9h1eacPSR7iPnOUqxJ1RukTd1EO4juD1jKU9XZsh3OiHF5+a2GpoL165u/nfJfbOeuVWkq bUNTIXdHWYbquTVq/cEOXBSUy+eQ/6um3ORFb1W/chGqwcM8pawAEHNz+KeHzr2w6Y8+LZXfF1AO tfOjHozG0jyvAsCTQKy9uM4n/7am2qjPTU/YsMt6lUwLnBqyVWSm6vNz1JpSy3cMkrUL0TTxX8Rw 2E4hsleSoNl8Wp8VGTWtb1KcI4CCEZ0RPkbtBNFob1NBomybxrBWjO4PWg+kqrQFfJ/lFbMfV2Jo Xd6yAoQysITIPMrM1w1JpR03cLsLjfceS86zesN2pEYTzrq1RMtiUZufafmBbRky4xI29QIfvOO1 lrxhOj+GonuUZ6+0b91zxhcku6/tSlZtOeGaRnPTfWbVIUfgATZJL3I7xKIfLDp96+Ak2fp1Y5Xd j1sumhlqz9re7sZ2CtuI5wtOfX8fX3ndUpjcOiAXCzKP8tiF+iyj9Rq5ePzroxuLO25MC3Zwdtz5 dnLlp36SpQl3mzGLTLAmNvEF9RHOtCF//xfs9rPorr1yVbUjMCvzKFMvv+us0e+z+7ANDPo+rVJt Ccv4M41QDcTe6BFAm3KzoFlG8bCIAKVLZj2WrNcWsus7baoPGjtftbGWneM0MdiaK2z0LaJocQTq wWiAUAaeXuRCWWU41U8kqceSubF1MBQas+9fW9/LGvfA8NVR9hyhXYimif8SJpQjeyUJms2n9KrK qMUL5+ZmBtu3G9uHxhXnSFA6I0onKOuVgiN20+bwVowmXU3JRZ1eInCnb1/1yp4TlB3lpCIx1C5v eQFCGVhCRBUr6mAWLGHTiiwe0jQExl2NmUabF1uBaZd5fZGNbda4dUkv86WbbO4pfFRocpN95qSC 9qHR6FMvmMvNhSbHnbkxe+Wu923HK9vdU7PuNm1xlx/Je2juwkDAUf0q11wxaLgjdxdJoaS3KJ26 JJQnnLWrWZtCELQ+f+0dx8Gshl4+62jEatBZroclgNiM65//ucV8qrPXVs/pY0ko0y5nnLWv1Dkn SBktUJqseITSkG7c0kObciN7JlwaFhHgQ6SBMtVnFreItTXOCfYHLcvUireg2khpUwDwlCDWXlmd 580O62rZUt3RL2pQ5Tl0oSw0B0U7wl1MpM0fp/aqkVEHHKZXGi5McxfOjFiLMy1XH0QmT4ayM5Js qZjCMWdNlvDavbIV4391pOeVELJD6SiViaH2mNyv5QIIZWAJEXvuiLaksAIPvm1JMvAzLnBbWlXe TTy7/GnIZ9u1Tnx7T7x2xte1L6nkT7Zj0YQyVueHkxovjjmP6NoG7zvq9JbBH217s4i7WmmS7uEj L2rLjzc2mvnP+46RuIWydBo5zJ/JH8Thr08vrxeCbTT/wTEyKw8NZ2R/2sFzHuaep6su9bkIoUy7 /KY8OmXGVzTBUVfbXnZUblNqxcfssxNtUBIXPmW4UDmih0svueR4/c7Vmpb+Cfr8mfBwIqbcsCxo llGUGT5h1axnUB6gLA2JG/ZaBoi/R1EOk2FpEAOMkuWwkeKIqT488ipKHnRfFUSzgCwclVoYwBVr I7UQQsygtVK9KT2fO/izFEXQc6akoO78zeB894gNBwCeOGIDEeu8vCGHmKHupmJtapG5eyggDISG n8N/EcORtzjZ+RxSyBjuX9JnCeeLB9mmJ48aX/i8tuKY0H00mt91eGcjkydC64ykqGlZDks2hyLx 4pGwXIgXKstK2WNylywXQCgDS0i8HuVZd9s2rDwKCneST156QhL7PCq2N/n4i6wRzgy261SqhHVR hDL7MK090fGH/a2Dk8jftaey7aODxawcp5ikaZdZRV4WDIdiIyTi8yiPuxr1FfZR9i8ReWi+7rd0 fMpFfSwJZdrlFO9CeMZXMGj00hdX2Hlst+0VGrae0AYlSfcQfbhQqlG49Nal1v6TFWTKMcoJWjiy +y4h8+bGnmVE/ZdSzWQBSmlAUwPvZXKTgijlEH4JCTBaliNGimUVT0JMCZm2eMpobOnnm6+AFM7c 1OVW3W62RQu1kZrNyT7zRu4gCt72DDPTfBToXn/Lm7vaLzNo3nsEAMsEsYEIdR4jNWSOEPP9+4aN Ta7JG5Rz+C9iOPJOQRYmR9weZe6XFPW9/zUnHLDzbqYIxOSJLYvWGUmZElO4hB5lbpolRkxMgNZj Li9AKANLSJzqgUiQTc3fPuB/Bv1d5WuI+0oyFmS6JP/2ntyChMYcNa/+4jdRhTLynjGuX/PaYWJf 0A+W7a+tSWoiM5WpJmnyUsvWYss14npEzPd//eBfpLem2AgJmWCKMUcZTfaf1OSdvsa/L3juQ+ft cJf2PXxtWddN/DcKOKpeihDKtMvRqMOU/azOUQ4xni8szSdaOz87c0RDbj31sYFy46gjerJqQxmj FJ928BHplsUUyrGfCaP8S4lFqXrJV3byopENUFEOlEvmy7IYcnShPO227tWrk4r/MhTrZT6xz+MO UrvwqbCDBC4Kp9del2n6lNXB8yUYAJYLYlNVNig0M+y6yL1/gk06kYY+e7mWVZbTPntNItfo+JPF cMQvGEWdp9p8Sq+qjPpef3N+vsVN3Ezo/kCn9Sv/jOIcsTOmdUaS/RFTiHve2iWaozytSEyI1mMu L0AoA0vILNN3Ik2Vll7yVy+iDsWyYDlblNHQe4//SQ5Y8143u6alV2VZ91IBuyRcuAWZcVsMKlYc UHtTLMHzhfUucF+uf5kfPqaaJDTltlVlbEnfkafLKGnpCV+5IuwSAeaiecsmrXZfp/dBrFUv5hi3 rUaXklG4I1NnPNlD8i4PDRu+80dz8yqO1FUd2qP/FadXxlyNWYmazLJOD6Jczl6SkfQMrnqBfJ+U bak+67nHeLpq1exgglTOGOFuUm4c/ks5oierNvgS5RglrQLEFMoR9SSiWkb5lxJLFKEsXEIpB8ol cWSZCzmWRxmD+8W6bfVfMyF3x54idtjH1OF2y7ImnswFTh0UjjiIIVf9Orsgf/UbXN/MnhkzwQCw XIio8/IGFWKGztXpSFcidAdBf09D6urNObn5lUcqtVyj408Ww5G3OGWdp9p8Za+qjBp3fUNnTNlq bV5hRuau5i99lOSJ0Dojyf7IUhi86WjQq+Zb9aJQv01HxoJirHpBTYyyy1tegFAGAGDZEvJ37V3L G2VBF8brUabOgZF1SNN9lDFKWiexDDzKE5RyoFwyX5bFkOcRyuFp4JH35fiJ1Lg4j/IL6oYvh/5Z l1bNLjgzX4IBAACeNCCUAQBYtqCJ3qOqkq5RrIqR32FSE11IHZSkSE/qHBi5CAsoxijp3pSln6M8 Zq9YxWp9aRwzXPXK5yhnWTyztHKgCOX5sizmLopQfrHgQ3bGBZnj9AZZLob/jwWHI5+jzE7pFgNf 0BxlaSR33nsEAADwhAGhDADAMoYM+RXllNfVmUz/mb2B1YW0QUmawMVSUjGiFy7CIsco2YW0leHI ptywl2Him2VEoP2LbvfUadeGjWPKAvRRV71QlkP4JXyyY2ZZyp18qg8HyS+3/UGhXq3KUGYEh7PY VS92ZKdm1IeteoF89sqsyq4b+AlhnnsEAADwRAGhDAAAsJyQ5OzjRP6AAQAAAPCAUAYAAFhOgFAG AABYNoBQBgAAWE6AUAYAAFg2gFAGAAAAAAAAAAoglAEAAAAAAACAAghlAAAAAACAhfIoV2hBzM3h nx7HVKjFRBRibnrvPDObzINQBgAAAAAAWCiPUCjPeixZrx12jstXZX8kiBGF+ptVb3X5+cMxmb1q 2Z5W67zL/1zpgFAGAAAAAABYKCtqzW/azkoAAYQysIRgq/FGZtsg2eqMINs57AmAZjwfl6nT9Pmn Lk2HjRAhjyXzFxtqnWP8b0zQ19tamqTS6FOSdLXn3GRzMpyX11TavJ0FheRTdMI5FqIMUT220bH5 EVctWPSgGAre+lfrW+pErU6dkFnVOcDuKIGZ9jmOZaZoSeE0nCe7ckg8+qUS4l0CIurtfhIs9BYs yTgmLFsBAI8SsumPXhW2TxAnlO/5bGWbWwe43fBDg62bi2w+JOy2ky9swYPuD1jKU9XZhdotmbwh xZcLm/ikGI5+8rc/VeQb9OrEotPuKfnmR4qgRPA5/OZE+K+jn3zWXpmbm5Oy2WgZnML/xo4xYcMu 61XSWbMRXRy07tGuf2HV5pw9Vjfp676zFGtS9QaSMMdN1qqQa0uO1+9crWnp/zf/hCAlQKt6pbTD M0lOpBTU0w0IZWAJwQ3pN798pcaBNSXhyQrlycFWfablB4X6CPpse5JTNiU29gn2hhloLcxsuUR0 IbrX35K/rfnSJG8Bw1wFyrGwxzY6FgeCTlr0oBi6ba/MrztPbCIa//poUpHFg0sIzQy1Z+ne7ccP D2jMdfLkP/xyo7d8hHK02/34kAYuF3oLlmYcE4QyADw6Zsedb7P7ruOmJu48z3cTyGvN29rmJv3A lLutMM/qQZH7t89Il89NuNuMWcSjhC/ntoVHE866l1U1dqKnf7DodC39E5LpiwyK615Z8Dn8dvdj zppNiaZPsRomnqDXmy+HZpne328q6vRifYzuXmjIyrd6ZqUYWYfRxtZBHJgQkcyjPHahPstovYYj J33BxuKOG9yWmetSa/8pCG5BKPMJmL5uKUwmTwvUgnq6AaEMLCGkEWq16k2Nfexz5ZMVytFiH7WX F7Z++XFFCmsjsCHwd5VubHJNChJr6obr4g0GCYbgqeHhdRIK3r//M18MYukxl5tzjTavUDoRLB+h /GQrG+FJD1yCUAaARwdWolnCOKTY1oRuAnk6DLuJZwHL3O0lHd5pLHzXHnQE2LNZ7jgOZjX08gfQ iNWgs1yX9TIy6yHToMT0EQ0dHpQMyTzKDCB/ECdYZ3LcIUewzHe3bQuPUbpW+CKlYcJZu7raEeAc QFj657M+CHmfGJFIfEQsE2pBPd2AUAbmZTb40/Ufv7v+8/S8flPSeBr/bqtaV3bGNxPWdCljQCLy tiQ0v6khW0Vmqj4/R60ptXzH+npjhKAcJwqNOc26hJfWpOj3knEkGQGHaXWdk7nWYShsd+Nn9NCY ff/a+l7ZaBaH3CgISEZBgD9CsvDym4d+V2Qo0KpeNVo9M/Lk4aCE0S6Vms8Oe1AYxpqgjXMph9tC zMDpUnVazg7ZABwa7W0qSKSMBuKUy+IVR9niHRQTjR0OhCsoKrEzvhTgEhaG9hI37LUM3CcRRFaG iNutLCg2nW81NBWsX9/cH4pZl3Dgg9YDqSptgfBvtFFIedlOueUDlzFuAa22i19kmY13HJNSAajD pozbZkpXZ+/Up6UWnx4g4wMxCwEAgDDE1ooRW7F4kHckh7zW/DyrF8mbOQc+c316eb25sZH//MEx MiuFGV0oK4OSIXVJSqEsTzDtoHit8EVKgxQsRplZTEQio50WM/FPDyCUgdiEJi6etK79j/Y1Gz40 tI2Mh2lOBVwLueO1lrxhOj+GxKZLHQMSkbclLoSAJF5RYPjqaFA+miONW4lQx4moLkbx6Vx8Sp64 3JylOA0jb+0CYeaDhT9CsvBi7vus/vjBotO3DrIShwcHxY92zU1dbtUZ24cm2IPiMNZdZ41+n91H Mjcz2L6dPUE53DbeU7uxyk5mPrDTIba3u2dCMUYD5fEKo2xxDopN+/v+Z5fhfwamELad5lW5jW1H DNrsnChzlKNnfCnAJcwP7aGpgfcysyyeWWplkN1u5uuGJK7oQuO9x5JxvzVL0vmC+ggrmmPXJTTp akrm6urc9O2rXgZFG4WMHMGkdHWU05S1nTuN/SJlNs5xTOq/tASP2StWN1wgs7dDzLDndlBWcyiF AABABDE9yqzLVlts++6Tfdq2K7NSRyMy7mrUV9hH+V880uXgUV7OgFAGYuMfOqBpX4OFMv5oPv0s 9tIxQuPBIi+poH1oVGi61BbL/cJQpAMRgluqO/qxROagjltxv6K1aqpQxtYqk51IgKZd5vXklQvq aRicEsXLfJJREOCPUNWPiPwIFkDGSKMTcJhe4UQMZmbEWpxpucpEGsfZgKP6VdHzjYY7cndZPLdi 2m5ZFHw64zBhY05zUUFOypbS0+zLfEQov5RmvjhOvg+fKdaFT6WNnfGlQF7ms1fa04osnpu0yiDe x/B+hb9kQpbOmHUpvK4S5u0zhBRGEcoRp1FLTPgiZVY8LfYto/1LTTB5AMussn7j559zYhcCAAAR hMYctYqHUlkDx6ZGk5a+VRh/i/R0BCf7T2ryTl8jY24hZuDch87bcjMSXSjPN0eZtxhKoRxtjrKQ YPFa4YssDdG8A8K1ykRK1olaUE83IJSB2Ny/cfz/CEL5/3xx8T5/mI7YkGZ8XfuSSv5kO8Y1XXkD k7dtDqp0CDFD3U3F2tQic/dQgDUoynEr9mpMWIBiaDQF/ODbliQDb8iwnlhV3u2fHLHuZl13EYSn mSMy5eIRahZE5EfEM2UHcSDPayuOCVlrNL/r8PwoBchBLnxRW35cLIHG9x0jV2OGHB4FSSc1JTTQ qMOUSzQxUeQlHSOctxFfUkKmLrA/WOSByANfOsLKnItikFYZxNsdkS/uknvh6Yxel5S5CEuAspCl Ex6NUJaFEJk1DO1feoLnEHOl21yapt5t7rrCTsGPUQgAACiIuuoF1wCZy83aX6Zxr/RhhLlzO7JT M+rZsSzGbavRpWQU7sjUGU/2kCPS5bGEMiUoAekcpVDGbV45vUqWYPE08Qtz0bxlk1a7r9P7IMp8 MzGzykTKrBOsegE8Y6DQrX99XZH3oSqv+7//FQgbdlcia0gzg+06lSphHdt0F+xRZo9jQsz37xvI m3YB2riVQNweZRL1qs05nJO4IC89IQmnihzccmpQnFwbHL//M5aCESlhkYyCAH8kRhYw8iM0j/J0 nznhgJ1fKoRDOdxGXOCqcjvnPBSguhvFkGVR8OmM7Z6UI/4rv2RG8VARO+NLgbzMyewOo8Vzh1YZ xNs9r0eZOgYqElZXCSvDo8z+wCCm/1Ruttk1ErMQAACIAW5rES4DDFlPSUPmXQAi1IJ6+gChDCwh MllAxl9qXv3Fb1jtEnuOMnmdbk2Nc2IOBX2fVqm24BBmhl0X2edmFHBUkV4/RBu3EolzjjKZ97mp +dsH/M+gv6ucxIv8zlq9sf0ymWkwN+3rOphMJljL8yIgF20csdSPCD4in6PMvhwddlqgvzk/3+Im blt0f6DT+pU/SBlum7zUsrXYco1MAkbM93/94F9+FHs0UBYFn86Yg2Jo1FFX9Ufubbngje4KPTvL Ak26Tmgquog3Inito0hvdsnUe5h0U2Z8KcApl89RJjOzZ2mVQXa7o8xRFtKJYtal+OcoR5RtnEKZ Utul04SgZAUbexyT+i8twTM3Llz8kVyI/A5Thsnhj1kIAABEgILeL865xkgzoUxCw///2F1csPQv aTx9zFdQTyEglIElJFwqzbgtBhWvXWK+Yo/8nx9Wv6HW5xoqag9qtmEpxgydq9NtSd+RF/7afsS4 lQT1Nf9IoYy8Z4oyGnrv8T/JAWve62bXNELMlbP1+YnshiPpps5BMgkM52UJ5yhTV72QnTY1dMaU rdbmFWZk7mr+ki0f5XAbmnLbqjJIsegySlp62GzGGg2URSGmPNagWIjx/KO5aHOiVp+u2mzkk4Gj 5e6dLl2lqbSKu5BwPBahrFz1glIZ5LcbKz/KqheyzMaqSzi/3KoXhfptOvZty3lGIcWylQYuf4hx CxS1XXaaGJQ8wbHHMWn/KhNManhtLqlgUgOMWQgAAISBn2zPH81IUuvzc1KSDeYvwnox/z9qM9J0 dZ+TR9ZnnZgF9XQCQhkAHjWPRkE+LFiKrYRBsWcJuGUAAACPGxDKAPCoWT5CeQUOiq104JYBAAA8 SUAoA8CjZjkJ5RU3KLbSgVsGAADwJAGhDAAAAAAAAAAUQCgDAAAAAAAAAAUQygAAAAAAAABAAYQy AAAAAAAAAFAAoQwAAAAAAAAAFEAoA48aNOP5uEydps8/dWk67IV95LFk/mKDsAEvuyPDc+vTdxTu LMhWJ+hlOzu8kdk2SHatI4j7SlCWkkCMb/hOlH0TEHNz+KewnRrmQsxN75151xCgXAgAAAA8ewR9 va2lSezWVLrac26yNdViofQsEfsiLRULD3aeXi++rnMxPLqQHwoQysCjZnKwVZ9p+UFR98nO+Mkp mxIb+3htK21Lxm69m/Rmh/cBK4h/88tXahxjnEmKIZSnPZbCdTU94/zPMGY9lqzXDjvHZ0P9zaq3 uvzk0FXL9rQoq9JOXG7Wl3T58DfxQu4PAAAA4JmEGWgtzGy5RHYnRff6W/K3NV9a9I7VtJ5luQhl KW2h/paE8m4/6Xzj6zofjkcX8sMBQhl41Ci2kuYZtZcXtn75cUVK6yCngWVCeW4ucKFeV2EfZQWx SqtVb2rsY01SLI9yPARdjWsKbLf4X9GIlmbg8YJGHSbNLtsN4SkLTbqaNuna3TPLzuVAJ6xKsyiP PASxhlCWChhRAQAW5O8q3djkmhSMz9QN18Ub4Vv6PyTLxqMsEnSZVxWfuUUuja/rXJmAUAaWEsR8 ZynWpOoN6SkGdu5EaMxp1iW8tCZFv9fqDhumCjhMq+uczLUOQ2G7e4ociRTKWtanSwRx499tVevK zvhmYgpl0Rzgv5J/W1Nt1OemJ2zYZb1Kpm2wgV8ctO7Rrn9h1eacPTg1QgjBUVfb3lR1dqF2U2rF x+6pSbd1f7qYZilVIWbgdKk6LWdHhlp3zOHDAoXE+PKbh35XZCjQql41Wj1Pi4B7ekA+2y6xc0I3 zhj1ZleA/edp4NEK5VhDKA/Hw4yoSNcCwLJnNvjT9R+/u/7z9Lw1PDRm37+2vlf5YKro9dhm/lJR 7eE3c/K1qldKOzyT+Kwp98eV2m05Bdmp6nLLwH0kmgI02ttUkJiSZcitqD+g5RUtuj9gKWd7pS2Z DefZbYZIv1ZyvH7nak1L/wQbMyZ6sFKHKO+nkpKKTw+QGSOyXhIn+5O//aki36BXJxaddk8h3kxN uzvKMlTPrVHrD/7Z1kbpOinZxNHedDToVRHZ4YmaEiFf/xa6dWVvy5Xq7sYm49rXmy+HiYlHDghl YAkZu1CfZbReI21//OujG4s7buD6TfXOogln3dqDjsDclLstn5+YIbXwiKkXuOXc8VpL3jCdH0Nx CmWV4VQ/ftYn06A3sh5rIXDZY7EQAhq99MUVdjTttr1CY3LcCUuzmCrm64ak0o4bWNOHxnuPJedZ vbMkxhdz3yetHf1g0elbBxc9EAdEI+BqzGQnqeOHriObjDbfU/QwIqvSPMojy5GHGVF5mGsB4HES mrh40rr2P9rXbPjQ0DYyHlt84SfALFrFpvV6uJk/X3Dq+/tobvq6pTC5dSBERlB1Db3kIR8x3qu3 2XOIKZgdd76dXPmpH5u14IjdtJntwmQH5ybcbcYsYgBxh7Uutfaf4XtzRgsWHwgTynw/xc4eybZc nZV6SdIXv6yqsWMxSnoxHVHhYiB0j7LQdVKySc2OSGRKFPkSQqb0tqzxfE5Td557eemxAkIZWDom nLWrqx0B7tFcVMDUjnMcqx+jzYul7LTLvL6IVT+kGYgv82VW2YZYP7PQcib7zEkF7UOj8Qll4S+x wQtfKK0dP7x6vrA0n2jt/OzMEQ0buFIoi8qeZfZKe1qRxTMhxIhRpgeIzvRP/u8G/T+xd3g+iFN5 XY3j9nftukziTqb7Wmh3XOHUEbaDzjVU1B7UbOMuieIQUroupv197ayTQ5uoPmhz42tJlVMMKQT9 vc0GlTonN7/ySKWWS4wIJVU4BcocRcaFC8G4seXyA/zX3NyDb1s2lp3xTYnVL+4s4IIS3Egqdanl O/J8uJQjKvJrr/wc4evikgAAywX/0AFN+xoslPFH8+lnZP5tdKI8AVJ7PanViL0S1rtFaSZrv19w SfPnjDlrsoQ32sWT7zgOZnHyF4NGrAad5TqidjHRgsXfxNDEL4RZd9u28NDoCpgLZF6hHBkXNTsi YUeIGysyX9z3cVpvK38GeNyAUAaWjrB6LDYJmn3BPX2SgZ9xgQ3NqvJuf1C4fMZnK2Odx+yZkgaa 8XXtSyr5k+3YEgtl5PukbEv1Wc89xtNVq14XRShHtHnu2nuyg8r0AFG4d+GL9GTSOalKvv7mHn8w FsT3oNXrWEfFLNP7+01FnV6sJtHdCw1Z+VYP6x2h3fFIb8ddZ41+nx0/lGHF/GmVagt7iXgQV7HB 9u3G9iHWoUJxXQT9rt5/E19I6K79wBpix0mtiBxSGO+p3Vhlx/V5btpnr0nkEiNCSRXVe6SIC3nE SUq4q9MYrF4k1sn4s4ALih9smZu63Kpjz4xzREXKF5oZas/a3u6eoWVfulbh6wKA5cX9G8f/jyCU /88XF+/zh+nMjFh3sw02HLGBEIQmKR0UGyluBgF314nSLduMjd1kuQz+HHnHIZ6MD65PL683Nzby nz84RmajdDH0YPEfYmiyNGAU8S6pUJYnMjxewjwpoXWs4kF5dI8bEMrA0hG3R5k81K7anFNQuJN8 8tITkkj3LDYDsbMnyFoRPq5TqRI4LStvXRy0tiqGKXxRtPb7/q69a/nWJyZVKRTAo7xUhCY+q/sj 3zn9xx8POMTZdjFAd+2Vv8pqHcTnjjlrdKyYIyi9I8o7LlUMXD9fqXNOED0p3a+Aw/RKwwV+4ULc FxaHO4TCQMy1zy0nm1ptvbY6thbJ7T4XIPGFvFrj5DOlDEeZKrr3SBnXA6+1WNN2ZZa0rMI8qweJ ISwgC/JaipW6kW2h8YyozAYc1a+KEzTRcEfurij1X7xW4esCgOUFCt3619cVeR+q8rr/+1+BsCkN FIi12XJqUHwRJTh+/+dQ3B5lAXR/4FRRcmPfJH8O1QU77mrUs++yy5E3XgWRweJDYmhhaVD6cZdU KINHGQDmIc45ysSXtqn52wf8z6C/q3wN1hZSMwiNOWre4GejylsROf7qL37DhiY/ziE2QtlfYpjC F0VrH5/oPaoq6RrFcSG/w6SOIhTwMfocZaHZK9MDUEEPLr5j4YXyBsvx/xWqQUwkex1ezvzdiXXH pYohHcEIl+CDz2srjgmem0bzuw7vbNiZAmiku0RvOutmmKvdNZoX6EI53BeiDEeZKnKhwnsUUsY1 h7zWfFzrQp6OvDJ2+r4sX3FmIaz0+Mtn4h5ReVFbflxMZOP7jpHYQhmnONzXBQBPNcjvrNUb2y+T 4Ze5aV/XwWQy8hlljnJkM58cvvANO6sqFHAcIiqQPwd3arWKSb1osv+kJu/0NSLKQ8zAuQ+dt1FY 4xVRBDtmr1jFugOk0NjGS5kZzIe2pEKZmh2RyJQIs6XFfAnfo81R5qN73IBQBpYSylxJpVBG3jNF GQ290pg7VgB5r5tdw7JmQJzH7ITUsFaEj7stBhUbWvhxgthWZX+JTUv8wlw0b9mk1e7r9P7An0be 0i3KKa+rM5n+M3sDG/gs03ciTZWWXvJXr09MFX2OpmAIlOkBohD0ef7bZFVtsVa0e27F526U7PVS e5Sn+8wJB+z8Kt0CVIvs7ypZzR8U+gxlBViER5nmPaLEhdsJlsgVtr6PduFug2RCCCH+LITVUs6j fGU0vhGVaZdZVW4XNgfioNZ/ZXsXfF38bwB4WkHMlbP1+YnshiPpps5B9vGP/oZARDPHD41nD2em ZBSK3Yd4Dn2ZCMZtq9GR8zN1xpM9pLuRN14BZbDodk+ddm1YaCQNtLUm+NBiKuAxV2NWoiazrNOD lF2nMpvk6yJWvRDzJX6PsuoFH93jBoQyAADLHkkoU+coj9rLtex4n2xaMKWvGnWYshVzlAP9zfn5 FjdZQxBLuk7rV9J0eTZqkYnehoTK7lF8lDhvXqYLZQaNna+KPUc5IlVU7xElLgyZdKHRagvIvAt5 CHFngSRSPkd5t8UzFe+IyuSllq3FlmtE7iLm+79+8C+/NEmaC5nr4cRrFb4uchoAAM8I2D6UrG/u lz3Byy3G0wQIZQAAlj2yEUCiBSPXiAj6expSV28OW2iCJkmpq17MTQ2dMWWrtXmFGZm7mr8kAdJV 5rTPcdygL6+vrf6vvZm/jiKU2dOO6RKir3oRmSqM0nukjItAPOi/0PNvwcpDiDcLOJHKVS/iHFFB U25bVcaW9B15uoySlp6b4XMfxewL1xb/999t4b4uAABWOCjo/eKci30VPzh8plgXvs2e3GI8TYBQ BgDgGQQLuyzZuv3PCKKcBQAAWHJEZ0R+TkqywfwF68gQAaEMAACwrJny/uPvl8i2Aij449nS1xe0 4dzKAIQyAADAwgChDADAM4IwKaIgW60qaCKTB541QCgDAAAsDBDKAAAAAAAAAEABhDIAAAAAAAAA UAChDAAAAAAAAAAUQCgDAAAAAAAsKfQlGucBMb7hOwtfSxExN4d/eriXLkLMTe8dskjFpMe2L1Wd WdB6aenXdFxMOp/8mxUglAEAAAAAAJaAUH+z6q0uP/62GKE87bEUrqvpGed/xmbicrO+pMuHv816 LFmvPdwyPrNXLdvTyLLHoYHWjYUWzyNZ+HxR6QShDAAAAAAAsCKQdoRelEd5ISi2i18S5Ls7LQtA KAMAACwLYOm0h2AJRn4BYDmDgv6L7cWaVL0hXaWptA2R7TEVG21Ou617tOtfWLU5Z4/VfdO286Wi 2sNv5uRrVa+UdnjI9u+0jUWx5UkuOV6/c7WmpT/Ab8kx5jQXFe4sKNyp37zmudx2HFtw1NW2l71w U2rFx+6pSbd1f3rCS2tS9Hut7pCYkijh8/txJmzYZb1K9rqnwBlAj/N4ruq5NWr9wQ5+B1AMyd3L bzU0FawnW1JTosCn3HQ06FUpWYbcivoDWnZXEZlFFZPHf5k/QOT/qik3OXIX1ScECGUAAJ4NQv0t CeXd/hD/M5KHEcrSGOizyRKM/ALA8gb5+78YvI9FHLprr1xV7QjMKoUy/hrmUX6+4NT3+JLp65bC 5NaB0Nws0/v7TUWdXqwF0d0LDVn5Vs8ssTzrUmv/yQrEiL3rQmOO2mTTebIlNBq99MUVsuc8um2v 0Jgcd8I8ynxKooWvMpzqx9cijyVzY+sg3QQKBpDiUSapekF9hN2Ifnbc+XZy5ad+omYn3G3GrLbB GS6d3MHgiN20OR6hHDPAu84a/T67Dyc56Pu0SrUFhDIAAMCjZ54hxYcRyo9mDBQAgOUDGr/++Z9b zKc6e231nCWZVyhH/jvmrNGxGpcw627bprNcR3LLEy6UJ/vMG0s7bnCe3RDj+cLSfKK187MzRzSs tVEK5fnCl5KkZB6hLKTqjuNgVkNvgD0+h0asBhIFjjer1jnGHhNPnkcoxwqQcda+UuecINr54Szz 0gBCGQCAZQw2rPzwZYZad/STz9orc3NzUjYbLYNTysFQ5D1TlNc6yA5xzk0OtuYZbV7O1s6F3B1l GeKQImK+s3AXphiOOrgt+kRzHGIGTpeq03J24BiPsT4PYtalgcLYY6CUy0XYcN489LsiQwEZZLR9 9uFBQ26WWlViGWK7gXmGZSdoyRaZ9ve1s/FqE9UHbW42QMp4KAr6zh/NSAof05wvlqkhW0Vmqj4/ R60ptXzHIDTl/rhSuy2nIDtVXW4ZuI/4/g+Xf25LP9elMZebc0n5UwdqAeApY8bXtT/t4DkPc8/T VZf63OKEcrjm40+QH5QryMlruB02X+LMGfJ9Ural+qznHuPpqlWviyKU5wtfSpIS4bR5hDI+bX16 eb25sZH//MExMkvNAi1e/st8Ad6Up1Me+JMBhDIAAMsYbFj54csxZ82mRNOnWGmRAcTXmy+HlIOh U15rsabtCpkBMHulfWtxh/cBFwxB6gDGLtRnGa3X8Dc0/vXRjcUdN7CcFczxeE/txiq7n/w5M9Se tb3dPUPMujBQiA/HHAOlXC5KQxLOi7nvDzChuQln7Uubq+wjQTIsW0D09/zDsuJwJO61B9u3G9uH JrhwWYJ+V++/cchzobv2A2sOOgLyMU1pPJQ6phk7lvEx+/619b0k8ygwfHU0ODdqL9dxTiDEeK/e nhb6vweK8p+ijasCwFOHr/stHS/XREsi6U5J+S2VRxmNna/aWOsY4+ZJhPxde9dygUnW5ol4lMdd jfoK+yh7XORhPMq0ALF5BI8yAABAXEiWXdkr4M4kcjAUea1523HfQGbjZRmsgj+ZRewAsBVezU4x JEy52/IzLT8g3hwHAo7qVzlRiEHDHbm7LJ4JmVnHxBgDnaVdzv8K62+k3kg8OF8nF3CYXmm4MM1l aWbEWswmWwIx1z63nGxqtfXa6tiumtZ70Xug2LFcfYAV/5bqjn4skTmw5C1KM1n7/ULWhDtCyn9r m3uWpF9Dyp86UMv9AoCniHv46bqs6yauvCjgqHqJbbxj9opVbGuSHkRjC+VoD8OiEBTPDGD5yD3M s6CJ3qOqkq5REr3fYVJHEcrzhS8lafrOsI887UsIp80jlNFk/0lN3ulr5Pk/xAyc+9B5G9GfyfHj tJa1P9M+e00iFy+fgPkCRKMOU7bieR4F73hvEl/A4waEMgAAyxjJsit7BdpgKO/IZLzWMtxJhHUE FD8QOSqYbK6fuId/vqgtPy6OAza+7xgJE8oo1hgoCU1xeZxCWd5finkM7+Se11YcE0M2v+vwSm/P oZHuEr3prJthrnbXaF4gXbU8QCGWsLyLJ8wbS4gZ6m4q1qYWmbuHAqRUUcDddaJ0yzZjY7cbd11i sMjTkVfWIZU/Dlk5UEviAYCnCnbOUm5exZG6qkN79L9iGy+63VOnXRs2tQkbg4vmLZu02n2dX/9Z aGuyhk+fXqVop1iCP79GrS8gC18UmMgCFGQaVVFOeV2dyfSf2RtYazPL9J1IU6Wll/zV6xMbYMzw xXY6dt60+o1wP65w2jxCGcO4bTW6lIzCHZk648kebpyNMssr6O9pSF29OSc3v/JIpZaLl0/AvAFS Z4j5HQc3vFhu5x79HycglAEAWMZIwk4plGmDocRDvKv0k95Pine1S8sbsYjnxPIoM9MusyrSFsvN euwxUES7XEQWDkUoz+dRnu4zJxyw80OxCvxdJav5ZAk+rUV5lGPFEmK+f9+wsck1KTyA4F75VFFy Y9+kdJseeK17dtm+tBn3sPNeqAO1AAA8UYi/uUx4nWBpiRDBS0hovLdR3/ytbDrdYwKEMgAAy5hY Qpk2GMpKTO1WrUZDJgCEIWnTmHOUJy+1bC22XCOv0CDm+79+8C8/kpv++cZAKZeTwyyxhfK8w7KB /ub8fIubzPHFCrXT+hWZCS0w0duQUNlNJkeEAo5DLxOhTFuziT6mGTuWmZlh10XWb0TKmTxjMMMX vmGdVSSutQcdAek28eWvzefmvVAHagEAeJKgsYt/6fw+fOrFUvHIhDK6c+HP/5e84PHYAaEMAMAy JpZQpg2GYh5825L08jbulbIwxlyNWYmazLJOz2ysVS/QlNtWlbElfUeeLqOkpQf/G276Y4+BkhUh Ii4XiS2Uccyxh2XJ6hNnTNlqbV5hRuau5i/ZE0SmfY7jBn15fW31f+3N/DU3S3IBq17EiCXEDJ2r 05Ec8cWFAu6zhzPJUKmwsodMKJPZL2m/kZU/baAWAICVySMTyk8OEMoAAKwsyCJxRZHzLp51cO9V wq6tIQfr46yWfvnSGQAAAEAYIJQBAFhRIH9XaUq03aeeKVDQ+8U5F9nVay44fKZYV+u8Ozc35f3H 3y+N49JBwR/Plr4O2+kBAADEAoQyAAArhpDf/rZOrT/cAxNhMeIsi/yclGSD+Qt2qsa0z3FMl6DO KchWqwqawmaGAAAAAJGAUAYAAAAAAAAACiCUAQAAAAAAAIACCGUAAAAAAIClJZ71H0LMTe+dsOVr aMhXlXloEOMbvjPv4jPiSjjxpTCSxV21TAGhDAAAAAAAsLTEIZRnr1q2p7Fv2cZkKYXytMdSuK6m Z3xu4nKzvqTLxx+ORBDKcaaQI9TfklDe7Q8t7KplDwhlAAAAAACApWXpVhReUo+ygGxlegrha6vH ibQ8/IoChDIAAE8JC+otEHNz+KeVZrABAHhSUPYDmvb3tZeq03J2aBPVB21uLCuJOH75rYamgvXr m/tGOKHssxmThQUrQwOtyWVnfKJlEvUo/pL825pqoz43PWHDLutVsjWmCDZ9LxXVHn4zJ1+reqW0 w8Nt/KncNYlx20zp6uyd+rTU4tMDzDRJzJuHfldkKNAmJZEjOBGcfO8ZtO5PT3hpTYp+r9UdCo66 2vayWduUWvGxewpnTZ4w/CUw5jxhLCjcWVCQk7Lmha1t7pAi7yF3R1mG6rk1av3BDrdb1NmUdNKy s5wBoQwAwFPCQoTyrMeS9RosEgwAwJIwO+58m98Qfm7C3WbMahucmQv6Xb3/JuozdNd+YM1BR4CV oS+oj5DtKkWPMvJ0GAq5LZBm3W0aA7e7O4dcj6oMp/oZNIc8lsyN4SvBY9P3fMGp7++juenrlsLk 1oEQdR/+MXvF6oYL0zj0EDPsuR0kCXgx931WHzMDrYVcmvlUyT3KaPTSF1fIjtbotr1CY3LcUQhl Inm5Mx0mfZVjFFHyLvcoi1fR0knJzrIGhDIAAE8JCxHKAAAAS8cdx8Gshl6iBjFoxGrQWa5jUctc +9xysqnV1murW0P2jRdlKEb8/sBrLcmy/MDqwt15Vo+kk6l6VGnopCNCmBPO2tXVjgDnCJhyt+Vn 4vBnBtu3Z1ZZv/Hzb9HJE8Pqb5JmmlDGwtrzhaX5RGvnZ2eOaNiDVKGMJl1NyUWdXjZ8Rd5pQpma TmV22L+XLSCUAQBYzgT9vc0GlTonN7/ySKWWM6+UMdCIMceQ0LUQQywMPqpeNVo9M8RtIuzEkWuo qD2o2SZ0AwAAAFSw8lufXl5vbmzkP39wjIRGukv0prNuhrnaXaN5IapQFhzJIU9HXlmH9wEbIAdN j8YjlMPOkSJCzJVuc2maere56wojaWIWmUlkD0pCGfk+KdtSfdZzj/F01arXRRXKM25LXn5LP/u0 gJR5xwlRCGVqOpXZ4f5froBQBgBgGTPeU7uxyu7HhnTaZ69JJOZ1lun9/SbOq4HuXmjIyrd6ZiPH HJG8V+AHH9EPFp2+dXBybu6us0a/z+7D1wd9n1aptvDdAAAAAJ1xV6O+wj7K/+Lwd5Ws5lVe0NUY 3aOMlfKVds2+T76zlWra3GHTwRYrlKmeWvYHBjH9p3Kzza67chka3aMc8nftXcufJh5UJiw05qhN Np1n98Sn5p18A48yAADA4wRNOOterXFOcL948zrmrNGxs+gIs+62bdj6P4gYc1S6TzAy2/1KnXOC O1PWPwEAANBBk/0nNXmnr5EhqRAzcO5D52000duQUNk9iq1LKOA49HIMoUw0YqFGm6ZtuxKmkyl6 ND6hTJ37O3PjwsUfyVnI7zBlmBy38MnyOcrZlquzUgiiJsb5OKoq6RrFOSMXqulCebLPvLG04waZ aU2g5J0mlKPNUQahDAAAsBSEm1HevMp6FOlgxJhjTKEsmWnZQQAAgFgwbluNLiWjcEemzniyh7yu N+1zHDfoy+trq/9rb+avYwll9KC/ZdMv9NwrfTJE+yMzRGEGikU6IoWpXE0C28CztblqbZ4wJ42c HGXVCxzCLNN3Ik2Vll7yV+/MTUdDUU55XZ3J9J/ZG2hCOTBm3//iqs05ZOGLwp17rO6QMu+YMVdj VqIms6zz/MdCduirXiiys5wBoQwAwLIlbo+y4EcWxhwDwslyQyyYfvAoAwDweEE+m3FrxLyLR83T IUOXPyCUAQBYvqCx81XxzFGOHHO8E0sokxWOsmGOMgAAj4ugv6tS/bjXQQOhvDSAUAYAYDkz7XMc 0yXMs+qFYswx7GW+SKEMq14AAPD4wM/4+tSMoz3kgf9xAkJ5aQChDADAswxWz1kt/fzkDgAAAACQ A0IZAIBnjSnvP/5+aTxEXMs/ni19HTbwAwAAAOiAUAYA4FlDmM5RkK1WFTT1sC9iAwAAAIACEMoA AAAAAAAAQAGEMgAAAAAAAABQAKEMAAAAAAAAABRAKAMAAAAAAAAABRDKAAAAAAAAAEABhDIAAAAA AEAMHsPmHVIUiPEN35nmDz8G+O2Z+F8LADE3h39aVJmEmJveO0HE/1oYKOj7sqVoc6JWp07IrOoc YEgwI2cKXlNp83YWFJJP0QnnWIjk67n16TvwkWx1gv6oY5ELHIFQBgAAAAAAiMHjFMrTHkvhupqe cf54GKH+ZtVbXX7+1xKxMKE8cblZX9Llw99mPZas1xa1Dv3sVcv2tFrnXf7nQkDjF5u27jr1/X0i j4M3uiuyqxyjSNp4VYYsX2j866NJb3Z4H7B/LAwQygAAAAAAADF4rB7lGARdjWsKbLf4X0vEwoQy 42rU7rSN8L8eNw+81jc3NfZN8j9F5hHKc3OBC/W6Cvso92NBgFAGAGCZM32r972SDUnp2WpVxuGz Q4HFDNc9mSHCWDzu0VVKCdC6FgB4hpgN/nT9x++u/zw9r09UVLHky8tvHvpdkaFAuyWzwfbZhwcN uVlqVYllCDcl3KaSf1tTbdTnpqcYjn7ytz9V5Bv06sSi0+4pbENCzMDpUnVazo4Mte6Yw8c2fzTa 21SQmJJlyK2oP6AVo+Bcy/6+dvZ8baL6oM3NhNzWPdr1L6zanLPH6g7hNv2dpViTqjeQuCLnFZCU lByv37la09I/QTsz6O9tNqjUObn5lUcqtZyglJSlpNoRM9BRoUnU6tlrrw5Y96cnvLQmRb8XJ0E8 H90fsJSnqrMLSZmc9xGDKSuKhA27rFdnSKQigvHBIbxUVHv4zZx8reqV0g5PuACmBDtqL9c19Ab4 EyRo1ixSKGs5R/hCAaEMAMByBk0NvJepe7efCZFupv/dzLST/ZNxytYnPERIIdTfklDe7cd5iTW6 SuUhh1zFEpCFQ+taAOBZITRx8aR17X+0r9nwoaFthOxpH4Mwofxi7vsD2CJNOGtf2lxlH8GK9rql YH1zf4i0KZXhVD+D0ISz7mVVjR2rYfSDRafDanVuvKd2Y5XdT3TlzFB71vZ290xo3Pl2cuWnfmzS giN20+ZwoRz0u3r/zZq+u/YDaw46sDyUeZTvOmv0++w+Yg1nBtu3G9uHJshhHpySdam1/2TFJe1M KTHTPntNYlShHHA16o3Wa+yx0avDAST3KPPnzzK9v99U1OnFcaG7Fxqy8q2eWako5pDHkrmxdTCs gAXjg0N4voCdR4HLsDC5dUB21qxUOHMT7jZjVtvgTGigdWPpmVskOeHQrJlMKMPUCwAAVijox+7i XLNL9B/8POz6xkt6jnh4skOENIIu86pimpWfn6UacpWFQ+taAOBZwT90QNO+Bgtl/NF8+lnsh9Aw ocx+kTdn8aDUphQNLRBwVL9a38uPIqHhjtxdFs8tZ01WrXOMPUSJAjHXPrecbGq19drquNCkYAMO 0ysNF6aJisT6d8RanGn5gfvBImvdlDOvMs66V2ucvLIWBaVSKOOHgdXVjoDcxaAUymPOGp3JcYf9 d27W3bZNZ7mOZAmQCVYB4V9ljNz/hDuOg1mi8xiNWA042BmhzEPujj1F7Kt7RcS3TQKM/TJfZpVt aIoLa4GAUAYA4LEz/ZP/u0H/T3FYrTF7xWrRxItEjkiSY5EGt2cw3iFCcr4wlqp61Wj1zMijkxn0 GEOEsn8TN+y1DNxHcyjov9jODXeqNJXYRmPLXpahem6NWn+ww83I+kLlqCiONGzUcipsyJVx20zp 6uyd+rTU4tPEs8WBvGeKitrdpFRJX/UrrnubDTgOqep7J9gSuDgoDycylvCxUQBY2dy/cfz/CEL5 /3xx8T5/mI4o42R6bmFC+R4+50Vt+fHGRjP/ed8xclVSk8oo0Eh3id501s0wV7trNC9ECGXcop/X VhwTQzO/6/DK9KyUEtqZnh/FXHAncOZR/CKmQToiohTKsrioBymBCP8qY+T+J+Bz1qeX1wvJbjT/ wTESwg8YBZyVYxGvCk8DBx/4jM9W9obp/FhENxI3IJQBAHi83LvwRXoy6ZxUJV9/c48/GIVQf/N6 vrORQxmRpBncOIcIyfn8WCoZJNW3DspFsMygRx0iZMPn/2XnipBBVYT8/V8Mklez0V175SpWtlJ6 Vur4KY40ctRS6iClh4cQM+y5TbQ+x5S7rcho86K5oM+2NzEhy+wan5sbdzUaiLNHKJ/w/jvG2CgA rGxQ6Na/vq7I+1CV1/3f/wpI7YiK2GDFL/jYgoQyM+0yq8rtnPdYYCyWR9nfVbKai0kKTQp2us+c cMA+Fq3RSimhnUlmhix7jzK2XXrF63cTg635BotbOI1S8hJi4JSpKQsAhDIAAI+T0MRndX/kvTj/ 8ccDjtimS9bZhKEckaQZ3DgNutxAK61tPAY9vCcgatto8UzPofHrn/+5xXyqs9dWz3Woyp6VPn5K 6WOkoiBGP7PK+o0/smtHD/pb1OSxYdResf8vtt8b2q7Mzl5p1+zr9gcp4dBiAQCAhtjqZc1/gUJ5 bvJSy9ZiyzXyHI6Y7//6wb/8KDTmqI06R3mityGhsnsUhx8KOA69zIYmCzbQ35yfb3GTgSB0f6DT +hWZcCwia920M9HY+SrlHGX8EL6qzjmBn7XFxDzMHOUY5kX4V/pLVrA8aLL/pCbv9DUyxBdiBs59 6LyNvyH/p/uSiv9IRu3wjzGXWSfMDhfzKyAFjsu55g2jjXVILBgQygAAPE7Qg4vvWHihvMFy/H9j v1tB5qUpPZ20EUmawY1ziFBuoJXWNh6DHtETcJeM+br2px0852HuebrqUp+LIpTxhZTxU1kyhJDl zwyIudJtLk1T7zZ3XWEX2xeYcNZuwDH31Ga0ue85TNkWz48243b8MEANhxILAAA0xFYva/4LFcpz aMptq8rYkr4jT5dR0tLDzrMK3nQ06FVRVr3wOY4b9OX1tdX/tTfz11xozEXzlk1a7b5O74O5qaEz pmy1Nq8wI3NX85fsRDIRWevGUM7EgR/TJYSveoFu99Rp14YlBlsbbtULQ45aX3cep3mW6TuRpkpL L/mr1yfYDcqUttjmRfhX+ktWsBKM21ajS8ko3JGpM57s4dYJwaJ56FxD7iZ2w5FtpeZuNxldDM8v hzzemcF2XabsdZcFAEIZAIDHS9Dn+W+TVbXFWtHuuTXf+mizV9rTclsHRb/zg/v3JhBtRJJmcJ+s R9nT/ZaOD0rsUJU9K338lNLHyIUyB2L6T+Vmh5v+O46Dxf9jbcprHQihH7vLDv3lo6r0titk3JQS DiUWAAAAQA4IZQAAljOhMWd9WtGH7CtrKOjrqtxY6xhxKkckaYOGcQ4RLpFQls9RzrJ4Zu9dqM8q 67qJcLoDjqqXoghl+vhpTKE8c+PCxR9J7MjvMGWIup8l6LOVrV21mZ31SOZSr1mFw2HXoFOGA0IZ AABgPkAoAwCwvEEB99kGg4rdcER7qJO8HkcbkaQMGsY5RLhEQlm56oXv/NHcvIojdVWH9uh/xenj MVdjVqIms6zT7RMDoYyK0iSsMOTa8X3/2dpccr6UBQnyWh6/3gXrMn+JfXjAKMLp9P4AQhkAACA2 IJQBAAAeGhCaAAAAKxEQygAAAA8NCGUAAICVCAhlAACAhwaEMgAAwEoEhDIAAAAAAAAAUAChDAAA AAAAADwyZm86qguNNdWl5R8OMPJ9/p4CQCgDAAAAAADEgLbWTRwgn23X87/hF6mMCtn7IzNFq09J 0inWsYlF2IyvoM+2v6zrx1gXI+bm8E8xsoBTu7uky4/Q1NBp42q1tP5PyN2xp2hnQSH57NCqntvW 0n/3Vu97JRvkixHFhl0CnxRjrRgsYnzDd+ZbSn8ZAEIZAAAAAAAgBosSysjvrM1UJayLKZTRzFB7 lu7dfiZENmQ+efIfYTtRxyRMKN9xmPZ1eGNtdTrrsWS9dtg5Hs2hOxtwHC60emZ8/6zTbVG/vkUS yjKwmDauO9o78um+rUccZKu80HjvsU3bLZ543MRkF6Q6YX+laY+lcF1ND7vM+7IGhDIAAAAAAEAM FiGU0dTA/+SV/cl2TNj2iA5zuTnXaPPG7UaWIRfKE06ycf1DTWoYc9aUtrvHPJ1N/9Pfb4tcUZ4j 6O+qWF/fO8F7iLlj4j5KsXngszfss/6wkDJcFoBQBgBgBaDcKOSJIyYpxNz03ol/OBUAgGUHEcov v3nod0WGAm1SUvHpAWbaZyvb3DrAeUdDg62bi2w+eSsPXuswvtk+NCrtD0oHG4rCdvcU/ysS/G/y b2uqjfrc9BTD0U/+9qeKfINenVh02j2FZEIZPej/Q07ztw/iPB9/ETZIUr1S2uGZJFE9+LZF/4fL D7g8RLGo6Mfu4syG3nv8Tw6s0V9hNzaSgs1Q645+8ll7ZW5uTspmo2Vwag4FPdY3K879KFlC8dkD Tbk/rtRuyynITlWXs7s1LS9AKAMAsAKIYtafJEKSZq9atqfVOu/yhwEAePogqu7F3PfZvfSZgdbC bMvVkNeat5Vz4k652wrzrB6ZwguNOeo0DV+PI9lG+lSIOza3se2IQZudQ5mjjM2IynCqn0Fowln3 sqrG7pueQz9YdLqW/gmZUMYJKGU3ro/vfPyF33KfbHSfzMr9WXebrsY5wUUbxaIif1fp60cvCK5k QnDUdaosr/UyUfpSsGPOmk2Jpk9xXsheoa83X34w0LpxbXp5vbmx1e7hngpEoTxqL9c19AbwIcR4 r95edrOWQSgDALACWMZCGQCAp56wqRdkc3id5fqsp8Ow2+Jhlej2krD5wZN95q3VdjLbOB6h/FKa +eI4Fp/B4TPFuvCHasmMBF2Na7jt+sWDovDFCciuYzeuj+988YuUL6yY95gcd8jpBKr5EuddcITG nCeMBdnqDXv/PBQg2lkKVpZr6WAEYtQT7raiNJO1379MX+wDoQwAwDIGG1lhiDBxw152VE7eY4nW XNYTRB37w93J/QFLeao6u1C7JZP33JDQhBFV1atGq2cGxzDqatvLnrYpteJjMmRJwk8uOV6/c7Wm +ZM/GpNbB/kB14HW5LIzPqkTQP6vmnKT1fpcQ0XtQc22sLRNDdkqMlP1+TlqTanlOwbNIeY7S7Em VW8gg6SOm2wo0/6+9lJ1Ws4ObaL6oM2NL1eOS4aYgdPsOTiPx9j3aQAAeKSECWVB/PGO5JDXmp9n lc0yDvm79r6wanMOWSYiLz3hpTUphWbbR+YidtUI+WeP1R0a7sgt6RiZYS/EsZSsb+7nrAuLJFhj CF/k7yrbxU38iOt86YuYL/Rjd8l+mSmTwpGgzrvAh8fOV218m7wjKAW7IKGMgwi4u06UbtlmbOx2 E5/98gKEMgAAyxhsZPmxPDQ18F7m9nb3jLzHEq25rCeINvYXmmV6f7+pqNOL9TG6e6EhK9/qmWWN NT+iSgYo9a2Dk3No9NIXV7CQnUO37RUa1suCw1+XWvtPoq2Rp8PAzymcdbdpDPIO8q6zRr/Pjjss FPR9WqXiXhvn0hYYs+9fW99LVC0KDF8dDUonz83NDLZvN7YPTeDOw+/q/TfpKkJ37QfWHHQElOOS 4z21G6tYZxX7vjwpEykFAAA8AuRmB9sAS6bOch0RC6Attn33yT5t25Uo79HN51EmliqLnTWBmRmx 7uYmQghIgjW68J0NOOr0lh9YKxDP+TShHHCYskmOBKRwRCjzLngU4S9UKHOg+wOnipIb+9gZ08sI EMoAACxj5EaWCFmjxTMxj1COaqlxh6QTxxb5wVNEld0hxvOFpflEa+dnZ45o2EDk3cYDr7Uki3RL 09ctu8MmJoovtRAi00ZE7Zbqjn4skVlwz/RKw4Vp7mTcQRZnsl0dYq59bjnZ1GrrtdWx/VzEuCTu FKtf5QQ3Bg135O4ig78AADxCZE/U7BzlrLZB4gSevdKuSUvfGuNtvHmFMpp0ndBUdJGH8OC1jiI9 fqjm/yFIlie68L13ob6UPOHL/1qYUO4L9B7T0QX69J2rHvZd5KC/q/w35NGdgMYch8s+ZEsDBX1d lQ/lUZ4cvvANO74XCjgOrRWiWD6AUAYAYBkTZmQ5231vsUJZPJmFP0gRysj3SdmW6rOee4ynq1bN rYEadi3vSA55OvLKwiYmUlIrSxvW30PdTcXa1CJz91AA4ZOf11YcazQ3ch/zuw7vLBrpLtGbzroZ 5mp3jeYFrp8LG5ecJh22tvw4fxX+vO8YAaEMAI8UYijCV73gVCVzuVn7y7QY67LNK5RxA+emhOnS VZpK6wAZy5KQLE9U4Ts90Ko74eIfueM4HxsoyVJxBvDLy617zC75isbCJeM9ta8kk2nTZN5FmjSJ GY177O8YNySlk0lxu1t62JljUrALEcrYvp09nJmSUbhc55KBUAYAYBkjN7KPyaN839+1dy1/RAxE jIiFuJH2ffKdrVQT3kHG9CizBzEh5vv3DRubXPf+15xwQFh7X8DfVbKaj1vWz7Hw45L/e89lVpXb uZFaAACeKEGfbY8m6ryLx8KU5ysnv5DEYvn5uvPCdfIyBkABhDIAAMsYrHHlc5SzLJ7Z0Jh9/xqy jJFyHnBsoRx1jnK4UB6f6D2qKukaxb0G8jtMaopQZleD0mjTIicmolGHKTvKHGVmZth1kXWWoICj anW1I3Cvvzk/3+ImA7hYBHdav/IH5yZ6GxIqu8nsDDIK+TIRyopxyclLLVuLLdfISCtivv/rB//y QwcHAE8E4mctEKY9ACsTEMoAACxjsMaNXPUCy9fPD6vfoK8sEUsos3qUtupFpH86eNPRUJRTXldn Mv1n9gaaUEYP+ls2/UKvmJiI9fH5oxlJtLQFmKFzdbot6TvypDUupobOmLLV2rzCjMxdzV+y6Zn2 OY4b9OX1tdX/tTfz11goU8Yl0ZTbVpVBgtJllPCDngAAPGb8/6jNSNPVfQ5PqisbEMoAACxjJOG7 vEA+m5HfawAAAABYsYBQBgBgGbNMhXLQ31WpDntJHAAAAFiBgFAGAGAZsxyFss9eo0/NONpDVjIG AAAAVjIglAEAAAAAAACAAghlAAAAAAAAAKAAQhkAAAAAAOCpIGIFnsWxJIGIyNcOWhLQjOfjMnWa Pv/UJX4jFTlLm/j5AaEMAAAAAADw5Aj1tySUd/vjeT34CQvlUH+z6q0uP/+LY8mF8uRgq57b0p8G CGUAAAAAAIBnh6DLvKr4zK14pOYTFsqRO4YSllwoy1bBpwBCGQAAAAAAYFkRuV1RcMxRm2w6P4bm 5mYG27cb24cCWC++/Oah3xUZCrRJScWnBxjWQ0zZ52gOMQMdFZpErZ5sP/QPu6UsQ/XcGrX+YId7 in6+/6um3OTwnYxEpv197aXqtJwd2kT1QZsb/0WUq5AS1atGq2dm3kCw+kz+bU21UZ+bnrBhl/Uq 2TF0LsQMnGZD5nc7Crmte7TrX1i1OWeP1S25v2nRBUddbXvZXGxKrfjYTfbHJlGUHK/fuVrT0v9v KTpcAp/87U8V+Qa9OrHotHsqOOY06xJeWpOi32sduKncEAqEMgAAAAAAwHJidtz5dnLlp+wmfBPu NmNW2+AMGuku29XS/5Ov62BW86VJVi++mPs+q4+ZgdZCcg71wrmAq1FvtF4j+i84enU4gCSPMvX8 u84avWJvfJGg39X7bxJp6K79wJqDjoA8JegHi07PbrIdOxCsPlWGU/0M/ttjydzYOkgy8XVDUmnH jSkc8njvseQ8q3c2qkc5Mjo0eumLKzi0OXTbXqExOe6wUaxLrf0nK/3F6NCEs+5lVY3dN81eq2vp n5B5lEnIIJQBAAAAAACWM3ccB7MaegPcDzRiNegs1xGaGWrP1u9+M63OMYZ1pVzVsXKTnEO7kHHW rq52BGQbe0pCOcr5r9Q5J4h2pspExFz73HKyqdXWa6tjVSxNX07EDkR2hF+9nkjYtUR2s8xeaU8r snim55t6IYYTYjxfWJpPtHZ+duaIhlW98kil77IAxYMglAEAAAAAAJ4asDhbn15eb25s5D9/cIxg oYu8Z4rWvtHYN03OCRPKgtykXXhTsY+SJJTnPV8hE9FId4nedNbNMFe7azQvRBPKYZs3KQKRH+HP DM+OcEKcQhn5PinbUn3Wc4/xdNWq14FQBgAAAAAAWKmMuxr1FfZR/hcPmuz/Q3Z5/RGDqds3EyGU BY8y7cKJGB7lKOfHcAb7u0pW87EKopOmLx+rR/m+v2vvWv6IqHrlkUrfQSgDAAAAAAA81WBNfFKT d/oaeSsuxAyc+9B5G80Mtmft7bjx85izfht5q4+oOvkc5WzL1VnqhbHmKNPOR6MOU3bU6cUTvQ0J ld2j+NpQwHHo5WhCOXYgcvUp+p4XMkc5PLrxid6jqpKuUZwJ5HeY1IsVyqEx+/41Nc6JsDTLw3kc gFAGAAAAAACIDeO21ehSMgp3ZOqMJ3t8973WvVmtl7GKnEM+e2XB0d5RH3XVi8gLyTQNYdULQ45a X3f+ZnBuzNWYlajJLOv0IMr5WCaeP5qRFG3VC5/juEFfXl9b/V97M38dTSjPE4hMfUqTNCJXvSD/ MhfNWzZptfs6vQ/ITwItuuBNR0NRTnldncn0n9kbFiuUscz+/LD6jfA0y8N5HIBQBgAAAAAAeEjk ehFYOYBQBgAAAAAAeEhAKK9MQCgDAAAAAAA8JCCUVyYglAEAAAAAAACAAghlAAAAAAAAAKAAQhkA AAAAAAAAKIBQBgAAAAAAAAAKcQnlczty4QMf+MAHPvCBD3zgA58V8+FlbkzAowwAAAAAAAAAFEAo AwAAAAAAAAAFEMoAAAAAAAAAQAGEMgAAAAAAAABQAKEMAAAAAAAAABRAKAMAAAAAAAAABRDKAAAA AAAAAEABhDIAAAAAAED8BAbaDpYeqiw5/PkdxB8CVipxCuWRMwWvqbR5OwsKclKSdA3nfUFq1Qje shWvaXQF+Z9RQYxv+M40/2NxIObm8E+0iHBStWYXw/9aPIsOJ8Tc9N6hl88iQDOej8vUafr8U5em n0RzvGXb+dz69B2FOwuy1Qn6o46bYpkjjyXzFxtqnWP8bw70g0X30ss1zgnhd9D3ZUvR5kStPl21 2fjOPzxMiP+HA4e/KqLGTPt6ThpV69TZWnXGoc7B+1y2ETPQUaFJ1KQlqg908AcZ90dVxoqqyqIq 6xC5U8h3dm/1+bEnUU5A3Ezf6n2vZENSerZapRXvL5oaOm1crWZbHNxWIH44C7NpbYouPSW7qnOA IfWEcTWq16Rk7yzAhqtwZ9EJ5xg2O1CvgAjkZodml6auWCverKypMFZY3VP4wIzPVnPIMUr+GrPv r3IE5kI/3xufV/AATzvxC2VBNaK7Fxoy86wemnmJKZRD/S0J5d1+bLCmPZbCdTU94/wfi2HWY8l6 7bBzfJb/LfFkhHKov1n1Vpcff5u9atmeVuu8yx1/aCYHW/WZlh+emDGXCVk0/vXRpDc7vA/YP4I+ 257klE2JjX3yJx7ksxk3blarzC5O1qMfu4u1VZxlQfcH/+a8PhOeFYVQRv5P9xn+u5/o6RDT/64u uXWQSOtAf3PBLuu1IO4Xb3Tu2nqyfxIhf1dZvtWLSKRvlnX5UcBlNrUPCRIdWJagu/Z9W484fLjW hMZ7j23abvHMYq3zzzrdFvXrW3CLg9sKLADks1eWnOy/h80KYi6dzMhtHZxkhbJ2p22EP4cF6hUQ TrjZodiloL/rYAGROlgfH9jT9SOa7Gva/aGb7cKCrncKGz/qPNXePRQI79KAFcjChfIcmu5tWFtu D3ckcsQUykGXeVXxmVuP+unryQjloKtxTYHtFv9rCaFY/MdKmJANXKjXVdhH2e+j9vLC1i8/rkjh hCxHaMx+UN1q/xv+i3RXcdx0ikdZhnj5dJ9ZdcgR4J6L7jgOGsyucVzmKu5SfFpCY98N8A89FTy4 f2+Cv0v8/R33dDb9T3+/jW1xcFuBxSJaS4rZhHoFhDMpNzs0u3TP1VjIaQC28nztFd3J5EhTqulT 36Tbkn9Y6JiAFcsihfIa4j0NMQOnS9VpOTsy1Lpj7KOYKJRR0H+xvViTqjekqzSVtqGpkLujLEP1 3Bq1/mCHm2FP6/XaypKbv2X9k+hBf0tykc2HlGHKwKLqpd2NTca1rzdfHhEE1tSQrSIzVZ+fo9aU Wr5jkJhUFMQR6OplgZDkvfxWQ1PB+vXN/SF0f8BSnqrOLtRuyRQmkyD/V025yWp9rqGi9qBmGxuO LO+iqkP3B60HUlXaAvbakYGP9mjXv7Bqc84eqzsknk/LC8lCUe3hN3PytapXSjs8rJoUiUxSaMxp 1iW8tCZFvxcHzJ/0eIkUytqSLh/71WFaXedkrnUYCtvdU+y/GCxhdbXO215rsabtCms87jpr0tIb Pr8VbS5KTKGM/F2lCcQ5jUasBp3lOh/G9HXLLoN1GPlsu3fhOkNcRLt3vWdrBP/Q08aEs/aVOiff PfENB24rsEjI+FU2foSme5ShXgEU5NpGgLdLMz7bvt22G6xHed/uD/9iFtzJhFvn/r/WgRDpEw89 evcf8IR5iKkX4z21G6vsfiIbZ4bas7a3u2ckjzLy93/BzvJBd+2Vq6rJIxf/lIb/5E+b8Vrztra5 iZ6acrcVRglTJrCwqHpOU3eenSbLC6zQmH3/2vpeIkJRYPjqaFDsbplLJw17/jjAz3BlIfG+oOaG V2bHnW8nV37qJ39PuNuMWW2DM0TV6ffZiS0N+j6tUpERGZpQRpOupuSiTi8Rf9O3r3oZRJ44BY+y cD7zdUNSaccNLCLJUE5yntWLc4pDeL7g1Pc4VVjtFSaTliYyy/T+fhMXLCnkrHyrZ3Y5eZRlUy/Q hLNu7UFHgNy4fGlmCLYvq8m9nnW3bRN0LWKunDFtezGlsu3za+z0wXBk4StgBloL2fsiL16MUM3w c0V7haG8qrLI9Ke/vbcH/ENPF8FR16myvNbLwmOW0HDgtgKLAU0NvJfJdxnYbG5Zr8nQZRhyUpIN TV8ROw/1CqAg6985ZHYJMZf/WFxYQeYot/29zSS6kwlotOfwnsqj++FlvmeBxbzMl26yuadCAUf1 q5xCxaDhjtxdFs+EKJSxqrr++Z9bzKc6e231nD5WCOUg8vD+yNkr7VuLO7xTtDD5XwS5qBI0K9HT W6o7+rFE5mDrfe+g3VRYZR8JF2CSjmd9n1kNvQH2+BzvsGQo/q2whsRHOuas0Zkcd9jTeBRCeVyQ kiw4g2lFJC9SFuSJ4QgLVtCay0AoSy/zZVbZhlhZM+5qzDTayHy/aZd5PRkKwAdl36f7zK+XnvGJ mZv299uO5m7WHf2SfTKRIb+nYaCpoQ/ytp5wjZNHCbpQ5n9i2OmG3//g6jzV1Gpz3ZLVGWA5Ehpz njDiGrVh75+lGX6yhsYDtxWIm6mBdkNeUx+nfoP+3o8+cLIuleC1jiJdQ+89cpgH6hUgIjc7VLvE QmYnfzBw42Jna3NrZ1/UAVJghbIwjzLy2Xatq3GQN4iJWHlRW368sdHMf953jIhCecbXtT/t4DkP c8/TVZf6XBShPPfAay3Lt3pCXmt+ntWLqGHGFsr4W4gZ6m4q1qYWmdlp9TipG/QFWWt/VdEtimce ucDCp61PL68XImo0/8ExclMu2sT2I2tIfKSyIwIKoXxPFpd4kJElW6n2woPlz1wmHuUZn63sDZPg g3nwbUuSgZ9xMeGsXVXeTQYBmMvNmdv4GRdY9GtKu34MMydTl1szslv677itJvZt9CIyn0QqkDDQ +MWmNL3Q7QlPMnxwwtQL7hf+l7y93vnZO2XVdu+k79PqvHf7J8NiBpYnaOx81ca3hVdyI5sV3FYg XtCYy6zfZr44TqkgMyPWXWSuHf8T6hUgh9Kbh9slDLvYxf/9pDnvsN0X8NkP5zdfCp80CaxwFjr1 QpylQNyHqshX+kTx5+t+S8dXPlEfU4TyHMIS2fhRn60Cy2XOPakIU4ZcVEUKrBDz/fuGjU2uyRtn Ctal1v1z6Mv6bfzMChG5Nh13NeqF99IEaDMmwxoSH+kz5lHmEjwz2L7dyM3qI2lbtTmHW3qpIC89 IYkkm+RxnVpfwC3JVKhd/7KYfR5aXiLvI0vwRndFmqFtQBiUZ13Uipf52O8Y1j80+FVLspkNB8ey u6UfZh8+Fch7Kfl3DNxWIE6mfV0H3sj9YIgs4KUEC+XdskluUK8AORFmhyP8ILvYxWDfO5v5rttl Tm6+LJs0Cax4FjxHmTxsrSs745uZm7zUsrXYco08WSHm+79+8C8/6xJmxd+9C/VZZV03sd1CAUfV S1GFMlFXmrR0TRm/6BglTHKYRy6q+O9oZth1kX1PjkREJsgO80lFow5TNjvhWESuTdFk/0lN3ulr ZEJbiBk496HzNpIukc9RHrWXa9nVgqd99ppENtKHmqPMZ0EplJf5HOXQmKPmDaPNh8js6k38W5iY oL+rfE2Nk/FYMpNaLj/gy5u8h7eqrufWhZPVpwfYtZPJrHHd7rC5NBiKUGbclpKkYhtbvCKU5eHY 42jm2l/2NvVNIk/Hjhr73dAcum2vrBTWsAOWHWjMcbjsQ7ZK4FbWVUn3KMNtBeKEXQp3Q8UZr/RY TYx/1e6jPWTuF2t28lsHfub+gHoFhMObneh2afKapbbJFUBea2Gl/S7pnO37dpB1BoFnh4W/zEec ygWbGvsmsYVy26oytqTvyNNllLT03MRaWBB/uKqdP5qbV3GkrurQHv2vOH085mrMStRklnW6fZJG nHK36X+Zxr3Sh1GGKYMilEPM0Lk6HTk/PcXAboch0/T+T/dtPNgdvuqFTJsybluNLiWjcEemzniy h5zGJjsjKXzVi6C/pyF19eac3PzKI5VaLgHCqheF+m262n+SFTOYi+Ytm7TafZ3eH4QERFn1gs+C UiiTYBULcSwfocw6lXWZ5r7LZ4oy5HP+sAXJe73edrrkjfpeyTNDJqDrzH0j7rMNhoR1an2WOiG7 7uyVyPf5lELZ31Xy3P/DTohnPdb8ZgG4wxM2HNmw1yK+o4l7xOoa8thGSvvPlUUVtRVvVpLFT7i/ geUHGvfY3zFuSErP1yZu2C1r4zIjA7cViBdf91trX0jQFvIDXCVmpx9XoOCtf7W+lRy+CwnUK0CJ YHai2CU0dv7QnrPE30Z6ZxO7YY1J6oCAZ4M4hTIAAAAAAAAAPFuAUAYAAAAAAAAACiCUAQAAAAAA AIACCGUAAAAAAAAAoABCGQAAAAAAAAAogFAGAAAAAAAAAAoglAEAAAAAAACAAghlYCWA7nxep99d W7O3ou0yI//O/w8AAAAAALBgQCgDKwHEeK/enp5Dwx1F77juyb6HbegCAAAAAACwABYtlMWN5eSb 9q0ghB3jEOMbvhO+63IMEHNz+KeVp82Qx5L5iw3sPt4c+Ka/xm6eV5CTkqTjNxHEB9/IbBuc4c8R 9xSk1ZDgzZ7m3YmrN+u1W3SmzkF2j2vuYJJKo09JSucPMu6PqtjNkKqsQyQE5Du7t/r8GL8tEq6E tbKQUXDUfmh/N7vtufw7AAAAAADAYniGhXKovyWhvNvPSjQlvFCe9lgK19X0jM9NXG7Wl3T5+H+j MOuxZL12WNgjfsUQ9Nn2JKdsSmzsE54YZDcd3b3QkJln9SBy8De/fKXGwe44HVMoB/32mryWS2Tn WHSvv8WwuXUghA92VbxhYkUwezC5+dtpf1dZPtlVH/lsb5Z1+VHAZTa1D4n7ZIcJ5ZDH/k7Nnirb MH5QkX8HAAAAAABYHM+wUA66zKuKz9yKIqUEj7KAKPueQUbt5YWtX35ckdI6yD9WyG86mu5tWFtu HyMHVVqtelNj3yQ5HtOjLCPoalxTYLsVXsLcwRFXo4q7CfhmJTT23ZC5k5n+DvOx2oIt6eX15j84 Rsbv3+e82m81u+7LvoNSBgAAAABgscQplKf9fe2l6rScHdpE9UGbG4ue2EI5xAxaK9Wb0vMz1Lpj Dt/0XHDU1bY3VZ1dqN2UWvGxe4rVMeKFoiqdGrJVZKbq83PUmlLLdwyaQ8x3lmJNqt6QnmI46rgZ LntwCMm/rak26nPJv5/87U8V+Qa9OrHoNBt+iBk4zaZZSAOb5pffamgqWL++6cPTZRmq59ao9Qc7 3PcVuROTxGWzZ9C6Pz3hpTUp+r0f/b2zKK91kJWCc5ODrXlGm5dTbgTZVS+/eeh3RYYCrepVo9Uz I53y9BFwmFbXOZlrHYbCdvcUe0h+04lQXvNWl5892Ph3W9W6sjO+mbiFMnEkq4ivepbpPbatoovM 4kBjLnPeLtuNWZ9t9y6bj/Uo7971nq1R7k7G4HLmPMqzzMAHu3IrjpMX+L65JX2Hl/kAAAAAAFg8 cQrloN/V+28yZzR0135gzUFHILZQnuwzbyztuIFFFQre9gzjC9HopS+usEPtt+0VGpPjDk0oh8bs +9fW95LxfRQYvjoanLvrrNHvs2OlNDc3M9i+3Riuk3AIKsOpfgahCWfdy6oaO1bD6AeLTtfSPzHH fN2QxKUhNN57LDnP6p0laX5BfYQVzThPokdZmbsIoYyzKcq+B15rsabtCpldMXulfWtxh/cBCY1D dtWLue8PkIzj9OgFYf00Qsp2LSmTKXdbfqblB1byy+5d2NQLfPCO11rCzqCITyhPXW7VCbcVBdy2 Gl1G6cECnbHlq1tEMd8faK8wlFdVFpn+9Lf39kizkzlEoQwAAAAAALD0xDv1AjHXPrecbGq19drq 2IHyGEJZlFZyQoznC0vzidbOz84c0UTqJ15fopmh9qwt1R39WCKzBBymVxouTHPiaGbEWiwINQ4p BGH4Xjw4HpYGrGjTiiyeCSHNLLKpF4rcxRDKc8hrzdtuuY5VnMeSZSAzaCUir8LElIlPAeOuxkzW a46mXeb1RcS/y2ZKepkv3WQLGyLAj0lJBe1Do3EIZWaobbfGfHGcLUPEXP6jMbeirdthO5qnq+ef Z3jY2cnf/+DqPIVvk+sW9xcIZQAAAAAAHiHxCWU00l2iN511M8zV7hrNCzShHHJb9xYU7sSfPRZH p0yPsiDfJ2Vbqs967jGerlr1uihCGX8LMUPdTcXa1CJz91AA4ePPayuONZobuY/5XYdX9qKcFIJC KN8L08TUg6JQpuQullAWHMmM11qWTzypMlaeUH7wbUuSgZ9xMeGsXVXe7cfZ4jOFfLZd68S398Sc zvi69iWV/Ml2LLZQDo33ndiWdsI1zl0+7bHszuIXzQiNOWqTyTuUPOxiF52fvVNWbfdO+j6tznu3 fxIXPJryfHP5jnCTAQAAAAAAlpT4hLK/q2Q1r/sESRoplNnzOJQe5ZC/a+9aPgDaiLwklDlCzPfv GzY2ue79rznhgJ3XYUqkEB7Ko0zJXUyhTCYh7Cr9pPeT4l3CnF2BFSeUZ91t21ZtzuEegQry0hOS wqfNTLjbjIK6leV0ZrBdp1IlKJ6IJFDQ11W5rqidXfSNJfy0sCrBupMHv2pJNrNH8L3YTWbXAAAA AAAAPEriE8oTvQ0Jld1kQkQo4Dj08jxCWTlHOTjRe1RV0jVKnIB+h0nN6qdRe7mWXZp32mevSSSq CM0Muy6yA+4o4KhaXe0I3Otvzs+3uIkOQ/cHOq1fEXemiBS1Qigz0eYoU4QyJXexhTKRj9qtWo2m zR2xENxKE8rT1y2Fm5q/FWZhB/1d5WtqnBOyTKGx88Lbe/KchsYcNa/+4jdRhfLUoKVIU2rzyG7n zwOt+ZncmnFz0z/ayt+o+JRbEXnm2l/2NvVNIk/Hjhr73RCZ5l5ZGTY1HAAAAAAA4BEQ5xzlaZ/j uEFfXl9b/V97M389r1AWV73YkZ2awU42Dd50NBTllNfVmUz/mb2B1U9Bf09D6urNObn5lUcqtURf hpihc3W6Lek78qQ1LqaGzpiy1dq8wozMXc1fshtbiEhRU4RylFUvJKE8N+ZqzErUZJZ1Dv4YmTul 5J1l+k6kqdLSS/5KJiWTCQkvb+Ne6ZOzwoQy8p4pymjovcf/JAesea+bXdNeWaYm3G0F7JJw4Tmd cVsMqihCmYwwvPDc+vQdnKO60NhIHpgQM9Bp0q1N0OhT1iUWnezh5iijUUd1DSvE8Q39c2VRRW3F m5XsiigAAAAAAACPlHhf5gPCIAqyKHLeBQAAAAAAALCCAKG8GJC/q1TafQMAAAAAAABYgYBQXigh v/1tnVp/uOc2DP4DAAAAAACsYEAoAwAAAAAAAAAFEMoAAAAAAAAAQAGEMgAAAAAAAABQeKaFMrrz eZ1+d23N3oq2ywHfPw/l8t+fzrXcAAAAAAAAgKXk2RbKjPfq7ek5NNxR9I5ravz+zyGy6O9bzeJK ywAAAAAAAMAzy9MslMN2OY4JYm4O/xTlRBQctR/a381uAkfWfdtTaR9j/wAAAAAAAACeZR6VUA71 N6ve6vLzvx4NcQvlWY8l67XDzvHIffQwIY/9nZo9VbZhEszsTXt1bYcHthEBAAAAAAAAHplQlu0p /ciI36McBfTz/ftkT2xuusXUdeuBSk4xAwAAAAAAAM88cQrlkTMFyb+tqTbqc9NTDEc/+dufKvIN enVi0Wn3FBaaIWbgdKk6LWdHhlp3zOGbDrmte7TrX1i1OWeP1R2a9ve1s/9qE9UHbe6IN+VQ0H+x vViTqjekqzSVtiHizsUK+KWi2sNv5uRrVa+Udngmo56GhbLXZkwWNskLDbQml53x3XPbTOnq7J36 tNTi0wNMSJDUaMr9caV2W05Bdqq63DIwNj7wwa7ciuPcy3yDrcnPayuONZpP2K/DlnsAAAAAAADP PPELZZXhVD+D0ISz7mVVjd03PYd+sOh0Lf0Tc+M9tRur7P4glrMzQ+1Z29vdM0jmUQ76Xb3/xmp1 LnTXfmDNQUeADVEE+fu/GLyP5Ta6a69cVe0IzBJd+3zBqe/xwenrlsLk1gF8Mf00LH9nPB2GwnY3 Uc6z7jaNweq9a69Y3XBhmlXww57bQSQI5VF7ua6hl8TPv8YHAAAAAAAAAFGIXyhrzS7iDJYpYO5g IOCofrW+l1edaLgjd5fFMy2feoGYa59bTja12nptdZT5GGj8+ud/bjGf6uy11a8qPnMrKOha/F/w lq14Dfc16mkPvNaSLMsPrKrenWf1oJnB9u2ZVdZv/GRaBQt/5oS7rSjNZO33g0QGAAAAAAAA5uHh hfI9rGVf1JYfb2w085/3HSMyoYxGukv0prNuhrnaXaN5AR8MuTv2FO0sKNxZYOpwj/u69qcdPOdh 7nm66lKfiyaUZ2KcxjuSQ56OvLIO7wMSJ3Ol21yapt5t7rrCYLUsBogC7q4TpVu2GRu73cTJDQAA AAAAAAB0Hl4oM9Mus6o8ckk16TR/V8lqTvVS3/Dzdb+l40LGf5ujepRjnjZ7pV2z75PvbKWaNrds ZQvE9J/KzTa7ArIAWdD9gVNFyY19k/xvAAAAAAAAAIhkCYTy3OSllq3FlmtEdiLm+79+8C8/kp02 0duQUNk9ilVqKOA49HKkUL53oT6rrOsmmXwccFS9FE0oxz5tyt1WqNGmaduuEJ08c+PCxR/JYeR3 mDJMjjvCmZPDF77xkfkYJCVrFbOlAQAAAAAAAEDsVQFeAACyZ0lEQVRkKYTyHJpy26oytqTvyNNl lLT03CQilblo3rJJq93X6R33OY4b9OX1tdX/tTfz15FCGQV954/m5lUcqas6tEf/q2hCOfZp6EF/ y6Zf6LlX+hBz5WxtrlqbV6jdktlwnihj/syA++zhzJSMQmF1DhI/AAAAAAAAANCIUygvd5DPZtwa Nu8CAAAAAAAAAB6GlSGUg/6uSjW7ihwAAAAAAAAALAkrQCj77DX61IyjPWQhZwAAAAAAAABYGlbI 1AsAAAAAAAAAWFpAKAMAAAAAAAAABRDKAAAAAAAAAEAhLqF8bkcufOADH/jABz7wgQ984LNiPrzM jQl4lAEAAAAAAACAAghlAAAAAAAAAKAAQhkAAAAAAAAAKIBQBgAAAAAAAAAKIJQBAAAAAAAAgAII ZQAAAAAAAACgAEIZAAAAAAAAACiAUAZWHGi0p7bQWFNdWv7hADM7Nxf0d5W/WGC7xf8NPN2gO5/X 6XfX1uytaLvM3LLt0pYfb2w0W1z3+f8BYGGE1ai5wEDbwdJDlSWHP7+D+BMAIDpQYVY+IJSBFQcK DF8dDc7NjFirzC5m7sG3Jwt02l0glFcIiPFevT09h4Y7it5xjdhKGl1B/h8AWAxhNcpv31/lCMyF fr43DvUKmJ8xqDArnziF8siZgtdU2rydBQU5KUm6hvO+IPXRKXjLVrwmjn4LMb7hO9P8j8WBmJvD P9EiwknVEnn0sCw6nBBz03uHXj6LAM14Pi5Tp+nzT12afhKPq7dsO59bn76jcGdBtjpBf9RxUyxz 5LFk/mJDrXOM/82BfrDoXnq5xjkh/A76vmwp2pyo1aerNhvf+YeHCfH/cODwV4XXmKCvt7U0SaXR pySlmzoHyfkoeOtfrW+pE7U6dUJmVecAQ0qCcX9UZayoqiyqsg6R24R8Z/dWnx8TCyl40179drf/ Z8/pqqM9fzO/BUJ5mTB9q/e9kg1J6dlqlfZQ5+B9NDfltpp2FuA6hj956QkvrW/uD01dsVa8WVlT YaywuqfwTZ3x2WoOOUaF24uCo/ZD+7v9Ptubbx3/oKWteyjwJJoH8MThLMymtSm69JRswTgo69jc XHw1ytf3TmHjR52n2qFGPQNM+3pOGlXr1NladYZQT4Iu86o1an0BZ5GMjWwPF73yBF1QYVY+8Qtl QTWiuxcaMvOsHlqdiCmUQ/0tCeXdfqx7pj2WwnU1PeP8H4th1mPJeu2wc3yW/y3xZIRyqL9Z9VaX H3+bvWrZnlbrvMsdf2gmB1v1mZYfnlgLlAlZNP710aQ3O7wP2D+CPtue5JRNiY198ice5LMZN25W q8wuTtajH7uLtVVcb4TuD/7NeX0mPCuRQjl0116tqf0neRIjNU2XZbk6i27bK/PrzhONzqahyOKZ Rv6usnyrF5+FpVJZlx8FXGZT+5Cgz0Me+4lDu03nfrz75e+wnMK2D4Ty8gDdte/besThw7UmNN57 bNN2i0feiJH3TFFGQ+8df9fBAmJkcId0YE/Xj2iyr2n3h26h8uDb+07NnirbcJAZ7O4eZGbcll2/ p1kDYKWDfPbKkpP993DNQMylkxm5rYOTtDoWjLNGTbmaUk2f+ibdlvzDjgDUqJUM8n+6z/Df/cQX E2L639Ultw7ir0QoF5+5Fea8iVF5glBhngEWLpTn0HRvw9pye7gjkSOmUKbUv0fBkxHKQVfjmkcy C5ZxNWp32kb4X4+fMCEbuFCvq7CPst9H7eWFrV9+XJHCGhee0Jj9oLrV/jf81+AkOTDvTad4lMfv /8yHKJQqCt6//zPfo/EFgv9ScdfhKBIa+27I3Mlo4v59rOZxbaw9aul4p7HRfKw8fcPuVtdSPb0A D8OD+/cm+JupqB74+af09aMXJsZdjYVc62Nv9NdemfMP/Xz/PhmxGTnzVrNrauzWT1gP4Zp56NHb FmCZI1pLZR27F2+NGjn3/7UOhKBGPWuItojSZ+F6FbXyzN2CCrPyWaRQXkO8pyFm4HSpOi1nR4Za d4x9fBeFMgr6L7YXa1L1hnSVptI2NBVyd5RlqJ5bo9Yf7HAz7Gm9XltZcvO3rH8SPehvSS6y+ZAy TBlYVL20u7HJuPb15ssjgsCaGrJVZKbq83PUmlLLdwwSk4qCOAJdvSwQkryX32poKlhPxnbR/QFL eao6u1C7JVOYTIL8XzXlJqv1uYaK2oOabWw4sryLqg7dH7QeSFVpC9hrRwY+2qNd/8KqzTl7rO6Q eD4tLyQLRbWH38zJ16peKe3wsGpSJDJJoTGnWZfw0poU/V4cMH/S4yVSKGtLunzsV4dpdZ2TudZh KGx3T7H/Yu44Dupqnbe91mJN2xX24fqusyYtveHzW9HmoiiFsgSacNa9Ks3i4Bhz1mTVOseQz7Z7 F64wxKO8e9d7tkaZO5m53G4sqDhWI7zMxxpB8CgvQyacta/UOQVJg++Tv6tifX3vBBmv2LfbdoN1 4ezb/eFfzJLzb5YZ+GBXbsVx7tUrpv9UcUltze6cWniT5pmHjF9lm13hQ5V8HWMrUjw1Co32HN5T eXQ/vJv1TEEe0RPYgVCKUI5hjvCVUGFWPg8x9WK8p3Zjld1PZOPMUHvW9nb3jORRRv7+L9gZP+iu vXJVNRmSkOoff9qM15q3tc1NlMyUu60wSpiyqodF1XMabgheEFihMfv+tfW9RITyr3DxSSXDcIY9 fxxgZx3xkHhfUHNDcrPjzreTKz/1k78n3G3GrLbBGaLq9PvsRH0FfZ9WqbZEEcpo0tWUXNTpJeJv +vZVL0Mal+hRFs5nvm5IKu24gUUkGf5LzrN6cU5xCM8XnPoep2r6uqUwmTyJiswyvb/fxAVLCjkr 3+qZXU4eZdnUCyJh1x50BMiNy5dmhuA+aTW517Putm06y3X2KGKunDFtezGlsu3za+z0wXBk4YdD nrVOGYtbB9iS55n29/3PLsP/DEzhIro/0F5hKK+qLDL96W/v7ZHPTgaeCoKjrlNlea2XxccsVuhk NvTeI1+Zy38sLqwgkwLb/t5mks0lBQAqaGrgvcyILkNWx6BGAdFhBloLWQ2A6wwWKm9oMzJ0O7LV qoKmXlJPoPI84yzmZb50k809FQo4ql/lFCoGDXfk7rJ4JkShjFXV9c//3GI+1dlrq48c0RD0NPLw /sjZK+1bizu8U7Qw+V8EuagSNCvR01uqO/qxROZgdWrvoN1UWGUfCRdgko5nfZ9ZDb0B9vgcGrEa sLBj5P4tUR8rhfKYs0ZnctxhT+NRCOVxQUqy4AymkZm1sizIE8MRFqygNZeBUJZe5sussg2xsmbc 1ZhptJEZwtMu83oyFIAPyr5P95lfLz3jEzM37e+3Hc3drDv6JftkIkN+TyX8zsaSnXp1UvFfhsSX /8ac5iJc/baUnube1xFhZyd//4Or81RTq811S1ZhgGVKaMx5wohr1Ia9f5a9ASPMuwivImQ64AcD Ny52tja3dvZFHZoAnnGmBtoNeU194vMyvY4RoEYBYaCpoQ/ytp5wjbN9DRq98MFfnMSbhoI3Oo0R FgkqzzPJwjzKyGfbta7GMYbrE9F5L3IrmPKf9x0jolCe8XXtTzt4zsPc83TVpT4XRSjPPfBay/Kt npDXmp9n9SJqmLGFMv4WYoa6m4q1qUVm9rVTnNQN+oKstb+q6BbFM49cm+LT1qeX1wsRNZr/4Bi5 KRdtoj4Wv4iRyo4IKITyPVlc4kFGlmylUA4Plj9zmXiUZ3y2sjdMgtf2wbctSQZ+xsWEs3ZVeTcZ BGAuN2du42dcYNGvKe36McyKTF1uzchu6b8jLHFQROaTSAWiJDTmqE2OeOkTjTpMufJ3JdnFLjo/ e6es2u6d9H1anfdu/yQYr6cDNHa+auPbwkt44rwLObji1Rz6v5805x22+wI+++H85kvh05UAgNQk l1m/zXxxXNH0w+sYBmoUEAYav9iUppc9Yskg3rrMln7RJkHleUZZ6NQLcZYCcR+qIl/pE8Wfr/st Ha/5RH1MEcpzCEtk40d9tgoslzn3pCJMGXJRFSmwQsz37xs2Nrkmb5wpWJda98+hL+u38TMrROTa dNzVqBfeSxMImzEpZlmmX/lInzGPMpfgmcH27UZuHjBJ26rNOdJ6Xkkk2SSP68RVdQq1618Ws89D y0vkfQyH8m9EubHu5MGvWpLN7CEcxW6ZXQOWObLGJZt3IcG+XT7Y985m7o5jG5LcfPnJzNYHli3T vq4Db+R+METW7VIiq2MYqFGAnOCN7oo0Q9uANAFMDhHKZB0V/idUnmeVBc9RJg/o68rO+GbmJi+1 bC22XCN1CDHf//WDf/lZlzArYu5dqM8q67qJ7RYKOKpeiiqUibrSpKVryvhFxyhhksM8ctnEf0cz w66L7HtyJCIyQXaYTypxPWazE45F5BoLTfaf1OSdvkYmtIWYgXMfOm8j6RL5HOVRe7mWXS142mev SWQjfag5ynwWlEJ5mc9RDo05at4w2nyIzK7exL+FiSH73q2pcTIeS2ZSy+UHfHmTYfRVdT23Lpys Pj3ATp8gs8Z1u8Pm0mAipTCO5die9svcYqi+roPEo4zvS10VP92c2DW94FFGM9f+srepbxJ5OnbU 2O+G5shCcpXCAnbAcgSNOQ6XfchWCdzKuioFbx+pMP8v+zKDxOQ1S22TK4Afpwsr7XdJs7Dv20HW BAQAATQ1dNq4oeKMV5I60eoY1CggHMZtKUkqtrFdOQ9WONVZx3v8uJ8ia8Zlbj01wHdqUHmeXRb+ Mh9xKhdsauybxBbKbavK2JK+I0+XUdLScxNrYUH8YfN0/mhuXsWRuqpDe/S/4vTxmKsxK1GTWdbp 9kkaccrdpv9lGvdKH0YZpgyKUA4xQ+fqdOT89BQDux2GTNP7P9238WB3+KoXMm3KuG01upSMwh2Z OuPJHm5OEk52RlL4qhdBf09D6urNObn5lUcqtVwChFUvCvXbdNyiv8xF85ZNWu2+Tu8PQgKirHrB Z0EplEmwioU4lo9QZp3Kukxz32V2pVvJ84cNR97r9bbTJW/Ix83JBHSduW/EfbbBkLBOrc9SJ2TX nb0S+T5fpFDGevoH+zu7k8iKIklJRdx9CTGefzSLu5Y0f8nvd4MFdHUNeWYjRf3nyqKK2oo3K8nK J2xAwPIEjXvs7xg3JKXnaxM37BbaOHnc+k34EATusQ7tOUuedEm7MLGby5gsYa/nAoCv+621LyRo C/kBrhKz0x+ljkGNAsLxd5U89/+wL1+xlafohJNMK2V3q4nYhQQqz7NNnEIZAAAAAAAAAJ4tQCgD AAAAAAAAAAUQygAAAAAAAABAAYQyAAAAAAAAAFAAoQwAAAAAAAAAFEAoAwAAAAAAAAAFEMrA0w8a 7aktNNZUl5Z/OMD4ZN/li/ICAAAAAAAsDBDKwNMPCgxfHQ3OzYxYq8x9P0rf+ZW/AQAAAAAAFkOc Qjl8F1BpFwx8/DXFet0Cir0kHgbE+IbviFuHRENMZ4i56b0j224nTuKLhQZibg7/tER5XXYgjyXz FxvY7Qk5xPtekJOSpOP3RsEH38gk25tzyCuJvPLIQDfOGNf+kt/RcNrXc9KoTtNr1WkVf+E285ub umKteLOypsJYYXWT/WnZrfYdo8J9HTnzVrNUwYI37dVvd/u5/Stk3wEAAAAAABbFwwvlKBoIs5RC edpjKVxX0zM+N3G5WV/S5eMPRyKkZ/aqZXuasNHxfIT6WxLKu/1kSx4hlgUz67FkvXZY2Ch1hRH0 2fYkp2xKbOwTniFk953stp2ZZ/UgcvA3v3ylxsE/LM1bSUJjzgZtwroXWaGMfJ+UbannNkbydZk0 ZOvHoL/rYAEJGevjA3u6fkTsVvtusus4h0wohzz2E4d2m879iCW7/DsAAAAAAMBieVqEsogYNZWY 6YlG0GVexW2yDVAZtZcXtn75cUVK6yA/YCAvZzTd27C23D5GDqq0WjW7vTlmvkoydbnVYDpje3sN EcqhMfv+tfW9vBCfcNa+UuecGHc1FnIXBl2NqsavvZI7eZbp/2tT46GdG3QVx8zvOobG7j/AZ92y 1Zr7Ru+L3xdaEwAAAAAAAGQ8YqH8UlHt4Tdz8rWqV0o7PKx8Ivukl6eqswu1WzL5IXvGbTOlq7N3 6tNSi0+TMXfZhYkb9rLbqWPdU7ymsWfQuj894aU1Kfq9VncoOOpq28sGtSm14mN2aF5MD/clMOY8 YSTTQgpyUta8sLXNHUJB/8X2Yk2q3pCu0lTahqZC7o6yDNVza9T6gx1uho2FaHvEfGfhTksxHHXc ZEU0DjP5tzXVRn1uesKGXdarwhwDFv6pgKTz5TcP/a7IUKBVvWq0eiT351NLwGFaXedkrnUYCtvd U+wh+X0nQnnNW11+9mDj321V68rO+HDZxK4kU17r3uy2wUlXIyeU/V1714pPVegHi664Y2TSZ9u3 23aD9Sjv2/3hX8xh7mSM4FFmLrcbCyqO1ZAX+G59I32Hl/n+//bexiuq62r8/1PyXUl+Xcmz0m9s TFayTJRllorOEiKzZMIwS2ZweNOGF+1gbECtYBOxEfwasS32KbR9xjRgg6bBtjyNk0SSopEmGKE6 xpEgGRQiChNkYIbLb5+3+36HQUmiZn8WazFz59xzz9ln7332OffcexAEQRAEuQO+5UD5Ye+hcxDm Ri/781IbeuIz05HOX60oONIP8TG5Ze/MbQ5Nj7SXP1FzKgoBUDzSF7oKPyknShM9v8t6sSk4xQJl CIpUM8rStX9/cD4C50lX28szKgPDqvJoCyZdC1S6ttHJSGmo+4NeyBmu375lwfbA6LRqRlm+ysip 3c7C5kskYh77157lxS1fRmmeKe5D3XBFsmZ3uTy9SlEFyo/k/J6E+yTaczX00uHBPYw03lH9VEVg dGYi2Jib5f+CBqoq8WqWXsDB4f7mkucqT4xIiZREGjmx7YW9p8biMR4o07Ury16HI2TpxYnXVj+4 Ck6RImf/UJxXTtYoN/69sVK1OpmhXaOMIAiCIAgyryQfKKse2vN61i5+RsRAyTzMpwSgHTsdNKIl TAcb1zj8lyd7m17M2tb86ZC8olQ5EUIqCDcL/aFxk0AZAuvQB/4D+xuOvHf0tQxtTKYOzqRbXftS WXROvo1dfv/N+rpDRzpbd7P42Bgoj3dUPUFjaIIcIKryVJeQoQqUaTkBdRnuXca6arMKW/thdBDt qltS0BomUpTbnTzMt7ayVTOdf+tM3TJv04Vr1oHyaFdt3svtJCc5UCY3Ft7yLUux57kc7prf1mZn aE4hq5P/2PPl6SMNBxqOnBnkqoKBMoIgCIIg3yLfzRplOXzUphcJpMj543Wl6bYNdW10hlgThrJT bhgDZYk8/rX9WOhGJNRWZVtkGShPBf2e3PruUfJ5ZirctjW94p1Q5EaorXr1gxaBsqYAZoXXJKDw I/ddoDz5Wf0yN19xAeOHBT76KgleNSncWrRIfnpPri8I+eVlJf/T+rqFkgy1lZC1Ll4YXOXZl/xo wSp3rfJCDcL0+ab0MtoiDPqyi7++e8Czqz08Gm7flXvg33Si/pvLp3uGWcyMIAiCIAgy33zHgbLZ jLIIdKRI96Gc7LquUU0YajmjrF7VaiyP/CE+EqhKJSsBaG4z4eMvOXiB5fgYZ5StIW20YNU65U7C Mu0Sl/FgY6GTvxJOVd+p3iZHSspi3ejFBNWMsoLU3+xJVa1soS+76D3zxiomWGiv1ANn1eteEARB EARBvgW+40DZbI3y1JenTn9FUklDgcpMEofBieo1yk5/aFrOQb60NN65J6Wkja07DlTazAPlW2fq lpe2fMkeQQNunNrtLGsbICeNBrY9ZhEoW65RFpX9oQTKZHH5igOfTfKvsaE238KdHeOqqpHVxvzp PXV9YXyy8+kHfjKHQHny3B9e/StVjBvd9V4RfAO3Lvmr9nWNQvSct6X9OlGc9pfXN/fjRDKCIAiC IN8y33GgDIGV/q0XUuT8saocm92jvAcDTjR/6wXkMB05sz89JX1tyV/6pwYCNQXrfNXVlZU/y37e LFAeHWnf+og8Ibqpmbz1InxiT46n/LXqbTs2uR5l8fFIV61zaUZW2ZFgWJTT4q0XorI/kEBZ6j9a kFnTeYN/JQeaPc/WdUX7VVUbDzZ66SvhtPWdCvrdKXMIlEExDm9NX2l3KTuYECAQ37HpGFnOTDSn srB825aCSqoSCIIgCIIg3y5JBsrfLcYwFEEQBEEQBEG+WzBQRhAEQRAEQRATMFBGEARBEARBEBPu ykAZQRAEQRAEQb5vMFBGEARBEARBEBMwUEYQBEEQBEEQEzBQRhAEQRAEQRATMFBGEARBEARBEBPu 5UA5+ZdjSJGBvq/xLRoIgiAIgiBI8nxbgXK8+0DKS21D/Nu3Q9KB8nTI73xmV8fYNP+OIAiCIAiC ILPxbQXKytbE3x74umUEQRAEQRDkWyPJQPnKUW/qT3duL3TlrF3p3vPu3/6nPNftsi0tOByckGZm 4pGew6W29HXrM22O1wPhaDzYvMm+5EcLVq3b1ByMR4fONNFf7UttFa3BCM+SI8WGTjcVZ6x2udem ZGxpvTABxyACfqygatfGdbn2lCdLW0K3LJNBoNzfWpja0BunmcV7GlLLjoZvBFsr19qy813pq4sP 90TiIqSWJoJvb7GvWefNXm3z+XtuQtERBEEQBEEQxJTkA+UU96HuiCSNd1Q/nrKzPRydkb7wOxz1 3eMzYyerlm9rH4pBODt1ocn5YlNwSlLNKMeGujr/A9HqTPx6+ysLKwKjNEcZaaj7g14Ss0rX27cs 2B4YnSZx7cPeQ+fgYPSyPy+1oQdONk8G4e9UqMWd1xQkkfN0sDHD3dx/vb38iZpTURrB94WuxiQR KF9r9zlqOsn1pUj/xatRen0EQRAEQRAEMSH5QNle10Umg1URMDs4OhrY/vTuTh51Sn0tOUX+UFS9 9EKKXHrff3BfQ2tna7XJegxp7PL7b9bXHTrS2bp7QfHRwZiIa+G32GBr8UL20TLZZH9zidP/BY2q N3iaQ9JUb9OLWduaPx2CEJnBU44HGwvSK5u7hzBERhAEQRAEQWbhzgPlGxDLPmL37a2treN/vw9c UQXK0pXjJa7KY8FI5OLxnRk/goPxYMumgnxvXr63siU4Fm7bml7xTihyI9RWvfpBq0B5KkEyPpEc D7V4ylr6J8k1I+eP15Wm2zbUtZ2PQLQsZyiNBtv2l6atKaw9HiST3AiCIAiCIAhizp0HypFoV12K r32EHFFQkg21lTzBol7TJ/zCx19ysJzh5zrLGeWEyabPN2W8/O7nraUZjUHVmy2kSPehnOy6rlFV hhTpZs+hgtTaM7f4dwRBEARBEATRMw+B8sytf9e/UOy/RMJOKXLuL3/8eEhSJRvvrFm85fg1iFLj o4Edj+sD5RundjvL2gbI4uPRwLbHrALlxMkmgo15GfZ0e+N5EidPfXnq9FfksDQUqMysDAyLlLf6 Tn0aJusxSEmeMqyWRhAEQRAEQRCZ+QiUZ6SJYOu2zLS16z2OzJL6kwMkSI2crktbYbe/fKR/LBzY 63b5dldt/8XmrB/rA2UpFj6xJ8dT/lr1th2bXI9aBcqJk0mT3fUrHnCxR/qkyPljVTk2uyfPnpZV c4JExjzlaPDYrqyVmXni7Rzk+giCIAiCIAhiRpKB8t2OFG4tfEGz7gJBEARBEARB7oT7I1CODbVt sdG3yCEIgiAIgiDIvHAfBMrh9p2u1Zl7TpIXOSMIgiAIgiDI/HCfLL1AEARBEARBkPkFA2UEQRAE QRAEMQEDZQRBEARBEAQxAQNlBEEQBEEQBDEhqUD5nfU5+Id/+Id/+Id/+Id/+Id/980fD3MTgjPK CIIgCIIgCGICBsoIgiAIgiAIYgIGygiCIAiCIAhiAgbKCIIgCIIgCGICBsoIgiAIgiAIYgIGygiC IAiCIAhiAgbKCIIgCIIgCGICBsoIgiAIgiAIYkLygbIUG/y44SXbUrvDtji7+tj5iDQzM9iav6C2 KzYjRcJ9w1GeUIcUGej7Osa/zIbIUMF45A6Z+qK1JGN1dklD143IQP9wDKpxh8QN+cQGW4sX6ktt TGZELeSsbUd6iJDJ4Zu9za+sTkm3p2RsaRYHTZlfcUnXApUZRa1figtKt7r2rXA0BacS1wJBrIiP BHY+V9galjXo1pm6Zd6mC+P8K4LMAVQn5HbB3g1JmqQD5YmzDQ7vwe4boERS5N8HHe767lERlkVD /rxFO0+O8aQapkN+5zO7Osam+ffEfPuBcry3IdXhvwzVmL7ofzG9quP6TLy7frHv+FCcp5grJvmY BcpysgRIV9u35FafGIATpbF/7VlW4A/B8EO61X0wo/BIPwTZsUsthV4ieSvmW1xSuLVo+b6uW9R3 SF8eLXTVdVlfHUFmRaNFU+HWTam1Z27RLwgyZ1CdkNsFezckSZIMlGNDbVtUDkia6Pv0dH9Emu+w 7DsIlGNdtQu9rYP8GyXWVbeg+OjgHV9Dycd0RjkZpNjNm9/wAW2kq9ae33plZmasq9ZdGRimB6dH AzuW1p6xmL2ff3HNzIx21WZlNfZOzcRHOl5boZ68QZDbQZm5kUY+rF626Wh4iv+CIHMG1Qm5bbB3 Q5IiyUD5WrvPUdNpGGzxsEyOC68c9ab+dOf2QlfO2sXPFzVfJB5LDt34+gG7156WVXMiHJNiQ6eb ijNWu9xrUzK2tF6YUCeWgSOPFVTt2rgu1770+c3+nptEk6WbPX7falt2nsiKxaaPb9zxywK3157y dGFziNxAiUd6Dpfa0tetz7Q5Xg+EozMjHbWZS360YNW6Tc3BOJTWXnf6TEtZZsqDC22uipbgrYng 21vsa9Z5s1fbfPxahFi4dVNG43kyKz59vil9GQ9bRwOVi/ecGv/SkE/ErDD0cl0RdY1SnixtCVlN f4x07HRWdYzMSH0tOUV0apkghfxZOc1XRMkosaHOA+4U27qc3C2vbbETARpkK/UfLfA09LJr3ept 8BS2fnnLvLJ6yLB70c7A1c+bHFlkwG0i/EiwtXKtLTvflb66+HBP5Hbn5pEfCGTyJmNbIHSh0buC DL8NdgpD8eSUE0EM6jQjRT73M++30r0nQG7QzUxcaC3PWu3KXWfLKPV/nmj1GvJDIoneDX0RkmSg HO+uf7bEZM7VJFBOcR/qBjdE4rnlDb0QMvE0ZNyfWkDXD8xEr17sJ2mGuj/oJWonXW/fsmB7YHTa PFB+2HvoHCSTJnp+l+X0h6anxzpeTd3yjyGisOPBxkInGRGSMjyS83sSpUlf+B0uEhSOnaxavq19 iATpUxeanC+SWQfVjLKIXJWZYGU8IEX6L15V5m2ng40ZBWS4CXa1ISUlnczpStGuuqUVgVGTfMwK ow6UeY2il/15qQ09ZnFldOjMfxe5/7tnQtJPeBtFpFQzGm7fuZT+apDtRH9zsRLrv1Dc0t9vVVkD kZ6GPLvLQWVuJvyR9vInak5F4VA80he6SpoYQRJAbTkj28X01sROryatnAiiVaeZ6x07XS+308nB qd6mFwubLoyNtG99ancnUSNptO/iNbX7RH7YzNa7WUcFyA+H5AJlq8UJPGhTB8o0FlR+kj+MdOx0 iPUDAmns8vtv1tcdOtLZupvlb4wC1UfIbG6BPzQQqHDK09vSlWY3WXMslwFgxRgdDWx/mjlHQMzL JgyUwTYK0iubu4cMxjD5Wf3KnYHR2Ej7zg1vvlWb0xScngg2FpW2fSVZBMrawoBMxAelRupkKkY6 6gq861amlR6mz+3NEihL4x3VT+/s4E+vyL8aZCv1N3teJIuzYQzjdDf3S9aVNUCi7UedDb1wkWET 4U9Cb5S1rfnTIQyRkSSRrraXP5/ecG6KrCYy2ulI8sqJICp1ojf6nmTjdmDqSnNxlv/iJAzA0ra3 dGOIjOiZpXebS0eJ3K8kFyiT3itH3LhXwcOyZAJl1U+cqXDb1vSKd0KRG6G26tUPJhEo8/x7j3qX rPXtrqut5X+/DlyZNsamN+DII3bfXjlZ7e8DVxIHylDT0WDb/tK0NYW1x4OaJQQQ6OfWdfV17Cxt Cl4JVGzyhy4eLdhIV0QY87mzQJlBnsnNIQ//zbL0QpsJz9xMtnwiOdLfXJbbHCIZWFbWgFI1qIVR +DDUPn+8rjTdtqGujb4OBUFmQV6CTxTYaKdzUE4EUdSJ+sCH7eWvy+pU95tA//RMPHLh+L5i++qC uuMXRtFFIQqz9W7oi5Ak1yhPBBs9fLxOEM+c8bBMjtXkoFAV4PIPxhnl8PGXHDyxrKnyWTLqI2QZ Q6E/NNxV6ypvv0YPyZjEptGuuhRf+wj9WWaWQJkh3ew5VKB9enp6NFC19neHf+P+XW88NtS24+U/ /7HS3hgkSxmM+ZgURvmg1Egb4+qRf038MJ/pjLKZbEkjFpW+2/lucVFTkCwI55hU1oCSCRTGKHyO FOk+lJONDw4jSSBHNmQJk9FOOckoJ4KoA+XombrFr7SPmAY08ci537vlFx0gCJBc74a+6IdMkoHy DHmgOK3kD2wle+zL4+XZ2wLXxFsvkgmUjWuUb5za7SxrG4Dv0mhg22NUU5UgUgBH1GuUyfrFafK6 NM/hS/xxvXf+1HFVMo1Nb/27/oVi/yWi2FLk3F/++PEQWfGbIFC+1XfqU7p+Pw7x6FNk/bECWfX/ xE8W0ZCUrF5YsHAFD1iN+dxuoCxdC1RvUwnZRV8nN8vr4aSRE9v0a5TNZEtXWttfsGdksPg+UWX1 KFWjhdEJf+rLU6e/IheQhgKVmfoFNghigiqyMbHTuSgngqjVaWa0+0Burj9IpnUguDnS/NHQ1FRf 12nykCj1h0/Q52EQhJG4d5tTR4ncpyQbKBO9ufBOTc4KzV4YPOZLJlAmPou99SLPtcZR9U/QvFj4 xJ4cT/lr1dt2bHI9SjVVCSIFcMT41gvymoWdjpWZeeuzHIUHTxIPaBqbShPB1m2ZaWvXexyZJfUn yePPJoHyzEhXrXNpRlZZy7/PH9uVRbKVn75XQeazV/AokKyWTiWvpCAY8jkSDN9eoAxCDv3vgYJV S+2utSmrCg98SO1TFl26PcVm9sh2NBx43bFY+9YLo2yByc/qlz2+hj3SJ40GE1RWh+JKAL3wpcj5 Y1U5NrtH9aQwgiRGHdkY7HROyokgGnUi77g4WplNPFJmVhHxoqTzqnYQBVPeg4EgjIS929w6SuQ+ JflAGbn3IS+JK9Csu0AQBEEQBEEswED5B4Q01Fa6kr6zD0EQBEEQBJkNDJR/IMSH2l912Fy7Tl7F hREIgiAIgiDJgIEygiAIgiAIgpiAgTKCIAiCIAiCmICBMoIgCIIgCIKYgIEygiAIgiAIgpiAgTKC IAiCIAiCmHAngfKtUOvLq21Z3oZ/y+/gliLhvmGLN3JLkYG+r7Vveo9HBvqHZ9+fIslkiTHu7nGP wjYuGY2E/labk7ba5VT2f0EQBEEQBEHmjzsIlOM9Dcvz/CF1WBwN+fMW7Tw5xr9qmA75nc/s6hib nol31y/2HR+Kz0xf9L+YTndpNiHefSDlpbYh+JQwWdJ8D4GyUoXZSD6lCJRvDHW8/c6FUQiPpbF/ 7Vm2saV/kv+OIAiCIAiCzAd3EChrNn6cC8mdqNprel74HgLl5Kswl8rKe2ILpL6WnJyG3lv8K4Ig CIIgCDIfJBsoS5HP/cUZq11usVf+UMfenJQHF9pcFS3KlshyMEo+PL5xxy8L3F57ytOFzaEpaWaw NX9BbVc02FKWKU4MipgvOnSmqdSWvm69famtojUYiQebN9mX/GjBqnWbmoNxOTSMR3oO02SqXdch 28cKqnZtXJdrT3mytCWkjRela537vEtXOt055btfsbNA2VAXAC6R+tOd2wtdOeTgu3/7n/Jct8u2 tOBwcEIyu65ZBck28ZVrbdn5rvTVxYfPnjmsrUJqyd7d+U9k1HePJKysafFmpKGP9uWk2lw57vKq iow1qkA5Hun+jdNz+BIpAIIgCIIgCDJvJBkoj5za7SxsvkSizLF/7Vle3PJl1GxiWBMoP5Lz+54I xH1f+B0uMt/JAmVIrpwoR8Cxoa7O/0Dimfj19lcWVgRGSSp5klUki/yrZllpy5cQl8fHOl9P9TT3 T9NA+WHvoXM3pZnoZX9eakOPaofm6bGOV1O3/GMIYsjYlfbKVbRs1zt2ul5uD5O4cqq36cXCpgvj 9BIp7kPdEUka76h+PGVnO0TDpOSO+u5xs+uaVXCkvfyJmlNRGlj3ha7GJG0VFq2u+meYrLROXFnT 4skHpVj4H9tS0kSgDBH8n4ocu/mYAUEQBEEQBJk/kguUxzuqntgeGIWwFJgINuZm+b+AMDBxoMym b5UwN1GgPCNFLr3vP7ivobWztZqFjIZAeQxC2KdoWEmYPt+UXkBWSMvZai7KGOnY6azqGKGfxa+j gconWTgLTF1pLiZ1UZUkueuOm1SQxLVZ25o/HRLPHZrE+pRElTUtHsj/yeqOcXZQldWtM3XLWQSP IAiCIAiCzDPJBcpKMAqIiHMeA2XpyvESV+WxYCRy8fjOjB/pYkee7IYqT/mgKluTQFkVU8q/QvqH 7eWv19bVsr+63wT6p1Upk7uu+qByrhQ5f7yuNN22oa7tfESyCJQTV9a0eBr5q7KCqPqJHYFR1Rw6 giAIgiAIMk/cHTPKQ20lT/DUcshoiDLnaUY5eqZu8SvtI7rgUok+k7uu2YyyQIp0H8rJrusaNQ+U E1fWtHhWM8oz0au9QXkCG0EQBEEQBJlHvsU1ynMIlMc7axZvOX4NjsRHAzse18WOcjKrNcqWgXJ8 JFBlWKM82n0gN9cfnILfpZs9R5o/GlKVJNnrmlVw6stTp78iR6ShQGVmZWDYPFCepbJmxZOuBSqz zdcoX/niClnujCAIgiAIgswzSQbKZq9iuO1AeWakq9a5NCOr7MiJt3n4GA0H9rpdvt1V23+xOevH LGSMnK5LW2G3v3yk/wsRZVq89cIyUIZjA4EaV4r2rRczExeOVmbb7J68zKyiAx/SB+wSBsom1zWp oBQ5f6wqh2RrT8uqOUGyNakCkLiyk2bFg/j4xJ7MZfq3XpA3TC9y+i+yqX4EQRAEQRBkHkk2UEYQ BEEQBEGQHxQYKCMIgiAIgiCICRgoIwiCIAiCIIgJGCgjCIIgCIIgiAkYKCMIgiAIgiCICRgoIwiC IAiCIIgJGCgjCIIgCIIgiAlJBcrvrM/BP/zDP/zDP/zDP/zDP/y7b/54mJsQnFFGEARBEARBEBMw UEYQBEEQBEEQEzBQRhAEQRAEQRATMFBGEARBEARBEBMwUEYQBEEQBEEQEzBQRhAEQRAEQRATMFBG EARBEARBEBMwUEYQBEEQBEEQE5IMlK8c9drruiL82+0x2Jq/oLYrxr/dJreRiRQZ6Pva4oz5qNf9 DQj8wSVr1+fle7Nti117AgOxmdhga/FC0QhS5Pyx3blLU9LtKSvcu98JRuL0MAj2uazG3in6ZWYm 0lVrz2+9MkPP/dFie54XMoS/krqOIdUlyF9hbceIOpnLlpL5eiAc5TlxNGUAYl21C72tg6b567HM XAr5sx54vgquzzCpO0efktT3mRS7h6ZcU1r/YTgmieOygkmx8If1BauW2h22xVnbjvRESBJI8JMf FbSGWXLCjVO7Vz2kV3Kr+qoLKUvPlOhg5+9Knl+2NhuqvOvYhVFJr/xyGzGil/25Dz1W3THOSmYh NLj6AwsLW/uV4o931jzzkLqoBhJWOVllEAIZ6agroA204DEq/4LNzUGmggTITS3JWFfdguKjg/Bd bi96oYL9HSPKSSqk2ODHDS/ZaJNlVx87T5sMDo8Gj9W4U5bZM5YtzamhwgTkPL3rVi5z1JygOmC8 UNRSkg96mi6Mk8+AXFRNFYyNaK0YsYGTBzYsS7F77cuWFbzRHhpT5H1H6K/IiYU7G0qXpWS4oO5V zA/ICqYIIQ8KU3y4R/OrbBeutSmrCt/43xD3IQJZArrW5JiKnWGiw9qSq1SL/DF3MVt5OMaWjZMS WpqD6lpKu8tCYGhtUPrC73js8Z0dQifMCqbIJBo+ebAQdCPXvvT5DQfav+C6yrHSE1MJ6DBNYyZ2 XQPNYm7GAlsVEj59O8oMBWbeBlrEVnbwpOLhDcqjSqztDgx9gYq5CUSLcjnyJ3vChx4sORqWc5TG O/csemCV1sq0LZKUO2WZJe/W1JgmMNMZK2lbSgkw93jW2qjrf+eN+ylQHj97wFXSFubfBNMhv/OZ XR1j0/y7hvmo1/2NSuDS2L/2LN90NHxLcWfSUEeVq7DpLHHK0s2eppL0qg9HiIqCYH/y0JM7A9z+ NYGytq8ybVN1svhY5+sr3M2qzgfQ56P2+/r89egzTy1kQVss3LopdeWKpbVnuOfQ1X3Zxpb+SfqD IaVakYgcyrJqPhJy4MelsdP7Xig6dO4mvdSXx8uztwWu0Wj1Jw897Ds+JIocPVO36KG5BcqWFiEj TfT8Lsvxm27S5ccj3b/JSj/YfevLhJ10/9ECm22lo65rjH63aBG4+gP/55HitiHeOlK0q+65B/5P wiZIWOVklUEnEJX81ehy03RUSRj+xNkGh/dg9w2onBT590GHu757FMow0rE7veBPNNqLR3r+VJi2 m/Zzqjyl66dqsotavzSMRoAEknzo6coTVG1URVWqYNqIUxaKERtqK3+O5xaP9AbeD91iCe4YvSpS Ij0NeVn1/6Z+4EZ3fe6aA/++pdRdLYSxswecqQ09cfmg9NXxYju1BTj3Zu/fOi5PMREIZAmY6Aag E3uWpznEz0+kwwyzusxaHo6xZVkjWpmDvt2p29FlorFBKdxauHyVLaWuK0qzMy2YkIk01Fa6iPtb KdL79/dDYpKCoa/p7TpMGZ3YqbbrGiihuZkV2LKQ35YyqwosRc7+odC7p3NYNJ1OebSJeVcIMjb2 BSrmIhA9unMJRD4PPfBMadtXvJAzY121aQ8pgfJsLUJQC1nlf5J1ayr74pgmMNMZK2lbSikpj0dR l0Hd/84b91OgrJsSS4b5qNf9jUbgo6d2O8rbB2RNnQ42rkk71Ct3JFPnGtIL/SE2U5Jit9tW1J6h Lu1OAmUIpDprntjazmNuhj6f2/f7SubX2n15DR++Xb6yoZddyqTu1+hnQ0qdIhE5FNOoWj4+2d+8 UUhDDSRYlLI4Vfg+abK7ftXiJc8lFohS3+TMinSxOXVdEOQxvunr+rQ/0qdVfq35jLSXrzz44d8q bCSmASyEBld/GMq/RUS9EQiDUhY/lbAJElY5WWUg87Kqq2jlL6PLbW6BMnTPW1KVJpMm+j493R+R ps83pec09Ippvpnx3gaP039xWpOnBMV8ytc+YnIha0k+alubnsWbyRgomzeiTg6yYtyGM0wSvSoC JOhZvq/rlvADE192nf4yokSBGiGIEoqDSqNYIEvARDcAU7FTEuswwaQus5eHY2xZWkJLczBt9wQ2 GB9ph5K3/w1cTS/VQdOCCZkoDsEcfU1v32FyzMSua6CE5mZWYKtCfmvKrCmwNNV7aI08I6NXHl1i uTsw9gUq5iIQPbpzCUQ+jyxekiKPxCY/q09dkrIojWaVRIsQtEKW/c/c3Joa0wRmOmMlbSspJefx KFp5Kv3vvHG7gXLsWlfj5tW27Dz7itXlbwcnoLqQJvWnO7cXunLWLn6+qPkiHdHGhjoPuFNs63Jy t7y2xc7EAXJ5rKBq18Z1uZk2x55332vakpOzbuWqQn/vxIwUGzrdVJyx2uVem5KxpfXCBORB0m+o 3Vf41LMHzl6RZTrR37o1q+qfYo59Iti8de3ixxaudJF7ryanmOUs12viQmt51mpX7jpbRqn/c+1N qx82GiXWBcpgDKV0ckjmVm+Dm3o0Itjav7duW1RGh913HCgv2Hx8SO2H9Pncvt+XPcVooPKJ6o7I pRZ3XlOQaoe+7nZ+v8KYUm8g8s0N+Tj4U0dNp2zzMpAg45cHqldx3wc9q6f0wK/yEgtEqa+p9AyA 03+i5hSbl1LQlVndG02PBrY/tbMj0t/seaExSG7GWLQIuXpFfa2HR73EcZfW789L2AQJq5ysMnwH gbJFk0GeyzWdYry3IZW0hTpPucMwXiiBJGv+3r7zOXZ/Qy6qXAXzRrRSjOmxjl2L7HtPDprMc6mw 8rfMP9tTnixtYbN30rXOfd6lK53unPLdr9i17Qsh3dandncariTXXSOZ8Y7qpyoCo8rB6x0709fW vD9odbdUloD8QYNe7AtfaqOrB2bTYYLxCDBbeTjGlmUltDIHQ7vPEigPByocVR1X+5uLMxrP0/uh ZgWTZTJ2suoZ556TX+nFw7HSE1MJ6DBNoxf7XANlswJbFTJJZZ47ugLHu+sX+2hHY1QeXWIRKJv0 BSrmJBAdunMJVD679telspEYnWIorn1jPcsqiRYhaIWs9j/JuTVhXzKmCcx0RlcYWdpWUkrO41F0 8jRfXHAn3G6gLF379wd0xZ50tb08ozIwTNOkuA91w0GyaocJHYxh+bZ20qjRcPvOpUwcIJeHvfQe 9EjHzhVLK/8BwS45BYLa+Iw01P1BL7k9LV1v37Jge2B0mqR/MKP6BF3RwmUaj3T/1lPIbhPIqLyM ySlmOfN6jSqOXhrtu3hN2wY/bIT0ALH8YFxoqnGgLysxE+xwf3MJvWV2J4Gy+vaQjD6f2/X7cuZy /z0RbMzN8n9BrmZSdxikmqXUG4h8CXE83tOwvJS6SB00wQf/qHm2nPg+0rNuOf5Zc0KBEOYUKMe7 DyxhiTXoyqxuTTBMBzFqMs1QQG8RmAqNXf31Dzr2LCFRL3PcrZ/N0gQJq5ysMugEoquLQJfbnDoq 8OPPlhibTJG8DL+KKk/lFqTxQgkkWds1camlIIPcXjcEyhaNaK0Y0miwdcfqh9PKG9+/rPGTGsz9 LffP0cv+PDoShkjl1dQt/yADm9iV9spV2vaFbsmp9QMMue7yByk23P1meSG95apIRoqcP1q55pGV Wxrfv2QySSE3ovxBg6nYgcQ6zDAeIcxSHo6xZVkJrczBtN11mahscLyj6gnSHOSuncN/mRbDpGCK TOKRC63bbE/ZfL9/32QJr5WemEtAi2kaM7HrGmgWczMW2KqQcImklHnO6DVKLqdReTSJRXcQNesL VMxNIFr0ZQOYfNo7dmfRkRidYmj7uJVnlUSLENRCVvzPHN2aGtMEZjqjL4w40UJKSXo8ik6epmnu iNteehGPhD7wH9jfcOS9o69lUNtWpeE1JyHF0/KzCLI4FLloQ1t2UBq7/P6b9XWHjnS27tZ2FSLZ 3s7+f2xzVLfLi9A5ZrmpPxtzFmWeutDkTNve0o0hsgGQHn8awLN2pVv7MJ86tGLIPwlluHWmbpm3 6cI1kZIksFzjTw+aPHBg33k0qNY9QJdPXp59yY+E3zes9NehSrM+0+ZgTzOMddVm0adwyLLCJexR M6Vg2eTxO34XwiylpaGK47KLjAdbNhXQsrHHzliCK6d2O8vbr0LPmgpuK6zSXo5VfdWFJH+mD/OZ OEECXFr1QAm07+JneGtGz9Q9W0ofGZErqyqAukWYcY121jz7SvvIKIzjPc3B8CxOKmGVk1UGWcLq PHVKos8tf7095UHZ8FV1N32YRunVNCTsUXieefa0LP5Qi/FC2of5dJKMSbe69q1wNAXBcLTez6IR dXLQJZNiQ58drcldmlnbwRcDGEjkb+XMIW5wiseV9FfUDrHUyI2iEoJr1VP2us5hOFv+lREd6m7d k7PKsedDscBXIJdHKZgaOXPyLNHaylZ6e9NSh7UlJ0dUZqV2F9bl4RhbVsyNmZuD6lqK29Fmotig yrcoFWFoC6aTSewa/OhOce3puKotta6mt+swlTRKyRVth8LM1dw0BSYXuiNlnit6jYJyUp00UR6a mNdO7gpN+wIVtyEQGe25sidcWHtmtHPPEl/7yORn9cshWL9ktDKrFknQtybh1rT2pWCawExneIb8 NEXauuPC8SbweGbaqHYmekW6c24zUJbC75albT8WuhEJtVXZFlHbVqXhNdcWVxaHIhdjaDsVbtua XvFOKHIj1Fa9mmmVWo7w+dHMfM9zPy5pow81qEkcKJvlrJQZRrfH9xXbVxfUHecPeyIUtSQ5crPC h0RLL6hgQewvLyv5n9bXlUBZr8EJLiF9ebSQTrDBMSXErGwJRnT5CKMyy1+PWRpwOsvc/N7ZeEfV Avqomaw5rWXiURKLlHoDMchB6mvJ8aruzcllYAnGxjv3pFT89eMGt2oaYCLYXEnrCyF1z4B5fU2l p0e60uzW3laj6Mosmw+ZCVuRzm44krHuQjI9ZtYiAL/6jVO7XZX/+15DqvqGgxUJqpy0MugbUalL PNi8mfnQTc3BAW1uc5rRIU2Ww5eHqoESzn6PUsZ4MLEkSWsdL7GXtTbv1YatFo2ok4NZh0eetPOk HvjMbMleYn8rZ66uhf6KkMmV5g1aP8CQz1KfHh8JVKXuPDlmKq6Jsw2Z2fXdwyrNp+voWHmUgqnh +Ujh1iLxcNgsOkxTUIxHtPDyaAvJMSs/L6GpOZheS5eJbIORswey1vAVFzBKyRAL+gVywUxkQh6B ciyvP3vrwrfoMBNVn39L2txEgSf1F5qjMs8dXYHFfT8z5TFTP7O+YN78j0nLCvmMd9Ys3vHPj3+9 SnNTIokWIYhMjP4noVvT2JemLw6aJDDVGQtp648LKSXp8Si6usv977xxe4FyfKht81O8rLJtq9Lw mt/GjHL4+EsOnomsVWo5wucHM3Z92P1hlefldt34LXGgbJazoV6Rc793q59KQdSS5CiaavIwX5qH Og6VYKd6mxwpKYvZaCoJ+yHIySQy2f9iU1D/4Lk+nzv0+6QiC1atYw6OzOssI/fd5IJBFV4sZK/u Mk+pUyTNQ43s+HhvQ67bHxQXlcsgEpA7rctsy+kjCAllzphToGx4UGPy5o1xw6oA2Xwmgo05C1dm 0wrSWZDHtgdGJ0UBtC3Cr04s/amVq8jcsEk4oiNhlRPVXX1p3VV0dRHocptTR0Xk4ElvOCfeHiDF bt78Bq5s8tRLDo1pTPM0HjStjrqo5HjWs0tSHtZ6P/NG5IspxVHaEOResAazgIOR2N/KRU08o2zw A7Gxm99A/ybXXSsEnr+puFQ+XEYuj1IwNXI+48HGQmcjeyVlYh2WMamLFrPycMzKz0toag6m19Jl Ii5H2nqRzeVl5c+zL3lc36YipalMFD2X0V/9bgqU5ZSTd6bMc0dTYPp42Yv+0LSp8tAlSVpRW/QF Km5bIIBJy8oNAfaYZlu5ii5ykLNKokUIciZa/zO7W1PblxrTBGY6Yy5t8cyP/Bo+0i9QgZt7vCS0 Uel/543bC5TJ2/tS2JyuNBSotFFXokojJCKNnNhmukaZy0vlhvhBGIs7y9oGSMajgW2P6Ry3ac4y xtzo4QQ5izJP9XWdpgs5yE+skRCGWpIclaYmej2crDDxkcDOpx/4CW2aWe2Hob7EtUBlBn3Tlhp9 PtZ+X4oN9w9olrUZ05C1mCuUWYrYUJtvIfhrpWCkCvQpK4uU6vpavR5u6B8vLyv+Qw9ZDwrq21Xn WHKgW3lJFnl2Z8mPSM86m0AoiQLl2Nd9A7qllepX/0ixcNuW5VWBkcuqNgKE+ZC3tzqVWTTy6HFG VceQeYvIVwdn9+hPtKvTjJJnJKxy4rorl9YJRK1vKnS5JeqoosN9YZ3UpJEPq9NKeJMpb/RL4j1K CsaDptXRFpUcX/bQAzrvZ9qIcdCrLcsqjrN1aKSQWVvawxIo2MGaP3Jlu9Fd780mD7AbWySxv5WL SqeBLdcow8kqPwCuvq0ildyBkeuuFkJ8tOPVJWSKjh+Uxk4f3M7erDxD38G3Qd/DyeXRtSZHyZx0 Cuzp4Vl1mKPTIoJFeYzqYWxZVQlNzMHkWoZMuA2SJ3aW1Z+d5NcjLxVZUH1y8JRJwfgV42Nn/nvH H5n86Yu0nDQEUdBf/c4cJpCw+oxE5mZe4Lko83ygKrDywjJz5RkxqJ9VX6AieYEYnbb+coDcEGR4 /OMHi7QvVkqiRQiq1tT0rbO7NcW+NJgmMNMZU2mTL+F2aOi2L+kvxHusKKeuxtzjzfbWC03/a+LV b4/kA2XVkppNzcHoQKCmYJ2vurqy8mfZz9MYSFVWRSLRcOB1x2LDWy/4r8bQFsRxYk+Op/y16m07 Nrke1Tlu9bmxofZtqeVt4q0XwHTkzP70lPS1JX/RrPJMkDMv82jkwjvVjrS16+W1R4hALXyOxgas NxwRygBMBf3uFDlQNlm6ZL4Yi12CTrAt003z6+3Q2u8PBSqef4S8f0DGkIa8MjOzpvMG/0oONHue revqU9WdzItn1Z05a54y2i8MJNv2xIrCA6YbjsRBzWpyVtDdK9aU1h3XbsoAvq9qLbvZOpvMAetA GWKaHU89TN/joUa8TJ68ud2+4wh5fkvbRnInHW4tXLTnlDy+Jy+227CktrPPtEWUq0PUW0xvJshF NUqekbDKySqD7m2auroIdMJJ0FGNnKh84jnx+j8ZdZPJe8QowjS8md9YBjio8pxijXJCSdLjlw57 dDPK5LCxEQH6Tv6URTby5gpbScPH9K0IrOTPP7XSSXYB4DuAGFsksb9VST4GDt+VYv7WC4LwA2TD kbWVR3o1uq0SgrIsUvzKKrUYyu/U7OoiI5dH15octdjHg43eFbVnxq11WOV8+IIEvTsyLY+Jehhb Vv38vtEc9CZMURceYDYYCreWPre7Uwm5pFCL21F35opJwcQVmfxTnli1DiTMt2ZQo7/6XB3mbKtC KboG0pibXlYWBU5emecDKDDzNq5VT6VsqKdbYFg4wDNgt5raWfUa6rc0JBKIWnpmTlsuGxWa3hPC SMzOFofIWVm0SPJ96+xujduXdjmaaQIznTGTNkWi+zqlPrUym2xI9NLvOuXXm5h4PCttNOt/zb36 7ZBkoIwg9yjxsc5a13ytabsXIE9kZ/9ano76/rinJE+e1y6zWI163/CDs4V54wehHgxUku+Bu8Zp 31/Mn9lioIzc10jDp978K7tf+cMgPnLq7b+w25TfL/eU5KWR038+cm5ebtLdvfzgbGHe+EGoBwOV 5HvgrnHa9xfzaLYYKCMIgiAIgiCICRgoIwiCIAiCIIgJGCgjCIIgCIIgiAkYKCMIgiAIgiCICRgo IwiCIAiCIIgJGCgjCIIgCIIgiAkYKCPWkHeqp4utawkm71Rn6N6sTlC/2Jyg7JFhytQXrSUZq7NL GrrG+BFTZnmDOkMcGemoK4Bk2bYFj9G3kRdsbg7GTXKQkbMy5qmH7J71wPNUOPGRjv2FkJtr1UKe M9/LwCyH6GV/7kOPqXbsjA2cPLBhWYrda1+2rOCN9tCY+dtszJOJHTEy0pem5NbImzWom8OqEfvk 17/bUmxlB5XXv6uJhk8eLExZZMu22zLlHS4QBEHufSx6k4ceLDkalt0h2Yd40QOrxKYebGMLL9n6 pOYE39iCbOb32OO6bfk4pqeQqxh2zQCov31et6MQ8v2DgTKSgCR26WTccaAc721Idfgvg2OId9cv 9h0fsniRZxIXMhxRbx1kmoOMfKIxTx2xcOum1JUrltaeUfbb1eRskQMJW222lY46Ph4AkZY/R/b7 hc/xSG/g/ZB22yOOeTL1HstkU9ACV3UH3ftTU5JZN+jWbiiqgmy77f5tN3mpKtlm1pHa0IvvV0UQ 5P7Aojd56IFnStu+Es5wrKs27SElUBZdCdnMIpvt/0w281u+ypZiNoWkPyVLu7G5mvjYmf0Z7t9r d2xGh3tXgIEykojpYOOadLZVJjAcqLBXBobZFw0WHkftCxIHysqvyj6fZiRxIcORbyNQvtbuy2v4 8O3ylarYUZOzRQ4j7eUrD374twpbQw89T7WLeyJMk00EGz3pDefE1vvSVO+hNS/6Q9BY2jqaN6Im DT3X3dxv9PMyidsFQRDk3sKiN3lk8ZKU4jY65TAzM/lZfeqSlEVp+kB5Rop21jxF9vqOj7SDP2// G/QIvcZpDtNTzHoHslG5s65rlH9F7iYwUEYSAm5iWZ4/RKdNxzuqFviOD8ViQ6ebijNWk+34M7a0 XpiAnyw8jtoXKKGwdLPH71tty86zp2WxW1EjHbWZS360YNW6n272bcxMeXChzVXREiQZ60niQoYj 30KgPBqofKK6I3KpxZ3XJJdTk7NpDtOjge1P7eyI9Dd7XmCR6/RYx65F9r0n5d3tzTFNBvVya1xz vKdheSmJZXV1NGtEfZrEE/nQaENtpYtNp0wQBEHuQax6k13761K3ECc5I012168qrn1jPetBTKPe 4UCFo6rjan9zcUbjeT4doaA/ZeFLbUOmvcNIe/kTNafQwd6VYKCMJGasqzarsLVfoi4jtaA1DJ+G uj+gy6ek6+1bFmwPjE5behzVMREoQ8z3auqWf9Dx+niwsdDZ2Dul/Eo+3fUzytJ4R/VTFYFRMqeb m+X/gvs2Tc6mOYx07HSQ2dzp803pBTxylUaDrTtWP5xW3vj+5QQ7xxqTmQhK1FRfR5NGNKTRSklP pKchj7UUgiDI/YBlb9LesTuLrr6InD3gKW37uJX7RpWTlNdRjHdUPUE6QXLjjq0e1GB2ilnvQBYf Wt9xRb5fMFBGEmMWFEpjl99/s77u0JHO1t0sVrPwOKrnFfLy7Et+RBwBjL+dNZ38BpN0pdlNncsc AuXkH+bjXw2B8p0+zKfEndGuuiUs7gQ0QjDLIXqm7tlS+piInANDig19drQmd2lmbQeZxrBCm2wO gbJZI+rTJAiUpYkLf/S8sL9rzDqORxAEubew7E3OjHbuWeJrH5n8rH75xpb+S8I3gpNkT+ZBd8Zv hypdgOLe1cinkIf51la2BicgKbmK7mE+uQeMB5s38+OV5rdVke8cDJSR2eDLDIJ+Ry5dZjAVbtua XvFOKHIj1Fa9+kFVoBwNtmwqEBauf+2DcATgOJas9e2uq63lf78OXJmeS6BsFpFrQ1LdEW0IaJKD jHyiMU8VZCWDm6+4kFcyAJqcjTmQ2dwVfK0wiVwXysvgOJGeBk+q8tSdFXIyqFdySy8AfSMa5MDP jQSbK2kL0jeE0F+ksdP70l37ztAnCREEQe4PEvQm4501i3f88+NfryJPbsg9iLYrIUTOHshaw1dc jHTszCDz0HF1Pxhkp0jh1qJFO8XDeSb9C5kzUp4kAYzXQr43MFBGZuVau89V2/r7Qv7Sg/Dxlxzc gOWgNoHH4V/lUHisq9ZV3n6NHxXcQ4EyucW2YNU6Puj3rF28jD/gqMnZmMNEsDFn4cpselZe/np7 ymN01YoKRQgJEclMHuZLZ67WpI66RtSlUT0IqCP25fHydHdjD85sIAhyX5GoN4GoN822chVdKWEd KJNFdItsLi/z6nn2JY+TG3dq5FOUdYZmvcPMzNS5hvQN/pDsaDFQvovAQBmZlVi4tWzJ4udS+KvQ bpza7SxrG5AgvBoNbHtsroGydKv7YIbn8KUpyCAe6XnnTx1Xyb0o00A59nXfAH81MCeJCxmO3Fmg rC+D9SvzNDkbSkXetems7xbFkL46XpxRdfJi18GaP9L3u81IN7rrvdn+i9MzUmy4f0C9XlkaMUuW 5OvhGLpG1KSxej3czEwk6C9ZVtzaz14XyokO94W1rYIgCHKvkag3IQ9e//jBopZ+8PSWgTJ5m/6y +rOT3BuSJ54XqN6RT1BOkUZObFtUdjRMHsnR9w6E2FD7thUFf6KvhwOffHqfLbO+2+zVzMh3DgbK yOyoNtcg32LhE3tyPOWvVW/bscn16FwDZSASbN3pWJmZtz7LUXjwZJhEbqpfR7pqnUszssqOXLwe 2PHUw1vb1e+ShAuZrSpTrfcyrvowBMpzWKMcH9GVgbwIObOm8wb/Sg6ITVg0QtCXqvm9/ylctOeU 4kMn+5s3LKk99TXZMeT5p1Y6yevoq94JEi85FKh4/hHyPLUM21hEl0w+brbhiFJHvohC24iqNK5V T6VsqDfdcGSoreTB/2Jr8shfwf4OkMPIiconnjPeE0AQBLmXsOhNeN8xGqi0s7UQVoFyLNxa+tzu TiWYJa94k9+Rz1CfMh5s9K6oPXNL3zuIDUek0eCxGncK3XDEVrqvTfhz5PsGA2Xk7kUa+9ee7F/L 4/Xvhe+jDPGxzlrX7IuVvyfIs9tlytQ4giAIgty/YKCM3LXER069/Re23uB74/sogzR86s2/shtw dyHSyOk/HzmHUx0IgiDIDwEMlBEEQRAEQRDEBAyUEQRBEARBEMQEDJQRBEEQBEEQxAQMlBEEQRAE QRDEBAyUEQRBEARBEMQEDJQRBEEQBEEQxAQMlBEEQRAEQRDEBAyUkcREwycPFj6/bG2ufenzGw60 f8FeoCtFzh/bnbs0Jd2essK9W94oTr0LUSzcWvITtrczg+9adO6o9xm62Vu2bfGa0voPw5rtkREE QRAEQe4WMFBGEkE2r1+0M0A3cJYivX9/PzRFj3ZUuQqbzpKgWbrZ01SSXvXhCAl3NTt8WuyD/6WS hpxbllXzET0XQRAEQRDk7gIDZSQRsa7ahd7WQf6NMx1sXJN2qHdKhLdT5xrSC/2hqH4r/OnzTeme puAE+zIa2L6wIjCqS0POLW7pv0t3a0YQBEEQ5IcMBspIQsZOVj3j3HPyqxj/DsQGW0tTG3pUOyzf 6m1w57de0QfKM5GzB5xZ/i9oQD3SsTOjtO0rSZ9m/OwBV0lbmH9DEARBEAS5a8BAGUlMPHKhdZvt KZvv9++HxmjIG+mqtdOwWAZC5+KFtV0xfRAsRbvqlhS0huG0yc/ql5cdDUO8rUsjn4sgCIIgCHJ3 gYEykgSxa92te9wprj0dV6U5BMozM+MdVU9sD4xOk9UaDv9lEmhjoIwgCIIgyL0BBspIkkgTPb9z LK8/O5n80gtgOFDhqOoYvOwvWNN4fpoc0aWRz0UQBEEQBLm7wEAZSZpYV92C4qODMZOH+dLYQ3vG QDk+0v5Kyt63/lzgaei9RY9o0ygPAiIIgiAIgtxdYKCMJCA+dua/d/yRvgZuJh7p/k2W0x+aJm96 S+b1cAwp3Fr47JKUxXVdURZYq9Lg6+EQBEEQBLmLwUAZSQTbWCTliVXrXLaUzF3HLoyymNZ6wxG2 mUge+dvUHITD0hd+x2OPKzuPyGmybU+sKDyAG44gCIIgCHKXgoEygiAIgiAIgpiAgTKCIAiCIAiC mICBMoIgCIIgCIKYgIEygiAIgiAIgpiAgTKCIAiCIAiCmICBMoIgCIIgCIKYkFSg/M76HPzDP/zD P/zDP/zDP/zDv/vmj4e5CcEZZQRBEARBEAQxAQNlBEEQBEEQBDEBA2UEQRAEQRAEMQEDZQRBEARB EAQxAQNlBEEQBEEQBDEBA2UEQRAEQRAEMQEDZQRBEARBEAQxAQNlBEEQBEEQBDEh2UBZigxdHe1u KPhjcBq+XWv3paxpPE8+zszEumoXVQRG6ef7jumxjl1Pe1sH+VdKrKvu2ZpTUYl/lYn3NNh2BkZj JqfMjcnwiVezcjbvau6d5EesMCuekenzTRmV7SNx/nXOqK4iDbRv3xcwzYpXnymFVcGMWU1ZVyE2 2P56TeBastXUMdian9N8xdBKKuT8GUldZTrYaPe1j/Bvt4FyFWnwHzt2v2+aVby3YbViU7MLU2Rl XYXZpT1/TA8EtrvdvpqW3m/4kdtGb2uxwdbN7ua+RK2aNLL877hNdUS6an1NwQnyUbrZe2SHY2Wm 175ite+t3gizjvkjgT2qsXJZ3yOJSs4Mc3A+dPVWb0NhZWCYf5sbV456S1uuTPFviUjKdcydWQt/ O9edDv9zh8NTXn2kd5Lpw/RoYMeildn5Xs/alMwdJwaojsaG2nyPLKjtitEko4HKZ1at8+bl2dOy dr0XFlosDbWVPryqritCv6nyWeneExigp4LBlvFQITYQqHHb7K61KY7qE+zX4UDFkkcU06MXfXS7 6EQoI+3lT4piEMtyUYFABJJqc3nzvXnwV3Sgc4z9PtpR5/Hmu1YtXEBKm1/461NjkFVCKWm6LT3a CsYjvUe2ZaatzbUvtW1t7gX3HB9pf+VpUmVSjPzCA3//685vzbsmqkWCriQh35LeJs+ddfHfIUkG ytLkBX9+WclPcytf29TQNX6mbsH/eYhHIVNXmkvmq+u6J4BudY1pi84emSUH9GrPaJ3FHTJfBQPA Y9oaek17t7leJUFWHHCjhQ29t/i3uSFFO3+1pqEnYQRxG/nPY6AG/crO1eYlnOtVEmQlmF3a88Y8 jpwNtjZ6anfx7aqEDllo8xl8U661v/IGjUonw+07syr/EY7B5/ELjQV2MbkwbyTXrJYu63skUcnv xPB1JB/sGoh21qR/RyZjwR0U3hI51pSBcNyd33oFPk2H/M5UWuXJz+pTl6Sk8AgSxu2pTH+mL/pf zBFNEzl7wJmyOE3kBjk7y9vJvIMUOb0vrdAfitKDuTWdozPS9c4ad1lrH4l4I6frbPRXCFKX/38P yZo59nHN8/8l4goOOJOFiuoKgUAXuaD46CAPn3UopU2GRN2WpoLT4b9vdVS3h6FSEA41OTMag9NQ OzsT3fdKEv7/LmUeLf3bJclAOTp45nCl7ScLn9joD00Q3Up1rnu+7GgYNBWq6iJDrtjAyboNbt/W wsxyf89NleJJscGPDnoz833e1a43OodjhpTQzNsXOr0b3GXlOe7qk9ek6YHArtx1vqpyl5cOTOOR nj9tyPH9sthb5v88AlmDk11gzysqKPd5HFXvD0uT4cAep6t8j8/trDkRjt08tTuXjgJhwFdJOid9 hgIyxi3K31zkKKysyCgGCwTfuIQNX2EgSywBOmaWVTQc2Ovxlv40LbdyqyOVKKW+VGDSKeRcdsqo vlLEfZz9Q5G3fFeZu+RwTyROJt6MpYqH/r7V/rjdt7epc1iKhk/uz83Z/IsCVym5BBOUK/t5z4HO 6zS1XDyDDOnPDBK4aH6SYuEP9nlyy3cUOYpNSwL278h2ubJeKnJkvhoID/GrRHvf3pTxuL38jdae CBddYbp7y88zNoHPEtVnyAUD9UjLXp/n8ZW5M2tODl83ZNXRzlOqJezKb+3tfbti7WP28v3v9EZG +Fmzag6/OjARbMxNXblGVGGSdHvPsvJda/dtaAoOq/Jn0YtVmRV9oX7fof1J10bgT9/75Yvu8j3l 6158PQBelQx7MtZ5ckpecjq2/zMsNCrae2Szfcla3/6jvTdj4RN73AU/2+jwVGy2ExcPV8mjJWGI gunV3pjVl7KgNK3Td9YgbYMOJKi1vgoaPdRpdTzU9nNSmF/9ofOaXuFJ+TPWOW1Zb3x8xToHM1sT TJ9vemGFLSObl2Syq24xa1MyIfFccduQrAEG/dSZ9uefy0IbMLSpQThKyT84r3E1ajsDpMlQx9t/ qS18scrf+o+u8+1Vi8qPD6kkCRj8pDDPovzM4gN/3lvoKMjPLPVfGOfKppihQYc//7dij0YnaSVG aE0uNCnaVZdChHazp2mz27etNOdllVmR1tn31mGNMuuNaFTreIU09AoDZUlQcivDb6z3raPKPGuB ZQwSk8816MNMLNxZv2G1tzTf5t0HumrIE0YXGcttdkdRSaaLz7Na9nHMEk18vgA0SmvjeluGNDo5 XGGFP9Up+9XrHTszS9/pVPnqcye5Oet6QPnKOu80cfnvVUS2r/tPKQYO0aedZiLrRmyobcuqA2// 2eujwSiMJIsX8jIoronMtqbWHf/zZhEpQj55/EYKcb955LjU15KzGTKZ7K5PfdEf4sPEeOTqEFFR CCSWrbI9w7KOhvwFTy14TFyIAZcuVVRX1iI4cbnVGAZOYXPYsho/99ADC0UFE3dbGrQVpMJv+0rV pgBU2a2K8+QeZFYM+mDifoU+ZG6oeiXb3fxpp4XrVvl/GJDo1NiQraavl/UnQZcXHez8DdhIude+ ru4jQ0wCldZq8uzWKrfLslXOLG0Xb7QgWVCuop3l9vma75s7SQbKoNlfBVur606c/uDUQKSz5rnd 7R+x4SPIhYztvrncvLnQHwT5SOHWwhcgxORnzkxfaina2gLhNWTSF7oamzCkhBGtx32oW441J7pq l+zuhIHbTOzaxb5R0Ncyz+EQGD90k+kbIZyFIaMt5/ekA2OtMiHfWIxevdgficsrDcCqyegZstVk SMsFxnzJX5xLSiLFgk0OcpsJzHsDGxOT3qsChtM8KxhqZ7tpGWLnmzJXQJ6GUo1faS4lFsVPiegq FZO+Ol6yiQwziBPxupv7LEolgnuQXOgtb8Gb5BJS/9GCgqbgSG9D9uq607QXpIji0VkB7eV4CmDq SnOZ5idokVxWkli4dVNG4/lJXUlIjZz7ukbgDPCYtoOHf8evAj7IR70GOLWNHo3o4Cq0+gy5YPGe hpUFh86BeVAPe/oTUWCRlUiplfAaYr3gDdnEAE8zPqvmqGoNLixHqUJDz5R8ex10hk3Yy/kzrMqs dnzg9z0b1D8Z2miYz6CAZK6G+iJxMpln298FugoKUOxt+PzfQgJQQtoPTV/0O4tpc9wKNrpJPyF6 F35RUTC92k+KAitZcUEZWkcvbWKVWh2Ytq61vgq9Xyt6aNBqiYdQE8afyEwPy4eoq2UOcYOt8XIA 0GSakpxXZJhd1ESCS4ZRPw2mLQvN0KZG4UzJJQfJq12NbIkqpCtHfkYH0iPtr6TUniFmpRA16DAY zkYqCtLBiw+isdRmaKLDk8IeSaeuc5JGl0ULAMgVBxl66rtvDLVVUDdIG5p0RXLrgED0yqwpwPXT ptIwKMwt/YmqklsavqyrsxeYXhUwSCx+pdlNbNyoD9AQL5c2f0EaItJ/8eo3hjzl5qAB00oIy4xt xy8rzMrg8/nPkEBv41GdLYMKG+QgscILNwUJXM6mno/3Kr76UmcjE5GFWhq804SYAOIJCBB9PrGV ypnWHa41+Vn98gJ/6KKYz4b4z8Fsh0q4jLQFmW3Ndvp7v5LvxkA+i+TlPUKHIYoicTDk4NQYMkGC M57bubuaxVVjJ6uWb6rams60QqA5kQuEnviUsmBDB5zipkor1FiJB2brtjRoKwhyW1zXxWsnUImO oGgsIzbc6a+rrRV/e/e393HBG32+wf3GL/ldzKKZPpwWXafRdcsGQtReq8aGbEEzTfQngfMPNW8o PnKZqNBo38VrUYNG6XulWPLuhfpzqtuWFhQP+rNLNIJixfrOuY2H+aDLgcFiPyjJ09DfQFXTG4O3 ztSl7OCrBYTlU8ioYqn6PmzUmBIkywySay0x78zdZAKDAGKV12mxVrwh3yrllkNUxy2WPcmTwfCJ 56zNUKAqibBA0ccTOxfmwe+wiNtVJIgpabkyaijV5UBFscoT6SsF+iSvOmVKMGlaKpIbu9ZYV61b e4le1ZCdYqipfDn2OwUGi1tUP/WrW8S8JJAt6RjIR5Jgk6+EX0WMmKHhxOIQEF0u8VlwFVp9hlww UA/Wk7Hg71ybKLDIylTCnu1gvaBgmtl9Ex2zrjUkeEFVhdrTQ2L4IYpEvC3Pn2FVZuKABOD3c9U/ jRja6OvLzWWOqn+KSR2IlipIhy0n+HsLvwpcns6OQPHEQgWohY90SHAVO5MShRdM6CSVOVFXucAi K55y0tg6OmlrrJLpAORuUWtDFVR6aNTqmNANw0+dV+TVikRdrXIInNLbGrQvJ9a1L0NfEnDKk2Md r6buPMnXKQIm+mkwbVlo+jaNGYSjKrnO1ZgA4np1Oyk/lJBFmSpMvB8YDrv5KNpI3VhqMzTRYfkU o5McNLgsWYwgfNKTkcjM6Q9NqdZoKmbFWgdCQ50yawsQN5WGUWFG9ScqJYcEFoYvq/fsBSYfCQaJ XQ9UrYXrGvVB3RAABAr6PKFgpXyykB0ZN7Yd+UjgRbV0R1AYrY0P6G3ZRA5To6zwIDGS4HrHTndV x3VNXyaLyFwtjT0IiZN0y6JI+EJmZ6XY8NkjlRuqTw5cayt/jlgTP4UGx9lEFNJY6NgOR+V7w2zw sGhXxxiIFuRMJMGDbJ4rtC+JVkkUBdIGcT2pCig5LJDooI37Tci/Idv/v2/rOjhol+WPp9g9bBFw nv35VUSv4ETXjxbb89jBne1XeWqKEsoLNZalZFQDXbelQldBZfJOBanyg0vWrqcLlNfvbu+Re7dZ MOjDNUOno+pZ2BHedZq5btmVGdX4it6rm+uP/uqyHqlVCDBqlCEYm4N7UXXB5hakjlX0NvUdcxuB MlSG3qmBDubJ3e+/v/u53Z0Q7StGAkKH0JmrC3jwPD4YpWjMiaVU7p/KfUY80nO41EYfCCAtZ8vf +Todk+0ut7sbeoe4AZM5fL40R4p87i+2Z9G7TmCca/iYSc5ZlSG5MEG0KyDyAT1L/xUdEytuhZiH Wnv4ENlQqu4P2Zien6JcmlVq9ErzhhTvDja43Otz0I7EpFRUvFRXFINnB/OaejvEtAGHX4t+0l7u yqkDZcR6Pfs7rp8WP4HzKm7oHeE3xQgQNLAIQFMSlRmTqMLhyoQmJlcRI2YT0UEBVGWTCwYfmBsl crM1nD0tCiyy4il1EiaLFzVTgJDGRMdMNIcDJfSqquBu7ulpKGZRiyiSkj/Dqsy9NzrrC8EVenNr O67LP4GJpzf0ThnaCOxfutnj96120FvV6v6Ptqy/+VV2FTAEOsemtn9eC7kkDPFV9FtC5lGRTGTF U04YW0cnbd5FaXRgUldrpVPTV6El9C/R1lB4g1Zzn2v86V+n5cBR0RZDst+2vqm3NfKRAom3aEpy BbqTvLrT//Y7N9AFkZxkTFstNE2bEsXTCeeTT1Qhr9rVsCNabv3nfw7+4yrkByUkHQY/TDHxfnJH ItpI7qugYGozNNFhzSlad9TTY3BZ5COFSaCPBV5EVovzqqj86173rYVAE3on2ZY1ygzOXGdEptIw KAyZVkhQcnPDh5TCCmYrsNBVg8Q+Z2MVoz5MsQCOHCGY5dnXklvNO3iq0n0XrPo4cl1SVL0Tlt2R 0cYNXZiJHKDWVOtotp9coGEHuaLiq9XRm0lDgJD13ikihzUCGNVs/TENOgt9e/yd4djkZ/XLHPXd bAxDCwlBzKMQDmbbFqwoOfSvQZJ/5OwBx4oDn00qmgACl5dn0AHh4ldgOML7Fy6u6dGO/bkk3l3y YyJ8GLvmNfR+CaFqY8dft6W91jH0MZmTHlL8LZmGI/O+LFMhEFIXsVbECJSWPfwnnIysSCZuQdtt qdBVEIbK/AaICiK6p+XSyWrAv0EePUcP1FGTZHp1rJdfyKgPxOdzL8RbX68Pous0cd0x4cqMagxn abOFTyb6Y7g6yZ0AbnNlBbFTholGDes1eQ7uRemCuej0FgRRk15Q9PP3wNwDZagMH5aBoqettadB TRRBE3ntWKrccBTGJjBJKauvtlWk0ZPVz77SPiTHeQLFp2ijcOnrjqoss8E6h2co8leVRMzHUIeo GldN8KyU9iMTYHyIrCsVnEuuxRx0n3JpXqlRnRxkdKUi4mU5qy8B6psCuifuU3DEtdQ11Wk2wAtG tZx0TuqSgPK567r4TJwoCQRa8tOZkMCe783mX6EYdKbTXHRK2eSCKR6Byq3tnCiwyEqk1EqYTjHC pdlYn6dJXnNogmqvUgUXnXpUD1WhSHL+DKsyK70pTSPuFzPfZGwj7grjox2vLoEERJFK+GQeJHhm 99FmdhUoIZ0uUhsI1ILETMpdaYoomF7tZT2XszIKSrSOTtoaq2Q6cN2y1voq0FkK3tZ66wbE1Y0/ qQJHRVsMybSaoJU/FJXdGxElIdN+np/v3KSZTlbKAFiZ9qRKaNo2NRHOOX3Iy12NMsoyg8WItLQC Ex2GgrGQCzp4FvNB1UhfBXqoNkMzHebNqhEaJ5EYQSaltX/1l2WTwEtVJIHGlgGhzEqNFBsh6KRh VBjjnR+zkmsNPyJ0FZitwBxTiZGGM+qDLhOTPKGE7D4Daanti+icokgj2o58BoRZWbojlUZxG7+k 78JM5CDshfxUWlVBwg7yM4X66p81/LpY1Jeiawi1VkB1iHcyWiUcUT+OFiPvneCzpJ61i5+Bn0A4 9HE6EKmdmBJcZ6it9OH/YhO9EPX+iPwK+cijI8hEnpOmoa1Go0QzQfFIIAH90ZqUxSlO/0UI+JSh CAUu/bSsurIDhBNN5qc5yin8orLTIz/p1MCg6hxDBZu7FG2UgdrxhxcpyoVmQ9UKXB+gK9O6X70+ tJ/nmavO5d7phnBl6goyFDvVOQGt/lgmI6KWVQgw0ajLek2e1VoVmTNLV7r4RFETFxTU8vthzoEy qQzrcsgSmZIfPUBengJ9TEZBa5goY9BfsLlFmd0hVgE2APWTvrl5MyYZUt4SAxEx/R4d+LjjEnkt Wux804vb2od7ml5gz8/yHEgL8UEPu516M/xx50Xypptbwcbi8vYvuHClkc/qPWSKK6bNUBgY0Qn6 9A95RNdGVvWJRo2PffabLNJpCaUkzbaFPJQjjXTVOckQGYJObanETQR2yqi+UtMwePIyOcxI4zdv Ts5YlErRFXKJTfRxyYmQf5O3+YtbuqUCis2A49ZdjiUAoGDi5Q9KSQoKW/uh3rHQm4W5b13WCXzk WqBihQPGqSTBYY/zgH8PV1ZqsWTCxig65R4KQS4YWAIbBbKbtp98wo/LWZlK2EVsRjEMnmZ2zVFq DaesUVXBHxJzz9JY10EHffxCb3hWZSYOSMCm5FU/GdooGj7z0cVxEHss2OQEjwO6+qi7KQinQILi bP+/hQSEpyYfvPQZEdC2/auJZcl3pRmiYHq1l4fyclY8pbF19NImQ3mtDkxb11pfhaBKDw1arfhc w0+gIuz+oPqOmzGZ0dZIMgq46QXqksBZ4GGLH1qwUeVwCEYJGExbFpqhTY3CgQrzkke1ruZq7ObN b+CbOZBPnpsuziPzsm/++siFcaOfhIKxSR3RRvIHaBG1GZrosHwK9RVaJ5lAjERom1IWp7Ink0iR +FNW8W9ujMEJonWkmE6ZRTcpCjCilYaIGPQKc5GsfLAquaXhq8fziQssY5CYaDijPoCb9bBMqNYZ 84R2WZjZFARJQku5N4JsjW3Hrirszujz2a+Awcb1tjxhIgfFXiBiXrjQA0YKl1b76sLyTTlURDq1 FA2h906XppXBtoAckd9iQV92waeTARA7jCEvXWneQB+nIwOGhdSNyLOtBBb3KKOjeCT0zracPeSB MPlypE3Lj35FJRbrO1qcB1cUgQR4jMKHntzVMRbTTdBSZ7JRUV0QGr0xQk5UTedrIfEGDf50PTKp kVENRJrJmzfGQXwCkwp+Ba2fQ1cMkxnZI3uPnJ8ktfOqplqUC82G0ecb3K9eHz63dt2yKzOahiFb c/2xdv5QRze7WUczNGqUUZOTdS9wQNfFGy3IKCj47fthroEyH14zbQYprHmYju3Ig40lq71by3M2 7DupWSlFbwk53FtLHem7yGPI+pTQ8Nrp98lga1mmw1dVnplNF13ROwVpnspXi1enbX83RDobdqOB dJxkDv+bYOvW9EzfHp9zDVlOFxs+WePIKSt35+U56Ytd9BkKpgcC212Ol4qyVqY8R+/vSMPvV2d6 yn0FG9bbiUeQ7Zy+2NiRWVTicK1zOqhu6Up1ndeCnxLRV0qWQ8WOElvm1ncvTZqXSi1euMSfCm0F v/Dl5tZ9EFY9jcRRimeQIUtAMPmJvGSgIDN/x2a3Z//JcFQvH1Df5Y6fV+SmbyzNd+8NhM/LvjUe eis/x+v1vTMoi86Tk02cl7ZscsHArtgNVmIJuTWdn+qz+tkvd/MjBgnHv2jxuvNztx0NX+Rnzao5 9OIU6FpcqipEZ6RrJ6vcbl+Zp8ibvYDeD5Hzp+WxLjPpzTkmP+naSJoM/mVTmrN8j8+R/hpcF1xz asbmSrfjp5sLPDUnwlPy+Hsi1Oxze/PKW6+Q15pmOkteysl1ZZCmV65CEQXTq/2EMav3RRV0rWOU tkEHrGutr4K2rfVaTXwufQeO4Sc4jZdf1XCAIQejrQmgx9KUBLwm9IsblC5NxiABvWnLQjvyN2PF dcJRJD8zrnE10XMNy5coam8kcv7ozhyb3b3OllHS8DG5Z63XYXlcAb0LmzESH/RmaKLDij0anKSZ y5IhTubHy+rPstfoQpH8vvScra+9lJH+8juhSbl19MpsKMCY1vHyTsygMFDrBCW3MHzPMw89sJHp 6mwFFp2nQWJKwxn0QWSy+WeZTvJGC32epLO3b93iSSv8mbeIL43Tt53A2ufL6Gx8Ut+FQRX0clAK T/LP5sGr2le/94Gfm7NWLUVDGL2THGsqwJEn5bUHZDr5cRpKsq90NUVbe4WTOwQIX/7v9sDFd0of 85EYjgFWuaC263qg8jE6D+1KX11wkLgUQLkc1U9b+jqvx5FZUk+kJ/d0ROHpUBkMUD1BCyjOBACp 0qliTQRiQD5FqLHs2AGLbotoLAtjKGQ62VjB2GiwtTprZWYeVPCl33UORkntWJXJUumyhjOfKRea DWufL3shWR9WpSxKqzvzuZy53nWruhK9aUwYsjXVnwRdnnAsP9/sXENeX6PXKEMwBqqTpHuBvHVd vIkFCUE5bYuf+h6f5ANuY43y/YE8GzGtfxLoBw74BcvxOjInoA9gS8DvXe7uKpC3vdJ5l/uPe9UM vz+FuT8dlzTZXb9KCV6RHwT8vhBAXgbyagfZNuWHh8TuUgL8SVb6+fvhhxooS0Nd9QWL7L5fVeQs K/gTebkJQlDfFkfuEN0iinuRu7YKUrS7aUOmd5f+Sf/7g3vXDL8vhbkvHVfkbOMmR84eMp2P/ICI fX3mt3nPZJbveWXd88V/0Lyx+weE9PWpg+tT1/qqK13phU1n5Zcefi/8YGeUEQRBEARBECQRGCgj CIIgCIIgiAkYKCMIgiAIgiCICRgoIwiCIAiCIIgJGCgjCIIgCIIgiAkYKCMIgiAIgiCICXdzoDw9 1rHrabMdJlVbAJBvqmTyXqkM+afYYPvrNQH1y8yTh+7qSV45Tr+Rl6ivWkd2tkzL2vVemLzf8Fq7 L9Xm8uZ7s1dn7v7WXuVjKQ1AGvzHjt3vC4EkT6I8vx3m2hC6BpX3LZsVza4Wt4P01fHiZ5SXnJu3 e4r8ythYV+0iUjAocJ5qu6Z5JGFjSQPt2/cFxDvzk+a7V4Db1tU7RKlpEio0q1isE+j2i1FSWrmm 2xXISHv5k0Qh811rHHybCVOFnB4N7Fi0MpvsSJySSTbXoL8mhOwBQXc/SYZZZZUMRrdwm9kKYc5L qQxwK5syy9y4WYMlUqTnSGW2ze5am5JR/lZPhOiGXXmnnmZ7vPmGbAzxy7//b/X8C8ccZd+4O0OK hU/scaStzbUvTaPb3xDknpfs+lF04OMrsqqvzPllIBlVnxVZM29Ho5Iz7Vk1Z75kaMWc8ic7oWTl lBSvfOQhKg3uTpPrgL4187yTAC8p7sUZZWs/Hu2sSWcbKuqQN2mcO2RTgyUpKXy7Y7KLD2vg6Yv+ F+nmn+B6+NbzJKTWbsL53QB9odj78W5njg2hb9Dku3B5R83bg77nf/GSpSKiMm/3Bf/nIb6vptg6 Vdmg6LsF4ni+lehdzveuq3OKAufOYGu+6Varlq7pNgUiNioDVYURXRYJs0wVkvSCbrr538x0yO9M TUZJ5G29vzPuwD9r+Ja1K4GVwQApvSypjdmmB9pf9m5rv0KSTvY2vQjjank7evIzxBDPfWs7jEwH G9fMZ4AyK/qZjttDGv14z8otdBPsabKbMdsVmSh8sUrmt6Hqs3InmpmcNs6uOfMjQ2vmkj/I/Bm6 tS1HuNOkOqBvzzzny4FYknSgTDbw3Oz2bSvNedlP3oANdd6+0Ond4C4rz3FXn7wmxUPt+2vral+v 8i5b6Pmtf4+w/LGTVYvKj4c7656x5xXllXizC99orCvI+anX6fWfJ/uu6HOWYe+uH9VfiIzAHNnr 8zy+Mndmzcnh6/Ir7sELZCy32R1FJZkuOnfCchjsfbti7WP28v3v9EZuhU/uz83Z/IsCV6n/c/IK a2jgBRnrnLasNz7qa9/6yHJdY0Psu2XVgbf/7PVRVQa1KBazjFAMWkdlR6jkX3ofDQf2erylP03L rdzqIrZNigHyKSj3eRxV7w9DwWIDgZqi/M1FjsLKiozilivDopowtv5gnye3fEeRo/hwTyQe7T2y 2b5krW//0d5Rsr9lkbd8V5m7hPxEFShNJavYdPi9X77oLt9Tvu7F1wPhayJPfTJeTN7KruznPQc6 rxsyjw52/ibf5i332tfVfQRl1icgRpWxzpNT8pLTQTbAjKgaIq6rBS+DK3OZ48ApsRGRoUGFzEGA unbUFUYErKRIJVvJO9t1ZUvc7iT48NS3NebzTsWi3VOd654vo3vfQ+HJ1qnSlWZ3Uv0QnSBxF/xs o8NTsdlOTjE2gVCSzA1Vr2S7mz/tFHoOunGyboPbt7Uws5yYTLT37U0Zj9vL32jticxqp9MDgV25 63xV5S7vnsC5kzxPQzJaSoIiqM4xfeZSbPCjg97MfJ93teuNTiizPgE1VZcr66UiR+argXBUrav6 WmiVjV9dwayEs1wOvIusVNuqNq2jNaXN1xmoW8yak8Ulf/n0xB6nq3yPz+0kuy7f5HZhtEqO2FbD kIDM42oKyVNauKaISiA3E1lE39/KH3aoegJQSHkDPFEYM4WkvaCYrQSj4LVOCPTcL6ywZWQLs9Xo wHW93lqKQmCt2Nz79arcwjVDe4n8Z+Ij7ZV2qLKqMKNao1YJ80txlt5HMWgz5eQqzWHUJUMaxco6 2nnmWismPoTs8bshx/fLYm8Z80sj7dqGM42DQSftLMKj43CxYXViYuHO+g2rvaVQu32d1yTeXxSm u7f8PGPT0cFJlTWFVQJ3pDZ0fMTLD5lobVDRECnaVZcC5ZzSZjvQp/IeA2DwWg8g98WiseQMExTv r3/SisjErs8eyKbbXLNfI1evUpcPCq/x23NXdZKZtl/QuMf/dCuaOcKqJgy8KD+z+MCf9xY6CvIz S/0XxvXK4G3tS9QvGzWHl8fg9unkC6mLvt+nakMDoZe8joJ9f67dmLXR68j1B8ne0To9VLvWUNJt NKj4H9Yjx0N/32p/3O7b2/S3Y6+xTKg7/eiU0gFZ+wqVQBTzNIvHrN0IL8wtawcyNZsB3iZJBsoQ L1ZAE4AwyZCUTFrA6M3jPtQNRQHVSZF1MnK6zrbBH4oMtvqo5UdD/o3Zjb1RCCBs+7ugdUG55Q/E zxpzZhlRf01uYkb0F5L6WjwbDp1j/WJe3elPxL1O0nmsrjsNKcl27SsbeqfEbVB+LRhovuUteDMU gxT9RwsKmoITZKaQlQdQtkwUTH5Wv7zAH7oohlzgtR38hr4YCEJw/DSbd5S+7qjyKBstStdONe2v q4XBA/3b+9v2Pr4qA8a72e7DpBix802Za0BjoBi2nN8T7edaO3HJX0zFIsWCTY4FtV2Toi7Tl1py N/lDE1DfcOumDNJZgoOgcTyEdyXsp4lgo5fYWLynYWWBIquuQXGXR4pdDfWN9vA89cmoryFAK2cz kRozj4eaNxQfuUyEOdp38VrMmAAalMmWxJ1eoqyiIUxqAWVYnrWva0QxDWODxvnG/cZ2nNYWZooF rLEvWorKSL2MZUvU7mQ6OfVFf+greXbQvN2f293+Ua2THIdWI3MbxPuTvftJOiA23OlXFKB27/72 Pu7roTt0FtPy3Ao2ukkIbmiC+CW/y6NSEkXPo5ebNxdSk5HCrYUvwCANBMXMbXY7nRDb6M/Erl28 1NnI87QwZ/CNiqAMmccvtRRtbSG1iEf6QldjxgQgKydtU/hpi43MJQhdNamFStlMMJYwicvJSsWd CagiU6EQLwY0RHZR07n3xX2A6NWL/RHIhyY2WCUvinBNxgSgd2WaQvKUUUvXJAtkFouQt9xngEI6 2d1SafRkdeqrHWNxM4WMkZnsJ9j9LiolZn3kNEvvpLhoYbaKDhj11lIUPDOjbzF6P8UtGNtL/kBO d0GVlcIYjFpShMnP0rkFUShI79E6FoMuSSZpuJUpZdNI48fQCwy1lTGbhTTpG2mXoWu4a+0+GMCM 8W8c2X71YbQ03PkHuY1qa2v/n+xBwHxeLm3+AnKWIv0Xr45CP+sh5Rf9RUyxJq3AV1T+80MhUqMN qrqSYk9999e6bE91qrxH36gESqv2AFF9Y4mJAxIGWBXPICJDW0x01jypnsVkkGmpp5QVmFAbC1VP 4IcNKgRmq6mg0mGxqk1cad5Iiy33TbJWGEwjQb9s1BxaHEDv9uXJF6N/IK7MRf0DXChHfCBXBI3V 6uGoIm1Ze2dto6ixRxaxtZwJd6cTQoFV/UUCgYjTTeMxSzciCpPAgRgqbjTA2yS5QBlKaeNrD0QF oM4sdoS+oZTJaGbmBoje2dg7KVs+36k8Jqbc5TlX8cEkZ5oTAEOBDGa62gvBmCOXhi+skc610WRw AjR8KR86sKyGWA7yRce6at1iLQ7z2jdUEzNGwGLLn9t5cownjlDpZ5NLSGOhYzscle8NE3/q+tFi ex5ZvWrz0D5yNriCko8k6N9O+1F+O5hrbfRMXcoOJhZ+hEuDDPTl9QC8M4bqPUuqB0omL77kP4EC EacvZDX4zeXmMrGiUZaw6n4xTya3AQifr7g1ZP7eKUWYBEOC00PtFTQ2ArgAldY31gLKwCfmZQwN ej0AZhqcNrZjWHUEgAH0ztVvvPu/1ZvYFseGsnVeSdDupJPIJAMeWSHN2z0vv7UfakSGSbzw4P3z klkYDWWg60cB0GofOUXfBCNKjXR6rtINUUIx65aEnRLfJK+klxWANLTRnAHSH3BB6TPf+1Gn0ogE 49XBAEmEwQ7QVha6alYLRdnMMJQwmcvJSiXXFLwHUSHIDVz25FjHq6lg4KQTclfLu2HzxHC21irZ r4BlguFAxRZNIXlKgyZz10R7dyKQJC1CQBTyJyl2D1mO+XwhDUNNFZJGDGS+SooNnz1SuUFzr8CC WNe+DI3ZKk7SRG9nlZVesUkfofV+JMTnN+KM7SV/4ApwSy6MibuTtYufpXYUaiBazdM0B8QEesMx pJGtTBRJK40Sd3NPj7LWk3s8+lkFZGWyNAukR7tLEi7kJDWdrDYfALIVN8RB/rkkfJStCUqiEnhO Scun73KRmtsgCWVILOL0hyb12Q6rvYfWjRP0jRUdDVSthcZKVDwDBruG6JyvMtKg9Lz50PnubA9z VYeRQ/BYhXdb4Oqsqm5UoUldBWXN5FUDA2e3+IUyiA8mpiG00XiVCb3mEMOhqDSW28skk+Eto38A V8ZWO8hqzz9AN6TTw15F2sm3kYn/EbokZ8LdqSwN0GRrX5HIPGVXY+1GeGG0+qxxIMaKJ2FKyZFU oEwKvTivig3IXvethd4ITITYFfwoq440eaHJld10gcz8s7bsCPo3ZJM7JnIFQLnZI1YgO9KRmORM PTTLgYztuAHDAX4hriVwAMST3nD2tBgCgtRyq7mBUe98+Qz7SVyU9C7yYiBmqMOJ1tErD1UIoUMD P7pk7fps24IVJYf+BSM36nMdNId45FxjYdm7g1zlpyO979SzepG/vXtbe5nxCQOgxeC6LjcqjfCg l1K0hB+J8pEu6w5ZHMOVMsYfbQSRbkjx7mBX3OtzQJAKZ3FZyUYl3ezx+1Y7XgdfwCXMG0ubjAHC 527dkPnBPx5cWUEHpgzj1f91WlZobpNjovVNajEpD+VlrBrU2I7/OdOgKQzomyt15fOPLKs/S7TR tGxW7U6mk1ewE2XdM2l3uC69zQcSe3L3++/vfo4UnimV8P6RnqMH6thFyd/rx3p5B8mVn342aDVv Ar2SyHqumSxh7gMG1nSAnpydxiM9h0tt7j2BAdXssjEZAzSTC8qQ+ev+g5pRgfHqUGbhK3kgFReP 4ZrUAnplpmxjnfWFpPNT/tyvB4ZO60qYzOXUGq79QC3u9L/9zg3+EBGAFPncX2zPIusuJE0atVWS nAmWCRQxQs9BlvnylJauiciBCiQ5i5ABhXyCygrM+dCmTW0DdDLJqJDxkfatP6bBRKFvj7+TrMmg WHsnopxbtGYLYzamA+Z6O6usEit2b1zuFIzNRIKMNUwIXLayQhqNumdKaBc/HUIujVsQQFbyOkva HP39ZoajTUPuV1ArE2XTScNVd+bzlhxb/s7XaZF2l9vdKjsSQFbq7p/DArIz4931qzSrMkZ7W3/D Kkj/DhztBQkTQCw2WlMGsQVtf0FUkVmTrrt5RpkVNrFBMqKDduzr2Omu6rhukq3Ke9C4ROMBrBor UfEMGOz6QPsRFnt93VG7kYwMF6fQiwqF5whVd61auLj0kKLqif2wXoW0FTRophzEQx+kmVK9ZTQN YdrGq3zap9McuRbmsQHI8JrRP0yJ+FtcSKgByUSrh90fytJOvo1EyKGGOYQpvZ3K0lD6CxNfIZdT OcskHkvsck1FJJrJWHGjAd4uSQXKUEru7ASKWGVnNNnblL2hiSzWIZBTtu6sJNPJ4GuYFCCAkIfp ip/V5SzgXZ3hQlF5kp/Kve2cGIIQqbGZZiLl7YvIrCH7Ca5VTK7ONQMS0MQpdV3Rfn4vwIQYednF gxAeQVcNxvkMXBRKu5AUBjK0874E8pSfJ1DnnwBVMj7WVNqeux6VWNgYY1CMtJgjY3YFxXDDIIyP CDU/MRRl1TrW+GjHq0sU0VklU7t1Q+b6yhoSkEqV0Nk17qC7YqIhTGoBw1ferAomDUrTGNtx/Iy2 MKBvK3L97/+d5DxmUjaSwKLdyXTyM3yiYr095UHSuObtzvtRUOm0tfY0XjAL769FVR7ueaP6JtAr Sft5oecq3QCx7FhaeyYKQiDDevVPHBM7ZcdHT1Y/+7OGXxezPK2SqQVlyFwvVUMC0Ct5sgREB/3B qNBVs1qYxxAcYwmTuNwNoVTCmZAP7AgU3vPznZvIdDI9mUCWTmWVtw/wxAar5Mnk3IwJ5CrwnkPc KTLRZFYe+Go0XmuLEEDdqULyz0QOpgpJshWLX5MFrs4mxWWzlXXAqLeTs8nK4Fv0ig09PVyRuQW5 ddTtxT7ICmBWGI4sTHGW6lpqSFZskps3B5nh0+qSSRoygUesTC6SVhqgk8pYzhrQEJ6tBtKIe/9y lKx2UNfIEp3yq76y/mJYUUWtwG2qHlN1FtSR2iA5vbT2r/6ybPK0nEm2FOo9XmkfGdU2gWVjJSqe AV3VaLYqQ5C7FagXf4aeIVQdmmmBGOHMglGFOKKC11SaSasGxWbzmjBSZZN6cDkezupMA/TFql82 aI5cCxPrYDK8ocpE9g9s/AAjBHbnFhpRDEJ0eqhIO/k2gpDD4H94znImomm4aUCKBL5CFog4XV1O yIHEY5etXa4ojImIhAMxVnz+SCpQhpA0gz1nyhd8iCaBA3wWffxCY96qA58pKz2hbR54Jrf5EjkJ KsACCC4yaFz+wZCzDBM09Ky6C/GpGkhPl8t88oloD2jphZlNQbJyJeh3b/SHvuZNJV8Ueq8XNtEn XSZC/k1eKJt8L8CI5h09rJ0uwdAwlWvk9oV0MEe0jd8RYNGnKsq0gtjGluNDsRlppKvORTSGGxv8 Bp0ceVcD8Wh0akGKnN5n20gndVg1YfBUUNjaD7/EQm8W5r51mdzuZy4MfvLyJx74oltQIDIaEbI6 Hw2f+egifewg2OT0tfyd56lPRnIgqG48GTMHh+Vms3Gs4QwJoFKPupuCkC1Iu5jcWJAbwqQW8r0b BUODikcPje2oKwxvVrmZDGWzbHfVdDKBmf0t83bnHV4s3FryowdWQcGE65kVaDJvadtXYA/kCW6S j6EJ9Eryuex3iMkUtIZJRxf0F2xuCUWFv0jCTqMDH3dcIkYaO9/0YmH5phyap9Gc4RNFJShD5iQw ZVKVvrl5MyYZEkClVjgaz5NFb6HDHif8JOuqsRYTKmUzYlLCJC4nK5XstdW3CIsfWrARpAeVDH/c eZG0+K1gY3F5+xc8scEqSUEIIjdDgmjnr9ZoCslTWromJf5IyiIEIPmNtI8E0bPg/pqpQtKogr6h JXnAVy/Qmq2iA0a9tRQFzQuYVbHpcxTcLRjbS3yQRj6r95BoQCmMwagVYcpn6XwUg1jxjzXNETUz HH0aYWVy2bTSYDd2Xiikl+MWQS+nhfguKBKRjxT5/M+vt9JHr4gy2xcvIQ/PmZ1kBJrbwwpM627o L6YUa9II3LlG1WMabBBKDnaxKWVxKq0XDazV2YYuq7zHNrpgV+0BLBsrUfEMGNqCxkPFx74i8pRi Xx0rpZqm6nkpiqqDyonpjFkwqFBM7R63tQ93C83kVQNDZvOaQhnkD0bTUJu2UVG1miPXwmgdXIZG /wBFYnO38oXEB6JjGj1USTv5NpJfHqAgOjjZBLjBytJQ9RcJBCJON/bjlm5E5QwTOBBDxUn6eSK5 Ncr0fn16ztbXXspIf/md0CQ0m+aWxK2Q3/ng83TSm9/FIzIVAYeQr2o8LX/Q5yzqRvQexhYR/b0P kIVmkv9TMQQhFm7fusWTVvgzbxG5b8JzABX4osXrzs/ddnQwGun5U6Gt4Be+3Ny6D8K0a2f3Ami7 Oh5Rwlwynfy44rZIt7qwtq29wklVk3aE/xeGrTBI2v7jBfRtpuszbXQ9A02fGPImQkdmUYnDtc7p gOZXiiGPKKYHAttdjpeKslamPLcANE/UBQQTOfuHgsz8HZvdnv0nyeUmQs0+tzevvBW6rc/9xQ53 xY4SW+bWdy9N6mV1czL4l01pzvI9Pkf6a4HweZ6nPhmtIEFpZUCfORhAz+HSNM/PNzvX0EfjdQlA oKkZmyvdjp9uLvDQO9qqhojpa6GUQcbQoEoa8kivuh3pEaUwA+eFPKNn6haXg1HpygYVM293Mp28 inUSFAiU7XVdlwNm7S4/tAfNt+bhre0jU+qDiZkO/3NHprPkpZxcVwY5xaQJZCVZlbIojd7V5QpA HwkvWe3dWp6zYd9JugI79FZ+jtfre2dwNjuNTgZbyzIdvqryzOzq9z7w8zwNychlCCoDodfVmiqX 6tZSR/ou8ooJXYJb5xqWO35ekZu+sTTfvZeahqKrhlpolM2AWQlnvZwsVdkVKHKGWHPDCj6wHw+2 bk3P9O3xOddU/TM8xWc1TKySIXIzJDAUkqecsHRNGuO1tAjoh1KJgsnWAaFAykLyvlj6Vm9iXHEz haSvdnkymVscKsAza81WrQN6vbUUhbhiIsXm3k9xCwPn9O01Exs+WePIKSt35+U506CXVRfG4JFk Yb4vTtf7KAqYvEvTHCQvnW6PG9NwK/vZL3fzzA3SEJerfLV4ddr2d0PjhoYDpiMXjlU50tauz15t K2uQVwiQeSV7ktPJBF7gzT/LdJI3csj9hScnm9wEUFuTVuAJPQkUj/Ro8kyBLlswFNl70AX9Wg8w btlY1sUzEZG+LSB2I0dW27Lz12c5Cg/SXo+UU+NsFVWHIdnWn7C4bTb0KqR2j1BBWTPDF6nQ5PUV 0DfJU6p8gtagDNb9skliGa3bV8UGev+g2Ah0UmQ5hOqDTg+vq5TB2qB0bSS/PEBByFy+tLBuuQP6 SmWe1gJRm6dFPGbpRgBrB0ICvFkN8DZJLlCeM5GzBzyqgOOuRxq7dPiVfDb//f0jz39M84eN6NF7 CvAg7MbQ3c3d1e4KyoCYPw57twvSBOj71ZMl3zZzuhx5OTqdlrgHiEcuvVXufevyPagCdyUQT6ge JDAnmTSzgg03KygiDfeD27+LmE/t+hYC5Wh3U5HTXS1erXBPEBs8ezqUxAsrvhOkoa76gkV2368q cpYV/Im8KuXeI8GN47uJu6rdFWJfn/lt3jOZ5XteWfd8MXkJND9+D6G+3/cdkPzlJPBPGzK97HUo 9wLRwe5PL9+TTuCuRLk7bE0yaWYHG25WUERq7gO3f1cxn9r1Lc0oIwiCIAiCIMi9DQbKCIIgCIIg CGICBsoIgiAIgiAIYgIGygiCIAiCIAhiAgbKCIIgCIIgCGJC8oHytXafU36PQYxv5A0HU20uL9tp tuhA56wvMlO/CPN2kAbat+8LqF+MR97/53b7alp6v+FHONNjHbueJu9vlt90fSeQtzM+LT8JHRP7 YI0GKp8h71EmLzTd9Z54VWdCNC8FnDtGCSQiNtj+ek2AvUNxVoYDFUt0L5N+5FH22uAdi8h7Wz1r V+b8MjAgakkTLLjzx8PllrozlJ0L7gAu3qmki2RWeN1rIOeZObVpMsxvhpatKQ3+Y8fu981sf9pc weguiQs1+qVVOfGC1Tz7smXFh7Xvh5mXN3zpmCdF1ZMoW2uhJeY2i6rsHSDQvVrbkrn5pW+bO1Fp a9HpXbecUn6FLUPJ4faaj755N2O1y702xVbq/5y8lmekvfxJ+sJ+1xpHFXujFLhrG+l819uXptEX mc8rCUpOleSfV2ZRMOUdw4Lb64h1b/e/azBzPlKk50hlts3uWpuSUf5Wz13/1qekmaVbvE1vcw+R dKAMfb+8V7NsA5qDyWA0njmi7N3CESF7AnRe7PYAc1VtBis2TCFvtGb6MX3R/2Jym2CJc28TgwQS Iu+MlQQQaC7//x6S1X3s45rn/+shvqeOm9V9OuR3poqrk5fRLklJuePYdL64Q8Ey5iZec2A0uOZb 9BpzadOkmPcMTYFoWOyup8dUwcguiasWL1mqtm6NyknRrrqlfMuuaPjUx/9RB8rf7ljlOyOB0L4N jP55ItiYp/i9BMyH4cwf345KW3mYaGdNumndb6/5xrpqXaWtfaRbjX116v3zEChDN/c0m8Igo8cs us8CuOtS2vlGQ/6CVfOsJAlKnmQnPir20JW5rY4YBifpZXOJMb4bzJzP9ED7y95t7VdIWSd7m16c 94H698fdZd3fA0kHyuAjlsuSEm/J1RxMBgg3Hdnr8zy+Mndmzclh0CiyO8uGHN8vi71lbOgMahfY 6/GW/jQtt3Kri/hoaKQFGeuctqya+t9tynjcXv5GKx+rxUNtP7cvWev71R86r0mxgUBNUf7mwnT3 lp9nbDo6eJ0XErpMsgO4/GZfsZmqnO0bnWNkj6LNbt+20pyX/eT9hWT++BFN1cDI3cLs5Ze2gsso FjNeUDW2r+MskMje6d3gLivPcVefvAY1JpvuFHnLd5W5S9jAdA4SoB5t+0KnK/t5z4HOsPbE3t63 K9Y+Zi/f/05vZNpwlWvtviV0Z2YBtOayVTaycxJ8Ic73qQWP0dpB3e28alyY5NNQ25ZVB97+M9/b fXZExYvyM4sP/HlvoaMgP7PUf2FcqNMorUhiyUD/l5btylzmOHBq7JZOSpA/3a1eioU/2OfJLd9R 5OADfSk2+NFBb2a+z7va9UbncMyQQGS73JaduZqKt6Oda4v+3JnYwMm6DW7f1sLMcqoqsl6pW82h Eqy6ga4b23qw8zf5Nm+5176u7qNhsoOoNgEI/JmMdZ6ckpecDrK7WETVpnF9RdQqza8O0jixx13w s40OT8VmOwnfaWUVG7yhzVCXWD7dVbSz3E6iBKN4dRkKu5seCOzKXeerKnd59wSufNN7ZDMx1f1H ey/oFc9UwUhA4Klva8xXhhw6lUvUYSu7gc6CWqOm9L6IyNOeV1RQ7vM4qt4flkRb64/zvCgGgZsk FqqSuaHqlWx386edsrJpZRtVhDZqbgsqXzodfu+XL7rL95Sve/H1QFjs925IxkpJMeqGcGIaX+oi fk+v9pPhwB6nq3yPz+2sORH+pvdt2S/pfanWQZ3cn5uz+RcFLj5RaiIcY49A0ajTwAQ3duB6x87M 0nc6Vb/+pzuB3yMGBVfMK/FmF77RWFeQ81Ov0+s/r5qPtWxlg+vmKWFgnLHcZncUlWS6yD554riq +W5a+hxQvL6/lT/sUMWUxoASVF3ev0kUD9y1uLUiXF9iNE3W37nXWoBqazWWnCnJgFAwg4dkQID7 wgpbRrZwXLJpGx2I6RGVZmo6YhpCuFxZLxU5Ml8l8+ikmaz6ca2WRjUqFFPeli02TFZlNao3N113 aXQ+ZFb1OWU3X4bavcwynaS13yjdN9HKjkJC+CKYmV2rdc00qBRsdER7IaicNpTqOyusW+4WdV5F +Hwzb6M3wJF2rbbfGyQZKJPQ8Gl5akfsYQgHnzJZRxEb7vTX1daKv7372/u4jsCJng2HzkFjcI8s DbWVeQ6HYFhGBo5kF/jpkD/bTY/EzjdlroE0ZNbWth/+U+30aac3hIqTwG6jxx8kcVKwyQEeROzB yLtM5a4ZXNpVGRhWZzvUVpFLzqVzgWzOgG/LLoCqPknXWhCmxFaW4LMcfHNI7cBXGu78gyKB2tr/ J4sAzi1zH+pmkwTEVUFAULKJ7v4/EWz0gu3F5yaBW70N2avrTkOGRtERZ8rCBcNVSBU1+6GTJn5u 5+5qFqaQnYE2VW1NJ9eCH57g+0Aqc6WTn9UvL/CHLup8esKKb6TlJE5ffKB14U0T6W3wJJYM2dV9 eda+rhEotKGyI7xRpi+15LKzYuHWTRngROBI0dYWciQe6QtdjX6hT6BkqytSnOSmPjc2cbl5cyFV FSncWvhCYxCuTlNqy7NCdYdRaSBjK8RDzRuKj1yGs6TRvovXTJQBBM6aHn4q9hL/IrepoaZTip4I pi/6ncU0za1go5sMe6CyKwvUNqjK0Jg46M8u0RwxileX4elPmECgEfkt+9i1i32jEun++ZhKvxG/ iYKR6eTUF/2hr1RzeAaVmw69lZuy8dCZa9zqFEinot4b1lItVRpl9EVgd7ac3xPnzvp44VL0x9WX N8gwakgcv+R3sQsx1RUSM1FdWWimtqBpx0Fxh1qKXQ31jfbwPI3NLWNsbu7Yv9H4UrL46pZe7Sfl Cfvo1Yv9ii2b+FK1g3rLW/AmqbjUf7SgAPy2UZLGVmCF1auTUFqwO5ezqefjvaa/msgNugNmI5BG /sASM4TtG8pmcN08ZVQ4NFL40pUNvVPCe8jNZ2o1QvFAC8VWrIzo5ebipQX/3TUkL3iBjsbJXIo0 erI69dWOsbiq84WqKbP+lqoOtVA3WTihABOUnCmJvN84JNB4SGardNpF67hER2zI0OSIRjN/rL6n RLTCyXw1DJttDT0qp2fQPW2Vb5zRqBC4VmXDZLqQUulnjWoDgtV6LYPzgVDEVdelXXyqaWWKdO1U 0365der2/ra9j7UymKfKfiPRBHakdE/kLBLMJKHVuk7wnNzlGS5kCKVihm5R51VkD2b0NiaS1Gn7 vUGSgTI0kuNHi+15dC1y/np7Crk9CjV3yQfzdrZf5YmtgRFbLgtDmUceUy1aYpIFd08anhwgUfV2 5ob0g2kZoeLKBzjvSnMuGAAMXDIag9PQZVathdP5V/idjddvKdlC68prWyEfXc9HISb04JK162n1 vZ61i7NJyEKMln6QxkLHdjgq39POLZkCQ64t1PvzaBtylhcFUv8bODUnCZDqsFs83GbIMX4icaZs uzLDVYxVZN62g/pH6Ck3ZPv/922aM7EfOqaXIsFjFd5tgavUusqfI3trC3uYHag4uxkqV0F84E3D 2iWBZLrAXsU2xcbKXgtUFENpyR0xzVlnxlVHILUhgTpbXZE0iQnRM3UpOzSqMsRSasuTUyJ38KoG MrbCe6dq3fwsiiHB6aH2CugMaOTLRS3a1FiRziuGbcPhuFiYBFL1kUEdVJaFnqScfLjLlMSQ+Krq EqxR+s2lp87wXBszNBIVZe4mUyMMuIzFbmcmCkY618yqjutwDWGPpioXj1x4p9ph59OTCuCv8vgI NjFK08MpOl90Q5404n081wqosfY4PYdhkOGAIfFYl9zoGomZaaYQmrktaNrxm8vNZWL1Kl3SSlvB 2Nw0D4KhqNeIf7bTIFjlS91wulHtJyG4cVcruxsKwzHxpbL+qypuJWGTVuC+Ra9OUC+S/nrHTjfo ifZXZZtGo0Fd5ysK5DRKYo5lK+tdt0gJ5Sylnk1UmfsEWecT+xwzpNHgsV1ZNh+f4SMdzU9S7B7S 9TxfSAMRcNduOsEZHe45si1nj/ZegRkkHlU1WSIBJiw5U5JhVkeDhxTEuvZlaBzXKOuIb+kz1Phn dokJjWaWsFbggMxhKELzpYlVTs+oe1ot1dZRzMXCR24j0CY8KxNzo5+1aJ0PXNG41itxK2uA0ZHK fhPZkcq6eTATFetkrLTa0ExywYwXmjCEUvpuUZYYpND4fP3xwVhykrwHSDJQhvYQ90ZphenITHNQ IdJz9ECdMmZ6/Viv0B5FUtCMZFEXSNOWv/N1mnJ3ud3d0NOjeHMwSLIsBsxMrOVXBlIC0TDClwEQ GROlifJC8tOhwdbw0SRTOyVbcu7ivCpeWt9aYYcqwITkJRY0B2YSoDePQvScbVuwouTQvwaV4eZo b+tvFAnUHjjaK6TErw6fQPmKG3pHrzRvSPHuYCn3+hy237a+OScJyIVRd4T8RHCmG2i4AO5GexXu wtTAgDivofdLCDcbO/66Le21jqGPaxZBzmQVyo9hOORatXBx6aHOMLnA5Gf1yxz13VAp5gRlHbCu uGyQchVEgbk6KZJhIbVBMkqbKnZIcmaVBU9A5MDCfTa5whzfvz/XxEzGBOcn5WxF2YSG6+MtEtJx NeO+pvc0TakrD1++QpEbyNgKB/94cGWFqjWNzfSv03L8zX3imGhTY0U++UTWE47o0Ql8oKLYoImS 6BJDE+iOjJhKT53hWSYQkiAe6TlcanOTu5xUdBZP8RoVjEwnr1hWf3aSzN1xrbBUOQivuw/lZNV1 XT51oIyMYz37O0b7tE/yWaqlaGimUVpf1DskLmR0KerjZ290/rqIjJ831nUMGiSmzyRuUF0hMRPN jHGhmdgvFEbbjlAF+nSRg9y3leulb+4bnfWFUFRvbu2Jz810A86a0PhSMjE/aVB76BTpA2f2rJoT pGsXhmPiS7lhshli+Z4b6/WHzYSjawX5Fq1GnZhifHLBn+30h0ifrv5VrdI6uZ3+nAfipmpPEKLT tXIPOAWt6+biIrafW81DDdofXRYzl0LnTVpW8TmWxCPnfu9eXNfFOponmJO/2XNo06a2AYm46xQa OheV737z1KCck7UHJpaiarJEApy95N/w8luNSEGqW7SOa4T2YtcMGX56Xn/k8z6NZrpoK3BA5iKG hsQwkvk8cT+uqbKmjlDyYnaisBG5nzUxN0N3yRHOZ4w0vWwjAqFLMtOR3nfqedPA3969rb3Kryr7 TWRHUA19MCMPL620Wt9McsGMF+rp04dScX23KEtM58H0x3vjc5DkXU5ygTK0x5P83qjSBpqDyQCa zZcNcDtUXI9AdUSMRcDM+B1bIn0Yy1KPxJAbRmkhPicxKOYD2OkThukBJVvVuVaACTllPRM5kBMX kg9gzHbhFGZDNieufKPCHQvmKAElQ5MToWBkktUYW5gAp5NxJJRnTcriFKf/InTStHeEc+lTjHDp BWygGSNvHuDz6561i59RGaQ1on9VpgS4LTF/R2+JsopASE3CR4NkVPpjUlkuB3VNofruuq6wNh9j ghElWy5eUSSD3FSqAk5kx9Lazj6WUlsemzoiVByooRVUZ1EMCUjcUMInp6FsJP42bVNWkXOKnnBU afhAJSo7UFFOswx5YlUTGI/wi17XZth2Thgag9wpfvaV9pEpfmOHH1YD19UqGJlOfobfqlpvT3mw GOw3ocqpFIMBghWdSkLMNYqjRLSsmxFzw/rj6ijBKMNL+sR61W0/b6JsTLY3hNDUPzGUjlCrb/HR jleXKK1glQwwFnWSSUPrS0mZDWp/hvfu0tcdVVmkUtxw1AYiMHNQJH0KhICXEwjHFKFObDlEaVUF mQ3lvym/8ptLmjpywJeyERSbF4AoHERNBgn8dx5+mbWyXBHuuqM8JdSF3SYlwoFxRecVLnz4amw+ 1rIqn5MI7vlFR0PgEobqz+0xeoHcZIkEKFurVclDVh5SAInZ7LvsuFhdbhgyVPtnwxHQTP1UgjzB DIkhhu6dvR+Xq8y+8TrCWFpzA1OWtpnaJED4EFAPNpmqYPBLs8Pstx2G15Z2JKso1EUJZhJrta5G SsGMQlMdAc2n8Te3bvm6Oq+SwNvMSZJ3NUkFyqQ9lDsITEEj2oPJwAfiIEZ+1wM8zguF/hDxunwB EDGMLceHYjPSSFedi0if3wMi59N+hU/jU7QNQ9fRS5HT+2wb6fiVthA/XTSYNPJZvYcMa1TZQtSe 8SIfVZuvniFO00sVEWDeEE6Fq2+gN7/IkYWaglkBtfnVGjao4ncxYAjohaiUXJytip6bBFR3WIwn 8v4P8jZcxQBpTWLnUKnCh57c1TEW46/DI3Vnb/OAdqfjAWVuD0jWF4D5sUGnXAXxgTXNKB+8QlIr ycg3gAB9ZS9PcDnAWQWFrf2gCLHQm4W5b12ehhqVsHyojhkTKNlqiwRHdOdKRFUKWsPgomJBf8Hm ltDXPKWmPM41SkSovgVmqBHI1r2B6j9TPEMC8FCPupuCIPyJkL84G37StKm2IrcUPRGAp/OWtn0F dhXp2r+atK/sQIUNKhkaExuPGKWny/CTT5hAYgMfd1wiehY73/TiNroAXb6lrsWgYMp0MoH2Xn1n DCp3PnT8j3/hj570HS1m3QNHGXTNgkqjjL4IhM9makn3s0GZ/tQfZ26BYZCYMbFedT8XymaUreio jIqhdIS8HaPhMx9dHIefY8Emp6/l7zxPQ3PTUlKMjculofWlHiizQe1Hwx93XiQNdCvYWAwhiGzU Bl+q0n8i4U1HyR0pUOZN3uZL4Df1wjG2AkOvTnAOKMbChR6QkuHX4W5LvwfRIRtByWqv6D9D2L6h bAbXzVOCZ1uY2RQkc7RBv3ujX/YJcpxh0rIqxdMxeen4b46RhdGQ+KtjpaQM4IU2cpciYj6i4XS1 UtJEdU2WSICKtVqVfFDUUe8h2cWInBdoHRfvxYwZGo9oNVMTY4A+r3A0nge9ioUOe5z+kMrpGXRP W+V3z2jqOHSaDcmksa6DDnrjQulnDWqjZ9zE+RDVBWdOvIEU+fzPr7cGJ29atrIeKaax3/bhBHYk q6gczMyu1bpmUgpmDH605s8f1dB2ixY+38TbzCrJe4ZkAmU5NKRAq5CJZBh0ah6XmR3QJDqBT1ua 3eOgt0LSPJWvFq9O2/5uCBRlMnziVUdmUYnDtc7pAOlDQ8p3bOOht/JzvF7fO6ILhIYR92XI25Rd jpeKsjw52WT8yucDxOmx4ZM1jpyycndenjMNXIA6W3bLIz1n62svZaS//E5ocry3waF6nbA8JmZf oPBsdhmu7uR3usF1/l++rCchoDfszogSONJ7Qw53xY4SW+bWd8GS5yQBJUOj6GbiX7R43fm520AO +quAIS1fIk4E5CYmo0aq2aKaUPcn2eQcaP/Wn1S0X2zzPa482wvpVYtSLAFDZUMaeVQqPvCZm8js klH0B9BVFhwLP508Y1uQmb9js9uz/yRdjsbz2VrqSCdvG9UnUGXLxfuzX+7mk0n6c+mTyCWrvVvL czbsOzkgHn6ClAbhc9QNZGxrrv8/3+xcQx8M1yWAHiM1Y3Ol2/HTzQUedvdQ06aaimhUWjAd/ueO TGfJSzm5rgzSvkYbVGWoT6yc7rQtfoq1srX0WIafcoFMBlvLMh2+qvLMbLpGcCLU7HN788qP/FWr eNS41Ar2yn//qXgV7SYZ0J2v2vjSOoPKnb554VhV5jKby712ZXZls/qVpVp/lQCNRul9kSJP1g9N 8OlP/XHtvLVOhpMmiWVVWZWyKK3uzOdChQyylYXWesXaFpjYb04G/7IpzVm+x+dIfy0QPs/zNDa3 Ckvd0PtSKJlW7WfGg61b0zN9e3zONXRVpeKX9L5Urf8g4T8V2gp+4cvNrfsAzjKTpLFHoOjVCYoE ppfNx066X639XlQeQcnzf7qJQGHRhrIZXDdPOTHYusm+dYsnrfBn3iJyT1/xCerms/Y5YOMPq2/M jgZbqx2LbevWZ9oyt7f0QpNBR5OykLxlnL6tn/iBOGj409RJJo2+yRIJcNaSX5fvkxg8JAOkqnVc sjwNSm5yxOiIOKTbcvy8Ijd9Y2m+e29A5/T0uveNpsrjFzR1lK6drHK7fWWeIm82vZGlzkpvbobu MmLifOhBR9ra9dmrbWUNnWGVs50VSWu/UUNd1HakD2aUeQErrZZrxJppoFspmP5CktH89d2i3qsI n68/TryNTpKkR9No+z1DkmuUf0hIY5cOv5LffGnWsPfeRYqcf9P3cguduUHuViAiJIsCvzc9VOYA +BM/9PMdgYqnTLyRF8u82jHbS6MQM+g7tpWx071LPHLprXIvndb9Trk3BQjx39xuYs8P6LXmie9L 2+cBDJQNxAbPng5pH6K/z5Big+dOh8bu5yreD1jfn/1OkL4+dXB96lpfdaUrvbDp7HxYBCpe7Osz v817JrN8zyvrni/+A7t7i8yNyNnGTY6cPeL1Bfc00cHuTy+ThRbfJfeoANXLD75L0GvNF9+Lts8P GCgjCIIgCIIgiAkYKCMIgiAIgiCICRgoIwiCIAiCIIgJGCgjCIIgCIIgiAkYKCMIgiAIgiCICUkH yvR9e6tt2Xn2ZcuKD/M3oodP7HGkrc21L02jL/8DRtrLnxQPpo521Hm8+a5VCxesWufNyy/89anr XwZq3Da7e50tg+6QPj3WsevppLYGmAvkzZe//Pv/Vs9jzvIb9b8/YoPtr9cEVC+g/Q6QBtq37wvM 4a2H0XDg9ayVmXmu9NVcSRjWDa1/2aSc8orYOYmh5CAN/mPH7vf5uzOT5euO2o353mzbgqdsLm++ t6y+87oUOX+0MjODvH9tOFBhI8fXZ9roDqL8pMTMWThmSKPB1h2rX7B459Gsmmx4X6aB21ab6dGO /ble77qVT7F3uBYd6LzO7J28KNTnJ29smB4N7FhEfvWsXSn2Fk6C22pBHcL5KIUxgb7y9uMhSycj v9U7AbctQFBg1Q7/fJuey7ejafMJe8XpiLAmeVMMPfPRRgiCIPcDSQbKUrSrbmnxsa/IG0Cj4VMf /ycSl0Y/3rNyy9GvwNdPkx106P4u0DM9Lb8AnEJeqM57KSkWav8j601Jt1HK3lg+70zzvZfnkWQ6 1G8bedub7xBle6rkiF06/keylQB5A9EBVzI79lmGetHOmnTTS0NwJvbwmyvkvfFc68hb7kty1qam kfeiQzzKN2Mne0Gl852KZmOuwjECg8+mLevsyxZa7B0wmyZLym5hltyh2kAg5RbtOHH5eDON7chL WFeQgkHUxbd2J9s4pfE91WbjDlpQwVgYIxPBxryESjgq9gpNwG0LEITDNqwCyDDvueK2odvTtHkE xqXpZSrHqxuOysxLGyEIgtwPJBkoGyNFiISy+eaEgBS5ejVCt1vTbZFgsWkChCxkD/eRJN8UOx1+ 75cvusv3lK97kU3DRMMn9+fmbP5FgYvOTEOSaDiw1+Mt/WlabuVWR2pDx0c8Z/lltGJbReirnrHn FeWVeLML32isK8j5qdfp9Z9X7a5IJ6vcBT/b6CraWW4nYRzv85T3OPJdTKXY4EcHvZn5Pu9q1xud w7GZ2MDJug1u39bCzHIyyzU9ENiVu85XVe7ysvk2Ep8Vect3lblL1BOuQHSw8zf5Nm+5176u7qNh SVfBSO/bFWsfs5fvf6f3q39WLshY57RlvdE5FhsI1BTlby5Md2/5ecamo4OTo4HtC53eDe6y8hx3 9clrhgJARRzZLlfWS0WOzFfpRkoGSUL8x/Kvqf/dpozH7eVvtPZESEi32e3bVprzsphKhAu5sp/3 HOg03YcCAqw81VZGohVI5iD8gnKfx1H1/jBoTFftInWBRUqIETOW2+yOopJM144TA9PieLT3yGb7 krW+/Ud7b8bCH+zz5JbvKHLw2WuIadKyXZnLHAdO9f2t/GGHPr5R3lcPTdz1wbl/NbKgQf0ee30k YUG0920unM6AHA+NnaxaVH483Fn3TMY6T07JS04H3W+PBsRq6QliX516/9MufTBnpcmyWjo8FZvt JDSEQDA3deUaVWvqFGxUUZvItF73dLoBKm2UGAmk8rS7NBPINqdkPKz+ddaolCHJLdjSsCWF33y6 3rEzs7TtvEE5E9iLgiiMQGMUrobeQeEBDAKEtn5hhS0jW2kpsjPcnzbk+H5Z7C3T2Z1BgHqnpBcg 2JqdC2T6ov9FugvabWga+Cu61y4RXVddCkTbUzqrHw8H9jhd5Xt8bifbvlHnhXQVJ1sfC3vkmesl 05ekleFuKQiC/ABIdunFdOit3JSNh85c434dYsYnjZs2g/91azdKNR4BYsOB6vSdJ8d0t92la6ea 9tfV1vK/vb9t72MTVNDlsB0RpdjVUB90UaG3vAVvhsg+nP1HCwqgq54O+bPdh8mR2PmmzBWV//yQ 56xcAjJx8f0ebfu7wONDpyV/UM9IxYP+7BK6afutYKOb7NzLdyXVbLO8qAJqf6mlaGsLSRmP9IWu xiYuN28u9AdBRFK4tfCFxt7TfDfmmdi1i32jkvTV8ZJNNGeIKrzqgcd0qHlD8ZHLpEajfRevRQ0V lAtJZuhZsWeiIf9GD7kc2SDesQAKCuGpx32omwxZumohCpkQ20HzApC+2bmvawR+H2rbYmvomTJc SJU/DHJ8tKeHxBW5tF5kjpOMHOBC2avrTlttQiENv7ct7TVl1zHRCiSmyfk96W55Dz11pblMXWCx 7WcUxlcsf2morXRlQ++U3I4QnPlIeAHCz2XCjIVbN5EVFGTCOIvWDuA716sg76t/Tj13y5cJ6Y6L /CnScOcfZIWsra39f+19vE6KcMQH0hzZjb3QtGuYAKG5i70NvWMG6bEcGNfafU4eZ1OsNfmi31ms UUtS1Bx1a8aNCibrtuEnELhGN0wkRs18kX6X5hnpaqDSQzbq0/wqy4ERG+70y3Krq927X5acLGFR Nqiyy9l0YUKvnCbV4TmokAvD0RrFo9sDN3otBSh7AN5St0DZyjxU+MRSNpKpVksBfq5zSgaVkwUi ppOl29M0kYwU0lPf/bXe6ifk/Z+jVy/2R6SozgsFY5qK/5g4Lm5NfPNbc9VKxsoQBEHuf5J/mC8e ufBOtcPO5h2hl9UtsSCQ3kU7R2I8Av79q2Nl6btPDsfEvCz/wRpw/WUOtkM9Yayr1i3W1bG53kEW BJMDJKgtafn0XZ6zcglw/aUtV6LilqK8zY/8gUEXmfDlyBDGlZKubjRQaYdMIKbZQOfPoAvc7G6+ rEpJiZ6pS9nBBw80EPwk+JY3c7e8EhHCRHmhM48L6WdtjQBjBeXJbLi0mKEnU+N8rAIdXi6f4WM3 UnnJyYhCVQAiDQg6oU/nBXjvlP5CN1R3AMS0E3SNtp3qenXF4EImE42cWN/REjY9LOCtwORGwh2x Pf1woGKLusAiJRSmlE/OsSsOiXYEQTwLBVA3kxAmxDSJNjiF+EYz5Sl0WHsc8jeGhiYI4cjxEN+R eGqkvYIEeSQNFenpfxmkRz5y4Ai/F8+AU8w1GUpLxmbkB5CVjwzY4NwX1K3ZFdUr2JlvhG4bdW9S pxtmmK39iH7V+vIaejdA+6vpkNgM3oJ0gp+cLvbH1iunsToayVGUwnBAJiqjcMOw5DrXHMhBJ8BY 174MdUt1DakW7LIjyk0kgwA7ghqnZEQoBhmC5pDp5NvUNB6zkhGU0x+aNFg9iWXd1SfEAnGDFzrV qa54CTFAbmXTo4GqtY3nJ42qdftWhiAIcr+RfKBMkCLdh3Ky6rpGRDjFnpHyrF2cQtwr+F/5ST6G /ogUC/+z2lHa1EN8L3hePqdFmI70vlOvzKns3dvaq/Th7FFC9viLJvimEduF/9AZX3oEgtpnSN/A cobubQ2fNmMxivzwCnRabHpYhGgc9Ve+PJGXE+LF9F/Rjk3uVtWrC7RxA+9O4pGew6U29pwT5Lwh xbuDVXCvzyHCKSglW4gioiVjBYM3RGnh0mweS441AbGgkNcRjsgLK9UFIAIXPSKNWd98l689ILAL Dcv5k2LI006L86pYu7zuWwvRDPSffBLr+qkDZfnevHzP/g7eNw8EqnILG88qc6RKQ/Pgw6zAEGaR 1aI8JcSIudW8swdJ5jRfPsMbFIRs10e3UBeijdDfszQW6OZu+VnTpOLyQ1f07rYyAhztbf2NUEj4 O3C0V5wuhAMfocwkbPJvyCYrkaCOItIlOZc2n/yTXnqinQm6sIPfu6AtotFkE7WEdvGqW7M52K9X sDP/UZTcqHsa3TAjPtK+9WmNQUfDJ3ZnFfyxJwIlhosW09lH9suZusWvKDoc6Tl6oI5djvy9fqxX RISiBYngoPU/uUDjP00ga1UdYS8cdWE4WqPYvki5qWIU4OiV5i3qlmrpD7bk2PJ3vk6vuLvc7m7o HVF5CUNh1E7JBDYCPzPeXb+KTCfDkdvSNG41fWw4YWL1kFfkc3+xPYuuuzB4od+0v6muuAsKoLJH MPZho2rdgZUhCILcb8wtUKbu0pffGtLcZmVTX1emVF0dB46oJp5ZlFz2B75Mk3WHyT8hFx/teHUJ 5KZEVzSYSKnrGodOmh8hN/d9bed4zsolRAfDwsEJGjbl0VBSjikZcjBH41cyFzjJK0sjNnLfnEcz N5SUFBowsVJAH7Zjae0Z1p1Ioyern4UYYlSXXkFdI8BYwSgUspgWG8rPb9eqLsejf6UT1UbeogAT fD6JHKNdZmfAcKF+5XYwHCHz6OoLCUAUcmeshkbJRU1ntUsyRCsoUaBYwSznw+POKE8Jl85lSxRY uNN5hbcjfCVzYDQelYUJdXHTwZtKJ42AVDVzt2IGFI6LKTp6dztTdR/fGiEcgMhn685KMp08LdsC T0MjXbOpUIbuXjwtpLkmG9UyNhqo9qpbk9xX0SmYrDZqcWkQuqENQTlwFn9Wj0ID08I/ibXC8Ks8 JIgNtZU/t/PkGP2SELkFWWVLqyrodDKJRLXKaVIdNbrCcLRGATo2IDyAUYDXxN0M3lJkDYPaDAmz ClA4Jf5VAynM3r8cJesl6Im3p2mkIqW1f/WXZfPhhM7qaRrI8OuOqixoLFUC5oVOfKSuOHELwsq4 M1H5MUW1btfKEARB7juSCZTHQ8f/+BcW3cb6jhaT+JLciOQvwSBLKUrJ4//qro6hPqKLkgGrvkcH nHjmo4vj5EOwyQl9EgRVL2w6Goa+YCLk3+RtvkSWza3ccnwoNiONdNU51zR+8gnPWVxCGvms3kMm gaCvYlOhvEuYVj5woPvxlrZ9BSnIqzxIZMxvsoseKD722W+yyLwgqR17nFH65uZNOpeTUdAahurF gv6CzS0XLn3ccYk8kRQ73/TitvaR8WCjlz/+KI3fvKl+erCvxb2BvjGALnM0rSArJL8lSk4igRSd qSIvHLBtVK0qEUsdogPaAkBksMLReJ6sbgwd9jj9ITiuu5A2f3avmdSLP57PVmHqFqsIzKNkQLQC hCP8NRF8EYvy0gZ+L5inBFEvzGwKknW6Qb97oz/0tVAVOTiYCDYWFLb2Q+1joTcLc9+6PC2vhTCH jCLU64NByHQ2XTkujYWOVbnV9/GtkYVDgHD/gWdyQXrwGer4qLspCOMuEGlxtv9iTC89Ndp78YCl JhvVEmS1RtOa05CbVsEU3Tb8FNPphibc5KiDfmNgqvwaj4Te2Zazhyymmh11eAeB2sKFHmg7+Axx mFY5jdVRMI+SAa1ReOgdEgsBgitYoGmpaWJ3/MUdzKKtBRjVOyV6dR1kXnbxEvL4HdWo29M0aKHB 1k0pi1Np4Y1WHwl/3HlxEn65FWwshkBZ74VCI5qKk9sXwh65sRtVKxkrm7x5Yzyp4iMIgtzjJBMo T0cuHKvKXGZzudeuzK5s7iHBCLvtaMvOX5/lKDx4ktx8hK5uWYrdQ27EezfWdXwtZoZo7AJdzvL/ 70eL7Xnk17y8yrYBZX4xMdJk8C+b0pzle3yOdPa2ZvJkeqGt4Be+3Nw69jKyyfCJVx2ZRSUO1zqn o+7M5yLn2PDJGkdOWbk7L8+ZBq5fmXOVp4flD4Lp8D93ZDpLXnLaFj9F7izzyc64NPx+daan3Few Yb19IQ2S6B1Ph3trqSN9F3lIn7zcoGS1d2t5zoZ9Jwdik8HWskyHr6o8M5utIOTpK3aU2DK3vkvD FA69CZ7m+flm5xry9L2hgvEvWrzu/NxtfznRwG9bA9MDge0ux0tFWZ6c7GegoNCrKc8aktujugKQ JnD8vCI3fWNpvnuvqSTFLVdCPPRWfo7X63tnkLZ1es7W117KSH/5ndCkciEV0Lk6Hnpwydr1pH3z 11cfH2ABFlSbN7SSOR+uGArMU05AZGDfusWTVvgzbxFZGKCoykSo2ef25pW3QqB49g8Fmfk7Nrs9 +4n6iWaC3CCYSH1YPXkMsJlpVXDPFwWR448TtfSus60pPPCh9ZJTDYpwoH6gVMvqz5JghV46Y3Ol 2/HTzQUe9goCvfTU+euf5LPWZFktc3JdGbQiEGW6tK1pUDChNpCD/ietbkRNJCbmWanISL0e+C9h 3YXb2r4ks/6P0eZ2pa8uYB4gGZQWpIpB3wUBmCinpb2YFIb/YjQKxcnoBQiGr2spYYaVrxavTtv+ bmhctjuDAL+IaJ2SmcqxEZSdV5Bq4G1oGjvxx0LBDBUcD7ZuTc/07fE517AF0zovZKy4wR4NqjW7 lZnXF0EQ5H5krksv7neUuSvxjNF9A3TbP4incOKRS2+Ve9k85XdA5OwBD5vtg4Bf9SjkPcR3LDEG ef/xKjHbeo8r5/ciQARBEOS7AANlDdLXpw6uT13rq650pRearCK4d7FYL3EfEh3s/vSy4ab8t0K0 u6nI6a6WX30wy/KPu5XvUGKcyNnGTY6cPWzm+N5Xzu9egAiCIMh3BAbKCIIgCIIgCGICBsoIgiAI giAIYgIGygiCIAiCIAhiAgbKCIIgCIIgCGICBsoIgiAIgiAIYgIGygiCIAiCIAhiAgbKCIIgCIIg CGICBsoIgiAIgiAIYgIGygiCIAiCIAhiAgbKCIIgCIIgCGICBsoIgiAIgiAIYmBm5v8HoQeyhgJV dBEAAAAASUVORK5CYII= ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: text/css Content-Transfer-Encoding: quoted-printable Content-Location: https://cdn.datatables.net/keytable/2.8.2/css/keyTable.dataTables.css @charset "utf-8"; table.dataTable tbody th.focus, table.dataTable tbody td.focus { outline: r= gb(51, 102, 255) solid 2px; outline-offset: -2px; } div.dtk-focus-alt table.dataTable tbody th.focus, div.dtk-focus-alt table.d= ataTable tbody td.focus { outline: rgb(255, 139, 51) solid 2px; outline-off= set: -2px; } ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: text/css Content-Transfer-Encoding: quoted-printable Content-Location: https://cdn.datatables.net/1.13.4/css/jquery.dataTables.css @charset "utf-8"; :root { --dt-row-selected: 13, 110, 253; --dt-row-selected-text: 255, 255, = 255; --dt-row-selected-link: 9, 10, 11; } table.dataTable td.dt-control { text-align: center; cursor: pointer; } table.dataTable td.dt-control::before { height: 1em; width: 1em; margin-top= : -9px; display: inline-block; color: white; border: 0.15em solid white; bo= rder-radius: 1em; box-shadow: rgb(68, 68, 68) 0px 0px 0.2em; box-sizing: co= ntent-box; text-align: center; font-family: "Courier New", Courier, monospa= ce; line-height: 1em; content: "+"; background-color: rgb(49, 177, 49); tex= t-indent: 0px !important; } table.dataTable tr.dt-hasChild td.dt-control::before { content: "-"; backgr= ound-color: rgb(211, 51, 51); } table.dataTable thead > tr > th.sorting, table.dataTable thead > tr > th.so= rting_asc, table.dataTable thead > tr > th.sorting_desc, table.dataTable th= ead > tr > th.sorting_asc_disabled, table.dataTable thead > tr > th.sorting= _desc_disabled, table.dataTable thead > tr > td.sorting, table.dataTable th= ead > tr > td.sorting_asc, table.dataTable thead > tr > td.sorting_desc, ta= ble.dataTable thead > tr > td.sorting_asc_disabled, table.dataTable thead >= tr > td.sorting_desc_disabled { cursor: pointer; position: relative; paddi= ng-right: 26px; } table.dataTable thead > tr > th.sorting::before, table.dataTable thead > tr= > th.sorting::after, table.dataTable thead > tr > th.sorting_asc::before, = table.dataTable thead > tr > th.sorting_asc::after, table.dataTable thead >= tr > th.sorting_desc::before, table.dataTable thead > tr > th.sorting_desc= ::after, table.dataTable thead > tr > th.sorting_asc_disabled::before, tabl= e.dataTable thead > tr > th.sorting_asc_disabled::after, table.dataTable th= ead > tr > th.sorting_desc_disabled::before, table.dataTable thead > tr > t= h.sorting_desc_disabled::after, table.dataTable thead > tr > td.sorting::be= fore, table.dataTable thead > tr > td.sorting::after, table.dataTable thead= > tr > td.sorting_asc::before, table.dataTable thead > tr > td.sorting_asc= ::after, table.dataTable thead > tr > td.sorting_desc::before, table.dataTa= ble thead > tr > td.sorting_desc::after, table.dataTable thead > tr > td.so= rting_asc_disabled::before, table.dataTable thead > tr > td.sorting_asc_dis= abled::after, table.dataTable thead > tr > td.sorting_desc_disabled::before= , table.dataTable thead > tr > td.sorting_desc_disabled::after { position: = absolute; display: block; opacity: 0.125; right: 10px; line-height: 9px; fo= nt-size: 0.8em; } table.dataTable thead > tr > th.sorting::before, table.dataTable thead > tr= > th.sorting_asc::before, table.dataTable thead > tr > th.sorting_desc::be= fore, table.dataTable thead > tr > th.sorting_asc_disabled::before, table.d= ataTable thead > tr > th.sorting_desc_disabled::before, table.dataTable the= ad > tr > td.sorting::before, table.dataTable thead > tr > td.sorting_asc::= before, table.dataTable thead > tr > td.sorting_desc::before, table.dataTab= le thead > tr > td.sorting_asc_disabled::before, table.dataTable thead > tr= > td.sorting_desc_disabled::before { bottom: 50%; content: "=E2=96=B2" / "= "; } table.dataTable thead > tr > th.sorting::after, table.dataTable thead > tr = > th.sorting_asc::after, table.dataTable thead > tr > th.sorting_desc::afte= r, table.dataTable thead > tr > th.sorting_asc_disabled::after, table.dataT= able thead > tr > th.sorting_desc_disabled::after, table.dataTable thead > = tr > td.sorting::after, table.dataTable thead > tr > td.sorting_asc::after,= table.dataTable thead > tr > td.sorting_desc::after, table.dataTable thead= > tr > td.sorting_asc_disabled::after, table.dataTable thead > tr > td.sor= ting_desc_disabled::after { top: 50%; content: "=E2=96=BC" / ""; } table.dataTable thead > tr > th.sorting_asc::before, table.dataTable thead = > tr > th.sorting_desc::after, table.dataTable thead > tr > td.sorting_asc:= :before, table.dataTable thead > tr > td.sorting_desc::after { opacity: 0.6= ; } table.dataTable thead > tr > th.sorting_desc_disabled::after, table.dataTab= le thead > tr > th.sorting_asc_disabled::before, table.dataTable thead > tr= > td.sorting_desc_disabled::after, table.dataTable thead > tr > td.sorting= _asc_disabled::before { display: none; } table.dataTable thead > tr > th:active, table.dataTable thead > tr > td:act= ive { outline: none; } div.dataTables_scrollBody > table.dataTable > thead > tr > th::before, div.= dataTables_scrollBody > table.dataTable > thead > tr > th::after, div.dataT= ables_scrollBody > table.dataTable > thead > tr > td::before, div.dataTable= s_scrollBody > table.dataTable > thead > tr > td::after { display: none; } div.dataTables_processing { position: absolute; top: 50%; left: 50%; width:= 200px; margin-left: -100px; margin-top: -26px; text-align: center; padding= : 2px; } div.dataTables_processing > div:last-child { position: relative; width: 80p= x; height: 15px; margin: 1em auto; } div.dataTables_processing > div:last-child > div { position: absolute; top:= 0px; width: 13px; height: 13px; border-radius: 50%; background: rgb(var(--= dt-row-selected)); animation-timing-function: cubic-bezier(0, 1, 1, 0); } div.dataTables_processing > div:last-child > div:nth-child(1) { left: 8px; = animation: 0.6s ease 0s infinite normal none running datatables-loader-1; } div.dataTables_processing > div:last-child > div:nth-child(2) { left: 8px; = animation: 0.6s ease 0s infinite normal none running datatables-loader-2; } div.dataTables_processing > div:last-child > div:nth-child(3) { left: 32px;= animation: 0.6s ease 0s infinite normal none running datatables-loader-2; = } div.dataTables_processing > div:last-child > div:nth-child(4) { left: 56px;= animation: 0.6s ease 0s infinite normal none running datatables-loader-3; = } @keyframes datatables-loader-1 {=20 0% { transform: scale(0); } 100% { transform: scale(1); } } @keyframes datatables-loader-3 {=20 0% { transform: scale(1); } 100% { transform: scale(0); } } @keyframes datatables-loader-2 {=20 0% { transform: translate(0px, 0px); } 100% { transform: translate(24px, 0px); } } table.dataTable.nowrap th, table.dataTable.nowrap td { white-space: nowrap;= } table.dataTable th.dt-left, table.dataTable td.dt-left { text-align: left; = } table.dataTable th.dt-center, table.dataTable td.dt-center, table.dataTable= td.dataTables_empty { text-align: center; } table.dataTable th.dt-right, table.dataTable td.dt-right { text-align: righ= t; } table.dataTable th.dt-justify, table.dataTable td.dt-justify { text-align: = justify; } table.dataTable th.dt-nowrap, table.dataTable td.dt-nowrap { white-space: n= owrap; } table.dataTable thead th, table.dataTable thead td, table.dataTable tfoot t= h, table.dataTable tfoot td { text-align: left; } table.dataTable thead th.dt-head-left, table.dataTable thead td.dt-head-lef= t, table.dataTable tfoot th.dt-head-left, table.dataTable tfoot td.dt-head-= left { text-align: left; } table.dataTable thead th.dt-head-center, table.dataTable thead td.dt-head-c= enter, table.dataTable tfoot th.dt-head-center, table.dataTable tfoot td.dt= -head-center { text-align: center; } table.dataTable thead th.dt-head-right, table.dataTable thead td.dt-head-ri= ght, table.dataTable tfoot th.dt-head-right, table.dataTable tfoot td.dt-he= ad-right { text-align: right; } table.dataTable thead th.dt-head-justify, table.dataTable thead td.dt-head-= justify, table.dataTable tfoot th.dt-head-justify, table.dataTable tfoot td= .dt-head-justify { text-align: justify; } table.dataTable thead th.dt-head-nowrap, table.dataTable thead td.dt-head-n= owrap, table.dataTable tfoot th.dt-head-nowrap, table.dataTable tfoot td.dt= -head-nowrap { white-space: nowrap; } table.dataTable tbody th.dt-body-left, table.dataTable tbody td.dt-body-lef= t { text-align: left; } table.dataTable tbody th.dt-body-center, table.dataTable tbody td.dt-body-c= enter { text-align: center; } table.dataTable tbody th.dt-body-right, table.dataTable tbody td.dt-body-ri= ght { text-align: right; } table.dataTable tbody th.dt-body-justify, table.dataTable tbody td.dt-body-= justify { text-align: justify; } table.dataTable tbody th.dt-body-nowrap, table.dataTable tbody td.dt-body-n= owrap { white-space: nowrap; } table.dataTable { width: 100%; margin: 0px auto; clear: both; border-collap= se: separate; border-spacing: 0px; } table.dataTable thead th, table.dataTable tfoot th { font-weight: bold; } table.dataTable thead th, table.dataTable thead td { padding: 10px; border-= bottom: 1px solid rgba(0, 0, 0, 0.3); } table.dataTable thead th:active, table.dataTable thead td:active { outline:= none; } table.dataTable tfoot th, table.dataTable tfoot td { padding: 10px 10px 6px= ; border-top: 1px solid rgba(0, 0, 0, 0.3); } table.dataTable tbody tr { background-color: transparent; } table.dataTable tbody tr.selected > * { box-shadow: inset 0 0 0 9999px rgba= (var(--dt-row-selected), 0.9); color: rgb(var(--dt-row-selected-text)); } table.dataTable tbody tr.selected a { color: rgb(var(--dt-row-selected-link= )); } table.dataTable tbody th, table.dataTable tbody td { padding: 8px 10px; } table.dataTable.row-border tbody th, table.dataTable.row-border tbody td, t= able.dataTable.display tbody th, table.dataTable.display tbody td { border-= top: 1px solid rgba(0, 0, 0, 0.15); } table.dataTable.row-border tbody tr:first-child th, table.dataTable.row-bor= der tbody tr:first-child td, table.dataTable.display tbody tr:first-child t= h, table.dataTable.display tbody tr:first-child td { border-top: none; } table.dataTable.cell-border tbody th, table.dataTable.cell-border tbody td = { border-top: 1px solid rgba(0, 0, 0, 0.15); border-right: 1px solid rgba(0= , 0, 0, 0.15); } table.dataTable.cell-border tbody tr th:first-child, table.dataTable.cell-b= order tbody tr td:first-child { border-left: 1px solid rgba(0, 0, 0, 0.15);= } table.dataTable.cell-border tbody tr:first-child th, table.dataTable.cell-b= order tbody tr:first-child td { border-top: none; } table.dataTable.stripe > tbody > tr.odd > *, table.dataTable.display > tbod= y > tr.odd > * { box-shadow: rgba(0, 0, 0, 0.024) 0px 0px 0px 9999px inset;= } table.dataTable.stripe > tbody > tr.odd.selected > *, table.dataTable.displ= ay > tbody > tr.odd.selected > * { box-shadow: inset 0 0 0 9999px rgba(var(= --dt-row-selected, 0.923)); } table.dataTable.hover > tbody > tr:hover > *, table.dataTable.display > tbo= dy > tr:hover > * { box-shadow: rgba(0, 0, 0, 0.035) 0px 0px 0px 9999px ins= et; } table.dataTable.hover > tbody > tr.selected:hover > *, table.dataTable.disp= lay > tbody > tr.selected:hover > * { box-shadow: inset 0 0 0 9999px rgba(v= ar(--dt-row-selected, 1)) !important; } table.dataTable.order-column > tbody tr > .sorting_1, table.dataTable.order= -column > tbody tr > .sorting_2, table.dataTable.order-column > tbody tr > = .sorting_3, table.dataTable.display > tbody tr > .sorting_1, table.dataTabl= e.display > tbody tr > .sorting_2, table.dataTable.display > tbody tr > .so= rting_3 { box-shadow: rgba(0, 0, 0, 0.02) 0px 0px 0px 9999px inset; } table.dataTable.order-column > tbody tr.selected > .sorting_1, table.dataTa= ble.order-column > tbody tr.selected > .sorting_2, table.dataTable.order-co= lumn > tbody tr.selected > .sorting_3, table.dataTable.display > tbody tr.s= elected > .sorting_1, table.dataTable.display > tbody tr.selected > .sortin= g_2, table.dataTable.display > tbody tr.selected > .sorting_3 { box-shadow:= inset 0 0 0 9999px rgba(var(--dt-row-selected, 0.919)); } table.dataTable.display > tbody > tr.odd > .sorting_1, table.dataTable.orde= r-column.stripe > tbody > tr.odd > .sorting_1 { box-shadow: rgba(0, 0, 0, 0= .055) 0px 0px 0px 9999px inset; } table.dataTable.display > tbody > tr.odd > .sorting_2, table.dataTable.orde= r-column.stripe > tbody > tr.odd > .sorting_2 { box-shadow: rgba(0, 0, 0, 0= .047) 0px 0px 0px 9999px inset; } table.dataTable.display > tbody > tr.odd > .sorting_3, table.dataTable.orde= r-column.stripe > tbody > tr.odd > .sorting_3 { box-shadow: rgba(0, 0, 0, 0= .04) 0px 0px 0px 9999px inset; } table.dataTable.display > tbody > tr.odd.selected > .sorting_1, table.dataT= able.order-column.stripe > tbody > tr.odd.selected > .sorting_1 { box-shado= w: inset 0 0 0 9999px rgba(var(--dt-row-selected, 0.954)); } table.dataTable.display > tbody > tr.odd.selected > .sorting_2, table.dataT= able.order-column.stripe > tbody > tr.odd.selected > .sorting_2 { box-shado= w: inset 0 0 0 9999px rgba(var(--dt-row-selected, 0.947)); } table.dataTable.display > tbody > tr.odd.selected > .sorting_3, table.dataT= able.order-column.stripe > tbody > tr.odd.selected > .sorting_3 { box-shado= w: inset 0 0 0 9999px rgba(var(--dt-row-selected, 0.939)); } table.dataTable.display > tbody > tr.even > .sorting_1, table.dataTable.ord= er-column.stripe > tbody > tr.even > .sorting_1 { box-shadow: rgba(0, 0, 0,= 0.02) 0px 0px 0px 9999px inset; } table.dataTable.display > tbody > tr.even > .sorting_2, table.dataTable.ord= er-column.stripe > tbody > tr.even > .sorting_2 { box-shadow: rgba(0, 0, 0,= 0.01) 0px 0px 0px 9999px inset; } table.dataTable.display > tbody > tr.even > .sorting_3, table.dataTable.ord= er-column.stripe > tbody > tr.even > .sorting_3 { box-shadow: rgba(0, 0, 0,= 0.004) 0px 0px 0px 9999px inset; } table.dataTable.display > tbody > tr.even.selected > .sorting_1, table.data= Table.order-column.stripe > tbody > tr.even.selected > .sorting_1 { box-sha= dow: inset 0 0 0 9999px rgba(var(--dt-row-selected, 0.919)); } table.dataTable.display > tbody > tr.even.selected > .sorting_2, table.data= Table.order-column.stripe > tbody > tr.even.selected > .sorting_2 { box-sha= dow: inset 0 0 0 9999px rgba(var(--dt-row-selected, 0.911)); } table.dataTable.display > tbody > tr.even.selected > .sorting_3, table.data= Table.order-column.stripe > tbody > tr.even.selected > .sorting_3 { box-sha= dow: inset 0 0 0 9999px rgba(var(--dt-row-selected, 0.903)); } table.dataTable.display tbody tr:hover > .sorting_1, table.dataTable.order-= column.hover tbody tr:hover > .sorting_1 { box-shadow: rgba(0, 0, 0, 0.082)= 0px 0px 0px 9999px inset; } table.dataTable.display tbody tr:hover > .sorting_2, table.dataTable.order-= column.hover tbody tr:hover > .sorting_2 { box-shadow: rgba(0, 0, 0, 0.075)= 0px 0px 0px 9999px inset; } table.dataTable.display tbody tr:hover > .sorting_3, table.dataTable.order-= column.hover tbody tr:hover > .sorting_3 { box-shadow: rgba(0, 0, 0, 0.063)= 0px 0px 0px 9999px inset; } table.dataTable.display tbody tr:hover.selected > .sorting_1, table.dataTab= le.order-column.hover tbody tr:hover.selected > .sorting_1 { box-shadow: in= set 0 0 0 9999px rgba(var(--dt-row-selected, 0.982)); } table.dataTable.display tbody tr:hover.selected > .sorting_2, table.dataTab= le.order-column.hover tbody tr:hover.selected > .sorting_2 { box-shadow: in= set 0 0 0 9999px rgba(var(--dt-row-selected, 0.974)); } table.dataTable.display tbody tr:hover.selected > .sorting_3, table.dataTab= le.order-column.hover tbody tr:hover.selected > .sorting_3 { box-shadow: in= set 0 0 0 9999px rgba(var(--dt-row-selected, 0.962)); } table.dataTable.no-footer { border-bottom: 1px solid rgba(0, 0, 0, 0.3); } table.dataTable.compact thead th, table.dataTable.compact thead td, table.d= ataTable.compact tfoot th, table.dataTable.compact tfoot td, table.dataTabl= e.compact tbody th, table.dataTable.compact tbody td { padding: 4px; } table.dataTable th, table.dataTable td { box-sizing: content-box; } .dataTables_wrapper { position: relative; clear: both; } .dataTables_wrapper .dataTables_length { float: left; } .dataTables_wrapper .dataTables_length select { border: 1px solid rgb(170, = 170, 170); border-radius: 3px; background-color: transparent; padding: 4px;= } .dataTables_wrapper .dataTables_filter { float: right; text-align: right; } .dataTables_wrapper .dataTables_filter input { border: 1px solid rgb(170, 1= 70, 170); border-radius: 3px; padding: 5px; background-color: transparent; = margin-left: 3px; } .dataTables_wrapper .dataTables_info { clear: both; float: left; padding-to= p: 0.755em; } .dataTables_wrapper .dataTables_paginate { float: right; text-align: right;= padding-top: 0.25em; } .dataTables_wrapper .dataTables_paginate .paginate_button { box-sizing: bor= der-box; display: inline-block; min-width: 1.5em; padding: 0.5em 1em; margi= n-left: 2px; text-align: center; cursor: pointer; border: 1px solid transpa= rent; border-radius: 2px; background: transparent; text-decoration: none !i= mportant; color: inherit !important; } .dataTables_wrapper .dataTables_paginate .paginate_button.current, .dataTab= les_wrapper .dataTables_paginate .paginate_button.current:hover { border: 1= px solid rgba(0, 0, 0, 0.3); background: linear-gradient(rgba(230, 230, 230= , 0.1) 0%, rgba(0, 0, 0, 0.1) 100%); color: inherit !important; } .dataTables_wrapper .dataTables_paginate .paginate_button.disabled, .dataTa= bles_wrapper .dataTables_paginate .paginate_button.disabled:hover, .dataTab= les_wrapper .dataTables_paginate .paginate_button.disabled:active { cursor:= default; border: 1px solid transparent; background: transparent; box-shado= w: none; color: rgb(102, 102, 102) !important; } .dataTables_wrapper .dataTables_paginate .paginate_button:hover { border: 1= px solid rgb(17, 17, 17); background: linear-gradient(rgb(88, 88, 88) 0%, r= gb(17, 17, 17) 100%); color: white !important; } .dataTables_wrapper .dataTables_paginate .paginate_button:active { outline:= none; background: linear-gradient(rgb(43, 43, 43) 0%, rgb(12, 12, 12) 100%= ); box-shadow: rgb(17, 17, 17) 0px 0px 3px inset; } .dataTables_wrapper .dataTables_paginate .ellipsis { padding: 0px 1em; } .dataTables_wrapper .dataTables_length, .dataTables_wrapper .dataTables_fil= ter, .dataTables_wrapper .dataTables_info, .dataTables_wrapper .dataTables_= processing, .dataTables_wrapper .dataTables_paginate { color: inherit; } .dataTables_wrapper .dataTables_scroll { clear: both; } .dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody { } .dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody > table > = thead > tr > th, .dataTables_wrapper .dataTables_scroll div.dataTables_scro= llBody > table > thead > tr > td, .dataTables_wrapper .dataTables_scroll di= v.dataTables_scrollBody > table > tbody > tr > th, .dataTables_wrapper .dat= aTables_scroll div.dataTables_scrollBody > table > tbody > tr > td { vertic= al-align: middle; } .dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody > table > = thead > tr > th > div.dataTables_sizing, .dataTables_wrapper .dataTables_sc= roll div.dataTables_scrollBody > table > thead > tr > td > div.dataTables_s= izing, .dataTables_wrapper .dataTables_scroll div.dataTables_scrollBody > t= able > tbody > tr > th > div.dataTables_sizing, .dataTables_wrapper .dataTa= bles_scroll div.dataTables_scrollBody > table > tbody > tr > td > div.dataT= ables_sizing { height: 0px; overflow: hidden; margin: 0px !important; paddi= ng: 0px !important; } .dataTables_wrapper.no-footer .dataTables_scrollBody { border-bottom: 1px s= olid rgba(0, 0, 0, 0.3); } .dataTables_wrapper.no-footer div.dataTables_scrollHead table.dataTable, .d= ataTables_wrapper.no-footer div.dataTables_scrollBody > table { border-bott= om: none; } .dataTables_wrapper::after { visibility: hidden; display: block; content: "= "; clear: both; height: 0px; } @media screen and (max-width: 767px) { .dataTables_wrapper .dataTables_info, .dataTables_wrapper .dataTables_pag= inate { float: none; text-align: center; } .dataTables_wrapper .dataTables_paginate { margin-top: 0.5em; } } @media screen and (max-width: 640px) { .dataTables_wrapper .dataTables_length, .dataTables_wrapper .dataTables_f= ilter { float: none; text-align: center; } .dataTables_wrapper .dataTables_filter { margin-top: 0.5em; } } ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq---- Content-Type: text/css Content-Transfer-Encoding: quoted-printable Content-Location: https://kennylist.com/styles.css @charset "utf-8"; * { font-family: Arial, Helvetica, sans-serif; font-size: small; } html, body { margin: 0px; border: 0px; padding: 0px; background-color: rgb(= 255, 255, 255); } main { margin: auto; } input[type=3D"search"] { width: 100%; margin-top: 2px; } .header { position: sticky; top: 0px; padding: 2px; background-color: white= ; z-index: 1; } table.dataTable thead { position: sticky; top: 49.5px; background-color: wh= ite; } table.dataTable tbody td { vertical-align: top; text-align: left; } ------MultipartBoundary--Yd4QSIItwqeJrkzzbBbApaMA56dkdwrxco1c4TDMTq------